<SEC-DOCUMENT>0001213900-25-036798.txt : 20250429
<SEC-HEADER>0001213900-25-036798.hdr.sgml : 20250429
<ACCEPTANCE-DATETIME>20250429160532
ACCESSION NUMBER:		0001213900-25-036798
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		146
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20250429
DATE AS OF CHANGE:		20250429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Universe Pharmaceuticals INC
		CENTRAL INDEX KEY:			0001809616
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			F4
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40231
		FILM NUMBER:		25887129

	BUSINESS ADDRESS:	
		STREET 1:		265 JINGJIU AVENUE
		STREET 2:		JINGGANGSHAN ECON. AND TECH. DEV. ZONE
		CITY:			JI'AN, JIANGXI
		STATE:			F4
		ZIP:			343100
		BUSINESS PHONE:		86-0796-8403309

	MAIL ADDRESS:	
		STREET 1:		265 JINGJIU AVENUE
		STREET 2:		JINGGANGSHAN ECON. AND TECH. DEV. ZONE
		CITY:			JI'AN, JIANGXI
		STATE:			F4
		ZIP:			343100
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>ea0228075-20f_universe.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Apr 29 14:31:09 UTC 2025 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2024" xmlns:upc="http://www.UniversePharmaceuticalsINC.com/20240930" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>



</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin: 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>WASHINGTON, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM&#160;<ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-22388">20-F</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentRegistrationStatement" id="ixv-22389">&#9744;</ix:nonNumeric> <b>REGISTRATION STATEMENT PURSUANT TO SECTION&#160;12(b)&#160;OR
(g)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport" id="ixv-22390">&#9746;</ix:nonNumeric> <b>ANNUAL REPORT PURSUANT TO SECTION&#160;13
OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>For the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-22391"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-22392">September&#160;30</ix:nonNumeric>,
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-22393">2024</ix:nonNumeric></ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="ixv-22394">&#9744;</ix:nonNumeric> <b>TRANSITION
REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentShellCompanyReport" id="ixv-22395">&#9744;</ix:nonNumeric> <b>SHELL
COMPANY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of event requiring this shell company report</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>For the transition
period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to
&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission file number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-22396">001-40231</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-87"><b>Universe Pharmaceuticals INC</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of Registrant as specified in its charter)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>N/A</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Translation of Registrant&#8217;s name into English)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="ixv-102"><b>Cayman Islands</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Jurisdiction of incorporation or organization)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-22397">265 Jingjiu Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2" id="ixv-22398">Jinggangshan Economic and
Technological Development Zone</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-22399">Ji&#8217;an, Jiangxi</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-22400">China</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode" id="ixv-22401"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-22402">343100</ix:nonNumeric></ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>+86-0796-8403309</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName" id="ixv-22403">Gang Lai</ix:nonNumeric>, Chief Executive Officer</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Telephone: <ix:nonNumeric contextRef="c1" name="dei:CityAreaCode" id="ixv-22404">+86</ix:nonNumeric>-<ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber" id="ixv-22405">0796-8403309</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Email: <ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelEmailAddress" id="ixv-22406">gang.lai@universe-pharmacy.com</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1" id="ixv-22407">265 Jingjiu Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine2" id="ixv-22408">Jinggangshan Economic and
Technological Development Zone</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown" id="ixv-135"><b>Ji&#8217;an, Jiangxi Province</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>People&#8217;s Republic of <ix:nonNumeric contextRef="c1" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-22409">China</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Name, Telephone, E-mail and/or Facsimile number
and Address of Company Contact Person)</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Securities registered or to be registered pursuant
to Section&#160;12(b)&#160;of the Act.</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="padding: 0pt; border-bottom: black 1.5pt solid; width: 32%; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="padding: 0pt; width: 2%; text-align: center; text-indent: 0pt">&#160;</td> <td style="padding: 0pt; border-bottom: black 1.5pt solid; width: 32%; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td> <td style="padding: 0pt; width: 2%; text-align: center; text-indent: 0pt">&#160;</td> <td style="padding: 0pt; border-bottom: black 1.5pt solid; width: 32%; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding: 0pt; vertical-align: top; text-align: center; text-indent: 0pt"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-165"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ordinary Shares</b></span></ix:nonNumeric></td> <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td> <td style="padding: 0pt; vertical-align: top; text-align: center; text-indent: 0pt"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-170"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UPC</b></span></ix:nonNumeric></td> <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td> <td style="padding: 0pt; vertical-align: top; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The <ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-22410">Nasdaq</ix:nonNumeric> Stock Market</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Securities registered or to be registered pursuant
to Section&#160;12(g)&#160;of the Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>None</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Title of Class)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Securities for which there is a reporting obligation
pursuant to Section&#160;15(d)&#160;of the Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>None</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Title of Class)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate the number of outstanding shares of each
of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An aggregate of <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-22411">23,645,974</ix:nonFraction> ordinary shares, par
value $0.01875 per share, as of September 30, 2024 (before retroactively taking into account the share consolidation at a ratio of 15-to-1
and the share consolidation at a ratio of 40-to-1, effective as of November 12, 2024 and March 24, 2025, respectively).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is a well-known seasoned issuer,
as defined in Rule&#160;405 of the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Yes&#160;&#9744;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-22412">No</ix:nonNumeric>&#160;&#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this report is an annual or transition report,
indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange
Act of 1934.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Yes&#160;&#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-22413">No</ix:nonNumeric>&#160;&#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note &#8211; Checking the box above will not relieve
any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations
under those Sections.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject
to such filing requirements for the past 90 days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-22414">Yes</ix:nonNumeric>&#160;&#9746; No&#160;&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-22415">Yes</ix:nonNumeric>&#160;&#9746; No&#160;&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of &#8220;large
accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange
Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td> <td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 45%">&#160;</td> <td style="width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td> <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: top"> <td><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-273"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging&#160;growth&#160;company</span></td> <td><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntityEmergingGrowthCompany" id="ixv-281"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company that prepares its
financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange
Act. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityExTransitionPeriod" id="ixv-22416">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial
reporting under Section&#160;404(b)&#160;of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared
or issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag" id="ixv-22417">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If securities are registered pursuant to Section
12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction
of an error to previously issued financial statements. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-22418">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive- based compensation received by any of the registrant&#8217;s
executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).&#160;&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark which basis of accounting
the registrant has used to prepare the financial statements included in this filing:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:DocumentAccountingStandard" id="ixv-22419">U.S. GAAP</ix:nonNumeric> &#9746;</span></td> <td style="width: 70%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International Financial Reporting Standards as issued by the<br/>
International Accounting Standards Board &#9744;</span></td> <td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other &#9744;</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow. Item 17 &#9744; Item 18 &#9744;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this is an annual report, indicate by check
mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;&#9744; No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-22420">&#9746;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PAST FIVE YEARS)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent
to the distribution of securities under a plan confirmed by a court. Yes&#160;&#9744;&#160;No&#160;&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">INTRODUCTION</a></span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</span></td></tr>
  <tr style="background-color: White">
    <td colspan="2" style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">PART&#160;I</a></span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: White">
    <td style="padding: 0pt; width: 9%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; width: 82%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; width: 9%; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1.</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</a></span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: White">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 2.</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">OFFER STATISTICS AND EXPECTED TIMETABLE</a></span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: White">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 3.</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">KEY INFORMATION</a></span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: White">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4.</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">INFORMATION ON THE COMPANY</a></span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td></tr>
  <tr style="background-color: White">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4A.</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">UNRESOLVED STAFF COMMENTS</a></span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="background-color: White">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 5.</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="background-color: White">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 6.</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</a></span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td></tr>
  <tr style="background-color: White">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 7.</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</a></span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</span></td></tr>
  <tr style="background-color: White">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 8.</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">FINANCIAL INFORMATION</a></span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td></tr>
  <tr style="background-color: White">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 9.</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">THE OFFER AND LISTING</a></span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</span></td></tr>
  <tr style="background-color: White">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 10.</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">ADDITIONAL INFORMATION</a></span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</span></td></tr>
  <tr style="background-color: White">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 11.</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td></tr>
  <tr style="background-color: White">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 12.</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_015">DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</a></span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</span></td></tr>
  <tr style="background-color: White">
    <td colspan="2" style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_016">PART&#160;II</a></span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">106</span></td></tr>
  <tr style="background-color: White">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 13.</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_017">DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</a></span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">106</span></td></tr>
  <tr style="background-color: White">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 14.</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_018">MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</a></span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">106</span></td></tr>
  <tr style="background-color: White">
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 15.</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_019">CONTROLS AND PROCEDURES</a></span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">106</span></td></tr>

<tr style="background-color: White">
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16.</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt; width: 82%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_020">[RESERVED]</a></span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td></tr>
  <tr style="background-color: White">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16A.</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_021">AUDIT COMMITTEE FINANCIAL EXPERT</a></span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td></tr>
  <tr style="background-color: White">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16B.</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_022">CODE OF ETHICS</a></span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">108</span></td></tr>
  <tr style="background-color: White">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16C.</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_023">PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">108</span></td></tr>
  <tr style="background-color: White">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16D.</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_024">EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</a></span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">108</span></td></tr>
  <tr style="background-color: White">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16E.</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_025">PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</a></span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">108</span></td></tr>
  <tr style="background-color: White">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16F.</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_026">CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</a></span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td></tr>

<tr style="background-color: White">
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16G.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_027">CORPORATE GOVERNANCE</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td></tr>
  <tr style="background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16H.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_028">MINE SAFETY DISCLOSURE</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16I.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_029">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16J.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_030">INSIDER TRADING POLICIES</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16K.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_031">CYBERSECURITY</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td></tr>
  <tr style="background-color: White">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_032">PART&#160;III</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td></tr>
  <tr style="background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 17.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_033">FINANCIAL STATEMENTS</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td></tr>
  <tr style="background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 18.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_034">FINANCIAL STATEMENTS</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td></tr>
  <tr style="background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 19.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_035">EXHIBITS</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>INTRODUCTION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this annual report on Form 20-F, unless the
context otherwise requires, references to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;China&#8221; or the &#8220;PRC&#8221; are to the People&#8217;s Republic of China, including the special administrative regions of Hong Kong and Macau and excluding Taiwan for the purposes of this annual report only;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Exchange Act&#8221; are to the Securities Exchange Act of 1934, as amended;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;fiscal year&#8221; are to the period from October 1 to September 30 of the next calendar year;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Jiangxi Universe&#8221; are to Jiangxi Universe Pharmaceuticals Co., Ltd., a limited liability company organized under the laws of the PRC, which is wholly owned by Universe Technology (as defined below) and an indirect wholly owned subsidiary of the Company;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;PRC operating entities&#8221; are to Jiangxi Universe and its subsidiaries;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;RMB&#8221; and Renminbi&#8221; are to the legal currency of China;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify">&#8220;shares&#8221; or &#8220;ordinary shares&#8221; are to the ordinary
shares of the Company, par value $11.25 per share;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;SEC&#8221; are to the U.S. Securities Exchange Commission;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Securities Act&#8221; are to the Securities Act of 1933, as amended;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;TCM&#8221; are to traditional Chinese medicine;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;TCMD&#8221; are to traditional Chinese medicine derivatives;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Universe Hanhe&#8221; are to Guangzhou Universe Hanhe Medical Research Co., Ltd., a PRC formed on May 12, 2021, a wholly-owned subsidiary of Jiangxi Universe;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Universe HK&#8221; are to the Company&#8217;s wholly owned subsidiary, Universe Pharmaceuticals Group (International) Limited, a company incorporated in Hong Kong;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Universe Technology&#8221; are to Jiangxi Universe Pharmaceuticals Technology Co., Ltd., a limited liability company organized under the laws of the PRC, and is wholly owned by Universe HK;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Universe Trade&#8221; are to Jiangxi Universe Pharmaceuticals Trade Co., Ltd., a PRC company formed in 2010, a wholly-owned subsidiary of Jiangxi Universe;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;US$,&#8221; &#8220;U.S. dollars,&#8221; &#8220;$&#8221; and &#8220;dollars&#8221; are to the legal currency of the United States; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our Company,&#8221; or the &#8220;Company&#8221;, are to one or more of Universe Pharmaceuticals INC, an exempted company incorporated in the Cayman Islands.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This annual report on Form&#160;20-F includes
our audited consolidated financial statements for the fiscal years ended September&#160;30, 2024, 2023, and 2022. In this annual report,
we refer to assets, obligations, commitments, and liabilities in our consolidated financial statements in United States dollars. These
dollar references are based on the exchange rate of RMB to United States dollars, determined as of a specific date or for a specific period.
Changes in the exchange rate will affect the amount of our obligations and the value of our assets in terms of United States dollars which
may result in an increase or decrease in the amount of our obligations and the value of our assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This annual report contains translations of certain
RMB amounts into U.S. dollars at specified rates. Unless otherwise stated, the following exchange rates are used in this annual report:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td colspan="9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 37%; font-weight: bold; text-align: left; padding-bottom: 1.5pt">US$ Exchange Rate</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 18%; font-weight: bold; text-align: center">2024</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 18%; font-weight: bold; text-align: center">2023</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 18%; font-weight: bold; text-align: center">2022</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">At the end of the fiscal year - RMB</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RMB7.0176 to $1.00</span></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RMB7.2960 to $1.00</span></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RMB7.1135 to $1.00</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Average rate for the fiscal year - RMB</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RMB7.2043 to $1.00</span></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RMB7.0533 to $1.00</span></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RMB6.5532 to $1.00</span></td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</p><div>


</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Part&#160;I</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not Applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not Applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 3. KEY INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This annual report refers to (i) Universe Pharmaceuticals
INC, the Cayman Islands holding company, as &#8220;we&#8221;, &#8220;our&#8221;, &#8220;us&#8221;, or the &#8220;Company&#8221;, (ii)
the Company&#8217;s subsidiaries, as &#8220;our subsidiaries,&#8221; (iii) Jiangxi Universe Pharmaceuticals Co., Ltd., the Company&#8217;s
indirect wholly owned subsidiary in China (&#8220;Jiangxi Universe&#8221;) and its subsidiaries, which are domiciled in China and conducting
business operations in China, as the &#8220;PRC operating entities.&#8221; The Company does not conduct any operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a Cayman Islands holding company with no
operations of our own and not a PRC operating company. Our operations are conducted in China by our PRC subsidiaries. Investors in our
securities are not purchasing equity interests in our subsidiaries but instead are purchasing equity interests in the ultimate Cayman
Islands holding company. Therefore, you will not directly hold any equity interests in our operating companies. The Chinese regulatory
authorities could disallow this structure, which would likely result in a material change in our operations and/or a material change in
the value of the securities we are registering for sale, including that it could cause the value of such securities to significantly decline
or become worthless. For risks facing our Company as a result of our organizational structure and doing business in China, see &#8220;Item
3. Key Information&#8212;D. Risk Factors&#8212;Risks Related to Doing Business in China.&#8221; We directly hold 100% equity interests
in our subsidiaries, and we do not currently use a variable interest entity (&#8220;VIE&#8221;) structure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We face legal and operational risks
associated with having all of our operations in China, which could significantly limit or completely hinder our ability to offer
securities to investors and cause the value of our securities to significantly decline or be worthless. The Chinese government has
significant authority to exert influence on the ability of a China-based company, such as us, to conduct its business. Therefore,
investors of our Company and our business face potential uncertainty from the PRC government. Changes in China&#8217;s economic,
political or social conditions or government policies could materially adversely affect our business and results of operations.
These risks could result in a material change in our operations and/or the value of our ordinary shares or could significantly limit
or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to
significantly decline or be worthless. In particular, recent statements and regulatory actions by China&#8217;s government, such as
those related to the use of variable interest entities and data security or anti-monopoly concerns, as well as the ability <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
the U.S. Public Company Accounting Oversight Board, or the PCAOB, to inspect our auditors, may impact our Company&#8217;s ability to
conduct our business, accept foreign investments, or be listed on a U.S. or other foreign stock exchange. See &#8220;Item 3. Key
Information &#8212; D. Risk Factors &#8212; Risks Related to Doing Business in China &#8212; The PRC government has significant
authority to intervene or influence the China operations of an offshore holding company, such as ours, at any time. The PRC
government may exert more control over offerings conducted overseas and/or foreign investment in China-based issuers. If the PRC
government exerts more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based
issuers and we were to be subject to such oversight and control, it may result in a material adverse change to our business
operations, significantly limit or completely hinder our ability to offer or continue to offer securities to investors, and cause
the ordinary shares to significantly decline in value or become worthless&#8221; and &#8220;Item 3. Key Information &#8212; D. Risk
Factors &#8212; Risks Related to Doing Business in China &#8212; Uncertainties arising from the legal system in China, including
uncertainties regarding the interpretation and enforcement of PRC laws and the possibility that regulations and rules can change
quickly with little advance notice, could hinder our ability to offer or continue to offer the ordinary shares, result in a material
adverse change to our business operations, and damage our reputation, which would materially and adversely affect our financial
condition and results of operations and cause the ordinary shares to significantly decline in value or become
worthless.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this annual report, we and our
subsidiaries have not been involved in any investigations on cybersecurity review initiated by any PRC regulatory authority, nor have
any of them received any inquiry, notice, or sanction. As advised by our PRC counsel, AllBright Law Offices (Fuzhou), we are not subject
to cybersecurity review by the Cyberspace Administration of China, or the CAC, since we currently do not possess any personal information
of users in our business operations. It is unlikely for us to have over one million users&#8217; personal information and we do not anticipate
that we will be collecting over one million users&#8217; personal information in the foreseeable future, which we understand might otherwise
subject us to the Cybersecurity Review Measures. Pursuant to the Regulations on Network Data Security Administration (the &#8220;Data
Security Administration&#8221;) which became effective on January 1, 2025, we are not subject to network data security review by the government
authorities, because we currently do not have over one million users&#8217; personal information, we do not collect data that affect or
may affect national security and we do not anticipate that we will be collecting over one million users&#8217; personal information or
data that affect or may affect national security in the foreseeable future, which we understand might otherwise subject us to the Data
Security Administration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">On
February 17, 2023, the China Securities Regulatory Commission (the &#8220;CSRC&#8221;) issued the Trial Administrative Measures of
Overseas Securities Offering and Listing by Domestic Enterprises (the &#8220;Trial Measures&#8221;) and five supporting guidelines
(collectively, the &#8220;Overseas Listings Rules&#8221;), which became effective on March 31, 2023. These rules propose to
establish a new filing-based regime to regulate overseas offerings and listings by Chinese domestic companies. Under the Overseas
Listings Rules, Chinese domestic companies conducting overseas securities offering and listing activities, either in direct or
indirect form, shall complete filing procedures with the CSRC pursuant to the requirements of the Trial Measures within three
working days following its submission of initial public offering or listing application. Since the date of effectiveness of the
Trial Measures, the domestic enterprises otherwise subject to filing that have been listed overseas or met the following
circumstances are considered existing enterprises: the application of such enterprises for indirect overseas securities issuance and
listing has been approved by the applicable overseas regulators or overseas stock exchanges (e.g., an applicable registration
statement has been declared effective by the </span>U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;)<span style="background-color: white">)
before the effectiveness of the Trial Measures, and are not required to re-perform issuance and listing supervision procedures with
the overseas regulators or overseas stock exchanges, and the overseas issuance and listing of such enterprises have been completed
by September 30, 2023. Existing enterprises are not required to file immediately, and filing should be made as required if they
conduct refinancing activities or other matters requiring filings in the future. In the opinion of our PRC legal counsel, AllBright
Law Offices (Fuzhou), as a domestic company listed on Nasdaq since March 2021, and not currently conducting refinancing or other
activities that require filings, we are not required to file with the CSRC in accordance with the Trial Measures at this time.
However, in the event that we </span>conduct subsequent offerings, we could be subject to filing requirements with the CSRC. In the
event that filings with the CSRC are required, we cannot assure you that we can complete the filing procedures, obtain the approvals
or complete other compliance procedures in a timely manner, or at all, or that any completion of filing or approval or other
compliance procedures would not be rescinded. Any such failure would subject us to sanctions by the CSRC or other PRC regulatory
authorities. These regulatory authorities may impose restrictions and penalties on the operations in China, significantly limit or
completely hinder our ability to launch any new offering of our securities, limit our ability to pay dividends outside of China,
delay or restrict the repatriation of the proceeds from future capital raising activities into China, or take other actions that
could materially and adversely affect our business, results of operations, financial condition and prospects, as well as the trading
price of our ordinary shares. Furthermore, the PRC government authorities may further strengthen oversight and control over listings
and offerings that are conducted overseas. Any such action may adversely affect our operations and significantly limit or completely
hinder our ability to offer or continue to offer securities to you and cause the value of such securities to significantly decline
or be worthless. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See &#8220;Item 3. Key
Information&#8212;Risk Factors&#8212;Risks Relating to Doing Business in China&#8212; The approval and/or other requirements of the
China Securities Regulatory Commission, or the CSRC, or other PRC governmental authorities may be required in connection with an
offering under PRC rules, regulations or policies, and, if required, we cannot predict whether or how soon we will be able to obtain
such approval.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we do not receive or maintain any required
approvals, or we inadvertently conclude that such approvals are not required, or applicable laws, regulations, or interpretations change
such that we are required to obtain approval in the future, we may be subject to an investigation by competent regulators, fines or penalties,
ordered to suspend our relevant business and rectify, prohibited from engaging in relevant business, or subject to an order prohibiting
us from conducting an offering, and these risks could result in a material adverse change in our operations, significantly limit or completely
hinder our ability to continue to offer securities to investors, or cause such securities to significantly decline in value or become
worthless. See &#8220;Item 3. Key Information&#8212;Risk Factors&#8212;Risks Relating to Doing Business in China&#8212;Failure to comply
with cybersecurity, data privacy, data protection, or any other laws and regulations related to data may materially and adversely affect
our business, financial condition, and results of operations.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, trading in our securities may be prohibited under the
Holding Foreign Companies Accountable Act if the PCAOB determines that it cannot inspect the workpapers prepared by our auditor, and that
as a result an exchange may determine to delist our securities. On June 22, 2021, the U.S. Senate passed the Accelerating Holding Foreign
Companies Accountable Act, which, if passed by the U.S. House of Representatives and signed into law, would reduce the period of time
for foreign companies to comply with PCAOB audits to two consecutive years instead of three, thus reducing the time period for triggering
the prohibition on trading. On December 16, 2021, the PCAOB issued a report on its determination that it is unable to inspect or investigate
completely PCAOB-registered public accounting firms headquartered in China and in Hong Kong because of positions taken by PRC and Hong
Kong authorities in those jurisdictions. Our current auditor, Enrome LLP, and our former auditor, YCM CPA INC., the independent registered
public accounting firms that issue the audit reports included elsewhere in this annual report, as auditors of companies that are traded
publicly in the U.S.&#160;and firms registered with the PCAOB, are subject to laws in the U.S., pursuant to which the PCAOB conducts regular
inspections to assess their compliance with the applicable professional standards. Our auditor, Enrome LLP, is headquartered in Singapore,
and subject to inspect by the PCAOB on a regular basis, and our former auditor, YCM CPA INC., is headquartered in California, has been
inspected by the PCAOB. Both our auditor and former auditor are not subject to the determination issued by the PCAOB on December 16, 2021.
On August 26, 2022, the CSRC, the Ministry of Finance of the PRC, and the PCAOB signed a Statement of Protocol (the &#8220;Protocol&#8221;),
governing inspections and investigations of audit firms based in China and Hong Kong. The Protocol remains unpublished and is subject
to further explanation and implementation. Pursuant to the fact sheet with respect to the Protocol disclosed by the SEC, the PCAOB shall
have independent discretion to select any issuer audits for inspection or investigation and has the unfettered ability to transfer information
to the SEC. On December 15, 2022, the PCAOB Board determined that the PCAOB was able to secure complete access to inspect and investigate
registered public accounting firms headquartered in mainland China and Hong Kong and voted to vacate its previous determinations to the
contrary. However, should PRC authorities obstruct or otherwise fail to facilitate the PCAOB&#8217;s access in the future, the PCAOB Board
will consider the need to issue a new determination. See &#8220;Item 3. Key Information &#8212; D. Risk Factors &#8212;&#160;Risks Related
to Doing Business in China &#8212; Our ordinary shares may be delisted or prohibited from being traded over-the-counter under the Holding
Foreign Companies Accountable Act, if the PCAOB is unable to inspect our auditors. The delisting or the cessation of trading of our ordinary
shares, or the threat of their being delisted or prohibited from being traded, may materially and adversely affect the value of your investment.
Additionally, the inability of the PCAOB to conduct inspections would deprive our investors with the benefits of such inspections. Our
auditor has not been inspected by the PCAOB, but according to our auditor, it will be inspected by the PCAOB on a regular basis.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Cayman Islands holding company has not declared
or paid dividends or made any distributions to our shareholders in the past, nor were any dividends or distributions made by a subsidiary
to the Cayman Islands holding company. Our board of directors has complete discretion on whether to distribute dividends, subject to applicable
laws. We intend to keep any future earnings to finance the expansion of our business, and we do not have any current plan to declare or
pay any cash dividends on our ordinary shares in the foreseeable future. See &#8220;Item 3. Key Information &#8212; D. Risk Factors &#8212;
Risks Related to Our Ordinary Shares&#8212;We currently do not expect to pay dividends on our ordinary shares in the foreseeable future.&#8221;
If we determine to pay dividends on any of our ordinary shares in the future, as a holding company, we will rely on payments from subsidiaries
of Jiangxi Universe to Jiangxi Universe, and from Jiangxi Universe to Universe Technology, and the distribution of such payments to Universe
HK, and then to our Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to certain contractual, legal and regulatory
restrictions, and our internal cash management policy, cash and capital contributions may be transferred among our Cayman Islands holding
company and our subsidiaries. If needed, our Cayman Islands holding company can transfer cash to our PRC subsidiaries through loans and/or
capital contributions, and our PRC subsidiaries can transfer cash to our Cayman Islands holding company through issuing dividends or other
distributions. Our finance department supervises cash management, following the instructions of our management. Our finance department
is responsible for establishing our cash operation plan and coordinating cash management matters among our subsidiaries and departments.
Each subsidiary and department initiate a cash request by putting forward a cash demand plan, which explains the specific amount and timing
of cash requested, and submitting it to our finance department. The finance department reviews the cash demand plan and prepares a summary
for the management of our Company. Management examines and approves the allocation of cash based on the sources of cash and the priorities
of the needs. Other than the above, we currently do not have other cash management policies or procedures that dictate how funds are transferred.
Cash flows have occurred between our Cayman Islands holding company and our subsidiaries. From October 1, 2024 to the date of this annual
report, the Cayman Islands holding company did not receive cash transfer from its subsidiaries. For the <span style="background-color: white">fiscal
</span>year ended September 30, 2024, 2023 and 2022, the Cayman Islands holding company received cash in the amount of $100,062, $127,827
and $303,746 from its subsidiary in Hong Kong for the payment of directors&#8217; compensation and professional service fees, respectively.
There was no distribution of earnings by our PRC subsidiaries to the Cayman Islands holding company during the <span style="background-color: white">fiscal
</span>years ended September 30, 2022, 2023 and 2024, and from October 1, 2024 to the date of this annual report. In the <span style="background-color: white">fiscal
</span>years ended September 30, 2022, 2023 and 2024, there was no cash transferred from the Cayman Islands holding company to its PRC
subsidiaries. From October 1, 2024 to the date of this annual report, there was no cash transferred from the Cayman Islands holding company
to its PRC subsidiaries. See also &#8220;Item 8. Financial Information&#8212;A. Consolidated Statements and Other Financial Information&#8212;Dividend
Policy&#8221; and our audited consolidated financial statements for the fiscal years ended September&#160;30, 2024, 2023, and 2022.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash transfers from our Cayman Islands holding
company are subject to applicable PRC laws and regulations on loans and direct investment. We may rely on dividends from our subsidiaries
in China for our cash requirements, including any payment of dividends to our shareholders. PRC regulations may restrict the ability of
our PRC subsidiaries to pay dividends to us, and as a holding company, we will be dependent on receipt of funds from our Hong Kong subsidiary,
Universe HK.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Current PRC regulations permit our indirect
PRC subsidiaries to pay dividends to Universe HK only out of their respective accumulated profits, if any, determined in accordance
with Chinese accounting standards and regulations. In addition, each of our subsidiaries in China is required to set aside at least
10% of its after-tax profits each year, if any, to fund a statutory reserve until such reserve reaches 50% of its registered
capital. Each of such entity in China is also required to further set aside a portion of its after-tax profits to fund the employee
welfare fund, although the amount to be set aside, if any, is determined at the discretion of its board of directors. Although the
statutory reserves can be used, among other ways, to increase the registered capital and eliminate future losses in excess of
retained earnings of the respective companies, the reserve funds are not distributable as cash dividends except in the event of
liquidation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The PRC government also imposes controls on the
conversion of RMB into foreign currencies and the remittance of currencies out of the PRC. Therefore, we may experience difficulties in
complying with the administrative requirements necessary to obtain and remit foreign currency for the payment of dividends from our profits,
if any. Furthermore, if our subsidiaries and affiliates in the PRC incur debt on their own in the future, the instruments governing the
debt may restrict their ability to pay dividends or make other payments. If we or our subsidiaries are unable to receive all of the revenue
from our operations, we may be unable to pay dividends on our ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash dividends, if any, on our ordinary shares
will be paid in U.S. dollars. Universe HK may be considered a non-resident enterprise for tax purposes, so that any dividends our PRC
subsidiaries pay to Universe HK may be regarded as China-sourced income and as a result may be subject to PRC withholding tax at a rate
of up to 10%. See &#8220;Item 10. Additional Information&#8212;E. Taxation&#8212;People&#8217;s Republic of China Taxation.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order for us to pay dividends to our shareholders,
we will rely on payments made from Universe Technology&#8217;s subsidiary, Jiangxi Universe, to Universe Technology and from Universe
Technology to Universe HK and then to our Company. According to the Enterprise Income Tax Law, or the EIT Law, such payments from subsidiaries
to parent companies in China are subject to the PRC enterprise income tax at a rate of 25%. In addition, if Jiangxi Universe or its subsidiary
or branches incur debt on their own behalf in the future, the instruments governing the debt may restrict its ability to pay dividends
or make other distributions to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Double Tax Avoidance
Arrangement, the 10% withholding tax rate may be lowered to 5% if a Hong Kong resident enterprise owns no less than 25% of a PRC
project. The 5% withholding tax rate, however, does not automatically apply and certain requirements must be satisfied, including
without limitation that (a) the Hong Kong project must be the beneficial owner of the relevant dividends; and (b) the Hong Kong
project must directly hold no less than 25% share ownership in the PRC project during the 12 consecutive months preceding its
receipt of the dividends. In current practice, a Hong Kong project must obtain a tax resident certificate from the Hong Kong tax
authority to apply for the 5% lower PRC withholding tax rate. As the Hong Kong tax authority will issue such a tax resident
certificate on a case-by-case basis, we cannot assure you that we will be able to obtain the tax resident certificate from the
relevant Hong Kong tax authority and enjoy the preferential withholding tax rate of 5% under the Double Taxation Arrangement with
respect to any dividends paid by our PRC subsidiaries to its immediate holding company, Universe HK. As of the date of this annual
report, we have not applied for the tax resident certificate from the relevant Hong Kong tax authority. Universe HK intends to apply
for the tax resident certificate if and when Universe Technology plans to declare and pay dividends to Universe HK. See &#8220;Item
3. Key Information&#8212;D. Risk Factors&#8212; There are significant uncertainties under the EIT Law, relating to the withholding
tax liabilities of our PRC subsidiaries, and dividends payable by our PRC subsidiaries to our offshore subsidiaries may not qualify
to enjoy certain treaty benefits.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent cash is located in the PRC or within
a PRC domiciled entity and may need to be used to fund operations outside of the PRC, the funds may not be available due to limitations
placed on us and our subsidiaries by the PRC government. To the extent cash in and assets of the business is in the PRC or a PRC entity,
the funds and assets may not be available to fund operations or for other use outside of the PRC due to interventions in or the imposition
of restrictions and limitations on the ability of us or our subsidiaries by the PRC government to transfer cash and assets. See &#8220;Item
3. Key Information&#8212;D. Risk Factors&#160;&#8212;&#160;Risks Related to Doing Business in China&#160;&#8212; To the extent cash and
assets of in the business is in the PRC or a PRC entity, the funds may not be available to fund operations or for other use outside of
the PRC due to interventions in or the imposition of restrictions and limitations on the ability of our Company or our subsidiaries by
the PRC government to transfer cash and assets.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. <span style="text-decoration:underline">[Reserved]</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. <span style="text-decoration:underline">Capitalization and Indebtedness</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C. <span style="text-decoration:underline">Reasons for the Offer and Use of Proceeds</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>D. <span style="text-decoration:underline">Risk Factors</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Summary of Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investing in our securities involves significant
risks. You should carefully consider all of the information in this annual report before investing in our securities. Below is a summary
of the principal risks we face. These risks are discussed more fully under &#8220;Item 3. Key Information&#8212;D. Risk Factors.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks Related to Our Business and Industry
(for a more detailed discussion, see &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212;Risks Related to Our Business and Industry&#8221;)</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risks and uncertainties related to our business
include, but are not limited to, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">price increases in raw materials and sourced products could harm our financial results;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">high quality materials for our products may be difficult to obtain or substantially increase our production costs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are exposed to a number of risks related to our supply chain for the materials required to manufacture our products which could adversely affect our business operations and future development;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we operate in a highly competitive industry. Our failure to compete effectively could adversely affect our market share, revenues and growth prospects;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">high quality materials for our products may be difficult to obtain or substantially increase our production costs;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our future success depends in part on our ability to increase our production capacity, and we may not able to do so in a cost-effective manner. We have engaged a third-party sub-contractor to build manufacturing facilities and an office building for us, and we may encounter challenges relating to the construction, management and operation of such facilities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are subject to evolving regulatory requirements, non-compliance with which, or changes in which, may adversely affect our business and prospects; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if we fail to maintain or renew requisite licenses, permits, registrations and filings applicable to our business operations, or fail to obtain additional licenses, permits, registrations or filings that become necessary as a result of new enactment or promulgation of government policies, laws or regulations or the expansion of our business, our business and results of operations may be materially and adversely affected.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>


</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks Related to Doing Business in China
(for a more detailed discussion, see &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212;Risks Related to Doing Business in China&#8221;)</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We face risks and uncertainties relating to doing
business in the PRC in general, including, but not limited to, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the PRC government has significant authority to intervene or influence the China operations of an offshore holding company, such as ours, at any time. The PRC government may exert more control over offerings conducted overseas and/or foreign investment in China-based issuers. If the PRC government exerts more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers and we were to be subject to such oversight and control, it may result in a material adverse change to our business operations, significantly limit or completely hinder our ability to offer or continue to offer securities to investors, and cause the ordinary shares to significantly decline in value or become worthless;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">uncertainties arising from the legal system in China, including uncertainties regarding the interpretation and enforcement of PRC laws and the possibility that regulations and rules can change quickly with little advance notice, could hinder our ability to offer or continue to offer the ordinary shares, result in a material adverse change to our business operations, and damage our reputation, which would materially and adversely affect our financial condition and results of operations and cause the ordinary shares to significantly decline in value or become worthless;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ordinary shares may be delisted or prohibited from being traded over-the-counter under the Holding Foreign Companies Accountable Act, if the PCAOB is unable to inspect our auditors. The delisting or the cessation of trading of our ordinary shares, or the threat of their being delisted or prohibited from being traded, may materially and adversely affect the value of your investment. Additionally, the inability of the PCAOB to conduct inspections would deprive our investors with the benefits of such inspections. Our auditor has not been inspected by the PCAOB, but according to our auditor, it will be inspected by the PCAOB on a regular basis;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to comply with cybersecurity, data privacy, data protection, or any other laws and regulations related to data may materially and adversely affect our business, financial condition, and results of operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the approval and/or other requirements of the CSRC or other PRC governmental authorities may be required in connection with an offering under PRC rules, regulations or policies, and, if required, we cannot predict whether or how soon we will be able to obtain such approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC regulation of loans to, and direct investments in, PRC entities by offshore holding companies may delay or prevent us from using proceeds from our offerings and/or other financing activities to make loans or additional capital contributions to our PRC operating subsidiaries;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse changes in political, economic and social conditions, as well as government policies in China could have a material adverse effect on our business results of operations, financial conditions and prospects;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes to the PRC legal system could have an adverse effect on us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b>&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recent greater oversight by the Cyberspace Administration of China over data security, particularly for companies seeking to list on a foreign exchange, could adversely impact our business and our offering. See &#8220;Risk Factors&#8212;Risks Related to Doing Business in China&#8212;Recent greater oversight by the Cyberspace Administration of China over data security, particularly for companies seeking to list on a foreign exchange, could adversely impact our business and our offering&#8221;; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to the extent cash and assets of in the business is in the PRC or a PRC entity, the funds may not be available to fund operations or for other use outside of the PRC due to interventions in or the imposition of restrictions and limitations on the ability of our Company or our subsidiaries by the PRC government to transfer cash and assets. See &#8220;Risk Factors&#8212;Risks Related to Doing Business in China&#8212;To the extent cash and assets of in the business is in the PRC or a PRC entity, the funds may not be available to fund operations or for other use outside of the PRC due to interventions in or the imposition of restrictions and limitations on the ability of our Company or our subsidiaries by the PRC government to transfer cash and assets.&#8221;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks Relating to Our Ordinary Shares and
the Trading Market (for a more detailed discussion, see &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212;Risks Relating to Our
Ordinary Shares&#8221;)</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the risks described above, we are
subject to general risks and uncertainties relating to our ordinary shares and the trading market, including, but not limited to, the
following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our share price has recently declined substantially, and our ordinary shares could be delisted from the Nasdaq or trading could be suspended;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may issue additional ordinary shares or other equity securities without your approval, which would dilute your ownership interests and may depress the market price of our ordinary shares;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as a foreign private issuer, we are not subject to certain U.S. securities law disclosure requirements that apply to a domestic U.S. issuer, which may limit the information publicly available to our shareholders; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as a foreign private issuer, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from the Nasdaq listing standards. These practices may afford less protection to shareholders than they would enjoy if we complied fully with corporate governance listing standards.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Business and Industry</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Price increases in raw materials and sourced
products could harm our financial results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal raw materials include angelica,
codonopsis, poria mushroom isatis root, ginseng, and other herbs and plant extracts. These raw materials are subject to price volatility
and inflationary pressures. Our success is dependent, in part, on our ability to reduce our exposure to increases in such costs through
a variety of ways, while maintaining and improving margins and market share. The manufacturers of such raw materials are also subject
to price volatility and labor cost and other inflationary pressures, which may in turn result in an increase in the amount we pay for
sourced products. Raw materials and sourced product price increases may offset our productivity gains and price increases and may adversely
impact our financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>High quality materials for our products
may be difficult to obtain or substantially increase our production costs.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Raw materials account for a portion of our
manufacturing costs and we rely on third-party suppliers to provide almost all raw materials. Suppliers may be unable or unwilling
to provide the raw materials we need in the quantities requested, at prices we are willing to pay, or that meet our quality
standards. We are also subject to potential delays in the delivery of raw materials caused by events beyond our control, including
transportation interruptions, delivery delays, labor disputes, other supply chain issues, and changes in government regulations. See <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">also
&#8220;&#8212;We are exposed to a number of risks related to our supply chain for the materials required to manufacture our
products&#8221; for details. Our business could be adversely affected if we are unable to obtain reliable sources of the raw
materials used in the manufacturing of our products that meet our quality standards. Any significant delay in or disruption of the
supply of raw materials could, among other things, substantially increase the cost of such materials, require reformulation or
repackaging of products, require the qualification of new suppliers, or result in our inability to meet customer demands, which
could in turn adversely affect our financial results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are exposed to a number of risks related
to our supply chain for the materials required to manufacture our products which could adversely affect our business operations and future
development.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on third-party suppliers to provide almost
all raw materials, and manufacturing our products is highly complex and requires sourcing specialty materials or materials with quality
standards. Many of the risks associated with the complexity of manufacturing our products are applicable to the manufacture and supply
of the raw materials. Minor deviations in the manufacturing process for these raw materials could result in supply disruption and reduced
production yields for our products, which is beyond our control. In addition, we rely on third parties for the supply of these materials
exposing us to similar risks of reliance on third parties for final products. See &#8220;&#8212;We face risks related to our sales of
products obtained from third-party suppliers&#8221; for further details.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our manufacturing processes requires many equipment
and raw materials such as medicinal plants. We established supplier qualification procedures to verify the operation conditions, production
capabilities, credit-worthiness and quality standard of potential suppliers, in order to procure quality raw materials in a timely manner.
Although we are not relying on a single supplier for any of our raw materials, we may in the future rely on sole source vendors or a limited
number of vendors for some of our equipment and materials. We currently depend on a limited number of suppliers for certain materials
and equipment used in the manufacture of our products. Some of these suppliers are small companies with limited resources and experience
to support commercial production and may be&#160;ill-equipped&#160;to support our needs from time to time. Accordingly, we may experience
delays in receiving key materials and equipment to support manufacturing. An inability to continue to source product from any of these
suppliers, which could be due to regulatory actions or requirements affecting the supplier, adverse financial or other strategic developments
experienced by a supplier, labor disputes or shortages, unexpected demands, or quality issues, could adversely affect our ability to satisfy
demand for our products, which could adversely and materially affect our product sales and operating results or our ability to conduct
clinical trials, either of which could significantly harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we continue to develop and scale our manufacturing
process, we expect that we will need to obtain supplies of certain raw materials and equipment to be used as part of that process. We
may not be able to obtain rights to such materials on commercially reasonable terms, or at all, and if we are unable to alter our process
in a commercially viable manner to avoid the use of such materials or find a suitable substitute, it would have a material adverse effect
on our business. Even if we are able to alter our process so as to use other materials or equipment, such a change may lead to a delay
in our clinical development and/or commercialization plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We operate in a highly competitive industry.
Our failure to compete effectively could adversely affect our market share, revenues and growth prospects</i></b><i>.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Chinese patent medicine industry in the PRC
is subject to significant competition and pricing pressures. We will experience significant competitive pricing pressures as well as competitive
products. Several significant competitors may offer products at the same or lower prices than our products. The market is highly sensitive
to the introduction of new products, which may rapidly capture a significant share of the market. It is possible that one or more of our
competitors could develop a significant research advantage over us that allows them to provide superior products that are more attractive
to consumers, which could put us in a competitive disadvantage. Continued pricing pressure or improvements in research and shifts in customer
preference could adversely impact our customer base or pricing structure and have a material and adverse effect on our business, financial
conditions, results of operations and cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to maintain or enhance our brands
or image could have a material adverse effect on our business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe several of our brands, such as &#8220;Bai
Nian Dan (&#30334;&#24180;&#20025;)&#8221;, &#8220;Hu Zhuo Ren (&#32993;&#21331;&#20161;)&#8221; and &#8220;Long Zhong (&#40857;&#31181;)&#8221;,
are well-recognized among our clients and other Chinese patent medicine industry players. Our brand is integral to our sales and marketing
efforts. Our continued success in maintaining and enhancing our brand and image depends to a large extent on our ability to satisfy customer
needs by further developing effective and better-quality products, as well as our ability to respond to competitive pressures. If we are
unable to satisfy customer needs or if our public image or reputation were otherwise diminished, our business transactions with our customers
may decline, which could in turn adversely affect our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our failure to appropriately respond to
changing consumer preferences and demand for new products could significantly harm our customer relationships and product sales.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business is particularly subject to changing
consumer trends and preferences. Our continued success depends in part on our ability to anticipate and respond to these changes, and
we may not be able to respond in a timely or commercially appropriate manner to these changes. If we are unable to do so, our customer
relationships and product sales could be harmed significantly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, the Chinese patent medicine industry
is characterized by rapid and frequent changes in demand and new product introductions. Our failure to accurately depict these trends
could negatively impact consumer opinion of our stores as a source for latest products. This could harm our customer relationships and
cause losses to our market share. The success of our new product offerings depends upon a number of factors, including our ability to:
accurately anticipate customer needs; innovate and develop new products; successfully commercialize new products in a timely manner; price
our products competitively; manufacture and deliver our products in sufficient volumes and in a timely manner; and differentiate our product
offerings from those our competitors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we do not introduce new products or make enhancements
to meet the changing needs of our customers in a timely manner, some of our products could become obsolete, which could have a material
adverse effect on our revenues and operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If our products do not have the effects
intended or cause undesirable side effects, our business may suffer</i>.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many of the ingredients in our current products
have a long history of human consumption, and although we believe that all of these products and the combinations of ingredients in them
are safe when taken as directed, the products could have certain undesirable side effects if not taken as directed or if taken by a consumer
who has certain medical conditions. In addition, these products may not have the effect intended if they are not taken in accordance with
instructions, which may include dietary restrictions. Furthermore, there can be no assurance that any of these products, even when used
as directed, will have the effects intended or will not have harmful side effects in an unforeseen way or on an unforeseen cohort. If
any of our products or products we develop or commercialize in the future are shown to be harmful or generate negative publicity from
perceived harmful effects, our business, financial condition, results of operations, and prospects could be harmed significantly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have made substantial investment in advertising
our products in order to improve our brand awareness and our market position, which efforts may not be successful, and in such event,
our financial position and results of operations may be materially and negatively affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have made substantial investment in advertising
our products in order to improve our brand awareness and our market position. In the fiscal year ended September 30, 2022, we entered
into an advertising service agreement with a third-party, Health Headline Technology Co., Ltd. (&#8220;Health Headline&#8221;), pursuant
to which, Health Headline provided media advertising services to promote our brand on the Health Headline website and mobile app, with
a service period of ten months from March 1, 2022 to December 31, 2022. For the fiscal year ended September 30, 2023, we renewed the advertising
services arrangement with Health Headline by entering a new service agreement with Health Headline with a service period of ten months
from March 1, 2023 to December 31, 2023. For the fiscal year ended September 30, 2024, we renewed the advertising services arrangement
with Health Headline by entering into a new service agreement with Health Headline with a service period of ten months from March 1, 2024
to December 31, 2024. In addition, we incurred substantial advertising expenditures to maintain and enhance our brand and
our products, which may not prove successful. Television advertising and other brand promotion activities may not generate customer awareness
or increase revenue, and even if they do, any increase in revenue may not offset the expenses we incur in building our brand. Additionally,
there could be a negative reaction to certain advertising campaigns. If we fail to promote our brand, or if we incur excessive expenses
in this effort, we may fail to attract or retain customers necessary to realize a sufficient return on our brand-building efforts or to
achieve the desired brand awareness that is critical for our success.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our future success depends in part on our
ability to increase our production capacity, and we may not able to do so in a cost-effective manner. We have engaged a third-party sub-contractor
to build manufacturing facilities and an office building for us, and we may encounter challenges relating to the construction, management
and operation of such facilities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent we are successful in growing
our business, we may need to increase our production capacity. We entered into a construction agreement with a sub-contractor, who
will construct four manufacturing factories and an office building for us, with a total maximum budget of approximately RMB165
million (US$23.5 million). The construction started on August 8, 2021, with an originally estimated completion date on August 7,
2023. However, due to resurgence in the number of COVID cases, which resulted in logistic disruptions, material and labor shortage,
and domestic travel restriction. At the beginning of 2024, the Company had estimated the construction work to be completed in
December 2024. During 2024, new information was discovered about the topographical and surface structures of the land, which
required Chenyuan to redo the geological survey. As a result, the construction work <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">has
been further delayed, and the construction of the four manufacturing factory buildings and the office building is expected to be
fully completed and put into use by December 2025 and December 2026, respectively. Our ability to construct such additional
facilities is subject to risks and uncertainties. The construction of any new facilities will be subject to risks inherent in the
development and construction, including risks of delays and cost overruns as a result of factors outside of our control, which may
include delays in government approvals, burdensome permitting conditions, and delays in the delivery of manufacturing equipment or
raw materials required for the construction. Additionally, we also depend on the third-party sub-contractor for the development of
new facilities, and as such, we are subject to the risk that such third parties do not fulfill their obligations to us under the
contraction agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the sub-contractor is unable to deliver the
new facilities to us on time, or if we are unable to expand our manufacturing facilities in general, we may be unable to further scale
our business, which would negatively affect our results of operations and financial condition. If we are unable to transition manufacturing
operations to such new facilities in a cost-efficient and timely manner, then we may experience disruptions in operations, which could
negatively impact our business and financial results. Further, if the demand for our products decreases or if we do not produce the expected
output after any such new facilities are operational, we may not be able to spread a significant amount of our fixed costs over the production
volume, thereby increasing our per product fixed cost, which would have a negative impact on our business, financial condition and results
of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are subject to evolving regulatory requirements,
non-compliance with which, or changes in which, may adversely affect our business and prospects.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a manufacturer of products designed for human
consumption, we are subject to legal and regulatory requirements applicable to the Chinese patent medicine industry in the PRC. We have
been subject to penalties by PRC regulatory authorities in the past due to our failure to comply with their requirements, including noncompliance
with the Good Manufacturing Practice for Drugs and the National Drug Standard.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The regulations to which we are subject in this
area are evolving. As a result, the interpretation of these laws and their enforcement is often uncertain. Predicting the application
of these laws can be difficult, and unexpected outcomes in the interpretation and enforcement of the applicable regulations may have an
adverse impact on our business and operations. Additionally, any future changes in regulations may render our business non-compliant or
require changes to our business practices or licensing arrangements to ensure compliance. These changes may involve significant costs,
which in turn may adversely affect our business and financial prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Various regulatory authorities of the PRC government
regulate the manufacturing and trading of Chinese patent medicine. Violations of regulations may lead to the imposition of significant
penalties which may affect our business, operations, reputation and financial prospects. See &#8220;Item 4. Information on the Company&#8212;B.
Business Overview&#8212;Regulations&#8221; for details.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we introduce new products to our customers,
we may be required to comply with additional laws and regulations that are yet to be determined. To comply with such additional laws and
regulations, we may be required to obtain necessary certificates, licenses or permits, as well as expend additional resources to monitor
regulatory and policy developments. Our failure to adequately comply with such additional laws and regulations may delay, or possibly
prevent, some of our products from being offered to customers, which may have a material adverse effect on our business, financial condition
and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to maintain or renew requisite
licenses, permits, registrations and filings applicable to our business operations, or fail to obtain additional licenses, permits, registrations
or filings that become necessary as a result of new enactment or promulgation of government policies, laws or regulations or the expansion
of our business, our business and results of operations may be materially and adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Chinese patent medicine industry in China
is highly regulated, and multiple licenses, permits, filings and approvals are required to operate our business. Currently, through our
PRC subsidiaries, we have obtained a valid pharmaceutical manufacturing license, a medical device selling license, and a pharmaceutical
trade license. We have made efforts to obtain all applicable approvals, licenses and permits, but due to the complexities, uncertainties
and frequent changes in laws, rules, regulations and their interpretation and implementation, we may not always be able to do so, and
we may be penalized by governmental authorities for conducting pharmaceutical manufacturing or sales activities without proper approvals,
licenses or permits. Moreover, as we continue to increase our product variety, we may also become subject to new or existing laws and
regulations that did not affect us in the past. Failure to obtain, renew or retain requisite licenses, permits or approvals may adversely
affect our ability to conduct or expand our business, and may have a material adverse impact on our business prospects, results of operations
and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business is subject to inherent risks
relating to product liability and personal injury claims.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a manufacturer of products designed for human
consumption, we are subject to product liability claims if the use of our products is alleged to have resulted in injury. For instance,
adverse reactions resulting from human consumption of the ingredients contained in our products could occur. We may also be obligated
to recall affected products. If we are found liable for product liability claims, we could be required to pay substantial monetary damages.
Furthermore, even if we successfully defend ourselves against this type of claim, we could be required to spend significant management,
financial and other resources, which could disrupt our business, and our reputation as well as our brand name may also suffer. We, like
many other similar companies in China, do not carry product liability insurance. As a result, any imposition of product liability could
materially harm our business, financial condition and results of operations. In addition, we do not have any business interruption insurance,
due to the limited coverage of any available business interruption insurance in China, and as a result, any business disruption or natural
disaster could severely disrupt our business and operations and significantly decrease our revenue and profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be successful in expanding a
distribution network.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we intend to expand our distribution
network to include additional cities and rural areas in the PRC in an effort to increase our geographic presence, our distribution, logistics
and products may encounter competition from various similar or substitutive businesses. Therefore, the success of expansion will depend
upon many factors, including our ability to form relationships with, and manage an increasing number of, customers base and optimize our
distribution network. If we fail to expand our distribution network as planned, our business, financial condition and results of operations
may be materially and adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The COVID-19 pandemic has been and could
continue to materially and adversely affect our business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business operations have been affected and
may continue to be affected by the COVID-19 pandemic. Although on December 9, 2022, China announced that it was officially moving towards
reopening and gradually lifting travel restrictions, after nearly three years of adhering to its dynamic zero-COVID policy, the COVID-19
pandemic continues to threaten global economies and cause significant market volatility and declines in general economic activities of
China. In the fiscal year ended September 30, 2024, as affected by the economic downturn in China following the COVID-19 pandemic, we
saw a decrease in overall consumer spending and the demand for our products. In the fiscal year ended September 30, 2023, slowdown in
economy caused by the COVID-19 pandemic has led to a decline in customers&#8217; spending power, and we changed our pricing strategy to
decrease the per unit price of our TCMD products in an effort to increase sales volume and market share during this challenging period.
The average selling price of our TCMD products decreased by 50.0% in the fiscal year ended September 30, 2023 as compared to the fiscal
year ended September 30, 2022. In the fiscal year ended September 30, 2022, due to resurgence of COVID-19 pandemic in China and related
restrictive measures, including travel restrictions, the PRC operating entities experienced delays in the receipt of purchased raw materials
from suppliers and in delivering products to customers. The prices of the raw materials increased by about 5% as compared to the fiscal
year ended September 30, 2021. In addition, we granted some customers extended payment terms of 30 days to 120 days. However, based on
our present relationship with these customers and our evaluation of their financial conditions, we do not anticipate any material collectability
problems. The continued uncertainties associated with the COVID-19 pandemic worldwide may cause our revenue and cash flows to underperform
in the next 12 months from the date of this annual report. The extent of the future impact of the COVID-19 pandemic on our business and
the results of operations is still uncertain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are dependent on certain key personnel
and loss of these key personnel could have a material effect on our business, financial condition and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success is, to a certain extent,
attributable to the management, sales and marketing, and research and development expertise of key personnel. We are dependent upon
the services of Mr. Gang Lai, the chairman of our board of directors and our chief executive officer, for the continued growth and
operation of our Company, due to his industry experiences and management experiences. Although we have no reason to believe that Mr.
Gang Lai will discontinue his services with us, the interruption or loss of his services would adversely affect our ability to
effectively run our business and pursue our business strategy as well as our results of operation. We currently do not have
&#8220;key person&#8221; insurance on any of our executives or employees. There can be no assurance that we will be able to retain
our key personnel after the terms of their employment expire. The loss of the services of one or more of our key personnel could
have a material adverse effect upon our business, financial condition, and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not effectively manage our growth,
which could materially harm our business</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect that our business will grow in the long
run, which may place a significant strain on our management, personnel, systems and resources. We must continue to improve our operational
and financial systems and managerial controls and procedures, and we will need to continue to expand, train and manage our technology
and workforce. We must also maintain close coordination among our compliance, accounting, finance, marketing and sales organizations.
We cannot assure you that we will manage our growth effectively. If we fail to do so, our business could be materially harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our continued growth will require an increased
investment by us in technology, facilities, personnel and financial and management systems and controls. It also will require expansion
of our procedures for monitoring and assuring our compliance with applicable regulations, and we will need to integrate, train and manage
a growing employee base. The expansion of our existing businesses, any expansion into new businesses and the resulting growth of our employee
base will increase our need for internal audit and monitoring processes that are more extensive and broader in scope than those we have
historically acquired. We may not be successful in identifying or implementing all of the processes that are necessary. Further, unless
our growth results in an increase in our revenues that is proportionate to the increase in our costs associated with this growth, our
operating margins and profitability will be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to hire and retain qualified
personnel to support our growth and if we are unable to retain and hire these personnel in the future, our ability to improve our products
and implement our business objects could be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We must attract, recruit and retain a sizeable
workforce of technically competent employees. Competition for senior management and personnel in the PRC is intense and the pool of qualified
candidates in the PRC is very limited. We may not be able to retain the services of our senior executives or personnel, or attract and
retain high-quality senior executives or personnel in the future. This failure could materially and adversely affect our future growth
and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our success depends on our ability to protect
our intellectual property.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently own 65 patents and 98 trademarks
in China. We believe that our success depends on our ability to obtain and maintain patent protection for products developed utilizing
our technologies, in the PRC and in other countries, and to enforce these patents. There is no assurance that any of our existing and
future patents will be deemed to be valid and enforceable against third-party infringement or that our products will not infringe any
third-party patent or intellectual property by a court or administrative body having jurisdiction over such matters. Although we have
filed additional patent applications with Patent Administration Department of PRC, there is no assurance that they will be granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any patents relating to our technologies may not
be sufficiently broad to protect our products. In addition, our patents may be challenged, potentially invalidated or potentially circumvented.
Our patents may not afford us protection against competitors with similar technology or permit the commercialization of our products without
infringing third-party patents or other intellectual property rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also rely, or intend to rely, on our trademarks,
trade names and brand names to distinguish our products from the products of our competitors, and have registered or will apply to register
a number of these trademarks. However, third parties may oppose our trademark applications or otherwise challenge our use of the trademarks.
In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of
brand recognition and could require us to devote resources to advertising and marketing these new brands. Further, our competitors may
infringe our trademarks, or we may not have adequate resources to enforce our trademarks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we also have trade secrets, non-patented
proprietary expertise and continuing technological innovations that we expect to seek to protect, in part, by entering into confidentiality
agreements with licensees, suppliers, employees and consultants. These agreements may be breached and there may not be adequate remedies
in the event of a breach. Disputes may arise concerning the ownership of intellectual property or the applicability of confidentiality
agreements. Moreover, our trade secrets and proprietary technology may otherwise become known or be independently developed by our competitors.
If patents are not issued with respect to products arising from research, we may not be able to maintain the confidentiality of information
relating to these products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, the application and interpretation of
China&#8217;s intellectual property laws are still evolving and are uncertain. If we are found to have violated the intellectual property
rights of others, we may be subject to liability and penalty for our infringement activities or may be prohibited from using such intellectual
property, and we may incur licensing fees or be forced to develop alternatives of our own. In addition, we may incur significant expenses,
and may be forced to divert management&#8217;s time and other resources from our business and operations to defend against these infringement
claims, regardless of their merits. Successful infringement or licensing claims made against us may result in significant monetary liabilities
and may materially disrupt our reputation, business and operations by restricting or prohibiting our use of the intellectual property
at issue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Because we rely on our manufacturing operations
to produce a significant amount of the products we sell, disruptions in our manufacturing system or losses of manufacturing certifications
could adversely affect our sales and customer relationships.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our manufacturing operations produced approximately
60.9%, 57.5% and 59.8% of the total value of the products we sold for the fiscal year ended September&#160;30, 2024, 2023 and 2022, respectively.
Our products are produced in our manufacturing facility located in Jinggangshan, Jiangxi Province, China. For the <span style="background-color: white">fiscal</span>
year ended September 30, 2024, two suppliers accounted for 28.0% and 13.4% of our total purchases, respectively. For the <span style="background-color: white">fiscal
</span>years ended September 30, 2023 and 2022, one supplier accounted for 29.6% and 10.3% of our total purchases, respectively. No other
suppliers individually accounted for more than 10% of our total purchases in the fiscal years ended September 30, 2024, 2023 and 2022.
In the event any of our third-party suppliers or vendors becomes unable or unwilling to continue to provide raw materials in the required
volumes or quality levels or in a timely manner, we would be required to identify and obtain acceptable replacement supply sources. If
we are unable to identity and obtain alternative supply sources, our business could be adversely affected. Any significant disruption
in our operations at our manufacturing facility for any reason, including government-imposed regulatory requirements, the loss of certifications,
power interruptions, fires, war, or other force of nature, could disrupt our supply of products, adversely affecting our sales and customer
relationships.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face risks related to our sales of products
obtained from third-party suppliers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We sell a significant number of products that
are manufactured by third-party suppliers over which we have no direct control. While we have implemented processes and procedures to
try to ensure that the suppliers we use are complying with all applicable regulations, there can be no assurance that such suppliers in
all instances will comply with such processes and procedures or otherwise with applicable regulations. Noncompliance could result in our
marketing and distribution of contaminated or dangerous products which would subject us to liabilities and could result in the imposition
by government authorities of penalties that could restrict or eliminate our ability to purchase products. Any or all of these effects
could adversely affect our business, financial condition and results of operation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The growth of our business depends on our
ability to finance new product innovations and these increased costs may reduce our cash flows and, if the products in which we have invested
fail, it would reduce our profitability.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We operate in the Chinese patent medicine industry,
which is characterized by significant competition and rapid change. New products appear with increasing frequency to supplant existing
products. If we fail to adapt to those conditions in a timely and efficient manner, our revenues and profits would likely decline. To
remain competitive, we must continue to incur significant costs in product research and development, marketing, equipment and facilities
and to make capital investment. These costs may increase, resulting in greater fixed costs and operating expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the fiscal year ended September 30, 2024,
we incurred $3.0 million in research and development expenses, a 37.6% decrease compared to the expenses in the fiscal year ended
September 30, 2023. In the fiscal year ended September 30, 2023, we incurred $4.9 million research and development expenses, a 36.4%
decrease compared to the expenses in the fiscal year ended September 30, 2022. In the fiscal year ended September 30, 2022, we
incurred $7.6 million of research and development expenses, a 39.9% increase compared to the expenses in the fiscal year ended
September 30, 2021. In order to diversify our profit portfolio, a large portion of the research and development expenses in the
fiscal year ended September 30, 2022 was spent on developing and testing eight new products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our future operating results will depend to a
significant extent on our ability to continue to provide new products that compare favorably based on time to market, cost and performance
with the design and manufacturing capabilities and competing third-party suppliers and technologies. Furthermore, our research and development
efforts may not produce successful results, and our new products may not achieve market acceptance, create additional revenue for us,
or bring us profits. Our failure to increase our net sales sufficient to offset these increased costs would reduce our profitability and
may materially and adversely affect our business operations and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Future acquisitions may have an adverse
effect on our ability to manage our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may acquire businesses, technologies, services
or products which are complementary to our core business of manufacturing and selling TCMD products. Future acquisitions may expose us
to potential risks, including risks associated with: (i) the integration of new products, services and personnel; unforeseen or hidden
liabilities; (ii) the diversion of resources from our existing business; (iii) our potential inability to generate sufficient revenue
to offset new costs; the expenses of acquisitions; or (iv) the potential loss of or harm to relationships with both employees and advertising
clients resulting from our integration of new businesses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any of the potential risks listed above could
have a material and adverse effect on our ability to manage our business, our revenues and net income. We may need to raise additional
debt funding or sell additional equity securities to make such acquisitions. The raising of additional debt funding by us, if required,
would result in increased debt service obligations and could result in additional operating and financing covenants, or liens on our assets,
that could restrict our operations. The sale of additional equity securities could result in additional dilution to our shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Increase in labor costs in the PRC may adversely
affect our business and our profitability.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">China&#8217;s economy has experienced increases
in labor costs in recent years, and the average wage in China are expected to continue to grow. The average wage level for our employees
has also increased in recent years. We expect that our labor costs, including wages and employee benefits, will continue to increase as
we continue to grow our business. Unless we are able to pass on these increased labor costs to our customers by increasing prices for
our products or services, our profitability and results of operations may be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we have been subject to stricter
regulatory requirements in terms of entering into labor contracts with our employees and paying various statutory employee benefits,
including pensions, housing fund, medical insurance, work-related injury insurance, unemployment insurance and childbearing insurance
to designated government agencies for the benefit of our employees. Pursuant to the PRC Labor Contract Law (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#21171;&#21160;&#27861;&#12299;)
(the &#8220;Labor Contract Law&#8221;) that became effective in January 2008 and its implementing rules that became effective in September
2008 and its amendments that became effective in July 2013, employers are subject to stricter requirements in terms of signing labor
contracts, minimum wages, paying remuneration, determining the term of employees&#8217; probation and unilaterally terminating labor
contracts. In the event that we decide to terminate some of our employees or otherwise change our employment or labor practices, the
Labor Contract Law and its implementation rules may limit our ability to effect any such terminations or those changes in a desirable
or cost-effective manner, which could adversely affect our business and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this annual report, we believe
that we are in substantial compliance with labor-related laws and regulations in China, and we have not been notified of any instance
of noncompliance. As the interpretation and implementation of labor-related laws and regulations are still evolving, we cannot assure
you that our employment practice will not violate labor-related laws and regulations in China, which may subject us to labor disputes
or government investigations. If we are deemed to have violated relevant labor laws and regulations, we could be required to provide additional
compensation to our employees and our business, financial condition and results of operations could be materially and adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Natural disasters (whether or not caused
by climate change), unusually adverse weather conditions, pandemic outbreaks, terrorist acts and global political events could cause permanent
or temporary distribution center or store closures, impair our ability to purchase, receive or replenish inventory, or cause customer
traffic to decline, all of which could result in lost sales and otherwise adversely affect our financial performance.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The occurrence of one or more natural
disasters, such as hurricanes, fires, floods and earthquakes (whether or not caused by climate change), unusually adverse weather
conditions, pandemic outbreaks, terrorist acts or disruptive global political events, such as civil unrest in countries in which our
suppliers are located, or similar disruptions could adversely affect our operations and financial performance. To the extent these
events result in the closure of one or more of our distribution centers, a significant number of stores, a manufacturing facility or
our corporate headquarters, or impact one or more of our key suppliers, our operations and financial performance could be materially
adversely affected through an inability to make deliveries to our stores and through lost sales. In addition, these events could
result in increases in fuel (or other energy) prices or a fuel shortage, decrease in available raw materials of sufficient quality
and in sufficient amounts, delays in opening new stores, the temporary lack of an adequate work force in a market, the temporary or
long-term disruption in the supply of products from some local and overseas suppliers, the temporary disruption in the transport of
goods from overseas, delay in the delivery of goods to our distribution centers or stores, the temporary reduction in the
availability of products in our stores and disruption to our information systems. These events also could have indirect
consequences, such as increases in the cost of insurance, if any of such events was to result in significant loss of property or
other insurable damage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>


</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Doing Business in China</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The PRC government has significant authority
to intervene or influence the China operations of an offshore holding company, such as ours, at any time. The PRC government may exert
more control over offerings conducted overseas and/or foreign investment in China-based issuers. If the PRC government exerts more oversight
and control over offerings that are conducted overseas and/or foreign investment in China-based issuers and we were to be subject to such
oversight and control, it may result in a material adverse change to our business operations, significantly limit or completely hinder
our ability to offer or continue to offer securities to investors, and cause the ordinary shares to significantly decline in value or
become worthless.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business, prospects, financial condition,
and results of operations may be influenced to a significant degree by political, economic, and social conditions in China generally.
The PRC government has significant authority to intervene or influence the China operations of an offshore holding company at any time,
which could result in a material adverse change to our operations and the value of the ordinary shares. The PRC government has recently
indicated an intent to exert more oversight and control over listings conducted overseas and/or foreign investment in China-based issuers.
Any such action may hinder our ability to offer or continue to offer our securities to investors, result in a material adverse change
to our business operations, and damage our reputation, which could cause the ordinary shares to significantly decline in value or become
worthless. See also &#8220;&#8212;Failure to comply with cybersecurity, data privacy, data protection, or any other laws and regulations
related to data may materially and adversely affect our business, financial condition, and results of operations.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Uncertainties arising from the legal system
in China, including uncertainties regarding the interpretation and enforcement of PRC laws and the possibility that regulations and rules
can change quickly with little advance notice, could hinder our ability to offer or continue to offer the ordinary shares, result in a
material adverse change to our business operations, and damage our reputation, which would materially and adversely affect our financial
condition and results of operations and cause the ordinary shares to significantly decline in value or become worthless.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The legal system in China is a civil law
system based on written statutes. Unlike common law systems, it is a system in which decided legal cases may be cited for reference
but have less precedential value. The laws, regulations, and legal requirements in China are quickly evolving and their
interpretation and enforcement involve uncertainties. These uncertainties could limit the legal protections available to you and us.
In addition, we cannot predict the effect of future developments in the PRC legal system, particularly with regard to new economies,
including the promulgation of new laws, changes to existing laws or the interpretation or enforcement thereof, or the preemption of
local regulations by national laws. Furthermore, the PRC legal system is based in part on government policies and internal rules,
some of which are not published on a timely basis or at all. As a result, we may not be aware of our potential violation of these
policies and rules. In addition, any administrative and court proceedings in China may be protracted and result in substantial costs
and diversion of resources and management attention.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New laws and regulations may be enacted from time
to time and substantial uncertainties exist regarding the interpretation and implementation of current and any future PRC laws and regulations
applicable to our businesses. In particular, the PRC government authorities may continue to promulgate new laws, regulations, rules and
guidelines governing companies in the patent medicine industry with respect to a wide range of issues, such as intellectual property,
unfair competition and antitrust, privacy and data protection, and other matters. Compliance with these laws, regulations, rules, guidelines,
and implementations may be costly, and any incompliance or associated inquiries, investigations, and other governmental actions may divert
significant management time and attention and our financial resources, bring negative publicity, subject us to liabilities or administrative
penalties, or materially and adversely affect our business, financial condition, results of operations, and the value of the ordinary
shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ordinary shares may be delisted or prohibited
from being traded over-the-counter under the Holding Foreign Companies Accountable Act, if the PCAOB is unable to inspect our auditors.
The delisting or the cessation of trading of our ordinary shares, or the threat of their being delisted or prohibited from being traded,
may materially and adversely affect the value of your investment. Additionally, the inability of the PCAOB to conduct inspections would
deprive our investors with the benefits of such inspections. Our auditor has not been inspected by the PCAOB, but according to our auditor,
it will be inspected by the PCAOB on a regular basis.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Holding Foreign Companies Accountable Act
was enacted on December 18, 2020. The Holding Foreign Companies Accountable Act, as amended by the Accelerating Holding Foreign Companies
Accountable Act, states if the SEC determines that we have filed audit reports issued by a registered public accounting firm that has
not been subject to inspection by the PCAOB for three consecutive years, the SEC shall prohibit our shares from being traded on a national
securities exchange or in the over-the-counter trading market in the U.S.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our current auditor, Enrome LLP, and our former
auditor, YCM CPA INC., the independent registered public accounting firms that issue the audit reports included elsewhere in this annual
report, as auditors of companies that are traded publicly in the United States and firms registered with the PCAOB, are subject to laws
in the United States pursuant to which the PCAOB conducts regular inspections to assess their compliance with the applicable professional
standards. Our current auditor, Enrome LLP, is based in Singapore, and our former auditor, YCM CPA INC., is headquartered in California,
and are both subject to inspection by the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 24, 2021, the SEC adopted interim final
rules relating to the implementation of certain disclosure and documentation requirements of the Holding Foreign Companies Accountable
Act. We will be required to comply with these rules if the SEC identifies us as having a &#8220;non-inspection&#8221; year under a process
to be subsequently established by the SEC. The SEC is assessing how to implement other requirements of the Holding Foreign Companies Accountable
Act, including the listing and trading prohibition requirements described above. In May 2021, the PCAOB issued for public comment a proposed
rule related to the PCAOB&#8217;s responsibilities under the Holding Foreign Companies Accountable Act, which, according to the PCAOB,
would establish a framework for the PCAOB to use when determining, as contemplated under the Holding Foreign Companies Accountable Act,
whether the PCAOB is unable to inspect or investigate completely registered public accounting firms located in a foreign jurisdiction
because of a position taken by one or more authorities in that jurisdiction. The proposed rule was adopted by the PCAOB in September 2021,
pending the final approval of the SEC to become effective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 22, 2021, the U.S. Senate passed the Accelerating
Holding Foreign Companies Accountable Act, which was signed into law as part of the fiscal year 2023 omnibus spending legislation on December
29, 2022 and reduced the number of consecutive non-inspection years required for triggering the prohibitions under the Holding Foreign
Companies Accountable Act from three years to two.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 2, 2021, the SEC issued amendments
to finalize rules implementing the submission and disclosure requirements in the Holding Foreign Companies Accountable Act. The rules
apply to registrants that the SEC identifies as having filed an annual report with an audit report issued by a registered public accounting
firm that is located in a foreign jurisdiction and that PCAOB is unable to inspect or investigate completely because of a position taken
by an authority in foreign jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 16, 2021, the PCAOB issued a report
on its determination that it is unable to inspect or investigate completely PCAOB-registered public accounting firms headquartered in
China and in Hong Kong because of positions taken by PRC and Hong Kong authorities in those jurisdictions. The PCAOB has made such determination
as mandated under the Holding Foreign Companies Accountable Act. Pursuant to each annual determination by the PCAOB, the SEC will, on
an annual basis, identify issuers that have used non-inspected audit firms and thus are at risk of such suspensions in the future. Our
auditor is headquartered in California and is not subject to this determination announced by the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 15, 2022, the PCAOB announced
that it has completed a test inspection of two selected auditing firms in mainland China and Hong Kong and has voted to vacate its
previous Determination Report, which concluded in December 2021 that it could not inspect or investigate completely registered
public accounting firms based in mainland China or Hong Kong. Moving forward, the PCAOB will continue to demand complete access in
mainland China and Hong Kong. Despite the PCAOB&#8217;s announcement, Chinese authorities will need to ensure that the PCAOB
continues to have full access for inspections and investigations in 202<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5
and beyond, or the threat for Chinese companies listed on U.S. stock exchanges has not been relieved.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our auditor, Enrome LLP, is headquartered in Singapore.
Enrome LLP has been subject to PCAOB inspections and was not subject to the determinations announced by the PCAOB on December&#160;16,
2021. If, for whatever reason, the PCAOB is unable to conduct full inspections of our auditor, uncertainty under the Holding Foreign Companies
Accountable Act could cause the market price of our ordinary shares to be materially and adversely affected, and our securities could
be delisted or prohibited from being traded &#8220;over-the-counter.&#8221; The risk and uncertainty associated with a potential delisting
would have a negative impact on the price of our ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing recent developments would add uncertainties
to our future offerings and may result in prohibitions on the trading of our ordinary shares on the Nasdaq Stock Market, if our auditors
fail to meet the PCAOB inspection requirement in time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to comply with cybersecurity, data
privacy, data protection, or any other laws and regulations related to data may materially and adversely affect our business, financial
condition, and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may be subject to a variety of cybersecurity,
data privacy, data protection, and other laws and regulations related to data, including those relating to the collection, use, sharing,
retention, security, disclosure, and transfer of confidential and private information, such as personal information and other data. These
laws and regulations apply not only to third-party transactions, but also to transfers of information within our organization. These laws
and regulations may restrict our business activities and require us to incur increased costs and efforts to comply, and any breach or
noncompliance may subject us to proceedings against us, damage our reputation, or result in penalties and other significant legal liabilities,
and thus may materially and adversely affect our business, financial condition, and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In China, the cybersecurity, data privacy, data
protection, or other data-related laws and regulations are relatively new and evolving, and their interpretation and application may be
uncertain. For example, on September 24, 2024, the Data Security Administration was promulgated by the Standing Committee of the National
People&#8217;s Congress (the &#8220;SCNPC&#8221;), which took effect on January 1, 2025. According to the Data Security Administration,
data processors shall, in accordance with relevant state provisions, apply for cybersecurity review when carrying out the following activities:
(i)&#160;the merger, reorganization, or separation of internet platform operators that have acquired a large number of data resources
related to national security, economic development, or public interests, which affect or may affect national security; (ii)&#160;data
processors that handle personal data of more than one million individuals intend to list on a foreign stock exchange; (iii)&#160;data
processors that intend to list on Hong&#160;Kong exchange, which affects or may affect national security; and (iv)&#160;other data processing
activities that affect or may affect national security.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this annual report, we have
not engaged in the relevant businesses provided in the Data Security Administration. As such, we currently do not expect the Data Security
Administration or other recent regulations will have an impact on our business or results of operations, and we believe that we are compliant
with the regulations and policies that have been issued by the government authorities to date. As of the date of this annual report, we
have not received any investigation, notice, warning, or sanction from applicable government authorities (including the CAC) with regard
to our business operations concerning any issues related to cybersecurity and data security. In addition, we have not been involved in
any review, investigation, enquiry, penalty, or other legal proceedings initiated by applicable governmental or regulatory authorities
or third parties in relation to in relation to cyber security or data protection. However, we still face uncertainties regarding the interpretation
and implementation of these laws and regulations in the future. Cybersecurity review could result in disruption in our operations, negative
publicity with respect to our Company, and diversion of our managerial and financial resources. Furthermore, if we were found to be in
violation of applicable laws and regulations in China during such review, we could be subject to fines or other government sanctions and
reputational damage. Therefore, potential cybersecurity review, if applicable to us, could materially and adversely affect our business,
financial condition, and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the PRC Data Security Law,
which was promulgated by the SCNPC on June 10, 2021 and took effect on September 1, 2021, requires data collection to be conducted
in a legitimate and proper manner, and stipulates that, for the purpose of data protection, data processing activities must be
conducted based on data classification and hierarchical protection system for data security. Furthermore, the recently issued
Opinions on Strictly Cracking Down Illegal Securities Activities require (i) speeding up the revision of the provisions on
strengthening the confidentiality and archives management relating to overseas issuance and listing of securities and (ii) improving
the laws and regulations relating to data security, cross-border data flow, and management of confidential information. The PRC
Personal Information Protection Law, which was promulgated by the SCNPC on August 20, 2021 and took effect on November 1, 2021,
integrates the scattered rules with respect to personal information rights and privacy protection and applies to the processing of
personal information within China as well as certain personal information processing activities outside China, including those for
the provision of products and services to natural persons within China or for the analysis and assessment of acts of natural persons
within China. There remain uncertainties regarding the further interpretation and implementation of those laws and regulations, if
they are deemed to be applicable to us, we cannot assure you that we will be compliant with such new regulations in all respects,
and we may be ordered to rectify and terminate any actions that are deemed illegal by the government authorities and become subject
to fines and other government sanctions, which may materially and adversely affect our business, financial condition, and results of
operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recent greater oversight by the Cyberspace
Administration of China over data security, particularly for companies seeking to list on a foreign exchange, could adversely impact our
business and operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 28, 2021, the CAC and other relevant
PRC governmental authorities jointly promulgated the Cybersecurity Review Measures, which took effect on February 15, 2022. The Cybersecurity
Review Measures provide that, in addition to critical information infrastructure operators (the &#8220;CIIOs&#8221;) that intend to purchase
Internet products and services, net platform operators engaging in data processing activities that affect or may affect national security
must be subject to cybersecurity review by the Cybersecurity Review Office of the PRC. According to the Cybersecurity Review Measures,
a cybersecurity review assesses potential national security risks that may be brought about by any procurement, data processing, or overseas
listing. The Cybersecurity Review Measures require that an online platform operator which possesses the personal information of at least
one million users must apply for a cybersecurity review by the CAC if it intends to be listed in foreign countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 24, 2024, the SCNPC published the
Data Security Administration, which became effective on January 1, 2025. The Data Security Administration provides that data processing
operators engaging in data processing activities that affect or may affect national security must be subject to network data security
review by the relevant Cyberspace Administration of the PRC. According to the Data Security Administration, data processing operators
who possess personal data of at least one million users or collect data that affects or may affect national security must be subject to
network data security review by the relevant Cyberspace Administration of the PRC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this annual report, we
have not received any notice from any authorities identifying our PRC subsidiaries or the PRC operating entities as CIIOs or
requiring us to go through cybersecurity review or network data security review by the CAC. As advised by our PRC counsel, AllBright
Law Offices (Fuzhou), neither the operations of our PRC subsidiaries, nor of the PRC operating entities are expected to be affected,
and that we will not be subject to cybersecurity review by the CAC under the Cybersecurity Review Measures, nor is any such entity
subject to the Data Security Administration, given that our PRC subsidiaries and the PRC operating entities possess personal data of
fewer than one million individual clients and do not collect data that affects or may affect national security in their business
operations as of the date of this annual report and do not anticipate that they will be collecting over one million users&#8217;
personal information or data that affects or may affect national security in the near future. In general, we believe we are
compliant with the regulations or policies that have been issued by the government authorities to date. There remains uncertainty,
however, as to how the Cybersecurity Review Measures and the Data Security Administration will be interpreted or implemented and
whether the PRC regulatory agencies, including the CAC, may adopt new laws, regulations, rules, or detailed implementation and
interpretation related to the Cybersecurity Review Measures and the Data Security Administration. If any such new laws, regulations,
rules, or implementation and interpretation come into effect, we will take all reasonable measures and actions to comply and to
minimize the adverse effect of such laws on us. We cannot assure you that PRC regulatory agencies, including the CAC, would take the
same view as we do. In the event that we are subject to any mandatory cybersecurity review and other specific actions required by
the CAC, we face uncertainty as to whether any clearance or other required actions can be timely completed, or at all. If we
inadvertently conclude that such approval is not required, fail to obtain and maintain such approvals, licenses, or permits required
for our business or respond to changes in the regulatory environment, we could be subject to liabilities, penalties and operational
disruption, which may materially and adversely affect our business, operating results, financial condition, and the value of our
securities, significantly limit or completely hinder our ability to offer or continue to offer securities to investors, or cause
such securities to significantly decline in value or become worthless.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The approval and/or other requirements of
the CSRC or other PRC governmental authorities may be required in connection with an offering under PRC rules, regulations or policies,
and, if required, we cannot predict whether or how soon we will be able to obtain such approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Regulations on Mergers and Acquisitions of
Domestic Enterprises by Foreign Investors, or the M&amp;A Rules, purport to require offshore special purpose vehicles that are controlled
by PRC companies or individuals and that have been formed for the purpose of seeking a public listing on an overseas stock exchange through
acquisitions of PRC domestic companies or assets to obtain CSRC approval prior to publicly listing their securities on an overseas stock
exchange. The interpretation and application of the regulations remain unclear. If a governmental approval is required, it is uncertain
how long it will take for us to obtain such approval, and, even if we obtain such approval, the approval could be rescinded. Any failure
or delay in obtaining the requisite governmental approval for an offering, or a rescission of such CSRC approval, if obtained by us, may
subject us to sanctions imposed by the relevant PRC regulatory authority, which could include fines and penalties on our operations in
China, restrictions or limitations on our ability to pay dividends outside of China, and other forms of sanctions that may materially
and adversely affect our business, financial condition, and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">On February
17, 2023, the CSRC issued the Trial Measures, and five supporting guidelines, which became effective on March 31, 2023. Pursuant to the
Overseas Listings Rules, companies in mainland China that directly or indirectly offer or list their securities in an overseas market,
including a company in mainland China limited by shares and an offshore company whose main business operations are in mainland China and
intends to offer shares or be listed in an overseas market based on its equities, assets or similar interests in mainland China are required
to file with the CSRC within three business days after submitting their listing application documents to the regulator in the place of
intended listing. If the company fails to complete the filing procedure or conceals any material fact or falsifies any major content in
its filing documents, it may be subject to administrative penalties, such as order to rectify, warnings, fines, and its controlling shareholders,
actual controllers, the person directly in charge and other directly liable persons may also be subject to administrative penalties, such
as warnings and fines. The Overseas Listings Rules also provide that a company in mainland China must file with the CSRC within three
business days for its follow on offering of securities after it is listed in an overseas market. On February 17, 2023, the CSRC also issued
the Notice on Administration of the Filing of Overseas Offering and Listing by Domestic Companies and held a press conference for the
release of the Overseas Listings Rules, which, among others, clarified that the companies in mainland China that have been listed overseas
before March 31, 2023 are not required to file with the CSRC immediately, but these companies should complete filing with the CSRC for
their refinancing activities in accordance with the Overseas Listings Rules. </span>A fine between RMB1 million (approximately $157,255)
and RMB10 million (approximately $1,572,550) may be imposed if an applicant fails to fulfill the filing requirements with the CSRC or
conducts an overseas offering or listing in violation of the <span style="background-color: white">Overseas Listings Rules</span>, and
in cases of severe violations, a parallel order to suspend relevant businesses or halt operations for rectification may be issued, and
relevant business permits or operational license revoked.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 24, 2023, the CSRC, jointly with
other relevant governmental authorities, published the Provisions on Strengthening Confidentiality and Archives Management of
Overseas Securities Issuance and Listing by Domestic Enterprises, or the Confidentiality and Archives Management Provisions, which
became effective on March 31, 2023. Pursuant to the Confidentiality and Archives Management Provisions, China-based companies that
offer and list securities in overseas markets shall establish confidentiality and archives system. The &#8220;China-based
companies&#8221; refer to companies in mainland China limited by shares which are directly listed on a foreign stock exchange and
the domestic operating entities of an offshore company being indirectly listed on a foreign stock exchange. These China-based
companies shall obtain the approvals from relevant authorities and file with the competent confidential administration authorities
when providing or publicly filing documents and materials related to state secrets or secrets of the government authorities to the
relevant securities companies, securities service agencies or the offshore regulatory authorities, or providing or publicly filing
such documents and materials through its offshore listing entity. In addition, China-based companies shall complete corresponding
procedures when (i) providing or publicly filing documents and materials which may adversely affect national security and public
interests to the relevant securities companies, securities service agencies or the offshore regulatory authorities, (ii) providing
or publicly filing such documents and materials through its offshore listing entity, or (iii) providing accounting files or copies
to relevant securities companies, securities service institutions, overseas regulators and individuals. These China-based companies
are also required to provide written statements as to whether they have completed the approval or filing procedures as above when
providing documents and materials to securities companies and securities service providers, and the securities companies and
securities service providers should properly retain such written statements for inspection. If a China-based company finds that the
documents and materials related to state secrets or secrets of the government authorities or other materials, which may adversely
affect national security and public interests, have been leaked or have leakage risks, it should take remedial measures immediately
and report to the relevant authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In the opinion
of our PRC legal counsel, AllBright Law Offices (Fuzhou), as a domestic company listed on Nasdaq since March 2021, and not currently conducting
refinancing or other activities that require filings, we are not required to file with the CSRC in accordance with the Overseas Listing
Rules at this time. However, in the event that we conduct subsequent offerings, we could be subject to filing requirements with the CSRC.
In the event that filings with the CSRC are required, we cannot assure you that we can complete the filing procedures, obtain the approvals
or complete other compliance procedures in a timely manner, or at all, or that any completion of filing or approval or other compliance
procedures would not be rescinded. Any such failure would subject us to sanctions by the CSRC or other PRC regulatory authorities. These
regulatory authorities may impose restrictions and penalties on the operations in China, significantly limit or completely hinder our
ability to launch any new offering of our securities, limit our ability to pay dividends outside of China, delay or restrict the repatriation
of the proceeds from future capital raising activities into China, or take other actions that could materially and adversely affect our
business, results of operations, financial condition and prospects, as well as the trading price of our ordinary shares. Furthermore,
the PRC government authorities may further strengthen oversight and control over listings and offerings that are conducted overseas. Any
such action may adversely affect our operations and significantly limit or completely hinder our ability to offer or continue to offer
securities to you and cause the value of such securities to significantly decline or be worthless.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, the governmental authorities
may impose restrictions and penalties on our operations in China, such as the suspension of our apps and services, revocation of our
licenses, shutting down part or all of our operations, limiting our ability to pay dividends outside of China, delaying or
restricting the repatriation of the proceeds from an offering into China, or may take other actions that could have a material
adverse effect on our business, financial condition, results of operations and prospects, as well as the trading price of the
ordinary shares. The PRC governmental authorities may also take actions requiring us, or making it advisable for us, to halt an
offering before settlement and delivery of the ordinary shares offered hereby. Consequently, if you engage in market trading or
other activities in anticipation of and prior to settlement and delivery, you do so at the risk that settlement and delivery may not
occur. In addition, if the PRC governmental authorities later promulgate new rules or requirements that we obtain their approvals
for filings, registrations or other kinds of authorizations for an offering, we cannot assure you that we can obtain the approval,
authorizations, or complete required procedures or other requirements in a timely manner, or at all, or obtain a waiver of the
requisite requirements if and when procedures are established to obtain such a waiver.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>PRC regulation of loans to, and direct investments
in, PRC entities by offshore holding companies may delay or prevent us from using proceeds from our offerings and/or other financing activities
to make loans or additional capital contributions to our PRC operating subsidiaries.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As an offshore holding company with PRC subsidiaries,
we may transfer funds to our PRC subsidiaries or finance our operating entities by means of loans or capital contributions. Any capital
contributions or loans that we, as an offshore entity, make to our Company&#8217;s PRC subsidiaries are subject to PRC regulations. Any
loans to our PRC subsidiaries, which are foreign-invested enterprises, cannot exceed statutory limits based on the difference between
the amount of our investments and registered capital in such subsidiaries, and shall be registered with China&#8217;s State Administration
of Foreign Exchange (&#8220;SAFE&#8221;), or its local counterparts. Furthermore, any capital increase contributions we make to our PRC
subsidiaries, which are foreign-invested enterprises, are subject to the requirement of making necessary filings in the Foreign Investment
Comprehensive Management Information System, or FICMIS, and registration with other government authorities in China. We may not be able
to obtain these government registrations or approvals on a timely basis, if at all. If we fail to obtain such approvals or make such registration,
our ability to make equity contributions or provide loans to our Company&#8217;s PRC subsidiaries or to fund their operations may be negatively
affected, which may adversely affect their liquidity and ability to fund their working capital and expansion projects and meet their obligations
and commitments. As a result, our liquidity and our ability to fund and expand our business may be negatively affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We must remit proceeds of any future offerings
to China before they may be used to benefit our business in China, and this process may take several months to complete.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The proceeds of our future offerings must be sent
back to China, and the process for sending such proceeds back to China may take as long as six months after the closing of an offering.
As an offshore holding company of our PRC operating subsidiaries, we may make loans to our PRC subsidiaries, or we may make additional
capital contributions to our PRC subsidiaries. Any loans to our PRC subsidiaries are subject to PRC regulations. For example, loans by
us to our subsidiaries in China, which are foreign-invested enterprises, to finance their activities cannot exceed statutory limits and
must be registered with SAFE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To remit the proceeds of our offerings, we must
take the following steps:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First, we will open a special foreign exchange account for capital account transactions. To open this account, we must submit to SAFE certain application forms, identity documents, transaction documents, form of foreign exchange registration of overseas investments of the domestic residents, and foreign exchange registration certificate of the invested company.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second, we will remit the offering proceeds into this special foreign exchange account.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third, we will apply for settlement of the foreign exchange. In order to do so, we must submit to SAFE certain application forms, identity documents, payment order to a designated person, and a tax certificate.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The timing of the process is difficult to estimate
because the efficiencies of different SAFE branches can vary significantly. Ordinarily the process takes several months but is required
by law to be accomplished within 180 days of application.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may also decide to finance our subsidiaries
by means of capital contributions. These capital contributions must be subject to the requirement of making necessary filings in the FICMIS,
and registration with other government authorities in China. We cannot assure you that we will be able to obtain these government approvals
on a timely basis, if at all, with respect to future capital contributions by us to our subsidiaries. If we fail to receive such approvals,
our ability to use the proceeds of any future offerings and to capitalize our Chinese operations may be negatively affected, which could
adversely affect our liquidity and our ability to fund and expand our business. If we fail to receive such approvals, our ability to use
the proceeds of our future offerings and to capitalize our Chinese operations may be negatively affected, which could adversely affect
our liquidity and our ability to fund and expand our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may rely on dividends paid by our subsidiaries
for our cash needs, and any limitation on the ability of our subsidiaries to make payments to us could have a material adverse effect
on our ability to conduct business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a holding company, we conduct all of our business
through the PRC operating entities incorporated in China. We may rely on dividends paid by these PRC subsidiaries for our cash needs,
including the funds necessary to pay any dividends and other cash distributions to our shareholders, to service any debt we may incur
and to pay our operating expenses. The payment of dividends by entities established in China is subject to limitations. Regulations in
China currently permit payment of dividends only out of accumulated profits as determined in accordance with accounting standards and
regulations in China. In accordance with the Article 166, 168 of the Company Law of the PRC (Amended in 2018) (the &#8220;PRC Company
Law&#8221;), each of our PRC subsidiaries is required to set aside at least 10% of its after-tax profit based on PRC accounting standards
each year to its general reserves or statutory capital reserve fund until the aggregate amount of such reserves reaches 50% of its respective
registered capital. A company may discontinue the contribution when the aggregate sum of the statutory surplus reserve is more than 50%
of its registered capital. The statutory common reserve fund of a company shall be used to cover the losses of the company, expand the
business and production of the company or be converted into additional capital. As a result, our PRC subsidiaries are restricted in their
ability to transfer a portion of their net assets to us in the form of dividends. In addition, if any of our PRC subsidiaries incurs debt
on its own behalf in the future, the instruments governing the debt may restrict its ability to pay dividends or make other distributions
to us. Any limitations on the ability of our PRC subsidiaries to transfer funds to us could materially and adversely limit our ability
to grow, make investments or acquisitions that could be beneficial to our business, pay dividends and otherwise fund and conduct our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Adverse changes in political, economic and
social conditions, as well as government policies in China could have a material adverse effect on our business results of operations,
financial conditions and prospects.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of our business operations are conducted
in China. Accordingly, our financial condition, results of operations and prospects are, to a material extent, subject to economic,
political and legal developments in China. The economy in China differs from the economies of developed countries in many respects,
including, among other things, the degree of government involvement, control of investment, level of economic development, growth
rate, foreign exchange controls and resource allocation. Although the economy in China has been transitioning from a planned economy
to a more market-oriented economy for about four decades, a substantial portion of productive assets in China is still owned by the
PRC government. The PRC government also exercises significant control over the economic growth of China through allocating
resources, controlling payments of foreign currency denominated obligations, setting monetary policy and providing preferential
treatment to particular industries or companies. In recent years, the PRC government has implemented measures emphasizing the
utilization of market forces in economic reform, the reduction of state ownership of productive assets and the establishment of
sound corporate governance practices in business enterprises. Some of these measures benefit the overall economy in China, but may
adversely affect us. For example, our financial condition and results of operations may be adversely affected by government policies
on the Chinese patent medicine industry in China or changes in tax regulations applicable to us. If the business environment in
China deteriorates, our business in China may also be materially and adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes to the PRC legal system could have
an adverse effect on us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The PRC legal system is a civil law system based
on written statutes. Unlike the common law system, prior court decisions under the civil law system may be cited for reference but have
limited precedential value. Since these laws and regulations are relatively new and the PRC legal system continues to rapidly evolve,
the interpretations of many laws, regulations and rules are not always uniform and the enforcement of these laws, regulations and rules
involves uncertainties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 1979, the PRC government began to promulgate
a comprehensive system of laws and regulations governing economic matters in general. The overall effect of legislation over the past
decades has significantly enhanced the protections afforded to various forms of foreign investments in China. However, recently enacted
laws and regulations may not sufficiently cover all aspects of economic activities in China. In particular, the interpretation and&#160;enforcement
of these laws and regulations involve uncertainties. Since PRC administrative and court authorities have significant&#160;discretion in
interpreting and implementing statutory provisions and contractual terms, it may be difficult to evaluate the outcome of administrative
and court proceedings and the level of legal protection we enjoy. These uncertainties may affect our judgment on the relevance of legal
requirements and our ability to enforce our contractual rights or tort claims.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, the PRC legal system is based in
part on government policies and internal rules, some of which are not published on a timely basis or at all and may have retroactive effect.
As a result, we may not be aware of our violation of any of these policies and rules until sometime after the violation. In addition,
any administrative and court&#160;proceedings in China may be protracted, resulting in substantial costs and diversion of resources and
management attention.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Labor Contract Law and other labor-related
laws in the PRC may adversely affect our business and our results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 28, 2012, the PRC government released
the revision of the Labor Contract Law, which became effective on July 1, 2013. Pursuant to the Labor Contract Law, employers are subject
to stricter requirements in terms of signing labor contracts, minimum wages, paying remuneration, determining the term of employees&#8217;
probation and unilaterally terminating labor contracts. In the event that we decide to terminate some of our employees or otherwise change
our employment or labor practices, the Labor Contract Law and its implementation rules may limit our ability to effect those changes in
a desirable or cost-effective manner, which could adversely affect our business and results of operations. According to the PRC Social
Insurance Law (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#31038;&#20250;&#20445;&#38505;&#27861;&#12299;), employees
must participate in pension insurance, work-related injury insurance, medical insurance, unemployment insurance and maternity insurance
and the employers must, together with their employees or separately, pay the social insurance premiums for such employees. In accordance
with the Regulations on the Management of Housing Fund which was promulgated by the State Council in 1999 and amended in 2002 and 2019,
employers must register at the designated administrative centers and open bank accounts for depositing employees&#8217; housing funds.
As the interpretation and implementation of labor-related laws and regulations are still evolving, we cannot assure you that our employment
practices do not and will not violate labor-related laws and regulations in China, which may subject us to labor disputes or government
investigations. As of the date of this annual report, we believe that we are in substantial compliance with labor-related laws and regulations
in China, and we have not been notified of any instance of noncompliance. We cannot assure you that we will be able to comply with all
labor-related law and regulations regarding including those relating to obligations to make social insurance payments and contribute to
the housing provident fund. If we are deemed to have violated relevant labor laws and regulations, we could be required to provide additional
compensation to our employees and our business, financial condition and results of operations will be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>There are significant uncertainties under
the EIT Law, relating to the withholding tax liabilities of our PRC subsidiaries, and dividends payable by our PRC subsidiaries to our
offshore subsidiaries may not qualify to enjoy certain treaty benefits.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the PRC EIT Law and its implementation rules,
the profits of a foreign invested enterprise generated through operations, which are distributed to its immediate holding company outside
the PRC, will be subject to a withholding tax rate of 10%. Pursuant to a special arrangement between Hong Kong and the PRC, such rate
may be reduced to 5% if a Hong Kong resident enterprise owns more than 25% of the equity interest in the PRC company. Our PRC subsidiaries,
Universe Technology, Jiangxi Universe, Universe Trade and Universe Hanhe, are wholly-owned by our Hong Kong subsidiary. Moreover, under
the Notice of the State Administration of Taxation on Issues regarding the Administration of the Dividend Provision in Tax Treaties promulgated
on February 20, 2009, the taxpayer needs to satisfy certain conditions to enjoy the benefits under a tax treaty. The beneficial owner
of the relevant dividends and the corporate shareholder to receive dividends from the PRC subsidiary must have continuously met the direct
ownership thresholds during the 12 consecutive months preceding the receipt of the dividends. Further, the State Administration of Taxation
(the &#8220;SAT&#8221;) promulgated the Notice on How to Comprehend and Determine the &#8220;Beneficial Owner&#8221; in Tax Treaties (&#12298;&#22269;&#23478;&#31246;&#21153;&#24635;&#23616;&#20851;&#20110;&#31246;&#25910;&#21327;&#23450;&#20013;&#8221;&#21463;&#30410;&#25152;&#26377;&#20154;&#8221;&#26377;&#20851;&#38382;&#39064;&#30340;&#20844;&#21578;&#12299;)
on February 3, 2018, which limits the &#8220;beneficial owner&#8221; to individuals, projects or other organizations normally engaged
in substantive operations, and sets forth certain detailed factors in determining the &#8220;beneficial owner&#8221; status. In current
practice, a Hong Kong enterprise must obtain a tax resident certificate from the relevant Hong Kong tax authority to apply for the 5%
lower PRC withholding tax rate. As the Hong Kong tax authority will issue such a tax resident certificate on a case-by-case basis, we
cannot assure you that we will be able to obtain the tax resident certificate from the relevant Hong Kong tax authority. As of the date
of this annual report, we have not commenced the application process for a Hong Kong tax resident certificate from the relevant Hong Kong
tax authority, and there is no assurance that we will be granted such a Hong Kong tax resident certificate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even after we obtain the Hong Kong tax resident
certificate, we are required by applicable tax laws and regulations to file required forms and materials with relevant PRC tax authorities
to prove that we can enjoy 5% lower PRC withholding tax rate. Universe HK intends to obtain the required materials and file with the relevant
tax authorities when it plans to declare and pay dividends, but there is no assurance that the PRC tax authorities will approve the 5%
withholding tax rate on dividends received from Universe HK.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to qualify for or obtain any preferential
tax treatments that are available in China could adversely affect our results of operations and financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The EIT Law and its implementation rules generally
impose a uniform income tax rate of 25% on all enterprises, but grant preferential treatment to &#8220;high and new technology enterprises
strongly supported by the state,&#8221; or HNTEs, with a preferential enterprise tax rate of 15%. Our subsidiaries, Jiangxi Universe and
Universe Trade, were accredited as HNTE and enjoy the reduced income tax rate of 15% for three years through November 2025 and December
2023, respectively. Universe Trade did not successfully renew its HNTE status at the end of December 2023 and, therefore, has been subject
to the standard PRC enterprise income tax rate of 25% starting from January 2024. According to the relevant administrative measures, to
qualify as an &#8220;HNTE,&#8221; a company must meet certain financial and non-financial criteria and complete verification procedures
with the administrative authorities. Continued qualification as an HNTE is subject to review by the relevant government authorities in
China every three years, and in practice, certain local tax authorities may require annual evaluation of the qualification. In the event
that Jiangxi Universe fails to renew its status as&#160;HNTE&#160;with the local tax authority upon expiration of its HNTE status in November
2025, it will be subject to the standard PRC enterprise income tax rate of 25%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Under the EIT Law, we may be classified
as a &#8220;Resident Enterprise&#8221; of China. Such classification will likely result in unfavorable tax consequences to us and our
non-PRC shareholders.&#160;</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the EIT Law, an enterprise established outside
of China with &#8220;de facto management bodies&#8221; within China is considered a &#8220;resident enterprise,&#8221; meaning that it
can be treated in a manner similar to a Chinese enterprise for enterprise income tax purposes. The implementing rules of the EIT Law define
de facto management as &#8220;substantial and overall management and control over the production and operations, personnel, accounting,
and properties&#8221; of the enterprise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the PRC tax authorities determine that we
are a &#8220;resident enterprise&#8221; for PRC enterprise income tax purposes, a number of unfavorable PRC tax consequences could
follow. First, we may be subject to the enterprise income tax at a rate of 25% on our worldwide taxable income as well as PRC
enterprise income tax reporting obligations. In our case, this would mean that income such as non-China source income would be
subject to PRC enterprise income tax at a rate of 25%. Currently, we do not have any non-China source income, as we conduct our
sales in China. Second, under the EIT Law and its implementing rules, dividends paid to us from our PRC subsidiaries would be deemed
as &#8220;qualified investment income between resident enterprises&#8221; and therefore qualify as &#8220;tax-exempt income&#8221;
pursuant to the clause 26 of the EIT Law. Finally, it is possible that future guidance issued with respect to the new
&#8220;resident enterprise&#8221; classification could result in a situation in which the dividends we pay with respect to our
ordinary shares, or the gain our non-PRC shareholders may realize from the transfer of our ordinary shares, may be treated as
PRC-sourced income and may therefore be subject to a 10% PRC withholding tax. The EIT Law and its implementing regulations are,
however, relatively new and ambiguities exist with respect to the interpretation and identification of PRC-sourced income, and the
application and assessment of withholding taxes. If we are required under the EIT Law and its implementing regulations to withhold
PRC income tax on dividends payable to our non-PRC shareholders, or if non-PRC shareholders are required to pay PRC income tax on
gains on the transfer of their ordinary shares, our business could be negatively impacted and the value of your investment may be
materially reduced. Further, if we were to be treated as a &#8220;resident enterprise&#8221; by PRC tax authorities, we would be
subject to taxation in both China and such countries in which we have taxable income, and our PRC tax may not be creditable against
such other taxes.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>To the extent cash in and assets of the
business is in the PRC or a PRC entity, the funds and assets may not be available to fund operations or for other use outside of the PRC
due to interventions in or the imposition of restrictions and limitations on the ability of our Company or our subsidiaries by the PRC
government to transfer cash and assets.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Relevant PRC laws and regulations permit the companies
in mainland China to pay dividends only out of their retained earnings, if any, as determined in accordance with PRC accounting standards
and regulations. Additionally, each of the companies in mainland China are required to set aside at least 10% of its after-tax profits
each year, if any, to fund a statutory reserve until such reserve reaches 50% of its registered capital. The companies in mainland China
are also required to further set aside a portion of their after-tax profits to fund the employee welfare fund, although the amount to
be set aside, if any, is determined at their discretion. These reserves are not distributable as cash dividends. Furthermore, if we determine
to pay dividends on any of our ordinary shares in the future, as a holding company, we will rely on payments from subsidiaries of Jiangxi
Universe to Jiangxi Universe, and from Jiangxi Universe to Universe Technology, and the distribution of such payments to Universe HK,
and then to our Company. If our PRC subsidiaries incur debt on their own behalf in the future, the instruments governing the debt may
restrict their ability to pay dividends or make other payments to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our cash dividends, if any, will be paid in U.S.
dollars. If we are considered a tax resident enterprise of mainland China for tax purposes, any dividends we pay to our overseas shareholders
may be regarded as China-sourced income and as a result may be subject to PRC withholding tax. See &#8220;&#8212;Under the EIT Law, we
may be classified as a &#8216;Resident Enterprise&#8217; of China. Such classification will likely result in unfavorable tax consequences
to us and our non-PRC shareholders.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The PRC government also imposes controls on the
convertibility of Renminbi into foreign currencies and, in certain cases, the remittance of currency out of mainland China. The majority
of our and the PRC operating entities&#8217; income is received in Renminbi and shortages in foreign currencies may restrict our ability
to pay dividends or other payments, or otherwise satisfy our foreign currency denominated obligations, if any. Under existing PRC foreign
exchange regulations, payments of current account items, including profit distributions, interest payments and expenditures from trade-related
transactions, can be made in foreign currencies without prior approval from the State Administration of Foreign Exchange as long as certain
procedural requirements are met. Approval from appropriate government authorities is required if Renminbi is converted into foreign currency
and remitted out of mainland China to pay capital expenses such as the repayment of loans denominated in foreign currencies. The PRC government
may, at its discretion, impose restrictions on access to foreign currencies for current account transactions and if this occurs in the
future, we may not be able to pay dividends in foreign currencies to our shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any limitation on the ability of our PRC subsidiaries
and the PRC operating entities to distribute dividends or other payments to their respective shareholders could materially and adversely
limit our ability to conduct operations, make investments, engage in acquisitions, or undertake other activities requiring working capital.
However, our operations and business, including investment and/or acquisitions by our PRC subsidiaries and the PRC operating entities
within mainland China, will not be affected as long as the capital is not transferred in or out of mainland China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may be exposed to liabilities under the Foreign Corrupt Practices
Act and Chinese anti-corruption law.&#160;</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to the U.S. Foreign Corrupt Practices
Act (the &#8220;FCPA&#8221;), and other laws that prohibit improper payments or offers of payments to foreign governments and their officials
and political parties by U.S. persons and issuers, as defined by the statute, for the purpose of obtaining or retaining business. We are
also subject to Chinese anti-corruption laws, which strictly prohibit the payment of bribes to government officials. We have operations,
agreements with third parties, and make sales in China, which may expose us to claims of corruption. Our activities in China create the
risk of unauthorized payments or offers of payments by one of the employees of our Company, because these parties are not always subject
to our control.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we believe that, as of the date of
this annual report, we have complied in all material respects with the provisions of the FCPA and Chinese anti-corruption law, our
existing safeguards and any future improvements may prove to be less than effective, and the employees of our Company may engage in
conduct for which we might be held responsible. Violations of the FCPA or Chinese anti-corruption law may result in severe criminal
or civil sanctions, and we may be subject to other liabilities, which could negatively affect our business, operating results and
financial condition. In addition, the government may seek to hold our Company liable for successor liability FCPA violations
committed by companies in which we invest or that we acquire.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The enforcement of stricter advertisement
laws and regulations in the PRC may adversely affect our business and our profitability.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2018, the SCNPC promulgated the PRC
Advertising Law, effective on October 26, 2018. According to the Advertising Law, advertisements shall not have any false or misleading
content, or defraud or mislead consumers. Furthermore, an advertisement will be deemed as a &#8220;false advertisement&#8221; if any of
the following situations exist: (i) the advertised product or service does not exist; (ii) there is any inconsistency that has a material
impact on the decision to purchase in what is included in the advertisement with the actual circumstances with respect to the product&#8217;s
performance, functions, place of production, uses, quality, specification, ingredient, price, producer, term of validity, sales condition,
and honors received, among others, or the service&#8217;s contents, provider, form, quality, price, sales condition, and honors received,
among others, or any commitments, among others, made on the product or service; (iii) fabricated, forged or unverifiable scientific research
results, statistical data, investigation results, excerpts, quotations, or other information have been used as supporting material; (iv)
effect or results of using the good or receiving the service are fabricated; or (v) other circumstances where consumers are defrauded
or misled by any false or misleading content.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our current marketing relies on advertisements
on media platforms. The laws and regulations of advertising are relatively new and evolving and there is substantial uncertainty as to
the interpretation of &#8220;false advertisement&#8221; by the State Administration for Industry and Commerce of the PRC (the &#8220;SAIC&#8221;).
If any of the advertisements published by our customers is deemed to be a &#8220;false advertisement&#8221; by the SAIC or its local branch,
we could be subject to various penalties, such as discontinuation of publishing the target advertisement, imposition of fines and obligations
to eliminate any adverse effects incurred by such false advertisement. Any such penalties may disrupt our business and our competition
with competitors, and could affect our results of operations and financial conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We were not in compliance with the PRC&#8217;s
regulations relating to employee&#8217;s social insurance and housing funds prior to April 2020, and as a result, we may be subject to
penalties for such non-compliance.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Social Insurance Law of the
PRC (the &#8220;Social Insurance Law&#8221;), which was promulgated by the SCNPC on October 28, 2010 and amended on December 29,
2018, and the Administrative Regulations on the Housing Provident Funds, which was promulgated by the State Council on April 3, 1999
and last amended on March 24, 2019, employers are required to make contributions, on behalf of their employees, to a number of
social security funds, including funds for basic pension insurance, unemployment insurance, basic medical insurance, occupational
injury insurance, maternity insurance and to housing provident funds. Prior to April 2020, we only contributed to the social
insurance and housing provident funds for some, but not all, of our employees. Since April 2020, we have started contributing to the
social insurance and housing funds for our eligible full-time employees in accordance with the aforementioned PRC laws and
regulations. Even though we are currently making contributions in accordance with applicable PRC laws, there is a risk that the
labor security administration authority may take enforcement action to collect from us all the outstanding contributions of the
social insurance required to be made for the employees in the past, and we may be subject to a late charge at the rate of 0.05% per
day on the total outstanding contribution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>U.S. regulatory bodies may be limited in
their ability to conduct investigations or inspections of our operations in China.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEC, the U.S. Department of Justice and other
U.S. authorities may also have difficulties in bringing and enforcing actions against us or our directors or executive officers in the
PRC. The SEC has stated that there are significant legal and other obstacles to obtaining information needed for investigations or litigation
in China. Although the authorities in China may establish a regulatory cooperation mechanism with the securities regulatory authorities
of another country or region to implement cross-border supervision and administration, such cooperation with the securities regulatory
authorities in Hong Kong or other jurisdictions may not be efficient in the absence of mutual and practical cooperation mechanism. Furthermore,
China has recently adopted a revised securities law that became effective on March 1, 2020, Article 177 of which provides, among other
things, that no overseas securities regulator is allowed to directly conduct investigation or evidence collection activities within the
territory of the PRC. Accordingly, without governmental approval in China, no entity or individual in China may provide documents and
information relating to securities business activities to overseas regulators when it is under direct investigation or evidence discovery
conducted by overseas regulators. While detailed interpretation of or implementation rules under Article 177 have yet to be promulgated,
it could present significant legal and other obstacles to obtaining information needed for investigations and litigation conducted outside
of China, which may further increase difficulties faced by you in protecting your interests. See also &#8220;&#8212;You may experience
difficulty in effecting service of process, enforcing foreign judgments or bringing actions against our directors and officers.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>You may experience difficulty in effecting
service of process, enforcing foreign judgments or bringing actions against our directors and officers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a Cayman Islands exempted company with
limited liability and most of our assets are located outside of the United States. In addition, all of our directors and officers are
nationals or residents of the PRC, including our chief executive officer and chairman of the board of directors, Mr. Gang Lai, our chief
financial officer, Ms. Lin Yang, and our directors, Mr. Jiawen Pang, Mr. Yongping Yu and Mr. Ding Zheng, and all or a substantial portion
of their assets are located outside the United States. As a result, it may be difficult or impossible for you to effect service of process
within the United States upon our directors and executive officers. It may also be difficult for you to enforce in the United States courts
judgments obtained in the United States courts based on the civil liability provisions of the United States federal securities laws against
us and our officers and directors who reside and whose assets are located outside the United States.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have been advised by our Cayman Islands legal
counsel, Ogier (Cayman) LLP, that the courts of the Cayman Islands are unlikely (i) to recognize or enforce against us, judgments of courts
of the United States obtained against us or our directors or officers predicated upon the civil liability provisions of the securities
laws of the United States or any state in the United States; and (ii) in original actions brought in the Cayman Islands, to impose liabilities
against us or our directors or officers predicated upon the civil liability provisions of the securities laws of the United States or
any state in the United States, so far as the liabilities imposed by those provisions are penal in nature. In those circumstances, although
there is currently no statutory enforcement or treaty between the United States and the Cayman Islands providing for enforcement of judgments
obtained in the United States. The courts of the Cayman Islands will recognize and enforce a foreign money judgment of a foreign court
of competent jurisdiction without retrial on the merits based on the principle that a judgment of a competent foreign court imposes upon
the judgment debtor an obligation to pay the sum for which judgment has been given provided certain conditions are met. For a foreign
judgment to be enforced in the Cayman Islands, such judgment must be final and conclusive, given by a court of competent jurisdiction
(the courts of the Cayman Islands will apply the rules of Cayman Islands private international law to determine whether the foreign court
is a court of competent jurisdiction), and must not be in respect of taxes or a fine or penalty, inconsistent with a Cayman Islands judgment
in respect of the same matter, impeachable on the grounds of fraud or obtained in a manner, and or be of a kind the enforcement of which
is, contrary to natural justice or the public policy of the Cayman Islands. Furthermore, it is uncertain that Cayman Islands courts would
enforce: (1) judgments of U.S. courts obtained in actions against us or other persons that are predicated upon the civil liability provisions
of the U.S. federal securities laws; or (2) original actions brought against us or other persons predicated upon the Securities Act. Ogier
has informed us that there is uncertainty with regard to Cayman Islands law relating to whether a judgment obtained from the U.S. courts
under civil liability provisions of the securities laws will be determined by the courts of the Cayman Islands as penal, punitive in nature.
A Cayman Islands Court may stay enforcement proceedings if concurrent proceedings are being brought elsewhere.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, there is uncertainty as to whether
the courts of the PRC would recognize or enforce judgments of the United States courts against us or such persons predicated upon the
civil liability provisions of the securities laws of the United States or any state. The recognition and enforcement of foreign judgments
are provided for under the PRC Civil Procedures Law. PRC courts may recognize and enforce foreign judgments in accordance with the requirements
of the PRC Civil Procedures Law based either on treaties between China and the country where the judgment is made or on principles of
reciprocity between jurisdictions. China does not have any treaties or other forms of reciprocity with the United States that provide
for the reciprocal recognition and enforcement of foreign judgments. In addition, according to the PRC Civil Procedures Law, the PRC courts
will not enforce a foreign judgment against us or our directors and officers if they decide that the judgment violates the basic principles
of PRC laws or national sovereignty, security or public interest. As a result, it is uncertain whether and on what basis a PRC court would
enforce a judgment rendered by a court in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, pursuant to the PRC Civil Procedures
Law, any matter, including matters arising under U.S. federal securities laws, in relation to assets or personal relationships may be
brought as an original action in China, only if the institution of such action satisfies the conditions specified in the PRC Civil Procedures
Law. As a result of the conditions set forth in the PRC Civil Procedures Law and the discretion of the PRC courts to determine whether
the conditions are satisfied and whether to accept the action for adjudication, there remains uncertainty as to whether an investor will
be able to bring an original action in a PRC court based on U.S. federal securities laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Because our business is conducted in the
RMB and the price of our ordinary shares is quoted in United States dollars, changes in currency conversion rates may affect the value
of your investments.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business is conducted in the PRC, our books
and records are maintained in the RMB, the legal currency of the PRC, and the financial statements that we file with the SEC and provide
to our shareholders are presented in United States dollars. Changes in the exchange rate between the RMB and U.S. dollars affect the value
of our assets and the results of our operations in U.S. dollars. The value of the RMB against the U.S. dollar and other currencies may
fluctuate and is affected by, among other things, changes in the PRC&#8217;s political and economic conditions and perceived changes in
the economy of the PRC and the United States. Any significant revaluation of the RMB may materially and adversely affect our cash flows,
revenue and financial condition. Further, our securities will be offered in United States dollars, and we will need to convert any net
proceeds we receive into RMB in order to use the funds for our business. Changes in the conversion rate between the United States dollar
and the RMB will affect that amount of proceeds we will have available for our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Government control in currency conversion
may adversely affect our financial condition, our ability to remit dividends, and the value of your investment.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The PRC government imposes controls on the convertibility
of the Renminbi into foreign currencies and, in certain cases, the remittance of currency out of China. We receive substantially all of
our revenues in Renminbi. Under our current corporate structure, our Cayman Islands holding company may rely on dividend payments from
our PRC subsidiaries to fund any cash and financing requirements we may have.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under existing PRC foreign exchange regulations,
the Renminbi cannot be freely converted into any foreign currency, and conversion and remittance of foreign currencies are subject to
PRC foreign exchange regulations. It cannot be guaranteed that under a certain exchange rate, we will have sufficient foreign exchange
to meet our foreign exchange requirements. Under the current PRC foreign exchange control system, foreign exchange transactions under
the current account conducted by us, including the payment of dividends, do not require advance approval from SAFE, but we are required
to present documentary evidence of such transactions and conduct such transactions at designated foreign exchange banks within China that
have the licenses to carry out foreign exchange business. Foreign exchange transactions under the capital account conducted by us, however,
must be approved in advance by SAFE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under existing foreign exchange regulations, we
are able to pay dividends in foreign currencies without prior approval from SAFE by complying with certain procedural requirements. However,
we cannot assure you that these foreign exchange policies regarding payment of dividends in foreign currencies will continue in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In fact, in light of the flood of capital outflows
of China in 2016 due to the weakening Renminbi, the PRC government has imposed more restrictive foreign exchange policies and stepped
up scrutiny of major outbound capital movement including overseas direct investment. More restrictions and substantial vetting process
may be put in place by SAFE to regulate cross-border transactions falling under the capital account. If any of our shareholders regulated
by such policies fails to satisfy the applicable overseas direct investment filing or approval requirement timely or at all, it may be
subject to penalties from the relevant PRC authorities. The PRC government may, at its discretion, further restrict access in the future
to foreign currencies for current account transactions. If the foreign exchange control system prevents us from obtaining sufficient foreign
currencies to satisfy our foreign currency demands, we may not be able to pay dividends in foreign currencies to our shareholders, including
holders of the ordinary shares. Our capital expenditure plans and our business, operating results and financial condition may be materially
and adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business may be materially and adversely
affected if any of our PRC subsidiaries declare bankruptcy or become subject a dissolution or liquidation proceeding.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Enterprise Bankruptcy Law of the PRC, or the
Bankruptcy Law, came into effect on June 1, 2007. The Bankruptcy Law provides that an enterprise will be liquidated if the enterprise
fails to settle its debts as and when they fall due and if the enterprise&#8217;s assets are, or are demonstrably, insufficient to clear
such debts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our PRC subsidiaries hold certain assets that
are important to our business operations. If any of our PRC subsidiaries undergoes a voluntary or involuntary liquidation proceeding,
unrelated third-party creditors may claim rights to some or all of these assets, thereby hindering our ability to operate our business,
which could materially and adversely affect our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of our PRC subsidiaries undergoes a voluntary
or involuntary liquidation proceeding, prior approval from SAFE for remittance of foreign exchange to our shareholders abroad is no longer
required, but we still need to conduct a registration process with the SAFE local branch. It is not clear whether &#8220;registration&#8221;
is a mere formality or involves the kind of substantive review process undertaken by SAFE and its relevant branches in the past.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our current corporate structure and business
operations may be affected by the newly enacted PRC Foreign Investment Law.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 15, 2019, the National People&#8217;s
Congress approved the Foreign Investment Law, which became effective on January 1, 2020. The PRC Foreign Investment Law defines the &#8220;foreign
investment&#8221; as the investment activities in China conducted directly or indirectly by foreign investors in the following manners:
(i) the foreign investor, by itself or together with other investors establishes a foreign invested enterprises in China; (ii) the foreign
investor acquires shares, equities, asset tranches, or similar rights and interests of enterprises in China; (iii) the foreign investor,
by itself or together with other investors, invests and establishes new projects in China; (iv) the foreign investor invests through other
approaches as stipulated by laws, administrative regulations or otherwise regulated by the State Council. If our PRC subsidiaries are
recognized as &#8220;foreign investment enterprises,&#8221; PRC governmental authorities will regulate foreign investment by applying
the principle of re-entry national treatment together with a &#8220;negative list,&#8221; which will be promulgated by or promulgated
with approval by the State Council. Foreign investors are prohibited from making any investments in the industries which are listed as
&#8220;prohibited&#8221; in such negative list; and, after satisfying certain additional requirements and conditions as set forth in the
&#8220;negative list,&#8221; are allowed to make investments in industries which are listed as &#8220;restricted&#8221; in such negative
list. For any foreign investor that fails to comply with the negative list, the competent authorities are entitled to ban its investment
activities, require such investor to take measures to correct its non-compliance and impose other penalties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pharmaceutical production and distribution activities
that we conduct through our PRC subsidiaries are not subject to foreign investment restrictions or prohibitions set forth in the Special
Administrative Measures for the Access of Foreign Investment (Negative List) (Edition 2022) (the &#8220;2022 Negative List&#8221;). We
do not intend to conduct any types of business activities restricted or prohibited under the 2021 Negative List in the future. However,
it is unclear whether any updated &#8220;negative list&#8221; to be published by the State Council in the future will be different from
the 2022 Negative List. If future laws, administrative regulations or provisions of the State Council set forth restrictions or prohibitions
on foreign investment in our current business activities, and that our PRC subsidiaries are recognized as &#8220;foreign investment enterprises,&#8221;
we may be required to take appropriate and timely measures to comply with such regulatory requirements. If we fail to do so, our business
operations could be materially and adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to comply with PRC regulations relating
to the establishment of offshore special purpose companies by PRC residents may subject our PRC resident shareholders to personal liability,
may limit our ability to acquire PRC companies or to inject capital into our PRC subsidiaries, may limit the ability of our PRC subsidiaries
to distribute profits to us or may otherwise materially and adversely affect us</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Circular on relevant issues concerning
Foreign Exchange Administration of Overseas Investment and Financing and Return Investments Conducted by Domestic Residents through Overseas
Special Purpose Vehicle (the &#8220;Circular 37&#8221;), which was promulgated by SAFE, and became effective on July 4, 2014, (1) a PRC
resident must register with the local SAFE branch before he or she contributes assets or equity interests in an overseas special purpose
vehicle, or an Overseas SPV, that is directly established or indirectly controlled by the PRC resident for the purpose of conducting investment
or financing; and (2) following the initial registration, the PRC resident is also required to register with the local SAFE branch for
any major change, in respect of the Overseas SPV, including, among other things, a change in the Overseas SPV&#8217;s PRC resident shareholder,
name of the Overseas SPV, term of operation, or any increase or reduction of the contributions by the PRC resident, share transfer or
swap, and merger or division. Additionally, pursuant to the Circular of SAFE on Further Simplifying and Improving the Direct Investment-related
Foreign Exchange Administration Policies (the &#8220;Circular 13&#8221;), which was promulgated on February 13, 2015 and became effective
on June 1, 2015, the aforesaid registration shall be directly reviewed and handled by qualified banks in accordance with the Circular
13, and SAFE and its branches shall perform indirect regulation over the foreign exchange registration via qualified banks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Gang Lai completed the initial foreign exchange
registration on June 3, 2019. As it remains unclear how Circular 37 and Circular 13 will be interpreted and implemented, and how or whether
SAFE will apply them to us. Therefore, we cannot predict how they will affect our business operations or future strategies. For example,
the ability of our present and prospective PRC subsidiaries to conduct foreign exchange activities, such as the remittance of dividends
and foreign currency-denominated borrowings, may be subject to compliance with Circular 37 and Circular 13 by our PRC resident beneficial
holders. In addition, as we have little control over either our present or prospective, direct or indirect shareholders or the outcome
of such registration procedures, we cannot assure you that these shareholders who are PRC residents will amend or update their registration
as required under Circular 37 and Circular 13 in a timely manner or at all. Failure of our present or future shareholders who are PRC
residents to comply with Circular 37 and Circular 13 could subject these shareholders to fines or legal sanctions, restrict our overseas
or cross-border investment activities, limit the ability of our PRC subsidiaries to make distributions or pay dividends or affect our
ownership structure, which could adversely affect our business and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be unable to complete a business
combination transaction efficiently or on favorable terms due to complicated merger and acquisition regulations and certain other PRC
regulations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 8, 2006, six PRC regulatory
authorities, including the Ministry of Commerce of the People&#8217;s Republic of China, or MOFCOM, the State Assets Supervision and
Administration Commission, the SAT, the SAIC, the CSRC and the SAFE, jointly issued the M&amp;A Rules, which became effective on
September 8, 2006 and was amended in June 2009. The M&amp;A Rules, governing the approval process by which a PRC company may
participate in an acquisition of assets or equity interests by foreign investors, requires the PRC parties to make a series of
applications and supplemental applications to the government agencies, depending on the structure of the transaction. In some
instances, the application process may require presentation of economic data concerning a transaction, including appraisals of the
target business and evaluations of the acquirer, which are designed to allow the government to assess the transaction. Accordingly,
due to the M&amp;A Rules, our ability to engage in business combination transactions has become significantly more complicated,
time-consuming and expensive, and we may not be able to negotiate a transaction that is acceptable to our Shareholders or
sufficiently protect their interests in a transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The M&amp;A Rules allow PRC government agencies
to assess the economic terms of a business combination transaction. Parties to a business combination transaction may have to submit to
the MOFCOM and other relevant government agencies an appraisal report, an evaluation report and the acquisition agreement, all of which
form part of the application for approval, depending on the structure of the transaction. The M&amp;A Rules also prohibit a transaction
at an acquisition price obviously lower than the appraised value of the business or assets in China and in certain transaction structures,
require that consideration must be paid within defined periods, generally not in excess of a year. In addition, the M&amp;A Rules also
limit our ability to negotiate various terms of the acquisition, including aspects of the initial consideration, contingent consideration,
holdback provisions, indemnification provisions and provisions relating to the assumption and allocation of assets and liabilities. Transaction
structures involving trusts, nominees and similar entities are prohibited. Therefore, such regulation may impede our ability to negotiate
and complete a business combination transaction on legal and/or financial terms that satisfy our investors and protect our shareholders&#8217;
economic interests.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face uncertainties with respect to indirect
transfers of equity interests in PRC resident enterprises by their non-PRC holding companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SAT released a circular on December 15, 2009
that addresses the transfer of shares by nonresident companies, generally referred to as Circular 698. Circular 698, which became effective
retroactively to January 1, 2008, may have a significant impact on many companies that use offshore holding companies to invest in China.
Circular 698 has the effect of taxing foreign companies on gains derived from the indirect sale of a PRC company. Where a foreign investor
indirectly transfers equity interests in a PRC resident enterprise by selling the shares in an offshore holding company, and the latter
is located in a country or jurisdiction that has an effective tax rate less than 12.5% or does not tax foreign income of its residents,
the foreign investor must report this indirect transfer to the tax authority in charge of that PRC resident enterprise. Using a &#8220;substance
over form&#8221; principle, the PRC tax authority may disregard the existence of the overseas holding company if it lacks a reasonable
commercial purpose and was established for the purpose of avoiding PRC tax. As a result, gains derived from such indirect transfer may
be subject to PRC withholding tax at a rate of up to 10.0%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SAT subsequently released public notices to
clarify issues relating to Circular 698, including the Announcement on Several Issues concerning the EIT on the Indirect Transfers
of Properties by Nonresident Enterprises (the &#8220;SAT Notice 7&#8221;), which became effective on February 3, 2015. SAT Notice 7
abolished the compulsive reporting obligations originally set out in Circular 698. Under SAT Notice 7, if a non-resident enterprise
transfers its shares in an overseas holding company, which directly or indirectly owns PRC taxable properties, including shares in a
PRC company, via an arrangement without reasonable commercial purpose, such transfer shall be deemed as indirect transfer of the
underlying PRC taxable properties. Accordingly, the transferee shall be deemed as a withholding agent with the obligation to
withhold and remit the EIT to the competent PRC tax authorities. Factors that may be taken into consideration when determining
whether there is a &#8220;reasonable commercial purpose&#8221; include, among other factors, the economic essence of the transferred
shares, the economic essence of the assets held by the overseas holding company, the taxability of the transaction in offshore
jurisdictions, and economic essence and duration of the offshore structure. SAT Notice 7 also sets out safe harbors for the
&#8220;reasonable commercial purpose&#8221; test.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 17, 2017, the SAT released the Notice
on Several Issues concerning the Withholding and Collection of Income Tax of Non-resident Enterprises from the Source (the &#8220;SAT
Notice 37&#8221;). SAT Notice 37 clarifies: (1) matters concerning the withholding and collection of corporate income tax, and property
transfer of non-resident enterprises based on the EIT Law; (2) the currencies required to be used by the withholding agents (when the
payments is made in a currency rather than RMB), as well as the time, venue and business for the performance of the withholding and collection
obligations; and (3) the abolishment of Circular 698.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is little guidance and practical experience
regarding the application of SAT Notice 7 and SAT Notice 37 and the related SAT notices. Moreover, the relevant authority has not yet
promulgated any formal provisions or formally declared or stated how to calculate the effective tax rates in foreign tax jurisdictions.
As a result, due to our complex offshore restructuring, we may become at risk of being taxed under SAT Notice 7 and SAT Notice 37 and
we may be required to expend valuable resources to comply with SAT Notice 7 and SAT Notice 37 or to establish that we should not be taxed
under SAT Notice 7 and SAT Notice 37, which could have a material adverse effect on our financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to our Ordinary Shares and the
Trading Market</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our share price may be volatile and could
decline substantially, which could result in substantial losses to our investors.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The trading price of our ordinary shares is likely
to continue to be volatile and could fluctuate widely due to factors beyond our control. This may happen because of broad market and industry
factors, including the performance and fluctuation of the market prices of other companies with business operations located mainly in
China that have listed their securities in the United States. The securities of some of these companies have experienced significant volatility
since their initial public offerings, including, in some cases, substantial price declines in their trading prices. The trading performances
of other Chinese companies&#8217; securities after their offerings may affect the attitudes of investors toward Chinese companies listed
in the United States in general and consequently may impact the trading performance of our shares, regardless of our actual operating
performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The market price of our ordinary shares may be
volatile, both because of actual and perceived changes in the company&#8217;s financial results and prospects, and because of general
volatility in the stock market. The factors that could cause fluctuations in our share price may include, among other factors discussed
in this section, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated variations in the financial results and prospects of the company or other companies in the pharmaceutical business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in financial estimates by research analysts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the market valuations of other companies in the Chinese patent medicine industry;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by us or our competitors of new education services, expansions, investments, acquisitions, strategic partnerships or joint ventures;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">mergers or other business combinations involving us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions and departures of key personnel and senior management;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in accounting principles;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the passage of legislation or other developments affecting us or our industry;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the trading volume of our ordinary shares in the public market;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the release of lockup, escrow or other transfer restrictions on our outstanding equity securities or sales of additional equity securities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential litigation or regulatory investigations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in economic conditions, including fluctuations in global and Chinese economies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial market conditions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural disasters, terrorist acts, acts of war or periods of civil unrest; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the realization of some or all of the risks described in this section.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The listing of our ordinary shares on the Nasdaq
Capital Market is contingent on our compliance with the Nasdaq Capital Market&#8217;s conditions for continued listing. A decline in the
closing price of our ordinary shares could result in a breach of the requirements for listing on the Nasdaq Capital Market. If we do not
maintain compliance, Nasdaq could commence suspension or delisting procedures in respect of our ordinary shares. The commencement of suspension
or delisting procedures by an exchange remains at the discretion of such exchange and would be publicly announced by the exchange. If
a suspension or delisting were to occur, there would be significantly less liquidity in the suspended or delisted securities. In addition,
our ability to raise additional necessary capital through equity or debt financing would be greatly impaired. Furthermore, with respect
to any suspended or delisted ordinary shares, we would expect decreases in institutional and other investor demand, analyst coverage,
market making activity and information available concerning trading prices and volume, and fewer broker-dealers would be willing to execute
trades with respect to such ordinary shares. A suspension or delisting would likely decrease the attractiveness of our ordinary shares
to investors and cause the trading volume of our ordinary shares to decline, which could result in a further decline in the market price
of our ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the stock markets have experienced
significant price and trading volume fluctuations from time to time, and the market prices of the equity securities of pharmaceutical
companies are sometimes subject to sharp price and trading volume changes. These broad market fluctuations may materially and adversely
affect the market price of our ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may issue additional ordinary shares
or other equity securities without your approval, which would dilute your ownership interests and may depress the market price of our
ordinary shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue additional ordinary shares or our
other securities to investors. We may also issue additional ordinary shares or other equity securities of equal or senior rank in the
future for any reason or in connection with, among other things, future acquisitions or repayment of outstanding indebtedness, without
shareholder approval, in a number of circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our issuance of additional ordinary shares or
other equity securities of equal or senior rank would have the following effects:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our existing shareholders&#8217; proportionate ownership interest in us will decrease;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount of cash available per share, including for payment of dividends in the future, may decrease;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relative voting strength of each previously outstanding share may be diminished; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the market price of our ordinary shares may decline.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We currently do not expect to pay dividends
on our ordinary shares in the foreseeable future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently do not expect to pay dividends on
our ordinary shares in the foreseeable future. Instead, for the foreseeable future, it is expected that we will continue to retain any
earnings to finance the development and expansion of its business, and not to pay any cash dividends on its ordinary shares. Consequently,
you should not rely on an investment in the Company as a source for any future dividend income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors has complete discretion
as to whether to distribute dividends, subject to applicable laws. Even if our board of directors decides to declare and pay dividends,
the timing, amount and form of future dividends, if any, will depend on, among other things, our future results of operations and cash
flow, our capital requirements and surplus, the amount of distributions, if any, received by us from our subsidiaries, our financial condition,
contractual restrictions and other factors deemed relevant by our board of directors. Accordingly, the return on your investment in our
ordinary shares will likely depend entirely upon any future price appreciation of our ordinary shares. We cannot guarantee that our ordinary
shares will appreciate in value or even maintain the price at which you purchased the ordinary shares. You may not realize a return on
your investment in our ordinary shares and you may even lose your entire investment in our ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If securities or industry analysts do not
publish research or publish inaccurate or unfavorable research about us or our business, our ordinary share price and trading volume could
decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The trading market for our ordinary shares will
depend in part on the research and reports that securities or industry analysts publish about us or our business. Securities and industry
analysts do not currently, and may never, publish research on us. If no securities or industry analysts commence coverage of our Company,
the trading price for its ordinary shares would likely be negatively impacted. In the event securities or industry analysts initiate coverage,
if one or more of the analysts who cover us downgrade its securities or publish inaccurate or unfavorable research about its business,
its stock price would likely decline. If one or more of these analysts cease coverage of our Company or fail to publish reports on our
Company, demand for its ordinary shares could decrease, which might cause its ordinary share price and trading volume to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>A sale or perceived sale of a substantial
number of our ordinary shares may cause the price of our ordinary shares to decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our shareholders sell substantial amounts of
our ordinary shares in the public market, the market price of our ordinary shares could fall. Moreover, the perceived risk of this potential
dilution could cause shareholders to attempt to sell their shares and investors to short our ordinary shares. These sales also make it
more difficult for us to sell equity-related securities in the future at a time and price that we deem reasonable or appropriate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We incur substantial increased costs being
a public company.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We incur significant legal, accounting and other
expenses as a public company that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, as well as rules subsequently
implemented by the SEC and Nasdaq, impose various requirements on the corporate governance practices of public companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compliance with these rules and regulations increases
our legal and financial compliance costs and makes some corporate activities more time-consuming and costlier. We have incurred additional
costs in obtaining director and officer liability insurance. In addition, we incur additional costs associated with our public company
reporting requirements. It may also be more difficult for us to find qualified persons to serve on our board of directors or as executive
officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an &#8220;emerging growth company,&#8221;
as defined in the JOBS Act and will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following
the fifth anniversary of the completion of our initial public offering, (b) in which we have total annual gross revenue of at least $1.235
billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our ordinary shares that is held
by non-affiliates exceeds $700 million as of the prior March 31, and (2) the date on which we have issued more than $1.0 billion in non-convertible
debt during the prior three-year period. An emerging growth company may take advantage of specified reduced reporting and other requirements
that are otherwise applicable generally to public companies. These provisions include exemption from the auditor attestation requirement
under Section 404 in the assessment of the emerging growth company&#8217;s internal control over financial reporting and permission to
delay adopting new or revised accounting standards until such time as those standards apply to private companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After we are no longer an &#8220;emerging
growth company,&#8221; or until five years following the completion of our initial public offering, whichever is earlier, we expect
to incur significant additional expenses and devote substantial management effort toward ensuring compliance with the requirements
of Section 404 and the other rules and regulations of the SEC. For example, as a public company, we have been required to increase
the number of independent directors and adopt policies regarding internal controls and disclosure controls and procedures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are currently evaluating and monitoring developments
with respect to these rules and regulations, and we cannot predict or estimate with any degree of certainty the amount of additional costs
we may incur or the timing of such costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>There can be no assurance that we will not
be a passive foreign investment company (&#8220;PFIC&#8221;) for United States federal income tax purposes for any taxable year, which
could subject United States holders of our ordinary shares could be subject to adverse United States federal income tax consequences.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A non-United States corporation will be a PFIC
for United States federal income tax purposes for any taxable year if either (i) at least 75% of its gross income for such taxable year
is passive income or (ii) at least 50% of the value of its assets (based on average of the quarterly values of the assets) during such
year is attributable to assets that that produce or are held for the production of passive income. Based on the current and anticipated
value of our assets and the composition of our income assets, we are not currently a PFIC under the current PFIC rules for United States
federal income tax purposes. However, the determination of whether or not we are a PFIC according to the PFIC rules is made on an annual
basis and depends on the composition of our income and assets and the value of our assets from time to time. Therefore, changes in the
composition of our income or assets or value of our assets may cause us to become a PFIC. The determination of the value of our assets
(including goodwill not reflected on our balance sheet) may be based, in part, on the quarterly market value of ordinary shares, which
is subject to change and may be volatile.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The classification of certain of our income as
active or passive, and certain of our assets as producing active or passive income, and hence whether we are or will become a PFIC, depends
on the interpretation of certain United States Treasury Regulations as well as certain IRS guidance relating to the classification of
assets as producing active or passive income. Such regulations guidance is potentially subject to different interpretations. If due to
different interpretations of such regulations and guidance the percentage of our passive income or the percentage of our assets treated
as producing passive income increases, we may be a PFIC in one or more taxable years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are a PFIC for any taxable year during which
a United States person holds ordinary shares, certain adverse United States federal income tax consequences could apply to such United
States person. See &#8220;Item 10. Additional Information&#8212;E. Taxation&#8212;United States Federal Income Taxation&#8212;PFIC.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>For as long as we are an emerging growth
company, we will not be required to comply with certain reporting requirements, including those relating to accounting standards and disclosure
about our executive compensation, that apply to other public companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are classified as an &#8220;emerging growth
company&#8221; under the JOBS Act. For as long as we are an emerging growth company, unlike other public companies, we will not be required
to, among other things, (i) provide an auditor&#8217;s attestation report on management&#8217;s assessment of the effectiveness of our
system of internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act, (ii) comply with any new requirements
adopted by the PCAOB, requiring mandatory audit firm rotation or a supplement to the auditor&#8217;s report in which the auditor would
be required to provide additional information about the audit and the financial statements of the issuer, (iii) provide certain disclosure
regarding executive compensation required of larger public companies, or (iv) hold nonbinding advisory votes on executive compensation.
We will remain an emerging growth company for up to five years, although we will lose that status sooner if we have more than $1.235 billion
of revenues in a fiscal year, have more than $700 million in market value of our ordinary shares held by non-affiliates, or issue more
than $1.0 billion of non-convertible debt over a three-year period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent that we rely on any of the exemptions
available to emerging growth companies, you will receive less information about our executive compensation and internal control over financial
reporting than issuers that are not emerging growth companies. If some investors find our ordinary shares to be less attractive as a result,
there may be a less active trading market for our ordinary shares and our share price may be more volatile.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to produce accurate financial
statements have been materially adversely affected by our failure to establish proper internal financial reporting controls. If we fail
to establish and maintain proper internal financial reporting controls in a reasonably timely manner, our ability to produce accurate
financial statements or comply with applicable regulations may continue to be impaired.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our independent registered public accounting firm
has not conducted an audit of our internal control over financial reporting. In the course of auditing our consolidated financial statements
for the <span style="background-color: white">fiscal</span> year ended September 30, 2024, we identified material weaknesses in our internal
control over financial reporting and other control deficiencies as of September 30, 2024. A &#8220;material weakness&#8221; is a deficiency,
or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material
misstatement of the company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The material weakness identified to date relates
to a lack of accounting staff and resources with appropriate knowledge of generally accepted accounting principles in the United States
(&#8220;U.S. GAAP&#8221;) and SEC reporting and compliance requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the identification of the material weaknesses
and control deficiencies, we have undertaken certain remedial steps and plan to continue taking remedial measures, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recruiting qualified accounting personnel with relevant U.S. GAAP and SEC reporting experience and qualifications to strengthen the financial reporting function and to set up a financial and system control framework. Since very few companies in Ji&#8217;an, Jiangxi Province, the area in which our main PRC operating subsidiaries are located, have sought public listing on a U.S. exchange, we have difficulty identifying qualified accounting candidates with U.S. GAAP experience and expertise. We plan to search for qualified personnel in other regions of China; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">implementing regular and continuous U.S. GAAP accounting and financial reporting training programs for our accounting and financial reporting personnel.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The implementation of these measures may not
fully address the material weaknesses in our internal control over financial reporting, and we cannot conclude that they have been
fully remedied. Our failure to correct theses material weaknesses or our failure to discover and address any other material
weaknesses could result in inaccuracies in our financial statements and could also impair our ability to comply with applicable
financial reporting requirements and related regulatory filings on a timely basis. As a result, our business, financial condition,
results of operations and prospects, as well as the trading price of our ordinary shares, may be materially and adversely affected.
Moreover, ineffective internal control over financial reporting significantly hinders our ability to prevent fraud.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a public company, we will be subject to Sarbanes-Oxley
Act of 2002, or Sarbanes-Oxley Act. Since we qualify as an &#8220;emerging growth company&#8221; pursuant to the JOBS Act with less than
US$1.235&#160;billion in revenue for our last fiscal year. An emerging growth company may take advantage of specified reduced reporting
and other requirements that are otherwise applicable generally to public companies. These provisions include exemption from the auditor
attestation requirement under Section&#160;404 of the Sarbanes-Oxley&#160;Act of 2002, or Section 404, in the assessment of the emerging
growth company&#8217;s internal control over financial reporting. Moreover, even if management concludes that our internal control over
financial reporting is effective, our independent registered public accounting firm, after conducting its own independent testing, may
issue a report that is qualified if it is not satisfied with our internal controls or the level at which our controls are documented,
designed, operated or reviewed, or if it interprets the relevant requirements differently from us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the course of documenting and testing our
internal control procedures, we may identify other weaknesses and deficiencies in its internal control over financial reporting. In addition,
if we fail to maintain the adequacy of our internal control over financial reporting, as these standards are modified, supplemented or
amended from time to time, we may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting
in accordance with Section&#160;404. Generally speaking, if we fail to achieve and maintain an effective internal control environment,
we could suffer material misstatements in our financial statements and fail to meet our reporting obligations, which would likely cause
investors to lose confidence in our reported financial information. This could in turn limit our access to capital markets, harm our results
of operations, and lead to a decline in the trading price of our securities. Additionally, ineffective internal control over financial
reporting could expose us to increased risk of fraud or misuse of corporate assets and subject us to potential delisting from the stock
exchange on which we list, regulatory investigations and civil or criminal sanctions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>As a foreign private issuer, we are not
subject to certain U.S. securities law disclosure requirements that apply to a domestic U.S. issuer, which may limit the information publicly
available to our shareholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a foreign private issuer, we are not required
to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act and therefore there may be less publicly
available information about us than if we were a U.S. domestic issuer. We are exempt from certain provisions of the securities rules and
regulations in the United States that are applicable to U.S. domestic issuers, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q or current reports on Form 8-K;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the sections of the Exchange Act regulating the solicitation of proxies, consents, or authorizations in respect of a security registered under the Exchange Act;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and the selective disclosure rules by issuers of material non-public information under Regulation FD.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are required to file an annual report on Form
20-F within four months of the end of each fiscal year. However, the information we are required to file with or furnish to the SEC will
be less extensive and less timely compared to that required to be filed with the SEC by U.S. domestic issuers. As a result, you may not
be afforded the same protections or information that would be made available to you were you investing in a U.S. domestic issuer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>As a foreign private issuer, we are permitted
to adopt certain home country practices in relation to corporate governance matters that differ significantly from the Nasdaq listing
standards. These practices may afford less protection to shareholders than they would enjoy if we complied fully with corporate governance
listing standards.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a foreign private issuer, we are permitted
to take advantage of certain provisions in the Nasdaq listing standards that allow us to follow Cayman Islands law for certain governance
matters. Certain corporate governance practices in the Cayman Islands may differ significantly from corporate governance listing standards
as, except for general fiduciary duties and duties of care, Cayman Islands law does not have a comparable corporate governance regime
applicable to the Company which prescribes specific corporate governance standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nasdaq Listing Rule 5635 generally provides that
shareholder approval is required of U.S. domestic companies listed on the Nasdaq Capital Market prior to issuance (or potential issuance)
of securities (i) equaling 20% or more of the company&#8217;s common stock or voting power for less than the greater of market or book
value (ii) resulting in a change of control of the company; and (iii) which is being issued pursuant to a stock option or purchase plan
to be established or materially amended or other equity compensation arrangement made or materially amended. Notwithstanding this general
requirement, Nasdaq Listing Rule 5615(a)(3)(A) permits foreign private issuers to follow their home country practice rather than these
shareholder approval requirements. The Cayman Islands do not require shareholder approval prior to any of the foregoing types of issuances.
The Company, therefore, is not required to obtain such shareholder approval prior to entering into a transaction with the potential to
issue securities as described above. The board of directors of the Company has elected to follow the Company&#8217;s home country rules
as to such issuances and will not be required to seek shareholder approval prior to entering into such a transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than the above, we do not currently intend
to follow any additional home country practices in lieu of Nasdaq requirements. However, if we choose to follow such other home country
practice in the future, our shareholders may be afforded less protection than they otherwise would have under corporate governance listing
standards applicable to U.S. domestic issuers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may lose our foreign private issuer status
in the future, which could result in significant additional costs and expenses.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As discussed above, we are a foreign private issuer,
and therefore, we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act.
The determination of foreign private issuer status is made annually on the last business day of an issuer&#8217;s most recently completed
second fiscal quarter. We would lose our foreign private issuer status if, for example, more than 50% of our ordinary shares are directly
or indirectly held by residents of the U.S. and we fail to meet additional requirements necessary to maintain our foreign private issuer
status. If we lose our foreign private issuer status on this date, we will be required to file with the SEC periodic reports and registration
statements on U.S. domestic issuer forms, which are more detailed and extensive than the forms available to a foreign private issuer.
We will also have to mandatorily comply with U.S. federal proxy requirements, and our officers, directors and principal shareholders will
become subject to the short-swing profit disclosure and recovery provisions of Section 16 of the Exchange Act. In addition, we will lose
our ability to rely upon exemptions from certain corporate governance requirements under the Nasdaq listing standards. As a U.S. listed
public company that is not a foreign private issuer, we will incur significant additional legal, accounting and other expenses that we
will not incur as a foreign private issuer, and accounting, reporting and other expenses in order to maintain a listing on a U.S. securities
exchange.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The laws of the Cayman Islands may not provide
our shareholders with benefits comparable to those provided to shareholders of corporations incorporated in the United States.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our corporate affairs are governed by our amended
and restated memorandum and articles of association, by the Companies Act (Revised) of the Cayman Islands and by the common law of the
Cayman Islands. The rights of shareholders to take action against our directors, actions by minority shareholders and the fiduciary responsibilities
of our directors to us under Cayman Islands law are to a large extent governed by the common law of the Cayman Islands. The common law
in the Cayman Islands is derived in part from comparatively limited judicial precedent in the Cayman Islands and from English common law.
Appeals from the Cayman Islands Courts to the Privy Council (which is the final Court of Appeal for British overseas territories such
as the Cayman Islands) are binding on courts in the Cayman Islands. Decisions of the English courts, and particularly the Supreme Court
and the Court of Appeal are generally of persuasive authority but are not binding in the courts of the Cayman Islands. Decisions of courts
in other Commonwealth jurisdictions are similarly of persuasive but not binding authority. The rights of our shareholders and the fiduciary
responsibilities of our directors under Cayman Islands law are not as clearly established as they would be under statutes or judicial
precedents in the United States. In particular, the Cayman Islands has a less developed body of securities laws relative to the United
States. Therefore, our public shareholders may have more difficulty protecting their interests in the face of actions by our management,
directors or controlling shareholders than would shareholders of a corporation incorporated in a jurisdiction in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>You may be unable to present proposals before
annual general meetings or extraordinary general meetings not called by shareholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cayman Islands law provides shareholders with
only limited rights to requisition a general meeting, and does not provide shareholders with any right to put any proposal before a general
meeting. These rights, however, may be provided in a company&#8217;s amended and restated articles of association. Our amended and restated
articles of association allow our shareholders holding shares representing in aggregate not less than 10% of our voting share capital
in issue, to requisition a general meeting of our shareholders, in which case our directors are obliged to call such meeting. Advance
notice of at least 21 clear days is required for the convening of our annual general shareholders&#8217; meeting and at least 14 days&#8217;
notice any other general meeting of our shareholders. A quorum required for a meeting of shareholders consists of at least one shareholder
present or by proxy, representing not less than one-third of the total outstanding shares carrying the right to vote at such general meeting
of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The obligation to disclose information publicly
may put us at a disadvantage to competitors that are private companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a public company in the United States.
As a public company, we will be required to file periodic reports with the SEC upon the occurrence of matters that are material to our
Company and shareholders. Although we may be able to attain confidential treatment of some of our developments, in some cases, we will
need to disclose material agreements or results of financial operations that we would not be required to disclose if we were a private
company. Our competitors may have access to this information, which would otherwise be confidential. This may give them advantages in
competing with our Company. Similarly, as a U.S. public company, we will be governed by U.S. laws that our competitors, which are mostly
private Chinese companies, are not required to follow. To the extent compliance with U.S. laws increases our expenses or decreases our
competitiveness against such companies, our public company status could affect our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 4. INFORMATION ON THE COMPANY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. <span style="text-decoration:underline">History and Development of the Company</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Corporate History and Structure</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">We are an
offshore holding company incorporated in the Cayman Islands. As a holding company with no operations of our own, our operations are conducted
in China through our wholly owned indirect PRC subsidiary,&#160;Jiangxi Universe, and its subsidiaries. Investors in our securities are
not purchasing equity interests in our subsidiaries but instead are purchasing equity interests in the ultimate Cayman Islands holding
company. Therefore, you will not directly hold any equity interests in the operating entities. The Chinese regulatory authorities could
disallow this structure, which would likely result in a material change in our operations and/or a material change in the value of the
securities we are registering for sale, including that it could cause the value of such securities to significantly decline or become
worthless. For risks facing our Company as a result of our organizational structure and doing business in China, see &#8220;Item 3. Key
Information&#8212;D. Risk Factors&#8212;Risks Related to Doing Business in China.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We initially conducted our business through Jiangxi
Universe, a PRC company formed in 1998 and Universe Trade, a PRC company formed in 2010, a wholly-owned subsidiary of Jiangxi Universe.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With the growth of our business and in order
to facilitate international capital investment in our Company, we underwent an offshore reorganization in 2019 and 2020. On December
11, 2019, our holding company, Universe Pharmaceuticals INC, was incorporated under the laws of the Cayman Islands as an exempted
company with limited liability. Our wholly owned subsidiary Universe HK was formed in Hong Kong on May 21, 2014 as an intermediate
holding company. Universe HK in turn holds all the capital stocks of Universe Technology, a wholly foreign owned enterprise
incorporated in China on Aril 8, 2019. Universe Technology holds all the capital stocks and controls Jiangxi Universe. Jiangxi
Universe holds 100% of the equity interests in Universe Trade.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our holding company has no business operation
other than holding the shares in Universe HK. Universe HK is a pass-through entity with no business operation. Universe Technology is
exclusively engaged in the business of managing the operation of Jiangxi Universe. Jiangxi Universe specializes in manufacturing our own
TCMD products. Universe Trade specializes in the distribution and sales of our own TCMD products and third-party pharmaceutical products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foshan Shangyu Investment Holding Co., Ltd. (&#8220;Foshan
Shangyu&#8221;) is our affiliated entity, 90% owned by and controlled by Mr. Gang Lai, our chief executive officer and chairman of the
board of directors. Foshan Shangyu was formed in 2004 in China as a holding company of Mr. Gang Lai. Foshan Shangyu has no business operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 12, 2021, we formed Guangzhou Universe
Hanhe Medical Research Co., Ltd. in the PRC, as a wholly-owend subsidiary of Jiangxi Universe. Universe Hanhe does not conduct any business
operations as of the date of this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following diagram illustrates our corporate
structure as of the date of this annual report:</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_001.jpg" style="height: 396pt; width: 372pt"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Recent Development</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 15, 2024, we closed a self-underwritten
public offering of 20,000,000 ordinary shares, par value US$0.01875 per share, at an offering price of US$1.25 per share. We raised a
total of US$25 million through that offering, before deducting offering-related expenses, and net proceeds of $24.625 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 12, 2024, we effected a share consolidation of 15 ordinary
shares with par value of US$0.01875 per share each in the Company&#8217;s issued and unissued share capital into one ordinary share with
par value of US$0.28125. All fractional shares were rounded up to the whole number of shares. Immediately following the share consolidation,
the authorized share capital of the Company was US$140,625,000 divided into 450,000,000 ordinary shares, par value US$0.28125 per share
and 50,000,000 preferred shares, par value US$0.28125 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On December 6, 2024, we entered into a securities purchase agreement
(the &#8220;Securities Purchase Agreement&#8221;) with certain purchasers named thereto, pursuant to which the Company agreed to issue
and sell (i) 388,000 ordinary shares, par value US$0.28125 per share (the &#8220;Offered Shares&#8221;), (ii) 18,362,000 pre-funded warrants
to purchase 18,362,000 ordinary shares, par value US$0.28125 per share (the &#8220;Pre-funded Warrants&#8221;), and (iii) 18,750,000 common
warrants to purchase 18,750,000 ordinary shares, par value US$0.28125 per share (the &#8220;Common Warrants&#8221;), at a combined purchase
price of US0.80 per Offered Share and one accompanying Common Warrant, or at a combined purchase price of US$0.79 per Pre-funded Warrant
(in lieu of one Offered Share) and one accompanying Common Warrant, in a registered direct offering (the &#8220;Offering&#8221;). The
Company received approximately $15.0 million in gross proceeds from the Offering, before deducting placement agent fees and estimated
offering expenses. The Offered Shares and the ordinary shares underlying the Pre-funded Warrants and the Common Warrants offered under
the Securities Purchase Agreement were offered and sold pursuant to the Company&#8217;s effective registration statement on Form F-3 (Registration
No. 333-268028), initially filed by the Company with the SEC on October 27, 2022 and declared effective by the SEC on November 15, 2022,
and the base prospectus included therein, as supplemented by the prospectus supplement dated December 6, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Offering closed on December
10, 2024. For the period from the effectiveness of the registration statement on Form F-1 to September 30, 2024, we used approximately
US$7.0 million for research and development purposes, approximately US$6.75 million for upgrading and expanding our manufacturing facilities,
and approximately US$6.0 million for brand marketing. We still intend to use the remaining proceeds from our initial public offering in
the manner disclosed in our registration statement on Form F-1, as amended (File Number 333-248067). For the period from October 1, 2024
to the date of this annual report, we used approximately USD$280,000 for advertising purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 24, 2025, we effected a share consolidation
of 40 ordinary shares with par value of US$0.28125 per share each in the Company&#8217;s issued and unissued share capital into one ordinary
share with par value of US$11.25. All fractional shares were rounded up to the whole number of shares. Immediately following the share
consolidation, the authorized share capital of the Company was US$140,625,000 divided into 11,250,000 ordinary shares, par value US$11.25
per share and 1,250,000 preferred shares, par value US$11.25 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Corporate Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal executive offices are located at
265 Jingjiu Avenue, Jinggangshan Economic and Technological Development Zone, Ji&#8217;an, Jiangxi Province, People&#8217;s Republic of
China, and our phone number is +86-0796-8403309. Our registered office in the Cayman Islands is located at Vistra (Cayman) Limited, P.O.
Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KYI &#8211; 1205 Cayman Islands, and the phone number of our
registered office is +1-(345)769-9372. We maintain a corporate website at http://www.universe-pharmacy.com. The information contained
in, or accessible from, our website or any other website does not constitute a part of this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEC maintains a website at www.sec.gov that
contains reports, proxies, and information statements, and other information regarding issuers that file electronically with the SEC using
its EDGAR system.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For information regarding our principal capital
expenditures, see &#8220;Item 5. Operating and Financial Review and Prospects&#8212;B. Liquidity and Capital Resources&#8212;Capital Expenditures.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. <span style="text-decoration:underline">Business Overview</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TCM is a comprehensive form of healthcare that
has been widely adopted in China for more than 23 centuries. TCM rests upon the assumption that the human body is an ecosystem, embodying
the fusion of Shen (psyche), Essence (soma), Qi, Moisture (body fluids), and Blood (tissue). Health in the context of TCM is more than
just the absence of diseases, but to identify imbalance in human body and restore harmony. TCM is not only intended to cure diseases but
to enhance the capacity for fulfillment, happiness and general well-being of people.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through the PRC operating entities, we are a pharmaceutical
company based in Jiangxi, China, specializing in the manufacturing, marketing, sales and distribution of TCMD products targeting the elderly
with the goal of addressing their physical conditions in the aging process and to promote their general well-being. The PRC operating
entities have registered and obtained approval for 26 varieties of TCMD products from the National Medical Products Administration (the
&#8220;NMPA&#8221;), and we currently produce 13 varieties of TCMD products, which are sold in approximately 261 cities of 30 provinces
in China. In addition, through our subsidiary Universe Trade, we sell not only our own TCMD products, but also biomedical drugs medical
instruments, Traditional Chinese Medicine Pieces (&#8220;TCMPs&#8221;), and dietary supplements manufactured by third-party pharmaceutical
companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Products manufactured by us.&#160;</i>The 13
TCMD products currently manufactured by us fall into two categories: (1) treatment and relief for common chronic health conditions in
the elderly designed to achieve physical wellness and longevity (&#8220;chronic condition treatments&#8221;), and (2) cold and flu medications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chronic condition treatments</b>: Guben Yanling Pill, Shenrong Weisheng Pill, Quanlu Pill, Yangxue Danggui Syrup, Wuzi Yanzong Oral Liquid, Fengtong Medicinal Liquor, Shenrong Medicinal Liquor, Qishe Medicinal Liquor, Fengshitong Medicinal Liquor, and Shiquan Dabu Medicinal Liquor.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cold and flu medicines</b>: Paracetamol Granule for Children, Isatis Root Granule and Qiangli Pipa Syrup.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As people age, they have an increasing risk
of developing chronic health conditions. According to a report published by the Chinese Center for Disease Control and Prevention in
March 2019, 75.8% of seniors have at least one chronic health condition, and 35.1% of them have two or more. According to the
&#8220;Blue Book of Elderly Health (2020-2021)&#8221; released in December 2021 by the Chinese Academy of Medical Sciences, the
School of Public Health of Peking Union Medical College and the Social Sciences Literature Publishing House, the prevalence of
hypertension, diabetes and hypercholesterolemia in Chinese residents aged 60 and above is 58.3%, 19.4% and 10.5%, respectively, and
more than 3/4 of the residents have multiple disease coexistence, and with the increase of age, the prevalence of chronic diseases
increases. Some of the most common chronic diseases in the elderly include arthritis, chronic kidney disease, fatigue, and low back
pain. <span style="background-color: white">The PRC operating entities&#8217; products </span>under the category of chronic
condition treatments are designed to address some of the aforementioned diseases. <span style="background-color: white">The PRC
operating entities&#8217; </span>cold and flu medicines, on the other hand, include products designed to treat and relieve symptoms
of respiratory illnesses caused by bacteria and viruses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The PRC operating entities&#8217; third-party
products. </i>Through our subsidiary, Universe Trade, we also distribute and sell products manufactured by third-party producers, including
biomedical drugs, medical instruments, TCMPs and dietary supplements. For the <span style="background-color: white">fiscal </span>years
ended September 30, 2024, 2023 and 2022, we distributed around 2,552, 2,239 and 2,785 types of third-party products, respectively.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The PRC operating entities&#8217; Customers.&#160;</i>The
PRC operating entities&#8217; major customers are pharmaceutical distributors, hospitals, clinics and drugstore chains, primarily located
in Jiangxi Province, Jiangsu Province, Guangdong Province, Hubei Province, Fujian Province, Guangxi Province and Shandong Province, and
23 other provinces in China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The PRC operating entities&#8217; customer base
decreased from 2,651 as of September 30, 2022 to 2,541 as of September 30, 2023, and increased to 2,561 as of September 30, 2024. The
revenues from selling the PRC operating entities&#8217; own products decreased from $23,988,177 for the fiscal year ended September 30,
2022 to $18,572,658 for the fiscal year ended September 30, 2023, as we changed our pricing strategy and decreased selling price of our
TCMD products to increase sales volume and market share, and decreased to $14,026,049 for the fiscal year ended September 30, 2024 because
sales volume decreased by 29.1% as global economic slowdown has led to a decline in customers&#8217; spending power. The revenues from
distributing and selling third-party products decreased from $16,154,974 in the fiscal year ended September 30, 2022 to $13,736,077 for
the fiscal year ended September 30, 2023 due to decreased sales volume and negative impact from foreign currency fluctuation and decreased
to $8,998,409 for the fiscal year ended September 30, 2024 because sales volume decreased by 28.0%. Our net loss was $8,736,566 for the
fiscal year ended September 30, 2022, $6,163,061 for the fiscal year ended September 30, 2023, and $20,327,897 for the fiscal year ended
September 30, 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Competitive Strengths</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe we have the following competitive strengths:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>A recognized manufacturer of TCMD products
in China&#8217;s rapidly growing health and wellness market</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a recognized manufacturer of TCMD products
in China&#8217;s rapidly growing health and wellness market. We own a number of famous brands in the industry, which are also our registered
trademarks in China. For instance, our brand &#8220;Hu Zhuo Ren (&#32993;&#21331;&#20161;)&#8221; is especially well-recognized in Jiangxi
Province. Further, our brand &#8220;Bai Nian Dan (&#30334;&#24180;&#20025;)&#8221; is famous for specializing in products targeted at
the physical wellness of older population. Our other recognized brands include &#8220;Long Zhong (&#40857;&#31181;)&#8221;, &#8220;Yi
Ke Ting (&#30410;&#20811;&#20572;)&#8221;, &#8220;Xue Li (&#34880;&#21147;)&#8221;, &#8220;Duo Lai Mei (&#26421;&#26469;&#32654;)&#8221;,
&#8220;Shu Er Kang (&#33298;&#20799;&#24247;)&#8221;, &#8220;Hu Zhuo Ren (&#32993;&#21331;&#20161;)&#8221;, &#8220;Ai Bi Xin (&#29233;&#24517;&#27427;)&#8221;,
and &#8220;Yong He Shuang Feng (&#27704;&#21644;&#21452;&#20964;)&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Chinese patent medicine industry is growing
rapidly and steadily in China. The primary growth drivers of China&#8217;s Chinese patent medicine industry include the increasing disposable
income and healthcare awareness in China, growing aging population and the prevalence of chronic diseases, and favorable governmental
policies and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We attribute our success to our recognized brand
names, strong relationships with our suppliers, loyal and stable customer base, and proven capability to develop and manufacture TCMD
products aligned with the preferences of end consumers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Rigorous quality control standards and manufacturing
protocols</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that the quality of our products
is crucial to our success as a pharmaceutical company, and we have implemented an overall quality control system, as well as strict
manufacturing protocols specifically designed for each product. Our quality control system starts from procurement. The raw
materials we source from our suppliers must first be examined and certified for quality. We review the performance of our suppliers
based on the quality of their products and adjust future orders from them accordingly. Further, an average of three inspections are
made by our personnel throughout the manufacturing process to ensure that the manufacturing protocols are strictly followed, and
that the quality of semi-products are at or above standard. After completion of manufacturing, our personnel will perform an overall
quality examination. Through the implementation of a quality control system, we are able to identify the weakness in our production
process and improve our operations over time. We believe our quality control standards and manufacturing protocols have contributed
to the high quality and consistency of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Visionary management team with substantial
industry experience</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our visionary management team is the bedrock of
our success. Many members of our leadership possess extensive experience in the pharmaceutical, biomedical, chemical and related industries.
For instance, our chief executive officer, Mr. Gang Lai, has about 33 years of corporate management experiences. Mr. Xiaojun Deng, the
deputy manufacturing manager of Jiangxi Universe, holds a degree in Traditional Chinese Medicine Manufacturing from Jiangxi Medical School
with over 28 years of working experience in the Chinese patent medicine industry. Ms. Lin Yang, our chief financial officer, has over
16 years of finance and management experience working in pharmaceutical companies. Mr. Yajun Hu, the general manager of Jiangxi Universe,
has over 10 years of experiences in managing a pharmaceutical company. Mr. Baochang Liu, our chief operating officer, has over 19 years
of experience in pharmaceutical marketing and had previously held marketing and management positions at a number of listed pharmaceutical
companies in China. Moreover, many members of the team have worked together for an extended period of time and helped build the Company
from the ground up. The rapport that the team has built extends beyond the talent and skills of individual team members and contributes
to a collective sense of mission.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Growth Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Build a Strong Brand Image to Achieve National
Recognition</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that broader recognition and favorable
perception of our brand by consumers in our target markets are crucial to our future success. Our brand has gained a solid reputation
in Southern China, especially Jiangxi Province, and we plan to increase the awareness of our brand among consumers in other parts of China.
Specifically, we plan to build a strong brand image that we are a TCMD producer specializing in the development and manufacture of products
designed to address the physical conditions of the elderly during the aging process and to promote their general well-being. To achieve
our goal, we plan to spend most of our efforts on the development and marketing of our brand &#8220;Bai Nian Dan (&#30334;&#24180;&#20025;)&#8221;
as the brand to be associated with our ideal brand image because &#8220;Bai Nian&#8221; (&#30334;&#24180;) signifies longevity in the
Chinese language, and &#8220;Dan&#8221; (&#20025;) alludes to our signature product, Guben Yanling Pill.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have been advertising our products through
television advertisement. We also intend to advertise targeting older customers, including transmitting our advertisements through additional
traditional media platforms such as live radio stations, newspapers, as well as in-person marketing at drug stores and clinics. In the
fiscal year ended September 30, 2022, our marketing department explored direct selling strategy and increased its efforts to market products
directly to customers in Liaoning Province. In the fiscal year ended September 30, 2023, our marketing strategies are primarily focused
on digital marketing and brand promotion, and we launched in-app advertising campaigns and created brand films to enhance our recognition
among potential customers. In the fiscal year ended September 30, 2024, we continued adopting our marketing strategies for the fiscal
year ended September 30, 2023, with a focus on promoting our products with in-app advertising campaigns through Health Headline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Enhance Our Distribution Network to Increase
Market Penetration and Customer Stickiness</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, our products are sold in 30
provinces in China. We plan to enter the markets in other parts of China. To achieve this goal, we have made efforts to further
strengthen and expand our distribution network through connecting with more local distributors, chain drugstores, malls and
supermarkets in other parts of China. Currently, our strategic focus is to attract more marketing talents and build a stronger sales
and marketing team to keep us on top of the latest information of local markets, customer preferences and industry trends. We also
plan to create an online store to reach a wider consumer demographic. In the future, we plan to start our own retail chain stores,
and provide training programs to sales personnel to improve their skills and acquire knowledge of our products, in order to further
diversify our distribution channels to increase our market penetration and customer base.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Integrate Our Internal Manufacturing Capability
to Ensure Productivity, Supply, and Selection of Products</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to further optimize our production facilities
to increase the productivity, supply and selection of our products, so that we may gain competitive edges over our competitors. Specifically,
we intend to increase productivity and supply by expanding the existing production lines and converting them into automated production
lines. To increase the selection of our products, we plan to build additional production facilities for our licensed TCMD products to
be launched in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Further Grow Our Research and Development
Capacities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The size of the Chinese patent medicine market
has been growing steadily. To respond to increasing market demand, we will continue to provide financial and operational resources to
focus on the research and development of TCMD products and dietary supplements designed to address the physical conditions of the elderly
during the aging process and promote their general well-being.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Manufactured Products</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We manufacture, market and sell 13 different TCMD
products to customers in 30 different provinces in China. Our TCMD products fall under two categories: chronic condition treatments and
cold and flu medications. The following list outlines our current products:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; padding: 0pt 0pt 0pt 0in; text-align: left; text-indent: 0pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percentage of Gross Sales</td><td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold; vertical-align: top">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; padding: 0pt 0pt 0pt 0in; vertical-align: bottom; font-weight: bold; text-align: left">Product&#160;Category</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Product Name</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Posology</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Intended Uses</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding: 0pt 0pt 0pt 0in; width: 18%; font-weight: bold; text-align: left; text-indent: 0pt">Chronic Condition Treatments</td><td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 13%; text-align: center">Guben Yanling Pill</td><td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 12%; text-align: center">Pills</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="vertical-align: top; width: 7%; text-align: right">37.2</td><td style="vertical-align: top; width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="vertical-align: top; width: 7%; text-align: right">36.4</td><td style="vertical-align: top; width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="vertical-align: top; width: 7%; text-align: right">42.5</td><td style="vertical-align: top; width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 24%; text-align: center">To relieve fatigue, palpitation, low back pain, and generalized weakness and soreness.</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; padding: 0pt 0pt 0pt 0in; text-align: left; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Shenrong Weisheng Pill</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Pills</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">4.4</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">3.5</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">2.5</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">To relieve fatigue, dizziness, excessive sweating, and pain in the waist and the knees.</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding: 0pt 0pt 0pt 0in; text-align: left; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Quanlu Pill</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Pills</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">2.3</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">1.9</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">1.7</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">To improve kidney functions and spleen functions, and relieve fatigue, low back pain, and knee pain.</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; padding: 0pt 0pt 0pt 0in; text-align: left; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Wuzi Yanzong Oral Liquid</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Oral liquid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">0.1</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">0.1</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">0.5</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">To improve kidney functions.</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding: 0pt 0pt 0pt 0in; text-align: left; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Yangxue Danggui Syrup</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Syrup</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">0.8</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">0.3</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">0.4</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">To improve blood circulation and treating dizziness, headaches and menstrual pains.</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; padding: 0pt 0pt 0pt 0in; text-align: left; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Fengshitong Medicinal Liquor</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Medicinal liquor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">-</td><td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">0.8</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">0.6</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">To treat low back pain and numbness in the feet and hands, and relieve rheumatoid arthritis pain.</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding: 0pt 0pt 0pt 0in; text-align: left; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Shiquan Dabu Medicinal Liquor</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Medicinal liquor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">1.0</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">1.1</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">1.0</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">To treat dizziness, palpitation, fatigue, and weakness, and ease menstrual flow.</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; padding: 0pt 0pt 0pt 0in; text-align: left; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Fengtong Medicinal Liquor</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Medicinal liquor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">0.6</td><td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">-</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">0.2</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">To treat low back pain and numbness in the feet and hands, and relieve symptoms of arthritis.</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding: 0pt 0pt 0pt 0in; text-align: left; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Shenrong Medicinal Liquor</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Medicinal liquor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">1.2</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">0.6</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">0.5</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">To improve blood circulation and relieve symptoms of fatigue, low back pain and leg pain.</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; padding: 0pt 0pt 0pt 0in; text-align: left; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Qishe Medicinal Liquor</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Medicinal liquor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">0.3</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">0.3</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">0.5</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">To treat blood stasis, arthritis, and numbness in the feet and hands.</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding: 0pt 0pt 0pt 0in; font-weight: bold; text-align: left; text-indent: 0pt">Cold and Flu Medicines Medicinal Liquor</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Qiangli Pipa Syrup</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Syrup</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">3.7</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">4.9</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">5.9</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">Relieve cough and reduce mucus and phlegm.</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; padding: 0pt 0pt 0pt 0in; text-align: left; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Paracetamol Granule for Children</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Granules</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">2.2</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">3.4</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">1.9</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">To relieve children&#8217;s headaches, muscle aches, toothaches, colds and fevers.</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding: 0pt 0pt 0pt 0in; text-align: left; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Isatis Root Granule</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Granules</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">7.0</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">4.3</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">1.6</td><td style="vertical-align: top; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">To treat common colds and other infections of the upper respiratory tract.</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Among the 13 TCMD products we manufacture, Guben
Yanling Pill is our signature product. For the fiscal years ended September&#160;30, 2024, 2023 and 2022, the revenue derived from the
sale of Guben Yanling Pill represented 37.2%, 36.4% and 42.5% of our total revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our Manufacturing Process</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following chart illustrates our main manufacturing
process from raw material purchase to marketing:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_002.jpg" style="height: 208.5pt; width: 443.25pt"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Our Raw Materials and Suppliers</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We select our raw materials for the manufacturing
of our products strictly in accordance with the guidance in Pharmacopoeia of the People&#8217;s Republic of China (&#12298;&#20013;&#21326;&#33647;&#20856;&#12299;)
(the &#8220;PPRC&#8221;), an official compendium of drugs covering both TCM and western medications complied by the Pharmacopoeia Commission
of the Ministry of Health of People&#8217;s Republic of China. The PPRC specifies the standards of description, dosage, purity, storage,
and other material information for each drug. In the manufacturing of our TCMD products, more than 110 types of raw materials are regularly
used, among which angelica, codonopsis, poria mushroom, isatis root, ginseng loquat leaves, safflower, and Baijiu liquor represent our
main raw materials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, we have stable access to all the raw
materials necessary for our production. There are many suppliers in the industry for the regularly used raw materials, and therefore we
are not relying on a single supplier for any of our raw materials. If we are unable to purchase any of the raw materials from one supplier,
we do not expect to face material difficulties in locating another supplier at substantially the same price. While the prices of such
raw materials may vary greatly from time to time due to market forces beyond our control, we believe we can hedge such risk by adjusting
our price, or absorbing higher costs if and when necessary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To source the raw materials required for our products,
we regularly contract with our suppliers by placing bulk orders with them at below market prices. Our raw material suppliers include mostly
traditional Chinese medicine manufacturers and pharmaceutical trading companies. After years of business cooperation, we believe that
our relationships with our current suppliers are strong and stable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consider our raw materials suppliers whose
sales to us accounted for more than 10% of our overall purchases in any given period to be our major suppliers for such period. For the
<span style="background-color: white">fiscal </span>year ended September 30, 2024, two suppliers accounted for 28.0% and 13.4% of our
total purchases, respectively. For the <span style="background-color: white">fiscal </span>year ended September 30, 2023, one supplier
accounted for 29.6% of the total purchases. For the fiscal year ended September 30, 2022, one supplier, Jiangxi Hongjing Pharmaceutical
Co., Ltd., accounted for approximately 10.3% of our total purchases. No other supplier individually accounted for more than 10% of our
total purchases for the fiscal years ended September 30, 2024, 2023 and 2022.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Manufacturing Process</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a brief description of the manufacturing
process of the TCMD products we currently produce by dosage forms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Pill Products</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To make our pill products, the raw materials first
go through a preparation process, during which such materials are dried, roughly ground and sterilized. Processed raw materials are then
finely ground, mixed with honey, and made into pills before they are finally packaged.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Granule Products</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The raw materials of our granule products typically
go through a purifying process, during which such materials are stewed, filtered, condensed, and let stand. Processed raw materials are
then mixed with supplemental ingredients before they are made into granules, dried, and finally packaged.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Syrup Products</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The raw materials of our syrup products are first
stewed together and condensed. Condensed liquid is then filtered and mixed with supplemental ingredients before it is bottled and packaged.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Oral Liquid Products</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The raw materials of our oral liquid products
are first filtered, condensed, and fixed with other supplemental ingredients. The processed materials are then further filtered and sterilized
before being bottled and packaged.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Medicinal Liquor Products</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The raw materials of our medicinal liquor products
first go through a purifying process, during which such materials are selected, cut, rinsed, stewed, and refrigerated. Processed raw materials
then go through an extraction process that involves mixing with solvents and filtering. Then, the liquor products are bottled and packaged.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Quality Control and Assurance</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We seek to ensure the high quality of our products
through our quality control system and by conducting product testing and review. Our entire manufacturing process is strictly supervised
pursuant to internal quality control standards that have been set up in strict adherence to the guidelines provided in PPRC. We conduct
our quality testing by examining the quality of each and every type of raw materials. If the raw materials meet our quality standards,
we start the manufacturing process, during which we continue our quality testing for every substantial procedure, including filtering,
grinding, mixing, and pill making. After our products are packaged, we will examine various features of our final products thoroughly,
including appearance, weight, taste, water content, and microorganism content.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Third-party Product Distribution</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to manufacturing our own products,
we also distribute and sell, through our subsidiary Universe Trade, biomedical drugs, medical instruments, TCMPs and dietary supplements
manufactured by third-party pharmaceutical companies. For the fiscal year ended September 30, 2024, we had distributed roughly 2,532 third-party
products, of which approximately 39.0% are biochemical drugs, such as liquid glucose, prednisolone, and citicoline, approximately 9.0%
are medical instruments, such as drug-eluting stents, surgical tubes and syringes, approximately 48.0% are TCMPs, such as red sage tables,
Longdan Xiegan pills, and Chinese skullcap capsules, and approximately 4.0% are dietary supplements. For the fiscal year ended September
30, 2023, we had distributed roughly 2,239 third-party products, of which approximately 91.69% are biochemical drugs, such as liquid glucose,
prednisolone, and citicoline, approximately 8.29% are medical instruments, such as drug-eluting stents, surgical tubes and syringes, approximately
0.02% are TCMPs, such as red sage tables, Longdan Xiegan pills, and Chinese skullcap capsules. For the fiscal year ended September 30,
2022, we had distributed roughly 2,785 third-party products, of which approximately 85.0% are biochemical drugs, such as liquid glucose,
prednisolone, and citicoline, approximately 14.8% are medical instruments, such as drug-eluting stents, surgical tubes and syringes, approximately
0.2% are TCMPs, such as red sage tables, Longdan Xiegan pills, and Chinese skullcap capsules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our Suppliers of Third-party Products</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We source third-party pharmaceutical products
from their manufacturers in China. Our third-party product suppliers include mostly medical instrument manufacturers, pharmaceutical product
manufacturers and dietary supplement manufacturers. For all of the products that we source and sell, we can generally find similar replacements
in the market from the competitors of our current suppliers. Accordingly, we do not have any continuous or long-term supply agreements
with any of these suppliers. We purchase third-party medical products from our suppliers on a per purchase order basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the fiscal year ended September 30, 2024,
2023 and 2022, we purchased products from over 598, 661 and 658 suppliers, respectively. For the fiscal years ended September 30, 2024,
2023 and 2022, we did not have any supplier of third-party products whose sales to us accounted for more than 10% of our overall purchases
of that fiscal year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Customers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our customers are mostly pharmaceutical distributors,
hospitals, clinics and drugstore chains with pharmaceutical business qualification certificates, awarded and authorized by the NMPA and
are authorized to sell and deliver our products to end consumers. As of the date of this annual report, our customers are scattered over
261 cities of 30 provinces in China. We determine whether to establish long-term business relationships with our customers primarily based
on two factors, their ability to promote our products and their ability to make payments on time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2024, we had a total of 2,561
customers, of which 1,276 were pharmaceutical distributors, 231 were clinics, 358 were drug stores, and 696 were hospitals. As of September
30, 2023, we had a total of 2,541 customers, of which 1,267 were pharmaceutical distributors, 279 were clinics, 356 were drug stores,
and 639 were hospitals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the fiscal year ended September 30, 2024,
our revenues generated from sales to pharmaceutical distributors, hospitals, clinics and drugstore chains represented 65.68%, 20.77%,
9.07% and 4.49% of our total revenues, respectively. For the fiscal year ended September 30, 2023, our revenues generated from sales to
pharmaceutical distributors, hospitals, clinics and drugstore chains represented 59.26%, 22.02%, 13.50% and 5.22% of our total revenues,
respectively. For the fiscal year ended September 30, 2022, our revenues generated from sales to pharmaceutical distributors, hospitals,
clinics and drugstore chains represented 49.3%, 10.9%, 8.6%, and 31.2% of our total revenues, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of our customers generated more than 10%
of our revenue for the fiscal years ended September 30, 2024, 2023 and 2022. However, our top 10 customers aggregately accounted for 22.5%,
27.2% and 32.2% of our total revenue for the fiscal years ended September 30, 2024, 2023 and 2022, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Marketing and Sales</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that marketing activities are crucial
to our success in the competitive Chinese patent medicine industry. As of September 30, 2024, we had a total of 60 employees in our marketing
department. Employees in our marketing department are mainly responsible for performing various marketing activities, including researching
the most updated industry and market information, analyzing market trends and consumer preferences, setting up marketing strategies, executing
sales contracts, communicating with existing customers and networking with potential customers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our marketing and sales initiatives for the next
several years will focus on three objectives: developing a strong brand image, building a successful marketing team, and expanding retail
channels. To develop our brand image as a producer of TCMD products aiming at addressing the physical conditions of the elderly during
the aging process and promoting their general well-being, we seek to promote our brand &#8220;Bai Nian Dan (&#30334;&#24180;&#20025;)&#8221;
utilizing both online marketing channels such as WeChat official account and other social media and traditional platforms such as television,
newspapers, and live radio stations. As part of the efforts to build a successful marketing team, we intend to hire additional sales talents
and provide monetary and equity incentives to sales employees. For the purpose of expanding our retail channels, we plan to open an online
retail store, and according to the preferences of online shoppers, we may adjust the sizes, packaging, or prices of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We established a research and development department
in 1998. Our research and development team has been focusing on the upgrade of current products and the development of production techniques
to increase productivity. After years of continued development, our research and development department has become the core of our technological
innovation efforts. As of September 30, 2024, we had 17 employees dedicated to research and development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development (&#8220;R&amp;D&#8221;)
Achievements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our research and development team has invented
patented technologies to enhance the quality of our products and our manufacturing efficiency. For instance, our patented TCM mixer is
able to mix powders more evenly and thoroughly compared to a traditional mixing machine, thereby increasing the quality of the mixed medicine
powder. The special design of our patented TCM concentration device is able to increase the contact area of the liquid medicine as compared
to a regular concentration device, thereby increasing the manufacturing efficiency of our products in liquid dosage form.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of our efforts, our subsidiary, Jiangxi
Universe, is certified as a high and new technology enterprise by the Science and Technology Department of Jiangxi Province, with the
current certification expiring in November 2025. This certification entitles Jiangxi Universe to a favorable corporate income tax of 15%,
rather than the unified tax rate of 25% it would pay if it were not certified.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>R&amp;D Development Plan</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To further our strong brand image, we plan to
develop products designed to address the physical conditions of the elderly during the aging process and promoting their general well-being,
including TCMD products and dietary supplements. In the upcoming years, we intend to focus on the development of immunity boost products
and sleep aids.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to our own efforts, our research and
development team also intends to collaborate with other industry professionals and TCM experts with respect to the development of products
we plan to launch in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We compete with pharmaceutical companies in China
that manufacture and sell products similar to ours. Furthermore, many of these companies are more established than we are, and have significantly
greater financial, technical, and other resources than we presently possess. Some of our competitors may be able to respond more quickly
to new opportunities, market changes or changes of customer preferences, and may be able to undertake more extensive promotional activities,
offer more attractive terms to distributors, and adopt more aggressive pricing strategies than we are. Despite that, we believe we are
well-positioned to compete in this market with our diversified product portfolio, recognized brand name, established sales and marketing
network and experienced management team with a proven track record.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Competitors of our products</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the competitors
of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Products</b></span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competitors</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guben Yanling Pill</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taiyuan Daningtang Pharmaceuticals Co., Ltd.;<br/>
Shenyang Dongxin Pharmaceutical Industry Co., Ltd.</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shenrong Weisheng Pill</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China Beijing Tong Ren Tang Group Co., Ltd.;<br/>
Jiangxi Zhongyuan Pharmaceutical Co., Ltd.</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quanlu Pill</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renhe Pharmaceuticals Co.;<br/>
Guangzhou Pharmaceutical Co., Ltd.</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fuzi Lizhong Pill</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China Beijing Tong Ren Tang Group Co., Ltd.</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yangxue Danggui Syrup</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sichuan Tiancheng Pharmaceuticals Co., Ltd.</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qiangli Pipa Syrup</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangzhong Pharmaceuticals Co., Ltd.;<br/>
China Resources Sanjiu Medical &amp; Pharmaceuticals Co., Ltd.;<br/>
Jiangxi Tengwangge Pharmaceuticals Co., Ltd.</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paracetamol and Chlorpheniramine Maleate<br/>
Granules for Children</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China Resources Sanjiu Medical &amp; Pharmaceuticals Co., Ltd.;<br/>
Sunflower Pharmaceutical Group Co., Ltd.</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Isatis Root Granules</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guangzhou Pharmaceuticals Co., Ltd.;<br/>
China Resources Sanjiu Medicine &amp; Pharmaceuticals Co., Ltd.;<br/>
China Beijing Tong Ren Tang Group Co., Ltd.</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wuzi Yanzong Oral Liquid</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China Beijing Tong Ren Tang Group Co., Ltd.</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuquan Dabu Medicinal Liquor</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Puzheng Pharmaceuticals Co., Ltd.</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shenrong Medicinal Liquor</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Puzheng Pharmaceuticals Co., Ltd.</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qishe Medicinal Liquor</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Zhongyuan Pharmaceuticals Co., Ltd.</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fengtong Medicinal Liquor</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Zhongyuan Pharmaceuticals Co., Ltd.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Competitors of Third-party Products</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our competitors of pharmaceutical products,
including biochemical drugs and TCMPs, are many internationally and nationally well-known manufacturers and distributors, including
China Beijing Tong Ren Tang Group Co., Ltd., Yunnan Baiyao Group, China Resources Sanjiu Medicine &amp; Pharmaceuticals Co., Ltd.,
and Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our competitors in the medical instrument market
include many well-known manufacturers and distributors of medical instruments, including Shinva Medical Instrument Co., Ltd., Jiangsu
Yuyue Medical Equipment &amp; Supply Co., Ltd., Lepu Medical Technology (Beijing) Co., Ltd., and Shanghai Runda Medical Technology Co.,
Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our competitors in the dietary supplement market
include internationally and nationally well-known manufacturers and distributors of dietary supplements, such as By-health Co., Ltd.,
Amway (China) Co., Ltd., and Perfect (China) Co., Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to compete with these larger companies
by appealing to the specific needs and preferences of our customers and offering competitive prices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September&#160;30, 2024, 2023 and 2022,
we had a total of 225, 225 and 224 employees, all of whom are located in China. The following table sets forth the number of our employees
by function as of September 30, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Function</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number
of<br/>
Employees</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>% of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Total</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Purchasing Department</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Warehouse Department</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Manufacturing Department</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Quality Control Department</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Research and Development Department</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Marketing Department</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Finance Department</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Administration Department</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">225</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success depends on our ability to attract,
retain and motivate qualified personnel. As part of our human resources strategy, we offer employees competitive salaries and other bonuses
and incentives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We primarily recruit our employees in China through
direct hiring. We provide training to new employees that we hire. We also conduct regular and specialized internal training to meet the
needs of our employees in different departments. We believe that such training is effective in equipping our employees with the skill
set and work ethics we require.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As required under PRC regulations, we participate
in various employee social security plans that are organized by applicable local municipal and provincial governments, including housing,
pension, medical, work-related injury, maternity and unemployment benefit plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We enter into standard contracts and agreements
regarding confidentiality, intellectual property, employment, ethic policies and non-competition with most of our executive officers,
managers and employees. These contracts typically include a non-competition provision effective during and up to one year after termination
of their employment with us and a confidentiality provision effective during and up to one year after their employment with us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our employees have not formed any employee union
or association. We believe that we maintain a good working relationship with our employees and we have not experienced any difficulty
in recruiting staff for our operations as of the date of this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Properties and Facilities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our corporate headquarters are located in Jinggangshan,
Jiangxi Province, China. We own properties in Jingggangshan as office spaces, storage facilities and manufacturing facilities with an
aggregate gross floor area of approximately 825,563 square feet. We believe that our existing facilities are generally adequate to meet
our current needs, but we expect to seek additional space as needed to accommodate future growth. Following is a list of our properties
all of which we own the land use rights to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No.</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Land Use<br/>
Right Holder</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property Address</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of<br/>
Property</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Area in<br/>
Square Feet</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Terms of<br/>
 Use</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Universe</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">265 Jingjiu Avenue, Economy and Technology Development District, Jinggangshan, Ji&#8217;an, Jiangxi, China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">173,467</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2053</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Universe</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">265 Jingjiu Avenue, Economy and Technology Development District, Jinggangshan, Ji&#8217;an, Jiangxi, China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">470,921</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2053</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Universe</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">265 Jingjiu Avenue, Economy and Technology Development District, Jinggangshan, Ji&#8217;an, Jiangxi, China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57,010</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2053</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Universe</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">265 Jingjiu Avenue, Economy and Technology Development District, Jinggangshan, Ji&#8217;an, Jiangxi, China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Storage</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,426</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2053</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Universe</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">265 Jingjiu Avenue, Economy and Technology Development District, Jinggangshan, Ji&#8217;an, Jiangxi, China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,276</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2053</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Universe</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">265 Jingjiu Avenue, Economy and Technology Development District, Jinggangshan, Ji&#8217;an, Jiangxi, China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Storage</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57,083</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2053</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Universe</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">265 Jingjiu Avenue, Economy and Technology Development District, Jinggangshan, Ji&#8217;an, Jiangxi, China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,380</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2053</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We manufacture all of our products at the properties
listed above. Currently, we are capable of producing a maximum of approximately 12 million bottles of liquid products, 13 million boxes
of pill products, and 10 million boxes of solid products annually.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We regard our patents, trademarks, domain names
and other intellectual property critical to our business operations. We rely on laws and regulations on patents, trademarks and domain
names to protect our intellectual property. As of the date of this annual report, we have registered 65 patents in China, including 36
utility model patents, 17 design patents, and 12 invention patents, and 98 trademarks in China, including our well-recognized brands
&#8220;Bai Nian Dan (<span style="font-family: Times New Roman, Times, Serif">&#30334;&#24180;&#20025;</span>)&#8221;, &#8220;Hu Zhuo
Ren (<span style="font-family: Times New Roman, Times, Serif">&#32993;&#21331;&#20161;</span>)&#8221; and &#8220;Long Zhong (<span style="font-family: Times New Roman, Times, Serif">&#40857;&#31181;</span>).&#8221;
Under certain trademark licensing agreements entered into by and between Jiangxi Universe and Guangzhou Ningjing Investment Co., Ltd (&#8220;Guangzhou
Ningjing&#8221;), a related company controlled by Mr. Gang Lai, our chief executive officer and chairman of the Board of Directors, Jiangxi
Universe is authorized to use three trademarks held by Guangzhou Ningjing for commercial purposes, with the licensing authorization for
two of such trademarks expiring on August 14, 2028 and one expiring on January 9, 2029. Jiangxi Universe is obligated to pay an aggregate
of RMB500,000 (approximately US$71,249) to Guangzhou Nanjing annually as trademark licensing fees.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We implement a set of comprehensive measures to
protect our intellectual property, in addition to making trademark and patent registration application. Key measures include: (i) timely
registration, filing and application for ownership of our intellectual property, (ii) actively tracking the registration and authorization
status of our intellectual property and take action in a timely manner if any potential conflicts with our intellectual property are identified,
and (iii) clearly stating all rights and obligations regarding the ownership and protection of our intellectual property in all employment
contracts and commercial contracts we enter into.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this annual report, we have
not been subject to any material dispute or claims for infringement upon third parties&#8217; trademarks, licenses and other intellectual
property rights in China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Seasonality</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently do not experience seasonality in
our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Environmental Matters</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We comply with the Environmental Protection Law
of China as well as applicable local regulations. In addition to statutory and regulatory compliance, we actively ensure the environmental
sustainability of our operations. Parties may be levied upon us if we fail to adhere to and maintain certain standards. Such failure has
not occurred in the past, and we generally do not anticipate that it will occur in the future, but no assurance can be given in this regard.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Insurance</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We maintain certain insurance policies to safeguard
us against risks and unexpected events. For example, we provide social security insurance including pension insurance, unemployment insurance,
work-related injury insurance and medical insurance for our employees in compliance with applicable PRC laws. We also maintain directors
and officers&#8217; liability insurance. We do not maintain business interruption insurance or product liability insurance, which are
not mandatory under PRC laws. We do not maintain key man insurance, insurance policies covering damages to our network infrastructures
or information technology systems nor any insurance policies for our properties. During the fiscal years ended September 30, 2024, 2023
and 2022, we did not make any material insurance claims in relation to our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may from time to time become a party to various
legal administrative proceedings arising in our ordinary course of our business. As of the date of this annual report, neither we nor
any of our subsidiaries is a party of any material legal proceeding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Regulations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This section sets forth a summary of the principal
PRC laws, regulations, and rules relevant to our PRC operating entities&#8217; business and operations in China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a pharmaceutical manufacturer in China.
This section sets forth a summary of applicable laws, rules, regulations, government and industry policies and requirement that have a
significant impact on our operations and business in China. This summary does not purport to be a complete description of all laws and
regulations, which apply to our business and operations. Investors should note that the following summary is based on relevant laws and
regulations in force as of the date of this annual report, which may be subject to change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Major Regulatory Authorities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The pharmaceutical industry in the PRC is mainly
administered by four governmental agencies: (i) the NMPA, a department under the State Administration for Market Regulation (the &#8220;SAMR&#8221;)
(&#22269;&#23478;&#24066;&#22330;&#30417;&#30563;&#31649;&#29702;&#24635;&#23616;), (ii) the National Health Commission (the &#8220;NHC&#8221;)
(&#22269;&#23478;&#21355;&#29983;&#20581;&#24247;&#22996;&#21592;&#20250;), (iii) the National Administration of Traditional Chinese Medicine
(the &#8220;NATCM&#8221;) (&#22269;&#23478;&#20013;&#21307;&#33647;&#31649;&#29702;&#23616;), and (iv) the National Healthcare Bureau
(the &#8220;NHB&#8221;) (&#22269;&#23478;&#21307;&#30103;&#20445;&#38556;&#23616;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The NMPA, whose predecessor is the China Food
and Drug Administration, or the CFDA, is the primary regulator of almost all key stages of the life-cycle of pharmaceutical products,
including non-clinical researches, clinical trials, marketing approvals, manufacturing, advertising and promotion, distribution and pharmacovigilance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The NHC, formerly known as the National
Health and Family Planning Commission, is the principal regulator of healthcare in China. It is primarily responsible for drafting
national healthcare policies and regulating public health, medical services and health contingency system, coordinating the
healthcare reform and overseeing the operation of medical institutions and professional practice of medical personnel. The NHC is
responsible for (1) the research, production, circulation and use of Chinese medicines, including traditional Chinese medicine; (2)
the preparation and publication of the Chinese Pharmacopoeia; and (3) the supervision of the selection, approval, distribution and
revision of the National OTC Drug Catalogue. In addition, the CFDA and its local administrative authorities may take a number of
enforcement actions to enforce their regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The NATCM is an agency under the NHC that oversees
China&#8217;s traditional Chinese medicine industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The NHB, a new authority established in May 2018,
is responsible for (1) drafting and implementing policies, plans and standards on medical insurance, maternity insurance and medical assistance;
(2) administering healthcare fund; (3) formulating a uniform medical insurance catalogue and payment standards on drugs, medical disposables
and healthcare services; and (4) formulating and administering the bidding and tendering policies for drugs and medical disposables.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Regulations Related to Pharmaceutical Manufacture</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Manufacturing License</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Pharmaceutical Administration
Law of the People&#8217;s Republic of China (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#33647;&#21697;&#31649;&#29702;&#27861;&#12299;),
which was promulgated in 1984 by the SCNPC and last amended in August 2019, a pharmaceutical manufacturer is required to obtain its manufacturing
license from the NMPA before it starts to manufacture pharmaceutical products. Prior to granting such permit, the relevant government
authority will inspect the applicant&#8217;s production facilities, and assess whether the sanitary conditions, quality assurance system,
management structure and equipment at the production facilities have met the required standards. A manufacturing license is valid for
a period of five years and the manufacturer is required to apply for renewal within six months prior to its expiration date. The manufacturer
will be subject to reassessment by the authority in accordance with then prevailing legal and regulatory requirements for the purposes
of such renewal. Currently, our subsidiary Jiangxi Universe holds a valid manufacturing license from the NMPA issued on December 21, 2020
and valid until December 20, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Contract Manufacturing of Drugs</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Administrative Regulations for
the Contract Manufacturing of Drugs (&#12298;&#33647;&#21697;&#22996;&#25176;&#29983;&#20135;&#30417;&#30563;&#31649;&#29702;&#35268;&#23450;&#12299;)
(the &#8220;Contract Manufacturing Regulations&#8221;) issued by the NMPA in August 2014, in the event that a drug manufacturer in China
with drug marketing authorization temporarily lacks manufacturing capability as a result of technology upgrade or is unable to meet market
demand due to insufficient manufacturing capacity, it may use contract manufacturer for its drug manufacturing. Contract manufacturing
arrangements need to be approved by the provincial branch of the NMPA. The Contract Manufacturing Regulations prohibit contract manufacturing
arrangements for certain special drugs, including narcotic drugs, psychoactive drugs, biochemical drugs and active pharmaceutical ingredients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other Regulations in relation to the Pharmaceutical
Industry</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#8220;Two-vote system&#8221; for drug sales</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The NHC and other six ministries and commissions
issued the Notice on the Opinions on the Implementation of the &#8220;Two-Invoice System&#8221; in Drug Procurement by Public Medical
Institutions (for Trial Implementation) (&#12298;&#20851;&#20110;&#22312;&#20844;&#31435;&#21307;&#30103;&#26426;&#26500;&#33647;&#21697;&#37319;&#36141;&#20013;&#25512;&#34892;&#8220;&#20004;&#31080;&#21046;&#8221;&#30340;&#23454;&#26045;&#24847;&#35265;
(&#35797;&#34892;) &#30340;&#36890;&#30693;&#12299;) (the &#8220;Notice on Two-Invoice System&#8221;) on January 11, 2017. &#8220;Two-invoice
system&#8221; means that one invoice shall be issued by a pharmaceutical manufacturer to a distributor, and another invoice shall be issued
by the distributor to a hospital. An internal transfer of drugs from a group pharmaceutical distributor to its wholly owned or controlled
subsidiary or a transfer of drugs between such wholly owned subsidiaries may not be deemed as &#8220;one invoice&#8221; however, the invoicing
for the whole group can be done only once. Pharmaceutical manufacturers and distributors shall reasonably determine the markup level in
the spirit of fairness, legality, legitimacy and integrity. Public medical institutions is encouraged to settle the payment for drugs
directly with pharmaceutical manufacturers, and pharmaceutical manufacturers and are encouraged to settle the delivery cost with distributors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the sale of drugs, drug manufacturers and distributors
shall issue value-added tax (&#8220;VAT&#8221;) special invoices or normal VAT invoices in accordance with the regulations regarding invoice
control. The sold drug shall also be delivered in a way that confirms to the requirements of the Good Supply Practice for Pharmaceutical
Products (2016 version) (&#12298;&#33647;&#21697;&#32463;&#33829;&#36136;&#37327;&#31649;&#29702;&#35268;&#33539;(2016&#20462;&#35746;)&#12299;),
and the names of the purchaser and seller on the invoices shall be consistent with the delivery form, payment flow and amount.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Drug Advertisements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Interim Administrative Measures
for the Review of Advertisements for Drugs, Medical Devices, Health Food and Formula Food for Special Medical Purposes (&#12298;&#33647;&#21697;&#12289;&#21307;&#30103;&#22120;&#26800;&#12289;&#20445;&#20581;&#39135;&#21697;&#12289;&#29305;&#27530;&#21307;&#23398;&#29992;&#36884;&#37197;&#26041;&#39135;&#21697;&#24191;&#21578;&#23457;&#26597;&#31649;&#29702;&#26242;&#34892;&#21150;&#27861;&#12299;)
promulgated on December 24, 2019 and effective on March 1, 2020, an enterprise seeking to advertise its drugs must apply for an advertising
approval code. An advertising approval code shall expire on the earlier of the expiration dates of the product&#8217;s registration certificate,
filing certificate or production license. If an expiration date is not prescribed in the product&#8217;s registration certificate, filing
certificate or production license, the advertising approval code shall be valid for two years. The contents of an approved advertisement
shall not be altered without prior approval. Where an advertisement needs to be edited, the enterprise shall submit an application for
a new advertisement approval code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Insert Sheet, Labels and Packaging of Pharmaceutical
Products</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the Measures for the Administration
of the Insert Sheets and Labels of Drugs (&#12298;&#33647;&#21697;&#35828;&#26126;&#20070;&#21644;&#26631;&#31614;&#31649;&#29702;&#35268;&#23450;&#12299;)
effective on June 1, 2006, the insert sheets and labels of a pharmaceutical product shall be reviewed and approved by the NMPA. A drug
insert sheet should include the scientific data, conclusions and information concerning drug safety and efficacy in order to direct the
safe and reasonable use of pharmaceutical products. The inner label of a pharmaceutical product shall indicate the product name, indication
or function, strength, dose and usage, production date, batch number, expiration date and drug manufacturer, and the outer label of a
pharmaceutical product shall indicate the product name, ingredients, description, indication or function, strength, dose and usage and
adverse reactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the Measures for the Administration
of Pharmaceutical Packaging (&#12298;&#33647;&#21697;&#21253;&#35013;&#31649;&#29702;&#21150;&#27861;&#12299;) effective on September
1, 1988, pharmaceutical packaging must comply with national and professional standards. If no national or professional standards are available,
a manufacturer can formulate and implement its own standards after it receives approval from the provincial food and drug administration
or bureau of standards. The company shall reapply for approval if it were to change its own packaging standards. Pharmaceutical products
with no approved packing standards shall not be sold or traded in the PRC, except for drugs for military use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Drug Technology Transfer</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 19, 2009, the NMPA promulgated the Administrative
Regulations for Technology Transfer Registration of Drugs (&#12298;&#33647;&#21697;&#25216;&#26415;&#36716;&#35753;&#27880;&#20876;&#31649;&#29702;&#35268;&#23450;&#12299;)
(the &#8220;Technology Transfer Regulations&#8221;) to regulate the drug technology transfer process, including the application, evaluation,
examination, approval and monitoring of, drug technology transfer. Drug technology transfer means that the owner transfers its pharmaceutical
manufacturing technology to a pharmaceutical manufacturer and that the transferee applies for drug registration pursuant to the Technology
Transfer Regulations. Drug technology transfer includes the transfer of new drug technology and drug manufacturing technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Applications for drug technology transfer
shall be submitted to the provincial drug regulatory authority where the transferee is located. The drug regulatory authority
examines application materials and conducts on-site inspections of the transferee&#8217;s manufacturing facilities. If the
transferor and the transferee are located in different provinces, the provincial drug regulatory authority where the transferor is
located shall issue examination opinions as well. The Center for Drug Evaluation (the &#8220;CDE&#8221;), a branch of the NMPA,
shall further review the application materials, provide technical evaluation opinions and form a comprehensive evaluation opinion
based on the on-site inspection reports and the testing results of the samples. The NMPA shall determine whether to approve the
application according to the comprehensive evaluation opinion of the CDE. An approval letter of supplementary application and a drug
approval number will be issued for qualified applications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Price of drugs</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Drug Administration Law (&#12298;&#33647;&#21697;&#31649;&#29702;&#27861;&#12299;),
for those drugs whose prices are determined by market, manufacturers and distributors of pharmaceutical products and medical institutions
shall set the prices in accordance with the principles of fairness, rationality, and good faith, and provide consumers with drugs at reasonable
prices. Pharmaceutical product manufacturers, distributors and medical institutions shall determine and indicate their products&#8217;
retail prices in accordance with the regulations over drug prices promulgated by the pricing department of the State Council of the People&#8217;s
Republic of China (the &#8220;State Council&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 4, 2015, the National Development and Reform
Commission, the National Health and Family Planning Commission, the Ministry of Human Resources and Social Security, the Ministry of Industry
and Information Technology, the Ministry of Finance, the MOFCOM and the NMPA jointly issued the Notice Regarding Reforms to the Price
of Medical Products (&#12298;&#20851;&#20110;&#21360;&#21457;&#25512;&#36827;&#33647;&#21697;&#20215;&#26684;&#25913;&#38761;&#24847;&#35265;&#30340;&#36890;&#30693;&#12299;),
pursuant to which, since June 1, 2015, other than anesthetics and Class 1 psychotropic drugs, the actual price of pharmaceutical products
shall be decided by market instead of by the government. As of the date of this annual report, the actual price of all products we sell,
including TCMD products and third-party products, are determined by market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this annual report, we are engaged
in the business of manufacturing and selling drugs. We obtained our latest drug manufacturing license on May 31,2024 which is valid until
December 20, 2025, in compliance with the applicable PRC laws and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Regulation relating to Company Establishment
and Foreign Investment</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The PRC Company Law applies to the establishment,
operation and management of both PRC domestic companies and foreign-invested enterprises. Foreign investment in the PRC corporate entities
are also regulated by the foreign-Owned Enterprise Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22806;&#36164;&#20225;&#19994;&#27861;&#12299;)
(the &#8220;Foreign-Owned Enterprise Law&#8221;) promulgated on April 12, 1986 and amended on October 31, 2000 and September 3, 2016,
the Implementing Rules for the Foreign-Owned Enterprise Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22806;&#36164;&#20225;&#19994;&#27861;&#23454;&#26045;&#32454;&#21017;&#12299;)
promulgated on December 12, 1990 and amended on April 12, 2001 and February 19, 2014, and the Interim Administrative Measures for the
Record-filing of the Incorporation and Change of Foreign-invested Enterprises (&#12298;&#22806;&#21830;&#25237;&#36164;&#20225;&#19994;&#35774;&#31435;&#21450;&#21464;&#26356;&#22791;&#26696;&#31649;&#29702;&#26242;&#34892;&#21150;&#27861;&#12299;)
(the &#8220;Record-filing Measures&#8221;) promulgated on October 8, 2016 and amended on July 30, 2017 and June 29, 2018. Under these
laws and regulations, the establishment of a wholly foreign-owned enterprise is subject to the approval of, or the filing with the MOFCOM
or its local counterpart, and such wholly foreign-owned enterprises must register and file with the appropriate administrative bureau
of industry and commerce.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Foreign Investment Law of the
People&#8217;s Republic of China
(&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22806;&#21830;&#25237;&#36164;&#27861;&#12299;) (the
&#8220;Foreign Investment Law&#8221;), which was promulgated by the National People&#8217;s Congress On March 15, 2019, and came
into effect on January 1, 2020, provides that foreign investment refers to the investment activities in China carried out directly
or indirectly by foreign natural persons, enterprises or other organizations (the &#8220;Foreign Investors&#8221;), including the
following: (1) Foreign Investors establishing foreign-invested enterprises in China alone or collectively with other investors; (2)
Foreign Investors acquiring shares, equities, properties or other similar rights of Chinese domestic enterprises; (3) Foreign
Investors investing in new projects in China alone or collectively with other investors; and (4) Foreign Investors investing through
other ways prescribed by laws and regulations or the State Council. The State adopts the management system of pre-establishment
national treatment and negative list for foreign investment. The pre-entry national treatment means the treatment given to Foreign
Investors and their investments at the stage of investment access is not lower than that of domestic investors and their
investments. The negative list management system means that the state implements special administrative measures for access of
foreign investment in specific fields. Foreign investors shall not invest in any forbidden fields stipulated in the negative list
and shall mean the conditions stipulated in the negative list before investing in any restricted fields. The negative list is
released upon approval of the State Council. After the Foreign Investment Law came into effect, it replaced the Foreign-Owned
Enterprise Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Implementation Regulations for the Foreign
Investment Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22806;&#21830;&#25237;&#36164;&#27861;&#23454;&#26045;&#26465;&#20363;&#12299;)
(the &#8220;Implementation Regulations for the FIL&#8221;) was adopted at the 74th executive meeting of the State Council on December
12, 2019 and came into effect on January 1, 2020. The purpose of the Implementation Regulations for the FIL is to encourage and promote
foreign investment, protect the legitimate rights and interests of investors, regulate the administration of foreign investment, and continuously
optimize the foreign investment environment. For those foreign-invested enterprises established prior to the implementation of the Foreign
Investment Law and established in accordance with the Law of the People&#8217;s Republic of China on Sino-foreign Joint Ventures (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#20013;&#22806;&#21512;&#36164;&#32463;&#33829;&#20225;&#19994;&#27861;&#12299;),
the Law of the People&#8217;s Republic of China on Foreign-invested Enterprises, and the Law of the People&#8217;s Republic of China on
Sino-Foreign Cooperative Enterprises, they can modify or retain their organizational forms and organizational structures in accordance
with the PRC Company Law, Partnership Law of the People&#8217;s Republic of China and other applicable laws within 5 years since the implementation
of the Foreign Investment Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign investment in China shall comply with
the Catalogue for Encouraged Foreign Investment (2022 Revision) (&#12298;&#40723;&#21169;&#22806;&#21830;&#25237;&#36164;&#20135;&#19994;&#30446;&#24405;(2022&#24180;&#29256;)&#12299;),
or the 2022 Catalogue, and the Special Administrative Measures for the Access of Foreign Investment (Negative List) (Edition 2022) (&#12298;&#22806;&#21830;&#25237;&#36164;&#20934;&#20837;&#29305;&#21035;&#31649;&#29702;&#25514;&#26045;(&#36127;&#38754;&#28165;&#21333;)
(2022&#24180;&#29256;)&#12299;), or the 2022 Negative List, which were issued on March 12, 2022 and came into effect on the same date.
The Catalogue classifies foreign-invested industries into two categories, (1) encouraged foreign-invested industries; and (2) foreign-invested
industries that are subject to the 2018 Negative List. The 2018 Negative List set out restrictions such as shareholding requirements and
qualifications of the senior management. According to the Record-filing Measures, foreign investments that are not subject to special
access administrative measures are only required to complete an online filing with the MOFCOM or its local counterpart. The scope of our
business as approved by the licensing authority and the actual scope of our business are not subject to the restrictions set forth in
the 2021 Negative List.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The M&amp;A Rules were jointly promulgated by
the MOFCOM, the State-Owned Assets Supervision and Administration Commission of the State Council, the SAT, the SAIC, the CSRC, and the
SAFE on August 8, 2006 and was amended by MOFCOM on June 22, 2009. The M&amp;A Rules provides that a foreign investor is required to obtain
necessary approvals when it: (1) acquires equity interests in a domestic enterprise or subscribes to additional shares in a domestic enterprise;
(2) purchases the assets of a domestic enterprise through establishment of a foreign-invested enterprise; or (3) establishes a foreign-invested
enterprise through which it purchases the assets of a domestic enterprise and operates these assets. In particular, any PRC company, enterprise
or individual is required to obtain approval from the MOFCOM and comply with applicable laws and regulations if it establishes an offshore
company and attempts to acquire a domestic enterprise related to such offshore company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Regulations Related to Overseas Listing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Overseas
Listings Rules</span> <span style="font-family: Times New Roman, Times, Serif">refine the regulatory system for domestic company&#8217;s
overseas offering and listing by subjecting both direct and indirect overseas offering and listing activities to the filing-based administration,
and clearly define the circumstances where provisions for direct and indirect overseas offering and listing apply and the relevant regulatory
requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">According
to the Overseas Listings</span> <span style="background-color: white">Rules</span><span style="font-family: Times New Roman, Times, Serif">,
among other things, a domestic company in the PRC that seeks to offer and list securities on overseas markets shall fulfill the
filing procedures with the CSRC as per requirement of the Trial Measures. Where a domestic company seeks to directly offer and list
securities on overseas markets, the issuer shall file with the CSRC.&#160;Where a domestic company seeks to indirectly offer and
list securities on overseas markets, the issuer shall designate a major domestic operating entity, which shall, as the domestic
responsible entity, </span>file with the CSRC.&#160;Initial public offerings or listings on overseas markets shall be filed with the
CSRC within three working&#160;days after the relevant application is submitted overseas. If an issuer subsequently offers
securities on the same overseas market where it has previously offered and listed securities, filings shall be made with the CSRC
within three working&#160;days after the offering is completed. Upon occurrence of any material event, such as change of control,
investigations or sanctions imposed by overseas securities regulatory agencies or other relevant competent authorities, change of
listing status or transfer of listing segment, or voluntary or mandatory delisting, after an issuer has offered and listed
securities on an overseas market, the issuer shall submit a report thereof to the CSRC within three working&#160;days after the
occurrence and public disclosure of such event.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Trial Measures provide that an overseas listing
or offering is explicitly prohibited, if any of the following happens: (i)&#160;such securities offering and listing is explicitly prohibited
by provisions in laws, administrative regulations, and relevant state rules; (ii)&#160;the intended securities offering and listing may
endanger national security as reviewed and determined by competent authorities under the State Council in accordance with law; (iii)&#160;the
domestic company intending to make the securities offering and listing, or its controlling shareholder(s)&#160;and the actual controller(s),
have committed relevant crimes such as corruption, bribery, embezzlement, misappropriation of property, or undermining the order of the
socialist market economy during the latest three&#160;years; (iv)&#160;the domestic company intending to make the securities offering
and listing is currently under investigations for suspicion of criminal offenses or major violations of laws and regulations, and no conclusion
has yet been made thereof; or (v)&#160;there are material ownership disputes over equity held by the domestic company&#8217;s controlling
shareholder(s)&#160;or by other shareholder(s)&#160;that are controlled by the controlling shareholder(s)&#160;and/or actual controller.
Moreover, a domestic company that seeks to offer and list securities on overseas markets shall abide by certain other regulatory requirements
as set out in the Trial Measures, including compliance with laws of national secrecy, foreign investment, cybersecurity, data security,
cross-border investment and financing, foreign exchange, and other laws and relevant provisions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Trial Measures also provide that if the issuer
meets the following criteria, the overseas securities offering and listing conducted by such issuer will be deemed to be an indirect overseas
offering by PRC domestic companies: (i)&#160;domestic companies accounted for 50% or more of any of the issuer&#8217;s operating revenue,
total profit, total assets, or net assets as documented in its audited consolidated financial statements for the most recent fiscal year;
and (ii)&#160;the main parts of the issuer&#8217;s business activities are conducted in mainland China, or its main place(s)&#160;of business
are located in mainland China, or the majority of senior management staff in charge of its business operations and management are PRC
citizens or have their usual place(s)&#160;of residence located in mainland China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Trial Measures, if a domestic
company fails to fulfill the filing procedures or offers and lists securities on an overseas market in violation of the relevant
provisions of the Trial Measures, the CSRC shall order rectification, issue warnings to such domestic company, and impose a fine
between RMB1,000,000 (approximately US$0.14 million<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">) and
RMB10,000,000 (approximately US$1.42 million). Directly liable persons-in-charge and other directly liable persons shall be warned
and each subject to a fine between RMB500,000 (approximately US$0.07 million) and RMB5,000,000 (approximately US$0.71 million).
Controlling shareholders and actual controllers of the domestic company that organize or instruct the aforementioned violations
shall be subject to a fine between RMB1,000,000 (approximately US$0.14 million) and RMB10,000,000 (approximately US$1.42
million).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February&#160;24, 2023, the CSRC promulgated
the Provisions on Strengthening Confidentiality and Archives Administration of Overseas Securities Offering and Listing by Domestic Companies
(the &#8220;Confidentiality and Archives Administration Provisions&#8221;), which became effective on March&#160;31, 2023. According to
the Confidentiality and Archives Administration Provisions, domestic companies that seek overseas offering and listing (either in direct
or indirect means) and the securities companies and securities service providers (either incorporated domestically or overseas) that undertake
relevant businesses shall institute a sound confidentiality and archives administration system and take necessary measures to fulfill
confidentiality and archives administration obligations. They shall not leak any state secret or working secret of government agencies,
or harm national security and public interests. Therefore, a domestic company that plans to, either directly or through its overseas listed
entity, publicly disclose or provide to relevant individuals or entities, including securities companies, securities service providers,
and overseas regulators, any documents and materials that contain state secrets or working secrets of government agencies, shall first
obtain approval from competent authorities according to laws, and file with the secrecy administrative department at the same level. Moreover,
if the leakage of any other documents and materials which a domestic company plans to publicly disclose or provide to relevant individuals
and entities aforementioned, either directly or through its overseas listed entity, will be detrimental to national security or public
interest, the domestic company shall strictly fulfill relevant procedures stipulated by applicable regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, the Confidentiality and Archives
Administration Provisions stipulate that a domestic company that provides accounting archives or copies of accounting archives to any
entities, including securities companies, securities service providers, and overseas regulators and individuals, shall fulfill due procedures
in compliance with applicable regulations. Working papers produced in mainland China by securities companies and securities service providers
in the process of undertaking businesses related to overseas offering and listing by domestic companies shall be retained in mainland
China. Where such documents need to be transferred or transmitted to areas outside of mainland China, relevant approval procedures stipulated
by regulations shall be followed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Laws and Regulations Related to Cyber Security
and Data Protection</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Data Security Law of the PRC</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Data Security Law of the PRC (the &#8220;Data
Security Law&#8221;) was promulgated by the SCNPC on June&#160;10, 2021, and took effect on September&#160;1, 2021. Pursuant to the Data
Security Law, data refers to any record of information in electronic or any other form and data processing including the collection,
storage, use, processing, transmission, provision, and public disclosure of data. The Data Security Law establishes a classified and
tiered system for data protection based on the level of importance of the data to the economic and social development, as well as the
level of danger of the data imposed on national security, public interests, or the legal interests of individuals and organizations upon
any manipulation, destruction, leakage, illegal acquisition, or illegal usage thereof. The data processors shall comply with the provisions
of laws and regulations when conducting data processing activities, establish and improve a whole-process data security management system,
organize data security educational trainings, and take corresponding technical measures and other necessary measures to safeguard data
security.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Regulations on Network Data Security Administration</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Data Security Administration was promulgated
by SCNPC on September 24, 2024 and took effect on January 1, 2025. According to the Data Security Regulations, data processors shall,
in accordance with relevant state provisions, apply for cybersecurity review when carrying out the following activities: (i)&#160;the
merger, reorganization, or separation of internet platform operators that have acquired a large number of data resources related to national
security, economic development, or public interests, which affect or may affect national security; (ii)&#160;data processors that handle
personal data of more than one million individuals intend to list on a foreign stock exchange; (iii)&#160;data processors that intend
to list on Hong&#160;Kong exchange, which affects or may affect national security; and (iv)&#160;other data processing activities that
affect or may affect national security.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Cybersecurity Review Measures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December&#160;28, 2021, 13 government departments,
including the CAC, jointly promulgated the Cybersecurity Review Measures, which became effective on February&#160;15, 2022. Under the
Cybersecurity Review Measures, (i)&#160;where a critical information infrastructure operator procures network products and services, it
shall anticipate the national security risks that may be posed by the products and services once they are put into use. Those that affect
or may affect national security shall be reported to the Cybersecurity Review Office of the PRC for cybersecurity review; (ii)&#160;online
platform operators controlling personal information of more than one million users, which are listed on a foreign exchange, must apply
for a cybersecurity review with the Cybersecurity Review Office of the PRC; and (iii)&#160;the Cybersecurity Review Office of the PRC
will conduct a cybersecurity review on critical information infrastructure operators and network platform operators in accordance with
the laws if it considers necessary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AllBright Law Offices (Fuzhou), our PRC legal
counsel, has advised us that, as of the date of this annual report, the PRC operating entities are not subject to cybersecurity review
with the CAC, since they currently do not have over one million users&#8217; personal information and do not anticipate that they will
be collecting over one million users&#8217; personal information in the foreseeable future, which we understand might otherwise subject
the PRC operating entities to the cybersecurity review with the CAC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Laws and Regulations Related to Personal Information Protection</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Personal Information Protection Law of the
PRC (the &#8220;Personal Informational Protection Law&#8221;) was promulgated by the SCNPC on August&#160;20, 2021 and became effective
on November&#160;1, 2021. The Personal Informational Protection Law stipulates, among others, that (i)&#160;the processing of personal
information should have a clear and reasonable purpose, which should be directly related to the processing purpose, in a method that has
the least impact on personal rights and interests, and (ii)&#160;the collection of personal information shall be limited to the minimum
scope necessary for achieving the processing purpose and shall not be excessive. Personal information processors shall bear responsibilities
and take necessary measures to guarantee the security of the personal information they handle. Otherwise, the personal information processors
could be ordered to correct, suspend or terminate services, and face confiscation of illegal income, fines, or other penalties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AllBright Law Offices (Fuzhou), our PRC legal
counsel has advised us that, as of the date of this annual report, neither we nor our PRC subsidiaries have received any notification
of non-compliance related to personal information protection from any Chinese authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Regulation in relation to Intellectual Property
Rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In terms of international conventions, China has
entered into (including but not limited to) the Agreement on Trade-Related Aspects of Intellectual Property Rights (&#12298;&#19982;&#36152;&#26131;&#26377;&#20851;&#30340;&#30693;&#35782;&#20135;&#26435;&#21327;&#23450;&#12299;),
the Paris Convention for the Protection of Industrial Property (&#12298;&#20445;&#25252;&#24037;&#19994;&#20135;&#26435;&#24052;&#40654;&#20844;&#32422;&#12299;),
the Madrid Agreement Concerning the International Registration of Marks (&#12298;&#21830;&#26631;&#22269;&#38469;&#27880;&#20876;&#39532;&#24503;&#37324;&#21327;&#23450;&#12299;)
and the Patent Cooperation Treaty (&#12298;&#19987;&#21033;&#21512;&#20316;&#21327;&#23450;&#12299;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patents</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Patent Law of the PRC
(&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#19987;&#21033;&#27861;&#12299;), or the Patent Law, promulgated
by the SCNPC on March 12, 1984 and last amended on October 17, 2020 and effective from June 1, 2021 and the Implementation Rules of
the Patent Law of the PRC
(&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#19987;&#21033;&#27861;&#23454;&#26045;&#32454;&#21017;&#12299;),
promulgated by the State Council on June 15, 2001 and amended on December 28, 2002 and January 9, 2010, respectively, patents in
China fall into three categories: invention patents, utility model patents and design patents. The term of patent protection starts
from the date of application and lasts 20 years for invention patents and 10 years for utility model patents and design patents. Any
individual or entity that utilizes a patent or conducts any other activity that infringes a patent without the patent holder&#8217;s
authorization shall pay compensation to the patent holder and be subject to a fine imposed by regulatory authorities and, if such
behavior constitutes a crime, shall be held criminally liable in accordance with applicable laws. According to the Patent Law, for
public health purposes, the State Intellectual Property Office of the PRC, or SIPO, may grant a compulsory license for manufacturing
patented drugs and exporting them to countries or regions covered under relevant international treaties to which PRC has acceded. In
addition, under the Patent Law, any organization or individual that applies for a patent in a foreign country for an invention or
utility model patent established in China is required to report to the SIPO for confidentiality examination. Patent holders may
apply for extending the terms of patented drugs to compensate for commercialization delays due to regulatory review, and may seek
punitive damages for willful patent infringement under severe circumstances.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Trade Secrets</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the PRC Anti-Unfair Competition Law
(&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#21453;&#19981;&#27491;&#24403;&#31454;&#20105;&#27861;&#12299;) promulgated
by the SCNPC in September 1993, as amended on November 4, 2017 and April 23, 2019 respectively, the term &#8220;trade secrets&#8221; refers
to technical and business information that is unknown to the public, has utility, may create business interests or profits for its legal
owners or holders, and is maintained as a secret by its legal owners or holders. Under the PRC Anti-Unfair Competition Law, business persons
are prohibited from infringing others&#8217; trade secrets by: (1) obtaining trade secrets from the legal owners or holders by any unfair
methods, such as theft, bribery, fraud, coercion, electronic intrusion, or any other illicit means; (2) disclosing, using or permitting
others to use the trade secrets obtained illegally under item (1) above; or (3) disclosing, using or permitting others to use the trade
secrets, in violation of any contractual agreements or any requirements of the legal owners or holders to keep such trade secrets in confidence.
If a third party knows or should have known of the above- mentioned illegal conduct but nevertheless obtains, uses or discloses trade
secrets of others, the third party may be deemed to have committed a misappropriation of the others&#8217; trade secrets. The parties
whose trade secrets are being misappropriated may petition for administrative corrections, and regulatory authorities may stop any illegal
activities and impose fines on the infringing parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Trademarks</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the Trademark Law of the PRC
(&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#21830;&#26631;&#27861;&#12299;) (the &#8220;Trademark Law&#8221;),
which was promulgated by the SCNPC on August 23, 1982, and was last amended on April 23, 2019 and came into effect on November 1, 2019,
any trademark which is registered with the approval of the Trademark Office is a registered trademark, including commodity trademark,
service trademark, collective trademark, certification trademark, and the trademark registrant has the exclusive right to use a registered
trademark and such right is protected by law. A registered trademark is valid for a period of 10 years commencing from the date on which
the registration is approved. Upon expiration of the trademark, the registrant shall apply for renewal within twelve months prior to the
expiration date if it intends to maintain exclusive use of the trademark. If the registrant fails to apply for renewal, a grace period
of six months may be granted. In the absence of a renewal upon the expiration of a trademark registration, the registered trademark shall
be canceled. Use of a trademark that is identical with or similar to a registered trademark, for the same kind of or similar commodities,
without authorization of the trademark registrant, constitutes infringement of the exclusive right to use a registered trademark. Industrial
and commercial administrative authorities have the authority to investigate any behavior that may constitute an infringement of the exclusive
right under a registered trademark.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Domain names</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Domain names are protected under the Administrative
Measures on the Internet Domain Names (&#12298;&#20114;&#32852;&#32593;&#22495;&#21517;&#31649;&#29702;&#21150;&#27861;&#12299;), which
was promulgated by the Ministry of Industry and Information Technology, or the MIIT, on August 24, 2017 and came into effect on November
1, 2017, and the Implementing Rules of China Internet Network Information Center on the Registration of Domain Names (&#12298;&#20013;&#22269;&#20114;&#32852;&#32593;&#32476;&#20449;&#24687;&#20013;&#24515;&#22495;&#21517;&#27880;&#20876;&#23454;&#26045;&#32454;&#21017;&#12299;)
issued by China Internet Network Information Center (the &#8220;CNNIC&#8221;) on May 28, 2012 and came into effect on May 29, 2012. Domain
name registrations are handled through domain name service agencies established under the relevant regulations, and the applicant becomes
domain name holder upon successful registration. Domain name disputes shall be submitted to an organization authorized by CNNIC for resolution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other laws</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Product Liability</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Product Quality Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#20135;&#21697;&#36136;&#37327;&#27861;&#12299;),
promulgated by the SCNPC on February 22, 1993 and last amended on December 29, 2018, governs the supervision and administration of product
quality and specifies the liabilities of manufacturers and sellers. A manufacture shall be liable for compensating for any bodily injuries
or property damages, other than the defective product itself, resulting from the defects in the product, unless the manufacturer is able
to prove that: (1) the product has never been distributed; (2) the defects causing injuries or damage did not exist at the time when the
product was distributed; or (3) the science and technology at the time when the product was distributed was at a level incapable of detecting
the defects. A seller shall pay compensation if it fails to indicate either the manufacturer or the supplier of the defective product.
A person who is injured or whose property is damaged by the defects in the product may claim for compensation from the manufacturer or
the seller.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Civil Code of the People&#8217;s
Republic of China (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#27665;&#27861;&#20856;&#12299;), promulgated by the
SCNPC on May 28, 2020 and became effective on January 1, 2021, manufacturers shall assume tort liabilities where the defects in products
cause damage to others. Sellers shall assume tort liability where the defects in products that have caused damage to others are attributable
to the sellers. The aggrieved party may claim for compensation from the manufacturer or the seller of the defected product that has caused
damage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Environmental Protection</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Environmental Protection Law of
the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#29615;&#22659;&#20445;&#25252;&#27861;&#12299;) promulgated
by the SCNPC on December 26, 1989 and amended on April 24, 2014, the Environmental Impact Assessment Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#29615;&#22659;&#24433;&#21709;&#35780;&#20215;&#27861;&#12299;),
promulgated by the SCNPC on October 28, 2002 and amended on July 2, 2016 and December 29, 2018 respectively, the Administrative Regulations
on the Environmental Protection of Construction Project (&#12298;&#24314;&#35774;&#39033;&#30446;&#29615;&#22659;&#20445;&#25252;&#31649;&#29702;&#26465;&#20363;&#12299;)
promulgated by the State Council on November 29, 1998 and amended on July 16, 2017, and other applicable environmental laws and regulations,
an enterprise with a project construction plan shall submit an environmental impact assessment report, stating the environmental impacts
the project is likely to have, to the administrative authority of environmental protection for approval. Enterprises shall engage qualified
institutions to issue the environmental impact assessment reports.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the Law of the PRC on the Prevention
and Control of Water Pollution (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#27700;&#27745;&#26579;&#38450;&#27835;&#27861;&#12299;)
promulgated by the SCNPC on May 11, 1984 and last amended on June 27, 2017, and effective on January 1, 2018, the Law of the PRC on the
Prevention and Control of Atmospheric Pollution (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22823;&#27668;&#27745;&#26579;&#38450;&#27835;&#27861;&#12299;)
promulgated by the SCNPC on September 5, 1987 and last amended on October 26, 2018, the Law of the PRC on the Prevention and Control of
Pollution from Environmental Noise (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#29615;&#22659;&#22122;&#22768;&#27745;&#26579;&#38450;&#27835;&#27861;&#12299;)
promulgated by the SCNPC on October 29, 1996 and amended on December 29, 2018, and the Law of the PRC on the Prevention and Control of
Environmental Pollution of Solid Waste (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22266;&#20307;&#24223;&#29289;&#27745;&#26579;&#29615;&#22659;&#38450;&#27835;&#27861;&#12299;),
promulgated by the SCNPC on October 30, 1995 and last amended on April 29, 2020, all the enterprises that may cause environmental pollution
in the course of their business operation shall implement preventive and curative environmental protection measures in their plants and
establish a reliable environmental protection system.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We strictly complied with the applicable
environmental laws and regulations in constructing our factory. On December 8, 2004, the environmental protection bureau of local
government determined that the environmental protection facilities we constructed for our factory satisfied the relevant standards.
According to the certificate issued by the ecological environment bureau of local government (the &#8220;Bureau&#8221;), our factory
has not been assessed on its environmental impacts since its establishment in 2004. Although there were certain procedural defects
in the original construction process, we constructed our environmental protection facilities for our factory in strict compliance
with the requirements of applicable PRC environmental laws and regulations. Our environmental protection facilities were approved by
the Bureau in December 2004 and have since been under normal operations. As of the date of the date of this annual report, we have
not been found in violation of applicable environmental laws or regulations, or imposed of administrative penalties by environmental
protection authorities in the past three years. No environmental pollution incident has occurred on our manufacturing facility.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Foreign Exchange Control</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Foreign Exchange Administration
Regulations of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22806;&#27719;&#31649;&#29702;&#26465;&#20363;&#12299;),
as amended on August 5, 2008, and the Regulation on the Administration of the Foreign Exchange Settlement, Sales and Payment (&#12298;&#32467;&#27719;&#12289;&#21806;&#27719;&#21450;&#20184;&#27719;&#31649;&#29702;&#35268;&#23450;&#12299;),
or the Settlement Regulations, promulgated by the People&#8217;s Bank of China on June 20, 1996 and came into effect on July 1, 1996,
foreign exchanges required for profit distributions and dividend payments may be purchased from designated foreign exchange banks in the
PRC upon presentation of a board resolution authorizing distribution of profits or payment of dividends.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the Notice of SAFE on Further Improving
and Adjusting Foreign Exchange Administration Policies on Direct Investment (&#12298;&#22269;&#23478;&#22806;&#27719;&#31649;&#29702;&#23616;&#20851;&#20110;&#36827;&#19968;&#27493;&#25913;&#36827;&#21644;&#35843;&#25972;&#30452;&#25509;&#25237;&#36164;&#22806;&#27719;&#31649;&#29702;&#25919;&#31574;&#30340;&#36890;&#30693;&#12299;)
(the &#8220;Circular No. 59&#8221;), promulgated on November 19, 2012 and last amended on December 30, 2019 by the State Administration
of Exchange Control, or the SAFE, (1) the opening of and payment into foreign exchange accounts under direct investment accounts are no
longer subject to approval by the SAFE; (2) reinvestment with legal income of foreign investors in China is no longer subject to approval
by SAFE; (3) the procedures for capital verification and confirmation that foreign-funded enterprises need to go through are simplified;
(4) purchase and external payment of foreign exchange under direct investment accounts are no longer subject to approval by SAFE; (5)
domestic transfer of foreign exchange under direct investment account is no longer subject to approval by SAFE; and (6) the administration
over the conversion of foreign exchange capital of foreign-invested enterprises is improved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Circular on Further Simplifying
and Improving the Direct Investment-related Foreign Exchange Administration Policies (&#12298;&#20851;&#20110;&#36827;&#19968;&#27493;&#31616;&#21270;&#21644;&#25913;&#36827;&#30452;&#25509;&#25237;&#36164;&#22806;&#27719;&#31649;&#29702;&#25919;&#31574;&#30340;&#36890;&#30693;&#12299;)
(the &#8220;SAFE Circular No. 13&#8221;), which was promulgated on February 13, 2015 and became effective on June 1, 2015, the foreign
exchange registration under domestic direct investment and the foreign exchange registration under foreign direct investment is directly
reviewed and handled by banks in accordance with the Circular No. 13, and the SAFE and its branches shall perform indirect regulation
over the foreign exchange registration via banks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Circular on the Reform of
the Management Method for the Settlement of Foreign Exchange Capital of Foreign-invested Enterprises
(&#12298;&#22269;&#23478;&#22806;&#27719;&#31649;&#29702;&#23616;&#20851;&#20110;&#25913;&#38761;&#22806;&#21830;&#25237;&#36164;&#20225;&#19994;&#22806;&#27719;&#36164;&#26412;&#37329;&#32467;&#27719;&#31649;&#29702;&#26041;&#24335;&#30340;&#36890;&#30693;&#12299;)
promulgated by the SAFE on March 30, 2015 and became effective on June 1, 2015, and the Circular on the Reform and Standardization
of the Management Policy of the Settlement of Capital Projects
(&#12298;&#22269;&#23478;&#22806;&#27719;&#31649;&#29702;&#23616;&#20851;&#20110;&#25913;&#38761;&#21644;&#35268;&#33539;&#36164;&#26412;&#39033;&#30446;&#32467;&#27719;&#31649;&#29702;&#25919;&#31574;&#30340;&#36890;&#30693;&#12299;)
promulgated by the SAFE on June 9, 2016, the settlement of foreign exchange by foreign invested enterprises shall be governed by the
policy of foreign exchange settlement on a discretionary basis. However, the settlement of foreign exchange shall only be used for
its own operation purposes within the business scope of the foreign invested enterprises in accordance with the principle of
authenticity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Circular 37, a PRC resident shall
register with the local SAFE branch before he or she contributes assets or equity interests in an overseas special purpose vehicle (&#8220;Overseas
SPV&#8221;), which is directly established or controlled by the PRC Resident for the purpose of conducting investment for financing. Failure
to comply with the SAFE registration requirements could result in penalties for evasion of foreign exchange controls. The Circular No.
13 provides that banks can directly handle the initial foreign exchange registration and amendment registration under the Circular 37.
Mr. Gang Lai completed the initial foreign registration on June 3, 2019.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Labor and Social Insurance</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Labor Contract Law (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#21171;&#21160;&#21512;&#21516;&#27861;&#12299;),
which was promulgated by the SCNPC on June 29, 2007 and became effective on January 1, 2008, and amended on December 28, 2012 and became
effective on July 1, 2013, and the Implementing Regulations of the Labor Contracts Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#21171;&#21160;&#21512;&#21516;&#27861;&#23454;&#26045;&#26465;&#20363;&#12299;),
which was promulgated by the State Council on September 18, 2008, labor contracts shall be concluded in writing if employment relationships
are to be or have been established between employers and employees. In addition, employee wages cannot be lower than local standards on
minimum wages.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Labor Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#21171;&#21160;&#27861;&#12299;),
which was promulgated by the SCNPC on July 5, 1994 and last amended and came into effect on December 29, 2018, employers shall establish
and improve their system of workplace safety and sanitation, strictly abide by state rules and standards on workplace safety, educate
employees in occupational safety and sanitation in the PRC. Occupational safety and sanitation facilities shall comply with state-fixed
standards. Enterprises and institutions shall provide employees whose work involves occupational hazards with health examinations on a
regular basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the Social Insurance Law, the Interim
Regulations on the Collection and Payment of Social Security Funds (&#12298;&#31038;&#20250;&#20445;&#38505;&#36153;&#24449;&#32564;&#26242;&#34892;&#26465;&#20363;&#12299;),
which was promulgated by the State Council on January 22, 1999 and amended on March 24, 2019, and the Administrative Regulations on the
Housing Provident Funds (&#12298;&#20303;&#25151;&#20844;&#31215;&#37329;&#31649;&#29702;&#26465;&#20363;&#12299;), which was promulgated
by the State Council on April 3, 1999 and last amended on March 24, 2019, employers are required to make contributions, on behalf of their
employees, to a number of social security funds, including funds for basic pension insurance, unemployment insurance, basic medical insurance,
occupational injury insurance, maternity insurance and to housing provident funds. Any employer who fails to make contributions may be
fined and ordered to make good the deficit within a stipulated time limit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to April 2020, we only contributed to the
social insurance and housing provident funds for some, but not all, of our employees. There is a risk that the labor security administration
authority may take enforcement action to collect from us all the outstanding contributions of the social insurance and housing provident
funds required to be made for the employees in the past, and we may be subject to a late charge at the rate of 0.2% per day on the total
outstanding contribution. We started to contribute to the social insurance and housing provident funds for all of our employees since
April 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since April 2020, we have been contributing to
the social insurance and housing provident funds for our employees in accordance with the minimum contribution requirements. Pursuant
to the aforementioned applicable laws and regulations, the government or an employee has the right to demand us to contribute to the employee&#8217;s
social insurance and housing provident funds calculated based on his or her actual salary, and an employee who has not received contributions
from us has the right to demand us to contribute to his or her social insurance and housing provident funds. As confirmed in writing by
the local government, our contributions of the social insurance and housing provident funds are in compliance with the PRC laws and the
local regulations and policies, and therefore the local government is very unlikely to impose any penalty on us for our contributions
since April 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Enterprise Income Tax</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the EIT Law, promulgated by the National
People&#8217;s Congress on March 16, 2007, effective on January 1, 2008 and last amended on December 29, 2018, and the Implementation
Regulations for the Enterprise Income Tax Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#20225;&#19994;&#25152;&#24471;&#31246;&#27861;&#23454;&#26045;&#26465;&#20363;&#12299;)
promulgated by the State Council on December 6, 2007 and amended on April 23, 2019, other than a few exceptions, the income tax rate for
both domestic enterprises and foreign-invested enterprises is 25%. Enterprise taxpayers are classified as either resident enterprises
or non-resident enterprises. Resident enterprises are defined as enterprises that are established in China in accordance with PRC laws,
or that are established in accordance with the laws of foreign countries but whose actual or de facto management bodies are located in
China. Non-resident enterprise refers to an entity established under foreign law whose de facto management bodies are not within the PRC
but which have an establishment or place of business in the PRC, or which do not have an establishment or place of business in the PRC
but have income sourced within the PRC. An income tax rate of 10% will normally be applicable to dividends declared to non-PRC resident
enterprise investors that do not have an establishment or place of business in the PRC, or that have such establishment or place of business
but the relevant income is not effectively connected with the establishment or place of business, to the extent such dividends are derived
from sources within the PRC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Arrangement between the Mainland
of China and the Hong Kong Special Administrative Region for the Avoidance of Double Taxation and Prevention of Fiscal Evasion with respect
to Taxes on Incomes (&#12298;&#20869;&#22320;&#21644;&#39321;&#28207;&#29305;&#21035;&#34892;&#25919;&#21306;&#20851;&#20110;&#23545;&#25152;&#24471;&#36991;&#20813;&#21452;&#37325;&#24449;&#31246;&#21644;&#38450;&#27490;&#20599;&#28431;&#31246;&#30340;&#23433;&#25490;&#12299;),
or the Double Tax Avoidance Arrangement, and other applicable PRC laws, 5% withholding tax rate shall apply to the dividends paid by a
PRC company to a Hong Kong resident, provided that such Hong Kong resident directly holds at least 25% of the equity interests in the
PRC company, and 10% of withholding tax rate shall apply if the Hong Kong resident holds less than 25% of the equity interests in the
PRC company. However, pursuant to the Circular on Certain Issues Relating to the Implementation of Dividend Provisions in Tax Treaties
(&#12298;&#20851;&#20110;&#25191;&#34892;&#31246;&#25910;&#21327;&#23450;&#32929;&#24687;&#26465;&#27454;&#26377;&#20851;&#38382;&#39064;&#30340;&#36890;&#30693;&#12299;)
issued on February 20, 2009 by the SAT, if a PRC tax authority determines, in its discretion, that a company benefits from such reduced
income tax rate as a result of an arrangement that is primarily tax-driven, such PRC tax authority may adjust the preferential tax treatment
of the company. Based on the Announcement on Certain Issues with Respect to the Beneficial Owner in Tax Treaties (&#12298;&#22269;&#23478;&#31246;&#21153;&#24635;&#23616;&#20851;&#20110;&#31246;&#25910;&#21327;&#23450;&#20013;&#21463;&#30410;&#25152;&#26377;&#20154;&#26377;&#20851;&#38382;&#39064;&#30340;&#20844;&#21578;&#12299;)
issued by the SAT on February 3, 2018 and effective on April 1, 2018, if an applicant&#8217;s business activities do not constitute substantive
business activities, it could result in the negative determination of the applicant&#8217;s status as a beneficial owner, and consequently,
the applicant could be precluded from enjoying the above-mentioned reduced income tax rate of 5% under the Double Tax Avoidance Arrangement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. <span style="text-decoration:underline">Organizational Structure</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See &#8220;&#8212;A. History and Development of
the Company.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>D. <span style="text-decoration:underline">Property, Plants and Equipment</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See &#8220;&#8212;B. Business Overview&#8212;Properties
and Facilities.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 4A. UNRESOLVED STAFF COMMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following discussion of our financial condition
and results of operations is based upon and should be read in conjunction with our consolidated financial statements and their related
notes included elsewhere in this annual report. This report contains forward-looking statements. In evaluating our business, you should
carefully consider the information provided under the caption &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8221; in this annual
report. We caution you that our businesses and financial performance are subject to substantial risks and uncertainties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. <span style="text-decoration:underline">Operating Results</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through the PRC operating entities in China, the
Company is a pharmaceutical company specializing in the development, manufacturing, marketing and sale of TCMD products targeted to the
elderly to address their physical conditions in the aging process and to promote their general well-being. We have registered and obtained
approval for 26 varieties of TCMD products from the National Medical Products Administration (the &#8220;NMPA&#8221;), and we currently
produce 13 varieties of TCMD products and sell them in 261 cities in 30 provinces in China as of the date of this annual report. In addition,
we also sell biomedical drugs, medical instruments, TCMPs and dietary supplements manufactured by third-party pharmaceutical companies
(collectively referred to as &#8220;third-party products&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our major customers are pharmaceutical companies,
hospitals, clinics and drugstore chains, primarily located in Jiangxi Province, Jiangsu Province, Guangdong Province, Hubei Province,
Fujian Province, Guangxi Province and Shandong Province, and 23 other provinces in China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Key Factors that Affect Our Results of
Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">We believe the following key factors may affect
our financial condition and results of operations:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Our Ability to
Attract Additional Customers and Increase the Spending Per Customer</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our major customers are
pharmaceutical distributors, hospitals, clinics and drugstore chains. We currently sell our products to these customers in 261 cities
in 30 provinces in China, with significant customers located in Jiangxi Province, Jiangsu Province, Guangdong Province, Hubei Province,
Fujian Province, Guangxi Province and Shandong Province in China. Our top 10 customers in the aggregate accounted for 22.5%, 27.2% and
32.2% of our total revenues for the fiscal years ended September 30, 2024, 2023 and 2022, respectively. No single customer contributed
to more than 10% of our total revenues for the fiscal years ended September 30, 2024, 2023 and 2022. Our dependence on a small number
of larger customers could expose us to the risk of substantial losses if any single large customer stops purchasing our products, purchases
fewer of our products or goes out of business and we cannot find substitute customers on equivalent terms. If any of our significant customers
reduces the quantity of the products they purchase from us or stops purchasing from us, our net revenues would be materially and adversely
affected. Therefore, the success of our business in the future depends on our effective marketing efforts to expand our distribution network
including additional cities and rural areas in the PRC in an effort to increase our geographic appearance. The success of expansion will
depend upon many factors, including our ability to form relationships with, and manage an increasing number of, customers base and optimize
our distribution network. If our marketing efforts fail to convince customers to accept our products, we may find it difficult to maintain
the existing level of sales or to increase such sales. Should this happen, our net revenues would decline and our growth prospects would
be severely impaired.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Our Ability to
Increase Awareness of Our Brand and Develop Customer Loyalty</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our brands, such as
&#8220;Bai Nian Dan (&#30334;&#24180;&#20025;)&#8221; and &#8220;Hu Zhuo Ren (&#32993;&#21331;&#20161;)&#8221;, are well-recognized
among our clients and other Chinese medicine industry players. Our brand is integral to our sales and marketing efforts. We believe
that maintaining and enhancing our brand name recognition in a cost-effective manner is critical to achieving widespread acceptance
of our current and future products and is an important element in our effort to increase our customer base. Successful promotion of
our brand name will depend largely on our marketing efforts and ability to provide reliable and quality products at competitive
prices. Brand promotion activities may not necessarily yield increased revenue, and even if they do, any increased revenue may not
offset the expenses we will incur in marketing activities. If we fail to successfully promote and maintain our brand, if we incur
substantial expenses in an unsuccessful attempt to promote and maintain our brand, or if we fail to generate the desired level of
brand recognition and awareness through our recent television advertising efforts, or at all, we may fail to attract new customers
or retain our existing customers, in which case our business, operating results and financial condition, would be materially
adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Our Ability to Control Costs and Expenses
and Improve Our Operating Efficiency</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our business growth is
dependent on our ability to attract and retain qualified and productive employees, identify business opportunities, secure new contracts
with customers, and our ability to control costs and expenses to improve our operating efficiency. Our inventory costs (including raw
materials, labor, packaging cost, depreciation and amortization, freight costs, overhead and third-party products purchase costs) have
a direct impact on our profitability. The raw materials used in manufacturing of our TCMD products are subject to price volatility and
inflationary pressures. Our success is dependent, in part, on our ability to reduce our exposure to increase in those costs through a
variety of ways, while maintaining and improving margins and market share. We also rely on third-party manufacturers as a source for a
portion of the components used for producing our products. These manufacturers are also subject to price volatility, labor costs and other
inflationary pressures, which may, in turn, result in an increase in the amount we pay for sourced products. Raw materials and sourced
product price increases may offset our productivity gains and price increases and may adversely impact our financial results. In addition,
our staffing costs (including payroll and employee benefit expense) and administrative expenses also have a direct impact on our profitability.
Our ability to drive the productivity of our staff and enhance our operating efficiency affects our profitability. To the extent that
the costs we are required to pay to our suppliers and our staffs exceed our estimates, our profit may be impaired. If we fail to implement
initiatives to control costs and improve our operating efficiency over time, our profitability will be negatively impacted.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Our Ability to Compete Successfully</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Chinese patent
medicine industry we are in is highly competitive and evolving in China. The development and commercialization of new pharmaceutical
products is highly competitive, and the industry currently is characterized by rapidly changing technologies, significant
competition and a strong emphasis on intellectual property. We will face competition with respect to our current and future
pharmaceutical product candidates from major pharmaceutical companies in China. Potential competitors also include academic
institutions, government agencies and other public and private research organizations that conduct research, seek patent protection
and establish collaborative arrangements for research, development, manufacturing and commercialization of pharmaceutical products.
Some of our current or potential competitors may have significantly greater financial resources and expertise in research and
development, manufacturing, product testing, obtaining regulatory approvals and marketing approved products than we do, and in the
event that any of these happens, our competitors may be able to establish a strong market position before our new products are able
to enter the market. Additionally, technologies developed by our competitors may render our product candidates uneconomical or
obsolete. If we do not compete effectively, our operating results could be harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The Recent Wave
of Tariffs and Other Trade Controls Could Materially and Adversely Affect Our Business and Our Financial Condition</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The trade war between the
United States and China has reached unprecedented levels. After President Donald Trump announced widespread tariffs on April 2, 2025,
China retaliated with similar measures. Within a week, both countries had imposed additional tariffs of 125% on each other's imports.
Reciprocal tariffs of over 100% are anticipated to make trade between the two countries prohibitively expensive. The risk of recession,
both for the U.S. economy and the global economy, has increased significantly. Economic conditions in China are sensitive to global economic
conditions, as well as changes in domestic economic and political policies and the expected or perceived overall economic growth rate
in China. Any severe or prolonged slowdown in the global or Chinese economy would likely materially and adversely affect our business,
results of operations and financial condition. In addition, continued turbulence in the international markets may adversely affect our
ability to access capital markets to meet liquidity needs.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Key Financial Performance Indicators</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In assessing our financial performance, we consider
a variety of financial performance measures, including principal growth in net revenue and gross profit, our ability to control costs
and operating expenses to improve our operating efficiency and net income. Our review of these indicators facilitates timely evaluation
of the performance of our business and effective communication of results and key decisions, allowing our business to respond promptly
to competitive market conditions and different demands and preferences from our customers. The key measures that we use to evaluate the
performance of our business are set forth below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net Revenue</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our revenue is reported net of all value added
taxes (&#8220;VAT&#8221;). Our products are sold with no right of return and we do not provide other credits or sales incentive to customers.
Our revenue is driven by sales volume, selling price, and mix of products sold.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Fiscal Years Ended
    September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance<br/> comparing<br/> Fiscal Year 2024 to<br/> Fiscal Year 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance<br/> comparing<br/> Fiscal Year 2023 to<br/> Fiscal Year 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 40%; text-align: left">Revenue from sales of self-manufactured TCMD products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">60.9</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">57.5</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">59.8</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3.4</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2.3</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Revenue from sales of third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3.4</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Sales volume by unit- TCMD products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,881,087</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,753,432</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,799,254</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(29.1</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Sales volume by unit- third party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,321,624</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,777,877</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,226,027</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28.0</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4.9</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total sales volume</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">18,202,711</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">25,531,309</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">20,025,281</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(28.7</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">27.5</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">Average selling price per unit- TCMD products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.18</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(50.0</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">Average selling price per unit- Third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.42</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.56</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.75</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9.0</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10.9</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues from sales of TCMD products manufactured
by us accounted for 60.9%, 57.5% and 59.8% of our total revenues for the fiscal years ended September 30, 2024, 2023 and 2022, respectively.
The 13 TCMD products manufactured by us fall into two categories: (i) treatment and relief for common chronic health conditions in the
elderly designed to achieve physical wellness and longevity (the &#8220;Chronic Condition Treatments&#8221;) and (ii) cold and flu medications.
Our Chronic Condition Treatments primarily include Guben Yanling Pill, Shenrong Weisheng Pill, Quanlu Pill, Yangxue Danggui Syrup, Wuzi
Yanzong Oral Liquid, Fengtong Medicinal Liquor, Shenrong Medicinal Liquor, Qishe Medicinal Liquor, Fengshitong Medicinal Liquor, and Shiquan
Dabu Medicinal Liquor, and our cold and flu medications primarily include Paracetamol Granule for Children, Isatis Root Granule and Qiangli
Pipa Syrup.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to diversify our product offerings
and product mix, in addition to selling our self-manufactured TCMD products, we also sell products manufactured by third-party
pharmaceutical companies, including (i) biomedical drugs, such as liquid glucose, prednisolone, and citicoline, (ii) medical
instruments, such as drug-eluting stents, surgical tubes and syringes, (iii) TCMPs, such as red sage tables, Longdan Xiegan pills,
and Chinese skullcap capsules, and (iv) dietary supplements, such as vitamins, probiotic powder, and calcium tablets. Revenues from
sales of third-party products accounted for <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39.1%, 42.5%
and 40.2% of our total revenues for the fiscal years ended September 30, 2024, 2023 and 2022, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Gross Profit</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gross profit is equal to net revenue minus cost
of goods sold. Cost of goods sold primarily includes inventory costs (raw materials, labor, packaging costs, depreciation and amortization,
third-party products purchase price, freight costs and overhead). Cost of goods sold generally changes as our production costs change,
as these are affected by factors including the market price of raw materials, labor productivity, or the purchase price of third-party
products, and as the customer and product mix changes. Our cost of revenues accounted for 73.6%, 68.1% and 45.5% of our total revenue
for the fiscal years ended September 30, 2024, 2023 and 2022, respectively. We expect our cost of revenues to increase as we further expand
our operations in the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our gross margin was 26.4%, 31.9% and 54.5% for
the fiscal years ended September 30, 2024, 2023 and 2022, respectively. Our gross profit and gross margin are affected by the different
product mix, the average selling price and unit cost of those products sold during each fiscal year. See detailed discussion under &#8220;&#8211;&#8211;Results
of Operation&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our operating expenses consist of selling expenses,
general and administrative expenses and research and development expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our selling expenses primarily include salary
and welfare benefit expenses paid to our sales personnel, advertising expenses to increase the awareness of our brand, shipping and delivery
expenses, expenses incurred for our business travel, meals and other sales promotion and marketing activities related expenses. Our selling
expenses accounted for 35.5%, 21.0% and 47.5% of our total revenue for the fiscal years ended September 30, 2024, 2023 and 2022, respectively.
We expect our overall selling expenses, including but not limited to, advertising expenses and brand promotion expenses and salaries,
to increase in the foreseeable future and facilitate the growth of our business, especially when we continue to expand our business and
promote our products to customers located at extended geographic areas.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our general and administrative expenses
primarily consist of employee salaries, welfare and insurance expenses, depreciation, bad debt reserve expenses, inspection and
maintenance expenses, office supply and utility expenses, business travel and meals expenses, land and property taxes and
professional service expenses. General and administrative expenses were 12.6%, 8.2% and 5.4% of our revenue for the fiscal years
ended September 30, 2024, 2023 and 2022, respectively. We expect our general and administrative expenses, including, but not limited
to, salaries and business consulting expenses, to increase in the foreseeable future, as we plan to hire additional personnel and
incur additional expenses in connection with the expansion of our business operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Chinese patent medicine industry is characterized
by rapid and frequent changes in customer demand and launches of new products. If we do not launch new products or improve our existing
products to meet the changing demands of our customers in a timely manner, some of our products could become uncompetitive in the market,
thereby adversely affecting on our revenues and operating results. Our research and development expenses primarily consist of salaries,
welfare and insurance expenses paid to our employees involved in the research and development activities, materials and supplies used
in the development and testing of new TCMD products, depreciation, and other miscellaneous expenses. Research and development expenses
accounted for 13.2%, 15.0% and 19.0% of our revenue for the fiscal years ended September 30, 2024, 2023 and 2022, respectively. As we
continue to develop new products and diversify our product offerings to satisfy customer demand, we expect our research and development
expenses to increase in the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fiscal year ended September 30, 2024 compared
to fiscal year ended September 30, 2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the results of
our operations during the fiscal years ended September 30, 2024 and 2023, respectively, and provides information regarding the dollar
and percentage increase or (decrease) during such periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Fiscal Years Ended
    September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of<br/> revenue</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of<br/> revenue</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-indent: -9pt; padding-left: 9pt">REVENUE</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">23,024,458</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">100.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">32,308,735</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">100.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(9,284,277</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(28.7</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">COST OF REVENUE</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,952,556</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">73.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,993,601</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,041,045</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22.9</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">GROSS PROFIT</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,071,902</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">26.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,315,134</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">31.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,243,232</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(41.1</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">OPERATING EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,170,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,783,703</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,387,272</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,889,652</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,638,984</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,668</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,031,115</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,858,548</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,827,433</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(37.6</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,091,742</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,281,235</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">44.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(189,493</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1.3</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">LOSS FROM OPERATIONS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,019,840</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(34.8</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,966,101</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12.3</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,053,739</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">102.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">OTHER INCOME (EXPENSE)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Interest expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(278,172</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.2</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(156,788</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.5</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(121,384</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77.4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other income (expense), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145,476</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(235,614</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.7</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">381,090</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(161.7</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Equity investment income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">31,942</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">31,072</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">870</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total other expense, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(100,754</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.4</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(361,330</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1.1</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">260,576</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(72.1</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">LOSS BEFORE INCOME TAX</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,120,594</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(35.3</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,327,431</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13.4</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,793,163</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">INCOME TAX EXPENSE</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">606,704</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,253,593</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,646,889</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(73.1</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">NET LOSS</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(8,727,298</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(37.9</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(6,581,024</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(20.4</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(2,146,274</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">32.6</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenues.&#160;</i></b>We currently produce
and sell 13 varieties of TCMD products and also sell products manufactured by third-party pharmaceutical companies, to our customers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Fiscal Years Ended
    September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Revenue from sales of self-manufactured TCMD products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">14,026,049</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,572,658</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(4,546,609</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(24.5</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Revenue from sales of third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,998,409</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,736,077</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,737,668</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(34.5</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">23,024,458</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">32,308,735</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(9,284,277</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(28.7</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our revenues decreased by $9,284,277, or 28.7%,
to $23,024,458 for the fiscal year ended September 30, 2024, from $32,308,735 for the fiscal year ended September 30, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue from sales of our TCMD products</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of TCMD products decreased by $4,546,609,
or 24.5%, to $14,026,049 for the fiscal year ended September 30, 2024, from $18,572,658 for the fiscal year ended September 30, 2023.
The decrease in the sales of our TCMD product was due to the following specific reasons:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global economic slowdown has led to a decline in customers&#8217; spending power, and sales volume of our TCMD products decreased by 29.1%, to 11,881,087 units sold for the year ended September 30, 2024, from 16,753,432 units sold for the year ended September 30, 2023.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The average selling price of our TCMD products increased by $0.07 per unit, or 6.3%, to $1.18 per unit for the fiscal year ended September 30, 2024, from $1.11 per unit for the fiscal year ended September 30, 2023, due to a change in product mix.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The exchange rate between RMB and US$ was US$1.00 to RMB7.2043 for the fiscal year ended September 30, 2023 as compared to US$1.00 to RMB7.0533 for the fiscal year ended September 30, 2024. The depreciation of RMB against US$ had a 2.1% negative impact on our reported revenues.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue from sales of third-party products</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of third-party products decreased by $4,737,668,
or 34.5%, to $8,998,409 for the fiscal year ended September 30, 2024, from $13,736,077 for the fiscal year ended September 30, 2023. Sales
volume of third-party products decreased by 28.0%, to 6,321,624 units sold in the fiscal year ended September 30, 2024, from 8,777,877
units sold in the fiscal year ended September 30, 2023. Average selling price of third-party products decreased by $0.14 per unit, or
9.0%, to $1.42 per unit in the fiscal year ended September 30, 2024, from $1.56 per unit in the fiscal year ended September 30, 2023,
due to a change in our product mix and the 2.1% negative impact from foreign currency fluctuation as discussed above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cost of Revenues.&#160;</i></b>Our cost
of revenues primarily consists of inventory costs (raw materials, labor, packaging cost, depreciation and amortization, third-party products
purchase price, freight costs and overhead) and business tax. Cost of revenues generally changes as our production costs change, which
are affected by factors including the market price of raw materials, labor productivity, and the purchase price of third-party products,
and as the customer and product mix changes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Fiscal Years Ended
    September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Cost of revenue- TCMD products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,145,847</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,404,804</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(2,258,957</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(16.9</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cost of revenue- third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,806,709</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,588,797</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,782,088</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(32.4</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total cost of revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">16,952,556</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">21,993,601</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(5,041,045</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(22.9</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of revenues decreased by $5,041,045, or 22.9%,
to $16,952,556 for the fiscal year ended September 30, 2024, from $21,993,601 for the fiscal year ended September 30, 2023, mainly due
to a decrease in sales volume.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cost of revenues of TCMD products</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of revenues of TCMD products accounted
for 65.7% and 60.9% of our total costs of revenues for the fiscal years ended September 30, 2024 and 2023, respectively. Cost of
revenues of TCMD products decreased by $<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,258,957, or
16.9%, from $13,404,804 for the fiscal year ended September 30, 2023 to $11,145,847 for the fiscal year ended September 30, 2024.
The decrease in cost of revenues of our TCMD products was due to the following reasons:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales volume of our TCMD products decreased by 29.1%, to 11,881,087 units sold in the fiscal year ended September 30, 2024, from 16,753,432 units sold in the fiscal year ended September 30, 2023.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">In the summer of 2023, a severe flood in Anhui Province and Hubei Province
of China, which are two main producing areas of traditional Chinese medicinal materials, led to a decrease in the supply of such materials,
and the prices of the traditional Chinese medicine raw materials increased during the <span style="background-color: white">fiscal </span>year
ended September 30, 2024. The average per unit cost of our TCMD products increased by $0.14, or 17.2%, from $0.80 per unit for the <span style="background-color: white">fiscal
</span>year ended September 30, 2023 to $0.94 per unit for the <span style="background-color: white">fiscal </span>year ended September
30, 2024.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2.1% negative impact from foreign currency fluctuation as discussed above.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cost of revenues of third-party products</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of revenues of third-party products accounted
for 34.3% and 39.1% of our total costs of revenues for the fiscal years ended September 30, 2024 and 2023, respectively. Cost of revenues
of third-party products decreased by $2,782,088, or 32.4%, from $8,588,797 for the fiscal year ended September 30, 2023 to $5,806,709
for the fiscal year ended September 30, 2024, because of the decrease in sales volume of third-party products by 28.0%, from 8,777,877
units sold in the fiscal year ended September 30, 2023 to 6,321,624 units sold in the fiscal year ended September 30, 2024. The average
per unit cost of third-party products decreased by $0.06 per unit, or 6.1%, from $0.98 per unit for the fiscal year ended September 30,
2023 to $0.92 per unit for the fiscal year ended September 30, 2024, due to a change in product mix and the 2.1% negative impact from
foreign currency fluctuation as discussed above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Gross profit</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our gross profit decreased by $4,243,232, to $6,071,902
for the fiscal year ended September 30, 2024, from $10,315,134 for the fiscal year ended September 30, 2023. Our margin decreased by 5.5%,
to 26.4% for the fiscal year ended September 30, 2024, from 31.9% for the fiscal year ended September 30, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Fiscal Years Ended
    September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">Gross profit- TCMD products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,880,202</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,167,854</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(2,287,652</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(44.3</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Gross profit- third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,191,700</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,147,280</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,955,580</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(38.0</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total gross profit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,071,902</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,315,134</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(4,243,232</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(41.1</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Gross margin- TCMD products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7.3</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Gross margin- third party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">35.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">37.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2.0</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Total gross margin</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">26.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">31.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5.5</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Average selling price per unit- TCMD products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.18</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.07</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Average cost per unit- TCMD products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.94</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.80</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.14</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Average selling price per unit- third party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.42</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.56</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.14</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9.0</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Average cost per unit - third party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.92</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.98</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.06</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6.1</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gross profit from the sales of our TCMD products
decreased by $2,287,652, or 44.3%, from $5,167,854 for the fiscal year ended September 30, 2023 to $2,880,202 for the fiscal year ended
September 30, 2024, and the gross margin of our TCMD products decreased by 7.3 percentage point, from 27.8% for the fiscal year ended
September 30, 2023 to 20.5% for the fiscal year ended September 30, 2024. The decrease in our gross profit from the sales of TCMD products
was affected by the decrease in sales volume, increase in the average per unit cost, and partially offset by the increase in the average
unit selling price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gross profit from third-party product sales decreased
by $1,955,580, or 38.0%, from $5,147,280 for the fiscal year ended September 30, 2023 to $3,191,700 for the fiscal year ended September
30, 2024, while the gross margin of third-party product sales slightly decreased by 2.0%, from 37.5% for the fiscal year ended September
30, 2023 to 35.5% for the fiscal year ended September 30, 2024. The decrease in our gross profit from third-party products was affected
by the decrease in sales volume and the average unit selling price, and partially offset by the decrease in the average per unit cost.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the breakdown of
our operating expenses for the fiscal years ended September 30, 2024 and 2023:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Fiscal Years Ended
    September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of<br/> revenue</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of<br/> revenue</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-weight: bold; text-align: justify; text-indent: -9pt; padding-left: 9pt">Total revenue</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">23,024,458</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">100.0</td><td style="width: 1%; font-weight: bold; text-align: left">%</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">32,308,735</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">100.0</td><td style="width: 1%; font-weight: bold; text-align: left">%</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">(9,284,277</td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">(28.7</td><td style="width: 1%; font-weight: bold; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,170,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,783,703</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,387,272</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,889,652</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,638,984</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,668</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,031,115</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,858,548</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,827,433</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(37.6</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total operating expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,091,742</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">61.2</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,281,235</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">44.2</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(189,493</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(1.3</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Selling expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our selling expenses primarily include salaries
and welfare benefit expenses paid to our sales personnel, advertising expenses to increase our brand awareness, shipping and delivery
expenses, expenses incurred for our business travel, meals and other sales promotion and marketing activities related expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Fiscal Years Ended
    September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left">Salary and employee benefit expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">915,850</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11.2</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">778,138</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11.5</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">137,712</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">17.7</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Advertising expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,144,579</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,653,633</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">490,946</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Shipping and delivery expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,183,046</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,033,213</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">149,833</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Business travel and meals expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,237</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208,108</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,129</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Market research expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">567,312</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">567,312</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Other sales promotion related expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">120,951</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">110,611</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,340</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total selling expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,170,975</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,783,703</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,387,272</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">20.5</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our selling expenses increased by $1,387,272,
or 20.5%, to $8,170,975 for the fiscal year ended September 30, 2024, from $6,783,703 for the fiscal year ended September 30, 2023, primarily
attributable to (i) an increase in advertising expenses by $490,946 and increase in market research expenses by $567,312. We entered into
advertising service agreement with Health Headline to promote our brand on Health Headline&#8217;s website and mobile app. Due to global
economic slowdown and intense competition in the Chinese patent medicine industry, we increased advertising and market research expenses
to increase our brand awareness, maintain existing customer base and attract new customers. Customer number increased from 2,541 during
the fiscal year ended September 30, 2023 to 2,561 during the fiscal year ended September 30, 2024. Although our revenue decreased during
the fiscal year ended September 30, 2024, these market efforts will help us to achieve long-term revenue growth; (ii) an increase in shipping
and delivery expenses by $149,833, due to increased freight costs and rising fuel prices during the fiscal year ended September 30, 2024;
and (iii) an increase in salary and employee benefit expenses by $137,712, or 17.7%, as we recruited new employees in the marketing department
to promote sales of our products.<b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General and Administrative Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our general and administrative expenses primarily
consist of employee salaries, welfare and insurance expenses, depreciation, bad debt reserve expenses, inspection and maintenance expenses,
office supply and utility expenses, business travel and meals expenses, land and property taxes and professional service expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Fiscal Years Ended
    September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt">Salary and employee benefit expense</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">729,515</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25.2</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">728,499</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">27.6</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,016</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.1</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">209,604</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">195,451</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,153</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Bad debt reserve expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">131,581</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">131,581</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Land and property tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,573</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96,412</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(94,839</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(98.4</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Office supply and utility expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">180,347</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">440,873</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(260,526</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(59.1</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Transportation, business travel and meals expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">152,086</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,122</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,964</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25.6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Consulting fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,211,434</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">926,694</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">284,740</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Inspection and maintenance fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,844</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,154</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,310</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(38.8</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Stamp tax and other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">244,668</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">82,779</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">161,889</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">195.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total general and administrative expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,889,652</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,638,984</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">250,668</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9.5</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses increased by $250,668, or 9.5%,
to $2,889,652 for the fiscal year ended September 30, 2024, from $2,638,984 for the fiscal year ended September 30, 2023, primarily attributable
to (i) an increase in consulting fees by $284,740 due to increased legal fees in connection with our self-underwritten public offering
closed in July 2024; (ii) bad debt reserve expense increased by $131,581, because we accrued bad debt expenses based on our assessment
of the collectability of the accounts receivable; and partially offset by (iii) a decrease in office supply and utility expense by $260,526
due to decreased investor relations management expense.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and development expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our research and development expenses primarily
consist of salaries, welfare and insurance expenses paid to our employees involved in the research and development activities, materials
and supplies used in the development and testing new TCMD products, depreciation and other miscellaneous expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Fiscal Years Ended
    September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left">Salary and employee benefit expenses to research and development staff</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">137,423</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.5</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">140,528</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.9</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3,105</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2.2</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Materials used in research and development activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134,532</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">881,753</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(747,221</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(84.7</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expenditure on new product development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,720,597</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,794,464</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,073,867</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(28.3</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Depreciation and others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">38,563</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41,803</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,240</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7.8</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total research and development expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,031,115</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,858,548</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,827,433</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(37.6</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses decreased by
$1,827,433, or 37.6%, to $3,031,115 for the fiscal year ended September 30, 2024, from $4,858,548 for the fiscal year ended September
30, 2023, primarily attributable to (i) a decrease in development expenditure on improving production process of our Chinese medicine
products in the amount of $1,073,867. We entered into several cooperative agreements with external academic and research institutions
to jointly conduct development of eight production process to improve production efficiency and product quality, with activities beginning
in August 2022, and incurred significant amount of research and development expense in connection with such efforts during the fiscal
year ended September 30, 2023. These development activities were completed and results were integrated in production in September 2023,
and development expenditure decreased significantly during the fiscal year ended September 30, 2024; and (ii) a decrease in the materials
used in the research and development activities by $747,221 in connection with development activities on improving production process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other income (expenses), net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total other expenses, net, decreased by $260,576, to $100,754 for the
fiscal year ended September 30, 2024 from $361,330 for the fiscal year ended September 30, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Income Tax Expense</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Income tax expense was $606,704 for the fiscal
year ended September 30, 2024, representing a decrease of $1,646,889, or 73.1%, from $2,253,593 for the fiscal year ended September 30,
2023, due to decreased taxable income. As our principal PRC subsidiaries, Jiangxi Universe and Universe Trade, incurred net loss during
the <span style="background-color: white">fiscal </span>years ended September 30, 2024 and 2023, we evaluated the likelihood of the realization
of deferred tax assets, determined that deferred tax assets arising from net operating loss carry-forwards in previous <span style="background-color: white">fiscal
</span>years might not be realized, and therefore recognized $606,704 and $1,567,656 in valuation allowance for deferred tax assets during
the <span style="background-color: white">fiscal </span>years ended September 30, 2024 and 2023, respectively.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net Loss</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net loss was $8,727,298 for the fiscal year ended September 30, 2024,
representing a $2,146,274 increase from net loss of $6,581,024 for the fiscal year ended September 30, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic and diluted loss per share were $15.67 for the fiscal year ended
September 30, 2024, compared with basic and diluted loss per share of $27.23 for the fiscal year ended September 30, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Fiscal year ended September 30, 2023
compared to fiscal year ended September 30, 2022</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the results of
our operations during the fiscal years ended September 30, 2023 and 2022, respectively, and provides information regarding the dollar
and percentage increase or (decrease) during such periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Fiscal Years Ended
    September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of<br/> revenue</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of<br/> revenue</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-indent: -9pt; padding-left: 9pt">REVENUE</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">32,308,735</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">100.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40,143,151</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">100.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(7,834,416</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(19.5</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">COST OF REVENUE</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,993,601</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,251,815</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,741,786</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">GROSS PROFIT</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,315,134</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">31.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,891,336</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,576,202</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(52.9</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">OPERATING EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,783,703</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,083,135</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,299,432</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(64.5</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,638,984</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,183,270</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">455,714</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,858,548</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,644,375</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,785,827</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(36.4</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,281,235</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">44.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28,910,780</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">72.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,629,545</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(50.6</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">LOSS FROM OPERATIONS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,966,101</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12.3</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,019,444</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17.5</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,053,343</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(43.5</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">OTHER INCOME (EXPENSE)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Interest expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(156,788</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.5</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(162,400</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.4</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,612</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.5</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other income (expense), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(235,614</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.7</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,940</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(284,554</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(581.4</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Equity investment income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">31,072</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">38,588</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,516</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19.5</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total other expense, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(361,330</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1.1</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(74,872</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.2</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(286,458</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">382.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">LOSS BEFORE INCOME TAX</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,327,431</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13.4</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,094,316</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17.7</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,766,885</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(39.0</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">INCOME TAX EXPENSE</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,253,593</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">815,322</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,438,271</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">176.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">NET LOSS</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(6,581,024</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(20.4</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(7,909,638</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(19.7</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,328,614</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(16.8</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenues.&#160;</i></b>We currently produce
and sell 13 varieties of TCMD products and also sell products manufactured by third-party pharmaceutical companies, to our customers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Fiscal Years Ended
    September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Revenue - TCMD products sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,572,658</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">23,988,177</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(5,415,519</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(22.6</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Revenue &#8211; third-party products sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,736,077</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,154,974</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,418,897</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15.0</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">32,308,735</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">40,143,151</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(7,834,416</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(19.5</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our revenues decreased by $7,834,416, or 19.5%,
to $32,308,735 for the fiscal year ended September 30, 2023, from $40,143,151 for the fiscal year ended September 30, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenue from sales of our TCMD products</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of TCMD products decreased by $5,415,519,
or 22.6%, to $18,572,658 for the fiscal year ended September 30, 2023, from $23,988,177 for the fiscal year ended September 30, 2022.
The decrease in the sales of our TCMD product was due to the following specific reasons:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Slowdown in economy caused by the COVID-19 pandemic has led to a decline in customers&#8217; spending power, and we changed our pricing strategy decrease the per unit price of our TCMD products in an effort to increase sales volume and market share during this challenging period. Average selling price of our TCMD products decreased by $1.11 per unit, or 50.0%, to $1.11 per unit for the fiscal year ended September 30, 2023, from $2.22 per unit for the fiscal year ended September 30, 2022.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of our new pricing strategy, sales volume of TCMD products increased by 55.1%, to 16,753,432 units sold for the fiscal year ended September 30, 2023, from 10,799,254 units sold for the fiscal year ended September 30, 2022.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The average exchange rate between RMB and US$ was US$1.00 to RMB7.0533 for the fiscal year ended September 30, 2023 as compared to US$1.00 to RMB6.5532 for the fiscal year ended September 30, 2022. The depreciation of RMB against US$ had a 7.6% negative impact on our reported revenues.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenue from sales of third-party products</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of third-party products decreased by $2,418,897,
or 15.0%, to $13,736,077 for the fiscal year ended September 30, 2023, from $16,154,974 for the fiscal year ended September 30, 2022.
Sales volume of third-party products decreased by 4.9%, to 8,777,877 units sold in the fiscal year ended September 30, 2023, from 9,226,027
units sold in the fiscal year ended September 30, 2022. Average selling price of third-party products decreased by $0.19 per unit, or
10.9%, to $1.56 per unit for the fiscal year ended September 30, 2023, from $1.75 per unit for the fiscal year ended September 30, 2022,
due to a change in our product mix and the 7.6% negative impact from foreign currency fluctuation as discussed above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cost of Revenues.&#160;</i></b>Our cost
of revenues primarily consists of inventory costs (raw materials, labor, packaging costs, depreciation and amortization, third-party products
purchase price, freight costs and overhead) and business tax. Cost of revenues generally changes as our production costs change, which
are affected by factors including the market price of raw materials, labor productivity, and the purchase price of third-party products,
and as the customer and product mix changes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Fiscal Years Ended
    September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Cost of revenue- TCMD products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,404,804</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,187,182</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,217,622</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">63.7</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cost of revenue- third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,588,797</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,064,633</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,475,836</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14.7</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total cost of revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">21,993,601</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">18,251,815</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,741,786</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">20.5</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of revenues increased by $3,741,786, or 20.5%,
to $21,993,601 for the fiscal year ended September 30, 2023, from $18,251,815 for the fiscal year ended September 30, 2022, due to an
increase in sales volume and rising prices of traditional Chinese medicine raw materials caused by the imbalance between supply and demand
starting from the fourth quarter of 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cost of revenues of TCMD products</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of revenues of TCMD products accounted for
60.9% and 44.9% of our total costs of revenues for the fiscal years ended September 30, 2023 and 2022, respectively. Cost of revenues
of TCMD products increased by $5,217,622, or 63.7%, from $8,187,182 for the fiscal year ended September 30, 2022 to $13,404,804 for the
fiscal year ended September 30, 2023. The increase in cost of revenues of our TCMD products was due to the following reasons:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of our new pricing strategy to promote sales, sales volume of TCMD products increased by 55.1%, to 16,753,432 units sold for the fiscal year ended September 30, 2023, from 10,799,254 units sold for the fiscal year ended September 30, 2022.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The average unit cost of our TCMD products increased by $0.04, or 5.5%, from $0.76 per unit for the fiscal year ended September 30, 2022 to $0.80 per unit for the fiscal year ended September 30, 2023. A severe drought in the Yangtze River Basin in China in 2022 led to a decrease in the supply of traditional Chinese medicinal materials, and the COVID-19 pandemic resulted in increased demand of traditional Chinese medicinal materials for recuperating and improving immunity. Due to imbalance between supply and demand starting from the fourth quarter of 2022, prices of the traditional Chinese medicine raw materials increased by about 14% for the fiscal year ended September 30, 2023 as compared to the fiscal year ended September 30, 2022.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The average exchange rate between RMB and US$ was US$1.00 to RMB7.0533 for the fiscal year ended September 30, 2023 as compared to US$1.00 to RMB6.5532 for the fiscal year ended September 30, 2022. The depreciation of RMB against US$ had a 7.6% negative impact on our reported cost of revenues.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cost of revenues of third-party products</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of revenues of third-party products accounted
for 39.1% and 55.1% of our total costs of revenues for the fiscal years ended September 30, 2023 and 2022, respectively. Cost of revenues
of third-party products decreased by $1,475,836, or 14.7%, from $10,064,633 for the fiscal year ended September 30, 2022 to $8,588,797
for the fiscal year ended September 30, 2023. Sales volume of third-party products decreased by 4.9% from 9,226,027 units sold for the
fiscal year ended September 30, 2022 to 8,777,877 units sold for the fiscal year ended September 30, 2023. Average unit cost of third-party
products decreased by $0.11 per unit, or 10.3%, from $1.09 per unit for the fiscal year ended September 30, 2022 to $0.98 per unit for
the fiscal year ended September 30, 2023, due to change in product mix and the 7.6% negative impact from foreign currency fluctuation
as discussed above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Gross profit</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our gross profit decreased by $11,576,202 to $10,315,134
for the fiscal year ended September 30, 2023, from $21,891,336 for the fiscal year ended September 30, 2022. Our margin decreased by 22.6%
to 31.9% for the fiscal year ended September 30, 2023, from 54.5% for the fiscal year ended September 30, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Fiscal Years Ended
    September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Gross profit- TCMD products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,167,854</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">15,800,995</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(10,633,141</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(67.3</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Gross profit- third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,147,280</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,090,341</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(943,061</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15.5</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total gross profit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,315,134</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">21,891,336</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(11,576,202</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(52.9</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross margin- TCMD products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(38.0</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Gross margin- third party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">37.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">37.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.2</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total gross margin</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">31.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22.6</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Average selling price per unit- TCMD products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1.11</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(50.0</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Average cost per unit- TCMD products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.80</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.76</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.04</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Average selling price per unit- third party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.56</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.75</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.19</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10.9</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Average cost per unit - third party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.98</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.09</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.11</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10.1</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gross profit from the sales of our TCMD
products decreased by $10,633,141, or 67.3%, from $15,800,995 for the fiscal year ended September 30, 2022 to $5,167,854 for the
fiscal year ended September 30, 2023, and the gross margin of our TCMD products decreased by 38.0 percentage point, from 65.9% for
the fiscal year ended September 30, 2022 to 27.8% for the fiscal year ended September 30, 2023. The decrease in our gross profit
from the sales of TCMD products was due to the following reasons: (i) as discussed above, we changed our pricing strategy to
decrease the per unit price of our TCMD products in an effort to promote sales, and average selling price of our TCMD products
decreased by $1.11 per unit, or 50.0%, to $1.11 per unit for the fiscal year ended September 30, 2023, from $2.22 per unit for the
fiscal year ended September 30, 2022; (ii) average unit cost of our TCMD products increased by $0.04, or 5.5%, from $0.76 per unit
for the fiscal year ended September 30, 2022 to $0.80 per unit for the fiscal year ended September 30, 2023, due to increased price
of traditional Chinese medicine raw materials, and (iii) the depreciation of RMB against US$ had a 7.6% negative impact on our gross
profit from sales of TCMD products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gross profit from third-party product sales decreased
by $943,061, or 15.5%, from $6,090,341 for the fiscal year ended September 30, 2022 to $5,147,280 for the fiscal year ended September
30, 2023, while the gross margin of third-party product sales slightly decreased by 0.2%, from 37.7% for the fiscal year ended September
30, 2022 to 37.5% for the fiscal year ended September 30, 2023. The decrease in our gross profit from third-party products was affected
by the decrease in sales volume and the 7.6% negative impact from depreciation of RMB against US$.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following table sets
forth the breakdown of our operating expenses for the fiscal years ended September 30, 2023 and 2022:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Fiscal Years Ended
    September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of<br/> revenue</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of<br/> revenue</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Total revenue</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">32,308,735</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">100.0</td><td style="width: 1%; font-weight: bold; text-align: left">%</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">40,143,151</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">100.0</td><td style="width: 1%; font-weight: bold; text-align: left">%</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">(7,834,416</td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">(19.5</td><td style="width: 1%; font-weight: bold; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,783,703</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,083,135</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,299,432</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(64.5</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,638,984</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,183,270</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">455,714</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,858,548</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,644,375</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,785,827</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(36.4</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total operating expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,281,235</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">44.2</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">28,910,780</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">72.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(14,629,545</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(50.6</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Selling expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our selling expenses primarily include salaries
and welfare benefit expenses paid to our sales personnel, advertising expenses to increase our brand awareness, shipping and delivery
expenses, expenses incurred for our business travel, meals and other sales promotion and marketing activities related expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Fiscal Years Ended
    September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left">Salary and employee benefit expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">778,138</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11.5</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">778,656</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.1</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(518</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(0.1</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Advertising expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,653,633</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,527,318</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,873,685</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(73.4</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Shipping and delivery expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,033,213</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">638,286</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">394,927</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Business travel and meals expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208,108</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125,553</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82,555</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Other sales promotion related expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">110,611</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,322</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">97,289</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">730.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total selling expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,783,703</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">19,083,135</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(12,299,432</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(64.5</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our selling expenses decreased by $12,299,432,
or 64.5%, to $6,783,703 for the fiscal year ended September 30, 2023, from $19,083,135 for the fiscal year ended September 30, 2022,
primarily attributable to (i) a decrease in advertising expenses by $12,873,685, or 73.4%, from $17,527,318 for the fiscal year ended
September 30, 2022, to $4,653,633 for the fiscal year ended September 30, 2023. In September 2021, we entered into an advertising service
agreement with a third party, Guangdong Fengyang Legend Consulting Co., Ltd. (&#8220;Fengyang Legend&#8221;) to promote the sales of
our major TCMD products, Bai Nian Dan and Guben Yanling Pill with a service period of one year, from October 1, 2021 to September 30,
2022. In March 2022, we entered into an advertising service agreement with a third-party, Health Headline to promote our brand on the
Health Headline&#8217;s website and mobile app, with a service period of ten months from March 1, 2022 to December 31, 2022. In March
2023, we renewed the advertising services arrangement with Health Headline by entering a new service agreement with Health Headline with
a service period of ten months from March 1, 2023 to December 31, 2023. As our agreement with Fengyang Legend expired in September 2022,
advertising expenses decreased significantly during the fiscal year ended September 30, 2023; and (ii) partially offset by an increase
in shipping and delivery expenses by $394,927, or 61.9%, from $638,286 for the fiscal year ended September 30, 2022 to $1,033,213 for
the fiscal year ended September 30, 2023, due to an increase in our sales volume, increased freight cost and rising fuel prices during
the fiscal year ended September 30, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General and Administrative Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our general and administrative expenses primarily
consist of employee salaries, welfare and insurance expenses, depreciation, bad debt reserve expenses, inspection and maintenance expenses,
office supply and utility expenses, business travel and meals expenses, land and property taxes and professional service expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Fiscal Years Ended
    September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt">Salary and employee benefit expense</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">728,499</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">27.6</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">641,622</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">29.4</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">86,877</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13.5</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">195,451</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">185,169</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,282</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Land and property tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96,412</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">103,769</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,357</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7.1</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Office supply and utility expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">440,873</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">307,883</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">132,990</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Transportation, business travel and meals expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,122</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,029</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,093</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Consulting fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">926,694</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">720,430</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206,264</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28.6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Inspection and maintenance fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,154</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,555</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,599</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Stamp tax and other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">82,779</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">101,813</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19,034</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18.7</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total general and administrative expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,638,984</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,183,270</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">455,714</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">20.9</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses increased
by $455,714, or 20.9%, to $2,638,984 for the fiscal year ended September 30, 2023 from $2,183,270 for the fiscal year ended September
30, 2022, primarily attributable to (i) an increase in consulting fee by $206,264, or 28.6% due to consulting services retained to improve
product knowledge and sales tactics of our employees; and (ii) an increase in office supplies and utility expense by $132,990, or 43.2%
due to the registration fees paid to U.S. Securities and Exchange Commission, annual listings fees paid to the Nasdaq Stock Market, and
increased investor relations expense for the fiscal year ended September 30, 2023.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and development expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our research and development expenses primarily
consist of salaries, welfare and insurance expenses paid to our employees involved in the research and development activities, materials
and supplies used in the development and testing new TCMD products, depreciation and other miscellaneous expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Fiscal Years Ended
    September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left">Salary and employee benefit expenses to research and development staff</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">140,528</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.9</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">159,924</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.1</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(19,396</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(12.1</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Materials used in research and development activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">881,753</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">489,692</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">392,061</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expenditure on new product development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,794,464</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78.1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,973,683</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,179,219</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(45.6</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Depreciation and others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41,803</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,076</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,727</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">98.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total research and development expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,858,548</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,644,375</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(2,785,827</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(36.4</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses decreased
by $2,785,827, or 36.4%, to $4,858,548 for the fiscal year ended September 30, 2023, from $7,644,375 for the fiscal year ended
September 30, 2022, primarily attributable to a decrease in research and development expense of $3,179,219 to develop and test new
Chinese medicine products in order to diversify our future product portfolio. During the fiscal year ended September 30, 2022, we
cooperated with external academic and research institutions to jointly develop and test eight new Chinese medicine products and
accordingly incurred significant amount of research and development expense in connection with such efforts. As these development
activities reached their final stage, expenditure on new product development decreased significantly in the fiscal year ended
September 30, 2023; and (ii) an increase in the materials used in the research and development activities by $392,061. In order to
develop new products and improve the formulation of several existing products, we conducted more testing on product stability and
safety, and as a result, more materials were used in <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">research
and development activities for the fiscal year ended September 30, 2023 than in the fiscal year ended September 30, 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other expenses, net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total other expenses, net, increased by $286,458,
to $361,330 for the fiscal year ended September 30, 2023 from $74,872 for the fiscal year ended September 30, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Income Tax Expense</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Income tax expense was $2,253,593 for the fiscal
year ended September 30, 2023, representing an increase of $1,438,271, or 176.4%, from $815,322 for the fiscal year ended September 30,
2022.&#160;As our principal PRC subsidiaries, Jiangxi Universe and Universe Trade, incurred net loss during the <span style="background-color: white">fiscal
</span>years ended September 30, 2023 and 2022, we evaluated the likelihood of the realization of deferred tax assets, determined that
deferred tax assets arose from net operating loss carry-forwards in previous <span style="background-color: white">fiscal </span>years
might not be fully realized, and recognized $1,567,656 valuation allowance for deferred tax assets during the fiscal year ended September
30, 2023.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net Loss</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net loss was $6,581,024 for the fiscal year ended
September 30, 2023, representing a $1,328,614 decrease from net loss of $7,909,638 for the fiscal year ended September 30, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>B.&#160;<span style="text-decoration:underline">Liquidity
and Capital Resources</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2024, we had $29.5 million of cash on hand and
$12.9 million in accounts receivable. Our accounts receivable primarily include balance due from customers for our pharmaceutical products
sold and delivered to customers. <span style="background-color: white">As of date of this report, approximately</span> 98.4%, or $12.8
million, of our net accounts receivable balance as of September 30, 2024 has been subsequently collected.&#160;Collected accounts receivable
will be used as working capital in our operations, if necessary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2024, our inventory balance
amounted to $1.7 million, primarily consisting of raw materials, work-in-progress and finished TCMD products, which we believe are able
to be sold quickly based on the analysis of the current trends in demand for our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 25, 2021, we signed a construction sub-contract
with sub-contractor Jiangxi Chenyuan Construction Project Co., Ltd. (&#8220;Chenyuan&#8221;), pursuant to which, Chenyuan will help us
construct four manufacturing plant buildings and an office building with a total estimated budget of RMB165 million (approximately $23.5
million). As of September 30, 2024, we had made a prepayment of approximately RMB69.2 million (approximately $<span style="background-color: white">9.9</span>
million) to Chenyuan and future additional capital expenditure on this constriction-in-process (&#8220;CIP&#8221;) project was estimated
to be approximately RMB95.8 million (equivalent to $<span style="background-color: white">13.7</span> million), among which approximately
$7.1 million is required for the next 12 months. We currently plan to support our ongoing CIP project through cash collected from accounts
receivable, <span style="background-color: white">and if necessary,</span> borrowings from banks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 6, 2021, we entered into a real estate
property purchase agreement with a related party, Jiangxi Yueshang Investment Co., Ltd. (&#8220;Jiangxi Yueshang&#8221;), an entity in
which our chief executive officer, Mr. Gang Lai, owned 5% of its equity interests as of the date of that agreement. Pursuant to this purchase
agreement, Jiangxi Yueshang will sell and we will purchase certain residential apartments and commercial office space totaling 2,749.30
square meters, with a total purchase price of RMB32 million (approximately $4.6 million). As of September 30, 2024, we had made a prepayment
of RMB16 million (approximately $2.3 million) to Jiangxi Yueshang. The remaining balance is expected to be paid by <span style="background-color: white">April
2025</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2024, we also had short-term
bank loans of $5.9 million and long-term bank loans of $2.1 million that we obtained from several PRC banks for working capital purposes.
We expect that we will be able to renew all of the existing bank loans upon their maturity based on our past experiences and our outstanding
credit history.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2024, our working capital
balance was $31.3 million. In assessing our liquidity, management monitors and analyzes our cash on-hand, our ability to generate sufficient
revenue in the future, and our operating and capital expenditure commitments. We believe that our current cash and cash flows provided
by operating activities, borrowings from banks and from our principal shareholders will be sufficient to meet our working capital needs
in the next 12 months from the date of this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth summary of our
cash flows for the periods indicated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Fiscal Years Ended
    September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Net cash provided by (used in) operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(9,506,683</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,116,775</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,301,555</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(361,285</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(44,169</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,908,105</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Net cash (used in) provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,954,326</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,390,646</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,317,943</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Effect of exchange rate change on cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">126,088</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(108,171</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(474,733</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Net increase (decrease) in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,212,446</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(426,211</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,366,450</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cash, beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,285,247</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,711,458</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,077,908</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">29,497,693</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,285,247</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,711,458</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in operating activities was $9,506,683 for the fiscal
year ended September 30, 2024, primarily consisted of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss of $8,727,298 for the period.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A decrease in inventories of $1,643,131 due to our efforts to accelerate inventory turnover. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An increase in accounts receivable of $1,547,834. We provided longer credit terms
for our regular customers to maintain customer relationship and promote sales. As of date of this report, approximately 98.4%, or $12.8
million of our net accounts receivable balance as of September 30, 2024 has been subsequently collected.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A decrease in accrued expenses and other current liabilities of $1,167,206 due to decreased unpaid advertising expense.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by operating activities was
$1,116,775 for the fiscal year ended September 30, 2023, primarily consisted of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss of $6,581,024 for the fiscal year.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A decrease in accounts receivable of $4,718,118. Our accounts receivable primarily includes balance due from customers for our pharmaceutical products sold and delivered to customers. We enhanced our accounts receivable management and shortened accounts receivable collection period during the fiscal year ended September 30, 2023.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An increase in accounts payable of $1,641,426 due to pending invoices from suppliers for raw materials purchased in the third quarter of 2023. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An increase in inventory balance of $1,183,823 because we increased inventory stockpiles to reduce the negative impact from increased market price of Chinese traditional medicine raw materials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in operating activities was $1,301,555
for the fiscal year ended September 30, 2022, primarily consisted of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss of $7,909,638 for the fiscal year.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An increase in accounts receivable of $1,526,243. Our accounts receivable primarily includes balance due from customers for our pharmaceutical products sold and delivered to customers. As of September 30, 2022, most of our outstanding accounts receivable aged below six months. Collected accounts receivable will be used as working capital in our operations, if necessary.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A decrease in advance to suppliers of $2,681,214 because we made significant advance payments to suppliers for raw material purchase as of September 30, 2021 and we received purchased raw materials valued at approximately $2.7 million during the fiscal year ended September 30, 2022.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A decrease in prepayment for advertising of $7,385,695. In September 2021, we engaged a third-party advertising agency to develop and produce TV advertisement for promoting the sales of our major TCMD product, Bai Nian Dan and Guben Yanling Pill, and coordinate with a TV channel to broadcast the advertisement to targeted geographic market areas. Such prepayment was charged to expense when our TV advertisement was broadcasted in the fiscal year ended September 30, 2022.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An increase in other receivable of $1,030,121 related to VAT of advertising expense
deductible upon receipt of invoice, as well as prepaid income tax deductible from future taxable income.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A decrease in accounts payable of $1,919,690 because we made payment to raw material suppliers when we received the invoices from them.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Investing Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in investing activities amounted
to $361,285 for the fiscal year ended September 30, 2024, mainly due to purchase of fixed assets of $208,320, prepayments for construction
in progress of $37,478 and purchase of intangible asset of $117,291.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in investing activities amounted
to $44,169 for the fiscal year ended September 30, 2023 due to purchase of fixed assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in investing activities
amounted to $3,908,105 for the fiscal year ended September 30, 2022, which primarily included prepayment for acquisition of
$3,814,925. On September 26, 2022, we entered into a letter of intent for an equity transfer with an individual, Mr. Xibo Liu,
pursuant to which Mr. Xibo Liu shall transfer his 51% ownership in Yunnan Faxi to us in consideration for RMB72 million
(approximately $10.1 million). We prepaid RMB25 million (approximately $3.9 million) in the fiscal year ended September 30,
2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Financing Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by financing activities amounted
to $33,954,326 for the fiscal year ended September 30, 2024, primarily include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net proceeds from issuance of ordinary shares of $24,999,992.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds from bank loans of $7,787,016 and repayment of bank loans of $5,552,240.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds from related party borrowings of $6,719,557. The balance due to related party mainly consisted of advances from Mr. Gang Lai for working capital purposes during our normal course of business. These advances were non-interest bearing and due on demand.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in financing activities amounted
to $1,390,646 for the fiscal year ended September 30, 2023, primarily include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds from short-term bank loans of $5,671,104 and repayment of bank loans of $3,969,773.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Repayment of related party borrowings of
$3,091,977. The balance due to related party mainly consisted of advances from Mr. Gang Lai, the chairman of our board of directors and
our chief executive officer, for working capital purposes during our normal course of business. These advances were non-interest bearing
and due on demand.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by financing activities amounted
to $3,317,943 for the fiscal year ended September 30, 2022, primarily including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Proceeds from short-term bank loans in the amount of $4,272,716
and repayment of bank loans in the amount of $4,272,716.</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds from related party borrowings of $3,317,943. The balance due to related party mainly consisted of advances from Mr. Gang Lai for working capital purposes during our normal course of business. These advances were non-interest bearing and due on demand.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Commitments and contingencies</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, we may be a party to
various legal actions arising in the ordinary course of business. We accrue costs associated with these matters when they become
probable and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as
incurred. For the fiscal years ended September 30, 202<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,
2023 and 2022, we did not have any material legal claims or litigation that, individually or in aggregate, could have a material
adverse impact on our consolidated financial position, results of operations and cash flows.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2024, we had the following
contractual obligations:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Payments Due by Period</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic; text-align: justify; border-bottom: Black 1.5pt solid">Contractual Obligations</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid">Less than<br/> 1&#160;year</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid">1-2 years</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid">2-3 years</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">(1) Debt Obligations</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,994,186</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,856,703</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,137,483</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">(2) Capital expenditure commitment on CIP project</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,651,391</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,124,943</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,350,832</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,175,616</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">(3) Capital expenditure commitment for purchase of property</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,279,982</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,279,982</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">23,925,559</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">15,261,628</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">7,488,315</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,175,616</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2024, we had total of $5,856,703&#160;in short-term borrowings and $2,137,483&#160;in long-term borrowings from&#160;several
PRC banks&#160;(see Footnotes 13 and 14 of our consolidated financial statements and footnotes included elsewhere in this annual report
for details).</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 25, 2021, we signed a construction sub-contract with Chenyuan, pursuant to which, Chenyuan will help us construct four manufacturing
plant buildings and an office building with a total estimated budget of RMB165 million (approximately $23.5 million). As of September
30, 2024, we had made a prepayment of approximately RMB69.2 million (approximately $9.9 million) to Chenyuan and future additional capital
expenditure on this CIP project was estimated to be approximately RMB95.8 million (approximately $13.7 million) (see Footnote 11&#160;of
our consolidated financial statements and footnotes included elsewhere in this annual report, Prepayment for CIP project, for details).</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 6, 2021, we entered into a real estate property purchase agreement with a related party, Jiangxi Yueshang, an entity in which our
chief executive officer, Mr. Gang Lai, owned 5% of its equity interests as of the date of that agreement. Pursuant to this purchase agreement,
Jiangxi Yueshang will sell and we will purchase certain residential apartments and commercial office space totaling 2,749.30 square meters,
with a total purchase price of RMB32 million (approximately $4.6 million). As of September 30, 2024, we had made a prepayment of RMB16
million (approximately $2.3 million) to Jiangxi Yueshang. The remaining balance is expected to be paid by <span style="background-color: white">April
2025</span> (see Footnote 12&#160;of our consolidated financial statements and footnotes included elsewhere in this annual report,&#160;Prepayment
for purchase of a property, for details).</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Trend Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than as disclosed elsewhere in this report,
we are not aware of any trends, uncertainties, demands, commitments, or events that are reasonably likely to have a material effect on
our net revenues, income from continuing operations, profitability, liquidity or capital resources, or that would cause reported financial
information not necessarily to be indicative of future operating results or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Off-Balance Sheet Arrangements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not have any off-balance sheet arrangements
as of September 30, 2024 and 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Inflation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inflation does not materially affect our business
or the results of our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Seasonality</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Seasonality does not materially affect our business
or the results of our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>C.&#160;<span style="text-decoration:underline">Research
and Development, Patents and Licenses,&#160;etc.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">See &#8220;Item 4. Information
on the Company&#8212;B. Business Overview&#8212;Intellectual Property&#8221; and &#8220;Item 4. Information on the Company&#8212;B. Business
Overview&#8212;Research and Development.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>D.&#160;<span style="text-decoration:underline">Trend Information</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Other than as disclosed
below and elsewhere in this annual report on Form&#160;20-F, we are not aware of any trends, uncertainties, demands, commitments, or events
for the period from October 1, 2023 to September 30, 2024 that are reasonably likely to have a material adverse effect on our net revenue,
income, profitability, liquidity, or capital resources, or that caused the disclosed financial information to be not necessarily indicative
of future operating results or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>E.&#160;<span style="text-decoration:underline">Critical
Accounting Policies and Estimates</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our discussion and
analysis of our financial condition and results of operations are based upon our consolidated financial statements. These financial
statements are prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S.
GAAP&#8221;), which requires us to make estimates and assumptions that affect the reported amounts of our assets and liabilities and
revenues and expenses, to disclose contingent assets and liabilities on the date of the consolidated financial statements, and to
disclose the reported amounts of revenues and expenses incurred during the financial reporting period. We continue to evaluate these
estimates and assumptions that we believe to be reasonable under the circumstances. We rely on these evaluations as the basis for
making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Since the use
of estimates is an integral component of the financial reporting process, actual results could differ from those estimates. Some of
our accounting policies require higher degrees of judgment than others in their application. We believe critical accounting policies
as disclosed in this annual report reflect the more significant judgments and estimates used in preparation of our consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Risks and Uncertainties</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Through our PRC subsidiaries,
we conduct our operations in the PRC. Accordingly, our business, financial condition, and results of operations may be influenced by political,
economic, and legal environments in the PRC, as well as by the general state of the PRC economy. Our results may be adversely affected
by changes in the political, regulatory and social conditions in the PRC. Although we have not experienced losses from these situations
and believes that we are in compliance with existing laws and regulations including our organization and structure, this may not be indicative
of future results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The development and commercialization
of new pharmaceutical products is highly competitive, and the industry currently is characterized by rapidly changing technologies, significant
competition and a strong emphasis on intellectual property. We may face competition with respect to our current and future pharmaceutical
product candidates from major pharmaceutical companies in China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our business, financial
condition and results of operations may also be negatively impacted by risks related to natural disasters, extreme weather conditions,
health epidemics and other catastrophic incidents, which could significantly disrupt our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following critical
accounting policies rely upon assumptions and estimates and were used in the preparation of our consolidated financial statements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Uses of estimates</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In preparing the consolidated
financial statements in conformity with U.S. GAAP, management makes estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of
revenues and expenses during the reporting period. These estimates are based on information as of the date of the consolidated financial
statements. Significant estimates required to be made by management include, but are not limited to, the allowance for estimated uncollectible
receivables, the realizability of advance to suppliers, inventory valuation, useful lives of property, plant and equipment, intangible
assets, the recoverability of long-lived assets, provision necessary for contingent liabilities, revenue recognition and realization of
deferred tax assets. Actual results could differ from those estimates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Accounts receivable,
net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Accounts receivables are presented net of allowance for doubtful accounts.
We determine the adequacy of reserves for doubtful accounts based on individual account analysis and historical collection trends. We
establish a provision for doubtful receivables when there is objective evidence that we may not be able to collect the amounts due. The
allowance is based on management&#8217;s best estimate of specific losses on individual exposures, as well as a provision on historical
trends of collections. Actual amounts received may differ from management&#8217;s estimate of credit worthiness and the economic environment.
Delinquent account balances are written-off against the allowance for doubtful accounts after management has determined that the likelihood
of collection is not probable. Allowance for uncollectable balances amounted to $135,082 and $Nil as of September 30, 2024 and 2023, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Inventories, net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Inventories are stated at net realizable value using weighted average
method. Costs include the costs of raw materials, freight, direct labor and related production overhead. Any excess of the costs over
the net realizable value of each item of inventories is recognized as a provision for diminution in the value of inventories. Net realizable
value is the estimated selling price in the normal course of business less any costs to complete and sell products. We evaluate inventories
on a quarterly basis for its net realizable value adjustments, and reduces the carrying value of those inventories that are obsolete or
in excess of the forecasted usage to their estimated net realizable value based on various factors including aging, expiration dates,
as applicable, taking into consideration historical and expected future product sales. We recorded inventory reserve of $124,512 and $69,746
as of September 30, 2024 and 2023, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Revenue recognition</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">To determine revenue
recognition for contracts with customers, we perform the following five steps: (i) identify the contract(s) with the customer, (ii) identify
the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that
it is probable that a significant future reversal will&#160;<i>not</i>&#160;occur, (iv) allocate the transaction price to the respective
performance obligations in the contract, and (v) recognize revenue when (or as) we satisfy the performance obligation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We recognize
revenue when we transfer our goods and services to customers in an amount that reflects the consideration to which we expect to be
entitled in such exchange. We account for the revenue generated from sales of our TCMD and third-party products on a gross basis as
we are acting as a principal in these transactions, are subject to inventory risk, have latitude in establishing prices, and are
responsible for fulfilling the promise to provide customers the specified goods, which we have control of the goods and has the
ability to direct the use of goods to obtain substantially all the benefits. All of our contracts have one single performance
obligation as the promise is to transfer the individual goods to customers, and there are no separately identifiable other promises
in the contracts. Our revenue streams are recognized at a point in time when <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
title and risk of loss passes and the customer accepts the goods, which generally occurs at delivery. Our products are sold with no
right of return and we do not provide other credits or sales incentives to customers. Revenue is reported net of all
VAT.&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Income Tax</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We account for current
income tax in accordance with the laws of the relevant tax authorities. Deferred income tax are recognized when temporary differences
exist between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Deferred tax
assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the <span style="background-color: white">fiscal
</span>years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities
of a change in tax rates is recognized in income in the period including the enactment date. Valuation allowances are established, when
necessary, to reduce deferred tax assets to the amount expected to be realized.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">An uncertain tax position
is recognized only if it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax examination. The amount
recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not
meeting the &#8220;more likely than not&#8221; test, no tax benefit is recorded. Penalties and interest incurred related to underpayment
of income tax are classified as income tax expense in the period incurred. No significant penalties or interest relating to income taxes
were incurred during the fiscal years ended September 30, 2024, 2023 and 2022. We do not believe there was any uncertain tax provision
as of September 30, 2024 and 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our operating subsidiaries
in China are subject to the income tax laws of the PRC. No significant income was generated outside the PRC for the fiscal years ended
September 30, 2024, 2023 and 2022. As of September 30, 2024 and 2023, all of our tax returns of our PRC subsidiaries remained open for
statutory examination by PRC tax authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Recently Issued
Accounting Pronouncements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">We consider
the applicability and impact of all accounting standards updates (&#8220;ASUs&#8221;). Management periodically reviews new accounting
standards that are issued. Under the Jumpstart Our Business Startups Act of 2012, as amended (the &#8220;JOBS Act&#8221;), we meet the
definition of an emerging growth company, or EGC, and has elected the extended transition period for complying with new or revised accounting
standards, which delays the adoption of these accounting standards until they would apply to private companies.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In November
2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amended guidance
requires incremental reportable segment disclosures, primarily about significant segment expenses. The amendments also require entities
with a single reportable segment to provide all disclosures required by these amendments, and all existing segment disclosures. The amendments
will be applied retrospectively to all prior periods presented in the financial statements and is effective for fiscal years beginning
after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. The guidance should be adopted retrospectively.
We are currently in the process of evaluating the impact this amended guidance may have on the footnotes to our consolidated financial
statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In December
2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amended guidance enhances income
tax disclosures primarily related to the effective tax rate reconciliation and income taxes paid information. This guidance requires disclosure
of specific categories in the effective tax rate reconciliation and further information on reconciling items meeting a quantitative threshold.
In addition, the amended guidance requires disaggregating income taxes paid (net of refunds received) by federal, state, and foreign taxes.
It also requires disaggregating individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than
5 percent of total income taxes paid (net of refunds received). The amended guidance is effective for fiscal years beginning after December
15, 2024. The guidance can be applied either prospectively or retrospectively. We are currently in the process of evaluating the impact
this amended guidance may have on the footnotes to our consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In March
2024, the FASB issued ASU 2024-01, Compensation&#8212;Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar
Awards. The amended guidance added an illustrative example that includes four fact patterns to demonstrate how an entity should apply
the scope guidance in paragraph 718-10-15-3 to determine whether a profits interest award should be accounted for in accordance with Topic
718. The amendments guidance is effective for annual periods beginning after December 15, 2024, and interim periods within those annual
periods. The guidance can be applied either prospectively or retrospectively. We are currently in the process of evaluating the impact
this amended guidance may have on our consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In November
2024, the FASB issued ASU 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses. The amended guidance improves the disclosures about a public business entity&#8217;s
expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory,
employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions (such as cost of sales, SG&amp;A,
and research and development). The amended guidance is effective for annual reporting periods beginning after December 15, 2026, and interim
reporting periods beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective
application. We are currently in the process of evaluating the impact this amended guidance may have on the footnotes to our consolidated
financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In November
2024, the FASB issued ASU 2024-04, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible
Debt Instruments. This guidance clarifies the assessment of whether a transaction should be accounted for as an induced conversion or
extinguishment of convertible debt when changes are made to conversion features as part of an offer to settle the instrument. The amended
guidance is effective for all entities for annual reporting periods beginning after December 15, 2025, and interim reporting periods within
those annual reporting periods. The guidance can be applied either prospectively or retrospectively. We are currently in the process of
evaluating the impact this amended guidance may have on our consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In January
2025, the FASB issued ASU 2025-01, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic
220-40): Clarifying the Effective Date. This guidance amends the effective date of Update 2024-03 to clarify that all public business
entities are required to adopt the guidance in annual reporting periods beginning after December 15, 2026, and interim periods within
annual reporting periods beginning after December 15, 2027. Early adoption of Update 2024-03 is permitted. We are currently in the process
of evaluating the impact this amended guidance may have on the footnotes to our consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Other accounting
standards that have been issued by FASB that do not require adoption until a future date are not expected to have a material impact on
the consolidated financial statements upon adoption. We do not discuss recent standards that are not anticipated to have an impact on
or are unrelated to our consolidated financial condition, results of operations, cash flows or disclosures.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. <span style="text-decoration:underline">Directors and Senior Management</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth information regarding
our directors and executive officers as of the date of this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 28%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 65%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position(s)</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gang Lai</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board of Directors and Chief Executive Officer</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lin Yang</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer and Director</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Baochang Liu</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operating Officer</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiawen Pang</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yongping Yu</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ding Zheng</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a brief biography of each of
our executive officers and directors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Mr. Gang Lai</i></b><i>&#160;</i>is our
chief executive officer and chairman of the board. Mr. Lai has served as the chief executive officer of Jiangxi Universe since 2004 and
founded Universe Trade in 2010. Before joining us, Mr. Lai was a successful entrepreneur. He founded Jiangxi Lvzhouyuan Timber Joint Stock
Co., Ltd. in 2001, a company listed on PRC National Equities Exchange and Quotations (NEEQ: 838893), and has since served as its chairman
of the board. Mr. Lai graduated from Jingdezhen Ceramic Institute in China with a bachelor&#8217;s degree in mechanical engineering in
1988.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Ms. Lin Yang</i></b>&#160;is our chief financial
officer and director. Ms. Lin Yang has served as the financial director of Jiangxi Universe since April 2006 and the financial director
of Universe Trade since its formation in 2010. Before joining us, Ms. Yang served as an accountant at Jiangxi Automobile Engineering Plastic
Co., Ltd. from 1998 to March 2006. Ms. Yang graduated from Jiangxi University of Finance and Economics in China with a bachelor&#8217;s
degree in accounting in1991.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Mr. Baochang Liu </i></b>has served as
our chief operating officer since December 2021. Mr. Liu has over 17 years of experience in pharmaceutical marketing. From January
2020 to December 2021, Mr. Baochang Liu worked as the vice president of marketing at China Shineway Pharmaceutical Group Ltd. (HKEX:
2877), responsible for designing and implementing the company&#8217;s overall marketing strategies<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
From November 2015 to December 2019, Mr. Baochang Liu served as the general manager of OTC department and director of marketing at
Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773), responsible for overseeing the implementation of the company&#8217;s
marketing strategies and brand building. Mr. Baochang Liu obtained his bachelor&#8217;s degree in accounting and in marketing
management from Harbin University of Commerce in 2004 and his master of business administration from Fudan University in
2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Mr. Jiawen Pang</i></b>&#160;has served
as our independent director since March 2021. Since January 2021, Mr. Jiawen Pang has served as the vice president at Guangzhou Dahua
Food Technology Co., Ltd., a food manufacturing company, where Mr. Pang is responsible for overseeing the company&#8217;s general management
and marketing function. From January 2018 to December 2020, Mr. Jiawen Pang served the general manager at Pangbei (Shanghai) Medical Technology
Center, a medical device company, where Mr. Pang was responsible for overseeing the general management and marketing function of the company.
Mr. Jiawen Pang graduated from Tianjin University of Commerce in China with a bachelor&#8217;s degree in refrigeration and food freezing
engineering in 1989 and from Sun Yat-sen University in China with a master of business administration in healthcare and medicine in 2004.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Mr. Yongping Yu</i></b> has served as our
independent director since May 2023. Mr. Yongping Yu has served as the General Manager of Zhuhai Qirong Venture Capital Investment Management
Co., Ltd. since August 2019, a venture capital company focused on the healthcare industry. Mr. Yongping Yu served as a director and Executive
Deputy General Manager of Xinhua Kangmei Health Think Tank Co., Ltd. from May 2017 to July 2019. Mr. Yu obtained a Bachelor of Medicine
degree from Nanchang University in the PRC in 1992 and obtained Bachelor of Arts degree in in Chinese language and literature from Tsinghua
University in the PRC in 1995.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Mr. Ding Zheng</i></b><i>&#160;</i>has served
as our independent director since March 2021. Mr. Ding Zheng has served as the chairman of the board at Guangzhou Roujing Sunshade Energy-saving
Technology Co., Ltd. since 2018. Mr. Zheng has also served as the general manager at Hande Manufacturing (China) Co., Ltd., since 2015.
Mr. Zheng obtained a bachelor&#8217;s degree in technology economics from Shanghai Jiao Tong University in China in 2000 and a master
of business administration degree from Tsinghua University in China in 2005. Mr. Zheng studied business administration at New York University
from September 2024 to January 2005. Mr. Zheng is a member of the China Institute of Certified Public Accountants (CICPA).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board Diversity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below provides certain information regarding
the diversity of our board of directors as of the date of this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Board Diversity Matrix</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Country of Principal Executive Offices:</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign Private Issuer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Disclosure Prohibited under Home Country Law</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Number of Directors</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">5</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: bottom; width: 65%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Female</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Male</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-&#160;Binary</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Did Not<br/>
Disclose<br/>
Gender</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Part I: Gender Identity</b></span></td>
    <td colspan="7" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Part II: Demographic Background</b></span></td>
    <td colspan="7" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underrepresented Individual in Home Country Jurisdiction</span></td>
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LGBTQ+</span></td>
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Did Not Disclose Demographic Background</span></td>
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Family Relationships</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of our directors or executive officers has
a family relationship as defined in Item 401 of Regulation S-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. <span style="text-decoration:underline">Compensation</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the fiscal year ended September 30, 2024,
we paid an aggregate of approximately US$241 thousand as compensation to our executive officers and directors. None of our non-employee
directors have any service contracts with us that provide for benefits upon termination of employment. We have not set aside or accrued
any amount to provide pension, retirement, or other similar benefits to our directors and executive officers. Our PRC subsidiaries are
required by law to make contributions equal to certain percentages of each employee&#8217;s salary for his or her pension insurance, medical
insurance, unemployment insurance, and other statutory benefits and a housing provident fund.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. <span style="text-decoration:underline">Board Practices</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors consists of five
directors, including three independent directors. A director is not required to hold any shares in our company to qualify to serve
as a director. A director shall not, as a director, vote in respect of any contract, transaction, arrangement or proposal in which
they have an interest which (together with any interest of any person connected with them) is a material interest (otherwise then by
virtue of their interests, direct or indirect, in shares or debentures or other securities of, or otherwise in or through, the
Company) and if they shall do so their vote shall not be counted, nor in relation thereto shall they be counted in the quorum
present at the meeting, but (in the absence of some other material interest than is mentioned below) none of these prohibitions
shall apply to: (a) the giving of any security, guarantee or indemnity in respect of: (i) money lent or obligations incurred by them
or by any other person for the benefit of the Company or any of its subsidiaries; or (ii) a debt or obligation of the Company or any
of its subsidiaries for which a director has assumed responsibility in whole or in part and whether alone or jointly with others
under a guarantee or indemnity or by the giving of security; (b) where the Company or any of its subsidiaries is offering securities
in which offer the director is or may be entitled to participate as a holder of securities or in the underwriting or
sub-underwriting of which the director is to or may participate; (c) any contract, transaction, arrangement or proposal affecting
any other body corporate in which he is interested, directly or indirectly and whether as an officer, shareholder, creditor or
otherwise howsoever, provided that he (together with persons connected with them) does not to their knowledge hold an interest
representing one per cent or more of any class of the equity share capital of such body corporate (or of any third body corporate
through which his interest is derived) or of the voting rights available to members of the relevant body corporate; (d) any act or
thing done or to be done in respect of any arrangement for the benefit of the employees of the Company or any of its subsidiaries
under which they are not accorded as a director any privilege or advantage not generally accorded to the employees to whom such
arrangement relates; (e) any matter connected with the purchase or maintenance for any director of insurance against any liability
or (to the extent permitted by the Companies Act (Revised) of the Cayman Islands) indemnities in favor of directors, the funding of
expenditure by one or more directors in defending proceedings against him or them or the doing of anything to enable such director
or directors to avoid incurring such expenditure; or (f) any contract, transaction, arrangement or proposal in which the director
has an interest which is not a material interest. The directors may exercise all the powers of the company to borrow money, mortgage
its undertaking, property and uncalled capital, and issue debentures or other securities whenever money is borrowed or as security
for any obligation of the company or of any third party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Committees of the Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have established three committees under the
board of directors: an audit committee, a compensation committee, and a nominating and corporate governance committee. We have adopted
a charter for each of the three committees. Each committee&#8217;s members and functions are described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Audit Committee.</i>&#160;Our audit committee
consists of Jiawen Pang, Yongping Yu, and Ding Zheng. Ding Zheng serves as the chairman of our audit committee. We have determined that
Jiawen Pang, Yongping Yu, and Ding Zheng satisfy the &#8220;independence&#8221; requirements of&#160;Rule 5605(a)(2) of the Listing Rules
of the Nasdaq Stock Market&#160;and Rule 10A-3 under the Securities Exchange Act. Our board also has determined that Ding Zheng qualifies
as an audit committee financial expert within the meaning of the SEC rules or possesses financial sophistication within the meaning of
the Nasdaq corporate governance rules. The audit committee oversees our accounting and financial reporting processes and the audits of
the financial statements of our company. The audit committee is responsible for, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointing the independent auditors and pre-approving all auditing and non-auditing services permitted to be performed by the independent auditors;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing with the independent auditors any audit problems or difficulties and management&#8217;s response;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussing the annual audited financial statements with management and the independent auditors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing the adequacy and effectiveness of our accounting and internal control policies and procedures and any steps taken to monitor and control major financial risk exposures;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving all proposed related party transactions;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">meeting separately and periodically with management and the independent auditors; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitoring compliance with our code of business conduct and ethics, including reviewing the adequacy and effectiveness of our procedures to ensure proper compliance.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Compensation Committee.</i>&#160;Our
compensation committee consists of Jiawen Pang, Yongping Yu, and Ding Zheng. Jiawen Pang serves as the chairperson of our
compensation committee. We have determined that Jiawen Pang, Yongping Yu, and Ding Zheng satisfy the &#8220;independence&#8221;
requirements of&#160;Rule 5605(a)(2) of the Listing Rules of the Nasdaq Stock Market&#160;and Rule 10C-1 under the Securities
Exchange Act. The compensation committee assists the board in reviewing and approving the compensation structure, including all
forms of compensation, relating to our directors and executive officers. Our chief executive officer may not be present at any
committee meeting during which his compensation is deliberated. The compensation committee is responsible for, among other
things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving the total compensation package for our most senior executive officers;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving and overseeing the total compensation package for our executives other than the most senior executive officers;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and recommending to the board with respect to the compensation of our directors;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing periodically and approving any long-term incentive compensation or equity plans;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">selecting compensation consultants, legal counsel or other advisors after taking into consideration all factors relevant to that person&#8217;s independence from management; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing programs or similar arrangements, annual bonuses, employee pension and welfare benefit plans.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Nominating and Corporate Governance Committee.</i>&#160;Our
nominating and corporate governance committee consists of Jiawen Pang, Yongping Yu and Ding Zheng. Yongping Yu serves as the chairperson
of our nominating and corporate governance committee. Jiawen Pang, Yongping Yu, and Ding Zheng satisfy the &#8220;independence&#8221;
requirements of&#160;Rule 5605(a)(2) of the Listing Rules of the Nasdaq Stock Market. The nominating and corporate governance committee
assists the board of directors in selecting individuals qualified to become our directors and in determining the composition of the board
and its committees. The nominating and corporate governance committee is responsible for, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying and recommending nominees for election or re-election to our board of directors or for appointment to fill any vacancy;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing annually with our board of directors its current composition in light of the characteristics of independence, age, skills, experience and availability of service to us;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying and recommending to our board the directors to serve as members of committees;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advising the board periodically with respect to significant developments in the law and practice of corporate governance as well as our compliance with applicable laws and regulations, and making recommendations to our board of directors on all matters of corporate governance and on any corrective action to be taken; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitoring compliance with our code of business conduct and ethics, including reviewing the adequacy and effectiveness of our procedures to ensure proper compliance.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Duties of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under Cayman Islands law, all of our
directors owe three types of duties to us: (i) statutory duties, (ii) fiduciary duties, and (iii) common law duties. The Companies
Act (Revised) of the Cayman Islands imposes a number of statutory duties on a director. A Cayman Islands director&#8217;s fiduciary
duties are not codified, however, the courts of the Cayman Islands have held that a director owes the following fiduciary duties:
(a) a duty to act in what the director <i>bona fide</i> considers to be in the best interests of the company, (b) a duty to exercise
their powers for the purposes they were conferred, (c) a duty to avoid fettering his or her discretion in the future and (d) a duty
to avoid conflicts of interest and of duty. The common law duties owed by a director are those to act with skill, care and diligence
that may reasonably be expected of a person carrying out the same functions as are carried out by that director in relation to the
company and, also, to act with the skill, care and diligence in keeping with a standard of care commensurate with any particular
skill they have which enables them to meet a higher standard than a director without those skills. In fulfilling their duty of care
to us, our directors must ensure compliance with our amended and restated articles of association. We have the right to seek damages
if a duty owed by any of our directors is breached.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors has all powers necessary
for managing, and for directing and supervising, our business affairs. The functions and powers of our board of directors include, among
others:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">convening shareholders&#8217; annual general meetings and reporting its work to shareholders at such meetings;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">declaring dividends and distributions;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointing officers and determining the terms of office of the officers;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercising the borrowing powers of our company and mortgaging the property of our Company; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving the transfer of shares in our Company, including the registration of such shares in our share register.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Terms of Directors and Executive Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our directors may be elected by a resolution of
our board of directors or by an ordinary resolution of our shareholders. Unless re-appointed or removed from office pursuant to the provisions
of our amended and restated articles of association, each director shall be appointed for a term expiring at the next-following annual
general meeting of the Company. A director will cease to be a director if, among other things, the director (i) becomes bankrupt or makes
any arrangement or composition with his creditors; (ii) in the opinion of a registered medical practitioner by whom the director is being
treated, the director becomes physically or mentally incapable of acting as a director; (iii) resigned his or her office by notice in
writing to the company; or (iv) without the consent of the other directors, is absent from meetings of directors for a continuous period
of six months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our officers are elected by and serve at the discretion
of the board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Qualification</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is currently no shareholding qualification
for directors, although a shareholding qualification for directors may be fixed by our shareholders by ordinary resolution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employment Agreements and Indemnification Agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have entered into employment agreements with
each of our executive officers. Pursuant to these employment agreements, we agree to employ each of our executive officers for a specified
time period, which may be renewed automatically unless either party gives the other party a two-month prior written notice before the
end of the current employment term. We may terminate the employment for cause, at any time, without notice or remuneration, for certain
acts of the executive officer, including but not limited to, the commitments of any serious or persistent breach or non-observance of
the terms and conditions of the employment, conviction of a criminal offense, willful disobedience of a lawful and reasonable order, fraud
or dishonesty, receipt of bribery, or severe neglect of his or her duties. An executive officer may terminate his or her employment at
any time with two months&#8217; prior written notice. Each executive officer agrees to hold, both during and after the employment agreement
expires, in strict confidence and not to use or disclose to any person, corporation or other entity without written consent, any confidential
information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have also entered into indemnification agreements
with each of our directors and executive officers. Under these agreements, we agree to indemnify our directors and executive officers
against certain liabilities and expenses incurred by such persons in connection with claims made by reason of their being a director or
officer of our Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Insider Participation Concerning Executive
Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our director, Mr. Gang Lai, was making all determinations
regarding executive officer compensation from the inception of the Company until our Compensation Committee was set up in March 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Code of Business Conduct and Ethics</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors has adopted a code of business
conduct and ethics, which is applicable to all of our directors, officers, and employees. Our code of business conduct and ethics is publicly
available on our website.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Compensation&#160;Recovery&#160;Policy&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have adopted a&#160;compensation&#160;recovery&#160;policy&#160;to
provide for the recovery of erroneously-awarded incentive compensation, as required by the&#160;Dodd-Frank Wall Street Reform and Consumer
Protection Act, final SEC rules and applicable listing standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. <span style="text-decoration:underline">Employees</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See &#8220;Item 4. Information on the Company&#8212;B.
Business Overview&#8212;Employees.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. <span style="text-decoration:underline">Share Ownership</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth information with
respect to the beneficial ownership, within the meaning of Rule 13d-3 under the Exchange Act, of our ordinary shares as of the date of
this annual report for:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each of our directors and executive officers; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each person known to us to own beneficially more than 5% of our ordinary shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beneficial ownership includes voting or investment
power with respect to the securities. Except as indicated below, and subject to applicable community property laws, the persons named
in the table have sole voting and investment power with respect to all ordinary shares shown as beneficially owned by them. Percentage
of beneficial ownership of each listed person is based on 563,338 ordinary shares outstanding as of the date of this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information with respect to beneficial ownership
has been furnished by each director, officer, or beneficial owner of 5% or more of our ordinary shares. Beneficial ownership is determined
in accordance with the rules of the SEC and generally requires that such person have voting or investment power with respect to securities.
In computing the number of ordinary shares beneficially owned by a person listed below and the percentage ownership of such person, ordinary
shares underlying options, warrants, or convertible securities held by each such person that are exercisable or convertible within 60
days of the date of this annual report are deemed outstanding, but are not deemed outstanding for computing the percentage ownership of
any other person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Ordinary Shares<br/> Beneficially Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Voting<br/> Power</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors and Executive Officers<sup>*</sup>:</b></span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gang Lai<sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,467</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.615</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.615</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Lin Yang</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Baochang Liu</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Jiawen Pang</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Yongping Yu</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Ding Zheng</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 9pt">All directors and executive officers as a group:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,467</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.615</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.615</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-left: 9pt">5% Shareholders:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sununion Holding Group Limited<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,467</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.615</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.615</td><td style="text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless otherwise indicated, the business address of each of our directors and officers is 265 Jingjiu Avenue, Jinggangshan Economic and Technological Development Zone, Ji&#8217;an, Jiangxi, People&#8217;s Republic of China.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents 3,467 ordinary shares held by Sununion Holding Group Limited,
a business company incorporated in the British Virgin Islands, which is owned as to 100% and controlled by Gang Lai. The registered address
of Sununion Holding Group Limited is Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola, VG1110, British Virgin Islands.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this annual report, approximately
99.385% of our issued and outstanding ordinary shares are held in the United States by four record holders, including Cede and Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not aware of any other arrangement that
may, at a subsequent date, result in a change of control of our Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>F. <span style="text-decoration:underline">Disclosure of a Registrant&#8217;s Action
to Recover Erroneously Awarded Compensation</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. <span style="text-decoration:underline">Major Shareholders</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See &#8220;Item 6. Directors, Senior Management
and Employees&#8212;E. Share Ownership.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. <span style="text-decoration:underline">Related Party Transactions</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employment Agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See &#8220;Item 6. Directors, Senior Management
and Employees&#8212;C. Board Practices&#8212;Employment Agreements and Indemnification Agreements.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Material Transactions with Related Parties</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(a) Nature of relationships with related parties</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1.5pt solid; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship with the Company</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Gang Lai</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and chairman of the Company&#8217;s Board of Directors</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Yajun Hu</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General Manager of Jiangxi Universe</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.1pt; text-indent: -0.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms. Lin Yang</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer of the Company</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guangzhou Ningjing Investment Co., Ltd (&#8220;Guangzhou Ningjing&#8221;)</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under common control of Mr. Gang Lai</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>(b) Due from related parties</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Mr. Yajun Hu</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">61,678</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total due from related parties</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">61,678</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2023, the balance due from
related parties consisted of advanced funds to the Company&#8217;s director and general manager, Mr. Yajun Hu. These advances were non-interest
bearing and fully repaid on October 12, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>(c) Due to related parties</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Mr. Gang Lai</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,900,499</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">540,096</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Ms. Lin Yang</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">85</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total due to related parties</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,900,584</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">540,096</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">As of September
30, 2024, the balance due to related parties mainly consisted of advances from Mr. Gang Lai, the Company&#8217;s chief executive officer
and the chairman of the board of directors, for working capital purposes during the Company&#8217;s normal course of business, as well
as payment of expenses made by Ms. Lin Yang on behalf of the Company. These advances are non-interest bearing and due on demand.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>(d) Loan guarantee provided
by related parties</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In connection
with the Company&#8217;s bank borrowings from commercial banks in China, Mr. Gang Lai, the Company&#8217;s chairman of the board of directors
and chief executive officer, signed guarantee agreements with these banks to provide credit guarantee for the Company&#8217;s certain
loans (see Note 13 and 14 of our audited consolidated financial statements and footnotes included elsewhere in this annual report).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>(e) Prepayment to related
party for property purchase</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">As disclosed
in Note 12 of our audited consolidated financial statements and footnotes included elsewhere in this annual report, on May 6, 2021, the
Company entered into a real estate property purchase agreement with a related party, Jiangxi Yueshang, to purchase certain residential
apartment and commercial office space totaling 2,749.30 square meters with total purchase price of RMB32 million (approximately $4.6 million).&#160;As
of September 30, 2024, the Company had made a prepayment of RMB16&#160;million ($2.3 million) to Jiangxi Yueshang. The remaining balance
is expected to be paid by April 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">On January
13, 2022, Mr. Gang Lai transferred the&#160;5% equity interest he owned in Jiangxi Yueshang to a third party. As such, after this date,
Jiangxi Yueshang is no longer the Company&#8217;s related party.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>(f) Prepaid
expenses-related party, non-current</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">As of September
30, 2024 and 2023, the Company prepaid Guangzhou Ningjing nil and $35,864 for right to use trademarks, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. <span style="text-decoration:underline">Interests of Experts and Counsel</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 8. FINANCIAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. <span style="text-decoration:underline">Consolidated Statements and Other Financial
Information</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have appended consolidated financial statements
filed as part of this annual report. See &#8220;Item 18. Financial Statements.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, we may become a party to various
legal or administrative proceedings arising in the ordinary course of our business, including actions with respect to intellectual property
infringement, violation of third-party licenses or other rights, breach of contract, and labor and employment claims. We are currently
not a party to, and we are not aware of any threat of, any legal or administrative proceedings that, in the opinion of our management,
are likely to have any material and adverse effect on our business, financial condition, cash flow, or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividend Policy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this annual report, none of
our subsidiaries have made any dividends or distributions to Universe Pharmaceuticals INC and Universe Pharmaceuticals INC has not made
any dividends or distributions to U.S. investors. We intend to keep any future earnings to finance the expansion of our business, and
we do not anticipate that any cash dividends will be paid in the foreseeable future. Subject to the PFIC rules, the gross amount of distributions
we make to investors with respect to our ordinary shares (including the amount of any taxes withheld therefrom) will be taxable as a dividend,
to the extent that the distribution is paid out of our current or accumulated earnings and profits, as determined under U.S. federal income
tax principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors has discretion on whether
to distribute dividends. In addition, our shareholders may by ordinary resolution declare a dividend, but no dividend may exceed the amount
recommended by our board of directors. In either case, all dividends are subject to certain restrictions under Cayman Islands law, namely
that the company may only pay dividends out of profits or share premium, and provided always that in no circumstances may a dividend be
paid if this would result in the company being unable to pay its debts as they fall due in the ordinary course of business. Even if we
decide to pay dividends, the form, frequency and amount will depend upon our future operations and earnings, capital requirements and
surplus, general financial condition, contractual restrictions and other factors that the board of directors may deem relevant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an exempted company with limited liability
incorporated in the Cayman Islands. We may rely on dividends from our subsidiaries in China for our cash requirements, including any payment
of dividends to our shareholders. PRC regulations may restrict the ability of our PRC subsidiaries to pay dividends to us, and as a holding
company, we will be dependent on receipt of funds from our Hong Kong subsidiary, Universe HK.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Current PRC regulations permit our indirect PRC
subsidiaries to pay dividends to Universe HK only out of their accumulated profits, if any, determined in accordance with Chinese accounting
standards and regulations. In addition, each of our subsidiaries in China is required to set aside at least 10% of its after-tax profits
each year, if any, to fund a statutory reserve until such reserve reaches 50% of its registered capital. Each of such entity in China
is also required to further set aside a portion of its after-tax profits to fund the employee welfare fund, although the amount to be
set aside, if any, is determined at the discretion of its board of directors. Although the statutory reserves can be used, among other
ways, to increase the registered capital and eliminate future losses in excess of retained earnings of the respective companies, the reserve
funds are not distributable as cash dividends except in the event of liquidation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The PRC government also imposes controls on the
conversion of RMB into foreign currencies and the remittance of currencies out of the PRC. Therefore, we may experience difficulties in
complying with the administrative requirements necessary to obtain and remit foreign currency for the payment of dividends from our profits,
if any. Furthermore, if our subsidiaries and affiliates in the PRC incur debt on their own in the future, the instruments governing the
debt may restrict their ability to pay dividends or make other payments. If we or our subsidiaries are unable to receive all of the revenue
from our operations, we may be unable to pay dividends on our ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash dividends, if any, on our ordinary shares
will be paid in U.S. dollars. Universe HK may be considered a non-resident enterprise for tax purposes, so that any dividends our PRC
subsidiaries pay to Universe HK may be regarded as China-sourced income and as a result may be subject to PRC withholding tax at a rate
of up to 10%. See &#8220;Item 10. Additional Information&#8212;E. Taxation&#8212;People&#8217;s Republic of China Taxation.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order for us to pay dividends to our shareholders,
we will rely on payments made from Universe Technology&#8217;s subsidiary, Jiangxi Universe, to Universe Technology and from Universe
Technology to Universe HK and then to our Company. According to the EIT Law, such payments from subsidiaries to parent companies in China
are subject to the PRC enterprise income tax at a rate of 25%. In addition, if Jiangxi Universe or its subsidiary or branches incur debt
on their own behalf in the future, the instruments governing the debt may restrict its ability to pay dividends or make other distributions
to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Double Tax Avoidance Arrangement,
the 10% withholding tax rate may be lowered to 5% if a Hong Kong resident enterprise owns no less than 25% of a PRC project. The 5% withholding
tax rate, however, does not automatically apply and certain requirements must be satisfied, including without limitation that (a) the
Hong Kong project must be the beneficial owner of the relevant dividends; and (b) the Hong Kong project must directly hold no less than
25% share ownership in the PRC project during the 12 consecutive months preceding its receipt of the dividends. In current practice, a
Hong Kong project must obtain a tax resident certificate from the Hong Kong tax authority to apply for the 5% lower PRC withholding tax
rate. As the Hong Kong tax authority will issue such a tax resident certificate on a case-by-case basis, we cannot assure you that we
will be able to obtain the tax resident certificate from the relevant Hong Kong tax authority and enjoy the preferential withholding tax
rate of 5% under the Double Taxation Arrangement with respect to any dividends paid by our PRC subsidiaries to its immediate holding company,
Universe HK. As of the date of this annual report, we have not applied for the tax resident certificate from the relevant Hong Kong tax
authority. Universe HK intends to apply for the tax resident certificate if and when Universe Technology plan to declare and pay dividends
to Universe HK. See &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212; There are significant uncertainties under the Enterprise
Income Tax Law, or the EIT Law, relating to the withholding tax liabilities of our PRC subsidiaries, and dividends payable by our PRC
subsidiaries to our offshore subsidiaries may not qualify to enjoy certain treaty benefits.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. <span style="text-decoration:underline">Significant Changes</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as disclosed elsewhere in this annual report,
we have not experienced any significant changes since the date of our audited consolidated financial statements included elsewhere in
this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9. THE OFFER AND LISTING</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. <span style="text-decoration:underline">Offer and Listing Details.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ordinary shares were listed on the Nasdaq
Global Market from March 23, 2021 to January 31, 2024, and have been listed on the Nasdaq Capital Market since February 1, 2024 under
the symbol &#8220;UPC.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. <span style="text-decoration:underline">Plan of Distribution</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. <span style="text-decoration:underline">Markets</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ordinary shares were listed on the Nasdaq
Global Market from March 23, 2021 to January 31, 2024, and have been listed on the Nasdaq Capital Market since February 1, 2024 under
the symbol &#8220;UPC.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. <span style="text-decoration:underline">Selling Shareholders</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. <span style="text-decoration:underline">Dilution</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>F. <span style="text-decoration:underline">Expenses of the Issue</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 10. ADDITIONAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. <span style="text-decoration:underline">Share Capital</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. <span style="text-decoration:underline">Memorandum and Articles of Association</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an exempted company incorporated under
the laws of the Cayman Islands and our affairs are governed by our amended and restated memorandum and articles of association, as amended
and restated from time to time, and Companies Act (As Revised) of the Cayman Islands, which we refer to as the Companies Act below, and
the common law of the Cayman Islands.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We incorporate by reference into this annual report
the description of our fourth amended and restated memorandum of association and our second amended and restated articles of association,
which is filed as Exhibit 1.1 to this annual report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Registered Office</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our registered office in the Cayman Islands is
located at Vistra (Cayman) Limited, P.O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KYI &#8211; 1205 Cayman
Islands, and the phone number of our registered office is +1-(345)769-9372.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See &#8220;Item 6. Directors, Senior Management
and Employees.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Ordinary Shares</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of our issued and outstanding ordinary shares
are fully paid and non-assessable. Our ordinary shares are issued in registered form, and are issued when registered in our register of
members. Unless the board of directors determine otherwise, each holder of our ordinary shares will not receive a certificate in respect
of such ordinary shares. Our shareholders who are non-residents of the Cayman Islands may freely hold and vote their ordinary shares.
We may not issue shares or warrants to bearer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized share capital is $140,625,000 divided into 11,250,000
ordinary shares, par value $11.25 per share and 1,250,000 preferred shares, par value $11.25 per share. Subject to the provisions of the
Companies Act and our articles regarding redemption and purchase of the shares, the directors have general and unconditional authority
to allot (with or without confirming rights of renunciation), grant options over or otherwise deal with any unissued shares to such persons,
at such times and on such terms and conditions as they may decide. Such authority could be exercised by the directors to allot shares
which carry rights and privileges that are preferential to the rights attaching to ordinary shares. No share may be issued at a discount
except in accordance with the provisions of the Companies Act. The directors may refuse to accept any application for shares, and may
accept any application in whole or in part, for any reason or for no reason.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Dividends</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the provisions of the Companies Act
and any rights attaching to any class or classes of shares under and in accordance with the articles:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the directors may declare dividends or distributions out of our funds which are lawfully available for that purpose; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company&#8217;s shareholders may, by ordinary resolution, declare dividends but no such dividend shall exceed the amount recommended by the directors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the requirements of the Companies Act
regarding the application of a company&#8217;s share premium account and with the sanction of an ordinary resolution, dividends may also
be declared and paid out of any share premium account. The directors when paying dividends to shareholders may make such payment either
in cash or in specie.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless provided by the rights attached to a share,
no dividend shall bear interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Voting Rights</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to any rights or restrictions as to voting
attached to any shares, unless any share carries special voting rights, on a show of hands every shareholder who is present in person
and every person representing a shareholder by proxy shall have one vote per ordinary share. On a poll, every shareholder who is present
in person and every person representing a shareholder by proxy shall have one vote for each share of which he or the person represented
by proxy is the holder. In addition, all shareholders holding shares of a particular class are entitled to vote at a meeting of the holders
of that class of shares. Votes may be given either personally or by proxy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Variation of Rights of Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Whenever our capital is divided into different
classes of shares, the rights attaching to any class of share (unless otherwise provided by the terms of issue of the shares of that class)
may be varied either with the consent in writing of the holders of not less than two-thirds of the issued shares of that class, or with
the sanction of a resolution passed by a majority of not less than two-thirds of the holders of shares of the class present in person
or by proxy at a separate general meeting of the holders of shares of that class.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless the terms on which a class of shares was
issued state otherwise, the rights conferred on the shareholder holding shares of any class shall not be deemed to be varied by the creation
or issue of further shares ranking pari passu with the existing shares of that class.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Alteration of Share Capital</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the Companies Act, our shareholders
may, by ordinary resolution:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase our share capital by new shares of the amount fixed by that ordinary resolution and with the attached rights, priorities and privileges set out in that ordinary resolution;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidate and divide all or any of our share capital into shares of larger amount than our existing shares;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">convert all or any of our paid up shares into stock, and reconvert that stock into paid up shares of any denomination;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sub-divide our shares or any of them into shares of an amount smaller than that fixed, so, however, that in the sub-division, the proportion between the amount paid and the amount, if any, unpaid on each reduced share shall be the same as it was in case of the share from which the reduced share is derived; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancel shares which, at the date of the passing of that ordinary resolution, have not been taken or agreed to be taken by any person and diminish the amount of our share capital by the amount of the shares so cancelled or, in the case of shares without nominal par value, diminish the number of shares into which our capital is divided.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the Companies Act and to any rights
for the time being conferred on the shareholders holding a particular class of shares, our shareholders may, by special resolution, reduce
its share capital in any way.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Calls on Shares and Forfeiture</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the terms of allotment, the directors
may make calls on the shareholders in respect of any monies unpaid on their shares including any premium and each shareholder shall (subject
to receiving at least 14 clear days&#8217; notice specifying when and where payment is to be made), pay to us the amount called on his
shares. Shareholders registered as the joint holders of a share shall be jointly and severally liable to pay all calls in respect of the
share. If a call remains unpaid after it has become due and payable the person from whom it is due and payable shall pay interest on the
amount unpaid from the day it became due and payable until it is paid at the rate fixed by the terms of allotment of the share or in the
notice of the call or if no rate is fixed, at the rate of ten percent per annum. The directors may, at their discretion, waive payment
of the interest wholly or in part.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have a first and paramount lien on all shares
(whether fully paid up or not) registered in the name of a shareholder (whether solely or jointly with others). The lien is for all monies
payable to us by the shareholder or the shareholder&#8217;s estate:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">either alone or jointly with any other person, whether or not that other person is a shareholder; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether or not those monies are presently payable.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At any time the directors may declare any share
to be wholly or partly exempt from the lien on shares provisions of the articles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may sell, in such manner as the directors may
determine, any share on which the sum in respect of which the lien exists is presently payable, if due notice that such sum is payable
has been given (as prescribed by the articles) and, within 14 days of the date on which the notice is deemed to be given under the articles,
such notice has not been complied with.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Unclaimed Dividend</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A dividend that remains unclaimed for a period
of six years after it became due for payment shall be forfeited to, and shall cease to remain owing by, the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Forfeiture or Surrender of Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a shareholder fails to pay any capital call,
the directors may give to such shareholder not less than 14 clear days&#8217; notice requiring payment and specifying the amount unpaid
including any interest which may have accrued, any expenses which have been incurred by us due to that person&#8217;s default and the
place where payment is to be made. The notice shall also state the place where payment is to be made and contain a warning that if the
notice is not complied with, the shares in respect of which the call is made will be liable to be forfeited.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If such notice is not complied with, the directors
may, before the payment required by the notice has been received, resolve that any share the subject of that notice be forfeited (which
forfeiture shall include all dividends or other monies payable in respect of the forfeited share and not paid before such forfeiture).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A forfeited share may be sold, re-allotted or
otherwise disposed of on such terms and in such manner as the directors determine and at any time before a sale, re-allotment or disposition
the forfeiture may be cancelled on such terms as the directors think fit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A person whose shares have been forfeited shall
cease to be a shareholder in respect of the forfeited shares, but shall, notwithstanding such forfeiture, remain liable to pay to us all
monies which at the date of forfeiture were payable by him to us in respect of the shares, together with all expenses and interest from
the date of forfeiture or surrender until payment, but his liability shall cease if and when we receive payment in full of the unpaid
amount. The directors, however, may waive payment wholly or in part.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A declaration, whether statutory or under oath,
made by a director or the secretary shall be conclusive evidence that the person making the declaration is our director or secretary and
that the particular shares have been forfeited or surrendered on a particular date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the execution of an instrument of transfer,
if necessary, the declaration shall constitute good title to the shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Share Premium Account</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors shall establish a share premium
account and shall carry the credit of such account from time to time to a sum equal to the amount or value of the premium paid on the
issue of any share or capital contributed or such other amounts required by the Companies Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Redemption and Purchase of Own Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the Companies Act and any rights for
the time being conferred on the shareholders holding a particular class of shares, we may by action of our directors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue shares that are to be redeemed or liable to be redeemed, at our option or the shareholder holding those redeemable shares, on the terms and in the manner our directors determine before the issue of those shares;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with the consent by special resolution of the shareholders holding shares of a particular class, vary the rights attaching to that class of shares so as to provide that those shares are to be redeemed or are liable to be redeemed at our option on the terms and in the manner which the directors determine at the time of such variation; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchase all or any of our own shares of any class including any redeemable shares on the terms and in the manner which the directors determine at the time of such purchase.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may make a payment in respect of the redemption
or purchase of its own shares in any manner authorized by the Companies Act, including out of any combination of capital, our profits
and the proceeds of a fresh issue of shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When making a payment in respect of the redemption
or purchase of shares, the directors may make the payment in cash or in specie (or partly in one and partly in the other) if so authorized
by the terms of the allotment of those shares or by the terms applying to those shares, or otherwise by agreement with the shareholder
holding those shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Transfer of Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provided that a transfer of ordinary shares complies
with applicable rules of Nasdaq, a shareholder may transfer ordinary shares to another person by completing an instrument of transfer
in a common form or in a form prescribed by Nasdaq or in any other form approved by the directors, executed:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">where the ordinary shares are fully paid, by or on behalf of that shareholder; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">where the ordinary shares are partly paid, by or on behalf of that shareholder and the transferee.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transferor shall be deemed to remain the holder
of an ordinary share until the name of the transferee is entered into the register of members of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors may, in its absolute discretion,
decline to register any transfer of any ordinary share that has not been fully paid up or is subject to a company lien. Our board of directors
may also decline to register any transfer of such ordinary share unless:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the instrument of transfer is lodged with the Company, accompanied by the certificate for the ordinary shares to which it relates and such other evidence as our board of directors may reasonably require to show the right of the transferor to make the transfer;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the instrument of transfer is in respect of only one class of shares;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the instrument of transfer is properly stamped, if required;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ordinary shares transferred is fully paid and free of any lien in favor of us;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any fee related to the transfer has been paid to us; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the transfer is not to more than four joint holders.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our directors refuse to register a transfer,
they are required, within three months after the date on which the instrument of transfer was lodged, to send to each of the transferor
and the transferee notice of such refusal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This, however, is unlikely to affect market transactions
of the ordinary shares purchased by investors in the public offering. The legal title to such ordinary shares and the registration details
of those ordinary shares in the Company&#8217;s register of members will remain with Depository Trust Company (&#8220;DTC&#8221;). All
market transactions with respect to those ordinary shares will then be carried out without the need for any kind of registration by the
directors, as the market transactions will all be conducted through the DTC systems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The registration of transfers may, on 14 calendar
days&#8217; notice being given by advertisement in such one or more newspapers or by electronic means, be suspended and our register of
members closed at such times and for such periods as our board of directors may from time to time determine. The registration of transfers,
however, may not be suspended, and the register may not be closed, for more than 30 days in any year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Inspection of Books and Records</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of our ordinary shares will have no general
right under the Companies Act to inspect or obtain copies of our register of members or our corporate records.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General Meetings</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a Cayman Islands exempted company, we are not
obligated by the Companies Act to call shareholders&#8217; annual general meetings; accordingly, we may, but shall not be obliged to,
in each year hold a general meeting as an annual general meeting. Any annual general meeting held shall be held at such time and place
as may be determined by our board of directors. All general meetings other than annual general meetings shall be called extraordinary
general meetings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors may convene general meetings whenever
they think fit. General meetings shall also be convened on the written requisition of one or more of the shareholders entitled to attend
and vote at our general meetings who (together) hold not less than ten percent of the rights to vote at such general meeting in accordance
with the notice provisions in the articles, specifying the purpose of the meeting and signed by each of the shareholders making the requisition.
If the directors do not convene such meeting for a date not later than 21 clear days&#8217; after the date of receipt of the written requisition,
those shareholders who requested the meeting may convene the general meeting themselves within three months after the end of such period
of 21 clear days in which case reasonable expenses incurred by them as a result of the directors failing to convene a meeting shall be
reimbursed by us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At least 14 days&#8217; notice of an extraordinary
general meeting and 21 days&#8217; notice of an annual general meeting shall be given to shareholders entitled to attend and vote at such
meeting. The notice shall specify the place, the day and the hour of the meeting and the general nature of that business. In addition,
if a resolution is proposed as a special resolution, the text of that resolution shall be given to all shareholders. Notice of every general
meeting shall also be given to the directors and our auditors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the Companies Act and with the consent
of the shareholders who, individually or collectively, hold at least 90 percent of the voting rights of all those who have a right to
vote at a general meeting, a general meeting may be convened on shorter notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A quorum shall consist of the presence (whether
in person or represented by proxy) of one or more shareholders holding shares that represent not less than one-third of the outstanding
shares carrying the right to vote at such general meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If, within 15 minutes from the time appointed
for the general meeting, or at any time during the meeting, a quorum is not present, the meeting, if convened upon the requisition of
shareholders, shall be cancelled. In any other case it shall stand adjourned to the same time and place seven days or to such other time
or place as is determined by the directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The chairman may, with the consent of a meeting
at which a quorum is present, adjourn the meeting. When a meeting is adjourned for seven days or more, notice of the adjourned meeting
shall be given in accordance with the articles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At any general meeting a resolution put to the
vote of the meeting shall be decided on a show of hands, unless a poll is (before, or on, the declaration of the result of the show of
hands) demanded by the chairman of the meeting or by at least two shareholders having the right to vote on the resolutions or one or more
shareholders present who together hold not less than ten percent of the voting rights of all those who are entitled to vote on the resolution.
Unless a poll is so demanded, a declaration by the chairman as to the result of a resolution and an entry to that effect in the minutes
of the meeting, shall be conclusive evidence of the outcome of a show of hands, without proof of the number or proportion of the votes
recorded in favor of, or against, that resolution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a poll is duly demanded it shall be taken in
such manner as the chairman directs and the result of the poll shall be deemed to be the resolution of the meeting at which the poll was
demanded.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the case of an equality of votes, whether on
a show of hands or on a poll, the chairman of the meeting at which the show of hands takes place or at which the poll is demanded, shall
not be entitled to a second or casting vote.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may by ordinary resolution, from time to time,
fix the maximum and minimum number of directors to be appointed. Under the articles, we are required to have a minimum of one director
and the maximum number of directors shall be unlimited.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A director may be appointed by ordinary resolution
or by the directors. Any appointment may be to fill a vacancy or as an additional director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless the remuneration of the directors is determined
by the shareholders by ordinary resolution, the directors shall be entitled to such remuneration as the directors may determine.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shareholding qualification for directors may
be fixed by our shareholders by ordinary resolution and unless and until so fixed no share qualification shall be required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless removed or re-appointed, each director
shall be appointed for a term expiring at the next-following annual general meeting, if one is held. At any annual general meeting held,
our directors will be elected by an ordinary resolution of our shareholders. At each annual general meeting, each director so elected
shall hold office for a one-year term and until the election of their respective successors in office or removed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A director may be removed by ordinary resolution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A director may at any time resign or retire from
office by giving us notice in writing. Unless the notice specifies a different date, the director shall be deemed to have resigned on
the date that the notice is delivered to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the provisions of the articles, the
office of a director may be terminated forthwith if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">he is prohibited by the law of the Cayman Islands from acting as a director;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">he is made bankrupt or makes an arrangement or composition with his creditors generally;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">he resigns his office by notice to us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">he only held office as a director for a fixed term and such term expires;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
the opinion of a registered medical practitioner by whom he is being treated he becomes physically or mentally incapable of acting as
a director;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">he
is given notice by the majority of the other directors (not being less than two in number) to vacate office (without prejudice to any
claim for damages for breach of any agreement relating to the provision of the services of such director);</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">he
is made subject to any law relating to mental health or incompetence, whether by court order or otherwise; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">without
the consent of the other directors, he is absent from meetings of directors for continuous period of six months.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of the compensation committee and the nominating
and corporate governance committee shall consist of at least three directors and the majority of the committee members shall be independent
within the meaning of Rule 5605(a)(2) of the Listing Rules of the Nasdaq Stock Market. The audit committee shall consist of at least three
directors, all of whom shall be independent within the meaning of Rule 5605(a)(2) of the Listing Rules of the Nasdaq Stock Market and
will meet the criteria for independence set forth in Rule 10A-3 or Rule 10C-1 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Powers and Duties of Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the provisions of the Companies Act
and our memorandum and articles of association, our business shall be managed by the directors, who may exercise all our powers. No prior
act of the directors shall be invalidated by any subsequent alteration of our memorandum or articles of association. To the extent allowed
by the Companies Act, however, shareholders may by special resolution validate any prior or future act of the directors which would otherwise
be in breach of their duties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors may delegate any of their powers
to any committee consisting of one or more persons who need not be shareholders and may include non-directors so long as the majority
of those persons are directors; any committee so formed shall in the exercise of the powers so delegated conform to any regulations that
may be imposed on it by the directors. Our board of directors have established an audit committee, compensation committee, and nomination
and corporate governance committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board of directors may establish any
local or divisional board of directors or agency and delegate to it its powers and authorities (with power to sub-delegate) for
managing any of our affairs whether in the Cayman Islands or elsewhere and may appoint any persons to be members of a local or
divisional board of directors, or to be managers or agents, and may fix their remuneration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors may from time to time and at any
time by power of attorney or in any other manner they determine appoint any person, either generally or in respect of any specific matter,
to be our agent with or without authority for that person to delegate all or any of that person&#8217;s powers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors may from time to time and at any
time by power of attorney or in any other manner they determine appoint any person, whether nominated directly or indirectly by the directors,
to be our attorney or our authorized signatory and for such period and subject to such conditions as they may think fit. The powers, authorities
and discretions, however, must not exceed those vested in, or exercisable, by the directors under the articles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board of directors may remove any person so
appointed and may revoke or vary the delegation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors may exercise all of our powers to
borrow money and to mortgage or charge its undertaking, property and assets both present and future and uncalled capital or any part thereof,
to issue debentures and other securities whether outright or as collateral security for any debt, liability or obligation of ours or our
parent undertaking (if any) or any subsidiary undertaking of us or of any third party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A director shall not, as a director, vote in respect
of any contract, transaction, arrangement or proposal in which he has an interest which (together with any interest of any person connected
with him) is a material interest (otherwise than by virtue of his interests, direct or indirect, in shares or debentures or other securities
of, or otherwise in or through, us) and if he shall do so his vote shall not be counted, nor in relation thereto shall he be counted in
the quorum present at the meeting, but (in the absence of some other material interest than is mentioned below) none of these prohibitions
shall apply to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
giving of any security, guarantee or indemnity in respect of:</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">money
lent or obligations incurred by him or by any other person for our benefit or any of our subsidiaries; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
debt or obligation of ours or any of our subsidiaries for which the director himself has assumed responsibility in whole or in part and
whether alone or jointly with others under a guarantee or indemnity or by the giving of security;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">where
we or any of our subsidiaries is offering securities in which offer the director is or may be entitled to participate as a holder of
securities or in the underwriting or sub-underwriting of which the director is to or may participate;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
contract, transaction, arrangement or proposal affecting any other body corporate in which he is interested, directly or indirectly and
whether as an officer, shareholder, creditor or otherwise howsoever, provided that he (together with persons connected with him) does
not to his knowledge hold an interest representing one percent or more of any class of the equity share capital of such body corporate
(or of any third body corporate through which his interest is derived) or of the voting rights available to shareholders of the relevant
body corporate;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
act or thing done or to be done in respect of any arrangement for the benefit of the employees of us or any of our subsidiaries under
which he is not accorded as a director any privilege or advantage not generally accorded to the employees to whom such arrangement relates;
or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
matter connected with the purchase or maintenance for any director of insurance against any liability or (to the extent permitted by
the Companies Act) indemnities in favor of directors, the funding of expenditure by one or more directors in defending proceedings against
him or them or the doing of anything to enable such director or directors to avoid incurring such expenditure.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A director may, as a director, vote (and be counted
in the quorum) in respect of any contract, transaction, arrangement or proposal in which he has an interest which is not a material interest
or as described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Capitalization of Profits</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The directors may resolve to capitalize:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
part of our profits not required for paying any preferential dividend (whether or not those profits are available for distribution);
or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
sum standing to the credit of our share premium account or capital redemption reserve, if any.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount resolved to be capitalized must be
appropriated to the shareholders who would have been entitled to it had it been distributed by way of dividend and in the same proportions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Liquidation Rights</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are wound up, the shareholders may, subject
to the articles and any other sanction required by the Companies Act, pass a special resolution allowing the liquidator to do either or
both of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
divide in specie among the shareholders the whole or any part of our assets and, for that purpose, to value any assets and to determine
how the division shall be carried out as between the shareholders or different classes of shareholders; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
vest the whole or any part of the assets in trustees for the benefit of shareholders and those liable to contribute to the winding up.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors have the authority to present a
petition for our winding up to the Grand Court of the Cayman Islands on our behalf without the sanction of a resolution passed at a general
meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Register of Members</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Companies Act, we must keep a register
of members and there should be entered therein:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the names and addresses of our shareholders, a statement of the shares held by each shareholder, and of the amount paid or agreed to be considered as paid, on the shares of each shareholder;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date on which the name of any person was entered on the register as a shareholder; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date on which any person ceased to be a shareholder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Companies Act, the register of members
of our company is prima facie evidence of the matters set out therein (that is, the register of members will raise a presumption of fact
on the matters referred to above unless rebutted) and a shareholder registered in the register of members is deemed as a matter of the
Companies Act to have legal title to the shares as set against its name in the register of members.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the name of any person is incorrectly entered
in or omitted from our register of members, or if there is any default or unnecessary delay in entering on the register the fact of any
person having ceased to be a shareholder of our company, the person or shareholder aggrieved (or any shareholder of our company or our
company itself) may apply to the Grand Court of the Cayman Islands for an order that the register be rectified, and the Court may either
refuse such application or it may, if satisfied of the justice of the case, make an order for the rectification of the register.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Preferred Shares</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors are empowered to designate and issue
from time to time one or more classes or series of preference shares and to fix and determine the relative rights, preferences, designations,
qualifications, privileges, options, conversion rights, limitations and other special or relative rights of each such class or series
so authorized. Such action could adversely affect the voting power and other rights of the holders of our ordinary shares or could have
the effect of discouraging any attempt by a person or group to obtain control of us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this annual report, no preferred
shares are issued and outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. <span style="text-decoration:underline">Material Contracts</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not entered into any material contracts
other than in the ordinary course of business and other than those described in &#8220;Item 4. Information on the Company&#8221; or elsewhere
in this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. <span style="text-decoration:underline">Exchange Controls</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See &#8220;Item 4. Information on the Company&#8212;B.
Business Overview&#8212;Regulations&#8212;Other Laws&#8212;Foreign Exchange Control.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. <span style="text-decoration:underline">Taxation</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>People&#8217;s Republic of China Taxation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following brief description of Chinese enterprise
laws is designed to highlight the enterprise-level taxation on our earnings, which will affect the amount of dividends, if any, we are
ultimately able to pay to our shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Enterprise Income Tax</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the Enterprise Income Tax Law of
the People&#8217;s Republic of China, or the EIT Law, which was promulgated by the SCNPC on March 16, 2007, and became effective on January
1, 2008, and then amended on February 24, 2017, and the Implementation Rules of the EIT Law, or the Implementation Rules, which were promulgated
by the State Council on December 6, 2007, effective on January 1, 2008, and amended on April 23, 2019, enterprises are divided into resident
enterprises and non-resident enterprises. Resident enterprises pay enterprise income tax on their incomes obtained in and outside the
PRC at the rate of 25%. Non-resident enterprises setting up institutions in the PRC pay enterprise income tax on the incomes obtained
by such institutions in and outside the PRC at the rate of 25%. Non-resident enterprises with no institutions in the PRC, and non-resident
enterprises with income having no substantial connection with their institutions in the PRC, pay enterprise income tax on their income
obtained in the PRC at a reduced rate of 10%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an exempted company incorporated with limited
liability in the Cayman Islands and we gain substantial income by way of dividends paid to us from our PRC subsidiaries, Universe Technology,
Jiangxi Universe, and Universe Trade. The EIT Law and its implementation rules provide that China-sourced income of foreign enterprises,
such as dividends paid by a PRC subsidiary to its equity holders that are non-resident enterprises, will normally be subject to PRC withholding
tax at a rate of 10%, unless any such foreign investor&#8217;s jurisdiction of incorporation has a tax treaty with China that provides
for a preferential tax rate or a tax exemption.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the EIT Law, an enterprise established outside
of China with a &#8220;de facto management body&#8221; within China is considered a &#8220;resident enterprise,&#8221; which means that
it is treated in a manner similar to a Chinese enterprise for enterprise income tax purposes. Although the implementation rules of the
EIT Law define &#8220;de facto management body&#8221; as a managing body that actually, comprehensively manage and control the production
and operation, staff, accounting, property and other aspects of an enterprise, the only official guidance for this definition currently
available is set forth in SAT Notice 82, which provides guidance on the determination of the tax residence status of a Chinese-controlled
offshore incorporated enterprise, defined as an enterprise that is incorporated under the laws of a foreign country or territory and that
has a PRC enterprise or enterprise group as its primary controlling shareholder. Although the Company does not have a PRC enterprise or
enterprise group as our primary controlling shareholder and is therefore not a Chinese-controlled offshore incorporated enterprise within
the meaning of SAT Notice 82, in the absence of guidance specifically applicable to us, we have applied the guidance set forth in SAT
Notice 82 to evaluate the tax residence status of the Company and its subsidiaries organized outside the PRC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to SAT Notice 82, a Chinese-controlled
offshore incorporated enterprise will be regarded as a PRC tax resident by virtue of having a &#8220;de facto management body&#8221; in
China and will be subject to PRC enterprise income tax on its worldwide income only if all of the following criteria are met: (i) the
places where senior management and senior management departments that are responsible for daily production, operation and management of
the enterprise perform their duties are mainly located within the territory of China; (ii) financial decisions (such as money borrowing,
lending, financing and financial risk management) and personnel decisions (such as appointment, dismissal and salary and wages) are decided
or need to be decided by organizations or persons located within the territory of China; (iii) main property, accounting books, corporate
seal, the board of directors and files of the minutes of shareholders&#8217; meetings of the enterprise are located or preserved within
the territory of China; and (iv) one half (or more) of the directors or senior management staff having the right to vote habitually reside
within the territory of China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that we do not meet some of the conditions
outlined in the immediately preceding paragraph. For example, as a holding company, the key assets and records of the Company, including
the resolutions and meeting minutes of our board of directors and the resolutions and meeting minutes of our shareholders, are located
and maintained outside the PRC. In addition, we are not aware of any offshore holding companies with a corporate structure similar to
ours that has been deemed a PRC &#8220;resident enterprise&#8221; by the PRC tax authorities. Accordingly, we believe that the Company
and its offshore subsidiaries should not be treated as a &#8220;resident enterprise&#8221; for PRC tax purposes if the criteria for &#8220;de
facto management body&#8221; as set forth in SAT Notice 82 were deemed applicable to us. However, as the tax residency status of an enterprise
is subject to determination by the PRC tax authorities and uncertainties remain with respect to the interpretation of the term &#8220;de
facto management body&#8221; as applicable to our offshore entities, we will continue to monitor our tax status.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The implementation rules of the EIT law provides
that, (i) if the enterprise that distributes dividends is domiciled in the PRC or (ii) if gains are realized from transferring equity
interests of enterprises domiciled in the PRC, then such dividends or gains are treated as China-sourced income. It is not clear how &#8220;domicile&#8221;
may be interpreted under the EIT Law, and it may be interpreted as the jurisdiction where the enterprise is a tax resident. Therefore,
if we are considered as a PRC tax resident enterprise for PRC tax purposes, any dividends we pay to our overseas shareholders which are
non-resident enterprises as well as gains realized by such shareholders from the transfer of our shares may be regarded as China-sourced
income and as a result become subject to PRC withholding tax at a rate of up to 10%. AllBright Law Offices (Fuzhou), our PRC counsel,
is unable to provide a &#8220;will&#8221; opinion because it believes that it is more likely than not that we and our offshore subsidiaries
would be treated as non-resident enterprises for PRC tax purposes because we do not meet some of the conditions outlined in SAT Notice
82. In addition, AllBright Law Offices (Fuzhou) is not aware of any offshore holding companies with a corporate structure similar to ours
that has been deemed a PRC &#8220;resident enterprise&#8221; by the PRC tax authorities as of the date of this annual report. Therefore,
AllBright Law Offices (Fuzhou) believes that it is possible but highly unlikely that the income received by our overseas shareholders
will be regarded as China-sourced income. See &#8220;Item 3. Key Information&#8212;Risk Factors&#8212;Risks Related to Doing Business
in China&#8212;Under the EIT Law, we may be classified as a &#8216;Resident Enterprise&#8217; of China. Such classification will likely
result in unfavorable tax consequences to us and our non-PRC shareholders.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, as resident enterprises in the
PRC, Universe Technology as well as Jiangxi Universe and its subsidiaries in PRC are subject to the enterprise income tax at the
rate of 25%, except that once an enterprise meets certain requirements and is identified as a small-scale minimal profit enterprise,
the part of its taxable income not more than RMB1 million is subject to a reduced rate of 5% and the part between RMB1 million and 3
million is subject to a reduced rate of 10%. The EIT is calculated based on the entity&#8217;s global income as determined under PRC
tax laws and accounting standards. If the PRC tax authorities determine that Jiangxi Universe is a PRC resident enterprise for
enterprise income tax purposes, we may be required to withhold a 10% withholding tax from dividends we pay to our shareholders that
are non-resident enterprises. In addition, non-resident enterprise shareholders may be subject to a 10% PRC withholding tax on gains
realized on the sale or other disposition of our ordinary shares, if such income is treated as sourced from within the PRC. It is
unclear whether our non-PRC individual shareholders would be subject to any PRC tax on dividends or gains obtained by such non-PRC
individual shareholders in the event we are determined to be a PRC resident enterprise. If any PRC tax were to apply to dividends or
gains realized by non-PRC individuals, it would generally apply at a rate of 20% unless a reduced rate is available under an
applicable tax treaty. However, it is also unclear whether our non-PRC shareholders would be able to claim the benefits of any tax
treaties between their country of tax residence and the PRC in the event that we are treated as a PRC resident enterprise. There is
no guidance from the PRC government to indicate whether or not any tax treaties between the PRC and other countries would apply in
circumstances where a non-PRC company was deemed to be a PRC tax resident, and thus there is no basis for expecting how tax treaty
between the PRC and other countries may impact non-resident enterprises.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Value-added Tax</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Provisional Regulations on Value-Added
Tax of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22686;&#20540;&#31246;&#26242;&#34892;&#26465;&#20363;&#12299;),
or the VAT Regulations, which were promulgated by the State Council on December 13, 1993, and amended on November 10, 2008, February 6,
2016, and November 19, 2017, respectively, and the Implementation Rules of the Provisional Regulations on Value Added Tax of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22686;&#20540;&#31246;&#26242;&#34892;&#26465;&#20363;&#23454;&#26045;&#32454;&#21017;&#12299;)
promulgated by the MOF on December 25, 1993 and amended on December 15, 2008 and October 28, 2011, respectively, entities and individuals
that sell goods or labor services of processing, repair or replacement, sell services, intangible assets, or immovables, or import goods
within the territory of the People&#8217;s Republic of China are taxpayers of value-added tax.&#160;The VAT rate is 17% for taxpayers
selling goods, labor services, or tangible movable property leasing services or importing goods, except otherwise specified; 11% for taxpayers
selling goods, labor services, or tangible movable property leasing services or importing goods, except otherwise specified; 6% for taxpayers
selling services or intangible assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to Provisions in the Notice on Adjusting
the Value added Tax Rates (Cai Shui [2018] No. 32), or the Notice, issued by the SAT and the MOF, where taxpayers make VAT taxable sales
or import goods, the applicable tax rates shall be adjusted from 17% to 16% and from 11% to 10%, respectively. The Notice took effect
on May 1, 2018, and the adjusted VAT rates took effect at the same time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 23, 2016, the MOF and the SAT jointly
issued the Circular of Full Implementation of Business Tax to VAT Reform (the &#8220;Circular 36&#8221;) (&#12298;&#20851;&#20110;&#20840;&#38754;&#25512;&#24320;&#33829;&#19994;&#31246;&#25913;&#24449;&#22686;&#20540;&#31246;&#35797;&#28857;&#30340;&#36890;&#30693;&#12299;),
which confirms that business tax will be completely replaced by VAT from May 1, 2016. The Notice of the MOF and the SAT on the Adjustment
to VAT Rates (&#12298;&#20851;&#20110;&#35843;&#25972;&#22686;&#20540;&#31246;&#31246;&#29575;&#30340;&#36890;&#30693;&#12299;), promulgated
on April 4, 2018 and effective as of May 1, 2018, adjusted the applicative rate of VAT. The deduction rates of 17% and 11% applicable
to the taxpayers who have VAT taxable sales activities or imported goods are adjusted to 16% and 10%, respectively. For the export goods
to which a tax rate of 17% was originally applicable and the export rebate rate was 17%, the export rebate rate is adjusted to 16%. For
the export goods and cross-border taxable activities to which a tax rate of 11% was originally applicable and the export rebate rate was
11%, the export rebate rate is adjusted to 10%. Pursuant to such circular, the Value Added Tax Pilot Program has been applicable nationwide
since May 1, 2016.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subsequently, the Notice on Policies for Deepening
Reform of Value-added Tax was issued by the SAT, the MOF and the General Administration of Customs on March 30, 2019 and took effective
on April 1, 2019, which further adjusted the applicable tax rate for taxpayers making VAT taxable sales or importing goods. The applicable
tax rates shall be adjusted from 16% to 13% and from 10% to 9%, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the VAT Regulations and the related
rules, as of the date of this annual report, as taxpayers selling goods, Jiangxi Universe and its consolidated affiliated entities are
generally subject to 13% VAT rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dividend Withholding Tax</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Arrangement between Mainland China
and Hong Kong for the Avoidance of Double Taxation and Prevention of Fiscal Evasion with respect to Taxes on Income (&#12298;&#20869;&#22320;&#21644;&#39321;&#28207;&#29305;&#21035;&#34892;&#25919;&#21306;&#20851;&#20110;&#25152;&#24471;&#31246;&#36991;&#20813;&#21452;&#37325;&#24449;&#31246;&#21644;&#38450;&#27490;&#20599;&#31246;&#28431;&#31246;&#30340;&#23433;&#25490;&#12299;)
effective on August 21, 2006, no more than 5% withholding tax rate applies to dividends paid by a PRC company to a Hong Kong resident,
provided that the recipient is a company that holds at least 25% of the capital of the PRC company. The 10% withholding tax rate applies
to dividends paid by a PRC company to a Hong Kong resident if the recipient is a company that holds less than 25% of the capital of the
PRC company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, pursuant to the Notice of the
SAT on Issues Relating to the Implementation of Dividend Clauses in Tax Treaties (Guo Shui Han [2009] No.81)
(&#12298;&#22269;&#23478;&#31246;&#21153;&#24635;&#23616;&#20851;&#20110;&#25191;&#34892;&#31246;&#25910;&#21327;&#23450;&#32929;&#24687;&#26465;&#27454;&#26377;&#20851;&#38382;&#39064;&#30340;&#36890;&#30693;&#12299;&#65288;&#22269;&#31246;&#20989;[2009]
81&#21495;&#65289;), which was promulgated and effective on February 20, 2009, all of the following requirements should be satisfied
where a fiscal resident of the other party to the tax agreement needs to be entitled to such tax agreement treatment as being taxed
at a tax rate specified in the tax agreement for the dividends paid to it by a PRC resident company: (1) such a fiscal resident who
obtains dividends should be a company as provided in the tax agreement; (2) owner&#8217;s equity interests and voting shares of the
PRC resident company directly owned by such a fiscal resident reaches a specified percentage; and (3) the equity interests of the
PRC resident company directly owned by such a fiscal resident, at any time during the 12 months prior to the acquisition of the
dividends, reaches a percentage specified in the tax agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, according to the Administrative Measures
on Non-resident Taxpayers Enjoying Treaty Benefits (&#12298;&#38750;&#23621;&#27665;&#32435;&#31246;&#20154;&#20139;&#21463;&#21327;&#23450;&#24453;&#36935;&#31649;&#29702;&#21150;&#27861;&#12299;)
promulgated by the SAT on October 14, 2019 and became effective on January 1, 2020, non-resident taxpayers claiming treaty benefits shall
adhere to the principle of &#8220;self-assessment, claiming benefits, retention of the relevant materials for future inspection.&#8221;
Where a non-resident taxpayer self-assesses and concludes that it satisfies the criteria for claiming treaty benefits, it may enjoy treaty
benefits at the time of tax declaration or withholding. However such non-resident taxpayers shall retain relevant tax-reporting materials
pursuant to the provisions of these Measures for potential future inspection, and accept follow-up administration by relevant tax authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this annual report, when considered
as a non-PRC resident investor, which is much more likely to happen than not, Universe HK shall be subject to the dividend withholding
tax at the rate of 10%. Upon identified as the Hong Kong resident enterprise stipulated by the Double Tax Avoidance Arrangement and other
applicable laws, the withholding tax may be reduced to 5%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Hong Kong Taxation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summary of certain relevant taxation
provisions under the laws of Hong Kong is based on current law and practice and is subject to changes therein. This summary does not purport
to address all possible tax consequences relating to purchasing, holding or selling the ordinary shares, and does not take into account
the specific circumstances of any particular investors, some of whom may be subject to special rules. Accordingly, holders or prospective
purchasers (particularly those subject to special tax rules, such as banks, dealers, insurance companies and tax-exempt entities) should
consult their own tax advisors regarding the tax consequences of purchasing, holding or selling the Ordinary Shares. Under the current
laws of Hong Kong:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No profit tax is imposed in Hong Kong in respect of capital gains from the sale of the ordinary shares.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue gains from the sale of ordinary shares by persons carrying on a trade, profession or business in Hong Kong where the gains are derived from or arise in Hong Kong from the trade, profession or business will be chargeable to Hong Kong profits tax, which is currently imposed at the rate of 16.5% on corporations and at a maximum rate of 15% on individuals and unincorporated businesses.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gains
arising from the sale of ordinary Shares, where the purchases and sales of ordinary shares are effected outside of Hong Kong such as,
for example, on the Nasdaq, should not be subject to Hong Kong profits tax.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the current tax practice of the Hong
Kong Inland Revenue Department, dividends paid on the ordinary shares would not be subject to any Hong Kong tax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No Hong Kong stamp duty is payable on the purchase
and sale of the ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>United States Federal Income Taxation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following brief summary does not address the
tax consequences to any particular investor or to persons in special tax situations such as:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">banks;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial institutions;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insurance companies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulated investment companies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">real estate investment trusts;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">broker-dealers;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons that elect to mark their securities to market;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. expatriates or former long-term residents of the U.S.;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">governments or agencies or instrumentalities thereof;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-exempt entities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons liable for alternative minimum tax;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons holding our ordinary shares as part of a straddle, hedging, conversion or integrated transaction;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons that actually or constructively own 10% or more of our voting power or value (including by reason of owning our ordinary shares);</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons who acquired our ordinary shares pursuant to the exercise of any employee share option or otherwise as compensation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons holding our ordinary shares through partnerships or other pass-through entities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">beneficiaries of a trust holding our ordinary shares; or</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons holding our ordinary shares through a trust.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The brief discussion set forth below is addressed
only to U.S. Holders (defined below) that purchased our ordinary shares. Purchasers are urged to consult their own tax advisors about
the application of the U.S. federal income tax rules to their particular circumstances as well as the state, local, foreign, and other
tax consequences to them of the purchase, ownership, and disposition of our ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Material U.S. Federal Tax Consequences Applicable
to U.S. Holders of Our Ordinary Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following brief summary sets forth the material
U.S. federal income tax consequences related to the ownership and disposition of our ordinary shares. It is directed to U.S. Holders (as
defined below) of our ordinary shares and is based upon laws and relevant interpretations thereof in effect as of the date of this annual
report, all of which are subject to change. This brief summary description does not deal with all possible tax consequences relating to
ownership and disposition of our ordinary shares or U.S. tax laws, other than the U.S. federal income tax laws, such as the tax consequences
under non-U.S. tax laws, state, local, and other tax laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following brief description applies only to
U.S. Holders (defined below) that hold ordinary shares as capital assets and that have the U.S. dollar as their functional currency. This
brief description is based on the federal income tax laws of the United States in effect as of the date of this annual report and on U.S.
Treasury regulations in effect or, in some cases, proposed, as of the date of this annual report, as well as judicial and administrative
interpretations thereof available on or before such date. All of the foregoing authorities are subject to change, which change could apply
retroactively and could affect the tax consequences described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The brief description below of the U.S. federal
income tax consequences to &#8220;U.S. Holders&#8221; will apply to you if you are a beneficial owner of ordinary shares and you are,
for U.S. federal income tax purposes,</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an individual who is a citizen or resident of the United States;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) organized under the laws of the United States, any state thereof or the District of Columbia;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an estate whose income is subject to U.S. federal income taxation regardless of its source; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">a trust that (1) is subject to the primary supervision
    of a court within the United States and the control of one or more U.S. persons for all substantial decisions or (2) has a valid election
    in effect under applicable U.S. Treasury regulations to be treated as a U.S. person.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a partnership (or other entity treated as a
    partnership for United&#160;States federal income tax purposes) is a beneficial owner of our ordinary shares, the tax treatment of a partner
    in the partnership will depend upon the status of the partner and the activities of the partnership. Partnerships and partners of a partnership
    holding our ordinary shares are urged to consult their tax advisors regarding an investment in our ordinary shares.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxation of Dividends and Other Distributions
on Our Ordinary Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the PFIC rules discussed below, the
gross amount of distributions made by us to you with respect to the ordinary shares (including the amount of any taxes withheld therefrom)
will generally be includable in your gross income as dividend income on the date of receipt by you, but only to the extent that the distribution
is paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). With respect
to corporate U.S. Holders, the dividends will not be eligible for the dividends-received deduction allowed to corporations in respect
of dividends received from other U.S. corporations. There were no cash dividends paid during the years ended September 30, 2024, 2023
and 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to non-corporate U.S. Holders,
including individual U.S. Holders, dividends will be taxed at the lower capital gains rate applicable to qualified dividend income,
provided that (1) the ordinary shares are readily tradable on an established securities market in the United States, or we are
eligible for the benefits of an approved qualifying income tax treaty with the United States that includes an exchange of
information program, (2) we are not a PFIC for either our taxable year in which the dividend is paid or the preceding taxable year,
and (3) certain holding period requirements are met. Because there is no income tax treaty between the United States and the Cayman
Islands, clause (1) above can be satisfied only if the ordinary shares are readily tradable on an established securities market in
the United States. Under U.S. Internal Revenue Service authority, ordinary shares are considered for purpose of clause (1) above to
be readily tradable on an established securities market in the United States if they are listed on certain exchanges, which
presently includes the NYSE and the Nasdaq Stock Market. Our ordinary shares have been listed on the Nasdaq Stock Market since March
23, 2021 under the symbol &#8220;UPC.&#8221; You are urged to consult your tax advisors regarding the availability of the lower rate
for dividends paid with respect to our ordinary shares, including the effects of any change in law after the date of this annual
report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dividends will constitute foreign source income
for foreign tax credit limitation purposes. If the dividends are taxed as qualified dividend income (as discussed above), the amount of
the dividend taken into account for purposes of calculating the foreign tax credit limitation will be limited to the gross amount of the
dividend, multiplied by the reduced rate divided by the highest rate of tax normally applicable to dividends. The limitation on foreign
taxes eligible for credit is calculated separately with respect to specific classes of income. For this purpose, dividends distributed
by us with respect to our ordinary shares will constitute &#8220;passive category income&#8221; but could, in the case of certain U.S.
Holders, constitute &#8220;general category income.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent that the amount of the distribution
exceeds our current and accumulated earnings and profits (as determined under U.S. federal income tax principles), it will be treated
first as a tax-free return of your tax basis in your ordinary shares, and to the extent the amount of the distribution exceeds your tax
basis, the excess will be taxed as capital gain. We do not intend to calculate our earnings and profits under U.S. federal income tax
principles. Therefore, a U.S. Holder should expect that a distribution will be treated as a dividend even if that distribution would otherwise
be treated as a non-taxable return of capital or as capital gain under the rules described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxation of Dispositions of Ordinary Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the PFIC rules discussed below, you
will recognize taxable gain or loss on any sale, exchange, or other taxable disposition of a share equal to the difference between the
amount realized (in U.S. dollars) for the share and your tax basis (in U.S. dollars) in the ordinary shares. The gain or loss will be
capital gain or loss. If you are a non-corporate U.S. Holder, including an individual U.S. Holder, who has held the ordinary shares for
more than one year, you will generally be eligible for reduced tax rates. The deductibility of capital losses is subject to limitations.
Any such gain or loss that you recognize will generally be treated as United States source income or loss for foreign tax credit limitation
purposes which will generally limit the availability of foreign tax credits.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Passive Foreign Investment Company (PFIC)
Consequences </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A non-U.S. corporation is considered a PFIC, as
defined in Section 1297(a) of the U.S. Internal Revenue Code, for any taxable year if either:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least 75% of its gross income for such taxable year is passive income; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least 50% of the value of its assets (based on an average of the quarterly values of the assets during a taxable year) is attributable to assets that produce or are held for the production of passive income (the &#8220;asset test&#8221;).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Passive income generally includes dividends, interest,
rents and royalties (other than rents or royalties derived from the active conduct of a trade or business), and gains from the disposition
of passive assets. We will be treated as owning our proportionate share of the assets and earning our proportionate share of the income
of any other corporation in which we own, directly or indirectly, at least 25% (by value) of the stock. In determining the value and composition
of our assets for purposes of the PFIC asset test, the value of our assets must be determined based on the market value of our ordinary
shares from time to time, which could cause the value of our non-passive assets to be less than 50% of the value of all of our assets
on any particular quarterly testing date for purposes of the asset test.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on our operations and the composition
of our assets, we are not a PFIC this fiscal year ended, under the current PFIC rules. We must make a separate determination each
year as to whether we are a PFIC, however, and there can be no assurance with respect to our status as a PFIC for any future taxable
years. Depending on the amount of assets held for the production of passive income, it is possible that, for any subsequent taxable
year, more than 50% of our assets may be assets held for the production of passive income. We will make this determination following
the end of any particular tax year. In addition, because the value of our assets for purposes of the asset test will generally be
determined based on the market price of our ordinary shares, our PFIC status will depend in large part on the market price of our
ordinary shares. Accordingly, fluctuations in the market price of the ordinary shares may cause us to become a PFIC. In addition,
the application of the PFIC rules is subject to uncertainty in several respects and the composition of our income and assets will be
affected by how, and how quickly, we spend our liquid assets. We are under no obligation to take steps to reduce the risk of our
being classified as a PFIC, and as stated above, the determination of the value of our assets will depend upon material facts
(including the market price of our ordinary shares from time to time) that may not be within our control. If we are a PFIC for any
year during which you hold ordinary shares, we will continue to be treated as a PFIC for all succeeding years during which you hold
ordinary shares. If we cease to be a PFIC and you did not previously make a timely &#8220;mark-to-market&#8221; election as
described below, you may avoid some of the adverse effects of the PFIC regime by making a &#8220;purging election&#8221; (as
described below) with respect to the ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are a PFIC for your taxable year(s) during
which you hold ordinary shares, you will be subject to special tax rules with respect to any &#8220;excess distribution&#8221; that you
receive and any gain you realize from a sale or other disposition (including a pledge) of the ordinary shares, unless you make a &#8220;mark-to-market&#8221;
election as discussed below. Distributions you receive in a taxable year that are greater than 125% of the average annual distributions
you received during the shorter of the three preceding taxable years or your holding period for the ordinary shares will be treated as
an excess distribution. Under these special tax rules:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the excess distribution or gain will be allocated ratably over your holding period for the ordinary shares;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount allocated to your current taxable year, and any amount allocated to any of your taxable year(s) prior to the first taxable year in which we were a PFIC, will be treated as ordinary income, and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount allocated to each of your other taxable year(s) will be subject to the highest tax rate in effect for that year and the interest charge generally applicable to underpayments of tax will be imposed on the resulting tax attributable to each such year.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The tax liability for amounts allocated to years
prior to the year of disposition or &#8220;excess distribution&#8221; cannot be offset by any net operating losses for such years, and
gains (but not losses) realized on the sale of the ordinary shares cannot be treated as capital, even if you hold the ordinary shares
as capital assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder of &#8220;marketable
stock&#8221; (as defined below) in a PFIC may make a mark-to-market election under Section 1296 of the US Internal Revenue Code for
such stock to elect out of the tax treatment discussed above. If you make a mark-to-market election for first taxable year which you
hold (or are deemed to hold) ordinary shares and for which we are determined to be a PFIC, you will include in your income each year
an amount equal to the excess, if any, of the fair market value of the ordinary shares as of the close of such taxable year over
your adjusted basis in such ordinary shares, which excess will be treated as ordinary income and not capital gain. You are allowed
an ordinary loss for the excess, if any, of the adjusted basis of the ordinary shares over their fair market value as of the close
of the taxable year. Such ordinary loss, however, is allowable only to the extent of any net mark-to-market gains on the ordinary
shares included in your income for prior taxable years. Amounts included in your income under a mark-to-market election, as well as
gain on the actual sale or other disposition of the ordinary shares, are treated as ordinary income. Ordinary loss treatment also
applies to any loss realized on the actual sale or disposition of the ordinary shares, to the extent that the amount of such loss
does not exceed the net mark-to-market gains previously included for such ordinary shares. Your basis in the ordinary shares will be
adjusted to reflect any such income or loss amounts. If you make a valid mark-to-market election, the tax rules that apply to
distributions by corporations which are not PFICs would apply to distributions by us, except that the lower applicable capital gains
rate for qualified dividend income discussed above under &#8220;&#8212;Taxation of Dividends and Other Distributions on our Ordinary
Shares&#8221; generally would not apply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The mark-to-market election is available only
for &#8220;marketable stock,&#8221; which is stock that is traded in other than de minimis quantities on at least 15 days during each
calendar quarter (&#8220;regularly traded&#8221;) on a qualified exchange or other market (as defined in applicable U.S. Treasury regulations),
including the Nasdaq Capital Market. If the ordinary shares continue to be regularly traded on the Nasdaq Capital Market and if you are
a holder of ordinary shares, the mark-to-market election would be available to you were we to be or become a PFIC. Our ordinary shares
have been listed on the Nasdaq Global Market from March 23, 2021 to January 31, 2024 and since February 1, 2024 under the symbol &#8220;UPC.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alternatively, a U.S. Holder of stock in a PFIC
may make a &#8220;qualified electing fund&#8221; election under Section 1295(b) of the US Internal Revenue Code with respect to such PFIC
to elect out of the tax treatment discussed above. A U.S. Holder who makes a valid qualified electing fund election with respect to a
PFIC will generally include in gross income for a taxable year such holder&#8217;s pro rata share of the corporation&#8217;s earnings
and profits for the taxable year. The qualified electing fund election, however, is available only if such PFIC provides such U.S. Holder
with certain information regarding its earnings and profits as required under applicable U.S. Treasury regulations. We do not currently
intend to prepare or provide the information that would enable you to make a qualified electing fund election. If you hold ordinary shares
in any taxable year in which we are a PFIC, you will be required to file U.S. Internal Revenue Service Form 8621 in each such year and
provide certain annual information regarding such ordinary shares, including regarding distributions received on the ordinary shares and
any gain realized on the disposition of the ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you do not make a timely &#8220;mark-to-market&#8221;
election (as described above), and if we were a PFIC at any time during the period you hold our ordinary shares, then such ordinary shares
will continue to be treated as stock of a PFIC with respect to you even if we cease to be a PFIC in a future year, unless you make a &#8220;purging
election&#8221; for the year we cease to be a PFIC. A &#8220;purging election&#8221; creates a deemed sale of such ordinary shares at
their fair market value on the last day of the last year in which we are treated as a PFIC. The gain recognized by the purging election
will be subject to the special tax and interest charge rules treating the gain as an excess distribution, as described above. As a result
of the purging election, you will have a new basis (equal to the fair market value of the ordinary shares on the last day of the last
year in which we are treated as a PFIC) and holding period (which new holding period will begin the day after such last day) in your ordinary
shares for tax purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IRC Section 1014(a) provides for a step-up in
basis to the fair market value for our ordinary shares when inherited from a decedent that was previously a holder of our ordinary shares.
However, if we are determined to be a PFIC and a decedent that was a U.S. Holder did not make either a timely qualified electing fund
election for our first taxable year as a PFIC in which the U.S. Holder held (or was deemed to hold) our ordinary shares, or a mark-to-market
election and ownership of those ordinary shares are inherited, a special provision in IRC Section 1291(e) provides that the new U.S. Holder&#8217;s
basis should be reduced by an amount equal to the Section 1014 basis minus the decedent&#8217;s adjusted basis just before death. As such
if we are determined to be a PFIC at any time prior to a decedent&#8217;s passing, the PFIC rules will cause any new U.S. Holder that
inherits our ordinary shares from a U.S. Holder to not get a step-up in basis under Section 1014 and instead will receive a carryover
basis in those ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You are urged to consult your tax advisors regarding
the application of the PFIC rules to your investment in our ordinary shares and the elections discussed above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Information Reporting and Backup Withholding</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dividend payments with respect to our
ordinary shares and proceeds from the sale, exchange, or redemption of our ordinary shares may be subject to information reporting
to the U.S. Internal Revenue Service and possible U.S. backup withholding under Section 3406 of the U.S. Internal Revenue Code with
at a current flat rate of 24%. Backup withholding will not apply, however, to a U.S. Holder who furnishes a correct taxpayer
identification number and makes any other required certification on U.S. Internal Revenue Service Form W-9 or who is otherwise
exempt from backup withholding. U.S. Holders who are required to establish their exempt status generally must provide such
certification on U.S. Internal Revenue Service Form W-9. U.S. Holders are urged to consult their tax advisors regarding the
application of the U.S. information reporting and backup withholding rules.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Backup withholding is not an additional tax. Amounts
withheld as backup withholding may be credited against your U.S. federal income tax liability, and you may obtain a refund of any excess
amounts withheld under the backup withholding rules by filing the appropriate claim for refund with the U.S. Internal Revenue Service
and furnishing any required information. We do not intend to withhold taxes for individual shareholders. Transactions effected through
certain brokers or other intermediaries, however, may be subject to withholding taxes (including backup withholding), and such brokers
or intermediaries may be required by law to withhold such taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Hiring Incentives to Restore Employment
Act of 2010, certain U.S. Holders are required to report information relating to our ordinary shares, subject to certain exceptions (including
an exception for ordinary shares held in accounts maintained by certain financial institutions), by attaching a complete Internal Revenue
Service Form 8938, Statement of Specified Foreign Financial Assets, with their tax return for each year in which they hold ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>F. <span style="text-decoration:underline">Dividends and Paying Agents</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>G. <span style="text-decoration:underline">Statement by Experts</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>H. <span style="text-decoration:underline">Documents on Display</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to the periodic reporting and other
informational requirements of the Exchange Act. Under the Exchange Act, we are required to file reports and other information with the
SEC. Specifically, we are required to file annually a Form&#160;20-F within four months after the end of each fiscal year. The SEC maintains
a website at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding registrants that
make electronic filings with the SEC using its EDGAR system. As a foreign private issuer, we are exempt from the rules&#160;of the Exchange
Act prescribing, among other things, the furnishing and content of proxy statements to shareholders, and our executive officers, directors
and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&#160;16 of the
Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>I. <span style="text-decoration:underline">Subsidiary Information</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>J. <span style="text-decoration:underline">Annual Report to Security Holders</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Foreign Exchange Risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Substantially all of our revenues are denominated
in Renminbi. The Renminbi is not freely convertible into foreign currencies for capital account transactions. The value of the Renminbi
against the U.S. dollar and other currencies is affected by, among other things, changes in China&#8217;s political and economic conditions
and China&#8217;s foreign exchange policies. On July 21, 2005, the PRC government changed its decade-old policy of pegging the value of
the Renminbi to the U.S. dollar, and the Renminbi appreciated more than 20% against the U.S. dollar over the following three years. Between
July 2008 and June 2010, this appreciation halted and the exchange rate between the Renminbi and the U.S. dollar remained within a narrow
band. Since June 2010, the Renminbi has fluctuated against the U.S. dollar, at times significantly and unpredictably. It is difficult
to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the Renminbi and the U.S. dollar in
the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, we have not entered into any hedging
transactions in an effort to reduce our exposure to foreign currency exchange risk. To the extent that we need to convert U.S. dollars
we received from our offerings into Renminbi for our operations or capital expenditures, appreciation of the Renminbi against the U.S.
dollar would have an adverse effect on the Renminbi amount we would receive from the conversion. Conversely, if we decide to convert our
Renminbi into U.S. dollars for the purpose of making payments for dividends on our ordinary shares or for other business purposes, appreciation
of the U.S. dollar against the Renminbi would have a negative effect on the U.S. dollar amount available to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2024 and 2023, we had U.S.
dollar-denominated cash and cash equivalents of US$29.5 million and US$5.3 million, respectively. A 10% depreciation of U.S. dollar against
the Renminbi based on the foreign exchange rate on September 30, 2024 would result in a decrease of RMB17.6 million in cash and cash equivalents.
A 10% appreciation of U.S. dollar against the Renminbi based on the foreign exchange rate on September 30, 2024 would result in an increase
of RMB17.6 million in cash and cash equivalents.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Credit Risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable are typically unsecured and
derived from revenue earned from customers, thereby exposed to credit risk. The risk is mitigated by our assessment of its customers&#8217;
creditworthiness and its ongoing monitoring of outstanding balances.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Interest Rate Risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not used derivative financial instruments
to hedge interest rate risk. Interest-earning instruments carry a degree of interest rate risk. We have not been exposed, nor do we anticipate
being exposed to material risks due to changes in market interest rates. However, our future interest income may fall short of expectations
due to changes in market interest rates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Inflation Risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In recent years, inflation has not had a material
impact on our results of operations. According to the National Bureau of Statistics of China, the consumer price index in China increased
by 2.0%, 0.2% and 0.2% in 2022, 2023 and 2024, respectively. Although we have not in the past been materially affected by inflation since
our inception, we can provide no assurance that we will not be affected in the future by higher rates of inflation in China. If inflation
rises, it may materially and adversely affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. <span style="text-decoration:underline">Debt Securities</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. <span style="text-decoration:underline">Warrants and Rights</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C. <span style="text-decoration:underline">Other Securities</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>D. <span style="text-decoration:underline">American Depositary Shares</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Part&#160;II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 14. MATERIAL MODIFICATIONS TO THE RIGHTS
OF SECURITY HOLDERS AND USE OF PROCEEDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See &#8220;Item 10. Additional Information&#8221;
for a description of the rights of securities holders, which remain unchanged.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Use of Proceeds</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with our initial public offering,
we issued and sold an aggregate of 5,750,000 ordinary shares, at a price of $5.00 per share with gross proceeds of $28.75 million. Univest
Securities, LLC was the underwriter of our initial public offering. We incurred approximately $2,953,114 in expenses in connection with
our initial public offering and $178,758 in expenses in connection with the issuance of overallotment shares. None of the transaction
expenses included payments to directors or officers of our company or their associates, persons owning more than 10% or more of our equity
securities or our affiliates. None of the net proceeds we received from the initial public offering were paid, directly or indirectly,
to any of our directors or officers or their associates, persons owning 10% or more of our equity securities or our affiliates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The net proceeds raised from the initial public offering
were $25,618,128 after deducting underwriting discounts and the offering expenses payable by us. For the period from the effectiveness
of the registration statement on Form F-1 to September 30, 2024, we used approximately US$7.0 million for research and development purposes,
approximately US$6.75 million for upgrading and expanding our manufacturing facilities, and approximately US$6.0 million for brand marketing.
We still intend to use the remaining proceeds from our initial public offering in the manner disclosed in our registration statement on
Form F-1, as amended (File Number 333-248067). For the period from October 1, 2024 to the date of this annual report, US$280,000 were
used for advertising purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 15, 2024, we closed our self-underwritten
public offering of 20,000,000 ordinary shares. The ordinary shares were priced at $1.25 per share. The Company raised net proceeds of
$24.625 million through that offering. For the period from the closing of that offering to September 30, 2024, we did not use any net
proceeds received from that offering. As of the date of this annual report, approximately US$2.10 million were used for working capital
expenses, approximately $1.44 million were used for upgrading and expanding our manufacturing facilities, and US$0.26 million were used
for advertising purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 15. CONTROLS AND PROCEDURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Disclosure Controls and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management, with the participation of our
chief executive officer and chief financial officer, has performed an evaluation of the effectiveness of our disclosure controls and procedures
(as defined in Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report, as required by Rule 13a-15(b)
under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based upon this evaluation, our management has
concluded that, as of September 30, 2024, our existing disclosure controls and procedures were ineffective because of a lack of accounting
staff and resources with appropriate knowledge of U.S. GAAP and SEC reporting and compliance requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Management&#8217;s Annual Report on Internal Control over Financial
Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management is responsible for establishing
and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act.
Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of consolidated financial statements in accordance with U.S. GAAP and includes those policies and procedures
that (i)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions
of a company&#8217;s assets, (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation
of consolidated financial statements in accordance with generally accepted accounting principles, and that a company&#8217;s receipts
and expenditures are being made only in accordance with authorizations of a company&#8217;s management and directors, and (iii)&#160;provide
reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of a company&#8217;s assets
that could have a material effect on the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management, with the participation of our
chief executive officer and chief financial officer, conducted an evaluation of the effectiveness of our Company&#8217;s internal control
over financial reporting as of September 30, 2024 based on criteria established in Internal Control&#8212;Integrated Framework issued
by the Committee of Sponsoring Organizations of the Treadway Commission (COSO 2013 Framework). Based on this evaluation, we identified
one deficiency, which related to a lack of accounting staff and resources with appropriate knowledge of U.S. GAAP and SEC reporting and
compliance requirements<span style="background-color: white">, and which we believe to be a material weakness as of September 30, 2024</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As a result of the above
material weakness, management has concluded that our internal control over financial reporting was not effective as of September 30, 2024.
To remedy our identified material weakness as of September 30, 2024, we have undertaken the remedial steps and also plan to adopt certain
measures to improve our internal control over financial reporting as set forth below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Remediation plan
of the Material Weakness in Internal Control over Financial Reporting Reported as of September 30, 2024</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">As of the
date of this annual report, we have not fully addressed the above-referenced weakness. However, we have made progress in implementing
remedial measures, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recruiting
qualified accounting personnel with relevant U.S. GAAP and SEC reporting experience and qualifications to strengthen the financial reporting
function and to set up a financial and system control framework. Since very few companies in Ji&#8217;an, Jiangxi Province, the area
in which our main PRC operating subsidiaries are located, have sought public listing on a U.S. exchange, we have difficulty identifying
qualified accounting candidates with U.S. GAAP experience and expertise. We plan to search for qualified personnel in other regions of
China; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">implementing
regular and continuous U.S. GAAP accounting and financial reporting training programs for our accounting and financial reporting personnel.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Attestation Report of the Registered Public
Accounting Firm</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This annual report on Form 20-F does not include
an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management&#8217;s
report was not subject to attestation by our registered public accounting firm pursuant to rules&#160;of the SEC where domestic and foreign
registrants that are non-accelerated filers, which we are, and &#8220;emerging growth companies,&#8221; which we also are, are not required
to provide the auditor attestation report.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Changes in Internal Control over Financial
Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no changes in our internal controls
over financial reporting that occurred during the period covered by this annual report on Form 20-F that have materially affected, or
are reasonably likely to materially affect, our internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16. [RESERVED]</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16A. AUDIT COMMITTEE FINANCIAL EXPERT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Ding Zheng qualifies as an &#8220;audit committee
financial expert&#8221; as defined in Item 16A of Form&#160;20-F. Mr. Ding Zheng satisfies the &#8220;independence&#8221; requirements
of Section&#160;5605(a)(2)&#160;of the Nasdaq Listing Rules&#160;as well as the independence requirements of Rule&#160;10A-3 under the
Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16B. CODE OF ETHICS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors has adopted a code of business
conduct and ethics, which is applicable to all of our directors, officers, and employees. Our code of business conduct and ethics is publicly
available on our website.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the aggregate fees
by categories specified below in connection with certain professional services rendered and billed by Enrome LLP and YCM CPA INC., our
independent registered public accounting firms for the periods indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Enrome LLP</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Fiscal Years Ended<br/>
    September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit fees <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;270,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">160,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-related fees <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax fees <sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">All other fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">270,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">160,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit fees include the aggregate fees billed for each of the fiscal years for professional services rendered by our independent registered public accounting firm for the audit of our annual financial statements or for the audits of our financial statements and review of the interim financial statements.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit related fees include the aggregate fees billed for related services by our principal accountant that are reasonably related to the performance of the audit or review of our financial statements and are not reported under audit fees.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax fees represent the aggregated fees billed for professional services rendered by our independent registered public accounting firm for tax compliance, tax advice, and tax planning. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>YCM CPA INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Fiscal&#8239;Years Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit fees <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">265,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-related fees <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax fees <sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">All other fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">265,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit fees include the aggregate fees billed for each of the fiscal years for professional services rendered by our independent registered public accounting firm for the audit of our annual financial statements or for the audits of our financial statements and review of the interim financial statements.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit related fees include the aggregate fees billed for related services by our principal accountant that are reasonably related to the performance of the audit or review of our financial statements and are not reported under audit fees.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax fees represent the aggregated fees billed for professional services rendered by our independent registered public accounting firm for tax compliance, tax advice, and tax planning. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The audit committee of our board of directors
has established its pre-approval policies and procedures, pursuant to which the audit committee approved the foregoing audit, tax and
non-audit services provided by our independent auditors in fiscal years 2023 and 2024. Consistent with our audit committee&#8217;s responsibility
for engaging our independent auditors, all audit and permitted non-audit services require pre-approval by the audit committee. The full
audit committee approves proposed services and fee estimates for these services. One or more independent directors serving on the audit
committee may be delegated by the full audit committee to pre-approve any audit and non-audit services. Any such delegation shall be presented
to the full audit committee at its next scheduled meeting. Pursuant to these procedures, the audit committee approved the foregoing audit
services provided by our independent auditors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16D. EXEMPTIONS FROM THE LISTING STANDARDS
FOR AUDIT COMMITTEES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16E. PURCHASES OF EQUITY SECURITIES BY
THE ISSUER AND AFFILIATED PURCHASERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16F. CHANGE IN REGISTRANT&#8217;S CERTIFYING
ACCOUNTANT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 8, 2024, the Company dismissed YCM
CPA INC, the former independent registered public accounting firm. The termination of auditor relationship was disclosed in a Form 6-K
dated October 10, 2024. The Company believes that the termination was not the result of any disagreement between the Company and YCM CPA
INC.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 8, 2024, the Company, following approval
by the audit committee, appointed Enrome LLP as its independent public accounting firm. The appointment of auditor was disclosed in a
Form 6-K dated October 10, 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During each of the years ended September 30, 2023
and 2022 and the subsequent interim period through October 10, 2024, neither the Company nor anyone on behalf of the Company consulted
Enrome LLP regarding (i) the application of accounting principles to a specific transaction, either completed or proposed, or the type
of audit opinion that might be rendered on our consolidated financial statements, and neither a written report nor oral advice was provided
to us that Enrome LLP concluded was an important factor considered by us in reaching a decision as to any accounting, auditing, or financial
reporting issue, (ii) any matter that was the subject of a disagreement pursuant to Item 16F(a)(1)(iv) of Form 20-F, or (iii) any reportable
event pursuant to Item 16F(a)(1)(v) of Form 20-F.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_027"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16G. CORPORATE GOVERNANCE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a Cayman Islands company listed on the Nasdaq
Capital Market, we are subject to the Nasdaq corporate governance listing standards. Nasdaq rules, however,&#160;permit a foreign private
issuer like us to follow the corporate governance practices of its home country. Certain corporate governance practices in the Cayman
Islands, which is our home country, may differ significantly from the Nasdaq corporate governance listing standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nasdaq Listing Rule 5635 generally provides that
shareholder approval is required of U.S. domestic companies listed on Nasdaq prior to issuance (or potential issuance) of securities (i)
equaling 20% or more of the company&#8217;s common stock or voting power for less than the greater of market or book value (ii) resulting
in a change of control of the company; and (iii) which is being issued pursuant to a stock option or purchase plan to be established or
materially amended or other equity compensation arrangement made or materially amended. Notwithstanding this general requirement, Nasdaq
Listing Rule 5615(a)(3)(A) permits foreign private issuers to follow their home country practice rather than these shareholder approval
requirements. The Companies Act does not require shareholder approval prior to any of the foregoing types of issuances. We, therefore,
are not required to obtain such shareholder approval prior to entering into a transaction with the potential to issue securities as described
above. Specifically, our board of directors has elected to follow our home country rules and be exempt from the requirements to obtain
shareholder approval for the issuance of 20% or more of our outstanding ordinary shares under Nasdaq Listing Rule 5635(d).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nasdaq Listing Rule 5605(b)(1) requires
listed companies to have, among other things, a majority of its board members be independent. As a foreign private issuer, however,
we are permitted to follow home country practice in lieu of the above requirements. The corporate governance practice in our home
country, the Cayman Islands, does not require a majority of our board to consist of independent directors. Currently, a majority of
our board members are independent. However, if we change our board composition such that independent directors do not constitute a
majority of our board of directors, our shareholders may be afforded less protection than they would otherwise enjoy under
Nasdaq&#8217;s corporate governance requirements applicable to U.S. domestic issuers. See &#8220;Item 3. Key Information&#8212;D.
Risk Factors&#8212;Risks Related to Our Ordinary Shares&#8212; As a foreign private issuer, we are permitted to adopt certain home
country practices in relation to corporate governance matters that differ significantly from the Nasdaq listing standards. These
practices may afford less protection to shareholders than they would enjoy if we complied fully with corporate governance listing
standards.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than those described above, there are no
significant differences between our corporate governance practices and those followed by U.S. domestic companies under Nasdaq corporate
governance listing standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_028"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16H. MINE SAFETY DISCLOSURE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_029"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS
THAT PREVENT INSPECTIONS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_030"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 16J. INSIDER TRADING POLICIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="ixv-22421">adopted</ix:nonNumeric> insider trading policies governing
the purchase, sale, and other dispositions of our securities by directors, senior management, and employees. A copy of the insider trading
policies is filed as an exhibit to this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_031"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 16K. CYBERSECURITY.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" id="ixv-15000"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="ixv-15001"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="ixv-15002"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have established cybersecurity risk management
to identify, assess, and mitigate cybersecurity risks alongside other business risks. The process is in alignment with our strategic objectives
and risk appetite. We may engage assessors, consultants, auditors, or other <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" id="ixv-22422">third parties</ix:nonNumeric> to enhance our cyber security risk management
processes. <ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="ixv-22423">Any cybersecurity incidents are closely monitored for their potential impact on our business strategy, operations, and financial
condition.</ix:nonNumeric> <ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" id="ixv-22424">As of the date of this annual report, we have <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="ixv-22425">not</ix:nonNumeric> experienced any cybersecurity incidents that have materially affected or
are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition.</ix:nonNumeric> We continuously
adapt our business strategy to enhance resilience, strengthen defenses and ensure the sustainability of our operations.</p></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_032"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Part III</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_033"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 17. FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have elected to provide financial statements
pursuant to Item 18.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_034"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 18. FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements of Universe
Pharmaceuticals INC and its subsidiaries are included at the end of this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_035"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 19. EXHIBITS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXHIBIT INDEX</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 90%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea022807501ex1-1_universe.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Memorandum of Association and Amended and Restated Articles of Association</span></a></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea022807501ex2-1_universe.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Certificate for Ordinary Shares</span></a></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1809616/000121390020037560/ea129847ex4-2_universe.htm">Form of Underwriter Warrants (incorporated by reference to Exhibit 4.2 of our Registration Statement on Form F-1 (file No. 333-248067), as amended, initially filed with the Securities and Exchange Commission on August 17, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea022807501ex2-3_universe.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities</span></a></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1809616/000121390020022480/ea125531ex10-1_universepharm.htm">Form of Employment Agreement by and between executive officers and the Registrant (incorporated by reference to Exhibit 10.1 of our Registration Statement on Form F-1 (file No. 333-248067), as amended, initially filed with the Securities and Exchange Commission on August 17, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1809616/000121390020022480/ea125531ex10-2_universepharm.htm">Form of Indemnification Agreement with the Registrant&#8217;s directors and officers (incorporated by reference to Exhibit 10.2 of our Registration Statement on Form F-1 (file No. 333-248067), as amended, initially filed with the Securities and Exchange Commission on August 17, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1809616/000121390020022480/ea125531ex10-7_universepharm.htm">Form of Sales and Distribution Agreement by and between Universe Trade and customers (incorporated by reference to Exhibit 10.7 of our Registration Statement on Form F-1 (file No. 333-248067), as amended, initially filed with the Securities and Exchange Commission on August 17, 2020)</a></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1809616/000121390022004359/f20f2021ex4-13_universephar.htm">English translation of the real estate property purchase agreement entered into by and between Jiangxi Universe and Jiangxi Yueshang Investment Co., Ltd., dated May 16, 2021 (incorporated by reference to Exhibit 4.13 of our annual report on Form 20-F (file No. 001-40231), filed with the Securities and Exchange Commission on January 31, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1809616/000121390022004359/f20f2021ex4-15_universephar.htm">English translation of the construction agreement entered into by and between Jiangxi Universe and Jiangxi Chenyuan Construction Project Co., Ltd., dated June 25, 2021 (incorporated by reference to Exhibit 4.15 of our annual report on Form 20-F (file No. 001-40231), filed with the Securities and Exchange Commission on January 31, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea022807501ex4-6_universe.htm">English translation of the working capital loan contract entered into by and between Jiangxi Universe and Bank of Communications Co., Ltd., dated June 16, 2024</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea022807501ex4-7_universe.htm">English translation of the loan contract between Jiangxi Universe and Nanchang Branch of Bank of Beijing Co., Ltd., dated July 3, 2024</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea022807501ex4-8_universe.htm">English translation of the working capital loan contract between Jiangxi Universe and Jiangxi Rural Commercial Bank, dated May 17, 2024</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9*</span></td>
    <td>&#160;</td>
    <td><a href="ea022807501ex4-9_universe.htm">English translation of the working capital loan contract between Jiangxi Universe and Jiangxi Rural Commercial Bank, dated April 22, 2025</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea022807501ex4-10_universe.htm">English translation of&#160;the working capital loan contract between Jiangxi Universe and Jiangxi Rural Commercial Bank, dated March 3, 2025</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea022807501ex4-11_universe.htm">English translation of&#160;the corporate loan contract between Jiangxi Universe and Jizhou Zhujiang Rural Bank Co., Ltd., dated April 18, 2025</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>4.12*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea022807501ex4-12_universe.htm">English translation of the loan agreement between Jiangxi Universe and Jiangxi Rural Commercial Bank, dated November 23, 2023</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1809616/000121390022004359/f20f2021ex8-1_universephar.htm">List of subsidiaries of the Registrant (incorporated by reference to Exhibit 8.1 of our annual report on Form 20-F (file No. 001-40231), filed with the Securities and Exchange Commission on January 31, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1809616/000121390020022480/ea125531ex99-1_universepharm.htm">Code of Business Conduct and Ethics of the Registrant (incorporated by reference to Exhibit 99.1 of our Registration Statement on Form F-1 (file No. 333-248067), as amended, initially filed with the Securities and Exchange Commission on August 17, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1809616/000121390024007745/f20f2023ex11-2_universe.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insider Trading Policy <span style="text-decoration:underline">(incorporated by reference to Exhibit 11.2 of our annual report on Form 20-F (file No. 001-40231), filed with the Securities and Exchange Commission on January 30, 2024)</span></span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea022807501ex12-1_universe.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea022807501ex12-2_universe.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1**</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea022807501ex13-1_universe.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2**</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea022807501ex13-2_universe.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea022807501ex15-1_universe.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of AllBright Law
    Offices (Fuzhou)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.2*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea022807501ex15-2_universe.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Enrome LLP</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1809616/000121390024007745/f20f2023ex97-1_universe.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation Recovery Policy <span style="text-decoration:underline">(incorporated by reference to Exhibit 97.1 of our annual report on Form 20-F (file No. 001-40231), filed with the Securities and Exchange Commission on January 30, 2024)</span></span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">101.INS*</p></td>
    <td>&#160;</td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Inline XBRL Instance Document</p></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>101.SCH*</td>
    <td>&#160;</td>
    <td style="text-align: justify">Inline XBRL Taxonomy Extension Schema Document</td></tr>
<tr style="vertical-align: top; background-color: White">
    <td>101.CAL*</td>
    <td>&#160;</td>
    <td style="text-align: justify">Inline XBRL Taxonomy Extension Calculation Linkbase Document</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>101.DEF*</td>
    <td>&#160;</td>
    <td style="text-align: justify">Inline XBRL Taxonomy Extension Definition Linkbase Document</td></tr>
<tr style="vertical-align: top; background-color: White">
    <td>101.LAB*</td>
    <td>&#160;</td>
    <td style="text-align: justify">Inline XBRL Taxonomy Extension Label Linkbase Document</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>101.PRE*</td>
    <td>&#160;</td>
    <td style="text-align: justify">Inline XBRL Taxonomy Extension Presentation Linkbase Document</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: White">
    <td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104*</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed with this annual report on Form&#160;20-F</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished with this annual report on Form&#160;20-F</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The registrant hereby certifies that it meets
all of the requirements for filing on Form&#160;20-F and that it has duly caused and authorized the undersigned to sign this annual report
on its behalf.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Universe Pharmaceuticals INC</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 37%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gang Lai</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gang Lai</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, Director, and </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board of Directors</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: April 29, 2025</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONTENTS</b></span></td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PAGE(S)</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_001">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB&#160;ID: <ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-22426">6907</ix:nonNumeric>)</a></span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_003">CONSOLIDATED BALANCE SHEETS AS OF SEPTEMBER&#160;30, 2024 AND&#160;2023</a></span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_004">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS FOR THE YEARS ENDED SEPTEMBER&#160;30, 2024, 2023 AND&#160;2022</a></span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_005">CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY FOR THE YEARS ENDED SEPTEMBER&#160;30, 2024, 2023 AND&#160;2022</a></span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_006">CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER&#160;30, 2024, 2023 AND&#160;2022</a></span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_007">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</a></span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 117; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="fin_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and Shareholders of</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
Pharmaceuticals INC<b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AuditorOpinionTextBlock-c0_cont_1" escape="true" name="dei:AuditorOpinionTextBlock" id="ixv-15491"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_AuditorOpinionTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Universe Pharmaceuticals INC and its subsidiaries. (the
&#8220;Company&#8221;) as of September&#160;30, 2024 and 2023, the related consolidated statements of operations and comprehensive
loss, changes in shareholders&#8217; equity and cash flows for the year ended September 30, 2024, 2023 and 2022 and the related
notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial
statements present fairly, in all material respects, the financial position of the Company as of September 30, 2024 and 2023, and
the results of its operations and its cash flows for the year ended September 30, 2024, 2023 and 2022, in conformity with accounting
principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion
on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing
an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audit provides a reasonable basis for our opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-22427">Enrome LLP</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2024</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-15542"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">April 29, 2025</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNIVERSE
PHARMACEUTICALS INC AND SUBSIDIARIES</b></span></p><div>

</div><div><a id="fin_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">CURRENT ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 10pt">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-22428">29,497,693</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-22429">5,285,247</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-22430">12,905,821</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-22431">11,014,908</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Due from related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-22432">61,678</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Inventories, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-22433">1,737,054</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-22434">3,343,266</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Advance to suppliers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Supplies" scale="0" unitRef="usd" id="ixv-22435">978,203</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Supplies" scale="0" unitRef="usd" id="ixv-22436">180,643</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Prepayment for acquisition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="upc:PrepaymentForAcquisitionCurrent" scale="0" unitRef="usd" id="ixv-22437">3,426,535</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Other receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="0" unitRef="usd" id="ixv-22438">5,666,596</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="0" unitRef="usd" id="ixv-22439">1,920,251</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-22440">852,417</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-22441">37,178</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt; padding-left: 1.15pt">TOTAL CURRENT ASSETS</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-22442">51,637,784</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-22443">25,269,706</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Property, plant and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-22444">3,568,050</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-22445">3,699,965</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Prepayments made to a related party for purchase of property</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="upc:PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" scale="0" unitRef="usd" id="ixv-22446">2,279,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="upc:PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" scale="0" unitRef="usd" id="ixv-22447">2,192,982</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Prepayments for construction in progress</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="upc:PrepaymentsForConstructionInProgress" scale="0" unitRef="usd" id="ixv-22448">9,492,205</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="upc:PrepaymentsForConstructionInProgress" scale="0" unitRef="usd" id="ixv-22449">9,092,996</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd" id="ixv-22450">262,878</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd" id="ixv-22451">148,584</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Investment in equity securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd" id="ixv-22452">712,494</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd" id="ixv-22453">685,307</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="0" unitRef="usd" id="ixv-22454">599,078</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Prepaid expenses-related party, non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-22455">35,864</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">TOTAL NONCURRENT ASSETS</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-22456">16,315,609</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-22457">16,454,776</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">TOTAL ASSETS</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-22458">67,953,393</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-22459">41,724,482</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Short-term bank loans</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-22460">5,856,703</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-22461">5,482,456</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd" id="ixv-22462">4,914,762</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd" id="ixv-22463">4,585,283</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Taxes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="0" unitRef="usd" id="ixv-22464">1,021,181</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="0" unitRef="usd" id="ixv-22465">434,758</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Due to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-22466">6,900,584</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-22467">540,096</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Accrued expenses and other current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-22468">1,619,739</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-22469">2,711,736</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt; padding-left: 1.15pt">TOTAL CURRENT LIABILITIES</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-22470">20,312,969</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-22471">13,754,329</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Long-term bank loans</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermLoansFromBank" scale="0" unitRef="usd" id="ixv-22472">2,137,483</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL LIABILITIES</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-22473">22,450,452</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-22474">13,754,329</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">COMMITMENTS AND CONTINGENCIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 0.25in">Ordinary shares, $<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" id="ix_6_fact" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" id="ix_7_fact" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">11.25</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_2_fact" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_3_fact" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">11,250,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_4_fact" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_5_fact" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">42,880</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_8_fact" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_9_fact" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">6,062</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September 30, 2024 and 2023, respectively *</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">482,400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">67,973</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-22485">53,864,720</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-22486">29,279,155</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Statutory reserve</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="upc:StatutoryReserve" scale="0" unitRef="usd" id="ixv-22487">2,439,535</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="upc:StatutoryReserve" scale="0" unitRef="usd" id="ixv-22488">2,439,535</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-22489">10,171,568</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-22490">1,444,270</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated other comprehensive loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-22491">1,112,146</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-22492">2,372,240</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">TOTAL SHAREHOLDERS&#8217; EQUITY</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-22493">45,502,941</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-22494">27,970,153</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-22495">67,953,393</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-22496">41,724,482</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retrospectively restated for effect of 15-for-1 and 40-for-1 share
consolidations.</span></ix:footnote></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNIVERSE
PHARMACEUTICALS INC AND SUBSIDIARIES</b></span></p><div>

</div><div><a id="fin_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Revenue</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-22497">23,024,458</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-22498">32,308,735</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-22499">40,143,151</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Cost of revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd" id="ixv-22500">16,952,556</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd" id="ixv-22501">21,993,601</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd" id="ixv-22502">18,251,815</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Gross profit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-22503">6,071,902</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-22504">10,315,134</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-22505">21,891,336</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd" id="ixv-22506">8,170,975</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd" id="ixv-22507">6,783,703</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd" id="ixv-22508">19,083,135</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-22509">2,889,652</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-22510">2,638,984</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-22511">2,183,270</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-22512">3,031,115</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-22513">4,858,548</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-22514">7,644,375</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-22515">14,091,742</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-22516">14,281,235</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-22517">28,910,780</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Loss from operations</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-22518">8,019,840</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-22519">3,966,101</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-22520">7,019,444</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other income (expenses)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" unitRef="usd" id="ixv-22521">278,172</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" unitRef="usd" id="ixv-22522">156,788</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" unitRef="usd" id="ixv-22523">162,400</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expense), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" unitRef="usd" id="ixv-22524">145,476</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-22525">235,614</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" unitRef="usd" id="ixv-22526">48,940</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity investment income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" unitRef="usd" id="ixv-22527">31,942</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" unitRef="usd" id="ixv-22528">31,072</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" unitRef="usd" id="ixv-22529">38,588</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total other expense, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-22530">100,754</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-22531">361,330</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-22532">74,872</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss before income tax expense</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-22533">8,120,594</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-22534">4,327,431</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-22535">7,094,316</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Income tax expense</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-22536">606,704</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-22537">2,253,593</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-22538">815,322</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net loss</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-22539">8,727,298</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-22540">6,581,024</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-22541">7,909,638</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other comprehensive income (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" sign="-" unitRef="usd" id="ixv-22542">1,260,094</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" unitRef="usd" id="ixv-22543">779,351</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" unitRef="usd" id="ixv-22544">3,752,143</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Comprehensive loss</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-22545">7,467,204</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-22546">7,360,375</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-22547">11,661,781</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.1pt; padding-left: 0.1pt">Net loss per share - Basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-22548"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-22549">626.96</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-22550"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-22551">1,089.21</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-22552"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-22553">1,309.11</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Weighted average number of shares outstanding used in calculating basic and diluted loss per share *</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" id="ix_10_fact" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" id="ix_11_fact" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">13,920</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_12_fact" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_13_fact" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">6,042</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_14_fact" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_15_fact" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">6,042</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retrospectively restated for effect of 15-for-1 and 40-for-1 share
consolidations.</span></ix:footnote></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNIVERSE
PHARMACEUTICALS INC AND SUBSIDIARIES</b></span></p><div>

</div><div><a id="fin_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE YEARS ENDED SEPTEMBER 30, 2024, 2023 AND 2022</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Ordinary Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Additional<br/> Paid-in</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Statutory</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Retained Earnings<br/> (Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated<br/> Other<br/> Comprehensive</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> Shareholders&#8217;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares *</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Reserve</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Income (Loss)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40.5%; font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance as of September 30, 2021</td><td style="width: 0.5%; font-weight: bold">&#160;</td>
    <td style="width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" id="ix_16_fact" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">6,042</ix:nonFraction></td><td style="width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold">&#160;</td>
    <td style="width: 0.5%; font-weight: bold; text-align: left">$</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-22561">67,973</ix:nonFraction></td><td style="width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold">&#160;</td>
    <td style="width: 0.5%; font-weight: bold; text-align: left">$</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-22562">29,279,155</ix:nonFraction></td><td style="width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold">&#160;</td>
    <td style="width: 0.5%; font-weight: bold; text-align: left">$</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-22563">2,439,535</ix:nonFraction></td><td style="width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold">&#160;</td>
    <td style="width: 0.5%; font-weight: bold; text-align: left">$</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-22564">13,046,392</ix:nonFraction></td><td style="width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold">&#160;</td>
    <td style="width: 0.5%; font-weight: bold; text-align: left">$</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-22565">2,159,254</ix:nonFraction></td><td style="width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold">&#160;</td>
    <td style="width: 0.5%; font-weight: bold; text-align: left">$</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-22566">46,992,309</ix:nonFraction></td><td style="width: 0.5%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-22567">7,909,638</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-22568">7,909,638</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Foreign currency translation adjustment</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" unitRef="usd" id="ixv-22569">3,752,143</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" unitRef="usd" id="ixv-22570">3,752,143</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance as of September 30, 2022</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" id="ix_17_fact" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">6,042</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-22572">67,973</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-22573">29,279,155</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-22574">2,439,535</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-22575">5,136,754</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-22576">1,592,889</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-22577">35,330,528</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-22578">6,581,024</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-22579">6,581,024</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Statutory reserve</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" unitRef="usd" id="ixv-22580">779,351</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" unitRef="usd" id="ixv-22581">779,351</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance as of September 30, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" id="ix_18_fact" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">6,042</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-22583">67,973</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-22584">29,279,155</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-22585">2,439,535</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-22586">1,444,270</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-22587">2,372,240</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-22588">27,970,153</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Issuance of ordinary shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" id="ix_19_fact" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">33,333</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-22590">374,996</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-22591">24,624,996</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-22592">24,999,992</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Reverse share-split adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" id="ix_20_fact" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="0" unitRef="shares">3,505</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="upc:StockIssuedDuringPeriodValueReverseShareSplitAdjustment" scale="0" unitRef="usd" id="ixv-22594">39,431</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="upc:StockIssuedDuringPeriodValueReverseShareSplitAdjustment" scale="0" sign="-" unitRef="usd" id="ixv-22595">39,431</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-22596">8,727,298</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-22597">8,727,298</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" sign="-" unitRef="usd" id="ixv-22598">1,260,094</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" sign="-" unitRef="usd" id="ixv-22599">1,260,094</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance as of September 30, 2024</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" id="ix_21_fact" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">42,880</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-22601">482,400</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-22602">53,864,720</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-22603">2,439,535</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-22604">10,171,568</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-22605">1,112,146</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-22606">45,502,941</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><ix:footnote id="ix_2_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retrospectively restated for effect of 15-for-1 and 40-for-1 share
consolidations.</span></ix:footnote></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNIVERSE
PHARMACEUTICALS INC AND SUBSIDIARIES</b></span></p><div>

</div><div><a id="fin_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cash flows from operating activities</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 10pt">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-22607">8,727,298</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-22608">6,581,024</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-22609">7,909,638</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Adjustments to reconcile net income to net cash provided by (used in) operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd" id="ixv-22610">485,734</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd" id="ixv-22611">508,785</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd" id="ixv-22612">533,949</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Loss from disposal of property, plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="0" sign="-" unitRef="usd" id="ixv-22613">3,958</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="0" sign="-" unitRef="usd" id="ixv-22614">114</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="0" sign="-" unitRef="usd" id="ixv-22615">983</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Allowance for doubtful accounts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" unitRef="usd" id="ixv-22616">131,581</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Allowance (reversal) of inventory reserve</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryLIFOReservePeriodCharge" scale="0" unitRef="usd" id="ixv-22617">50,651</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryLIFOReservePeriodCharge" scale="0" sign="-" unitRef="usd" id="ixv-22618">49,166</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryLIFOReservePeriodCharge" scale="0" unitRef="usd" id="ixv-22619">15,774</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Deferred income tax expense (benefit)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="upc:ChangeInFairValueOfShorttermInvestments" scale="0" sign="-" unitRef="usd" id="ixv-22620">606,704</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="upc:ChangeInFairValueOfShorttermInvestments" scale="0" sign="-" unitRef="usd" id="ixv-22621">1,567,656</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="upc:ChangeInFairValueOfShorttermInvestments" scale="0" unitRef="usd" id="ixv-22622">542,375</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd" id="ixv-22623">1,547,834</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" sign="-" unitRef="usd" id="ixv-22624">4,718,118</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd" id="ixv-22625">1,526,243</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Inventory, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" sign="-" unitRef="usd" id="ixv-22626">1,643,131</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" unitRef="usd" id="ixv-22627">1,183,823</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" sign="-" unitRef="usd" id="ixv-22628">16,586</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Advance to suppliers, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidSupplies" scale="0" unitRef="usd" id="ixv-22629">769,911</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidSupplies" scale="0" unitRef="usd" id="ixv-22630">170,016</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidSupplies" scale="0" sign="-" unitRef="usd" id="ixv-22631">2,681,214</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Prepayment for advertising</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidAdvertising" scale="0" sign="-" unitRef="usd" id="ixv-22632">7,385,695</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Advances to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" scale="0" unitRef="usd" id="ixv-22633">236,982</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Other receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="0" unitRef="usd" id="ixv-22634">158,011</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="0" sign="-" unitRef="usd" id="ixv-22635">391,568</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="0" unitRef="usd" id="ixv-22636">1,030,121</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" unitRef="usd" id="ixv-22637">792,675</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" sign="-" unitRef="usd" id="ixv-22638">696,147</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" unitRef="usd" id="ixv-22639">659,017</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="0" unitRef="usd" id="ixv-22640">947,964</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Prepaid expenses-related party, non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="upc:IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent" scale="0" sign="-" unitRef="usd" id="ixv-22641">36,321</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" unitRef="usd" id="ixv-22642">143,747</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" unitRef="usd" id="ixv-22643">1,641,426</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" sign="-" unitRef="usd" id="ixv-22644">1,919,691</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Taxes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="0" unitRef="usd" id="ixv-22645">554,425</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="0" unitRef="usd" id="ixv-22646">280,939</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="0" sign="-" unitRef="usd" id="ixv-22647">904,127</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Accrued expenses and other current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" sign="-" unitRef="usd" id="ixv-22648">1,167,206</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" unitRef="usd" id="ixv-22649">244,015</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" unitRef="usd" id="ixv-22650">2,318,474</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash (used in) provided by operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-22651">9,506,683</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" unitRef="usd" id="ixv-22652">1,116,775</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-22653">1,301,555</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Purchases of property, plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-22654">208,320</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-22655">44,169</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-22656">93,703</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Prepayments for construction in progress</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="upc:ProceedsFromPaymentForConstructionInProgress" scale="0" sign="-" unitRef="usd" id="ixv-22657">37,478</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="upc:ProceedsFromPaymentForConstructionInProgress" scale="0" unitRef="usd" id="ixv-22658">523</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Purchase of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" unitRef="usd" id="ixv-22659">117,291</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 21.3pt">Prepayment for acquisition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" unitRef="usd" id="ixv-22660">3,814,925</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 21.3pt">Proceeds from disposal of property, plant and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-22661">1,804</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-22662">361,285</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-22663">44,169</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-22664">3,908,105</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net proceeds from issuance of ordinary shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-22665">24,999,992</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Proceeds from bank loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromBankDebt" scale="0" unitRef="usd" id="ixv-22666">7,787,016</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromBankDebt" scale="0" unitRef="usd" id="ixv-22667">5,671,104</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromBankDebt" scale="0" unitRef="usd" id="ixv-22668">4,272,716</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Repayment of bank loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-22669">5,552,240</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-22670">3,969,773</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-22671">4,272,716</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Proceeds from (prepayments for) related parties borrowings</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-22672">6,719,557</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" scale="0" sign="-" unitRef="usd" id="ixv-22673">3,091,977</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-22674">3,317,943</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by (used in) financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-22675">33,954,325</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" sign="-" unitRef="usd" id="ixv-22676">1,390,646</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-22677">3,317,943</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of exchange rate changes on cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-22678">126,089</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" sign="-" unitRef="usd" id="ixv-22679">108,171</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" sign="-" unitRef="usd" id="ixv-22680">474,733</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net increase (decrease) in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd" id="ixv-22681">24,212,446</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd" id="ixv-22682">426,211</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd" id="ixv-22683">2,366,450</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash, beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-22684">5,285,247</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-22685">5,711,458</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-22686">8,077,908</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Cash, end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-22687">29,497,693</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-22688">5,285,247</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-22689">5,711,458</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 20pt">Cash paid for interest</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-22690">304,516</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-22691">190,184</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-22692">199,852</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 20pt">Cash paid for income tax</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="0" unitRef="usd" id="ixv-22693">863,800</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="0" unitRef="usd" id="ixv-22694">2,748,629</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNIVERSE
PHARMACEUTICALS INC AND SUBSIDIARIES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="fin_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_NatureOfOperations-c0_cont_1" escape="true" name="us-gaap:NatureOfOperations" id="ixv-18026"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
1 &#8212; ORGANIZATION AND BUSINESS DESCRIPTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Universe
Pharmaceuticals INC (&#8220;Universe INC&#8221; or the &#8220;Company&#8221;) was incorporated under the laws of the Cayman Islands on
<ix:nonNumeric contextRef="c45" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation" id="ixv-22695">December 11, 2019</ix:nonNumeric> as an exempted company with limited liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Universe
INC owns&#160;<ix:nonFraction contextRef="c46" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-22696">100</ix:nonFraction>% equity interest of Universe Pharmaceuticals (International) Group (&#8220;Universe HK&#8221;), an entity incorporated
on <ix:nonNumeric contextRef="c47" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation" id="ixv-22697">May 21, 2014</ix:nonNumeric> in accordance with the laws and regulations in Hong Kong.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Jiangxi
Universe Pharmaceuticals Technology Co., Ltd. (&#8220;Universe Technology&#8221;) was formed on April 8, 2019, as a wholly foreign-owned
enterprise (&#8220;WFOE&#8221;) in the People&#8217;s Republic of China (the &#8220;PRC&#8221; or &#8220;China&#8221;). </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Universe
INC, Universe HK and Universe Technology are currently not engaging in any active business operations and are merely acting as holding
companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Jiangxi
Universe Pharmaceuticals Co., Ltd.&#160;(&#8220;Jiangxi Universe&#8221;) was incorporated on <ix:nonNumeric contextRef="c48" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation" id="ixv-22698">March 2, 1998</ix:nonNumeric> in accordance with PRC laws
and is engaged in the research and development and manufacturing of modernized traditional Chinese medicines.&#160;Jiangxi Universe owns&#160;<ix:nonFraction contextRef="c49" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-22699">100</ix:nonFraction>%
of the equity interests of Jiangxi Universe Pharmaceuticals Commercial Trade Co., Ltd. (&#8220;Universe Trade&#8221;), which was incorporated
on March 10, 2010 for the purposes of handling the sales and distribution of the pharmaceutical products manufactured by Jiangxi Universe.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Reorganization</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">A
reorganization of the Company&#8217;s legal structure (the &#8220;Reorganization&#8221;) was completed on December 11, 2019. The Reorganization
involved the incorporation of Universe INC and Universe Technology, and the transfer of&#160;<ix:nonFraction contextRef="c50" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-22700">100</ix:nonFraction>% of the equity interests of Jiangxi
Universe to Universe Technology. Consequently, Universe INC, through its subsidiary Universe HK, directly controls Universe Technology
and Jiangxi Universe, and became the ultimate holding company of all other entities mentioned above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Reorganization has been accounted for as a recapitalization among entities under common control, since the same controlling shareholders
controlled all these entities before and after the Reorganization. Results of operations for the periods presented eliminate the effects
of intra-entity transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
March 25, 2021, the Company closed its initial public offering (the &#8220;IPO&#8221;) of&#160;<ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-22701">5,000,000</ix:nonFraction>&#160;ordinary shares, par value
$<ix:nonFraction contextRef="c52" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22702">0.003125</ix:nonFraction>&#160;per share at a public offering price of $<ix:nonFraction contextRef="c53" decimals="2" format="ixt:num-dot-decimal" name="upc:PublicOfferingPrice" scale="0" unitRef="usdPershares" id="ixv-22703">5.00</ix:nonFraction>&#160;per share. On March 29, 2021, the underwriter exercised in full its
over-allotment option to purchase an additional&#160;<ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares" id="ixv-22704">750,000</ix:nonFraction>&#160;ordinary shares. The closing for the sale of the over-allotment shares
took place on September 30, 2021. Gross proceeds from the IPO totaled $<ix:nonFraction contextRef="c55" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" unitRef="usd" id="ixv-22705">28.75</ix:nonFraction>&#160;million. Net proceeds of the IPO, including over-allotment
shares, were approximately $<ix:nonFraction contextRef="c56" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" unitRef="usd" id="ixv-22706">25.6</ix:nonFraction>&#160;million. In connection with the IPO, the Company&#8217;s ordinary shares began trading on the Nasdaq
Global Market under the symbol &#8220;UPC&#8221; on March 23, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
May 12, 2021, through the Company&#8217;s PRC subsidiary, Jiangxi Universe, the Company established an indirect wholly controlled subsidiary,
Guangzhou Universe Hanhe Medical Research Co., Ltd. (&#8220;Universe Hanhe&#8221;) in Guangzhou City, China, for the business purpose
of conducting research and development of new pharmaceutical products in order to diversify the Company&#8217;s product offerings. As
of September 30, 2024 and as of the date of this report, Universe Hanhe has no active business operations.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_2" id="_NatureOfOperations-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 3, 2023, the Company held an annual general meeting of shareholders at which shareholders, among other things, resolved:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with immediate effect, to increase the Company&#8217;s authorized share capital from US$<ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalUnits" scale="0" unitRef="usd" id="ixv-22707">312,500</ix:nonFraction> divided into <ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22708">90,000,000</ix:nonFraction> ordinary shares of par value US$<ix:nonFraction contextRef="c57" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22709">0.003125</ix:nonFraction> each and <ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22710">10,000,000</ix:nonFraction> preferred shares of par value US$<ix:nonFraction contextRef="c57" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22711">0.003125</ix:nonFraction> each, to US$<ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalUnits" scale="0" unitRef="usd" id="ixv-22712">3,125,000</ix:nonFraction> divided into <ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22713">900,000,000</ix:nonFraction> ordinary shares of par value US$<ix:nonFraction contextRef="c61" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22714">0.003125</ix:nonFraction> each and <ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22715">100,000,000</ix:nonFraction> preferred shares of par value US$<ix:nonFraction contextRef="c61" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22716">0.003125</ix:nonFraction> each;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that, conditional upon the approval of the board of directors of the Company in its sole discretion, with effect as of the date the board of directors of the Company may determine, the authorized, issued and outstanding shares of the Company be consolidated by consolidating each 10 shares of the Company, or such lesser whole share amount as the board of directors may determine in its sole discretion, such amount not to be less than 2, into 1 share of the Company, with such consolidated shares having the same rights and being subject to the same restrictions (save as to nominal value) as the then existing shares of par value US$<ix:nonFraction contextRef="c40" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22717">0.003125</ix:nonFraction> each in the capital of the Company (the &#8220;2023 Share Consolidation&#8221;); and</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that, upon the effectiveness
    of the 2023 Share Consolidation, the Company adopt amended and restated articles of association, in substantially the form set out
    in Annex B in the proxy statement dated May 24, 2023, in substitution for and to the exclusion of, the memorandum of association
    of the Company in effect immediately prior to effectiveness of the Share Consolidation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors of the Company resolved to effect the 2023 Share Consolidation on July 27, 2023 with the authorized, issued and outstanding
shares to be consolidated on a six (6) for one (1) ratio, which had the effect of reducing the number of: (a) authorized ordinary shares
from <ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22718">900,000,000</ix:nonFraction> ordinary shares with a par value of US$<ix:nonFraction contextRef="c62" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22719">0.003125</ix:nonFraction> per share to <ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22720">150,000,000</ix:nonFraction> ordinary shares with a par value of US$<ix:nonFraction contextRef="c64" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22721">0.01875</ix:nonFraction>
per share; (b) issued and outstanding ordinary shares from <ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-22722"><ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-22723">21,750,000</ix:nonFraction></ix:nonFraction> ordinary shares with a par value of US$<ix:nonFraction contextRef="c65" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22724">0.003125</ix:nonFraction> per share to <ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-22725"><ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-22726">3,625,000</ix:nonFraction></ix:nonFraction>
ordinary shares with a par value of US$<ix:nonFraction contextRef="c66" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22727">0.01875</ix:nonFraction> per share; and (c) authorized preferred shares from <ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22728">100,000,000</ix:nonFraction> preferred shares with
a par value of US$<ix:nonFraction contextRef="c67" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22729">0.003125</ix:nonFraction> per share to <ix:nonFraction contextRef="c68" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22730">16,666,666.6666</ix:nonFraction> preferred shares with a par value of US$<ix:nonFraction contextRef="c68" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22731">0.01875</ix:nonFraction> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 15, 2024, the Company closed its self-underwritten public offering of <ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-22732">20,000,000</ix:nonFraction> ordinary shares, par value $<ix:nonFraction contextRef="c70" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22733">0.01875</ix:nonFraction> per share.
The ordinary shares were priced at $<ix:nonFraction contextRef="c71" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-22734">1.25</ix:nonFraction> per share. The Company raised a total of $<ix:nonFraction contextRef="c72" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" unitRef="usd" id="ixv-22735">25</ix:nonFraction> million through that offering, before deducting
offering-related expenses, and net proceeds of $<ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" unitRef="usd" id="ixv-22736">24.625</ix:nonFraction> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 27, 2024, the Company held an annual general meeting of shareholders at which shareholders, among other things, resolved:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with immediate effect, to increase the Company&#8217;s authorized share capital from US$<ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalUnits" scale="0" unitRef="usd" id="ixv-22737">3,125,000</ix:nonFraction> divided into <ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22738">150,000,000</ix:nonFraction> ordinary shares of par value US$<ix:nonFraction contextRef="c74" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22739">0.01875</ix:nonFraction> each and <ix:nonFraction contextRef="c75" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22740">16,666,666.6666</ix:nonFraction> preferred shares of par value US$<ix:nonFraction contextRef="c76" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22741">0.01875</ix:nonFraction> each, to US$<ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalUnits" scale="0" unitRef="usd" id="ixv-22742">140,625,000</ix:nonFraction> divided into <ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockDividendsShares" scale="0" unitRef="shares" id="ixv-22743">6,750,000,000</ix:nonFraction> ordinary shares of par value US$<ix:nonFraction contextRef="c79" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22744">0.01875</ix:nonFraction> each and <ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22745">750,000,000</ix:nonFraction> preferred shares of par value US$<ix:nonFraction contextRef="c76" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22746">0.01875</ix:nonFraction> each (the &#8220;Authorized Share Capital Increase&#8221;);</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that, subject to and immediately
    following the Authorized Share Capital Increase being effected, the Company adopt an amended and restated memorandum of association
    in substitution for, and to the exclusion of, the Company&#8217;s existing memorandum of association, to reflect the Authorized Share
    Capital Increase; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that, conditional upon
    the approval of the board of directors of the Company in its sole discretion, with effect as of the date the board of directors of
    the Company may determine, the authorized, issued, and outstanding shares of the Company (collectively, the &#8220;Shares&#8221;)
    be consolidated by consolidating each 15 Shares of the Company, or such lesser whole share amount as the Company&#8217;s board of
    directors may determine in its sole discretion, such amount not to be less than 2, into 1 Share of the Company, with such consolidated
    Shares having the same rights and being subject to the same restrictions (save as to nominal value) as the existing Shares of such
    class as set out in the Company&#8217;s memorandum and articles of association (the &#8220;2024 Share Consolidation&#8221;).</span></td></tr>
  </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_NatureOfOperations-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 12, 2024, the Company effected a share consolidation of <ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-22747">15</ix:nonFraction> ordinary shares with par value of US$<ix:nonFraction contextRef="c80" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-22748">0.01875</ix:nonFraction> per share each in the
Company&#8217;s issued and unissued share capital into one (<ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares" id="ixv-22749">1</ix:nonFraction>) ordinary share with par value of US$<ix:nonFraction contextRef="c82" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22750">0.28125</ix:nonFraction>. All fractional shares were
rounded up to the whole number of shares. Immediately following the 2024 Share Consolidation, the authorized share capital of the Company
was US$<ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalUnits" scale="0" unitRef="usd" id="ixv-22751">140,625,000</ix:nonFraction> divided into <ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22752">450,000,000</ix:nonFraction> ordinary shares, par value US$<ix:nonFraction contextRef="c80" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22753">0.28125</ix:nonFraction> per share and <ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22754">50,000,000</ix:nonFraction> preferred shares, par value
US$<ix:nonFraction contextRef="c83" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22755">0.28125</ix:nonFraction> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 24, 2025, the Company effected a share consolidation
of <ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-22756">40</ix:nonFraction> ordinary shares with par value of US$<ix:nonFraction contextRef="c84" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-22757">0.28125</ix:nonFraction> per share each in the Company&#8217;s issued and unissued share capital into one ordinary
share with par value of US$<ix:nonFraction contextRef="c84" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22758">11.25</ix:nonFraction>. All fractional shares were rounded up to the whole number of shares (the &#8220;2025 Share Consolidation&#8221;).
Immediately following the Share Consolidation, the authorized share capital of the Company was US$<ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalUnits" scale="0" unitRef="usd" id="ixv-22759">140,625,000</ix:nonFraction> divided into <ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22760">11,250,000</ix:nonFraction>
ordinary shares, par value US$<ix:nonFraction contextRef="c84" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22761">11.25</ix:nonFraction> per share and <ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22762">1,250,000</ix:nonFraction> preferred shares, par value US$<ix:nonFraction contextRef="c84" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22763">11.25</ix:nonFraction> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company&#8217;s consolidated
financial statements were retrospectively restated for effect of the 15-for-1 and 40-for-1 share consolidations. Giving effect to the
share consolidations, there were <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-22764"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-22765">42,880</ix:nonFraction></ix:nonFraction> ordinary shares issued and outstanding as of September 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" id="ixv-18189"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Details
of the subsidiaries of the Company as of September 30, 2024 are set out below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date of</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Place of</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>% of</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of Entity</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporation</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporation</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal Activities</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe INC</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c85" format="ixt:date-monthname-day-year-en" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate" id="ixv-18247"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 11, 2019</span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c85" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-18252"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cayman Islands</span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent, <ix:nonFraction contextRef="c85" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-22766">100</ix:nonFraction>%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c85" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-18261"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></ix:nonNumeric></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe HK</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 18%; text-align: center"><ix:nonNumeric contextRef="c47" format="ixt:date-monthname-day-year-en" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate" id="ixv-18288"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 21, 2014</span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 15%; text-align: center"><ix:nonNumeric contextRef="c47" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-18293"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c47" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-22767">100</ix:nonFraction>%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 28%; text-align: center"><ix:nonNumeric contextRef="c47" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-18302"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></ix:nonNumeric></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe Technology</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c86" format="ixt:date-monthname-day-year-en" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate" id="ixv-18329"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 18, 2019</span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c86" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-18334"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC</span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c86" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-22768">100</ix:nonFraction>%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c86" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-18343"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WFOE, Investment holding</span></ix:nonNumeric></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Universe</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c48" format="ixt:date-monthname-day-year-en" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate" id="ixv-18370"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2, 1998</span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c48" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-18375"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC</span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c48" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-22769">100</ix:nonFraction>%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c48" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-18384"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development and manufacturing of modernized traditional Chinese medicines</span></ix:nonNumeric></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe Trade</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c87" format="ixt:date-monthname-day-year-en" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate" id="ixv-18411"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 10, 2010</span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c87" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-18416"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC</span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c87" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-22770">100</ix:nonFraction>%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c87" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-18425"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales of modernized traditional Chinese medicines</span></ix:nonNumeric></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe Hanhe</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c88" format="ixt:date-monthname-day-year-en" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate" id="ixv-18452"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 12, 2021</span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c88" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-18457"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC</span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c88" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-22771">100</ix:nonFraction>%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c88" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-18466"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development of new pharmaceutical products</span></ix:nonNumeric></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company, through its wholly-owned subsidiaries, is primarily engaged in the development, manufacturing and sale of traditional Chinese
medicines derivatives (&#8220;TCMD&#8221;) products targeted to the elderly to address their physical conditions in the aging process
and to promote their general well-being. In addition, the Company also sells biochemical drugs, medical instruments, traditional Chinese
medicine pieces products and dietary supplements (collectively, &#8220;third-party products&#8221;). All of these TCMD and third-party
products are currently sold to customers including pharmaceutical companies, hospitals, clinics and drugstore chains throughout China.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-18476"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
2 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-18482"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration:underline">Basis
of Presentation and Principles of Consolidation</span></i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_2" id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
accompanying consolidated financial statements include the Company and its subsidiaries, which include Universe HK, Universe Technology,
Jiangxi Universe, Universe Trade and Universe Hanhe. All inter-company balances and transactions are eliminated upon consolidation.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">A
subsidiary is an entity in which (i) the Company directly or indirectly controls more than <ix:nonFraction contextRef="c89" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" unitRef="pure" id="ixv-22772">50</ix:nonFraction>% of the voting power; or (ii) the Company
has the power to appoint or remove the majority of the members of the board of directors or to cast a majority of votes at the meetings
of the board of directors or to govern the financial and operating policies of the investee pursuant to a statute or under an agreement
among the shareholders or equity holders.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="upc_ReclassificationsPolicyTextBlock-c0_cont_1" escape="true" name="upc:ReclassificationsPolicyTextBlock" id="ixv-18500"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Reclassifications</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<ix:continuation id="upc_ReclassificationsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Certain
amounts on the prior-years&#8217; consolidated balance sheets and cash flows were reclassified to conform to current-year presentation,
with no effect on ending shareholders&#8217; equity.</span></p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-18529"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Uses
of estimates</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
preparing the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America
(&#8220;U.S. GAAP&#8221;), management makes estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses
during the reporting period. These estimates are based on information as of the date of the consolidated financial statements. Significant
estimates required to be made by management include, but are not limited to, the allowance for estimated uncollectible receivables, the
realizability of advance to suppliers, inventory valuations, useful lives of property, plant and equipment, intangible assets, the recoverability
of long-lived assets, provision necessary for contingent liabilities, revenue recognition and realization of deferred tax assets. Actual
results could differ from those estimates.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-18541"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Risks
and Uncertainties</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
business operations of the Company are located in the PRC. Accordingly, the Company&#8217;s business, financial condition, and results
of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC
economy. The Company&#8217;s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC.
Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations
including its organization and structure disclosed in Note 1, this may not be indicative of future results.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_3" id="_ConcentrationRiskCreditRisk-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
development and commercialization of new pharmaceutical products is highly competitive, and the industry currently is characterized by
rapidly changing technologies, significant competition and a strong emphasis on intellectual property. The Company may face competition
with respect to its current and future pharmaceutical product candidates from major pharmaceutical companies in China.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company&#8217;s business, financial condition and results of operations may also be negatively impacted by risks related to natural disasters,
extreme weather conditions, health epidemics and other catastrophic incidents, which could significantly disrupt the Company&#8217;s
operations.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-18563"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Cash</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Cash
includes currency on hand and deposits held by banks that can be added or withdrawn without limitation. The Company maintains most of
its bank accounts in the PRC. Cash maintained in banks within the People&#8217;s Republic of China of less than RMB<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" unitRef="cny" id="ixv-22773">0.5</ix:nonFraction> million (equivalent
to $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-22774">71,249</ix:nonFraction>) per bank are covered by &#8220;deposit insurance regulation&#8221; promulgated by the State Council of the People&#8217;s
Republic of China.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1" escape="true" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="ixv-18577"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Accounts
receivable, net</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Accounts receivables are presented
net of allowance for doubtful accounts. The Company determines the adequacy of reserves for doubtful accounts based on individual account
analysis and historical collection trends. The Company establishes a provision for doubtful receivables when there is objective evidence
that the Company may not be able to collect amounts due. The allowance is based on management&#8217;s best estimate of specific losses
on individual exposures, as well as a provision on historical trends of collections. Actual amounts received may differ from management&#8217;s
estimate of credit worthiness and the economic environment. Delinquent account balances are written-off against the allowance for doubtful
accounts after management has determined that collection is not probable. </span>Allowance for uncollectable balances amounted to $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" unitRef="usd" id="ixv-22775">135,082</ix:nonFraction>
and $<span style="-sec-ix-hidden: hidden-fact-62">Nil</span> as of September 30, 2024 and 2023, respectively.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_InventoryPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryPolicyTextBlock" id="ixv-18607"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Inventories,
net</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_InventoryPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Inventories
are stated at net realizable value using weighted average method. Costs include the cost of raw materials, freight, direct labor and
related production overhead. Any excess of the cost over the net realizable value of each item of inventories is recognized as a provision
for diminution in the value of inventories. Net realizable value is the estimated selling price in the normal course of business less
any costs to complete and sell products. The Company evaluates inventories on a quarterly basis for its net realizable value adjustments,
and reduces the carrying value of those inventories that are obsolete or in excess of the forecasted usage to their estimated net realizable
value based on various factors including aging, expiration dates, as applicable, taking into consideration historical and expected future
product sales. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We recorded inventory reserve of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" unitRef="usd" id="ixv-22776">124,512</ix:nonFraction>
and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" unitRef="usd" id="ixv-22777">69,746</ix:nonFraction> as of September 30, 2024 and 2023, respectively.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="upc_AdvancesToSuppliersNetPolicyTextBlock-c0_cont_1" escape="true" name="upc:AdvancesToSuppliersNetPolicyTextBlock" id="ixv-18622"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Advances
to suppliers, net</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="upc_AdvancesToSuppliersNetPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Advances
to suppliers represent prepayments made to ensure continuous high-quality supplies and favorable purchase prices of raw materials. These
advances are directly related to the purchases of raw materials used to fulfill sales orders. The Company is required from time to time
to make cash advances when placing its purchase orders. These advances are settled upon suppliers delivering raw materials to the Company
when the transfer of ownership occurs. The Company reviews its advances to suppliers on a periodic basis and makes general and specific
allowances when there is doubt as to the ability of a supplier to provide supplies to the Company or refund an advance. As of September
30, 2024 and 2023, the Company recorded no allowance for doubtful accounts, as the Company believed that all advances to suppliers were
fully realizable.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_1" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="ixv-18635"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Fair
value of financial instruments</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_2" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The
hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of
inputs used to measure fair value are as follows:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_3" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 62px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&#8201;&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8201;inputs to the valuation
    methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_4" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 62px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2&#8201;&#8212;&#8201;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inputs to the valuation
    methodology include quoted prices for similar assets and liabilities in active markets, quoted market prices for identical or similar
    assets in markets that are not active, inputs other than quoted prices that are observable and inputs derived from or corroborated
    by observable market data.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_5" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 62px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3&#8201;&#8212;&#8201;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inputs to the valuation
    methodology are unobservable.</span></td></tr>
  </table></ix:continuation></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:continuation id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Unless
otherwise disclosed, the fair value of the Company&#8217;s financial instruments, including cash, accounts receivable, inventories, advances
to suppliers, prepaid expenses and other current assets, accounts payable, short-term bank loans, accrued expenses and other current
liabilities, taxes payable and due to related parties, approximate the fair value of the respective assets and liabilities as of September
30, 2024 based upon the short-term nature of the assets and liabilities. The Company&#8217;s investment in equity securities is accounted
for using the measurement alternative in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 321, &#8220;Investments&#8212;Equity
Securities&#8221; (&#8220;ASC 321&#8221;), which also approximates its recorded value.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-18706"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property,
plant and equipment</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Property,
plant and equipment are stated at cost less accumulated depreciation. <ix:nonNumeric contextRef="c0" continuedAt="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock-c0_cont_1" escape="true" name="upc:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" id="ixv-22778">Depreciation of property, plant and equipment is provided using
the straight-line method over their expected useful lives, as follows:</ix:nonNumeric></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock-c0_cont_1"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    life</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 89%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Buildings</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c93" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-22779">20</ix:nonNumeric>&#160;years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c94" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-22780">5</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="c95" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-22781">10</ix:nonNumeric>&#160;years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Automobiles</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c96" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-22782">3</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="c97" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-22783">5</ix:nonNumeric>&#160;years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office and electric equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c98" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-22784">3</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="c99" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-22785">5</ix:nonNumeric>&#160;years</span></td></tr>
  </table></ix:continuation></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_4" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Expenditures
for maintenance and repairs, which do not materially extend the useful lives of the assets, are charged to expense as incurred. Expenditures
for major renewals and betterments which substantially extend the useful life of assets are capitalized. The cost and related accumulated
depreciation of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized in the consolidated
statements of operations and comprehensive loss in other income or expenses.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company reviews the carrying value of property, plant and equipment for impairment whenever events and circumstances indicate that the
carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition.
In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an
amount by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment
include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand,
competition and other economic factors. Based on this assessment, no impairment expenses for property, plant and equipment were recorded
in operating expenses for the years ended September 30, 2024, 2023 and 2022.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_IntangibleAssetsFiniteLivedPolicy-c0_cont_1" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="ixv-18784"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Intangible
Assets</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_IntangibleAssetsFiniteLivedPolicy-c0_cont_2" id="_IntangibleAssetsFiniteLivedPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Intangible
assets consist primarily of land use rights, trademark and software. Under the PRC law, all land in the PRC is owned by the government
and cannot be sold to an individual or company. The government grants individuals and companies the right to use parcels of land for
specified periods of time. Land use rights are stated at cost less accumulated amortization. <ix:nonNumeric contextRef="c0" continuedAt="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock-c0_cont_1" escape="true" name="upc:ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock" id="ixv-22786">Intangible assets are amortized using the
straight-line method with the following estimated useful lives:</ix:nonNumeric></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock-c0_cont_1"><ix:continuation continuedAt="_IntangibleAssetsFiniteLivedPolicy-c0_cont_3" id="_IntangibleAssetsFiniteLivedPolicy-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; width: 89%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful life</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Land use rights</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c100" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ixv-22787">50</ix:nonNumeric>&#160;years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trademark</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c101" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ixv-22788">5</ix:nonNumeric>&#160;years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Software</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c102" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ixv-22789">3</ix:nonNumeric>&#160;years</span></td></tr> </table></ix:continuation></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_IntangibleAssetsFiniteLivedPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company reviews the carrying value of land use rights for impairment whenever events and circumstances indicate that the carrying value
of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In
cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount
by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include
current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition
and other economic factors.&#160;Based on this assessment, no impairment of land use rights was deemed necessary for the years ended
September 30, 2024, 2023 and 2022.&#160;&#160;</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="upc_ConstructioninProgressPolicyTextBlock-c0_cont_1" escape="true" name="upc:ConstructioninProgressPolicyTextBlock" id="ixv-18835"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Construction-in-Progress
(&#8220;CIP&#8221;)</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="upc_ConstructioninProgressPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">CIP
represents property and buildings under construction and consists of construction expenditures, equipment procurement, and other direct
costs attributable to the construction. CIP is not depreciated. Upon completion and ready for intended use, CIP is reclassified to the
appropriate category within property, plant and equipment.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="ixv-18849"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Impairment
of long-lived Assets</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Long-lived
assets with finite lives, primarily property, plant and equipment and intangible assets, are reviewed for impairment whenever events
or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the estimated undiscounted cash
flows from the use of the asset and its eventual disposition below are the asset&#8217;s carrying value, then the asset is deemed to
be impaired and written down to its fair value. The Company recorded no impairments of these assets for the years ended September 30,
2024, 2023 and 2022.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_InvestmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InvestmentPolicyTextBlock" id="ixv-18862"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Investments
in Equity Securities</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<ix:continuation continuedAt="_InvestmentPolicyTextBlock-c0_cont_2" id="_InvestmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company accounts for its equity investments in accordance with ASC 321. In accordance with ASC 321, equity investment which the Company
has no significant influence (generally less than a <ix:nonFraction contextRef="c90" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-22790">20</ix:nonFraction>% ownership interest) with readily determinable fair values are accounted for at
fair value based on quoted market prices with the changes in fair value recognized as unrealized gains or losses in earnings. Equity
investments without readily determinable fair values are accounted for either at fair value or using the measurement alternative. Under
the measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting
from observable price changes in orderly transactions for the identical or a similar investment.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_InvestmentPolicyTextBlock-c0_cont_3" id="_InvestmentPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">From
March 2009 to September 2017, the Company invested approximately $<ix:nonFraction contextRef="c91" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="6" unitRef="usd" id="ixv-22791">0.7</ix:nonFraction>&#160;million (RMB<ix:nonFraction contextRef="c91" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="6" unitRef="cny" id="ixv-22792">5</ix:nonFraction>&#160;million) in Jiangxi Jian Rural Commercial
Bank (&#8220;JX RCB Bank&#8221;) in exchange for&#160;<ix:nonFraction contextRef="c92" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-22793">5</ix:nonFraction>% ownership interest in the bank. The purpose of entering into these equity investment
agreements with JX RCB Bank was to earn investment income as the bank continues to grow. The Company determined that this investment
in equity securities does not have a readily determinable fair value and, accordingly, elected the measurement alternative noted above.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:continuation continuedAt="_InvestmentPolicyTextBlock-c0_cont_4" id="_InvestmentPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company initially recorded the investments at historical cost and subsequently records any dividends received from the net accumulated
earnings of the investee as income. As of September 30, 2024 and 2023, the Company&#8217;s investment in JX RBC Bank amounted to $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd" id="ixv-22794">712,494</ix:nonFraction>&#160;(RMB<ix:nonFraction contextRef="c2" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="6" unitRef="cny" id="ixv-22795">5</ix:nonFraction>&#160;million)
and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd" id="ixv-22796">685,307</ix:nonFraction> (RMB<ix:nonFraction contextRef="c3" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="6" unitRef="cny" id="ixv-22797">5</ix:nonFraction>&#160;million), respectively, and was reported as long-term investment in equity investee on the consolidated balance
sheets. Investment income amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" unitRef="usd" id="ixv-22798">31,942</ix:nonFraction>, $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" unitRef="usd" id="ixv-22799">31,072</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" unitRef="usd" id="ixv-22800">38,588</ix:nonFraction> for the years ended September 30, 2024, 2023 and 2022, respectively.
</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_InvestmentPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
investments in equity securities are evaluated for impairment when facts or circumstances indicate that the fair value of the investments
is less than their carrying value. An impairment is recognized when a decline in fair value is determined to be other-than-temporary.
The Company reviews several factors to determine whether a loss is other-than-temporary. These factors include, but are not limited to,
the: (i) nature of the investment; (ii) cause and duration of the impairment; (iii) extent to which fair value is less than cost; (iv)
financial condition and near-term prospects of the investments; and (v) ability to hold the investment for a period of time sufficient
to allow for any anticipated recovery in fair value. There was no impairment for the Company&#8217;s investments in equity securities
as of September 30, 2024 and 2023.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="ixv-18906"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Revenue
recognition</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">To
determine revenue recognition for contracts with customers, the Company performs the following five steps : (i) identify the contract(s)
with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable
consideration to the extent that it is probable that a significant future reversal will&#160;<i>not</i>&#160;occur, (iv) allocate the
transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies
the performance obligation.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company recognizes revenue when it transfers its goods and services to customers in an amount that reflects the consideration to which
the Company expects to be entitled in such exchange. The Company accounts for the revenue generated from sales of its TCMD and third-party
products on a gross basis, as the Company is acting as a principal in these transactions, is subject to inventory risk, has latitude
in establishing prices, and is responsible for fulfilling the promise to provide customers the specified goods, which the Company has
control of the goods and has the ability to direct the use of goods to obtain substantially all the benefits. All of the Company&#8217;s
contracts have one single performance obligation, namely, the promise is to transfer the individual goods to customers, and there is
no separately identifiable other promise in the contracts. The Company&#8217;s revenue streams are recognized at a point in time when
title and risk of loss passes and the customer accepts the goods, which generally occurs at delivery. The Company&#8217;s products are
sold with no right of return and the Company does not provide other credits or sales incentive to customers. Revenue is reported net
of all value added taxes (&#8220;VAT&#8221;).</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="upc_DisaggregationOfRevenuesPolicyTextBlock-c0_cont_1" escape="true" name="upc:DisaggregationOfRevenuesPolicyTextBlock" id="ixv-18924"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disaggregation
of Revenues</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="upc_DisaggregationOfRevenuesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company disaggregates its revenue from contracts by product types, as the Company believes it best depicts how the nature, amount, timing
and uncertainty of the revenue and cash flows are affected by economic factors. </span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CostOfSalesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CostOfSalesPolicyTextBlock" id="ixv-18937"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Cost
of Revenue</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<ix:continuation id="_CostOfSalesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Cost
of revenue consists primarily of the costs of raw materials, freight charges, direct labor, depreciation of buildings and machinery,
warehousing and overhead associated with the manufacturing process.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-18967"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Research
and Development Expenses</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company expenses all internal research and development costs as incurred, which primarily comprise of employee costs, internal and external
costs related to execution of studies, manufacturing costs, facility costs of the research center, and amortization and depreciation
to intangible assets and property, plant and equipment used in the research and development activities. For the&#160;years ended September
30, 2024, 2023 and 2022, total research and development expenses were approximately $</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-22801">3,031,115</ix:nonFraction>,
<span style="background-color: white">$<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-22802">4,858,548</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-22803">7,644,375</ix:nonFraction>, respectively.</span></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ShippingAndHandlingCostPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ShippingAndHandlingCostPolicyTextBlock" id="ixv-18984"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Shipping
and handling costs</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<ix:continuation id="_ShippingAndHandlingCostPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Shipping
and handling costs are expensed as incurred. Inbound shipping and handling cost associated with bringing the purchased raw materials
and third-party products from suppliers to the Company&#8217;s warehouse are included in cost of revenue. Outbound shipping and handling
costs associated with shipping and delivery the products to customers are included in selling expenses.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_AdvertisingCostsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="ixv-19000"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Advertising
expense</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_AdvertisingCostsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Advertising
expenses primarily relate to promotion of the Company&#8217;s brand name and products through outdoor billboards, social media such as
Weibo and WeChat, and TV advertisement. Advertising costs are expensed as incurred or deferred and then expensed the first time the advertising
takes place. Advertising expenses are included in selling expenses in the consolidated statements of operations and comprehensive loss.
Advertising expenses amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdvertisingExpense" scale="0" unitRef="usd" id="ixv-22804">5,144,579</ix:nonFraction>, $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdvertisingExpense" scale="0" unitRef="usd" id="ixv-22805">4,653,633</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdvertisingExpense" scale="0" unitRef="usd" id="ixv-22806">17,527,318</ix:nonFraction> for the&#160;years ended September 30, 2024, 2023 and 2022,
respectively.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-19014"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Segment
Reporting</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company uses the management approach in determining reportable operating segments. The management approach considers the internal reporting
used by the Company&#8217;s chief operating decision maker for making operating decisions about the allocation of resources of the segment
and the assessment of its performance in determining the Company&#8217;s reportable operating segments. Management has determined that
the Company has <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" unitRef="pure" id="ixv-22807">one</ix:nonFraction> operating segment.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-19026"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
taxes</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company accounts for current income taxes in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized
when temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the consolidated financial
statements. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years
in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a
change in tax rates is recognized in income in the period including the enactment date. Valuation allowances are established, when necessary,
to reduce deferred tax assets to the amount expected to be realized.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_3" id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">An
uncertain tax position is recognized only if it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax
examination. The amount recognized is the largest amount of tax benefit that is greater than&#160;<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="upc:TaxBenefitPercentage" scale="-2" unitRef="pure" id="ixv-22808">50</ix:nonFraction>% likely of being realized on examination.
For tax positions not meeting the &#8220;more likely than not&#8221; test, no tax benefit is recorded. Penalties and interest incurred
related to underpayment of income tax are classified as income tax expense in the period incurred. No significant penalties or interest
relating to income taxes have been incurred during the years ended September 30, 2024, 2023 and 2022. The Company does not believe there
was any uncertain tax provision as of September 30, 2024 and 2023.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company&#8217;s operating subsidiaries in China are subject to the income tax laws of the PRC. No significant income was generated outside
the PRC for the years ended September 30, 2024, 2023 and 2022. As of September 30, 2024 and 2023, all of the tax returns of the Company&#8217;s
PRC subsidiaries remained open for statutory examination by PRC tax authorities.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_8" id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" continuedAt="upc_ValueAddedTaxPolicyTextBlock-c0_cont_1" escape="true" name="upc:ValueAddedTaxPolicyTextBlock" id="ixv-19063"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Value
added tax (&#8220;VAT&#8221;)</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="upc_ValueAddedTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Sales
revenue represents the invoiced value of goods, net of VAT. The VAT is based on gross sales price and VAT rates range up to&#160;<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="upc:PercentageOfVatRate" scale="-2" unitRef="pure" id="ixv-22809">13</ix:nonFraction>%,
depending on the type of products sold. The VAT may be offset by VAT paid by the Company on raw materials and other materials included
in the cost of producing or acquiring its finished products. The Company recorded a VAT payable or receivable net of payments in the
accompanying consolidated financial statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-19075"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Earnings
per Share</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company computes earnings per share (&#8220;EPS&#8221;) in accordance with ASC 260, &#8220;Earnings per Share&#8221; (&#8220;ASC 260&#8221;).
ASC 260 requires companies with complex capital structures to present basic and diluted EPS. Basic EPS is measured as net income divided
by the weighted average ordinary shares outstanding for the period. Diluted presents the dilutive effect on a per share basis of potential
ordinary shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented,
or issuance date, if later. Potential ordinary shares that have an anti-dilutive effect (i.e., those that increase income per share or
decrease loss per share) are excluded from the calculation of diluted EPS. For the years ended September 30, 2024, 2023 and 2022, there
were no dilutive shares.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="ixv-19089"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Foreign
currency translation</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
functional currency for Universe INC is the U.S. Dollar (&#8220;US$&#8221;). Universe HK uses Hong Kong dollar as its functional currency.
However, Universe INC and Universe HK currently only serve as holding companies and did not have active operations as of the date of
this report. The Company operates only in the PRC and the Company&#8217;s functional currency is the Chinese Yuan (&#8220;RMB&#8221;).
The Company&#8217;s consolidated financial statements have been translated into the reporting currency US$.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_3" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Assets
and liabilities of the Company are translated at the exchange rate at each reporting period end date. Equity is translated at historical
rates. Income and expense accounts are translated at the average rate of exchange during the reporting period. The resulting translation
adjustments are reported under other comprehensive income. Gains and losses resulting from the translations of foreign currency transactions
and balances are reflected in the results of operations.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;
</span></p>

<ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_4" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions.
No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" id="ixv-19110"><ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_5" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table outlines the currency exchange rates that were used in creating the consolidated financial statements in this report:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_5"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid">September 30, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid">September 30, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Period-end US$: RMB exchange rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c103" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeForwardExchangeRate1" scale="0" unitRef="pure" id="ixv-22810">7.0176</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c104" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeForwardExchangeRate1" scale="0" unitRef="pure" id="ixv-22811">7.2960</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c105" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeForwardExchangeRate1" scale="0" unitRef="pure" id="ixv-22812">7.1135</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Period-end US$: HK exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c106" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeForwardExchangeRate1" scale="0" unitRef="pure" id="ixv-22813">7.7693</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c107" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeForwardExchangeRate1" scale="0" unitRef="pure" id="ixv-22814">7.8308</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c108" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeForwardExchangeRate1" scale="0" unitRef="pure" id="ixv-22815">7.8498</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Period average US$: RMB exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c103" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeAverageForwardExchangeRate1" scale="0" unitRef="pure" id="ixv-22816">7.2043</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c104" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeAverageForwardExchangeRate1" scale="0" unitRef="pure" id="ixv-22817">7.0533</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c105" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeAverageForwardExchangeRate1" scale="0" unitRef="pure" id="ixv-22818">6.5532</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Period average US$: HK exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c106" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeAverageForwardExchangeRate1" scale="0" unitRef="pure" id="ixv-22819">7.8127</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c107" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeAverageForwardExchangeRate1" scale="0" unitRef="pure" id="ixv-22820">7.8310</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c108" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeAverageForwardExchangeRate1" scale="0" unitRef="pure" id="ixv-22821">7.8228</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ComprehensiveIncomePolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="ixv-19190"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Comprehensive
Income</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ComprehensiveIncomePolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Comprehensive
income consists of two components, net income and other comprehensive income. The foreign currency translation gain resulting from translation
of the financial statements expressed in RMB to US$ is reported in other comprehensive income in the consolidated statements of operations
and comprehensive loss.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="upc_StatementOfCashFlowsPolicyTextBlock-c0_cont_1" escape="true" name="upc:StatementOfCashFlowsPolicyTextBlock" id="ixv-19203"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Statement
of Cash Flows</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="upc_StatementOfCashFlowsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
accordance with ASC 230, &#8220;Statement of Cash Flows&#8221;, cash flows from the Company&#8217;s operations are formulated based upon
the local currencies. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily
agree with changes in the corresponding balances on the balance sheets.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="upc_EmployeeDefinedContributionPlanPolicyTextBlock-c0_cont_1" escape="true" name="upc:EmployeeDefinedContributionPlanPolicyTextBlock" id="ixv-19215"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employee
Defined Contribution Plan</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="upc_EmployeeDefinedContributionPlanPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company&#8217;s subsidiaries in the PRC participate in a government-mandated multi-employer defined contribution plan pursuant to which
pension, work-related injury benefits, maternity insurance, medical insurance, unemployment benefit and housing fund are provided to
eligible full-time employees. The relevant labor regulations require the Company&#8217;s subsidiaries in the PRC to pay the local labor
and social welfare authorities monthly contributions based on the applicable benchmarks and rates stipulated by the local government.
The contributions to the plan are expensed as incurred. Employee social security and welfare benefits included as expenses in the accompanying
consolidated statements of operations and comprehensive loss amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" unitRef="usd" id="ixv-22822">247,249</ix:nonFraction>, $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" unitRef="usd" id="ixv-22823">440,962</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" unitRef="usd" id="ixv-22824">465,689</ix:nonFraction>&#160;for the years ended
September 30, 2024, 2023 and 2022, respectively.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-19246"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
Issued <span style="background-color: white">Accounting Pronouncements</span></i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
considers the applicability and impact of all accounting standards updates (&#8220;ASUs&#8221;). Management periodically reviews new accounting
standards that are issued. Under the Jumpstart Our Business Startups Act of 2012, as amended (the &#8220;JOBS Act&#8221;), the Company
meets the definition of an emerging growth company, or EGC, and has elected the extended transition period for complying with new or revised
accounting standards, which delays the adoption of these accounting standards until they would apply to private companies.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In November
2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amended guidance
requires incremental reportable segment disclosures, primarily about significant segment expenses. The amendments also require entities
with a single reportable segment to provide all disclosures required by these amendments, and all existing segment disclosures. The amendments
will be applied retrospectively to all prior periods presented in the financial statements and is effective for fiscal years beginning
after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. The guidance should be adopted retrospectively.
The Company is currently in the process of evaluating the impact this amended guidance may have on the footnotes to its consolidated financial
statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In December
2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amended guidance enhances income
tax disclosures primarily related to the effective tax rate reconciliation and income taxes paid information. This guidance requires disclosure
of specific categories in the effective tax rate reconciliation and further information on reconciling items meeting a quantitative threshold.
In addition, the amended guidance requires disaggregating income taxes paid (net of refunds received) by federal, state, and foreign taxes.
It also requires disaggregating individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than
5 percent of total income taxes paid (net of refunds received). The amended guidance is effective for fiscal years beginning after December
15, 2024. The guidance can be applied either prospectively or retrospectively. The Company is currently in the process of evaluating the
impact this amended guidance may have on the footnotes to its consolidated financial statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_5" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In March
2024, the FASB issued ASU 2024-01, Compensation&#8212;Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar
Awards. The amended guidance added an illustrative example that includes four fact patterns to demonstrate how an entity should apply
the scope guidance in paragraph 718-10-15-3 to determine whether a profits interest award should be accounted for in accordance with Topic
718. The amendments guidance is effective for annual periods beginning after December 15, 2024, and interim periods within those annual
periods. The guidance can be applied either prospectively or retrospectively. The Company is currently in the process of evaluating the
impact this amended guidance may have on its consolidated financial statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_6" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In November
2024, the FASB issued ASU 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses. The amended guidance improves the disclosures about a public business entity&#8217;s
expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory,
employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions (such as cost of sales, SG&amp;A,
and research and development). The amended guidance is effective for annual reporting periods beginning after December 15, 2026, and interim
reporting periods beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective
application. The Company is currently in the process of evaluating the impact this amended guidance may have on the footnotes to its consolidated
financial statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_7" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In November
2024, the FASB issued ASU 2024-04, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible
Debt Instruments. This guidance clarifies the assessment of whether a transaction should be accounted for as an induced conversion or
extinguishment of convertible debt when changes are made to conversion features as part of an offer to settle the instrument. The amended
guidance is effective for all entities for annual reporting periods beginning after December 15, 2025, and interim reporting periods within
those annual reporting periods. The guidance can be applied either prospectively or retrospectively. The Company is currently in the process
of evaluating the impact this amended guidance may have on its consolidated financial statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_8" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In January
2025, the FASB issued ASU 2025-01, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic
220-40): Clarifying the Effective Date. This guidance amends the effective date of Update 2024-03 to clarify that all public business
entities are required to adopt the guidance in annual reporting periods beginning after December 15, 2026, and interim periods within
annual reporting periods beginning after December 15, 2027. Early adoption of Update 2024-03 is permitted. The Company is currently in
the process of evaluating the impact this amended guidance may have on the footnotes to its consolidated financial statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Other accounting
standards that have been issued by FASB that do not require adoption until a future date are not expected to have a material impact on
the consolidated financial statements upon adoption. The Company does not discuss recent standards that are not anticipated to have an
impact on or are unrelated to its consolidated financial condition, results of operations, cash flows or disclosures.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="ixv-19307"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
3 &#8212; ACCOUNTS RECEIVABLE, NET</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="ixv-19314"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Accounts
receivable consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Accounts receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableGrossCurrent" scale="0" unitRef="usd" id="ixv-22825">13,040,903</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableGrossCurrent" scale="0" unitRef="usd" id="ixv-22826">11,014,908</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" unitRef="usd" id="ixv-22827">135,082</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Accounts receivable, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-22828">12,905,821</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-22829">11,014,908</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company&#8217;s accounts
receivable primarily includes the balance due from customers when the Company&#8217;s pharmaceutical products are sold and delivered to
customers. As of date of this report, approximately <ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="upc:NetAccountReceivablePercentage" scale="-2" unitRef="pure" id="ixv-22830">98.4</ix:nonFraction>%</span>, or $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNet" scale="6" unitRef="usd" id="ixv-22831">12.8</ix:nonFraction> <span style="background-color: white">million, of the Company&#8217;s
net account receivable balance as of September 30, 2024 has been subsequently collected, and the remaining balance is expected to be substantially
collected before June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" id="ixv-19374"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Allowance
for doubtful accounts movement is as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Beginning balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Reversal of allowance for doubtful accounts</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" unitRef="usd" id="ixv-22832">131,581</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" scale="0" sign="-" unitRef="usd" id="ixv-22833">3,501</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Ending balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-22834">135,082</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:InventoryDisclosureTextBlock" id="ixv-19441"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
4 &#8212; INVENTORIES, NET</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="ixv-19447"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Inventories
consist of the following:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="0" unitRef="usd" id="ixv-22835">720,041</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="0" unitRef="usd" id="ixv-22836">635,395</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Finished goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="0" unitRef="usd" id="ixv-22837">1,141,526</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="0" unitRef="usd" id="ixv-22838">2,777,617</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Inventories valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" unitRef="usd" id="ixv-22839">124,512</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" unitRef="usd" id="ixv-22840">69,746</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total inventories, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-22841">1,737,054</ix:nonFraction></p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-22842">3,343,266</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="ixv-19510"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories valuation allowance <span style="background-color: white">movement
is as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Beginning balance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" unitRef="usd" id="ixv-22843">69,746</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" unitRef="usd" id="ixv-22844">120,286</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Reversal of inventories valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryLIFOReservePeriodCharge" scale="0" unitRef="usd" id="ixv-22845">50,651</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryLIFOReservePeriodCharge" scale="0" sign="-" unitRef="usd" id="ixv-22846">49,166</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="upc:InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments" scale="0" unitRef="usd" id="ixv-22847">4,115</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="upc:InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments" scale="0" sign="-" unitRef="usd" id="ixv-22848">1,374</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" unitRef="usd" id="ixv-22849">124,512</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" unitRef="usd" id="ixv-22850">69,746</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="upc:AdvancesToSuppliersTextBlock" id="ixv-19573"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
5 &#8212; ADVANCE TO SUPPLIERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="upc:ScheduleOfAdvancesToSuppliersNet" id="ixv-19579"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Advances
to suppliers consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 76%; text-align: justify">Advances to suppliers for inventories raw material purchase</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsAndSupplies" scale="0" unitRef="usd" id="ixv-22851">978,203</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsAndSupplies" scale="0" unitRef="usd" id="ixv-22852">180,643</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Advances to suppliers</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Supplies" scale="0" unitRef="usd" id="ixv-22853">978,203</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Supplies" scale="0" unitRef="usd" id="ixv-22854">180,643</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Advances
to suppliers represent prepayments made to suppliers to ensure continuous high-quality supplies and favorable purchase prices of raw
materials. </span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AssetAcquisitionTextBlock" id="ixv-19640"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE 6 &#8212; PREPAYMENT FOR ACQUISITION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
September 26, 2022, the Company entered into a letter of intent for an equity transfer with an individual, Mr. Xibo Liu, pursuant to
which, Mr. Xibo Liu transfers his&#160;<ix:nonFraction contextRef="c109" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" unitRef="pure" id="ixv-22855">51</ix:nonFraction>% ownership in Yunnan Faxi Pharmaceuticals Co., Ltd. (&#8220;Yunnan Faxi&#8221;) to the Company
at the price of RMB<ix:nonFraction contextRef="c110" decimals="-6" format="ixt:num-dot-decimal" name="upc:PrepaymentForAcquisition" scale="6" unitRef="cny" id="ixv-22856">72</ix:nonFraction>&#160;million (approximately $<ix:nonFraction contextRef="c110" decimals="-5" format="ixt:num-dot-decimal" name="upc:PrepaymentForAcquisition" scale="6" unitRef="usd" id="ixv-22857">10.0</ix:nonFraction>&#160;million). Based on contract terms, the Company prepaid RMB<ix:nonFraction contextRef="c111" decimals="-6" format="ixt:num-dot-decimal" name="upc:PrepaymentForAcquisitionCurrent" scale="6" unitRef="cny" id="ixv-22858">25</ix:nonFraction>&#160;million
(approximately $<ix:nonFraction contextRef="c111" decimals="-5" format="ixt:num-dot-decimal" name="upc:PrepaymentForAcquisitionCurrent" scale="6" unitRef="usd" id="ixv-22859">3.4</ix:nonFraction>&#160;million) within three (3) business days upon signing the letter of intent. As of September 30, 2023, the prepayment
was recorded as prepayment for acquisition on the balance sheets. However, due to unsatisfactory performance of Yunnan Faxi, the equity
transfer contract was terminated on December 20, 2024. The amount of $<ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="0" unitRef="usd" id="ixv-22860">3,562,472</ix:nonFraction> (RMB<ix:nonFraction contextRef="c112" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="6" unitRef="cny" id="ixv-22861">25</ix:nonFraction>&#160;million) was reclassified to other receivable
as of September 30, 2024, and collected back subsequently. </span></p></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ReceivablesPolicyTextBlock" id="ixv-19653"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>NOTE 7 &#8212; OTHER RECEIVABLE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="ixv-19658"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Other receivable
consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivable from Yunan Faxi <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_22_fact" name="us-gaap:ReceivablesNetCurrent" scale="0" unitRef="usd">3,562,472</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Redemption of short-term investment <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_23_fact" name="us-gaap:OtherShortTermInvestments" scale="0" unitRef="usd">1,377,873</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_24_fact" name="us-gaap:OtherShortTermInvestments" scale="0" unitRef="usd">1,367,052</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Prepaid value added tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="0" unitRef="usd" id="ixv-22865">475,331</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="0" unitRef="usd" id="ixv-22866">478,899</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Prepayment for advertising</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidAdvertising" scale="0" unitRef="usd" id="ixv-22867">219,830</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-22868">31,090</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-22869">74,300</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Other receivable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="0" unitRef="usd" id="ixv-22870">5,666,596</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="0" unitRef="usd" id="ixv-22871">1,920,251</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">(1)</span></td><td style="text-align: justify"><ix:footnote id="ix_3_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
September 26, 2022, the Company entered into a letter of intent for an equity transfer with an individual, Mr. Xibo Liu, pursuant to
which, Mr. Xibo Liu transfers his&#160;<ix:nonFraction contextRef="c113" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-22872">51</ix:nonFraction>% ownership in Yunnan Faxi to the Company at the price of RMB<ix:nonFraction contextRef="c111" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" unitRef="cny" id="ixv-22873">72</ix:nonFraction>&#160;million (approximately
$<ix:nonFraction contextRef="c111" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" unitRef="usd" id="ixv-22874">10.0</ix:nonFraction>&#160;million). Based on contract terms, the Company prepaid RMB<ix:nonFraction contextRef="c2" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" scale="6" unitRef="cny" id="ixv-22875">25</ix:nonFraction>&#160;million (approximately $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" scale="6" unitRef="usd" id="ixv-22876">3.4</ix:nonFraction>&#160;million) within three (3)
business days upon signing the letter of intent. However, due to unsatisfactory performance of Yunnan Faxi, the equity transfer contract
was terminated on December 20, 2024. The amount of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-22877">3,562,472</ix:nonFraction> (RMB<ix:nonFraction contextRef="c2" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesGrossCurrent" scale="6" unitRef="cny" id="ixv-22878">25</ix:nonFraction>&#160;million) was recorded as other receivable as of September 30,
2024.</span></ix:footnote></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">(2)</span></td><td style="text-align: justify"><ix:footnote id="ix_4_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
September 24, 2024, the Company entered into an agreement with a third party to transfer its short-term investment at the price of $</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherShortTermInvestments" scale="0" unitRef="usd" id="ixv-22879">1,377,873</ix:nonFraction>.
<span style="background-color: white">The amount was recorded as other receivable as of September 30, 2024 and 2023.</span></span></ix:footnote></td>
</tr></table></ix:nonNumeric>



<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white">As of date of this report, approximately
</span><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="upc:OtherReceivablePercentage" scale="-2" unitRef="pure" id="ixv-22880">99.4</ix:nonFraction>%, or $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesGrossCurrent" scale="6" unitRef="usd" id="ixv-22881">5.6</ix:nonFraction> <span style="background-color: white">million, of the Company&#8217;s other receivable balance as of September 30,
2024 has been subsequently collected.</span></p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-19772"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
8 &#8212; PROPERTY, PLANT AND EQUIPMENT, NET</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-19778"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Property,
plant and equipment, net, consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Useful life</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: justify">Buildings</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center"><ix:nonNumeric contextRef="c93" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-22882">20</ix:nonNumeric>&#160;years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-22883">7,594,735</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-22884">7,304,936</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c94" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-22885">5</ix:nonNumeric>-<ix:nonNumeric contextRef="c95" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-22886">10</ix:nonNumeric>&#160;years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-22887">2,007,399</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-22888">1,896,976</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Automobiles</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c96" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-22889">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c97" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-22890">5</ix:nonNumeric>&#160;years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-22891">67,374</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-22892">73,703</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Office and electric equipment</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c120" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-22893">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c121" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-22894">5</ix:nonNumeric>&#160;years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-22895">527,336</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-22896">474,830</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Construction-in-progress</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-22897">35,971</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Subtotal</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-22898">10,232,815</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-22899">9,750,445</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-22900">6,664,765</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-22901">6,050,480</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Property, plant and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-22902">3,568,050</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-22903">3,699,965</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Depreciation
expense was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-22904">474,034</ix:nonFraction>, $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-22905">503,687</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-22906">528,919</ix:nonFraction>&#160;for the years ended September 30, 2024, 2023 and 2022, respectively. Loss from
disposal of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">property, plant and equipment <span style="background-color: white">amounted
to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="0" sign="-" unitRef="usd" id="ixv-22907">3,958</ix:nonFraction>, $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="0" sign="-" unitRef="usd" id="ixv-22908">114</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="0" sign="-" unitRef="usd" id="ixv-22909">983</ix:nonFraction> for the years ended September 30, 2024, 2023 and 2022, respectively.</span></span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="ixv-19920"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
9 &#8212; INTANGIBLE ASSETS, NET</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="ixv-19926"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Intangible
assets, net consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Useful life</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: justify">Land use rights</td><td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: center"><ix:nonNumeric contextRef="c126" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ixv-22910">50</ix:nonNumeric>&#160;years</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-22911">256,211</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-22912">246,434</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Trademark</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c128" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ixv-22913">5</ix:nonNumeric>&#160;years</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-22914">120,412</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Software</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c130" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ixv-22915">3</ix:nonNumeric>&#160;years</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-22916">21,506</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-22917">20,687</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-22918">398,129</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-22919">267,121</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-22920">135,251</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-22921">118,537</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Intangible assets, net</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd" id="ixv-22922">262,878</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd" id="ixv-22923">148,584</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Amortization
expense was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-22924">11,700</ix:nonFraction>, $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-22925">5,098</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-22926">5,030</ix:nonFraction> for the years ended September 30, 2024, 2023 and 2022,&#160;respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="ixv-20028"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Estimated
future amortization expense for intangible assets is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; border-bottom: Black 1.5pt solid; font-weight: bold">Years Ending September 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortization<br/> expense</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="0" unitRef="usd" id="ixv-22927">17,165</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="0" unitRef="usd" id="ixv-22928">17,165</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="0" unitRef="usd" id="ixv-22929">17,165</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="0" unitRef="usd" id="ixv-22930">17,165</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="0" unitRef="usd" id="ixv-22931">17,165</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="0" unitRef="usd" id="ixv-22932">177,053</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd" id="ixv-22933">262,878</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="upc_PrepaymentForConstructionInProgressTextBlock-c0_cont_1" escape="true" name="upc:PrepaymentForConstructionInProgressTextBlock" id="ixv-20093"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
10 &#8212; PREPAYMENT FOR CIP PROJECT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">CIP
represents direct costs of construction incurred for the Company&#8217;s manufacturing facilities. On June 25, 2021, the Company signed
a construction sub-contract with sub-contractor Jiangxi Chenyuan Construction Project Co., Ltd. (&#8220;Chenyuan&#8221;), pursuant to
which, Chenyuan agreed to help the Company construct four manufacturing factory buildings and an office building with a total estimated
budget of RMB<ix:nonFraction contextRef="c132" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InvestmentBuildingAndBuildingImprovements" scale="6" unitRef="cny" id="ixv-22934">165</ix:nonFraction> million (approximately $<ix:nonFraction contextRef="c132" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InvestmentBuildingAndBuildingImprovements" scale="6" unitRef="usd" id="ixv-22935">23.5</ix:nonFraction> million). The construction work started on August 8, 2021, with an originally estimated
completion date on August 7, 2023. However, due to resurgence of the COVID-19 pandemic, which resulted in lingering logistic disruption,
material and labor shortage, and domestic travel restriction, at the beginning of 2024, the Company estimated the construction work to
be completed in December 2024. During 2024, new information was discovered about the topographical and surface structures of the land,
which required Chenyuan to redo the geological survey. As a result, the construction work is further delayed, and the construction of
the four manufacturing factory buildings and the office building is expected to be fully completed and put into use by December 2025
and December 2026, respectively. As of September 30, 2024, the Company had made a prepayment of approximately RMB<ix:nonFraction contextRef="c133" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InvestmentBuildingAndBuildingImprovements" scale="6" unitRef="cny" id="ixv-22936">69.2</ix:nonFraction> million (approximately
$<ix:nonFraction contextRef="c133" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InvestmentBuildingAndBuildingImprovements" scale="6" unitRef="usd" id="ixv-22937">9.9</ix:nonFraction> million) to Chenyuan for land improvement, building foundation and the construction of the manufacturing factories.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During
the year ended September 30, 2022, $<ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConstructionContractCostProgressPaymentOffset" scale="0" unitRef="usd" id="ixv-22938">407,190</ix:nonFraction> (approximately RMB<ix:nonFraction contextRef="c134" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ConstructionContractCostProgressPaymentOffset" scale="6" unitRef="cny" id="ixv-22939">2.9</ix:nonFraction> million) of the prepayment for the CIP project was used for construction
work, and the amount was recorded as property, plant and equipment in the consolidated balance sheets. As of September 30, 2024, the
remaining $<ix:nonFraction contextRef="c135" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PrepaymentFeesOnAdvancesNet" scale="6" unitRef="usd" id="ixv-22940">9.5</ix:nonFraction> million prepayment to Chenyuan was recorded as a prepayment for CIP project on the balance sheets.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="upc_PrepaymentForConstructionInProgressTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of September 30, 2024, future additional capital expenditure on this CIP project is estimated to be approximately RMB<ix:nonFraction contextRef="c136" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" unitRef="cny" id="ixv-22941">95.8</ix:nonFraction> million (equivalent
to $<ix:nonFraction contextRef="c136" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" unitRef="usd" id="ixv-22942">13.7</ix:nonFraction> million), among which approximately $<ix:nonFraction contextRef="c137" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" unitRef="usd" id="ixv-22943">7.1</ix:nonFraction> million is required for the next 12 months. The Company currently plans to support
its ongoing CIP project construction through cash collected from accounts receivable, and if necessary, borrowings from PRC banks in
the future. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="upc:ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock" id="ixv-20126"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of September 30, 2024, future minimum capital expenditures on the Company&#8217;s CIP project are estimated as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Twelve months ending September 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital<br/> Expenditure<br/> on CIP</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-22944">7,124,943</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractualObligationDueInSecondYear" scale="0" unitRef="usd" id="ixv-22945">5,350,832</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractualObligationDueInThirdYear" scale="0" unitRef="usd" id="ixv-22946">1,175,616</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractualObligation" scale="0" unitRef="usd" id="ixv-22947">13,651,391</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="upc:PrepaymentForPurchaseOfAPropertyTextBlock" id="ixv-20173"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
11 &#8212; PREPAYMENT FOR PURCHASE OF A PROPERTY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
May 6, 2021, the Company entered into a real estate property purchase agreement with related party Jiangxi Yueshang Investment Co., Ltd.
(&#8220;Jiangxi Yueshang&#8221;), an entity in which the Company&#8217;s chief executive officer, Mr. Gang Lai, owned <ix:nonFraction contextRef="c138" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-22948">5</ix:nonFraction>% equity interest
as of the date of that agreement. Pursuant to the property purchase agreement, Jiangxi Yueshang will sell and the Company will purchase
a certain residential apartment and commercial office space totaling <ix:nonFraction contextRef="c139" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" unitRef="sqm" id="ixv-22949">2,749.30</ix:nonFraction> square meters, with a total purchase price of RMB<ix:nonFraction contextRef="c139" decimals="-6" format="ixt:num-dot-decimal" name="upc:PrepaymentsMadeToARelatedPartyForPurchasesOfProperty" scale="6" unitRef="cny" id="ixv-22950">32</ix:nonFraction> million
(approximately $<ix:nonFraction contextRef="c139" decimals="-5" format="ixt:num-dot-decimal" name="upc:PrepaymentsMadeToARelatedPartyForPurchasesOfProperty" scale="6" unitRef="usd" id="ixv-22951">4.6</ix:nonFraction> million). Pursuant to this agreement, the Company was required to make a prepayment in the amount of <ix:nonFraction contextRef="c140" decimals="2" format="ixt:num-dot-decimal" name="upc:PercentageOfPrepayment" scale="-2" unitRef="pure" id="ixv-22952">50</ix:nonFraction>% of the total
purchase price, with <ix:nonFraction contextRef="c139" decimals="2" format="ixt:num-dot-decimal" name="upc:PercentageOfTotalPurchasePricePayable" scale="-2" unitRef="pure" id="ixv-22953">20</ix:nonFraction>% of the total purchase price payable upon the availability of a certificate of occupancy, and <ix:nonFraction contextRef="c140" decimals="2" format="ixt:num-dot-decimal" name="upc:PayableDeliveryPropertyPercentage" scale="-2" unitRef="pure" id="ixv-22954">30</ix:nonFraction>% of the total
purchase price payable upon delivery of the property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of September 30, 2024, the Company had made a prepayment of RMB<ix:nonFraction contextRef="c141" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PrepaymentFeesOnAdvancesNet" scale="6" unitRef="cny" id="ixv-22955">16</ix:nonFraction> million (approximately $<ix:nonFraction contextRef="c141" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PrepaymentFeesOnAdvancesNet" scale="6" unitRef="usd" id="ixv-22956">2.3</ix:nonFraction> million) to Jiangxi Yueshang. The remaining
balance is expected to be paid by April 2025. Since the property is located in the urban downtown area of Ji&#8217;an City, the Company
plans to use the property for offices in June 2025.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ShortTermDebtTextBlock-c0_cont_1" escape="true" name="us-gaap:ShortTermDebtTextBlock" id="ixv-20191"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
12 &#8212; SHORT-TERM BANK LOANS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShortTermDebtTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShortTermDebtTextBlock" id="ixv-20197"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Short-term
bank loans consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Note</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Short-term bank loans:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;)</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">(1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c177" decimals="0" format="ixt:num-dot-decimal" id="ix_25_fact" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">2,849,976</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c178" decimals="0" format="ixt:num-dot-decimal" id="ix_26_fact" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">2,467,105</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Bank of Communications Co., Ltd</td><td>&#160;</td>
    <td style="text-align: center">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c179" decimals="0" format="ixt:num-dot-decimal" id="ix_27_fact" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">1,154,241</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c180" decimals="0" format="ixt:num-dot-decimal" id="ix_28_fact" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">1,233,553</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Zhujiang Rural Bank</td><td>&#160;</td>
    <td style="text-align: center">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" id="ix_29_fact" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">427,497</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" id="ix_30_fact" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">411,184</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Beijing Bank</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">(4)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" id="ix_31_fact" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">1,424,989</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" id="ix_32_fact" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">1,370,614</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total short-term loans</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-22965">5,856,703</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-22966">5,482,456</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_ScheduleOfShortTermDebtTextBlock-c0_cont_1"><ix:continuation id="_ShortTermDebtTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:footnote continuedAt="ix_5_footnote_cont_1" id="ix_5_footnote" xml:lang="en-US"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 13, 2023, a subsidiary of the Company, Universe Trade, signed a loan agreement with LRC Bank to borrow RMB<ix:nonFraction contextRef="c142" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="6" unitRef="cny" id="ixv-22967">8</ix:nonFraction> million (equivalent to $<ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-22968">1,096,491</ix:nonFraction>) as working capital for <ix:nonNumeric contextRef="c143" name="us-gaap:ShortTermDebtTerms" id="ixv-22969">one</ix:nonNumeric> year, with the maturity date on <ix:nonNumeric contextRef="c143" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-22970">March 12, 2024</ix:nonNumeric>. The fixed interest rate of the loan was <ix:nonFraction contextRef="c142" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-22971">4.56</ix:nonFraction>% per annum. Mr. Gang Lai signed guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 15, 2023, a subsidiary of the Company, Jiangxi Universe, signed a loan agreement with LRC Bank to borrow RMB<ix:nonFraction contextRef="c144" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="6" unitRef="cny" id="ixv-22972">10</ix:nonFraction> million (equivalent to $<ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-22973">1,370,614</ix:nonFraction>) as working capital for <ix:nonNumeric contextRef="c145" name="us-gaap:ShortTermDebtTerms" id="ixv-22974">eleven</ix:nonNumeric> months, with the maturity date on <ix:nonNumeric contextRef="c146" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-22975">May 14, 2024</ix:nonNumeric>. The fixed interest rate of the loan was <ix:nonFraction contextRef="c144" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-22976">4.56</ix:nonFraction>% per annum. Mr. Gang Lai signed guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 4, 2024, a subsidiary of the Company, Universe
Trade, signed a loan agreement with LRC Bank to borrow RMB<ix:nonFraction contextRef="c147" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="6" unitRef="cny" id="ixv-22977">5</ix:nonFraction> million (equivalent to $<ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-22978">712,494</ix:nonFraction>) as working capital for <ix:nonNumeric contextRef="c148" name="us-gaap:ShortTermDebtTerms" id="ixv-22979">one</ix:nonNumeric> year, with the
maturity date on <ix:nonNumeric contextRef="c148" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-22980">March 3, 2025</ix:nonNumeric>. The fixed interest rate of the loan was <ix:nonFraction contextRef="c147" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-22981">4.75</ix:nonFraction>% per annum. Mr. Gang Lai and Jiangxi Universe jointly signed
guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 26, 2024, a subsidiary of the Company, Jiangxi
Universe, signed a loan agreement with LRC Bank to borrow RMB<ix:nonFraction contextRef="c149" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="6" unitRef="cny" id="ixv-22982">10</ix:nonFraction> million (equivalent to $<ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-22983">1,424,989</ix:nonFraction>) as working capital for <ix:nonNumeric contextRef="c150" name="us-gaap:ShortTermDebtTerms" id="ixv-22984">one</ix:nonNumeric> year, with
the maturity date on <ix:nonNumeric contextRef="c150" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-22985">April 25, 2025</ix:nonNumeric>. The fixed interest rate of the loan was <ix:nonFraction contextRef="c149" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-22986">4.31</ix:nonFraction>% per annum. Mr. Gang Lai and Universe Technology jointly
signed guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 17, 2024, a subsidiary of the Company, Universe
trade, signed a loan agreement with LRC Bank to borrow RMB<ix:nonFraction contextRef="c151" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="6" unitRef="cny" id="ixv-22987">5</ix:nonFraction> million (equivalent to $<ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-22988">712,494</ix:nonFraction>) as working capital for <ix:nonNumeric contextRef="c152" name="us-gaap:ShortTermDebtTerms" id="ixv-22989">one</ix:nonNumeric> year, with the
maturity date on <ix:nonNumeric contextRef="c152" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-22990">May 16, 2025</ix:nonNumeric>. The fixed interest rate of the loan was <ix:nonFraction contextRef="c151" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-22991">3.65</ix:nonFraction>% per annum. Mr. Gang Lai and Jiangxi Universe jointly signed
guarantee agreements with LRC Bank to provide credit guarantee for this loan.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
March 3, 2025, a subsidiary of the Company, Universe Trade, signed a loan agreement with LRC Bank to borrow RMB<ix:nonFraction contextRef="c153" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="6" unitRef="cny" id="ixv-22992">5</ix:nonFraction> million (equivalent to
$<ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-22993">712,494</ix:nonFraction>) as working capital for <ix:nonNumeric contextRef="c154" name="us-gaap:ShortTermDebtTerms" id="ixv-22994">one</ix:nonNumeric> year, with the maturity date on <ix:nonNumeric contextRef="c155" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-22995">March 2, 2026</ix:nonNumeric>. The fixed interest rate of the loan was <ix:nonFraction contextRef="c153" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-22996">3.65</ix:nonFraction>% per
annum. Mr. Gang Lai and Jiangxi Universe jointly signed guarantee agreements with LRC Bank to provide credit guarantee for this loan.</span>
&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
</ix:footnote><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><ix:continuation id="ix_5_footnote_cont_1">On April 22, 2024, a subsidiary of the Company, Jiangxi Universe, signed
a loan agreement with LRC Bank to borrow RMB<ix:nonFraction contextRef="c156" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="6" unitRef="cny" id="ixv-22998">10</ix:nonFraction> million (equivalent to $<ix:nonFraction contextRef="c156" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-22999">1,424,989</ix:nonFraction>) as working capital for <ix:nonNumeric contextRef="c157" name="us-gaap:ShortTermDebtTerms" id="ixv-23000">one</ix:nonNumeric> year, with the maturity date
on <ix:nonNumeric contextRef="c157" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-23001">April 21, 2026</ix:nonNumeric>. The fixed interest rate of the loan was <ix:nonFraction contextRef="c156" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-23002">3.60</ix:nonFraction>% per annum. Mr. Gang Lai and Universe Technology jointly signed guarantee
agreements with LRC Bank to provide credit guarantee for this loan.</ix:continuation> &#160;</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:footnote id="ix_6_footnote" xml:lang="en-US"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 15, 2023, the Company&#8217;s subsidiary, Jiangxi Universe, signed a loan agreement with Bank of Communications to borrow RMB<ix:nonFraction contextRef="c158" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="6" unitRef="cny" id="ixv-23003">9</ix:nonFraction> million (equivalent to $<ix:nonFraction contextRef="c158" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-23004">1,246,486</ix:nonFraction>) as working capital for <ix:nonNumeric contextRef="c159" name="us-gaap:ShortTermDebtTerms" id="ixv-23005">eleven</ix:nonNumeric> months, with the maturity date on May 18, 2024. The fixed interest rate of the loan was <ix:nonFraction contextRef="c158" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-23006">4.0</ix:nonFraction>% per annum. Mr. Gang Lai, Universe Trade, and an unrelated third party, Jiangxi Province Financing Guarantee Group Co., Ltd., jointly signed guarantee agreements with Bank of Communications to provide credit guarantee for this loan. The loan was fully repaid upon maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 16, 2024, the Company&#8217;s subsidiary, Jiangxi Universe, signed a loan agreement with Bank of Communications to borrow RMB<ix:nonFraction contextRef="c160" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="6" unitRef="cny" id="ixv-23007">8.1</ix:nonFraction> million (equivalent to $<ix:nonFraction contextRef="c160" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-23008">1,154,241</ix:nonFraction>) as working capital for <ix:nonNumeric contextRef="c161" name="us-gaap:ShortTermDebtTerms" id="ixv-23009">eleven</ix:nonNumeric> months, with the maturity date on <ix:nonNumeric contextRef="c161" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-23010">May 13, 2025</ix:nonNumeric>. The fixed interest rate of the loan was <ix:nonFraction contextRef="c160" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-23011">3.9</ix:nonFraction>% per annum. Mr. Gang Lai, Universe Trade, and an unrelated third party, Jiangxi Province Financing Guarantee Group Co., Ltd., jointly signed guarantee agreements with Bank of Communications to provide credit guarantee for this loan.</span></p></ix:footnote></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:footnote continuedAt="ix_7_footnote_cont_1" id="ix_7_footnote" xml:lang="en-US"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 5, 2023, a subsidiary of the Company, Jiangxi Universe, entered into a loan agreement with Zhujiang Rural Bank to borrow RMB <ix:nonFraction contextRef="c162" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="6" unitRef="cny" id="ixv-23012">3</ix:nonFraction> million (equivalent to $<ix:nonFraction contextRef="c162" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-23013">415,495</ix:nonFraction>) as working capital for <ix:nonNumeric contextRef="c163" name="us-gaap:ShortTermDebtTerms" id="ixv-23014">one</ix:nonNumeric> year, with the maturity date on <ix:nonNumeric contextRef="c163" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-23015">May 4, 2024</ix:nonNumeric>. The fixed interest rate of the loan was <ix:nonFraction contextRef="c164" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-23016">3.65</ix:nonFraction>% per annum. The Company pledged certain patents owned by the Company as collateral to guarantee this loan. The loan was fully repaid upon maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> </ix:footnote><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><ix:continuation continuedAt="ix_7_footnote_cont_2" id="ix_7_footnote_cont_1">
</ix:continuation><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><ix:continuation id="ix_7_footnote_cont_2">On April 24, 2024, a subsidiary of the Company, Jiangxi
Universe, entered into a loan agreement with Zhujiang Rural Bank to borrow RMB<ix:nonFraction contextRef="c165" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="6" unitRef="cny" id="ixv-23019">3</ix:nonFraction> million (equivalent to $<ix:nonFraction contextRef="c165" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-23020">427,497</ix:nonFraction>) as working capital for
<ix:nonNumeric contextRef="c166" name="us-gaap:ShortTermDebtTerms" id="ixv-23021">one</ix:nonNumeric> year, with the maturity date on <ix:nonNumeric contextRef="c166" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-23022">April 24, 2025</ix:nonNumeric>. The fixed interest rate of the loan was <ix:nonFraction contextRef="c167" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-23023">3.65</ix:nonFraction>% per annum. The Company pledged certain
trademarks owned by the Company as collateral to guarantee this loan.</ix:continuation> The loan was fully repaid upon maturity</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="text-align: justify; margin: 0; font: 10pt Times New Roman, Times, Serif">On April 18, 2025, a subsidiary of the Company, Jiangxi Universe, signed
a loan agreement with Zhujiang Rural Bank to borrow RMB<ix:nonFraction contextRef="c168" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="6" unitRef="cny" id="ixv-23024">2.9</ix:nonFraction> million (equivalent to $<ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-23025">413,247</ix:nonFraction>&#160;) as working capital for <ix:nonNumeric contextRef="c169" name="us-gaap:ShortTermDebtTerms" id="ixv-23026">one</ix:nonNumeric> year, with
the maturity date on <ix:nonNumeric contextRef="c170" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-23027">April 18, 2026</ix:nonNumeric>. The fixed interest rate of the loan was <ix:nonFraction contextRef="c168" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-23028">5.00</ix:nonFraction>% per annum. The Company pledged certain trademarks owned
by the Company as collateral to guarantee this loan.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:footnote id="ix_8_footnote" xml:lang="en-US"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 24, 2023, a subsidiary of the Company, Jiangxi Universe, entered into a loan agreement with Beijing Bank to borrow RMB <ix:nonFraction contextRef="c171" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="6" unitRef="cny" id="ixv-23029">10</ix:nonFraction> million (equivalent to $<ix:nonFraction contextRef="c171" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-23030">1,384,984</ix:nonFraction>) as working capital for <ix:nonNumeric contextRef="c172" name="us-gaap:ShortTermDebtTerms" id="ixv-23031">one</ix:nonNumeric> year, with the maturity date on <ix:nonNumeric contextRef="c172" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-23032">July 18, 2024</ix:nonNumeric>. The fixed interest rate of the loan was <ix:nonFraction contextRef="c173" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-23033">4.25</ix:nonFraction>% per annum. There was no guarantee requirement for this loan. The loan was fully repaid upon maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 3, 2024, a subsidiary of the Company, Jiangxi Universe, entered into a loan agreement with Beijing Bank to borrow RMB <ix:nonFraction contextRef="c174" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="6" unitRef="cny" id="ixv-23034">10</ix:nonFraction> million (equivalent to $<ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-23035">1,424,989</ix:nonFraction>) as working capital for <ix:nonNumeric contextRef="c175" name="us-gaap:ShortTermDebtTerms" id="ixv-23036">one</ix:nonNumeric> year, with the maturity date on <ix:nonNumeric contextRef="c175" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-23037">July 3, 2025</ix:nonNumeric>. The fixed interest rate of the loan was <ix:nonFraction contextRef="c176" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-23038">4.15</ix:nonFraction>% per annum. Mr. Gang Lai provided credit guarantee for this loan.</span></p></ix:footnote></td></tr> </table></ix:continuation></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LongTermDebtTextBlock" id="ixv-20395"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
13 &#8212; LONG-TERM BANK LOANS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="ixv-20401"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Long-term
bank loans consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Note</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Long-term bank loans:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">LRC Bank</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">(1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" id="ix_33_fact" name="us-gaap:LongTermLoansFromBank" scale="0" unitRef="usd">2,137,483</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:footnote id="ix_9_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 23, 2023, a subsidiary of the Company, Jiangxi Universe, signed a loan agreement with LRC Bank to borrow RMB<ix:nonFraction contextRef="c185" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" unitRef="cny" id="ixv-23040">15</ix:nonFraction> million (equivalent to $<ix:nonFraction contextRef="c185" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-23041">2,137,483</ix:nonFraction>) as working capital for <ix:nonNumeric contextRef="c185" format="ixt-sec:durwordsen" name="us-gaap:LongTermDebtTerm" id="ixv-23042">two years</ix:nonNumeric>, with the maturity date on <ix:nonNumeric contextRef="c186" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-23043">November 14, 2025</ix:nonNumeric>. The fixed interest rate of the loan was <ix:nonFraction contextRef="c185" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-23044">3.95</ix:nonFraction>% per annum. The Company pledged buildings of Jiangxi Universe as collateral to guarantee this loan.</span></ix:footnote></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For
the above-mentioned loans, the Company recorded a total interest expense of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-23045">304,516</ix:nonFraction>, $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-23046">190,184</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-23047">199,852</ix:nonFraction> for the years ended September
30, 2024, 2023 and 2022, respectively.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-20465"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
14 &#8212; RELATED PARTY TRANSACTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="upc:ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock" id="ixv-20471"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)
Nature of relationships with related parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship with the Company</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Gang Lai</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><ix:nonNumeric contextRef="c193" name="us-gaap:NatureOfCommonOwnershipOrManagementControlRelationships" id="ixv-20493"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and chairman of the Company&#8217;s Board of Directors</span></ix:nonNumeric></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Yajun Hu</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:nonNumeric contextRef="c194" name="us-gaap:NatureOfCommonOwnershipOrManagementControlRelationships" id="ixv-20501"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General Manager of Jiangxi Universe</span></ix:nonNumeric></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms. Lin Yang</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:nonNumeric contextRef="c195" name="us-gaap:NatureOfCommonOwnershipOrManagementControlRelationships" id="ixv-20509"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer of the Company</span></ix:nonNumeric></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guangzhou Ningjing Investment Co., Ltd (Guangzhou Ningjing)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left"><ix:nonNumeric contextRef="c196" name="us-gaap:NatureOfCommonOwnershipOrManagementControlRelationships" id="ixv-20517"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under common control of Mr. Gang Lai</span></ix:nonNumeric></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="ixv-20522"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>(b)
Due from related parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Mr. Yajun Hu</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c197" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-23048">61,678</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total due from related parties</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-23049">61,678</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023, the balance due from related parties consisted of advanced funds to the Company&#8217;s director and general manager,
Mr. Yajun Hu. These advances were non-interest bearing and fully repaid on October 12, 2023.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1"><ix:continuation id="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>(c)
Due to related parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Mr. Gang Lai</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c198" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-23050">6,900,499</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-23051">540,096</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Ms. Lin Yang</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c200" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-23052">85</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total due to related parties</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-23053">6,900,584</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-23054">540,096</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of September 30, 2024, the balance due to related parties mainly consisted of advances from Mr. Gang Lai, the Company&#8217;s chief executive
officer and the chairman of the board of directors for working capital purposes during the Company&#8217;s normal course of business,
as well as payment of expenses made by Ms. Lin Yang on behalf of the Company. These advances are unsecured, non-interest bearing and
due on demand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>(d)
Loan guarantee provided by related parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In connection with the Company&#8217;s
bank borrowings from commercial banks in China, Mr. Gang Lai, the Company&#8217;s chairman of the board of directors and chief executive
officer, signed guarantee agreements with these banks to provide credit guarantee for the Company&#8217;s certain loans (see Note 13 and
14).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>(e)
Prepayment to related party for property purchase</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
disclosed in Note 12, on May 6, 2021, the Company entered into a real estate property purchase agreement with a related party, Jiangxi
Yueshang, to purchase certain residential apartment and commercial office space totaling <ix:nonFraction contextRef="c139" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" unitRef="sqm" id="ixv-23055">2,749.30</ix:nonFraction> square meters with total purchase price
of RMB<ix:nonFraction contextRef="c139" decimals="-6" format="ixt:num-dot-decimal" name="upc:PrepaymentsMadeToARelatedPartyForPurchasesOfProperty" scale="6" unitRef="cny" id="ixv-23056">32</ix:nonFraction> million (approximately $<ix:nonFraction contextRef="c139" decimals="-5" format="ixt:num-dot-decimal" name="upc:PrepaymentsMadeToARelatedPartyForPurchasesOfProperty" scale="6" unitRef="usd" id="ixv-23057">4.6</ix:nonFraction> million).&#160;As of September 30, 2024, the Company had made a prepayment of RMB<ix:nonFraction contextRef="c189" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PrepaymentFeesOnAdvancesNet" scale="6" unitRef="cny" id="ixv-23058">16</ix:nonFraction>&#160;million
($<ix:nonFraction contextRef="c189" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PrepaymentFeesOnAdvancesNet" scale="6" unitRef="usd" id="ixv-23059">2.3</ix:nonFraction> million) to Jiangxi Yueshang. The remaining balance is expected to be paid by April 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
January 13, 2022, Mr. Gang Lai transferred the&#160;<ix:nonFraction contextRef="c190" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-23060">5</ix:nonFraction>% equity interest he owned in Jiangxi Yueshang to a third party. As such, after
this date, Jiangxi Yueshang is no longer the Company&#8217;s related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>(f)
Prepaid expenses-related party, non-current</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of September 30, 2024 and 2023, the Company prepaid Guangzhou Ningjing <span style="-sec-ix-hidden: hidden-fact-74">nil</span> and $<ix:nonFraction contextRef="c192" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-23061">35,864</ix:nonFraction> for right to use trademarks, respectively.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-20677"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
15 &#8212; TAXES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>(a)
Corporate Income Taxes (&#8220;CIT&#8221;)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration:underline">Cayman
Islands</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Under
the current tax laws of the Cayman Islands, Universe INC is not subject to tax on its income or capital gains. In addition, no Cayman
Islands withholding tax will be imposed upon the payment of dividends by the Company to its shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration:underline">Hong
Kong</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Universe
HK is incorporated in Hong Kong and is subject to profit taxes in Hong Kong at a rate of <ix:nonFraction contextRef="c201" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-23062">16.5</ix:nonFraction>%. However, Universe HK did not generate
any assessable profits derived from Hong Kong sources for the years ended September 30, 2024, 2023 and 2022, and accordingly no provision
for Hong Kong profits tax has been made in these periods.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_2" id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration:underline">PRC</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxHolidayDescription-c0_cont_1" name="us-gaap:IncomeTaxHolidayDescription" id="ixv-20729"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Under
the Enterprise Income Tax (&#8220;EIT&#8221;) Law of PRC, domestic enterprises and Foreign Investment Enterprises (&#8220;FIEs&#8221;)
are usually subject to a unified 25% enterprise income tax rate while preferential tax rates, tax holidays and even tax exemption may
be granted on a case-by-case basis. EIT grants preferential tax treatment to High and New Technology Enterprises (&#8220;HNTEs&#8221;).
Under this preferential tax treatment, HNTEs are entitled to an income tax rate of 15%, subject to a requirement that they re-apply for
their HNTE status every three years. Jiangxi Universe, one of the Company&#8217;s main operating subsidiaries in the PRC, was approved
as a HNTE and is entitled to a reduced income tax rate of 15% beginning November 2016 with a term of three years. In December 2019 and
November 2022, Jiangxi Universe successfully renewed its HNTE certification with local government and will continue to enjoy the reduced
income tax rate of 15% for three years, respectively, through November 2025. Universe Trade, another operating subsidiary of the Company
in the PRC, was approved as a HNTE and was entitled to a reduced income tax rate of 15% beginning December 2020 with a term of three
years through December 2023. </span></ix:nonNumeric><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:continuation continuedAt="_IncomeTaxHolidayDescription-c0_cont_2" id="_IncomeTaxHolidayDescription-c0_cont_1">Universe Trade did not
successfully renew its HNTE status at the end of December 2023 and, therefore, has been subject to the standard PRC enterprise income
tax rate of 25% starting from January 2024. </ix:continuation><span style="background-color: white"><ix:continuation id="_IncomeTaxHolidayDescription-c0_cont_2">EIT is typically governed by the local tax authority
in the PRC. Each local tax authority at times may grant tax holidays to local enterprises as a way to encourage entrepreneurship and
stimulate local economy. The corporate income taxes for the years ended September 30, 2024, 2023 and 2022 were reported at a blended
reduced rate as a result of certain of the PRC subsidiaries of the Company&#8217;s being approved as a HNTE and enjoying a 15% reduced
income tax rate. Although Jiangxi Universe was approved as a HNTE and enjoying a <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" unitRef="pure" id="ixv-23065">15</ix:nonFraction>% reduced income tax rate, it incurred operating loss
for the year ended September 30, 2024, with no impact of the tax holidays on PRC corporate income taxes for the year ended September
30, 2024.</ix:continuation> The impact of the tax holidays noted above decreased PRC corporate income taxes by $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxHolidayAggregateDollarAmount" scale="0" unitRef="usd" id="ixv-23066">309,840</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxHolidayAggregateDollarAmount" scale="0" unitRef="usd" id="ixv-23067">694,955</ix:nonFraction> for the years ended
September 30, 2023 and 2022, respectively. The benefit of the tax holidays on net income per share (basic and diluted) was $<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare" scale="0" unitRef="usdPershares" id="ixv-23068">0.09</ix:nonFraction> and
$<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare" scale="0" unitRef="usdPershares" id="ixv-23069">0.19</ix:nonFraction> for the years ended September 30, 2023 and 2022, respectively.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="ixv-20735"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
components of the income tax </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expense <span style="background-color: white">(benefit)
are as follows:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current tax expense:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cayman</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Hong Kong</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 1.5pt">PRC</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-23070">685,937</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-23071">1,357,697</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Sub-total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-23072">685,937</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-23073">1,357,697</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax expense (benefit):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cayman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Hong Kong</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">PRC</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-23074">606,704</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-23075">1,567,656</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd" id="ixv-23076">542,375</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Sub-total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-23077">606,704</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-23078">1,567,656</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd" id="ixv-23079">542,375</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total income tax expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-23080">606,704</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-23081">2,253,593</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-23082">815,322</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-20925"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table reconciles the China statutory rates to the Company&#8217;s effective tax rate for the years ended September 30, 2024,
2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Statutory PRC income tax rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-23083">25.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-23084">25.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-23085">25.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of income tax holiday</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays" scale="-2" unitRef="pure" id="ixv-23086">5.9</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays" scale="-2" unitRef="pure" id="ixv-23087">8.2</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays" scale="-2" unitRef="pure" id="ixv-23088">9.2</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent difference</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" scale="-2" sign="-" unitRef="pure" id="ixv-23089">0.1</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" scale="-2" sign="-" unitRef="pure" id="ixv-23090">25.1</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-PRC entities not subject to PRC income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" sign="-" unitRef="pure" id="ixv-23091">2.7</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" sign="-" unitRef="pure" id="ixv-23092">4.4</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" sign="-" unitRef="pure" id="ixv-23093">2.2</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" sign="-" unitRef="pure" id="ixv-23094">23.9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" sign="-" unitRef="pure" id="ixv-23095">64.4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Effective tax rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" sign="-" unitRef="pure" id="ixv-23096">7.5</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" sign="-" unitRef="pure" id="ixv-23097">52.1</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" sign="-" unitRef="pure" id="ixv-23098">11.5</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative
rulings. As of September 30, 2024, all of the Company&#8217;s tax returns of its PRC subsidiaries remain open for statutory examination
by PRC tax authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-21054"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Deferred
tax assets are composed of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Net operating loss carry-forwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-23099">599,078</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd" id="ixv-23100">599,078</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total deferred tax assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" unitRef="usd" id="ixv-23101">599,078</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company periodically evaluates the likelihood of the realization of deferred tax assets, and reduces the carrying amount of the deferred
tax assets by a valuation allowance to the extent it believes a portion will not be realized. Management considers new evidence, both
positive and negative, that could affect the Company&#8217;s future realization of deferred tax assets including its recent cumulative
earnings experience, expectation of future income, the carry forward periods available for tax reporting purposes and other relevant
factors. Jiangxi Universe and Universe Trade incurred net loss during the years ended September 30, 2024 and 2023, the Company determined
that its deferred tax assets might not be realized, and recognized valuation allowance for all deferred tax assets as of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September&#160;30,
2024<span style="background-color: white">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>(b)
Taxes payable</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="upc:ScheduleOfTaxPayableTableTextBlock" id="ixv-21150"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Taxes
payable consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Value added tax payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="upc:ValueAddedTaxPayable" scale="0" unitRef="usd" id="ixv-23102">873,750</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="upc:ValueAddedTaxPayable" scale="0" unitRef="usd" id="ixv-23103">303,713</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other taxes payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="upc:OtherTaxesPayable" scale="0" unitRef="usd" id="ixv-23104">147,431</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="upc:OtherTaxesPayable" scale="0" unitRef="usd" id="ixv-23105">131,045</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total taxes payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="0" unitRef="usd" id="ixv-23106">1,021,181</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="0" unitRef="usd" id="ixv-23107">434,758</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="ixv-21203"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
16 &#8212; CONCENTRATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">A
majority of the Company&#8217;s revenue and expense transactions are denominated in RMB and a significant portion of the Company&#8217;s
and its subsidiaries&#8217; assets and liabilities are denominated in RMB. RMB is not freely convertible into foreign currencies. In
the PRC, certain foreign exchange transactions are required by law to be transacted only by authorized financial institutions at exchange
rates set by the People&#8217;s Bank of China (&#8220;PBOC&#8221;). Remittances in currencies other than RMB by the Company in China
must be processed through the PBOC or other China foreign exchange regulatory bodies which require certain supporting documentation in
order to affect the remittance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of September 30, 2024 and 2023, $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignFinancialInstitutionsMandatedDeposits" scale="0" unitRef="usd" id="ixv-23108">4,430,607</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignFinancialInstitutionsMandatedDeposits" scale="0" unitRef="usd" id="ixv-23109">5,223,573</ix:nonFraction>&#160;of the Company&#8217;s cash, respectively, was on deposit at financial
institutions in the PRC. For the years ended September 30, 2024, 2023 and 2022, the Company&#8217;s substantial assets were located in
the PRC and the Company&#8217;s substantial revenues were derived from its subsidiaries located in the PRC.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_ConcentrationRiskDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For
the years ended September 30, 2024, 2023 and 2022, no single customer accounted for more than 10% of the Company&#8217;s total revenue.
The Company&#8217;s top 10 customers aggregately accounted for <ix:nonFraction contextRef="c210" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-23110">22.5</ix:nonFraction>%, <ix:nonFraction contextRef="c211" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-23111">27.2</ix:nonFraction>% and <ix:nonFraction contextRef="c212" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-23112">32.2</ix:nonFraction>% of the Company&#8217;s total revenue for the years
ended September 30, 2024, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Sales
of one of the Company&#8217;s major products, Guben Yanling Pill, accounted for&#160;<ix:nonFraction contextRef="c213" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-23113">37.2</ix:nonFraction>%, <ix:nonFraction contextRef="c214" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-23114">36.4</ix:nonFraction>% and <ix:nonFraction contextRef="c215" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-23115">42.5</ix:nonFraction>% of the Company&#8217;s total
revenue for the years ended September 30, 2024, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of September 30, 2024 and 2023, no customer accounted for more than&#160;10% of the total accounts receivable balance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For
the year ended September 30, 2024, two suppliers accounted for <ix:nonFraction contextRef="c216" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-23116">28.0</ix:nonFraction>% and <ix:nonFraction contextRef="c217" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-23117">13.4</ix:nonFraction>% of the total purchases, respectively. For the years ended
September 30, 2023 and 2022, one supplier accounted for <ix:nonFraction contextRef="c218" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-23118">29.6</ix:nonFraction>% and <ix:nonFraction contextRef="c219" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-23119">10.3</ix:nonFraction>% of the total purchases, respectively. </span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-21252"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
17 &#8212; SHAREHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Ordinary
Shares</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Universe
INC was incorporated under the laws of the Cayman Islands on December 11, 2019. The original authorized number of ordinary shares upon
incorporation was&#160;<ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23120">50,000</ix:nonFraction>&#160;shares with par value of US$<ix:nonFraction contextRef="c220" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23121">1.00</ix:nonFraction>&#160;per share and&#160;<ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-23122">50,000</ix:nonFraction>&#160;shares were issued. On August
7, 2020, the Company amended its Memorandum of Association to increase the authorized number of shares to&#160;<ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23123">100,000,000</ix:nonFraction>&#160;shares
with par value of $<ix:nonFraction contextRef="c221" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23124">0.003125</ix:nonFraction>&#160;per share, and subdivide the original issued shares from&#160;<ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="upc:OriginalShareIssued" scale="0" unitRef="shares" id="ixv-23125">50,000</ix:nonFraction>&#160;shares at par value of $<ix:nonFraction contextRef="c222" decimals="2" format="ixt:num-dot-decimal" name="upc:OriginalSharesParValue" scale="0" unitRef="usdPershares" id="ixv-23126">1.00</ix:nonFraction>&#160;per
share to&#160;<ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-23127">16,000,000</ix:nonFraction>&#160;ordinary shares with par value of $<ix:nonFraction contextRef="c221" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23128">0.003125</ix:nonFraction>&#160;per share.&#160;As a result of this forward split of the
<ix:nonNumeric contextRef="c0" name="us-gaap:StockholdersEquityNoteStockSplit" id="ixv-23129">outstanding ordinary shares at a ratio of 320-for-1 share</ix:nonNumeric>, a total of <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="upc:ShareIssuedAfterTheSplit" scale="0" unitRef="shares" id="ixv-23130"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="upc:ShareOutstandingAfterTheSplit" scale="0" unitRef="shares" id="ixv-23131">16,000,000</ix:nonFraction></ix:nonFraction> shares were issued and outstanding after the split.&#160;The
issuance of these&#160;<ix:nonFraction contextRef="c222" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-23132">16,000,000</ix:nonFraction>&#160;shares is considered as a part of the Reorganization of the Company, which was retroactively applied
as if the transaction occurred at the beginning of the period presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Increased
authorized share capital and share consolidation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 3, 2023, the Company held an annual general meeting of shareholders at which shareholders, among other things, resolved:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with immediate effect, to increase the Company&#8217;s authorized share capital from US$<ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalUnits" scale="0" unitRef="usd" id="ixv-23133">312,500</ix:nonFraction> divided into <ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23134">90,000,000</ix:nonFraction> ordinary shares of par value US$<ix:nonFraction contextRef="c57" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23135">0.003125</ix:nonFraction> each and <ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23136">10,000,000</ix:nonFraction> preferred shares of par value US$<ix:nonFraction contextRef="c57" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23137">0.003125</ix:nonFraction> each, to US$<ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalUnits" scale="0" unitRef="usd" id="ixv-23138">3,125,000</ix:nonFraction> divided into <ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23139">900,000,000</ix:nonFraction> ordinary shares of par value US$<ix:nonFraction contextRef="c61" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23140">0.003125</ix:nonFraction> each and <ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23141">100,000,000</ix:nonFraction> preferred shares of par value US$<ix:nonFraction contextRef="c61" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23142">0.003125</ix:nonFraction> each;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that, conditional upon the approval of the board of directors of the Company in its sole discretion, with effect as of the date the board of directors of the Company may determine, the authorized, issued and outstanding shares of the Company be consolidated by consolidating each 10 shares of the Company, or such lesser whole share amount as the board of directors may determine in its sole discretion, such amount not to be less than 2, into 1 share of the Company, with such consolidated shares having the same rights and being subject to the same restrictions (save as to nominal value) as the then existing shares of par value US$<ix:nonFraction contextRef="c40" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23143">0.003125</ix:nonFraction> each in the capital of the Company; and</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that, upon the effectiveness
    of the 2023 Share Consolidation, the Company adopt amended and restated articles of association, in substantially the form set out
    in Annex B in the proxy statement dated May 24, 2023, in substitution for and to the exclusion of, the memorandum of association
    of the Company in effect immediately prior to effectiveness of the 2023 Share Consolidation.</span></td></tr>
  </table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
board of directors of the Company resolved to effect the 2023 Share Consolidation on July 27, 2023 with the authorized, issued and outstanding
shares to be consolidated on a six (6) for one (1) ratio, which had the effect of reducing the number of: (a) authorized ordinary shares
from <ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23144">900,000,000</ix:nonFraction> ordinary shares with a par value of US$<ix:nonFraction contextRef="c62" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23145">0.003125</ix:nonFraction> per share to <ix:nonFraction contextRef="c223" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23146">150,000,000</ix:nonFraction> ordinary shares with a par value of US$<ix:nonFraction contextRef="c224" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23147">0.01875</ix:nonFraction>
per share; (b) issued and outstanding ordinary shares from <ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-23148"><ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-23149">21,750,000</ix:nonFraction></ix:nonFraction> ordinary shares with a par value of US$<ix:nonFraction contextRef="c65" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23150">0.003125</ix:nonFraction> per share to <ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-23151"><ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-23152">3,625,000</ix:nonFraction></ix:nonFraction>
ordinary shares with a par value of US$<ix:nonFraction contextRef="c66" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23153">0.01875</ix:nonFraction> per share; and (c) authorized preferred shares from <ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23154">100,000,000</ix:nonFraction> preferred shares with
a par value of US$<ix:nonFraction contextRef="c67" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23155">0.003125</ix:nonFraction> per share to <ix:nonFraction contextRef="c68" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23156">16,666,666.6666</ix:nonFraction> preferred shares with a par value of US$<ix:nonFraction contextRef="c68" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23157">0.01875</ix:nonFraction> per share. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 15, 2024, the Company closed its self-underwritten public offering of <ix:nonFraction contextRef="c225" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-23158">20,000,000</ix:nonFraction> ordinary shares, par value $<ix:nonFraction contextRef="c226" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23159">0.01875</ix:nonFraction> per share.
The ordinary shares were priced at $<ix:nonFraction contextRef="c70" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-23160">1.25</ix:nonFraction> per share. The Company raised a total of $<ix:nonFraction contextRef="c227" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" unitRef="usd" id="ixv-23161">25</ix:nonFraction> million through that offering, before deducting
offering-related expenses, and net proceeds of $<ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" unitRef="usd" id="ixv-23162">24.625</ix:nonFraction> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 27, 2024, the Company held an annual general meeting of shareholders at which shareholders, among other things, resolved:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with immediate effect, to increase the Company&#8217;s authorized share capital from US$<ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalUnits" scale="0" unitRef="usd" id="ixv-23163">3,125,000</ix:nonFraction> divided into <ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23164">150,000,000</ix:nonFraction> ordinary shares of par value US$<ix:nonFraction contextRef="c79" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23165">0.01875</ix:nonFraction> each and <ix:nonFraction contextRef="c228" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23166">16,666,666.6666</ix:nonFraction> preferred shares of par value US$<ix:nonFraction contextRef="c228" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23167">0.01875</ix:nonFraction> each, to US$<ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalUnits" scale="0" unitRef="usd" id="ixv-23168">140,625,000</ix:nonFraction> divided into <ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockDividendsShares" scale="0" unitRef="shares" id="ixv-23169">6,750,000,000</ix:nonFraction> ordinary shares of par value US$<ix:nonFraction contextRef="c229" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23170">0.01875</ix:nonFraction> each and <ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23171">750,000,000</ix:nonFraction> preferred shares of par value US$<ix:nonFraction contextRef="c76" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23172">0.01875</ix:nonFraction> each;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that, subject to and immediately
    following the Authorized Share Capital Increase being effected, the Company adopt an amended and restated memorandum of association
    in substitution for, and to the exclusion of, the Company&#8217;s existing memorandum of association, to reflect the Authorized Share
    Capital Increase; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that, conditional upon
    the approval of the board of directors of the Company in its sole discretion, with effect as of the date the board of directors of
    the Company may determine, the authorized, issued, and outstanding shares of the Company be consolidated by consolidating each 15
    Shares of the Company, or such lesser whole share amount as the board of directors of the Company may determine in its sole discretion,
    such amount not to be less than 2, into 1 Share of the Company, with such consolidated Shares having the same rights and being subject
    to the same restrictions (save as to nominal value) as the existing Shares of such class as set out in the Company&#8217;s memorandum
    and articles of association.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 12, 2024, the Company effected a
share consolidation of <ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-23173">15</ix:nonFraction> ordinary shares with par value of US$0.01875 per share each in the Company&#8217;s issued and unissued share
capital into <ix:nonFraction contextRef="c81" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares" id="ixv-23174">one</ix:nonFraction> (1) ordinary share with par value of US$<ix:nonFraction contextRef="c81" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23175">0.28125</ix:nonFraction>. All fractional shares were rounded up to the whole number of shares.
Immediately following the Share Consolidation, the authorized share capital of the Company was US$<ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalUnits" scale="0" unitRef="usd" id="ixv-23176">140,625,000</ix:nonFraction> divided into <ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23177">450,000,000</ix:nonFraction>
ordinary shares, par value US$<ix:nonFraction contextRef="c81" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23178">0.28125</ix:nonFraction> per share and <ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23179">50,000,000</ix:nonFraction> preferred shares, par value US$<ix:nonFraction contextRef="c83" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23180">0.28125</ix:nonFraction> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 24, 2025, the Company effected a share consolidation
of <ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-23181">40</ix:nonFraction> ordinary shares with par value of US$<ix:nonFraction contextRef="c84" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-23182">0.28125</ix:nonFraction> per share each in the Company&#8217;s issued and unissued share capital into one ordinary
share with par value of US$<ix:nonFraction contextRef="c84" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23183">11.25</ix:nonFraction>. All fractional shares were rounded up to the whole number of shares. Immediately following the Share
Consolidation, the authorized share capital of the Company was US$<ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalUnits" scale="0" unitRef="usd" id="ixv-23184">140,625,000</ix:nonFraction> divided into <ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23185">11,250,000</ix:nonFraction> ordinary shares, par value US$<ix:nonFraction contextRef="c84" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23186">11.25</ix:nonFraction>
per share and <ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23187">1,250,000</ix:nonFraction> preferred shares, par value US$<ix:nonFraction contextRef="c84" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23188">11.25</ix:nonFraction> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company&#8217;s
consolidated financial statements were retrospectively restated for effect of the 15-for-1 and 40-for-1 Shares Consolidations (see Note
1). Giving effect to the Share Consolidation, there were <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-23189"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-23190">42,880</ix:nonFraction></ix:nonFraction> ordinary shares issued and outstanding as of September 30, 2024.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">As of September
30, 2024 and 2023, the Company had a total of&#160;<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-23191"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-23192">42,880</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-23193"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-23194">6,062</ix:nonFraction></ix:nonFraction>&#160;ordinary shares issued and outstanding, respectively.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Underwriter
warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
connection with the Company&#8217;s IPO, the Company also agreed to issue warrants to the underwriter, for a nominal consideration of
$<ix:nonFraction contextRef="c230" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-23195">0.001</ix:nonFraction>&#160;per warrant, to purchase&#160;<ix:nonFraction contextRef="c231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-23196">300,000</ix:nonFraction>&#160;ordinary shares of the Company (equal to&#160;<ix:nonFraction contextRef="c230" decimals="2" format="ixt:num-dot-decimal" name="upc:OrdinarySharesSoldPercentage" scale="-2" unitRef="pure" id="ixv-23197">6</ix:nonFraction>% of the total number of ordinary
shares sold in the IPO, not including any ordinary shares sold in the over-allotment option) (the &#8220;Underwriter Warrants&#8221;).
The Underwriter Warrants have a term of <ix:nonNumeric contextRef="c2" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="ixv-23198">five years</ix:nonNumeric>, each warrant is exercisable for 1/90 share, with an exercise price of $<ix:nonFraction contextRef="c230" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" unitRef="usd" id="ixv-23199">495</ix:nonFraction> after
adjustments due to share consolidations. The Underwriter Warrants may be purchased in cash or via cashless exercise, are exercisable
for five (<ix:nonNumeric contextRef="c230" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="ixv-23200">5</ix:nonNumeric>) years, and will terminate on the fifth anniversary of the closing of the IPO. Management determined that the Underwriter
Warrants meet the requirements for equity classification under ASC 815-40 because they are indexed to its own stock. As of September
30, 2024, the Underwriter Warrants were issued and outstanding, but none of them had been exercised. For the years ended September 30,
2024, 2023 and 2022, the Underwriter Warrants were antidilutive and accordingly were not included in the diluted EPS calculation based
on treasury stock method.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 144; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Statutory
reserve and restricted net assets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company&#8217;s PRC subsidiaries are restricted in their ability to transfer a portion of their net assets to the Company. The payment
of dividends by entities organized in China is subject to limitations, procedures and formalities. Regulations in the PRC currently permit
payment of dividends only out of accumulated profits as determined in accordance with accounting standards and regulations in China.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company is required to make appropriations to certain reserve funds, comprising the statutory surplus reserve and the discretionary surplus
reserve, based on after-tax net income determined in accordance with generally accepted accounting principles of the PRC (&#8220;PRC
GAAP&#8221;). Appropriations to the statutory surplus reserve are required to be at least&#160;<ix:nonFraction contextRef="c232" decimals="2" format="ixt:num-dot-decimal" name="upc:StatutorySurplusPercentage" scale="-2" unitRef="pure" id="ixv-23201">10</ix:nonFraction>% of the after-tax net income determined
in accordance with PRC GAAP until the reserve is equal to&#160;<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="upc:ReserveIsEqualPercentage" scale="-2" unitRef="pure" id="ixv-23202">50</ix:nonFraction>% of the entity&#8217;s registered capital. Appropriations to the discretionary
surplus reserve are made at the discretion of the board of directors. The statutory reserve may be applied against prior year losses,
if any, and may be used for general business expansion and production or increase in registered capital, but are not distributable as
cash dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Relevant
PRC laws and regulations restrict the Company&#8217;s PRC subsidiaries from transferring a portion of their net assets, equivalent to
their statutory reserves and their share capital, to the Company in the form of loans, advances or cash dividends. Only PRC entities&#8217;
accumulated profits may be distributed as dividends to the Company without the consent of a third party. As of September 30, 2024 and
2023, the restricted amounts as determined pursuant to PRC statutory laws totaled $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="upc:StatutoryReserve" scale="0" unitRef="usd" id="ixv-23203">2,439,535</ix:nonFraction>, and total restricted net assets amounted
to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="upc:RestrictedNetAssets" scale="0" unitRef="usd" id="ixv-23204">56,786,656</ix:nonFraction> and $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="upc:RestrictedNetAssets" scale="0" unitRef="usd" id="ixv-23205">31,786,663</ix:nonFraction>, respectively.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-21420"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
18 &#8212; COMMITMENTS AND CONTINGENCIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">From
time to time, the Company may become a party to various legal actions arising in the ordinary course of business. The Company accrues
costs associated with these matters when they become probable and the amount can be reasonably estimated. Legal costs incurred in connection
with loss contingencies are expensed as incurred. For the years ended September 30, 2024, 2023 and 2022, the Company did not have any
material legal claims or litigation that, individually or in aggregate, could have a material adverse impact on the Company&#8217;s consolidated
financial position, results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company has an ongoing CIP project associated with the construction of a new manufacturing facility. As of September 30, 2024, future
minimum capital expenditures on the Company&#8217;s CIP project amounted to approximately $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractualObligation" scale="6" unitRef="usd" id="ixv-23206">13.7</ix:nonFraction>&#160;million, among which, approximately
$<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="6" unitRef="usd" id="ixv-23207">7.1</ix:nonFraction>&#160;million is required for the next 12 months from the date of this report (see Note 11).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
May 6, 2021, the Company entered into a real estate property purchase agreement with Jiangxi Yueshang, an entity in which the Company&#8217;s
chief executive officer, Mr. Gang Lai, owned <ix:nonFraction contextRef="c233" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-23208">5</ix:nonFraction>% of its equity interests as of the date of that agreement. Pursuant to this purchase agreement,
Jiangxi Yueshang will sell and the Company will purchase certain residential apartments and commercial office space totaling <ix:nonFraction contextRef="c139" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" unitRef="sqm" id="ixv-23209">2,749.30</ix:nonFraction>
square meters, with a total purchase price of RMB<ix:nonFraction contextRef="c139" decimals="-6" format="ixt:num-dot-decimal" name="upc:PrepaymentsMadeToARelatedPartyForPurchasesOfProperty" scale="6" unitRef="cny" id="ixv-23210">32</ix:nonFraction> million (approximately $<ix:nonFraction contextRef="c139" decimals="-5" format="ixt:num-dot-decimal" name="upc:PrepaymentsMadeToARelatedPartyForPurchasesOfProperty" scale="6" unitRef="usd" id="ixv-23211">4.6</ix:nonFraction> million). As of September 30, 2024, the Company had made
a prepayment of RMB<ix:nonFraction contextRef="c234" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" scale="6" unitRef="cny" id="ixv-23212">16</ix:nonFraction> million (approximately $<ix:nonFraction contextRef="c234" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" scale="6" unitRef="usd" id="ixv-23213">2.3</ix:nonFraction> million) to Jiangxi Yueshang. The remaining balance is expected to be paid by April
2025 (see Note 12).</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 145; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-21452"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
19 &#8212; SUBSEQUENT EVENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 12, 2024, the Company effected a share consolidation of <ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-23214">15</ix:nonFraction> ordinary shares with par value of US$<ix:nonFraction contextRef="c80" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-23215">0.01875</ix:nonFraction> per share each in the
Company&#8217;s issued and unissued share capital into one (<ix:nonFraction contextRef="c235" decimals="0" format="ixt:num-dot-decimal" name="upc:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-23216">1</ix:nonFraction>) ordinary share with par value of US$<ix:nonFraction contextRef="c80" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23217">0.28125</ix:nonFraction>. All fractional shares were
rounded up to the whole number of shares. Immediately following the Share Consolidation, the authorized share capital of the Company
was US$<ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalUnits" scale="0" unitRef="usd" id="ixv-23218">140,625,000</ix:nonFraction> divided into <ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23219">450,000,000</ix:nonFraction> ordinary shares, par value US$<ix:nonFraction contextRef="c81" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23220">0.28125</ix:nonFraction> per share and <ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23221">50,000,000</ix:nonFraction> preferred shares, par value
US$<ix:nonFraction contextRef="c83" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23222">0.28125</ix:nonFraction> per share. The Company&#8217;s consolidated financial statements were retrospectively restated for effect of the 15-for-1
share consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 6, 2024, the Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with
certain purchasers named thereto, pursuant to which the Company agreed to issue and sell (i) <ix:nonFraction contextRef="c236" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-23223">388,000</ix:nonFraction> ordinary shares (the
&#8220;Offered Shares&#8221;), par value $<ix:nonFraction contextRef="c237" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23224">0.28125</ix:nonFraction> per share (the &#8220;ordinary shares&#8221;), (ii) <ix:nonFraction contextRef="c238" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-23225">18,362,000</ix:nonFraction> pre-funded warrants
to purchase <ix:nonFraction contextRef="c239" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-23226">18,362,000</ix:nonFraction> ordinary shares (the &#8220;Pre-funded Warrants&#8221;), and (iii) <ix:nonFraction contextRef="c240" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-23227">18,750,000</ix:nonFraction> common warrants to purchase
<ix:nonFraction contextRef="c241" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-23228">18,750,000</ix:nonFraction> ordinary shares (the &#8220;Common Warrants&#8221;), at a combined purchase price of US0.80 per Offered Share and one
accompanying Common Warrant, or at a combined purchase price of US$<ix:nonFraction contextRef="c238" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-23229">0.79</ix:nonFraction> per Pre-funded Warrant (in lieu of one Offered Share) and
one accompanying Common Warrant, in a registered direct offering (the &#8220;Offering&#8221;). The Company received approximately
$<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" unitRef="usd" id="ixv-23230">15.0</ix:nonFraction> million in gross proceeds from the Offering, before deducting placement agent fees and estimated offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
December 20, 2024, the equity transfer contract to transfer <ix:nonFraction contextRef="c242" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-23231">51</ix:nonFraction>% ownership in Yunnan Faxi was terminated due to unsatisfactory performance
of Yunnan Faxi. The prepayment for acquisition of $<ix:nonFraction contextRef="c243" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="0" unitRef="usd" id="ixv-23232">3,562,472</ix:nonFraction> (RMB<ix:nonFraction contextRef="c243" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="6" unitRef="cny" id="ixv-23233">25</ix:nonFraction>&#160;million) was reclassified to other receivable as of September
30, 2024, and collected back subsequently. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On March 24, 2025, the Company
effected a share consolidation of <ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-23234">40</ix:nonFraction> ordinary shares with par value of US$<ix:nonFraction contextRef="c84" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-23235">0.28125</ix:nonFraction> per share each in the Company&#8217;s issued and unissued
share capital into one ordinary share with par value of US$<ix:nonFraction contextRef="c84" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23236">11.25</ix:nonFraction>. All fractional shares were rounded up to the whole number of shares.
Immediately following the Share Consolidation, the authorized share capital of the Company was US$<ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalUnits" scale="0" unitRef="usd" id="ixv-23237">140,625,000</ix:nonFraction> divided into <ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23238">11,250,000</ix:nonFraction>
ordinary shares, par value US$<ix:nonFraction contextRef="c84" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23239">11.25</ix:nonFraction> per share and <ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23240">1,250,000</ix:nonFraction> preferred shares, par value US$<ix:nonFraction contextRef="c84" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23241">11.25</ix:nonFraction> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has assessed all subsequent events through the date that these consolidated financial statements are issued and there are no
further material subsequent events that require disclosure in these consolidated financial statements.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" id="ixv-21478"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
20 &#8212;FINANCIAL INFORMATION OF THE PARENT COMPANY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Pursuant
to the requirements of Rule 12-04(a), 5-04(c) and 4-08(e)(3) of Regulation S-X, the financial information of the parent company shall
be filed when the restricted net assets of consolidated subsidiaries exceed <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeNetAssetsPercentage" scale="-2" unitRef="pure" id="ixv-23242">25</ix:nonFraction> percent of consolidated net assets as of the end of the
most recently completed fiscal year. The Company performed a test on the restricted net assets of consolidated subsidiaries in accordance
with such requirement and concluded that it was applicable to the Company as the restricted net assets of the Company&#8217;s subsidiaries
exceeded&#160;<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="upc:MinorityInterestsOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-23243">25</ix:nonFraction>% of the consolidated net assets of the Company. Therefore, the financial statements for the parent company are included
herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For
purposes of the above test, restricted net assets of consolidated subsidiaries shall mean that amount of the Company&#8217;s proportionate
share of net assets of consolidated subsidiaries (after intercompany eliminations) which as of the end of the most recent fiscal year
may not be transferred to the parent company by subsidiaries in the form of loans, advances or cash dividends without the consent of
a third party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
financial information of the parent company has been prepared using the same accounting policies as set out in the Company&#8217;s consolidated
financial statements except that the parent company used the equity method to account for investment in its subsidiaries. Such investment
is presented on the balance sheets as &#8220;Investment in subsidiaries&#8221; and the respective profit or loss as &#8220;Equity in
earnings of subsidiaries&#8221; on the consolidated statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
footnote disclosures contain supplemental information relating to the operations of the Company and, as such, these statements should
be read in conjunction with the notes to the consolidated financial statements of the Company. Certain information and footnote disclosures
normally included in financial statements prepared in accordance with U.S GAAP have been or omitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of September 30, 2024 and 2023, there were no material contingencies, significant provisions for long-term obligations, or guarantees
of the Company, except for those which have been separately disclosed in the consolidated financial statements, if any.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNIVERSE
PHARMACEUTICALS INC AND SUBSIDIARIES</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="srt:ScheduleOfCondensedBalanceSheetTableTextBlock" id="ixv-21522"><ix:continuation continuedAt="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_2" id="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PARENT
COMPANY BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 9pt">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-23244">25,058,414</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-23245">9,248</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Other receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="0" unitRef="usd" id="ixv-23246">1,377,873</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="0" unitRef="usd" id="ixv-23247">1,367,052</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Due from subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c246" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-23248">10,863,833</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c247" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-23249">10,878,344</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c246" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-23250">37,300,120</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c247" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-23251">12,254,644</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; text-indent: -9pt; padding-left: 9pt">Non-current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Investment in subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="0" unitRef="usd" id="ixv-23252">8,749,310</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="0" unitRef="usd" id="ixv-23253">15,715,509</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-23254">46,049,430</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-23255">27,970,153</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Due to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c246" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-23256">497,014</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Accrued expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-23257">49,475</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">TOTAL CURRENT LIABILITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-23258">546,489</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">COMMITMENTS AND CONTINGENCIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Ordinary shares, $<ix:nonFraction contextRef="c244" decimals="2" format="ixt:num-dot-decimal" id="ix_40_fact" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c245" decimals="2" format="ixt:num-dot-decimal" id="ix_41_fact" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">11.25</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" id="ix_36_fact" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" id="ix_37_fact" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">11,250,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" id="ix_38_fact" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" id="ix_39_fact" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">42,880</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" id="ix_42_fact" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" id="ix_43_fact" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">6,062</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September 30, 2024 and 2023, respectively *</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" id="ix_34_fact" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">482,400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" id="ix_35_fact" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">67,973</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-23269">53,864,720</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-23270">29,279,155</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">(Accumulated deficit) Retained earnings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-23271">7,732,033</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" unitRef="usd" id="ixv-23272">995,265</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Accumulated other comprehensive loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-23273">1,112,146</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-23274">2,372,240</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total shareholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-23275">45,502,941</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-23276">27,970,153</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 27pt">Total liabilities and shareholders&#8217; equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-23277">46,049,430</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-23278">27,970,153</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><ix:footnote id="ix_10_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retrospectively restated for effect of 15-for-1 and 40-for-1 shares
consolidations.</span></ix:footnote></td>
</tr></table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 147; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNIVERSE
PHARMACEUTICALS INC AND SUBSIDIARIES</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="srt:CondensedStatementOfComprehensiveIncomeTableTextBlock" id="ixv-21856"><ix:continuation continuedAt="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_3" id="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PARENT
COMPANY STATEMENTS OF <span style="background-color: white">OPERATIONS AND COMPREHENSIVE LOSS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Operating costs and expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">General and administrative expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c248" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-23279">592,021</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c249" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-23280">134,141</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c250" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-23281">384,214</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expenses):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c248" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="0" unitRef="usd" id="ixv-23282">87,292</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c249" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="0" unitRef="usd" id="ixv-23283">730</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c250" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="0" unitRef="usd" id="ixv-23284">420</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity in earnings of subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c248" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" sign="-" unitRef="usd" id="ixv-23285">8,047,985</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c249" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" sign="-" unitRef="usd" id="ixv-23286">6,446,153</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c250" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" sign="-" unitRef="usd" id="ixv-23287">7,525,004</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c248" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-23288">8,727,298</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c249" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-23289">6,581,024</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c250" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-23290">7,909,638</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c248" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-23291">1,260,094</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c249" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-23292">779,351</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c250" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-23293">3,752,143</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Comprehensive loss attributable to the Company</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c248" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-23294">7,467,204</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c249" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-23295">7,360,375</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c250" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-23296">11,661,781</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 148; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNIVERSE
PHARMACEUTICALS INC AND SUBSIDIARIES</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="srt:ScheduleOfCondensedCashFlowStatementTableTextBlock" id="ixv-22053"><ix:continuation id="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PARENT
COMPANY STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c251" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-23297">8,727,298</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-23298">6,581,024</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c253" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-23299">7,909,638</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Adjustments to reconcile net cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 11.3pt; padding-left: 10pt">Equity in earnings of subsidiary</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c251" decimals="0" format="ixt:num-dot-decimal" name="upc:ChangeInFairValueOfShorttermInvestments" scale="0" sign="-" unitRef="usd" id="ixv-23300">8,047,985</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="upc:ChangeInFairValueOfShorttermInvestments" scale="0" sign="-" unitRef="usd" id="ixv-23301">6,446,153</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c253" decimals="0" format="ixt:num-dot-decimal" name="upc:ChangeInFairValueOfShorttermInvestments" scale="0" sign="-" unitRef="usd" id="ixv-23302">7,525,004</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Due to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c251" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" scale="0" unitRef="usd" id="ixv-23303">497,014</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Accrued expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c251" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-23304">49,475</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 3.3pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c251" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-23305">132,824</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-23306">134,871</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c253" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-23307">384,634</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net proceeds from issuance of ordinary shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c251" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-23308">24,999,992</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash repayment from subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c251" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromContributionsFromAffiliates" scale="0" unitRef="usd" id="ixv-23309">14,511</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromContributionsFromAffiliates" scale="0" unitRef="usd" id="ixv-23310">115,133</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c253" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromContributionsFromAffiliates" scale="0" unitRef="usd" id="ixv-23311">303,746</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c251" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-23312">25,014,503</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-23313">115,133</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c253" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-23314">303,746</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 1.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">EFFECT OF CHANGES OF FOREIGN EXCHANGE RATES ON CASH</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c251" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-23315">167,487</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-23316">69</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c253" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" sign="-" unitRef="usd" id="ixv-23317">588</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CHANGES IN CASH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c251" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd" id="ixv-23318">25,049,166</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd" id="ixv-23319">19,669</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c253" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd" id="ixv-23320">81,476</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">CASH, beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c254" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-23321">9,248</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c255" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-23322">28,917</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c256" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-23323">110,393</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">CASH, end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c257" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-23324">25,058,414</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c254" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-23325">9,248</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c255" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-23326">28,917</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-33</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c4" id="hidden-fact-0" name="us-gaap:OtherReceivablesNetCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-1" name="upc:PrepaymentForAcquisitionCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-2" name="us-gaap:DeferredIncomeTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-4" name="us-gaap:LongTermLoansFromBank" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-5" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-6" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-7" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-8" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-9" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-10" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-11" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-12" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-13" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-14" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-15" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-16" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-17" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-18" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-19" name="upc:StockIssuedDuringPeriodValueStatutoryReserve" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-20" name="upc:StockIssuedDuringPeriodValueStatutoryReserve" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-21" name="upc:StockIssuedDuringPeriodValueStatutoryReserve" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-22" name="upc:StockIssuedDuringPeriodValueStatutoryReserve" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-23" name="upc:StockIssuedDuringPeriodValueStatutoryReserve" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-24" name="upc:StockIssuedDuringPeriodValueStatutoryReserve" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-25" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-26" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-27" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-28" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-29" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-30" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-31" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-32" name="upc:StockIssuedDuringPeriodValueReverseShareSplitAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-33" name="upc:StockIssuedDuringPeriodValueReverseShareSplitAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-34" name="upc:StockIssuedDuringPeriodValueReverseShareSplitAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-35" name="upc:StockIssuedDuringPeriodValueReverseShareSplitAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-36" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-37" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-38" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-39" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-40" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-41" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-42" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-43" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-44" name="us-gaap:IncreaseDecreaseInPrepaidAdvertising" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-45" name="us-gaap:IncreaseDecreaseInPrepaidAdvertising" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-46" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-47" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-48" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-49" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-50" name="upc:IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-51" name="upc:IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-52" name="upc:ProceedsFromPaymentForConstructionInProgress" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-53" name="us-gaap:PaymentsToAcquireIntangibleAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-54" name="us-gaap:PaymentsToAcquireIntangibleAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-55" name="us-gaap:PaymentsToAcquireBusinessesGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-56" name="us-gaap:PaymentsToAcquireBusinessesGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-57" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-58" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-59" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-60" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-61" name="us-gaap:IncomeTaxesPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-62" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-63" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-64" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-65" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-66" name="us-gaap:ProvisionForDoubtfulAccounts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-67" name="us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-68" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-69" name="us-gaap:ReceivablesNetCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-70" name="us-gaap:PrepaidAdvertising" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c125" id="hidden-fact-71" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c129" id="hidden-fact-72" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c188" id="hidden-fact-73" name="us-gaap:LongTermLoansFromBank" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c191" id="hidden-fact-74" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c202" id="hidden-fact-75" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c203" id="hidden-fact-76" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c204" id="hidden-fact-77" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c201" id="hidden-fact-78" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c205" id="hidden-fact-79" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c206" id="hidden-fact-80" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c207" id="hidden-fact-81" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-82" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c202" id="hidden-fact-83" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c203" id="hidden-fact-84" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c204" id="hidden-fact-85" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c201" id="hidden-fact-86" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c205" id="hidden-fact-87" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c206" id="hidden-fact-88" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-89" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-90" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-91" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-92" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-93" name="us-gaap:DeferredTaxAssetsGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-94" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-95" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-96" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c247" id="hidden-fact-97" name="us-gaap:OtherLiabilitiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c245" id="hidden-fact-98" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c245" id="hidden-fact-99" name="us-gaap:LiabilitiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c244" id="hidden-fact-100" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c245" id="hidden-fact-101" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c252" id="hidden-fact-102" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c253" id="hidden-fact-103" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c252" id="hidden-fact-104" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c253" id="hidden-fact-105" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-23435">0001809616</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-23436">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-23437">FY</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="upc-20240930.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship xmlns="" fromRefs="ix_0_fact ix_1_fact ix_2_fact ix_3_fact ix_4_fact ix_5_fact ix_6_fact ix_7_fact ix_8_fact ix_9_fact" toRefs="ix_0_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_10_fact ix_11_fact ix_12_fact ix_13_fact ix_14_fact ix_15_fact" toRefs="ix_1_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_16_fact ix_17_fact ix_18_fact ix_19_fact ix_20_fact ix_21_fact" toRefs="ix_2_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_22_fact hidden-fact-69" toRefs="ix_3_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_23_fact ix_24_fact" toRefs="ix_4_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_25_fact ix_26_fact" toRefs="ix_5_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_27_fact ix_28_fact" toRefs="ix_6_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_29_fact ix_30_fact" toRefs="ix_7_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_31_fact ix_32_fact" toRefs="ix_8_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_33_fact hidden-fact-73" toRefs="ix_9_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_34_fact ix_35_fact ix_36_fact ix_37_fact ix_38_fact ix_39_fact ix_40_fact ix_41_fact ix_42_fact ix_43_fact" toRefs="ix_10_footnote"/>
<xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">upc:UniverseIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">upc:UniverseIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">upc:UniverseHKMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">upc:UniverseTechnologyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-29</xbrli:startDate>
    <xbrli:endDate>2021-03-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-29</xbrli:startDate>
    <xbrli:endDate>2021-03-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:CommonStockOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:CommonStockOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-15</xbrli:startDate>
    <xbrli:endDate>2024-07-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-07-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-07-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-15</xbrli:startDate>
    <xbrli:endDate>2024-07-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-27</xbrli:startDate>
    <xbrli:endDate>2024-09-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">upc:UniverseINCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">upc:UniverseTechnologyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">upc:UniverseHanheMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">upc:UniverseHKMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:UniversePharmaceuticalsIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:JxRcbBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:JxRcbBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">upc:OfficeAndElectricEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">upc:OfficeAndElectricEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UseRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">upc:YunnanFaxiPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrXiboLiuMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">upc:YunnanFaxiPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:YunnanFaxiPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:YunnanFaxiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">upc:LandUseRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">upc:LandUseRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYZDqnPZexC+e00+Rf6r37QtPu3oRrVmmTX8PuYVCFDMbRocUzw9EKKPK5NWC0WpJsOIuWkqeF3WWYzAuBG72bAUNWZ0EJoh7tCz07VxkYX3MUSJ7UFcJNPwN8yHmeKHRgkhMTd18uQzeusIsu/5w+1sTLgk4s48vHUWCmlxzr3HAZpsa+LfmHnFaLaCmPS0f6K1sduUUfaD9sRn5i3Vzu5VnzV9KOEHGDWQhDnV/BFeewWkVFaS1UAsDT9fYmumlUiO276JfSNTg==] CSR-->
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:ChenyuanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:ChenyuanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">upc:ConstructionInProgressTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:JiangxiYueshangMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-06</xbrli:startDate>
    <xbrli:endDate>2021-05-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiYueshangMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:LRCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:WorkingCapitalLoanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:LRCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-13</xbrli:startDate>
    <xbrli:endDate>2023-03-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:LRCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:LRCBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-15</xbrli:startDate>
    <xbrli:endDate>2023-06-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:WorkingCapitalLoanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-15</xbrli:startDate>
    <xbrli:endDate>2023-06-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:LRCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:LRCBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-04</xbrli:startDate>
    <xbrli:endDate>2024-03-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:LRCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:LRCBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-26</xbrli:startDate>
    <xbrli:endDate>2024-04-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:LRCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-05-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:LRCBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-05-17</xbrli:startDate>
    <xbrli:endDate>2024-05-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-03</xbrli:startDate>
    <xbrli:endDate>2025-03-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:LRCBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-03</xbrli:startDate>
    <xbrli:endDate>2025-03-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-22</xbrli:startDate>
    <xbrli:endDate>2024-04-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:BankOfCommunicationsCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:BankOfCommunicationsCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-15</xbrli:startDate>
    <xbrli:endDate>2023-06-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:BankOfCommunicationsCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:BankOfCommunicationsCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-16</xbrli:startDate>
    <xbrli:endDate>2023-06-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:ZhujiangRuralBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:ZhujiangRuralBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-05</xbrli:startDate>
    <xbrli:endDate>2023-05-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:ZhujiangRuralBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:ZhujiangRuralBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:ZhujiangRuralBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-24</xbrli:startDate>
    <xbrli:endDate>2024-04-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-18</xbrli:startDate>
    <xbrli:endDate>2025-04-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:ZhujiangRuralBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-18</xbrli:startDate>
    <xbrli:endDate>2025-04-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:BeijingBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:BeijingBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-24</xbrli:startDate>
    <xbrli:endDate>2023-07-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:BeijingBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:BeijingBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-07-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:BeijingBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-03</xbrli:startDate>
    <xbrli:endDate>2024-07-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:BeijingBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-07-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiLulingRuralCommercialBankLRCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiLulingRuralCommercialBankLRCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:BankOfCommunicationsCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:BankOfCommunicationsCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:ZhujiangRuralBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:ZhujiangRuralBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:BeijingBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:BeijingBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">upc:LRCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">upc:LRCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-23</xbrli:startDate>
    <xbrli:endDate>2023-11-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">upc:LRCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">upc:LRCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">upc:JiangxiYueshangMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:MrGangLaiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrGangLaiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrYajunHuMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MsLinYangMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:GuangzhouNingjingInvestmentCoLtdGuangzhouNingjingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrYajunHuMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrGangLaiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrGangLaiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MsLinYangMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KY</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KY</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KY</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:TopTenCustomersMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:TopTenCustomersMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:TopTenCustomersMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:CustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">upc:GubenYanlingPillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:CustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">upc:GubenYanlingPillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:CustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">upc:GubenYanlingPillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">upc:PurchaseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:supplierMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">upc:PurchaseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:TwoSupplierMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">upc:PurchaseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:supplierMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">upc:PurchaseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:supplierMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseINCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseINCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-08-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseINCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-07</xbrli:startDate>
    <xbrli:endDate>2020-08-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:CommonStockOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-15</xbrli:startDate>
    <xbrli:endDate>2024-07-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-07-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-15</xbrli:startDate>
    <xbrli:endDate>2024-07-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">upc:UnderwriterWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:UnderwriterWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:StatutoryReserveAndRestrictedNetAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:MrGangLaiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiYueshangMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-12</xbrli:startDate>
    <xbrli:endDate>2024-11-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-06</xbrli:startDate>
    <xbrli:endDate>2024-12-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c237">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c238">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">upc:PrefundedWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c239">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c240">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">upc:CommonWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c241">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">upc:CommonWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c242">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:YunnanFaxiMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-20</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c243">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:YunnanFaxiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c244">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c245">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c246">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:ParentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c247">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:ParentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c248">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c249">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c250">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c251">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c252">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c253">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c254">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c255">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c256">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c257">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="cny">
  <xbrli:measure>iso4217:CNY</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="sqm">
  <xbrli:measure>utr:sqm</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ea022807501ex1-1_universe.htm
<DESCRIPTION>AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION AND AMENDED AND RESTATED ARTICLES OF ASSOCIATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 1.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Companies Act (Revised)</P>
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Company Limited by Shares</P>
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; width: 70%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">AMENDED AND RESTATED<BR>
    memorandum of association<BR>
    OF<BR>
    UNIVERSE PHARMACEUTICALS INC</P>
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#22823;&#33258;&#28982;&#34277;&#26989;&#32929;&#20221;&#26377;&#38480;&#20844;&#21496;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P></TD>
    <TD STYLE="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Adopted by special resolution passed on 1 March
2025 and unanimous written director resolutions<BR>
 passed on 20 February 2025, and made effective on 24 March 2025)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex1-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Companies Act (Revised)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Company Limited by Shares</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Amended and Restated<BR>
Memorandum of Association</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">of</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Universe Pharmaceuticals INC</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#22823;&#33258;&#28982;&#34277;&#26989;&#32929;&#20221;&#26377;&#38480;&#20844;&#21496;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">(Adopted by special
resolution passed on 1 March 2025 and unanimous written director resolutions<BR>
 passed on 20 February 2025, and made effective on 24 March
2025)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">1</FONT></TD><TD STYLE="text-align: justify">The name of the Company is Universe Pharmaceuticals INC.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">2</FONT></TD><TD STYLE="text-align: justify">The Company's registered office will be situated at the offices of Vistra (Cayman) Limited P.O. Box 31119,
Grand Pavillion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1 &ndash; 1205, Cayman Islands or at such other place in the Cayman
Islands as the directors may at any time decide.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">3</FONT></TD><TD STYLE="text-align: justify">The Company's objects are unrestricted. As provided by section 7(4) of the Companies Act (Revised), the
Company has full power and authority to carry out any object not prohibited by any law of the Cayman Islands.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">4</FONT></TD><TD STYLE="text-align: justify">The Company has unrestricted corporate capacity. Without limitation to the foregoing, as provided by section
27 (2) of the Companies Act (Revised), the Company has and is capable of exercising all the functions of a natural person of full capacity
irrespective of any question of corporate benefit.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">5</FONT></TD><TD STYLE="text-align: justify">Nothing in any of the preceding paragraphs permits the Company to carry on any of the following businesses
without being duly licensed, namely:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the business of a bank or trust company without being licensed in that behalf under the Banks and Trust
Companies Act (Revised); or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">insurance business from within the Cayman Islands or the business of an insurance manager, agent, sub-agent
or broker without being licensed in that behalf under the Insurance Act (Revised);or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the business of company management without being licensed in that behalf under the Companies Management
Act (Revised).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">6</FONT></TD><TD STYLE="text-align: justify">Unless licensed to do so, the Company will not trade in the Cayman Islands with any person, firm or corporation
except in furtherance of its business carried on outside the Cayman Islands. Despite this, the Company may effect and conclude contracts
in the Cayman Islands and exercise in the Cayman Islands any of its powers necessary for the carrying on of its business outside the Cayman
Islands.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">7</FONT></TD><TD STYLE="text-align: justify">The Company is a company limited by shares and accordingly the liability of each member is limited to
the amount (if any) unpaid on that member's shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">8</FONT></TD><TD STYLE="text-align: justify">The share capital of the Company is US$140,625,000 divided into 11,250,000 Ordinary Shares of par value
US$11.25 each and 1,250,000 Preferred Shares of par value US$11.25 each. However, subject to the Companies Act (Revised) and the Company's
articles of association, the Company has power to do any one or more of the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">to redeem or repurchase any of its shares; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">to increase or reduce its capital; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">to issue any part of its capital (whether original, redeemed, increased or reduced):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 35.4pt">(i)</TD><TD STYLE="text-align: justify">with or without any preferential, deferred, qualified or special rights, privileges or conditions; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 35.4pt">(ii)</TD><TD STYLE="text-align: justify">subject to any limitations or restrictions</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify">and unless the condition of issue expressly
declares otherwise, every issue of shares (whether declared to be ordinary, preference or otherwise) is subject to this power; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">to alter any of those rights, privileges, conditions, limitations or restrictions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">9</FONT></TD><TD STYLE="text-align: justify">The Company has power to register by way of continuation as a body corporate limited by shares under the
laws of any jurisdiction outside the Cayman Islands and to be deregistered in the Cayman Islands.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Companies Act (Revised)</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Company Limited By Shares</B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.9pt; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECOND AMENDED AND RESTATED<BR>
 ARTICLES
    OF ASSOCIATION</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>OF</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNIVERSE PHARMACEUTICALS INC</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#22823;&#33258;&#28982;&#34277;&#26989;&#32929;&#20221;&#26377;&#38480;&#20844;&#21496;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.9pt; text-align: center">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(Adopted by special resolution passed on 23 September 2022)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex1-1_001.jpg" ALT=""></P>




<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.9pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.9pt; text-align: center"><B>CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.65in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.65in; text-indent: -0.5in"><FONT STYLE="font-weight: normal"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 5%; text-indent: 0in; font-weight: bold">1</TD>
    <TD STYLE="width: 85%; text-indent: 0in; font-weight: bold">Definitions, interpretation and exclusion of Table A</TD>
    <TD STYLE="text-align: center; width: 10%; font-weight: bold">1</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Definitions</TD>
    <TD STYLE="text-align: center">1</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Interpretation</TD>
    <TD STYLE="text-align: center">4</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Exclusion of Table A Articles</TD>
    <TD STYLE="text-align: center">5</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.05pt"></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; font-weight: bold">2</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Shares</TD>
    <TD STYLE="text-align: center; font-weight: bold">5</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Power to issue Shares and options, with or without special rights</TD>
    <TD STYLE="text-align: center">5</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Power to pay commissions and brokerage fees</TD>
    <TD STYLE="text-align: center">6</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Trusts not recognised</TD>
    <TD STYLE="text-align: center">7</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Security interests</TD>
    <TD STYLE="text-align: center">7</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Power to vary class rights</TD>
    <TD STYLE="text-align: center">7</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Effect of new Share issue on existing class rights</TD>
    <TD STYLE="text-align: center">7</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">No bearer Shares or warrants</TD>
    <TD STYLE="text-align: center">8</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Treasury Shares</TD>
    <TD STYLE="text-align: center">8</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Rights attaching to Treasury Shares and related matters</TD>
    <TD STYLE="text-align: center">8</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Register of Members</TD>
    <TD STYLE="text-align: center">8</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Annual Return</TD>
    <TD STYLE="text-align: center">9</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.05pt"></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; font-weight: bold">3</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Share certificates</TD>
    <TD STYLE="text-align: center; font-weight: bold">9</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Issue of share certificates</TD>
    <TD STYLE="text-align: center">9</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Renewal of lost or damaged share certificates</TD>
    <TD STYLE="text-align: center">9</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.05pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; font-weight: bold">4</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Lien on Shares</TD>
    <TD STYLE="text-align: center; font-weight: bold">10</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Nature and scope of lien</TD>
    <TD STYLE="text-align: center">10</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Company may sell Shares to satisfy lien</TD>
    <TD STYLE="text-align: center">10</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Authority to execute instrument of transfer</TD>
    <TD STYLE="text-align: center">10</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Consequences of sale of Shares to satisfy lien</TD>
    <TD STYLE="text-align: center">11</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Application of proceeds of sale</TD>
    <TD STYLE="text-align: center">11</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.05pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; font-weight: bold">5</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Calls on Shares and forfeiture</TD>
    <TD STYLE="text-align: center; font-weight: bold">11</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Power to make calls and effect of calls</TD>
    <TD STYLE="text-align: center">11</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Time when call made</TD>
    <TD STYLE="text-align: center">12</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Liability of joint holders</TD>
    <TD STYLE="text-align: center">12</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Interest on unpaid calls</TD>
    <TD STYLE="text-align: center">12</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Deemed calls</TD>
    <TD STYLE="text-align: center">12</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Power to accept early payment</TD>
    <TD STYLE="text-align: center">12</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Power to make different arrangements at time of issue of Shares</TD>
    <TD STYLE="text-align: center">12</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Notice of default</TD>
    <TD STYLE="text-align: center">13</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Forfeiture or surrender of Shares</TD>
    <TD STYLE="text-align: center">13</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Disposal of forfeited or surrendered Share and power to cancel forfeiture or surrender</TD>
    <TD STYLE="text-align: center">13</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Effect of forfeiture or surrender on former Member</TD>
    <TD STYLE="text-align: center">13</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Evidence of forfeiture or surrender</TD>
    <TD STYLE="text-align: center">14</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Sale of forfeited or surrendered Shares</TD>
    <TD STYLE="text-align: center">14</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.05pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; font-weight: bold">6</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Transfer of Shares</TD>
    <TD STYLE="text-align: center; font-weight: bold">14</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Right to transfer</TD>
    <TD STYLE="text-align: center">14</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Suspension of transfers</TD>
    <TD STYLE="text-align: center">15</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Company may retain instrument of transfer</TD>
    <TD STYLE="text-align: center">15</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Notice of refusal to register</TD>
    <TD STYLE="text-align: center">15</TD></TR>

<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; font-weight: bold">7</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Transmission of Shares</TD>
    <TD STYLE="text-align: center; font-weight: bold">16</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Persons entitled on death of a Member</TD>
    <TD STYLE="text-align: center">16</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Registration of transfer of a Share following death or bankruptcy</TD>
    <TD STYLE="text-align: center">16</TD></TR>

<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Indemnity</TD>
    <TD STYLE="text-align: center">16</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Rights of person entitled to a Share following death or bankruptcy</TD>
    <TD STYLE="text-align: center">17</TD></TR>
</TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; font-weight: bold; width: 5%">8</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold; width: 85%">Alteration of capital</TD>
    <TD STYLE="text-align: center; font-weight: bold; width: 10%">17</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Increasing, consolidating, converting, dividing and cancelling share capital</TD>
    <TD STYLE="text-align: center">17</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Dealing with fractions resulting from consolidation of Shares</TD>
    <TD STYLE="text-align: center">17</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Reducing share capital</TD>
    <TD STYLE="text-align: center">18</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.05pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; font-weight: bold">9</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Redemption and purchase of own Shares</TD>
    <TD STYLE="text-align: center; font-weight: bold">18</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Power to issue redeemable Shares and to purchase own Shares</TD>
    <TD STYLE="text-align: center">18</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Power to pay for redemption or purchase in cash or in specie</TD>
    <TD STYLE="text-align: center">18</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Effect of redemption or purchase of a Share</TD>
    <TD STYLE="text-align: center">19</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.05pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; font-weight: bold">10</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Meetings of Members</TD>
    <TD STYLE="text-align: center; font-weight: bold">19</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Annual and extraordinary general meetings</TD>
    <TD STYLE="text-align: center">19</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Power to call meetings</TD>
    <TD STYLE="text-align: center">19</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Content of notice</TD>
    <TD STYLE="text-align: center">20</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Period of notice</TD>
    <TD STYLE="text-align: center">21</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Persons entitled to receive notice</TD>
    <TD STYLE="text-align: center">21</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Accidental omission to give notice or non-receipt of notice</TD>
    <TD STYLE="text-align: center">21</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.05pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; font-weight: bold">11</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Proceedings at meetings of Members</TD>
    <TD STYLE="text-align: center; font-weight: bold">22</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Quorum</TD>
    <TD STYLE="text-align: center">22</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Lack of quorum</TD>
    <TD STYLE="text-align: center">22</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Chairman</TD>
    <TD STYLE="text-align: center">22</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Right of a Director to attend and speak</TD>
    <TD STYLE="text-align: center">22</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Accommodation of Members at meeting</TD>
    <TD STYLE="text-align: center">23</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Security</TD>
    <TD STYLE="text-align: center">23</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Adjournment</TD>
    <TD STYLE="text-align: center">23</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Method of voting</TD>
    <TD STYLE="text-align: center">23</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Outcome of vote by show of hands</TD>
    <TD STYLE="text-align: center">24</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Withdrawal of demand for a poll</TD>
    <TD STYLE="text-align: center">24</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Taking of a poll</TD>
    <TD STYLE="text-align: center">24</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Chairman&rsquo;s casting vote</TD>
    <TD STYLE="text-align: center">24</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Written resolutions</TD>
    <TD STYLE="text-align: center">24</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Sole-Member Company</TD>
    <TD STYLE="text-align: center">25</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.05pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; font-weight: bold">12</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Voting rights of Members</TD>
    <TD STYLE="text-align: center; font-weight: bold">25</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Right to vote</TD>
    <TD STYLE="text-align: center">25</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Rights of joint holders</TD>
    <TD STYLE="text-align: center">26</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Representation of corporate Members</TD>
    <TD STYLE="text-align: center">26</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Member with mental disorder</TD>
    <TD STYLE="text-align: center">26</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Objections to admissibility of votes</TD>
    <TD STYLE="text-align: center">27</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Form of proxy</TD>
    <TD STYLE="text-align: center">27</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">How and when proxy is to be delivered</TD>
    <TD STYLE="text-align: center">27</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Voting by proxy</TD>
    <TD STYLE="text-align: center">29</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.05pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; font-weight: bold">13</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Number of Directors</TD>
    <TD STYLE="text-align: center; font-weight: bold">29</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; font-weight: bold">14</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Appointment, disqualification and removal of Directors</TD>
    <TD STYLE="text-align: center; font-weight: bold">29</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">First Directors</TD>
    <TD STYLE="text-align: center">29</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">No age limit</TD>
    <TD STYLE="text-align: center">29</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Corporate Directors</TD>
    <TD STYLE="text-align: center">30</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">No shareholding qualification</TD>
    <TD STYLE="text-align: center">30</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Appointment of Directors</TD>
    <TD STYLE="text-align: center">30</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Board&rsquo;s power to appoint Directors</TD>
    <TD STYLE="text-align: center">30</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Eligibility</TD>
    <TD STYLE="text-align: center">30</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Appointment at annual general meeting</TD>
    <TD STYLE="text-align: center">31</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Removal of Directors</TD>
    <TD STYLE="text-align: center">31</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Resignation of Directors</TD>
    <TD STYLE="text-align: center">31</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Termination of the office of Director</TD>
    <TD STYLE="text-align: center">31</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.05pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; font-weight: bold; width: 5%">15</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold; width: 85%">Alternate Directors</TD>
    <TD STYLE="text-align: center; font-weight: bold; width: 10%">32</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Appointment and removal</TD>
    <TD STYLE="text-align: center">32</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Notices</TD>
    <TD STYLE="text-align: center">33</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Rights of alternate Director</TD>
    <TD STYLE="text-align: center">33</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Appointment ceases when the appointor ceases to be a Director</TD>
    <TD STYLE="text-align: center">33</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Status of alternate Director</TD>
    <TD STYLE="text-align: center">33</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Status of the Director making the appointment</TD>
    <TD STYLE="text-align: center">33</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.05pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; font-weight: bold">16</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Powers of Directors</TD>
    <TD STYLE="text-align: center; font-weight: bold">34</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Powers of Directors</TD>
    <TD STYLE="text-align: center">34</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Directors below the minimum number</TD>
    <TD STYLE="text-align: center">34</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Appointments to office</TD>
    <TD STYLE="text-align: center">34</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Provisions for employees</TD>
    <TD STYLE="text-align: center">35</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Exercise of voting rights</TD>
    <TD STYLE="text-align: center">35</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Remuneration</TD>
    <TD STYLE="text-align: center">35</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Disclosure of information</TD>
    <TD STYLE="text-align: center">36</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.05pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; font-weight: bold">17</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Delegation of powers</TD>
    <TD STYLE="text-align: center; font-weight: bold">36</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Power to delegate any of the Directors&rsquo; powers to a committee</TD>
    <TD STYLE="text-align: center">36</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Local boards</TD>
    <TD STYLE="text-align: center">37</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Power to appoint an agent of the Company</TD>
    <TD STYLE="text-align: center">37</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Power to appoint an attorney or authorised signatory of the Company</TD>
    <TD STYLE="text-align: center">37</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Borrowing Powers</TD>
    <TD STYLE="text-align: center">38</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Corporate Governance</TD>
    <TD STYLE="text-align: center">38</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.05pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; font-weight: bold">18</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Meetings of Directors</TD>
    <TD STYLE="text-align: center; font-weight: bold">38</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Regulation of Directors&rsquo; meetings</TD>
    <TD STYLE="text-align: center">38</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Calling meetings</TD>
    <TD STYLE="text-align: center">38</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Notice of meetings</TD>
    <TD STYLE="text-align: center">38</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Use of technology</TD>
    <TD STYLE="text-align: center">38</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Quorum</TD>
    <TD STYLE="text-align: center">39</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Chairman or deputy to preside</TD>
    <TD STYLE="text-align: center">39</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Voting</TD>
    <TD STYLE="text-align: center">39</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Recording of dissent</TD>
    <TD STYLE="text-align: center">39</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Written resolutions</TD>
    <TD STYLE="text-align: center">39</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Validity of acts of Directors in spite of formal defect</TD>
    <TD STYLE="text-align: center">40</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.05pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; font-weight: bold">19</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Permissible Directors&rsquo; interests and disclosure</TD>
    <TD STYLE="text-align: center; font-weight: bold">40</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; font-weight: bold">20</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Minutes</TD>
    <TD STYLE="text-align: center; font-weight: bold">41</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; font-weight: bold">21</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Accounts and audit</TD>
    <TD STYLE="text-align: center; font-weight: bold">41</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Auditors</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">42</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.05pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; font-weight: bold">22</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Record dates</TD>
    <TD STYLE="text-align: center; font-weight: bold">42</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; font-weight: bold">23</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Dividends</TD>
    <TD STYLE="text-align: center; font-weight: bold">42</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Source of dividends</TD>
    <TD STYLE="text-align: center">42</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Declaration of dividends by Members</TD>
    <TD STYLE="text-align: center">43</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Payment of interim dividends and declaration of final dividends by Directors</TD>
    <TD STYLE="text-align: center">43</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Apportionment of dividends</TD>
    <TD STYLE="text-align: center">44</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Right of set off</TD>
    <TD STYLE="text-align: center">44</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Power to pay other than in cash</TD>
    <TD STYLE="text-align: center">44</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">How payments may be made</TD>
    <TD STYLE="text-align: center">44</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Dividends or other monies not to bear interest in absence of special rights</TD>
    <TD STYLE="text-align: center">45</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Dividends unable to be paid or unclaimed</TD>
    <TD STYLE="text-align: center">45</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-top: 0.05pt; width: 5%">&nbsp;</TD>
    <TD STYLE="padding-top: 0.05pt; width: 85%">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.05pt; width: 10%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; font-weight: bold">24</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Capitalisation of profits</TD>
    <TD STYLE="text-align: center; font-weight: bold">45</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Capitalisation of profits or of any share premium account or capital redemption reserve;</TD>
    <TD STYLE="text-align: center">45</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Applying an amount for the benefit of Members</TD>
    <TD STYLE="text-align: center">46</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.05pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; font-weight: bold">25</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Share Premium Account</TD>
    <TD STYLE="text-align: center; font-weight: bold">46</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Directors to maintain share premium account</TD>
    <TD STYLE="text-align: center">46</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Debits to share premium account</TD>
    <TD STYLE="text-align: center">46</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.05pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; font-weight: bold">26</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Seal</TD>
    <TD STYLE="text-align: center; font-weight: bold">46</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Company seal</TD>
    <TD STYLE="text-align: center">46</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Duplicate seal</TD>
    <TD STYLE="text-align: center">47</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">When and how seal is to be used</TD>
    <TD STYLE="text-align: center">47</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">If no seal is adopted or used</TD>
    <TD STYLE="text-align: center">47</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Power to allow non-manual signatures and facsimile printing of seal</TD>
    <TD STYLE="text-align: center">47</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Validity of execution</TD>
    <TD STYLE="text-align: center">47</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.05pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; font-weight: bold">27</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Indemnity</TD>
    <TD STYLE="text-align: center; font-weight: bold">48</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Release</TD>
    <TD STYLE="text-align: center">48</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Insurance</TD>
    <TD STYLE="text-align: center">48</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.05pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; font-weight: bold">28</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Notices</TD>
    <TD STYLE="text-align: center; font-weight: bold">49</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Form of notices</TD>
    <TD STYLE="text-align: center">49</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Electronic communications</TD>
    <TD STYLE="text-align: center">49</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Persons entitled to notices</TD>
    <TD STYLE="text-align: center">50</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Persons authorised to give notices</TD>
    <TD STYLE="text-align: center">50</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Delivery of written notices</TD>
    <TD STYLE="text-align: center">51</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Joint holders</TD>
    <TD STYLE="text-align: center">51</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Signatures</TD>
    <TD STYLE="text-align: center">51</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Giving notice to a deceased or bankrupt Member</TD>
    <TD STYLE="text-align: center">51</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Date of giving notices</TD>
    <TD STYLE="text-align: center">52</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Saving provision</TD>
    <TD STYLE="text-align: center">52</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.05pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; font-weight: bold">29</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Authentication of Electronic Records</TD>
    <TD STYLE="text-align: center; font-weight: bold">52</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Application of Articles</TD>
    <TD STYLE="text-align: center">52</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Authentication of documents sent by Members by Electronic means</TD>
    <TD STYLE="text-align: center">52</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Authentication of document sent by the Secretary or Officers of the Company by Electronic means</TD>
    <TD STYLE="text-align: center">53</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Manner of signing</TD>
    <TD STYLE="text-align: center">53</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Saving provision</TD>
    <TD STYLE="text-align: center">53</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.05pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; font-weight: bold">30</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Transfer by way of continuation</TD>
    <TD STYLE="text-align: center; font-weight: bold">54</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; font-weight: bold">31</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Winding up</TD>
    <TD STYLE="text-align: center; font-weight: bold">54</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Distribution of assets in specie</TD>
    <TD STYLE="text-align: center">54</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">No obligation to accept liability</TD>
    <TD STYLE="text-align: center">55</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="padding-top: 0.05pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.05pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; font-weight: bold">32</TD>
    <TD STYLE="text-indent: 0in; font-weight: bold">Amendment of Memorandum and Articles</TD>
    <TD STYLE="text-align: center; font-weight: bold">55</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Power to change name or amend Memorandum</TD>
    <TD STYLE="text-align: center">55</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Power to amend these Articles</TD>
    <TD STYLE="text-align: center">55</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.65in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.65in; text-indent: -0.5in"></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vi<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Companies Act
(Revised) <BR>
Company Limited by Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Second Amended and Restated <BR>
Articles
of Association</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.9pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Universe Pharmaceuticals INC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#22823;&#33258;&#28982;&#34277;&#26989;&#32929;&#20221;&#26377;&#38480;&#20844;&#21496;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center">(Adopted by special resolution passed on
23 September 2022)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">1</TD><TD STYLE="text-align: justify">Definitions, interpretation and exclusion of Table A </TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"><B>Definitions</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">1.1</TD><TD STYLE="text-align: justify">In these Articles, the following definitions
                                            apply:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Act
</B></FONT>means the Companies Act (Revised) of the Cayman Islands, including any statutory modification or re-enactment thereof for the
time being in force;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ADS</B></FONT>
means an American depository share representing an Ordinary Share;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Articles</B></FONT>
means, as appropriate:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">these articles of association as amended from time to time:
or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">two or more particular
articles of these Articles;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">and <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
</B></FONT>refers to a particular article of these Articles;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Auditors</B></FONT>
means the auditor or auditors for the time being of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Board</B></FONT>
means the board of Directors from time to time;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Business
Day</B></FONT> means a day when banks in Grand Cayman, the Cayman Islands are open for the transaction of normal banking business and
for the avoidance of doubt, shall not include a Saturday, Sunday or public holiday in the Cayman Islands;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Cayman
Islands</B></FONT> means the British Overseas Territory of the Cayman Islands;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Clear
Days</B></FONT>, in relation to a period of notice, means that period excluding:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the day when the notice is given or deemed to be given; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the day for which it is given or on which it is to take effect;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Commission
</B></FONT>means Securities and Exchange Commission of the United States of America or other federal agency for the time being administering
the U.S. Securities Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Company</B></FONT>
means the above-named company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Default
Rate</B></FONT> means ten per cent per annum;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Designated
Stock Exchanges </B></FONT>means the Nasdaq Global Market in the United States of America for so long as the Company&rsquo;s Shares or
ADSs are there listed and any other stock exchange on which the Company&rsquo;s Shares or ADSs are listed for trading;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Designated
Stock Exchange Rules </B></FONT>means the relevant code, rules and regulations, as amended, from time to time, applicable as a result
of the original and continued listing of any Shares or ADSs on the Designated Stock Exchanges;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Directors</B></FONT>
means the directors for the time being of the Company and the expression Director shall be construed accordingly;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Electronic
</B></FONT>has the meaning given to that term in the Electronic Transactions Act (Revised) of the Cayman Islands<FONT STYLE="font-size: 10pt">;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Electronic
Record </B></FONT>has the meaning given to that term in the Electronic Transactions Act (Revised) of the Cayman Islands;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Electronic
Signature </B></FONT>has the meaning given to that term in the Electronic Transactions Act (Revised) of the Cayman Islands;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Fully
Paid Up</B></FONT> means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">in relation to a Share with par value, means that the par
value for that Share and any premium payable in respect of the issue of that Share, has been fully paid or credited as paid in money
or money&rsquo;s worth; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">in relation to a Share without par value, means that the agreed
issue price for that Share has been fully paid or credited as paid in money or money&rsquo;s worth;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>General
Meeting </B></FONT>means a general meeting of the Company duly constituted in accordance with the Articles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Independent
Director </B></FONT>means a Director who is an independent director as defined in the Designated Stock Exchange Rules as determined by
the Board;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Member
</B></FONT>means any person or persons entered on the register of Members from time to time as the holder of a Share;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Memorandum
</B></FONT>means the memorandum of association of the Company as amended from time to time;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>month</B></FONT>
means a calendar month;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Officer
</B></FONT>means a person appointed to hold an office in the Company including a Director, alternate Director or liquidator and excluding
the Secretary;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Ordinary
Resolution </B></FONT>means a resolution of a General Meeting passed by a simple majority of Members who (being entitled to do so) vote
in person or by proxy at that meeting. The expression includes a unanimous written resolution;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Ordinary
Share</B></FONT> means an ordinary share in the capital of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Partly
Paid Up</B></FONT> means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">in relation to a Share with par value, that the par value
for that Share and any premium payable in respect of the issue of that Share, has not been fully paid or credited as paid in money or
money&rsquo;s worth; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">in relation to a Share without par value, means that the agreed
issue price for that Share has not been fully paid or credited as paid in money or money&rsquo;s worth;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Preferred
Share</B></FONT> means a preferred share in the capital of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Secretary
</B></FONT>means a person appointed to perform the duties of the secretary of the Company, including a joint, assistant or deputy secretary;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Share</B></FONT>
means a share in the capital of the Company and the expression:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">includes stock (except where a distinction between shares
and stock is expressed or implied); and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.65pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">where the context permits, also includes a fraction of a Share;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Special
Resolution </B></FONT>means a resolution of a General Meeting or a resolution of a meeting of the holders of any class of Shares in a
class meeting duly constituted in accordance with the Articles in each case passed by a majority of not less than two-thirds of Members
who (being entitled to do so) vote in person or by proxy at that meeting. The expression includes a unanimous written resolution;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Treasury
Shares</B></FONT> means Shares held in treasury pursuant to the Act and Article 2.13; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>U.S.
Securities Act </B></FONT>means the Securities Act of 1933 of the United States of America, as amended, or any similar federal statute
and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Interpretation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.2</TD><TD>In the interpretation of these Articles, the following provisions apply unless the context otherwise requires:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">A reference in these Articles to a statute is a reference
to a statute of the Cayman Islands as known by its short title, and includes:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">any statutory modification, amendment or re-enactment; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">any subordinate legislation or regulations issued under that
statute.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Without limitation to the preceding
sentence, a reference to a revised Act of the Cayman Islands is taken to be a reference to the revision of that Act in force from time
to time as amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Headings are inserted for convenience only and do not affect
the interpretation of these Articles, unless there is ambiguity.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">If a day on which any act, matter or thing is to be done under
these Articles is not a Business Day, the act, matter or thing must be done on the next Business Day.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">A word which denotes the singular also denotes the plural,
a word which denotes the plural also denotes the singular, and a reference to any gender also denotes the other genders.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(e)</TD><TD STYLE="text-align: justify">A reference to a <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>person
</B></FONT>includes, as appropriate, a company, trust, partnership, joint venture, association, body corporate or government agency.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(f)</TD><TD STYLE="text-align: justify">Where a word or phrase is given a defined meaning another
part of speech or grammatical form in respect to that word or phrase has a corresponding meaning.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(g)</TD><TD STYLE="text-align: justify">All references to time are to be calculated by reference to
time in the place where the Company&rsquo;s registered office is located.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(h)</TD><TD STYLE="text-align: justify">The words <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>written
</B></FONT>and <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>in writing </B></FONT>include all modes of representing or
reproducing words in a visible form, but do not include an Electronic Record where the distinction between a document in writing and
an Electronic Record is expressed or implied.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">The words <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>including</B></FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>include </B></FONT>and <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>in
particular </B></FONT>or any similar expression are to be construed without limitation.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.3</TD><TD>The headings in these Articles are intended for convenience only and shall not affect the interpretation of these Articles.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Exclusion of Table A Articles</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">1.4</TD><TD STYLE="text-align: justify">The regulations contained in Table A in the First Schedule
of the Act and any other regulations contained in any statute or subordinate legislation are expressly excluded and do not apply to the
Company.</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">2</TD><TD>Shares</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Power to issue Shares and options, with or without
special rights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.1</TD><TD STYLE="text-align: justify">Subject to the provisions of the Act and these Articles about the redemption and purchase of the Shares,
the Directors have general and unconditional authority to allot (with or without confirming rights of renunciation), grant options over
or otherwise deal with any unissued Shares to such persons, at such times and on such terms and conditions as they may decide. No Share
may be issued at a discount except in accordance with the provisions of the Act.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">2.2</TD><TD STYLE="text-align: justify">Without limitation to the preceding Article, the Directors may so deal with the unissued Shares:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">either at a premium or at par; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">with or without preferred, deferred or other special rights
or restrictions, whether in regard to dividend, voting, return of capital or otherwise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">2.3</TD><TD STYLE="text-align: justify">Without limitation to the two preceding Articles, the Directors may refuse to accept any application for
Shares, and may accept any application in whole or in part, for any reason or for no reason.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">2.4</TD><TD STYLE="text-align: justify">Before any Preferred Shares of any series are issued, the Directors shall fix, by resolution or resolutions,
the following provisions of such series:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the designation of such series and the number of Preferred
Shares to constitute such series;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">whether the shares of such series shall have voting rights,
in addition to any voting rights provided by law, and, if so, the terms of such voting rights, which may be general or limited;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">the dividends, if any, payable on such series, whether any
such dividends shall be cumulative, and, if so, from what dates, the conditions and dates upon which such dividends shall be payable,
the preference or relation which such dividends shall bear to the dividends payable on any Shares of any other class of Shares or any
other series of Preferred Shares;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">whether the Preferred Shares or such series shall be subject
to redemption by the Company, and, if so, the times, prices and other conditions of such redemption;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(e)</TD><TD STYLE="text-align: justify">the amount or amounts payable upon Preferred Shares of such
series upon, and the rights of the holders of such series in, a voluntary or involuntary liquidation, dissolution or winding up, or upon
any distribution of the assets, of the Company;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(f)</TD><TD STYLE="text-align: justify">whether the Preferred Shares of such series shall be subject
to the operation of a retirement or sinking fund and, if so, the extent to and manner in which any such retirement or sinking fund shall
be applied to the purchase or redemption of the Preferred Shares of such series for retirement or other corporate purposes and the terms
and provisions relative to the operation of the retirement or sinking fund;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(g)</TD><TD STYLE="text-align: justify">whether the Preferred Shares of such series shall be convertible
into, or exchangeable for, Shares of any other class of Shares or any other series of Preferred Shares or any other securities and, if
so, the price or prices or the rate or rates of conversion or exchange and the method, if any, of adjusting the same, and any other terms
and conditions of conversion or exchange;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(h)</TD><TD STYLE="text-align: justify">the limitations and restrictions, if any, to be effective
while any Preferred Shares of such series are outstanding upon the payment of dividends or the making of other distributions on, and
upon the purchase, redemption or other acquisition by the Company of, the existing Shares or Shares of any other class of Shares or any
other series of Preferred Shares;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">the conditions or restrictions, if any, upon the creation
of indebtedness of the Company or upon the issue of any additional Shares, including additional shares of such series or of any other
class of Shares or any other series of Preferred Shares; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(j)</TD><TD STYLE="text-align: justify">any other powers, preferences and relative, participating,
optional and other special rights, and any qualifications, limitations and restrictions of any other class of Shares or any other series
of Preferred Shares.</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Power to pay commissions and brokerage fees</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">2.5</TD><TD STYLE="text-align: left">The Company may pay a commission to any person in consideration of that person:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">subscribing or agreeing to subscribe, whether absolutely or
conditionally; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">procuring or agreeing to procure subscriptions, whether absolute
or conditional,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">for any Shares. That commission may be satisfied by the
payment of cash or the allotment of Fully Paid Up or Partly Paid Up Shares or partly in one way and partly in another.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.6</TD><TD>The Company may employ a broker in the issue of its capital and pay him any proper commission or brokerage.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Trusts not recognised</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.7</TD><TD>Except as required by law:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">no person shall be recognised by the Company as holding any
Share on any trust; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">no person other than the Member shall be recognised by the
Company as having any right in a Share.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Security interests</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.8</TD><TD STYLE="text-align: justify">Notwithstanding the preceding Article, the Company may (but shall not be obliged to) recognise a security
interest of which it has actual notice over shares. The Company shall not be treated as having recognised any such security interest unless
it has so agreed in writing with the secured party.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Power to vary class rights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.9</TD><TD STYLE="text-align: justify">If the share capital is divided into different classes of Shares then, unless the terms on which a class
of Shares was issued state otherwise, the rights attaching to a class of Shares may only be varied if one of the following applies:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the Members holding not less than two-thirds of the issued
Shares of that class consent in writing to the variation; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the variation is made with the sanction of a Special Resolution
passed at a separate general meeting of the Members holding the issued Shares of that class.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.10</TD><TD STYLE="text-align: justify">For the purpose of Article 2.9(b), all the provisions of these Articles relating to general meetings apply,
mutatis mutandis, to every such separate meeting except that:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the necessary quorum shall be one or more persons holding,
or representing by proxy, not less than one third of the issued Shares of the class; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">any Member holding issued Shares of the class, present in
person or by proxy or, in the case of a corporate Member, by its duly authorised representative, may demand a poll.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Effect of new Share issue on existing class rights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.11</TD><TD STYLE="text-align: justify">Unless the terms on which a class of Shares was issued state otherwise, the rights conferred on the Member
holding Shares of any class shall not be deemed to be varied by the creation or issue of further Shares ranking <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>pari
passu </I></FONT>with the existing Shares of that class.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">No bearer Shares or warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.12</TD><TD>The Company shall not issue Shares or warrants to bearers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Treasury Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.13</TD><TD STYLE="text-align: justify">Shares that the Company purchases, redeems or acquires by way of surrender in accordance with the Act
shall be held as Treasury Shares and not treated as cancelled if:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the Directors so determine prior to the purchase, redemption
or surrender of those shares; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the relevant provisions of the Memorandum and Articles and
the Act are otherwise complied with.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Rights attaching to Treasury Shares and related matters</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.14</TD><TD STYLE="text-align: justify">No dividend may be declared or paid, and no other distribution (whether in cash or otherwise) of the Company&rsquo;s
assets (including any distribution of assets to Members on a winding up) may be made to the Company in respect of a Treasury Share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.15</TD><TD STYLE="text-align: justify">The Company shall be entered in the register of Members as the holder of the Treasury Shares. However:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the Company shall not be treated as a Member for any purpose
and shall not exercise any right in respect of the Treasury Shares, and any purported exercise of such a right shall be void; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">a Treasury Share shall not be voted, directly or indirectly,
at any meeting of the Company and shall not be counted in determining the total number of issued shares at any given time, whether for
the purposes of these Articles or the Act.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.16</TD><TD STYLE="text-align: justify">Nothing in Article 2.15 prevents an allotment of Shares as Fully Paid Up bonus shares in respect of a
Treasury Share and Shares allotted as Fully Paid Up bonus shares in respect of a Treasury Share shall be treated as Treasury Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.17</TD><TD STYLE="text-align: justify">Treasury Shares may be disposed of by the Company in accordance with the Act and otherwise on such terms
and conditions as the Directors determine.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Register of Members</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.18</TD><TD STYLE="text-align: justify">The Directors shall keep or cause to be kept a register of Members as required by the Act and may cause
the Company to maintain one or more branch registers as contemplated by the Act, provided that where the Company is maintaining one or
more branch registers, the Directors shall ensure that a duplicate of each branch register is kept with the Company&rsquo;s principal register
of Members and updated within such number of days of any amendment having been made to such branch register as may be required by the
Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Annual Return</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">2.19</TD><TD STYLE="padding-left: -0.125in; text-align: justify">The Directors in each calendar year shall prepare or cause to be prepared an annual return and declaration
setting forth the particulars required by the Act and shall deliver a copy thereof to the registrar of companies for the Cayman Islands.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35.4pt; text-align: left"><B>3</B></TD><TD STYLE="text-align: justify"><B>Share certificates </B></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"><B>Issue of share certificates</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">3.1</TD><TD STYLE="text-align: justify">A Member shall only be entitled to a share certificate if the Directors resolve that share certificates
shall be issued. Share certificates representing Shares, if any, shall be in such form as the Directors may determine. If the Directors
resolve that share certificates shall be issued, upon being entered in the register of Members as the holder of a Share, the Directors
may issue to any Member:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">without payment, one certificate for all the Shares of each
class held by that Member (and, upon transferring a part of the Member&rsquo;s holding of Shares of any class, to a certificate for the
balance of that holding); and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">upon payment of such reasonable sum as the Directors may determine
for every certificate after the first, several certificates each for one or more of that Member&rsquo;s Shares.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">3.2</TD><TD STYLE="text-align: justify">Every certificate shall specify the number, class and distinguishing numbers (if any) of the Shares to
which it relates and whether they are Fully Paid Up or Partly Paid Up. A certificate may be executed under seal or executed in such other
manner as the Directors determine.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">3.3</TD><TD STYLE="text-align: justify">Every certificate shall bear legends required under the applicable laws, including the U.S. Securities
Act.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">3.4</TD><TD STYLE="text-align: justify">The Company shall not be bound to issue more than one certificate for Shares held jointly by several persons
and delivery of a certificate for a Share to one joint holder shall be a sufficient delivery to all of them.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Renewal of lost or damaged share certificates</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">3.5</TD><TD STYLE="text-align: justify">If a share certificate is defaced, worn-out, lost or destroyed, it may be renewed on such terms (if any)
as to:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">evidence;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">indemnity;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">payment of the expenses reasonably incurred by the Company
in investigating the evidence; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">payment of a reasonable fee, if any for issuing a replacement
share certificate,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">as the Directors may determine, and (in the case of defacement
or wearing-out) on delivery to the Company of the old certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">4</TD><TD STYLE="text-align: justify">Lien on Shares </TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nature and scope of lien</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">4.1</TD><TD STYLE="text-align: justify">The Company has a first and paramount lien on all Shares (whether Fully Paid Up or not) registered in
the name of a Member (whether solely or jointly with others). The lien is for all monies payable to the Company by the Member or the Member&rsquo;s
estate:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">either alone or jointly with any other person, whether or
not that other person is a Member; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">whether or not those monies are presently payable.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">4.2</TD><TD STYLE="text-align: justify">At any time the Board may declare any Share to be wholly or partly exempt from the provisions of this
Article.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Company may sell Shares to satisfy lien</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">4.3</TD><TD STYLE="text-align: justify">The Company may sell any Shares over which it has a lien if all of the following conditions are met:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the sum in respect of which the lien exists is presently payable;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the Company gives notice to the Member holding the Share (or
to the person entitled to it in consequence of the death or bankruptcy of that Member) demanding payment and stating that if the notice
is not complied with the Shares may be sold; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">that sum is not paid within fourteen Clear Days after that
notice is deemed to be given under these Articles,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">and Shares to which this Article 4.3 applies shall be referred
to as Lien Default Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">4.4</TD><TD>The Lien Default Shares may be sold in such manner as the Board determines.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">4.5</TD><TD STYLE="text-align: justify">To the maximum extent permitted by law, the Directors shall incur no personal liability to the Member
concerned in respect of the sale.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Authority to execute instrument of transfer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">4.6</TD><TD STYLE="text-align: justify">To give effect to a sale, the Directors may authorise any person to execute an instrument of transfer
of the Lien Default Shares sold to, or in accordance with the directions of, the purchaser.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">4.7</TD><TD STYLE="text-align: justify">The title of the transferee of the Lien Default Shares shall not be affected by any irregularity or invalidity
in the proceedings in respect of the sale.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Consequences of sale of Shares to satisfy lien</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">4.8</TD><TD>On a sale pursuant to the preceding Articles:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the name of the Member concerned shall be removed from the
register of Members as the holder of those Lien Default Shares; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">that person shall deliver to the Company for cancellation
the certificate (if any) for those Lien Default Shares.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">4.9</TD><TD STYLE="text-align: justify">Notwithstanding the provisions of Article 4.8, such person shall remain liable to the Company for all
monies which, at the date of sale, were presently payable by him to the Company in respect of those Lien Default Shares. That person shall
also be liable to pay interest on those monies from the date of sale until payment at the rate at which interest was payable before that
sale or, failing that, at the Default Rate. The Board may waive payment wholly or in part or enforce payment without any allowance for
the value of the Lien Default Shares at the time of sale or for any consideration received on their disposal.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Application of proceeds of sale</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">4.10</TD><TD STYLE="text-align: justify">The net proceeds of the sale, after payment of the costs, shall be applied in payment of so much of the
sum for which the lien exists as is presently payable. Any residue shall be paid to the person whose Lien Default Shares have been sold:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">if no certificate for the Lien Default Shares was issued,
at the date of the sale; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">if a certificate for the Lien Default Shares was issued, upon
surrender to the Company of that certificate for cancellation</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">but, in either case, subject to the Company retaining a
like lien for all sums not presently payable as existed on the Lien Default Shares before the sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in">5</TD>
  <TD>Calls on Shares and forfeiture </TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"><B>Power to make calls and effect of calls</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">5.1</TD><TD STYLE="text-align: justify">Subject to the terms of allotment, the Board may make calls on the Members in respect of any monies unpaid
on their Shares including any premium. The call may provide for payment to be by instalments. Subject to receiving at least 14 Clear Days&rsquo;
notice specifying when and where payment is to be made, each Member shall pay to the Company the amount called on his Shares as required
by the notice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">5.2</TD><TD STYLE="text-align: justify">Before receipt by the Company of any sum due under a call, that call may be revoked in whole or in part
and payment of a call may be postponed in whole or in part. Where a call is to be paid in instalments, the Company
may revoke the call in respect of all or any remaining instalments in whole or in part and may postpone payment of all or any of the remaining
instalments in whole or in part.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">5.3</TD><TD STYLE="text-align: justify">A Member on whom a call is made shall remain liable for that call notwithstanding the subsequent transfer
of the Shares in respect of which the call was made. He shall not be liable for calls made after he is no longer registered as Member
in respect of those Shares.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Time when call made</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">5.4</TD><TD STYLE="text-align: justify">A call shall be deemed to have been made at the time when the resolution of the Directors authorising
the call was passed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Liability of joint holders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">5.5</TD><TD STYLE="text-align: justify">Members registered as the joint holders of a Share shall be jointly and severally liable to pay all calls
in respect of the Share.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Interest on unpaid calls</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">5.6</TD><TD STYLE="text-align: justify">If a call remains unpaid after it has become due and payable the person from whom it is due and payable
shall pay interest on the amount unpaid from the day it became due and payable until it is paid:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">at the rate fixed by the terms of allotment of the Share or
in the notice of the call; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">if no rate is fixed, at the Default Rate.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Directors may waive payment of
the interest wholly or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Deemed calls</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">5.7</TD><TD STYLE="text-align: justify">Any amount payable in respect of a Share, whether on allotment or on a fixed date or otherwise, shall
be deemed to be payable as a call. If the amount is not paid when due the provisions of these Articles shall apply as if the amount had
become due and payable by virtue of a call.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Power to accept early payment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">5.8</TD><TD STYLE="text-align: justify">The Company may accept from a Member the whole or a part of the amount remaining unpaid on Shares held
by him although no part of that amount has been called up.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Power to make different arrangements at time of issue
of Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">5.9</TD><TD STYLE="text-align: justify">Subject to the terms of allotment, the Directors may make arrangements on the issue of Shares to distinguish
between Members in the amounts and times of payment of calls on their Shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Notice of default</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">5.10</TD><TD STYLE="text-align: justify">If a call remains unpaid after it has become due and payable the Directors may give to the person from
whom it is due not less than 14 Clear Days&rsquo; notice requiring payment of:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the amount unpaid;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">any interest which may have accrued;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">any expenses which have been incurred by the Company due to
that person&rsquo;s default.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">5.11</TD><TD>The notice shall state the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the place where payment is to be made; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">a warning that if the notice is not complied with the Shares
in respect of which the call is made will be liable to be forfeited.</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Forfeiture or surrender of Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">5.12</TD><TD STYLE="text-align: justify">If the notice given pursuant to Article 5.10 is not complied with, the Directors may, before the payment
required by the notice has been received, resolve that any Share the subject of that notice be forfeited. The forfeiture shall include
all dividends or other monies payable in respect of the forfeited Share and not paid before the forfeiture. Despite the foregoing, the
Board may determine that any Share the subject of that notice be accepted by the Company as surrendered by the Member holding that Share
in lieu of forfeiture.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Disposal of forfeited or surrendered Share and power
to cancel forfeiture or surrender</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">5.13</TD><TD STYLE="text-align: justify">A forfeited or surrendered Share may be sold, re-allotted or otherwise disposed of on such terms and in
such manner as the Board determine either to the former Member who held that Share or to any other person. The forfeiture or surrender
may be cancelled on such terms as the Directors think fit at any time before a sale, re-allotment or other disposition. Where, for the
purposes of its disposal, a forfeited or surrendered Share is to be transferred to any person, the Directors may authorise some person
to execute an instrument of transfer of the Share to the transferee.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Effect of forfeiture or surrender on former Member</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">5.14</TD><TD>On forfeiture or surrender:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the name of the Member concerned shall be removed from the
register of Members as the holder of those Shares and that person shall cease to be a Member in respect of those Shares; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">that person shall surrender to the Company for cancellation
the certificate (if any) for the forfeited or surrendered Shares.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">5.15</TD><TD STYLE="text-align: justify">Despite the forfeiture or surrender of his Shares, that person shall remain liable to the Company for
all monies which at the date of forfeiture or surrender were presently payable by him to the Company in respect of those Shares together
with:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">all expenses; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">interest from the date of forfeiture or surrender until payment:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">at the rate of which interest was payable on those monies
before forfeiture; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">if no interest was so payable, at the Default Rate.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Directors, however, may waive payment wholly or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Evidence of forfeiture or surrender</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">5.16</TD><TD STYLE="text-align: justify">A declaration, whether statutory or under oath, made by a Director or the Secretary shall be conclusive
evidence of the following matters stated in it as against all persons claiming to be entitled to forfeited Shares:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">that the person making the declaration is a Director or Secretary
of the Company, and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">that the particular Shares have been forfeited or surrendered
on a particular date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Subject to the execution of an instrument of transfer, if
necessary, the declaration shall constitute good title to the Shares.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Sale of forfeited or surrendered Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">5.17</TD><TD STYLE="text-align: justify">Any person to whom the forfeited or surrendered Shares are disposed of shall not be bound to see to the
application of the consideration, if any, of those Shares nor shall his title to the Shares be affected by any irregularity in, or invalidity
of the proceedings in respect of, the forfeiture, surrender or disposal of those Shares.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in">6</TD>
  <TD>Transfer of Shares </TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Right to transfer</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">6.1</TD><TD STYLE="text-align: justify">The instrument of transfer of any Share shall be in writing and in any usual or common form or such other
form as the Directors may, in their absolute discretion, approve and be executed by or on behalf of the transferor and if in respect of
a nil or Partly Paid Up Share, or if so required by the Directors, shall also be executed on behalf of the transferee and shall be accompanied
by the certificate (if any) of the Shares to which it relates and such other evidence as the Directors may reasonably require to show
the right of the transferor to make the transfer. The transferor shall be deemed to remain a Member until the name of the transferee is
entered in the register of Members in respect of the relevant Shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">6.2</TD><TD STYLE="text-align: justify">The Directors may in their absolute discretion decline to register any transfer of Shares which is not
Fully Paid Up or on which the Company has a lien.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">6.3</TD><TD STYLE="text-align: justify">The Directors may also, but are not required to, decline to register any transfer of any Share unless:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -36.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the instrument of transfer is lodged with the Company, accompanied
by the certificate (if any) for the Shares to which it relates and such other evidence as the Board may reasonably require to show the
right of the transferor to make the transfer;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the instrument of transfer is in respect of only one class
of Shares;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">the instrument of transfer is properly stamped, if required;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">in the case of a transfer to joint holders, the number of
joint holders to whom the Share is to be transferred does not exceed four;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(e)</TD><TD STYLE="text-align: justify">the Shares transferred are Fully Paid Up and free of any lien
in favour of the Company; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(f)</TD><TD STYLE="text-align: justify">any applicable fee of such maximum sum as the Designated Stock
Exchanges may determine to be payable, or such lesser sum as the Board may from time to time require, related to the transfer is paid
to the Company.</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Suspension of transfers</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">6.4</TD><TD STYLE="text-align: justify">The registration of transfers may, on 14 days&rsquo; notice being given by advertisement in such one or
more newspapers or by electronic means, be suspended and the register of Members closed at such times and for such periods as the Directors
may, in their absolute discretion, from time to time determine, provided always that such registration of transfer shall not be suspended
nor the register of Members closed for more than 30 days in any year.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Company may retain instrument of transfer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">6.5</TD><TD>All instruments of transfer that are registered shall be retained by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Notice of refusal to register</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">6.6</TD><TD STYLE="text-align: justify">If the Directors refuse to register a transfer of any Shares, they shall within three months after the
date on which the instrument of transfer was lodged with the Company send to each of the transferor and the transferee notice of the refusal.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in">7</TD>
  <TD>Transmission of Shares </TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Persons entitled on death of a Member</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">7.1</TD><TD STYLE="text-align: justify">If a Member dies, the only persons recognised by the Company as having any title to the deceased Members&rsquo;
interest are the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">where the deceased Member was a joint holder, the survivor
or survivors; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">where the deceased Member was a sole holder, that Member&rsquo;s
personal representative or representatives.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">7.2</TD><TD STYLE="text-align: justify">Nothing in these Articles shall release the deceased Member&rsquo;s estate from any liability in respect
of any Share, whether the deceased was a sole holder or a joint holder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Registration of transfer of a Share following death
or bankruptcy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">7.3</TD><TD STYLE="text-align: justify">A person becoming entitled to a Share in consequence of the death or bankruptcy of a Member may elect
to do either of the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">to become the holder of the Share; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">to transfer the Share to another person.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">7.4</TD><TD STYLE="text-align: justify">That person must produce such evidence of his entitlement as the Directors may properly require.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">7.5</TD><TD STYLE="text-align: justify">If the person elects to become the holder of the Share, he must give notice to the Company to that effect.
For the purposes of these Articles, that notice shall be treated as though it were an executed instrument of transfer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">7.6</TD><TD>If the person elects to transfer the Share to another person then:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">if the Share is Fully Paid Up, the transferor must execute
an instrument of transfer; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">if the Share is nil or Partly Paid Up, the transferor and
the transferee must execute an instrument of transfer.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">7.7</TD><TD STYLE="text-align: justify">All the Articles relating to the transfer of Shares shall apply to the notice or, as appropriate, the
instrument of transfer.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Indemnity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">7.8</TD><TD STYLE="text-align: justify">A person registered as a Member by reason of the death or bankruptcy of another Member shall indemnify
the Company and the Directors against any loss or damage suffered by the Company or the Directors as a result of that registration.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Rights of person entitled to a Share following death
or bankruptcy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">7.9</TD><TD STYLE="text-align: justify">A person becoming entitled to a Share by reason of the death or bankruptcy of a Member shall have the
rights to which he would be entitled if he were registered as the holder of the Share. But, until he is registered as Member in respect
of the Share, he shall not be entitled to attend or vote at any meeting of the Company or at any separate meeting of the holders of that
class of Shares.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">8</TD><TD>Alteration of capital</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Increasing, consolidating, converting, dividing and
cancelling share capital</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">8.1</TD><TD STYLE="text-align: justify">To the fullest extent permitted by the Act, the Company may by Ordinary Resolution do any of the following
and amend its Memorandum for that purpose:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">increase its share capital by new Shares of the amount fixed
by that Ordinary Resolution and with the attached rights, priorities and privileges set out in that Ordinary Resolution;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">consolidate and divide all or any of its share capital into
Shares of larger amount than its existing Shares;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">convert all or any of its Paid Up Shares into stock, and reconvert
that stock into Paid Up Shares of any denomination;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">sub-divide its Shares or any of them into Shares of an amount
smaller than that fixed by the Memorandum, so, however, that in the sub-division, the proportion between the amount paid and the amount,
if any, unpaid on each reduced Share shall be the same as it was in case of the Share from which the reduced Share is derived; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(e)</TD><TD STYLE="text-align: justify">cancel Shares which, at the date of the passing of that Ordinary
Resolution, have not been taken or agreed to be taken by any person, and diminish the amount of its share capital by the amount of the
Shares so cancelled or, in the case of Shares without nominal par value, diminish the number of Shares into which its capital is divided.</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Dealing with fractions resulting from consolidation
of Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">8.2</TD><TD STYLE="text-align: justify">Whenever, as a result of a consolidation of Shares, any Members would become entitled to fractions of
a Share the Directors may on behalf of those Members deal with the fractions as it thinks fit, including (without limitation):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">either round up or down the fraction to the nearest whole
number, such rounding to be determined by the Directors acting in their sole discretion; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">sell the Shares representing the fractions for the best price
reasonably obtainable to any person (including, subject to the provisions of the Act, the Company); and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">distribute the net proceeds in due proportion among those
Members.</TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">8.3</TD><TD STYLE="text-align: justify">For the purposes of Article 8.2, the Directors may authorise some person to execute an instrument of transfer
of the Shares to, in accordance with the directions of, the purchaser. The transferee shall not be bound to see to the application of
the purchase money nor shall the transferee&rsquo;s title to the Shares be affected by any irregularity in, or invalidity of, the proceedings
in respect of the sale.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Reducing share capital</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">8.4</TD><TD STYLE="text-align: justify">Subject to the Act and to any rights for the time being conferred on the Members holding a particular
class of Shares, the Company may, by Special Resolution, reduce its share capital in any way.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">9</TD><TD>Redemption and purchase of own Shares</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Power to issue redeemable Shares and to purchase own
Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">9.1</TD><TD STYLE="text-align: justify">Subject to the Act and to any rights for the time being conferred on the Members holding a particular
class of Shares, the Company may by its Directors:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">issue Shares that are to be redeemed or liable to be redeemed,
at the option of the Company or the Member holding those redeemable Shares, on the terms and in the manner its Directors determine before
the issue of those Shares;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">with the consent by Special Resolution of the Members holding
Shares of a particular class, vary the rights attaching to that class of Shares so as to provide that those Shares are to be redeemed
or are liable to be redeemed at the option of the Company on the terms and in the manner which the Directors determine at the time of
such variation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">purchase all or any of its own Shares of any class including
any redeemable Shares on the terms and in the manner which the Directors determine at the time of such purchase.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company may make a payment in respect
of the redemption or purchase of its own Shares in any manner authorised by the Act, including out of any combination of the following:
capital, its profits and the proceeds of a fresh issue of Shares.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Power to pay for redemption or purchase in cash or
in specie</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">9.2</TD><TD STYLE="text-align: justify">When making a payment in respect of the redemption or purchase of Shares, the Directors may make the payment
in cash or <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>in specie </I></FONT>(or partly in one and partly in the other)
if so authorised by the terms of the allotment of those Shares or by the terms applying to those Shares in accordance with Article 9.1,
or otherwise by agreement with the Member holding those Shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Effect of redemption or purchase of a Share</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">9.3</TD><TD>Upon the date of redemption or purchase of a Share:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the Member holding that Share shall cease to be entitled to
any rights in respect of the Share other than the right to receive:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117.1pt; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">the price for the Share; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">any dividend declared in respect of the Share prior to the
date of redemption or purchase;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the Member&rsquo;s name shall be removed from the register
of Members with respect to the Share; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">the Share shall be cancelled or held as a Treasury Share,
as the Directors may determine.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt">9.4</TD><TD STYLE="text-align: justify">For the purpose of Article 9.3, the date of redemption or purchase is the date when the Member&rsquo;s name
is removed from the register of Members with respect to the Shares the subject of the redemption or purchase.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">10</TD><TD>Meetings of Members</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Annual and extraordinary general meetings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">10.1</TD><TD STYLE="text-align: justify">The Company may, but shall not (unless required by the Designated Stock Exchange Rules) be obligated to,
in each year hold a general meeting as an annual general meeting, which, if held, shall be convened by the Board, in accordance with these
Articles.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">10.2</TD><TD STYLE="text-align: justify">All general meetings other than annual general meetings shall be called extraordinary general meetings.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Power to call meetings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">10.3</TD><TD>The Directors may call a general meeting at any time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">10.4</TD><TD STYLE="text-align: justify">If there are insufficient Directors to constitute a quorum and the remaining Directors are unable to agree
on the appointment of additional Directors, the Directors must call a general meeting for the purpose of appointing additional Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">10.5</TD><TD STYLE="text-align: justify">The Directors must also call a general meeting if requisitioned in the manner set out in the next two
Articles.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">10.6</TD><TD STYLE="text-align: justify">The requisition must be in writing and given by one or more Members who together hold at least ten per
cent of the rights to vote at such general meeting.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">10.7</TD><TD>The requisition must also:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">specify the purpose of the meeting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">be signed by or on behalf of each requisitioner (and for this
purpose each joint holder shall be obliged to sign). The requisition may consist of several documents in like form signed by one or more
of the requisitioners; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">be delivered in accordance with the notice provisions.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">10.8</TD><TD STYLE="text-align: justify">Should the Directors fail to call a general meeting within 21 Clear Days&rsquo; from the date of receipt
of a requisition, the requisitioners or any of them may call a general meeting within three months after the end of that period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">10.9</TD><TD STYLE="text-align: justify">Without limitation to the foregoing, if there are insufficient Directors to constitute a quorum and the
remaining Directors are unable to agree on the appointment of additional Directors, any one or more Members who together hold at least
five per cent of the rights to vote at a general meeting may call a general meeting for the purpose of considering the business specified
in the notice of meeting which shall include as an item of business the appointment of additional Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">10.10</TD><TD STYLE="text-align: justify">If the Members call a meeting under the above provisions, the Company shall reimburse their reasonable
expenses.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Content of notice</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.35pt">10.11</TD><TD>Notice of a general meeting shall specify each of the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the place, the date and the hour of the meeting;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">if the meeting is to be held in two or more places, the technology
that will be used to facilitate the meeting;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">subject to paragraph (d) and the requirements of (to the extent
applicable) the Designated Stock Exchange Rules, the general nature of the business to be transacted; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">if a resolution is proposed as a Special Resolution, the text
of that resolution.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.35pt">10.12</TD><TD>In each notice there shall appear with reasonable prominence the following statements:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">that a Member who is entitled to attend and vote is entitled
to appoint one or more proxies to attend and vote instead of that Member; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">that a proxyholder need not be a Member.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Period of notice</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">10.13</TD><TD STYLE="text-align: justify">At least twenty-one Clear Days&rsquo; notice of an annual general meeting must be given to Members. For any
other general meeting, at least fourteen Clear Days&rsquo; notice must be given to Members.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">10.14</TD><TD STYLE="text-align: justify">Subject to the Act, a meeting may be convened on shorter notice, subject to the Act with the consent of
the Member or Members who, individually or collectively, hold at least ninety per cent of the voting rights of all those who have a right
to vote at that meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Persons entitled to receive notice</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">10.15</TD><TD STYLE="text-align: justify">Subject to the provisions of these Articles and to any restrictions imposed on any Shares, the notice
shall be given to the following people:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the Members</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">persons entitled to a Share in consequence of the death or
bankruptcy of a Member;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">the Directors; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">the Auditors.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">10.16</TD><TD STYLE="text-align: justify">The Board may determine that the Members entitled to receive notice of a meeting are those persons entered
on the register of Members at the close of business on a day determined by the Board.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Accidental omission to give notice or non-receipt of
notice</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.35pt">10.17</TD><TD>Proceedings at a meeting shall not be invalidated by the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">an accidental failure to give notice of the meeting to any
person entitled to notice; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">non-receipt of notice of the meeting by any person entitled
to notice.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">10.18</TD><TD STYLE="text-align: justify">In addition, where a notice of meeting is published on a website proceedings at the meeting shall not
be invalidated merely because it is accidentally published:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">in a different place on the website; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">for part only of the period from the date of the notification
until the conclusion of the meeting to which the notice relates.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in">11</TD>
  <TD>Proceedings at meetings of Members Quorum</TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">11.1</TD><TD STYLE="text-align: justify">Save as provided in the following Article, no business shall be transacted at any meeting unless a quorum
is present in person or by proxy. A quorum is as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">if the Company has only one Member: that Member;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">if the Company has more than one Member: one or more Members
holding Shares that represent not less than one-third of the outstanding Shares carrying the right to vote at such general meeting.</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Lack of quorum</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">11.2</TD><TD STYLE="text-align: justify">If a quorum is not present within fifteen minutes of the time appointed for the meeting, or if at any
time during the meeting it becomes inquorate, then the following provisions apply:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">If the meeting was requisitioned by Members, it shall be cancelled.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">In any other case, the meeting shall stand adjourned to the
same time and place seven days hence, or to such other time or place as is determined by the Directors. If a quorum is not present within
fifteen minutes of the time appointed for the adjourned meeting, then the Members present in person or by proxy shall constitute a quorum.</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Chairman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">11.3</TD><TD STYLE="text-align: justify">The chairman of a general meeting shall be the chairman of the Board or such other Director as the Directors
have nominated to chair Board meetings in the absence of the chairman of the Board. Absent any such person being present within fifteen
minutes of the time appointed for the meeting, the Directors present shall elect one of their number to chair the meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">11.4</TD><TD STYLE="text-align: justify">If no Director is present within fifteen minutes of the time appointed for the meeting, or if no Director
is willing to act as chairman, the Members present in person or by proxy and entitled to vote shall choose one of their number to chair
the meeting.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Right of a Director to attend and speak</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">11.5</TD><TD STYLE="text-align: justify">Even if a Director is not a Member, he shall be entitled to attend and speak at any general meeting and
at any separate meeting of Members holding a particular class of Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accommodation of Members at meeting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">11.6</TD><TD STYLE="text-align: justify">lf it appears to the chairman of the meeting that the meeting place specified in the notice convening
the meeting is inadequate to accommodate all Members entitled and wishing to attend, the meeting will be duly constituted and its proceedings
valid if the chairman is satisfied that adequate facilities are available to ensure
that a Member who is unable to be accommodated is able (whether at the meeting place or elsewhere):</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">to participate in the business for which the meeting has been
convened;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">to hear and see all persons present who speak (whether by
the use of microphones, loud-speakers, audio-visual communications equipment or otherwise); and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">to be heard and seen by all other persons present in the same
way.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Security</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">11.7</TD><TD STYLE="text-align: justify">In addition to any measures which the Board may be required to take due to the location or venue of the
meeting, the Board may make any arrangement and impose any restriction it considers appropriate and reasonable in the circumstances to
ensure the security of a meeting including, without limitation, the searching of any person attending the meeting and the imposing of
restrictions on the items of personal property that may be taken into the meeting place. The Board may refuse entry to, or eject from,
a meeting a person who refuses to comply with any such arrangements or restrictions.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Adjournment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">11.8</TD><TD STYLE="text-align: justify">The chairman may at any time adjourn a meeting with the consent of the Members constituting a quorum.
The chairman must adjourn the meeting if so directed by the meeting. No business, however, can be transacted at an adjourned meeting other
than business which might properly have been transacted at the original meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">11.9</TD><TD STYLE="text-align: justify">Should a meeting be adjourned for more than 7 Clear Days, whether because of a lack of quorum or otherwise,
Members shall be given at least seven Clear Days&rsquo; notice of the date, time and place of the adjourned meeting and the general nature of
the business to be transacted. Otherwise it shall not be necessary to give any notice of the adjournment.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Method of voting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">11.10</TD><TD STYLE="text-align: justify">A resolution put to the vote of the meeting shall be decided on a show of hands unless before, or on,
the declaration of the result of the show of hands, a poll is duly demanded. Subject to the Act, a poll may be demanded:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">by the chairman of the meeting;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">by at least two Members having the right to vote on the resolutions;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">by any Member or Members present who, individually or collectively,
hold at least ten per cent of the voting rights of all those who have a right to vote on the resolution.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Outcome of vote by show of hands</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">11.11</TD><TD STYLE="text-align: justify">Unless a poll is duly demanded, a declaration by the chairman as to the result of a resolution and an
entry to that effect in the minutes of the meeting shall be conclusive evidence of the outcome of a show of hands without proof of the
number or proportion of the votes recorded in favour of or against the resolution.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Withdrawal of demand for a poll</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">11.12</TD><TD STYLE="text-align: justify">The demand for a poll may be withdrawn before the poll is taken, but only with the consent of the chairman.
The chairman shall announce any such withdrawal to the meeting and, unless another person forthwith demands a poll, any earlier show of
hands on that resolution shall be treated as the vote on that resolution; if there has been no earlier show of hands, then the resolution
shall be put to the vote of the meeting.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Taking of a poll</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.35pt">11.13</TD><TD>A poll demanded on the question of adjournment shall be taken immediately.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">11.14</TD><TD STYLE="text-align: justify">A poll demanded on any other question shall be taken either immediately or at an adjourned meeting at
such time and place as the chairman directs, not being more than thirty Clear Days after the poll was demanded.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">11.15</TD><TD STYLE="text-align: justify">The demand for a poll shall not prevent the meeting continuing to transact any business other than the
question on which the poll was demanded.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">11.16</TD><TD STYLE="text-align: justify">A poll shall be taken in such manner as the chairman directs. He may appoint scrutineers (who need not
be Members) and fix a place and time for declaring the result of the poll. If, through the aid of technology, the meeting is held in more
than place, the chairman may appoint scrutineers in more than place; but if he considers that the poll cannot be effectively monitored
at that meeting, the chairman shall adjourn the holding of the poll to a date, place and time when that can occur.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Chairman&rsquo;s casting vote</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">11.17</TD><TD STYLE="text-align: justify">In the case of an equality of votes, whether on a show of hands or on a poll, the Chairman of the meeting
at which the show of hands takes place or at which the poll is demanded shall not be entitled to a second or casting vote.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Written resolutions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">11.18</TD><TD STYLE="text-align: justify">Members may pass a resolution in writing without holding a meeting if the following conditions are met:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">all Members entitled to vote are given notice of the resolution
as if the same were being proposed at a meeting of Members;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">all Members entitled so to vote;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">sign a document; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">sign several documents in the like form each signed by one
or more of those Members; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">the signed document or documents is or are delivered to the
Company, including, if the Company so nominates, by delivery of an Electronic Record by Electronic means to the address specified for
that purpose.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Such written resolution shall be as effective as if it had
been passed at a meeting of the Members entitled to vote duly convened and held.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">11.19</TD><TD STYLE="text-align: justify">If a written resolution is described as a Special Resolution or as an Ordinary Resolution, it has effect
accordingly.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">11.20</TD><TD STYLE="text-align: justify">The Directors may determine the manner in which written resolutions shall be put to Members. In particular,
they may provide, in the form of any written resolution, for each Member to indicate, out of the number of votes the Member would have
been entitled to cast at a meeting to consider the resolution, how many votes he wishes to cast in favour of the resolution and how many
against the resolution or to be treated as abstentions. The result of any such written resolution shall be determined on the same basis
as on a poll.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Sole-Member Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">11.21</TD><TD STYLE="text-align: justify">If the Company has only one Member, and the Member records in writing his decision on a question, that
record shall constitute both the passing of a resolution and the minute of it.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in">12</TD>
  <TD>Voting rights of Members </TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Right to vote</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">12.1</TD><TD STYLE="text-align: justify">Unless their Shares carry no right to vote, or unless a call or other amount presently payable has not
been paid, all Members are entitled to vote at a general meeting, whether on a show of hands or on a poll, and all Members holding Shares
of a particular class of Shares are entitled to vote at a meeting of the holders of that class of Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">12.2</TD><TD>Members may vote in person or by proxy.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">12.3</TD><TD STYLE="text-align: justify">On a show of hands, every Member shall have one vote. For the avoidance of doubt, an individual who represents
two or more Members, including a Member in that individual&rsquo;s own right, that individual shall be entitled to a separate vote for
each Member.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">12.4</TD><TD STYLE="text-align: justify">On a poll a Member shall have one vote for each Share he holds, unless any Share carries special voting
rights.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">12.5</TD><TD STYLE="text-align: justify">No Member is bound to vote on his Shares or any of them; nor is he bound to vote each of his Shares in
the same way.</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Rights of joint holders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">12.6</TD><TD STYLE="text-align: justify">If Shares are held jointly, only one of the joint holders may vote. If more than one of the joint holders
tenders a vote, the vote of the holder whose name in respect of those Shares appears first in the register of Members shall be accepted
to the exclusion of the votes of the other joint holder.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Representation of corporate Members</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">12.7</TD><TD STYLE="text-align: justify">Save where otherwise provided, a corporate Member must act by a duly authorised representative.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">12.8</TD><TD STYLE="text-align: justify">A corporate Member wishing to act by a duly authorised representative must identify that person to the
Company by notice in writing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">12.9</TD><TD STYLE="text-align: justify">The authorisation may be for any period of time, and must be delivered to the Company before the commencement
of the meeting at which it is first used.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">12.10</TD><TD STYLE="text-align: justify">The Directors of the Company may require the production of any evidence which they consider necessary
to determine the validity of the notice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">12.11</TD><TD STYLE="text-align: justify">Where a duly authorised representative is present at a meeting that Member is deemed to be present in
person; and the acts of the duly authorised representative are personal acts of that Member.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">12.12</TD><TD STYLE="text-align: justify">A corporate Member may revoke the appointment of a duly authorised representative at any time by notice
to the Company; but such revocation will not affect the validity of any acts carried out by the duly authorised representative before
the Directors of the Company had actual notice of the revocation.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Member with mental disorder</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">12.13</TD><TD STYLE="text-align: justify">A Member in respect of whom an order has been made by any court having jurisdiction (whether in the Cayman
Islands or elsewhere) in matters concerning mental disorder may vote, whether on a show of hands or on a poll, by that Member&rsquo;s
receiver, <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>curator bonis </I></FONT>or other person authorised in that behalf
appointed by that court.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">12.14</TD><TD STYLE="text-align: justify">For the purpose of the preceding Article, evidence to the satisfaction of the Directors of the authority
of the person claiming to exercise the right to vote must be received not less than 24 hours before holding the relevant meeting or the
adjourned meeting in any manner specified for the delivery of forms of appointment of a proxy, whether in writing or by Electronic means.
In default, the right to vote shall not be exercisable.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Objections to admissibility of votes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">12.15</TD><TD STYLE="text-align: justify">An objection to the validity of a person&rsquo;s vote may only be raised at the meeting or at the adjourned
meeting at which the vote is sought to be tendered. Any objection duly made shall be referred to the chairman whose decision shall be
final and conclusive.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Form of proxy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">12.16</TD><TD STYLE="text-align: justify">An instrument appointing a proxy shall be in any common form or in any other form approved by the Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.15pt; text-indent: -35.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.35pt">12.17</TD><TD>The instrument must be in writing and signed in one of the following ways:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">by the Member; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">by the Member&rsquo;s authorised attorney; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">if the Member is a corporation or other body corporate, under
seal or signed by an authorised officer, secretary or attorney.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">If the Directors so resolve, the Company
may accept an Electronic Record of that instrument delivered in the manner specified below and otherwise satisfying the Articles about
authentication of Electronic Records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">12.18</TD><TD STYLE="text-align: justify">The Directors may require the production of any evidence which they consider necessary to determine the
validity of any appointment of a proxy.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">12.19</TD><TD STYLE="text-align: justify">A Member may revoke the appointment of a proxy at any time by notice to the Company duly signed in accordance
with Article 12.17.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.15pt; text-indent: -35.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.35pt">12.20</TD><TD STYLE="text-align: justify">No revocation by a Member of the appointment of a proxy made in accordance with Article 12.19 will affect the validity of any acts carried out by
the relevant proxy before the Directors of the Company had actual notice of the revocation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">How and when proxy is to be delivered</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">12.21</TD><TD STYLE="text-align: justify">Subject to the following Articles, the Directors may, in the notice convening any meeting or
                                    adjourned meeting, or in an instrument of proxy sent out by the Company, specify the manner by which the instrument appointing a
                                    proxy shall be deposited and the place and the time (being not later than the time appointed for the commencement of the meeting or
                                    adjourned meeting to which the proxy relates) at which the instrument appointing a proxy shall be deposited. In the absence of any
                                    such direction from the Directors in the notice convening any meeting or adjourned meeting or in an instrument of proxy sent out by
                                    the Company, the form of appointment of a proxy and any authority under which it is signed (or a copy of the authority certified
                                    notarially or in any other way approved by the Directors) must be delivered so that it is received by the Company before the time
                                    for holding the meeting or adjourned meeting at which the person named in the form of appointment
of proxy proposes to vote. They must be delivered in either of the following ways:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">In the case of an instrument in writing, it must be left at
or sent by post:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">to the registered office of the Company; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">to such other place within the Cayman Islands specified in
the notice convening the meeting or in any form of appointment of proxy sent out by the Company in relation to the meeting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">If, pursuant to the notice provisions, a notice may be given
to the Company in an Electronic Record, an Electronic Record of an appointment of a proxy must be sent to the address specified pursuant
to those provisions unless another address for that purpose is specified:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117.1pt; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">in the notice convening the meeting; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">in any form of appointment of a proxy sent out by the Company
in relation to the meeting; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">in any invitation to appoint a proxy issued by the Company
in relation to the meeting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Notwithstanding Article 12.21(a) and Article 12.21(b), the
chairman of the Company may, in any event at his discretion, direct that an instrument of proxy shall be deemed to have been duly deposited.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.15pt; text-indent: -35.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.35pt">12.22</TD><TD>Where a poll is taken:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">if it is taken more than seven Clear Days after it is demanded,
the form of appointment of a proxy and any accompanying authority (or an Electronic Record of the same) must be delivered in accordance
with Article 12.21 before the time appointed for the taking of the poll;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">if it to be taken within seven Clear Days after it was demanded,
the form of appointment of a proxy and any accompanying authority (or an Electronic Record of the same) must be delivered in accordance
with Article 12.21 before the time appointed for the taking of the poll.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.15pt; text-indent: -35.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.35pt">12.23</TD><TD>If the form of appointment of proxy is not delivered on time, it is invalid.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">12.24</TD><TD STYLE="text-align: justify">When two or more valid but differing appointments of proxy are delivered or received in respect of
                                    the same Share for use at the same meeting and in respect of the same matter, the one which is last validly delivered or received
                                    (regardless of its date or of the date of its execution) shall be treated as replacing and revoking the other or others as regards
                                    that Share. lf the Company is unable to determine which appointment
was last validly delivered or received, none of them shall be treated as valid in respect of that Share.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">12.25</TD><TD STYLE="text-align: justify">The Board may at the expense of the Company send forms of appointment of proxy to the Members by post
(that is to say, pre-paying and posting a letter), or by Electronic communication or otherwise (with or without provision for their return
by pre-paid post) for use at any general meeting or at any separate meeting of the holders of any class of Shares, either blank or nominating
as proxy in the alternative any one or more of the Directors or any other person. lf for the purpose of any meeting invitations to appoint
as proxy a person or one of a number of persons specified in the invitations are issued at the Company&rsquo;s expense, they shall be
issued to all (and not to some only) of the Members entitled to be sent notice of the meeting and to vote at it. The accidental omission
to send such a form of appointment or to give such an invitation to, or the non-receipt of such form of appointment by, any Member entitled
to attend and vote at a meeting shall not invalidate the proceedings at that meeting</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Voting by proxy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">12.26</TD><TD STYLE="text-align: justify">A proxy shall have the same voting rights at a meeting or adjourned meeting as the Member would have had
except to the extent that the instrument appointing him limits those rights. Notwithstanding the appointment of a proxy, a Member may
attend and vote at a meeting or adjourned meeting. If a Member votes on any resolution a vote by his proxy on the same resolution, unless
in respect of different Shares, shall be invalid.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">12.27</TD><TD STYLE="text-align: justify">The instrument appointing a proxy to vote at a meeting shall be deemed also to confer authority to demand
or join in demanding a poll and, for the purposes of Article 11.11, a demand by a person as proxy for a Member shall be the same as a
demand by a Member. Such appointment shall not confer any further right to speak at the meeting, except with the permission of the chairman
of the meeting.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">13</TD><TD>Number of Directors</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">13.1</TD><TD STYLE="text-align: justify">There shall be a Board consisting of not less than one person provided however that the Company may by
Ordinary Resolution increase or reduce the limits in the number of Directors. Unless fixed by Ordinary Resolution, the maximum number
of Directors shall be unlimited.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">14</TD><TD STYLE="text-align: justify">Appointment, disqualification and removal of Directors </TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"><B>First Directors</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">14.1</TD><TD STYLE="text-align: justify">The first Directors shall be appointed in writing by the subscriber or subscribers to the Memorandum,
or a majority of them.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">No age limit</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">14.2</TD><TD>There is no age limit for Directors save that they must be at least eighteen years of age.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Corporate Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">14.3</TD><TD STYLE="text-align: justify">Unless prohibited by law, a body corporate may be a Director. If a body corporate is a Director, the Articles
about representation of corporate Members at general meetings apply, mutatis mutandis, to the Articles about Directors&rsquo; meetings.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">No shareholding qualification</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">14.4</TD><TD STYLE="text-align: justify">Unless a shareholding qualification for Directors is fixed by Ordinary Resolution, no Director shall be
required to own Shares as a condition of his appointment.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Appointment of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">14.5</TD><TD STYLE="text-align: justify">A Director may be appointed by Ordinary Resolution or by the Directors. Any appointment may be to fill
a vacancy or as an additional Director.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">14.6</TD><TD>A remaining Director may appoint a Director even though there is not a quorum of Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">14.7</TD><TD STYLE="text-align: justify">No appointment can cause the number of Directors to exceed the maximum (if one is set); and any such appointment
shall be invalid.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">14.8</TD><TD STYLE="text-align: justify">For so long as Shares or ADSs are listed on a Designated Stock Exchange, the Directors shall include at
least such number of Independent Directors as applicable law, rules or regulations or the Designated Stock Exchange Rules require as determined
by the Board.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Board&rsquo;s power to appoint Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">14.9</TD><TD STYLE="text-align: justify">Without prejudice to the Company&rsquo;s power to appoint a person to be a Director pursuant to these
Articles, the Board shall have power at any time to appoint any person who is willing to act as a Director, either to fill a vacancy or
as an addition to the existing Board, subject to the total number of Directors not exceeding any maximum number fixed by or in accordance
with these Articles.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">14.10</TD><TD STYLE="text-align: justify">Any Director so appointed shall, if still a Director, retire at the next annual general meeting after
his appointment and be eligible to stand for election as a Director at such meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Eligibility</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">14.11</TD><TD STYLE="text-align: justify">No person (other than a Director retiring in accordance with these Articles) shall be appointed or re-appointed
a Director at any general meeting unless:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">he is recommended by the Board; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">not less than seven nor more than forty-two Clear Days before
the date appointed for the meeting, a Member (other than the person to be proposed) entitled to vote at the meeting has given to the
Company notice of his intention to propose a resolution for the appointment of that person, stating the particulars which would, if he
were so appointed, be required to be included in the Company&rsquo;s
register of Directors and a notice executed by that person of his willingness to be appointed.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Appointment at annual general meeting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">14.12</TD><TD STYLE="text-align: justify">Unless re-appointed pursuant to the provisions of Article 14.5 or removed from office pursuant to the
provisions of Article 14.13, each Director shall be appointed for a term expiring at the next-following annual general meeting of the
Company. At any such annual general meeting, Directors will be elected by Ordinary Resolution. At each annual general meeting of the Company,
each Director elected at such meeting shall be elected to hold office for a one-year term and until the election of their respective successors
in office or removal pursuant to Articles 14.5 and 14.13.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Removal of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.35pt">14.13</TD><TD>A Director may be removed by Ordinary Resolution.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Resignation of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">14.14</TD><TD STYLE="text-align: justify">A Director may at any time resign office by giving to the Company notice in writing or, if permitted pursuant
to the notice provisions, in an Electronic Record delivered in either case in accordance with those provisions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">14.15</TD><TD STYLE="text-align: justify">Unless the notice specifies a different date, the Director shall be deemed to have resigned on the date
that the notice is delivered to the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Termination of the office of Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">14.16</TD><TD STYLE="text-align: justify">A Director may retire from office as a Director by giving notice in writing to that effect to the Company
at the registered office, which notice shall be effective upon such date as may be specified in the notice, failing which upon delivery
to the registered office.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">14.17</TD><TD STYLE="text-align: justify">Without prejudice to the provisions in these Articles for retirement (by rotation or otherwise), a Director&rsquo;s
office shall be terminated forthwith if:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">he is prohibited by the law of the Cayman Islands from acting
as a Director; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">he is made bankrupt or makes an arrangement or composition
with his creditors generally; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">he resigns his office by notice to the Company; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">he only held office as a Director for a fixed term and such
term expires; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(e)</TD><TD STYLE="text-align: justify">in the opinion of a registered medical practitioner by whom
he is being treated he becomes physically or mentally incapable of acting as a Director; or</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(f)</TD><TD STYLE="text-align: justify">he is given notice by the majority of the other Directors
(not being less than two in number) to vacate office (without prejudice to any claim for damages for breach of any agreement relating
to the provision of the services of such Director); or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(g)</TD><TD STYLE="text-align: justify">he is made subject to any law relating to mental health or
incompetence, whether by court order or otherwise; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(h)</TD><TD STYLE="text-align: justify">without the consent of the other Directors, he is absent from
meetings of Directors for a continuous period of six months.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">15</TD><TD STYLE="text-align: justify">Alternate Directors</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Appointment and removal</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">15.1</TD><TD STYLE="text-align: justify">Any Director may appoint any other person, including another Director, to act in his place as an alternate
Director. No appointment shall take effect until the Director has given notice of the appointment to the Board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">15.2</TD><TD STYLE="text-align: justify">A Director may revoke his appointment of an alternate at any time. No revocation shall take effect until
the Director has given notice of the revocation to the Board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">15.3</TD><TD STYLE="text-align: justify">A notice of appointment or removal of an alternate Director shall be effective only if given to the Company
by one or more of the following methods:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">by notice in writing in accordance with the notice provisions
contained in these Articles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">if the Company has a facsimile address for the time being,
by sending by facsimile transmission to that facsimile address a facsimile copy or, otherwise, by sending by facsimile transmission to
the facsimile address of the Company&rsquo;s registered office a facsimile copy (in either case, the facsimile copy being deemed to be the
notice unless Article 29.7 applies), in which event notice shall be taken to be given on the date of an error-free transmission report
from the sender&rsquo;s fax machine;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">if the Company has an email address for the time being, by
emailing to that email address a scanned copy of the notice as a PDF attachment or, otherwise, by emailing to the email address provided
by the Company&rsquo;s registered office a scanned copy of the notice as a PDF attachment (in either case, the PDF version being deemed to
be the notice unless Article 29.7 applies), in which event notice shall be taken to be given on the date of receipt by the Company or
the Company&rsquo;s registered office (as appropriate) in readable form; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">if permitted pursuant to the notice provisions, in some other
form of approved Electronic Record delivered in accordance with those provisions in writing.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Notices</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">15.4</TD><TD STYLE="text-align: justify">All notices of meetings of Directors shall continue to be given to the appointing Director and not to
the alternate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Rights of alternate Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">15.5</TD><TD STYLE="text-align: justify">An alternate Director shall be entitled to attend and vote at any Board meeting or meeting of a committee
of the Directors at which the appointing Director is not personally present, and generally to perform all the functions of the appointing
Director in his absence. An alternate Director, however, is not entitled to receive any remuneration from the Company for services rendered
as an alternate Director.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Appointment ceases when the appointor ceases to be
a Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">15.6</TD><TD>An alternate Director shall cease to be an alternate Director if:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the Director who appointed him ceases to be a Director; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the Director who appointed him revokes his appointment by
notice delivered to the Board or to the registered office of the Company or in any other manner approved by the Board; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">in any event happens in relation to him which, if he were
a Director of the Company, would cause his office as Director to be vacated.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Status of alternate Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">15.7</TD><TD>An alternate Director shall carry out all functions of the Director who made the appointment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">15.8</TD><TD STYLE="text-align: justify">Save where otherwise expressed, an alternate Director shall be treated as a Director under these Articles.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">15.9</TD><TD>An alternate Director is not the agent of the Director appointing him.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.35pt">15.10</TD><TD>An alternate Director is not entitled to any remuneration for acting as alternate Director.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Status of the Director making the appointment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">15.11</TD><TD STYLE="text-align: justify">A Director who has appointed an alternate is not thereby relieved from the duties which he owes the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">16</TD><TD STYLE="text-align: justify">Powers of Directors </TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Powers of Directors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">16.1</TD><TD STYLE="text-align: justify">Subject to the provisions of the Act, the Memorandum and these Articles the business of the Company shall
be managed by the Directors who may for that purpose exercise all the powers of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">16.2</TD><TD STYLE="text-align: justify">No prior act of the Directors shall be invalidated by any subsequent alteration of the Memorandum or these
Articles. However, to the extent allowed by the Act, Members may, by Special Resolution, validate any prior or future act of the Directors
which would otherwise be in breach of their duties.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Directors below the minimum number</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">16.3</TD><TD STYLE="text-align: justify">lf the number of Directors is less than the minimum prescribed in accordance with these Articles, the
remaining Director or Directors shall act only for the purposes of appointing an additional Director or Directors to make up such minimum
or of convening a general meeting of the Company for the purpose of making such appointment. lf there are no Director or Directors able
or willing to act, any two Members may summon a general meeting for the purpose of appointing Directors. Any additional Director so appointed
shall hold office (subject to these Articles) only until the dissolution of the annual general meeting next following such appointment
unless he is re-elected during such meeting.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Appointments to office</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">16.4</TD><TD>The Directors may appoint a Director:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">as chairman of the Board;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">as managing Director;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">to any other executive office,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">for such period, and on such terms, including as to remuneration
as they think fit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">16.5</TD><TD>The appointee must consent in writing to holding that office.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">16.6</TD><TD STYLE="text-align: justify">Where a chairman is appointed he shall, unless unable to do so, preside at every meeting of Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">16.7</TD><TD STYLE="text-align: justify">If there is no chairman, or if the chairman is unable to preside at a meeting, that meeting may select
its own chairman; or the Directors may nominate one of their number to act in place of the chairman should he ever not be available.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">16.8</TD><TD STYLE="text-align: justify">Subject to the provisions of the Act, the Directors may also appoint and remove any person, who need not
be a Director:</TD></TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">as Secretary; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">to any office that may be required</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">for such period and on such terms, including as to remuneration,
as they think fit. In the case of an Officer, that Officer may be given any title the Directors decide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">16.9</TD><TD>The Secretary or Officer must consent in writing to holding that office.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">16.10</TD><TD STYLE="text-align: justify">A Director, Secretary or other Officer of the Company may not the hold the office, or perform the services,
of auditor.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Provisions for employees</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">16.11</TD><TD STYLE="text-align: justify">The Board may make provision for the benefit of any persons employed or formerly employed by the Company
or any of its subsidiary undertakings (or any member of his family or any person who is dependent on him) in connection with the cessation
or the transfer to any person of the whole or part of the undertaking of the Company or any of its subsidiary undertakings.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Exercise of voting rights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">16.12</TD><TD STYLE="text-align: justify">The Board may exercise the voting power conferred by the Shares in any body corporate held or owned by
the Company in such manner in all respects as it thinks fit (including, without limitation, the exercise of that power in favour of any
resolution appointing any Director as a Director of such body corporate, or voting or providing for the payment of remuneration to the
Directors of such body corporate).</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Remuneration</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">16.13</TD><TD STYLE="text-align: justify">Every Director may be remunerated by the Company for the services he provides for the benefit of the Company,
whether as Director, employee or otherwise, and shall be entitled to be paid for the expenses incurred in the Company&rsquo;s business
including attendance at Directors&rsquo; meetings.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">16.14</TD><TD STYLE="text-align: justify">Until otherwise determined by the Company by Ordinary Resolution, the Directors (other than alternate
Directors) shall be entitled to such remuneration by way of fees for their services in the office of Director as the Directors may determine.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">16.15</TD><TD STYLE="text-align: justify">Remuneration may take any form and may include arrangements to pay pensions, health insurance, death or
sickness benefits, whether to the Director or to any other person connected to or related to him.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">16.16</TD><TD STYLE="text-align: justify">Unless his fellow Directors determine otherwise, a Director is not accountable to the Company for remuneration
or other benefits received from any other company which is in the same group as the Company or which has common shareholdings.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Disclosure of information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">16.17</TD><TD STYLE="text-align: justify">The Directors may release or disclose to a third party any information regarding the affairs of the Company,
including any information contained in the register of Members relating to a Member, (and they may authorise any Director, Officer or
other authorised agent of the Company to release or disclose to a third party any such information in his possession) if:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the Company or that person, as the case may be, is lawfully
required to do so under the laws of any jurisdiction to which the Company is subject; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">such disclosure is in compliance with the Designated Stock
Exchange Rules; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">such disclosure is in accordance with any contract entered
into by the Company; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">the Directors are of the opinion such disclosure would assist
or facilitate the Company&rsquo;s operations.</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">17</TD><TD>Delegation of powers</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt "><B>Power to delegate any of the Directors&rsquo; powers
to a committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">17.1</TD><TD STYLE="text-align: justify">The Directors may delegate any of their powers to any committee consisting of one or more persons who
need not be Members. Persons on the committee may include non-Directors so long as the majority of those persons are Directors. Any such
committee shall be made up of such number of Independent Directors as required from time to time by the Designated Stock Exchange Rules
or otherwise required by applicable law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">17.2</TD><TD>The delegation may be collateral with, or to the exclusion of, the Directors&rsquo; own powers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">17.3</TD><TD STYLE="text-align: justify">The delegation may be on such terms as the Directors think fit, including provision for the committee
itself to delegate to a sub-committee; save that any delegation must be capable of being revoked or altered by the Directors at will.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">17.4</TD><TD STYLE="text-align: justify">Unless otherwise permitted by the Directors, a committee must follow the procedures prescribed for the
taking of decisions by Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">17.5</TD><TD STYLE="text-align: justify">The Board shall establish an audit committee, a compensation committee and a nominating and corporate
governance committee. Each of these committees shall be empowered to do all things necessary to exercise the rights of such committee
set forth in these Articles. Each of the audit committee, compensation committee and nominating and corporate governance committee shall
consist of at least three Directors (or such larger minimum number as may be required from time to time by the Designated Stock Exchange
Rules). The majority of the committee members on each of the compensation committee and nominating and corporate governance committee
shall be Independent Directors. The audit committee shall be made up of such number of Independent Directors as required from time to
time by the Designated Stock Exchange Rules or otherwise required by applicable law.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Local boards</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">17.6</TD><TD STYLE="text-align: justify">The Board may establish any local or divisional board or agency for managing any of the affairs of the
Company whether in the Cayman Islands or elsewhere and may appoint any persons to be members of a local or divisional Board, or to be
managers or agents, and may fix their remuneration.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">17.7</TD><TD STYLE="text-align: justify">The Board may delegate to any local or divisional board, manager or agent any of its powers and authorities
(with power to sub-delegate) and may authorise the members of any local or divisional board or any of them to fill any vacancies and to
act notwithstanding vacancies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">17.8</TD><TD STYLE="text-align: justify">Any appointment or delegation under this Article 17.8 may be made on such terms and subject to such conditions
as the Board thinks fit and the Board may remove any person so appointed, and may revoke or vary any delegation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Power to appoint an agent of the Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">17.9</TD><TD STYLE="text-align: justify">The Directors may appoint any person, either generally or in respect of any specific matter, to be the
agent of the Company with or without authority for that person to delegate all or any of that person&rsquo;s powers. The Directors may
make that appointment:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">by causing the Company to enter into a power of attorney or
agreement; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">in any other manner they determine.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Power to appoint an attorney or authorised signatory
of the Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">17.10</TD><TD STYLE="text-align: justify">The Directors may appoint any person, whether nominated directly or indirectly by the Directors, to be
the attorney or the authorised signatory of the Company. The appointment may be:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">for any purpose;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">with the powers, authorities and discretions;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">for the period; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">subject to such conditions</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">as they think fit. The powers, authorities
and discretions, however, must not exceed those vested in, or exercisable, by the Directors under these Articles. The Directors may do
so by power of attorney or any other manner they think fit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">17.11</TD><TD STYLE="text-align: justify">Any power of attorney or other appointment may contain such provision for the protection and convenience
for persons dealing with the attorney or authorised signatory as the Directors think fit. Any power of attorney or other appointment may
also authorise the attorney or authorised signatory to delegate all or any of the powers,
authorities and discretions vested in that person.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">17.12</TD><TD STYLE="text-align: justify">The Board may remove any person appointed under Article 17.10 and may revoke or vary the delegation.</TD></TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Borrowing Powers</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">17.13</TD><TD STYLE="text-align: justify">The Directors may exercise all the powers of the Company to borrow money and to mortgage or charge its
undertaking, property and assets both present and future and uncalled capital, or any part thereof, and to issue debentures and other
securities, whether outright or as collateral security for any debt, liability or obligation of the Company or its parent undertaking
(if any) or any subsidiary undertaking of the Company or of any third party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Corporate Governance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">17.14</TD><TD STYLE="text-align: justify">The Board may, from time to time, and except as required by applicable law or the Designated Stock Exchange
Rules, adopt, institute, amend, modify or revoke the corporate governance policies or initiatives of the Company, which shall be intended
to set forth the guiding principles and policies of the Company and the Board on various corporate governance related matters as the Board
shall determine by resolution from time to time.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">18</TD><TD STYLE="text-align: justify">Meetings of Directors </TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regulation of Directors&rsquo; meetings</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">18.1</TD><TD STYLE="text-align: justify">Subject to the provisions of these Articles, the Directors may regulate their proceedings as they think
fit.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Calling meetings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">18.2</TD><TD STYLE="text-align: justify">Any Director may call a meeting of Directors at any time. The Secretary must call a meeting of the Directors
if requested to do so by a Director.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Notice of meetings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">18.3</TD><TD STYLE="text-align: justify">Notice of a Board meeting may be given to a Director personally or by word of mouth or given in writing
or by Electronic communications at such address as he may from time to time specify for this purpose (or, if he does not specify an address,
at his last known address). A Director may waive his right to receive notice of any meeting either prospectively or retrospectively.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Use of technology</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">18.4</TD><TD STYLE="text-align: justify">A Director may participate in a meeting of Directors through the medium of conference telephone, video
or any other form of communications equipment providing all persons participating in the meeting are able to hear and speak to each other
throughout the meeting.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">18.5</TD><TD>A Director participating in this way is deemed to be present in person at the meeting.</TD></TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Quorum</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">18.6</TD><TD STYLE="text-align: justify">The quorum for the transaction of business at a meeting of Directors shall be two unless the Directors
fix some other number.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Chairman or deputy to preside</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">18.7</TD><TD STYLE="text-align: justify">The Board may appoint a chairman and one or more deputy chairman or chairmen and may at any time revoke
any such appointment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">18.8</TD><TD STYLE="text-align: justify">The chairman, or failing him any deputy chairman (the longest in office taking precedence if more than
one is present), shall preside at all Board meetings. If no chairman or deputy chairman has been appointed, or if he is not present within
five minutes after the time fixed for holding the meeting, or is unwilling to act as chairman of the meeting, the Directors present shall
choose one of their number to act as chairman of the meeting.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Voting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">18.9</TD><TD STYLE="text-align: justify">A question which arises at a Board meeting shall be decided by a majority of votes. If votes are equal
the chairman may, if he wishes, exercise a casting vote.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Recording of dissent</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">18.10</TD><TD STYLE="text-align: justify">A Director present at a meeting of Directors shall be presumed to have assented to any action taken at
that meeting unless:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">his dissent is entered in the minutes of the meeting; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">he has filed with the meeting before it is concluded signed
dissent from that action; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">he has forwarded to the Company as soon as practical following
the conclusion of that meeting signed dissent.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">A Director who votes in favour of an action is not entitled
to record his dissent to it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Written resolutions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">18.11</TD><TD STYLE="text-align: justify">The Directors may pass a resolution in writing without holding a meeting if all Directors sign a document
or sign several documents in the like form each signed by one or more of those Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">18.12</TD><TD STYLE="text-align: justify">A written resolution signed by a validly appointed alternate Director need not also be signed by the appointing
Director.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">18.13</TD><TD STYLE="text-align: justify">A written resolution signed personally by the appointing Director need not also be signed by his alternate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">18.14</TD><TD STYLE="text-align: justify">A resolution in writing passed pursuant to Article 18.11, Article 18.12 and/or Article 18.13 shall be
as effective as if it had been passed at a meeting of the Directors duly convened and held; and it shall be treated as having been passed
on the day and at the time that the last Director signs (and for the avoidance of doubt, such day may or may not be a Business Day).</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Validity of acts of Directors in spite of formal defect</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">18.15</TD><TD STYLE="text-align: justify">All acts done by a meeting of the Board, or of a committee of the Board, or by any person acting as a
Director or an alternate Director, shall, notwithstanding that it is afterwards discovered that there was some defect in the appointment
of any Director or alternate Director or member of the committee, or that any of them were disqualified or had vacated office or were
not entitled to vote, be as valid as if every such person had been duly appointed and qualified and had continued to be a Director or
alternate Director and had been entitled to vote.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">19</TD><TD>Permissible Directors&rsquo; interests and disclosure</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">19.1</TD><TD STYLE="text-align: justify">A Director shall not, as a Director, vote in respect of any contract, transaction, arrangement or proposal
in which he has an interest which (together with any interest of any person connected with him) is a material interest (otherwise then
by virtue of his interests, direct or indirect, in Shares or debentures or other securities of, or otherwise in or through, the Company)
and if he shall do so his vote shall not be counted, nor in relation thereto shall he be counted in the quorum present at the meeting,
but (in the absence of some other material interest than is mentioned below) none of these prohibitions shall apply to:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the giving of any security, guarantee or indemnity in respect
of:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">money lent or obligations incurred by him or by any other
person for the benefit of the Company or any of its subsidiaries; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">a debt or obligation of the Company or any of its subsidiaries
for which the Director himself has assumed responsibility in whole or in part and whether alone or jointly with others under a guarantee
or indemnity or by the giving of security;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">where the Company or any of its subsidiaries is offering securities
in which offer the Director is or may be entitled to participate as a holder of securities or in the underwriting or sub-underwriting
of which the Director is to or may participate;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">any contract, transaction, arrangement or proposal affecting
any other body corporate in which he is interested, directly or indirectly and whether as an officer, shareholder, creditor or otherwise
howsoever, provided that he (together with persons connected with him) does not to his knowledge hold an interest representing one per
cent or more of any class of the equity share
capital of such body corporate (or of any third body corporate through which his interest is derived) or of the voting rights available
to members of the relevant body corporate (any such interest being deemed for the purposes of this Article 19.1 to be a material interest
in all circumstances);</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">any act or thing done or to be done in respect of any arrangement
for the benefit of the employees of the Company or any of its subsidiaries under which he is not accorded as a Director any privilege
or advantage not generally accorded to the employees to whom such arrangement relates; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(e)</TD><TD STYLE="text-align: justify">any matter connected with the purchase or maintenance for
any Director of insurance against any liability or (to the extent permitted by the Act) indemnities in favour of Directors, the funding
of expenditure by one or more Directors in defending proceedings against him or them or the doing of any thing to enable such Director
or Directors to avoid incurring such expenditure.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">19.2</TD><TD STYLE="text-align: justify">A Director may, as a Director, vote (and be counted in the quorum) in respect of any contract, transaction,
arrangement or proposal in which he has an interest which is not a material interest or which falls within Article 19.1.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">20</TD><TD>Minutes</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">20.1</TD><TD>The Company shall cause minutes to be made in books of:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">all appointments of Officers and committees made by the Board
and of any such Officer&rsquo;s remuneration; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the names of Directors present at every meeting of the Directors,
a committee of the Board, the Company or the holders of any class of shares or debentures, and all orders, resolutions and proceedings
of such meetings.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">20.2</TD><TD STYLE="text-align: justify">Any such minutes, if purporting to be signed by the chairman of the meeting at which the proceedings were
held or by the chairman of the next succeeding meeting or the Secretary, shall be prima facie evidence of the matters stated in them.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">21</TD><TD>Accounts and audit</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">21.1</TD><TD STYLE="text-align: justify">The Directors must ensure that proper accounting and other records are kept, and that accounts and associated
reports are distributed in accordance with the requirements of the Act.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">21.2</TD><TD STYLE="text-align: justify">The books of account shall be kept at the registered office of the Company and shall always be open to
inspection by the Directors. No Member (other than a Director) shall have any right of inspecting any account or book or document of the
Company except as conferred by the Act or as authorised by the Directors or by Ordinary Resolution.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">21.3</TD><TD STYLE="text-align: justify">Unless the Directors otherwise prescribe, the financial year of the Company shall end on 30 September
in each year and begin on 1 October in each year.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Auditors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">21.4</TD><TD STYLE="text-align: justify">The Directors may appoint an Auditor of the Company who shall hold office on such terms as the Directors
determine.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">21.5</TD><TD STYLE="text-align: justify">At any general meeting convened and held at any time in accordance with these Articles, the Members may,
by Ordinary Resolution, remove the Auditor before the expiration of his term of office. If they do so, the Members shall, by Ordinary
Resolution, at that meeting appoint another Auditor in his stead for the remainder of his term.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">21.6</TD><TD STYLE="text-align: justify">The Auditors shall examine such books, accounts and vouchers; as may be necessary for the performance
of their duties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">21.7</TD><TD STYLE="text-align: justify">The Auditors shall, if so requested by the Directors, make a report on the accounts of the Company during
their tenure of office at the next annual general meeting following their appointment, and at any time during their term of office, upon
request of the Directors or any general meeting of the Company.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">22</TD><TD>Record dates</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">22.1</TD><TD STYLE="text-align: justify">Except to the extent of any conflicting rights attached to Shares, the resolution declaring a dividend
on Shares of any class, whether it be an Ordinary Resolution of the Members or a Director&rsquo;s resolution, may specify that the dividend
is payable or distributable to the persons registered as the holders of those Shares at the close of business on a particular date, notwithstanding
that the date may be a date prior to that on which the resolution is passed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">22.2</TD><TD STYLE="text-align: justify">If the resolution does so specify, the dividend shall be payable or distributable to the persons registered
as the holders of those Shares at the close of business on the specified date in accordance with their respective holdings so registered,
but without prejudice to the rights <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>inter se </I></FONT>in respect of the
dividend of transferors and transferees of any of those Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">22.3</TD><TD STYLE="text-align: justify">The provisions of this Article apply, <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>mutatis
mutandis</I></FONT>, to bonuses, capitalisation issues, distributions of realised capital profits or offers or grants made by the Company
to the Members.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">23</TD><TD STYLE="text-align: justify">Dividends </TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Source of dividends</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">23.1</TD><TD STYLE="text-align: justify">Dividends may be declared and paid out of any funds of the Company lawfully available for distribution.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">23.2</TD><TD STYLE="text-align: justify">Subject to the requirements of the Act regarding the application of a company&rsquo;s Share premium account
and with the sanction of an Ordinary Resolution, dividends may also be declared and paid out of any share premium account.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Declaration of dividends by Members</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">23.3</TD><TD STYLE="text-align: justify">Subject to the provisions of the Act, the Company may by Ordinary Resolution declare dividends in accordance
with the respective rights of the Members but no dividend shall exceed the amount recommended by the Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Payment of interim dividends and declaration of final
dividends by Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">23.4</TD><TD STYLE="text-align: justify">The Directors may declare and pay interim dividends or recommend final dividends in accordance with the
respective rights of the Members if it appears to them that they are justified by the financial position of the Company and that such
dividends may lawfully be paid.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">23.5</TD><TD STYLE="text-align: justify">Subject to the provisions of the Act, in relation to the distinction between interim dividends and final
dividends, the following applies:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Upon determination to pay a dividend or dividends described
as interim by the Directors in the dividend resolution, no debt shall be created by the declaration until such time as payment is made.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Upon declaration of a dividend or dividends described as final
by the Directors in the dividend resolution, a debt shall be created immediately following the declaration, the due date to be the date
the dividend is stated to be payable in the resolution.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">If the resolution fails to specify whether a dividend is
final or interim, it shall be assumed to be interim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">23.6</TD><TD STYLE="text-align: justify">In relation to Shares carrying differing rights to dividends or rights to dividends at a fixed rate, the
following applies:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">If the share capital is divided into different classes, the
Directors may pay dividends on Shares which confer deferred or non-preferred rights with regard to dividends as well as on Shares which
confer preferential rights with regard to dividends but no dividend shall be paid on Shares carrying deferred or non-preferred rights
if, at the time of payment, any preferential dividend is in arrears.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">The Directors may also pay, at intervals settled by them,
any dividend payable at a fixed rate if it appears to them that there are sufficient funds of the Company lawfully available for distribution
to justify the payment.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">If the Directors act in good faith, they shall not incur any
liability to the Members holding Shares conferring preferred rights for any loss those Members may suffer by the lawful payment of the dividend on any Shares having
deferred or non-preferred rights.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Apportionment of dividends</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">23.7</TD><TD STYLE="text-align: justify">Except as otherwise provided by the rights attached to Shares all dividends shall be declared and paid
according to the amounts Paid Up on the Shares on which the dividend is paid. All dividends shall be apportioned and paid proportionately
to the amount Paid Up on the Shares during the time or part of the time in respect of which the dividend is paid. But if a Share is issued
on terms providing that it shall rank for dividend as from a particular date, that Share shall rank for dividend accordingly.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Right of set off</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">23.8</TD><TD STYLE="text-align: justify">The Directors may deduct from a dividend or any other amount payable to a person in respect of a Share
any amount due by that person to the Company on a call or otherwise in relation to a Share.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Power to pay other than in cash</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">23.9</TD><TD STYLE="text-align: justify">If the Directors so determine, any resolution declaring a dividend may direct that it shall be satisfied
wholly or partly by the distribution of assets. If a difficulty arises in relation to the distribution, the Directors may settle that
difficulty in any way they consider appropriate. For example, they may do any one or more of the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">issue fractional Shares;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">fix the value of assets for distribution and make cash payments
to some Members on the footing of the value so fixed in order to adjust the rights of Members; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">vest some assets in trustees.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">How payments may be made</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">23.10</TD><TD STYLE="text-align: justify">A dividend or other monies payable on or in respect of a Share may be paid in any of the following ways:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">if the Member holding that Share or other person entitled
to that Share nominates a bank account for that purpose - by wire transfer to that bank account; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">by cheque or warrant sent by post to the registered address
of the Member holding that Share or other person entitled to that Share.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">23.11</TD><TD STYLE="text-align: justify">For the purposes of Article 23.10(a), the nomination may be in writing or in an Electronic Record
                                    and the bank account nominated may be the bank account of another person. For the purposes of Article 23.10(b), subject to any
                                    applicable law or regulation, the cheque or warrant shall be made to the order of the Member holding that Share or other person
                                    entitled to the Share or to his nominee, whether nominated in writing
or in an Electronic Record, and payment of the cheque or warrant shall be a good discharge to the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">23.12</TD><TD STYLE="text-align: justify">If two or more persons are registered as the holders of the Share or are jointly entitled to it by reason
of the death or bankruptcy of the registered holder (<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Joint Holders</B></FONT>),
a dividend (or other amount) payable on or in respect of that Share may be paid as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">to the registered address of the Joint Holder of the Share
who is named first on the register of Members or to the registered address of the deceased or bankrupt holder, as the case may be; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">to the address or bank account of another person nominated
by the Joint Holders, whether that nomination is in writing or in an Electronic Record.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">23.13</TD><TD STYLE="text-align: justify">Any Joint Holder of a Share may give a valid receipt for a dividend (or other amount) payable in respect
of that Share.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Dividends or other monies not to bear interest in absence
of special rights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">23.14</TD><TD STYLE="text-align: justify">Unless provided for by the rights attached to a Share, no dividend or other monies payable by the Company
in respect of a Share shall bear interest.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Dividends unable to be paid or unclaimed</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">23.15</TD><TD STYLE="text-align: justify">If a dividend cannot be paid to a Member or remains unclaimed within six weeks after it was declared or
both, the Directors may pay it into a separate account in the Company&rsquo;s name. If a dividend is paid into a separate account, the
Company shall not be constituted trustee in respect of that account and the dividend shall remain a debt due to the Member.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">23.16</TD><TD STYLE="text-align: justify">A dividend that remains unclaimed for a period of six years after it became due for payment shall be forfeited
to, and shall cease to remain owing by, the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">24</TD><TD>Capitalisation of profits</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Capitalisation of profits or of any share premium account
or capital redemption reserve;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">24.1</TD><TD>The Directors may resolve to capitalise:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">any part of the Company&rsquo;s profits not required for paying
any preferential dividend (whether or not those profits are available for distribution); or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">any sum standing to the credit of the Company&rsquo;s share premium
account or capital redemption reserve, if any.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">24.2</TD><TD STYLE="text-align: justify">The amount resolved to be capitalised must be appropriated to the Members who would have been entitled
to it had it been distributed by way of dividend and in the same proportions. The benefit to each Member so entitled must be given in
either or both of the following ways:</TD></TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">by paying up the amounts unpaid on that Member&rsquo;s Shares;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">by issuing Fully Paid Up Shares, debentures or other securities
of the Company to that Member or as that Member directs. The Directors may resolve that any Shares issued to the Member in respect of
Partly Paid Up Shares (<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Original Shares</B></FONT>) rank for dividend only
to the extent that the Original Shares rank for dividend while those Original Shares remain Partly Paid Up.</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Applying an amount for the benefit of Members</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">24.3</TD><TD STYLE="text-align: justify">The amount capitalised must be applied to the benefit of Members in the proportions to which the Members
would have been entitled to dividends if the amount capitalised had been distributed as a dividend.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">24.4</TD><TD STYLE="text-align: justify">Subject to the Act, if a fraction of a Share, a debenture or other security is allocated to a Member,
the Directors may issue a fractional certificate to that Member or pay him the cash equivalent of the fraction.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">25</TD><TD>Share Premium Account</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Directors to maintain share premium account</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">25.1</TD><TD STYLE="text-align: justify">The Directors shall establish a share premium account in accordance with the Act. They shall carry to
the credit of that account from time to time an amount equal to the amount or value of the premium paid on the issue of any Share or capital
contributed or such other amounts required by the Act.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Debits to share premium account</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">25.2</TD><TD>The following amounts shall be debited to any share premium account:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">on the redemption or purchase of a Share, the difference between
the nominal value of that Share and the redemption or purchase price; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">any other amount paid out of a share premium account as permitted
by the Act.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">25.3</TD><TD STYLE="text-align: justify">Notwithstanding the preceding Article, on the redemption or purchase of a Share, the Directors may pay
the difference between the nominal value of that Share and the redemption purchase price out of the profits of the Company or, as permitted
by the Act, out of capital.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">26</TD><TD STYLE="text-align: justify">Seal </TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Company seal</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">26.1</TD><TD>The Company may have a seal if the Directors so determine.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Duplicate seal</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">26.2</TD><TD STYLE="text-align: justify">Subject to the provisions of the Act, the Company may also have a duplicate seal or seals for use in any
place or places outside the Cayman Islands. Each duplicate seal shall be a facsimile of the original seal of the Company. However, if
the Directors so determine, a duplicate seal shall have added on its face the name of the place where it is to be used.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">When and how seal is to be used</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">26.3</TD><TD STYLE="text-align: justify">A seal may only be used by the authority of the Directors. Unless the Directors otherwise determine, a
document to which a seal is affixed must be signed in one of the following ways:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">by a Director (or his alternate) and the Secretary; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">by a single Director (or his alternate).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">If no seal is adopted or used</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">26.4</TD><TD STYLE="text-align: justify">If the Directors do not adopt a seal, or a seal is not used, a document may be executed in the following
manner:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">by a Director (or his alternate) and the Secretary; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">by a single Director (or his alternate); or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">in any other manner permitted by the Act.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Power to allow non-manual signatures and facsimile
printing of seal</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">26.5</TD><TD>The Directors may determine that either or both of the following applies:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">that the seal or a duplicate seal need not be affixed manually
but may be affixed by some other method or system of reproduction;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">that a signature required by these Articles need not be manual
but may be a mechanical or Electronic Signature.</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Validity of execution</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">26.6</TD><TD STYLE="text-align: justify">If a document is duly executed and delivered by or on behalf of the Company, it shall not be regarded
as invalid merely because, at the date of the delivery, the Secretary, or the Director, or other Officer or person who signed the document
or affixed the seal for and on behalf of the Company ceased to be the Secretary or hold that office and authority on behalf of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">27</TD><TD>Indemnity</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">27.1</TD><TD STYLE="text-align: justify">To the extent permitted by law, the Company shall indemnify each existing or former Director (including
alternate Director), Secretary and other Officer of the Company (including an investment adviser or an administrator or liquidator) and
their personal representatives against:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">all actions, proceedings, costs, charges, expenses, losses,
damages or liabilities incurred or sustained by the existing or former Director (including alternate Director), Secretary or Officer
in or about the conduct of the Company&rsquo;s business or affairs or in the execution or discharge of the existing or former Director&rsquo;s (including
alternate Director&rsquo;s), Secretary&rsquo;s or Officer&rsquo;s duties, powers, authorities or discretions; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">without limitation to paragraph (a), all costs, expenses,
losses or liabilities incurred by the existing or former Director (including alternate Director), Secretary or Officer in defending (whether
successfully or otherwise) any civil, criminal, administrative or investigative proceedings (whether threatened, pending or completed)
concerning the Company or its affairs in any court or tribunal, whether in the Cayman Islands or elsewhere.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">No such existing or former Director (including alternate
Director), Secretary or Officer, however, shall be indemnified in respect of any matter arising out of his own dishonesty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">27.2</TD><TD STYLE="text-align: justify">To the extent permitted by Act, the Company may make a payment, or agree to make a payment, whether by
way of advance, loan or otherwise, for any legal costs incurred by an existing or former Director (including alternate Director), Secretary
or Officer of the Company in respect of any matter identified in Article 27.1 on condition that the Director (including alternate Director),
Secretary or Officer must repay the amount paid by the Company to the extent that it is ultimately found not liable to indemnify the Director
(including alternate Director), Secretary or that Officer for those legal costs.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Release</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">27.3</TD><TD STYLE="text-align: justify">To the extent permitted by Act, the Company may by Special Resolution release any existing or former Director
(including alternate Director), Secretary or other Officer of the Company from liability for any loss or damage or right to compensation
which may arise out of or in connection with the execution or discharge of the duties, powers, authorities or discretions of his office;
but there may be no release from liability arising out of or in connection with that person&rsquo;s own dishonesty.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Insurance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">27.4</TD><TD STYLE="text-align: justify">To the extent permitted by Act, the Company may pay, or agree to pay, a premium in respect of a contract
insuring each of the following persons against risks determined by the Directors, other than liability arising out of that person&rsquo;s
own dishonesty:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">an existing or former Director (including alternate Director),
Secretary or Officer or auditor of:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117.1pt; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">the Company;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">a company which is or was a subsidiary of the Company;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">a company in which the Company has or had an interest (whether
direct or indirect); and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">a trustee of an employee or retirement benefits scheme or
other trust in which any of the persons referred to in paragraph (a) is or was interested.</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">28</TD><TD STYLE="text-align: justify">Notices </TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Form of notices</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">28.1</TD><TD>Save where these Articles provide otherwise, and subject to the Designated Stock Exchange Rules, any notice to be given to or by any
person pursuant to these Articles shall be:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">in writing signed by or on behalf of the giver in the manner
set out below for written notices; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">subject to the next Article, in an Electronic Record signed
by or on behalf of the giver by Electronic Signature and authenticated in accordance with Articles about authentication of Electronic
Records; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">where these Articles expressly permit, by the Company by means
of a website.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Electronic communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">28.2</TD><TD>A notice may only be given to the Company in an Electronic Record if:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the Directors so resolve;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the resolution states how an Electronic Record may be given
and, if applicable, specifies an email address for the Company; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">the terms of that resolution are notified to the Members for
the time being and, if applicable, to those Directors who were absent from the meeting at which the resolution was passed.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">If the resolution is revoked or varied, the revocation or
variation shall only become effective when its terms have been similarly notified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">28.3</TD><TD>A notice may not be given by Electronic Record to a person other than the Company unless the recipient has notified the giver of an
Electronic address to which notice may be sent.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">28.4</TD><TD STYLE="text-align: justify">Subject to the Act, the Designated Stock Exchange Rules and to any other rules which the Company is bound
to follow, the Company may also send any notice or other document pursuant to these Articles to a Member by publishing that notice or
other document on a website where:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the Company and the Member have agreed to his having access
to the notice or document on a website (instead of it being sent to him);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.5pt; text-align: right; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the notice or document is one to which that agreement applies;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">the Member is notified (in accordance with any requirements
laid down by the Act and, in a manner for the time being agreed between him and the Company for the purpose) of:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.35pt; text-align: right; text-indent: -35.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">the publication of the notice or document on a website;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">the address of that website; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">the place on that website where the notice or document may
be accessed, and how it may be accessed; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">the notice or document is published on that website throughout
the publication period, provided that, if the notice or document is published on that website for a part, but not all of, the publication
period, the notice or document shall be treated as being published throughout that period if the failure to publish that notice of document
throughout that period is wholly attributable to circumstances which it would not be reasonable to have expected the Company to prevent
or avoid. For the purposes of this Article 28.4 &ldquo;publication period&rdquo; means a period of not less than twenty-one days, beginning
on the day on which the notification referred to in Article 28.4(c) is deemed sent.</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Persons entitled to notices</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">28.5</TD><TD STYLE="text-align: justify">Any notice or other document to be given to a Member may be given by reference to the register of Members
as it stands at any time within the period of twenty-one days before the day that the notice is given or (where and as applicable) within
any other period permitted by, or in accordance with the requirements of, (to the extent applicable) the Designated Stock Exchange Rules
and/or the Designated Stock Exchanges. No change in the register of Members after that time shall invalidate the giving of such notice
or document or require the Company to give such item to any other person.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Persons authorised to give notices</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">28.6</TD><TD STYLE="text-align: justify">A notice by either the Company or a Member pursuant to these Articles may be given on behalf of the Company
or a Member by a Director or company secretary of the Company or a Member.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Delivery of written notices</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">28.7</TD><TD STYLE="text-align: justify">Save where these Articles provide otherwise, a notice in writing may be given personally to the recipient,
or left at (as appropriate) the Member&rsquo;s or Director&rsquo;s registered address or the Company&rsquo;s registered office, or posted
to that registered address or registered office.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Joint holders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">28.8</TD><TD STYLE="text-align: justify">Where Members are joint holders of a Share, all notices shall be given to the Member whose name first
appears in the register of Members.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Signatures</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">28.9</TD><TD STYLE="text-align: justify">A written notice shall be signed when it is autographed by or on behalf of the giver, or is marked in
such a way as to indicate its execution or adoption by the giver.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.15pt; text-indent: -35.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.35pt">28.10</TD><TD>An Electronic Record may be signed by an Electronic Signature.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Evidence of transmission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">28.11</TD><TD STYLE="text-align: justify">A notice given by Electronic Record shall be deemed sent if an Electronic Record is kept demonstrating
the time, date and content of the transmission, and if no notification of failure to transmit is received by the giver.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">28.12</TD><TD STYLE="text-align: justify">A notice given in writing shall be deemed sent if the giver can provide proof that the envelope containing
the notice was properly addressed, pre-paid and posted, or that the written notice was otherwise properly transmitted to the recipient.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">28.13</TD><TD STYLE="text-align: justify">A Member present, either in person or by proxy, at any meeting of the Company or of the holders of any
class of Shares shall be deemed to have received due notice of the meeting and, where requisite, of the purposes for which it was called.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Giving notice to a deceased or bankrupt Member</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">28.14</TD><TD STYLE="text-align: justify">A notice may be given by the Company to the persons entitled to a Share in consequence of the death or
bankruptcy of a Member by sending or delivering it, in any manner authorised by these Articles for the giving of notice to a Member, addressed
to them by name, or by the title of representatives of the deceased, or trustee of the bankrupt or by any like description, at the address,
if any, supplied for that purpose by the persons claiming to be so entitled.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">28.15</TD><TD STYLE="text-align: justify">Until such an address has been supplied, a notice may be given in any manner in which it might have been
given if the death or bankruptcy had not occurred.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date of giving notices</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.35pt">28.16</TD><TD>A notice is given on the date identified in the following table</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border: black 1pt solid; padding-left: 5.35pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Method for giving notices</B></FONT></TD>
    <TD STYLE="width: 50%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.35pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>When taken to be given</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.35pt; font-size: 10pt">(A) Personally</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.35pt; font-size: 10pt">At the time and date of delivery</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.35pt">(B) By leaving it at the Member&rsquo;s registered
    address</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.35pt; font-size: 10pt">At the time and date it was left</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.35pt">(C) By posting it by prepaid post to the street or
    postal address of that recipient</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.35pt; font-size: 10pt">48 hours after the date it was posted</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.35pt">(D) By Electronic Record (other than publication on
a website), to recipient&rsquo;s Electronic address</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.35pt; font-size: 10pt">48 hours after the date it was sent</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.35pt; font-size: 10pt">(E) By publication on a website</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.35pt; text-align: justify">24 hours after the date on which
the Member is deemed to have been notified of the publication of the notice or document on the website</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Saving provision</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">28.17</TD><TD STYLE="text-align: justify">None of the preceding notice provisions shall derogate from the Articles about the delivery of written
resolutions of Directors and written resolutions of Members.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">29</TD><TD STYLE="text-align: justify">Authentication of Electronic Records </TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Application of Articles</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">29.1</TD><TD STYLE="text-align: justify">Without limitation to any other provision of these Articles, any notice, written resolution or other document
under these Articles that is sent by Electronic means by a Member, or by the Secretary, or by a Director or other Officer of the Company,
shall be deemed to be authentic if either Article 29.2 or Article 29.4 applies.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Authentication of documents sent by Members by Electronic
means</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">29.2</TD><TD STYLE="text-align: justify">An Electronic Record of a notice, written resolution or other document sent by Electronic means by or
on behalf of one or more Members shall be deemed to be authentic if the following conditions are satisfied:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the Member or each Member, as the case may be, signed the
original document, and for this purpose <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Original Document </B></FONT>includes
several documents in like form signed by one or more of those Members; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the Electronic Record of the Original Document was sent by
Electronic means by, or at the direction of, that Member to an address specified in accordance with these Articles for the purpose for
which it was sent; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Article 29.7 does not apply.</TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">29.3</TD><TD STYLE="text-align: justify">For example, where a sole Member signs a resolution and sends the Electronic Record of the original resolution,
or causes it to be sent, by facsimile transmission to the address in these Articles specified for that purpose, the facsimile copy shall
be deemed to be the written resolution of that Member unless Article 28.7 applies.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Authentication of document sent by the Secretary or
Officers of the Company by Electronic means</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">29.4</TD><TD STYLE="text-align: justify">An Electronic Record of a notice, written resolution or other document sent by or on behalf of the Secretary
or an Officer or Officers of the Company shall be deemed to be authentic if the following conditions are satisfied:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the Secretary or the Officer or each Officer, as the case
may be, signed the original document, and for this purpose <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Original Document
</B></FONT>includes several documents in like form signed by the Secretary or one or more of those Officers; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the Electronic Record of the Original Document was sent by
Electronic means by, or at the direction of, the Secretary or that Officer to an address specified in accordance with these Articles
for the purpose for which it was sent; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Article 29.7 does not apply.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">This Article 29.4 applies whether the document is sent by
or on behalf of the Secretary or Officer in his own right or as a representative of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">29.5</TD><TD STYLE="text-align: justify">For example, where a sole Director signs a resolution and scans the resolution, or causes it to be scanned,
as a PDF version which is attached to an email sent to the address in these Articles specified for that purpose, the PDF version shall
be deemed to be the written resolution of that Director unless Article 29.7 applies.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Manner of signing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">29.6</TD><TD STYLE="text-align: justify">For the purposes of these Articles about the authentication of Electronic Records, a document will be
taken to be signed if it is signed manually or in any other manner permitted by these Articles.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Saving provision</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">29.7</TD><TD STYLE="text-align: justify">A notice, written resolution or other document under these Articles will not be deemed to be authentic
if the recipient, acting reasonably:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">believes that the signature of the signatory has been altered
after the signatory had signed the original document; or</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">believes that the original document, or the Electronic Record
of it, was altered, without the approval of the signatory, after the signatory signed the original document; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">otherwise doubts the authenticity of the Electronic Record
of the document</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">and the recipient promptly gives notice
to the sender setting the grounds of its objection. If the recipient invokes this Article, the sender may seek to establish the authenticity
of the Electronic Record in any way the sender thinks fit.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">30</TD><TD>Transfer by way of continuation</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.25pt">30.1</TD><TD STYLE="text-align: justify">The Company may, by Special Resolution, resolve to be registered by way of continuation in a jurisdiction
outside:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-indent: -35.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the Cayman Islands; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">such other jurisdiction in which it is, for the time being,
incorporated, registered or existing.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.25pt">30.2</TD><TD STYLE="text-align: justify">To give effect to any resolution made pursuant to the preceding Article, the Directors may cause the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">an application be made to the Registrar of Companies of the
Cayman Islands to deregister the Company in the Cayman Islands or in the other jurisdiction in which it is for the time being incorporated,
registered or existing; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">all such further steps as they consider appropriate to be
taken to effect the transfer by way of continuation of the Company.</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">31</TD><TD>Winding up</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Distribution of assets in specie</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">31.1</TD><TD STYLE="text-align: justify">If the Company is wound up the Members may, subject to these Articles and any other sanction required
by the Act, pass a Special Resolution allowing the liquidator to do either or both of the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">to divide in specie among the Members the whole or any part
of the assets of the Company and, for that purpose, to value any assets and to determine how the division shall be carried out as between
the Members or different classes of Members; and/or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.7pt; text-align: justify; text-indent: -35.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">to vest the whole or any part of the assets in trustees for
the benefit of Members and those liable to contribute to the winding up.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">No obligation to accept liability</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">31.2</TD><TD>No Member shall be compelled to accept any assets if an obligation attaches to them.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">31.3</TD><TD>The Directors are authorised to present a winding up petition</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">31.4</TD><TD STYLE="text-align: justify">The Directors have the authority to present a petition for the winding up of the Company to the Grand
Court of the Cayman Islands on behalf of the Company without the sanction of a resolution passed at a general meeting.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">32</TD><TD STYLE="text-align: justify">Amendment of Memorandum and Articles</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Power to change name or amend Memorandum</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">32.1</TD><TD>Subject to the Act, the Company may, by Special Resolution:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">change its name; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">change the provisions of its Memorandum with respect to its
objects, powers or any other matter specified in the Memorandum.</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt ">Power to amend these Articles</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt">32.2</TD><TD STYLE="text-align: justify">Subject to the Act and as provided in these Articles, the Company may, by Special Resolution, further
amend these Articles in whole or in part.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 63; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>3
<FILENAME>ea022807501ex2-1_universe.htm
<DESCRIPTION>SPECIMEN CERTIFICATE FOR ORDINARY SHARES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 2.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>SHARE CERTIFICATE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1.5pt solid; width: 20%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</FONT></TD>
    <TD STYLE="width: 60%; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border: Black 1.5pt solid; width: 20%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Universe Pharmaceuticals INC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&#22823;&#33258;&#28982;&#34277;&#26989;&#32929;&#20221;&#26377;&#38480;&#20844;&#21496;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">THIS SHARE CERTIFICATE CERTIFIES THAT
as of [Transfer date], [Name] of [Address] is the registered holder of [Number] fully paid Ordinary Share(s) of $11.25 par value per
share in the above named Company which are held subject to, and transferable in accordance with, the Memorandum and Articles of Association
of the Company (as Revised).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In Witness Whereof the Company has authorized
this certificate to be issued on [Transfer date].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14pt; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.3
<SEQUENCE>4
<FILENAME>ea022807501ex2-3_universe.htm
<DESCRIPTION>DESCRIPTION OF SECURITIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 2.3</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Description of Rights of Each Class of Securities<BR>
Registered under Section 12 of the Securities Exchange Act of 1934, as Amended (the &ldquo;Exchange Act&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The share capital of Universe Pharmaceuticals
INC (&ldquo;we,&rdquo; &ldquo;our,&rdquo; &ldquo;our company,&rdquo; or &ldquo;us&rdquo;) is US$140,625,000 divided into 11,250,000 Ordinary
Shares of par value US$11.25 each (&ldquo;Ordinary Shares&rdquo;) and 1,250,000 Preferred Shares of par value US$11.25 each (&ldquo;Preferred
Shares&rdquo;, and together with the Ordinary Shares, the &ldquo;Shares&rdquo;). As of September 30, 2024, we had one class of securities
registered under Section 12(b) of the Exchange Act and our Ordinary Shares are listed and traded on the Nasdaq Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Description of Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of material provisions
of our currently effective amended and restated memorandum of association and articles of association (the &ldquo;Memorandum and Articles
of Association&rdquo; and the &ldquo;Articles&rdquo;), as well as the Companies Act (Revised) of the Cayman Islands (the &ldquo;Cayman
Companies Act&rdquo;) insofar as they relate to the material terms of our Shares. Notwithstanding this, because it is a summary, it may
not contain all the information that you may otherwise deem important. For more complete information, you should read the entire Amended
and Restated Memorandum of Association Articles of Association, which have been filed with the U.S. Securities and Exchange Commission
as Exhibit 1.1 to our annual report on Form 20-F for the fiscal year ended September 30, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Type and Class of Securities (Item 9.A.5 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We had one class of securities, our Ordinary Shares,
registered pursuant to Section 12 of the Exchange Act. Each Ordinary Share has a par value of US$11.25 each. The number of Ordinary
Shares that have been issued as of the last day of the financial year ended September 30, 2024 is provided on the cover of the annual
report on Form 20-F for the fiscal year ended September 30, 2024. Our Ordinary Shares may be held in either certificated or uncertificated
form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Preferred Share has a par value of US$11.25
each. No Preferred Shares were issued as of the last day of the fiscal year ended September 30, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Preemptive Rights (Item 9.A.3 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Ordinary Shares are not subject to any pre-emptive
or similar rights under the Cayman Companies Act or pursuant to the Memorandum and Articles of Association.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Limitations or Qualifications (Item 9.A.6 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Ordinary Share entitles the holder thereof
to one vote on all matters subject to the vote at general meetings of our company, voting together as one class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Rights of Other Types of Securities (Item 9.A.7 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Rights of Ordinary Shares (Item 10.B.3 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Ordinary Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized share capital is US$140,625,000
divided into 11,250,000 Ordinary Shares of par value US$11.25 each (&ldquo;Ordinary Shares&rdquo;) and 1,250,000 Preferred Shares
of par value US$11.25 each. All of our issued and outstanding Ordinary Shares are fully paid and non-assessable. Shareholders who are
non-residents of the Cayman Islands may freely hold and transfer their Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Dividends</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the provisions of the Cayman Companies
Act and any rights attaching to any class or classes of shares under and in accordance with the Articles:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the directors may declare dividends or distributions out of our funds which are lawfully available for that purpose; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company&rsquo;s shareholders may, by ordinary resolution, declare dividends but no such dividend shall exceed the amount recommended by the directors.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the requirements of the Cayman Companies
Act regarding the application of a company&rsquo;s share premium account and with the sanction of an ordinary resolution, dividends may
also be declared and paid out of any share premium account. The directors when paying dividends to shareholders may make such payment
either in cash or in specie.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless provided by the rights attached to a share,
no dividend shall bear interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Voting Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to any rights or restrictions as to voting
attached to any shares, unless any share carries special voting rights, on a show of hands every shareholder who is present in person
and every person representing a shareholder by proxy shall have one vote per Ordinary Share. On a poll, every shareholder who is present
in person and every person representing a shareholder by proxy shall have one vote for each share of which he or the person represented
by proxy is the holder. In addition, all shareholders holding shares of a particular class are entitled to vote at a meeting of the holders
of that class of shares. Votes may be given either personally or by proxy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Calls on shares and forfeiture</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the terms of allotment, the directors
may make calls on the shareholders in respect of any monies unpaid on their shares including any premium and each shareholder shall (subject
to receiving at least 14 clear days&rsquo; notice specifying when and where payment is to be made), pay to us the amount called on his
shares. Shareholders registered as the joint holders of a share shall be jointly and severally liable to pay all calls in respect of the
share. If a call remains unpaid after it has become due and payable the person from whom it is due and payable shall pay interest on the
amount unpaid from the day it became due and payable until it is paid at the rate fixed by the terms of allotment of the share or in the
notice of the call or if no rate is fixed, at the rate of ten percent per annum. The directors may, at their discretion, waive payment
of the interest wholly or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have a first and paramount lien on all shares
(whether fully paid up or not) registered in the name of a shareholder (whether solely or jointly with others). The lien is for all monies
payable to us by the shareholder or the shareholder&rsquo;s estate:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;either alone or jointly with any other person, whether or not that other person is a shareholder; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;whether or not those monies are presently payable.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At any time the directors may declare any share
to be wholly or partly exempt from the lien on shares provisions of the Articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may sell, in such manner as the directors may
determine, any share on which the sum in respect of which the lien exists is presently payable, if due notice that such sum is payable
has been given (as prescribed by the Articles) and, within 14 days of the date on which the notice is deemed to be given under the Articles,
such notice has not been complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Unclaimed Dividend</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A dividend that remains unclaimed for a period
of six years after it became due for payment shall be forfeited to, and shall cease to remain owing by, the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Forfeiture or Surrender of Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a shareholder fails to pay any capital call,
the directors may give to such shareholder not less than 14 clear days&rsquo; notice requiring payment and specifying the amount unpaid
including any interest which may have accrued, any expenses which have been incurred by us due to that person&rsquo;s default and the
place where payment is to be made. The notice shall state the place where payment is to be made and also contain a warning that if the
notice is not complied with, the shares in respect of which the call is made will be liable to be forfeited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If such notice is not complied with, the directors
may, before the payment required by the notice has been received, resolve that any share the subject of that notice be forfeited (which
forfeiture shall include all dividends or other monies payable in respect of the forfeited share and not paid before such forfeiture).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A forfeited share may be sold, re-allotted or
otherwise disposed of on such terms and in such manner as the directors determine and at any time before a sale, re-allotment or disposition
the forfeiture may be cancelled on such terms as the directors think fit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A person whose shares have been forfeited shall
cease to be a shareholder in respect of the forfeited shares, but shall, notwithstanding such forfeiture, remain liable to pay to us all
monies which at the date of forfeiture were payable by him to us in respect of the shares, together with all expenses and interest from
the date of forfeiture or surrender until payment, but his liability shall cease if and when we receive payment in full of the unpaid
amount. The directors, however, may waive payment wholly or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A declaration, whether statutory or under oath,
made by a director or the secretary shall be conclusive evidence that the person making the declaration is our director or secretary and
that the particular shares have been forfeited or surrendered on a particular date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to the execution of an instrument of transfer, if necessary,
the declaration shall constitute good title to the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Share Premium Account</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors shall establish a share premium
account and shall carry the credit of such account from time to time to a sum equal to the amount or value of the premium paid on the
issue of any share or capital contributed or such other amounts required by the Cayman Companies Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Redemption and Purchase of Own Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the Cayman Companies Act and any rights
for the time being conferred on the shareholders holding a particular class of shares, we may by action of our directors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue shares that are to be redeemed or liable to be redeemed, at our option or the shareholder holding those redeemable shares, on the terms and in the manner our directors determine before the issue of those shares;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with the consent by special resolution of the shareholders holding shares of a particular class, vary the rights attaching to that class of shares so as to provide that those shares are to be redeemed or are liable to be redeemed at our option on the terms and in the manner which the directors determine at the time of such variation; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchase all or any of our own shares of any class including any redeemable shares on the terms and in the manner which the directors determine at the time of such purchase.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may make a payment in respect of the redemption
or purchase of its own shares in any manner authorized by the Cayman Companies Act, including out of any combination of capital, our profits
and the proceeds of a fresh issue of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When making a payment in respect of the redemption
or purchase of shares, the directors may make the payment in cash or in specie (or partly in one and partly in the other) if so authorized
by the terms of the allotment of those shares or by the terms applying to those shares, or otherwise by agreement with the shareholder
holding those shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Transfer of Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provided that a transfer of Ordinary Shares complies
with applicable rules of the Nasdaq Global Market, a shareholder may transfer Ordinary Shares to another person by completing an instrument
of transfer in a common form or in a form prescribed by Nasdaq or in any other form approved by the directors, executed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where the Ordinary Shares are fully paid, by or on behalf of that shareholder; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where the Ordinary Shares are partly paid, by or on behalf of that shareholder and the transferee.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transferor shall be deemed to remain the holder
of an Ordinary Share until the name of the transferee is entered into the register of members of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors may, in its absolute discretion,
decline to register any transfer of any Ordinary Share that has not been fully paid up or is subject to a company lien. Our board of directors
may also decline to register any transfer of such Ordinary Share unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the instrument of transfer is lodged with the Company, accompanied by the certificate for the Ordinary Shares to which it relates and such other evidence as our board of directors may reasonably require to show the right of the transferor to make the transfer;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the instrument of transfer is in respect of only one class of Shares;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the instrument of transfer is properly stamped, if required;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Ordinary Share transferred is fully paid and free of any lien in favor of us;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any fee related to the transfer has been paid to us; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the transfer is not to more than four joint holders.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our directors refuse to register a transfer,
they are required, within three months after the date on which the instrument of transfer was lodged, to send to each of the transferor
and the transferee notice of such refusal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This, however, is unlikely to affect market transactions
of the Ordinary Shares purchased by investors in the public offering. Once the Ordinary Shares have been listed, the legal title to such
Ordinary Shares and the registration details of those Ordinary Shares in our register of members will remain with Depository Trust Company
(&ldquo;DTC&rdquo;)/Cede &amp; Co. All market transactions with respect to those Ordinary Shares will then be carried out without the
need for any kind of registration by the directors, as the market transactions will all be conducted through the DTC systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The registration of transfers may, on 14 calendar
days&rsquo; notice being given by advertisement in such one or more newspapers or by electronic means, be suspended and our register of
members closed at such times and for such periods as our board of directors may from time to time determine. The registration of transfers,
however, may not be suspended, and the register may not be closed, for more than 30 days in any year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Capitalization of Profits</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The directors may resolve to capitalize:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any part of our profits not required for paying any preferential dividend (whether or not those profits are available for distribution); or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any sum standing to the credit of our share premium account or capital redemption reserve, if any.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount resolved to be capitalized must be
appropriated to the shareholders who would have been entitled to it had it been distributed by way of dividend and in the same proportions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Liquidation Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are wound up, the shareholders may, subject
to the Articles and any other sanction required by the Cayman Companies Act, pass a special resolution allowing the liquidator to do either
or both of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to divide in specie among the shareholders the whole or any part of our assets and, for that purpose, to value any assets and to determine how the division shall be carried out as between the shareholders or different classes of shareholders; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to vest the whole or any part of the assets in trustees for the benefit of shareholders and those liable to contribute to the winding up.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors have the authority to present a
petition for our winding up to the Grand Court of the Cayman Islands on our behalf without the sanction of a resolution passed at a general
meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Requirements to Change the Rights of Holders of Ordinary Shares
(Item 10.B.4 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Variations of Rights of Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Whenever our capital is divided into different
classes of shares, the rights attaching to any class of share (unless otherwise provided by the terms of issue of the shares of that class)
may be varied either with the consent in writing of the holders of not less than two-thirds of the issued shares of that class, or with
the sanction of a resolution passed by a majority of not less than two-thirds of the holders of shares of the class present in person
or by proxy at a separate general meeting of the holders of shares of that class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless the terms on which a class of shares was
issued state otherwise, the rights conferred on the shareholder holding shares of any class shall not be deemed to be varied by the creation
or issue of further shares ranking pari passu with the existing shares of that class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Limitations on the Rights to Own Ordinary Shares (Item 10.B.6
of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no limitations under the laws of the
Cayman Islands or under the Memorandum and Articles of Association that limit the right of non-resident or foreign owners to hold or vote
ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Provisions Affecting Any Change of Control (Item 10.B.7 of Form
20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Anti-Takeover Provisions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some provisions of the Memorandum and Articles
of Association may discourage, delay, or prevent a change in control of our company or management that shareholders may consider favorable,
including, among other things, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provisions that authorize our board of directors to issue shares with preferred, deferred, or other special rights or restrictions without any further vote or action by our shareholders; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provisions that restrict the ability of our shareholders to call meetings and to propose special matters for consideration at shareholder meetings.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Cayman Companies Act, our directors
may only exercise the rights and powers granted to them under the Articles for what they believe in good faith to be in the best interests
of our company and for a proper purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Ownership Threshold (Item 10.B.8 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no provisions under the Cayman Companies
Act or under the Memorandum and Articles of Association that govern the ownership threshold above which shareholder ownership must be
disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Differences Between the Law of Different Jurisdictions (Item
10.B.9 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Cayman Companies Act is derived, to a large
extent, from the older Companies Acts of England and Wales but does not follow recent United Kingdom statutory enactments, and accordingly
there are significant differences between the Cayman Companies Act and the current Companies Act of the UK. In addition, the Cayman Companies
Act differs from laws applicable to United States corporations and their shareholders. Set forth below is a summary of certain significant
differences between the provisions of the Cayman Companies Act applicable to us and the comparable laws applicable to companies incorporated
in the State of Delaware in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cayman Islands</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Title of Organizational Documents</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation and Bylaws</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation and Memorandum and Articles of Association</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Duties of Directors</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under Delaware law, the business and affairs of a corporation are managed by or under the direction of its board of directors. In exercising their powers, directors are charged with a fiduciary duty of care to protect the interests of the corporation and a fiduciary duty of loyalty to act in the best interests of its shareholders. The duty of care requires that directors act in an informed and deliberative manner and inform themselves, prior to making a business decision, of all material information reasonably available to them. The duty of care also requires that directors exercise care in overseeing and investigating the conduct of the corporation&rsquo;s employees. The duty of loyalty may be summarized as the duty to act in good faith, not out of self-interest, and in a manner which the director reasonably believes to be in the best interests of the shareholders.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a matter of Cayman Islands law, a director owes three types of duties to the company: (i) statutory duties, (ii) fiduciary duties, and (iii) common law duties. The Cayman Companies Act imposes a number of statutory duties on a director. A Cayman Islands director&rsquo;s fiduciary duties are not codified, however the courts of the Cayman Islands have held that a director owes the following fiduciary duties (a) a duty to act in what the director bona fide considers to be in the best interests of the company, (b) a duty to exercise their powers for the purposes they were conferred, (c) a duty to avoid fettering his or her discretion in the future and (d) a duty to avoid conflicts of interest and of duty. The common law duties owed by a director are those to act with skill, care and diligence that may reasonably be expected of a person carrying out the same functions as are carried out by that director in relation to the company and, also, to act with the skill, care and diligence in keeping with a standard of care commensurate with any particular skill they have which enables them to meet a higher standard than a director without those skills. In fulfilling their duty of care to us, our directors must ensure compliance with our amended articles of association, as amended and restated from time to time. We have the right to seek damages if a duty owed by any of our directors is breached.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Limitations on Personal Liability of Directors</I></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to the limitations described below, a certificate of incorporation may provide for the elimination or limitation of the personal liability of a director to the corporation or its shareholders for monetary damages for a breach of fiduciary duty as a director. Such provision cannot limit liability for breach of loyalty, bad faith, intentional misconduct, unlawful payment of dividends or unlawful share purchase or redemption. In addition, the certificate of incorporation cannot limit liability for any act or omission occurring prior to the date when such provision becomes effective.</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cayman Islands law does not limit the extent to which a company&rsquo;s articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Indemnification of Directors, Officers, Agents, and Others</I></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A corporation has the power to indemnify any director, officer, employee, or agent of corporation who was, is, or is threatened to be made a party who acted in good faith and in a manner he believed to be in the best interests of the corporation, and if with respect to a criminal proceeding, had no reasonable cause to believe his conduct would be unlawful, against amounts actually and reasonably incurred.</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cayman Islands law does not limit the extent to
    which a company&rsquo;s memorandum and articles of association may provide for indemnification of directors and officers, except to the
    extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification
    against the consequences of committing a crime, or against the indemnified person&rsquo;s own fraud or dishonesty.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our articles of association provide to the extent
    permitted by law, we shall indemnify each existing or former secretary, director (including alternate director), and any of our other
    officers (including an investment adviser or an administrator or liquidator) and their personal representatives against: (a) all actions,
    proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by the existing or former director (including
    alternate director), secretary or officer in or about the conduct of our business or affairs or in the execution or discharge of the existing
    or former director (including alternate director), secretary&rsquo;s or officer&rsquo;s duties, powers, authorities or discretions; and
    (b) without limitation to paragraph (a) above, all costs, expenses, losses or liabilities incurred by the existing or former director
    (including alternate director), secretary or officer in defending (whether successfully or otherwise) any civil, criminal, administrative
    or investigative proceedings (whether threatened, pending or completed) concerning us or our affairs in any court or tribunal, whether
    in the Cayman Islands or elsewhere.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No such existing or former director (including
    alternate director), secretary or officer, however, shall be indemnified in respect of any matter arising out of his own dishonesty.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent permitted by law, we may make a
    payment, or agree to make a payment, whether by way of advance, loan or otherwise, for any legal costs incurred by an existing or former
    director (including alternate director), secretary or any of our officers in respect of any matter identified in above on condition that
    the director (including alternate director), secretary or officer must repay the amount paid by us to the extent that it is ultimately
    found not liable to indemnify the director (including alternate director), the secretary or that officer for those legal costs.</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Interested Directors</I></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under Delaware law, a transaction in which a director who has an interest in such transaction would not be voidable if (i) the material facts as to such interested director&rsquo;s relationship or interests are disclosed or are known to the board of directors and the board in good faith authorizes the transaction by the affirmative vote of a majority of the disinterested directors, even though the disinterested directors are less than a quorum, (ii) such material facts are disclosed or are known to the shareholders entitled to vote on such transaction and the transaction is specifically approved in good faith by vote of the shareholders, or (iii) the transaction is fair as to the corporation as of the time it is authorized, approved or ratified. Under Delaware law, a director could be held liable for any transaction in which such director derived an improper personal benefit.</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interested director transactions are governed by the terms of a company&rsquo;s memorandum and articles of association.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting Requirements</I></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The certificate of incorporation may include a
    provision requiring supermajority approval by the directors or shareholders for any corporate action.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, under Delaware law, certain business
    combinations involving interested shareholders require approval by a supermajority of the non-interested shareholders.</P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the protection of shareholders, certain matters
    must be approved by special resolution of the shareholders as a matter of Cayman Islands law, including alteration of the memorandum or
    articles of association, appointment of inspectors to examine company affairs, reduction of share capital (subject, in relevant circumstances,
    to court approval), change of name, authorization of a plan of merger or transfer by way of continuation to another jurisdiction or consolidation
    or voluntary winding up of the company.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Cayman Companies Act requires that a special
    resolution be passed by a majority of at least two-thirds or such higher percentage as set forth in the memorandum and articles of association,
    of shareholders being entitled to vote and do vote in person or by proxy at a general meeting, or by unanimous written consent of shareholders
    entitled to vote at a general meeting.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting for Directors</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under Delaware law, unless otherwise specified in the certificate of incorporation or bylaws of the corporation, directors shall be elected by a plurality of the votes of the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Cayman Companies Act defines &ldquo;special resolutions&rdquo; only. A company&rsquo;s memorandum and articles of association can therefore tailor the definition of &ldquo;ordinary resolutions&rdquo; as a whole, or with respect to specific provisions.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cumulative Voting</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No cumulative voting for the election of directors unless so provided in the certificate of incorporation.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No cumulative voting for the election of directors unless so provided in the memorandum and articles of association.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Directors&rsquo; Powers Regarding Bylaws</I></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The certificate of incorporation may grant the directors the power to adopt, amend or repeal bylaws.</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The memorandum and articles of association may only be amended by a special resolution of the shareholders.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nomination and Removal of Directors and Filling Vacancies on Board</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders may generally nominate directors if they comply with advance notice provisions and other procedural requirements in company bylaws. Holders of a majority of the shares may remove a director with or without cause, except in certain cases involving a classified board or if the company uses cumulative voting. Unless otherwise provided for in the certificate of incorporation, directorship vacancies are filled by a majority of the directors elected or then in office.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nomination and removal of directors and filling of board vacancies are governed by the terms of the memorandum and articles of association.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Mergers and Similar Arrangements</I></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under Delaware law, with certain exceptions, a
    merger, consolidation, exchange or sale of all or substantially all the assets of a corporation must be approved by the board of directors
    and a majority of the outstanding shares entitled to vote thereon. Under Delaware law, a shareholder of a corporation participating in
    certain major corporate transactions may, under certain circumstances, be entitled to appraisal rights pursuant to which such shareholder
    may receive cash in the amount of the fair value of the shares held by such shareholder (as determined by a court) in lieu of the consideration
    such shareholder would otherwise receive in the transaction.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Delaware law also provides that a parent corporation,
    by resolution of its board of directors, may merge with any subsidiary, of which it owns at least 90% of each class of capital stock without
    a vote by shareholders of such subsidiary. Upon any such merger, dissenting shareholders of the subsidiary would have appraisal rights.</P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75pt; text-align: justify">The Cayman Companies Act permits mergers
    and consolidations between Cayman Islands companies and between Cayman Islands companies and non-Cayman Islands companies. For these purposes,
    (a) &ldquo;merger&rdquo; means the merging of two or more constituent companies and the vesting of their undertaking, property and liabilities
    in one of such companies as the surviving company, and (b) a &ldquo;consolidation&rdquo; means the combination of two or more constituent
    companies into a consolidated company and the vesting of the undertaking, property and liabilities of such companies to the consolidated
    company. In order to effect such a merger or consolidation, the directors of each constituent company must approve a written plan of merger
    or consolidation, which must then be authorized by (a) a special resolution of the shareholders of each constituent company, and (b) such
    other authorization, if any, as may be specified in such constituent company&rsquo;s articles of association. The plan must be filed with
    the Registrar of Companies together with a declaration as to the solvency of the consolidated or surviving company, a list of the assets
    and liabilities of each constituent company and an undertaking that a copy of the certificate of merger or consolidation will be given
    to the shareholders and creditors of each constituent company and that notification of the merger or consolidation will be published in
    the Cayman Islands Gazette. Court approval is not required for a merger or consolidation which is effected in compliance with these statutory
    procedures.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A merger between a Cayman Islands parent company
    and its Cayman Islands subsidiary or subsidiaries does not require authorization by a resolution of shareholders. For this purpose a subsidiary
    is a company of which at least 90% of the issued shares entitled to vote are owned by the parent company.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consent of each holder of a fixed or floating
    security interest of a constituent company is required unless this requirement is waived by a court in the Cayman Islands.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except in certain limited circumstances, a dissenting
    shareholder of a Cayman Islands constituent company is entitled to payment of the fair value of his or her shares upon dissenting from
    a merger or consolidation. The exercise of such dissenter rights will preclude the exercise by the dissenting shareholder of any other
    rights to which he or she might otherwise be entitled by virtue of holding shares, except for the right to seek relief on the grounds
    that the merger or consolidation is void or unlawful.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, there are statutory provisions that
    facilitate the reconstruction and amalgamation of companies, provided that the arrangement is approved by a majority in number of each
    class of shareholders and creditors with whom the arrangement is to be made, and who must, in addition, represent three-fourths in value
    of each such class of shareholders or creditors, as the case may be, that are present and voting either in person or by proxy at a meeting,
    or meetings, convened for that purpose. The convening of the meetings and subsequently the arrangement must be sanctioned by the Grand
    Court of the Cayman Islands. While a dissenting shareholder has the right to express to the court the view that the transaction ought
    not to be approved, the court can be expected to approve the arrangement if it determines that: (a) the statutory provisions as to the
    required majority vote have been met; (b) the shareholders have been fairly represented at the meeting in question and the statutory majority
    are acting bona fide without coercion of the minority to promote interests adverse to those of the class; (c) the arrangement is such
    that may be reasonably approved by an intelligent and honest man of that class acting in respect of his interest; and (d) the arrangement
    is not one that would more properly be sanctioned under some other provision of the Cayman Companies Act.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When a takeover offer is made and accepted by
    holders of 90% of the shares affected within four months the offeror may, within a two-month period commencing on the expiration of such
    four month period, require the holders of the remaining shares to transfer such shares on the terms of the offer. An objection can be
    made to the Grand Court of the Cayman Islands but this is unlikely to succeed in the case of an offer which has been so approved unless
    there is evidence of fraud, bad faith or collusion.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an arrangement and reconstruction is thus approved,
    or if a takeover offer is made and accepted, a dissenting shareholder would have no rights comparable to appraisal rights, which would
    otherwise ordinarily be available to dissenting shareholders of Delaware corporations, providing rights to receive payment in cash for
    the judicially determined value of the shares.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shareholder Suits</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class actions and derivative actions generally are available to shareholders under Delaware law for, among other things, breach of fiduciary duty, corporate waste and actions not taken in accordance with applicable law. In such actions, the court generally has discretion to permit the winning party to recover attorneys&rsquo; fees incurred in connection with such action.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In principle, we will normally be the proper plaintiff and as a general rule a derivative action may not be brought by a minority shareholder. However, based on English authorities, which would in all likelihood be of persuasive authority in the Cayman Islands, the Cayman Islands courts can be expected to follow and apply the common law principles (namely the rule in <I>Foss v. Harbottle</I> and the exceptions thereto) so that a non-controlling shareholder may be permitted to commence a class action against or derivative actions in the name of the company to challenge: (a) an act which is illegal or ultra vires with respect to the company and is therefore incapable of ratification by the shareholders; (b) an act which, although not ultra vires, requires authorization by a qualified (or special) majority (that is, more than a simple majority) which has not been obtained; and (c) an act which constitutes a &ldquo;fraud on the minority&rdquo; where the wrongdoers are themselves in control of the company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Inspection of Corporate Records</I></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under Delaware law, shareholders of a Delaware corporation have the right during normal business hours to inspect for any proper purpose, and to obtain copies of list(s) of shareholders and other books and records of the corporation and its subsidiaries, if any, to the extent the books and records of such subsidiaries are available to the corporation.</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%; padding-left: 2.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders of a Cayman Islands exempted company have no general right under Cayman Islands law to inspect or obtain copies of a list of shareholders or other corporate records (other than the register of mortgages or charges) of the company. However, these rights may be provided in the company&rsquo;s memorandum and articles of association.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shareholder Proposals</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless provided in the corporation&rsquo;s certificate of incorporation or bylaws, Delaware law does not include a provision restricting the manner in which shareholders may bring business before a meeting.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Cayman Companies Act provides shareholders with only limited rights to requisition a general meeting, and does not provide shareholders with any right to put any proposal before a general meeting. However, these rights may be provided in a company&rsquo;s articles of association. Our articles of association provide that general meetings shall be convened on the written requisition of one or more of the shareholders entitled to attend and vote at our general meetings who (together) hold not less than 10 percent of the rights to vote at such general meeting in accordance with the notice provisions in the articles of association, specifying the purpose of the meeting and signed by each of the shareholders making the requisition. If the directors do not convene such meeting for a date not later than twenty-one clear days&rsquo; after the date of receipt of the written requisition, those shareholders who requested the meeting may convene the general meeting themselves within three months after the end of such period of twenty-one clear days in which case reasonable expenses incurred by them as a result of the directors failing to convene a meeting shall be reimbursed by us. Our articles of association provide no other right to put any proposals before annual general meetings or extraordinary general meetings. As a Cayman Islands exempted company, we are not obligated by law to call shareholders&rsquo; annual general meetings. However, our corporate governance guidelines require us to call such meetings every year.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Approval of Corporate Matters by Written Consent</I></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware law permits shareholders to take action by written consent signed by the holders of outstanding shares having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting of shareholders.</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%; padding-left: 2.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Cayman Companies Act allows a special resolution to be passed in writing if signed by all the voting shareholders (if authorized by the memorandum and articles of association).</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Calling of Special Shareholders Meetings</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware law permits the board of directors or any person who is authorized under a corporation&rsquo;s certificate of incorporation or bylaws to call a special meeting of shareholders.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Cayman Companies Act does not have provisions governing the proceedings of shareholders meetings which are usually provided in the memorandum and articles of association. Please see above.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dissolution; Winding Up</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the Delaware General Corporation Law, unless the board of directors approves the proposal to dissolve, dissolution must be approved by shareholders holding 100% of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved by a simple majority of the corporation&rsquo;s outstanding shares. Delaware law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board of directors.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the Cayman Companies Act and our articles of association, the Company may be wound up by a special resolution of our shareholders, or if the winding up is initiated by our board of directors, by either a special resolution of our members or, if our company is unable to pay its debts as they fall due, by an ordinary resolution of our members. In addition, a company may be wound up by an order of the courts of the Cayman Islands. The court has authority to order winding up in a number of specified circumstances including where it is, in the opinion of the court, just and equitable to do so.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Changes in Capital (Item 10.B.10 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to the Cayman Companies Act, we may, by ordinary resolution:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase our share capital by new shares of the amount fixed by that ordinary resolution and with the attached rights, priorities and privileges set out in that ordinary resolution;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidate and divide all or any of our share capital into shares of larger amount than our existing shares;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">convert all or any of our paid up shares into stock, and reconvert that stock into paid up shares of any denomination;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sub-divide our shares or any of them into shares of an amount smaller than that fixed, so, however, that in the sub-division, the proportion between the amount paid and the amount, if any, unpaid on each reduced share shall be the same as it was in case of the share from which the reduced share is derived; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancel shares which, at the date of the passing of that ordinary resolution, have not been taken or agreed to be taken by any person and diminish the amount of our share capital by the amount of the shares so cancelled or, in the case of shares without nominal par value, diminish the number of shares into which our capital is divided.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the Cayman Companies Act and to any
rights for the time being conferred on the shareholders holding a particular class of shares, our shareholders may, by special resolution,
reduce our share capital in any way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Debt Securities (Item 12.A of Form&nbsp;20-F)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Warrants and Rights (Item 12.B of Form&nbsp;20-F)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Other Securities (Item 12.C of Form&nbsp;20-F)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Description of American Depositary Shares (Items 12.D.1 and 12.D.2
of Form 20-F)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>5
<FILENAME>ea022807501ex4-6_universe.htm
<DESCRIPTION>ENGLISH TRANSLATION OF THE WORKING CAPITAL LOAN CONTRACT ENTERED INTO BY AND BETWEEN JIANGXI UNIVERSE AND BANK OF COMMUNICATIONS CO., LTD., DATED JUNE 16, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0"><B>Exhibit 4.6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">[2024] J.N.S.H.J.L.Z. No.: <U>17138202405171003001</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Working Capital Loan Contract </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">Borrower <I><U>Jiangxi Universe Pharmaceuticals Commerce and Trade Co., Ltd.</U></I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Lender <I><U>
Ji&rsquo;an Rural Communications Bank Co., Ltd.Jingkaiqu Branch</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><IMG SRC="ex4-6_001.jpg" ALT=""></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 12pt"><B>Jiangxi Rural Commercial Bank</B></FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Special Notice: In order to protect the legitimate
rights and interests of the Borrower, the Lender hereby requests the Borrower to give full attention to all provisions concerning the
rights and obligations of the parties, especially those shown in bold. If the Borrower has any objection, it shall raise the objection
to the Lender. Otherwise, after this Contract is entered into by and between the Borrower and the Lender, all the terms and conditions
herein represent the true intention of both parties, are protected by law, and shall be legally binding on both parties herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Working Capital Loan Contract</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ex4-6_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">[2024] ___LJZ No.: <U>17138202405171003001</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 7%">Borrower:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 93%"><I>Jiangxi Universe Pharmaceuticals Commerce and Trade Co., Ltd.</I></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 14%">Business License No.:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 86%">913608215508749684</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 26%">Legal Representative / Person in Charge:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 74%">LAI Gang</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 12%">Business Address:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 88%">No. 265, Jingjiu Avenue, Jinggangshan Economic and Technological Development Zone, Ji&rsquo;an County</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 12%">Mailing Address: </TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 88%">The same as above</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 8%">Postal Code:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 49%">343100</TD>
  <TD STYLE="width: 4%">Tel.:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 39%">*</TD></TR>
</TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 43%">Electronic Contact Information (Email and WeChat
Account No.):</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 57%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 6%">Lender: </TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 94%">Ji&rsquo;an Rural Communications Bank Co., Ltd.Jingkaiqu Branch.</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 26%">Legal Representative / Person in Charge:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 74%">Fang Juan</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 12%">Business Address:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 88%">The northeast corner of the
intersection between Junshan Avenue and Chuangxin Avenue, </TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid">Jinggangshan Economic and Technological Development Zone</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 8%">Postal Code:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 92%">343000</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 3%">Tel.:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 62%">0796-8736999</TD>
  <TD STYLE="width: 4%">Fax:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 31%"></TD></TR>
</TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the laws and regulations of the People&rsquo;s
Republic of China and other relevant regulations, the Borrower and the Lender have reached an agreement with respect to the matter that
the Lender grants a working capital loan to the Borrower, and hereby execute this Contract by consensus, which shall be binding on both
parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chapter 1 Execution Provisions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 1 Loan Amount and Currency </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Loan Amount (in words): <U>CNY Five Million. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(In Figures) <U>CNY 5,000,000.00.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan amount under this Contract is: <FONT STYLE="font-family: Wingdings 2">&pound;</FONT>revolving
borrowing limit <FONT STYLE="font-family: Wingdings 2">R</FONT>non-revolving loan amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 2Loan Term </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The valid loan term under this Contract shall
be: <U>12</U> months from <U>May 17</U>, <U>2024</U> to <U>May 16</U>, <U>2025</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744;&nbsp;In the event that the loan amount hereunder is
a revolving borrowing limit, the term of borrowing limit shall be the same as the valid loan term as agreed herein. The term of each
loan shall be subject to the term recorded in the loan note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&thorn;</FONT>
In the event that the loan amount hereunder is a non-revolving borrowing limit, the loan term shall be the same as the valid loan
term as agreed herein. The specific loan term shall be subject to the term recorded in the loan note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If the Borrower has any default circumstance
listed in Article 19 of this Contract, and the Borrower agrees that the Lender may recover the loan in advance, then the Lender may announce
that the date of recovering the loan in advance is the due date of the loan.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 3 Loan Purpose </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan borrowed hereunder shall be used for
turnover of working <U>capital</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Without the written consent of the Lender, the
Borrower may neither change the loan purpose nor use the loan for any other purposes. The Lender shall have the right to supervise the
Borrower&rsquo;s use of the loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 4 Loan Interest Rate, Interest
Calculation and Settlement </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1. Loan
Interest Rate </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The method as described in following Item <U>(1)</U>
shall apply for the determination of loan interest rate and a <B>simple interest calculation</B> shall be applied:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(1) Fixed
Interest Rate. The annual interest rate shall be <U>3.65</U>%. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan prime rate (LPR) recently published
on <FONT STYLE="font-family: Wingdings">&thorn;</FONT> the date of signature hereof <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
withdrawal date for &nbsp;<U>1&nbsp;</U> years&rsquo; loan, which is 3.45, and <FONT STYLE="font-family: Wingdings">&thorn;</FONT> increased
percentage points <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744; </FONT>decreased percentage points, which is <U>20</U>
bp (1bp = 0.01%). The annual interest rate shall be <U>3.65</U>%. The interest rate shall remain unchanged during the loan term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(2) Floating
Interest Rate. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan interest rate shall be determined
by the loan prime rate (LPR) recently published on the working day before the withdrawal date for _____ years&rsquo; loan and <FONT STYLE="font-family: Wingdings 2">&pound;</FONT>increased
percentage points <FONT STYLE="font-family: Wingdings 2">&pound;</FONT>decreased percentage points, which is ____ bp. <B>The
increased or decreased percentage points shall remain unchanged during the term of this Contract. In case of any adjustment to the
LPR, its loan interest rate determination method shall be handled according to the following Item and the Lender will not give a
further notice to the Borrower:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9312; Annual Adjustment. From January 1 of
the next year, the loan interest rate shall be adjusted, on the basis of the LPR recently published, in accordance with the
increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9313; Annual Adjustment. From the
corresponding date of the corresponding month in the corresponding year, the loan interest rate shall be adjusted, on the basis of
the LPR recently published, in accordance with the increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9314; Quarterly Adjustment. From the
corresponding date of the first month in the corresponding quarter, the loan interest rate shall be adjusted, on the basis of the
LPR recently published, in accordance with the increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9315; Quarterly Adjustment. From the first
day of the first month in the corresponding quarter, the loan interest rate shall be adjusted, on the basis of the LPR recently
published, in accordance with the increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9316; &nbsp;Monthly Adjustment. From the
corresponding date of the corresponding month, the loan interest rate shall be adjusted, on the basis of the LPR recently published,
in accordance with the increased or decreased percentage points agreed herein (If there is no corresponding day in the month of
adjustment, the last day of such month shall be treated as the corresponding day);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9317; &nbsp;Monthly Adjustment. From the
corresponding date of the corresponding month, the loan interest rate shall be adjusted, on the basis of the LPR recently published,
in accordance with the increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9318; &nbsp;Immediate Adjustment. From the date
immediately following the date of the LRP recently published, the loan interest rate shall be adjusted, on the basis of the new LPR, in
accordance with the increased or decreased percentage points agreed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) The
loan interest rate shall be determined by other methods: ________/________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If the Borrower chooses the &ldquo;(2) floating
interest rate&rdquo; method, and when the loan prime rate (LPR) of the loan market increases, the monthly repayment amount of the Borrower
will increase. If the Borrower still makes the repayment according to the repayment amount before adjustment, the monthly repayment amount
will be insufficient, resulting in penalty interest and compound interest and affecting the credit record of the Borrower.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2. Interest
Settlement Method</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower will settle the interest in a method
as described in following Item <U>(2) </U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Quarterly
Interest Settlement. The 20<SUP>th</SUP> day of the last month of each quarter shall be the interest settlement date, and the 21<SUP>st</SUP>
day shall be the interest payment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) Monthly
Interest Settlement. The 20<SUP>th</SUP> day of each month shall be the interest settlement date, and the 21<SUP>st</SUP> day shall be
the interest payment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) The
interest shall be settled by other methods: _____/__________________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the repayment date of the last
installment of loan principal is not the interestpayment date, such repayment date of the last installment of loan principal shall be
the interest payment date on which the Borrower shall pay off all the interests payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3. Penalty
Interest Rate </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) In
the event that the Borrower fails to repay the loan within the agreed time limit, interest shall be calculated and charged over the overdue
part at the penalty interest rate for overdue loan from the overdue day, until the principal and interest are paid off;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) In
the event that the Borrower uses the loan for any purposes other than those agreed herein, interest shall be calculated and charged over
the misappropriated part at the penalty interest rate for misappropriated loan from the misappropriation date, until the principal and
interest are paid off;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) In
the event that the loan is overdue and misappropriated, interest shall be calculated and charged at the penalty interest rate for misappropriated
loan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) With
respect to the interest and penalty interest that the Borrower fails to pay as scheduled, compound interest shall be calculated and charged
at the penalty interest rate agreed in this paragraph in the interest settlement method as agreed in Paragraph 2 hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) In
case of any adjustment to the loan interest rate agreed herein, the penalty interest and compound interest shall be calculated at the
adjusted interest rate from the adjustment date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6) Penalty
Interest Rate</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The penalty interest rate for overdue loan shall
be <U>30</U>% higher than the loan interest rate agreed in Paragraph 1 hereof; the penalty interest rate for misappropriated loan shall
be <U>50</U>% higher than the loan interest rate agreed in Paragraph 1 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 5 Loan Disbursement and Repayment
Account </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower shall open an account as follows
with the Lender as the loan disbursement and repayment account, which shall be used for loan disbursement, payment and repayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bank of deposit: <U>Ji&rsquo;an Rural Communications
Bank Co., Ltd.Jingkaiqu Branch</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Account Name: <U>Jiangxi Universe Pharmaceuticals
Commerce and Trade Co., Ltd. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Account Number: <U>*</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 6 Repayment </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise agreed by the parties, the Borrower
shall repay the loan hereunder in accordance with the repayment schedule as set forth in Item <U>1</U> below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. Repay
the loan hereunder in full upon the expiration of the loan term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Repay
the loan hereunder in accordance with the following repayment schedule:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt"><B>Repayment Time </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 54%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt"><B>Repayment Amount </B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">1. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">2. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">3. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">4. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">5. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">6. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">7. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">8. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">9. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">Total </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Other
Repayment Schedule: ________/____________________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. Where
the Borrower makes repayment in advance, it shall obtain the consent from the Lender <U>7</U> banking days in advance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 7 Guarantee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The loan hereunder shall be a <U>guaranteed</U>
(credit/ guaranteed) loan. The guarantee type shall be <U>guarantee</U> (guarantee/ mortgage/ pledge), and the guarantee contract shall
be executed separately.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 8 Contract Agreements on the
Borrower&rsquo;s Financial Indicators: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ex4-6_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 9 Dispute Resolution </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. After
this Contract takes effect, any dispute arising from the execution or performance hereof or in connection with this Contract shall be
settled by both parties through negotiation. If such negotiation fails, either party may file a lawsuit with the People&rsquo;s Court having
jurisdiction over the place of the Lender in accordance with the law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. During
the dispute resolution, in the event that the dispute does not affect the performance of the remaining provisions of this Contract, such
remaining provisions shall continue to be performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. After
negotiation between the parties, the parties may conduct notarization for the compulsory enforcement of this Contract. The Borrower agrees
that this Contract shall have the compulsory enforcement effect after it is notarized. In the event that the Borrower fails to perform
its obligations under this Contract, the Lender may apply to the People&rsquo;s Court having jurisdiction for compulsory enforcement according
to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 10 Effectiveness of the Contract
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract shall take effect from the date
when both parties affix their signatures and seals hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract is made out in <U>duplicate</U>,
with <U>the Borrower, the Lender </U>holding <U>one</U> counterpart each. Each counterpart shall have the same legal effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 11 Other Agreements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ex4-6_004.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chapter 2 Standard Provisions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 12 Interest Calculation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The interest shall be calculated from the Borrower&rsquo;s
actual withdrawal date and shall be calculated according to the actual withdrawal amount and use days of loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest Formula: Interest = Principal &times;
Actual Days &times; Daily Interest Rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The daily interest rate is calculated on a base
of 360 days a year. Conversion Formula: Daily Interest Rate = Annual Interest Rate / 360.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 13 Loan Disbursement Conditions
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1. The
Borrower must meet all the following conditions for loan disbursement, otherwise the Lender shall have no obligation to disburse any loan
to the Borrower, unless the Lender agrees to disburse the loan in advance:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The
Contract and its appendixes have become effective;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) The
Borrower has reserved to the Lender the Borrower&rsquo;s documents, receipts, seals, lists of persons and specimen signatures in relation to
the execution and performance of this Contract and filled in the relevant vouchers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) The
Borrower has, according to the Lender&rsquo;s requirements, opened an account necessary for the performance of this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) The
Borrower, within 3 banking days prior to the withdrawal, has submitted to the Lender the written withdrawal notice and the relevant supporting
documents for loan purpose which is consistent with the purpose as agreed herein, and has completed the relevant withdrawal procedures;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) The
Borrower has submitted to the Lender the resolution and letter of authorization of the board of directors or other competent authorities,
which agree to the execution and performance of this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6) In
accordance with relevant regulatory provisions and management requirements of the Lender, if the loan exceeds a certain amount or meets
other conditions, the Lender shall, according to the Borrower&rsquo;s withdrawal application and payment authorization, pay the loan to the
payment object conforming to the purpose agreed herein in a manner of authorized payment by the Lender;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7) In
addition to the credit loan, the Borrower has provided the corresponding guarantee as required by the Lender and has completed the relevant
guarantee procedures, and the guarantee is legal and valid;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8) The
Borrower has not breached this Contract or any other contracts executed by and between the Borrower and the Lender;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. In
the event that the Borrower fails to make any withdrawal for 3 consecutive months from the contract execution date, the Lender shall be
entitled to cancel the borrowing limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 14 Special Arrangements on
Revolving Loan (Maximum Loan)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. During
the term of revolving borrowing limit, the sum of the loan principal balance of at any time shall not exceed the revolving borrowing limit;
the repayment date of any withdrawal shall not exceed the term of revolving borrowing limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. As
agreed by both parties, the Lender shall reasonably set the amount and term of each revolving loan according to the scale and cycle of
the Borrower&rsquo;s production and operation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 15 Loan Amount Payment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. The
authorized payment by the Lender means that the Lender pays the loan fund to the Borrower&rsquo;s counter-party in a transaction conforming
to the purpose agreed herein according to the Borrower&rsquo;s withdrawal notice and payment authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payment of the Borrower&rsquo;s loan fund for which
the amount of a single payment under this Contract exceeds the specified amount shall be made in a manner of authorized payment by the
Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of the authorized payment by the
Lender, the Borrower shall make express payment authorization and provide other necessary payment information (including name of counter-party
who receives payment, account number of such counter-party, and amount of payment) in the withdrawal notice, and submit to the Lender
the supporting documents for loan purpose such as business contracts required for the examination. In this case, the Lender shall pay
the loan fund to the counter-party of the Borrower via the Borrower&rsquo;s account upon examination and approval. In the event of the Lender&rsquo;s
failure to perform its obligation to pay upon authorization resulting from untruthfulness, incorrectness, and incompleteness of the information
of payment authorization and relevant transactions furnished by the Borrower, the Lender shall not be held liable for such failure whatsoever
and the Borrower&rsquo;s obligation to repay under the Contract shall not be affected. The Lender will make payment to the account of the Borrower&rsquo;s
counter-party in accordance with the Borrower&rsquo;s withdrawal notice and the payment certificate as required by the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Lender, upon examination,
discovers that the supporting documents for loan purpose such as business contracts furnished by the Borrower fail to comply with the
Contract or there is any other defects, the Lender shall be entitled to request the Borrower to supplement, replace, explain or re-furnish
such documents, and the Lender may suspend granting or paying of such loans until the Borrower has furnished the supporting documents
such as business contracts to the satisfaction of the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the account-holding bank of
the counterparty returns such payments, resulting in the Lender&rsquo;s failure to transfer such loans to the Borrower&rsquo;s counterparty as authorized
by the Borrower in a timely manner, the Lender shall not be liable for such failure whatsoever and the Borrower&rsquo;s obligation to repay
under the Contract shall not be affected. With respect to the funds returned by the account-holding bank of the counterparty, the Borrower
shall re-furnish the payment authorization and the supporting documents for loan purpose such as business contracts required for the examination,
and the Lender shall pay the loan fund to the counterparty of the Borrower via the Borrower&rsquo;s account upon examination and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All the expenses incurred by the payment of loan
to the counterparty designated by the Borrower in a manner of authorized payment under this Contract shall be borne by the Borrower. The
Borrower shall pay the above expenses to the Lender at the time of the authorized payment of each loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower shall not violate the above provisions
to dodge the authorized payment by the Lender by way of breaking up a large amount into several small amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Except
for the cases where the authorized payment by the Lender must be adopted as stipulated in the preceding paragraph, unless otherwise agreed
by both parties, payment of other loans shall be made by the Borrower itself, namely, after the Lender disburses the loans to the Borrower&rsquo;s
account pursuant to the withdrawal application submitted by the Borrower, the Borrower pay by itself to the its counterparty that complies
with the purpose as agreed in the Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Borrower needs to change
the aforesaid repayment schedule, it shall submit a written application to the Lender <U>10</U> banking days prior to the maturity date
of the loan, and the changed repayment schedule is subject to the written confirmation by the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. In
the event that the Borrower needs to extend the loan term agreed herein, it shall submit a written application of extension to the Lender
<U>30</U> banking days prior to the maturity date of the loan, and the Lender shall decide whether to approve the extension. In applying
for the extension of a guaranteed loan, mortgage loan or pledged loan, the guarantor, mortgagor or pledgor shall also issue a written
certificate of approval. the parties shall enter into a renewal agreement after the Lender approves the extension. In the event that the
Borrower&rsquo;s application for extension is not approved by the Lender, the Borrower shall still repay the loan in full according to the repayment
term agreed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4. Unless
otherwise agreed by the Parties, if both the principal and the interests are overdue by the Borrower, the Lender shall be entitled to
decide on the sequences for repaying the principal or the interests; under the condition of installment repayment, if several mature installments
and overdue installments exist under this Contract, the Lender shall be entitled to decide the sequences of repayment; if several outstanding
loan contracts exist between the Parties, the Lender shall be entitled to decide the sequences for repaying any contract.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The
Borrower shall repay the loan principal, interests and other amounts payable in full and on time according to provisions stated herein.
The Borrower shall, before the end of counter business on the repayment date and each interest settlement date, deposit in full the current
interests, principal and other amounts payable to the repayment account opened with the Lender, and the Borrower shall authorize the Lender
to collect the funds on the repayment date or the interest settlement date or the Borrower shall be required to cooperate in handling
the relevant transfer procedures. In the event that the amount in the repayment account is insufficient to pay the full amount due from
the Borrower, the Borrower shall agree that Lender is entitled to decide the sequences for repayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6. The
Lender shall be entitled to collect the loan in advance on the basis of the capital withdrawal of the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7. Loan
Note: The loan note shall be an integral part of this Contract. In the event that there is no record in this Contract, or the loan amount,
withdrawal amount, repayment amount, borrow date and maturity date of the loan, loan term, loan interest rate and loan purpose as recorded
in this Contract is inconsistent with those recorded in the loan note, the loan note shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 16 Guarantee</B><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that any event occurs to the Borrower
or the guarantor, and causes the Lender to believe that it may affect the performing capability of the Borrower or the guarantor; or the
guarantee contracts are deemed as invalid, canceled or resolved; or the performing capability of the Borrower or guarantor may be affected
due to the deterioration in their financial condition or that the Borrower and the guarantor are involved in substantial lawsuit or arbitration
or other reasons; or the guarantor breaches the guarantee contracts or other contracts with the Lender; or the collateral value decreases
or gets lost due to the devaluation, damage, lost or sequestration of the collateral; the Lender shall be entitled to require, and the
Borrower shall have the obligation to provide new guarantee, supplement or replace the guarantor to guarantee the liabilities under this
Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 17 Representations and
Undertakings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. The
Borrower is a legal entity incorporated, registered and existing under the administration for industry and commerce or other competent
authorities and has full capacity of civil rights and conduct to conclude and perform the Contract, and capacity of loan repayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. The
Borrower fully agrees to the contents and terms of this Contract, executes and performs this Contract out of true intention, has obtained
all legal and valid authorizations required by the Borrower&rsquo;s Articles of Association and bylaws, and will not be in violation of any
agreement, contract, or other legal documents with binding force to the Borrower. The Borrower has obtained or will obtain all the required
approval, consent, documentation or registration for executing and performing this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. The
Borrower is in good faith and all the documents, financial statements, certifications and other information provided by the Borrower to
the Lender under this Contract are true, complete, accurate and valid, and free from false records, material omissions or misleading statements.
The financial and accounting reports provided to the Lender are prepared in accordance with Chinese accounting standards, and truly, fairly
and completely present the Borrower&rsquo;s operating and liability condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The
transaction background that the Borrower represents to the Lender is real and legal, not for any illegal purposes such as money laundering.
The loan purpose and the source of repayment are clear and legal. The loan purpose and the source of repayment are clear and legal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The
Borrower has a good credit status, does not have material bad credit record, and does not conceal from the Lender any fact that may affect
the Borrower&rsquo;s and the Guarantor&rsquo;s financial condition and performance capability. The Borrower does not conceal from the Lender any litigation,
arbitration or claim in which it is involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6. The
borrower has repaid other debts payable as scheduled and has not maliciously defaulted on the payment of principal and interest of the
bank loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>7. The
Borrower shall withdraw and use the loan in accordance with the term and purpose agreed herein. The loan borrowed hereunder shall neither
be used for the investment in fixed asset and equity and other investments, nor flow into the securities market or the futures market
in any form, or be used for other purposes prohibited or restricted by relevant laws and regulations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8. The
Borrower shall deliver its financial statements (including but not limited to annual, quarterly and monthly reports) and other relevant
documents to the Lender on a regularly and timely basis in accordance with the requirements of the Lender; the Borrower shall ensure that
the financial indicators will comply with the Contract all the time. If the production and operation qualification/license is subject
to the annual audit, such qualification/license will pass the annual examination as scheduled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9. The
Borrower shall withdraw, repay and use the loan as stipulated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10. If
the Borrower has executed or will execute with the guarantor under this Contract a counter-guarantee agreement or similar agreement regarding
its guarantee obligations, this counter-guarantee agreement or similar agreement will not prejudice any Lender&rsquo;s right under this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11. The
Borrower shall accept the credit inspection and supervision conducted by the Lender, and provide sufficient assistance and cooperation;
from the effective date of this Contract and prior to discharge of the principal and interests and related expenses hereunder, the Borrower
agrees and authorizes the Lender to monitor the account opened with the Lender, examine and analyze the Borrower&rsquo;s production and operation
(including but not limited to the construction and operation of the Borrower&rsquo;s projects), and make dynamic monitoring on the income cash
flow and overall fund flow of the Borrower; <B>the Borrower shall accept and actively cooperate with the examination and supervision made
by the Lender on the usage of the loan funds including the loan purpose by account analysis, proof inspection and site investigation,
</B>and make summary report in a periodic manner as required by the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>12. The
Borrower&rsquo;s merger, division, decrease of capital, equity transfer, external investment, substantial increase of debt financing, transfer
of material assets and claims and other events which may have adverse effect on the solvency of the Borrower shall be subject to the written
consent of the Lender.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower shall give a notice to the Lender
within <U>7</U> days after it becomes or should have become aware of any of the following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Change
of the Articles of Association, business scope, registered capital, legal representative of the Borrower or the guarantor;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) Change
of management mode such as joint management in any form, cooperation with foreign enterprises, cooperation, contracting management, reorganization,
reform and planned listing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Involved
in material litigation or arbitration cases, sequestration, attachment or supervision of properties or collateral, or establishment of
new material liabilities on the collateral;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) Winding
up, dissolution, liquidation, stopping business for rectification, cancellation, revocation of business license, (applied for) applying
for bankruptcy;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) Shareholders,
directors and current senior managers are suspected of being involved in material cases or economic disputes; or the legal representative/person
in charge and current senior executives are found to be in bad health or other material conditions that the they are unqualified for their
job;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6) Events
of default by the Borrower under other contracts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7) Difficulty
in business operation and deterioration of financial position;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8) In
the event that the Borrower is closed, suspended, merged or changes the line of production due to change, restructuring and contracting
or with the approval of the competent departments, the Borrower undertakes to give a notice to the Lender in writing within one month
prior to the occurrence of the above events and to discharge all debts owed to the Lender immediately. Subject to the consent of the Lender,
the Borrower may transfer the debts to the receiving entity or the newly incorporated entity (The Borrower shall, in the process of debt
transfer, present and submit to the Lender the documents issued by its competent authority or the contract-issuing party or relevant documents);
however, the debt receiving entity must execute a new loan contract with Lender and submit a written certificate of the corresponding
guarantor&rsquo;s approval or implement new guarantee measures, and before the execution of the new contract, the Lender shall have the right
to recover the debts from the Borrower, the Guarantor or the Borrower&rsquo;s receiver at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">13. Liquidation
of the debts owed by the Borrower to the Lender shall have priority to the loan extended by the shareholders of the Borrower, and precede
the debts of the same kind owed by the Borrower to other creditors. In addition, from the effectiveness of the Contract to the time when
all the principal, interests and relative fees under the Contract are paid off, the Borrower shall not return the loan from its shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14. In
respect of the loan hereunder, the loan conditions such as guarantee conditions, loan rate pricing, discharge sequence provided by the
Borrower for the Lender shall be no less than the current or future conditions provided for any other financial institution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">15. <B>The
Borrower shall bear the expenses incurred in connection with the execution and performance of this Contract and the expenses paid and
payable by the Lender for realization of its creditor&rsquo;s right hereunder, including but not limited to litigation or arbitration fees,
property preservation costs, attorney fees, enforcement fees, evaluation fees, auction fees, and announcement fees.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>16. Account
Management</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The
repayment account opened by the Borrower with the Lender (the account stipulated in Article 5) is a special capital withdrawal account,
which is used to collect the corresponding sales revenue or the planned repayment fund. Where the corresponding sales revenue is settled
in a non-cash manner, the Borrower shall ensure that it will be promptly transferred into the capital withdrawal account upon receipt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) The
Lender shall have the right to supervise the capital withdrawal account, including but not limited to the understanding and supervision
of the fund income and expenditure of the account, and the Borrower shall provide relevant cooperation. At the request of the Lender,
the Borrower shall execute a special account supervision agreement with the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">17. The
Borrower shall dispose the assets in a manner that will not reduce its repayment capability. The Borrower undertakes that the total amount
of the Borrower&rsquo;s external guarantee is equal to or less than _____ times of its net asset, and the total amount of external guarantee
as well as the amount of a single guarantee may not exceed the limit as stipulated in its Articles of Association; without the consent
of the Lender, the Borrower shall not provide guarantee to any third party or the loans borrowed by the Borrower from any other financial
institution with the assets formed by the loans under the Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 18 the Related-party Transaction
within the Borrower</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;&nbsp;</FONT>1.The
Borrower is not identified by the Lender as the group client in accordance with the Guidelines on the Management of Risks of Credits
Granted by Commercial Banks to Group Clients (hereinafter referred to the &ldquo;Guidelines&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;&nbsp;</FONT>2.If
the Borrower is identified by the Lender as the group client in accordance with the Guidelines, it shall report to the Lender any of
the related-party transaction in a timely manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;&nbsp;</FONT>3.The
Borrower is subject to such events as major merger, acquisition or reorganization, which in the opinion of the Lender may affect the
safety of the loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 19 Breach of Contract and
Settlement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. The
Borrower shall constitute or be deemed to have breached the Contract and shall be liable for breach of contract under any of the following
circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The
Borrower fails to perform the obligations of payment and liquidation to the Lender according to the stipulations of the Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) The
Borrower fails to use the loan in a purpose and way stipulated in this Contract or fails to use the loan borrowed hereunder for the purpose
stipulated in the Contract; or the Borrower fails to go through the withdrawal procedures as scheduled according to the withdrawal plan,
or changes the withdrawal plan without the Lender&rsquo;s consent; or the Borrower is in violation of this Contract and dodges the authorized
payment by the Lender by way of breaking up a large amount into several small amounts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) The
Borrower provides an untrue representation or violates the undertaking it made in this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) If
any circumstance under Subparagraph 12 of Article 17 arises, and the Lender believes that may affect the financial condition and performing
capability of the Borrower or guarantor, but the Borrower refuses to provide new guarantee or change a guarantor according to this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) The
Borrower violates any stipulation under any other contract between the Borrower and the Lender; the Borrower violates any stipulation
under any Credit Extension Contract between the Borrower and any other financial institution;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6) The
guarantor violates the stipulations of the guarantee contract, or any default events arise under other contract between the guarantor
and the Lender;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7) The
Borrower closes down or is dissolved, withdraw or bankrupted;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8) Where
the Borrower involves in or possibly involves in material economic disputes, litigation, arbitration, or its capital is sealed up, seized
or enforced for execution, or the administrative organs such as judicial organs or taxation authorities, and industrial and commercial
administration file for investigation or adopt punishment measures on the Borrower according to law which has influenced or may influence
the performance of the liabilities under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(9) Where
the main individual investors and key managerial personnel of the Borrower are changed abnormally, disappear or are investigated or the
personal freedom thereof is limited by judicial organs according to law which has influenced or may influence the performance of the liabilities
under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(10) Where
the credit circumstances of the Borrower lowers or finance indexes of the Borrower such as profitability, debt-paying ability, operating
capacity and cash flow seriously deteriorate and break through the index binding of this Contract or other financial agreements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(11) The
Borrower takes advantage of the false contracts between the Borrower and the affiliated party to obtain funds or credit from the Lender
through transactions without true transaction background, and the affiliated party is subject to such events as major merger, acquisition
or reorganization which in the opinion of the Lender may affect the safety of the loan; or the Borrower intends to evade the creditor&rsquo;s
right of the Lender through related-party transactions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(12) The
Borrower causes any liability accident due to its violation of food safety, production safety, environmental protection and other relevant
laws and regulations, regulatory provisions or industrial standards which has influenced or may influence the performance of the liabilities
under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(13) In
the event that the loan under this Contract is granted on the basis of credit rating, the Borrower&rsquo;s credit rating, profitability, asset-liability
ratio, net cash flow from operating activities and other indicators do not meet the Lender&rsquo;s credit loan conditions; or the Borrower,
without the written consent of the Lender, establishes mortgage/pledge guarantee or provide guarantee to others with its valid operating
assets, which has influenced or may influence the performance of the liabilities under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(14) Other
circumstances that may have adverse effect on the realization of the creditor&rsquo;s rights of the Lender under this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. When
the aforesaid breaches arise, as the case maybe, the Borrower agrees that the Lender may take following measures respectively or simultaneously:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Require
the Borrower and guarantor to rectify their breach within time limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) Decrease,
suspend or terminate all or part of the credit lines of the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Suspend
or terminate all or part of the business application (such as withdrawal) of the Borrower under this Contract or other contracts between
the Borrower and the Lender; partly or totally suspend or cancel to issue, pay and transact the unissued loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) Declare
that all or part of the outstanding principal and interest of the loan and other amounts payable of the Borrower under this Contract and
other contracts between the Borrower and the Lender shall become due immediately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) Negotiate
with the Borrower to supplement the terms of loan issuance and payment; or the Lender shall have the right to change the loan disbursement
and payment conditions in accordance with the credit status of the Borrower such as lowering the minimum amount of authorized payment
of the Borrower; or the Lender shall have the right to transfer back the loan fund which the Borrower has paid for default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6) Terminate
or dissolve this Contract, partly or totally terminate or dissolve other contracts between the Borrower and the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7) Require
the Borrower to compensate the Lender for the Lender&rsquo;s loss caused by the Borrower&rsquo;s default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8) <B>Deduct
from the Borrower&rsquo;s account which is opened in the Rural Commercial Bank system within the jurisdiction of Jiangxi </B>with notice before
or after the deduction, <B>so as to discharge all or part of the Borrower&rsquo;s debts to the Lender hereunder. The undue deposit in the account
shall be deemed to become due in advance.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(9) Exercise
security interest; and require the guarantor to take guarantee responsibility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(10) In
the event that the Borrower fails to repay the principal, interest (including penalty interest and compound interest) or other amounts
payable as scheduled, the Lender may disclose the default information of the Borrower and the Guarantor and make an announcement for collection
through the media or other forms.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(11) Have
the right to deduct and debit the deposits and dividends within any account opened by the Borrower in the Rural Commercial Bank system
within the jurisdiction of Jiangxi, and to dispose of the Borrower&rsquo;s equities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(12) Other
measures stipulated by laws and regulations and deemed necessary and possible by the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 20 Reservation of Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any failure by a party to exercise all or part
of its rights hereunder or to require the other party to perform or assume all or part of obligations or responsibilities shall not constitute
a waiver of such rights or release of the obligations and responsibilities of such party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any tolerance, grace or postponement for exercising
the rights under this Contract of one Party shall not affect its rights stipulated by this Contract, laws and regulations, and shall not
be deemed as a waiver of such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 21 Confidentiality</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each party undertakes to keep confidential the
trade secrets, technical information, business information and other business secrets obtained from the other party which are not available
through public channels. Without the consent of the original provider of the trade secret, neither party shall disclose all or part of
the trade secret to any third party, unless otherwise stipulated by laws and regulations or otherwise agreed by both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that either party is in violation
of the aforesaid confidentiality obligation, it shall assume the corresponding liability for breach of contract and compensate for the
losses caused thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 22 Force Majeure</B><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The term Force Majeure as specified in this Contract
refers to the objective events that cannot be foreseen, overcome, or avoided and have a significant impact on one party, including but
not limited to the natural disasters such as flood, earthquake, fire and storm, as well as the social events such as war and turmoil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Contract cannot be performed
as a result of the occurrence of force majeure events, the party affected by the force majeure shall immediately notify the other party
of the event in writing, and within 7 days, provide written documents certifying the details of accident and the reasons for non-performance
or delay in performance hereof. Upon consensus through negotiation, both Parties may terminate or temporarily delay the performance of
the Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 23 Alteration, Amendment and
Termination</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract can be altered and amended in written
form upon consensus through negotiation of the Parties, and any alternation and amendment agreed on by the Parties shall constitute an
integral part of this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract may not be terminated until all
the rights and obligations are fully preformed, unless otherwise stipulated in laws and regulations or agreed by the both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The invalidity of any provision of this Contract
shall not affect the legal validity of other provisions, unless otherwise stipulated in laws and regulations or agreed by the both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 24 Agreements on Service</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. The
contact information (including mailing address, telephone number, fax number, etc.) provided by the Borrower in this Contract shall be
true and valid and shall be the address for service of any notice of the Lender for the Borrower. In case of any change to the contact
information, the Borrower shall immediately send/mail the change information in writing to the mailing address provided by the Lender
in this Contract. Such information change shall become effective upon the Lender&rsquo;s receipt of the change notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Unless
otherwise expressly provided for in this Contract, the Lender shall be entitled to give notice to the Borrower in any of the following
methods. The Lender shall be entitled to choose the notification method as it thinks fit and shall not be held liable for any error, omission
or delay in delivery by mail, fax, telephone, WeChat or any other communication system. Where the Lender simultaneously chooses several
notification methods, the one by which the notice is served to the Borrower earlier shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) By
announcement. The notice shall be deemed to be served on the date on which the Lender publishes the announcement on its website, online
banking, telephone banking or business outlets;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) By
hand. The notice shall be deemed to be served on the date on which the Borrower signs for the receipt, or if the Borrower refuses to sign
for the receipt, the date on which the server makes a record on the proof of service on the spot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) By
mail (including express mail, surface mail or registered mail). The notice, when addressed to the Borrower&rsquo;s mailing address last known
to the Lender, shall be deemed to be served on the date on which the Borrower signs for the receipt, or if the Borrower fails to sign
for the receipt, the date on which the mail is returned;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) By
fax, mobile phone SMS, WeChat or other electronic communication methods. The notice, when sent to the Borrower&rsquo;s fax number, the mobile
phone number, WeChat account number or email address designated by the Borrower which is last known to the Lender, shall be deemed to
be served on the date on which the notice is sent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Borrower
agrees that, unless the Lender receives from the Borrower a written notice concerning the change of mailing address, the Borrower&rsquo;s domicile
stated in this Contract is the correspondence and contact address. In the future, the delivery addresses of bank statements, collection
statements, relevant legal instruments and litigation documents related to the loans under this Contract shall prevail. The Borrower promises
to notify the Lender in time when the communication and contact information change, otherwise the documents delivered by the Lender according
to the communication and contact information stated in this Contract will be effectively delivered, and the relevant economic and legal
responsibilities arising therefrom will be borne by the Borrower and the Mortgagor. During the dispute settlement, if the court serves
the judicial documents or other written documents by mail (including express mail, surface mail or registered mail) to the Borrower mailing
address last known to the Lender, such documents shall be deemed to be served on the date on which the Borrower signs for receipt of the
proof of service; or if Borrower fails to sign for receipt of the proof of service, the date on which the mail is returned;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The court or notary organ shall be entitled to
give any notice to the Borrower by any methods of communication agreed in this Paragraph 2. The court or notary organ shall be entitled
to choose the communication method as it thinks fit and shall not be held liable for any error, omission or delay in delivery by mail,
fax, telephone, telex or any other communication system. Where the court or notary organ simultaneously chooses several communication
methods, the one by which the notice is served on the Borrower earlier shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 25 Appendix</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The appendixes confirmed by both parties shall
constitute an integral part of this Contract and shall have the same legal effect as this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 26 Other Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. The
Borrower shall not transfer any rights and obligations under this Contract to the third party without written consent of the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. The
Lender has the right to transfer the creditor&rsquo;s rights under this Contract to the third party, and shall notify the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. This
Contract shall be legally binding upon both Parties and their successors and assignees without prejudice to other provisions of this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. All
the transactions under this Contract are carried out for each Party&rsquo;s independent benefits. If, in accordance with relevant laws, regulations
and regulatory provisions, other parties to the transaction become the related parties or affiliated persons of the Lender, no Party may
seek to affect the fairness of the transaction out of this related-party relationship.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The
headings and business names in this Contract are used only for convenient reference, which shall not be used to interpret the provisions
or the rights and obligations of both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6. In
accordance with relevant laws, regulations and regulatory provisions, the Lender shall have the right to provide the information related
to this Contract and other relevant information of the Borrower to the credit reference system of the People&rsquo;s Bank of China and other
credit information database established according to law for reference and use by the institutions or individuals with proper qualification
according to law. The Lender shall also have the right to refer the relevant information of the Borrower through credit reference system
of the People&rsquo;s Bank of China and other credit information database established according to law for the purpose of the execution and
performance of this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The parties acknowledge that the Borrower and
the Lender have made a full negotiation in connection with all the terms of this Contract. The Lender has requested the Borrower to give
special attention to and make a comprehensive and accurate understanding of all provisions concerning the rights and obligations of the
parties, and has made explanations to the relevant provisions upon the Borrower&rsquo;s request. The Borrower has carefully read and fully understood
all the contents and provisions of the Contract. The Borrower confirms that there is no misunderstanding or doubt about all the contents
and terms of the Contract. Both the Borrower and the Lender have the same understanding of the contents and provisions of the Contract
and have no objection to the contents and provisions of the Contract.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Borrower and the Lender have made a full
negotiation in connection with all the provisions of this Contract. The Lender has requested the Borrower to give special attention to
and make a comprehensive and accurate understanding of all provisions concerning the rights and obligations of the parties, and has made
explanations to the relevant provisions upon the Borrower&rsquo;s request. The Borrower has carefully read and fully understood all the contents
and terms of the Contract. The <FONT STYLE="border: Black 1pt solid">Borrower</FONT></B><B> confirms that there is <FONT STYLE="border: Black 1pt solid">no
misunderstanding or ambiguity </FONT></B><B>about all the contents and provisions of the <FONT STYLE="border: Black 1pt solid">Contract</FONT></B><B>.
Both the Borrower and the Lender have the same understanding of the contents and provisions of the Contract and have no objection to the
contents and provisions of the Contract.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(The Borrower shall fill in the following by
contrast)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(The remainder of this page is intentionally left
blank for signatures)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 20%; text-align: left">Borrower (Official Seal):</TD><TD STYLE="text-align: justify; width: 80%"> Jiangxi Universe Pharmaceuticals Commerce
and Trade Co.,Ltd. 3608013004965 [seal]</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
  Representative or Authorized Agent (Signature &amp; Seal):</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
  Lai Gang</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>May
  17, 2024</U></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 10%">Lender (Seal):</TD>
  <TD STYLE="width: 80%">Ji&rsquo;an Rural Communications Co., Ltd.Jingkaiqu Branch Special Seal for Credit Business Contract 3601000182066.
[seal]</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Representative or Authorized
  Agent (Signature &amp; Seal):</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
  Fan Juan</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>May 17, 2024</U></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-left: 0.125in; width: 25%">Contract Execution Place: </TD>
  <TD STYLE="width: 75%">Ji&rsquo;an Rural Communications
Bank Co., Ltd.Jingkaiqu Branch </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">19</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.7
<SEQUENCE>6
<FILENAME>ea022807501ex4-7_universe.htm
<DESCRIPTION>ENGLISH TRANSLATION OF THE LOAN CONTRACT BETWEEN JIANGXI UNIVERSE AND NANCHANG BRANCH OF BANK OF BEIJING CO., LTD., DATED JULY 3, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 4.7</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><IMG SRC="ex4-7_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">C22017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">Contract No.: [A705558]</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Loan Contract</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Applicable to online signing of working capital
revolving loan for corporate customers of channels such as</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Internet Banking/&ldquo;Little Giant&rdquo; APP/ Bank of Beijing Corporate
Banking APP)</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%"><B>Borrower</B>:&nbsp; </TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 62%"><U>Jiangxi Universe Pharmaceuticals Co., Ltd.</U></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><B>Lender</B>: </TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><U>Nanchang Branch of <B>Bank of Beijing Co., Ltd.</B></U></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><B>Date of Conclusion</B>: <U>July 3, 2024</U></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In accordance with
the Civil Code of the People&rsquo;s Republic of China and other laws and regulations, and on the basis of equality, willingness and consensus,
<B>this Contract is hereby made by and between and shall be binding on the parties hereto</B> on the date of conclusion as set out on
the cover page hereof at the domicile of <U>Nanchang Branch</U> of <B>Bank of Beijing Co., Ltd. (hereinafter referred to as the &ldquo;Lender&rdquo;
or &ldquo;BOB&rdquo;)</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Borrower</B>: <U>Jiangxi Universe Pharmaceuticals Co.,
Ltd.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Unified Social Credit Code: 913608217670218430 Business
License No.: 913608217670218430</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Legal Representative/Person in Charge: Lai Gang</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Correspondence Address: No. 265, Jingjiu Avenue, Jinggangshan
Economic and Technological Development Zone, Ji&rsquo;an County, Ji&rsquo;an City, Jiangxi Province</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Tel.:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">8403309</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Zip Code:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">343100</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fax: 8403637</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Contact Person:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Yang Lin</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Position: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 18%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Contact Person&rsquo;s Phone No.:</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 28%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 6%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">Email:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 46%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">*</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Lender</B>: <U>Nanchang Branch of <B>Bank of Beijing
Co., Ltd.</B></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Legal Representative/Person in Charge: Yang Yungaung</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Correspondence Address: No. 1115, Middle Fenghuang Avenue,
Honggutan New District, Nanchang City, Jiangxi Province</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Tel.:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">0791-86712706</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Zip Code:</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif">330038</FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fax:</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif">0791-83792320</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Part I Schedule of Contract Terms</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin: 0"> <B>A.</B> <B>Related contract</B> (fill in if applicable):</P>



<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">This Contract is a specific business
contract under the Comprehensive Credit Contract (No. [<U>A074631</U>]) entered into by and between the creditor <U>Nanchang Branch</U>
of Bank of Beijing Co., Ltd. and the debtor <U>Jiangxi Universe Pharmaceuticals Co., Ltd.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin: 0"> <B>B.</B> <B>Loan amount and term:</B></P>



<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">B.1</FONT></TD><TD STYLE="text-align: justify">The currency of the loan hereunder shall be <U>RMB</U>, and
the amount shall be (in case of inconsistency between the amount in words and the amount in figures, the amount in words shall prevail;
the same below):</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(in
words) <U>RMB Ten Million Only</U>, (in figures) </FONT><U>&#65509;<FONT STYLE="font-family: Times New Roman, Times, Serif">10000000.00</FONT></U><FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">B.2</FONT></TD><TD STYLE="text-align: justify">The loan term of this Contract is (it applies if you tick the
box &square;; it does not apply if you cross the box &square;; the same below):</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#9746; __/___ from the date of the first withdrawal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#9745; &nbsp;From the date of withdrawal
until July 3, 2025.

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">B.3</FONT></TD><TD STYLE="text-align: justify">The final maturity date of the loan shall be the date of expiration
of the loan term as agreed in Paragraph <B>B.2</B> above.</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>C.</B></TD><TD STYLE="text-align: justify"><B>Contractual interest rate (annual interest rate, interest
shall be calculated at the simple interest)</B> (it applies if you tick the box &square;; it does not apply if you cross the box &square;;
the same below):</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">C.1</FONT></TD><TD STYLE="text-align: justify">In case of a RMB loan, the contractual interest rate hereunder
shall be:</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#9745; (1) Fixed interest rate, i.e.,
the interest rate for <U>&#9745; 1 year &#9746; 5 years or more</U> &#9746; <U>Other [ / ]</U> of the day before the withdrawal date (&#9745;
<U>the Central Bank&rsquo;s LPR &#9746; this Bank&rsquo;s LPR</U>) <U>plus [70.000000] bps </U>&#9746; <U>minus [ / ] bps</U>, which will
not be adjusted in accordance with the changes in the Central Bank&rsquo;s LPR or this Bank&rsquo;s LPR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#9746; (2) Floating
interest rate, i.e., the interest rate for <U>&#9746;1 year &#9746;5 years or more &#9746; Other [ / ]</U> of the day before the
withdrawal date (<U>&#9746; the Central Bank&rsquo;s LPR &#9746; this Bank&rsquo;s LPR</U>) <U>&#9746; plus [ / ] bps &#9746; minus
[ / ] bps</U>, and floating in accordance with Paragraph 2.4 hereof; the contractual interest rate shall be adjusted as follows: <U>&#9746;
on the monthly first day &#9746; on the monthly corresponding day &#9746; on the quarterly first day &#9746; on the quarterly
corresponding day &#9746; on the yearly first day &#9746; on the yearly corresponding day &#9746; on the fixed day of each month
(the specified date is [ / ] (month) [ / ] (day), [ / ] (year)) &#9746; on the fixed day of each quarter (the specified date is [ /
] (month) [ / ] (day), [ / ] (year)) &#9746; on the fixed day of each six months (the specified date is [ / ] (month) [ / ] (day), [
/ ] (year)) &#9746; on the fixed day of each year (the specified date is [ / ] (month) [ / ] (day), [ / ] (year)) &#9746;
Immediately</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">C.2 </FONT>In
case of a foreign currency loan, the interest rate shall be determined by adding points to the &ldquo;HIBOR (for Hong Kong dollar) or
LIBOR (for other foreign currencies)&rdquo; for a term of <U>/ </U>month (based on the interest rate of the second business day prior
to the date of withdrawal), with the additional basis points not less than <U>[ / ]</U> basis points, and shall fluctuate in accordance
with Paragraph 2.4 of this Agreement. The details shall be subject to the records in the loan receipt reviewed and approved by BOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0"> <B>D.</B> <B>Withdrawal period, disbursement of loan fund and account monitoring:</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>



<P STYLE="margin: 0"> <FONT STYLE="font-size: 10pt">D.1</FONT> The withdrawal period is <U>364</U> days from the date of conclusion of this Contract.</P>



<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">D.2 </FONT>The
method of disbursement of the loan fund shall be subject to the records in the loan receipt reviewed and approved by BOB; however, if
the amount of a single disbursement exceeds RMB 10 million, the Lender&rsquo;s entrusted disbursement shall be adopted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0"> <FONT STYLE="font-size: 10pt">D.3</FONT> The loan fund shall be disbursed to the Borrower&rsquo;s account at BOB:</P>

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The account number is <U>*</U> (the
account may be changed with the consent of BOB, but the Borrower shall choose the changed account when the withdrawal application is initiated
on the Internet banking system). If the Borrower makes payment with the loan fund, the Borrower shall process with such account and accept
the inspection and supervision of BOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">D.4 </FONT>The
account opened by the Borrower at <U>Nanchang Xihu Sub-branch of Bank of Beijing Co., Ltd.</U> (name of account bank) (account no.: <U>*</U>,
account name: <U>Jiangxi Universe Pharmaceuticals Co., Ltd.</U>) shall be the Borrower&rsquo;s fund withdrawal account (the account may
be changed with the consent of BOB); the Borrower shall regularly (i.e., <U>at the end of each quarter</U>) provide BOB with the information
on fund withdrawal and transaction flow of the account, and undertake to cooperate for BOB&rsquo;s supervision and inspection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">D.5 </FONT>With
respect to the said account, BOB shall carry out inspection, supervision and management in accordance with &#9745; &nbsp;the provisions of this
Contract &#9746; the provisions of the account supervision agreement separately signed by both parties and this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0"> <B>E.</B> <B>Loan purpose:</B></P>

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><U>Business turnover, purchase of goods and materials for
production, etc.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin: 0"> <B>F.</B> <B>Loan principal repayment plan:</B></P>



<P STYLE="margin-top: 0; margin-bottom: 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">All loan principal
must be paid off on the final maturity date, and the loan principal will be repaid during the loan term in accordance with the following
provisions, and the specific repayment plan shall be subject to the loan receipt reviewed and approved by BOB:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#9745; &nbsp;All loan principal shall be
repaid in one lump sum at maturity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0"> <B>G.</B> <B>Interest repayment plan:</B></P>



<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">All interest must be paid off on the
final maturity date and shall be repaid in installments during the loan term as agreed below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>&#9745;</U></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
  is payable on a fixed day on a monthly basis (the 21st day of each month).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&#9746;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
  is payable on a fixed day on a quarterly basis (the 21st day of the last month of each quarter).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&#9746;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other:
  __/____.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#9746; (For foreign currency loan
option only) Interest shall be paid once per period in light of the number of months of the interest rate term selected in accordance
with Paragraph <B>C.2</B>, and the interest payment date shall be the day immediately following the corresponding day of the last month
of each period from the fund withdrawal date (or, if there is no corresponding day, the last day of current month).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>M. Guarantee</B> (Other guarantees
are listed in the column of Special Agreements of this Contract, details of which are subject to the guarantee documents):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#9746; Security guarantee, name of guarantor ________________________
/ _______________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#9746; Pledge guarantee, name of pledgor________________________
/_______________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#9746; Mortgage guarantee, name of mortgagee ________________________
/_______________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>U. Attachments </B>(The loan receipt and the following
attachments constitute an integral part of this Contract):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">__________________________________ /___________________________________________&#12290;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>W. Enforcement notarization:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#9746; Enforcement notarization shall be completed within
___/____ days from the date of conclusion of this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#9745; &nbsp;This Contract is not subject to the enforcement
notarization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>X. Special agreements:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>X.1 This Contract is executed by
the Borrower and the Lender through the electronic channel of BOB, and both parties shall, in addition to complying with this Contract
and the effective amendments and supplements thereof, also comply with relevant service agreements, regulations and policies for the electronic
channel of BOB as well as relevant business rules such as reminders, announcements and notices related to this business which the Lender
may from time to time announce to the Borrower through such channel, and the said agreements, regulations, policies and business rules
shall be applicable to the relationship of rights and obligations between the Borrower and the Lender under this Contract.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 2%">/</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 98%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Part II Basic Terms of Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin: 0"> <B><U>1.</U></B> <B><U>Definitions and interpretations</U></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">1.1 For the purposes of this Contract,
unless otherwise expressly stated, the following terms are defined as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>This Contract</B>: refers to the
entirety of the following documents: the Schedule of Contract Terms, the Basic Terms of Contract, the Electronic Loan Receipt generated
on the Bank of Beijing&rsquo;s online corporate loan platform under which the loan has been successfully released, the attachments hereto,
and any other documents (including, but not limited to, the supplementary agreements, letters of undertaking, etc.) that effectively determine
the rights and obligations of the parties hereunder in accordance with the laws; if not stated differently, only the agreements in the
Schedule of Contract Terms and the Basic Terms of Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>BOB&rsquo;s electronic channel (or
e-channel)</B>: refers to the electronic channel provided by BOB to its customers, through which customers may submit their need instructions
to the account bank via the Internet, so as to meet the business needs such as application for withdrawal and inquiry as the BOB service
system. At present, the electronic channels available for use are the &ldquo;Little Giant&rdquo; APP developed by BOB, the Bank of Beijing
Corporate Banking APP, and the Bank of Beijing Corporate Internet Banking.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>The Central Bank&rsquo;s loan prime
rate (the Central Bank&rsquo;s LPR)</B>: refers to the basic loan reference rate quoted by a representative quoting bank based on the
bank&rsquo;s loan rate to the highest-quality customers in the form of the open market operation interest rate plus basis points, and
calculated and published by China Foreign Exchange Trade System (CFETS) under the authorization of the People&rsquo;s Bank of China; if
the Central Bank&rsquo;s LPR for corresponding term has not been published by the CFETS on the day immediately preceding the date of withdrawal
hereof/the corresponding date determined in line with the adjustment frequency, the Central Bank&rsquo;s LPR published on the second day
immediately preceding the said date shall prevail, and so on. If the Central Bank&rsquo;s LPR is canceled, the applicable interest rate
determined and announced by BOB in accordance with the laws shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>This Bank&rsquo;s loan prime rate
(this Bank&rsquo;s LPR)</B>: refers to this Bank&rsquo;s loan prime rate independently proposed and published by Bank of Beijing Co.,
Ltd.; if this Bank&rsquo;s LPR for corresponding term has not been published by Bank of Beijing Co., Ltd. on the day immediately preceding
the date of withdrawal hereof/the corresponding date determined in line with the adjustment frequency, this Bank&rsquo;s LPR published
on the second day immediately preceding the said date shall prevail, and so on.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>LIBOR (HIBOR)</B>: refers to the
London (Hong Kong) Interbank Offered Rate published on relevant pages of the authoritative financial telecommunications systems such as
Reuters or Bloomberg at around 11:00 a.m. (London (Hong Kong) time) on the current day. If the abovementioned interest rate data does
not exist on the current day, the data of the latest day shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Entrusted disbursement:</B> refers
to that BOB, on the basis of the Borrower&rsquo;s withdrawal application and payment entrustment, pays the loan fund through the Borrower&rsquo;s
account to the Borrower&rsquo;s counterparty which meets the agreed purposes of this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Independent disbursement</B>: refers
to that after BOB disburses the loan fund to the Borrower&rsquo;s account on the basis of the Borrower&rsquo;s withdrawal application,
the Borrower will independently make disbursement to the Borrower&rsquo;s counterparty which meets the agreed purposes of this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Guarantee document</B>: refers to
any guarantee contract, guarantee clauses, guarantee letter and other documents and commitments setting guarantee and signed or approved
by the guarantor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Actual controller</B>: refers to
a natural person who is a controlling shareholder of the Borrower/guarantor or a natural person who is able to practically dominate the
Borrower&rsquo;s/guarantor&rsquo;s behaviors through an investment relationship, agreement or other arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Missing</B>: refers to that BOB
is still unable to contact relevant party with reasonable efforts in light of the contact information listed on the top of this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Laws and regulations</B>: refer
to laws, administrative regulations and judicial interpretations of the Supreme People&rsquo;s Court that are applicable in the mainland
of the People&rsquo;s Republic of China, except for Hong Kong, Macao and Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Financial regulations</B>: refer
to the regulations, rules and orders of the banking regulators, the People&rsquo;s Bank of China and the foreign exchange administrations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Business day</B>: refers to any
day on which BOB processes general corporate businesses, excluding statutory holidays and Saturdays and Sundays, but including Saturdays
and Sundays on which the government temporarily stipulates that the public shall work.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Corresponding day</B>: the monthly
corresponding day refers to the corresponding day in each month of the withdrawal date under this Contract (the last day of current month
if there is no corresponding day); the quarterly corresponding day refers to the corresponding day in the last month of each three months
of the withdrawal date under this Contract (the last day of current month if there is no corresponding day), and the yearly corresponding
day refers to the corresponding day in each year of the withdrawal date under this Contract (the last day of current month if there is
no corresponding day).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Fixed day</B>: the monthly fixed
day refers to the corresponding day of each month from the specified date (the last day of current month if there is no corresponding
day), the quarterly fixed day refers to the corresponding day of each three months from the specified date (the last day of current month
if there is no corresponding day), the semi-annual fixed day refers to the corresponding day of each six months from the specified date
(the last day of current month if there is no corresponding day), and the annual fixed day refers to the corresponding day of each twelve
months from the specified date (the last day of current month if there is no corresponding day).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">1.2 In any document prepared under
or pursuant to this Contract, the foregoing definitions shall apply unless otherwise expressly stated in such document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">1.3 The order of the clauses in this
Schedule of Contract Terms shall follow the arrangement of serial numbers given herein other than the natural alphabetical order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0"> <B><U>2.</U></B> <B><U>Loan</U></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">2.1 The
currency, amount and term of the loan hereunder are set out in Paragraph <B>B</B> hereof. The actual amount and date of each withdrawal
hereunder shall be subject to the records in the loan receipt reviewed and approved by BOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>2.2 The
Borrower may request the withdrawal during the withdrawal period as agreed in Paragraph D hereof, and any loan fund not withdrawn after
the expiration of the withdrawal period shall be automatically canceled and may not be withdrawn again. Each time the Borrower requests
a withdrawal, all of the following conditions shall be met:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>(1) The
guarantee documents for the guarantees referred to herein have been concluded and are in force and the procedures for delivery and registration
have been completed (in other words, the registration shall be respectively completed with corresponding legal registration authorities
for types such as real estate (if any) mortgage, chattel (if any) mortgage and right (if any) pledge); if the guarantor is a legal person
or non-legal person organization, the Borrower has provided BOB with relevant internal effective resolution or reply for guarantee that
the guarantor agrees to provide (except for entities that are not required by the laws and regulations to provide internal resolutions
such as financial institutions issuing guarantee letters or guarantee companies providing guarantees). If the guarantor is a listed company,
a publicly disclosed controlled subsidiary of a listed company, or a company whose shares are traded on other national securities exchanges
approved by the State Council, the resolutions shall also be publicly disclosed in accordance with the laws and regulations;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>(2) The
Borrower has completed relevant procedures reasonably required by BOB such as account opening, and has provided BOB with documents and
relevant certificates reasonably describing the specific purpose of the fund and the fund flow arrangement, which have been examined and
certified by BOB, and in the event that this Contract is a credit granted under the Comprehensive Credit Contract referred to in Paragraph
A, a sufficient available credit line of the Borrower shall be retained under such Comprehensive Credit Contract;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>(3) The
Borrower has successfully registered with the BOB&rsquo;s e-channel as an e-channel user;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>(4) The
Borrower has not committed any breach of contract under this Contract, and the guarantor has not committed any breach of contract under
the guarantee documents;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>(5) The
laws and regulations and financial regulations, national credit policies, and credit line management requirements then in effect have
not had material adverse effect on the performance of this Contract by one party hereto, nor have they prohibited or restricted the release
or withdrawal of loan under this Contract;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>(6) Other
conditions specified by this Contract and stipulated by laws, regulations and financial regulations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">2.3 After
the Borrower meets the conditions for withdrawal, the Borrower shall initiate an irrevocable application for withdrawal through BOB&rsquo;s
electronic channel on a business day, and if the Borrower meets the conditions for withdrawal, with review and approval of BOB, BOB shall
disburse the full amount of the loan within 3 business days. Once the loan is disbursed to the Borrower&rsquo;s account, the loan is deemed
to have been withdrawn and used by the Borrower, and the same day will be the withdrawal date of the loan and the loan interest shall
start to be calculated at the contractual interest rate on a simple interest basis (interest shall be calculated on a daily basis at the
daily interest rate). If the RMB loan is withdrawn in several installments, the contractual interest rate applicable to each withdrawal
shall be respectively determined at the Central Bank&rsquo;s loan prime rate (the Central Bank&rsquo;s LPR) or this Bank&rsquo;s loan
prime rate (this Bank&rsquo;s LPR) of the day immediately preceding the date of withdrawal plus or minus basis points as stated in Paragraph
C.1 of this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>If BOB&rsquo;s entrusted disbursement
is adopted for the loan fund, (i) the Borrower shall submit complete business contracts and other relevant transaction materials (including
but not limited to transaction documents or certificates with clear transaction subjects and complete signatures and seals and filled
in normatively) at least 3 business days in advance (or within such other period as reasonably required by BOB), so that BOB may review
whether the said materials are consistent with the conditions as agreed in this Contract before the disbursement of the loan fund. After
the materials are reviewed and approved by BOB, BOB shall disburse the loan fund to the Borrower&rsquo;s counterparty through the Borrower&rsquo;s
account (the Borrower is not required to separately provide a settlement certificate for the disbursement) and keep records appropriately,
and the time for the loan fund received by the account of the Borrower&rsquo;s counterparty shall be determined with reference to the
time of receipt through the foreign exchange settlement method and be affected by the opening time of relevant system, and the settlement
fees shall be deducted by BOB one by one or in a lump sum from the Borrower&rsquo;s account in line with then in-effect charge standards
(the Borrower may also take the initiative to pay such fees in advance); (ii) as the disbursement or the entrusted disbursement is delayed
on the grounds that materials submitted by the Borrower are incomplete, unqualified, untimely or bear reasonable doubts, the Borrower
shall be responsible; (iii) if the fund is not timely paid or fails to timely reach the account of the Borrower&rsquo;s counterparty after
the fund is received by the Borrower&rsquo;s account due to abnormal status of the Borrower&rsquo;s account, incomplete and inaccurate
information or abnormal status of the counterparty&rsquo;s account provided by the Borrower, the interbank payment system or the clearing
system and other reasons unattributable to BOB, the settlement service charges, loan interest and other losses and delays and other adverse
consequences arising accordingly shall be borne by the Borrower provided, however, that BOB shall make reasonable efforts to continuously
complete the procedures for disbursement to the account of the Borrower&rsquo;s counterparty, or leave it in the Borrower&rsquo;s account/pending
item and notify the Borrower to complete relevant procedures.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">If the independent disbursement by
the Borrower is adopted for the loan fund, the Borrower shall, as required by BOB, timely provide a loan fund use plan, and summarize
and report the fund payment information to BOB within 10 days at the beginning of each month after the disbursement of the loan, and BOB
shall have the right to verify whether the disbursement of the loan fund is consistent with the provisions of this Contract by means of
account analysis, fund transfer proof checking, on-site investigation and so on, and the Borrower shall cooperate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>If the loan fund is subject to BOB&rsquo;s
entrusted disbursement or use supervision, BOB has the right to monitor relevant account and the use of fund in the account by refusing
to sell the check, process the universal deposit and withdrawal and open Internet banking or mobile banking.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>In the course of loan disbursement,
if BOB determines that the Borrower&rsquo;s credit status has declined, the profitability of the main business is not strong, or the use
of the loan fund has become abnormal, BOB has the right to request a change in the loan fund disbursement method, and the Borrower shall
accept and cooperate for the same.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">2.4 If
the interest rate of the loan contract under this Contract is the floating interest rate or the loan belongs to a foreign currency loan,
the interest rate shall be adjusted as follows: (i) for the floating interest rate for the RMB loan, in accordance with the adjustment
frequency agreed in Paragraph C.1 hereof, the interest rate shall be automatically adjusted at the Central Bank&rsquo;s loan prime rate
(the Central Bank&rsquo;s LPR) or this Bank&rsquo;s loan prime rate (this Bank&rsquo;s LPR) of the day immediately preceding the corresponding
date as specified in Paragraph <B>C.1</B> plus or minus the basis points (1 basis point is 0.01%) as specified in Paragraph <B>C.1 </B>on
the corresponding date, and the interest shall be calculated by period; (ii) for the foreign currency loan, the contractual interest rate
applicable to each interest calculation period (the first but the last day shall be counted) shall be LIBOR (HIBOR) (annual interest rate
expressed in the form of percent) for corresponding currency and term of the second business day of such foreign currency market before
the day immediately preceding the start day of the interest calculation period plus additional basis points as agreed in Paragraph <B>C.2</B>
hereof (1 basis point is 0.01%); the said automatic adjustment shall not be considered as a modification to this Contract. Where the contractual
interest rate is converted from an annual interest rate to a daily interest rate, the Hong Kong dollar interest rate shall be calculated
on the basis of 365 days per year, and the interest rate for RMB and other foreign currencies shall be calculated on the basis of 365
days per year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>2.5 The
Borrower guarantees that the loan will be used for the purposes stated in Paragraph E hereof and that the said purposes do not violate
the laws, regulations and financial regulations; the Borrower undertakes that the loan will not be used for investment in fixed assets,
equity, real estate, etc., or for fields and purposes which are prohibited by the State in terms of production and operation, nor will
it be used for any other projects or businesses for which the commercial bank loan is prohibited by laws, regulations or financial regulations.
If the Borrower needs to change the use of the loan, the Borrower shall obtain the prior written consent of BOB. The Borrower guarantees
that the information provided by the Borrower to BOB, such as transaction materials and counterparty information, is true, accurate, complete,
legal and valid, and is consistent with the purposes as agreed in this Contract.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">2.6 The
Borrower shall repay the principal of the loan in accordance with Paragraph <B>F</B> hereof and pay the loan interest on schedule in accordance
with Paragraph <B>G </B>hereof; each interest payment date (inclusive) to the next interest payment date (exclusive) shall be an interest-bearing
period (with the first interest-bearing period commencing on the withdrawal date, and the last interest-bearing period ending on the maturity
date of the loan principal); where each loan principal is repaid, all interest accrued of such loan principal shall be paid off, and on
the final maturity date, all loan principal, interest and other payables shall be paid off. In case of a non-business day, the Borrower
shall deposit sufficient amount into the account in advance so that BOB may deduct relevant amount from the account on the same day or
the first business day thereafter, and the interest for the extension period shall still be calculated on a simple interest rate basis
in light of the contractual interest rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>2.7 </B>In
order to timely repay relevant payables, the Borrower shall open and maintain at all times relevant account with BOB as agreed in this
Contract (in case of change of the account number, this Contract shall continuously apply after the change) and deposit the repayable
amount in full and in a timely manner into the agreed account for the deduction of BOB, or the Borrower may also directly transfer funds
to the BOB account for repayment and shall notify BOB in a timely manner of the disbursement business number corresponding to the loan
repayment. <B>BBO may independently deduct the amount due and payable by the Borrower from the Borrower&rsquo;s account opened in the
system of Bank of Beijing Co., Ltd. and notify the Borrower by means of statement or other forms after the deduction.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">2.8 The
loan under this Contract is a revolving loan, i.e., after relevant debt has been fully repaid and until the expiration date of the withdrawal
period, the Borrower may apply for withdrawal again in accordance with the terms and conditions of this Contract within the range of the
principal balance of the loan not exceeding the total amount agreed in Paragraph B.1 of this Contract, and the number of revolving may
be unlimited during the withdrawal period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>2.9 The
bank vouchers internally generated by BOB are valid evidences for the disbursement of the loan and the repayment of principal and interest
hereunder, unless there are conclusive and sufficient evidences to the contrary.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0"> <B><U>3.</U></B> <B><U>Early repayment and grace period</U></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">3.1 After
the loan is disbursed, the Borrower may apply for early repayment. The early repayment includes partial early repayment and full early
repayment. The Borrower shall initiate an irrevocable early repayment application through BOB&rsquo;s electronic channel from 9:00 a.m.
to 8:00 p.m. on weekdays. If the Borrower chooses the partial early repayment, with BOB&rsquo;s review and approval, the Borrower shall
repay the principal amount of the early repayment on the early repayment date, and the corresponding interest arising from the principal
portion repaid early shall still be paid off in accordance with the agreements of this Contract on the interest payment date; if the Borrower
chooses the full early repayment, with BOB&rsquo;s review and approval, the Borrower shall settle all the loan principal, interest and
other payables (if any) on the early repayment date. In case of early repayment, the Borrower shall initiate the repayment on its own
in accordance with BOB&rsquo;s requirements in its Internet banking system and other electronic channels, or submit a written application
to BOB with the written consent of BOB, and complete the early repayment outside of the electronic channels in accordance with BOB&rsquo;s
instructions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">3.2 If
the Borrower requests a grace period, the Borrower shall submit a written application for a grace period to BOB at least 30 days prior
to the maturity date, stating the reasons for the grace period and making repayment fund arrangements after the grace period, and with
the review and approval of BOB and after relevant conditions required by BOB are met, both parties shall sign an agreement for the grace
period and complete the procedures for the grace period in accordance with the agreement. If BOB does not agree with the grace period
or both parties fail to sign an agreement for the grace period, the Borrower shall still make repayment in accordance with the period
as agreed in this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">3.3 During
the loan term, BOB has the right to request the Borrower to repay the loan in advance on the basis of the Borrower&rsquo;s fund withdrawal
situation (including, but not limited to, the early fund withdrawal proposed by the Borrower for repayment, and the Borrower&rsquo;s available
working capital being sufficient and still able to meet the normal fund need after the early repayment, etc.); after BOB&rsquo;s notice
of early repayment is served on the Borrower, the principal and interest of relevant loan shall become due on the early repayment date
designated by BOB, and the Borrower shall make timely repayment as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0"> <B><U>4.</U></B> <B><U>Undertakings and warranties</U></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">4.1 The
parties mutually undertake and warrant that: (1) the parties have the qualification and ability to execute and perform this Contract,
and the persons signing this Contract on behalf of the parties have been fully authorized to enter into this Contract on behalf of the
parties; (2) the parties&rsquo; execution and performance of this Contract do not violate the parties&rsquo; Articles of Association and
other organizational documents, laws, regulations and financial regulations, and other legal documents that shall be complied with by
the parties, and any necessary internal and external authorizations, permits, filings and other procedures have been obtained or completed
to ensure that this Contract is legally binding on and enforceable by the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>4.2</B></TD><TD STYLE="text-align: justify"><B>The Borrower undertakes and warrants to perform the following
obligations prior to the completion of the performance of this Contract:</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(1) The
Borrower shall always be legally existing, with good credit and no significant adverse records, and prior to the execution of this Contract
and each withdrawal application, provide BOB with truthful and complete information about its financial and operation status and other
important information related to this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0"> (2) Have sufficient and legal sources of repayment to match the repayment plan and have sufficient solvency;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(3) Production
and operation are legal and compliant, and comply with and meet the environmental protection standards and requirements, tax/fee payment
provisions and other provisions stipulated in laws, regulations and other normative documents, and the Borrower obtains the necessary
approvals and licenses in a timely, legal and effective manner;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(4) Provide
BOB with complete, true and effective materials, and accept and actively cooperate for BOB&rsquo;s inspection and supervision on its financial
status, operation status and payment and utilization of the loan hereunder, including but not limited to: (i) reasonably explain the fund
flow of each loan hereunder as required by BOB, and provide relevant payment vouchers and the basis for payment and certify the compliance
with the provisions of this Contract, and (ii) provide BOB with the complete audited financial statements (including notes) for the previous
year and the audit report by the end of each April, and provide BOB with copies of the balance sheet, statement of profit and loss, cash
flow statement and other financial statements as of the end of the previous quarter in the first month of each quarter (or the complete
audited statements and the audit report if there are audited semiannual or quarterly financial statements); and (iii) such other information
as BOB may reasonably require;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(5) Abide
by the principle of honesty and trustworthiness, all application materials, financial statements and other information provided by the
Borrower to BOB are true, accurate, complete, legal and valid, and there is no fraud, material omission or significant misleading;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(6) <B>In
case of merger, separation, reduction in registered capital, application for rectification after business suspension/takeover/dissolution/bankruptcy
or other matters affecting the existence or continuous operation of the applicant as subject, or equity transfer, external investment,
substantive increase in debts and financings and other events of the Borrower, the Borrower shall notify BOB in writing and obtain the
written consent of BOB at least 30 days in advance; if a third party applies for or an administrative/judicial body orders the Borrower
to carry out rectification for business suspension/takeover/dissolution/bankruptcy, or suspension or cancellation of licenses for main
or significant businesses of the Borrower, the Borrower shall notify BOB in writing as soon as possible (no later than 3 business days)
after the Borrower is aware, and timely take measures to make remedy;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(7) The
Borrower shall notify BOB in writing as soon as possible (no later than 5 business days) where the Borrower changes its industrial and
commercial registration/filing items, actual controller, top ten shareholders, directors, financial controller or contact address;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(8) <B>If
the Borrower provides a third party with guarantee (or similar arrangements with the guarantee effect such as debt assumption), or conclude
significant transactions with a third party such as partnership/contracting, waiver of significant creditor&rsquo;s right, acquisition
and restructuring, main business transfer or other similar transactions that are likely to reduce the Borrower&rsquo;s solvency, or significant
adverse events having impact on the solvency occur, the Borrower shall promptly notify BOB in writing and obtain BOB&rsquo;s prior written
consent, except that the above events do not have a material adverse effect on the Borrower&rsquo;s ability to perform this Contract and
the total amount of the said material transactions or total guaranteed amount does not exceed 30% of total assets or 50% of net assets
of the Borrower;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(9) <B>The
Borrower shall promptly notify BOB in writing of any related transactions of which total amount reaches or exceeds more than 10% of the
net assets thereof (related parties and related transactions shall be determined in accordance with the Chinese or international accounting
standards legally applicable to the Borrower), including: the association relationship between the parties to the transactions, transaction
items and transaction nature, transaction amount or corresponding ratio, pricing policy (including transactions with no amount or only
nominal amount), etc., and the Borrower may not illegally withdraw registered capital or fake transactions, conclude related transactions
evading debts and seriously damaging its solvency by deceiving of the bank fund or credit, transferring assets and other means, or enter
into other improper transactions such as money laundering;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(10) The
Borrower shall always keep relevant financial indicators (calculated on the basis of the Chinese or international accounting standards
legally applicable to the Borrower) within the scope of relevant laws and regulations, financial regulations and BOB&rsquo;s requirements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(11) <B>In
the event that the net profit after tax for the fiscal year is zero or negative or insufficient to make good the accumulated losses of
previous fiscal years, or that the profit before tax is insufficient to settle the principal and interest of the loan payable in the next
installment, no dividends or bonuses will be distributed to shareholders in any form;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(12) <B>The
Borrower shall, no later than the date of the first withdrawal, provide BOB with the guarantees as agreed in this Contract; see the guarantee
documents for details; and the Borrower undertakes to maintain the pledge rate and the mortgage rate under the guarantee documents within
the scope as agreed in the guarantee documents (if any); the Borrower undertakes that it fully understands and accepts the terms and contents
of relevant guarantee documents, and guarantees that all the guarantees provided to BOB on the basis of relevant guarantee documents are
lawful and valid, and enforceable in accordance with the laws.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0"> <B><U>5.</U></B> <B><U>Taxes</U></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The amounts under this Contract are
all tax-inclusive, and relevant tax rates shall be implemented in accordance with laws and regulations. The Borrower and the Lender shall
each bear the stamp duty, and taxes and administrative fees imposed by the government or organizations exercising administrative authority,
etc. payable under this Contract. Other costs (if any) such as notarization fees, guarantee fees, insurance premiums and appraisal fees
shall be borne in accordance with laws and regulations; if not provided for by laws and regulations, they shall be borne by the parties
through negotiation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0"> <B><U>6.</U></B> <B><U>Default and remedies</U></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>6.1</B></TD><TD STYLE="text-align: justify"><B>The occurrence of any one or more following circumstances
constitutes an event of default by the Borrower:</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(1) The
Borrower fails to use the loan for the purpose agreed herein, or to use or disburse the loan fund in the agreed manner (or circumvents
the express provisions on BOB&rsquo;s entrusted disbursement herein by breaking up the whole into parts), or to pay the interest, the
principal amount of the Loan, or any other sums payable in full and on schedule;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0"> (2) The Borrower has breached any of the undertakings and warranties set forth in Article 4 of this Contract.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(3) The
information in the documents or material representations relating to the Borrower&rsquo;s application for a loan or application for a
withdrawal proves to be untrue or fraudulent, materially omitted or materially misleading, or the Borrower fails to, or expressly represents
or acts in a manner that it will not, fully and properly fulfill its undertakings, warranties, obligations or liabilities under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(4) Any
guarantor fails to fully and properly perform its undertakings, warranties, obligations or liabilities under the guarantee documents,
or any other event of default under the guarantee documents occurs, or the collateral/pledge (if any) is destroyed, lost, title transferred,
retained under any lien by any other third party, seized/frozen/detained or enforced, or the right of occupancy is set on the collateral
(real estate) (if any) without prior written consent of BOB, or the guarantee documents or BOB&rsquo;s guarantee interest is held to be
invalid, revoked or discharged without BOB&rsquo;s prior written consent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(5) The
Borrower is unable to perform any material credit facilities, guarantees, indemnities or other debt repayment liabilities as and when
they fall due, or the licenses for its main or significant businesses have been suspended or cancelled, or the Borrower is subject to
rectification after business suspension/takeover/dissolution/declaration of bankruptcy and other procedures;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(6) The
Borrower&rsquo;s financial or operation condition has undergone a material adverse change, or a bad credit record has been generated,
or the credit status declines, or the Borrower is involved in disputes or administrative penalties, etc. that have a material adverse
effect on its solvency or the fulfillment of this Contract, or any other circumstance has occurred that has a material adverse effect
on BOB&rsquo;s claims or guarantee interests;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0"> (7) The legal representative/person in charge/actual controller of the Borrower/guarantor, etc. is missing.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>6.2 If
the Borrower fails to repay in full and on schedule any loan principal due and payable (including the loan principal which has been declared
by BOB to be fully or partially matured in advance) and other payables, the Borrower shall additionally pay the penalty interest on the
overdue loan principal and other payables at a rate 50% higher than the applicable contractual interest rate for the same term (overdue
penalty interest rate) on a daily basis, and on the interest that is not paid on time, calculate and pay the compound interest in accordance
with the overdue penalty interest rate as agreed in this Contract, until the principal and interest are settled. If the Borrower fails
to use the loan principal for the purpose agreed in this Contract or violates the provisions of laws, regulations and financial regulations,
the Borrower shall immediately repay the principal and interest of the loan used in violation of this Contract above, and calculate and
pay the penalty interest on such loan principal portion at a rate 100% higher than the contractual interest rate applicable for the same
term (misappropriation penalty interest rate) on a daily basis, and calculate and pay the compound interest at the misappropriation penalty
interest rate as agreed in this Contract for the unpaid interest for the period when the loan principal is not used for the purpose as
agreed herein until the loan is paid off. If the loan is used in violation of this Contract and repaid late, the misappropriation penalty
interest rate shall be applicable to calculation and payment of penalty and compound interest. Calculation and collection of the penalty
and compound interest in accordance with the agreements above shall not prejudice other remedies for default enjoyed by BOB.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>6.3 In
case of an event of default by the Borrower, BOB shall be entitled to exercise its remedies in accordance with the provisions of this
Contract or/and laws, regulations and financial regulations, including, but not limited to, requesting the rectification of default, changing
the loan fund use or disbursement method, ceasing to release the loan, charging penalty and compound interest, exercising the guarantee
interest and lien in accordance with the laws, declaring that the debt hereunder shall, in whole or in part, become immediately due, and
announcing the collection, requesting compensation for losses and demanding the repayment of expenses incurred by BOB for realization
of claims and guarantee interests (including, but not limited to, litigation/arbitration costs, disposal costs such as appraisal/assessment/auction,
attorney&rsquo;s fees, costs of investigation and evidence collection, travel costs and other reasonable expenses), etc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>6.4 If
the currency of the amount recovered by BOB in exercising its rights is different from the currency of the amount owed by the Borrower,
the exchange rates announced by BOB for the currency of the overdue amount sold by the bank and the currency of the amount bought back
by the bank shall be applied to discharge the claims of BOB, and the Borrower shall bear the exchange rate loss and the exchange fee incurred
accordingly, and the Borrower shall be obliged to cooperate to complete the exchange procedures.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>6.5 Amounts
recovered by BOB in exercising its rights shall be used to discharge its claims in the following order: (1) costs for realizing claims
and guarantee interests and other fees that shall be borne by the Borrower, (2) damages, compensation and liquidated damages, (3) penalty
and compound interest, (4) loan interest, (5) the loan principal, and (6) other sums payable; provided, however, that BOB may change the
discharge order above. If the Borrower&rsquo;s multiple amounts are due and payable, the order of discharge determined by BOB shall prevail.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">6.6 If
one party is affected by force majeure and provides the other party with the certificate from the competent authority within 5 business
days from the occurrence of force majeure, the party may be exempted from corresponding liabilities for default in accordance with the
laws, but for the avoidance of doubt, the parties confirm that the Borrower may be exempted from corresponding liabilities for default
in accordance with the laws after the occurrence of force majeure, but it is still obliged to pay back the withdrawn loan principal, the
loan interest calculated in the form of simple interest in accordance with the contractual interest rate and the costs of realizing the
claims and guarantee interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0"> <B><U>7.</U></B> <B><U>Enforcement notarization</U></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>7.1 </B>If
Paragraph <B>W</B> of this Contract requires the enforcement notarization, the Borrower shall, with the period as agreed herein, process
the notarization in a notary office recognized by BOB. Both parties agree to process the notarization of relevant debt instrument having
the enforcement effect for this Contract, and both parties are fully aware of the meaning, content, procedure and effect of notarization
of the debt instrument with enforcement effect. The parties agree that this Contract shall have the enforcement effect upon the notarization,
and that if BOB&rsquo;s rights and interests under this Contract or/and the guarantee documents are not fully realized in a timely manner,
or if the Borrower/guarantor commits an event of default under this Contract or/and the guarantee documents, BOB shall have the right
to directly apply for an enforcement certificate and submit the enforcement application to relevant competent people&rsquo;s court by
virtue of this Contract or/and the guarantee documents, the performance records of the Borrower issued by BOB and the notary certificate,
to realize the interests of BOB under this Contract or/and the guarantee documents. <B>The Borrower hereby specifically undertakes to
voluntarily waive the right to defense and voluntarily and unconditionally accept the enforcement. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>7.2 </B>Both
parties hereto agree that the notary office has the right to verify whether the Borrower has fulfilled its debts to BOB in full and on
time by using any one of the methods of verification such as mail, telephone, fax and e-mail. The notary office has the right to verify
the information from the Borrower in light of the name of the contact person, the reserved contact telephone number, the reserved fax
number, the reserved mailing address and the reserved e-mail address as agreed in this Contract. <B>The Borrower agrees that the notary
office may issue an enforcement certificate on the basis of the supporting materials provided by BOB unilaterally under the following
circumstances: (1) the notary office notifies the Borrower of the reserved contact person in accordance with the contact information as
agreed in this Contract, and the contact person cannot be reached; (2) the Borrower disagrees with the supporting materials provided by
BOB, but fails to provide evidence to the contrary or provides insufficient evidence to the contrary within three days upon the receipt
of the notice from the notary office; and (3) the Borrower has no objection to the supporting materials provided by BOB.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0"> <B><U>8.</U></B> <B><U>Applicable laws and dispute settlement</U></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>8.1 This
Contract shall be governed by the laws and regulations of the People&rsquo;s Republic of China; all disputes under and in connection with
this Contract shall first be settled through amicable negotiation, and if the negotiation fails, the disputes shall be submitted to relevant
people&rsquo;s court in the place where this Contract is signed for litigation.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>8.2 If,
in the guarantee documents, there are other express written provisions regarding the application of laws and settlement of dispute under
such document and BOB only sues the guarantor, it shall proceed in accordance with such provisions, and if there is no written provision,
the written provision is unclear, the provision is invalid/revoked in accordance with the laws, or BOB initiates litigation against the
Borrower and the guarantor together, the provisions of this Contract shall apply.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0"> <B><U>9.</U></B> <B><U>Assignment</U></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>If the Borrower assigns any of its
rights, obligations or liabilities hereunder to other parties, or sets guarantees or trusts on its rights, it shall be subject to the
prior written consent of BOB. BOB has the right to unilaterally assign its interests under this Contract and relevant guarantee documents
to other parties, as investment assets for trust, etc., to create guarantees or/and trusts, or to process the securitization of assets,
etc., without the consent of the Borrower, and may inform the Borrower of the same by means of public announcements (which shall not be
deemed to be a breach of the confidentiality obligation), written notice and so on. The Borrower shall continue to assume the liabilities
to BOB and assignees and beneficiaries thereof in accordance with this Contract.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0"> <B><U>10.</U></B> <B><U>Supplementary provisions</U></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">10.1 This
Contract is a specific business contract under the related contract (if any) mentioned in Paragraph <B>A</B> hereof. Matters not covered
herein shall be executed in accordance with the related contract, and this Contract shall prevail in case of any inconsistency between
the two. In the event of any inconsistency between the special agreements in Paragraph <B>X</B> of this Contract and other provisions
in the body of this Contract, the special agreements in that paragraph shall prevail; unless otherwise expressly specified in writing,
the body of this Contract shall prevail in the event of any inconsistency between the attachments to this Contract and the body of this
Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>10.2 Notices
or documents sent by either party hereunder: (i) if delivered in person or by proxy, the date of service shall be the day on which the
notified party, or legal representative, person in charge, actual controller, major shareholder, or receiving agent thereof, signs for
the delivery; (ii) if sent by express mail service or registered mail in the same city (including urban and suburban areas), the date
of service shall be the third day following the date of posting, (iii) if sent by other means, the date of service shall be the 7<SUP>th</SUP>
day following the date of posting, (iv) if sent by fax, text, email or other electronic means, the date of service shall be the day on
which relevant information enters into the electronic system such as fax, phone number, telephone number or e-mail first written above,
or the day on which the sender receives such information and the information fails to enter into the aforesaid electronic system; in case
of inconsistency between the date of service determined in accordance with the aforesaid provisions and the date of actual receipt by
the notified party or the date of official signature, the earliest date shall prevail. However, for the avoidance of doubt, the parties
confirm that the documents required by BOB to be delivered in person by the Borrower shall be delivered by a person specially assigned
by the Borrower directly to the case officer authorized by BOB in person, and that BOB has the right to deliver the notices or documents
to the Borrower by means of official announcements and so on (including, but not limited to, the official website, Internet banking, mobile
banking, electronic channels, official WeChat public account, etc.), and the date of announcement shall be the date of service. Any party
changing its contact information shall promptly notify the other party in writing, otherwise the other party still has the right to regard
the contact information before the change as valid.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0"> <B>10.3</B> <B>The Borrower hereby irrevocably undertakes that its contact person, mailing address, zip code, telephone number, fax number, e-mail address and other contact information first written above shall be valid contact information (including, but not limited to, the receipt of various notices, agreements and other documents, as well as relevant documents and legal instruments in case of disputes over this Contract, and also including the receipt of relevant documents and legal instruments in the trial procedures such as the first instance, second instance and retrial and the enforcement procedure after disputes enter into arbitration and civil litigation procedures). The Borrower agrees that relevant people&rsquo;s court, arbitration institution, notary office and the like may use the said contact information directly as the service address of legal instruments and notarized documents that they have confirmed to be valid. Relevant notices, documents, legal instruments, notarized documents, etc. may be served in the manner agreed in Paragraph 10.2 of this Contract. The Borrower shall notify BOB in writing at least 3 business days in advance of the change of its service address, and shall fulfill the service address change notification obligation to the notary office, arbitration institution or court where the Borrower changes its service address in arbitration and civil litigation procedures. If the Borrower fails to fulfill the notification obligation in the aforesaid manner, the address of service first written and confirmed by the Borrower above shall still be regarded as a valid address of service. If notices or relevant legal instruments mailed and served by BOB, relevant people&rsquo;s court, arbitration institution or notary office fail to be delivered to or actually received by the Borrower on the grounds that the address of service provided or confirmed by the Borrower is inaccurate, the changed service address fails to be timely notified to BOB, relevant notary office, court and arbitration institution in writing, the Borrower or the designated agent thereof refuses to sign for such notices, etc., the date of return of the document or the date of proof of service indicating the situation shall be regarded as the date of service if sent by mail, and the earliest date shall prevail provided that the date of service determined in accordance with the provision is different from the date of actual receipt by the parties or the date of official signing; if served directly, the date of service shall be the day when the serving person indicates relevant situation in the proof of service on site. In case of fulfillment of the obligation to notify the change of service address, the changed service address shall be the valid service address. For the service address confirmed by the Borrower at the top of this Contract, relevant court or arbitration institution may directly serve by mail in case of service, and even if the party fails to directly receive the documents served by relevant court or arbitration institution by mail, it shall be deemed to have been served due to its aforementioned provision. If the Borrower accepts letters sent by BOB, the legal documents sent by relevant people&rsquo;s court or arbitration institution, or the notarized document sent by the notary office by any means of service and in any document format, regardless of whether they are actually received by the Borrower directly or not, the Borrower shall bear all the legal consequences that may occur as of the date of service or deemed service; at the time of signing this Contract, the Borrower has accurately and correctly understood and learned about the agreed matters regarding the service address, and is willing to bear the legal consequences arising from the service by relevant people&rsquo;s court, arbitration institution or notary office to the abovementioned service address, addressee or receiving agents, and the Borrower will not object to any terms related to the service for any reason such as material misunderstanding or unconscionability.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>10.4 The
Borrower agrees and authorizes Bank of Beijing Co., Ltd. and branches thereof to, in the course of providing financial products and services
to the Borrower, collect, inquire about, understand, analyze, print, save and use the Borrower&rsquo;s credit status related to credit,
loan, loan-related transaction, guarantee, guaranteed property (including but not limited to collateral, pledge, etc.) and other assets,
provident fund contribution, social insurance contribution, tax payment, consumption, indebtedness and so on, information on judicial
measures such as seizure, information on relevant administrative penalties for illegal loan fund misappropriation and other information
through the basic personal credit information database of the People&rsquo;s Bank of China, the basic enterprise credit information database
of the People&rsquo;s Bank of China, the information base legal established with the approval of relevant competent department of the
government and the qualified institution or authority (including but not limited to relevant public security bureau, court, industrial
or commercial administration, ownership registration authority, regulator, and institution which is able to provide data on real estate/provident
fund/social insurance/tax/credit). Bank of Beijing Co., Ltd. and branches thereof are allowed to enter the said information it knows and
situation and information provided by other borrowers into the said database and information base for inquiry and use by any qualified
institution or unit (including but not limited to relevant credit bureau, public security bureau, court, industrial and commercial administration,
ownership registration authority, regulator, and institution which is able to provide data on real estate/provident fund/social insurance/tax/credit).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>At the same time, Bank of Beijing
Co., Ltd. and branches thereof have the right to provide the said information of the Borrower that Bank of Beijing Co., Ltd. and branches
thereof learn about and situation and information provided by other borrowers to third parties in case that they assign the interests
under the business carried out by and between Bank of Beijing Co., Ltd. and branches thereof and the Borrower to other parties, as investment
assets for trust, etc., to set guarantee or trust, process the asset securitization, implement the financial service outsourcing and demand
the overdue amount; and also have the right to provide relevant information to relevant regulatory, judicial, administrative and other
departments in accordance with laws and regulations and regulatory requirements. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">10.5 Unless
otherwise agreed in this Contract, either party shall keep confidential the trade secrets belonging to the other party and other undisclosed
information expressly requested by the other party to be kept confidential in the course of conclusion and performance of this Contract
before the said information loses the confidentiality, and shall not disclose them publicly or to any third party without the written
permission of the other party; however, if one party discloses them in accordance with relevant laws and regulations, or in accordance
with requirements of relevant competent authorities or regulatory bodies or the exchange on which it is listed, or reasonably reveals
the same to the party&rsquo;s auditor, financial adviser, legal adviser or other intermediary institutions for the purpose of this Contract
(the party shall require the said institutions and persons to bear the obligation of confidentiality), it shall not be regarded as a breach
of obligation of confidentiality.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">10.6 <B>The
validity of this Contract is independent of the guarantee documents, related contracts (if any) and any contracts/agreements/undertakings,
and is not affected by the validity and enforceability of the said documents.</B> In the event that any provision or content of this Contract
is revoked or held invalid in accordance with the laws, the validity of other provisions and content shall not be affected and shall remain
valid. The failure of the other party to exercise corresponding right of remedy in the event of a breach by one party shall not be deemed
to be a waiver of the right or a consent to the breach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>10.7 This
Contract shall come into effect after it is electronically signed by both parties, and the electronic signature shall have the same legal
effect and evidential effect as the handwritten signature or seal; the Borrower expressly understands that it shall use the electronic
signature that can be certified by a third party in accordance with the Electronic Signature Law of the People&rsquo;s Republic of China
to sign this Contract online. The Borrower may log onto the online platform for contract signing to view and download the text of this
Contract. If there is a guarantor, the Borrower shall be responsible for providing the electronic copy of this Contract to the guarantor,
but the Borrower&rsquo;s failure to do so shall not adversely affect the claims and guarantee interests of BOB.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>10.8 The
Borrower and the Lender recognize that this Contract shall be signed by means of electronic signature. The Borrower guarantees that the
electronic signature used in the Lender&rsquo;s electronic channel is a reliable electronic signature consistent with the agreements between
the Borrower and the Lender; the Borrower shall log onto the Lender&rsquo;s electronic channel through the mutually recognized identity
authentication, and any operation after the identity authentication shall be regarded as done by the Borrower itself, and the Borrower
undertakes to be responsible for the legal consequences arising therefrom.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>The Borrower
hereby confirms that: it has fully reviewed this Contract, and BOB has drawn its attention to the clauses relating to the limitation of
liabilities or rights, and has provided sufficient explanations and clarifications in respect of this Contract; and after negotiation
and discussion with BOB, the Borrower fully understands and agrees with all the contents of this Contract including the Schedule of Contract
Terms, Basic Terms of Contract and the attachments to this Contract, and has a clear, accurate and comprehensive understanding of the
rights and obligations of both parties, and does not have any doubts or objections. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(No
text below)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>The parties sign below:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrower: Jiangxi Universe Pharmaceuticals Co., Ltd.</FONT></TD>
    <TD STYLE="width: 50%; text-align: justify; text-indent: 22pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank of Beijing</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Nanchang Branch of Bank of Beijing Co., Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Special Seal for Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(2)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">3601020107028</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">19</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.8
<SEQUENCE>7
<FILENAME>ea022807501ex4-8_universe.htm
<DESCRIPTION>ENGLISH TRANSLATION OF THE WORKING CAPITAL LOAN CONTRACT BETWEEN JIANGXI UNIVERSE AND JIANGXI RURAL COMMERCIAL BANK, DATED MAY 17, 2024
<TEXT>
<!doctype html>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Exhibit 4.8</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>No.: 68 (2024) 248 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt"><b>Working Capital
Loan Contract</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt">Bank of Communications
Co., Ltd.</font></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt">&nbsp;</font></p>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>No.: 68 (2024) 248 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt"><b>Working Capital
Loan Contract</b></font></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<table cellspacing="0" cellpadding="0" align="center" style="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: Black 1.5pt solid; width: 100%; padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>Important Notice</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>The borrower is requested
    to read the full text of this<br />
 contract carefully, especially the provisions marked with &#9650;&#9650;.<br />
 Please ask the Lender to explain
    in time in case of any doubt.</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.1pt">&nbsp;</p></td></tr>
  </table>
<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In view of the Borrower&#8217;s application
for working capital loan line of credit from the Lender, and in order to clarify the rights and obligations of both parties, the Borrower
and the Lender hereby conclude this contract through negotiation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Article 1 Definition</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Line of credit&#8221;
refers to the maximum amount of loan balance (under revolving line of credit) or total loan (under lump-sum line of credit) that the Lender
may issue to the Borrower according to the contract, and the line of credit can be revolving line of credit or lump-sum line of credit
(only used once or can be used several times) according to the contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Revolving line of credit&#8221;
means that the Borrower can apply for using the line of credit several times as agreed in this contract to obtain the loan, but the loan
balance cannot exceed the agreed line of credit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Lump-sum line of credit&#8221;
means that the Borrower can apply for using the line of credit at one time or several times as agreed in this contract to obtain the loan,
but the total amount of loans withdrawn cumulatively cannot exceed the agreed line of credit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Loan balance&#8221; refers
to the sum of the loan principal amount obtained by the Borrower under this contract and not yet paid off.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Line of credit balance&#8221;
refers to the amount after deducting the loan balance (under the revolving line of credit) or the total loan (under the lump-sum line
of credit) from the line of credit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Credit period&#8221; refers
to the period during which the Lender grants the loan to the Borrower according to the Borrower&#8217;s application and the agreement in this
contract, and which belongs to the loan occurrence period rather than the loan term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Loan term&#8221; refers
to the term of each loan determined by both parties in the corresponding Application for Use of Loan Line of Credit of Bank of Communications
(hereinafter referred to as &#8220;Application for Use of Line of Credit&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Pricing benchmarks&#8221;
refers to the benchmark chosen by the Borrower and the Lender to determine the lending rate, including but not limited to the following
specific pricing benchmarks and other types.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Loan prime rate (LPR)&#8221;
refers to the loan prime rate released by the National Interbank Funding Center on the 20th day of each month (postponed in case of holidays).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Secured Overnight Financing
Rate (SOFR)&#8221; refers to the secured overnight financing rate governed by the Federal Reserve Bank of New York (or other entities
that take over its pricing benchmark), displayed on certain pages of financial telecommunication terminals Bloomberg/Refinitv (or other
pages of information service institutions recognized by Lender showing this pricing benchmark) that can be applied to loans of the dollar.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Term SOFR Reference
Rate&#8221; refers to the term SOFR reference rate governed and published by CME Group Benchmark Administration Limited (or other entities
that take over its pricing benchmark), and displayed on certain pages of financial telecommunication terminals Bloomberg/Refinitv (or
other pages of information service institutions recognized by Lender showing this pricing benchmark) that can be applied to loans of the
dollar.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Euro Interbank Offered
Rate (EURIBOR)&#8221; refers to the Euro interbank offered rate governed by the European Money Markets Institute (or other entities that
take over its pricing benchmark), displayed on certain pages of financial telecommunication terminals Bloomberg/Refinitv (or other pages
of information service institutions recognized by Lender showing this pricing benchmark) that can be applied to loans of the euro.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Hong Kong Interbank
Offered Rate (HIBOR)&#8221; refers to the Hong Kong interbank offered rate governed by the Hong Kong Association of Banks (or other entities
that take over its pricing benchmark), displayed on certain pages of financial telecommunication terminals Bloomberg/Refinitv (or other
pages of information service institutions recognized by Lender showing this pricing benchmark) that can be applied to loans of the Hong
Kong dollar.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Tokyo Term Risk Free
Rate (TORF)&#8221; refers to the Tokyo term risk free rate governed by QUICK Benchmarks Co., Ltd (or other entities that take over its
pricing benchmark), displayed on certain pages of financial telecommunication terminals Bloomberg/Refinitv (or other pages of information
service institutions recognized by Lender showing this pricing benchmark) that can be applied to loans of the Japanese yen.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Term SONIA Reference
Rate (TSRR)&#8221; refers to the term SONIA reference rate governed and published by Intercontinental Exchange Benchmark Administration
Limited (or other entities that take over its pricing benchmark), displayed on certain pages of financial telecommunication terminals
Bloomberg/Refinitv (or other pages of information service institutions recognized by Lender showing this pricing benchmark) that can be
applied to loans of the British pound.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;London Interbank Offered
Rate (LIBOR)&#8221; refers to London interbank offered rate governed by Intercontinental Exchange, Inc. (or other entities that take over
its pricing benchmark), displayed on certain pages of financial telecommunication terminals Bloomberg/Refinitv (or other pages of information
service institutions recognized by Lender showing this pricing benchmark) that can be applied to loans of the dollar.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Bank working day&#8221;
and &#8220;working day&#8221; refer to the opening day of the bank&#8217;s corporate business in the place where the Lender is located, excluding
legal holidays and rest days (except for business due to holiday adjustment). If the loan date, repayment date, interest payment date,
maturity date and other obligation fulfillment dates meet non-bank working day, it shall be postponed to the next bank working day accordingly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Foreign currency working
day&#8221; refers to the bond trading days of the U.S. government (excluding Saturdays and Sundays) recommended by the Securities Industry
and Financial Markets Association (or its successor) to the Fixed Income divisions of its members for SOFR or Term SOFR Reference Rate;
refers to the normal opening day (excluding Saturdays and Sundays) of the commercial banks in London for LIBOR or TSRR; refers to Euro
payment cleaning days of TARGET 2 for EURIBOR; refers to the normal opening day (excluding Saturdays and Sundays) of banks in Hong Kong
for HIBOR; and refers to the normal opening day (excluding Saturdays and Sundays) of banks in Tokyo for TORF.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Related parties&#8221;
refer to the authorized handler, agent, legal representative, person in charge, controlling shareholder or actual controller, beneficial
owner and other related parties directly or indirectly of the Borrower.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Business related parties&#8221;
refer to all parties to the transaction under the basic transaction contract, other related entities other than the parties to the transaction,
as well as the parties to the transaction, authorized handlers, agents, legal representatives, persons in charge, controlling shareholders
or actual controllers, beneficial owners and other parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Related parties, related party
transactions, individual major investors and other words have the same meanings as those in Accounting Standards for Business Enterprises
No.36 - Related Party Disclosure (CAI KUAI No.3 [2006]) and subsequent amendments to the standards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Article 2 Use of Line of Credit</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">2.1 The Borrower should apply
to the Lender at least 5 banking days in advance when it needs to use the line of credit. When applying, the Borrower should fill in the
Application for Use of Line of Credit, which can only be used after being examined and approved by the Lender.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650; 2.2 Every use
of the line of credit is subject to all the following conditions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(1) The loan balance (under
the revolving line of credit) or the total loan (under the lump-sum line of credit) does not exceed the line of credit;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(2) The applied loan amount
does not exceed the balance of the line of credit;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(3) The application date and
loan date are within the credit period;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(4) The loan term and maturity
date of the loan are in line with this contract;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(5) The guarantee contract
under this contract (if any) has come into force and continues to be valid. If the guarantee contract is a mortgage contract and/or pledge
contract, the real rights granted by way of security have been established and continue to be valid;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(6) The Borrower has completed
the government permission, approval, registration and other procedures that must be handled by law when applying for the loan, and the
permission, approval or registration continues to be valid;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(7) After the contract comes
into effect, the Borrower&#8217;s operating and financial conditions have no significant adverse changes;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(8) The application of the
Borrower meets the requirements of relevant rules and regulations of the Lender;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(9) The Borrower has not violated
the contract;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(10) The payment method of
the loan is in accordance with this contract. If the Lender is entrusted to pay, the Lender agrees to pay;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(11) In case of drawing foreign
currency loans, the Borrower has provided proof documents that the loans comply with relevant foreign exchange management policies, including
but not limited to valid foreign exchange purpose certificates or registration documents;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(12) The Borrower has designated
a special fund withdrawal account and signed an account management agreement as required by the Lender.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;2.3 If the Lender
agrees to grant the loan, the final loan information shall be subject to the contents of the bank print column of the Application for
Use of Line of Credit. The Application for Use of Line of Credit is also used as the Loan Voucher.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;2.4 If the currency
of the Application for Use of Line of Credit is inconsistent with the currency of the line of credit, only for the purpose of determining
the line of credit balance, it shall be converted according to the exchange rate published by Bank of Communications Co., Ltd. at the
beginning of each day; if there is no directly applicable exchange rate, it shall be converted by Bank of Communications Co., Ltd. according
to the exchange rate determined in a reasonable way.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;2.5 After the
Borrower becomes the shareholder of the guarantor or the &#8220;actual controller&#8221; as defined in the Company Law, the Lender has the
right to suspend or cancel the unused loan line of credit of the Borrower before the guarantor provides the resolution on agreeing to
provide guarantee for the Borrower by its shareholders&#8217; meeting (General Meeting of Shareholders) accepted by the Lender.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Article 3 Interest Rate, Interest
Calculation and Payment</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.1 Basic rules for determining
the interest rate</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.1.1 The annual loan interest
rate (simple interest) under this contract shall be agreed by both parties in the Application for Use of Line of Credit after negotiation
every time the Borrower uses its line of credit, determined according to the pricing benchmark, and calculated according to the pricing
benchmark agreed in the Application for Use of Line of Credit plus (minus) points (1 basis point is 0.01 percent, 1 percentage point is
100 basis points).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.1.2 If both parties agree
to apply the fixed interest rate in the Application for Use of Line of Credit, and the specific value is recorded in the fixed interest
rate value field, the specific interest rate of each loan shall be subject to the value recorded in the fixed interest rate value field
in the Application for Use of Line of Credit (If the currency of the loan is RMB, the specific value will be determined based on the specific
value of the pricing benchmark applicable to the applicable date of the pricing benchmark agreed in the Application for Use of Line of
Credit (hereinafter referred to as &#8220;pricing benchmark value&#8221;) and according to the value of plus (minus) points agreed in the
Application for Use of Line of Credit.). If the specific value is not recorded in the fixed interest rate value field, the specific interest
rate of each loan shall be determined based on the pricing benchmark value applicable to the applicable date of the pricing benchmark
agreed in the Application for Use of Line of Credit and according to the value of plus (minus) points agreed in the Application for Use
of Line of Credit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If both parties agree to apply
the floating interest rate in the Application for Use of Line of Credit, the specific interest rate of each loan will be determined based
on the LPR value applicable to the applicable date of the pricing benchmark agreed in the Application for Use of Line of Credit, the value
of the plus (minus) points, the interest rate fluctuation rules, the interest rate fluctuation period, the unit of interest rate fluctuation
period and the floating start date of a specific date (if necessary) agreed in the Application for Use of Line of Credit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.1.3 If the currency is RMB,
the daily interest rate = interest rate/30, and the monthly interest rate = annual interest rate/12; If the currency is Hong Kong dollars,
British pounds and Australian dollars, the daily interest rate = annual interest rate/365; If the currency is USD, Euro, Japanese yen
and other foreign currencies accepted by the Lender, the daily interest rate = annual interest rate/360.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;3.2 Loan interest
rate</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If both parties agree to apply
the fixed interest rate in the Application for Use of Line of Credit, and the specific value is recorded in the fixed interest rate value
field, the interest rate of each loan shall be subject to the value recorded in the fixed interest rate value field. If both parties agree
to apply the fixed interest rate in the Application for Use of Line of Credit, and the specific value is not recorded in the fixed interest
rate value field and both parties agree to apply the floating interest rate in the Application for Use of Line of Credit, the loan interest
rate for each loan is determined based on the applicable LPR value of the &#8220;applicable date of the pricing benchmark&#8221; agreed
in the corresponding Application for Use of Line of Credit, and according to the plus (minus) point value agreed in the Application for
Use of Line of Credit. Take the &#8220;applicable date of the pricing benchmark&#8221; as the T-day, and value rules for the applicable
pricing benchmark value on T-day shall be executed according to Article 3.5.1 of this contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.3 Adjustment of the interest
rate</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.3.1 If a fixed interest rate
is recorded in the Application for Use of Line of Credit, the recorded interest rate will be implemented for the loan within the loan
term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;3.3.2 If a floating
interest rate is recorded in the Application for Use of Line of Credit, the loan interest rate adjustment date shall be determined according
to the interest rate fluctuation rules, interest rate fluctuation period, unit of interest rate fluctuation period and floating start
date of specific date (if necessary) agreed in the Application for Use of Line of Credit, and the adjusted interest rate shall apply from
the loan interest rate adjustment date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.3.2.1 During the loan period,
the period of adjustment of the loan interest rate will be calculated from the &#8220;loan entry date&#8221; or the &#8220;floating start
date of the specific date&#8221; according to the &#8220;floating by loan entry date&#8221; or &#8220;floating on specific starting date&#8221;
selected in &#8220;interest rate fluctuation rules&#8221;. The blank column of interest rate floating cycle shall be filled with the number
of interest rate floating cycles, and the unit of interest rate floating cycle can be selected as daily or monthly. If &#8220;1&#8221; is
filled in the number of interest rate floating cycles and &#8220;daily&#8221; is selected as the floating cycle unit, every day from the
&#8220;loan entry date&#8221; or the &#8220;floating start date of the specific date&#8221; will be taken as the adjustment date of loan interest
rate; If &#8220;3&#8221; is filled in the number of interest rate floating cycles and &#8220;daily&#8221; is selected as the floating cycle
unit, the loan interest rate adjustment date will be the date every 3 days from the &#8220;loan entry date&#8221; or &#8220;floating start
date of specific date&#8221;; If &#8220;1&#8221; is filled in the number of interest rate floating cycles and &#8220;monthly&#8221; is selected
as the floating cycle unit, the loan interest rate adjustment date will be the date of every month from the &#8220;loan entry date&#8221;
or &#8220;floating start date of specific date&#8221;; If &#8220;3&#8221; is filled in the number of interest rate floating cycles and &#8220;monthly&#8221;
is selected as the floating cycle unit, the loan interest rate adjustment date will be every 3 months from the &#8220;loan entry date&#8221;
or &#8220;floating start date of specific date&#8221;, and so on.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.3.2.2 The loan interest rate
on the loan interest rate adjustment date is determined on the basis of the applicable pricing benchmark value on the loan interest rate
adjustment date, and the value of interest rate plus (minus) points shall be executed according to the value of interest rate plus (minus)
points agreed in the Application for Use of Line of Credit, except for the value of plus (minus) points adjusted by both parties through
consultation in this contract. Take the &#8220;loan interest rate adjustment date&#8221; as the T-day, and the applicable pricing benchmark
value on the T-day shall be executed according to Article 3.5.1 of this contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;3.3.3 If applicable
pricing benchmark of certain loan is canceled or the corresponding publishing institution stops publishing, both parties shall negotiate
and adjust the loan interest rate separately, but the adjusted interest rate shall not be lower than the applicable interest rate at that
time; If the two parties still fail to reach an agreement on the adjusted interest rate after more than one month from the date when the
pricing benchmark is canceled or stopped publishing, the Lender has the right to declare the loan to expire in advance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;3.3.4 Both parties
can adjust the value of the plus (minus) points of the corresponding loan interest rate after consensus on each loan interest rate adjustment
date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.4 The penalty interest rate
of overdue loans will be increased by 50% according to the interest rate agreed in this contract, and the penalty interest rate of misappropriated
loans will be increased by 100% according to the interest rate agreed in this contract. In case of adjustment of pricing benchmark for
floating rate loans, the Lender has the right to adjust the applicable penalty interest rate for each loan accordingly, and apply the
new penalty interest rate from the adjustment date of loan interest rate agreed in the corresponding Application for Use of Line of Credit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.5 Calculation of interest</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.5.1 According to different
applicable pricing benchmarks, the value rules for applicable pricing benchmark in T-day (namely, &#8220;applicable date of the pricing
benchmark&#8221;, &#8220;loan interest rate adjustment date&#8221;, and &#8220;re-pricing day&#8221;) agreed in Article 3.2, Article 3.3.2.2
and Article 9. 3.3.2 are as follow:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the pricing benchmark is
LPR, the pricing benchmark value applicable for T-day will be the latest published value of LPR before T-day.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the pricing benchmark is
SOFR and the T-day is a foreign currency working day, the pricing benchmark value applicable for T-day will be the value of SOFR displayed
on the corresponding financial telecommunication terminal page on the fifth foreign currency working days before T-day; If the T-day is
not a foreign currency working day, the pricing benchmark value applicable for T-day will be the value of SOFR of the latest foreign currency
working day (which is the value of SOFR displayed on the corresponding financial telecommunication terminal page on the fifth foreign
currency working days before the latest foreign currency working day).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the pricing benchmark is
Term SONIA Reference Rate, LIBOR, EURIBOR, TORF, or TSRR, and the T-day is a foreign currency working day, the pricing benchmark value
applicable for T-day will be the value of the pricing benchmark displayed on the corresponding financial telecommunication terminal page
on the second foreign currency working days before T-day; if the T-day is not a foreign currency working day, the pricing benchmark value
applicable for T-day will be the value of the pricing benchmark of the latest foreign currency working day (which is the value of the
pricing benchmark displayed on the corresponding financial telecommunication terminal page on the second foreign currency working days
before the latest foreign currency working day).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the pricing benchmark is
HIBOR, and the T-day is a foreign currency working day, the pricing benchmark value applicable for T-day will be the value of HIBOR displayed
on the corresponding financial telecommunication terminal page on T-day; if the T-day is not a foreign currency working day, the pricing
benchmark value applicable for T-day will be the value of HIBOR of the latest foreign currency working day (which is the value of HIBOR
displayed on the corresponding financial telecommunication terminal page on the latest foreign currency working days).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the pricing benchmark value
displayed on the corresponding financial telecommunication terminal page is larger than or equal to 0, the value of the pricing benchmark
for determining the loan rate of this contract will be determined based on the pricing benchmark value displayed on the corresponding
financial telecommunication terminal page; If pricing benchmark value displayed on the corresponding financial telecommunication terminal
page is smaller than 0, the value of the pricing benchmark for determining the loan rate of this contract will be determined as 0.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.5.2 Normal interest = interest
rate agreed in this contract &times; loan amount &times; occupied days.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The occupied days are calculated
from the loan date (inclusive) to the expiration date (exclusive), which will be postponed when the expiration date is not a working day.
The postponed period will be counted as occupied days, and the interest will still be calculated according to the contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.5.3 The penalty interest
for overdue loans and misappropriated loans is calculated according to the overdue or misappropriated amount and actual days (from the
overdue or misappropriated date (inclusive) to the date of repayment of principal and interest (exclusive)).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.5.4 If the calculated interest/penalty
interest has a large number of decimal places, the Lender will keep two decimal places by rounding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;3.6 If the Borrower
repays the loan in advance or the Lender withdraws the loan in advance according to this contract, the corresponding interest rate grade
will not be adjusted, and the interest rate agreed in this contract will still be applied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.7 If the loan currency is
a currency rather than RMB, US dollar, Euro, Hong Kong dollar, Japanese yen, and British pound, the determination of the pricing benchmark
of the loan, the calculation rule of daily interest rate and applicable date of pricing benchmark, the adjustment date of loan interest
and the pricing benchmark value on repricing date shall be subject to the agreement in Article 17 of this contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Article 4 Payment of Loan</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">4.1 If the loan account designated
by the Borrower is a special loan issuance account opened at the Lender, the issuance and payment of the loan shall be handled through
this account. This account is only used for the issuance of loan funds and external payment, only for the sale of &#8220;Application for
Settlement Business&#8221; vouchers; It cannot be used for handling checks, bills of exchange, bank acceptance bills and other businesses,
and cannot be used for other settlements. When the Borrower pays for the loan fund allocation independently, it must be handled at the
counter of the account opening outlet. The deposit interest of this account is included in the Borrower&#8217;s repayment account.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">4.2 When the Borrower withdraws
the loan according to this contract, it should specify the payment method (the Lender&#8217;s entrusted payment or the Borrower&#8217;s independent
payment), and only one payment method can be used for each withdrawal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">4.3 The Lender&#8217;s entrusted
payment means that the Lender directly pays the loan funds to the Borrower&#8217;s counterparty that meets the purpose agreed in this contract
through the Borrower&#8217;s account after issuing the loan according to the Borrower&#8217;s entrusted payment power of attorney.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the single payment amount
exceeds the independent payment line of credit or meets one of the conditions agreed in Article 19.3, the entrusted loan payment method
shall be adopted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In case of the Lender&#8217;s entrusted
payment, the Borrower shall submit to the Lender the Application for Use of Line of Credit, the corresponding entrusted payment power
of attorney and other information required by the Lender (including but not limited to business contracts, invoices, receipt documents
and other transaction information), and specify the amount of the loan to withdraw and the object and amount of payment, and the amount
of the loan to withdraw should be equal to the total amount to be paid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;If the payment
to be made by the Borrower does not conform to this contract or the corresponding commercial contract or has other defects, the Lender
has the right to refuse the payment and return the entrusted payment power of attorney submitted by the Borrower.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;If the Lender
agrees to pay, and if it can&#8217;t be paid or it is refunded due to the wrong information provided by the Borrower, the Borrower must resubmit
the relevant documents and materials containing the correct information within the time line of credit specified by the Lender, and the
Lender will not be responsible for the delay or unsuccessful payment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">4.4 The Borrower&#8217;s independent
payment means that after the Lender grants the loan funds to the Borrower&#8217;s account according to the agreement in this contract, the Borrower
pays the loan funds to the Borrower&#8217;s counterparty that meets the purpose agreed in this contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the Borrower&#8217;s independent
payment is adopted, the Borrower shall submit to the Lender the Application for Use of Line of Credit, instructions on the use of funds
and other materials required by the Lender. The Borrower shall summarize and report the payment of loan funds to the Lender on time. The
Lender has the right to check whether the payment of loan funds meets the agreed purpose by means of account analysis, voucher inspection,
on-site investigation, etc. The Borrower shall cooperate with the Lender&#8217;s verification.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Article 5 Repayment of Loan</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">5.1 The Borrower shall repay
the loan according to the repayment date and amount recorded in the corresponding Application for Use of Line of Credit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;5.2 Without the
written consent of the Lender, the Borrower cannot repay the loan in advance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;5.3 The repayment
arrangement of the principal and interest agreed by the Borrower and the Lender in the Application for Use of Line of Credit is the real
intention reached by both parties on a voluntary basis after consultation. Under the repayment arrangement chosen by both parties, whether
the principal is repaid before the interest does not affect the Borrower&#8217;s repayment responsibility for the interest payable, and the
Borrower shall not argue against the repayment of the interest payable. Under any repayment arrangement, the Borrower shall bear the repayment
responsibility for all the principal and interest payable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;5.4 When the
repayment of the Borrower (including the repayment voluntarily repaid by the Borrower and deducted by the Lender according to this contract)
cannot fully pay off all the debts of the Borrower:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(1) It should be used to pay
off the overdue expenses first. If the principal and interest are overdue for less than 90 days, the balance after offsetting the expenses
shall be used to offset the overdue interest or penalty interest and compound interest, and then used to offset the overdue principal;
If the principal or interest is overdue for more than 90 days, the balance after offsetting the expenses shall be used to offset the overdue
principal first, and then used to offset the overdue interest or penalty interest and compound interest;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(2) If the Borrower has multiple
debts (including the debts of the Borrower to the Lender under other contracts), the Lender has the right to decide the repayment and
offset order of each debt of the Borrower by itself, as long as the offset order does not violate the mandatory provisions of laws, regulations,
rules and regulations as well as relevant regulatory requirements applicable to the Lender. The Lender shall inform the Borrower of the
result of debt repayment. Unless otherwise agreed by both parties to this article.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Article 6 Statement and Guarantee
of the Borrower</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">6.1 The Borrower is legally
established and legally exists; It has all necessary rights and capabilities, and it can perform the obligations of this contract in its
own name and bear civil liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">6.2 Signing and performing
this contract is the true intention of the Borrower after all necessary consent, approval and authorization, and there is no any legal
flaw.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">6.3 The Borrower&#8217;s production
and operation are legal and compliant, with the ability of going concern, legal sources of repayment, no major environmental and social
risks and no major bad credit record. The senior management of the Borrower has no bad record.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">6.4 All documents, statements,
data and information provided by the Borrower to the Lender during the signing and performance of this contract are true, accurate, complete
and effective. No information that may affect its financial status and repayment ability has been concealed from the Lender, and the financial
status of the Borrower has no significant adverse changes since the reporting date of the latest financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;6.5 The Borrower,
its related parties and business related parties are not listed in the sanctions list issued by the United Nations and related countries,
organizations and institutions, or the enterprises or individuals listed in the risk list related to terrorism and anti-money laundering
issued by Chinese government departments or authorities; They are not located in countries and regions that are not sanctioned by the
United Nations and related countries, organizations and institutions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;6.6 The Borrower
promises to abide by the national anti-money laundering laws, regulations and relevant policies, not to engage in illegal activities such
as assisting others in money laundering, terrorist financing, tax evasion, evasion of bank debts, cash extraction, telecom fraud, illegal
fund-raising, etc., actively cooperate with the Lender to carry out various anti-money laundering work such as customer identification,
transaction record keeping, due diligence on customer identity and transaction background, large and suspicious transaction reports, etc.,
and provide relevant certification materials as required by the Lender.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Article 7 Rights and Obligations
of the Lender</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">7.1 The Lender has the right
to recover the loan principal and interest (including compound interest, penalty interest for overdue loans and misappropriation of loans,
etc.) according to this contract, collect the fees payable by the Borrower, decide to recover the loan in advance according to the Borrower&#8217;s
fund withdrawal, and exercise other rights stipulated by law or this contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;7.2 During the
performance of this contract, the Lender only conducts formal review on the information provided by the Borrower. If the materials provided
by the Borrower are untrue, inaccurate or incomplete, or the Borrower violates the agreement of this contract to make payment, resulting
in the Lender&#8217;s failure to complete the entrusted payment in time, the Lender will not be liable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;7.3 The Lender
shall issue the loan and handle the payment according to this contract. If the Lender fails to issue the loan or make payment on time
due to any of the following reasons, the Lender will not be liable, but it will inform the Borrower in time: The loan account designated
by the Borrower is frozen, the payment object account is frozen, force majeure, communication or network failure, system failure of the
Lender, etc. Unless otherwise agreed in this contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;7.4 According
to the regulatory requirements for the Lender, the Lender shall conduct a dynamic evaluation of the Borrower&#8217;s risks of money laundering,
terrorist financing, and tax evasion and be entitled to adopt one or all of the measures agreed in Article 9.2 when it the risks of the
Borrower or the Borrower&#8217;s trading instructions of money laundering, terrorist financing, and tax evasion are considered high.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Article 8 Obligations of the
Borrower</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">8.1 The Borrower shall repay
the loan principal under this contract and pay the interest according to the time, amount, currency and interest rate recorded in this
contract and the corresponding Application for Use of Line of Credit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The fund withdrawal account
designated by the Borrower is used to collect the corresponding sales revenue or planned repayment funds. If the corresponding sales revenue
is settled in a non-cash manner, the Borrower shall ensure that the money is promptly transferred to the fund withdrawal account after
being received. The Borrower shall provide the capital inflow and outflow of the capital withdrawal account as required by the Lender.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">8.2 The Borrower shall use
the line of credit according to the purpose agreed in this contract, and use the loan according to the purpose determined in the corresponding
Application for Use of Line of Credit, and shall not use the loan for other purposes, or use the loan for fixed assets investment, equity
investment, fields and purposes prohibited by the state from production and operation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Borrower shall use the
loan funds as agreed, and shall not avoid the Lender&#8217;s entrusted payment by breaking up the whole into parts; If the Borrower&#8217;s independent
payment is adopted, the Borrower shall use the loan within a reasonable time according to the requirements of the Lender&#8217;s supervisory
authority, and the payment of loan funds shall comply with this contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;8.3 The Borrower
shall bear the settlement fees (if any) for the loan fund payment (including the Lender&#8217;s entrusted payment and the Borrower&#8217;s independent
payment), and the specific fees shall be implemented according to laws, regulations, rules, regulatory requirements and the Service Charges
List of the Bank of Communications effective at that time published by the Lender.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For loan fund payments involving
no cross-border payment, when the loan funds are paid (including the Lender&#8217;s entrusted payment and the Borrower&#8217;s independent payment),
if the collection account does not belong to the account opened in the Bank of Communications, the payment of the funds may be handled
through the payment system of the People&#8217;s Bank of China or the local exchange system. If the loan account is not a special loan issuing
account, when the loan funds are paid (including the Lender&#8217;s entrusted payment and the Borrower&#8217;s independent payment), if the collection
account is an account of another bank in different places, all the payment of funds will be handled through the payment system of the
People&#8217;s Bank of China.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For loan fund payments involving
cross-border payment, the loan fund payment may be handled through the SWIFT system or other payment systems.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;8.4 The Borrower
shall cooperate with the Lender to handle the loan payment and supervise and inspect the loan usage as well as the Borrower&#8217;s operation;
It shall timely provide the financial statements, loan fund usage records and materials, related party and related party transaction information,
environmental and social risk reports, other materials and information required by the Lender for post-loan risk management, and ensure
that the documents, materials and information provided are true, complete and accurate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;8.5 In case of
any of the following events, the Borrower shall notify the Lender in writing at least 30 days in advance, and shall not take any action
before paying off all the loan principal and interest under this contract or providing the repayment scheme and guarantee approved by
the Lender:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(1) The Borrower disposes of
all or most assets or important assets by selling, donating, leasing, lending, transfer, mortgage, pledge or otherwise;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(2) Significant changes have
taken place in the Borrower&#8217;s management system or property right organization form, including but not limited to the implementation of
contract, lease, joint venture, company system reform, joint-stock cooperation system reform, enterprise sale, merger (acquisition), joint
venture (cooperation), division, establishment of subsidiaries, equity transfer, property right transfer, capital reduction, etc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(3) The Borrower&#8217;s foreign
equity or increased debt financing exceeds the agreed line of credit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;8.6 The Borrower
shall notify the Lender in writing within 7 days from the date when the following events happen or may happen and submit relevant supporting
documents according to laws, regulatory provisions, and the Lender&#8217;s requirements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(1) The Borrower or its related
party modifies the articles of association, changes the business registration items such as enterprise name, legal representative (person
in charge), residence, postal address or business scope, or makes decisions that have a significant impact on finance and personnel;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(2) The Borrower, its related
party or guarantor intends to apply for bankruptcy or may have been or has been applied for bankruptcy by creditors;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(3) The Borrower or its related
party is involved in major litigation, arbitration and administrative measures, or property preservation or other compulsory measures
have been taken for its main assets or collateral under this contract, or the safety and integrity of its main assets or collateral under
this contract has been or may be affected, or its value is reduced or may be reduced;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(4) The Borrower or its related
party provides a guarantee for a third party, which has a significant adverse impact on its economic status, financial status or ability
to perform its obligations under this contract;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(5) The Borrower or its related
party signs a contract that has a significant impact on its operation and financial status;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(6) The Borrower pays off the
unexpired debts in advance or gives priority to paying off other due debts, adds any form of guarantee such as pledge for other existing
debts, or makes any arrangement or signs relevant documents with similar effect;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(7) The Borrower, its related
party or guarantor suspends production, closes down, dissolves or suspends business for rectification, is revoked or its business license
is revoked;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(8) The Borrower or its related
party, the individual principal investor of the Borrower or its related party, the legal representative (person in charge), director or
key management personnel of the Borrower or its related party is missing, involved in violations of laws and regulations or in violation
of applicable exchange rules or has any abnormal changes;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(9) The Borrower or its related
party has serious difficulties in operation, or its financial situation deteriorates, or other events that have a negative impact on the
operation, financial situation, solvency or economic situation of the Borrower or its related parties occur;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(10) Related party transactions
occur, and the monthly transaction amount reaches or exceeds 10% of the recently audited net assets;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(11) Before paying off all
debts under this contract, the Borrower becomes or may become the shareholder or the &#8220;actual controller&#8221; as defined in the Company
Law of the guarantor;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(12) The Borrower or its related
party is exposed by the media because of its violation of laws, regulations, regulatory requirements, national policies or industry standards,
etc.;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(13) The Borrower or its related
party has any safety or environmental accident;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(14) The controlling or controlled
relationship between the Borrower&#8217;s related party and the Borrower changes;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(15) The Borrower or its related
party has any significant equity change;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(16) The audit opinion issued
by the external auditor of the Borrower on its financial statements is not a standard unqualified opinion;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(17) The Borrower has been
or may be investigated, punished or taken other similar measures by the competent authority for violating laws, regulations and/or regulatory
requirements;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(18) The Borrower or its related
party or business related party is included in the sanctions list issued by the United Nations and related countries, organizations and
institutions, and the list of risks related to terrorism and anti-money laundering issued by Chinese government departments or authorities;
Or the country and region where the Borrower or its related person or business related party is located is included in the list of countries
and regions sanctioned by the United Nations and related countries, organizations and institutions;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(19) Other major adverse events
that affect the solvency of the Borrower or its related party occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(20) According to the Lender&#8217;s
environmental and social risk assessments standards, if the Borrower belongs to one of the clients in Category A or B of social risk,
any one of the following matters happen or may happen to the Borrower:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9312; Various
permissions, reviews, and approvals concerning environmental and social risk during commencement, construction, operation and
shutdown;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9313; The
environmental and social risk assessment and examination of the Borrower by environmental and social risk regulator or other
institutions it recognized;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9314; Supporting
construction and operation of environmental facilities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9315; Emission and
compliance of contaminants;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9316; Safety and
health condition of employees;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9317; Major
complaints or protests of the Borrower by neighboring communities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9318; Major
environmental and social claims;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9319; Other major
situations considered relevant to environmental and social risk by the Lender.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;8.7 When the
guarantee under this contract changes to the detriment of the Lender&#8217;s creditor&#8217;s rights, the Borrower shall provide other guarantees
recognized by the Lender in a timely manner as required by the Lender.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The &#8220;change&#8221; mentioned
in this paragraph includes but is not limited to: merger, division, suspension of production, suspension of business, dissolution, suspension
of business for rectification, being revoked, revocation of business license, application or being applied for bankruptcy of the guarantor;
Significant changes have taken place in the operation or financial status of the guarantor; The guarantor involves major litigation, arbitration,
administrative measures, or property preservation or other compulsory measures have been taken for its main assets; The security and integrity
of the collateral is or may be affected; The value of collateral is reduced or may be reduced, or compulsory measures such as property
preservation such as seizure are taken; The guarantor or its legal representative (person in charge) or key management personnel is involved
in violation of laws and regulations or the applicable exchange rules; If the guarantor is an individual, the guarantor is missing or
dead (declared dead); The guarantor has breached the contract under the guarantee contract; Disputes between the guarantor and the Borrower
occur; The guarantor asks to cancel the guarantee contract; The guarantee contract is ineffective, invalid or revoked; The real rights
granted by way of security are not established or invalid; Or other events affecting the security of the Lender&#8217;s creditor&#8217;s rights occur,
etc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;8.8 The Borrower
promises that: from the date of signing this contract until all the loan principal and interest and related expenses under this contract
are paid off, the financial indicators, external agency rating and production and operation qualifications/licenses of the Borrower always
comply with the contract, and if the production and operation qualifications/licenses need to be examined annually, they should pass the
annual examination on time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">8.9 The Borrower guarantees
that the Borrower, the Borrower&#8217;s employees and agents will not provide, give, ask for or accept material benefits in any form other than
those stipulated in this contract (including but not limited to cash, physical cards, travel, etc.) or other non-material benefits to
the Lender or the Lender&#8217;s employees in any form; The Borrower, the Borrower&#8217;s employees and agents will not directly or indirectly use
the funds or services provided by the Lender for activities related to corruption or bribery in any form; If the Borrower is aware of
any violation of this article, it should provide clues and relevant information to the Lender in a timely, truthful, complete and accurate
manner, and cooperate with relevant matters as required by the Lender.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">8.10 According to the Lender&#8217;s
environmental and social risk assessments standards, if the Borrower belongs to one of the clients in Category A or B of social risk,
the Borrower shall be borne the following obligations:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(1) Set up a sound internal
administrative system for environmental and social risks and set forth detailed responsibility, obligation, and penalty measures of relevant
responsible persons;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(2) Set up a sound environmental
and social risk emergency mechanism and a set of measures;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(3) Set up a special department
and/or assign special personnel to be responsible for environmental and social risk events;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(4) Cooperate with the Lender
or a third party recognized by the Lender to carry out environmental and social risk assessments and examinations for the Borrower;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(5) Provide appropriate responses
or take necessary actions when the public or other stakeholders express strong suspicion of the Borrower&#8217;s environmental and social
risk performance;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(6) Urge important affiliates
of the Borrower to enhance management to prevent the contagion of affiliates&#8217; environmental and social risks to the Borrower;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(7) Perform other obligations
of controlling environmental and social risks which are considered relevant by the Lender.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650; Article 9 Adjustment
of the Line of Credit, Premature Expiration of Loan and Risk Repricing</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">9.1 Any of the following events
shall be regarded as the &#8220;premature expiration event&#8221; of this contract:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(1) The Borrower fails to repay
the loan principal or pay interest as agreed in any Application for Use of Line of Credit under this contract;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(2) The statements and guarantees
made by the Borrower under this contract are untrue;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(3) Any of the notifiable matters
listed in Article 8.6 actually happens, which affects or may affect the security of the Lender&#8217;s creditor&#8217;s rights;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(4) The change of laws, regulations
and regulatory policies causes that the loan issuance by the Lender as agreed in this contract constitutes or may constitute violations
of laws or regulations;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(5) When the Borrower performs
other contracts with the Lender or contracts with a third party, there is a breach of contract or the debt may or has been announced to
be due in advance;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(6) The Borrower violates other
agreements in this contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(7) According to the Lender&#8217;s
environmental and social risk assessments standards, if the Borrower belongs to one of the clients in Category A or B of social risk,
the following events happen to the Borrower:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9312; The Borrower is
punished by the competent governmental department for poor management of environmental and social risk;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9313; The Borrower is
strongly questioned by the public and/or the media for poor management of environmental and social risk;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9314; he Borrower
breaches its obligations of the management of environmental and social risk agreed with the Lender in other contracts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">9.2 When any &#8220;premature
expiration event&#8221; occurs, the Lender has the right to take one, several or all of the following measures:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(1) Reduce, suspend or cancel
the line of credit under this contract;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(2) Stop issuing loans that
have not been drawn by the Borrower;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(3) Stop handle the payment
that the Borrower has withdrawn but not yet used;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(4) Require the Borrower to
negotiate with the Lender for supplementary loan issuance and payment conditions within a time limit;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(5) Require the Borrower to
change the payment method as required by the Lender;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37pt"></p>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>


<p style="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(6) Reprice the risk of loans
as agreed in Article 9.3;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(7) Unilaterally declare that
all the loan principal issued under the contract is due in advance and require the Borrower to immediately repay all the loan principal
due and settle the interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">9.3 According to the production
and operation situation of the Borrower at the time of signing this contract, the interest rate agreed in this contract and its adjustment
are determined by both parties through negotiation. The Borrower agrees that in the event of any &#8220;premature expiration event&#8221;,
the Lender has the right to reprice the risk of the loan according to this article.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">9.3.1 Risk repricing includes
negotiated repricing and direct increase of the loan interest rate. The risk repricing method adopted in this contract is agreed by both
parties in Article 21.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">9.3.2 &#8220;Negotiated repricing&#8221;
means that the Lender has the right to ask the Borrower to negotiate with the Lender to increase the loan interest rate within a time
limit, and both parties determine the &#8220;repricing date&#8221; and the specific agreement on relevant interest rates by means of supplementary
agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">9.3.3 &#8220;Direct increase
of the loan interest rate&#8221; means that the Lender has the right to directly increase the loan interest rate according to this article
and Article 21.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">9.3.3.1 Since the &#8220;repricing
date&#8221; notified by the Lender to the Borrower in writing, the increased loan interest rate will be applied to all loans that the borrower
has not repaid as of the &#8220;repricing date&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">9.3.3.2 If the loan currency
is RMB, US dollar, Euro, Hong Kong dollar, Japanese yen, or British pound, on the basis of the applicable pricing benchmark value on the
&#8220;repricing date&#8221;, the loan interest rate after each loan increase shall be determined according to the value of the plus (minus)
points agreed in Article 21.2.1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Take the &#8220;repricing date&#8221;
as the T-day, and the applicable pricing benchmark value on T-day is subject to Article 3.5.1 in this contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">9.3.3.3 If the loan currency
is other currencies rather than RMB, US dollar, Euro, Hong Kong dollar, Japanese yen, or British pound, the loan interest rate after the
increase shall be determined according to Article 21.2.2.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">9.3.4 After the Lender reprices
the risk according to the aforementioned agreement, the new interest rate will be implemented from the &#8220;repricing date&#8221;. On
the basis of this interest rate, it is still subject to the floating adjustment as agreed in Article 3 of this contract. If both parties
agree to change the relevant agreement through consultation, the agreement after the change shall prevail. In case of loans overdue (including
the Borrower&#8217;s failure to repay the loan on time or the Lender&#8217;s announcement of premature maturity) or misappropriation, the penalty
interest rate for overdue and misappropriation will be determined on the basis of the new interest rate (including the interest rate after
floating adjustment as agreed in this contract), and the interest rate for calculating compound interest will also be adjusted accordingly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">9.3.5 The implementation of
&#8220;risk repricing&#8221; shall not be deemed or interpreted as the Lender waiving other rights stipulated by laws and regulations and
agreed in this contract. The Lender has the right to take other creditor&#8217;s rights protection measures according to laws and regulations
and the contract, including but not limited to the measures agreed in Article 9.2.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;Article 10 Breach
of Contract</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">10.1 If the Borrower fails
to repay the loan principal in full and on time, pay interest or use the loan according to the purpose agreed in this contract, the Lender
will charge interest according to the penalty interest rate of overdue loans or the penalty interest rate of misappropriated loans, and
calculate compound interest on the unpaid interest payable. If the penalty interest rate is adjusted according to the contract, the interest
rate for calculating compound interest will also be adjusted accordingly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">10.2 If the Borrower fails
to repay the loan principal and pay the interest in full and on time, it shall bear the urging fees, litigation fees (or arbitration fees),
preservation fees, announcement fees, execution fees, legal fees, travel expenses and other fees paid by the Lender to realize the creditor&#8217;s
rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;Article 11 Agreement
on Deduction</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">11.1 When the Borrower authorizes
and there is the loan principal, interest, penalty interest, compound interest or other fees due and payable, the Lender has the right
to deduct the funds in any account opened by the Borrower in all branches of Bank of Communications Co., Ltd. for repayment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">11.2 After deduction, the Lender
shall notify the Borrower of the account number, contract number, number of Application for Use of Line of Credit, deduction amount and
remaining debt amount involved in deduction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">11.3 If the deduction proceeds
are not enough to pay off all the debts of the Borrower, the debts to be paid off and offset shall be determined according to this contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">11.4 If the currency of deduction
proceeds is inconsistent with that of the debt to be offset, it shall be converted into the amount of the debt to be offset according
to the exchange rate published by Bank of Communications Co., Ltd. at the time of deduction. If any foreign exchange settlement and sales
or foreign exchange conversion procedures need to be handled, the Borrower has the obligation to assist the Lender in handling the formalities
as required by the Lender, and the exchange rate risk shall be borne by the Borrower.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;Article 12 Notice</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">12.1 The contact information
(including postal address, telephone number, fax number, etc.) filled in by the Borrower in this contract is true and valid. In case of
any change of the contact information, the Borrower shall immediately mail/send the change information in writing to the postal address
filled in by the Lender in this contract. Such information change will take effect after the Lender receives the notice of change.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">12.2 Unless otherwise expressly
agreed in this contract, the Lender has the right to notice the Borrower in any of the following ways. The Lender has the right to choose
the notice method it deems appropriate, and does not need to be responsible for transmission errors, omissions or delays in postal, fax,
telephone or any other communication system. If the Lender chooses multiple notice methods at the same time, the one that arrives at the
Borrower sooner shall prevail. For the same matter, if the Lender sends more than one notice to the Borrower with different contents,
unless otherwise specified in the notice, the later notice shall prevail.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(1) For announcement, the date
when the Lender issues an announcement on its website, online banking, telephone banking or business outlets shall be regarded as the
date of delivery;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(2) For delivery by special
person, the date of receipt by the Borrower shall be regarded as the date of delivery;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(3) For delivery by post (including
express mail, ordinary mail and registered mail) to the latest known address of the Borrower, the 3rd day (in the same place)/5th day
(in different places) after the date of mailing shall be regarded as the delivery date;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(4) For fax, mobile phone short
message or other electronic communication methods to the latest known fax number of the Borrower, the mobile phone number or email address
designated by the Borrower to the Lender, the date of sending is regarded as the date of delivery. The aforementioned delivery means that
the relevant information enters the server terminal of the service provider without taking the actual display of the relevant information
in the client terminal as the standard.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">12.3 The Borrower agrees that
unless the Lender receives a written notice from the Borrower about changing its postal address, the postal address filled in by the Borrower
in this contract is the address where the court will serve judicial documents and other written documents to the Borrower. The applicable
scope of the aforementioned service address includes, but is not limited to, civil litigation first instance, jurisdiction objection and
reconsideration, second instance, retrial, remand for retrial and execution procedures, etc. If the Borrower responds to the lawsuit and
directly submits the confirmation of the service address to the court, and if the confirmed address is inconsistent with the latest known
postal address of the Lender, the court has the right to serve according to the address on the confirmation of the service address.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the settlement of this
contract dispute, the court may serve the judgment, ruling and conciliation statement to the Borrower in any of the following ways:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(1) For delivery by post (including
express mail, ordinary mail and registered mail), the date of receipt by the Borrower shall be regarded as the date of delivery;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(2) For delivery by special
person, the date on which the Borrower signs on the delivery receipt shall be regarded as the date of delivery.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the court uses delivery
by post (including express mail, ordinary mail and registered mail), and if the Borrower fails to sign on the service receipt, or the
postal address filled in by the Borrower is inaccurate or actually changed, but the Lender does not receive the written notice from the
Borrower about the change of postal address, which leads to the rejection of the judgment, ruling and conciliation statement, the date
when the statement is returned shall be regarded as the date of delivery.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the court uses delivery
by special person, and if the Borrower fails to sign on the service receipt, the date on which the server records the situation on the
service receipt on the spot shall be regarded as the date of delivery.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Except for the judgment, ruling
and conciliation statement, the court has the right to make any notice to the Borrower by any means of communication agreed in Article
12.2. The court has the right to choose the communication method it deems appropriate, and does not need to be responsible for transmission
errors, omissions or delays in postal, fax, telephone, telex or any other communication system. If the court chooses multiple modes of
communication at the same time, the one that arrives at the Borrower sooner shall prevail.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">12.4 The agreement in this
article belongs to the independent dispute settlement clause in the contract. The invalidity, cancellation or termination of this contract
will not affect the validity of this clause.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9650;&#9650;Article 13 Information
Disclosure and Confidentiality</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">13.1 For the undisclosed information
and materials of the Borrower obtained and known during the signing and performance of this contract, the use of relevant information
and materials by the Lender (including but not limited to collection, storage, use, processing, transmission, provision, disclosure, etc.)
shall not violate laws, regulations and regulatory requirements; The Lender shall bear the responsibility of confidentiality according
to law, and shall not disclose such information and materials to a third party, except for the following situations:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(1) The disclosure is required
by applicable laws and regulations;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(2) The disclosure is required
by judicial departments or regulatory agencies according to law;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(3) When the Borrower fails
to repay the loan principal and/or pay interest in full and on time, the Lender needs to disclose to the Lender&#8217;s external professional
consultant and allow the Lender&#8217;s external professional consultant to use it on the basis of confidentiality in order to realize the claims
under this contract;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(4) Other acts are reasonably
carried out to safeguard public interests or legitimate rights and interests of the Borrower;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(5) The Borrower agrees or
authorizes the Lender to make disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">13.2 The Borrower confirms
to have signed the Power of Attorney for Credit Information Inquiry and Provision. The Lender inquires, uses and saves the credit information
of the Borrower within the scope specified in the Power of Attorney.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">13.3 In addition to the situations
specified in Articles 13.1 and 13.2 of this contract, the Borrower further agrees that Bank of Communications Co., Ltd. can use or disclose
the Borrower&#8217;s information and materials in the following situations, including but not limited to the Borrower&#8217;s basic information, credit
transaction information, bad information and other related information and materials, and is willing to bear all the consequences arising
therefrom:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To disclose and allow business
outsourcing institutions, third-party service providers, other financial institutions and other institutions or individuals deemed necessary
by the Lender, including but not limited to other branches of Bank of Communications Co., Ltd., or wholly or partially owned subsidiaries
of Bank of Communications Co., Ltd., to use such information and materials on a confidential basis for the following purposes: &#9312;
To carry out or be related to bank credit business, such as promoting the credit business of Bank of Communications Co., Ltd., collecting
the Borrower&#8217;s arrears, transferring the creditor&#8217;s rights of bank credit business, etc.; &#9313; To provide or may provide new products
or services or further services for the Lender to the Borrower.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Whether Article 13.3 is applicable
or not shall be subject to the agreement of both parties in Article 24.1 of this contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Article 14 Applicable Law and
Dispute Resolution</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This contract shall be governed
by the laws of the People&#8217;s Republic of China (excluding the laws of Hongkong, Macau and Taiwan for the purpose of this contract). Any
dispute under this contract shall be brought to the court with jurisdiction where the Lender is located unless otherwise agreed in this
contract. During the dispute, all parties should continue to perform the provisions that are not involved in the dispute.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Article 15 Entry into Force,
Loan Attribute, and Composition of Contract</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">15.1 This contract shall come
into force after the legal representative (person in charge) or authorized representative of the Borrower signs (or seals) with the official
seal, and the persons in charge or authorized representative of the Lender signs (or seals) with the special contract seal. If the special
contract seal of the Lender is the special seal contract for offshore credit business (or any other special contract seal with the word
&#8220;Offshore&#8221;), the loan in this contract is an offshore business loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">15.2 The Application for Use
of Line of Credit signed when using the line of credit under this contract and other relevant documents and materials are integral parts
of this contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">15.3 The Application for Use
of Line of Credit is a supplement to this contract. Unless otherwise agreed in the Application for Use of Line of Credit, the rights and
obligations and related matters between the Borrower and the Lender shall still be implemented according to the agreement of this contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Article 16 Specific Content
of the Line of Credit</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">16.1
Currency of the line of credit: __<u>RMB</u>____; Amount in words: __<u>Eight Million One Hundred Thousand Yuan</u>___; It can be used
in </font><font style="font-family: Wingdings 2">P</font> <font style="font-family: Times New Roman, Times, Serif">Currency of the line
of credit </font><font style="font-family: Wingdings 2">&pound;</font> <font style="font-family: Times New Roman, Times, Serif">Currency
of the line of credit and other currencies accepted by the Lender; The line of credit belongs to </font><font style="font-family: Wingdings 2">P</font><font style="font-family: Times New Roman, Times, Serif">revolving
line of credit </font><font style="font-family: Wingdings 2">&pound;</font><font style="font-family: Times New Roman, Times, Serif">lump-sum
line of credit (can be used several times) </font><font style="font-family: Wingdings 2">&pound;</font><font style="font-family: Times New Roman, Times, Serif">lump-sum
line of credit (only used once).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">16.2 Purpose of the line of
credit: ___<u>Working Capital </u>__________.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">16.3 The term of credit is
from <u>06/16/2024</u> to <u>05/13/2025</u>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Article 17 Agreement on Interest
Rate</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the loan currency is other
currencies rather than RMB, US dollar, Euro, Hong Kong dollar, Japanese yen, and British pound, the relevant agreements on the determination
of the type of pricing benchmark of the loan, the calculation rule of daily interest rate and applicable date of pricing benchmark, the
adjustment date of loan interest are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">_______________<u>/</u>_______________________________________________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Article 18 Account Agreement</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">18.1
The Borrower designates the following account as the loan account, and this account </font><font style="font-family: Wingdings 2">&pound;</font><font style="font-family: Times New Roman, Times, Serif">is
</font><font style="font-family: Wingdings 2">&pound;</font><font style="font-family: Times New Roman, Times, Serif">is not a special
loan issuing account opened by the Borrower at the Lender. If both parties agree otherwise in the corresponding Application for Use of
Line of Credit, the agreement in the Application for Use of Line of Credit shall prevail.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Account Name: <u>Jiangxi Universe
Pharmaceuticals Co., Ltd.</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Account Number:*</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Bank of Deposit: <u>Business
Department of Ji&#8217;an Branch of Bank of Communications</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">18.2 Designation of the Borrower:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(1) The repayment account is</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Account Name: <u>Jiangxi Universe
Pharmaceuticals Co., Ltd.</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Account Number:*</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Bank of Deposit: <u>Business
Department of Ji&#8217;an Branch of Bank of Communications</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(2) The capital withdrawal
account is:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Account Name: <u>Jiangxi Universe
Pharmaceuticals Co., Ltd.</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Account Number: *</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Bank of Deposit: <u>Business
Department of Ji&#8217;an Branch of Bank of Communications</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Article 19 Specific Agreement
on Loan Issuance, Payment and Repayment</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">19.1
The term of each loan drawn under this contract shall not be longer than __12__ </font><font style="font-family: Wingdings 2">&pound;</font><font style="font-family: Times New Roman, Times, Serif">months
</font><font style="font-family: Wingdings 2">&pound;</font><font style="font-family: Times New Roman, Times, Serif">days, and the maturity
date of all loans shall not be later than <u>07/13/2025</u>_ .</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">19.2
The independent payment line of credit under this contract is </font><font style="font-family: Wingdings 2">&pound;</font> <font style="font-family: Times New Roman, Times, Serif">RMB
</font><font style="font-family: Wingdings 2">&pound;</font> <font style="font-family: Times New Roman, Times, Serif">___/____(foreign
currency) __/___&times;10000 Yuan or equivalent in other currencies.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">19.3 If one of the following conditions is met,
the method of the Lender&#8217;s entrusted payment shall be adopted:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: 6pt">_________<u>_/_</u>________________________________________________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: 6pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: 6pt">___<u>__ __/_</u>____________________<u>__
___</u>____________________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: 6pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">19.4 If the Borrower&#8217;s independent
payment is adopted, the Borrower shall report the payment of loan funds to the Lender within _/__ days after the loan is issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Article 20 Financial Restrictions,
External Agency Rating and Production and Operation Qualification/License</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">20.1 The Borrower&#8217;s foreign
investment line of credit is RMB __/____&times;10000 Yuan;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The increase of debt financing line of credit is RMB __/____&times;10000 Yuan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">20.2 Contract agreement on
financial indicators of the Borrower:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(1)___<u>/</u>_________________________________________________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(2) ___<u>/</u>__________________________________________________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(3) ___<u>_/__</u>_______________________________________________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">20.3 Specific agreement on external agency rating:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(1)___<u>/</u>___________________________________________________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(2) _<u>_/_</u>__________________________________________________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">20.4 Specific agreement on
the Borrower&#8217;s production and operation qualification/license:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(1) ______<u>/</u>_______________________________________________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(2) _____<u>/_</u>_______________________________________________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#9650;&#9650;Article 21 Specific Agreement on Risk
Repricing</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">21.1 This contract adopts the
following __1__ risk repricing method: (1) negotiated repricing; (2) raising the loan interest rate directly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">21.2 If the method of &#8220;raising
the loan interest rate directly&#8221; is adopted:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">21.2.1
If the loan currency is RMB, US dollar, Euro, Hong Kong dollar, Japanese yen, or British pound, the value of the interest rate plus (minus)
points after the increase is: </font><font style="font-family: Wingdings 2">&pound;</font><font style="font-family: Times New Roman, Times, Serif">no
plus or minus point </font><font style="font-family: Wingdings 2">&pound;</font><font style="font-family: Times New Roman, Times, Serif">plus
__/__ percentage points </font><font style="font-family: Wingdings 2">&pound;</font><font style="font-family: Times New Roman, Times, Serif">minus
__/__ percentage points. Unless otherwise agreed in a loan, the value of the interest rate plus (minus) points after the increase of the
loan shall be subject to the records in the applicable application for use of line of credit.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">21.2.2 If the loan currency
is another currency rather than RMB, US dollar, Euro, Hong Kong dollar, Japanese yen, and British pound, the value of the interest rate
plus (minus) points after the increase is: __/___</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Article 22 Contact Information</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The contact information of
the Borrower to receive the notice agreed in Article 12 includes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Postal Address: <u>Jingjiu
Avenue, Jinggangshan Economic and Technological Development Zone, Ji&#8217;an County, Ji&#8217;an City, Jiangxi Province</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 0.25in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
  <td style="width: 4%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:</font></td>
  <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Lai Gang</u></font></td></tr>
</table>

<p style="margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 0.25in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
  <td style="width: 8%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Postal Code:</font></td>
  <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>34300</u></font></td></tr>
</table>

<p style="margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 0.25in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
  <td style="width: 3%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel.:&nbsp;</font></td>
  <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</font></td></tr>
</table>

<p style="margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 0.25in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
  <td style="width: 10%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mobile Phone:</font></td>
  <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</font></td></tr>
</table>

<p style="margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 0.25in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
  <td style="width: 4%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax:</font></td>
  <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">__/__________________________________________________________________________________</font></td></tr>
</table>

<p style="margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 0.25in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
  <td style="width: 5%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</font></td>
  <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">__/__________________________________________________________________________________</font></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Article 23 Copies of Contract</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">There are _<u>3</u>_ originals of this contract,
with _<u>1</u>_ copy held by both parties and the guarantor (if any).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Article 24 Other Agreements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">24.1
Both parties agree that this contract </font><font style="font-family: Wingdings">&uuml;</font><font style="font-family: Times New Roman, Times, Serif">is
&nbsp;&#9744; is not applicable to Article 13.3.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">24.2 According to the
environmental and social risk evaluation standard, the Borrower &#9744; <font style="font-family: Times New Roman, Times, Serif">falls
into <font style="font-family: Wingdings">&uuml;</font></font>does not fall into the Category A or B of Client concerning environmental and social risk evaluation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="width: 0.25in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</font></td>
    <td style="border-bottom: Black 1.5pt solid; width: 40%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Jiangxi
    Universe</font></td>
    <td style="width: 60%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</font></td></tr>
  <tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</font></td></tr>
  <tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</font></td>
    <td style="border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Pharmaceuticals
    Co., Ltd.</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</font></td></tr>
  <tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</font></td></tr>
  <tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">3608013004966</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</font></td></tr>
  </table>



<p style="margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Borrower: <u>Jiangxi Universe Pharmaceutical Co.,
Ltd.</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal Representative (Person in Charge): <u>Lai
Gang</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal Address: <u>Jingjiu Avenue, Jinggangshan
Economic and Technological Development Zone, Ji&#8217;an County</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lender: Bank of Communications Co., Ltd. <u>Ji&#8217;an</u>__
(Sub) Branch</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Person in Charge: <u>Liu Shuang</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Postal Address: *</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" align="center" style="width: 75%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: Black 1.5pt solid; width: 100%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The Borrower has read through all the terms of the contract, and the Lender has made detailed explanations at the request of the Borrower. When signing the contract, the Borrower has no doubt or objection to all the contents, and understands the meaning and legal consequences of the terms of the contract, especially those marked with &#9650;&#9650;.</b></font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(This page is for signatures of the Working Capital Loan Contract and
is intentionally left blank)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 49%">Borrower (Official Seal)</td>
  <td style="width: 2%">&nbsp;</td>
  <td style="width: 49%">Lender (Special Seal for Contract)</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&nbsp;</td>
  <td>&nbsp;</td>
  <td>&nbsp;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>Jiangxi Universe </td>
  <td>&nbsp;</td>
  <td>Bank of Communications</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>Pharmaceuticals </td>
  <td>&nbsp;</td>
  <td>Co., Ltd.</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>Co., Ltd.</td>
  <td>&nbsp;</td>
  <td>(Ji&#8217;an Branch)</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>3608013004966</td>
  <td>&nbsp;</td>
  <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Special Seal for Credit Business Contract</p>

</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&nbsp;</td>
  <td>&nbsp;</td>
  <td>&nbsp;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td><p style="margin-top: 0; margin-bottom: 0">Seal of LAI</p>
      <p style="margin-top: 0; margin-bottom: 0">Gang.[seal]</p></td>
  <td>&nbsp;</td>
  <td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Seal of TONG</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Zhihong [seal]</p>
</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Working Capital Loan Contract</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>


<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Seal of LAI Gang.[seal] &nbsp; Borrower (Official Seal)</td>
    <td style="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lender (Special Seal for Contract)</font></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Legal Representative (Person in Charge) or</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Authorized Representative&nbsp;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Signature or Seal</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Person in Charge or Authorized Representative&nbsp;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Signature or Seal)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date of Signing: 06/16/2024</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date of Signing: 06/16/2024</font></td></tr>
  </table>
<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">23</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.9
<SEQUENCE>8
<FILENAME>ea022807501ex4-9_universe.htm
<DESCRIPTION>ENGLISH TRANSLATION OF THE WORKING CAPITAL LOAN CONTRACT BETWEEN JIANGXI UNIVERSE AND JIANGXI RURAL COMMERCIAL BANK, DATED APRIL 22, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.9</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">[2025] L.L.N.S.H.L.J.Z. No.: <U>17229202504221003004</U></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Working
Capital Loan Contract </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in">Borrower</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Jiangxi
                                       Universe Pharmaceuticals Co., Ltd.</U></I></FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>Lender</TD><TD STYLE="text-align: justify"><I><U>Jiangxi Luling Rural Commercial Bank Co., Ltd.</U></I></TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify; layout-grid-mode: char; font-size: 10pt"><IMG SRC="ex4-9_007.jpg" ALT=""></TD>
    <TD STYLE="vertical-align: middle; font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: left; layout-grid-mode: char"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jiangxi
    Rural Commercial Bank</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Special Notice: In order to protect the legitimate
rights and interests of the Borrower, the Lender hereby requests the Borrower to give full attention to all provisions concerning the
rights and obligations of the parties, especially those shown in bold. If the Borrower has any objection, it shall raise the objection
to the Lender. Otherwise, after this Contract is entered into by and between the Borrower and the Lender, all the terms and conditions
herein represent the true intention of both parties, are protected by law, and shall be legally binding on both parties herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Working Capital Loan Contract </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">[2025] <IMG SRC="ex4-9_008.jpg" ALT=""> <FONT STYLE="font-family: Sans-Serif; font-size: 9pt; color: Red"><B></B></FONT>LJZ
No.: <U>17229202504221003004 </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Borrower: <U>Jiangxi Universe Pharmaceutical Co.,
Ltd.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Business License No.: <U>913608217670218430</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal Representative / Person in Charge: <U>LAI
Gang </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Business Address: <U>No. 265, Jingjiu Avenue,
Jinggangshan Economic and Technological Development Zone, Ji&rsquo;an County</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mailing Address: <U>The same as above</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Postal Code: <U>343100</U>Tel.: <U>13970661293
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Electronic Contact Information (Email and WeChat
Account No.): </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lender: <U>Jiangxi Luling Rural Commercial Bank
Co., Ltd. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal Representative / Person in Charge: <U>Huang
jiaqiang </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Business Address: <U>No. 205, Fuchuan Road, Ji&rsquo;an
County</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Postal Code: <U>343100 </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel.: <U>8435534</U> Fax:_____________________ <U> </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the laws and regulations of the People&rsquo;s
Republic of China and other relevant regulations, the Borrower and the Lender have reached an agreement with respect to the matter that
the Lender grants a working capital loan to the Borrower, and hereby execute this Contract by consensus, which shall be binding on both
parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chapter 1 Execution Provisions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 1 Loan Amount and Currency </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Loan Amount (in words): <U>CNY Ten Million. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(In Figures) <U>CNY 10,000,000.00. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan amount under this Contract is: <FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9744; </FONT>revolving
borrowing limit <FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9746;</FONT> non-revolving loan amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 2 Loan Term </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The valid loan term under this Contract shall
be: <U>12</U> months from <U>April 22</U>, <U>2025</U> to <U>April 21</U>, <U>2026</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744;<FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif"> </FONT>In
the event that the loan amount hereunder is a revolving borrowing limit, the term of borrowing limit shall be the same as the valid
loan term as agreed herein. The term of each loan shall be subject to the term recorded in the loan note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9746;</FONT>  In
the event that the loan amount hereunder is a non-revolving borrowing limit, the loan term shall be the same as the valid loan term as
agreed herein. The specific loan term shall be subject to the term recorded in the loan note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If the Borrower has any default circumstance
listed in Article 19 of this Contract, and the Borrower agrees that the Lender may recover the loan in advance, then the Lender may announce
that the date of recovering the loan in advance is the due date of the loan. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 3 Loan Purpose </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan borrowed hereunder shall be used for
turnover of working <U>capital</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Without the written consent of the Lender, the
Borrower may neither change the loan purpose nor use the loan for any other purposes. The Lender shall have the right to supervise the
Borrower&rsquo;s use of the loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 4 Loan Interest Rate, Interest
Calculation and Settlement </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1.  Loan
Interest Rate </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The method as described in following Item <U>(1)</U>
shall apply for the determination of loan interest rate and a <B>simple interest calculation</B> shall be applied:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(1)  Fixed
Interest Rate. The annual interest rate shall be <U>3.6</U>%. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
loan prime rate (LPR) recently published on &#9746; the date of signature hereof &#9744; withdrawal date for <U>1</U> years&rsquo;
loan, which is 3.10, and &#9746; increased percentage points &#9744; decreased percentage points, which is <U>50</U> bp (1bp =
0.01%). The annual interest rate shall be <U>3.6</U>%. The interest rate shall remain unchanged during the loan term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(2)  Floating
Interest Rate. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
loan interest rate shall be determined by the loan prime rate (LPR) recently published on the working day before the withdrawal date
for _____ years&rsquo; loan and &#9744; increased percentage points &#9744; decreased percentage points, which is ____ bp. <B>The
increased or decreased percentage points shall remain unchanged during the term of this Contract. In case of any adjustment to the
LPR, its loan interest rate determination method shall be handled according to the following Item and the Lender will not give a
further notice to the Borrower:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9312; Annual Adjustment. From January 1 of
the next year, the loan interest rate shall be adjusted, on the basis of the LPR recently published, in accordance with the
increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9313; Annual Adjustment. From the
corresponding date of the corresponding month in the corresponding year, the loan interest rate shall be adjusted, on the basis of
the LPR recently published, in accordance with the increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9314; Quarterly Adjustment. From the
corresponding date of the first month in the corresponding quarter, the loan interest rate shall be adjusted, on the basis of the
LPR recently published, in accordance with the increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9315; Quarterly Adjustment. From the first
day of the first month in the corresponding quarter, the loan interest rate shall be adjusted, on the basis of the LPR recently
published, in accordance with the increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9316; Monthly Adjustment. From the
corresponding date of the corresponding month, the loan interest rate shall be adjusted, on the basis of the LPR recently published,
in accordance with the increased or decreased percentage points agreed herein (If there is no corresponding day in the month of
adjustment, the last day of such month shall be treated as the corresponding day);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9317; Monthly Adjustment. From the
corresponding date of the corresponding month, the loan interest rate shall be adjusted, on the basis of the LPR recently published,
in accordance with the increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9318; Immediate Adjustment. From the date
immediately following the date of the LRP recently published, the loan interest rate shall be adjusted, on the basis of the new LPR, in
accordance with the increased or decreased percentage points agreed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)  The
loan interest rate shall be determined by other methods: ________/________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If the Borrower chooses the &ldquo;(2) floating
interest rate&rdquo; method, and when the loan prime rate (LPR) of the loan market increases, the monthly repayment amount of the Borrower
will increase. If the Borrower still makes the repayment according to the repayment amount before adjustment, the monthly repayment amount
will be insufficient, resulting in penalty interest and compound interest and affecting the credit record of the Borrower. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.  Interest
Settlement Method </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower will settle the interest in a method
as described in following Item <U>(2) </U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)  Quarterly
Interest Settlement. The 20<SUP>th</SUP> day of the last month of each quarter shall be the interest settlement date, and the 21<SUP>st</SUP>
day shall be the interest payment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)  Monthly
Interest Settlement. The 20<SUP>th</SUP> day of each month shall be the interest settlement date, and the 21<SUP>st</SUP> day shall be
the interest payment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)  The
interest shall be settled by other methods: _____/__________________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the repayment date of the last
installment of loan principal is not the interest payment date, such repayment date of the last installment of loan principal shall be
the interest payment date on which the Borrower shall pay off all the interests payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.  Penalty
Interest Rate </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)  In
the event that the Borrower fails to repay the loan within the agreed time limit, interest shall be calculated and charged over the overdue
part at the penalty interest rate for overdue loan from the overdue day, until the principal and interest are paid off;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)  In
the event that the Borrower uses the loan for any purposes other than those agreed herein, interest shall be calculated and charged over
the misappropriated part at the penalty interest rate for misappropriated loan from the misappropriation date, until the principal and
interest are paid off;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)  In
the event that the loan is overdue and misappropriated, interest shall be calculated and charged at the penalty interest rate for misappropriated
loan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4)  With
respect to the interest and penalty interest that the Borrower fails to pay as scheduled, compound interest shall be calculated and charged
at the penalty interest rate agreed in this paragraph in the interest settlement method as agreed in Paragraph 2 hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5)  In
case of any adjustment to the loan interest rate agreed herein, the penalty interest and compound interest shall be calculated at the
adjusted interest rate from the adjustment date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6)  Penalty
Interest Rate</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The penalty interest rate for overdue loan shall
be <U>50</U>% higher than the loan interest rate agreed in Paragraph 1 hereof; the penalty interest rate for misappropriated loan shall
be <U>100</U>% higher than the loan interest rate agreed in Paragraph 1 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 5 Loan Disbursement and Repayment
Account </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower shall open an account as follows
with the Lender as the loan disbursement and repayment account, which shall be used for loan disbursement, payment and repayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bank of deposit: <U>Luling Rural Commercial Bank</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Account Name: <U>Jiangxi Universe Pharmaceuticals
Co., Ltd. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Account Number: <U>17229920100001758 </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 6 Repayment </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise agreed by the parties, the Borrower
shall repay the loan hereunder in accordance with the repayment schedule as set forth in Item <U>1</U> below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.  Repay
the loan hereunder in full upon the expiration of the loan term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  Repay
the loan hereunder in accordance with the following repayment schedule:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt"><B>Repayment Time </B></FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt"><B>Repayment Amount </B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">1. </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">2. </FONT></TD>
    <TD STYLE="vertical-align: top; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">3. </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">4. </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">5. </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">6. </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">7. </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">8. </FONT></TD>
    <TD STYLE="vertical-align: top; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">9. </FONT></TD>
    <TD STYLE="border: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">Total </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.  Other
Repayment Schedule: ________/____________________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.  Where
the Borrower makes repayment in advance, it shall obtain the consent from the Lender <U>3</U> banking days in advance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 7 Guarantee </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The loan hereunder shall be a <U>guaranteed</U>
(credit/ guaranteed) loan. The guarantee type shall be <U>guarantee</U> (guarantee/ mortgage/ pledge), and the guarantee contract shall
be executed separately. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 8 Contract Agreements on the
Borrower&rsquo;s Financial Indicators: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">1.</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 3in">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">2.</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">3.</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 9 Dispute Resolution </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.  After
this Contract takes effect, any dispute arising from the execution or performance hereof or in connection with this Contract shall be
settled by both parties through negotiation. If such negotiation fails, either party may file a lawsuit with the People&rsquo;s Court having
jurisdiction over the place of the Lender in accordance with the law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  During
the dispute resolution, in the event that the dispute does not affect the performance of the remaining provisions of this Contract, such
remaining provisions shall continue to be performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.  After
negotiation between the parties, the parties may conduct notarization for the compulsory enforcement of this Contract. The Borrower agrees
that this Contract shall have the compulsory enforcement effect after it is notarized. In the event that the Borrower fails to perform
its obligations under this Contract, the Lender may apply to the People&rsquo;s Court having jurisdiction for compulsory enforcement according
to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 10 Effectiveness of the Contract
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract shall take effect from the date
when both parties affix their signatures and seals hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract is made out in <U>duplicate</U>,
with <U>the Borrower, the Lender </U>holding <U>one</U> counterpart each. Each counterpart shall have the same legal effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 11 Other Agreements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 3in">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chapter 2 Standard Provisions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 12Interest Calculation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The interest shall be calculated from the Borrower&rsquo;s
actual withdrawal date and shall be calculated according to the actual withdrawal amount and use days of loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest Formula: Interest = Principal &times;
Actual Days &times; Daily Interest Rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The daily interest rate is calculated on a base
of 360 days a year. Conversion Formula: Daily Interest Rate = Annual Interest Rate / 360.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 13Loan Disbursement Conditions
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1.  The
Borrower must meet all the following conditions for loan disbursement, otherwise the Lender shall have no obligation to disburse any loan
to the Borrower, unless the Lender agrees to disburse the loan in advance: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)  The
Contract and its appendixes have become effective;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)  The
Borrower has reserved to the Lender the Borrower&rsquo;s documents, receipts, seals, lists of persons and specimen signatures in relation to
the execution and performance of this Contract and filled in the relevant vouchers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)  The
Borrower has, according to the Lender&rsquo;s requirements, opened an account necessary for the performance of this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4)  The
Borrower, within 3 banking days prior to the withdrawal, has submitted to the Lender the written withdrawal notice and the relevant supporting
documents for loan purpose which is consistent with the purpose as agreed herein, and has completed the relevant withdrawal procedures;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5)  The
Borrower has submitted to the Lender the resolution and letter of authorization of the board of directors or other competent authorities,
which agree to the execution and performance of this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6)  In
accordance with relevant regulatory provisions and management requirements of the Lender, if the loan exceeds a certain amount or meets
other conditions, the Lender shall, according to the Borrower&rsquo;s withdrawal application and payment authorization, pay the loan to the
payment object conforming to the purpose agreed herein in a manner of authorized payment by the Lender;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7)  In
addition to the credit loan, the Borrower has provided the corresponding guarantee as required by the Lender and has completed the relevant
guarantee procedures, and the guarantee is legal and valid;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8)  The
Borrower has not breached this Contract or any other contracts executed by and between the Borrower and the Lender;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  In
the event that the Borrower fails to make any withdrawal for 3 consecutive months from the contract execution date, the Lender shall be
entitled to cancel the borrowing limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 14 Special Arrangements on
Revolving Loan (Maximum Loan) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.  During
the term of revolving borrowing limit, the sum of the loan principal balance of at any time shall not exceed the revolving borrowing limit;
the repayment date of any withdrawal shall not exceed the term of revolving borrowing limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  As
agreed by both parties, the Lender shall reasonably set the amount and term of each revolving loan according to the scale and cycle of
the Borrower&rsquo;s production and operation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 15 Loan Amount Payment </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.  The
authorized payment by the Lender means that the Lender pays the loan fund to the Borrower&rsquo;s counter-party in a transaction conforming
to the purpose agreed herein according to the Borrower&rsquo;s withdrawal notice and payment authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payment of the Borrower&rsquo;s loan fund for which
the amount of a single payment under this Contract exceeds the specified amount shall be made in a manner of authorized payment by the
Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of the authorized payment by the
Lender, the Borrower shall make express payment authorization and provide other necessary payment information (including name of counter-party
who receives payment, account number of such counter-party, and amount of payment) in the withdrawal notice, and submit to the Lender
the supporting documents for loan purpose such as business contracts required for the examination. In this case, the Lender shall pay
the loan fund to the counter-party of the Borrower via the Borrower&rsquo;s account upon examination and approval. In the event of the Lender&rsquo;s
failure to perform its obligation to pay upon authorization resulting from untruthfulness, incorrectness, and incompleteness of the information
of payment authorization and relevant transactions furnished by the Borrower, the Lender shall not be held liable for such failure whatsoever
and the Borrower&rsquo;s obligation to repay under the Contract shall not be affected. The Lender will make payment to the account of the Borrower&rsquo;s
counter-party in accordance with the Borrower&rsquo;s withdrawal notice and the payment certificate as required by the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Lender, upon examination,
discovers that the supporting documents for loan purpose such as business contracts furnished by the Borrower fail to comply with the
Contract or there is any other defects, the Lender shall be entitled to request the Borrower to supplement, replace, explain or re-furnish
such documents, and the Lender may suspend granting or paying of such loans until the Borrower has furnished the supporting documents
such as business contracts to the satisfaction of the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the account-holding bank of
the counterparty returns such payments, resulting in the Lender&rsquo;s failure to transfer such loans to the Borrower&rsquo;s counterparty as authorized
by the Borrower in a timely manner, the Lender shall not be liable for such failure whatsoever and the Borrower&rsquo;s obligation to repay
under the Contract shall not be affected. With respect to the funds returned by the account-holding bank of the counterparty, the Borrower
shall re-furnish the payment authorization and the supporting documents for loan purpose such as business contracts required for the examination,
and the Lender shall pay the loan fund to the counterparty of the Borrower via the Borrower&rsquo;s account upon examination and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All the expenses incurred by the payment of loan
to the counterparty designated by the Borrower in a manner of authorized payment under this Contract shall be borne by the Borrower. The
Borrower shall pay the above expenses to the Lender at the time of the authorized payment of each loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower shall not violate the above provisions
to dodge the authorized payment by the Lender by way of breaking up a large amount into several small amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  Except
for the cases where the authorized payment by the Lender must be adopted as stipulated in the preceding paragraph, unless otherwise agreed
by both parties, payment of other loans shall be made by the Borrower itself, namely, after the Lender disburses the loans to the Borrower&rsquo;s
account pursuant to the withdrawal application submitted by the Borrower, the Borrower pay by itself to the its counterparty that complies
with the purpose as agreed in the Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Borrower needs to change
the aforesaid repayment schedule, it shall submit a written application to the Lender <U>10</U> banking days prior to the maturity date
of the loan, and the changed repayment schedule is subject to the written confirmation by the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.  In
the event that the Borrower needs to extend the loan term agreed herein, it shall submit a written application of extension to the Lender
<U>30</U> banking days prior to the maturity date of the loan, and the Lender shall decide whether to approve the extension. In applying
for the extension of a guaranteed loan, mortgage loan or pledged loan, the guarantor, mortgagor or pledgor shall also issue a written
certificate of approval. the parties shall enter into a renewal agreement after the Lender approves the extension. In the event that the
Borrower&rsquo;s application for extension is not approved by the Lender, the Borrower shall still repay the loan in full according to the repayment
term agreed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4.  Unless
otherwise agreed by the Parties, if both the principal and the interests are overdue by the Borrower, the Lender shall be entitled to
decide on the sequences for repaying the principal or the interests; under the condition of installment repayment, if several mature installments
and overdue installments exist under this Contract, the Lender shall be entitled to decide the sequences of repayment; if several outstanding
loan contracts exist between the Parties, the Lender shall be entitled to decide the sequences for repaying any contract. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.  The
Borrower shall repay the loan principal, interests and other amounts payable in full and on time according to provisions stated herein.
The Borrower shall, before the end of counter business on the repayment date and each interest settlement date, deposit in full the current
interests, principal and other amounts payable to the repayment account opened with the Lender, and the Borrower shall authorize the Lender
to collect the funds on the repayment date or the interest settlement date or the Borrower shall be required to cooperate in handling
the relevant transfer procedures. In the event that the amount in the repayment account is insufficient to pay the full amount due from
the Borrower, the Borrower shall agree that Lender is entitled to decide the sequences for repayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.  The
Lender shall be entitled to collect the loan in advance on the basis of the capital withdrawal of the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.  Loan
Note: The loan note shall be an integral part of this Contract. In the event that there is no record in this Contract, or the loan amount,
withdrawal amount, repayment amount, borrow date and maturity date of the loan, loan term, loan interest rate and loan purpose as recorded
in this Contract is inconsistent with those recorded in the loan note, the loan note shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 16 Guarantee </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that any event occurs to the Borrower
or the guarantor, and causes the Lender to believe that it may affect the performing capability of the Borrower or the guarantor; or the
guarantee contracts are deemed as invalid, canceled or resolved; or the performing capability of the Borrower or guarantor may be affected
due to the deterioration in their financial condition or that the Borrower and the guarantor are involved in substantial lawsuit or arbitration
or other reasons; or the guarantor breaches the guarantee contracts or other contracts with the Lender; or the collateral value decreases
or gets lost due to the devaluation, damage, lost or sequestration of the collateral; the Lender shall be entitled to require, and the
Borrower shall have the obligation to provide new guarantee, supplement or replace the guarantor to guarantee the liabilities under this
Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 17 Representations and
Undertakings </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.  The
Borrower is a legal entity incorporated, registered and existing under the administration for industry and commerce or other competent
authorities and has full capacity of civil rights and conduct to conclude and perform the Contract, and capacity of loan repayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  The
Borrower fully agrees to the contents and terms of this Contract, executes and performs this Contract out of true intention, has obtained
all legal and valid authorizations required by the Borrower&rsquo;s Articles of Association and bylaws, and will not be in violation of any
agreement, contract, or other legal documents with binding force to the Borrower. The Borrower has obtained or will obtain all the required
approval, consent, documentation or registration for executing and performing this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.  The
Borrower is in good faith and all the documents, financial statements, certifications and other information provided by the Borrower to
the Lender under this Contract are true, complete, accurate and valid, and free from false records, material omissions or misleading statements.
The financial and accounting reports provided to the Lender are prepared in accordance with Chinese accounting standards, and truly, fairly
and completely present the Borrower&rsquo;s operating and liability condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.  The
transaction background that the Borrower represents to the Lender is real and legal, not for any illegal purposes such as money laundering.
The loan purpose and the source of repayment are clear and legal. The loan purpose and the source of repayment are clear and legal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.  The
Borrower has a good credit status, does not have material bad credit record, and does not conceal from the Lender any fact that may affect
the Borrower&rsquo;s and the Guarantor&rsquo;s financial condition and performance capability. The Borrower does not conceal from the Lender any litigation,
arbitration or claim in which it is involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.  The
borrower has repaid other debts payable as scheduled and has not maliciously defaulted on the payment of principal and interest of the
bank loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>7.  The
Borrower shall withdraw and use the loan in accordance with the term and purpose agreed herein. The loan borrowed hereunder shall neither
be used for the investment in fixed asset and equity and other investments, nor flow into the securities market or the futures market
in any form, or be used for other purposes prohibited or restricted by relevant laws and regulations. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.  The
Borrower shall deliver its financial statements (including but not limited to annual, quarterly and monthly reports) and other relevant
documents to the Lender on a regularly and timely basis in accordance with the requirements of the Lender; the Borrower shall ensure that
the financial indicators will comply with the Contract all the time. If the production and operation qualification/license is subject
to the annual audit, such qualification/license will pass the annual examination as scheduled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9.  The
Borrower shall withdraw, repay and use the loan as stipulated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10.  If
the Borrower has executed or will execute with the guarantor under this Contract a counter-guarantee agreement or similar agreement regarding
its guarantee obligations, this counter-guarantee agreement or similar agreement will not prejudice any Lender&rsquo;s right under this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11.  The
Borrower shall accept the credit inspection and supervision conducted by the Lender, and provide sufficient assistance and cooperation;
from the effective date of this Contract and prior to discharge of the principal and interests and related expenses hereunder, the Borrower
agrees and authorizes the Lender to monitor the account opened with the Lender, examine and analyze the Borrower&rsquo;s production and operation
(including but not limited to the construction and operation of the Borrower&rsquo;s projects), and make dynamic monitoring on the income cash
flow and overall fund flow of the Borrower; <B>the Borrower shall accept and actively cooperate with the examination and supervision made
by the Lender on the usage of the loan funds including the loan purpose by account analysis, proof inspection and site investigation,
</B>and make summary report in a periodic manner as required by the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>12.  The
Borrower&rsquo;s merger, division, decrease of capital, equity transfer, external investment, substantial increase of debt financing, transfer
of material assets and claims and other events which may have adverse effect on the solvency of the Borrower shall be subject to the written
consent of the Lender. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower shall give a notice to the Lender
within <U>7</U> days after it becomes or should have become aware of any of the following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)  Change
of the Articles of Association, business scope, registered capital, legal representative of the Borrower or the guarantor;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)  Change
of management mode such as joint management in any form, cooperation with foreign enterprises, cooperation, contracting management, reorganization,
reform and planned listing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)  Involved
in material litigation or arbitration cases, sequestration, attachment or supervision of properties or collateral, or establishment of
new material liabilities on the collateral;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4)  Winding
up, dissolution, liquidation, stopping business for rectification, cancellation, revocation of business license, (applied for) applying
for bankruptcy;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5)  Shareholders,
directors and current senior managers are suspected of being involved in material cases or economic disputes; or the legal representative/person
in charge and current senior executives are found to be in bad health or other material conditions that the they are unqualified for their
job;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6)  Events
of default by the Borrower under other contracts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7)  Difficulty
in business operation and deterioration of financial position;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8)  In
the event that the Borrower is closed, suspended, merged or changes the line of production due to change, restructuring and contracting
or with the approval of the competent departments, the Borrower undertakes to give a notice to the Lender in writing within one month
prior to the occurrence of the above events and to discharge all debts owed to the Lender immediately. Subject to the consent of the Lender,
the Borrower may transfer the debts to the receiving entity or the newly incorporated entity (The Borrower shall, in the process of debt
transfer, present and submit to the Lender the documents issued by its competent authority or the contract-issuing party or relevant documents);
however, the debt receiving entity must execute a new loan contract with Lender and submit a written certificate of the corresponding
guarantor&rsquo;s approval or implement new guarantee measures, and before the execution of the new contract, the Lender shall have the right
to recover the debts from the Borrower, the Guarantor or the Borrower&rsquo;s receiver at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">13.  Liquidation
of the debts owed by the Borrower to the Lender shall have priority to the loan extended by the shareholders of the Borrower, and precede
the debts of the same kind owed by the Borrower to other creditors. In addition, from the effectiveness of the Contract to the time when
all the principal, interests and relative fees under the Contract are paid off, the Borrower shall not return the loan from its shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14.  In
respect of the loan hereunder, the loan conditions such as guarantee conditions, loan rate pricing, discharge sequence provided by the
Borrower for the Lender shall be no less than the current or future conditions provided for any other financial institution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">15.  <B>The
Borrower shall bear the expenses incurred in connection with the execution and performance of this Contract and the expenses paid and
payable by the Lender for realization of its creditor&rsquo;s right hereunder, including but not limited to litigation or arbitration fees,
property preservation costs, attorney fees, enforcement fees, evaluation fees, auction fees, and announcement fees. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>16.  Account
Management </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)  The
repayment account opened by the Borrower with the Lender (the account stipulated in Article 5) is a special capital withdrawal account,
which is used to collect the corresponding sales revenue or the planned repayment fund. Where the corresponding sales revenue is settled
in a non-cash manner, the Borrower shall ensure that it will be promptly transferred into the capital withdrawal account upon receipt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)  The
Lender shall have the right to supervise the capital withdrawal account, including but not limited to the understanding and supervision
of the fund income and expenditure of the account, and the Borrower shall provide relevant cooperation. At the request of the Lender,
the Borrower shall execute a special account supervision agreement with the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">17.  The
Borrower shall dispose the assets in a manner that will not reduce its repayment capability. The Borrower undertakes that the total amount
of the Borrower&rsquo;s external guarantee is equal to or less than _____ times of its net asset, and the total amount of external guarantee
as well as the amount of a single guarantee may not exceed the limit as stipulated in its Articles of Association; without the consent
of the Lender, the Borrower shall not provide guarantee to any third party or the loans borrowed by the Borrower from any other financial
institution with the assets formed by the loans under the Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 18 the Related-party Transaction
within the Borrower </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9744; </FONT>1.
The Borrower is not identified by the Lender as the group client in accordance with the Guidelines on the Management of Risks of
Credits Granted by Commercial Banks to Group Clients (hereinafter referred to the &ldquo;Guidelines&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9744; </FONT>2.
If the Borrower is identified by the Lender as the group client in accordance with the Guidelines, it shall report to the Lender any
of the related-party transaction in a timely manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9744; </FONT>3.
The Borrower is subject to such events as major merger, acquisition or reorganization, which in the opinion of the Lender may affect
the safety of the loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 19 Breach of Contract and
Settlement </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.  The
Borrower shall constitute or be deemed to have breached the Contract and shall be liable for breach of contract under any of the following
circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)  The
Borrower fails to perform the obligations of payment and liquidation to the Lender according to the stipulations of the Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)  The
Borrower fails to use the loan in a purpose and way stipulated in this Contract or fails to use the loan borrowed hereunder for the purpose
stipulated in the Contract; or the Borrower fails to go through the withdrawal procedures as scheduled according to the withdrawal plan,
or changes the withdrawal plan without the Lender&rsquo;s consent; or the Borrower is in violation of this Contract and dodges the authorized
payment by the Lender by way of breaking up a large amount into several small amounts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)  The
Borrower provides an untrue representation or violates the undertaking it made in this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4)  If
any circumstance under Subparagraph 12 of Article 17 arises, and the Lender believes that may affect the financial condition and performing
capability of the Borrower or guarantor, but the Borrower refuses to provide new guarantee or change a guarantor according to this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5)  The
Borrower violates any stipulation under any other contract between the Borrower and the Lender; the Borrower violates any stipulation
under any Credit Extension Contract between the Borrower and any other financial institution;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6)  The
guarantor violates the stipulations of the guarantee contract, or any default events arise under other contract between the guarantor
and the Lender;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7)  The
Borrower closes down or is dissolved, withdraw or bankrupted;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8)  Where
the Borrower involves in or possibly involves in material economic disputes, litigation, arbitration, or its capital is sealed up, seized
or enforced for execution, or the administrative organs such as judicial organs or taxation authorities, and industrial and commercial
administration file for investigation or adopt punishment measures on the Borrower according to law which has influenced or may influence
the performance of the liabilities under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(9)  Where
the main individual investors and key managerial personnel of the Borrower are changed abnormally, disappear or are investigated or the
personal freedom thereof is limited by judicial organs according to law which has influenced or may influence the performance of the liabilities
under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(10)  Where
the credit circumstances of the Borrower lowers or finance indexes of the Borrower such as profitability, debt-paying ability, operating
capacity and cash flow seriously deteriorate and break through the index binding of this Contract or other financial agreements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(11)  The
Borrower takes advantage of the false contracts between the Borrower and the affiliated party to obtain funds or credit from the Lender
through transactions without true transaction background, and the affiliated party is subject to such events as major merger, acquisition
or reorganization which in the opinion of the Lender may affect the safety of the loan; or the Borrower intends to evade the creditor&rsquo;s
right of the Lender through related-party transactions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(12)  The
Borrower causes any liability accident due to its violation of food safety, production safety, environmental protection and other relevant
laws and regulations, regulatory provisions or industrial standards which has influenced or may influence the performance of the liabilities
under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(13)  In
the event that the loan under this Contract is granted on the basis of credit rating, the Borrower&rsquo;s credit rating, profitability, asset-liability
ratio, net cash flow from operating activities and other indicators do not meet the Lender&rsquo;s credit loan conditions; or the Borrower,
without the written consent of the Lender, establishes mortgage/pledge guarantee or provide guarantee to others with its valid operating
assets, which has influenced or may influence the performance of the liabilities under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(14)  Other
circumstances that may have adverse effect on the realization of the creditor&rsquo;s rights of the Lender under this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  When
the aforesaid breaches arise, as the case maybe, the Borrower agrees that the Lender may take following measures respectively or simultaneously:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)  Require
the Borrower and guarantor to rectify their breach within time limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)  Decrease,
suspend or terminate all or part of the credit lines of the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)  Suspend
or terminate all or part of the business application (such as withdrawal) of the Borrower under this Contract or other contracts between
the Borrower and the Lender; partly or totally suspend or cancel to issue, pay and transact the unissued loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4)  Declare
that all or part of the outstanding principal and interest of the loan and other amounts payable of the Borrower under this Contract and
other contracts between the Borrower and the Lender shall become due immediately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5)  Negotiate
with the Borrower to supplement the terms of loan issuance and payment; or the Lender shall have the right to change the loan disbursement
and payment conditions in accordance with the credit status of the Borrower such as lowering the minimum amount of authorized payment
of the Borrower; or the Lender shall have the right to transfer back the loan fund which the Borrower has paid for default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6)  Terminate
or dissolve this Contract, partly or totally terminate or dissolve other contracts between the Borrower and the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7)  Require
the Borrower to compensate the Lender for the Lender&rsquo;s loss caused by the Borrower&rsquo;s default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8)  <B>Deduct
from the Borrower&rsquo;s account which is opened in the Rural Commercial Bank system within the jurisdiction of Jiangxi </B>with notice before
or after the deduction, <B>so as to discharge all or part of the Borrower&rsquo;s debts to the Lender hereunder. The undue deposit in the account
shall be deemed to become due in advance. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(9)  Exercise
security interest; and require the guarantor to take guarantee responsibility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(10)  In
the event that the Borrower fails to repay the principal, interest (including penalty interest and compound interest) or other amounts
payable as scheduled, the Lender may disclose the default information of the Borrower and the Guarantor and make an announcement for collection
through the media or other forms. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(11)  Have
the right to deduct and debit the deposits and dividends within any account opened by the Borrower in the Rural Commercial Bank system
within the jurisdiction of Jiangxi, and to dispose of the Borrower&rsquo;s equities. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(12)  Other
measures stipulated by laws and regulations and deemed necessary and possible by the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 20 Reservation of Rights </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any failure by a party to exercise all or part
of its rights hereunder or to require the other party to perform or assume all or part of obligations or responsibilities shall not constitute
a waiver of such rights or release of the obligations and responsibilities of such party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any tolerance, grace or postponement for exercising
the rights under this Contract of one Party shall not affect its rights stipulated by this Contract, laws and regulations, and shall not
be deemed as a waiver of such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 21 Confidentiality </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each party undertakes to keep confidential the
trade secrets, technical information, business information and other business secrets obtained from the other party which are not available
through public channels. Without the consent of the original provider of the trade secret, neither party shall disclose all or part of
the trade secret to any third party, unless otherwise stipulated by laws and regulations or otherwise agreed by both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that either party is in violation
of the aforesaid confidentiality obligation, it shall assume the corresponding liability for breach of contract and compensate for the
losses caused thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 22 Force Majeure </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The term Force Majeure as specified in this Contract
refers to the objective events that cannot be foreseen, overcome, or avoided and have a significant impact on one party, including but
not limited to the natural disasters such as flood, earthquake, fire and storm, as well as the social events such as war and turmoil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Contract cannot be performed
as a result of the occurrence of force majeure events, the party affected by the force majeure shall immediately notify the other party
of the event in writing, and within 7 days, provide written documents certifying the details of accident and the reasons for non-performance
or delay in performance hereof. Upon consensus through negotiation, both Parties may terminate or temporarily delay the performance of
the Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 23 Alteration, Amendment and
Termination </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract can be altered and amended in written
form upon consensus through negotiation of the Parties, and any alternation and amendment agreed on by the Parties shall constitute an
integral part of this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract may not be terminated until all
the rights and obligations are fully preformed, unless otherwise stipulated in laws and regulations or agreed by the both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The invalidity of any provision of this Contract
shall not affect the legal validity of other provisions, unless otherwise stipulated in laws and regulations or agreed by the both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 24 Agreements on Service </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.  The
contact information (including mailing address, telephone number, fax number, etc.) provided by the Borrower in this Contract shall be
true and valid and shall be the address for service of any notice of the Lender for the Borrower. In case of any change to the contact
information, the Borrower shall immediately send/mail the change information in writing to the mailing address provided by the Lender
in this Contract. Such information change shall become effective upon the Lender&rsquo;s receipt of the change notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  Unless
otherwise expressly provided for in this Contract, the Lender shall be entitled to give notice to the Borrower in any of the following
methods. The Lender shall be entitled to choose the notification method as it thinks fit and shall not be held liable for any error, omission
or delay in delivery by mail, fax, telephone, WeChat or any other communication system. Where the Lender simultaneously chooses several
notification methods, the one by which the notice is served to the Borrower earlier shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)  By
announcement. The notice shall be deemed to be served on the date on which the Lender publishes the announcement on its website, online
banking, telephone banking or business outlets;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)  By
hand. The notice shall be deemed to be served on the date on which the Borrower signs for the receipt, or if the Borrower refuses to sign
for the receipt, the date on which the server makes a record on the proof of service on the spot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)  By
mail (including express mail, surface mail or registered mail). The notice, when addressed to the Borrower&rsquo;s mailing address last known
to the Lender, shall be deemed to be served on the date on which the Borrower signs for the receipt, or if the Borrower fails to sign
for the receipt, the date on which the mail is returned;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4)  By
fax, mobile phone SMS, WeChat or other electronic communication methods. The notice, when sent to the Borrower&rsquo;s fax number, the mobile
phone number, WeChat account number or email address designated by the Borrower which is last known to the Lender, shall be deemed to
be served on the date on which the notice is sent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.  Borrower
agrees that, unless the Lender receives from the Borrower a written notice concerning the change of mailing address, the Borrower&rsquo;s domicile
stated in this Contract is the correspondence and contact address. In the future, the delivery addresses of bank statements, collection
statements, relevant legal instruments and litigation documents related to the loans under this Contract shall prevail. The Borrower promises
to notify the Lender in time when the communication and contact information change, otherwise the documents delivered by the Lender according
to the communication and contact information stated in this Contract will be effectively delivered, and the relevant economic and legal
responsibilities arising therefrom will be borne by the Borrower and the Mortgagor. During the dispute settlement, if the court serves
the judicial documents or other written documents by mail (including express mail, surface mail or registered mail) to the Borrower mailing
address last known to the Lender, such documents shall be deemed to be served on the date on which the Borrower signs for receipt of the
proof of service; or if Borrower fails to sign for receipt of the proof of service, the date on which the mail is returned;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The court or notary organ shall be entitled to
give any notice to the Borrower by any methods of communication agreed in this Paragraph 2. The court or notary organ shall be entitled
to choose the communication method as it thinks fit and shall not be held liable for any error, omission or delay in delivery by mail,
fax, telephone, telex or any other communication system. Where the court or notary organ simultaneously chooses several communication
methods, the one by which the notice is served on the Borrower earlier shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 25 Appendix </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The appendixes confirmed by both parties shall
constitute an integral part of this Contract and shall have the same legal effect as this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 26 Other Agreements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.  The
Borrower shall not transfer any rights and obligations under this Contract to the third party without written consent of the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  The
Lender has the right to transfer the creditor&rsquo;s rights under this Contract to the third party, and shall notify the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.  This
Contract shall be legally binding upon both Parties and their successors and assignees without prejudice to other provisions of this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.  All
the transactions under this Contract are carried out for each Party&rsquo;s independent benefits. If, in accordance with relevant laws, regulations
and regulatory provisions, other parties to the transaction become the related parties or affiliated persons of the Lender, no Party may
seek to affect the fairness of the transaction out of this related-party relationship.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.  The
headings and business names in this Contract are used only for convenient reference, which shall not be used to interpret the provisions
or the rights and obligations of both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.  In
accordance with relevant laws, regulations and regulatory provisions, the Lender shall have the right to provide the information related
to this Contract and other relevant information of the Borrower to the credit reference system of the People&rsquo;s Bank of China and other
credit information database established according to law for reference and use by the institutions or individuals with proper qualification
according to law. The Lender shall also have the right to refer the relevant information of the Borrower through credit reference system
of the People&rsquo;s Bank of China and other credit information database established according to law for the purpose of the execution and
performance of this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The parties acknowledge that the Borrower and
the Lender have made a full negotiation in connection with all the terms of this Contract. The Lender has requested the Borrower to give
special attention to and make a comprehensive and accurate understanding of all provisions concerning the rights and obligations of the
parties, and has made explanations to the relevant provisions upon the Borrower&rsquo;s request. The Borrower has carefully read and fully understood
all the contents and provisions of the Contract. The Borrower confirms that there is no misunderstanding or doubt about all the contents
and terms of the Contract. Both the Borrower and the Lender have the same understanding of the contents and provisions of the Contract
and have no objection to the contents and provisions of the Contract. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Borrower and the Lender have made a full
negotiation in connection with all the provisions of this Contract. The Lender has requested the Borrower to give special attention to
and make a comprehensive and accurate understanding of all provisions concerning the rights and obligations of the parties, and has made
explanations to the relevant provisions upon the Borrower&rsquo;s request. The Borrower has carefully read and fully understood all the contents
and terms of the Contract. The <FONT STYLE="border: Black 1pt solid">Borrower</FONT></B><B> confirms that there is <FONT STYLE="border: Black 1pt solid">no
misunderstanding or ambiguity </FONT></B><B>about all the contents and provisions of the <FONT STYLE="border: Black 1pt solid">Contract</FONT></B><B>.
Both the Borrower and the Lender have the same understanding of the contents and provisions of the Contract and have no objection to the
contents and provisions of the Contract. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(The Borrower shall fill in the following by
contrast) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(The remainder of this page is intentionally left
blank for signatures)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 25%; vertical-align: bottom">Borrower (Official Seal):</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 20%; text-align: center"><IMG SRC="ex4-9_001.jpg" ALT="" STYLE="height: 100px; width: 120px">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 55%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 70%; vertical-align: middle">Legal Representative or Authorized Agent (Signature &amp; Seal):</TD><TD STYLE="text-align: justify; width: 30%">&nbsp;<IMG SRC="ex4-9_003.jpg" ALT=""></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; vertical-align: bottom; width: 35%">/s/ Lai Gang</TD>
    <TD STYLE="width: 15%">&nbsp;</TD><TD STYLE="vertical-align: bottom; text-align: left; width: 50%"><U>(Signature)</U></TD>
</TR>
</TABLE>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>April 22, 2025</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 25%; vertical-align: bottom">Lender (Seal):</TD><TD STYLE="border-bottom: Black 1.5pt solid; padding-left: -0.375in; text-align: left; width: 75%">&nbsp;<IMG SRC="ex4-9_004.jpg" ALT="" STYLE="height: 112px; width: 120px"></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal Representative or Authorized Agent (Signature
&amp; Seal): &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; width: 35%; vertical-align: bottom">/s/ Luo Meng</TD>
    <TD STYLE="width: 15%">&nbsp;</TD><TD STYLE="vertical-align: bottom; text-align: left; width: 50%"><U>(Signature)</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>April 22, 2025</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40%"></TD><TD STYLE="vertical-align: bottom; width: 30%; text-align: right">Contract Execution Place:</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 30%">&nbsp;<IMG SRC="ex4-9_006.jpg" ALT=""></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.10
<SEQUENCE>9
<FILENAME>ea022807501ex4-10_universe.htm
<DESCRIPTION>ENGLISH TRANSLATION OF THE WORKING CAPITAL LOAN CONTRACT BETWEEN JIANGXI UNIVERSE AND JIANGXI RURAL COMMERCIAL BANK, DATED MARCH 3, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.10</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">[2025] J.N.S.H.J.L.Z. No.: <U>17138202503031003001</U></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Working
Capital Loan Contract </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.75in">Borrower</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U></U></I></FONT><I><U>Jiangxi Universe Pharmaceuticals Commerce and Trade Co., Ltd.</U></I> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U></U></I></FONT></TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>Lender</TD>
    <TD STYLE="text-align: justify"><I><U></U></I><I><U>Ji&rsquo;an Rural Communications Bank Co., Ltd.Jingkaiqu Branch</U></I> <I><U></U></I></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: center; layout-grid-mode: char; font-size: 10pt"><IMG SRC="ex4-10_006.jpg" ALT=""></TD>
    <TD STYLE="vertical-align: middle; font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: left; layout-grid-mode: char"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jiangxi
    Rural Commercial Bank</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Special Notice: In order to protect the legitimate
rights and interests of the Borrower, the Lender hereby requests the Borrower to give full attention to all provisions concerning the
rights and obligations of the parties, especially those shown in bold. If the Borrower has any objection, it shall raise the objection
to the Lender. Otherwise, after this Contract is entered into by and between the Borrower and the Lender, all the terms and conditions
herein represent the true intention of both parties, are protected by law, and shall be legally binding on both parties herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Working Capital Loan Contract </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">[2025] <IMG SRC="ex4-10_007.jpg" ALT="">LJZ No.: <U>17138202503031003001</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Borrower: <I><U>Jiangxi Universe Pharmaceuticals Commerce and Trade
Co., Ltd.</U></I></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Business License No.: <U>913608215508749684</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal Representative / Person in Charge: <U>LAI
Gang </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Business Address: <U>No. 265, Jingjiu Avenue,
Jinggangshan Economic and Technological Development Zone, Ji&rsquo;an County</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mailing Address: <U>The same as above</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Postal Code: <U>343100</U> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tel.:
<U>13632301188</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Electronic Contact Information (Email and WeChat
Account No.): </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lender: <U>Ji&rsquo;an Rural Communications Bank
Co., Ltd.Jingkaiqu Branch.</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal Representative / Person in Charge: <U>Zhang
Zhirong&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Business Address: <U>The northeast corner of
the intersection between Junshan Avenue and Chuangxin Avenue, Jinggangshan Economic and Technological Development Zone</U></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Postal Code: <U>343000</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel.: <U>0796-8736999</U> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fax:_____________________
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the laws and regulations of the People&rsquo;s
Republic of China and other relevant regulations, the Borrower and the Lender have reached an agreement with respect to the matter that
the Lender grants a working capital loan to the Borrower, and hereby execute this Contract by consensus, which shall be binding on both
parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chapter 1 Execution Provisions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 1 Loan Amount and Currency </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Loan Amount (in words): <U>CNY Five Million. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(In Figures) <U>CNY 5,000,000.00. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
loan amount under this Contract is: &#9744; revolving borrowing limit &#9746; non-revolving loan amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 2 Loan Term </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The valid loan term under this Contract shall be: <U>12</U> months
from <U>March 3</U>, <U>2025</U> to <U>March 2</U>, <U>2026</U>.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
In the event that the loan amount hereunder is a revolving borrowing limit, the term of borrowing limit shall be the same as the valid
loan term as agreed herein. The term of each loan shall be subject to the term recorded in the loan note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;
In the event that the loan amount hereunder is a non-revolving borrowing limit, the loan term shall be the same as the valid loan term
as agreed herein. The specific loan term shall be subject to the term recorded in the loan note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If the Borrower has any default circumstance
listed in Article 19 of this Contract, and the Borrower agrees that the Lender may recover the loan in advance, then the Lender may announce
that the date of recovering the loan in advance is the due date of the loan. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 3 Loan Purpose </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan borrowed hereunder shall be used for
turnover of working <U>capital</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Without the written consent of the Lender, the
Borrower may neither change the loan purpose nor use the loan for any other purposes. The Lender shall have the right to supervise the
Borrower&rsquo;s use of the loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 4 Loan Interest Rate, Interest
Calculation and Settlement </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1.  Loan
Interest Rate </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The method as described in following Item <U>(1)</U>
shall apply for the determination of loan interest rate and a <B>simple interest calculation</B> shall be applied:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(1)  Fixed
Interest Rate. The annual interest rate shall be <U>3.65</U>%. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
loan prime rate (LPR) recently published on &#9746; the date of signature hereof &#9744; withdrawal date for <U>1</U> years&rsquo;
loan, which is 3.1%, and &#9746; increased percentage points &#9744; decreased percentage points, which is <U>55</U> bp (1bp =
0.01%). The annual interest rate shall be <U>3.65</U>%. The interest rate shall remain unchanged during the loan term.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(2)  Floating
Interest Rate. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
loan interest rate shall be determined by the loan prime rate (LPR) recently published on the working day before the withdrawal date
for _____ years&rsquo; loan and &#9744; increased percentage points &#9744; decreased percentage points, which is ____ bp. <B>The increased
or decreased percentage points shall remain unchanged during the term of this Contract. In case of any adjustment to the LPR, its loan
interest rate determination method shall be handled according to the following Item and the Lender will not give a further notice to
the Borrower:</B></FONT><B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9312; Annual Adjustment. From January 1 of
the next year, the loan interest rate shall be adjusted, on the basis of the LPR recently published, in accordance with the
increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9313; Annual Adjustment. From the
corresponding date of the corresponding month in the corresponding year, the loan interest rate shall be adjusted, on the basis of
the LPR recently published, in accordance with the increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9314; Quarterly Adjustment. From the
corresponding date of the first month in the corresponding quarter, the loan interest rate shall be adjusted, on the basis of the
LPR recently published, in accordance with the increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9315; Quarterly Adjustment. From the first
day of the first month in the corresponding quarter, the loan interest rate shall be adjusted, on the basis of the LPR recently
published, in accordance with the increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9316; Monthly Adjustment. From the
corresponding date of the corresponding month, the loan interest rate shall be adjusted, on the basis of the LPR recently published,
in accordance with the increased or decreased percentage points agreed herein (If there is no corresponding day in the month of
adjustment, the last day of such month shall be treated as the corresponding day);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9317; Monthly Adjustment. From the
corresponding date of the corresponding month, the loan interest rate shall be adjusted, on the basis of the LPR recently published,
in accordance with the increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9318; Immediate Adjustment. From the date
immediately following the date of the LRP recently published, the loan interest rate shall be adjusted, on the basis of the new LPR, in
accordance with the increased or decreased percentage points agreed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)  The
loan interest rate shall be determined by other methods: ________/________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If the Borrower chooses the &ldquo;(2) floating
interest rate&rdquo; method, and when the loan prime rate (LPR) of the loan market increases, the monthly repayment amount of the Borrower
will increase. If the Borrower still makes the repayment according to the repayment amount before adjustment, the monthly repayment amount
will be insufficient, resulting in penalty interest and compound interest and affecting the credit record of the Borrower. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.  Interest
Settlement Method </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower will settle the interest in a method
as described in following Item <U>(2) </U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)  Quarterly
Interest Settlement. The 20<SUP>th</SUP> day of the last month of each quarter shall be the interest settlement date, and the 21<SUP>st</SUP>
day shall be the interest payment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)  Monthly
Interest Settlement. The 20<SUP>th</SUP> day of each month shall be the interest settlement date, and the 21<SUP>st</SUP> day shall be
the interest payment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)  The
interest shall be settled by other methods: _____/__________________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the repayment date of the
last installment of loan principal is not the interest payment date, such repayment date of the last installment of loan principal
shall be the interest payment date on which the Borrower shall pay off all the interests payable.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.  Penalty
Interest Rate </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)  In
the event that the Borrower fails to repay the loan within the agreed time limit, interest shall be calculated and charged over the overdue
part at the penalty interest rate for overdue loan from the overdue day, until the principal and interest are paid off;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)  In
the event that the Borrower uses the loan for any purposes other than those agreed herein, interest shall be calculated and charged over
the misappropriated part at the penalty interest rate for misappropriated loan from the misappropriation date, until the principal and
interest are paid off;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)  In
the event that the loan is overdue and misappropriated, interest shall be calculated and charged at the penalty interest rate for misappropriated
loan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4)  With
respect to the interest and penalty interest that the Borrower fails to pay as scheduled, compound interest shall be calculated and charged
at the penalty interest rate agreed in this paragraph in the interest settlement method as agreed in Paragraph 2 hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5)  In
case of any adjustment to the loan interest rate agreed herein, the penalty interest and compound interest shall be calculated at the
adjusted interest rate from the adjustment date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6)  Penalty
Interest Rate</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The penalty interest rate for overdue loan shall
be <U>30</U>% higher than the loan interest rate agreed in Paragraph 1 hereof; the penalty interest rate for misappropriated loan shall
be <U>50</U>% higher than the loan interest rate agreed in Paragraph 1 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 5 Loan Disbursement and Repayment
Account </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower shall open an account as follows
with the Lender as the loan disbursement and repayment account, which shall be used for loan disbursement, payment and repayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bank of deposit: <U>Ji&rsquo;an Rural Communications
Bank Co., Ltd.Jingkaiqu Branch</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Account Name: <U>Jiangxi Universe Pharmaceuticals
Commerce and Trade Co., Ltd.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Account Number: <U>171389101000053276</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 6 Repayment </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise agreed by the parties, the Borrower
shall repay the loan hereunder in accordance with the repayment schedule as set forth in Item <U>1</U> below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.  Repay
the loan hereunder in full upon the expiration of the loan term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  Repay
the loan hereunder in accordance with the following repayment schedule:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt"><B>Repayment Time </B></FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt"><B>Repayment Amount </B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">1. </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">2. </FONT></TD>
    <TD STYLE="vertical-align: top; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">3. </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">4. </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">5. </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">6. </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">7. </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">8. </FONT></TD>
    <TD STYLE="vertical-align: top; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">9. </FONT></TD>
    <TD STYLE="border: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">Total </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.  Other
Repayment Schedule: ________/____________________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.  Where
the Borrower makes repayment in advance, it shall obtain the consent from the Lender <U>7</U> banking days in advance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 7 Guarantee </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The loan hereunder shall be a <U>guaranteed</U>
(credit/ guaranteed) loan. The guarantee type shall be <U>guarantee</U> (guarantee/ mortgage/ pledge), and the guarantee contract shall
be executed separately. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 8 Contract Agreements on the
Borrower&rsquo;s Financial Indicators: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">1.</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 3in">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">2.</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">3.</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 9 Dispute Resolution </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.  After
this Contract takes effect, any dispute arising from the execution or performance hereof or in connection with this Contract shall be
settled by both parties through negotiation. If such negotiation fails, either party may file a lawsuit with the People&rsquo;s Court having
jurisdiction over the place of the Lender in accordance with the law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  During
the dispute resolution, in the event that the dispute does not affect the performance of the remaining provisions of this Contract, such
remaining provisions shall continue to be performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.  After
negotiation between the parties, the parties may conduct notarization for the compulsory enforcement of this Contract. The Borrower agrees
that this Contract shall have the compulsory enforcement effect after it is notarized. In the event that the Borrower fails to perform
its obligations under this Contract, the Lender may apply to the People&rsquo;s Court having jurisdiction for compulsory enforcement according
to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 10 Effectiveness of the Contract
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract shall take effect from the date
when both parties affix their signatures and seals hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract is made out in <U>duplicate</U>,
with <U>the Borrower, the Lender </U>holding <U>one</U> counterpart each. Each counterpart shall have the same legal effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 11 Other Agreements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 3in">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chapter 2 Standard Provisions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 12 Interest Calculation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The interest shall be calculated from the Borrower&rsquo;s
actual withdrawal date and shall be calculated according to the actual withdrawal amount and use days of loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest Formula: Interest = Principal &times;
Actual Days &times; Daily Interest Rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The daily interest rate is calculated on a base
of 360 days a year. Conversion Formula: Daily Interest Rate = Annual Interest Rate / 360.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 13 Loan Disbursement Conditions
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1.  The
Borrower must meet all the following conditions for loan disbursement, otherwise the Lender shall have no obligation to disburse any loan
to the Borrower, unless the Lender agrees to disburse the loan in advance: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)  The
Contract and its appendixes have become effective;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)  The
Borrower has reserved to the Lender the Borrower&rsquo;s documents, receipts, seals, lists of persons and specimen signatures in relation to
the execution and performance of this Contract and filled in the relevant vouchers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)  The
Borrower has, according to the Lender&rsquo;s requirements, opened an account necessary for the performance of this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4)  The
Borrower, within 3 banking days prior to the withdrawal, has submitted to the Lender the written withdrawal notice and the relevant supporting
documents for loan purpose which is consistent with the purpose as agreed herein, and has completed the relevant withdrawal procedures;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5)  The
Borrower has submitted to the Lender the resolution and letter of authorization of the board of directors or other competent authorities,
which agree to the execution and performance of this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6)  In
accordance with relevant regulatory provisions and management requirements of the Lender, if the loan exceeds a certain amount or meets
other conditions, the Lender shall, according to the Borrower&rsquo;s withdrawal application and payment authorization, pay the loan to the
payment object conforming to the purpose agreed herein in a manner of authorized payment by the Lender;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7)  In
addition to the credit loan, the Borrower has provided the corresponding guarantee as required by the Lender and has completed the relevant
guarantee procedures, and the guarantee is legal and valid;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8)  The
Borrower has not breached this Contract or any other contracts executed by and between the Borrower and the Lender;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  In
the event that the Borrower fails to make any withdrawal for 3 consecutive months from the contract execution date, the Lender shall be
entitled to cancel the borrowing limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 14 Special Arrangements on
Revolving Loan (Maximum Loan) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.  During
the term of revolving borrowing limit, the sum of the loan principal balance of at any time shall not exceed the revolving borrowing limit;
the repayment date of any withdrawal shall not exceed the term of revolving borrowing limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  As
agreed by both parties, the Lender shall reasonably set the amount and term of each revolving loan according to the scale and cycle of
the Borrower&rsquo;s production and operation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 15 Loan Amount Payment </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.  The
authorized payment by the Lender means that the Lender pays the loan fund to the Borrower&rsquo;s counter-party in a transaction conforming
to the purpose agreed herein according to the Borrower&rsquo;s withdrawal notice and payment authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payment of the Borrower&rsquo;s loan fund for which
the amount of a single payment under this Contract exceeds the specified amount shall be made in a manner of authorized payment by the
Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of the authorized payment by the
Lender, the Borrower shall make express payment authorization and provide other necessary payment information (including name of counter-party
who receives payment, account number of such counter-party, and amount of payment) in the withdrawal notice, and submit to the Lender
the supporting documents for loan purpose such as business contracts required for the examination. In this case, the Lender shall pay
the loan fund to the counter-party of the Borrower via the Borrower&rsquo;s account upon examination and approval. In the event of the Lender&rsquo;s
failure to perform its obligation to pay upon authorization resulting from untruthfulness, incorrectness, and incompleteness of the information
of payment authorization and relevant transactions furnished by the Borrower, the Lender shall not be held liable for such failure whatsoever
and the Borrower&rsquo;s obligation to repay under the Contract shall not be affected. The Lender will make payment to the account of the Borrower&rsquo;s
counter-party in accordance with the Borrower&rsquo;s withdrawal notice and the payment certificate as required by the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Lender, upon examination,
discovers that the supporting documents for loan purpose such as business contracts furnished by the Borrower fail to comply with the
Contract or there is any other defects, the Lender shall be entitled to request the Borrower to supplement, replace, explain or re-furnish
such documents, and the Lender may suspend granting or paying of such loans until the Borrower has furnished the supporting documents
such as business contracts to the satisfaction of the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the account-holding bank of
the counterparty returns such payments, resulting in the Lender&rsquo;s failure to transfer such loans to the Borrower&rsquo;s counterparty as authorized
by the Borrower in a timely manner, the Lender shall not be liable for such failure whatsoever and the Borrower&rsquo;s obligation to repay
under the Contract shall not be affected. With respect to the funds returned by the account-holding bank of the counterparty, the Borrower
shall re-furnish the payment authorization and the supporting documents for loan purpose such as business contracts required for the examination,
and the Lender shall pay the loan fund to the counterparty of the Borrower via the Borrower&rsquo;s account upon examination and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All the expenses incurred by the payment of loan
to the counterparty designated by the Borrower in a manner of authorized payment under this Contract shall be borne by the Borrower. The
Borrower shall pay the above expenses to the Lender at the time of the authorized payment of each loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower shall not violate the above provisions
to dodge the authorized payment by the Lender by way of breaking up a large amount into several small amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  Except
for the cases where the authorized payment by the Lender must be adopted as stipulated in the preceding paragraph, unless otherwise agreed
by both parties, payment of other loans shall be made by the Borrower itself, namely, after the Lender disburses the loans to the Borrower&rsquo;s
account pursuant to the withdrawal application submitted by the Borrower, the Borrower pay by itself to the its counterparty that complies
with the purpose as agreed in the Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Borrower needs to change
the aforesaid repayment schedule, it shall submit a written application to the Lender <U>10</U> banking days prior to the maturity date
of the loan, and the changed repayment schedule is subject to the written confirmation by the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.  In
the event that the Borrower needs to extend the loan term agreed herein, it shall submit a written application of extension to the Lender
<U>30</U> banking days prior to the maturity date of the loan, and the Lender shall decide whether to approve the extension. In applying
for the extension of a guaranteed loan, mortgage loan or pledged loan, the guarantor, mortgagor or pledgor shall also issue a written
certificate of approval. the parties shall enter into a renewal agreement after the Lender approves the extension. In the event that the
Borrower&rsquo;s application for extension is not approved by the Lender, the Borrower shall still repay the loan in full according to the repayment
term agreed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4.  Unless
otherwise agreed by the Parties, if both the principal and the interests are overdue by the Borrower, the Lender shall be entitled to
decide on the sequences for repaying the principal or the interests; under the condition of installment repayment, if several mature installments
and overdue installments exist under this Contract, the Lender shall be entitled to decide the sequences of repayment; if several outstanding
loan contracts exist between the Parties, the Lender shall be entitled to decide the sequences for repaying any contract. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.  The
Borrower shall repay the loan principal, interests and other amounts payable in full and on time according to provisions stated herein.
The Borrower shall, before the end of counter business on the repayment date and each interest settlement date, deposit in full the current
interests, principal and other amounts payable to the repayment account opened with the Lender, and the Borrower shall authorize the Lender
to collect the funds on the repayment date or the interest settlement date or the Borrower shall be required to cooperate in handling
the relevant transfer procedures. In the event that the amount in the repayment account is insufficient to pay the full amount due from
the Borrower, the Borrower shall agree that Lender is entitled to decide the sequences for repayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.  The
Lender shall be entitled to collect the loan in advance on the basis of the capital withdrawal of the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.  Loan
Note: The loan note shall be an integral part of this Contract. In the event that there is no record in this Contract, or the loan amount,
withdrawal amount, repayment amount, borrow date and maturity date of the loan, loan term, loan interest rate and loan purpose as recorded
in this Contract is inconsistent with those recorded in the loan note, the loan note shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 16 Guarantee </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that any event occurs to the Borrower
or the guarantor, and causes the Lender to believe that it may affect the performing capability of the Borrower or the guarantor; or the
guarantee contracts are deemed as invalid, canceled or resolved; or the performing capability of the Borrower or guarantor may be affected
due to the deterioration in their financial condition or that the Borrower and the guarantor are involved in substantial lawsuit or arbitration
or other reasons; or the guarantor breaches the guarantee contracts or other contracts with the Lender; or the collateral value decreases
or gets lost due to the devaluation, damage, lost or sequestration of the collateral; the Lender shall be entitled to require, and the
Borrower shall have the obligation to provide new guarantee, supplement or replace the guarantor to guarantee the liabilities under this
Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 17 Representations and
Undertakings </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.  The
Borrower is a legal entity incorporated, registered and existing under the administration for industry and commerce or other competent
authorities and has full capacity of civil rights and conduct to conclude and perform the Contract, and capacity of loan repayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  The
Borrower fully agrees to the contents and terms of this Contract, executes and performs this Contract out of true intention, has obtained
all legal and valid authorizations required by the Borrower&rsquo;s Articles of Association and bylaws, and will not be in violation of any
agreement, contract, or other legal documents with binding force to the Borrower. The Borrower has obtained or will obtain all the required
approval, consent, documentation or registration for executing and performing this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.  The
Borrower is in good faith and all the documents, financial statements, certifications and other information provided by the Borrower to
the Lender under this Contract are true, complete, accurate and valid, and free from false records, material omissions or misleading statements.
The financial and accounting reports provided to the Lender are prepared in accordance with Chinese accounting standards, and truly, fairly
and completely present the Borrower&rsquo;s operating and liability condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.  The
transaction background that the Borrower represents to the Lender is real and legal, not for any illegal purposes such as money laundering.
The loan purpose and the source of repayment are clear and legal. The loan purpose and the source of repayment are clear and legal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.  The
Borrower has a good credit status, does not have material bad credit record, and does not conceal from the Lender any fact that may affect
the Borrower&rsquo;s and the Guarantor&rsquo;s financial condition and performance capability. The Borrower does not conceal from the Lender any litigation,
arbitration or claim in which it is involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.  The
borrower has repaid other debts payable as scheduled and has not maliciously defaulted on the payment of principal and interest of the
bank loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>7.  The
Borrower shall withdraw and use the loan in accordance with the term and purpose agreed herein. The loan borrowed hereunder shall neither
be used for the investment in fixed asset and equity and other investments, nor flow into the securities market or the futures market
in any form, or be used for other purposes prohibited or restricted by relevant laws and regulations. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.  The
Borrower shall deliver its financial statements (including but not limited to annual, quarterly and monthly reports) and other relevant
documents to the Lender on a regularly and timely basis in accordance with the requirements of the Lender; the Borrower shall ensure that
the financial indicators will comply with the Contract all the time. If the production and operation qualification/license is subject
to the annual audit, such qualification/license will pass the annual examination as scheduled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9.  The
Borrower shall withdraw, repay and use the loan as stipulated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10.  If
the Borrower has executed or will execute with the guarantor under this Contract a counter-guarantee agreement or similar agreement regarding
its guarantee obligations, this counter-guarantee agreement or similar agreement will not prejudice any Lender&rsquo;s right under this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11.  The
Borrower shall accept the credit inspection and supervision conducted by the Lender, and provide sufficient assistance and cooperation;
from the effective date of this Contract and prior to discharge of the principal and interests and related expenses hereunder, the Borrower
agrees and authorizes the Lender to monitor the account opened with the Lender, examine and analyze the Borrower&rsquo;s production and operation
(including but not limited to the construction and operation of the Borrower&rsquo;s projects), and make dynamic monitoring on the income cash
flow and overall fund flow of the Borrower; <B>the Borrower shall accept and actively cooperate with the examination and supervision made
by the Lender on the usage of the loan funds including the loan purpose by account analysis, proof inspection and site investigation,
</B>and make summary report in a periodic manner as required by the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>12.  The
Borrower&rsquo;s merger, division, decrease of capital, equity transfer, external investment, substantial increase of debt financing, transfer
of material assets and claims and other events which may have adverse effect on the solvency of the Borrower shall be subject to the written
consent of the Lender. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower shall give a notice to the Lender
within <U>7</U> days after it becomes or should have become aware of any of the following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)  Change
of the Articles of Association, business scope, registered capital, legal representative of the Borrower or the guarantor;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)  Change
of management mode such as joint management in any form, cooperation with foreign enterprises, cooperation, contracting management, reorganization,
reform and planned listing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)  Involved
in material litigation or arbitration cases, sequestration, attachment or supervision of properties or collateral, or establishment of
new material liabilities on the collateral;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4)  Winding
up, dissolution, liquidation, stopping business for rectification, cancellation, revocation of business license, (applied for) applying
for bankruptcy;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5)  Shareholders,
directors and current senior managers are suspected of being involved in material cases or economic disputes; or the legal representative/person
in charge and current senior executives are found to be in bad health or other material conditions that the they are unqualified for their
job;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6)  Events
of default by the Borrower under other contracts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7)  Difficulty
in business operation and deterioration of financial position;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8)  In
the event that the Borrower is closed, suspended, merged or changes the line of production due to change, restructuring and contracting
or with the approval of the competent departments, the Borrower undertakes to give a notice to the Lender in writing within one month
prior to the occurrence of the above events and to discharge all debts owed to the Lender immediately. Subject to the consent of the Lender,
the Borrower may transfer the debts to the receiving entity or the newly incorporated entity (The Borrower shall, in the process of debt
transfer, present and submit to the Lender the documents issued by its competent authority or the contract-issuing party or relevant documents);
however, the debt receiving entity must execute a new loan contract with Lender and submit a written certificate of the corresponding
guarantor&rsquo;s approval or implement new guarantee measures, and before the execution of the new contract, the Lender shall have the right
to recover the debts from the Borrower, the Guarantor or the Borrower&rsquo;s receiver at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">13.  Liquidation
of the debts owed by the Borrower to the Lender shall have priority to the loan extended by the shareholders of the Borrower, and precede
the debts of the same kind owed by the Borrower to other creditors. In addition, from the effectiveness of the Contract to the time when
all the principal, interests and relative fees under the Contract are paid off, the Borrower shall not return the loan from its shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14.  In
respect of the loan hereunder, the loan conditions such as guarantee conditions, loan rate pricing, discharge sequence provided by the
Borrower for the Lender shall be no less than the current or future conditions provided for any other financial institution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">15.  <B>The
Borrower shall bear the expenses incurred in connection with the execution and performance of this Contract and the expenses paid and
payable by the Lender for realization of its creditor&rsquo;s right hereunder, including but not limited to litigation or arbitration fees,
property preservation costs, attorney fees, enforcement fees, evaluation fees, auction fees, and announcement fees. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>16.  Account
Management </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)  The
repayment account opened by the Borrower with the Lender (the account stipulated in Article 5) is a special capital withdrawal account,
which is used to collect the corresponding sales revenue or the planned repayment fund. Where the corresponding sales revenue is settled
in a non-cash manner, the Borrower shall ensure that it will be promptly transferred into the capital withdrawal account upon receipt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)  The
Lender shall have the right to supervise the capital withdrawal account, including but not limited to the understanding and supervision
of the fund income and expenditure of the account, and the Borrower shall provide relevant cooperation. At the request of the Lender,
the Borrower shall execute a special account supervision agreement with the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">17.  The
Borrower shall dispose the assets in a manner that will not reduce its repayment capability. The Borrower undertakes that the total amount
of the Borrower&rsquo;s external guarantee is equal to or less than _____ times of its net asset, and the total amount of external guarantee
as well as the amount of a single guarantee may not exceed the limit as stipulated in its Articles of Association; without the consent
of the Lender, the Borrower shall not provide guarantee to any third party or the loans borrowed by the Borrower from any other financial
institution with the assets formed by the loans under the Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 18 the Related-party Transaction
within the Borrower </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9744; </FONT>1.
The Borrower is not identified by the Lender as the group client in accordance with the Guidelines on the Management of Risks of
Credits Granted by Commercial Banks to Group Clients (hereinafter referred to the &ldquo;Guidelines&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9744; </FONT>2.
If the Borrower is identified by the Lender as the group client in accordance with the Guidelines, it shall report to the Lender any
of the related-party transaction in a timely manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9744; </FONT>3.
The Borrower is subject to such events as major merger, acquisition or reorganization, which in the opinion of the Lender may affect
the safety of the loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 19 Breach of Contract and
Settlement </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.  The
Borrower shall constitute or be deemed to have breached the Contract and shall be liable for breach of contract under any of the following
circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)  The
Borrower fails to perform the obligations of payment and liquidation to the Lender according to the stipulations of the Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)  The
Borrower fails to use the loan in a purpose and way stipulated in this Contract or fails to use the loan borrowed hereunder for the purpose
stipulated in the Contract; or the Borrower fails to go through the withdrawal procedures as scheduled according to the withdrawal plan,
or changes the withdrawal plan without the Lender&rsquo;s consent; or the Borrower is in violation of this Contract and dodges the authorized
payment by the Lender by way of breaking up a large amount into several small amounts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)  The
Borrower provides an untrue representation or violates the undertaking it made in this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4)  If
any circumstance under Subparagraph 12 of Article 17 arises, and the Lender believes that may affect the financial condition and performing
capability of the Borrower or guarantor, but the Borrower refuses to provide new guarantee or change a guarantor according to this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5)  The
Borrower violates any stipulation under any other contract between the Borrower and the Lender; the Borrower violates any stipulation
under any Credit Extension Contract between the Borrower and any other financial institution;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6)  The
guarantor violates the stipulations of the guarantee contract, or any default events arise under other contract between the guarantor
and the Lender;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7)  The
Borrower closes down or is dissolved, withdraw or bankrupted;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8)  Where
the Borrower involves in or possibly involves in material economic disputes, litigation, arbitration, or its capital is sealed up, seized
or enforced for execution, or the administrative organs such as judicial organs or taxation authorities, and industrial and commercial
administration file for investigation or adopt punishment measures on the Borrower according to law which has influenced or may influence
the performance of the liabilities under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(9)  Where
the main individual investors and key managerial personnel of the Borrower are changed abnormally, disappear or are investigated or the
personal freedom thereof is limited by judicial organs according to law which has influenced or may influence the performance of the liabilities
under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(10)  Where
the credit circumstances of the Borrower lowers or finance indexes of the Borrower such as profitability, debt-paying ability, operating
capacity and cash flow seriously deteriorate and break through the index binding of this Contract or other financial agreements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(11)  The
Borrower takes advantage of the false contracts between the Borrower and the affiliated party to obtain funds or credit from the Lender
through transactions without true transaction background, and the affiliated party is subject to such events as major merger, acquisition
or reorganization which in the opinion of the Lender may affect the safety of the loan; or the Borrower intends to evade the creditor&rsquo;s
right of the Lender through related-party transactions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(12)  The
Borrower causes any liability accident due to its violation of food safety, production safety, environmental protection and other relevant
laws and regulations, regulatory provisions or industrial standards which has influenced or may influence the performance of the liabilities
under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(13)  In
the event that the loan under this Contract is granted on the basis of credit rating, the Borrower&rsquo;s credit rating, profitability, asset-liability
ratio, net cash flow from operating activities and other indicators do not meet the Lender&rsquo;s credit loan conditions; or the Borrower,
without the written consent of the Lender, establishes mortgage/pledge guarantee or provide guarantee to others with its valid operating
assets, which has influenced or may influence the performance of the liabilities under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(14)  Other
circumstances that may have adverse effect on the realization of the creditor&rsquo;s rights of the Lender under this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  When
the aforesaid breaches arise, as the case maybe, the Borrower agrees that the Lender may take following measures respectively or simultaneously:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)  Require
the Borrower and guarantor to rectify their breach within time limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)  Decrease,
suspend or terminate all or part of the credit lines of the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)  Suspend
or terminate all or part of the business application (such as withdrawal) of the Borrower under this Contract or other contracts between
the Borrower and the Lender; partly or totally suspend or cancel to issue, pay and transact the unissued loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4)  Declare
that all or part of the outstanding principal and interest of the loan and other amounts payable of the Borrower under this Contract and
other contracts between the Borrower and the Lender shall become due immediately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5)  Negotiate
with the Borrower to supplement the terms of loan issuance and payment; or the Lender shall have the right to change the loan disbursement
and payment conditions in accordance with the credit status of the Borrower such as lowering the minimum amount of authorized payment
of the Borrower; or the Lender shall have the right to transfer back the loan fund which the Borrower has paid for default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6)  Terminate
or dissolve this Contract, partly or totally terminate or dissolve other contracts between the Borrower and the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7)  Require
the Borrower to compensate the Lender for the Lender&rsquo;s loss caused by the Borrower&rsquo;s default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8)  <B>Deduct
from the Borrower&rsquo;s account which is opened in the Rural Commercial Bank system within the jurisdiction of Jiangxi </B>with notice before
or after the deduction, <B>so as to discharge all or part of the Borrower&rsquo;s debts to the Lender hereunder. The undue deposit in the account
shall be deemed to become due in advance. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(9)  Exercise
security interest; and require the guarantor to take guarantee responsibility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(10)  In
the event that the Borrower fails to repay the principal, interest (including penalty interest and compound interest) or other amounts
payable as scheduled, the Lender may disclose the default information of the Borrower and the Guarantor and make an announcement for collection
through the media or other forms. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(11)  Have
the right to deduct and debit the deposits and dividends within any account opened by the Borrower in the Rural Commercial Bank system
within the jurisdiction of Jiangxi, and to dispose of the Borrower&rsquo;s equities. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(12)  Other
measures stipulated by laws and regulations and deemed necessary and possible by the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 20 Reservation of Rights </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any failure by a party to exercise all or part
of its rights hereunder or to require the other party to perform or assume all or part of obligations or responsibilities shall not constitute
a waiver of such rights or release of the obligations and responsibilities of such party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any tolerance, grace or postponement for exercising
the rights under this Contract of one Party shall not affect its rights stipulated by this Contract, laws and regulations, and shall not
be deemed as a waiver of such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 21 Confidentiality </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each party undertakes to keep confidential the
trade secrets, technical information, business information and other business secrets obtained from the other party which are not available
through public channels. Without the consent of the original provider of the trade secret, neither party shall disclose all or part of
the trade secret to any third party, unless otherwise stipulated by laws and regulations or otherwise agreed by both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that either party is in violation
of the aforesaid confidentiality obligation, it shall assume the corresponding liability for breach of contract and compensate for the
losses caused thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 22 Force Majeure </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The term Force Majeure as specified in this Contract
refers to the objective events that cannot be foreseen, overcome, or avoided and have a significant impact on one party, including but
not limited to the natural disasters such as flood, earthquake, fire and storm, as well as the social events such as war and turmoil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Contract cannot be performed
as a result of the occurrence of force majeure events, the party affected by the force majeure shall immediately notify the other party
of the event in writing, and within 7 days, provide written documents certifying the details of accident and the reasons for non-performance
or delay in performance hereof. Upon consensus through negotiation, both Parties may terminate or temporarily delay the performance of
the Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 23 Alteration, Amendment and
Termination </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract can be altered and amended in written
form upon consensus through negotiation of the Parties, and any alternation and amendment agreed on by the Parties shall constitute an
integral part of this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract may not be terminated until all
the rights and obligations are fully preformed, unless otherwise stipulated in laws and regulations or agreed by the both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The invalidity of any provision of this Contract
shall not affect the legal validity of other provisions, unless otherwise stipulated in laws and regulations or agreed by the both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 24 Agreements on Service </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.  The
contact information (including mailing address, telephone number, fax number, etc.) provided by the Borrower in this Contract shall be
true and valid and shall be the address for service of any notice of the Lender for the Borrower. In case of any change to the contact
information, the Borrower shall immediately send/mail the change information in writing to the mailing address provided by the Lender
in this Contract. Such information change shall become effective upon the Lender&rsquo;s receipt of the change notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  Unless
otherwise expressly provided for in this Contract, the Lender shall be entitled to give notice to the Borrower in any of the following
methods. The Lender shall be entitled to choose the notification method as it thinks fit and shall not be held liable for any error, omission
or delay in delivery by mail, fax, telephone, WeChat or any other communication system. Where the Lender simultaneously chooses several
notification methods, the one by which the notice is served to the Borrower earlier shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)  By
announcement. The notice shall be deemed to be served on the date on which the Lender publishes the announcement on its website, online
banking, telephone banking or business outlets;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)  By
hand. The notice shall be deemed to be served on the date on which the Borrower signs for the receipt, or if the Borrower refuses to sign
for the receipt, the date on which the server makes a record on the proof of service on the spot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)  By
mail (including express mail, surface mail or registered mail). The notice, when addressed to the Borrower&rsquo;s mailing address last known
to the Lender, shall be deemed to be served on the date on which the Borrower signs for the receipt, or if the Borrower fails to sign
for the receipt, the date on which the mail is returned;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4)  By
fax, mobile phone SMS, WeChat or other electronic communication methods. The notice, when sent to the Borrower&rsquo;s fax number, the mobile
phone number, WeChat account number or email address designated by the Borrower which is last known to the Lender, shall be deemed to
be served on the date on which the notice is sent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.  Borrower
agrees that, unless the Lender receives from the Borrower a written notice concerning the change of mailing address, the Borrower&rsquo;s domicile
stated in this Contract is the correspondence and contact address. In the future, the delivery addresses of bank statements, collection
statements, relevant legal instruments and litigation documents related to the loans under this Contract shall prevail. The Borrower promises
to notify the Lender in time when the communication and contact information change, otherwise the documents delivered by the Lender according
to the communication and contact information stated in this Contract will be effectively delivered, and the relevant economic and legal
responsibilities arising therefrom will be borne by the Borrower and the Mortgagor. During the dispute settlement, if the court serves
the judicial documents or other written documents by mail (including express mail, surface mail or registered mail) to the Borrower mailing
address last known to the Lender, such documents shall be deemed to be served on the date on which the Borrower signs for receipt of the
proof of service; or if Borrower fails to sign for receipt of the proof of service, the date on which the mail is returned;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The court or notary organ shall be entitled to
give any notice to the Borrower by any methods of communication agreed in this Paragraph 2. The court or notary organ shall be entitled
to choose the communication method as it thinks fit and shall not be held liable for any error, omission or delay in delivery by mail,
fax, telephone, telex or any other communication system. Where the court or notary organ simultaneously chooses several communication
methods, the one by which the notice is served on the Borrower earlier shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 25 Appendix </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The appendixes confirmed by both parties shall
constitute an integral part of this Contract and shall have the same legal effect as this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 26 Other Agreements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.  The
Borrower shall not transfer any rights and obligations under this Contract to the third party without written consent of the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  The
Lender has the right to transfer the creditor&rsquo;s rights under this Contract to the third party, and shall notify the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.  This
Contract shall be legally binding upon both Parties and their successors and assignees without prejudice to other provisions of this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.  All
the transactions under this Contract are carried out for each Party&rsquo;s independent benefits. If, in accordance with relevant laws, regulations
and regulatory provisions, other parties to the transaction become the related parties or affiliated persons of the Lender, no Party may
seek to affect the fairness of the transaction out of this related-party relationship.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.  The
headings and business names in this Contract are used only for convenient reference, which shall not be used to interpret the provisions
or the rights and obligations of both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.  In
accordance with relevant laws, regulations and regulatory provisions, the Lender shall have the right to provide the information related
to this Contract and other relevant information of the Borrower to the credit reference system of the People&rsquo;s Bank of China and other
credit information database established according to law for reference and use by the institutions or individuals with proper qualification
according to law. The Lender shall also have the right to refer the relevant information of the Borrower through credit reference system
of the People&rsquo;s Bank of China and other credit information database established according to law for the purpose of the execution and
performance of this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The parties acknowledge that the Borrower and
the Lender have made a full negotiation in connection with all the terms of this Contract. The Lender has requested the Borrower to give
special attention to and make a comprehensive and accurate understanding of all provisions concerning the rights and obligations of the
parties, and has made explanations to the relevant provisions upon the Borrower&rsquo;s request. The Borrower has carefully read and fully understood
all the contents and provisions of the Contract. The Borrower confirms that there is no misunderstanding or doubt about all the contents
and terms of the Contract. Both the Borrower and the Lender have the same understanding of the contents and provisions of the Contract
and have no objection to the contents and provisions of the Contract. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Borrower and the Lender have made a full
negotiation in connection with all the provisions of this Contract. The Lender has requested the Borrower to give special attention to
and make a comprehensive and accurate understanding of all provisions concerning the rights and obligations of the parties, and has made
explanations to the relevant provisions upon the Borrower&rsquo;s request. The Borrower has carefully read and fully understood all the contents
and terms of the Contract. The <FONT STYLE="border: Black 1pt solid">Borrower</FONT></B><B> confirms that there is <FONT STYLE="border: Black 1pt solid">no
misunderstanding or ambiguity </FONT></B><B>about all the contents and provisions of the <FONT STYLE="border: Black 1pt solid">Contract</FONT></B><B>.
Both the Borrower and the Lender have the same understanding of the contents and provisions of the Contract and have no objection to the
contents and provisions of the Contract. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(The Borrower shall fill in the following by
contrast) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(The remainder of this page is intentionally left
blank for signatures)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 30%; vertical-align: bottom">Borrower (Official Seal):</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 20%; text-align: center"><IMG SRC="ex4-10_001.jpg" ALT="">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 50%"><P STYLE="margin-top: 0; margin-bottom: 0"></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"></P></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">Legal Representative
or Authorized Agent (Signature &amp; Seal):</P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0in; margin-bottom: 0in; width: 100%">
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; vertical-align: middle; width: 40%">/s/ Lai Gang</TD>
    <TD STYLE="width: 10%">&nbsp;</TD><TD STYLE="text-align: justify; width: 50%"><U>(Signature)</U></TD>
</TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>March 3, 2025</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 25%; vertical-align: bottom">Lender (Seal):</TD><TD STYLE="border-bottom: Black 1.5pt solid; padding-left: -0.375in; text-align: left; width: 20%"><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="ex4-10_004.jpg" ALT="" STYLE="height: 110px; width: 120px"></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"></P></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 55%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 55%; vertical-align: bottom">Legal Representative or Authorized Agent (Signature
&amp; Seal):</TD><TD STYLE="width: 5%; text-align: left">&nbsp;</TD><TD STYLE="vertical-align: bottom; text-align: left; width: 40%"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0in; margin-bottom: 0in; width: 100%">
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; vertical-align: middle; width: 40%">/seal/ Zhang Ruirong</TD>
    <TD STYLE="width: 10%">&nbsp;</TD><TD STYLE="text-align: justify; width: 50%"></TD>
</TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>March 3, 2025</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 30%"></TD><TD STYLE="vertical-align: bottom; width: 30%; text-align: right">Contract Execution Place:</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 40%">&nbsp;<IMG SRC="ex4-10_005.jpg" ALT=""></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.11
<SEQUENCE>10
<FILENAME>ea022807501ex4-11_universe.htm
<DESCRIPTION>ENGLISH TRANSLATION OF THE CORPORATE LOAN CONTRACT BETWEEN JIANGXI UNIVERSE AND JIZHOU ZHUJIANG RURAL BANK CO., LTD., DATED APRIL 18, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.11</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Corporate Loan Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: right">No. <U>0100201202460236</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Party A (Borrower): <U>Jiangxi Universe Pharmaceuticals
Co., Ltd.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Address: No. 265, Jingjiu Avenue, Jinggangshan
Economic and Technological Development Zone, Jiangxi Province</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Zip Code: 343000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal Representative/Person in Charge: Lai Gang</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contact Person: Lai Gang</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel.: 13632301188</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fax:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Party B (Lender): Jizhou Zhujiang Rural Bank
Co., Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Address: No.33, Yangming West Road, Jizhou District</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Zip Code: 343000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal Representative/Person in Charge: Li Rongjiang</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contact Person: Xu Kai</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel.: 18679609990</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fax:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In accordance with the provisions
of relevant laws and regulations of China and on the basis of the principles of willingness, equality, mutual benefit and good faith,
this Contract is hereby made by and between Party A and Party B with the consensus through negotiation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Article 1 Amount and Currency of Loan</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The currency of the loan hereunder
is <U>RMB</U>, and the amount is: (in words) <U>RMB Two Million nine hundred thousand</U>. The loan amount referred to in this contract
refers to the limit of the loan principal balance provided by Party B to Party A during the validity period stipulated in this contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Within the credit limit, Party A can
(select can/cannot) recycle the loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 2 Purpose of Loan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The loan hereunder shall be used for
<U>the working capital of enterprise</U>, and Party A shall not change the use of the loan without Party B&rsquo;s written consent. Party
B has the right to inspect and supervise the use of the loan. Disbursement of the loan fund shall be subject to Party B&rsquo;s management
and control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The working capital loan disbursed
under this Contract shall not be used for investment in fixed assets, equity, etc., or for fields and purposes which are prohibited by
the State in terms of production and operation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 3  Loan Term </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The term from <U>April 18, 2025</U>
to <U>April 18, 2026</U>. The exact term of the loan shall be subject to the actual date of disbursement and maturity date as stated in
the loan receipt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Article 4 Interest Rate for RMB Loan</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">4.1</TD><TD STYLE="text-align: justify">Interest Rate of Loan</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The interest rate for loan hereunder
(simple interest rate, which does not affect the calculation and collection of compound interest on interest unpaid on time) shall be
implemented as stipulated in <U>Article 1</U> and Article 4.1.1 below, and shall be converted in line with the following formulas: monthly
interest rate = annual interest rate/12, daily interest rate = annual interest rate/360.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">4.1.1</TD><TD STYLE="text-align: justify">Fixed interest rate: <U>5</U>% (annual interest rate). The
said interest rate shall be calculated as follows: on the basis of the <U>1-year</U> (1 year/5 years or more) LPR of the business day
preceding <U>A</U> (A. The date of signing of the last signatory B. Loan disbursement date) of this Contract, <U>plus</U> (plus/minus)
<U>190</U> basis points (LPR, i.e., Loan Prime Rate, is the loan prime rate published by China Foreign Exchange Trade System; 1 basis
point = 0.01%, the same below). The interest rate remains unchanged during the term of the loan. In the event that the interest rate
set forth in this Contract is inconsistent with the interest rate calculated in accordance with the interest rate calculation method,
the parties hereby confirm that the interest rate set forth in this Contract shall prevail.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">4.1.2</TD><TD STYLE="text-align: justify">Floating interest rate. The annual interest rate of the first
period shall be calculated as follows: on the basis of _____ (1 year/5 years or more) LPR of the business day preceding _______ (A. The
date of signing of the last signatory B. Loan disbursement date) of this Contract, _____ (plus/minus) _____ basis points. The interest
rate is thereafter determined as follows:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Every <U>12 </U> months shall be regarded
as one interest rate adjustment cycle, and for the loan interest rate implemented for each period, corresponding LPR of the business day
preceding the corresponding day (if there is no corresponding day in the month, the last day of the month shall be the corresponding day
and such day shall be the interest rate adjustment date) in the first month of the period of the date of signing of the last signatory/loan
disbursement date (the same as the base date of the calculation method of the annual interest of the first period above) of this Contract
shall apply, and the loan interest rate shall be determined in line with the said interest rate calculation method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">4.1.3</TD><TD STYLE="text-align: justify">If the interest rate stated in the loan receipt conflicts
with the interest rate stated in this Contract, the loan receipt shall prevail.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">4.2</TD><TD STYLE="text-align: justify">The following method <U>B</U> is chosen for the settlement
and payment of interest on the loan under this Contract:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">A.</TD><TD STYLE="text-align: justify">Interest is settled and paid on a monthly basis, with the
corresponding day of the actual date of disbursement as the date of settlement and payment of interest; if there is no corresponding
day of the month, the last day of the month shall be the date of settlement and payment of interest.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">B.</TD><TD STYLE="text-align: justify">Interest is settled and paid on a monthly basis, with the
<U>20th</U> day of each month as the interest settlement date and the <U>20th</U> of each month as the interest payment date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">C.</TD><TD STYLE="text-align: justify">Interest is settled and paid on a quarterly basis, with the
___ day of the ___ month of each quarter as the interest settlement date and the ___ day of the ___ month of each quarter as the interest
payment date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">If the maturity date of the last installment
of the loan is not the interest settlement date and the interest payment date, the maturity date of the last installment of such loan
shall be the interest settlement date and the interest payment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Article 5 Withdrawal</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">5.1</TD><TD STYLE="text-align: justify">The following prerequisites must be satisfied in case of
withdrawals by Party A:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">5.1.1</TD><TD STYLE="text-align: justify">Party A has opened a repayment account with Party B;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">5.1.2</TD><TD STYLE="text-align: justify">This Contract has entered into force and Party A has completed
the administrative licenses, approvals, registrations and other legal formalities relating to the loan under this Contract in accordance
with relevant laws, regulations and rules and Party B&rsquo;s requirements;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">5.1.3</TD><TD STYLE="text-align: justify">Party A has submitted relevant documents that meet Party B&rsquo;s
requirements;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">5.1.4</TD><TD STYLE="text-align: justify">All mutually agreed formalities have been completed in respect
of the guarantee hereunder and Party B&rsquo;s mortgage and/or pledge has been established and remains in force;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">5.1.5</TD><TD STYLE="text-align: justify">The loan receipt has been signed and Party A has not violated
any of the matters as agreed in this Contract;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">5.1.6</TD><TD STYLE="text-align: justify">Up to the time of withdrawal, the representations and warranties
made by Party A due to execution of this Contract shall remain true, accurate and valid;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">5.1.7</TD><TD STYLE="text-align: justify">Up to the time of withdrawal, Party A&rsquo;s business and
financial conditions are basically the same as at the time of the signing of this Contract, and there have been no material unfavorable
changes;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">5.1.8</TD><TD STYLE="text-align: justify">For loan for which the Lender&rsquo;s entrusted disbursement
is adopted, provide relevant transaction materials and documents proving that the use of the loan is consistent with the conditions as
agreed in this Contract, as well as written documents authorizing Party B to disburse the loan fund to relevant counterparty of Party
A;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">5.1.9</TD><TD STYLE="text-align: justify">Other conditions that must be met by Party A in accordance
with the provisions of laws and regulations or Party B&rsquo;s requirements.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">5.2</TD><TD STYLE="text-align: justify">Party A chooses to withdraw the loan under this Contract
in the following manner <U>A</U>:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">A.</TD><TD STYLE="text-align: justify">Proceed on the basis of the loan receipt;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">B.</TD><TD STYLE="text-align: justify">Withdraw in a lump sum on <U>(month day, year)</U>;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">C.</TD><TD STYLE="text-align: justify">Withdraw in installments at the times and in the amounts listed
below:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>(month day, year),</U></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: justify; width: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">amount (in words) <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>(month day, year),</U></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">amount (in words) <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>(month day, year),</U></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">amount (in words) <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>(month day, year),</U></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">amount (in words) <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>(month day, year),</U></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">amount (in words) <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">5.3</TD><TD STYLE="text-align: justify">Method B below is adopted for the loan disbursement and payment
under this Contract:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">A.</TD><TD STYLE="text-align: justify">The Borrower&rsquo;s independent disbursement, i.e. Party
B disburses the loan fund directly to the loan disbursement account opened by Party A with Party B in accordance with Party A&rsquo;s
withdrawal application, then, Party A disburses the loan fund independently to the counterparty of Party A who is consistent with the
purpose as agreed in this Contract;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.65pt; text-align: justify; text-indent: -16.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">B.</TD><TD STYLE="text-align: justify">The Lender&rsquo;s entrusted disbursement, i.e. Party B, on
the basis of Party A&rsquo;s withdrawal application and disbursement entrustment, disburses the loan fund through the loan disbursement
account opened by Party A with Party B to Party A&rsquo;s counterparty who is consistent with the purpose as agreed in this Contract;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.65pt; text-align: justify; text-indent: -16.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">C.</TD><TD STYLE="text-align: justify">If the amount of a single disbursement is greater than or
equal to RMB _____ or equivalent amount in foreign currency, the Lender&rsquo;s entrusted disbursement shall be adopted, and if the amount
of a single payment does not exceed the above-mentioned standard, the Borrower&rsquo;s independent disbursement shall be adopted;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.65pt; text-align: justify; text-indent: -16.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">D.</TD><TD STYLE="text-align: justify">Other method</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.65pt; text-align: justify; text-indent: -16.3pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; text-align: justify; width: 1.5in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: justify; width: 2.5in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.65pt; text-align: justify; text-indent: -16.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">However, in the course of loan disbursement
and payment, in case of any of the following circumstances on the part of Party A, Party B has the right to supplement the conditions
of loan disbursement and payment, or to change the method of loan disbursement and payment from the Borrower&rsquo;s independent disbursement
to the Lender&rsquo;s entrusted disbursement, or to stop the disbursement and payment of the loan fund in accordance with the contractual
agreements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Decline in credit status;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">The profitability of main business is not strong;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Failure to pay the loan fund as agreed herein;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Anomalies in the use of the loan fund.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">5.4</TD><TD STYLE="text-align: justify">Regardless of which method of disbursement is adopted in
the preceding paragraph, Party A and Party B agree that the following account shall be the loan disbursement account and the principal
repayment and interest payment account under this Contract, and Party A hereby irrevocably authorizes Party B to transfer the loan to
the following account where the conditions set forth in Paragraph 6.1 above are fulfilled:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Account Name: <U>Jiangxi Universe Pharmaceuticals
Co., Ltd. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Account Bank: <U>Jizhou Zhujiang Rural
Bank</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Account No.: <U>80001837000000151</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">5.5</TD><TD STYLE="text-align: justify">Party A shall, after the conditions specified in Paragraph
1 of this Article are met, complete the disbursement procedures with Party B and sign the loan receipt with Party B as agreed in this
Contract.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">5.6</TD><TD STYLE="text-align: justify">Party B&rsquo;s disbursement in the event that Party A fails
to meet the conditions for withdrawal as agreed in the first paragraph of this Article shall not constitute a defect in Party B&rsquo;s
performance.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Article 6 Repayment</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">6.1</TD><TD STYLE="text-align: justify">Party A chooses Method <U>A</U> below to repay the principal
amount of the loan hereunder:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">A.</TD><TD STYLE="text-align: justify">The principal shall be repaid in a lump sum on the maturity
date of the loan;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">B.</TD><TD STYLE="text-align: justify">The principal shall be repaid in installments in the following
order, time, and amount:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 0.5in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1.5in; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>(month day, year),</U></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 2.5in; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">amount (in words) <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>;</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>(month day, year),</U></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">amount (in words) <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>(month day, year),</U></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">amount (in words) <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>(month day, year),</U></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">amount (in words) <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>(month day, year),</U></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">amount (in words) <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">C.</TD><TD STYLE="text-align: justify">The principal shall be repaid in a decreasing amount on a
__________ (monthly/quarterly) basis.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">D.</TD><TD STYLE="text-align: justify">The principal shall be repaid in equal amount on a __________
(monthly/quarterly) basis.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">E.</TD><TD STYLE="text-align: justify">Other: ______________________________________________________________________</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">6.2</TD><TD STYLE="text-align: justify">Party A shall deposit the repayable amount (interest and
principal) in full into the account opened with Party B before the termination of Party B&rsquo;s business hours (Beijing time) on the
repayment date (interest payment date and principal repayment date), and Party B shall have the right to transfer the amount directly
from Party A&rsquo;s account;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">6.3</TD><TD STYLE="text-align: justify">Party B shall have the right to collect the outstanding amount
repayable by Party A directly from any account opened by Party A in any institution of Jizhou Zhujiang Rural Bank Co., Ltd. If the currency
of the transferred amount is different from the currency under this Contract, it shall be converted at the selling rate announced by
Party B on the date of transfer;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">6.4</TD><TD STYLE="text-align: justify">Payments made by Party A (including payments transferred
and collected by Party B pursuant to this Contract) shall be used to satisfy the debt in the following order: costs of realizing claims
and guarantee rights, damages, liquidated damages, compound interest, overdue interest and penalty interest, interest, and principal,
and Party B shall have the right to change the abovementioned order.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">6.5</TD><TD STYLE="text-align: justify">Party A designates the account as agreed in Paragraph 6.4
of this Contract and/or the following account as the specialized fund withdrawal account and provides Party B with the information on
the capital flow of such accounts in a timely manner. Party A agrees that Party B may monitor such accounts and manage the inflow and
outflow of the withdrawn funds.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Account Name: <U>Jiangxi Universe Pharmaceuticals
Co., Ltd.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Account Bank: <U>Jizhou Zhujiang Rural
Bank</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Account No.: <U>80001837000000151</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Article 7 Early Repayment and Grace Period
of Loan</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">7.1</TD><TD STYLE="text-align: justify">Where Party A repays the principal amount of the loan in
advance, it shall submit a written application to Party B 30 days in advance, and with Party B&rsquo;s consent, it may repay the principal
amount in whole or in part in advance;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">7.2</TD><TD STYLE="text-align: justify">Party A may repay the principal in advance only if Party
A has repaid to Party B the amount due and payable. In case of early repayment of principal in part, Party A shall also settle the current
repayable amount first. For the principal Party A repays in advance, interest shall be calculated and collected as follows: interest
= the principal amount repaid in advance &times; the daily interest rate of the loan executed under this Contract at the time of early
repayment &times; the actual number of days of occupancy (from the last interest settlement date to the date of early repayment), and
interest on the loan that has been previously calculated and collected will not be adjusted.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">7.3</TD><TD STYLE="text-align: justify">The written notice of early repayment is irrevocable. If
Party A fails to repay the loan on the scheduled early repayment date, Party B has the right to calculate and collect penalty interest
at the overdue penalty interest rate.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">7.4</TD><TD STYLE="text-align: justify">In the event of early repayment by Party A, Party B shall
be entitled to charge the liquidated damages for the early repayment in accordance with Method _____ below:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">A.</TD><TD STYLE="text-align: justify">In case of early repayment within _____ months after the loan
is actually disbursed, the liquidated damages = the amount repaid in advance &times; _____%; in case of early repayment after the loan
has been actually disbursed for _____ months, the liquidated damages = the amount repaid in advance &times; _____%;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66.6pt; text-align: justify; text-indent: -24.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66.6pt; text-align: justify; text-indent: -24.25pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66.6pt; text-align: justify; text-indent: -24.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">B.</TD><TD STYLE="text-align: justify">Liquidated damages = Interest loss corresponding to the principal
amount repaid during the period from the repayment date to the maturity date x <U>____</U>_%;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66.6pt; text-align: justify; text-indent: -24.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">C.</TD><TD STYLE="text-align: justify">If the period between the early repayment date and the contractual
maturity date is more than one month (inclusive), one month&rsquo;s interest shall be charged on the principal amount repaid early as
the liquidated damages for the early repayment; if it is less than one month, interest shall be charged on the principal amount repaid
early in line with the actual number of days between the early repayment date and the contractual maturity date as the liquidated damages;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66.6pt; text-align: justify; text-indent: -24.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">D.</TD><TD STYLE="text-align: justify">Micro and small-sized enterprises are not charged.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66.6pt; text-align: justify; text-indent: -24.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">E.</TD><TD STYLE="text-align: justify">Other method:__________________________________________________________</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">________________________________________________________________________ </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">7.5</TD><TD STYLE="text-align: justify">Where Party A is unable to repay the principal and interest
of the loan under this Contract on time and needs to handle the grace period of the loan, it shall submit a written application to Party
B 30 days prior to the maturity date of the loan, and if Party B approves the grace period after review, the parties shall otherwise
sign a grace period agreement. If Party B does not agree with the grace period, Party A shall still repay the principal and interest
of the loan in accordance with this Contract.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Article 8 Guarantee of Loan</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The guarantee for the loan under this
Contract is a <U>maximum pledge and guarantee</U>, and the guarantee contract shall be signed separately. If the maximum guarantee is
adopted, the guarantee contract number is <U>2023050900085466, 2023051100086233</U>, and the additional guarantee under this Contract
is not restricted by this clause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Article 9 Rights and Obligations of Party
A</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">9.1</TD><TD STYLE="text-align: justify">Party A warrants that it is a legal entity incorporated and
validly existing in accordance with the laws, and has the right to dispose of the properties under its management and management, operate
the business related to the purpose of loan hereunder, and enter into and perform this Contract, and that its execution of this Contract
has been approved by the higher authorities or the shareholders&rsquo; meeting, the board of directors and other competent bodies of
the Company, and that it has obtained all the necessary authorizations;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">9.2</TD><TD STYLE="text-align: justify">Party A warrants that its execution and performance of this
Contract will not violate any provisions or stipulations binding on Party A and assets thereof, or the contents of any guarantee agreements,
other agreements and any other documents, stipulations and undertakings binding on Party A signed by Party A with others;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">9.3</TD><TD STYLE="text-align: justify">Party A guarantees that the loan will be used for the purpose
agreed in this Contract;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">9.4</TD><TD STYLE="text-align: justify">Party A guarantees to repay the principal and interest of
the loan as agreed in this Contract;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">9.5</TD><TD STYLE="text-align: justify">At the request of Party B, Party A shall cooperate with Party
B in pre-loan investigation, loan payment management, mid-loan review and post-loan inspection, and provide timely materials including
but not limited to:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">9.5.1</TD><TD STYLE="text-align: justify">Business license and annual inspection certificate, corporation
code certificate, legal representative&rsquo;s identity card and other necessary personal information, list of members of the board of
directors, person in charge and financial controller, operation permit, certificate of tax registration that has passed the annual inspection
by the tax department, copies of tax payment certificates from the taxation authority in light of the number of years required by Party
B, and loan certificates (cards);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">9.5.2</TD><TD STYLE="text-align: justify">Information on all account banks, account numbers and deposits
and loans;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">9.5.3</TD><TD STYLE="text-align: justify">Audited balance sheets, profit and loss statements, statements
of changes in owner&rsquo;s equity, and sales volume, cash flow statements, financial statements and notes and explanations as requested
by Party B;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">9.5.4</TD><TD STYLE="text-align: justify">Production and operation plans, statistical reports, and information
on project budget and final accounts;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">9.5.5</TD><TD STYLE="text-align: justify">All external guarantees (including to any institution of Party
B);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">9.5.6</TD><TD STYLE="text-align: justify">Information on all affiliates and related relationships, as
well as information on related transactions that have occurred and are about to occur that account for more than ten percent of its net
assets, and mutual guarantees within the group customer;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">9.5.7</TD><TD STYLE="text-align: justify">Information on lawsuits, arbitration, administrative penalties,
debt disputes with others, and criminal prosecution against individual management personnel:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">9.5.8</TD><TD STYLE="text-align: justify">Information on use of the loan under this Contract.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">9.6</TD><TD STYLE="text-align: justify">Party A shall, within thirty days prior to the date of occurrence
of the following matters, notify Party B in writing and perform the obligations to settle the debts under this Contract as agreed by
Party B in writing, or provide new guarantees approved by Party B in writing, otherwise it shall not carry out the activities described
below until it has settled all the debts under this Contract. These matters include, but are not limited to, operation activities such
as contracting, lease, trusteeship, asset restructuring, debt restructuring, equity restructuring, joint venture, consolidation (merger),
separation, equity joint venture (contractual joint venture), reduction of registered capital or filing for rectification after business
suspension, filing for dissolution (or cancellation), filing for reorganization, settlement of bankruptcy, issuance of bonds and borrowing
from a third party, and other financing activities that materially increase the indebtedness.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">9.7</TD><TD STYLE="text-align: justify">Within three days after being declared to be suspended for
rectification, declared to be shut down, declared to be dissolved (cancelled), applied for reorganization, bankruptcy and other changes
in its own system and legal status, or any other circumstances that are sufficient to jeopardize its own normal operation or the security
of Party B&rsquo;s claims, Party A shall notify Party B in writing, and at the same time, take sufficient and effective measures to preserve
Party B&rsquo;s claims.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">9.8</TD><TD STYLE="text-align: justify">Party A shall notify Party B in writing within seven days
after the change in domicile, name or legal representative or any significant change in other senior management personnel.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">9.9</TD><TD STYLE="text-align: justify">Party A shall not enter into any contract with any third
party which is detrimental to Party B&rsquo;s rights and interests under this Contract;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">9.10</TD><TD STYLE="text-align: justify">If Party A Party A belongs to a group customer, it shall
provide Party B with relevant information about the group company, including but not limited to the name, legal representative, actual
controller, place of incorporation, registered capital, main business, equity structure, situation of senior management personnel, financial
status, major asset items, guarantees and important litigations, etc. of each member of the group customer; it shall also report to Party
B in writing in a timely manner information on related transactions accounting for more than ten percent (inclusive) of its net assets,
including but not limited to the association relationship of the parties to the transaction, the transaction items and the nature of
transaction, the transaction amount or corresponding ratio and the pricing policy for the transaction;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">9.11</TD><TD STYLE="text-align: justify">In the event of guarantee, Party A shall immediately provide
a new guarantee recognized by Party B or repay the loan under this Contract in advance to the extent that the guarantor violates any
obligation or undertaking hereunder or loses the guarantee ability.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">9.12</TD><TD STYLE="text-align: justify">If the loan hereunder are secured by a third party guarantee,
Party A shall, in the event of any abnormality of the guarantor, including but not limited to being seriously ill, missing or declared
to be missing, dead or declared to be dead (applicable if the guarantor is a natural person), or shut-down, dissolution, liquidation,
bankruptcy, reorganization, reconciliation, rectification and/or similar legal proceedings (applicable if the guarantor is a company),
notify Party B in writing of the event within 7 days from the occurrence of the event, and provide an alternative guarantee to Party
B&rsquo;s satisfaction as requested by Party B.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">9.13</TD><TD STYLE="text-align: justify">Party A undertakes to provide necessary documents and materials
as requested by Party B and to ensure that the documents and materials provided are true, accurate, legal and effective.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">9.14</TD><TD STYLE="text-align: justify">Party A undertakes that the energy conservation and emission
reduction of the projects supported by the loan fund under this Contract shall be in compliance with national laws and regulations and
the provisions of the regulatory authorities, and that Party A shall submit an environmental and social risk report if significant environmental
and social risks are involved.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">If Party A fails to fulfill its commitment
or the risk of energy consumption or pollution arises, Party B may take the following measures: suspend this Contract; accelerate the
recovery of the loan hereunder; and announce the early maturity of the loan hereunder. Where Party B takes the aforesaid measures, Party
A agrees that Party B may exercise relevant guarantee rights in advance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">9.15</TD><TD STYLE="text-align: justify">Party A undertakes to notify Party B in a timely manner in
the event of material adverse events affecting Party A&rsquo;s solvency.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">9.16</TD><TD STYLE="text-align: justify">Party A undertakes to cooperate for Party B&rsquo;s inspection
related to the loan and summarize and report the payments of the loan fund on a regular basis as required by Party B. Party B has the
right to check whether the payment of the loan is in line with the agreed purpose through account analysis, voucher checking, on-site
investigation, etc.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">9.17</TD><TD STYLE="text-align: justify">If Party A uses the house as collateral, Party A shall promptly
inform Party B provided that Party B is aware that the mortgaged house will be demolished or relocated. If Party A fails to inform Party
B in a timely manner and the mortgaged property is lost, Party B has the right to stop releasing the loan or recover the loan in advance.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">9.18</TD><TD STYLE="text-align: justify">In order to strengthen the monitoring on the settlement cash
flow of Party A&rsquo;s business income and prevent the credit risk of Party B, Party A agrees to cooperate for Party B&rsquo;s monitoring
on Party A&rsquo;s settlement cash flow, and Party A undertakes that, in the settlement limit for all banks, the proportion for Party
B shall not be less than _____%.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Article 10 Rights and Obligations of Party
B</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">10.1</TD><TD STYLE="text-align: justify">Party B has the right to request Party A to provide information
in connection with the loan under this Contract.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">10.2</TD><TD STYLE="text-align: justify">Party B has the right to supervise and inspect the use of
the loan under this Contract, and understand Party A&rsquo;s business activities, financial status, provision of guarantees and debt
disputes, etc., and the right to request Party A to report or inform the payments of the loan on a regular basis, and Party B has the
right to verify whether the payments of the loan are in line with the agreed purpose through account analysis, voucher checking, on-site
investigation, etc.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">10.3</TD><TD STYLE="text-align: justify">Provided that Party A has fully performed the obligations
set out in this Contract and satisfied the conditions for withdrawal, Party B shall release the loan to Party A in accordance with the
term and amount determined in the loan receipt signed by the parties, except for delays due to reasons attributable to Party A.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">10.4</TD><TD STYLE="text-align: justify">Party B shall keep confidential the information and circumstances
provided by Party A relating to its debts, finance, production and operation, unless otherwise provided by laws and regulations.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">10.5</TD><TD STYLE="text-align: justify">Where Party B changes its domicile during the validity of
this Contract, it shall promptly publish an announcement of the change in address.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">10.6</TD><TD STYLE="text-align: justify">Party B has the right to recover the loan in advance in accordance
with Party A&rsquo;s fund withdrawal situation.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">10.7</TD><TD STYLE="text-align: justify">If Party A is liable to Party B for a number of debts and
Party A&rsquo;s payment is not sufficient to settle all the debts, Party A agrees that Party B has the right to specify the order of
performance of the debts at the time of repayment by Party A.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Article 11 Entry into Force, Modification
and Rescission of Contract</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">11.1</TD><TD STYLE="text-align: justify">This Contract shall enter into force as of the date on which
it is signed or sealed by the parties, and in the event of any discrepancy between the dates of signing/sealing of the parties, this
Contract shall enter into force on the date on which it is signed or sealed by the last party;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">11.2</TD><TD STYLE="text-align: justify">After this Contract comes into force, neither Party A nor
Party B may change this Contract without authorization. If any change is required, Party A and Party B shall conclude a written modification
agreement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">11.3</TD><TD STYLE="text-align: justify">During the performance of this Contract, in the event of
any of the following circumstances, Party B has the right to suspend or rescind this Contract, recover the principal and interest of
the loan released in advance and stop releasing the loan, and require Party A to compensate for all the losses caused to Party B as a
result of its breach of contract and bear all the expenses incurred by Party B for realization of its claims (including, but not limited
to, litigation costs, attorney&rsquo;s fees, property preservation fees, travel costs, execution fees, appraisal fees, auction fees,
etc.);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.3.1</TD><TD STYLE="text-align: justify">Party A delays the repayment and payment of the principal
and interest on any of the loans under this Contract;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.3.2</TD><TD STYLE="text-align: justify">Party A&rsquo;s operation and financial condition deteriorates,
making Party A unable to settle its debts as they fall due;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.3.3</TD><TD STYLE="text-align: justify">Party A is involved in economic or other legal disputes, thus
Party A is subject to litigation or arbitration;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.3.4</TD><TD STYLE="text-align: justify">Others have taken seizure or freezing measure against the
mortgaged (pledged) property corresponding to the loan;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.3.5</TD><TD STYLE="text-align: justify">There is a serious crisis in the overall credit status, operation
condition and financial condition of the group customer to which Party A belongs, which poses a significant threat to the security of
Party B&rsquo;s loan;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.3.6</TD><TD STYLE="text-align: justify">Party A goes out of business, is dissolved, shuts down, has
its business license revoked, or is canceled, etc.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.3.7</TD><TD STYLE="text-align: justify">Party A fails to use the loan for the purpose agreed herein
or fails to pay the principal, interest and other payables in full and on time;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.3.8</TD><TD STYLE="text-align: justify">Party A fails to make payments of the loan funds in accordance
with this Contract;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.3.9</TD><TD STYLE="text-align: justify">Party A provides Party B with the loan materials such as balance
sheets and profit and loss statements which are false or conceal material facts, or conceals material operation and financial facts;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.3.10</TD><TD STYLE="text-align: justify">Party A refuses to accept Party B&rsquo;s supervision and
inspection on its use of the loan and related production, operation and financial activities;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.3.11</TD><TD STYLE="text-align: justify">Party A uses the loan fund to engage in speculative operations
in marketable securities, futures, real estate, etc., or other unlawful or illegal transactions;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.3.12</TD><TD STYLE="text-align: justify">Party A deceives of the loan for borrowing and lending for
illegal income;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.3.13</TD><TD STYLE="text-align: justify">Party A adopts fraudulent means to obtain the loan;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.3.14</TD><TD STYLE="text-align: justify">Party A intends to evade Party B&rsquo;s claims through related
transactions;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.3.15</TD><TD STYLE="text-align: justify">Party A&rsquo;s mode of operation, own system or legal status
changes, including but not limited to contracting, lease, trusteeship, asset restructuring, debt restructuring, shareholding system reform,
joint venture, consolidation (merger), acquisition, separation, paid property ownership transfer, equity joint venture (contractual joint
venture), reduction of registered capital or application for rectification after business suspension, application for dissolution (or
revocation), application for reorganization, reconciliation and bankruptcy, etc.; Party A implements the debt repayment responsibility
hereunder or provide new guarantees recognized by Party B without Party B&rsquo;s written consent;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.3.16</TD><TD STYLE="text-align: justify">The guarantee under this Contract has changed to the detriment
of Party B&rsquo;s claim, including but not limited to the destruction, loss, or reduction in value of the collateral or pledge, or the
guarantor&rsquo;s breach of any of the obligations set for the guarantor in the guarantee contract, and Party A fails to provide a new
guarantee as required by Party B;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.3.17</TD><TD STYLE="text-align: justify">The guarantee contract or other guarantee form is not in force,
invalid, or declared revoked, or the guarantor becomes partially or totally incapable of guaranteeing or expressly refuses to fulfill
its guarantee obligations, or the guarantor is in breach of any of its obligations or undertakings as agreed in the guarantee contract
or in breach of the contract it has entered into with a third party, and Party A fails to separately provide a new guarantee as required
by Party B;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.3.18</TD><TD STYLE="text-align: justify">The representations and warranties made by Party A are untrue,
inaccurate or conceal material facts, or Part A fails to comply with its undertakings under this Contract;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.3.19</TD><TD STYLE="text-align: justify">Party A breaks the constraints of the financial indicators
agreed with Party B;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.3.20</TD><TD STYLE="text-align: justify">A material cross-default occurs in respect of Party A;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.3.21</TD><TD STYLE="text-align: justify">Party A expressly or by its own behavior indicates that it
will not perform its obligations under this Contract; other circumstances occur that may lead to a threat to the realization of Party
B&rsquo;s claims under this Contract or serious losses.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.3.22</TD><TD STYLE="text-align: justify">Party A violates other obligations stipulated (including,
but not limited to, this Contract, the supplementary agreement, the reorganization agreement, the grace period agreement, the escrow
agreement, the commitment letter, etc.).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">11.4</TD><TD STYLE="text-align: justify">If Party A violates the provisions in Paragraph 10.18 of
this Contract, Party B, in addition to having the right to take measures as agreed in the preceding paragraph, also has the right to
increase the loan interest rate agreed in this Contract by <U>50</U> % from the month following the month in which the aforesaid violation
occurs.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">11.5</TD><TD STYLE="text-align: justify">If the number of defaults by Party A, such as default in
interest payment, reaches three times cumulatively, Party B, in addition to having the right to take measures as agreed in Paragraph
12.3 of this Contract, also has the right to increase the loan interest rate as agreed herein by <U>100</U>% from the month following
the month in which the aforesaid defaults have cumulatively reached three times.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Article 12 Liabilities for Breach of Contract</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">12.1</TD><TD STYLE="text-align: justify">If corresponding guarantee formalities under this Contract
are not completed as agreed due to reasons attributable to Party A or the guarantor hereunder, or Party A fails to complete the withdrawal
formalities with Party B at the time agreed in this Contract, and the time has exceeded 30 days (including legal holidays and rest days)
after the date of disbursement of the loan as agreed in this Contract, Party B has the right to rescind this Contract and recover the
loan disbursed in advance.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">12.2</TD><TD STYLE="text-align: justify">If Party A fails to repay the principal amount of the loan
due and payable (including early maturity) in accordance with the repayment period as agreed herein, from the date of delay, interest
shall be calculated and collected at the interest rate agreed herein plus 50% as a penalty interest rate: for the interest that Party
A fails to pay on time, compound interest shall be calculated and collected at the penalty interest rate as agreed in the present paragraph.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">12.3</TD><TD STYLE="text-align: justify">If Party A does not use the loan in line with the purpose
of loan as agreed in this Contract (including but not limited to sub-lending the loan fund or purchasing other financial products for
arbitrage), fails to expend the loan fund in the agreed manner, fails to comply with the commitments, submits the loan application documents
with false information, breaks through the constraints of the stipulated financial indicators and breaches other obligations as agreed,
Party B has the right to increase the interest rate as agreed herein by <U>100</U>% as penalty interest rate to calculate and collect
the penalty and compound interest on the principal and interest of the loan from the date of breach by Party A.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">12.4</TD><TD STYLE="text-align: justify">In the event that a loan under this Contract is overdue or
not utilized for the purpose as agreed in this Contract, overdue, penalty and compound interest shall be charged on a monthly basis.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">12.5</TD><TD STYLE="text-align: justify">If the same loan is both overdue and misappropriated, the
penalty interest rate shall be the higher.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">12.6</TD><TD STYLE="text-align: justify">If Party B is unable to release credit loan to Party A in
accordance with this Contract due to reasons unattributable to Party B, such as the credit line obtained by Party A from Party B exceeding
the credit line that Party B may grant to a single customer or a group customer, or regulatory requirements such as the regulatory authorities&rsquo;
control on the limit of loan of the government financing platforms, or the regulatory authorities&rsquo; restrictions on the size of
loan released by Party B, Party B shall not bear the liabilities for breach of contract for failure to release the credit loan.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Article 13 Transfer</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">13.1</TD><TD STYLE="text-align: justify">Party B may assign its rights hereunder to any third party
without prior consent of Party A;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">13.2</TD><TD STYLE="text-align: justify">Without Party B&rsquo;s prior written consent, Party A shall
not assign any of its rights or obligations under this Contract to any third party.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Article 14 Settlement of Dispute</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">All disputes between Party A and Party
B arising out of this Contract shall be settled through negotiation, and if the negotiation fails, either party may settle the dispute
in accordance with Method <U>A</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">A.</TD><TD STYLE="text-align: justify">File a lawsuit with relevant competent people&rsquo;s court
in the place where Party B is located;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">B.</TD><TD STYLE="text-align: justify">Submit the dispute to the _____ Arbitration Commission for
arbitration.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Article 15 Notice and Service</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">15.1</TD><TD STYLE="text-align: justify">Notices, letters, etc. sent by one party to the other under
this Contract shall be sent to the address and contact person first written above. If one party changes its name, address, contact person
and contact number, it shall promptly notify the other party in writing of the change within 5 days after the change, and the service
before the other party actually receives the notice of the change shall still be valid service. In case of failure to notify the change
in the agreed manner, the original party, service address, contact person and contact number remain valid.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">15.2</TD><TD STYLE="text-align: justify">Notices, letters and other written materials sent by one
party to the other party shall be deemed to have been served on the third day after they are posted. If the date of service falls on
a day that is not a business day, it shall be deemed to have been served on the next business day.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">15.3</TD><TD STYLE="text-align: justify">The addresses and contact persons specified in this Contract
shall also be the addresses for the parties&rsquo; work contacts and the service of legal documents and legal instruments from relevant
people&rsquo;s court or arbitration institution in the event of dispute settlement, and if various litigation materials issued by relevant
people&rsquo;s court or arbitration institution (including the complaint, evidentiary materials, summons for the court hearing, various
notices, and judgments, etc.) are served on the other party hereto at the said address, it shall be deemed as valid service. The abovementioned
service address is continuously applicable during the period for the main contract performance, first instance, second instance and retrial
and enforcement by relevant people&rsquo;s court, and arbitration and award enforcement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">15.4</TD><TD STYLE="text-align: justify">Where the parties hereto or relevant people&rsquo;s court
or arbitration institution mail or send relevant documents to the other party at the abovementioned service address for performance,
modification, rescission and dispute settlement of the main contract, the date of return of the documents shall be regarded as the date
of service in the event of failure in service (including but not limited to no one signing for the documents, unknown address, relocation
of address, or failure to pick up the documents for a long time); and where the documents are directly served at the foregoing mailing
address, the date when the serving person indicates relevant situation in the proof of service or the documents are left or posted shall
be deemed as the date of service in the event of failure in service (including, but not limited to, no one signing for the documents,
unknown address, relocation of address, rejection of the documents, etc.).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">15.5</TD><TD STYLE="text-align: justify">The parties confirm that the contract number, names and addresses
of service are filled in by the parties on their own, and clearly knows that if the parties or relevant people&rsquo;s court or arbitration
institution serves the documents at the abovementioned addresses, even if the service fails, the legal consequences of constructive service
also arise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">15.6</TD><TD STYLE="text-align: justify">The service clause and the dispute settlement clause are
independent and not affected by the validity of this Contract as a whole or any other clause.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Article 16 Supplementary Provisions</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">16.1</TD><TD STYLE="text-align: justify">If Party A and Party B have entered into the Comprehensive
Credit Contract (No. ), this Contract shall be the specific business contract under such Comprehensive Credit Contract.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">16.2</TD><TD STYLE="text-align: justify">The reference to quarter herein means every three months
as a quarter rather than natural season.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">16.3</TD><TD STYLE="text-align: justify">In the event of any inconsistency between the contents of
this Loan Contract and the loan receipt hereunder, the loan receipt shall prevail;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">16.4</TD><TD STYLE="text-align: justify">This Contract shall be executed in <U>two</U> originals,
<U>one</U> copy for Party A and <U>one</U> copy for Party B, and each copy has the same legal effect.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">Article 17 Other
Agreements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="border-bottom: Black 1pt solid; width: 5in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify; text-indent: -48.6pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">Party A (Seal):</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Signature of Party A&rsquo;s Legal
Representative (or Authorized Representative):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">/s/ Gao Xiang /seal/ Lai Gang</TD><TD STYLE="text-align: justify; width: 60%">&nbsp;</TD>
</TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: right; width: 40%"><IMG SRC="ex4-11_001.jpg" ALT="" STYLE="height: 121px; width: 120px"></TD><TD STYLE="width: 10%; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; width: 50%"><P STYLE="margin-top: 0; margin-bottom: 0"></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"></P></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Date of Signing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">April 18, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Party B (Seal):</P>

<P STYLE="margin-bottom: 0pt; font-size: 10pt">Signature of Party B&rsquo;s Person in Charge (or Authorized Representative): (Signature)</P>

<P STYLE="margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; text-align: justify">Date of Signing:
April 18, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; margin-bottom: 0pt; text-align: justify"><IMG SRC="ex4-11_003.jpg" ALT="" STYLE="height: 144px; width: 180px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; text-align: justify">Place of Signing: <U>Jizhou Zhujiang
Rural Bank</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.12
<SEQUENCE>11
<FILENAME>ea022807501ex4-12_universe.htm
<DESCRIPTION>ENGLISH TRANSLATION OF THE LOAN AGREEMENT BETWEEN JIANGXI UNIVERSE AND JIANGXI RURAL COMMERCIAL BANK, DATED NOVEMBER 23, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.12</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">[2023] L.L.N.S.H.L.J.Z. No.: <U>17229202311231003001</U></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Working
Capital Loan Contract </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.75in">Borrower</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U></U></I></FONT><I><U>Jiangxi Universe Pharmaceuticals Co., Ltd.</U></I> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U></U></I></FONT></TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>Lender</TD>
    <TD STYLE="text-align: justify"><I><U></U></I><I><U>Jiangxi Luling Rural Commercial Bank Co., Ltd.</U></I> <I><U></U></I></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify; layout-grid-mode: char; font-size: 10pt"><IMG SRC="ex4-12_001.jpg" ALT=""></TD>
    <TD STYLE="vertical-align: middle; font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: left; layout-grid-mode: char"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jiangxi
    Rural Commercial Bank</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Special Notice: In order to protect the legitimate
rights and interests of the Borrower, the Lender hereby requests the Borrower to give full attention to all provisions concerning the
rights and obligations of the parties, especially those shown in bold. If the Borrower has any objection, it shall raise the objection
to the Lender. Otherwise, after this Contract is entered into by and between the Borrower and the Lender, all the terms and conditions
herein represent the true intention of both parties, are protected by law, and shall be legally binding on both parties herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Working Capital Loan Contract </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">[2023] LJZ No.: <U>17229202311231003001</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Borrower: <I><U>Jiangxi Universe Pharmaceutical
Co., Ltd.</U></I></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Business License No.: <U>913608217670218430</U></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal Representative / Person in Charge: <U>LAI
Gang </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Business Address: <U>No. 265, Jingjiu Avenue,
Jinggangshan Economic and Technological Development Zone, Ji&rsquo;an County</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mailing Address: <U>The same as above</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Postal Code: <U>343100</U> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tel.:
<U>13970661293</U></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Electronic Contact Information (Email and WeChat
Account No.): </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lender: <U>Jiangxi Luling Rural Commercial Bank
Co., Ltd.</U></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal Representative / Person in Charge: <U>HU Fushan</U></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Business Address: <U>No. 205, Fuchuan Road, Ji&rsquo;an County</U></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Postal Code: <U>343100</U></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel.: <U>8435534</U> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fax:_____________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the laws and regulations of the People&rsquo;s
Republic of China and other relevant regulations, the Borrower and the Lender have reached an agreement with respect to the matter that
the Lender grants a working capital loan to the Borrower, and hereby execute this Contract by consensus, which shall be binding on both
parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chapter 1 Execution Provisions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 1 Loan Amount and Currency </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Loan Amount (in words): <U>CNY Fifteen
Million. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(In Figures) <U>CNY 15,000,000.00. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
loan amount under this Contract is: &#9744; revolving borrowing limit &#9746; non-revolving loan amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 2 Loan Term </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The valid loan term under this Contract shall be: <U>24</U> months
from <U>November 11</U>, <U>2023</U> to <U>November 14</U>, <U>2025</U>.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
In the event that the loan amount hereunder is a revolving borrowing limit, the term of borrowing limit shall be the same as the valid
loan term as agreed herein. The term of each loan shall be subject to the term recorded in the loan note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9746; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
In the event that the loan amount hereunder is a non-revolving borrowing limit, the loan term shall be the same as the valid loan
term as agreed herein. The specific loan term shall be subject to the term recorded in the loan note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If the Borrower has any default circumstance
listed in Article 19 of this Contract, and the Borrower agrees that the Lender may recover the loan in advance, then the Lender may announce
that the date of recovering the loan in advance is the due date of the loan. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 3 Loan Purpose </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan borrowed hereunder shall be used for
turnover of working <U>capital</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Without the written consent of the Lender, the
Borrower may neither change the loan purpose nor use the loan for any other purposes. The Lender shall have the right to supervise the
Borrower&rsquo;s use of the loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 4 Loan Interest Rate, Interest
Calculation and Settlement </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1.  Loan
Interest Rate </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The method as described in following Item <U>(1)</U>
shall apply for the determination of loan interest rate and a <B>simple interest calculation</B> shall be applied:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(1)  Fixed
Interest Rate. The annual interest rate shall be <U>3.95</U>%. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
loan prime rate (LPR) recently published on &#9746; the date of signature hereof &#9744; withdrawal date for <U>1</U> years&rsquo;
loan, which is 3.45, and &#9746; increased percentage points &#9744; decreased percentage points, which is <U>50</U> bp (1bp =
0.01%). The annual interest rate shall be <U>3.95</U>%. The interest rate shall remain unchanged during the loan term.</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(2)  Floating
Interest Rate. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan interest rate shall be determined by
the loan prime rate (LPR) recently published on the working day before the withdrawal date for _____ years&rsquo; loan and <FONT STYLE="font-family: Wingdings 2">&pound;</FONT>increased
percentage points <FONT STYLE="font-family: Wingdings 2">&pound;</FONT>decreased percentage points, which is ____ bp. <B>The increased
or decreased percentage points shall remain unchanged during the term of this Contract. In case of any adjustment to the LPR, its loan
interest rate determination method shall be handled according to the following Item and the Lender will not give a further notice to the
Borrower: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9312; Annual Adjustment. From January 1 of
the next year, the loan interest rate shall be adjusted, on the basis of the LPR recently published, in accordance with the
increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9313; Annual Adjustment. From the
corresponding date of the corresponding month in the corresponding year, the loan interest rate shall be adjusted, on the basis of
the LPR recently published, in accordance with the increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9314; Quarterly Adjustment. From the
corresponding date of the first month in the corresponding quarter, the loan interest rate shall be adjusted, on the basis of the
LPR recently published, in accordance with the increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9315; Quarterly Adjustment. From the first
day of the first month in the corresponding quarter, the loan interest rate shall be adjusted, on the basis of the LPR recently
published, in accordance with the increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9316; Monthly Adjustment. From the
corresponding date of the corresponding month, the loan interest rate shall be adjusted, on the basis of the LPR recently published,
in accordance with the increased or decreased percentage points agreed herein (If there is no corresponding day in the month of
adjustment, the last day of such month shall be treated as the corresponding day);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9317; Monthly Adjustment. From the
corresponding date of the corresponding month, the loan interest rate shall be adjusted, on the basis of the LPR recently published,
in accordance with the increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9318; Immediate Adjustment. From the date
immediately following the date of the LRP recently published, the loan interest rate shall be adjusted, on the basis of the new LPR, in
accordance with the increased or decreased percentage points agreed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)  The
loan interest rate shall be determined by other methods: ________/________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If the Borrower chooses the &ldquo;(2) floating
interest rate&rdquo; method, and when the loan prime rate (LPR) of the loan market increases, the monthly repayment amount of the Borrower
will increase. If the Borrower still makes the repayment according to the repayment amount before adjustment, the monthly repayment amount
will be insufficient, resulting in penalty interest and compound interest and affecting the credit record of the Borrower. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.  Interest
Settlement Method </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower will settle the interest in a method
as described in following Item <U>(2) </U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)  Quarterly
Interest Settlement. The 20<SUP>th</SUP> day of the last month of each quarter shall be the interest settlement date, and the 21<SUP>st</SUP>
day shall be the interest payment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)  Monthly
Interest Settlement. The 20<SUP>th</SUP> day of each month shall be the interest settlement date, and the 21<SUP>st</SUP> day shall be
the interest payment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)  The
interest shall be settled by other methods: _____/__________________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the repayment date of the
last installment of loan principal is not the interest payment date, such repayment date of the last installment of loan principal
shall be the interest payment date on which the Borrower shall pay off all the interests payable.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.  Penalty
Interest Rate </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)  In
the event that the Borrower fails to repay the loan within the agreed time limit, interest shall be calculated and charged over the overdue
part at the penalty interest rate for overdue loan from the overdue day, until the principal and interest are paid off;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)  In
the event that the Borrower uses the loan for any purposes other than those agreed herein, interest shall be calculated and charged over
the misappropriated part at the penalty interest rate for misappropriated loan from the misappropriation date, until the principal and
interest are paid off;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)  In
the event that the loan is overdue and misappropriated, interest shall be calculated and charged at the penalty interest rate for misappropriated
loan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4)  With
respect to the interest and penalty interest that the Borrower fails to pay as scheduled, compound interest shall be calculated and charged
at the penalty interest rate agreed in this paragraph in the interest settlement method as agreed in Paragraph 2 hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5)  In
case of any adjustment to the loan interest rate agreed herein, the penalty interest and compound interest shall be calculated at the
adjusted interest rate from the adjustment date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6)  Penalty
Interest Rate</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The penalty interest rate for overdue loan shall
be <U>50</U>% higher than the loan interest rate agreed in Paragraph 1 hereof; the penalty interest rate for misappropriated loan shall
be <U>100</U>% higher than the loan interest rate agreed in Paragraph 1 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 5 Loan Disbursement and Repayment
Account </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower shall open an account as follows
with the Lender as the loan disbursement and repayment account, which shall be used for loan disbursement, payment and repayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bank of deposit: <U>Luling Rural Commercial Bank</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Account Name: <U>Jiangxi Universe Pharmaceuticals
Co., Ltd.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Account Number: <U>17229920100001758</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 6 Repayment </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise agreed by the parties, the Borrower
shall repay the loan hereunder in accordance with the repayment schedule as set forth in Item <U>1</U> below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.  Repay
the loan hereunder in full upon the expiration of the loan term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  Repay
the loan hereunder in accordance with the following repayment schedule:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt"><B>Repayment Time </B></FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt"><B>Repayment Amount </B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">1. </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">2. </FONT></TD>
    <TD STYLE="vertical-align: top; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">3. </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">4. </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">5. </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">6. </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">7. </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">8. </FONT></TD>
    <TD STYLE="vertical-align: top; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">9. </FONT></TD>
    <TD STYLE="border: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">Total </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.05in; padding-bottom: 0.05in; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.  Other
Repayment Schedule: ________/____________________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.  Where
the Borrower makes repayment in advance, it shall obtain the consent from the Lender <U>7</U> banking days in advance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 7 Guarantee </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The loan hereunder shall be a <U>guaranteed</U> (credit/ guaranteed)
loan. The guarantee type shall be <U>mortgage</U> (guarantee/ mortgage/ pledge), and the guarantee contract shall be executed separately.</B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 8 Contract Agreements on the
Borrower&rsquo;s Financial Indicators: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">1.</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 3in">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">2.</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">3.</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 9 Dispute Resolution </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.  After
this Contract takes effect, any dispute arising from the execution or performance hereof or in connection with this Contract shall be
settled by both parties through negotiation. If such negotiation fails, either party may file a lawsuit with the People&rsquo;s Court having
jurisdiction over the place of the Lender in accordance with the law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  During
the dispute resolution, in the event that the dispute does not affect the performance of the remaining provisions of this Contract, such
remaining provisions shall continue to be performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.  After
negotiation between the parties, the parties may conduct notarization for the compulsory enforcement of this Contract. The Borrower agrees
that this Contract shall have the compulsory enforcement effect after it is notarized. In the event that the Borrower fails to perform
its obligations under this Contract, the Lender may apply to the People&rsquo;s Court having jurisdiction for compulsory enforcement according
to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 10 Effectiveness of the Contract
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract shall take effect from the date
when both parties affix their signatures and seals hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">This Contract is made out in <U>triplicate</U>, with <U>the Borrower,
the Lender ,the Real Estate Registration Burear </U>holding <U>one</U> counterpart each. Each counterpart shall have the same legal effect.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 11 Other Agreements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 3in">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chapter 2 Standard Provisions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 12 Interest Calculation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The interest shall be calculated from the Borrower&rsquo;s
actual withdrawal date and shall be calculated according to the actual withdrawal amount and use days of loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest Formula: Interest = Principal &times;
Actual Days &times; Daily Interest Rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The daily interest rate is calculated on a base
of 360 days a year. Conversion Formula: Daily Interest Rate = Annual Interest Rate / 360.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 13 Loan Disbursement Conditions
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1.  The
Borrower must meet all the following conditions for loan disbursement, otherwise the Lender shall have no obligation to disburse any loan
to the Borrower, unless the Lender agrees to disburse the loan in advance: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)  The
Contract and its appendixes have become effective;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)  The
Borrower has reserved to the Lender the Borrower&rsquo;s documents, receipts, seals, lists of persons and specimen signatures in relation to
the execution and performance of this Contract and filled in the relevant vouchers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)  The
Borrower has, according to the Lender&rsquo;s requirements, opened an account necessary for the performance of this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4)  The
Borrower, within 3 banking days prior to the withdrawal, has submitted to the Lender the written withdrawal notice and the relevant supporting
documents for loan purpose which is consistent with the purpose as agreed herein, and has completed the relevant withdrawal procedures;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5)  The
Borrower has submitted to the Lender the resolution and letter of authorization of the board of directors or other competent authorities,
which agree to the execution and performance of this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6)  In
accordance with relevant regulatory provisions and management requirements of the Lender, if the loan exceeds a certain amount or meets
other conditions, the Lender shall, according to the Borrower&rsquo;s withdrawal application and payment authorization, pay the loan to the
payment object conforming to the purpose agreed herein in a manner of authorized payment by the Lender;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7)  In
addition to the credit loan, the Borrower has provided the corresponding guarantee as required by the Lender and has completed the relevant
guarantee procedures, and the guarantee is legal and valid;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8)  The
Borrower has not breached this Contract or any other contracts executed by and between the Borrower and the Lender;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  In
the event that the Borrower fails to make any withdrawal for 3 consecutive months from the contract execution date, the Lender shall be
entitled to cancel the borrowing limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 14 Special Arrangements on
Revolving Loan (Maximum Loan) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.  During
the term of revolving borrowing limit, the sum of the loan principal balance of at any time shall not exceed the revolving borrowing limit;
the repayment date of any withdrawal shall not exceed the term of revolving borrowing limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  As
agreed by both parties, the Lender shall reasonably set the amount and term of each revolving loan according to the scale and cycle of
the Borrower&rsquo;s production and operation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 15 Loan Amount Payment </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.  The
authorized payment by the Lender means that the Lender pays the loan fund to the Borrower&rsquo;s counter-party in a transaction conforming
to the purpose agreed herein according to the Borrower&rsquo;s withdrawal notice and payment authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payment of the Borrower&rsquo;s loan fund for which
the amount of a single payment under this Contract exceeds the specified amount shall be made in a manner of authorized payment by the
Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of the authorized payment by the
Lender, the Borrower shall make express payment authorization and provide other necessary payment information (including name of counter-party
who receives payment, account number of such counter-party, and amount of payment) in the withdrawal notice, and submit to the Lender
the supporting documents for loan purpose such as business contracts required for the examination. In this case, the Lender shall pay
the loan fund to the counter-party of the Borrower via the Borrower&rsquo;s account upon examination and approval. In the event of the Lender&rsquo;s
failure to perform its obligation to pay upon authorization resulting from untruthfulness, incorrectness, and incompleteness of the information
of payment authorization and relevant transactions furnished by the Borrower, the Lender shall not be held liable for such failure whatsoever
and the Borrower&rsquo;s obligation to repay under the Contract shall not be affected. The Lender will make payment to the account of the Borrower&rsquo;s
counter-party in accordance with the Borrower&rsquo;s withdrawal notice and the payment certificate as required by the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Lender, upon examination,
discovers that the supporting documents for loan purpose such as business contracts furnished by the Borrower fail to comply with the
Contract or there is any other defects, the Lender shall be entitled to request the Borrower to supplement, replace, explain or re-furnish
such documents, and the Lender may suspend granting or paying of such loans until the Borrower has furnished the supporting documents
such as business contracts to the satisfaction of the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the account-holding bank of
the counterparty returns such payments, resulting in the Lender&rsquo;s failure to transfer such loans to the Borrower&rsquo;s counterparty as authorized
by the Borrower in a timely manner, the Lender shall not be liable for such failure whatsoever and the Borrower&rsquo;s obligation to repay
under the Contract shall not be affected. With respect to the funds returned by the account-holding bank of the counterparty, the Borrower
shall re-furnish the payment authorization and the supporting documents for loan purpose such as business contracts required for the examination,
and the Lender shall pay the loan fund to the counterparty of the Borrower via the Borrower&rsquo;s account upon examination and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All the expenses incurred by the payment of loan
to the counterparty designated by the Borrower in a manner of authorized payment under this Contract shall be borne by the Borrower. The
Borrower shall pay the above expenses to the Lender at the time of the authorized payment of each loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower shall not violate the above provisions
to dodge the authorized payment by the Lender by way of breaking up a large amount into several small amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  Except
for the cases where the authorized payment by the Lender must be adopted as stipulated in the preceding paragraph, unless otherwise agreed
by both parties, payment of other loans shall be made by the Borrower itself, namely, after the Lender disburses the loans to the Borrower&rsquo;s
account pursuant to the withdrawal application submitted by the Borrower, the Borrower pay by itself to the its counterparty that complies
with the purpose as agreed in the Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Borrower needs to change
the aforesaid repayment schedule, it shall submit a written application to the Lender <U>10</U> banking days prior to the maturity date
of the loan, and the changed repayment schedule is subject to the written confirmation by the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.  In
the event that the Borrower needs to extend the loan term agreed herein, it shall submit a written application of extension to the Lender
<U>30</U> banking days prior to the maturity date of the loan, and the Lender shall decide whether to approve the extension. In applying
for the extension of a guaranteed loan, mortgage loan or pledged loan, the guarantor, mortgagor or pledgor shall also issue a written
certificate of approval. the parties shall enter into a renewal agreement after the Lender approves the extension. In the event that the
Borrower&rsquo;s application for extension is not approved by the Lender, the Borrower shall still repay the loan in full according to the repayment
term agreed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4.  Unless
otherwise agreed by the Parties, if both the principal and the interests are overdue by the Borrower, the Lender shall be entitled to
decide on the sequences for repaying the principal or the interests; under the condition of installment repayment, if several mature installments
and overdue installments exist under this Contract, the Lender shall be entitled to decide the sequences of repayment; if several outstanding
loan contracts exist between the Parties, the Lender shall be entitled to decide the sequences for repaying any contract. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.  The
Borrower shall repay the loan principal, interests and other amounts payable in full and on time according to provisions stated herein.
The Borrower shall, before the end of counter business on the repayment date and each interest settlement date, deposit in full the current
interests, principal and other amounts payable to the repayment account opened with the Lender, and the Borrower shall authorize the Lender
to collect the funds on the repayment date or the interest settlement date or the Borrower shall be required to cooperate in handling
the relevant transfer procedures. In the event that the amount in the repayment account is insufficient to pay the full amount due from
the Borrower, the Borrower shall agree that Lender is entitled to decide the sequences for repayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.  The
Lender shall be entitled to collect the loan in advance on the basis of the capital withdrawal of the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.  Loan
Note: The loan note shall be an integral part of this Contract. In the event that there is no record in this Contract, or the loan amount,
withdrawal amount, repayment amount, borrow date and maturity date of the loan, loan term, loan interest rate and loan purpose as recorded
in this Contract is inconsistent with those recorded in the loan note, the loan note shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 16 Guarantee </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that any event occurs to the Borrower
or the guarantor, and causes the Lender to believe that it may affect the performing capability of the Borrower or the guarantor; or the
guarantee contracts are deemed as invalid, canceled or resolved; or the performing capability of the Borrower or guarantor may be affected
due to the deterioration in their financial condition or that the Borrower and the guarantor are involved in substantial lawsuit or arbitration
or other reasons; or the guarantor breaches the guarantee contracts or other contracts with the Lender; or the collateral value decreases
or gets lost due to the devaluation, damage, lost or sequestration of the collateral; the Lender shall be entitled to require, and the
Borrower shall have the obligation to provide new guarantee, supplement or replace the guarantor to guarantee the liabilities under this
Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 17 Representations and
Undertakings </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.  The
Borrower is a legal entity incorporated, registered and existing under the administration for industry and commerce or other competent
authorities and has full capacity of civil rights and conduct to conclude and perform the Contract, and capacity of loan repayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  The
Borrower fully agrees to the contents and terms of this Contract, executes and performs this Contract out of true intention, has obtained
all legal and valid authorizations required by the Borrower&rsquo;s Articles of Association and bylaws, and will not be in violation of any
agreement, contract, or other legal documents with binding force to the Borrower. The Borrower has obtained or will obtain all the required
approval, consent, documentation or registration for executing and performing this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.  The
Borrower is in good faith and all the documents, financial statements, certifications and other information provided by the Borrower to
the Lender under this Contract are true, complete, accurate and valid, and free from false records, material omissions or misleading statements.
The financial and accounting reports provided to the Lender are prepared in accordance with Chinese accounting standards, and truly, fairly
and completely present the Borrower&rsquo;s operating and liability condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.  The
transaction background that the Borrower represents to the Lender is real and legal, not for any illegal purposes such as money laundering.
The loan purpose and the source of repayment are clear and legal. The loan purpose and the source of repayment are clear and legal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.  The
Borrower has a good credit status, does not have material bad credit record, and does not conceal from the Lender any fact that may affect
the Borrower&rsquo;s and the Guarantor&rsquo;s financial condition and performance capability. The Borrower does not conceal from the Lender any litigation,
arbitration or claim in which it is involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.  The
borrower has repaid other debts payable as scheduled and has not maliciously defaulted on the payment of principal and interest of the
bank loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>7.  The
Borrower shall withdraw and use the loan in accordance with the term and purpose agreed herein. The loan borrowed hereunder shall neither
be used for the investment in fixed asset and equity and other investments, nor flow into the securities market or the futures market
in any form, or be used for other purposes prohibited or restricted by relevant laws and regulations. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.  The
Borrower shall deliver its financial statements (including but not limited to annual, quarterly and monthly reports) and other relevant
documents to the Lender on a regularly and timely basis in accordance with the requirements of the Lender; the Borrower shall ensure that
the financial indicators will comply with the Contract all the time. If the production and operation qualification/license is subject
to the annual audit, such qualification/license will pass the annual examination as scheduled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9.  The
Borrower shall withdraw, repay and use the loan as stipulated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10.  If
the Borrower has executed or will execute with the guarantor under this Contract a counter-guarantee agreement or similar agreement regarding
its guarantee obligations, this counter-guarantee agreement or similar agreement will not prejudice any Lender&rsquo;s right under this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11.  The
Borrower shall accept the credit inspection and supervision conducted by the Lender, and provide sufficient assistance and cooperation;
from the effective date of this Contract and prior to discharge of the principal and interests and related expenses hereunder, the Borrower
agrees and authorizes the Lender to monitor the account opened with the Lender, examine and analyze the Borrower&rsquo;s production and operation
(including but not limited to the construction and operation of the Borrower&rsquo;s projects), and make dynamic monitoring on the income cash
flow and overall fund flow of the Borrower; <B>the Borrower shall accept and actively cooperate with the examination and supervision made
by the Lender on the usage of the loan funds including the loan purpose by account analysis, proof inspection and site investigation,
</B>and make summary report in a periodic manner as required by the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>12.  The
Borrower&rsquo;s merger, division, decrease of capital, equity transfer, external investment, substantial increase of debt financing, transfer
of material assets and claims and other events which may have adverse effect on the solvency of the Borrower shall be subject to the written
consent of the Lender. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower shall give a notice to the Lender
within <U>7</U> days after it becomes or should have become aware of any of the following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)  Change
of the Articles of Association, business scope, registered capital, legal representative of the Borrower or the guarantor;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)  Change
of management mode such as joint management in any form, cooperation with foreign enterprises, cooperation, contracting management, reorganization,
reform and planned listing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)  Involved
in material litigation or arbitration cases, sequestration, attachment or supervision of properties or collateral, or establishment of
new material liabilities on the collateral;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4)  Winding
up, dissolution, liquidation, stopping business for rectification, cancellation, revocation of business license, (applied for) applying
for bankruptcy;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5)  Shareholders,
directors and current senior managers are suspected of being involved in material cases or economic disputes; or the legal representative/person
in charge and current senior executives are found to be in bad health or other material conditions that the they are unqualified for their
job;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6)  Events
of default by the Borrower under other contracts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7)  Difficulty
in business operation and deterioration of financial position;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8)  In
the event that the Borrower is closed, suspended, merged or changes the line of production due to change, restructuring and contracting
or with the approval of the competent departments, the Borrower undertakes to give a notice to the Lender in writing within one month
prior to the occurrence of the above events and to discharge all debts owed to the Lender immediately. Subject to the consent of the Lender,
the Borrower may transfer the debts to the receiving entity or the newly incorporated entity (The Borrower shall, in the process of debt
transfer, present and submit to the Lender the documents issued by its competent authority or the contract-issuing party or relevant documents);
however, the debt receiving entity must execute a new loan contract with Lender and submit a written certificate of the corresponding
guarantor&rsquo;s approval or implement new guarantee measures, and before the execution of the new contract, the Lender shall have the right
to recover the debts from the Borrower, the Guarantor or the Borrower&rsquo;s receiver at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">13.  Liquidation
of the debts owed by the Borrower to the Lender shall have priority to the loan extended by the shareholders of the Borrower, and precede
the debts of the same kind owed by the Borrower to other creditors. In addition, from the effectiveness of the Contract to the time when
all the principal, interests and relative fees under the Contract are paid off, the Borrower shall not return the loan from its shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14.  In
respect of the loan hereunder, the loan conditions such as guarantee conditions, loan rate pricing, discharge sequence provided by the
Borrower for the Lender shall be no less than the current or future conditions provided for any other financial institution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">15.  <B>The
Borrower shall bear the expenses incurred in connection with the execution and performance of this Contract and the expenses paid and
payable by the Lender for realization of its creditor&rsquo;s right hereunder, including but not limited to litigation or arbitration fees,
property preservation costs, attorney fees, enforcement fees, evaluation fees, auction fees, and announcement fees. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>16.  Account
Management </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)  The
repayment account opened by the Borrower with the Lender (the account stipulated in Article 5) is a special capital withdrawal account,
which is used to collect the corresponding sales revenue or the planned repayment fund. Where the corresponding sales revenue is settled
in a non-cash manner, the Borrower shall ensure that it will be promptly transferred into the capital withdrawal account upon receipt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)  The
Lender shall have the right to supervise the capital withdrawal account, including but not limited to the understanding and supervision
of the fund income and expenditure of the account, and the Borrower shall provide relevant cooperation. At the request of the Lender,
the Borrower shall execute a special account supervision agreement with the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">17.  The
Borrower shall dispose the assets in a manner that will not reduce its repayment capability. The Borrower undertakes that the total amount
of the Borrower&rsquo;s external guarantee is equal to or less than _____ times of its net asset, and the total amount of external guarantee
as well as the amount of a single guarantee may not exceed the limit as stipulated in its Articles of Association; without the consent
of the Lender, the Borrower shall not provide guarantee to any third party or the loans borrowed by the Borrower from any other financial
institution with the assets formed by the loans under the Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 18 the Related-party Transaction
within the Borrower </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9744; </FONT>1.
The Borrower is not identified by the Lender as the group client in accordance with the Guidelines on the Management of Risks of
Credits Granted by Commercial Banks to Group Clients (hereinafter referred to the &ldquo;Guidelines&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9744; </FONT>2.
If the Borrower is identified by the Lender as the group client in accordance with the Guidelines, it shall report to the Lender any
of the related-party transaction in a timely manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9744; </FONT>3.
The Borrower is subject to such events as major merger, acquisition or reorganization, which in the opinion of the Lender may affect
the safety of the loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 19 Breach of Contract and
Settlement </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.  The
Borrower shall constitute or be deemed to have breached the Contract and shall be liable for breach of contract under any of the following
circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)  The
Borrower fails to perform the obligations of payment and liquidation to the Lender according to the stipulations of the Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)  The
Borrower fails to use the loan in a purpose and way stipulated in this Contract or fails to use the loan borrowed hereunder for the purpose
stipulated in the Contract; or the Borrower fails to go through the withdrawal procedures as scheduled according to the withdrawal plan,
or changes the withdrawal plan without the Lender&rsquo;s consent; or the Borrower is in violation of this Contract and dodges the authorized
payment by the Lender by way of breaking up a large amount into several small amounts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)  The
Borrower provides an untrue representation or violates the undertaking it made in this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4)  If
any circumstance under Subparagraph 12 of Article 17 arises, and the Lender believes that may affect the financial condition and performing
capability of the Borrower or guarantor, but the Borrower refuses to provide new guarantee or change a guarantor according to this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5)  The
Borrower violates any stipulation under any other contract between the Borrower and the Lender; the Borrower violates any stipulation
under any Credit Extension Contract between the Borrower and any other financial institution;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6)  The
guarantor violates the stipulations of the guarantee contract, or any default events arise under other contract between the guarantor
and the Lender;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7)  The
Borrower closes down or is dissolved, withdraw or bankrupted;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8)  Where
the Borrower involves in or possibly involves in material economic disputes, litigation, arbitration, or its capital is sealed up, seized
or enforced for execution, or the administrative organs such as judicial organs or taxation authorities, and industrial and commercial
administration file for investigation or adopt punishment measures on the Borrower according to law which has influenced or may influence
the performance of the liabilities under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(9)  Where
the main individual investors and key managerial personnel of the Borrower are changed abnormally, disappear or are investigated or the
personal freedom thereof is limited by judicial organs according to law which has influenced or may influence the performance of the liabilities
under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(10)  Where
the credit circumstances of the Borrower lowers or finance indexes of the Borrower such as profitability, debt-paying ability, operating
capacity and cash flow seriously deteriorate and break through the index binding of this Contract or other financial agreements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(11)  The
Borrower takes advantage of the false contracts between the Borrower and the affiliated party to obtain funds or credit from the Lender
through transactions without true transaction background, and the affiliated party is subject to such events as major merger, acquisition
or reorganization which in the opinion of the Lender may affect the safety of the loan; or the Borrower intends to evade the creditor&rsquo;s
right of the Lender through related-party transactions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(12)  The
Borrower causes any liability accident due to its violation of food safety, production safety, environmental protection and other relevant
laws and regulations, regulatory provisions or industrial standards which has influenced or may influence the performance of the liabilities
under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(13)  In
the event that the loan under this Contract is granted on the basis of credit rating, the Borrower&rsquo;s credit rating, profitability, asset-liability
ratio, net cash flow from operating activities and other indicators do not meet the Lender&rsquo;s credit loan conditions; or the Borrower,
without the written consent of the Lender, establishes mortgage/pledge guarantee or provide guarantee to others with its valid operating
assets, which has influenced or may influence the performance of the liabilities under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(14)  Other
circumstances that may have adverse effect on the realization of the creditor&rsquo;s rights of the Lender under this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  When
the aforesaid breaches arise, as the case maybe, the Borrower agrees that the Lender may take following measures respectively or simultaneously:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)  Require
the Borrower and guarantor to rectify their breach within time limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)  Decrease,
suspend or terminate all or part of the credit lines of the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)  Suspend
or terminate all or part of the business application (such as withdrawal) of the Borrower under this Contract or other contracts between
the Borrower and the Lender; partly or totally suspend or cancel to issue, pay and transact the unissued loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4)  Declare
that all or part of the outstanding principal and interest of the loan and other amounts payable of the Borrower under this Contract and
other contracts between the Borrower and the Lender shall become due immediately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5)  Negotiate
with the Borrower to supplement the terms of loan issuance and payment; or the Lender shall have the right to change the loan disbursement
and payment conditions in accordance with the credit status of the Borrower such as lowering the minimum amount of authorized payment
of the Borrower; or the Lender shall have the right to transfer back the loan fund which the Borrower has paid for default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6)  Terminate
or dissolve this Contract, partly or totally terminate or dissolve other contracts between the Borrower and the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7)  Require
the Borrower to compensate the Lender for the Lender&rsquo;s loss caused by the Borrower&rsquo;s default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8)  <B>Deduct
from the Borrower&rsquo;s account which is opened in the Rural Commercial Bank system within the jurisdiction of Jiangxi </B>with notice before
or after the deduction, <B>so as to discharge all or part of the Borrower&rsquo;s debts to the Lender hereunder. The undue deposit in the account
shall be deemed to become due in advance. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(9)  Exercise
security interest; and require the guarantor to take guarantee responsibility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(10)  In
the event that the Borrower fails to repay the principal, interest (including penalty interest and compound interest) or other amounts
payable as scheduled, the Lender may disclose the default information of the Borrower and the Guarantor and make an announcement for collection
through the media or other forms. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(11)  Have
the right to deduct and debit the deposits and dividends within any account opened by the Borrower in the Rural Commercial Bank system
within the jurisdiction of Jiangxi, and to dispose of the Borrower&rsquo;s equities. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(12)  Other
measures stipulated by laws and regulations and deemed necessary and possible by the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 20 Reservation of Rights </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any failure by a party to exercise all or part
of its rights hereunder or to require the other party to perform or assume all or part of obligations or responsibilities shall not constitute
a waiver of such rights or release of the obligations and responsibilities of such party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any tolerance, grace or postponement for exercising
the rights under this Contract of one Party shall not affect its rights stipulated by this Contract, laws and regulations, and shall not
be deemed as a waiver of such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 21 Confidentiality </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each party undertakes to keep confidential the
trade secrets, technical information, business information and other business secrets obtained from the other party which are not available
through public channels. Without the consent of the original provider of the trade secret, neither party shall disclose all or part of
the trade secret to any third party, unless otherwise stipulated by laws and regulations or otherwise agreed by both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that either party is in violation
of the aforesaid confidentiality obligation, it shall assume the corresponding liability for breach of contract and compensate for the
losses caused thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 22 Force Majeure </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The term Force Majeure as specified in this Contract
refers to the objective events that cannot be foreseen, overcome, or avoided and have a significant impact on one party, including but
not limited to the natural disasters such as flood, earthquake, fire and storm, as well as the social events such as war and turmoil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Contract cannot be performed
as a result of the occurrence of force majeure events, the party affected by the force majeure shall immediately notify the other party
of the event in writing, and within 7 days, provide written documents certifying the details of accident and the reasons for non-performance
or delay in performance hereof. Upon consensus through negotiation, both Parties may terminate or temporarily delay the performance of
the Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 23 Alteration, Amendment and
Termination </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract can be altered and amended in written
form upon consensus through negotiation of the Parties, and any alternation and amendment agreed on by the Parties shall constitute an
integral part of this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract may not be terminated until all
the rights and obligations are fully preformed, unless otherwise stipulated in laws and regulations or agreed by the both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The invalidity of any provision of this Contract
shall not affect the legal validity of other provisions, unless otherwise stipulated in laws and regulations or agreed by the both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 24 Agreements on Service </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.  The
contact information (including mailing address, telephone number, fax number, etc.) provided by the Borrower in this Contract shall be
true and valid and shall be the address for service of any notice of the Lender for the Borrower. In case of any change to the contact
information, the Borrower shall immediately send/mail the change information in writing to the mailing address provided by the Lender
in this Contract. Such information change shall become effective upon the Lender&rsquo;s receipt of the change notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  Unless
otherwise expressly provided for in this Contract, the Lender shall be entitled to give notice to the Borrower in any of the following
methods. The Lender shall be entitled to choose the notification method as it thinks fit and shall not be held liable for any error, omission
or delay in delivery by mail, fax, telephone, WeChat or any other communication system. Where the Lender simultaneously chooses several
notification methods, the one by which the notice is served to the Borrower earlier shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)  By
announcement. The notice shall be deemed to be served on the date on which the Lender publishes the announcement on its website, online
banking, telephone banking or business outlets;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)  By
hand. The notice shall be deemed to be served on the date on which the Borrower signs for the receipt, or if the Borrower refuses to sign
for the receipt, the date on which the server makes a record on the proof of service on the spot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)  By
mail (including express mail, surface mail or registered mail). The notice, when addressed to the Borrower&rsquo;s mailing address last known
to the Lender, shall be deemed to be served on the date on which the Borrower signs for the receipt, or if the Borrower fails to sign
for the receipt, the date on which the mail is returned;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4)  By
fax, mobile phone SMS, WeChat or other electronic communication methods. The notice, when sent to the Borrower&rsquo;s fax number, the mobile
phone number, WeChat account number or email address designated by the Borrower which is last known to the Lender, shall be deemed to
be served on the date on which the notice is sent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.  Borrower
agrees that, unless the Lender receives from the Borrower a written notice concerning the change of mailing address, the Borrower&rsquo;s domicile
stated in this Contract is the correspondence and contact address. In the future, the delivery addresses of bank statements, collection
statements, relevant legal instruments and litigation documents related to the loans under this Contract shall prevail. The Borrower promises
to notify the Lender in time when the communication and contact information change, otherwise the documents delivered by the Lender according
to the communication and contact information stated in this Contract will be effectively delivered, and the relevant economic and legal
responsibilities arising therefrom will be borne by the Borrower and the Mortgagor. During the dispute settlement, if the court serves
the judicial documents or other written documents by mail (including express mail, surface mail or registered mail) to the Borrower mailing
address last known to the Lender, such documents shall be deemed to be served on the date on which the Borrower signs for receipt of the
proof of service; or if Borrower fails to sign for receipt of the proof of service, the date on which the mail is returned;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The court or notary organ shall be entitled to
give any notice to the Borrower by any methods of communication agreed in this Paragraph 2. The court or notary organ shall be entitled
to choose the communication method as it thinks fit and shall not be held liable for any error, omission or delay in delivery by mail,
fax, telephone, telex or any other communication system. Where the court or notary organ simultaneously chooses several communication
methods, the one by which the notice is served on the Borrower earlier shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 25 Appendix </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The appendixes confirmed by both parties shall
constitute an integral part of this Contract and shall have the same legal effect as this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 26 Other Agreements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.  The
Borrower shall not transfer any rights and obligations under this Contract to the third party without written consent of the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.  The
Lender has the right to transfer the creditor&rsquo;s rights under this Contract to the third party, and shall notify the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.  This
Contract shall be legally binding upon both Parties and their successors and assignees without prejudice to other provisions of this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.  All
the transactions under this Contract are carried out for each Party&rsquo;s independent benefits. If, in accordance with relevant laws, regulations
and regulatory provisions, other parties to the transaction become the related parties or affiliated persons of the Lender, no Party may
seek to affect the fairness of the transaction out of this related-party relationship.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.  The
headings and business names in this Contract are used only for convenient reference, which shall not be used to interpret the provisions
or the rights and obligations of both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.  In
accordance with relevant laws, regulations and regulatory provisions, the Lender shall have the right to provide the information related
to this Contract and other relevant information of the Borrower to the credit reference system of the People&rsquo;s Bank of China and other
credit information database established according to law for reference and use by the institutions or individuals with proper qualification
according to law. The Lender shall also have the right to refer the relevant information of the Borrower through credit reference system
of the People&rsquo;s Bank of China and other credit information database established according to law for the purpose of the execution and
performance of this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The parties acknowledge that the Borrower and
the Lender have made a full negotiation in connection with all the terms of this Contract. The Lender has requested the Borrower to give
special attention to and make a comprehensive and accurate understanding of all provisions concerning the rights and obligations of the
parties, and has made explanations to the relevant provisions upon the Borrower&rsquo;s request. The Borrower has carefully read and fully understood
all the contents and provisions of the Contract. The Borrower confirms that there is no misunderstanding or doubt about all the contents
and terms of the Contract. Both the Borrower and the Lender have the same understanding of the contents and provisions of the Contract
and have no objection to the contents and provisions of the Contract. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Borrower and the Lender have made a full
negotiation in connection with all the provisions of this Contract. The Lender has requested the Borrower to give special attention to
and make a comprehensive and accurate understanding of all provisions concerning the rights and obligations of the parties, and has made
explanations to the relevant provisions upon the Borrower&rsquo;s request. The Borrower has carefully read and fully understood all the contents
and terms of the Contract. The <FONT STYLE="border: Black 1pt solid">Borrower</FONT></B><B> confirms that there is <FONT STYLE="border: Black 1pt solid">no
misunderstanding or ambiguity </FONT></B><B>about all the contents and provisions of the <FONT STYLE="border: Black 1pt solid">Contract</FONT></B><B>.
Both the Borrower and the Lender have the same understanding of the contents and provisions of the Contract and have no objection to the
contents and provisions of the Contract. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(The Borrower shall fill in the following by
contrast) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(The remainder of this page is intentionally left
blank for signatures)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 30%; vertical-align: bottom">Borrower (Official Seal):</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 20%; text-align: center"><IMG SRC="ex4-12_002.jpg" ALT=""></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 50%">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 70%; vertical-align: middle">Legal Representative or Authorized Agent (Signature &amp; Seal): Lai Gang <U>(Signature)</U></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 30%">&nbsp;<IMG SRC="ex4-12_003.jpg" ALT=""></TD>
</TR></TABLE>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>November 23, 2023</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left; width: 25%; vertical-align: bottom">Lender (Seal):</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-left: -0.375in; text-align: left; width: 20%">&nbsp;<IMG SRC="ex4-12_004.jpg" ALT="" STYLE="height: 110px; width: 120px"></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 55%">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 58%; vertical-align: bottom">Legal Representative or Authorized Agent (Signature
&amp; Seal):</TD><TD STYLE="vertical-align: bottom; text-align: left; width: 42%"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Fan
Juan<U> (Signature)</U></P></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>November 23, 2023</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 30%"></TD><TD STYLE="vertical-align: bottom; width: 30%; text-align: right">Contract Execution Place:</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 40%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>12
<FILENAME>ea022807501ex12-1_universe.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Gang Lai, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. I have reviewed this annual report on Form
20-F of Universe Pharmaceuticals INC (the &ldquo;Company&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Based on my knowledge, this report does not
contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the Company as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The Company&rsquo;s other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company
and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or
caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the Company&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the Company&rsquo;s internal
control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably
likely to materially affect, the Company&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The Company&rsquo;s other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&rsquo;s auditors
and the audit committee of the Company&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the Company&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: April 29, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Gang Lai</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 31%"><FONT STYLE="font-size: 10pt">Gang Lai</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>13
<FILENAME>ea022807501ex12-2_universe.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Lin Yang, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. I have reviewed this annual report on Form
20-F of Universe Pharmaceuticals INC (the &ldquo;Company&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Based on my knowledge, this report does not
contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the Company as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The Company&rsquo;s other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company
and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or
caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the Company&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the Company&rsquo;s internal
control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably
likely to materially affect, the Company&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The Company&rsquo;s other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&rsquo;s auditors
and the audit committee of the Company&rsquo;s board of directors (or persons performing the equivalent function):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the Company&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: April 29, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom"><FONT STYLE="font-size: 10pt">/s/ Lin Yang</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 31%"><FONT STYLE="font-size: 10pt">Lin Yang</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>14
<FILENAME>ea022807501ex13-1_universe.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 13.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 906 OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Annual Report of Universe
Pharmaceuticals INC (the &ldquo;Company&rdquo;) on Form 20-F for the year ended September 30, 2024, as filed with the Securities and Exchange
Commission on the date hereof (the &ldquo;Report&rdquo;), I, Gang Lai, Chief Executive Officer of the Company, certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of Section 13(a)
or 15(d) of the Securities Exchange Act of 1934; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">The information contained in the Report fairly presents, in
all material respects, the financial condition and results of operations of the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: April 29, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom"><FONT STYLE="font-size: 10pt">/s/ Gang Lai</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%"><FONT STYLE="font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 31%"><FONT STYLE="font-size: 10pt">Gang Lai</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>15
<FILENAME>ea022807501ex13-2_universe.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 13.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 906 OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Annual Report of Universe
Pharmaceuticals INC (the &ldquo;Company&rdquo;) on Form 20-F for the year ended September 30, 2024, as filed with the Securities and Exchange
Commission on the date hereof (the &ldquo;Report&rdquo;), I, Lin Yang, Chief Financial Officer of the Company, certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of Section 13(a)
or 15(d) of the Securities Exchange Act of 1934; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">The information contained in the Report fairly presents, in
all material respects, the financial condition and results of operations of the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: April 29, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom"><FONT STYLE="font-size: 10pt">/s/ Lin Yang</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 31%"><FONT STYLE="font-size: 10pt">Lin Yang</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>16
<FILENAME>ea022807501ex15-1_universe.htm
<DESCRIPTION>CONSENT OF ALLBRIGHT LAW OFFICES (FUZHOU)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 15.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><IMG SRC="ex15-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#31119;&#24314;&#30465;&#31119;&#24030;&#24066;&#21488;&#27743;&#21306;&#26395;&#40857;&#20108;&#36335;</FONT>1<FONT STYLE="font-family: Times New Roman, Times, Serif">&#21495;&#22269;&#38469;&#37329;&#34701;&#20013;&#24515;&#65288;</FONT>IFC<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65289;</FONT>37<FONT STYLE="font-family: Times New Roman, Times, Serif">&#23618;&#65288;</FONT>350005<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65289;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#30005;&#35805;&#65306;</FONT>+86-591-87850803
<FONT STYLE="font-family: Times New Roman, Times, Serif">&#20256;&#30495;&#65306;</FONT>+86-591-87816904</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">37/F, IFC, No.1, Wanglong 2nd Avenue, Taijiang
District, Fuzhou, Fujian 350005 P.R.China</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Tel<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT>+86-591-87850803
Fax<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT>+86-591-87816904</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">www.allbrightlaw.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 29, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe Pharmaceuticals INC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">P.O. Box 31119,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grand Pavillion, Hibiscus Way, 802 West Bay Road,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grand Cayman, KY1-1205, Cayman Islands</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Sir/Madam,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby consent to the references to our firm&rsquo;s name under
the headings &ldquo;Item 3 Key Information,&rdquo; &ldquo;Item 3 Key Information&mdash;D. Risk Factors&mdash;Risks Related to Doing Business
in China,&rdquo; &ldquo;Item 4. Information on the Company&mdash;B. Business Overview&mdash;Regulations,&rdquo; and &ldquo;Item 10. Additional
Information&mdash;E. Taxation&mdash;People&rsquo;s Republic of China Taxation&rdquo; in Universe Pharmaceuticals INC&rsquo;s annual report
on Form 20-F for the year ended September 30, 2024 (the &ldquo;Annual Report&rdquo;), which is filed with the U.S. Securities and Exchange
Commission (the &ldquo;SEC&rdquo;) on the date hereof. We also consent to the filing of this consent letter with the SEC as an exhibit
to the Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In giving such consent, we do not thereby admit
that we come within the category of persons whose consent is required under Section 7 of the Securities Act of 1933, or under the Securities
Exchange Act of 1934, in each case, as amended, or the regulations promulgated thereunder.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 48%">&nbsp;</TD>
    <TD STYLE="width: 52%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yours
sincerely,</FONT></P></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Zhang Biwang</P></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Zhang Biwang</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Lawyer</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>AllBright Law Offices (Fuzhou)</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.2
<SEQUENCE>17
<FILENAME>ea022807501ex15-2_universe.htm
<DESCRIPTION>CONSENT OF ENROME LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 15.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex15-2_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby consent to the incorporation by reference in the Registration
Statement on Form F-3 (File No. 333-268028) (&ldquo;Registration Statement&rdquo;) of our report dated April 29, 2025, relating to the
consolidated financial statements of Universe Pharmaceuticals INC included in its annual report on Form 20-F for the years ended September
30, 2024, 2023, and 2022. We also consent to the reference to us under the heading &ldquo;Experts&rdquo; in such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enrome
LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Singapore</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 29, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (0 ? # 2(  A$! Q$!_\0
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MK!N,_P"&[4_Z,V_;T_\ $<G_ /FGJ:/_ )2>W?\ V8?I7_K0&MU]Z4 ? O\
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MK;7=9T0L[Q+$TTBE=\L-P(/8Y]-LII[:>XL[>:XM=QL[@VBDV?'&TELJ,C@
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M6M(UGP_JT.M>'M>\/Z[HYA\1:!XD\,:_;KKOA/Q%X?EMY;:2%0A10LLO;?\
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M /#V>$O_ )V5'_##&H_]'K_MY_\ A[/"7_SLJ^]:* /@K_AAC4?^CU_V\_\
MP]GA+_YV5'_##&H_]'K_ +>?_A[/"7_SLJ^]:* /@K_AAC4?^CU_V\__  ]G
MA+_YV5'_  PQJ/\ T>O^WG_X>SPE_P#.RK[UHH ^"O\ AAC4?^CU_P!O/_P]
MGA+_ .=E1_PPQJ/_ $>O^WG_ .'L\)?_ #LJ^]:* /@K_AAC4?\ H]?]O/\
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M'?'UQXWA\':SH\7B!($UO1;B3P-XTAWV^Y1+I$OF)$P3?]6T %%%% !1110
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M*9&T;Q?H_E)*OB'P];EF7QEXA\++=6O@?]VWCN?PF1O3\X?V-O\ @G'^UO\
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M^)W[6GB^W_:+/[*WP"^#MA\:/C-HGP[L/BS\4&\5_$P_"KX7?"?P#XAUC6=
M\ G7_'%C\./BKX@G^('C/7_#NMMX/\&^'_!%TT?AS2+KQ?XQOO"UFUJTWRG\
M*OV&/VE_"G[3WP.^-=UJ?PM\#:)X=T?X<)\8]%\)?%/XD>//#?CS_A!OV:-
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M7:^,/"_@^27Q?>64%D!<M^1?B7_@G3^V9KVA:QHJ:?\ LY^'K72_V0_^"?\
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MS+X6\/?M._L;?%#]F/Q'X"\;_%?XNZGI7[/_ (I\;>-?B]X]TGQCX$\;Z_\
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M7_U-OVUZ^VZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M \-ZV?#'@U?%4 \&JLOB$^._^$)$J+. ?O/8_'/X,:GX4L/B#I/Q@^&U_P"
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?\%>/A1\4OBW^SA\+]3^$OA+6?B=?_ /]K[]E3]IGQ=\*/"0_M3Q+\5_AO\
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M$1%(P_J=TO[1_9]C]M\[S_L@^U_:?O[\#?YG;=GK_L]>]:U% !1110 4444
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MPG7G?\4[_8/7SO\ A'/W_P![;\^^N3NO^&R?^%<:!Y'_  S3_P +@_X25?\
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MJJW66*&!)Y1<3 %6N H4'WXXY''N:N44 %%%% !1110 4444 %%%% !1110
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M[UCX6:Y\8?AS_P +T^$/B#PPH0?&SPM\5SXM7P3XU\<#_A!?'4GF)Y/]@]%
M'\J?@7]I'Q/>:WX7^'OQ+^*W[3MS^P[X0_;6_;C^&?Q'^*6F^,OVC[#XD^#]
M*T230];_ &/M'\:?&_P_,GQT3X.^)HYO''_"(^+T\8'_ (K#0/"G@;QMXUN6
M40-?_9YO/VB_B?\ M$_L9?!/]H#]JO\ ;%T:VU7X _M-:Q:Z1I'B;QA\-M5\
M=^%/ _[3?A[6_P!C?QK\4M;T'PYN/QC^*/P3T+7W\;CQ5XO_ .*S\%^'_$R@
M>;)XR#?U.T4 ?S+?\$Q_BE\;?B'^U]K5C\;?V@/VZ)?C]H5A\:=%_:,_9J^(
M/P \8>&OV;/!TR>,D/AS7-"^*'B2";X5_P#".#=HTOP3F^ :>$O&'B_PAK2O
MX]@G7S/*_IIHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** /R?^,WP*^#OQ_P#^"CEAX9^-7PY\)?%+PWX:_8K;7O#F@^--(A\0
M:/H^K:Q\>GT?6]9TS2Y(I%36Y((([=[H*TBKY85E*C'O7_#M+_@G_P#]&A?
M'_PW.B__ !FJ,?\ RD]N_P#LP_2O_6@-;K[TH ^&?^':7_!/_P#Z-"^ /_AN
M=%_^,T?\.TO^"?\ _P!&A? '_P -SHO_ ,9K[FHH ^&?^':7_!/_ /Z-"^ /
M_AN=%_\ C-?*W[9_[+?[$_[*G[,OQ<_:+\._\$^/V=_BL/@]X,UCQ[J_@?\
MLOPG\.YK_P /Z#YFO:W+I'B!O"WB>.+6PL;%-]O&)Y"@24 JDW['U\W?M8?
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M.BU]^4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\/?$L?B+XK>(/"_C?XG>%?%_B_\ X3'P;X$\.*_@7S/%N/!8!]B_"'_@HO\
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MHH ^"X_^4GMW_P!F'Z5_ZT!K=?>E?!<?_*3V[_[,/TK_ -: UNOO2@ HHHH
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M%% !1110 4444 %%%% !1110!\%W?_*3CP__ -F(^*__ %H/P)7WI7P7=_\
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M%J70=).O?\)A+K_@^75]%+VA\)117XUJ(^"[CQ4'E50#V'SO^"G?_/C^P?\
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M.?%#N_A6(^,U\&O#XV/A_P D>,(YG\&R@'[I^=_P4[_Y\?V#_P#P=_'_ /\
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M)EX_\1Z'X(E\%>'=?\,>'/'WB'PQ'X\U?05\8M_PBEW-&VA3SVJ&!C+^MM%
M'X;>+O\ @E%\4O$'Q'\%?&4?M@6,?CWX>?$7X-_%CPCJOBG]FG1_&,N@^*/A
M3\%Y/A')X+\/RM\2[9O#7P9\4+K.O^+3\,/"DL%Q!XPUR22?QIXIDB /F_B'
M_@F/\6?@#\$/ 5YHGQJU7]H(_LT_LF_M9?L^Z1\*M _9O\#_ /"2_%[PQ^TE
MKFAZUK;XUWXF/X:/B#PK'X>\/,GAIA_Q6JZ+XBA)6?Q7-#%_0C10!_/7^R5^
MQ_XPU;P;\3/A=H?Q!\=WWPJ^(K?#"R^.OC7XZ?LD_M!_#CXF?%KP#X&T3_A
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M-9U/XO>#_B3\+OBS\"/'_P /_AGHG@;P1\%O'GPIU:37-#UF/X6:[XF\9?\
M"?-XC;5=?\+^/H?$_B]O^$R\":])X,MV\(W$;>*G]%^#'[-7CKX*W?B[QQ9_
M%+3O&7COXJ_$SQ7\6/VC=?O_ (6R:<WQ7\21_#'0_AYX&TGX8:&OQ&>#X0^'
MO"X\%>!-MNS^,SXO3P_.9Y$N?%$OBR/YRN?^"@?CF]\'?L_ZKX2^'/AO7_B/
M^WEX[\3Z3^Q#\+[N_P!7\,65G\,M#\%ZOXW_ .%S_M#^-?+\71:%H<_A70F^
M)$WA_P (^$!?6MKKWASP':IXL\<W'VJ'E/VE/VV?VSOV9-,\ :E\8/A)\"?
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M!CUO2?C'\%OBRA<>(,QK/X<^R[HG2,YVR-6;_P ,O?'K_I(A^UI_X0G[#_\
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M&4K'=],?\,O?'K_I(A^UI_X0G[#_ /\ 0E4?\,O?'K_I(A^UI_X0G[#_ /\
M0E4 ?G7X=_X)^?MO>%OBUX:^)UIXR_96U2W\-?MS_M.?M@V6CWS_ !C_ -,T
MO]HSX6^(?A2?!LAMX%"W'A@>(%\2GQ$&*F1%6UMT)D+^4>'_ /@EI^W3X=^&
M/P'^'WA[XV?LW>%];^"G[$/Q._9%_P"$VTO0_B?JFH7VL>.OB7X$^(">,]#T
MG6S);^'(V\-> -#\*^891XL\&S^(O$GB_P "/]K\+>#8#]E3> OVFH?VQ]'_
M &?#_P %!OVE?^$%NOV9M7^,GVG_ (5S^QF?$A\6:-\4?#_@=P=9/[)@C_L-
M]$UL!A_K#-EBQZU]0_\ #+WQZ_Z2(?M:?^$)^P__ /0E4 ?F)H7["O[0/PV_
M9\_:Z_9%O]&\#:A!_P %!/CX?'2:]\*(_B5XA\.?!#P3XX\&?"?P'\<]5^)O
MCCXQ./\ A)/$*^&? CS>"905\6>,_%^OF9O!R10W)B_H'L[*"QM+:RM_E@MK
M9+6WY!(55"CD=\(O3WKXS_X9>^/7_21#]K3_ ,(3]A__ .A*H_X9>^/7_21#
M]K3_ ,(3]A__ .A*H ^VJ*^)?^&7OCU_TD0_:T_\(3]A_P#^A*H_X9>^/7_2
M1#]K3_PA/V'_ /Z$J@#[:HKXE_X9>^/7_21#]K3_ ,(3]A__ .A*H_X9>^/7
M_21#]K3_ ,(3]A__ .A*H ^VJ*^)?^&7OCU_TD0_:T_\(3]A_P#^A*H_X9>^
M/7_21#]K3_PA/V'_ /Z$J@#[:HKXE_X9>^/7_21#]K3_ ,(3]A__ .A*H_X9
M>^/7_21#]K3_ ,(3]A__ .A*H ^VJ*^)?^&7OCU_TD0_:T_\(3]A_P#^A*H_
MX9>^/7_21#]K3_PA/V'_ /Z$J@#G?VA/^3X/^"?/_7U^U;_ZIG1:^_*^'O#7
M[(>NVGQ>^'/QA^(_[5/Q]^-VM?">Q\<6/@'P_P#$'1_V??#GAO2]3\=Z(- U
MG663X1? WX5^)-9E70MT:+-XIEC&QFVNRM&OW#0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:_\ X85__FFH_P"&UX_^C4?VU_\ PPK_ /S35]MT4 ?$G_#:\?\ T:C^VO\
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M&*_ML?\ A-?L_?\ T1U'_#7_ (W_ .C%?VV/_":_9^_^B.K[:HH ^)?^&O\
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M/#OCS1-1QX"\5^,O#]QI,_A[Q#ICP31>)6,D:-%*J2>5YWTW7Q/^SG_R<_\
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M_C)HW@H^']7'C:;X3'QA_P (2VBSOXOEM [*0 _X=C_L0_\ 1%Q_X<CXR?\
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M7W#1-(0#QS_AV/\ L0_]$7'_ (<CXR?_ #Q:/^'8_P"Q#_T1<?\ AR/C)_\
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MOV8/^2Y?\%#O^SL_ O\ ZQ5^R-7IW[3_ ,>O!7[*W[/OQE_:2^(-MJ%WX/\
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MOQ$\0_%?X8G]G/2/C]X[\#?L_>,O!OP-\#ZM^U3<Z'I?PLUN/5O$OB7Q- ?
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M:#KFE:5J^DZYI-X-5TW5],UI([C1]3TO6()/L^KZ3-'.9(Y4=E>%TF4[617
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M"T+PTOA\>7=O'X@?QM.L7@SPAXQEA /@+P7^P%^V/X!^*&I_M :3XI_9EO\
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M?^%C^&O#OAC0O%EPFK2VT'BOX0^.&\(2:YK;PS2,0\?C?QH_X)<_$/XK:O\
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MX<637_'/C;P^GQ4\-^+!XO\ ^$$7PWX&?P-OBF\8+[-XW_98^/GPW_:Q\?\
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MQ9X*\<^'O^$)\;6AD\4P_9OT%H _)G]EC]A7]IGX ?#C]GSX%:W^UYX*\6_
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M_$-?VQ__ )QE 'W-7X!>.?V-O%WQ8^%G[9?[%EWXJB^'_P 9O$/[:.H_M_\
M[./C7Q?H^IZK\./&]A_PN?P+\>?!::^+6-AK^@^%_B/H>L?"KQ[X6CN)O%W@
M[PA'X4\:P0J6\'22_HO_ ,/$OV8_^?SX]?\ B&O[8_\ \XRC_AXE^S'_ ,_G
MQZ_\0U_;'_\ G&4 ?.'[0=_^WC^T?^RI^T9\'[S]E3PA\+_%/CW]GSXI_#RV
ML]5^//ACQ"OC7QM\0? ^L>"/#]OX-UKPU"(?#OA_PMXFUI?$?BOQ5XU2*67P
MAH L8? \EYXME'A'\W/C!^PI^V7XG\)?&+P9X2_8W\ V^D>+_P!F_P#X)J^
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MM,8/V17PS_P\2_9C_P"?SX]?^(:_MC__ #C*/^'B7[,?_/Y\>O\ Q#7]L?\
M^<90!]S45\,_\/$OV8_^?SX]?^(:_MC_ /SC*/\ AXE^S'_S^?'K_P 0U_;'
M_P#G&4 ?<U%?#/\ P\2_9C_Y_/CU_P"(:_MC_P#SC*/^'B7[,?\ S^?'K_Q#
M7]L?_P"<90!]S45\,_\ #Q+]F/\ Y_/CU_XAK^V/_P#.,H_X>)?LQ_\ /Y\>
MO_$-?VQ__G&4 ?<U%?#/_#Q+]F/_ )_/CU_XAK^V/_\ .,H_X>)?LQ_\_GQZ
M_P#$-?VQ_P#YQE 'W-7Q-^WK_P D4\#_ /9W_P"P?_ZVE\!*I?\ #Q+]F/\
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M^?)0!]\T5\#?\-OZW_T9!^WG_P"&A\%?_/DH_P"&W];_ .C(/V\__#0^"O\
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M /#0^"O_ )\E'_#;^M_]&0?MY_\ AH?!7_SY* /OFBO@;_AM_6_^C(/V\_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E
M_P 6/AUX;^-'PO\ B/\ "3Q:;^7PE\4/ OBGX=^)O[(O#IFI-X8\;:+-H.OM
MI6L!2(&;1]6F59E1SYBX <C97SM^QQ^P!^R-^P'X!M_A[^RE\$/!WPQTXVME
M::QK=E9KJ/CGQ0805&I^-/&^L%O$GB.1\[G^U73CS5/DH@)2'[9HH **** /
MRY\6_LA_M/6W[9?Q8_:W^&?QX_9_T^#XD?!/P#^SU%\+_B7^SA\1_%]A;>"/
M WBSQ[X\35M8U_P]^TGX*MM?\2R^)/'NNVR%O"<-N/"C>4'0[#7P;^W?^Q;^
MT/\ "O\ 90_;9^+W@;]H/3OB'\1_CM^P_K'P7_:!\#G]FGQCXX'Q?\3:%I'Q
M$C^%<_[/?@[X4?$E?%7PB\2F?XJZW\,?"WA>5_C'X6B\,2>%WO#M\*&>7^CB
MB@#\ -1_X)O>/OVD_A1XTU[X:_M,S?!;P5^V#\,/V)]6^(NCZ[^SW=>)/B5X
M5\3?LL:%X=N- ;1D^(GB;PA!X?7Q7_86B0>-?#_C#X1-XKB>.1$FMB9;>+V.
M\_X)H_&;4M<\>>*)OVF/!0\4ZE^WOX%_;H\!Z@OP%U4:1H7B3P/\-(/A%)X/
M\;:*_P :5/B >(O#RGQ-)XD\(R>"77QCO+VTG@;[-X*'[.44 ?BM^QY\/- ^
M,7[:7Q]_;:\.>#_C]\-/AW-I6E>!+7P/\</AYK7PJT_QS^TSH.GGP+\3OV@_
M!'PMU]+7Q-&)?AKH'@7X72^*KA19^+!H$X\'37%K!/++]3_&O]F3XV_$/]KG
M]GW]I/P+\9?A;X2T7]G_ ,&_%'PUIWPW\3?!CQ=XVU'78_C<OAZ#QUJ^H^,M
M$^-?@V*$P?\ ""^'O^$.@_X0YU@,OB(32R>8A/Z!44 ?A1X!_P""3?Q?\,>"
M/V6_A_XC_:<^'^N^&_V>/AO^V5\+[^YTG]G_ %WPWXB\>>'/VO\ 2?(UO5(O
M/^.'BF'PSXB\,2$^20OBJ.['SR$[N;.F?\$N?VH? =_\#O&'P<_X*#-\)_B%
MX*^ _P ,/V:/CE=6/[,?A#QIX$^+/PF^!UTP^%.K^$? WCKXC7$WPA^,'A70
MM;\2V[?$U/%WC2'=KI8>!WC@^SO^YU% 'XU:E_P3-\<^)O@W^UG\(_%/[4$F
MF>+/CQ^U%X8_;"^#WQ@^&GPL?POXX^!GQ>\$/\.)/!&O:U#X@^)'B[PS\1)+
M37OA3X,=T:+P=-XK'_"4)(($O86\*\9\5/\ @F#\>?C_ /!7PAX/_:3_ &P/
M#7QP^*7AC7_%>NZ1\3)?V5-$^'=G\.-3UJYT.;P-XR^!NC_"_P")7A#XD_!_
MXL_#*31&\00>+E^,?B^W\7>*IS-XV\&^)[*U\)^%K+]R** /QH^(7_!+CQ)X
MZN?VEM!U?XX^%?'7PP_:6USX0^,?&'PZ^-?P$T'XL1>*O$7PG_9^\-_ E=(^
M*NM'Q7X5G\2>&O%B^"_#WQ*>3P;'\(/&/@OQW$S^"?&UK%M*_>W[)WP+O_V;
MO@'X!^#6J_$'Q-\3[CP/::K9?\)9X@N];:9X]9\0:WK2Z%HP\2^(?%WBN+PS
MX376H_#7@I/$_B_QAXLA\':3H4%]XU\4W$9N9/J&B@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
4B@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $6 D\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W6ZO$MF5"
M&9W!VHHR34(U)L?\>5U^*?\ UZ$YUFXSSB%,?FU7ATJ-6(H_VDW_ #XW7_?(
M_P :/[2;_GQNO^^1_C2ZMJ4&CZ;<:C=>8+>W0O*40L54=3@=<5G:/XMTK6[M
MK2U>=;CR5N1'/"T3-$W1QN'(IV8&A_:3?\^-U_WR/\:/[2;_ )\;K_OD?XU:
M$BX!W+@Y_BJ*[O(K2TEN7+M'"I=_+7>Q ZX Y-%F!%_:3?\ /C=?]\C_ !H_
MM)O^?&Z_[Y'^-8[>._#Z^&8O$/VQSILLGE(ZQ,6+YV[=F-V<CTK?CF6:)) "
MH90VU^" ?4=C19@0?VDW_/C=?]\C_&C^TF_Y\;K_ +Y'^-3PW$5Q#'+#,DD;
MC*,K AAZ@BHKO4;>R\CS6<^?*(H_+0M\Q!QG'0<=319@-_M)O^?&Z_[Y'^-'
M]I-_SXW7_?(_QJ+5M:LM#LQ=W\K) 95BWHI?#,<#..G/X5>,J["VX849)!Z4
M68%;^TF_Y\;K_OD?XT?VDW_/C=?]\C_&JFF>)--U9PEI+*Q9/,C+QE1(F<;E
M)&",UJ[U YD7ZYQ19@5?[2;_ )\;K_OD?XT?VDW_ #XW7_?(_P :LEQO +!<
MCUYJEI.N6.M0S2V<K$0S/!('0H5=3@C!_G19@2?VDW_/C=?]\C_&@ZDW/^A7
M7_?(_P :O)R,TN!Z4:@5[>Z2Y#;=P9.&5A@BK JB !K,F !FW4G'^\:O"A,!
M:***H84444 %%'>DH J75WY$J1(C22N,A1V]S40N[[_H'G_OZM*O_(:E';R%
M_P#0C5X"HW$4?M=]_P! \_\ ?U:/M5__ - \_P#?U:OTN*=@,_[5?_\ 0//_
M ']6C[5?_P#0//\ W]6C6M1_LC2KF_-M-<I A=HH<;V ZXR17/S?$+2DT31=
M4A@NKB+6)5AMDC"[@Q[-D@#'UHL!T'VJ_P#^@>?^_JT?:K__ *!Y_P"_JTX:
ME9;I5:[@5H1F53(,Q_[W/%!U2P"*_P!MM]A8J&\T8)')%%@&_:K_ /Z!Y_[^
MK1]JO_\ H'G_ +^K67?^+].L=6T_35\RZGO4,H\@J5CB'61CG[H]1FM8ZG8B
MU2Y^VV_V=VVK(90%)] :+ -^U7__ $#S_P!_5H^U7_\ T#S_ -_5J*/7=*DN
M9[8:C;F:!Q'(AD *L1D#ZXJ5M5L$17-_;!64,K&48(SC/TS18 ^U7_\ T#S_
M -_5H^U7_P#T#S_W]6JUAX@LKVU29Y5M6=B%BN)%#$!MN< G(/:KIO[,77V0
MW4/VGM%O&[\J+ 1_:K__ *!Y_P"_JT?:K_\ Z!Y_[^K5Y>_UIV*+ 9_VN^_Z
M!Y_[^K36OKF,%I;%U0<EED4X'TS6CCFF2@>6W'8TG< AD$L8=3E6&0?45)5'
M1_\ D%P?0_S-7JI;#"BBBF 4444 %%%% !1110 4444 %(:4TAI,"G/=2_:/
M(MXP\@7<Q9L!?K3=^I_\\[7_ +^'_"DM.=4OL^D?\C5_ J4KB*&[4_\ GG:_
M]_#_ (4N[4_^>5K_ -_#_A5UAV!Q7*KXJNKW5-1M]'TIKVWTU_*N)?."%I<9
M*1@_>('7)%/E W-VI_\ /*U_[^'_  HW:G_SRM?^_A_PJG%XIT:2<6SZA!'<
MABCPL_S(P7<5/N!S]*A/C/03-81Q:C'*;Z4Q0&,%@S 9/X8(Y]Q1R@:>[4_^
M>5K_ -]G_"DW:G_SRM?^_A_PJ@?%_A[[,]S_ &S:^0DHA>3S!A7/0?CCCUJ6
MT\4:%?B0VFJVLWEQ&9]L@^5 <%C[#!HY0+6[4_\ GE:_]_&_PHW:G_SSM?\
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M&%QJ3)%!9W%O-;R*MTS;E>,*N1[,.W&,8]:] _M>Q/67_P <-']KV)_Y:_\
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M7^\/SJMJ>1IMT02/W3=/I4,>EV1128><#^)O\:AL"_O']X4;Q_>%4O[*LO\
MGC_X^?\ &C^RK+_GC_X^?\:=V+4N[Q_>%&\?WA5+^R;+_GC_ ./G_&C^R;+_
M )X_^/G_ !I78:EW>/[PHWC^\*I?V59?\\?_ !\_XT?V39?\\?\ Q\_XT78:
MEW>/[PHWC^\/SJE_9-E_SQ_\?/\ C1_9-E_SP_\ 'S_C1=@7=X_O"C>/[PJE
M_9-E_P \?_'S_C1_9-E_SQ_\?/\ C1=BU+N\?WA^=&\?WA5+^R;+_GC_ ./G
M_&C^R;+_ )X?^/G_ !IW8]2[O']X4;Q_>%4O[)LO^>/_ (^?\:/[*LO^>/\
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MO[)LO^>/_CY_QH_LFR_YX_\ CY_QHNPU+N]?[PHWK_>%4O[)LO\ GC_X^?\
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MI:*H91U4SKIMR;:?R)Q&3'(4W!3CT[UQTGBK6)?#=FD?E0ZT+M+6^PF\1?,
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MC"YSM&1WQ5'^R+7TD_[^-_C1_9%KZ2?]_&_QHNQE[:O]T?E1M4$G:.?:J/\
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M,??;ZGM^%78(4@CV1H$4'H*6KV J_P!KVG]Y_P#OV?\ "C^U[7^\_P#W[/\
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M7RDX3\>YI78AL;B^O$F0?Z/!G:W]YCQ^G-:*FDC4*,   = !P*?0D"*FI?\
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M-\?H:+B':II-AJ\*0ZA:QW$:-O57SPWK]:K'P]I L8[$:= +6.3S4C"X ?\
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MDNAAW%CG[P.<@\5U40VH "Q [L>:IG5+7^%V<^B(2?Y4?;I7'[FRG;_>PO\
M.BX%^F.0!DG '<U2/]H2G_EC OKRY_PH73ED(:YD>X/HQPO_ 'R*5V(9/>M.
MQ@L?G?&#+_"GO[U<M(5M[9(E)(48R>_O4D:JB[54*HZ #&*?188AZ50M/^0E
M??5/Y5?/2J%I_P A*^^J?RI/<3+XI:04M6,**** "BBB@!"!2T44 (:#TH-!
MZ4F!2T__ %EY_P!?!_D*O51T_P#UEY_U\'^0J]0MA+8#24II*!ABHY(8I?\
M61H_^\H-/) Z]*K27]K%]Z=,CL#D_I1H+0:VF6;'/V=0?;(IO]EVYZ&4#VD-
M']J1'&R.>3W6,X_6C[=+U%E.1[X%2[!H-_LJ'/\ K;G_ +^FE_LNW[F5OK(:
M/MUQ_P ^$W_?0I?MLXY-C,![$&E9!H*NF6:MG[.A/J1G^=6DBCC&$15_W1BJ
M?]I(I^>"Y7ZQ\5(FH6KGB=0?1OE_G3T#0MXHIJL& (((]J=3& I:!15 5=2_
MY!ES_P!<F_E4MO\ \>\?^Z/Y5%J7_(,N?^N3?RJ6W_X]X_\ ='\JCJ!#J?\
MR#;K_KDW\JGB_P!4G^Z*@U/_ )!MU_UR;^53Q?ZI/]T?RHZB)**:>*KW-[#;
MD*S9<]$7EC^%5<99.**SME[=\NQMHO[JGYS]3VI1IJC_ )>[O_O^:FXC0HK/
M6QC8G;>W+8Z@3DTITY?^?J[_ ._QH OT50_L]"2HN[K/H)SFE_LY1_R\W?\
MW^- :EZBJ"Z>K#(N[HCU\XTO]G#_ )^KO_O\: +II15!M.QRMW=!NQ,I./P/
M6FB:[M?^/A//B_YZ1#YA]5_PHN!I45!;W$5S&'BD#KZCM]:F'-5<8&F3?ZI_
M]TT^HYO]4_\ NFA["9!I7_(+MO\ <%7*IZ5_R"[;_<%7*%L,****8!1110!1
MU?\ Y!LO_ ?_ $(5<7[HJGJ__(-E_P" _P#H0JXOW14=1"TM)15#"BHI94A&
MZ2147U8XJK_:<3'$*2S?]<T./UI7%<OXIK1HWWE4_452\^_?_5VB(/\ IH_]
M!2^7J+'F>%!Z*A/\Z5P)VM+=NL$9_P" BHSIMF>MO'^5,-I=-]Z_D_X#&HH^
MP/T-W<'_ (%B@!?[*L>IMH_UH&F6(Z6T?Y4#3\_\O=U_W]-!T\CI=W7_ '\H
M >NGVB\BWC_[YJ5;>$?=BC'T456-E,/NWTX^N#_.D^SWJCY;W)_VXA_2@"\%
M Z#%+5#&I(.MO)^:T?;+F,XELI/<QD-3T OT5234K5VVF38Y_AD&TC\ZN T7
M <**04M.XQ#TJA:?\A*^^J?RJ^>E4+3_ )"5]]4_E2>XF7Q2T@I:H84444 %
M%%% !1110 AH/2@T'I28%+3_ /67G_7P?Y"KU4=/_P!9>?\ 7P?Y"KAI1V$M
MAD\R0(7=PJ@9)-4OM%W=+F!!#$>DD@R2/9?\:&7[5J3+)]R  JIZ%CW_  K0
M6C=@4!IR2?-</+.>^]N/R'%6HK>&+B.-%QZ+4PKF_'9MAX7E-W((X_-C^8R%
M.=P[BG8+'1XHP*\R74Y-,U^6S\-7MN=*N9H8,W#M)%'.V=PB.>> "1G%3OXZ
MOX4N(Y)K SPPEI JL2CB78>,\_+@XS189Z/@4E>:WOB[7%L#$MWI\=R]GYRR
MQ+OYY)XSQQ]1P:EO/&^IV\$[PRZ=(4#*0VX&-EQAVY^XP/'X=:+ >BXIDD,<
MGWD5OJN:X*?QAK<%YJ%N8]/ M8]@EDEVEGP#O"]=IR>O''6NRT2^;4M&M+U]
MNZ:)7.P$#)],\T6 4Z; IS"7@;J#$Q%,9KVU&6'VJ/N47#C\.AK1-(:+"(K:
MXCN8_,C;<I_3ZCM4]9MTBVUW#.G'FN(Y /XL]#6@N>]),"OJ7_(-N?\ KDW\
MJEM_^/>/_='\JAU+_D&W/_7)OY5-;_\ 'O'_ +H_E2ZC(-4_Y!MU_P!<6_E4
MZ?ZM?]T8J#4_^09=?]<F_E5B+_5K]!1U$9E[<7*W'EONM[7_ )[H-Q/^%6[.
MVMXH]\ 5MW)DSN+?C5H@$<]*HR:>$8O9R&"0\D#E#]5HM9C+PZ4R3'?IBJ0O
MGMSLO8S%Z2J24;^H_&IO[2LN]W#_ -]BG<+GF6F6<]E%/XCTR>U@@MKJ:-DB
MA?,L;3C/F;NH5<E=HXJY;>+]7NY[MX;Z.2*W@:7:MFVYAYI3=R.@7#8ZFO0!
M?Z>%(%S;@'J-PH%_IZG(N+<'V84[BN>=MKT]CKRWJ:E!<LT,*3.ELX^T R,.
M!C P,$XIUGXVU:9RIN(B!>(.;9M[1L!QMQP021C.1CKQ7H/V[3AC_2+?CI\R
MT"^T\<BXM^N?O"BZ"YYU#XQOX;I5COK86Z2+YD8M&4N6N"AP<<?+\Q^F:Z'P
MEK6HZMJ&H"\NXWBC.(XA$$*G)R0>I7&,$\]:Z&2[TYP09[8@CG)7FJ.F6^DZ
M7N-O>%RP !FN=^U?[HST'M1<+FZO2@_K5,ZE9J"1=Q8'. P)J/S[J[_X]D\F
M+_GK(.3]%_QJ6[C$OH;2%O/:7[-+VD0\D_3O3].FNIHV^T1[5!^1^A<>I':G
MP6,43^:^99?[\AR?P]*N"A""HYO]4_\ NFI#4<W^J?\ W35/8&0:5_R"[;_<
M%7*IZ5_R"[;_ '!5RA;#"BBBF 4444 4=7_Y!LO_  '_ -"%7%^Z*IZO_P @
MV7_@/_H0JXOW14=1".0.I'3/6J GN+TG[,1'"#CS6'7_ '1_4U/J*N]A,(\[
MBAZ=?<#\,U):O&]M&T6/+VC;CTH;&0Q:?;HWF.#+)_?D.XU;  & ,#TI:*JP
M *1NN/\ (IU-;J*8')ZCXQ.EZXVGW-@GDB6.+S5NE,C;^C"/&2!WYK4/B71O
MLJ7']I0"%YC KE\ N#C'^)Z5"- <ZYJ&HS2P.;B,1PGR1YD. 1D-WK%T[P1>
MZ?+YR:G;O+YI8EK4$.& #;@3RQQG- &O;>*]/DLO/OI4LG&XLCOG #$9R.H/
M:K%QXET>WD2%]2@$KQ^8BEOOKC/7&!7-IX$U"&QN[2/68C'=S&:0/!D%B3D=
M>%(/053M_#&HV^J1V15F6*V^SI.]O^XQL*[^&X8 X Q0!V,'B+2II5M_[0MO
MM!0N\8DR5 &?RQSFK.E:MI^KQRO87<=PL3['*9^4^AS7'/X*U&V@DG-_!<N%
M7=&EH T@6/8!R?3G'2MOP/9W5EI$J7,,B,TF=TT6R1SC!+#)^@YZ4 =,:*6B
ME8"&6*.8;9$5@1T89JH;%H#FTF,7^P?F0_AV_"M&D-*P%2VNC([0S)Y<ZC.W
M/!'J#Z5;%9]X0]_:)'CSE8LQ'\*=_P ZOKTI(!3TJA:?\A*^^J?RJ_5"T_Y"
M5]]4_E3>XF7Q2T@I:H84444 %%%% !1110 AH/2@T'I28%+3_P#67G_7P?Y"
MKA&:IZ?_ *R\_P"O@_R%7J4=A+8S[J.6*<7,"[VV[9(^FX>H]ZGM;J*Y7,;Y
M8?>4\%3Z$=JL&JMQ90W#!V!5P<AT;:V?J*+6U M+S39(HYDV2QHZ_P!UAD52
M\J^ASLG25?21<'\Q1]KNH_\ 6V3G'>)@V?PXHN!;6VMT556"(*AW* @P#ZBJ
M&JZ):ZE!L):W<.)!-" K@_7'-2C5(!]\2QGT:)J=_:5F>MP@^O%',%PL=-MK
M.U2%(P^U=N]U!9@>3GZU8^RVYSF"+D 'Y!R!T%0?VG9?\_</_?8I#J5F.ES&
M?H<T7'<L-;0.Q9H8V9EVDE <CT^E2*JHH50%4#  ' JB=4M^=ID?_<C8_P!*
M3[9.^/*LI3GNY"?XT[BN7ZAN+B.V3?+(J+ZG^@[U6*:A,?FEB@7_ &!N;]>/
MTI\-A#'()&W2RC^.0[C^%+<"&(2WEPD\B-'#'S&C=6/]XCM6BO0TH^E+32 J
M:E_R#;G_ *Y-_*IK?_CWC_W1_*HM2_Y!MS_UR;^52V__ ![Q_P"Z/Y5'49#J
M?_(-NO\ KDW\JGB_U2?[HJ#4_P#D&W7_ %R;^53Q?ZI/]T?RJNHB04AHHIC$
M*AA@C(/K3/(B_P">2?\ ?(J2BBP6(_L\/_/-/^^11]GA_P">:?\ ?(J2BBP6
M(_L\/_/-/^^11]GA_P">:?\ ?(J2BBP6(_(A_P">:?\ ?(H\B'_GFG_?(J2B
MBP6&""('(C0'_=%/HHHL "EI** "HYO]4_\ NFI*CF_U4G^Z:'L)D&E?\@NV
M_P!P5<JGI/\ R"K;_<%7*%L,****8!1110!1U?\ Y!LO_ ?_ $(5<7[HJGJ_
M_(-E_P" _P#H0JXOW14=1 :H26<D+M+:2!&;EHVY5O\ #\*T:*IJXS/&H^5Q
M=0R0_P"UC<I_$?U%6H9XIE)BD23_ '2#4A&>*JRZ?:RMN:%0W4,O!_2EJ(MB
MEK/%C(G$-W/&!TR=_P#/-'DZ@I.VYB<>C1\_I1=@:%&*SPVI \I;,/9B*7S[
MX=;1&^DW_P!:CF"Y?Q15 W-\/^7 ?]_A_A0+F^/_ "X@?68?X4<R"Y?HJ@9=
M0(^6WB4_[4F?Z4 :DPY-NA]0":.8+E^FD\U0^S7LG#WNT?\ 3.,#^>:7^S(G
MXGDFF]G<X/X=*5V%R274+>!L-,I;^ZOS'\A4+3WER,0P^0O>24<_@O\ C5N"
MWAAR(XD3']T5,.].S JVEJEN&.YGD;EI'.6;_/I5JEHIV&(:H6G_ "$K[ZI_
M*KYZ50L_^0E??5/Y4GN)E\4M(*6J&%%%% !1110 4444 (:#TH-!Z4F!2T__
M %EY_P!?!_D*O51T_P#UEY_U\'^0J]0MA(*2@TA.*+C%HJM->00']Y,J'TSS
M^50_;R__ ![V\TO^UC:/S/\ A2NA7+^,TPQ(>J*?J*I^;J#CY;:)/]^3/\J7
M;J)ZR6Z_12?ZT 6O(B_YY)_WR*411CHBC\*I^5J/_/U#_P!^C_C2[-1'22W/
MU4BE<"]C%%4?,U!/O0PR?[K[?YYH%](A_?VDR#U W#]/\*- +U%5HKZVF;"3
M*6_NDX/Y&K&:=T,=124M.X%74O\ D&7/_7)OY5+;_P#'O'_NC^51:E_R#+G_
M *Y-_*I;?_CWC_W1_*IZ@0ZDC2:?<(BEG,;  =2<5734T"*/L]UT[1&M.BFT
M!G?VJ@_Y=KK_ +]&C^U4_P"?:Y_[]&M&BBS$9W]JI_S[7/\ WZ-']JI_S[7/
M_?HUHT468:F=_:J?\^US_P!^C1_:J?\ /M<_]^C6C119AJ9W]JI_S[7/_?HT
M?VJG_/M<_P#?HUHT468:F=_:J?\ /M<_]^C1_:J?\^US_P!^C6C119AJ9W]J
MI_S[7/\ WZ-']JI_S[7/_?HUHT468:F=_:J?\^US_P!^C1_:J?\ /M<_]^C6
MC119AJ9W]JI_S[7/_?HTV34T9&'V:YZ$?ZHUIT4N5@5-,1X]-MTD&'" $$=*
MMT458PHHHH **** *.K_ /(-E_X#_P"A"IY'"1[B2,#/X5!J_P#R#9O^ _\
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M^"DMXY+V>[$@,GFE8YWBW<J"#@-CH<]NM '8U%-(D:DNX&%)Q[#J:\_NM/\
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MQF:(JY&UY#A(_0*.F>:=D!ZL*6O+[+QMJVHWJV<>I6<+/.X5VMSDQ^67!QG
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M_P"^Q3NAW+-%5OM]K_S\P_\ ?8H^WVO_ #\P_P#?8I70:%FDP/2J_P!OM?\
MGYA_[[%'V^U_Y^8?^^Q1=!H6-JG^$4;0.E5_M]K_ ,_,/_?8H^WVO_/S#_WV
M*+H6A9Q15;[?:_\ /S#_ -]BC[?:_P#/S#_WV*+H>A9HJM]OM?\ GYA_[[%'
MV^U_Y^8?^^Q3N@NBU157[?:_\_,/_?8H^WVO_/S#_P!]BBZ"X:E_R#+G_KDW
M\JEM_P#CWC_W1_*J&H7MLVG7*BXB),;# <>E7K?_ (]X_P#='\JGJ!-1115@
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4AYHHI 0/;0.Q9X49CU)7-)]DMO\ GA'_ -\"BBE8
M0?9+;_GA'_WP*/LEM_SPC_[X%%%%D%@^R6W_ #PC_P"^!1]DMO\ GA'_ -\"
MBBBR"P?9+;_GA'_WP*/LEM_SPC_[X%%%%D%@^R6W_/"/_O@4?9+;_GA'_P!\
M"BBBR"P?9+;_ )X1_P#? H^R6W_/"/\ [X%%%%D%@^R6W_/"/_O@4?9+;_GA
M'_WP***+(+!]DMO^>$?_ 'P*/LEM_P \(_\ O@444606%%G;$_ZB/_OD5./:
&BBBPS__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ex1-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  O '8# 2(  A$! Q$!_\0
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MYB:QI.JX5>?FMRNW,G>]I7M=)VM^.Q3Y;QM;=;'K/_!1_P#Y.!N/^R=>'?\
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MN3Q%'IGA77+%Y&DL[BPNGT>[AT^\@A86U[8WUQ%ODB6ZM9)DN&C@]+NO _\
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+973ZH****D9__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ex4-6_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-6_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  9 !\# 2(  A$! Q$!_\0
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MT4=A81I<:O.NY4;[D"?WV]_0=Z\4?7O%/B?44M&U#4KVYF9F2"*0CG'.%'
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=GU*Z(:XF4?* .B+[#)^I-=?'_J%_"@_<_&@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ex4-6_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-6_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  J 'H# 2(  A$! Q$!_\0
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M2//S-8,223D]_>NTR<GDTH)]32LKW'SR4>2^FYQ2>(=.@UFZU$Z=KQDN46/
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0)*TFS:"]K34-K7_'_AC_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>ex4-6_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-6_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !& 7T# 2(  A$! Q$!_\0
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MN?\ XW3/^%@:03@6>MY_[!%Q_P#$47#E9U5%<M_PGNFXR-.UTC&?^01<<_\
MCE*GCFR==RZ3KY'_ &"9O_B:+A9G445R_P#PG-I_T!?$/_@JE_PH_P"$YMCP
MNA^(F/MI4H_F* Y6=117+KXVA/']@>(@<9YTQZ/^$WAW8_X1_P 1GW_LQZ L
MSJ**Y?\ X39,9'AWQ'_X+F_QI!XV0_\ ,N>),>O]G-_C0%CJ:*Y;_A-X\_\
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M0@MH1A(HKV1 /R-%%(5V2KX1T]<XN=5.>QU*?_XJFCP;I@ #7&J,!ZZC/_\
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6%%)@+1113 **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>ex4-6_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-6_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !2 F8# 2(  A$! Q$!_\0
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M/%SGT&E,/YFNYQ2=Z0SB!\2')Q_PA/B[_P %O_V5"_$:5L_\43XM ]]/ _\
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MDYW-G('8>M=D_P -?"<L@=],9FSGFXEY_P#'J0:'5[E'4BD,J+U=1]37*?\
M"L?!Q.3HD1/O(Y_]FIZ_#3P:IR- M3_O;C_,TPT.E-U HR9HP/=A3/[0L_\
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M4X6%FIR+2 'U$8H#0YL_$WP4IP?$EAG_ 'Z:?BAX)'_,QV1^C$_TKJ/LMO\
M\\(O^^!2BV@'2&,?110&ARO_  M'P5V\0VI'J W^%)_PM/P5D :] 2?1'_\
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M+KSZ#82D>&K&0#5+E/\ EYD!R($/=?[Q'T^OH<4201)%$BI&BA551@*!T %
M#@   . *6BB@ HHHH **** "BBB@ HQ110 44'I10 448YHH 3''%+110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !WHHHH **** "BBB@ HHHH **** "BBJFIZG::/IT]_?2B*V
M@7<[X)QSCH.2<D# H MT5G:)KEAXATU;_39C) 69/F0HRLIP05(!!![&M&@
MHHHH **Q=:L]?NIH3I&JVUC$H/F"2U\TN?KN&!66='\:ER3XILPO]T:</Y[J
M!V.NHKD1HOC+//BJV'TT\?\ Q5(NA>,@N&\8PGG.1I:YQZ??H'9=SKZ*Y)M
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MG'_A1_PC7A\?\P+3..G^B1_X4#LB@?B-X, S_P )1I7_ (%+_C2?\+'\%_\
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EB]J0444Q W0TU:**3&A]%%%,04444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>ex4-7_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-7_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  J *@# 2(  A$! Q$!_\0
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M>'8I"L4=[.O]Y8P!^IJ_IGQ+\-ZI*L0NGM9&. MRFT'\>17$6>N_#:UC$?\
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H7K$GB.#4+F\6.UCAVO:0R,5DD[-R!CZ45T7>BK44CFG4=2U^FA__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>ex4-9_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-9_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ? #0# 2(  A$! Q$!_\0
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F+;,<O$<C\0?6FV)+74Z>QL+;3K1+6UB$<2= ._N?4T59HJ"S_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>ex4-9_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-9_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  . "L# 2(  A$! Q$!_\0
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6/1]:M;&WMQKRXBC6/BR7' QZT ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>ex4-9_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-9_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !V (X# 2(  A$! Q$!_\0
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MQ+_:&M?#'B"X^'7@#P_?_%#XK/;P2S^$=%G%CHGA6+5%>32=8^)GC&6.?0O
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M-O\ !SXV16FG>-I9=23P%XXL+:73O"/Q>TG2I[AV_LP%%@T;Q_::1%'=>)?
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M&5:"E0O3E%33<5[DI1CJDXNRC-^]%Q3<DE_,N-=:BY5,3A,91Q-*JJ.'H8?
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1A",8Q24]%%%=! 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>ex4-9_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-9_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !2 &8# 2(  A$! Q$!_\0
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M@MUM)S 3'<F0LP )X*+@88?X5KTXR4E="JTY4I<DM_O\_P!3)TC_ )">O_\
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MNOO1C]5K_P#/N7_@+_R-:BLG_A*?#W_0>TO_ ,#(_P#&C_A*?#W_ $'M+_\
M R/_ !HYX]U]Z#ZK7_Y]R_\  7_D:U%9/_"4^'O^@]I?_@9'_C1_PE/A[_H/
M:7_X&1_XT<\>Z^]!]5K_ //N7_@+_P C6HK)_P"$I\/?]![2_P#P,C_QH_X2
MGP]_T'M+_P# R/\ QHYX]U]Z#ZK7_P"?<O\ P%_Y&M163_PE/A[_ *#VE_\
M@9'_ (T?\)3X>_Z#VE_^!D?^-'/'NOO0?5:__/N7_@+_ ,@TC_D)Z_\ ]?Z_
M^DT%%0^'KJWO;O7+BTGBG@>_7;+$X96Q;P@X(X/((HHA\/\ 7=CQ2:JM/LO_
C $F)N44459S!1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>ex4-9_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-9_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "D + # 2(  A$! Q$!_\0
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MP/'_ &P)/&FNFYF4:'X:#Z%K44OB&\9?#BMH5XL<Z-!,*N-Y.V]];725_/\
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M1\9?@Y\>M?\ VG]1^)/PE^#7BCX6?$^[\?\ @2VT#]H3X5_$KX>:9\-_B/\
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M)?"[P#IOPU^"'B#7&^)'P:\>_&SP3\1/B1XGC^'LUCX(\0:+XKU'PKIVK?\
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D2S&7-*4M7K*3D_AANY.4GZN3?F34445D<H4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>ex4-9_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-9_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  M +H# 2(  A$! Q$!_\0
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M:KJWPR^&)T7P[H/@#P?XTUO0$?09?%*^']%'_"7F#):8E26F"+08'[.T444
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M4[WPUXBM?$>D:K^W+^T/X8DTK"G0\ ^%_@!X<\3DX5VSXV@CW$NB,Y/YE?\
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MP<\#:0NO2D_#_P ':UHC)\:?$K8#>"(_$=N98(B9%^6?^":_[(VI_LL?&O\
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M0^1_VG=(^-?[./\ P3B_X*1_MX?'"V\/:)^V;\:_@7XFT=;+2+E-3T?X%^!
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M#RW=M!<RJCR2$1Q+&&JJSZRE][_S7X_H?R\?M >.OV;OVMOB]XL_8\_X(O\
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M_MD6O_7K^W+^U7^7_)3,US^L?\$*OV*=&L+_ %J\^*G[?%M8Z=:ZA?7GV?\
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I$A2!CY16S_PZ%O\ _I)7_P %._\ Q)QO_F7K]DZ* ^MXK^?\5_D?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>ex4-10_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-10_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  9 !\# 2(  A$! Q$!_\0
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MT4=A81I<:O.NY4;[D"?WV]_0=Z\4?7O%/B?44M&U#4KVYF9F2"*0CG'.%'
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=GU*Z(:XF4?* .B+[#)^I-=?'_J%_"@_<_&@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>ex4-10_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-10_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  [ +,# 2(  A$! Q$!_\0
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1U%%M;EJI)1Y4] HHHH(/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>ex4-10_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-10_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !\ )H# 2(  A$! Q$!_\0
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ME,EBCGB:*6-9(V&&5QD$>XHLULP]I3E\<?NT_#5?D/HK)_L9[+YM(N3:@?\
M+LXWP'V"]4_X"0/8U+;:KF=;2^@-I=-PJL=T<I_V'Z'Z'#>U/F[B=&ZO3=U^
M/W?Y7-&BBBJ, HHHH ***SKVXEGNAIUFY24@-/,/^6*'T_VCSCTP3V *;L7"
M#F[(2XNY[JX>ST\A60[9[DC*Q>RC^)_;H.I[ V;*P@L(V6%27<[I)7.YY#ZL
M>_\ 3M4EM;Q6END$"!(T& /_ *_<^_>I:275ESJ:<D-%^?K_ );+\2EJVI+I
M.FRWSV\T\<0RZP[=V/7YB!^M3P3/*"7MI8>%.)"IZC)'RD].A_3(YK-\20WM
MYIIL+2T\Y;K,4DOF*OD ]&(/WAZXY]C7.ZQHM]=W.I)'HC/;W%XL@;]RVX>2
M5+JC.%)W <N#C.0">F<YRB]%<[,/AJ56FN:2B^]UMHMKKS]?Q.ZHKSFVT+4H
M[J&[;0+@7*261\SS8"?W8 E;_6=2!C/4YJ&WT2*[BNGFT$W<E_;.;9@L \Q6
M<-YC2^:6=OF4[B$Z8ZD5'MI?R_G_ )'1_9M+_G[=>7+_ /)=M?D>DN[*T8$;
M.&;!92,(,$Y.3TX XR<D=LD4AJN=:ETP65R7CA$WG9CV,IR!CYMV<@CD=O3F
MN7TG1[VQN]+5]#826M].\UZAA7SE=&7S" ^1DE25'0+[ 5O7B7EGK_\ :$%A
M+>PRVH@98'0.C*Q8'#LH((8]\\#CFK4Y-7V.>>&I0FX)J5T[:I:W5NMM5T=O
MO+VFW_\ :5G]H^RSVPWLNR8INX."?E9AU![]JLH[,T@,;(%; 9B,., Y&#TY
M(YP<@]L$\!J_AN_G9Y$T8SW)T\JLD<D>U;AI-_\ $P)VY.&(^E: TBY>2[OU
MT39<P:H+VUCE,.9%9%20 AB%)PS<XYVGKTE5);-?U]QK/!T+<T9K7I=:?C^+
M76YV5%<+/X5D@UFW=;&>>UA6(Q+:FW5%.6,JMO&X!LDX4X;<0<=:@M_#-U;Z
M5H:QZ&5NX%_?C?%@-N4$N0P;[J\,C$X^4JP)6G[67\O]?<)8*@TFJN_IV;_F
M\OO9Z#45S;0W<#07$2RQ-U5AD5S'A?1;O3=4NI[N.Z$TBNLTSO#Y4QWY5@$&
M]C@GE^1G'/;K*TBW):HXJ].-&I:G*]K:K_A_Z\C)$L^C';<2//I_:=SN>#_?
M/\2_[74=\\M6L"",CD4A (((R#U!K*C)T:YCMF)_L^9ML+'_ )8.>B'_ &3_
M  ^A^7NHH^'T%_%_Q?G_ ,'\_7?6HHHJSG*NHWJZ?8RW+(7*X"1CJ[DX51[D
MD#\:9IEDUE:8E<27,K&6XD'\<AZX]AP!Z "JUQ_IOB.VMNL5E']ID'K(V5C_
M " D/UVFM:H6KN=$_<IJ/5ZO]%^OS044459SF7XBO;G3=!N[ZT>!98$\S]^A
M92!U& R_GFN>B\8727R))<6%W8B\2W:\M(7*R[H7?:@#M\ZE "!NSO7 !X/2
MZWI\VJZ1<6,-PD#3+M,CQ&0 =^ PY_&H=2TR]OFTR1+R"*6SF\]R;<LLC;&3
M@;QM'SL>I[<\<X34V[Q/4PM3#1I\M5)MM_)6TZ=]%][6P#Q+I+/;JEP[FX1'
MC*02,,-G:"0N%)P<*<'CI67::_X1L#]ILX4MC<AB)8M-D0S;>6 (3YB.<CDC
M!]#5>+P5?1?83_:]O(UGL,7F6;,$*L3E1YN%R" >YQUQQ5A/"M]'9V$"ZI;9
MM(IX]QLV^;S!C./,XQ^M3>J^G]?>='L\#%651V>^K7>WV?0TU\3Z1)#)+'<O
M(J,B_NX)&+EL[=@"Y<'!Y7(X/I3QXBTHO:HMR6-T$,96)R/G.$W$#"$D$ -C
MD&L8>$=0"NIU>W*M%!$R?8V"2+$&&UP)?F5MQRN<'@'(R#9TGPU>:2L<<.IP
MF$QQQ3I]D(WJA.-OS_*2IP>O3(Q5*56^J_K[S&=' J+<9W?S[?X>_P!^VFY>
M3Q-I,DJ1K<2;I)$C3,$@#;R0C E<%6P</]TXZU3;QCIS7 BA^TE#;2S&<V<I
M5/+;:05VYX(;/3H!U(JI:>"OL5FL-O<6,4L+Q/!+'IX0GRVR/-(8&0XXR"OK
MBEB\)7T,3*NK0%GAN879K,\K,YDR )."&)^H[#K4\U;M_7WFBI9>F[2;];_?
MI'^GH:__  D.FQS1V\UV/-9 2XA<1YV%\%L;5.T%MI.<56D\11W!L7TYPT<E
MXMO.L]O(C@,A8$!MI'&#D@@@TVVT#4;2.:*'5TCBG0>;LMB'$@C";D8N=H^5
M3C!.0<$9JE9^$;VTE5UU*TQ]JCNG"V3 NRKM)),I)+=2QR2<GG--NIV_K[R(
MT\$KOGUZ;Z[_ -W3I;7_ ('0:=JUEJJNUG,9 F-V8V0C(R.& ZCD>H(/0BKM
M9&@Z--HT,L<EVDRN5V)%#Y4:8')";B 2>3MP,]AS6O6T&VO>W/.KQIQJ-4G>
M/3^K+\@J*ZMHKRUEMIUW12J48>QJ6BJ,DVG=&=I%S*\<MI=-NN[1_+D;_GH,
M95_Q&,^^1VK1K)O_ /0M:L+Y>$G/V2?WSDQD_1@5'_72M:ICV[&U9*ZFMI?G
MU_'\S)T;][>:O='_ ):7AC7V6-%3'_?08_C6M63X=_X\;G/WOM]WG_O^^/TQ
M6M2A\(\3_%:[67W)!7,10RZYJ&M--J%W:FTG^SVZP3E!$!&K;RHX8L6/W@1@
M#'>NGK.N]"TZ]NFN9H7\QU"2>7,\:RJ,X#JI <<D88'@D=Z)Q;L5AJL:?-?1
MO9V3MK?9]UI_P+F:OB&:/RUAMH[JU69+/[49\%Y2H(;:%/R$D#=DGGH15*#Q
MK=2VD5T^C+'$]O#=$F[!*QR/L[+RV>0.A'4J?EK>DT'3I;Z2\,+B>3ERDSJI
M;;M#;0<;@. V,CUJG_PANB>2(1!<B,1+"%%]/@(IW*OW^@/2LG&KT?\ 7W';
M"M@+>_!W^?\ \DO/\-%8IGQ7J'VF2!=&C)6::!'^V85FC&XD_)D+MSS@G/&,
M<TZ+Q?)=WEM!9Z7-,LT43.X$F(VD3>N2(RH7E<DL",YVG%7CX3T@L6\NZ#%W
MDR+Z<?,XPQ^_W%9UU#X6TF;RI7N(3:PHLACEN"D:#)3S&4D C^$N<CC'04G[
M1;O^ON-(O!U-*=-MVZ)_?\7?^N@^R\3ZEJ%G:2V^C1--<V_VI8?MN#Y7RCJ4
MQN))P.F!R1G%6]-\1OJ6L2VB:?.MLIE5+K9)M+1MM()*!1DYQM9NG.#Q4P\-
M:2;.UMDAE$-M&8X=ES("(VP2A8-EE.!\I)' ]*9<PZ/X?E?598[A#++@^6)I
ME#N>HC7(4L>-P R3C//-)35FV8REA:G-&G3=W>V_=VZ]K?C>]U;/O_&$ME=Z
MA"NGQ2BU@FF5A<GYO*"EE8A"JG!R!DMTR%# U*OB2XN7>Q_LT+?/*(UA^U$#
M88O,W%PORMCC SSC!QR)[KPQH=R[2W$<Z_:2X*_;)HU8R?> 4. -W< <]ZC.
MA:!_:C692Z^VLBW(8W,^X!?D#+)NX.#@@'.",\5-JM]_Z^XT4L$XZ0=TNSZ;
M_:VOO^@NBVQU?PGI7VJYO0WEJ[LERZ.YP1AG4[CUSUZ@5FZ-=WFGZ?H!MTFO
MI]7M8VD:[U!R$<1[V8;@Q&<G...!QU-=/;:7:6>EKIMNLD5JJE%59G#*#V#9
MW#KQ@\=JKP^'M-MQ8"*.<"PR+8&ZE.P$8QRW(QQ@YP..E5R2TMN9_6J3YU+X
M6VTK=&G;:W6W7I\C*@\8---<0?88_.#1K;[+@LDA=R@RX7:,$<[2X&".6&*S
M[3Q/=:9;-;G3[N]NC<W#-$KRS-&BR;=JL%8GKQNVC ZCI6Z/".BJ&'V>8@J%
M -W*0H#;AM!;Y<'D8QCG&,TX>%-'5 H@G&&=]PNY=Q+XW@MNR0Q )!.">2,D
MU/+5[FRKY>KI0=G;\/G_ %WMH;(.0#Z^HI:0    8 Z 4M=)XAE>)5)\.WTB
MC+P1_:$'^U&0X_516HC!T5U.589!JGJ^#HM_N^[]GDS]-II^F[CI=IN^]Y*9
M^NT5'VOD=#UH+R;_ !2_R*>B_NKG5K4]8KUG'N'57S^;,/PK6K)E_P!"\2Q2
MGB*_A\ECV\U,LOYJ7_[Y%:U$-K!B-9*?=)_H_P 4%%%%6<X45%<2216[O#%Y
MTH'R1[L;CVR>P]36'<^*4L='%W>V\<-PT[VZ1_: (V<$C=YC  )QRQ''3!.
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@XH;'&D4:QQHJ(HPJJ, #V%.HHJSGW"BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>ex4-10_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-10_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "6 *,# 2(  A$! Q$!_\0
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M-%6?5?JOU7S79:5%%%48!1110 5EZC(]Y=)I5N[+N4274BG!2+I@'LS$$#T
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M\(P& PD2G^%!V'J>I[]@+]%%4E8RG-S=V%%%%,@**** "BBB@ HHHH ****
M*UYI]GJ$82\M89U'*^8@.T^H/8_2J7]AM!_QXZI?VW^PTOG+^4@8X^A%%%2X
MIZFT*]2"Y4].VZ^YW0>1K\7W+[3YQZ26KHWYAR/TH\WQ"O\ RYZ6_M]JD3/_
M )#.***7+YLKV_>,?N_R:#?XA;_EWTM/?SY'Q_XX,T?9==E_UNJ6D(]+>S.X
M?\"9R/\ QVBBCE\V'MVMHQ7R_P VP_X1^";_ (_KN]OO433E4/U1-JG\16C;
MVT%I"L-M!'#$O1(T"J/P%%%-12V(G6J35I/3\/NT7X$M%%%49!1110 4444
'%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>ex4-10_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-10_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Y 0@# 2(  A$! Q$!_\0
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M&C &?3ZT"%SD<\4#.>U(.N".:7 .: $)YH'THZ'CTHH ,T*<DTGMB@8SW!H
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4'/K3OX12#O3!MMW8=J*4T4"/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>ex4-11_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-11_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "G *8# 2(  A$! Q$!_\0
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MWX?!KY1\?>"]<^%GB2\^+_PBTRZU:/4[]9OC'\)-,W11_$;38%<OXN\&Z7;
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MFHHHK,#G3%$I$9M4V%6C(R2VPVT<</\ %G+!#;N=O!5"1D\^4_%OXCZ+\*?
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MIE\!?#6">70?"<#1P/<23^(_&EV/^$S\8^+KB[^E8_N.3U)'/X_XT_&X$DX
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MY,?%%]KG@B^\$R77B9-=\ >( N_3;_4W1_#1\,8N+C))A(MJ^H'*J?G/\);
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M3<(U7.,)<TZ--)\O?4444C@"BBB@"J-GE'"$*<?+G_ZPX'>H06QE$6,9^\Q
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D0A.<W3A5A7A2YG[.$'JOHVBBBND\(**** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>ex4-11_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-11_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "D ,T# 2(  A$! Q$!_\0
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MX:\0?#6R\7^%+[Q7X#\#-XY_:/TKQIXD\$^ ;/QA:VFJ^&XWG\=Z_P#!>/\
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M90@EC+ K$[*)1&5S\LH22-I. &W(P)JRF.<9[?3OTI"=S8Y &<_AU/\ 3_\
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ML_\ QA^)W[*7Q3^#GQ"U;X;>&]5UBWUW2KNS^+'@_3M2\*6%MXCU'PSK&B>
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MM:9\7O">@?%KPKXL\.:UX#7XSZI\6]>T:;X?P1>*-,N;#0;?X9Z=;76I>!?
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MW]U5/]#%O%6VM+V=SA8Q=S ]\"%#GK_TR/?'/8\CY/\ ^"?,07]D7X"W,?\
MQZZC\*_"&JV'K_9NL0WNL:5GI_S"]0LC^->R_'SQ_:_#+X+_ !9^(VH,4T_X
M?_#CQQXTOBO467A7PS<Z[<D#C)$-K(>3]3WJE^RWX E^%?[./P(^&UPP>Y\
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MU;"X>O5PN%Q<*5:%+Z?= 4D99;6.Y@ #S+%B2"W9E/EA5&[:8R K@88[B&V
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M>ZI\-_&'B_0K$7.FQW^I6^I7<MJ/I];B*#8NZ/;)D(WFQ(&"_P#/-&$(D&&
MS%N'*\_=SPGQ!\!^"OB9H]_X3^(G@_PSXZ\+72J;W0/&&C:5KNA3-&5:"X;3
M]82^TRXN;>3][:?;=/5HY1O2XA?F3YEN?V;?''@6:*?]G7XU^)_ -CF0Q_#[
MXH0ZA\<OA?&N^'R8[&S\4ZM;?$3PA;Q1QRVVEZ)X+^(>C>$M-MV L=!N(XHX
MX<IRS'#RA">7K'890O4Q,:E-2E>#J1DH33NU)KW5>ZV:E:_K1P_!F=>]@,XE
MP?CYOEJ8;B6KFV<<.4ZR]UQH8_)LLAQ+D]"LXN%">;Y+Q!A:565.-3/JN%C.
MI'[;$X+A&,:$XPK)*'.?3>"GY-CN"3S4#2NDA4+*>0!Y>"1U'.^., 'MM+=#
MN(XS\:P_%+]IWP.ZVWQ _9\L/B%IMN$7_A)OV?OB'I>I7DT*C,]]K7@3XF'P
M+J6D*(Q%(NEZ#K7C^^G'G1OMDMK8:C"_[<7[.ML%'CSQ/JWP:EAD>)U_: \
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J&9CB*'[IPBZ=J$5!QBX*+2:] HHHKM)"BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>ex4-12_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ? #0# 2(  A$! Q$!_\0
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F+;,<O$<C\0?6FV)+74Z>QL+;3K1+6UB$<2= ._N?4T59HJ"S_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>ex4-12_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !K (0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ I"
M0H))  Y)/:JE[J*6C)"B-/=2#,<$?WF]SV51W)X_' JJ-)>^(EUAUN.ZVJ9\
MA/J/XS[MQZ 5+ET1M&DK<TW9?B_1?J]/4#KB7!*:7;2W[=/,C^6$?60\'_@.
MX^U'V76[KF?4(;)?[EG$'8?\#D!!_P"^!6J %    '  [4M+E;W97MHQ_AQ7
MJ]7^.GX&3_PCUM)S<W6H7)[^9>2*#_P%2%_2C_A%]"/WM*M7]?,C#9^N>OXU
MK44<D>P?6JW2;7H[?E8R?^$7T(?=TFT3T\N(+CZ8Z4?\([:)S;3W]LW;RKR3
M:/\ @+$K^E:U%')'L'UJOUF_F[_G<R?L>LVO-OJ<=VO]R]A 8_\  XP,?]\F
MC^V_LORZK:2V/_3;/F0?]]C[H]V"UK44<MMF'ME+^)%/TT?X:?>AJ.LB*Z,&
M1AD,IR"*=64^C_97:;29%M)"<M#C,,A]U_A/^TN#ZYZ5/9:BMQ*UM/&;>\09
M:%CG(_O*?XE]Q^(!XIJ71DRI)KFINZ_%>O\ FM/0O44451B%%%% !5*_O7@*
M6ULJR7DV?+1NB@=7;_9&?Q.!WJ:\NHK&SENIB1'$I8X&2?8#N3T JMI=K+&C
MW=V!]MN<-+@Y"#^&,>RY_$DGO4MZV1M3BE'VDMNGF_\ )=?DNI-96*6:NQ=I
M9Y#F69_O.?Z =@.!5JBN>M-8NQ?W,%]<VRA;\6D'EVDGS?('(8[R 2& !.!\
MIZYP$VHV14:<ZW-+M_6G];'0T5B?\)=H@A\XW4BQED4,UM* =^=A&5Y5L'#=
M#ZTZ;Q5H\%M'</<2F.168;+:5F4*VTEE"DKAN/F YH]I#N/ZIB-N1_<;-%8T
M?BG29KMK2.2Y:X5F5HOL<VX%5#'C9Z$?7(QUJ/4=4NH_"\.IV%Q:R.ZQ.)'M
MWV2*Y R$W@K]X'DGTH]I&UT"PE7F49*UW97TW-VBL34M5ETB]ADO;J!-.%N\
MDQ6U=G#*47((8X7+@_=.,=>X>/$-A.8#;W#D/,\9!M)6+E8RY4<#!VX89SN
MX!SP<\;V8?5:KBI)73ZK;K^.AL45DKXDTMK>&=9IC'-%YL1^S2_.NX*,#;G)
M)&%ZG/ J-?%>CNVU;B4GRC,<6TORH,@L?EXP5(.>A&#SQ1SQ[B^JU_Y']QM5
M6O+**]B57+(Z'='*AP\;>H/^0>AR*HMXFTA(%F:Y<(693^XDRFW ;>-N4 )
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M)&_\=1J)_"R<+_&B_/\ +7]#6HHHJSG,F;_0O$D,YXBOHO(8^DB99/S4N/\
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-Y.["BBBF2%%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>ex4-12_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !* %T# 2(  A$! Q$!_\0
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MM:BG:7?\/^"3ST?Y'_X%_P#:F3_PD=C_ ,\-4_\ !5<__&Z/^$CL?^>&J?\
M@JN?_C=:U%%I=_P_X(<]'^1_^!?_ &ID_P#"1V/_ #PU3_P57/\ \;H_X2.Q
M_P">&J?^"JY_^-UK446EW_#_ ((<]'^1_P#@7_VID_\ "1V/_/#5/_!5<_\
MQNC_ (2.Q_YX:I_X*KG_ .-UK446EW_#_@AST?Y'_P"!?_:F3_PD=C_SPU3_
M ,%5S_\ &Z?X;BDM_"VD0S1M'+'90HZ.,%6" $$=C6G10HN]VQ3JP<.2$;:W
'WOTMV1__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>ex4-12_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "3 *$# 2(  A$! Q$!_\0
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MC$)N#;Q2O<_?8P><F5"9&1@-Z9&-W.->;P[I=Q' CV[_ +E65629U8ACE@S
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MK5K+=:9)]G&;J$B>#WD0[@/H<8/L35JTNHKVSANH3F*9 ZYZX([^]35DVO\
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M4]>*LOHVER16\3Z;9M';<P*T"D1?[HQ\O0=*Y^2?1V_X<]CZUADTZD>?1?\
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2***9 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>ex15-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex15-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  Y 2P# 2(  A$! Q$!_\0
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MKCV'A'XM_M0^#%:V/C;6)X].U[2/@;\)M=UG3='UWQ!?7WC#5K.YL]$T[[4
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M$_:P_P"")]]\$OV5_P!IO3IH_#7QS\ ZM9'PA\!_VE?AA9:;';^&]'\?^ ]
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M!\/O!/A35O#,>A>!O#;:/-%J?B[7==U#4]3:[L)]+\.I!,Q'5?&S]MO]M/X
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-44 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>ex15-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex15-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Q - # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WBZO+6QB$
MMW<PV\9.T/*X0$^F3]*J?\)#HG_08T__ ,"4_P :X'X\?\B):?\ 81C_ /1<
ME>/^%?A[K?C"SGNM+^R^7#)Y;^=(5.<9XX/K6\*:<>9NQG*;3LD?3W_"0Z)_
MT&-/_P# E/\ &GQ:YI-Q*L4.J64DCG"HEPA+'T !KY\_X4=XN]=/_P# @_\
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M::W_ -<D_P#1BUI.ERR2ON1&=TV;W_"0Z)_T&-/_ / E/\:/^$AT7_H,:?\
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MU/BB.'PL\9^$?BK2/"NL:A<:Q<M!%-;A$*QL^3NS_"#7K?\ PN+P1_T%9/\
MP%E_^)KP_P"'_@<>.=1N[0Z@;+[/")-PA\S=DXQC<,5Z!_PSXG_0S-_X _\
MVRJJ*GS>\]0@Y6T.P'QB\$DX_M63_P !9?\ XFN[KQ0?L^H"#_PDS<?]./\
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M/N@^^,UV53*HDN6"&H.]Y'C_ ,?_ /D":-_U\O\ ^@UL?!#_ ))]_P!ODO\
M):ZKQ1X/TGQ?;6\&JI*R0.73RY-O)&*G\.>&]/\ "VE?V=IBR+;^89,2/N.3
MC//X5+FO9\H^5\US7HHHK(L^7+;_ )+>O_8PG_THKW/XI_\ )--;_P"N2?\
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, !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>45
<FILENAME>upc-20240930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Apr 29 14:31:08 UTC 2025 -->
<xs:schema xmlns:upc="http://www.UniversePharmaceuticalsINC.com/20240930" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2024" targetNamespace="http://www.UniversePharmaceuticalsINC.com/20240930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="upc-20240930_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="upc-20240930_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="upc-20240930_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="upc-20240930_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet" id="upc_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet_Parentheticals" id="upc_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>995302 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement" id="upc_r_ConsolidatedIncomeStatement">
        <link:definition>995303 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3" id="upc_r_ShareholdersEquityType2or3">
        <link:definition>995304 - Statement - Consolidated Statements of Changes in Shareholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow" id="upc_r_ConsolidatedCashFlow">
        <link:definition>995305 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription" id="upc_r_OrganizationandBusinessDescription">
        <link:definition>995306 - Disclosure - Organization and Business Description</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies" id="upc_r_SummaryofSignificantAccountingPolicies">
        <link:definition>995307 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet" id="upc_r_AccountsReceivableNet">
        <link:definition>995308 - Disclosure - Accounts Receivable, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/InventoriesNet" id="upc_r_InventoriesNet">
        <link:definition>995309 - Disclosure - Inventories, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers" id="upc_r_AdvancetoSuppliers">
        <link:definition>995310 - Disclosure - Advance to Suppliers</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisition" id="upc_r_PrepaymentforAcquisition">
        <link:definition>995311 - Disclosure - Prepayment for Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/OtherReceivable" id="upc_r_OtherReceivable">
        <link:definition>995312 - Disclosure - Other Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet" id="upc_r_PropertyPlantandEquipmentNet">
        <link:definition>995313 - Disclosure - Property, Plant and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet" id="upc_r_IntangibleAssetsNet">
        <link:definition>995314 - Disclosure - Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProject" id="upc_r_PrepaymentforCIPProject">
        <link:definition>995315 - Disclosure - Prepayment for CIP Project</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty" id="upc_r_PrepaymentforPurchaseofaProperty">
        <link:definition>995316 - Disclosure - Prepayment for Purchase of a Property</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoans" id="upc_r_ShortTermBankLoans">
        <link:definition>995317 - Disclosure - Short-Term Bank Loans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoans" id="upc_r_LongTermBankLoans">
        <link:definition>995318 - Disclosure - Long-Term Bank Loans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions" id="upc_r_RelatedPartyTransactions">
        <link:definition>995319 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/Taxes" id="upc_r_Taxes">
        <link:definition>995320 - Disclosure - Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/Concentrations" id="upc_r_Concentrations">
        <link:definition>995321 - Disclosure - Concentrations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity" id="upc_r_ShareholdersEquity">
        <link:definition>995322 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies" id="upc_r_CommitmentsandContingencies">
        <link:definition>995323 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents" id="upc_r_SubsequentEvents">
        <link:definition>995324 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompany" id="upc_r_FinancialInformationoftheParentCompany">
        <link:definition>995325 - Disclosure - Financial Information of the Parent Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy" id="upc_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables" id="upc_r_OrganizationandBusinessDescriptionTables">
        <link:definition>996001 - Disclosure - Organization and Business Description (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables" id="upc_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>996002 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables" id="upc_r_AccountsReceivableNetTables">
        <link:definition>996003 - Disclosure - Accounts Receivable, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/InventoriesNetTables" id="upc_r_InventoriesNetTables">
        <link:definition>996004 - Disclosure - Inventories, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables" id="upc_r_AdvancetoSuppliersTables">
        <link:definition>996005 - Disclosure - Advance to Suppliers (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableTables" id="upc_r_OtherReceivableTables">
        <link:definition>996006 - Disclosure - Other Receivable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables" id="upc_r_PropertyPlantandEquipmentNetTables">
        <link:definition>996007 - Disclosure - Property, Plant and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables" id="upc_r_IntangibleAssetsNetTables">
        <link:definition>996008 - Disclosure - Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectTables" id="upc_r_PrepaymentforCIPProjectTables">
        <link:definition>996009 - Disclosure - Prepayment for CIP Project (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansTables" id="upc_r_ShortTermBankLoansTables">
        <link:definition>996010 - Disclosure - Short-Term Bank Loans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoansTables" id="upc_r_LongTermBankLoansTables">
        <link:definition>996011 - Disclosure - Long-Term Bank Loans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables" id="upc_r_RelatedPartyTransactionsTables">
        <link:definition>996012 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/TaxesTables" id="upc_r_TaxesTables">
        <link:definition>996013 - Disclosure - Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompanyTables" id="upc_r_FinancialInformationoftheParentCompanyTables">
        <link:definition>996014 - Disclosure - Financial Information of the Parent Company (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails" id="upc_r_OrganizationandBusinessDescriptionDetails">
        <link:definition>996015 - Disclosure - Organization and Business Description (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofSubsidiariesTable" id="upc_r_ScheduleofSubsidiariesTable">
        <link:definition>996016 - Disclosure - Organization and Business Description - Schedule of Subsidiaries (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails" id="upc_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996017 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesTable" id="upc_r_ScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesTable">
        <link:definition>996018 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property Plant and Equipment Estimated Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsEstimatedUsefulLivesTable" id="upc_r_ScheduleofIntangibleAssetsEstimatedUsefulLivesTable">
        <link:definition>996019 - Disclosure - Summary of Significant Accounting Policies - Schedule of Intangible Assets Estimated Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofCurrencyExchangeRateTable" id="upc_r_ScheduleofCurrencyExchangeRateTable">
        <link:definition>996020 - Disclosure - Summary of Significant Accounting Policies - Schedule of Currency Exchange Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetDetails" id="upc_r_AccountsReceivableNetDetails">
        <link:definition>996021 - Disclosure - Accounts Receivable, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAccountsReceivableTable" id="upc_r_ScheduleofAccountsReceivableTable">
        <link:definition>996022 - Disclosure - Accounts Receivable, Net - Schedule of Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAllowanceforDoubtfulAccountsTable" id="upc_r_ScheduleofAllowanceforDoubtfulAccountsTable">
        <link:definition>996023 - Disclosure - Accounts Receivable, Net - Schedule of Allowance for Doubtful Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesTable" id="upc_r_ScheduleofInventoriesTable">
        <link:definition>996024 - Disclosure - Inventories, Net - Schedule of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesValuationAllowanceTable" id="upc_r_ScheduleofInventoriesValuationAllowanceTable">
        <link:definition>996025 - Disclosure - Inventories, Net - Schedule of Inventories Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAdvancestoSuppliersTable" id="upc_r_ScheduleofAdvancestoSuppliersTable">
        <link:definition>996026 - Disclosure - Advance to Suppliers - Schedule of Advances to Suppliers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails" id="upc_r_PrepaymentforAcquisitionDetails">
        <link:definition>996027 - Disclosure - Prepayment for Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableDetails" id="upc_r_OtherReceivableDetails">
        <link:definition>996028 - Disclosure - Other Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYZDqnPZexC+e00+Rf6r37QtPu3oRrVmmTX8PuYVCFDMbRocUzw9EKKPK5NWC0WpJsOIuWkqeF3WWYzAuBG72bAUNWZ0EJoh7tCz07VxkYX3MUSJ7UFcJNPwN8yHmeKHRgkhMTd18uQzeusIsu/5w+1sTLgk4s48vHUWCmlxzr3HAZpsa+LfmHnFaLaCmPS0f6K1sduUUfaD9sRn5i3Vzu5VnzV9KOEHGDWQhDnV/BFeewWkVFaS1UAGZHpL/GWyprGohqqPVQHRw==] CSR-->
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofOtherReceivableTable" id="upc_r_ScheduleofOtherReceivableTable">
        <link:definition>996029 - Disclosure - Other Receivable - Schedule of Other Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails" id="upc_r_PropertyPlantandEquipmentNetDetails">
        <link:definition>996030 - Disclosure - Property, Plant and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentNetTable" id="upc_r_ScheduleofPropertyPlantandEquipmentNetTable">
        <link:definition>996031 - Disclosure - Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetDetails" id="upc_r_IntangibleAssetsNetDetails">
        <link:definition>996032 - Disclosure - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsNetTable" id="upc_r_ScheduleofIntangibleAssetsNetTable">
        <link:definition>996033 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable" id="upc_r_ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable">
        <link:definition>996034 - Disclosure - Intangible Assets, Net - Schedule of Estimated Future Amortization Expense for Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails" id="upc_r_PrepaymentforCIPProjectDetails">
        <link:definition>996035 - Disclosure - Prepayment for CIP Project (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofFutureMinimumCapitalExpendituresTable" id="upc_r_ScheduleofFutureMinimumCapitalExpendituresTable">
        <link:definition>996036 - Disclosure - Prepayment for CIP Project - Schedule of Future Minimum Capital Expenditures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails" id="upc_r_PrepaymentforPurchaseofaPropertyDetails">
        <link:definition>996037 - Disclosure - Prepayment for Purchase of a Property (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails" id="upc_r_ShortTermBankLoansDetails">
        <link:definition>996038 - Disclosure - Short-Term Bank Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofShortTermBankLoansTable" id="upc_r_ScheduleofShortTermBankLoansTable">
        <link:definition>996039 - Disclosure - Short-Term Bank Loans - Schedule of Short-Term Bank Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoansDetails" id="upc_r_LongTermBankLoansDetails">
        <link:definition>996040 - Disclosure - Long-Term Bank Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofLongTermBankLoansTable" id="upc_r_ScheduleofLongTermBankLoansTable">
        <link:definition>996041 - Disclosure - Long-Term Bank Loans - Schedule of Long-Term Bank Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails" id="upc_r_RelatedPartyTransactionsDetails">
        <link:definition>996042 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofNatureofRelationshipsWithRelatedPartiesTable" id="upc_r_ScheduleofNatureofRelationshipsWithRelatedPartiesTable">
        <link:definition>996043 - Disclosure - Related Party Transactions - Schedule of Nature of Relationships With Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofRelatedPartiesTable" id="upc_r_ScheduleofRelatedPartiesTable">
        <link:definition>996044 - Disclosure - Related Party Transactions - Schedule of Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails" id="upc_r_TaxesDetails">
        <link:definition>996045 - Disclosure - Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable" id="upc_r_ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable">
        <link:definition>996046 - Disclosure - Taxes - Schedule of Components of the Income Tax Provision (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTableReconcilestheChinaStatutoryRatestotheCompanysEffectiveTaxRateTable" id="upc_r_ScheduleofTableReconcilestheChinaStatutoryRatestotheCompanysEffectiveTaxRateTable">
        <link:definition>996047 - Disclosure - Taxes - Schedule of Table Reconciles the China Statutory Rates to the Company&#8217;s Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofDeferredTaxAssetsTable" id="upc_r_ScheduleofDeferredTaxAssetsTable">
        <link:definition>996048 - Disclosure - Taxes - Schedule of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTaxesPayableTable" id="upc_r_ScheduleofTaxesPayableTable">
        <link:definition>996049 - Disclosure - Taxes - Schedule of Taxes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails" id="upc_r_ConcentrationsDetails">
        <link:definition>996050 - Disclosure - Concentrations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails" id="upc_r_ShareholdersEquityDetails">
        <link:definition>996051 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails" id="upc_r_CommitmentsandContingenciesDetails">
        <link:definition>996052 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails" id="upc_r_SubsequentEventsDetails">
        <link:definition>996053 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompanyDetails" id="upc_r_FinancialInformationoftheParentCompanyDetails">
        <link:definition>996054 - Disclosure - Financial Information of the Parent Company (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable" id="upc_r_ScheduleofConsolidatedFinancialStatementsTable">
        <link:definition>996055 - Disclosure - Financial Information of the Parent Company - Schedule of Consolidated Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable_Parentheticals" id="upc_r_ScheduleofConsolidatedFinancialStatementsTable_Parentheticals">
        <link:definition>996056 - Disclosure - Financial Information of the Parent Company - Schedule of Consolidated Financial Statements (Parentheticals) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable" id="upc_r_ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable">
        <link:definition>996057 - Disclosure - Financial Information of the Parent Company - Schedule of Parent Company Statements of Operations and Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable" id="upc_r_ScheduleofParentCompanyStatementsofCashFlowsTable">
        <link:definition>996058 - Disclosure - Financial Information of the Parent Company - Schedule of Parent Company Statements of Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd"/>
  <xs:element name="ScheduleOfSubsidiariesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfSubsidiariesAbstract"/>
  <xs:element name="ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract"/>
  <xs:element name="ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract"/>
  <xs:element name="ScheduleOfCurrencyExchangeRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfCurrencyExchangeRateAbstract"/>
  <xs:element name="ScheduleOfInventoriesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfInventoriesAbstract"/>
  <xs:element name="AdvancesToSuppliersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_AdvancesToSuppliersAbstract"/>
  <xs:element name="ScheduleOfOtherReceivableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfOtherReceivableAbstract"/>
  <xs:element name="ScheduleOfPropertyPlantAndEquipmentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfPropertyPlantAndEquipmentNetAbstract"/>
  <xs:element name="ScheduleOfIntangibleAssetsNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfIntangibleAssetsNetAbstract"/>
  <xs:element name="PrepaymentForConstructionInProgressAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentForConstructionInProgressAbstract"/>
  <xs:element name="PrepaymentForPurchaseOfAPropertyAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentForPurchaseOfAPropertyAbstract"/>
  <xs:element name="ScheduleOfShortTermBankLoansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfShortTermBankLoansAbstract"/>
  <xs:element name="ScheduleOfLongTermBankLoansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfLongTermBankLoansAbstract"/>
  <xs:element name="ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract"/>
  <xs:element name="ScheduleOfDeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfDeferredTaxAssetsAbstract"/>
  <xs:element name="ScheduleOfConsolidatedFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfConsolidatedFinancialStatementsAbstract"/>
  <xs:element name="ScheduleOfParentCompanyStatementsOfOperationsAndComprehensiveLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfParentCompanyStatementsOfOperationsAndComprehensiveLossAbstract"/>
  <xs:element name="OtherIncomeExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_OtherIncomeExpensesAbstract"/>
  <xs:element name="OtherComprehensiveIncomeLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_OtherComprehensiveIncomeLossAbstract"/>
  <xs:element name="PrepaymentForAcquisitionCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentForAcquisitionCurrent"/>
  <xs:element name="PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent"/>
  <xs:element name="PrepaymentsForConstructionInProgress" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentsForConstructionInProgress"/>
  <xs:element name="StatutoryReserve" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_StatutoryReserve"/>
  <xs:element name="StockIssuedDuringPeriodValueStatutoryReserve" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_StockIssuedDuringPeriodValueStatutoryReserve"/>
  <xs:element name="StockIssuedDuringPeriodValueReverseShareSplitAdjustment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_StockIssuedDuringPeriodValueReverseShareSplitAdjustment"/>
  <xs:element name="ChangeInFairValueOfShorttermInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_ChangeInFairValueOfShorttermInvestments"/>
  <xs:element name="IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent"/>
  <xs:element name="ProceedsFromPaymentForConstructionInProgress" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_ProceedsFromPaymentForConstructionInProgress"/>
  <xs:element name="AdvancesToSuppliersTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_AdvancesToSuppliersTextBlock"/>
  <xs:element name="PrepaymentForConstructionInProgressTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentForConstructionInProgressTextBlock"/>
  <xs:element name="PrepaymentForPurchaseOfAPropertyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentForPurchaseOfAPropertyTextBlock"/>
  <xs:element name="ReclassificationsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ReclassificationsPolicyTextBlock"/>
  <xs:element name="AdvancesToSuppliersNetPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_AdvancesToSuppliersNetPolicyTextBlock"/>
  <xs:element name="ConstructioninProgressPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ConstructioninProgressPolicyTextBlock"/>
  <xs:element name="DisaggregationOfRevenuesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_DisaggregationOfRevenuesPolicyTextBlock"/>
  <xs:element name="ValueAddedTaxPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ValueAddedTaxPolicyTextBlock"/>
  <xs:element name="StatementOfCashFlowsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_StatementOfCashFlowsPolicyTextBlock"/>
  <xs:element name="EmployeeDefinedContributionPlanPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_EmployeeDefinedContributionPlanPolicyTextBlock"/>
  <xs:element name="PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
  <xs:element name="ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock"/>
  <xs:element name="ScheduleOfAdvancesToSuppliersNet" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfAdvancesToSuppliersNet"/>
  <xs:element name="ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock"/>
  <xs:element name="ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock"/>
  <xs:element name="ScheduleOfTaxPayableTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfTaxPayableTableTextBlock"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesDetailsTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsEstimatedUsefulLivesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_SummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsEstimatedUsefulLivesDetailsTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRateDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRateDetailsTable"/>
  <xs:element name="InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments"/>
  <xs:element name="RelatedPartyTransactionsScheduleofNatureofRelationshipsWithRelatedPartiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_RelatedPartyTransactionsScheduleofNatureofRelationshipsWithRelatedPartiesDetailsTable"/>
  <xs:element name="TaxesScheduleofComponentsoftheIncomeTaxProvisionBenefitDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_TaxesScheduleofComponentsoftheIncomeTaxProvisionBenefitDetailsTable"/>
  <xs:element name="ValueAddedTaxPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_ValueAddedTaxPayable"/>
  <xs:element name="OtherTaxesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_OtherTaxesPayable"/>
  <xs:element name="OrganizationandBusinessDescriptionDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_OrganizationandBusinessDescriptionDetailsTable"/>
  <xs:element name="OrganizationandBusinessDescriptionDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_OrganizationandBusinessDescriptionDetailsLineItems"/>
  <xs:element name="PublicOfferingPrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="upc_PublicOfferingPrice"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="TaxBenefitPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_TaxBenefitPercentage"/>
  <xs:element name="PercentageOfVatRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PercentageOfVatRate"/>
  <xs:element name="NetAccountReceivablePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="upc_NetAccountReceivablePercentage"/>
  <xs:element name="PrepaymentforAcquisitionDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_PrepaymentforAcquisitionDetailsTable"/>
  <xs:element name="PrepaymentForAcquisition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentForAcquisition"/>
  <xs:element name="OtherReceivableDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_OtherReceivableDetailsTable"/>
  <xs:element name="OtherReceivableDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_OtherReceivableDetailsLineItems"/>
  <xs:element name="OtherReceivablePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_OtherReceivablePercentage"/>
  <xs:element name="PrepaymentforCIPProjectDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_PrepaymentforCIPProjectDetailsTable"/>
  <xs:element name="PrepaymentforCIPProjectDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentforCIPProjectDetailsLineItems"/>
  <xs:element name="PrepaymentforPurchaseofaPropertyDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_PrepaymentforPurchaseofaPropertyDetailsTable"/>
  <xs:element name="PrepaymentforPurchaseofaPropertyDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems"/>
  <xs:element name="PrepaymentsMadeToARelatedPartyForPurchasesOfProperty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty"/>
  <xs:element name="PercentageOfPrepayment" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PercentageOfPrepayment"/>
  <xs:element name="PercentageOfTotalPurchasePricePayable" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="upc_PercentageOfTotalPurchasePricePayable"/>
  <xs:element name="PayableDeliveryPropertyPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PayableDeliveryPropertyPercentage"/>
  <xs:element name="ShortTermBankLoansDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_ShortTermBankLoansDetailsTable"/>
  <xs:element name="LongTermBankLoansDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_LongTermBankLoansDetailsTable"/>
  <xs:element name="LongTermBankLoansDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_LongTermBankLoansDetailsLineItems"/>
  <xs:element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="TaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_TaxesDetailsTable"/>
  <xs:element name="ConcentrationsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_ConcentrationsDetailsTable"/>
  <xs:element name="ShareholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_ShareholdersEquityDetailsTable"/>
  <xs:element name="OriginalShareIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="upc_OriginalShareIssued"/>
  <xs:element name="OriginalSharesParValue" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_OriginalSharesParValue"/>
  <xs:element name="ShareIssuedAfterTheSplit" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="upc_ShareIssuedAfterTheSplit"/>
  <xs:element name="ShareOutstandingAfterTheSplit" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="upc_ShareOutstandingAfterTheSplit"/>
  <xs:element name="OrdinarySharesSoldPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="upc_OrdinarySharesSoldPercentage"/>
  <xs:element name="StatutorySurplusPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_StatutorySurplusPercentage"/>
  <xs:element name="ReserveIsEqualPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ReserveIsEqualPercentage"/>
  <xs:element name="RestrictedNetAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_RestrictedNetAssets"/>
  <xs:element name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_CommitmentsandContingenciesDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_SubsequentEventsDetailsTable"/>
  <xs:element name="NumberOfSharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_NumberOfSharesIssued"/>
  <xs:element name="MinorityInterestsOwnershipPercentageByParent" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="upc_MinorityInterestsOwnershipPercentageByParent"/>
  <xs:element name="BankOfCommunicationsCoLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_BankOfCommunicationsCoLtdMember"/>
  <xs:element name="BeijingBankMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_BeijingBankMember"/>
  <xs:element name="ChenyuanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ChenyuanMember"/>
  <xs:element name="CommonStockOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CommonStockOneMember"/>
  <xs:element name="CommonWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CommonWarrantsMember"/>
  <xs:element name="ConstructionInProgressTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ConstructionInProgressTwoMember"/>
  <xs:element name="CustomerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CustomerMember"/>
  <xs:element name="GuangzhouNingjingInvestmentCoLtdGuangzhouNingjingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_GuangzhouNingjingInvestmentCoLtdGuangzhouNingjingMember"/>
  <xs:element name="GubenYanlingPillMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_GubenYanlingPillMember"/>
  <xs:element name="JiangxiLulingRuralCommercialBankLRCBankMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_JiangxiLulingRuralCommercialBankLRCBankMember"/>
  <xs:element name="JiangxiUniverseMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_JiangxiUniverseMember"/>
  <xs:element name="JiangxiYueshangMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_JiangxiYueshangMember"/>
  <xs:element name="JxRcbBankMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_JxRcbBankMember"/>
  <xs:element name="LRCBankMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_LRCBankMember"/>
  <xs:element name="LandUseRightsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_LandUseRightsMember"/>
  <xs:element name="MrGangLaiMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_MrGangLaiMember"/>
  <xs:element name="MrXiboLiuMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_MrXiboLiuMember"/>
  <xs:element name="MrYajunHuMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_MrYajunHuMember"/>
  <xs:element name="MsLinYangMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_MsLinYangMember"/>
  <xs:element name="OfficeAndElectricEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_OfficeAndElectricEquipmentMember"/>
  <xs:element name="PrefundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrefundedWarrantsMember"/>
  <xs:element name="PurchaseMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PurchaseMember"/>
  <xs:element name="StatutoryReserveAndRestrictedNetAssetsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_StatutoryReserveAndRestrictedNetAssetsMember"/>
  <xs:element name="StatutoryReservesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_StatutoryReservesMember"/>
  <xs:element name="TopTenCustomersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_TopTenCustomersMember"/>
  <xs:element name="TwoSupplierMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_TwoSupplierMember"/>
  <xs:element name="UnderwriterWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnderwriterWarrantsMember"/>
  <xs:element name="UniverseHKMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UniverseHKMember"/>
  <xs:element name="UniverseHanheMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UniverseHanheMember"/>
  <xs:element name="UniverseINCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UniverseINCMember"/>
  <xs:element name="UniverseIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UniverseIncMember"/>
  <xs:element name="UniversePharmaceuticalsIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UniversePharmaceuticalsIncMember"/>
  <xs:element name="UniverseTechnologyMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UniverseTechnologyMember"/>
  <xs:element name="UniverseTradeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UniverseTradeMember"/>
  <xs:element name="WorkingCapitalLoanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_WorkingCapitalLoanMember"/>
  <xs:element name="YunnanFaxiMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_YunnanFaxiMember"/>
  <xs:element name="YunnanFaxiPharmaceuticalsCoLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_YunnanFaxiPharmaceuticalsCoLtdMember"/>
  <xs:element name="ZhujiangRuralBankMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ZhujiangRuralBankMember"/>
  <xs:element name="supplierMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_supplierMember"/>
  <xs:element name="ScheduleOfInventoryValuationAllowanceAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfInventoryValuationAllowanceAbstract"/>
  <xs:element name="ScheduleOfLongTermBankLoansLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfLongTermBankLoansLineItems"/>
  <xs:element name="ShortTermBankLoansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ShortTermBankLoansAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>46
<FILENAME>upc-20240930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Apr 29 14:31:08 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ConsolidatedBalanceSheet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ConsolidatedIncomeStatement" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ConsolidatedCashFlow" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofAccountsReceivableTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAccountsReceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofInventoriesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofAdvancestoSuppliersTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAdvancestoSuppliersTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofOtherReceivableTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofOtherReceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofIntangibleAssetsNetTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsNetTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofFutureMinimumCapitalExpendituresTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofFutureMinimumCapitalExpendituresTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofTableReconcilestheChinaStatutoryRatestotheCompanysEffectiveTaxRateTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTableReconcilestheChinaStatutoryRatestotheCompanysEffectiveTaxRateTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofDeferredTaxAssetsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofDeferredTaxAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofTaxesPayableTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTaxesPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofConsolidatedFinancialStatementsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofParentCompanyStatementsofCashFlowsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable"/>
  <calculationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_Cash" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Supplies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_Supplies" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForAcquisitionCurrent" xlink:href="upc-20240930.xsd#upc_PrepaymentForAcquisitionCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="upc_PrepaymentForAcquisitionCurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherReceivables" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" xlink:href="upc-20240930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsForConstructionInProgress" xlink:href="upc-20240930.xsd#upc_PrepaymentsForConstructionInProgress"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="upc_PrepaymentsForConstructionInProgress" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_EquityMethodInvestments" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ShortTermBorrowings" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_TaxesPayableCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLoansFromBank" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermLoansFromBank"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermLoansFromBank" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="upc_StatutoryReserve" xlink:href="upc-20240930.xsd#upc_StatutoryReserve"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="upc_StatutoryReserve" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseNonoperating" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="upc_ChangeInFairValueOfShorttermInvestments" xlink:href="upc-20240930.xsd#upc_ChangeInFairValueOfShorttermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="upc_ChangeInFairValueOfShorttermInvestments" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidAdvertising" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidAdvertising"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidAdvertising" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="15" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="16" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" order="17" weight="-1"/>
    <loc xlink:type="locator" xlink:label="upc_IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent" xlink:href="upc-20240930.xsd#upc_IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="upc_IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent" order="18" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="upc_ProceedsFromPaymentForConstructionInProgress" xlink:href="upc-20240930.xsd#upc_ProceedsFromPaymentForConstructionInProgress"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="upc_ProceedsFromPaymentForConstructionInProgress" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYZDqnPZexC+e00+Rf6r37QtPu3oRrVmmTX8PuYVCFDMbRocUzw9EKKPK5NWC0WpJsOIuWkqeF3WWYzAuBG72bAUNWZ0EJoh7tCz07VxkYX3MUSJ7UFcJNPwN8yHmeKHRgkhMTd18uQzeusIsu/5w+1sTLgk4s48vHUWCmlxzr3HAZpsa+LfmHnFaLaCmPS0f6K1sduUUfaD9sRn5i3Vzu5VnzV9KOEHGDWQhDnV/BFeewWkVFaS1UAi7C0XEM9F+7cuAhtDe0r+w==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromBankDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromBankDebt" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfBankDebt" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAccountsReceivableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterials" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoods" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryValuationReserves" order="3" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAdvancestoSuppliersTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Supplies"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsAndSupplies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Supplies" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies" order="1" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofOtherReceivableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_ReceivablesNetCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherShortTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherShortTermInvestments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_ValueAddedTaxReceivableCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidAdvertising" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidAdvertising"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_PrepaidAdvertising" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="5" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="6" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofFutureMinimumCapitalExpendituresTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInSecondYear"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInSecondYear" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInThirdYear" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTableReconcilestheChinaStatutoryRatestotheCompanysEffectiveTaxRateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays" order="5" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofDeferredTaxAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTaxesPayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <loc xlink:type="locator" xlink:label="upc_ValueAddedTaxPayable" xlink:href="upc-20240930.xsd#upc_ValueAddedTaxPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="upc_ValueAddedTaxPayable" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="upc_OtherTaxesPayable" xlink:href="upc-20240930.xsd#upc_OtherTaxesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="upc_OtherTaxesPayable" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_Cash" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherReceivables" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingExpense" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="upc_ChangeInFairValueOfShorttermInvestments" xlink:href="upc-20240930.xsd#upc_ChangeInFairValueOfShorttermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="upc_ChangeInFairValueOfShorttermInvestments" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromContributionsFromAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromContributionsFromAffiliates" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>47
<FILENAME>upc-20240930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Apr 29 14:31:08 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ConsolidatedBalanceSheet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ConsolidatedIncomeStatement" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ShareholdersEquityType2or3" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ConsolidatedCashFlow" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_OrganizationandBusinessDescription" roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_AccountsReceivableNet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_InventoriesNet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/InventoriesNet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_AdvancetoSuppliers" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_PrepaymentforAcquisition" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisition"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_OtherReceivable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/OtherReceivable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_PropertyPlantandEquipmentNet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_IntangibleAssetsNet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_PrepaymentforCIPProject" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProject"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_PrepaymentforPurchaseofaProperty" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ShortTermBankLoans" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoans"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_LongTermBankLoans" roleURI="http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoans"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_RelatedPartyTransactions" roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_Taxes" roleURI="http://www.UniversePharmaceuticalsINC.com/role/Taxes"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_Concentrations" roleURI="http://www.UniversePharmaceuticalsINC.com/role/Concentrations"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ShareholdersEquity" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_CommitmentsandContingencies" roleURI="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_SubsequentEvents" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_FinancialInformationoftheParentCompany" roleURI="http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompany"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_AccountingPoliciesByPolicy" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_OrganizationandBusinessDescriptionTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_AccountsReceivableNetTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_InventoriesNetTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/InventoriesNetTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_AdvancetoSuppliersTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_OtherReceivableTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_PropertyPlantandEquipmentNetTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_IntangibleAssetsNetTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_PrepaymentforCIPProjectTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ShortTermBankLoansTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_LongTermBankLoansTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoansTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_RelatedPartyTransactionsTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_TaxesTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/TaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_FinancialInformationoftheParentCompanyTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompanyTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofSubsidiariesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofSubsidiariesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofIntangibleAssetsEstimatedUsefulLivesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsEstimatedUsefulLivesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofCurrencyExchangeRateTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofCurrencyExchangeRateTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofAccountsReceivableTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAccountsReceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofAllowanceforDoubtfulAccountsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAllowanceforDoubtfulAccountsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofInventoriesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofInventoriesValuationAllowanceTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesValuationAllowanceTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofAdvancestoSuppliersTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAdvancestoSuppliersTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofOtherReceivableTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofOtherReceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofPropertyPlantandEquipmentNetTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofIntangibleAssetsNetTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsNetTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofFutureMinimumCapitalExpendituresTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofFutureMinimumCapitalExpendituresTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofShortTermBankLoansTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofShortTermBankLoansTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofLongTermBankLoansTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofLongTermBankLoansTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofNatureofRelationshipsWithRelatedPartiesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofNatureofRelationshipsWithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofRelatedPartiesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofTableReconcilestheChinaStatutoryRatestotheCompanysEffectiveTaxRateTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTableReconcilestheChinaStatutoryRatestotheCompanysEffectiveTaxRateTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofDeferredTaxAssetsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofDeferredTaxAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofTaxesPayableTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTaxesPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofConsolidatedFinancialStatementsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofConsolidatedFinancialStatementsTable_Parentheticals" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofParentCompanyStatementsofCashFlowsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_OrganizationandBusinessDescriptionDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_AccountsReceivableNetDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_PrepaymentforAcquisitionDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_OtherReceivableDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_PropertyPlantandEquipmentNetDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_IntangibleAssetsNetDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_PrepaymentforCIPProjectDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_PrepaymentforPurchaseofaPropertyDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ShortTermBankLoansDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_LongTermBankLoansDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoansDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_RelatedPartyTransactionsDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_TaxesDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ConcentrationsDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ShareholdersEquityDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_CommitmentsandContingenciesDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_SubsequentEventsDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_FinancialInformationoftheParentCompanyDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompanyDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#DocumentAndEntityInformation" roleURI="http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Supplies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Supplies" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForAcquisitionCurrent" xlink:href="upc-20240930.xsd#upc_PrepaymentForAcquisitionCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="upc_PrepaymentForAcquisitionCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherReceivables" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" xlink:href="upc-20240930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsForConstructionInProgress" xlink:href="upc-20240930.xsd#upc_PrepaymentsForConstructionInProgress"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="upc_PrepaymentsForConstructionInProgress" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrent" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShortTermBorrowings" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableCurrent" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxesPayableCurrent" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLoansFromBank" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermLoansFromBank"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermLoansFromBank" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_StatutoryReserve" xlink:href="upc-20240930.xsd#upc_StatutoryReserve"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="upc_StatutoryReserve" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="33" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SellingExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="20" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_StatutoryReservesMember" xlink:href="upc-20240930.xsd#upc_StatutoryReservesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="upc_StatutoryReservesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_StockIssuedDuringPeriodValueStatutoryReserve" xlink:href="upc-20240930.xsd#upc_StockIssuedDuringPeriodValueStatutoryReserve"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="upc_StockIssuedDuringPeriodValueStatutoryReserve" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_StockIssuedDuringPeriodValueReverseShareSplitAdjustment" xlink:href="upc-20240930.xsd#upc_StockIssuedDuringPeriodValueReverseShareSplitAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="upc_StockIssuedDuringPeriodValueReverseShareSplitAdjustment" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ChangeInFairValueOfShorttermInvestments" xlink:href="upc-20240930.xsd#upc_ChangeInFairValueOfShorttermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="upc_ChangeInFairValueOfShorttermInvestments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidAdvertising" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidAdvertising"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidAdvertising" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent" xlink:href="upc-20240930.xsd#upc_IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="upc_IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ProceedsFromPaymentForConstructionInProgress" xlink:href="upc-20240930.xsd#upc_ProceedsFromPaymentForConstructionInProgress"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="upc_ProceedsFromPaymentForConstructionInProgress" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromBankDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromBankDebt" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RepaymentsOfBankDebt" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_InterestPaidNet" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="34" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/InventoriesNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="upc_AdvancesToSuppliersAbstract" xlink:href="upc-20240930.xsd#upc_AdvancesToSuppliersAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_AdvancesToSuppliersTextBlock" xlink:href="upc-20240930.xsd#upc_AdvancesToSuppliersTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_AdvancesToSuppliersAbstract" xlink:to="upc_AdvancesToSuppliersTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisition" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/OtherReceivable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherReceivablesNetCurrentAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProject" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForConstructionInProgressAbstract" xlink:href="upc-20240930.xsd#upc_PrepaymentForConstructionInProgressAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForConstructionInProgressTextBlock" xlink:href="upc-20240930.xsd#upc_PrepaymentForConstructionInProgressTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForConstructionInProgressAbstract" xlink:to="upc_PrepaymentForConstructionInProgressTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForPurchaseOfAPropertyAbstract" xlink:href="upc-20240930.xsd#upc_PrepaymentForPurchaseOfAPropertyAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForPurchaseOfAPropertyTextBlock" xlink:href="upc-20240930.xsd#upc_PrepaymentForPurchaseOfAPropertyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForPurchaseOfAPropertyAbstract" xlink:to="upc_PrepaymentForPurchaseOfAPropertyTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoans" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="upc_ShortTermBankLoansAbstract" xlink:href="upc-20240930.xsd#upc_ShortTermBankLoansAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShortTermBankLoansAbstract" xlink:to="us-gaap_ShortTermDebtTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoans" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/Taxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/Concentrations" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompany" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ReclassificationsPolicyTextBlock" xlink:href="upc-20240930.xsd#upc_ReclassificationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="upc_ReclassificationsPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_AdvancesToSuppliersNetPolicyTextBlock" xlink:href="upc-20240930.xsd#upc_AdvancesToSuppliersNetPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="upc_AdvancesToSuppliersNetPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ConstructioninProgressPolicyTextBlock" xlink:href="upc-20240930.xsd#upc_ConstructioninProgressPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="upc_ConstructioninProgressPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_DisaggregationOfRevenuesPolicyTextBlock" xlink:href="upc-20240930.xsd#upc_DisaggregationOfRevenuesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="upc_DisaggregationOfRevenuesPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ValueAddedTaxPolicyTextBlock" xlink:href="upc-20240930.xsd#upc_ValueAddedTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="upc_ValueAddedTaxPolicyTextBlock" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_StatementOfCashFlowsPolicyTextBlock" xlink:href="upc-20240930.xsd#upc_StatementOfCashFlowsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="upc_StatementOfCashFlowsPolicyTextBlock" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_EmployeeDefinedContributionPlanPolicyTextBlock" xlink:href="upc-20240930.xsd#upc_EmployeeDefinedContributionPlanPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="upc_EmployeeDefinedContributionPlanPolicyTextBlock" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="28" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:href="upc-20240930.xsd#upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock" xlink:href="upc-20240930.xsd#upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/InventoriesNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="upc_AdvancesToSuppliersAbstract" xlink:href="upc-20240930.xsd#upc_AdvancesToSuppliersAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfAdvancesToSuppliersNet" xlink:href="upc-20240930.xsd#upc_ScheduleOfAdvancesToSuppliersNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_AdvancesToSuppliersAbstract" xlink:to="upc_ScheduleOfAdvancesToSuppliersNet" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherReceivablesNetCurrentAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForConstructionInProgressAbstract" xlink:href="upc-20240930.xsd#upc_PrepaymentForConstructionInProgressAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock" xlink:href="upc-20240930.xsd#upc_ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForConstructionInProgressAbstract" xlink:to="upc_ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="upc_ShortTermBankLoansAbstract" xlink:href="upc-20240930.xsd#upc_ShortTermBankLoansAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShortTermBankLoansAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoansTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock" xlink:href="upc-20240930.xsd#upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/TaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfTaxPayableTableTextBlock" xlink:href="upc-20240930.xsd#upc_ScheduleOfTaxPayableTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="upc_ScheduleOfTaxPayableTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompanyTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfComprehensiveIncomeTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedCashFlowStatementTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofSubsidiariesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="srt_OwnershipAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseINCMember" xlink:href="upc-20240930.xsd#upc_UniverseINCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="upc_UniverseINCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseHKMember" xlink:href="upc-20240930.xsd#upc_UniverseHKMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="upc_UniverseHKMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseTechnologyMember" xlink:href="upc-20240930.xsd#upc_UniverseTechnologyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="upc_UniverseTechnologyMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_JiangxiUniverseMember" xlink:href="upc-20240930.xsd#upc_JiangxiUniverseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="upc_JiangxiUniverseMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseTradeMember" xlink:href="upc-20240930.xsd#upc_UniverseTradeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="upc_UniverseTradeMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseHanheMember" xlink:href="upc-20240930.xsd#upc_UniverseHanheMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="upc_UniverseHanheMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesDetailsTable" xlink:href="upc-20240930.xsd#upc_SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="upc_SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AutomobilesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AutomobilesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_AutomobilesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OfficeAndElectricEquipmentMember" xlink:href="upc-20240930.xsd#upc_OfficeAndElectricEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="upc_OfficeAndElectricEquipmentMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsEstimatedUsefulLivesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsEstimatedUsefulLivesDetailsTable" xlink:href="upc-20240930.xsd#upc_SummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsEstimatedUsefulLivesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="upc_SummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsEstimatedUsefulLivesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_SummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsEstimatedUsefulLivesDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseRightsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_UseRightsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TrademarksMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofCurrencyExchangeRateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRateDetailsTable" xlink:href="upc-20240930.xsd#upc_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRateDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DerivativeLineItems" xlink:to="upc_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRateDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRateDetailsTable" xlink:to="srt_CurrencyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain_0" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_CNY" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CNY"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_CNY" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_HKD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_HKD"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_HKD" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeForwardExchangeRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeForwardExchangeRate1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DerivativeForwardExchangeRate1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeAverageForwardExchangeRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAverageForwardExchangeRate1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DerivativeAverageForwardExchangeRate1" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAccountsReceivableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsReceivableNetCurrentAbstract" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsReceivableNetCurrentAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsReceivableNetCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAllowanceforDoubtfulAccountsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForCreditLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForCreditLossAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AllowanceForCreditLossAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AllowanceForCreditLossAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AllowanceForCreditLossAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfInventoriesAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfInventoriesAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfInventoriesAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfInventoriesAbstract" xlink:to="us-gaap_InventoryValuationReserves" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfInventoriesAbstract" xlink:to="us-gaap_InventoryNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesValuationAllowanceTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfInventoryValuationAllowanceAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfInventoryValuationAllowanceAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfInventoryValuationAllowanceAbstract" xlink:to="us-gaap_InventoryValuationReserves" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfInventoryValuationAllowanceAbstract" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments" xlink:href="upc-20240930.xsd#upc_InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfInventoryValuationAllowanceAbstract" xlink:to="upc_InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAdvancestoSuppliersTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsAndSuppliesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsAndSuppliesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsAndSupplies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryRawMaterialsAndSuppliesAbstract" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Supplies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryRawMaterialsAndSuppliesAbstract" xlink:to="us-gaap_Supplies" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofOtherReceivableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfOtherReceivableAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfOtherReceivableAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfOtherReceivableAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfOtherReceivableAbstract" xlink:to="us-gaap_OtherShortTermInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfOtherReceivableAbstract" xlink:to="us-gaap_ValueAddedTaxReceivableCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidAdvertising" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidAdvertising"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfOtherReceivableAbstract" xlink:to="us-gaap_PrepaidAdvertising" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfOtherReceivableAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfOtherReceivableAbstract" xlink:to="us-gaap_OtherReceivables" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AutomobilesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AutomobilesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_AutomobilesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_LandUseRightsMember" xlink:href="upc-20240930.xsd#upc_LandUseRightsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="upc_LandUseRightsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TrademarksMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofFutureMinimumCapitalExpendituresTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationFiscalYearMaturityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInSecondYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_ContractualObligationDueInSecondYear" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_ContractualObligationDueInThirdYear" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_ContractualObligation" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofShortTermBankLoansTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_JiangxiLulingRuralCommercialBankLRCBankMember" xlink:href="upc-20240930.xsd#upc_JiangxiLulingRuralCommercialBankLRCBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_JiangxiLulingRuralCommercialBankLRCBankMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_BankOfCommunicationsCoLtdMember" xlink:href="upc-20240930.xsd#upc_BankOfCommunicationsCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_BankOfCommunicationsCoLtdMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ZhujiangRuralBankMember" xlink:href="upc-20240930.xsd#upc_ZhujiangRuralBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_ZhujiangRuralBankMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_BeijingBankMember" xlink:href="upc-20240930.xsd#upc_BeijingBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_BeijingBankMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermBorrowings" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofLongTermBankLoansTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfLongTermBankLoansLineItems" xlink:href="upc-20240930.xsd#upc_ScheduleOfLongTermBankLoansLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_ScheduleOfLongTermBankLoansLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_LRCBankMember" xlink:href="upc-20240930.xsd#upc_LRCBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="upc_LRCBankMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLoansFromBank" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermLoansFromBank"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfLongTermBankLoansLineItems" xlink:to="us-gaap_LongTermLoansFromBank" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofNatureofRelationshipsWithRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_RelatedPartyTransactionsScheduleofNatureofRelationshipsWithRelatedPartiesDetailsTable" xlink:href="upc-20240930.xsd#upc_RelatedPartyTransactionsScheduleofNatureofRelationshipsWithRelatedPartiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="upc_RelatedPartyTransactionsScheduleofNatureofRelationshipsWithRelatedPartiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_RelatedPartyTransactionsScheduleofNatureofRelationshipsWithRelatedPartiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_MrGangLaiMember" xlink:href="upc-20240930.xsd#upc_MrGangLaiMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_MrGangLaiMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_MrYajunHuMember" xlink:href="upc-20240930.xsd#upc_MrYajunHuMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_MrYajunHuMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_MsLinYangMember" xlink:href="upc-20240930.xsd#upc_MsLinYangMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_MsLinYangMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_GuangzhouNingjingInvestmentCoLtdGuangzhouNingjingMember" xlink:href="upc-20240930.xsd#upc_GuangzhouNingjingInvestmentCoLtdGuangzhouNingjingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_GuangzhouNingjingInvestmentCoLtdGuangzhouNingjingMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_MrYajunHuMember" xlink:href="upc-20240930.xsd#upc_MrYajunHuMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_MrYajunHuMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_MrGangLaiMember" xlink:href="upc-20240930.xsd#upc_MrGangLaiMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_MrGangLaiMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_MsLinYangMember" xlink:href="upc-20240930.xsd#upc_MsLinYangMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_MsLinYangMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_TaxesScheduleofComponentsoftheIncomeTaxProvisionBenefitDetailsTable" xlink:href="upc-20240930.xsd#upc_TaxesScheduleofComponentsoftheIncomeTaxProvisionBenefitDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="upc_TaxesScheduleofComponentsoftheIncomeTaxProvisionBenefitDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_TaxesScheduleofComponentsoftheIncomeTaxProvisionBenefitDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_KY" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KY"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_KY" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_HK"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_HK" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTableReconcilestheChinaStatutoryRatestotheCompanysEffectiveTaxRateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofDeferredTaxAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfDeferredTaxAssetsAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTaxesPayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_ValueAddedTaxPayable" xlink:href="upc-20240930.xsd#upc_ValueAddedTaxPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxesPayableCurrentAbstract" xlink:to="upc_ValueAddedTaxPayable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OtherTaxesPayable" xlink:href="upc-20240930.xsd#upc_OtherTaxesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxesPayableCurrentAbstract" xlink:to="upc_OtherTaxesPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxesPayableCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable" xlink:type="extended">
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYZDqnPZexC+e00+Rf6r37QtPu3oRrVmmTX8PuYVCFDMbRocUzw9EKKPK5NWC0WpJsOIuWkqeF3WWYzAuBG72bAUNWZ0EJoh7tCz07VxkYX3MUSJ7UFcJNPwN8yHmeKHRgkhMTd18uQzeusIsu/5w+1sTLgk4s48vHUWCmlxzr3HAZpsa+LfmHnFaLaCmPS0f6K1sduUUfaD9sRn5i3Vzu5VnzV9KOEHGDWQhDnV/BFeewWkVFaS1UA/XUmxatt7jMNIt4td4zsiw==] CSR-->
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="srt_CondensedBalanceSheetStatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_ParentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OtherReceivables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_Assets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockValue" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_StockholdersEquity" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="srt_CondensedBalanceSheetStatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_ParentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfIncomeCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfComprehensiveIncomeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_ParentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedCashFlowStatementTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedCashFlowStatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="srt_CondensedCashFlowStatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ChangeInFairValueOfShorttermInvestments" xlink:href="upc-20240930.xsd#upc_ChangeInFairValueOfShorttermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="upc_ChangeInFairValueOfShorttermInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromContributionsFromAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_ProceedsFromContributionsFromAffiliates" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:href="upc-20240930.xsd#upc_OrganizationandBusinessDescriptionDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_OrganizationandBusinessDescriptionDetailsTable" xlink:href="upc-20240930.xsd#upc_OrganizationandBusinessDescriptionDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="upc_OrganizationandBusinessDescriptionDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_OrganizationandBusinessDescriptionDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_OrganizationandBusinessDescriptionDetailsTable" xlink:to="srt_StatementScenarioAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_OrganizationandBusinessDescriptionDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_OrganizationandBusinessDescriptionDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_OrganizationandBusinessDescriptionDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_OrganizationandBusinessDescriptionDetailsTable" xlink:to="srt_RangeAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_OrganizationandBusinessDescriptionDetailsTable" xlink:to="srt_OwnershipAxis" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CommonStockOneMember" xlink:href="upc-20240930.xsd#upc_CommonStockOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="upc_CommonStockOneMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseIncMember" xlink:href="upc-20240930.xsd#upc_UniverseIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="upc_UniverseIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseHKMember" xlink:href="upc-20240930.xsd#upc_UniverseHKMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="upc_UniverseHKMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_JiangxiUniverseMember" xlink:href="upc-20240930.xsd#upc_JiangxiUniverseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="upc_JiangxiUniverseMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseTradeMember" xlink:href="upc-20240930.xsd#upc_UniverseTradeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="upc_UniverseTradeMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseTechnologyMember" xlink:href="upc-20240930.xsd#upc_UniverseTechnologyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="upc_UniverseTechnologyMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationDateOfIncorporation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PublicOfferingPrice" xlink:href="upc-20240930.xsd#upc_PublicOfferingPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="upc_PublicOfferingPrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExcessStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_CapitalUnits" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_CommonStockDividendsShares" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="upc-20240930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="upc_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseHKMember" xlink:href="upc-20240930.xsd#upc_UniverseHKMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="upc_UniverseHKMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniversePharmaceuticalsIncMember" xlink:href="upc-20240930.xsd#upc_UniversePharmaceuticalsIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="upc_UniversePharmaceuticalsIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_JxRcbBankMember" xlink:href="upc-20240930.xsd#upc_JxRcbBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="upc_JxRcbBankMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_InventoryValuationReserves" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_EquityMethodInvestmentSoldCarryingAmount" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_AdvertisingExpense" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_TaxBenefitPercentage" xlink:href="upc-20240930.xsd#upc_TaxBenefitPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="upc_TaxBenefitPercentage" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PercentageOfVatRate" xlink:href="upc-20240930.xsd#upc_PercentageOfVatRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="upc_PercentageOfVatRate" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_NetAccountReceivablePercentage" xlink:href="upc-20240930.xsd#upc_NetAccountReceivablePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="upc_NetAccountReceivablePercentage" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsReceivableNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforAcquisitionDetailsTable" xlink:href="upc-20240930.xsd#upc_PrepaymentforAcquisitionDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="upc_PrepaymentforAcquisitionDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_PrepaymentforAcquisitionDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_PrepaymentforAcquisitionDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_PrepaymentforAcquisitionDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_YunnanFaxiPharmaceuticalsCoLtdMember" xlink:href="upc-20240930.xsd#upc_YunnanFaxiPharmaceuticalsCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="upc_YunnanFaxiPharmaceuticalsCoLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_MrXiboLiuMember" xlink:href="upc-20240930.xsd#upc_MrXiboLiuMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_MrXiboLiuMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="upc_YunnanFaxiPharmaceuticalsCoLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForAcquisition" xlink:href="upc-20240930.xsd#upc_PrepaymentForAcquisition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="upc_PrepaymentForAcquisition" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForAcquisitionCurrent" xlink:href="upc-20240930.xsd#upc_PrepaymentForAcquisitionCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="upc_PrepaymentForAcquisitionCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_OtherReceivables" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="upc_OtherReceivableDetailsLineItems" xlink:href="upc-20240930.xsd#upc_OtherReceivableDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_OtherReceivableDetailsTable" xlink:href="upc-20240930.xsd#upc_OtherReceivableDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_OtherReceivableDetailsLineItems" xlink:to="upc_OtherReceivableDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_OtherReceivableDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_YunnanFaxiMember" xlink:href="upc-20240930.xsd#upc_YunnanFaxiMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="upc_YunnanFaxiMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OtherReceivableDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OtherReceivableDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OtherReceivableDetailsLineItems" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OtherReceivableDetailsLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OtherReceivableDetailsLineItems" xlink:to="us-gaap_OtherReceivablesGrossCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OtherReceivableDetailsLineItems" xlink:to="us-gaap_OtherShortTermInvestments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OtherReceivablePercentage" xlink:href="upc-20240930.xsd#upc_OtherReceivablePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OtherReceivableDetailsLineItems" xlink:to="upc_OtherReceivablePercentage" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforCIPProjectDetailsLineItems" xlink:href="upc-20240930.xsd#upc_PrepaymentforCIPProjectDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforCIPProjectDetailsTable" xlink:href="upc-20240930.xsd#upc_PrepaymentforCIPProjectDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_PrepaymentforCIPProjectDetailsLineItems" xlink:to="upc_PrepaymentforCIPProjectDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_PrepaymentforCIPProjectDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_PrepaymentforCIPProjectDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ConstructionInProgressTwoMember" xlink:href="upc-20240930.xsd#upc_ConstructionInProgressTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="upc_ConstructionInProgressTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ChenyuanMember" xlink:href="upc-20240930.xsd#upc_ChenyuanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_ChenyuanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentBuildingAndBuildingImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentBuildingAndBuildingImprovements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforCIPProjectDetailsLineItems" xlink:to="us-gaap_InvestmentBuildingAndBuildingImprovements" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionContractCostProgressPaymentOffset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionContractCostProgressPaymentOffset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforCIPProjectDetailsLineItems" xlink:to="us-gaap_ConstructionContractCostProgressPaymentOffset" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforCIPProjectDetailsLineItems" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforCIPProjectDetailsLineItems" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:href="upc-20240930.xsd#upc_PrepaymentforPurchaseofaPropertyDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforPurchaseofaPropertyDetailsTable" xlink:href="upc-20240930.xsd#upc_PrepaymentforPurchaseofaPropertyDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="upc_PrepaymentforPurchaseofaPropertyDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_PrepaymentforPurchaseofaPropertyDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_PrepaymentforPurchaseofaPropertyDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_JiangxiYueshangMember" xlink:href="upc-20240930.xsd#upc_JiangxiYueshangMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="upc_JiangxiYueshangMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_JiangxiYueshangMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty" xlink:href="upc-20240930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PercentageOfPrepayment" xlink:href="upc-20240930.xsd#upc_PercentageOfPrepayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="upc_PercentageOfPrepayment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PercentageOfTotalPurchasePricePayable" xlink:href="upc-20240930.xsd#upc_PercentageOfTotalPurchasePricePayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="upc_PercentageOfTotalPurchasePricePayable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PayableDeliveryPropertyPercentage" xlink:href="upc-20240930.xsd#upc_PayableDeliveryPropertyPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="upc_PayableDeliveryPropertyPercentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_ShortTermBankLoansDetailsTable" xlink:href="upc-20240930.xsd#upc_ShortTermBankLoansDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="upc_ShortTermBankLoansDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ShortTermBankLoansDetailsTable" xlink:to="srt_StatementScenarioAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ShortTermBankLoansDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ShortTermBankLoansDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ShortTermBankLoansDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_LRCBankMember" xlink:href="upc-20240930.xsd#upc_LRCBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="upc_LRCBankMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_BankOfCommunicationsCoLtdMember" xlink:href="upc-20240930.xsd#upc_BankOfCommunicationsCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="upc_BankOfCommunicationsCoLtdMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ZhujiangRuralBankMember" xlink:href="upc-20240930.xsd#upc_ZhujiangRuralBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="upc_ZhujiangRuralBankMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_BeijingBankMember" xlink:href="upc-20240930.xsd#upc_BeijingBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="upc_BeijingBankMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseTradeMember" xlink:href="upc-20240930.xsd#upc_UniverseTradeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_UniverseTradeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_JiangxiUniverseMember" xlink:href="upc-20240930.xsd#upc_JiangxiUniverseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_JiangxiUniverseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_WorkingCapitalLoanMember" xlink:href="upc-20240930.xsd#upc_WorkingCapitalLoanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="upc_WorkingCapitalLoanMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="upc_LRCBankMember" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="upc_ZhujiangRuralBankMember" order="2" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="upc_BeijingBankMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermBorrowings" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtTerms" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoansDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="upc_LongTermBankLoansDetailsLineItems" xlink:href="upc-20240930.xsd#upc_LongTermBankLoansDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_LongTermBankLoansDetailsTable" xlink:href="upc-20240930.xsd#upc_LongTermBankLoansDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_LongTermBankLoansDetailsLineItems" xlink:to="upc_LongTermBankLoansDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_LongTermBankLoansDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_LRCBankMember" xlink:href="upc-20240930.xsd#upc_LRCBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="upc_LRCBankMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_LongTermBankLoansDetailsLineItems" xlink:to="us-gaap_LongTermDebt" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_LongTermBankLoansDetailsLineItems" xlink:to="us-gaap_LongTermDebtTerm" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_LongTermBankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_LongTermBankLoansDetailsLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_LongTermBankLoansDetailsLineItems" xlink:to="us-gaap_InterestPaidNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_RelatedPartyTransactionsDetailsTable" xlink:href="upc-20240930.xsd#upc_RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="upc_RelatedPartyTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_RelatedPartyTransactionsDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_JiangxiYueshangMember" xlink:href="upc-20240930.xsd#upc_JiangxiYueshangMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="upc_JiangxiYueshangMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_MrGangLaiMember" xlink:href="upc-20240930.xsd#upc_MrGangLaiMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="upc_MrGangLaiMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty" xlink:href="upc-20240930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxHolidayLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_TaxesDetailsTable" xlink:href="upc-20240930.xsd#upc_TaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxHolidayLineItems" xlink:to="upc_TaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_TaxesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_HK"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_HK" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxHolidayLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxHolidayDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxHolidayLineItems" xlink:to="us-gaap_IncomeTaxHolidayDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxHolidayLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayAggregateDollarAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxHolidayLineItems" xlink:to="us-gaap_IncomeTaxHolidayAggregateDollarAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxHolidayLineItems" xlink:to="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_ConcentrationsDetailsTable" xlink:href="upc-20240930.xsd#upc_ConcentrationsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="upc_ConcentrationsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ConcentrationsDetailsTable" xlink:to="srt_MajorCustomersAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ConcentrationsDetailsTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ConcentrationsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_GubenYanlingPillMember" xlink:href="upc-20240930.xsd#upc_GubenYanlingPillMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="upc_GubenYanlingPillMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_TopTenCustomersMember" xlink:href="upc-20240930.xsd#upc_TopTenCustomersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="upc_TopTenCustomersMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CustomerMember" xlink:href="upc-20240930.xsd#upc_CustomerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="upc_CustomerMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PurchaseMember" xlink:href="upc-20240930.xsd#upc_PurchaseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="upc_PurchaseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_SupplierConcentrationRiskMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_supplierMember" xlink:href="upc-20240930.xsd#upc_supplierMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="upc_supplierMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_TwoSupplierMember" xlink:href="upc-20240930.xsd#upc_TwoSupplierMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="upc_TwoSupplierMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignFinancialInstitutionsMandatedDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignFinancialInstitutionsMandatedDeposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ForeignFinancialInstitutionsMandatedDeposits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_ShareholdersEquityDetailsTable" xlink:href="upc-20240930.xsd#upc_ShareholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="upc_ShareholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ShareholdersEquityDetailsTable" xlink:to="srt_StatementScenarioAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ShareholdersEquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ShareholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ShareholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ShareholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UnderwriterWarrantsMember" xlink:href="upc-20240930.xsd#upc_UnderwriterWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="upc_UnderwriterWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_StatutoryReserveAndRestrictedNetAssetsMember" xlink:href="upc-20240930.xsd#upc_StatutoryReserveAndRestrictedNetAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="upc_StatutoryReserveAndRestrictedNetAssetsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CommonStockOneMember" xlink:href="upc-20240930.xsd#upc_CommonStockOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="upc_CommonStockOneMember" order="2" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="upc_UnderwriterWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseINCMember" xlink:href="upc-20240930.xsd#upc_UniverseINCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_UniverseINCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OriginalShareIssued" xlink:href="upc-20240930.xsd#upc_OriginalShareIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="upc_OriginalShareIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OriginalSharesParValue" xlink:href="upc-20240930.xsd#upc_OriginalSharesParValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="upc_OriginalSharesParValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ShareIssuedAfterTheSplit" xlink:href="upc-20240930.xsd#upc_ShareIssuedAfterTheSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="upc_ShareIssuedAfterTheSplit" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ShareOutstandingAfterTheSplit" xlink:href="upc-20240930.xsd#upc_ShareOutstandingAfterTheSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="upc_ShareOutstandingAfterTheSplit" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CapitalUnits" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockDividendsShares" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExcessStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OrdinarySharesSoldPercentage" xlink:href="upc-20240930.xsd#upc_OrdinarySharesSoldPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="upc_OrdinarySharesSoldPercentage" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_StatutorySurplusPercentage" xlink:href="upc-20240930.xsd#upc_StatutorySurplusPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="upc_StatutorySurplusPercentage" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ReserveIsEqualPercentage" xlink:href="upc-20240930.xsd#upc_ReserveIsEqualPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="upc_ReserveIsEqualPercentage" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_StatutoryReserve" xlink:href="upc-20240930.xsd#upc_StatutoryReserve"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="upc_StatutoryReserve" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_RestrictedNetAssets" xlink:href="upc-20240930.xsd#upc_RestrictedNetAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="upc_RestrictedNetAssets" order="27" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_CommitmentsandContingenciesDetailsTable" xlink:href="upc-20240930.xsd#upc_CommitmentsandContingenciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="upc_CommitmentsandContingenciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_CommitmentsandContingenciesDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_MrGangLaiMember" xlink:href="upc-20240930.xsd#upc_MrGangLaiMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="upc_MrGangLaiMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_JiangxiYueshangMember" xlink:href="upc-20240930.xsd#upc_JiangxiYueshangMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_JiangxiYueshangMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ContractualObligation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty" xlink:href="upc-20240930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_SubsequentEventsDetailsTable" xlink:href="upc-20240930.xsd#upc_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="upc_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_SubsequentEventsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_SubsequentEventsDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_SubsequentEventsDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_YunnanFaxiMember" xlink:href="upc-20240930.xsd#upc_YunnanFaxiMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="upc_YunnanFaxiMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PrefundedWarrantsMember" xlink:href="upc-20240930.xsd#upc_PrefundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="upc_PrefundedWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CommonWarrantsMember" xlink:href="upc-20240930.xsd#upc_CommonWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="upc_CommonWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_NumberOfSharesIssued" xlink:href="upc-20240930.xsd#upc_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="upc_NumberOfSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CapitalUnits" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_OtherReceivables" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompanyDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeNetAssetsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeNetAssetsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DerivativeNetAssetsPercentage" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_MinorityInterestsOwnershipPercentageByParent" xlink:href="upc-20240930.xsd#upc_MinorityInterestsOwnershipPercentageByParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="upc_MinorityInterestsOwnershipPercentageByParent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelEmailAddress" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelEmailAddress"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelEmailAddress" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorOpinionTextBlock" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorOpinionTextBlock" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="38" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>48
<FILENAME>upc-20240930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Apr 29 14:31:08 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">TOTAL NONCURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Total shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive loss attributable to the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Ordinary shares, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl2" xml:lang="en-US">Outstanding shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">CHANGES IN CASH</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash, end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization and Business Description [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetAbstract_lbl" xml:lang="en-US">Accounts Receivable, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsReceivableNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrentAbstract_lbl" xml:lang="en-US">Schedule of Accounts Receivable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl0" xml:lang="en-US">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForCreditLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForCreditLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForCreditLossAbstract_lbl" xml:lang="en-US">Schedule of Allowance for Doubtful Accounts [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForCreditLossAbstract" xlink:to="us-gaap_AllowanceForCreditLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl0" xml:lang="en-US">Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNetAbstract_lbl" xml:lang="en-US">Inventories, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfInventoriesAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfInventoriesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfInventoriesAbstract_lbl" xml:lang="en-US">Schedule of inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfInventoriesAbstract" xlink:to="upc_ScheduleOfInventoriesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventories, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventories, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfInventoryValuationAllowanceAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfInventoryValuationAllowanceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfInventoryValuationAllowanceAbstract_lbl" xml:lang="en-US">Schedule of Inventory Valuation Allowance [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfInventoryValuationAllowanceAbstract" xlink:to="upc_ScheduleOfInventoryValuationAllowanceAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US">Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_InventoryValuationReserves_lbl0" xml:lang="en-US">Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InventoryValuationReserves_lbl1" xml:lang="en-US">Inventories valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryValuationReserves_lbl2" xml:lang="en-US">Inventory reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl2"/>
    <loc xlink:type="locator" xlink:label="upc_AdvancesToSuppliersAbstract" xlink:href="upc-20240930.xsd#upc_AdvancesToSuppliersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AdvancesToSuppliersAbstract_lbl" xml:lang="en-US">Advance to Suppliers [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvancesToSuppliersAbstract" xlink:to="upc_AdvancesToSuppliersAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsAndSuppliesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsAndSuppliesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsAndSuppliesAbstract_lbl" xml:lang="en-US">Schedule of Advances to Suppliers Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsAndSuppliesAbstract" xlink:to="us-gaap_InventoryRawMaterialsAndSuppliesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Supplies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Supplies_lbl" xml:lang="en-US">Advances to suppliers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Supplies" xlink:to="us-gaap_Supplies_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Supplies_lbl0" xml:lang="en-US">Advance to suppliers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Supplies" xlink:to="us-gaap_Supplies_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAbstract_lbl" xml:lang="en-US">Prepayment for Acquisition [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrentAbstract_lbl" xml:lang="en-US">Other Receivable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfOtherReceivableAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfOtherReceivableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfOtherReceivableAbstract_lbl" xml:lang="en-US">Schedule of Other Receivable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfOtherReceivableAbstract" xlink:to="upc_ScheduleOfOtherReceivableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Intangible Assets, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US">Schedule of Estimated Future Amortization Expense for Intangible Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForConstructionInProgressAbstract" xlink:href="upc-20240930.xsd#upc_PrepaymentForConstructionInProgressAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentForConstructionInProgressAbstract_lbl" xml:lang="en-US">Prepayment for CIP Project [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForConstructionInProgressAbstract" xlink:to="upc_PrepaymentForConstructionInProgressAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationFiscalYearMaturityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityAbstract_lbl" xml:lang="en-US">Schedule of Future Minimum Capital Expenditures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_ContractualObligationFiscalYearMaturityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligation_lbl0" xml:lang="en-US">Capital expenditure cip project</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForPurchaseOfAPropertyAbstract" xlink:href="upc-20240930.xsd#upc_PrepaymentForPurchaseOfAPropertyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentForPurchaseOfAPropertyAbstract_lbl" xml:lang="en-US">Prepayment for Purchase of a Property [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForPurchaseOfAPropertyAbstract" xlink:to="upc_PrepaymentForPurchaseOfAPropertyAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ShortTermBankLoansAbstract" xlink:href="upc-20240930.xsd#upc_ShortTermBankLoansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ShortTermBankLoansAbstract_lbl" xml:lang="en-US">Short-Term Bank Loans [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShortTermBankLoansAbstract" xlink:to="upc_ShortTermBankLoansAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Long-Term Bank Loans [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-Term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US">Schedule of Effective Tax Rate [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfDeferredTaxAssetsAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfDeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfDeferredTaxAssetsAbstract" xlink:to="upc_ScheduleOfDeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrentAbstract_lbl" xml:lang="en-US">Schedule of Taxes Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Total taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl0" xml:lang="en-US">Taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Concentrations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Shareholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Financial Information of the Parent Company [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfConsolidatedFinancialStatementsAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfConsolidatedFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfConsolidatedFinancialStatementsAbstract_lbl" xml:lang="en-US">Schedule of Consolidated Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfConsolidatedFinancialStatementsAbstract" xlink:to="upc_ScheduleOfConsolidatedFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US">Consolidated Entities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfParentCompanyStatementsOfOperationsAndComprehensiveLossAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfParentCompanyStatementsOfOperationsAndComprehensiveLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfParentCompanyStatementsOfOperationsAndComprehensiveLossAbstract_lbl" xml:lang="en-US">Schedule of Parent Company Statements of Operations and Comprehensive Loss {Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfParentCompanyStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="upc_ScheduleOfParentCompanyStatementsOfOperationsAndComprehensiveLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Schedule of Parent Company Statements of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl0" xml:lang="en-US">Due from subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForAcquisitionCurrent" xlink:href="upc-20240930.xsd#upc_PrepaymentForAcquisitionCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PrepaymentForAcquisitionCurrent_lbl" xml:lang="en-US">Prepayment for acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForAcquisitionCurrent" xlink:to="upc_PrepaymentForAcquisitionCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="upc_PrepaymentForAcquisitionCurrent_lbl0" xml:lang="en-US">Prepayment for acquisition current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForAcquisitionCurrent" xlink:to="upc_PrepaymentForAcquisitionCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Other receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" xlink:href="upc-20240930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent_lbl" xml:lang="en-US">Prepayments made to a related party for purchase of property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsForConstructionInProgress" xlink:href="upc-20240930.xsd#upc_PrepaymentsForConstructionInProgress"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PrepaymentsForConstructionInProgress_lbl" xml:lang="en-US">Prepayments for construction in progress</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsForConstructionInProgress" xlink:to="upc_PrepaymentsForConstructionInProgress_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl" xml:lang="en-US">Investment in equity securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl0" xml:lang="en-US">Investment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl" xml:lang="en-US">Prepaid expenses-related party, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl0" xml:lang="en-US">Rights to use trademarks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Short-term bank loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl0" xml:lang="en-US">Total short-term loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl1" xml:lang="en-US">Borrowing amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Due to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLoansFromBank" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermLoansFromBank"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermLoansFromBank_lbl" xml:lang="en-US">Long-term bank loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansFromBank" xlink:to="us-gaap_LongTermLoansFromBank_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Ordinary shares, $11.25 par value, 11,250,000 shares authorized, 42,880 and 6,062 shares issued and outstanding as of September 30, 2024 and 2023, respectively *</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Ordinary shares, $11.25 par value, 11,250,000 shares authorized, 42,880 and 6,062 shares issued and outstanding as of September 30, 2024 and 2023, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Ordinary shares, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Ordinary shares par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Ordinary shares, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Ordinary shares, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_StatutoryReserve" xlink:href="upc-20240930.xsd#upc_StatutoryReserve"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_StatutoryReserve_lbl" xml:lang="en-US">Statutory reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutoryReserve" xlink:to="upc_StatutoryReserve_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="upc_StatutoryReserve_lbl0" xml:lang="en-US">Statutory amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutoryReserve" xlink:to="upc_StatutoryReserve_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">(Accumulated deficit) Retained earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OtherIncomeExpensesAbstract" xlink:href="upc-20240930.xsd#upc_OtherIncomeExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OtherIncomeExpensesAbstract_lbl" xml:lang="en-US">Other income (expenses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OtherIncomeExpensesAbstract" xlink:to="upc_OtherIncomeExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income (expense), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Equity investment income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl0" xml:lang="en-US">Equity in earnings of subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl1" xml:lang="en-US">Investment income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl1"/>
    <loc xlink:type="locator" xlink:label="upc_OtherComprehensiveIncomeLossAbstract" xlink:href="upc-20240930.xsd#upc_OtherComprehensiveIncomeLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OtherComprehensiveIncomeLossAbstract_lbl" xml:lang="en-US">Other comprehensive income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OtherComprehensiveIncomeLossAbstract" xlink:to="upc_OtherComprehensiveIncomeLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share - Basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share - Diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of shares outstanding used in calculating basic loss per share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of shares outstanding used in calculating diluted loss per share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_StockIssuedDuringPeriodValueStatutoryReserve" xlink:href="upc-20240930.xsd#upc_StockIssuedDuringPeriodValueStatutoryReserve"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_StockIssuedDuringPeriodValueStatutoryReserve_lbl" xml:lang="en-US">Statutory reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StockIssuedDuringPeriodValueStatutoryReserve" xlink:to="upc_StockIssuedDuringPeriodValueStatutoryReserve_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of ordinary shares and additional shares under overallotment option in initial public offerings, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of ordinary shares and additional shares under overallotment option in initial public offerings, gross (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Public offering ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Share issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2" xml:lang="en-US">Shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2"/>
    <loc xlink:type="locator" xlink:label="upc_StockIssuedDuringPeriodValueReverseShareSplitAdjustment" xlink:href="upc-20240930.xsd#upc_StockIssuedDuringPeriodValueReverseShareSplitAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_StockIssuedDuringPeriodValueReverseShareSplitAdjustment_lbl" xml:lang="en-US">Reverse share-split adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StockIssuedDuringPeriodValueReverseShareSplitAdjustment" xlink:to="upc_StockIssuedDuringPeriodValueReverseShareSplitAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Reverse share-split adjustment (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by (used in) operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to reconcile net cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Allowance for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl0" xml:lang="en-US">Reversal of allowance for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge_lbl" xml:lang="en-US">Allowance (reversal) of inventory reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLIFOReservePeriodCharge" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge_lbl0" xml:lang="en-US">Reversal of inventories valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLIFOReservePeriodCharge" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xml:lang="en-US">Advances to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl0" xml:lang="en-US">Due to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US">Taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ProceedsFromPaymentForConstructionInProgress" xlink:href="upc-20240930.xsd#upc_ProceedsFromPaymentForConstructionInProgress"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ProceedsFromPaymentForConstructionInProgress_lbl" xml:lang="en-US">Prepayments for construction in progress</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ProceedsFromPaymentForConstructionInProgress" xlink:to="upc_ProceedsFromPaymentForConstructionInProgress_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from disposal of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds from issuance of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromBankDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromBankDebt_lbl" xml:lang="en-US">Proceeds from bank loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromBankDebt" xlink:to="us-gaap_ProceedsFromBankDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from (prepayments for) related parties borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate changes on cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">EFFECT OF CHANGES OF FOREIGN EXCHANGE RATES ON CASH</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingExpense_lbl" xml:lang="en-US">Selling expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss from disposal of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0" xml:lang="en-US">Loss from disposal of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ChangeInFairValueOfShorttermInvestments" xlink:href="upc-20240930.xsd#upc_ChangeInFairValueOfShorttermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="upc_ChangeInFairValueOfShorttermInvestments_lbl" xml:lang="en-US">Deferred income tax expense (benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ChangeInFairValueOfShorttermInvestments" xlink:to="upc_ChangeInFairValueOfShorttermInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="upc_ChangeInFairValueOfShorttermInvestments_lbl0" xml:lang="en-US">Equity in earnings of subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ChangeInFairValueOfShorttermInvestments" xlink:to="upc_ChangeInFairValueOfShorttermInvestments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl" xml:lang="en-US">Advance to suppliers, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidAdvertising" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidAdvertising"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidAdvertising_lbl" xml:lang="en-US">Prepayment for advertising</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidAdvertising" xlink:to="us-gaap_IncreaseDecreaseInPrepaidAdvertising_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US">Other receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xml:lang="en-US">Deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent" xlink:href="upc-20240930.xsd#upc_IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="upc_IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent_lbl" xml:lang="en-US">Prepaid expenses-related party, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent" xlink:to="upc_IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Purchase of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US">Prepayment for acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfBankDebt_lbl" xml:lang="en-US">Repayment of bank loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfBankDebt" xlink:to="us-gaap_RepaymentsOfBankDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl0" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl2" xml:lang="en-US">Ordinary shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_StatutoryReservesMember" xlink:href="upc-20240930.xsd#upc_StatutoryReservesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_StatutoryReservesMember_lbl" xml:lang="en-US">Statutory reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutoryReservesMember" xlink:to="upc_StatutoryReservesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">ORGANIZATION AND BUSINESS DESCRIPTION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl" xml:lang="en-US">Schedule of Subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate_lbl" xml:lang="en-US">Date of Incorporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState_lbl" xml:lang="en-US">Place of Incorporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl" xml:lang="en-US">% of Ownership</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose_lbl" xml:lang="en-US">Principal Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:href="upc-20240930.xsd#upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xml:lang="en-US">Schedule of Property Plant and Equipment Estimated Useful Lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Expected useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock" xlink:href="upc-20240930.xsd#upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock_lbl" xml:lang="en-US">Schedule of Intangible Assets Estimated Useful Lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock" xlink:to="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_lbl" xml:lang="en-US">Schedule of Currency Exchange Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:to="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeForwardExchangeRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeForwardExchangeRate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeForwardExchangeRate1_lbl" xml:lang="en-US">Period-end US$</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeForwardExchangeRate1" xlink:to="us-gaap_DerivativeForwardExchangeRate1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeAverageForwardExchangeRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAverageForwardExchangeRate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeAverageForwardExchangeRate1_lbl" xml:lang="en-US">Period average US$</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAverageForwardExchangeRate1" xlink:to="us-gaap_DerivativeAverageForwardExchangeRate1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">ACCOUNTS RECEIVABLE, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl" xml:lang="en-US">Schedule of Allowance for Doubtful Accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xml:lang="en-US">Schedule of Inventories Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments" xlink:href="upc-20240930.xsd#upc_InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments_lbl" xml:lang="en-US">Foreign currency translation adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments" xlink:to="upc_InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AdvancesToSuppliersTextBlock" xlink:href="upc-20240930.xsd#upc_AdvancesToSuppliersTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AdvancesToSuppliersTextBlock_lbl" xml:lang="en-US">ADVANCE TO SUPPLIERS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvancesToSuppliersTextBlock" xlink:to="upc_AdvancesToSuppliersTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfAdvancesToSuppliersNet" xlink:href="upc-20240930.xsd#upc_ScheduleOfAdvancesToSuppliersNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ScheduleOfAdvancesToSuppliersNet_lbl" xml:lang="en-US">Schedule of Advances to Suppliers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfAdvancesToSuppliersNet" xlink:to="upc_ScheduleOfAdvancesToSuppliersNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsAndSupplies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies_lbl" xml:lang="en-US">Advances to suppliers for inventories raw material purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsAndSupplies" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl" xml:lang="en-US">PREPAYMENT FOR ACQUISITION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTextBlock" xlink:to="us-gaap_AssetAcquisitionTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US">OTHER RECEIVABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US">Receivable from Yunan Faxi</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl0" xml:lang="en-US">Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherShortTermInvestments_lbl" xml:lang="en-US">Redemption of short-term investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherShortTermInvestments" xlink:to="us-gaap_OtherShortTermInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherShortTermInvestments_lbl0" xml:lang="en-US">Short-term investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherShortTermInvestments" xlink:to="us-gaap_OtherShortTermInvestments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent_lbl" xml:lang="en-US">Prepaid value added tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="us-gaap_ValueAddedTaxReceivableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidAdvertising" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidAdvertising"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidAdvertising_lbl" xml:lang="en-US">Prepayment for advertising</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidAdvertising" xlink:to="us-gaap_PrepaidAdvertising_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Subtotal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Future Amortization Expense for Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2029</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForConstructionInProgressTextBlock" xlink:href="upc-20240930.xsd#upc_PrepaymentForConstructionInProgressTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PrepaymentForConstructionInProgressTextBlock_lbl" xml:lang="en-US">PREPAYMENT FOR CIP PROJECT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForConstructionInProgressTextBlock" xlink:to="upc_PrepaymentForConstructionInProgressTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock" xlink:href="upc-20240930.xsd#upc_ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Capital Expenditures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock" xlink:to="upc_ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl0" xml:lang="en-US">Future minimum capital expenditures for next 12 month</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInSecondYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInSecondYear" xlink:to="us-gaap_ContractualObligationDueInSecondYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInThirdYear_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInThirdYear" xlink:to="us-gaap_ContractualObligationDueInThirdYear_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForPurchaseOfAPropertyTextBlock" xlink:href="upc-20240930.xsd#upc_PrepaymentForPurchaseOfAPropertyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PrepaymentForPurchaseOfAPropertyTextBlock_lbl" xml:lang="en-US">PREPAYMENT FOR PURCHASE OF A PROPERTY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForPurchaseOfAPropertyTextBlock" xlink:to="upc_PrepaymentForPurchaseOfAPropertyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtTextBlock_lbl" xml:lang="en-US">SHORT-TERM BANK LOANS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTextBlock" xlink:to="us-gaap_ShortTermDebtTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl" xml:lang="en-US">Schedule of Short-Term Bank Loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBorrowingsAbstract_lbl" xml:lang="en-US">Short-term bank loans:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_ShortTermBorrowingsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">LONG-TERM BANK LOANS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US">Schedule of Long-Term Bank Loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLoansPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermLoansPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermLoansPayableAbstract_lbl" xml:lang="en-US">Long-term bank loans:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayableAbstract" xlink:to="us-gaap_LongTermLoansPayableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock" xlink:href="upc-20240930.xsd#upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Nature of Relationships With Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock" xlink:to="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships_lbl" xml:lang="en-US">Nature of relationships with related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships" xlink:to="us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of the Income Tax Provision (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Current tax expense:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Deferred tax expense (benefit):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Table Reconciles the China Statutory Rates to the Company&#8217;s Effective Tax Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory PRC income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Assessable profit rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_lbl" xml:lang="en-US">Permanent difference</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Non-PRC entities not subject to PRC income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry-forwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US">Allowance for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfTaxPayableTableTextBlock" xlink:href="upc-20240930.xsd#upc_ScheduleOfTaxPayableTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ScheduleOfTaxPayableTableTextBlock_lbl" xml:lang="en-US">Schedule of Taxes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfTaxPayableTableTextBlock" xlink:to="upc_ScheduleOfTaxPayableTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ValueAddedTaxPayable" xlink:href="upc-20240930.xsd#upc_ValueAddedTaxPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ValueAddedTaxPayable_lbl" xml:lang="en-US">Value added tax payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ValueAddedTaxPayable" xlink:to="upc_ValueAddedTaxPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OtherTaxesPayable" xlink:href="upc-20240930.xsd#upc_OtherTaxesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OtherTaxesPayable_lbl" xml:lang="en-US">Other taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OtherTaxesPayable" xlink:to="upc_OtherTaxesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">CONCENTRATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHAREHOLDERS&apos; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl" xml:lang="en-US">FINANCIAL INFORMATION OF THE PARENT COMPANY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xml:lang="en-US">Schedule of Consolidated Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl" xml:lang="en-US">Investment in subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfComprehensiveIncomeTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl" xml:lang="en-US">Schedule of Parent Company Statements of Operations and Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xml:lang="en-US">Operating costs and expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expenses):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedCashFlowStatementTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_lbl" xml:lang="en-US">Schedule of Parent Company Statements of Cash Flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromContributionsFromAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromContributionsFromAffiliates_lbl" xml:lang="en-US">Cash repayment from subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributionsFromAffiliates" xlink:to="us-gaap_ProceedsFromContributionsFromAffiliates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Less: allowance for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl0" xml:lang="en-US">Allowance for uncollectable balance amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_lbl" xml:lang="en-US">Foreign currency translation adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Less: accumulated amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays_lbl" xml:lang="en-US">Effect of income tax holiday</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseINCMember" xlink:href="upc-20240930.xsd#upc_UniverseINCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UniverseINCMember_lbl" xml:lang="en-US">Universe INC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseINCMember" xlink:to="upc_UniverseINCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseHKMember" xlink:href="upc-20240930.xsd#upc_UniverseHKMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UniverseHKMember_lbl" xml:lang="en-US">Universe HK [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseHKMember" xlink:to="upc_UniverseHKMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseTechnologyMember" xlink:href="upc-20240930.xsd#upc_UniverseTechnologyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UniverseTechnologyMember_lbl" xml:lang="en-US">Universe Technology [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseTechnologyMember" xlink:to="upc_UniverseTechnologyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_JiangxiUniverseMember" xlink:href="upc-20240930.xsd#upc_JiangxiUniverseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_JiangxiUniverseMember_lbl" xml:lang="en-US">Jiangxi Universe [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JiangxiUniverseMember" xlink:to="upc_JiangxiUniverseMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="upc_JiangxiUniverseMember_lbl0" xml:lang="en-US">Jiangxi Universe</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JiangxiUniverseMember" xlink:to="upc_JiangxiUniverseMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseTradeMember" xlink:href="upc-20240930.xsd#upc_UniverseTradeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UniverseTradeMember_lbl" xml:lang="en-US">Universe Trade [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseTradeMember" xlink:to="upc_UniverseTradeMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="upc_UniverseTradeMember_lbl0" xml:lang="en-US">Jiangxi Universe [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseTradeMember" xlink:to="upc_UniverseTradeMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseHanheMember" xlink:href="upc-20240930.xsd#upc_UniverseHanheMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UniverseHanheMember_lbl" xml:lang="en-US">Universe Hanhe [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseHanheMember" xlink:to="upc_UniverseHanheMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BuildingMember_lbl" xml:lang="en-US">Buildings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AutomobilesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AutomobilesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AutomobilesMember_lbl" xml:lang="en-US">Automobiles [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AutomobilesMember" xlink:to="us-gaap_AutomobilesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OfficeAndElectricEquipmentMember" xlink:href="upc-20240930.xsd#upc_OfficeAndElectricEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OfficeAndElectricEquipmentMember_lbl" xml:lang="en-US">Office and electric equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OfficeAndElectricEquipmentMember" xlink:to="upc_OfficeAndElectricEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseRightsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseRightsMember_lbl" xml:lang="en-US">Land use rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseRightsMember" xlink:to="us-gaap_UseRightsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TrademarksMember_lbl" xml:lang="en-US">Trademark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TrademarksMember" xlink:to="us-gaap_TrademarksMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US">Software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_CNY" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CNY"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_CNY_lbl" xml:lang="en-US">RMB exchange rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_CNY" xlink:to="currency_CNY_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_HKD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_HKD"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_HKD_lbl" xml:lang="en-US">HK exchange rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_HKD" xlink:to="currency_HKD_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office and electric equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction-in-progress [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConstructionInProgressMember_lbl0" xml:lang="en-US">Construction in Progress [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_LandUseRightsMember" xlink:href="upc-20240930.xsd#upc_LandUseRightsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_LandUseRightsMember_lbl" xml:lang="en-US">Land use rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_LandUseRightsMember" xlink:to="upc_LandUseRightsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xml:lang="en-US">Software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_JiangxiLulingRuralCommercialBankLRCBankMember" xlink:href="upc-20240930.xsd#upc_JiangxiLulingRuralCommercialBankLRCBankMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_JiangxiLulingRuralCommercialBankLRCBankMember_lbl" xml:lang="en-US">Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JiangxiLulingRuralCommercialBankLRCBankMember" xlink:to="upc_JiangxiLulingRuralCommercialBankLRCBankMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_BankOfCommunicationsCoLtdMember" xlink:href="upc-20240930.xsd#upc_BankOfCommunicationsCoLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_BankOfCommunicationsCoLtdMember_lbl" xml:lang="en-US">Bank of Communications Co., Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_BankOfCommunicationsCoLtdMember" xlink:to="upc_BankOfCommunicationsCoLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ZhujiangRuralBankMember" xlink:href="upc-20240930.xsd#upc_ZhujiangRuralBankMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ZhujiangRuralBankMember_lbl" xml:lang="en-US">Zhujiang Rural Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ZhujiangRuralBankMember" xlink:to="upc_ZhujiangRuralBankMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_BeijingBankMember" xlink:href="upc-20240930.xsd#upc_BeijingBankMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_BeijingBankMember_lbl" xml:lang="en-US">Beijing Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_BeijingBankMember" xlink:to="upc_BeijingBankMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_LRCBankMember" xlink:href="upc-20240930.xsd#upc_LRCBankMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_LRCBankMember_lbl" xml:lang="en-US">LRC Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_LRCBankMember" xlink:to="upc_LRCBankMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_MrGangLaiMember" xlink:href="upc-20240930.xsd#upc_MrGangLaiMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_MrGangLaiMember_lbl" xml:lang="en-US">Mr. Gang Lai [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MrGangLaiMember" xlink:to="upc_MrGangLaiMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_MrYajunHuMember" xlink:href="upc-20240930.xsd#upc_MrYajunHuMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_MrYajunHuMember_lbl" xml:lang="en-US">Mr. Yajun Hu [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MrYajunHuMember" xlink:to="upc_MrYajunHuMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_MsLinYangMember" xlink:href="upc-20240930.xsd#upc_MsLinYangMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_MsLinYangMember_lbl" xml:lang="en-US">Ms. Lin Yang [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MsLinYangMember" xlink:to="upc_MsLinYangMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_GuangzhouNingjingInvestmentCoLtdGuangzhouNingjingMember" xlink:href="upc-20240930.xsd#upc_GuangzhouNingjingInvestmentCoLtdGuangzhouNingjingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_GuangzhouNingjingInvestmentCoLtdGuangzhouNingjingMember_lbl" xml:lang="en-US">Guangzhou Ningjing Investment Co., Ltd (Guangzhou Ningjing) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_GuangzhouNingjingInvestmentCoLtdGuangzhouNingjingMember" xlink:to="upc_GuangzhouNingjingInvestmentCoLtdGuangzhouNingjingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_KY" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KY"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_KY_lbl" xml:lang="en-US">Cayman [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_KY" xlink:to="country_KY_lbl"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_HK"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_HK_lbl" xml:lang="en-US">Hong Kong [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_HK" xlink:to="country_HK_lbl"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_CN_lbl" xml:lang="en-US">PRC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ParentMember_lbl" xml:lang="en-US">Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl" xml:lang="en-US">Supplier [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationDateOfIncorporation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xml:lang="en-US">Incorporation date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US">Ownership interest percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PublicOfferingPrice" xlink:href="upc-20240930.xsd#upc_PublicOfferingPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PublicOfferingPrice_lbl" xml:lang="en-US">Public offering price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PublicOfferingPrice" xlink:to="upc_PublicOfferingPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExcessStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExcessStockSharesIssued_lbl" xml:lang="en-US">Additional shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ExcessStockSharesIssued_lbl0" xml:lang="en-US">Excess Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Net proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0" xml:lang="en-US">Gross proceed (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl1" xml:lang="en-US">Gross proceeds from offering (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Over allotment (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0" xml:lang="en-US">Net proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalUnits_lbl" xml:lang="en-US">Share capital (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnits" xlink:to="us-gaap_CapitalUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred shares par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Ordinary price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Offering price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockDividendsShares_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsShares" xlink:to="us-gaap_CommonStockDividendsShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockDividendsShares_lbl0" xml:lang="en-US">Ordinary shares divided</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsShares" xlink:to="us-gaap_CommonStockDividendsShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Ordinary shares par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Shares Issued, Price Per Share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl1" xml:lang="en-US">Shares issued price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xml:lang="en-US">Voting power percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl0" xml:lang="en-US">Equity interest percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash in banks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1" xml:lang="en-US">Percentage of equity interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl2" xml:lang="en-US">Equity interest ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl3" xml:lang="en-US">Equity interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl3"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount_lbl" xml:lang="en-US">Investment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:to="us-gaap_EquityMethodInvestmentSoldCarryingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Advertising expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_TaxBenefitPercentage" xlink:href="upc-20240930.xsd#upc_TaxBenefitPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_TaxBenefitPercentage_lbl" xml:lang="en-US">Tax benefit percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TaxBenefitPercentage" xlink:to="upc_TaxBenefitPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PercentageOfVatRate" xlink:href="upc-20240930.xsd#upc_PercentageOfVatRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PercentageOfVatRate_lbl" xml:lang="en-US">Percentage of vat rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfVatRate" xlink:to="upc_PercentageOfVatRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US">Comprehensive income amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_NetAccountReceivablePercentage" xlink:href="upc-20240930.xsd#upc_NetAccountReceivablePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_NetAccountReceivablePercentage_lbl" xml:lang="en-US">Net account receivable percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_NetAccountReceivablePercentage" xlink:to="upc_NetAccountReceivablePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US">Net account receivable amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForAcquisition" xlink:href="upc-20240930.xsd#upc_PrepaymentForAcquisition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PrepaymentForAcquisition_lbl" xml:lang="en-US">Prepayment for acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForAcquisition" xlink:to="upc_PrepaymentForAcquisition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xml:lang="en-US">Company price amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xml:lang="en-US">Prepaid amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl0" xml:lang="en-US">Prepayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesGrossCurrent_lbl" xml:lang="en-US">Other receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesGrossCurrent" xlink:to="us-gaap_OtherReceivablesGrossCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OtherReceivablePercentage" xlink:href="upc-20240930.xsd#upc_OtherReceivablePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OtherReceivablePercentage_lbl" xml:lang="en-US">Percentage of other receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OtherReceivablePercentage" xlink:to="upc_OtherReceivablePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentBuildingAndBuildingImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentBuildingAndBuildingImprovements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentBuildingAndBuildingImprovements_lbl" xml:lang="en-US">Total estimated budget</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentBuildingAndBuildingImprovements" xlink:to="us-gaap_InvestmentBuildingAndBuildingImprovements_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionContractCostProgressPaymentOffset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionContractCostProgressPaymentOffset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionContractCostProgressPaymentOffset_lbl" xml:lang="en-US">Construction amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionContractCostProgressPaymentOffset" xlink:to="us-gaap_ConstructionContractCostProgressPaymentOffset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet_lbl" xml:lang="en-US">Prepayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet_lbl0" xml:lang="en-US">Prepayment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capital expenditures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US">Office space square meters (in Square Meters)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl0" xml:lang="en-US">Office space totaling (in Square Meters)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl1" xml:lang="en-US">Commercial office space totaling (in Square Meters)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl1"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty" xlink:href="upc-20240930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty_lbl" xml:lang="en-US">Total purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty_lbl0" xml:lang="en-US">Prepayments made to a related party for purchase of property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_PercentageOfPrepayment" xlink:href="upc-20240930.xsd#upc_PercentageOfPrepayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PercentageOfPrepayment_lbl" xml:lang="en-US">Percentage of prepayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfPrepayment" xlink:to="upc_PercentageOfPrepayment_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PercentageOfTotalPurchasePricePayable" xlink:href="upc-20240930.xsd#upc_PercentageOfTotalPurchasePricePayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PercentageOfTotalPurchasePricePayable_lbl" xml:lang="en-US">Percentage of total purchase price payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfTotalPurchasePricePayable" xlink:to="upc_PercentageOfTotalPurchasePricePayable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PayableDeliveryPropertyPercentage" xlink:href="upc-20240930.xsd#upc_PayableDeliveryPropertyPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PayableDeliveryPropertyPercentage_lbl" xml:lang="en-US">Payable delivery property percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PayableDeliveryPropertyPercentage" xlink:to="upc_PayableDeliveryPropertyPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtTerms_lbl" xml:lang="en-US">Short term debt term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTerms" xlink:to="us-gaap_ShortTermDebtTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl0" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl" xml:lang="en-US">Fixed interest rate percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Borrowing amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtTerm_lbl" xml:lang="en-US">Working capital term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTerm" xlink:to="us-gaap_LongTermDebtTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl" xml:lang="en-US">Fixed interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxHolidayDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxHolidayDescription_lbl" xml:lang="en-US">Tax holiday description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxHolidayDescription" xlink:to="us-gaap_IncomeTaxHolidayDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_lbl" xml:lang="en-US">Income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayAggregateDollarAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxHolidayAggregateDollarAmount_lbl" xml:lang="en-US">Tax holidays decreased PRC corporate income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:to="us-gaap_IncomeTaxHolidayAggregateDollarAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_lbl" xml:lang="en-US">Tax holidays on net income per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:to="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignFinancialInstitutionsMandatedDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignFinancialInstitutionsMandatedDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignFinancialInstitutionsMandatedDeposits_lbl" xml:lang="en-US">Deposit at financial institutions (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignFinancialInstitutionsMandatedDeposits" xlink:to="us-gaap_ForeignFinancialInstitutionsMandatedDeposits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Revenue percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OriginalShareIssued" xlink:href="upc-20240930.xsd#upc_OriginalShareIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OriginalShareIssued_lbl" xml:lang="en-US">Original issued shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OriginalShareIssued" xlink:to="upc_OriginalShareIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OriginalSharesParValue" xlink:href="upc-20240930.xsd#upc_OriginalSharesParValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OriginalSharesParValue_lbl" xml:lang="en-US">Original shares par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OriginalSharesParValue" xlink:to="upc_OriginalSharesParValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xml:lang="en-US">Outstanding ordinary shares ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ShareIssuedAfterTheSplit" xlink:href="upc-20240930.xsd#upc_ShareIssuedAfterTheSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ShareIssuedAfterTheSplit_lbl" xml:lang="en-US">Share issued after the split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShareIssuedAfterTheSplit" xlink:to="upc_ShareIssuedAfterTheSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ShareOutstandingAfterTheSplit" xlink:href="upc-20240930.xsd#upc_ShareOutstandingAfterTheSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ShareOutstandingAfterTheSplit_lbl" xml:lang="en-US">Share outstanding after the split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShareOutstandingAfterTheSplit" xlink:to="upc_ShareOutstandingAfterTheSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Price per warrant (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Purchase price of offered share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Purchase to warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OrdinarySharesSoldPercentage" xlink:href="upc-20240930.xsd#upc_OrdinarySharesSoldPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OrdinarySharesSoldPercentage_lbl" xml:lang="en-US">Ordinary shares sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OrdinarySharesSoldPercentage" xlink:to="upc_OrdinarySharesSoldPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrant adjustments share (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_StatutorySurplusPercentage" xlink:href="upc-20240930.xsd#upc_StatutorySurplusPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_StatutorySurplusPercentage_lbl" xml:lang="en-US">Statutory surplus percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutorySurplusPercentage" xlink:to="upc_StatutorySurplusPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ReserveIsEqualPercentage" xlink:href="upc-20240930.xsd#upc_ReserveIsEqualPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ReserveIsEqualPercentage_lbl" xml:lang="en-US">Reserve is equal percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ReserveIsEqualPercentage" xlink:to="upc_ReserveIsEqualPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_RestrictedNetAssets" xlink:href="upc-20240930.xsd#upc_RestrictedNetAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_RestrictedNetAssets_lbl" xml:lang="en-US">Restricted net assets (in Dollars)</label>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYZDqnPZexC+e00+Rf6r37QtPu3oRrVmmTX8PuYVCFDMbRocUzw9EKKPK5NWC0WpJsOIuWkqeF3WWYzAuBG72bAUNWZ0EJoh7tCz07VxkYX3MUSJ7UFcJNPwN8yHmeKHRgkhMTd18uQzeusIsu/5w+1sTLgk4s48vHUWCmlxzr3HAZpsa+LfmHnFaLaCmPS0f6K1sduUUfaD9sRn5i3Vzu5VnzV9KOEHGDWQhDnV/BFeewWkVFaS1UA+p7gYWUuAou00d/FT2fESg==] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RestrictedNetAssets" xlink:to="upc_RestrictedNetAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_NumberOfSharesIssued" xlink:href="upc-20240930.xsd#upc_NumberOfSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_NumberOfSharesIssued_lbl" xml:lang="en-US">Shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_NumberOfSharesIssued" xlink:to="upc_NumberOfSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeNetAssetsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeNetAssetsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeNetAssetsPercentage_lbl" xml:lang="en-US">Net assets percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeNetAssetsPercentage" xlink:to="us-gaap_DerivativeNetAssetsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_MinorityInterestsOwnershipPercentageByParent" xlink:href="upc-20240930.xsd#upc_MinorityInterestsOwnershipPercentageByParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_MinorityInterestsOwnershipPercentageByParent_lbl" xml:lang="en-US">Subsidiary exceeded percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MinorityInterestsOwnershipPercentageByParent" xlink:to="upc_MinorityInterestsOwnershipPercentageByParent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ReclassificationsPolicyTextBlock" xlink:href="upc-20240930.xsd#upc_ReclassificationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ReclassificationsPolicyTextBlock_lbl" xml:lang="en-US">Reclassifications</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ReclassificationsPolicyTextBlock" xlink:to="upc_ReclassificationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Uses of estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Risks and Uncertainties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AdvancesToSuppliersNetPolicyTextBlock" xlink:href="upc-20240930.xsd#upc_AdvancesToSuppliersNetPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AdvancesToSuppliersNetPolicyTextBlock_lbl" xml:lang="en-US">Advances to suppliers, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvancesToSuppliersNetPolicyTextBlock" xlink:to="upc_AdvancesToSuppliersNetPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair value of financial instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ConstructioninProgressPolicyTextBlock" xlink:href="upc-20240930.xsd#upc_ConstructioninProgressPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ConstructioninProgressPolicyTextBlock_lbl" xml:lang="en-US">Construction-in-Progress (&#8220;CIP&#8221;)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ConstructioninProgressPolicyTextBlock" xlink:to="upc_ConstructioninProgressPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of long-lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">Investments in Equity Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_DisaggregationOfRevenuesPolicyTextBlock" xlink:href="upc-20240930.xsd#upc_DisaggregationOfRevenuesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_DisaggregationOfRevenuesPolicyTextBlock_lbl" xml:lang="en-US">Disaggregation of Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DisaggregationOfRevenuesPolicyTextBlock" xlink:to="upc_DisaggregationOfRevenuesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl" xml:lang="en-US">Shipping and handling costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ValueAddedTaxPolicyTextBlock" xlink:href="upc-20240930.xsd#upc_ValueAddedTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ValueAddedTaxPolicyTextBlock_lbl" xml:lang="en-US">Value added tax (&#8220;VAT&#8221;)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ValueAddedTaxPolicyTextBlock" xlink:to="upc_ValueAddedTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign currency translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_StatementOfCashFlowsPolicyTextBlock" xlink:href="upc-20240930.xsd#upc_StatementOfCashFlowsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_StatementOfCashFlowsPolicyTextBlock_lbl" xml:lang="en-US">Statement of Cash Flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatementOfCashFlowsPolicyTextBlock" xlink:to="upc_StatementOfCashFlowsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_EmployeeDefinedContributionPlanPolicyTextBlock" xlink:href="upc-20240930.xsd#upc_EmployeeDefinedContributionPlanPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_EmployeeDefinedContributionPlanPolicyTextBlock_lbl" xml:lang="en-US">Employee Defined Contribution Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EmployeeDefinedContributionPlanPolicyTextBlock" xlink:to="upc_EmployeeDefinedContributionPlanPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseIncMember" xlink:href="upc-20240930.xsd#upc_UniverseIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UniverseIncMember_lbl" xml:lang="en-US">Universe Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseIncMember" xlink:to="upc_UniverseIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockMember_lbl0" xml:lang="en-US">Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_DirectorMember_lbl0" xml:lang="en-US">Board of Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_CommonStockOneMember" xlink:href="upc-20240930.xsd#upc_CommonStockOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CommonStockOneMember_lbl" xml:lang="en-US">Common Stock One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CommonStockOneMember" xlink:to="upc_CommonStockOneMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="upc_CommonStockOneMember_lbl0" xml:lang="en-US">Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CommonStockOneMember" xlink:to="upc_CommonStockOneMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UniversePharmaceuticalsIncMember" xlink:href="upc-20240930.xsd#upc_UniversePharmaceuticalsIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UniversePharmaceuticalsIncMember_lbl" xml:lang="en-US">Universe Pharmaceuticals Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniversePharmaceuticalsIncMember" xlink:to="upc_UniversePharmaceuticalsIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_JxRcbBankMember" xlink:href="upc-20240930.xsd#upc_JxRcbBankMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_JxRcbBankMember_lbl" xml:lang="en-US">JX RCB Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JxRcbBankMember" xlink:to="upc_JxRcbBankMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_YunnanFaxiPharmaceuticalsCoLtdMember" xlink:href="upc-20240930.xsd#upc_YunnanFaxiPharmaceuticalsCoLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_YunnanFaxiPharmaceuticalsCoLtdMember_lbl" xml:lang="en-US">Yunnan Faxi Pharmaceuticals Co., Ltd. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_YunnanFaxiPharmaceuticalsCoLtdMember" xlink:to="upc_YunnanFaxiPharmaceuticalsCoLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_MrXiboLiuMember" xlink:href="upc-20240930.xsd#upc_MrXiboLiuMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_MrXiboLiuMember_lbl" xml:lang="en-US">Mr. Xibo Liu [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MrXiboLiuMember" xlink:to="upc_MrXiboLiuMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_YunnanFaxiMember" xlink:href="upc-20240930.xsd#upc_YunnanFaxiMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_YunnanFaxiMember_lbl" xml:lang="en-US">Yunnan Faxi [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_YunnanFaxiMember" xlink:to="upc_YunnanFaxiMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ChenyuanMember" xlink:href="upc-20240930.xsd#upc_ChenyuanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ChenyuanMember_lbl" xml:lang="en-US">Chenyuan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ChenyuanMember" xlink:to="upc_ChenyuanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ConstructionInProgressTwoMember" xlink:href="upc-20240930.xsd#upc_ConstructionInProgressTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ConstructionInProgressTwoMember_lbl" xml:lang="en-US">Construction In Progress for Next 12 Months [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ConstructionInProgressTwoMember" xlink:to="upc_ConstructionInProgressTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_JiangxiYueshangMember" xlink:href="upc-20240930.xsd#upc_JiangxiYueshangMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_JiangxiYueshangMember_lbl" xml:lang="en-US">Jiangxi Yueshang [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JiangxiYueshangMember" xlink:to="upc_JiangxiYueshangMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_WorkingCapitalLoanMember" xlink:href="upc-20240930.xsd#upc_WorkingCapitalLoanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_WorkingCapitalLoanMember_lbl" xml:lang="en-US">Working Capital Loan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_WorkingCapitalLoanMember" xlink:to="upc_WorkingCapitalLoanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_TopTenCustomersMember" xlink:href="upc-20240930.xsd#upc_TopTenCustomersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_TopTenCustomersMember_lbl" xml:lang="en-US">Top 10 customers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TopTenCustomersMember" xlink:to="upc_TopTenCustomersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CustomerMember" xlink:href="upc-20240930.xsd#upc_CustomerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CustomerMember_lbl" xml:lang="en-US">Customer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CustomerMember" xlink:to="upc_CustomerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_GubenYanlingPillMember" xlink:href="upc-20240930.xsd#upc_GubenYanlingPillMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_GubenYanlingPillMember_lbl" xml:lang="en-US">Guben Yanling Pill [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_GubenYanlingPillMember" xlink:to="upc_GubenYanlingPillMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PurchaseMember" xlink:href="upc-20240930.xsd#upc_PurchaseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PurchaseMember_lbl" xml:lang="en-US">Purchase [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PurchaseMember" xlink:to="upc_PurchaseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US">Supplier Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_supplierMember" xlink:href="upc-20240930.xsd#upc_supplierMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_supplierMember_lbl" xml:lang="en-US">Supplier One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_supplierMember" xlink:to="upc_supplierMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_TwoSupplierMember" xlink:href="upc-20240930.xsd#upc_TwoSupplierMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_TwoSupplierMember_lbl" xml:lang="en-US">Two Supplier [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TwoSupplierMember" xlink:to="upc_TwoSupplierMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnderwriterWarrantsMember" xlink:href="upc-20240930.xsd#upc_UnderwriterWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnderwriterWarrantsMember_lbl" xml:lang="en-US">Underwriter warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnderwriterWarrantsMember" xlink:to="upc_UnderwriterWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_StatutoryReserveAndRestrictedNetAssetsMember" xlink:href="upc-20240930.xsd#upc_StatutoryReserveAndRestrictedNetAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_StatutoryReserveAndRestrictedNetAssetsMember_lbl" xml:lang="en-US">Statutory Reserve and Restricted Net Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutoryReserveAndRestrictedNetAssetsMember" xlink:to="upc_StatutoryReserveAndRestrictedNetAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrefundedWarrantsMember" xlink:href="upc-20240930.xsd#upc_PrefundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PrefundedWarrantsMember_lbl" xml:lang="en-US">Pre-funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrefundedWarrantsMember" xlink:to="upc_PrefundedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CommonWarrantsMember" xlink:href="upc-20240930.xsd#upc_CommonWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CommonWarrantsMember_lbl" xml:lang="en-US">Common Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CommonWarrantsMember" xlink:to="upc_CommonWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_lbl" xml:lang="en-US">Subsidiary of LLC or LP [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_lbl" xml:lang="en-US">Schedule of Subsidiaries [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesDetailsTable" xlink:href="upc-20240930.xsd#upc_SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies - Schedule of Property Plant and Equipment Estimated Useful Lives (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesDetailsTable" xlink:to="upc_SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Schedule of Property Plant and Equipment Estimated Useful Lives [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsEstimatedUsefulLivesDetailsTable" xlink:href="upc-20240930.xsd#upc_SummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsEstimatedUsefulLivesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsEstimatedUsefulLivesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies - Schedule of Intangible Assets Estimated Useful Lives (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsEstimatedUsefulLivesDetailsTable" xlink:to="upc_SummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsEstimatedUsefulLivesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Schedule of Intangible Assets Estimated Useful Lives [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AllCurrenciesDomain_lbl" xml:lang="en-US">All Currencies [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRateDetailsTable" xlink:href="upc-20240930.xsd#upc_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRateDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRateDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies - Schedule of Currency Exchange Rate (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRateDetailsTable" xlink:to="upc_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRateDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLineItems_lbl" xml:lang="en-US">Schedule of Currency Exchange Rate [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DerivativeLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl0" xml:lang="en-US">Schedule of Property and Equipment, Net [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl0" xml:lang="en-US">Schedule of Intangible Assets, Net [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Short-Term Debt [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Schedule of Short-Term Bank Loans [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US">Long-Term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfLongTermBankLoansLineItems" xlink:href="upc-20240930.xsd#upc_ScheduleOfLongTermBankLoansLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfLongTermBankLoansLineItems_lbl" xml:lang="en-US">Schedule of Long-Term Bank Loans [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfLongTermBankLoansLineItems" xlink:to="upc_ScheduleOfLongTermBankLoansLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_RelatedPartyTransactionsScheduleofNatureofRelationshipsWithRelatedPartiesDetailsTable" xlink:href="upc-20240930.xsd#upc_RelatedPartyTransactionsScheduleofNatureofRelationshipsWithRelatedPartiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_RelatedPartyTransactionsScheduleofNatureofRelationshipsWithRelatedPartiesDetailsTable_lbl" xml:lang="en-US">Related Party Transactions - Schedule of Nature of Relationships With Related Parties (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RelatedPartyTransactionsScheduleofNatureofRelationshipsWithRelatedPartiesDetailsTable" xlink:to="upc_RelatedPartyTransactionsScheduleofNatureofRelationshipsWithRelatedPartiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_TaxesScheduleofComponentsoftheIncomeTaxProvisionBenefitDetailsTable" xlink:href="upc-20240930.xsd#upc_TaxesScheduleofComponentsoftheIncomeTaxProvisionBenefitDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_TaxesScheduleofComponentsoftheIncomeTaxProvisionBenefitDetailsTable_lbl" xml:lang="en-US">Taxes - Schedule of Components of the Income Tax Provision (Benefit) (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TaxesScheduleofComponentsoftheIncomeTaxProvisionBenefitDetailsTable" xlink:to="upc_TaxesScheduleofComponentsoftheIncomeTaxProvisionBenefitDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xml:lang="en-US">Schedule of Components of the Income Tax Provision (Benefit) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xml:lang="en-US">Consolidated Entities [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedBalanceSheetStatementTable_lbl" xml:lang="en-US">Condensed Balance Sheet Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_CondensedBalanceSheetStatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems_lbl" xml:lang="en-US">Condensed Balance Sheet Statements, Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="srt_CondensedBalanceSheetStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfComprehensiveIncomeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable_lbl" xml:lang="en-US">Condensed Statement of Comprehensive Income [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfIncomeCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedStatementOfIncomeCaptionsLineItems_lbl" xml:lang="en-US">Condensed Statement of Income Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="srt_CondensedStatementOfIncomeCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedCashFlowStatementTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedCashFlowStatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedCashFlowStatementTable_lbl" xml:lang="en-US">Condensed Cash Flow Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="srt_CondensedCashFlowStatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems_lbl" xml:lang="en-US">Condensed Cash Flow Statements, Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="srt_CondensedCashFlowStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title and Position [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OrganizationandBusinessDescriptionDetailsTable" xlink:href="upc-20240930.xsd#upc_OrganizationandBusinessDescriptionDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OrganizationandBusinessDescriptionDetailsTable_lbl" xml:lang="en-US">Organization and Business Description (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OrganizationandBusinessDescriptionDetailsTable" xlink:to="upc_OrganizationandBusinessDescriptionDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:href="upc-20240930.xsd#upc_OrganizationandBusinessDescriptionDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OrganizationandBusinessDescriptionDetailsLineItems_lbl" xml:lang="en-US">Organization and Business Description [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="upc_OrganizationandBusinessDescriptionDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US">Investment, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="upc-20240930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="upc_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ChangeInAccountingEstimateLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforAcquisitionDetailsTable" xlink:href="upc-20240930.xsd#upc_PrepaymentforAcquisitionDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentforAcquisitionDetailsTable_lbl" xml:lang="en-US">Prepayment for Acquisition (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentforAcquisitionDetailsTable" xlink:to="upc_PrepaymentforAcquisitionDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xml:lang="en-US">Prepayment for Acquisition [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OtherReceivableDetailsTable" xlink:href="upc-20240930.xsd#upc_OtherReceivableDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OtherReceivableDetailsTable_lbl" xml:lang="en-US">Other Receivable (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OtherReceivableDetailsTable" xlink:to="upc_OtherReceivableDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OtherReceivableDetailsLineItems" xlink:href="upc-20240930.xsd#upc_OtherReceivableDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OtherReceivableDetailsLineItems_lbl" xml:lang="en-US">Other Receivable (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OtherReceivableDetailsLineItems" xlink:to="upc_OtherReceivableDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforCIPProjectDetailsTable" xlink:href="upc-20240930.xsd#upc_PrepaymentforCIPProjectDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentforCIPProjectDetailsTable_lbl" xml:lang="en-US">Prepayment for CIP Project (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentforCIPProjectDetailsTable" xlink:to="upc_PrepaymentforCIPProjectDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforCIPProjectDetailsLineItems" xlink:href="upc-20240930.xsd#upc_PrepaymentforCIPProjectDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentforCIPProjectDetailsLineItems_lbl" xml:lang="en-US">Prepayment for CIP Project [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentforCIPProjectDetailsLineItems" xlink:to="upc_PrepaymentforCIPProjectDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforPurchaseofaPropertyDetailsTable" xlink:href="upc-20240930.xsd#upc_PrepaymentforPurchaseofaPropertyDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentforPurchaseofaPropertyDetailsTable_lbl" xml:lang="en-US">Prepayment for Purchase of a Property (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentforPurchaseofaPropertyDetailsTable" xlink:to="upc_PrepaymentforPurchaseofaPropertyDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:href="upc-20240930.xsd#upc_PrepaymentforPurchaseofaPropertyDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems_lbl" xml:lang="en-US">Prepayment for Purchase of a Property [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-Term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ShortTermBankLoansDetailsTable" xlink:href="upc-20240930.xsd#upc_ShortTermBankLoansDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ShortTermBankLoansDetailsTable_lbl" xml:lang="en-US">Short-Term Bank Loans (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShortTermBankLoansDetailsTable" xlink:to="upc_ShortTermBankLoansDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtLineItems_lbl0" xml:lang="en-US">Short-Term Bank Loans [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_LongTermBankLoansDetailsTable" xlink:href="upc-20240930.xsd#upc_LongTermBankLoansDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_LongTermBankLoansDetailsTable_lbl" xml:lang="en-US">Long-Term Bank Loans (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_LongTermBankLoansDetailsTable" xlink:to="upc_LongTermBankLoansDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_LongTermBankLoansDetailsLineItems" xlink:href="upc-20240930.xsd#upc_LongTermBankLoansDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_LongTermBankLoansDetailsLineItems_lbl" xml:lang="en-US">Long-Term Bank Loans [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_LongTermBankLoansDetailsLineItems" xlink:to="upc_LongTermBankLoansDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_RelatedPartyTransactionsDetailsTable" xlink:href="upc-20240930.xsd#upc_RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RelatedPartyTransactionsDetailsTable" xlink:to="upc_RelatedPartyTransactionsDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl0" xml:lang="en-US">Related Party Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_TaxesDetailsTable" xlink:href="upc-20240930.xsd#upc_TaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_TaxesDetailsTable_lbl" xml:lang="en-US">Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TaxesDetailsTable" xlink:to="upc_TaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxHolidayLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxHolidayLineItems_lbl" xml:lang="en-US">Taxes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxHolidayLineItems" xlink:to="us-gaap_IncomeTaxHolidayLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl" xml:lang="en-US">Supplier [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ConcentrationsDetailsTable" xlink:href="upc-20240930.xsd#upc_ConcentrationsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ConcentrationsDetailsTable_lbl" xml:lang="en-US">Concentrations (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ConcentrationsDetailsTable" xlink:to="upc_ConcentrationsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentrations [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ShareholdersEquityDetailsTable" xlink:href="upc-20240930.xsd#upc_ShareholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ShareholdersEquityDetailsTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShareholdersEquityDetailsTable" xlink:to="upc_ShareholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Shareholders&#8217; Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CommitmentsandContingenciesDetailsTable" xlink:href="upc-20240930.xsd#upc_CommitmentsandContingenciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CommitmentsandContingenciesDetailsTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CommitmentsandContingenciesDetailsTable" xlink:to="upc_CommitmentsandContingenciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SubsequentEventsDetailsTable" xlink:href="upc-20240930.xsd#upc_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SubsequentEventsDetailsTable" xlink:to="upc_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Events [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_AdvancesToSuppliersNetPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for advances to suppliers net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvancesToSuppliersNetPolicyTextBlock" xlink:to="upc_AdvancesToSuppliersNetPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_AdvancesToSuppliersTextBlock_lbl0" xml:lang="en-US">The entire disclosure for the advances to suppliers.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvancesToSuppliersTextBlock" xlink:to="upc_AdvancesToSuppliersTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ChangeInFairValueOfShorttermInvestments_lbl1" xml:lang="en-US">Represent the amount of change in fair value of short-term investments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ChangeInFairValueOfShorttermInvestments" xlink:to="upc_ChangeInFairValueOfShorttermInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ConstructioninProgressPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for construction in progress.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ConstructioninProgressPolicyTextBlock" xlink:to="upc_ConstructioninProgressPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_EmployeeDefinedContributionPlanPolicyTextBlock_lbl0" xml:lang="en-US">The entire disclosure of employee defined contribution plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EmployeeDefinedContributionPlanPolicyTextBlock" xlink:to="upc_EmployeeDefinedContributionPlanPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent_lbl0" xml:lang="en-US">Amount of increase (decrease) of prepaid expenses-related party, non-current.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent" xlink:to="upc_IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments_lbl0" xml:lang="en-US">Foreign currency translation adjustments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments" xlink:to="upc_InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_MinorityInterestsOwnershipPercentageByParent_lbl0" xml:lang="en-US">Subsidiary exceeded percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MinorityInterestsOwnershipPercentageByParent" xlink:to="upc_MinorityInterestsOwnershipPercentageByParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_NetAccountReceivablePercentage_lbl0" xml:lang="en-US">The percentage of net account receivable percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_NetAccountReceivablePercentage" xlink:to="upc_NetAccountReceivablePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_NumberOfSharesIssued_lbl0" xml:lang="en-US">Number of shares issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_NumberOfSharesIssued" xlink:to="upc_NumberOfSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_OrdinarySharesSoldPercentage_lbl0" xml:lang="en-US">Ordinary shares sold percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OrdinarySharesSoldPercentage" xlink:to="upc_OrdinarySharesSoldPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_OriginalShareIssued_lbl0" xml:lang="en-US">Represent the share of original share issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OriginalShareIssued" xlink:to="upc_OriginalShareIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_OriginalSharesParValue_lbl0" xml:lang="en-US">Original shares par value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OriginalSharesParValue" xlink:to="upc_OriginalSharesParValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_OtherReceivablePercentage_lbl0" xml:lang="en-US">Other receivable percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OtherReceivablePercentage" xlink:to="upc_OtherReceivablePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_OtherTaxesPayable_lbl0" xml:lang="en-US">Represents the amount of other taxes payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OtherTaxesPayable" xlink:to="upc_OtherTaxesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PayableDeliveryPropertyPercentage_lbl0" xml:lang="en-US">Payable delivery property percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PayableDeliveryPropertyPercentage" xlink:to="upc_PayableDeliveryPropertyPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PercentageOfPrepayment_lbl0" xml:lang="en-US">Percentage of prepayment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfPrepayment" xlink:to="upc_PercentageOfPrepayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PercentageOfTotalPurchasePricePayable_lbl0" xml:lang="en-US">Percentage of total purchase price payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfTotalPurchasePricePayable" xlink:to="upc_PercentageOfTotalPurchasePricePayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PercentageOfVatRate_lbl0" xml:lang="en-US">Percentage of VATrate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfVatRate" xlink:to="upc_PercentageOfVatRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PrepaymentForAcquisition_lbl0" xml:lang="en-US">Prepayment for acquisition.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForAcquisition" xlink:to="upc_PrepaymentForAcquisition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PrepaymentForAcquisitionCurrent_lbl1" xml:lang="en-US">The amount of prepayment for acquisition.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForAcquisitionCurrent" xlink:to="upc_PrepaymentForAcquisitionCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PrepaymentForConstructionInProgressTextBlock_lbl0" xml:lang="en-US">The entire disclosure for prepayment for construction in progress.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForConstructionInProgressTextBlock" xlink:to="upc_PrepaymentForConstructionInProgressTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PrepaymentsForConstructionInProgress_lbl0" xml:lang="en-US">Prepayments for construction in progress.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsForConstructionInProgress" xlink:to="upc_PrepaymentsForConstructionInProgress_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent_lbl0" xml:lang="en-US">Amount of prepayments made to a related party for purchase of property.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty_lbl1" xml:lang="en-US">Prepayments made to a related party for purchase of property.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ProceedsFromPaymentForConstructionInProgress_lbl0" xml:lang="en-US">Prepayments for construction in progress.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ProceedsFromPaymentForConstructionInProgress" xlink:to="upc_ProceedsFromPaymentForConstructionInProgress_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl0" xml:lang="en-US">The entire disclosure of property equipment estimated useful life during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PublicOfferingPrice_lbl0" xml:lang="en-US">Public offering price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PublicOfferingPrice" xlink:to="upc_PublicOfferingPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ReclassificationsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for reclassifications.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ReclassificationsPolicyTextBlock" xlink:to="upc_ReclassificationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ReserveIsEqualPercentage_lbl0" xml:lang="en-US">Reserve is equal percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ReserveIsEqualPercentage" xlink:to="upc_ReserveIsEqualPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_RestrictedNetAssets_lbl0" xml:lang="en-US">Restricted net assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RestrictedNetAssets" xlink:to="upc_RestrictedNetAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ScheduleOfAdvancesToSuppliersNet_lbl0" xml:lang="en-US">Tabular disclosure of advances to suppliers net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfAdvancesToSuppliersNet" xlink:to="upc_ScheduleOfAdvancesToSuppliersNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of future minimum capital expenditure.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock" xlink:to="upc_ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of Intangible assets estimated useful lives.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock" xlink:to="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of nature of relationship with related parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock" xlink:to="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ScheduleOfTaxPayableTableTextBlock_lbl0" xml:lang="en-US">The entire disclosure of tax payable during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfTaxPayableTableTextBlock" xlink:to="upc_ScheduleOfTaxPayableTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ShareIssuedAfterTheSplit_lbl0" xml:lang="en-US">Represent the share of stock issued after the split.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShareIssuedAfterTheSplit" xlink:to="upc_ShareIssuedAfterTheSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ShareOutstandingAfterTheSplit_lbl0" xml:lang="en-US">Represent the share outstanding after the split.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShareOutstandingAfterTheSplit" xlink:to="upc_ShareOutstandingAfterTheSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_StatementOfCashFlowsPolicyTextBlock_lbl0" xml:lang="en-US">The entire disclosure of statement of cash flows policy text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatementOfCashFlowsPolicyTextBlock" xlink:to="upc_StatementOfCashFlowsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_StatutoryReserve_lbl1" xml:lang="en-US">StatutoryReserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutoryReserve" xlink:to="upc_StatutoryReserve_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_StatutorySurplusPercentage_lbl0" xml:lang="en-US">Statutory surplus percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutorySurplusPercentage" xlink:to="upc_StatutorySurplusPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_StockIssuedDuringPeriodValueReverseShareSplitAdjustment_lbl0" xml:lang="en-US">Represents the value of reverse share-split adjustment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StockIssuedDuringPeriodValueReverseShareSplitAdjustment" xlink:to="upc_StockIssuedDuringPeriodValueReverseShareSplitAdjustment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_StockIssuedDuringPeriodValueStatutoryReserve_lbl0" xml:lang="en-US">Represent the amount of statutory reserve.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StockIssuedDuringPeriodValueStatutoryReserve" xlink:to="upc_StockIssuedDuringPeriodValueStatutoryReserve_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_TaxBenefitPercentage_lbl0" xml:lang="en-US">Tax benefit percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TaxBenefitPercentage" xlink:to="upc_TaxBenefitPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ValueAddedTaxPayable_lbl0" xml:lang="en-US">Represents the amount of value added tax payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ValueAddedTaxPayable" xlink:to="upc_ValueAddedTaxPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ValueAddedTaxPolicyTextBlock_lbl0" xml:lang="en-US">The entire disclosure of value added tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ValueAddedTaxPolicyTextBlock" xlink:to="upc_ValueAddedTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_UniverseINCMember_lbl0" xml:lang="en-US">Universe INC.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseINCMember" xlink:to="upc_UniverseINCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_JiangxiYueshangMember_lbl0" xml:lang="en-US">Jiangxi Yueshang Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JiangxiYueshangMember" xlink:to="upc_JiangxiYueshangMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl0" xml:lang="en-US">Computer Software, Intangible Asset [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ShareOutstandingAfterTheSplit_lbl1" xml:lang="en-US">Share Outstanding After The Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShareOutstandingAfterTheSplit" xlink:to="upc_ShareOutstandingAfterTheSplit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UniversePharmaceuticalsIncMember_lbl0" xml:lang="en-US">Universe Pharmaceuticals Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniversePharmaceuticalsIncMember" xlink:to="upc_UniversePharmaceuticalsIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UniverseTechnologyMember_lbl0" xml:lang="en-US">Universe Technology Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseTechnologyMember" xlink:to="upc_UniverseTechnologyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl0" xml:lang="en-US">Proceeds from (Repayments of) Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OriginalShareIssued_lbl1" xml:lang="en-US">Original Share Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OriginalShareIssued" xlink:to="upc_OriginalShareIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_TopTenCustomersMember_lbl0" xml:lang="en-US">Top Ten Customers Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TopTenCustomersMember" xlink:to="upc_TopTenCustomersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_HK_lbl0" xml:lang="en-US">HONG KONG</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_HK" xlink:to="country_HK_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl2" xml:lang="en-US">Area of Real Estate Property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl0" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_HKD_lbl0" xml:lang="en-US">Hong Kong, Dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_HKD" xlink:to="currency_HKD_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UniverseIncMember_lbl0" xml:lang="en-US">Universe Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseIncMember" xlink:to="upc_UniverseIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromContributionsFromAffiliates_lbl0" xml:lang="en-US">Proceeds from Contributions from Affiliates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributionsFromAffiliates" xlink:to="us-gaap_ProceedsFromContributionsFromAffiliates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Income Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentForPurchaseOfAPropertyTextBlock_lbl0" xml:lang="en-US">Prepayment For Purchase Of AProperty Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForPurchaseOfAPropertyTextBlock" xlink:to="upc_PrepaymentForPurchaseOfAPropertyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl0" xml:lang="en-US">Condensed Statement of Comprehensive Income [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl0" xml:lang="en-US">Equity Method Investment, Aggregate Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingMember_lbl0" xml:lang="en-US">Building [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl0" xml:lang="en-US">Operating Costs and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl0" xml:lang="en-US">Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Intangible Assets Estimated Useful Lives Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock" xlink:to="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ReserveIsEqualPercentage_lbl1" xml:lang="en-US">Reserve Is Equal Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ReserveIsEqualPercentage" xlink:to="upc_ReserveIsEqualPercentage_lbl1"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfRelatedPartiesAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule Of Related Parties Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfRelatedPartiesAbstract" xlink:to="upc_ScheduleOfRelatedPartiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CommonWarrantsMember_lbl0" xml:lang="en-US">Common Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CommonWarrantsMember" xlink:to="upc_CommonWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet_lbl1" xml:lang="en-US">Prepayment Fees on Advances, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl0" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl0" xml:lang="en-US">Warrants and Rights Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTerm_lbl0" xml:lang="en-US">Long-Term Debt, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTerm" xlink:to="us-gaap_LongTermDebtTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract_lbl" xml:lang="en-US">Schedule Of Intangible Assets Estimated Useful Lives Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract" xlink:to="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseRightsMember_lbl0" xml:lang="en-US">Use Rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseRightsMember" xlink:to="us-gaap_UseRightsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl1" xml:lang="en-US">Construction in Progress [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl0" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl0" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_StatutoryReserveAndRestrictedNetAssetsMember_lbl0" xml:lang="en-US">Statutory Reserve And Restricted Net Assets Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutoryReserveAndRestrictedNetAssetsMember" xlink:to="upc_StatutoryReserveAndRestrictedNetAssetsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent_lbl1" xml:lang="en-US">Increase Decrease In Prepaid Expensesrelated Party Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent" xlink:to="upc_IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl3" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_MrGangLaiMember_lbl0" xml:lang="en-US">Mr Gang Lai Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MrGangLaiMember" xlink:to="upc_MrGangLaiMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OfficeAndElectricEquipmentMember_lbl0" xml:lang="en-US">Office And Electric Equipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OfficeAndElectricEquipmentMember" xlink:to="upc_OfficeAndElectricEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl0" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl1" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl1" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl0" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty_lbl2" xml:lang="en-US">Prepayments Made To ARelated Party For Purchases Of Property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLoansFromBank_lbl0" xml:lang="en-US">Loans Payable to Bank, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansFromBank" xlink:to="us-gaap_LongTermLoansFromBank_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentForConstructionInProgressTextBlock_lbl1" xml:lang="en-US">Prepayment For Construction In Progress Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForConstructionInProgressTextBlock" xlink:to="upc_PrepaymentForConstructionInProgressTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OrdinarySharesSoldPercentage_lbl1" xml:lang="en-US">Ordinary Shares Sold Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OrdinarySharesSoldPercentage" xlink:to="upc_OrdinarySharesSoldPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl1" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl0" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl0" xml:lang="en-US">Short-Term Debt, Percentage Bearing Fixed Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl0" xml:lang="en-US">Shipping and Handling Cost, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_YunnanFaxiMember_lbl0" xml:lang="en-US">Yunnan Faxi Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_YunnanFaxiMember" xlink:to="upc_YunnanFaxiMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentBuildingAndBuildingImprovements_lbl0" xml:lang="en-US">Investment Building and Building Improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentBuildingAndBuildingImprovements" xlink:to="us-gaap_InvestmentBuildingAndBuildingImprovements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_TwoSupplierMember_lbl0" xml:lang="en-US">Two Supplier Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TwoSupplierMember" xlink:to="upc_TwoSupplierMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AutomobilesMember_lbl0" xml:lang="en-US">Automobiles [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AutomobilesMember" xlink:to="us-gaap_AutomobilesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl1" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfShortTermBankLoansAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfShortTermBankLoansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfShortTermBankLoansAbstract_lbl" xml:lang="en-US">Schedule Of Short Term Bank Loans Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfShortTermBankLoansAbstract" xlink:to="upc_ScheduleOfShortTermBankLoansAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_NetAccountReceivablePercentage_lbl1" xml:lang="en-US">Net Account Receivable Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_NetAccountReceivablePercentage" xlink:to="upc_NetAccountReceivablePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_NumberOfSharesIssued_lbl1" xml:lang="en-US">Number Of Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_NumberOfSharesIssued" xlink:to="upc_NumberOfSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments_lbl1" xml:lang="en-US">Inventory Valuation Allowancee Foreign Currency Translation Adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments" xlink:to="upc_InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ReclassificationsPolicyTextBlock_lbl1" xml:lang="en-US">Reclassifications Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ReclassificationsPolicyTextBlock" xlink:to="upc_ReclassificationsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_MsLinYangMember_lbl0" xml:lang="en-US">Ms Lin Yang Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MsLinYangMember" xlink:to="upc_MsLinYangMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_StatutorySurplusPercentage_lbl1" xml:lang="en-US">Statutory Surplus Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutorySurplusPercentage" xlink:to="upc_StatutorySurplusPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowingsAbstract_lbl0" xml:lang="en-US">Short-Term Debt [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_ShortTermBorrowingsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AdvancesToSuppliersNetPolicyTextBlock_lbl1" xml:lang="en-US">Advances To Suppliers Net Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvancesToSuppliersNetPolicyTextBlock" xlink:to="upc_AdvancesToSuppliersNetPolicyTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract_lbl" xml:lang="en-US">Schedule Of Property Plant And Equipment Estimated Useful Lives Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract" xlink:to="upc_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl1" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl0" xml:lang="en-US">Schedule of Short-Term Debt [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Stock Splits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge_lbl1" xml:lang="en-US">Inventory, LIFO Reserve, Period Charge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLIFOReservePeriodCharge" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionContractCostProgressPaymentOffset_lbl0" xml:lang="en-US">Construction Contract Cost, Progress Payment Offset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionContractCostProgressPaymentOffset" xlink:to="us-gaap_ConstructionContractCostProgressPaymentOffset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_JxRcbBankMember_lbl0" xml:lang="en-US">Jx Rcb Bank Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JxRcbBankMember" xlink:to="upc_JxRcbBankMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl1" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_StatementOfCashFlowsPolicyTextBlock_lbl1" xml:lang="en-US">Statement Of Cash Flows Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatementOfCashFlowsPolicyTextBlock" xlink:to="upc_StatementOfCashFlowsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ConstructionInProgressTwoMember_lbl0" xml:lang="en-US">Construction In Progress Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ConstructionInProgressTwoMember" xlink:to="upc_ConstructionInProgressTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ValueAddedTaxPolicyTextBlock_lbl1" xml:lang="en-US">Value Added Tax Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ValueAddedTaxPolicyTextBlock" xlink:to="upc_ValueAddedTaxPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl0" xml:lang="en-US">Asset Acquisition [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTextBlock" xlink:to="us-gaap_AssetAcquisitionTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl0" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl0" xml:lang="en-US">Payments to Acquire Businesses, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl0" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UniverseINCMember_lbl1" xml:lang="en-US">Universe INCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseINCMember" xlink:to="upc_UniverseINCMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromBankDebt_lbl0" xml:lang="en-US">Proceeds from Bank Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromBankDebt" xlink:to="us-gaap_ProceedsFromBankDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TrademarksMember_lbl0" xml:lang="en-US">Trademarks [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TrademarksMember" xlink:to="us-gaap_TrademarksMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_BeijingBankMember_lbl0" xml:lang="en-US">Beijing Bank Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_BeijingBankMember" xlink:to="upc_BeijingBankMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ConstructioninProgressPolicyTextBlock_lbl1" xml:lang="en-US">Constructionin Progress Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ConstructioninProgressPolicyTextBlock" xlink:to="upc_ConstructioninProgressPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl0" xml:lang="en-US">Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_LRCBankMember_lbl0" xml:lang="en-US">LRCBank Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_LRCBankMember" xlink:to="upc_LRCBankMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_YunnanFaxiPharmaceuticalsCoLtdMember_lbl0" xml:lang="en-US">Yunnan Faxi Pharmaceuticals Co Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_YunnanFaxiPharmaceuticalsCoLtdMember" xlink:to="upc_YunnanFaxiPharmaceuticalsCoLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl3" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships_lbl0" xml:lang="en-US">Nature of Common Ownership or Management Control Relationships</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships" xlink:to="us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract_lbl" xml:lang="en-US">Schedule Of Components Of The Income Tax Provision Benefit Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract" xlink:to="upc_ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OtherIncomeExpensesAbstract_lbl0" xml:lang="en-US">Other Income Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OtherIncomeExpensesAbstract" xlink:to="upc_OtherIncomeExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentForAcquisition_lbl1" xml:lang="en-US">Prepayment For Acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForAcquisition" xlink:to="upc_PrepaymentForAcquisition_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_lbl0" xml:lang="en-US">Condensed Cash Flow Statement [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl1" xml:lang="en-US">Contractual Obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OtherReceivablePercentage_lbl1" xml:lang="en-US">Other Receivable Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OtherReceivablePercentage" xlink:to="upc_OtherReceivablePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_lbl0" xml:lang="en-US">Income Tax Holiday, Income Tax Benefits Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:to="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OriginalSharesParValue_lbl1" xml:lang="en-US">Original Shares Par Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OriginalSharesParValue" xlink:to="upc_OriginalSharesParValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AdvancesToSuppliersTextBlock_lbl1" xml:lang="en-US">Advances To Suppliers Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvancesToSuppliersTextBlock" xlink:to="upc_AdvancesToSuppliersTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl0" xml:lang="en-US">Long-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ShareIssuedAfterTheSplit_lbl1" xml:lang="en-US">Share Issued After The Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShareIssuedAfterTheSplit" xlink:to="upc_ShareIssuedAfterTheSplit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_MinorityInterestsOwnershipPercentageByParent_lbl1" xml:lang="en-US">Minority Interests Ownership Percentage By Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MinorityInterestsOwnershipPercentageByParent" xlink:to="upc_MinorityInterestsOwnershipPercentageByParent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParentMember_lbl0" xml:lang="en-US">Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl0" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxHolidayDescription_lbl0" xml:lang="en-US">Income Tax Holiday, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxHolidayDescription" xlink:to="us-gaap_IncomeTaxHolidayDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_DisaggregationOfRevenuesPolicyTextBlock_lbl0" xml:lang="en-US">Disaggregation Of Revenues Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DisaggregationOfRevenuesPolicyTextBlock" xlink:to="upc_DisaggregationOfRevenuesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnderwriterWarrantsMember_lbl0" xml:lang="en-US">Underwriter Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnderwriterWarrantsMember" xlink:to="upc_UnderwriterWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl1" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_BankOfCommunicationsCoLtdMember_lbl0" xml:lang="en-US">Bank Of Communications Co Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_BankOfCommunicationsCoLtdMember" xlink:to="upc_BankOfCommunicationsCoLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl0" xml:lang="en-US">Increase (Decrease) in Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidAdvertising_lbl0" xml:lang="en-US">Prepaid Advertising</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidAdvertising" xlink:to="us-gaap_PrepaidAdvertising_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfLongTermBankLoansAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfLongTermBankLoansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfLongTermBankLoansAbstract_lbl" xml:lang="en-US">Schedule Of Long Term Bank Loans Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfLongTermBankLoansAbstract" xlink:to="upc_ScheduleOfLongTermBankLoansAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl0" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTextBlock_lbl0" xml:lang="en-US">Short-Term Debt [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTextBlock" xlink:to="us-gaap_ShortTermDebtTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl0" xml:lang="en-US">Defined Contribution Plan, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule Of Nature Of Relationships With Related Parties Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract" xlink:to="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl2" xml:lang="en-US">Short-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfTaxPayableTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Tax Payable Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfTaxPayableTableTextBlock" xlink:to="upc_ScheduleOfTaxPayableTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl0" xml:lang="en-US">Supplier Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl2" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentsForConstructionInProgress_lbl1" xml:lang="en-US">Prepayments For Construction In Progress</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsForConstructionInProgress" xlink:to="upc_PrepaymentsForConstructionInProgress_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherShortTermInvestments_lbl1" xml:lang="en-US">Other Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherShortTermInvestments" xlink:to="us-gaap_OtherShortTermInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CommonStockOneMember_lbl1" xml:lang="en-US">Common Stock One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CommonStockOneMember" xlink:to="upc_CommonStockOneMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_WorkingCapitalLoanMember_lbl0" xml:lang="en-US">Working Capital Loan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_WorkingCapitalLoanMember" xlink:to="upc_WorkingCapitalLoanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ChangeInFairValueOfShorttermInvestments_lbl2" xml:lang="en-US">Change In Fair Value Of Shortterm Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ChangeInFairValueOfShorttermInvestments" xlink:to="upc_ChangeInFairValueOfShorttermInvestments_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_GubenYanlingPillMember_lbl0" xml:lang="en-US">Guben Yanling Pill Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_GubenYanlingPillMember" xlink:to="upc_GubenYanlingPillMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxHolidayAggregateDollarAmount_lbl0" xml:lang="en-US">Income Tax Holiday, Aggregate Dollar Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:to="us-gaap_IncomeTaxHolidayAggregateDollarAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl1" xml:lang="en-US">Prepaid Expense and Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OtherComprehensiveIncomeLossAbstract_lbl0" xml:lang="en-US">Other Comprehensive Income Loss Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OtherComprehensiveIncomeLossAbstract" xlink:to="upc_OtherComprehensiveIncomeLossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl0" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl0" xml:lang="en-US">Condensed Balance Sheet [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl0" xml:lang="en-US">Contractual Obligation, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInSecondYear" xlink:to="us-gaap_ContractualObligationDueInSecondYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Supplies_lbl1" xml:lang="en-US">Prepaid Supplies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Supplies" xlink:to="us-gaap_Supplies_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_JiangxiLulingRuralCommercialBankLRCBankMember_lbl0" xml:lang="en-US">Jiangxi Luling Rural Commercial Bank LRCBank Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JiangxiLulingRuralCommercialBankLRCBankMember" xlink:to="upc_JiangxiLulingRuralCommercialBankLRCBankMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLoansPayableAbstract_lbl0" xml:lang="en-US">Loans Payable, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayableAbstract" xlink:to="us-gaap_LongTermLoansPayableAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PurchaseMember_lbl0" xml:lang="en-US">Purchase Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PurchaseMember" xlink:to="upc_PurchaseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl1" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl0" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl0" xml:lang="en-US">Income Taxes Paid, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Holiday, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl1" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose_lbl0" xml:lang="en-US">Subsidiary of Limited Liability Company or Limited Partnership, Business Purpose</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl1" xml:lang="en-US">Property And Equipment Estimated Useful Life Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl0" xml:lang="en-US">Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentForAcquisitionCurrent_lbl2" xml:lang="en-US">Prepayment For Acquisition Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForAcquisitionCurrent" xlink:to="upc_PrepaymentForAcquisitionCurrent_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl0" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfIntangibleAssetsNetAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfIntangibleAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfIntangibleAssetsNetAbstract_lbl" xml:lang="en-US">Schedule Of Intangible Assets Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfIntangibleAssetsNetAbstract" xlink:to="upc_ScheduleOfIntangibleAssetsNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OtherTaxesPayable_lbl1" xml:lang="en-US">Other Taxes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OtherTaxesPayable" xlink:to="upc_OtherTaxesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingExpense_lbl0" xml:lang="en-US">Selling Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl0" xml:lang="en-US">Other Nonoperating Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl0" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PayableDeliveryPropertyPercentage_lbl1" xml:lang="en-US">Payable Delivery Property Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PayableDeliveryPropertyPercentage" xlink:to="upc_PayableDeliveryPropertyPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl0" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ZhujiangRuralBankMember_lbl0" xml:lang="en-US">Zhujiang Rural Bank Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ZhujiangRuralBankMember" xlink:to="upc_ZhujiangRuralBankMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl0" xml:lang="en-US">Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState_lbl0" xml:lang="en-US">Subsidiary of Limited Liability Company or Limited Partnership, State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfSubsidiariesAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfSubsidiariesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfSubsidiariesAbstract_lbl" xml:lang="en-US">Schedule Of Subsidiaries Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfSubsidiariesAbstract" xlink:to="upc_ScheduleOfSubsidiariesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent_lbl0" xml:lang="en-US">Value Added Tax Receivable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="us-gaap_ValueAddedTaxReceivableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl0" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl0" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl0" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PercentageOfPrepayment_lbl1" xml:lang="en-US">Percentage Of Prepayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfPrepayment" xlink:to="upc_PercentageOfPrepayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UniverseHanheMember_lbl0" xml:lang="en-US">Universe Hanhe Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseHanheMember" xlink:to="upc_UniverseHanheMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl0" xml:lang="en-US">Inventory, Raw Materials, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignFinancialInstitutionsMandatedDeposits_lbl0" xml:lang="en-US">Foreign Financial Institutions, Mandated Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignFinancialInstitutionsMandatedDeposits" xlink:to="us-gaap_ForeignFinancialInstitutionsMandatedDeposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_GuangzhouNingjingInvestmentCoLtdGuangzhouNingjingMember_lbl0" xml:lang="en-US">Guangzhou Ningjing Investment Co Ltd Guangzhou Ningjing Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_GuangzhouNingjingInvestmentCoLtdGuangzhouNingjingMember" xlink:to="upc_GuangzhouNingjingInvestmentCoLtdGuangzhouNingjingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl0" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl1" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfCurrencyExchangeRateAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfCurrencyExchangeRateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfCurrencyExchangeRateAbstract_lbl" xml:lang="en-US">Schedule Of Currency Exchange Rate Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfCurrencyExchangeRateAbstract" xlink:to="upc_ScheduleOfCurrencyExchangeRateAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_StockIssuedDuringPeriodValueStatutoryReserve_lbl1" xml:lang="en-US">Stock Issued During Period Value Statutory Reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StockIssuedDuringPeriodValueStatutoryReserve" xlink:to="upc_StockIssuedDuringPeriodValueStatutoryReserve_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_MrXiboLiuMember_lbl0" xml:lang="en-US">Mr Xibo Liu Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MrXiboLiuMember" xlink:to="upc_MrXiboLiuMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl0" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeNetAssetsPercentage_lbl0" xml:lang="en-US">Derivative, Net Assets, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeNetAssetsPercentage" xlink:to="us-gaap_DerivativeNetAssetsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CN_lbl0" xml:lang="en-US">CHINA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl1" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl1" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_CNY_lbl0" xml:lang="en-US">China, Yuan Renminbi</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_CNY" xlink:to="currency_CNY_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_StockIssuedDuringPeriodValueReverseShareSplitAdjustment_lbl1" xml:lang="en-US">Stock Issued During Period Value Reverse Share Split Adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StockIssuedDuringPeriodValueReverseShareSplitAdjustment" xlink:to="upc_StockIssuedDuringPeriodValueReverseShareSplitAdjustment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl0" xml:lang="en-US">Schedule of Subsidiary of Limited Liability Company or Limited Partnership, Description [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl0" xml:lang="en-US">Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount_lbl0" xml:lang="en-US">Equity Method Investment, Amount Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:to="us-gaap_EquityMethodInvestmentSoldCarryingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl0" xml:lang="en-US">Software Development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UniverseTradeMember_lbl1" xml:lang="en-US">Universe Trade Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseTradeMember" xlink:to="upc_UniverseTradeMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl0" xml:lang="en-US">Machinery and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl0" xml:lang="en-US">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalUnits_lbl0" xml:lang="en-US">Capital Units, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnits" xlink:to="us-gaap_CapitalUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ProceedsFromPaymentForConstructionInProgress_lbl1" xml:lang="en-US">Proceeds From Payment For Construction In Progress</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ProceedsFromPaymentForConstructionInProgress" xlink:to="upc_ProceedsFromPaymentForConstructionInProgress_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl0" xml:lang="en-US">Subsidiary, Ownership Percentage, Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_lbl0" xml:lang="en-US">Interest Expense, Nonoperating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTerms_lbl0" xml:lang="en-US">Short-Term Debt, Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTerms" xlink:to="us-gaap_ShortTermDebtTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl1" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note, Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies_lbl0" xml:lang="en-US">Inventory, Raw Materials and Supplies, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsAndSupplies" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeForwardExchangeRate1_lbl0" xml:lang="en-US">Derivative, Forward Exchange Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeForwardExchangeRate1" xlink:to="us-gaap_DerivativeForwardExchangeRate1_lbl0"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl1" xml:lang="en-US">Contractual Obligation, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_lbl0" xml:lang="en-US">Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:to="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_MrYajunHuMember_lbl0" xml:lang="en-US">Mr Yajun Hu Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MrYajunHuMember" xlink:to="upc_MrYajunHuMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ChenyuanMember_lbl0" xml:lang="en-US">Chenyuan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ChenyuanMember" xlink:to="upc_ChenyuanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl1" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl2" xml:lang="en-US">Income (Loss) from Equity Method Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl1" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl1" xml:lang="en-US">Taxes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl2" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate_lbl0" xml:lang="en-US">Subsidiary of Limited Liability Company or Limited Partnership, Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfAdvancesToSuppliersNet_lbl1" xml:lang="en-US">Schedule Of Advances To Suppliers Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfAdvancesToSuppliersNet" xlink:to="upc_ScheduleOfAdvancesToSuppliersNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl0" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_lbl0" xml:lang="en-US">Advertising Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfPropertyPlantAndEquipmentNetAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfPropertyPlantAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfPropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US">Schedule Of Property Plant And Equipment Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfPropertyPlantAndEquipmentNetAbstract" xlink:to="upc_ScheduleOfPropertyPlantAndEquipmentNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent_lbl1" xml:lang="en-US">Prepayments Made To ARelated Party For Purchase Of Property Non Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Supplies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockDividendsShares_lbl1" xml:lang="en-US">Common Stock Dividends, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsShares" xlink:to="us-gaap_CommonStockDividendsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_supplierMember_lbl0" xml:lang="en-US">supplier Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_supplierMember" xlink:to="upc_supplierMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl0" xml:lang="en-US">Condensed Financial Information of Parent Company Only Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesGrossCurrent_lbl0" xml:lang="en-US">Other Receivables, Gross, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesGrossCurrent" xlink:to="us-gaap_OtherReceivablesGrossCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl0" xml:lang="en-US">Advertising Cost [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl1" xml:lang="en-US">Prepaid Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_TaxBenefitPercentage_lbl1" xml:lang="en-US">Tax Benefit Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TaxBenefitPercentage" xlink:to="upc_TaxBenefitPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_StatutoryReserve_lbl2" xml:lang="en-US">Statutory Reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutoryReserve" xlink:to="upc_StatutoryReserve_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_RestrictedNetAssets_lbl1" xml:lang="en-US">Restricted Net Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RestrictedNetAssets" xlink:to="upc_RestrictedNetAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl0" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Business, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl1" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl0" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_StatutoryReservesMember_lbl0" xml:lang="en-US">Statutory Reserves Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutoryReservesMember" xlink:to="upc_StatutoryReservesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl1" xml:lang="en-US">Other Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrefundedWarrantsMember_lbl0" xml:lang="en-US">Prefunded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrefundedWarrantsMember" xlink:to="upc_PrefundedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl1" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfBankDebt_lbl0" xml:lang="en-US">Repayments of Bank Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfBankDebt" xlink:to="us-gaap_RepaymentsOfBankDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_lbl0" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl0" xml:lang="en-US">Concentration Risk, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_LandUseRightsMember_lbl0" xml:lang="en-US">Land Use Rights Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_LandUseRightsMember" xlink:to="upc_LandUseRightsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_KY_lbl0" xml:lang="en-US">CAYMAN ISLANDS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_KY" xlink:to="country_KY_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Nature Of Relationships With Related Parties Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock" xlink:to="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl1" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl1" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl1" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl0" xml:lang="en-US">Long-Term Debt [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl1" xml:lang="en-US">Increase (Decrease) in Due to Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PublicOfferingPrice_lbl1" xml:lang="en-US">Public Offering Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PublicOfferingPrice" xlink:to="upc_PublicOfferingPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_lbl1" xml:lang="en-US">Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CustomerMember_lbl0" xml:lang="en-US">Customer Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CustomerMember" xlink:to="upc_CustomerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestments_lbl1" xml:lang="en-US">Equity Method Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl0" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_JiangxiUniverseMember_lbl1" xml:lang="en-US">Jiangxi Universe Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JiangxiUniverseMember" xlink:to="upc_JiangxiUniverseMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeAverageForwardExchangeRate1_lbl0" xml:lang="en-US">Derivative, Average Forward Exchange Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAverageForwardExchangeRate1" xlink:to="us-gaap_DerivativeAverageForwardExchangeRate1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl1" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_EmployeeDefinedContributionPlanPolicyTextBlock_lbl1" xml:lang="en-US">Employee Defined Contribution Plan Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EmployeeDefinedContributionPlanPolicyTextBlock" xlink:to="upc_EmployeeDefinedContributionPlanPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl0" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl0" xml:lang="en-US">Payments to Acquire Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl0" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UniverseHKMember_lbl0" xml:lang="en-US">Universe HKMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseHKMember" xlink:to="upc_UniverseHKMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PercentageOfTotalPurchasePricePayable_lbl1" xml:lang="en-US">Percentage Of Total Purchase Price Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfTotalPurchasePricePayable" xlink:to="upc_PercentageOfTotalPurchasePricePayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInThirdYear_lbl0" xml:lang="en-US">Contractual Obligation, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInThirdYear" xlink:to="us-gaap_ContractualObligationDueInThirdYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl0" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PercentageOfVatRate_lbl1" xml:lang="en-US">Percentage Of Vat Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfVatRate" xlink:to="upc_PercentageOfVatRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ValueAddedTaxPayable_lbl1" xml:lang="en-US">Value Added Tax Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ValueAddedTaxPayable" xlink:to="upc_ValueAddedTaxPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidAdvertising_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Advertising</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidAdvertising" xlink:to="us-gaap_IncreaseDecreaseInPrepaidAdvertising_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl1" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl0" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_lbl3" xml:lang="en-US">Inventory Valuation Reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesIssued_lbl1" xml:lang="en-US">Excess Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Future Minimum Capital Expenditures Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock" xlink:to="upc_ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>49
<FILENAME>upc-20240930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Apr 29 14:31:08 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ConsolidatedBalanceSheet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ConsolidatedIncomeStatement" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ShareholdersEquityType2or3" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ConsolidatedCashFlow" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_OrganizationandBusinessDescription" roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_AccountsReceivableNet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_InventoriesNet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/InventoriesNet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_AdvancetoSuppliers" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_PrepaymentforAcquisition" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisition"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_OtherReceivable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/OtherReceivable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_PropertyPlantandEquipmentNet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_IntangibleAssetsNet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_PrepaymentforCIPProject" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProject"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_PrepaymentforPurchaseofaProperty" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ShortTermBankLoans" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoans"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_LongTermBankLoans" roleURI="http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoans"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_RelatedPartyTransactions" roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_Taxes" roleURI="http://www.UniversePharmaceuticalsINC.com/role/Taxes"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_Concentrations" roleURI="http://www.UniversePharmaceuticalsINC.com/role/Concentrations"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ShareholdersEquity" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_CommitmentsandContingencies" roleURI="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_SubsequentEvents" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_FinancialInformationoftheParentCompany" roleURI="http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompany"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_AccountingPoliciesByPolicy" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_OrganizationandBusinessDescriptionTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_AccountsReceivableNetTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_InventoriesNetTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/InventoriesNetTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_AdvancetoSuppliersTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_OtherReceivableTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_PropertyPlantandEquipmentNetTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_IntangibleAssetsNetTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_PrepaymentforCIPProjectTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ShortTermBankLoansTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_LongTermBankLoansTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoansTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_RelatedPartyTransactionsTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_TaxesTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/TaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_FinancialInformationoftheParentCompanyTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompanyTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofSubsidiariesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofSubsidiariesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofIntangibleAssetsEstimatedUsefulLivesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsEstimatedUsefulLivesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofCurrencyExchangeRateTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofCurrencyExchangeRateTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofAccountsReceivableTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAccountsReceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofAllowanceforDoubtfulAccountsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAllowanceforDoubtfulAccountsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofInventoriesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofInventoriesValuationAllowanceTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesValuationAllowanceTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofAdvancestoSuppliersTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAdvancestoSuppliersTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofOtherReceivableTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofOtherReceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofPropertyPlantandEquipmentNetTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofIntangibleAssetsNetTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsNetTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofFutureMinimumCapitalExpendituresTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofFutureMinimumCapitalExpendituresTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofShortTermBankLoansTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofShortTermBankLoansTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofLongTermBankLoansTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofLongTermBankLoansTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofNatureofRelationshipsWithRelatedPartiesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofNatureofRelationshipsWithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofRelatedPartiesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofTableReconcilestheChinaStatutoryRatestotheCompanysEffectiveTaxRateTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTableReconcilestheChinaStatutoryRatestotheCompanysEffectiveTaxRateTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofDeferredTaxAssetsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofDeferredTaxAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofTaxesPayableTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTaxesPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofConsolidatedFinancialStatementsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofConsolidatedFinancialStatementsTable_Parentheticals" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ScheduleofParentCompanyStatementsofCashFlowsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_OrganizationandBusinessDescriptionDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_AccountsReceivableNetDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_PrepaymentforAcquisitionDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_OtherReceivableDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_PropertyPlantandEquipmentNetDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_IntangibleAssetsNetDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_PrepaymentforCIPProjectDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_PrepaymentforPurchaseofaPropertyDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ShortTermBankLoansDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_LongTermBankLoansDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoansDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_RelatedPartyTransactionsDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_TaxesDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ConcentrationsDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_ShareholdersEquityDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_CommitmentsandContingenciesDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_SubsequentEventsDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20240930.xsd#upc_r_FinancialInformationoftheParentCompanyDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompanyDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#ai" roleURI="http://xbrl.sec.gov/dei/role/document/AuditInformation"/>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Supplies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Supplies" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentForAcquisitionCurrent" xlink:href="upc-20240930.xsd#upc_PrepaymentForAcquisitionCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="PrepaymentForAcquisitionCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivables" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" xlink:href="upc-20240930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentsForConstructionInProgress" xlink:href="upc-20240930.xsd#upc_PrepaymentsForConstructionInProgress"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="PrepaymentsForConstructionInProgress" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_EquityMethodInvestments" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ShortTermBorrowings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLoansFromBank" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermLoansFromBank"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermLoansFromBank" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatutoryReserve" xlink:href="upc-20240930.xsd#upc_StatutoryReserve"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="StatutoryReserve" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="OtherIncomeExpensesAbstract" xlink:href="upc-20240930.xsd#upc_OtherIncomeExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="OtherIncomeExpensesAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpensesAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpensesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="OtherComprehensiveIncomeLossAbstract" xlink:href="upc-20240930.xsd#upc_OtherComprehensiveIncomeLossAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="OtherComprehensiveIncomeLossAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherComprehensiveIncomeLossAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherComprehensiveIncomeLossAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatutoryReservesMember" xlink:href="upc-20240930.xsd#upc_StatutoryReservesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="StatutoryReservesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="5.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueStatutoryReserve" xlink:href="upc-20240930.xsd#upc_StockIssuedDuringPeriodValueStatutoryReserve"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLoss" xlink:to="StockIssuedDuringPeriodValueStatutoryReserve" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueReverseShareSplitAdjustment" xlink:href="upc-20240930.xsd#upc_StockIssuedDuringPeriodValueReverseShareSplitAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="StockIssuedDuringPeriodValueReverseShareSplitAdjustment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInFairValueOfShorttermInvestments" xlink:href="upc-20240930.xsd#upc_ChangeInFairValueOfShorttermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ChangeInFairValueOfShorttermInvestments" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidAdvertising" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidAdvertising"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidAdvertising" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent" xlink:href="upc-20240930.xsd#upc_IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromPaymentForConstructionInProgress" xlink:href="upc-20240930.xsd#upc_ProceedsFromPaymentForConstructionInProgress"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="ProceedsFromPaymentForConstructionInProgress" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromBankDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromBankDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_RepaymentsOfBankDebt" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/InventoriesNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="AdvancesToSuppliersAbstract" xlink:href="upc-20240930.xsd#upc_AdvancesToSuppliersAbstract"/>
    <loc xlink:type="locator" xlink:label="AdvancesToSuppliersTextBlock" xlink:href="upc-20240930.xsd#upc_AdvancesToSuppliersTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdvancesToSuppliersAbstract" xlink:to="AdvancesToSuppliersTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisition" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/OtherReceivable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherReceivablesNetCurrentAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProject" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="PrepaymentForConstructionInProgressAbstract" xlink:href="upc-20240930.xsd#upc_PrepaymentForConstructionInProgressAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaymentForConstructionInProgressTextBlock" xlink:href="upc-20240930.xsd#upc_PrepaymentForConstructionInProgressTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForConstructionInProgressAbstract" xlink:to="PrepaymentForConstructionInProgressTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="PrepaymentForPurchaseOfAPropertyAbstract" xlink:href="upc-20240930.xsd#upc_PrepaymentForPurchaseOfAPropertyAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaymentForPurchaseOfAPropertyTextBlock" xlink:href="upc-20240930.xsd#upc_PrepaymentForPurchaseOfAPropertyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForPurchaseOfAPropertyAbstract" xlink:to="PrepaymentForPurchaseOfAPropertyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoans" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ShortTermBankLoansAbstract" xlink:href="upc-20240930.xsd#upc_ShortTermBankLoansAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermBankLoansAbstract" xlink:to="us-gaap_ShortTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoans" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/Taxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/Concentrations" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompany" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReclassificationsPolicyTextBlock" xlink:href="upc-20240930.xsd#upc_ReclassificationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ReclassificationsPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvancesToSuppliersNetPolicyTextBlock" xlink:href="upc-20240930.xsd#upc_AdvancesToSuppliersNetPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="AdvancesToSuppliersNetPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConstructioninProgressPolicyTextBlock" xlink:href="upc-20240930.xsd#upc_ConstructioninProgressPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ConstructioninProgressPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisaggregationOfRevenuesPolicyTextBlock" xlink:href="upc-20240930.xsd#upc_DisaggregationOfRevenuesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DisaggregationOfRevenuesPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ValueAddedTaxPolicyTextBlock" xlink:href="upc-20240930.xsd#upc_ValueAddedTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ValueAddedTaxPolicyTextBlock" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatementOfCashFlowsPolicyTextBlock" xlink:href="upc-20240930.xsd#upc_StatementOfCashFlowsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="StatementOfCashFlowsPolicyTextBlock" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeDefinedContributionPlanPolicyTextBlock" xlink:href="upc-20240930.xsd#upc_EmployeeDefinedContributionPlanPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="EmployeeDefinedContributionPlanPolicyTextBlock" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:href="upc-20240930.xsd#upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock" xlink:href="upc-20240930.xsd#upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/InventoriesNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="AdvancesToSuppliersAbstract" xlink:href="upc-20240930.xsd#upc_AdvancesToSuppliersAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfAdvancesToSuppliersNet" xlink:href="upc-20240930.xsd#upc_ScheduleOfAdvancesToSuppliersNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdvancesToSuppliersAbstract" xlink:to="ScheduleOfAdvancesToSuppliersNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherReceivablesNetCurrentAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="PrepaymentForConstructionInProgressAbstract" xlink:href="upc-20240930.xsd#upc_PrepaymentForConstructionInProgressAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock" xlink:href="upc-20240930.xsd#upc_ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForConstructionInProgressAbstract" xlink:to="ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ShortTermBankLoansAbstract" xlink:href="upc-20240930.xsd#upc_ShortTermBankLoansAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermBankLoansAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoansTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock" xlink:href="upc-20240930.xsd#upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/TaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfTaxPayableTableTextBlock" xlink:href="upc-20240930.xsd#upc_ScheduleOfTaxPayableTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfTaxPayableTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompanyTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfComprehensiveIncomeTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedCashFlowStatementTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofSubsidiariesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfSubsidiariesAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfSubsidiariesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSubsidiariesAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="srt_OwnershipAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="UniverseINCMember" xlink:href="upc-20240930.xsd#upc_UniverseINCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="UniverseINCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniverseHKMember" xlink:href="upc-20240930.xsd#upc_UniverseHKMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="UniverseHKMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniverseTechnologyMember" xlink:href="upc-20240930.xsd#upc_UniverseTechnologyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="UniverseTechnologyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JiangxiUniverseMember" xlink:href="upc-20240930.xsd#upc_JiangxiUniverseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="JiangxiUniverseMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniverseTradeMember" xlink:href="upc-20240930.xsd#upc_UniverseTradeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="UniverseTradeMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniverseHanheMember" xlink:href="upc-20240930.xsd#upc_UniverseHanheMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="UniverseHanheMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesDetailsTable" xlink:href="upc-20240930.xsd#upc_SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AutomobilesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AutomobilesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_AutomobilesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfficeAndElectricEquipmentMember" xlink:href="upc-20240930.xsd#upc_OfficeAndElectricEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="OfficeAndElectricEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsEstimatedUsefulLivesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsEstimatedUsefulLivesDetailsTable" xlink:href="upc-20240930.xsd#upc_SummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsEstimatedUsefulLivesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsEstimatedUsefulLivesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsEstimatedUsefulLivesDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseRightsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_UseRightsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_TrademarksMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsEstimatedUsefulLivesDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofCurrencyExchangeRateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCurrencyExchangeRateAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfCurrencyExchangeRateAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRateDetailsTable" xlink:href="upc-20240930.xsd#upc_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRateDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCurrencyExchangeRateAbstract" xlink:to="SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRateDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRateDetailsTable" xlink:to="srt_CurrencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="currency_CNY" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CNY"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_CNY" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="currency_HKD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_HKD"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_HKD" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRateDetailsTable" xlink:to="us-gaap_DerivativeLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeForwardExchangeRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeForwardExchangeRate1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DerivativeForwardExchangeRate1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeAverageForwardExchangeRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAverageForwardExchangeRate1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DerivativeAverageForwardExchangeRate1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAccountsReceivableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetCurrentAbstract" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetCurrentAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAllowanceforDoubtfulAccountsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForCreditLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForCreditLossAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AllowanceForCreditLossAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AllowanceForCreditLossAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AllowanceForCreditLossAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AllowanceForCreditLossAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfInventoriesAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoriesAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoriesAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoriesAbstract" xlink:to="us-gaap_InventoryValuationReserves" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoriesAbstract" xlink:to="us-gaap_InventoryNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesValuationAllowanceTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfInventoryValuationAllowanceAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfInventoryValuationAllowanceAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryValuationAllowanceAbstract" xlink:to="us-gaap_InventoryValuationReserves" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryValuationAllowanceAbstract" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments" xlink:href="upc-20240930.xsd#upc_InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryValuationAllowanceAbstract" xlink:to="InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryValuationAllowanceAbstract" xlink:to="us-gaap_InventoryValuationReserves_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAdvancestoSuppliersTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsAndSuppliesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsAndSuppliesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsAndSupplies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryRawMaterialsAndSuppliesAbstract" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Supplies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryRawMaterialsAndSuppliesAbstract" xlink:to="us-gaap_Supplies" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofOtherReceivableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherReceivableAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfOtherReceivableAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherReceivableAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherReceivableAbstract" xlink:to="us-gaap_OtherShortTermInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherReceivableAbstract" xlink:to="us-gaap_ValueAddedTaxReceivableCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidAdvertising" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidAdvertising"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherReceivableAbstract" xlink:to="us-gaap_PrepaidAdvertising" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherReceivableAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherReceivableAbstract" xlink:to="us-gaap_OtherReceivables" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyPlantAndEquipmentNetAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfPropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AutomobilesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AutomobilesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_AutomobilesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ConstructionInProgressMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfIntangibleAssetsNetAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfIntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsNetAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LandUseRightsMember" xlink:href="upc-20240930.xsd#upc_LandUseRightsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="LandUseRightsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_TrademarksMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_SoftwareDevelopmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofFutureMinimumCapitalExpendituresTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationFiscalYearMaturityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInSecondYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_ContractualObligationDueInSecondYear" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_ContractualObligationDueInThirdYear" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractualObligationDueInThirdYear" xlink:to="us-gaap_ContractualObligation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofShortTermBankLoansTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfShortTermBankLoansAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfShortTermBankLoansAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShortTermBankLoansAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="JiangxiLulingRuralCommercialBankLRCBankMember" xlink:href="upc-20240930.xsd#upc_JiangxiLulingRuralCommercialBankLRCBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="JiangxiLulingRuralCommercialBankLRCBankMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BankOfCommunicationsCoLtdMember" xlink:href="upc-20240930.xsd#upc_BankOfCommunicationsCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BankOfCommunicationsCoLtdMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ZhujiangRuralBankMember" xlink:href="upc-20240930.xsd#upc_ZhujiangRuralBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ZhujiangRuralBankMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BeijingBankMember" xlink:href="upc-20240930.xsd#upc_BeijingBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BeijingBankMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermBorrowingsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_ShortTermBorrowings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofLongTermBankLoansTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfLongTermBankLoansAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfLongTermBankLoansAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfLongTermBankLoansLineItems" xlink:href="upc-20240930.xsd#upc_ScheduleOfLongTermBankLoansLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLongTermBankLoansAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="LRCBankMember" xlink:href="upc-20240930.xsd#upc_LRCBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="LRCBankMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="ScheduleOfLongTermBankLoansLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLoansPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermLoansPayableAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLongTermBankLoansLineItems" xlink:to="us-gaap_LongTermLoansPayableAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLoansFromBank" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermLoansFromBank"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermLoansPayableAbstract" xlink:to="us-gaap_LongTermLoansFromBank" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofNatureofRelationshipsWithRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsScheduleofNatureofRelationshipsWithRelatedPartiesDetailsTable" xlink:href="upc-20240930.xsd#upc_RelatedPartyTransactionsScheduleofNatureofRelationshipsWithRelatedPartiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract" xlink:to="RelatedPartyTransactionsScheduleofNatureofRelationshipsWithRelatedPartiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsScheduleofNatureofRelationshipsWithRelatedPartiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MrGangLaiMember" xlink:href="upc-20240930.xsd#upc_MrGangLaiMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrGangLaiMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MrYajunHuMember" xlink:href="upc-20240930.xsd#upc_MrYajunHuMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrYajunHuMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MsLinYangMember" xlink:href="upc-20240930.xsd#upc_MsLinYangMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MsLinYangMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GuangzhouNingjingInvestmentCoLtdGuangzhouNingjingMember" xlink:href="upc-20240930.xsd#upc_GuangzhouNingjingInvestmentCoLtdGuangzhouNingjingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="GuangzhouNingjingInvestmentCoLtdGuangzhouNingjingMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsScheduleofNatureofRelationshipsWithRelatedPartiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRelatedPartiesAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartiesAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MrYajunHuMember" xlink:href="upc-20240930.xsd#upc_MrYajunHuMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrYajunHuMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="MrGangLaiMember" xlink:href="upc-20240930.xsd#upc_MrGangLaiMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrGangLaiMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MsLinYangMember" xlink:href="upc-20240930.xsd#upc_MsLinYangMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MsLinYangMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract"/>
    <loc xlink:type="locator" xlink:label="TaxesScheduleofComponentsoftheIncomeTaxProvisionBenefitDetailsTable" xlink:href="upc-20240930.xsd#upc_TaxesScheduleofComponentsoftheIncomeTaxProvisionBenefitDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract" xlink:to="TaxesScheduleofComponentsoftheIncomeTaxProvisionBenefitDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYZDqnPZexC+e00+Rf6r37QtPu3oRrVmmTX8PuYVCFDMbRocUzw9EKKPK5NWC0WpJsOIuWkqeF3WWYzAuBG72bAUNWZ0EJoh7tCz07VxkYX3MUSJ7UFcJNPwN8yHmeKHRgkhMTd18uQzeusIsu/5w+1sTLgk4s48vHUWCmlxzr3HAZpsa+LfmHnFaLaCmPS0f6K1sduUUfaD9sRn5i3Vzu5VnzV9KOEHGDWQhDnV/BFeewWkVFaS1UAAYdll7IkiuGL2HLaVLc//A==] CSR-->
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesScheduleofComponentsoftheIncomeTaxProvisionBenefitDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_KY" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KY"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_KY" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_HK"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_HK" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_CN" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesScheduleofComponentsoftheIncomeTaxProvisionBenefitDetailsTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTableReconcilestheChinaStatutoryRatestotheCompanysEffectiveTaxRateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofDeferredTaxAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfDeferredTaxAssetsAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTaxesPayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="ValueAddedTaxPayable" xlink:href="upc-20240930.xsd#upc_ValueAddedTaxPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxesPayableCurrentAbstract" xlink:to="ValueAddedTaxPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherTaxesPayable" xlink:href="upc-20240930.xsd#upc_OtherTaxesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxesPayableCurrentAbstract" xlink:to="OtherTaxesPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxesPayableCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfConsolidatedFinancialStatementsAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfConsolidatedFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConsolidatedFinancialStatementsAbstract" xlink:to="srt_CondensedBalanceSheetStatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="us-gaap_ParentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_CondensedBalanceSheetStatementsCaptionsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_AssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfConsolidatedFinancialStatementsAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfConsolidatedFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConsolidatedFinancialStatementsAbstract" xlink:to="srt_CondensedBalanceSheetStatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="us-gaap_ParentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_CondensedBalanceSheetStatementsCaptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfParentCompanyStatementsOfOperationsAndComprehensiveLossAbstract" xlink:href="upc-20240930.xsd#upc_ScheduleOfParentCompanyStatementsOfOperationsAndComprehensiveLossAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfComprehensiveIncomeTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfIncomeCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfParentCompanyStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="us-gaap_ParentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="srt_CondensedStatementOfIncomeCaptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedCashFlowStatementTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedCashFlowStatementTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="srt_CondensedCashFlowStatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_ParentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="srt_CondensedCashFlowStatementsCaptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInFairValueOfShorttermInvestments" xlink:href="upc-20240930.xsd#upc_ChangeInFairValueOfShorttermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ChangeInFairValueOfShorttermInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromContributionsFromAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromContributionsFromAffiliates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationandBusinessDescriptionDetailsTable" xlink:href="upc-20240930.xsd#upc_OrganizationandBusinessDescriptionDetailsTable"/>
    <loc xlink:type="locator" xlink:label="OrganizationandBusinessDescriptionDetailsLineItems" xlink:href="upc-20240930.xsd#upc_OrganizationandBusinessDescriptionDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationandBusinessDescriptionDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsTable" xlink:to="srt_StatementScenarioAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_BoardOfDirectorsChairmanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockOneMember" xlink:href="upc-20240930.xsd#upc_CommonStockOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="CommonStockOneMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsTable" xlink:to="srt_RangeAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsTable" xlink:to="srt_OwnershipAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="UniverseIncMember" xlink:href="upc-20240930.xsd#upc_UniverseIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="UniverseIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniverseHKMember" xlink:href="upc-20240930.xsd#upc_UniverseHKMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="UniverseHKMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JiangxiUniverseMember" xlink:href="upc-20240930.xsd#upc_JiangxiUniverseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="JiangxiUniverseMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="UniverseTradeMember" xlink:href="upc-20240930.xsd#upc_UniverseTradeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="UniverseTradeMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="UniverseTechnologyMember" xlink:href="upc-20240930.xsd#upc_UniverseTechnologyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="UniverseTechnologyMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsTable" xlink:to="OrganizationandBusinessDescriptionDetailsLineItems" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationDateOfIncorporation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PublicOfferingPrice" xlink:href="upc-20240930.xsd#upc_PublicOfferingPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="PublicOfferingPrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExcessStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_CapitalUnits" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_CommonStockDividendsShares" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="upc-20240930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="UniversePharmaceuticalsIncMember" xlink:href="upc-20240930.xsd#upc_UniversePharmaceuticalsIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="UniversePharmaceuticalsIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JxRcbBankMember" xlink:href="upc-20240930.xsd#upc_JxRcbBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="JxRcbBankMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="UniverseHKMember" xlink:href="upc-20240930.xsd#upc_UniverseHKMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="UniverseHKMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ChangeInAccountingEstimateLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_InventoryValuationReserves" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_EquityMethodInvestmentSoldCarryingAmount" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_AdvertisingExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxBenefitPercentage" xlink:href="upc-20240930.xsd#upc_TaxBenefitPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="TaxBenefitPercentage" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfVatRate" xlink:href="upc-20240930.xsd#upc_PercentageOfVatRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="PercentageOfVatRate" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetAbstract"/>
    <loc xlink:type="locator" xlink:label="NetAccountReceivablePercentage" xlink:href="upc-20240930.xsd#upc_NetAccountReceivablePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="NetAccountReceivablePercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsReceivableNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaymentforAcquisitionDetailsTable" xlink:href="upc-20240930.xsd#upc_PrepaymentforAcquisitionDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="PrepaymentforAcquisitionDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforAcquisitionDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="YunnanFaxiPharmaceuticalsCoLtdMember" xlink:href="upc-20240930.xsd#upc_YunnanFaxiPharmaceuticalsCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="YunnanFaxiPharmaceuticalsCoLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforAcquisitionDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="YunnanFaxiPharmaceuticalsCoLtdMember_0" xlink:href="upc-20240930.xsd#upc_YunnanFaxiPharmaceuticalsCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="YunnanFaxiPharmaceuticalsCoLtdMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforAcquisitionDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MrXiboLiuMember" xlink:href="upc-20240930.xsd#upc_MrXiboLiuMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrXiboLiuMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforAcquisitionDetailsTable" xlink:to="us-gaap_AssetAcquisitionLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentForAcquisition" xlink:href="upc-20240930.xsd#upc_PrepaymentForAcquisition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="PrepaymentForAcquisition" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentForAcquisitionCurrent" xlink:href="upc-20240930.xsd#upc_PrepaymentForAcquisitionCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="PrepaymentForAcquisitionCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_OtherReceivables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherReceivableDetailsTable" xlink:href="upc-20240930.xsd#upc_OtherReceivableDetailsTable"/>
    <loc xlink:type="locator" xlink:label="OtherReceivableDetailsLineItems" xlink:href="upc-20240930.xsd#upc_OtherReceivableDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherReceivablesNetCurrentAbstract" xlink:to="OtherReceivableDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivableDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="YunnanFaxiMember" xlink:href="upc-20240930.xsd#upc_YunnanFaxiMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="YunnanFaxiMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivableDetailsTable" xlink:to="OtherReceivableDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivableDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivableDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivableDetailsLineItems" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivableDetailsLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivableDetailsLineItems" xlink:to="us-gaap_OtherReceivablesGrossCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivableDetailsLineItems" xlink:to="us-gaap_OtherShortTermInvestments" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherReceivablePercentage" xlink:href="upc-20240930.xsd#upc_OtherReceivablePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivableDetailsLineItems" xlink:to="OtherReceivablePercentage" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="PrepaymentForConstructionInProgressAbstract" xlink:href="upc-20240930.xsd#upc_PrepaymentForConstructionInProgressAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaymentforCIPProjectDetailsTable" xlink:href="upc-20240930.xsd#upc_PrepaymentforCIPProjectDetailsTable"/>
    <loc xlink:type="locator" xlink:label="PrepaymentforCIPProjectDetailsLineItems" xlink:href="upc-20240930.xsd#upc_PrepaymentforCIPProjectDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForConstructionInProgressAbstract" xlink:to="PrepaymentforCIPProjectDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforCIPProjectDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ConstructionInProgressMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ConstructionInProgressTwoMember" xlink:href="upc-20240930.xsd#upc_ConstructionInProgressTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="ConstructionInProgressTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforCIPProjectDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ChenyuanMember" xlink:href="upc-20240930.xsd#upc_ChenyuanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ChenyuanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforCIPProjectDetailsTable" xlink:to="PrepaymentforCIPProjectDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentBuildingAndBuildingImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentBuildingAndBuildingImprovements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforCIPProjectDetailsLineItems" xlink:to="us-gaap_InvestmentBuildingAndBuildingImprovements" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionContractCostProgressPaymentOffset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionContractCostProgressPaymentOffset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforCIPProjectDetailsLineItems" xlink:to="us-gaap_ConstructionContractCostProgressPaymentOffset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforCIPProjectDetailsLineItems" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforCIPProjectDetailsLineItems" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="PrepaymentForPurchaseOfAPropertyAbstract" xlink:href="upc-20240930.xsd#upc_PrepaymentForPurchaseOfAPropertyAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaymentforPurchaseofaPropertyDetailsTable" xlink:href="upc-20240930.xsd#upc_PrepaymentforPurchaseofaPropertyDetailsTable"/>
    <loc xlink:type="locator" xlink:label="PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:href="upc-20240930.xsd#upc_PrepaymentforPurchaseofaPropertyDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForPurchaseOfAPropertyAbstract" xlink:to="PrepaymentforPurchaseofaPropertyDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforPurchaseofaPropertyDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="JiangxiYueshangMember" xlink:href="upc-20240930.xsd#upc_JiangxiYueshangMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="JiangxiYueshangMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforPurchaseofaPropertyDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="JiangxiYueshangMember_0" xlink:href="upc-20240930.xsd#upc_JiangxiYueshangMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="JiangxiYueshangMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforPurchaseofaPropertyDetailsTable" xlink:to="PrepaymentforPurchaseofaPropertyDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentsMadeToARelatedPartyForPurchasesOfProperty" xlink:href="upc-20240930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="PrepaymentsMadeToARelatedPartyForPurchasesOfProperty" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfPrepayment" xlink:href="upc-20240930.xsd#upc_PercentageOfPrepayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="PercentageOfPrepayment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfTotalPurchasePricePayable" xlink:href="upc-20240930.xsd#upc_PercentageOfTotalPurchasePricePayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="PercentageOfTotalPurchasePricePayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PayableDeliveryPropertyPercentage" xlink:href="upc-20240930.xsd#upc_PayableDeliveryPropertyPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="PayableDeliveryPropertyPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ShortTermBankLoansAbstract" xlink:href="upc-20240930.xsd#upc_ShortTermBankLoansAbstract"/>
    <loc xlink:type="locator" xlink:label="ShortTermBankLoansDetailsTable" xlink:href="upc-20240930.xsd#upc_ShortTermBankLoansDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermBankLoansAbstract" xlink:to="ShortTermBankLoansDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermBankLoansDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermBankLoansDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LRCBankMember" xlink:href="upc-20240930.xsd#upc_LRCBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="LRCBankMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BankOfCommunicationsCoLtdMember" xlink:href="upc-20240930.xsd#upc_BankOfCommunicationsCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="BankOfCommunicationsCoLtdMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ZhujiangRuralBankMember" xlink:href="upc-20240930.xsd#upc_ZhujiangRuralBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="ZhujiangRuralBankMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BeijingBankMember" xlink:href="upc-20240930.xsd#upc_BeijingBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="BeijingBankMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermBankLoansDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="WorkingCapitalLoanMember" xlink:href="upc-20240930.xsd#upc_WorkingCapitalLoanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="WorkingCapitalLoanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LRCBankMember_0" xlink:href="upc-20240930.xsd#upc_LRCBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="LRCBankMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ZhujiangRuralBankMember_0" xlink:href="upc-20240930.xsd#upc_ZhujiangRuralBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ZhujiangRuralBankMember_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BeijingBankMember_0" xlink:href="upc-20240930.xsd#upc_BeijingBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="BeijingBankMember_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermBankLoansDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="UniverseTradeMember" xlink:href="upc-20240930.xsd#upc_UniverseTradeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="UniverseTradeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JiangxiUniverseMember" xlink:href="upc-20240930.xsd#upc_JiangxiUniverseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="JiangxiUniverseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermBankLoansDetailsTable" xlink:to="us-gaap_ShortTermDebtLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermBorrowings" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtTerms" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoansDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="LongTermBankLoansDetailsTable" xlink:href="upc-20240930.xsd#upc_LongTermBankLoansDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LongTermBankLoansDetailsLineItems" xlink:href="upc-20240930.xsd#upc_LongTermBankLoansDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="LongTermBankLoansDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermBankLoansDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LRCBankMember" xlink:href="upc-20240930.xsd#upc_LRCBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="LRCBankMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermBankLoansDetailsTable" xlink:to="LongTermBankLoansDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermBankLoansDetailsLineItems" xlink:to="us-gaap_LongTermDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermBankLoansDetailsLineItems" xlink:to="us-gaap_LongTermDebtTerm" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermBankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermBankLoansDetailsLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermBankLoansDetailsLineItems" xlink:to="us-gaap_InterestPaidNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsTable" xlink:href="upc-20240930.xsd#upc_RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MrGangLaiMember" xlink:href="upc-20240930.xsd#upc_MrGangLaiMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="MrGangLaiMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="JiangxiYueshangMember" xlink:href="upc-20240930.xsd#upc_JiangxiYueshangMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="JiangxiYueshangMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentsMadeToARelatedPartyForPurchasesOfProperty" xlink:href="upc-20240930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="PrepaymentsMadeToARelatedPartyForPurchasesOfProperty" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="TaxesDetailsTable" xlink:href="upc-20240930.xsd#upc_TaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxHolidayLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="TaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_HK"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_HK" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesDetailsTable" xlink:to="us-gaap_IncomeTaxHolidayLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxHolidayLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxHolidayDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxHolidayLineItems" xlink:to="us-gaap_IncomeTaxHolidayDescription" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxHolidayLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayAggregateDollarAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxHolidayLineItems" xlink:to="us-gaap_IncomeTaxHolidayAggregateDollarAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxHolidayLineItems" xlink:to="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ConcentrationsDetailsTable" xlink:href="upc-20240930.xsd#upc_ConcentrationsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="ConcentrationsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_SupplierConcentrationRiskMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="srt_MajorCustomersAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TopTenCustomersMember" xlink:href="upc-20240930.xsd#upc_TopTenCustomersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="TopTenCustomersMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerMember" xlink:href="upc-20240930.xsd#upc_CustomerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CustomerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseMember" xlink:href="upc-20240930.xsd#upc_PurchaseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="PurchaseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="supplierMember" xlink:href="upc-20240930.xsd#upc_supplierMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="supplierMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoSupplierMember" xlink:href="upc-20240930.xsd#upc_TwoSupplierMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="TwoSupplierMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="GubenYanlingPillMember" xlink:href="upc-20240930.xsd#upc_GubenYanlingPillMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="GubenYanlingPillMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignFinancialInstitutionsMandatedDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignFinancialInstitutionsMandatedDeposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ForeignFinancialInstitutionsMandatedDeposits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsTable" xlink:href="upc-20240930.xsd#upc_ShareholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ShareholdersEquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnderwriterWarrantsMember" xlink:href="upc-20240930.xsd#upc_UnderwriterWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="UnderwriterWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatutoryReserveAndRestrictedNetAssetsMember" xlink:href="upc-20240930.xsd#upc_StatutoryReserveAndRestrictedNetAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="StatutoryReserveAndRestrictedNetAssetsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="srt_StatementScenarioAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_BoardOfDirectorsChairmanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="UniverseINCMember" xlink:href="upc-20240930.xsd#upc_UniverseINCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="UniverseINCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockOneMember" xlink:href="upc-20240930.xsd#upc_CommonStockOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="CommonStockOneMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="UnderwriterWarrantsMember_0" xlink:href="upc-20240930.xsd#upc_UnderwriterWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="UnderwriterWarrantsMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfStockLineItems" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginalShareIssued" xlink:href="upc-20240930.xsd#upc_OriginalShareIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="OriginalShareIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginalSharesParValue" xlink:href="upc-20240930.xsd#upc_OriginalSharesParValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="OriginalSharesParValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareIssuedAfterTheSplit" xlink:href="upc-20240930.xsd#upc_ShareIssuedAfterTheSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ShareIssuedAfterTheSplit" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareOutstandingAfterTheSplit" xlink:href="upc-20240930.xsd#upc_ShareOutstandingAfterTheSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ShareOutstandingAfterTheSplit" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CapitalUnits" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockDividendsShares" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExcessStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesSoldPercentage" xlink:href="upc-20240930.xsd#upc_OrdinarySharesSoldPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="OrdinarySharesSoldPercentage" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatutorySurplusPercentage" xlink:href="upc-20240930.xsd#upc_StatutorySurplusPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="StatutorySurplusPercentage" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReserveIsEqualPercentage" xlink:href="upc-20240930.xsd#upc_ReserveIsEqualPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ReserveIsEqualPercentage" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatutoryReserve" xlink:href="upc-20240930.xsd#upc_StatutoryReserve"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="StatutoryReserve" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedNetAssets" xlink:href="upc-20240930.xsd#upc_RestrictedNetAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="RestrictedNetAssets" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsTable" xlink:href="upc-20240930.xsd#upc_CommitmentsandContingenciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsandContingenciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MrGangLaiMember" xlink:href="upc-20240930.xsd#upc_MrGangLaiMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="MrGangLaiMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="JiangxiYueshangMember" xlink:href="upc-20240930.xsd#upc_JiangxiYueshangMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="JiangxiYueshangMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_LossContingenciesLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ContractualObligation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentsMadeToARelatedPartyForPurchasesOfProperty" xlink:href="upc-20240930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="PrepaymentsMadeToARelatedPartyForPurchasesOfProperty" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="upc-20240930.xsd#upc_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="YunnanFaxiMember" xlink:href="upc-20240930.xsd#upc_YunnanFaxiMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="YunnanFaxiMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrefundedWarrantsMember" xlink:href="upc-20240930.xsd#upc_PrefundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PrefundedWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonWarrantsMember" xlink:href="upc-20240930.xsd#upc_CommonWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="CommonWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesIssued" xlink:href="upc-20240930.xsd#upc_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="NumberOfSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CapitalUnits" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_OtherReceivables" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompanyDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeNetAssetsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeNetAssetsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DerivativeNetAssetsPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MinorityInterestsOwnershipPercentageByParent" xlink:href="upc-20240930.xsd#upc_MinorityInterestsOwnershipPercentageByParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="MinorityInterestsOwnershipPercentageByParent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/Cover" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/AuditInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AuditorTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="10.0"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Universe Pharmaceuticals INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001809616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">E9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">265 Jingjiu Avenue<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Jinggangshan Economic and
Technological Development Zone<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ji&#8217;an, Jiangxi<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">343100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">UPC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">23,645,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Gang Lai<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">gang.lai@universe-pharmacy.com<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">265 Jingjiu Avenue<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Jinggangshan Economic and
Technological Development Zone<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ji&#8217;an, Jiangxi Province<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">343100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">0796-8403309<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorTable', window );"><strong>Auditor [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Enrome LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">6907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Singapore<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Universe Pharmaceuticals INC and its subsidiaries. (the
&#8220;Company&#8221;) as of September&#160;30, 2024 and 2023, the related consolidated statements of operations and comprehensive
loss, changes in shareholders&#8217; equity and cash flows for the year ended September 30, 2024, 2023 and 2022 and the related
notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial
statements present fairly, in all material respects, the financial position of the Company as of September 30, 2024 and 2023, and
the results of its operations and its cash flows for the year ended September 30, 2024, 2023 and 2022, in conformity with accounting
principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets<br> &#165; in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 29,497,693<span></span>
</td>
<td class="nump">$ 5,285,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,905,821<span></span>
</td>
<td class="nump">11,014,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,737,054<span></span>
</td>
<td class="nump">3,343,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Supplies', window );">Advance to suppliers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">978,203<span></span>
</td>
<td class="nump">180,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentForAcquisitionCurrent', window );">Prepayment for acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,426,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,666,596<span></span>
</td>
<td class="nump">1,920,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">852,417<span></span>
</td>
<td class="nump">37,178<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">51,637,784<span></span>
</td>
<td class="nump">25,269,706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,568,050<span></span>
</td>
<td class="nump">3,699,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentsForConstructionInProgress', window );">Prepayments for construction in progress</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,492,205<span></span>
</td>
<td class="nump">9,092,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">262,878<span></span>
</td>
<td class="nump">148,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">712,494<span></span>
</td>
<td class="nump">685,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">599,078<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">TOTAL NONCURRENT ASSETS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,315,609<span></span>
</td>
<td class="nump">16,454,776<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">67,953,393<span></span>
</td>
<td class="nump">41,724,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term bank loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,856,703<span></span>
</td>
<td class="nump">5,482,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,914,762<span></span>
</td>
<td class="nump">4,585,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,021,181<span></span>
</td>
<td class="nump">434,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,619,739<span></span>
</td>
<td class="nump">2,711,736<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,312,969<span></span>
</td>
<td class="nump">13,754,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLoansFromBank', window );">Long-term bank loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,137,483<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,450,452<span></span>
</td>
<td class="nump">13,754,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS&#8217; EQUITY</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, $11.25 par value, 11,250,000 shares authorized, 42,880 and 6,062 shares issued and outstanding as of September 30, 2024 and 2023, respectively *</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">482,400<span></span>
</td>
<td class="nump">67,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">53,864,720<span></span>
</td>
<td class="nump">29,279,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_StatutoryReserve', window );">Statutory reserve</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,439,535<span></span>
</td>
<td class="nump">2,439,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,171,568)<span></span>
</td>
<td class="num">(1,444,270)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,112,146)<span></span>
</td>
<td class="num">(2,372,240)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,502,941<span></span>
</td>
<td class="nump">27,970,153<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">67,953,393<span></span>
</td>
<td class="nump">41,724,482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">61,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent', window );">Prepayments made to a related party for purchase of property</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,279,982<span></span>
</td>
<td class="nump">2,192,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses-related party, non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">35,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6,900,584<span></span>
</td>
<td class="nump">$ 540,096<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retrospectively restated for effect of 15-for-1 and 40-for-1 share
consolidations.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForAcquisitionCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of prepayment for acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForAcquisitionCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentsForConstructionInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayments for construction in progress.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentsForConstructionInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prepayments made to a related party for purchase of property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_StatutoryReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>StatutoryReserve</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_StatutoryReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansFromBank">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the operating cycle if longer, excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansFromBank</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Supplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Supplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Financial Information of the Parent Company [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="nump">$ 11.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">11,250,000<span></span>
</td>
<td class="nump">11,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">42,880<span></span>
</td>
<td class="nump">6,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">42,880<span></span>
</td>
<td class="nump">6,062<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retrospectively restated for effect of 15-for-1 and 40-for-1 share
consolidations.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 23,024,458<span></span>
</td>
<td class="nump">$ 32,308,735<span></span>
</td>
<td class="nump">$ 40,143,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(16,952,556)<span></span>
</td>
<td class="num">(21,993,601)<span></span>
</td>
<td class="num">(18,251,815)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,071,902<span></span>
</td>
<td class="nump">10,315,134<span></span>
</td>
<td class="nump">21,891,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Selling expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,170,975)<span></span>
</td>
<td class="num">(6,783,703)<span></span>
</td>
<td class="num">(19,083,135)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,889,652)<span></span>
</td>
<td class="num">(2,638,984)<span></span>
</td>
<td class="num">(2,183,270)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,031,115)<span></span>
</td>
<td class="num">(4,858,548)<span></span>
</td>
<td class="num">(7,644,375)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14,091,742)<span></span>
</td>
<td class="num">(14,281,235)<span></span>
</td>
<td class="num">(28,910,780)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,019,840)<span></span>
</td>
<td class="num">(3,966,101)<span></span>
</td>
<td class="num">(7,019,444)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OtherIncomeExpensesAbstract', window );"><strong>Other income (expenses)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(278,172)<span></span>
</td>
<td class="num">(156,788)<span></span>
</td>
<td class="num">(162,400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">145,476<span></span>
</td>
<td class="num">(235,614)<span></span>
</td>
<td class="nump">48,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity investment income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31,942<span></span>
</td>
<td class="nump">31,072<span></span>
</td>
<td class="nump">38,588<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(100,754)<span></span>
</td>
<td class="num">(361,330)<span></span>
</td>
<td class="num">(74,872)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,120,594)<span></span>
</td>
<td class="num">(4,327,431)<span></span>
</td>
<td class="num">(7,094,316)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(606,704)<span></span>
</td>
<td class="num">(2,253,593)<span></span>
</td>
<td class="num">(815,322)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,727,298)<span></span>
</td>
<td class="num">(6,581,024)<span></span>
</td>
<td class="num">(7,909,638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OtherComprehensiveIncomeLossAbstract', window );"><strong>Other comprehensive income (loss)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,260,094<span></span>
</td>
<td class="num">(779,351)<span></span>
</td>
<td class="num">(3,752,143)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (7,467,204)<span></span>
</td>
<td class="num">$ (7,360,375)<span></span>
</td>
<td class="num">$ (11,661,781)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - Basic (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (626.96)<span></span>
</td>
<td class="num">$ (1,089.21)<span></span>
</td>
<td class="num">$ (1,309.11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - Diluted (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (626.96)<span></span>
</td>
<td class="num">$ (1,089.21)<span></span>
</td>
<td class="num">$ (1,309.11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding used in calculating basic loss per share (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">13,920<span></span>
</td>
<td class="nump">6,042<span></span>
</td>
<td class="nump">6,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding used in calculating diluted loss per share (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">13,920<span></span>
</td>
<td class="nump">6,042<span></span>
</td>
<td class="nump">6,042<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retrospectively restated for effect of 15-for-1 and 40-for-1 share
consolidations.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OtherComprehensiveIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OtherComprehensiveIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OtherIncomeExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OtherIncomeExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized in the period that are directly related to the selling and distribution of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Shareholders&#8217; Equity - USD ($)<br></strong></div></th>
<th class="th" colspan="2"><div>Ordinary shares</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Statutory reserve</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th" colspan="2"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 67,973<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 29,279,155<span></span>
</td>
<td class="nump">$ 2,439,535<span></span>
</td>
<td class="nump">$ 13,046,392<span></span>
</td>
<td class="nump">$ 2,159,254<span></span>
</td>
<td class="nump">$ 46,992,309<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,042<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,909,638)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,909,638)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,752,143)<span></span>
</td>
<td class="num">(3,752,143)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 67,973<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">29,279,155<span></span>
</td>
<td class="nump">2,439,535<span></span>
</td>
<td class="nump">5,136,754<span></span>
</td>
<td class="num">(1,592,889)<span></span>
</td>
<td class="nump">35,330,528<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,042<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,581,024)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,581,024)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_StockIssuedDuringPeriodValueStatutoryReserve', window );">Statutory reserve</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(779,351)<span></span>
</td>
<td class="num">(779,351)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 67,973<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">29,279,155<span></span>
</td>
<td class="nump">2,439,535<span></span>
</td>
<td class="num">(1,444,270)<span></span>
</td>
<td class="num">(2,372,240)<span></span>
</td>
<td class="nump">$ 27,970,153<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,042<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,062<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,727,298)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (8,727,298)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares and additional shares under overallotment option in initial public offerings, gross</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 374,996<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">24,624,996<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,999,992<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares and additional shares under overallotment option in initial public offerings, gross (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">33,333<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_StockIssuedDuringPeriodValueReverseShareSplitAdjustment', window );">Reverse share-split adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 39,431<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(39,431)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse share-split adjustment (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,505<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,260,094<span></span>
</td>
<td class="nump">1,260,094<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 482,400<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 53,864,720<span></span>
</td>
<td class="nump">$ 2,439,535<span></span>
</td>
<td class="num">$ (10,171,568)<span></span>
</td>
<td class="num">$ (1,112,146)<span></span>
</td>
<td class="nump">$ 45,502,941<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42,880<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,880<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retrospectively restated for effect of 15-for-1 and 40-for-1 share
consolidations.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retrospectively restated for effect of 15-for-1 and 40-for-1 share
consolidations.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_StockIssuedDuringPeriodValueReverseShareSplitAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the value of reverse share-split adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_StockIssuedDuringPeriodValueReverseShareSplitAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_StockIssuedDuringPeriodValueStatutoryReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of statutory reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_StockIssuedDuringPeriodValueStatutoryReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,727,298)<span></span>
</td>
<td class="num">$ (6,581,024)<span></span>
</td>
<td class="num">$ (7,909,638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">485,734<span></span>
</td>
<td class="nump">508,785<span></span>
</td>
<td class="nump">533,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss from disposal of property, plant and equipment</a></td>
<td class="nump">3,958<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Allowance for doubtful accounts</a></td>
<td class="nump">131,581<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLIFOReservePeriodCharge', window );">Allowance (reversal) of inventory reserve</a></td>
<td class="nump">50,651<span></span>
</td>
<td class="num">(49,166)<span></span>
</td>
<td class="nump">15,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ChangeInFairValueOfShorttermInvestments', window );">Deferred income tax expense (benefit)</a></td>
<td class="nump">606,704<span></span>
</td>
<td class="nump">1,567,656<span></span>
</td>
<td class="num">(542,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,547,834)<span></span>
</td>
<td class="nump">4,718,118<span></span>
</td>
<td class="num">(1,526,243)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory, net</a></td>
<td class="nump">1,643,131<span></span>
</td>
<td class="num">(1,183,823)<span></span>
</td>
<td class="nump">16,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidSupplies', window );">Advance to suppliers, net</a></td>
<td class="num">(769,911)<span></span>
</td>
<td class="num">(170,016)<span></span>
</td>
<td class="nump">2,681,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidAdvertising', window );">Prepayment for advertising</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,385,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Advances to related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">236,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivable</a></td>
<td class="num">(158,011)<span></span>
</td>
<td class="nump">391,568<span></span>
</td>
<td class="num">(1,030,121)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(792,675)<span></span>
</td>
<td class="nump">696,147<span></span>
</td>
<td class="num">(659,017)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(947,964)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent', window );">Prepaid expenses-related party, non-current</a></td>
<td class="nump">36,321<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">143,747<span></span>
</td>
<td class="nump">1,641,426<span></span>
</td>
<td class="num">(1,919,691)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Taxes payable</a></td>
<td class="nump">554,425<span></span>
</td>
<td class="nump">280,939<span></span>
</td>
<td class="num">(904,127)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(1,167,206)<span></span>
</td>
<td class="nump">244,015<span></span>
</td>
<td class="nump">2,318,474<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(9,506,683)<span></span>
</td>
<td class="nump">1,116,775<span></span>
</td>
<td class="num">(1,301,555)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(208,320)<span></span>
</td>
<td class="num">(44,169)<span></span>
</td>
<td class="num">(93,703)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ProceedsFromPaymentForConstructionInProgress', window );">Prepayments for construction in progress</a></td>
<td class="num">(37,478)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible asset</a></td>
<td class="num">(117,291)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Prepayment for acquisition</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,814,925)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from disposal of property, plant and equipment</a></td>
<td class="nump">1,804<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(361,285)<span></span>
</td>
<td class="num">(44,169)<span></span>
</td>
<td class="num">(3,908,105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of ordinary shares</a></td>
<td class="nump">24,999,992<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromBankDebt', window );">Proceeds from bank loans</a></td>
<td class="nump">7,787,016<span></span>
</td>
<td class="nump">5,671,104<span></span>
</td>
<td class="nump">4,272,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Repayment of bank loans</a></td>
<td class="num">(5,552,240)<span></span>
</td>
<td class="num">(3,969,773)<span></span>
</td>
<td class="num">(4,272,716)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Proceeds from (prepayments for) related parties borrowings</a></td>
<td class="nump">6,719,557<span></span>
</td>
<td class="num">(3,091,977)<span></span>
</td>
<td class="nump">3,317,943<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">33,954,325<span></span>
</td>
<td class="num">(1,390,646)<span></span>
</td>
<td class="nump">3,317,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="nump">126,089<span></span>
</td>
<td class="num">(108,171)<span></span>
</td>
<td class="num">(474,733)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash</a></td>
<td class="nump">24,212,446<span></span>
</td>
<td class="num">(426,211)<span></span>
</td>
<td class="num">(2,366,450)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, beginning of year</a></td>
<td class="nump">5,285,247<span></span>
</td>
<td class="nump">5,711,458<span></span>
</td>
<td class="nump">8,077,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, end of year</a></td>
<td class="nump">29,497,693<span></span>
</td>
<td class="nump">5,285,247<span></span>
</td>
<td class="nump">5,711,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">304,516<span></span>
</td>
<td class="nump">190,184<span></span>
</td>
<td class="nump">199,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income tax</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 863,800<span></span>
</td>
<td class="nump">$ 2,748,629<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ChangeInFairValueOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of change in fair value of short-term investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ChangeInFairValueOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of prepaid expenses-related party, non-current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ProceedsFromPaymentForConstructionInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayments for construction in progress.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ProceedsFromPaymentForConstructionInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidAdvertising">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for advertising that provides economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidAdvertising</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for supplies that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReservePeriodCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReservePeriodCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromBankDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from bank borrowing during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromBankDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfBankDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle a bank borrowing during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfBankDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business Description<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Business Description [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">ORGANIZATION AND BUSINESS DESCRIPTION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
1 &#8212; ORGANIZATION AND BUSINESS DESCRIPTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Universe
Pharmaceuticals INC (&#8220;Universe INC&#8221; or the &#8220;Company&#8221;) was incorporated under the laws of the Cayman Islands on
December 11, 2019 as an exempted company with limited liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Universe
INC owns&#160;100% equity interest of Universe Pharmaceuticals (International) Group (&#8220;Universe HK&#8221;), an entity incorporated
on May 21, 2014 in accordance with the laws and regulations in Hong Kong.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Jiangxi
Universe Pharmaceuticals Technology Co., Ltd. (&#8220;Universe Technology&#8221;) was formed on April 8, 2019, as a wholly foreign-owned
enterprise (&#8220;WFOE&#8221;) in the People&#8217;s Republic of China (the &#8220;PRC&#8221; or &#8220;China&#8221;). </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Universe
INC, Universe HK and Universe Technology are currently not engaging in any active business operations and are merely acting as holding
companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Jiangxi
Universe Pharmaceuticals Co., Ltd.&#160;(&#8220;Jiangxi Universe&#8221;) was incorporated on March 2, 1998 in accordance with PRC laws
and is engaged in the research and development and manufacturing of modernized traditional Chinese medicines.&#160;Jiangxi Universe owns&#160;100%
of the equity interests of Jiangxi Universe Pharmaceuticals Commercial Trade Co., Ltd. (&#8220;Universe Trade&#8221;), which was incorporated
on March 10, 2010 for the purposes of handling the sales and distribution of the pharmaceutical products manufactured by Jiangxi Universe.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Reorganization</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">A
reorganization of the Company&#8217;s legal structure (the &#8220;Reorganization&#8221;) was completed on December 11, 2019. The Reorganization
involved the incorporation of Universe INC and Universe Technology, and the transfer of&#160;100% of the equity interests of Jiangxi
Universe to Universe Technology. Consequently, Universe INC, through its subsidiary Universe HK, directly controls Universe Technology
and Jiangxi Universe, and became the ultimate holding company of all other entities mentioned above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Reorganization has been accounted for as a recapitalization among entities under common control, since the same controlling shareholders
controlled all these entities before and after the Reorganization. Results of operations for the periods presented eliminate the effects
of intra-entity transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
March 25, 2021, the Company closed its initial public offering (the &#8220;IPO&#8221;) of&#160;5,000,000&#160;ordinary shares, par value
$0.003125&#160;per share at a public offering price of $5.00&#160;per share. On March 29, 2021, the underwriter exercised in full its
over-allotment option to purchase an additional&#160;750,000&#160;ordinary shares. The closing for the sale of the over-allotment shares
took place on September 30, 2021. Gross proceeds from the IPO totaled $28.75&#160;million. Net proceeds of the IPO, including over-allotment
shares, were approximately $25.6&#160;million. In connection with the IPO, the Company&#8217;s ordinary shares began trading on the Nasdaq
Global Market under the symbol &#8220;UPC&#8221; on March 23, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
May 12, 2021, through the Company&#8217;s PRC subsidiary, Jiangxi Universe, the Company established an indirect wholly controlled subsidiary,
Guangzhou Universe Hanhe Medical Research Co., Ltd. (&#8220;Universe Hanhe&#8221;) in Guangzhou City, China, for the business purpose
of conducting research and development of new pharmaceutical products in order to diversify the Company&#8217;s product offerings. As
of September 30, 2024 and as of the date of this report, Universe Hanhe has no active business operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 3, 2023, the Company held an annual general meeting of shareholders at which shareholders, among other things, resolved:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with immediate effect, to increase the Company&#8217;s authorized share capital from US$312,500 divided into 90,000,000 ordinary shares of par value US$0.003125 each and 10,000,000 preferred shares of par value US$0.003125 each, to US$3,125,000 divided into 900,000,000 ordinary shares of par value US$0.003125 each and 100,000,000 preferred shares of par value US$0.003125 each;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that, conditional upon the approval of the board of directors of the Company in its sole discretion, with effect as of the date the board of directors of the Company may determine, the authorized, issued and outstanding shares of the Company be consolidated by consolidating each 10 shares of the Company, or such lesser whole share amount as the board of directors may determine in its sole discretion, such amount not to be less than 2, into 1 share of the Company, with such consolidated shares having the same rights and being subject to the same restrictions (save as to nominal value) as the then existing shares of par value US$0.003125 each in the capital of the Company (the &#8220;2023 Share Consolidation&#8221;); and</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that, upon the effectiveness
    of the 2023 Share Consolidation, the Company adopt amended and restated articles of association, in substantially the form set out
    in Annex B in the proxy statement dated May 24, 2023, in substitution for and to the exclusion of, the memorandum of association
    of the Company in effect immediately prior to effectiveness of the Share Consolidation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors of the Company resolved to effect the 2023 Share Consolidation on July 27, 2023 with the authorized, issued and outstanding
shares to be consolidated on a six (6) for one (1) ratio, which had the effect of reducing the number of: (a) authorized ordinary shares
from 900,000,000 ordinary shares with a par value of US$0.003125 per share to 150,000,000 ordinary shares with a par value of US$0.01875
per share; (b) issued and outstanding ordinary shares from 21,750,000 ordinary shares with a par value of US$0.003125 per share to 3,625,000
ordinary shares with a par value of US$0.01875 per share; and (c) authorized preferred shares from 100,000,000 preferred shares with
a par value of US$0.003125 per share to 16,666,666.6666 preferred shares with a par value of US$0.01875 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 15, 2024, the Company closed its self-underwritten public offering of 20,000,000 ordinary shares, par value $0.01875 per share.
The ordinary shares were priced at $1.25 per share. The Company raised a total of $25 million through that offering, before deducting
offering-related expenses, and net proceeds of $24.625 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 27, 2024, the Company held an annual general meeting of shareholders at which shareholders, among other things, resolved:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with immediate effect, to increase the Company&#8217;s authorized share capital from US$3,125,000 divided into 150,000,000 ordinary shares of par value US$0.01875 each and 16,666,666.6666 preferred shares of par value US$0.01875 each, to US$140,625,000 divided into 6,750,000,000 ordinary shares of par value US$0.01875 each and 750,000,000 preferred shares of par value US$0.01875 each (the &#8220;Authorized Share Capital Increase&#8221;);</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that, subject to and immediately
    following the Authorized Share Capital Increase being effected, the Company adopt an amended and restated memorandum of association
    in substitution for, and to the exclusion of, the Company&#8217;s existing memorandum of association, to reflect the Authorized Share
    Capital Increase; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that, conditional upon
    the approval of the board of directors of the Company in its sole discretion, with effect as of the date the board of directors of
    the Company may determine, the authorized, issued, and outstanding shares of the Company (collectively, the &#8220;Shares&#8221;)
    be consolidated by consolidating each 15 Shares of the Company, or such lesser whole share amount as the Company&#8217;s board of
    directors may determine in its sole discretion, such amount not to be less than 2, into 1 Share of the Company, with such consolidated
    Shares having the same rights and being subject to the same restrictions (save as to nominal value) as the existing Shares of such
    class as set out in the Company&#8217;s memorandum and articles of association (the &#8220;2024 Share Consolidation&#8221;).</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 12, 2024, the Company effected a share consolidation of 15 ordinary shares with par value of US$0.01875 per share each in the
Company&#8217;s issued and unissued share capital into one (1) ordinary share with par value of US$0.28125. All fractional shares were
rounded up to the whole number of shares. Immediately following the 2024 Share Consolidation, the authorized share capital of the Company
was US$140,625,000 divided into 450,000,000 ordinary shares, par value US$0.28125 per share and 50,000,000 preferred shares, par value
US$0.28125 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 24, 2025, the Company effected a share consolidation
of 40 ordinary shares with par value of US$0.28125 per share each in the Company&#8217;s issued and unissued share capital into one ordinary
share with par value of US$11.25. All fractional shares were rounded up to the whole number of shares (the &#8220;2025 Share Consolidation&#8221;).
Immediately following the Share Consolidation, the authorized share capital of the Company was US$140,625,000 divided into 11,250,000
ordinary shares, par value US$11.25 per share and 1,250,000 preferred shares, par value US$11.25 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company&#8217;s consolidated
financial statements were retrospectively restated for effect of the 15-for-1 and 40-for-1 share consolidations. Giving effect to the
share consolidations, there were 42,880 ordinary shares issued and outstanding as of September 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Details
of the subsidiaries of the Company as of September 30, 2024 are set out below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date of</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Place of</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>% of</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of Entity</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporation</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporation</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal Activities</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe INC</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 11, 2019</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cayman Islands</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent, 100%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe HK</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 21, 2014</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 28%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe Technology</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 18, 2019</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WFOE, Investment holding</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Universe</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2, 1998</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development and manufacturing of modernized traditional Chinese medicines</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe Trade</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 10, 2010</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales of modernized traditional Chinese medicines</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe Hanhe</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 12, 2021</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development of new pharmaceutical products</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company, through its wholly-owned subsidiaries, is primarily engaged in the development, manufacturing and sale of traditional Chinese
medicines derivatives (&#8220;TCMD&#8221;) products targeted to the elderly to address their physical conditions in the aging process
and to promote their general well-being. In addition, the Company also sells biochemical drugs, medical instruments, traditional Chinese
medicine pieces products and dietary supplements (collectively, &#8220;third-party products&#8221;). All of these TCMD and third-party
products are currently sold to customers including pharmaceutical companies, hospitals, clinics and drugstore chains throughout China.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
2 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration:underline">Basis
of Presentation and Principles of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
accompanying consolidated financial statements include the Company and its subsidiaries, which include Universe HK, Universe Technology,
Jiangxi Universe, Universe Trade and Universe Hanhe. All inter-company balances and transactions are eliminated upon consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">A
subsidiary is an entity in which (i) the Company directly or indirectly controls more than 50% of the voting power; or (ii) the Company
has the power to appoint or remove the majority of the members of the board of directors or to cast a majority of votes at the meetings
of the board of directors or to govern the financial and operating policies of the investee pursuant to a statute or under an agreement
among the shareholders or equity holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Reclassifications</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Certain
amounts on the prior-years&#8217; consolidated balance sheets and cash flows were reclassified to conform to current-year presentation,
with no effect on ending shareholders&#8217; equity.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Uses
of estimates</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
preparing the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America
(&#8220;U.S. GAAP&#8221;), management makes estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses
during the reporting period. These estimates are based on information as of the date of the consolidated financial statements. Significant
estimates required to be made by management include, but are not limited to, the allowance for estimated uncollectible receivables, the
realizability of advance to suppliers, inventory valuations, useful lives of property, plant and equipment, intangible assets, the recoverability
of long-lived assets, provision necessary for contingent liabilities, revenue recognition and realization of deferred tax assets. Actual
results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Risks
and Uncertainties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
business operations of the Company are located in the PRC. Accordingly, the Company&#8217;s business, financial condition, and results
of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC
economy. The Company&#8217;s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC.
Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations
including its organization and structure disclosed in Note 1, this may not be indicative of future results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
development and commercialization of new pharmaceutical products is highly competitive, and the industry currently is characterized by
rapidly changing technologies, significant competition and a strong emphasis on intellectual property. The Company may face competition
with respect to its current and future pharmaceutical product candidates from major pharmaceutical companies in China.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company&#8217;s business, financial condition and results of operations may also be negatively impacted by risks related to natural disasters,
extreme weather conditions, health epidemics and other catastrophic incidents, which could significantly disrupt the Company&#8217;s
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Cash</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Cash
includes currency on hand and deposits held by banks that can be added or withdrawn without limitation. The Company maintains most of
its bank accounts in the PRC. Cash maintained in banks within the People&#8217;s Republic of China of less than RMB0.5 million (equivalent
to $71,249) per bank are covered by &#8220;deposit insurance regulation&#8221; promulgated by the State Council of the People&#8217;s
Republic of China.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Accounts
receivable, net</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Accounts receivables are presented
net of allowance for doubtful accounts. The Company determines the adequacy of reserves for doubtful accounts based on individual account
analysis and historical collection trends. The Company establishes a provision for doubtful receivables when there is objective evidence
that the Company may not be able to collect amounts due. The allowance is based on management&#8217;s best estimate of specific losses
on individual exposures, as well as a provision on historical trends of collections. Actual amounts received may differ from management&#8217;s
estimate of credit worthiness and the economic environment. Delinquent account balances are written-off against the allowance for doubtful
accounts after management has determined that collection is not probable. </span>Allowance for uncollectable balances amounted to $135,082
and $<span style="-sec-ix-hidden: hidden-fact-62">Nil</span> as of September 30, 2024 and 2023, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Inventories,
net</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Inventories
are stated at net realizable value using weighted average method. Costs include the cost of raw materials, freight, direct labor and
related production overhead. Any excess of the cost over the net realizable value of each item of inventories is recognized as a provision
for diminution in the value of inventories. Net realizable value is the estimated selling price in the normal course of business less
any costs to complete and sell products. The Company evaluates inventories on a quarterly basis for its net realizable value adjustments,
and reduces the carrying value of those inventories that are obsolete or in excess of the forecasted usage to their estimated net realizable
value based on various factors including aging, expiration dates, as applicable, taking into consideration historical and expected future
product sales. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We recorded inventory reserve of $124,512
and $69,746 as of September 30, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Advances
to suppliers, net</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Advances
to suppliers represent prepayments made to ensure continuous high-quality supplies and favorable purchase prices of raw materials. These
advances are directly related to the purchases of raw materials used to fulfill sales orders. The Company is required from time to time
to make cash advances when placing its purchase orders. These advances are settled upon suppliers delivering raw materials to the Company
when the transfer of ownership occurs. The Company reviews its advances to suppliers on a periodic basis and makes general and specific
allowances when there is doubt as to the ability of a supplier to provide supplies to the Company or refund an advance. As of September
30, 2024 and 2023, the Company recorded no allowance for doubtful accounts, as the Company believed that all advances to suppliers were
fully realizable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Fair
value of financial instruments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The
hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of
inputs used to measure fair value are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 62px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&#8201;&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8201;inputs to the valuation
    methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 62px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2&#8201;&#8212;&#8201;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inputs to the valuation
    methodology include quoted prices for similar assets and liabilities in active markets, quoted market prices for identical or similar
    assets in markets that are not active, inputs other than quoted prices that are observable and inputs derived from or corroborated
    by observable market data.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 62px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3&#8201;&#8212;&#8201;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inputs to the valuation
    methodology are unobservable.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Unless
otherwise disclosed, the fair value of the Company&#8217;s financial instruments, including cash, accounts receivable, inventories, advances
to suppliers, prepaid expenses and other current assets, accounts payable, short-term bank loans, accrued expenses and other current
liabilities, taxes payable and due to related parties, approximate the fair value of the respective assets and liabilities as of September
30, 2024 based upon the short-term nature of the assets and liabilities. The Company&#8217;s investment in equity securities is accounted
for using the measurement alternative in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 321, &#8220;Investments&#8212;Equity
Securities&#8221; (&#8220;ASC 321&#8221;), which also approximates its recorded value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property,
plant and equipment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Property,
plant and equipment are stated at cost less accumulated depreciation. Depreciation of property, plant and equipment is provided using
the straight-line method over their expected useful lives, as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    life</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 89%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Buildings</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20&#160;years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5&#8211;10&#160;years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Automobiles</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#8211;5&#160;years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office and electric equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#8211;5&#160;years</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Expenditures
for maintenance and repairs, which do not materially extend the useful lives of the assets, are charged to expense as incurred. Expenditures
for major renewals and betterments which substantially extend the useful life of assets are capitalized. The cost and related accumulated
depreciation of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized in the consolidated
statements of operations and comprehensive loss in other income or expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company reviews the carrying value of property, plant and equipment for impairment whenever events and circumstances indicate that the
carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition.
In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an
amount by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment
include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand,
competition and other economic factors. Based on this assessment, no impairment expenses for property, plant and equipment were recorded
in operating expenses for the years ended September 30, 2024, 2023 and 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Intangible
Assets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Intangible
assets consist primarily of land use rights, trademark and software. Under the PRC law, all land in the PRC is owned by the government
and cannot be sold to an individual or company. The government grants individuals and companies the right to use parcels of land for
specified periods of time. Land use rights are stated at cost less accumulated amortization. Intangible assets are amortized using the
straight-line method with the following estimated useful lives:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; width: 89%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful life</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Land use rights</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50&#160;years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trademark</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5&#160;years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Software</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;years</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company reviews the carrying value of land use rights for impairment whenever events and circumstances indicate that the carrying value
of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In
cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount
by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include
current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition
and other economic factors.&#160;Based on this assessment, no impairment of land use rights was deemed necessary for the years ended
September 30, 2024, 2023 and 2022.&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Construction-in-Progress
(&#8220;CIP&#8221;)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">CIP
represents property and buildings under construction and consists of construction expenditures, equipment procurement, and other direct
costs attributable to the construction. CIP is not depreciated. Upon completion and ready for intended use, CIP is reclassified to the
appropriate category within property, plant and equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Impairment
of long-lived Assets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Long-lived
assets with finite lives, primarily property, plant and equipment and intangible assets, are reviewed for impairment whenever events
or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the estimated undiscounted cash
flows from the use of the asset and its eventual disposition below are the asset&#8217;s carrying value, then the asset is deemed to
be impaired and written down to its fair value. The Company recorded no impairments of these assets for the years ended September 30,
2024, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Investments
in Equity Securities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company accounts for its equity investments in accordance with ASC 321. In accordance with ASC 321, equity investment which the Company
has no significant influence (generally less than a 20% ownership interest) with readily determinable fair values are accounted for at
fair value based on quoted market prices with the changes in fair value recognized as unrealized gains or losses in earnings. Equity
investments without readily determinable fair values are accounted for either at fair value or using the measurement alternative. Under
the measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting
from observable price changes in orderly transactions for the identical or a similar investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">From
March 2009 to September 2017, the Company invested approximately $0.7&#160;million (RMB5&#160;million) in Jiangxi Jian Rural Commercial
Bank (&#8220;JX RCB Bank&#8221;) in exchange for&#160;5% ownership interest in the bank. The purpose of entering into these equity investment
agreements with JX RCB Bank was to earn investment income as the bank continues to grow. The Company determined that this investment
in equity securities does not have a readily determinable fair value and, accordingly, elected the measurement alternative noted above.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company initially recorded the investments at historical cost and subsequently records any dividends received from the net accumulated
earnings of the investee as income. As of September 30, 2024 and 2023, the Company&#8217;s investment in JX RBC Bank amounted to $712,494&#160;(RMB5&#160;million)
and $685,307 (RMB5&#160;million), respectively, and was reported as long-term investment in equity investee on the consolidated balance
sheets. Investment income amounted to $31,942, $31,072 and $38,588 for the years ended September 30, 2024, 2023 and 2022, respectively.
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
investments in equity securities are evaluated for impairment when facts or circumstances indicate that the fair value of the investments
is less than their carrying value. An impairment is recognized when a decline in fair value is determined to be other-than-temporary.
The Company reviews several factors to determine whether a loss is other-than-temporary. These factors include, but are not limited to,
the: (i) nature of the investment; (ii) cause and duration of the impairment; (iii) extent to which fair value is less than cost; (iv)
financial condition and near-term prospects of the investments; and (v) ability to hold the investment for a period of time sufficient
to allow for any anticipated recovery in fair value. There was no impairment for the Company&#8217;s investments in equity securities
as of September 30, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Revenue
recognition</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">To
determine revenue recognition for contracts with customers, the Company performs the following five steps : (i) identify the contract(s)
with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable
consideration to the extent that it is probable that a significant future reversal will&#160;<i>not</i>&#160;occur, (iv) allocate the
transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies
the performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company recognizes revenue when it transfers its goods and services to customers in an amount that reflects the consideration to which
the Company expects to be entitled in such exchange. The Company accounts for the revenue generated from sales of its TCMD and third-party
products on a gross basis, as the Company is acting as a principal in these transactions, is subject to inventory risk, has latitude
in establishing prices, and is responsible for fulfilling the promise to provide customers the specified goods, which the Company has
control of the goods and has the ability to direct the use of goods to obtain substantially all the benefits. All of the Company&#8217;s
contracts have one single performance obligation, namely, the promise is to transfer the individual goods to customers, and there is
no separately identifiable other promise in the contracts. The Company&#8217;s revenue streams are recognized at a point in time when
title and risk of loss passes and the customer accepts the goods, which generally occurs at delivery. The Company&#8217;s products are
sold with no right of return and the Company does not provide other credits or sales incentive to customers. Revenue is reported net
of all value added taxes (&#8220;VAT&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disaggregation
of Revenues</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company disaggregates its revenue from contracts by product types, as the Company believes it best depicts how the nature, amount, timing
and uncertainty of the revenue and cash flows are affected by economic factors. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Cost
of Revenue</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Cost
of revenue consists primarily of the costs of raw materials, freight charges, direct labor, depreciation of buildings and machinery,
warehousing and overhead associated with the manufacturing process.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Research
and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company expenses all internal research and development costs as incurred, which primarily comprise of employee costs, internal and external
costs related to execution of studies, manufacturing costs, facility costs of the research center, and amortization and depreciation
to intangible assets and property, plant and equipment used in the research and development activities. For the&#160;years ended September
30, 2024, 2023 and 2022, total research and development expenses were approximately $</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,031,115,
<span style="background-color: white">$4,858,548 and $7,644,375, respectively.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Shipping
and handling costs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Shipping
and handling costs are expensed as incurred. Inbound shipping and handling cost associated with bringing the purchased raw materials
and third-party products from suppliers to the Company&#8217;s warehouse are included in cost of revenue. Outbound shipping and handling
costs associated with shipping and delivery the products to customers are included in selling expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Advertising
expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Advertising
expenses primarily relate to promotion of the Company&#8217;s brand name and products through outdoor billboards, social media such as
Weibo and WeChat, and TV advertisement. Advertising costs are expensed as incurred or deferred and then expensed the first time the advertising
takes place. Advertising expenses are included in selling expenses in the consolidated statements of operations and comprehensive loss.
Advertising expenses amounted to $5,144,579, $4,653,633&#160;and $17,527,318 for the&#160;years ended September 30, 2024, 2023 and 2022,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Segment
Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company uses the management approach in determining reportable operating segments. The management approach considers the internal reporting
used by the Company&#8217;s chief operating decision maker for making operating decisions about the allocation of resources of the segment
and the assessment of its performance in determining the Company&#8217;s reportable operating segments. Management has determined that
the Company has one operating segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
taxes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company accounts for current income taxes in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized
when temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the consolidated financial
statements. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years
in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a
change in tax rates is recognized in income in the period including the enactment date. Valuation allowances are established, when necessary,
to reduce deferred tax assets to the amount expected to be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">An
uncertain tax position is recognized only if it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax
examination. The amount recognized is the largest amount of tax benefit that is greater than&#160;50% likely of being realized on examination.
For tax positions not meeting the &#8220;more likely than not&#8221; test, no tax benefit is recorded. Penalties and interest incurred
related to underpayment of income tax are classified as income tax expense in the period incurred. No significant penalties or interest
relating to income taxes have been incurred during the years ended September 30, 2024, 2023 and 2022. The Company does not believe there
was any uncertain tax provision as of September 30, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company&#8217;s operating subsidiaries in China are subject to the income tax laws of the PRC. No significant income was generated outside
the PRC for the years ended September 30, 2024, 2023 and 2022. As of September 30, 2024 and 2023, all of the tax returns of the Company&#8217;s
PRC subsidiaries remained open for statutory examination by PRC tax authorities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Value
added tax (&#8220;VAT&#8221;)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Sales
revenue represents the invoiced value of goods, net of VAT. The VAT is based on gross sales price and VAT rates range up to&#160;13%,
depending on the type of products sold. The VAT may be offset by VAT paid by the Company on raw materials and other materials included
in the cost of producing or acquiring its finished products. The Company recorded a VAT payable or receivable net of payments in the
accompanying consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Earnings
per Share</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company computes earnings per share (&#8220;EPS&#8221;) in accordance with ASC 260, &#8220;Earnings per Share&#8221; (&#8220;ASC 260&#8221;).
ASC 260 requires companies with complex capital structures to present basic and diluted EPS. Basic EPS is measured as net income divided
by the weighted average ordinary shares outstanding for the period. Diluted presents the dilutive effect on a per share basis of potential
ordinary shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented,
or issuance date, if later. Potential ordinary shares that have an anti-dilutive effect (i.e., those that increase income per share or
decrease loss per share) are excluded from the calculation of diluted EPS. For the years ended September 30, 2024, 2023 and 2022, there
were no dilutive shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Foreign
currency translation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
functional currency for Universe INC is the U.S. Dollar (&#8220;US$&#8221;). Universe HK uses Hong Kong dollar as its functional currency.
However, Universe INC and Universe HK currently only serve as holding companies and did not have active operations as of the date of
this report. The Company operates only in the PRC and the Company&#8217;s functional currency is the Chinese Yuan (&#8220;RMB&#8221;).
The Company&#8217;s consolidated financial statements have been translated into the reporting currency US$.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Assets
and liabilities of the Company are translated at the exchange rate at each reporting period end date. Equity is translated at historical
rates. Income and expense accounts are translated at the average rate of exchange during the reporting period. The resulting translation
adjustments are reported under other comprehensive income. Gains and losses resulting from the translations of foreign currency transactions
and balances are reflected in the results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions.
No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table outlines the currency exchange rates that were used in creating the consolidated financial statements in this report:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid">September 30, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid">September 30, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Period-end US$: RMB exchange rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.0176</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.2960</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.1135</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Period-end US$: HK exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.7693</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8308</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8498</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Period average US$: RMB exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.2043</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.0533</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.5532</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Period average US$: HK exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8127</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8310</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8228</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Comprehensive
Income</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Comprehensive
income consists of two components, net income and other comprehensive income. The foreign currency translation gain resulting from translation
of the financial statements expressed in RMB to US$ is reported in other comprehensive income in the consolidated statements of operations
and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Statement
of Cash Flows</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
accordance with ASC 230, &#8220;Statement of Cash Flows&#8221;, cash flows from the Company&#8217;s operations are formulated based upon
the local currencies. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily
agree with changes in the corresponding balances on the balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employee
Defined Contribution Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company&#8217;s subsidiaries in the PRC participate in a government-mandated multi-employer defined contribution plan pursuant to which
pension, work-related injury benefits, maternity insurance, medical insurance, unemployment benefit and housing fund are provided to
eligible full-time employees. The relevant labor regulations require the Company&#8217;s subsidiaries in the PRC to pay the local labor
and social welfare authorities monthly contributions based on the applicable benchmarks and rates stipulated by the local government.
The contributions to the plan are expensed as incurred. Employee social security and welfare benefits included as expenses in the accompanying
consolidated statements of operations and comprehensive loss amounted to $247,249, $440,962&#160;and $465,689&#160;for the years ended
September 30, 2024, 2023 and 2022, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
Issued <span style="background-color: white">Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
considers the applicability and impact of all accounting standards updates (&#8220;ASUs&#8221;). Management periodically reviews new accounting
standards that are issued. Under the Jumpstart Our Business Startups Act of 2012, as amended (the &#8220;JOBS Act&#8221;), the Company
meets the definition of an emerging growth company, or EGC, and has elected the extended transition period for complying with new or revised
accounting standards, which delays the adoption of these accounting standards until they would apply to private companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In November
2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amended guidance
requires incremental reportable segment disclosures, primarily about significant segment expenses. The amendments also require entities
with a single reportable segment to provide all disclosures required by these amendments, and all existing segment disclosures. The amendments
will be applied retrospectively to all prior periods presented in the financial statements and is effective for fiscal years beginning
after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. The guidance should be adopted retrospectively.
The Company is currently in the process of evaluating the impact this amended guidance may have on the footnotes to its consolidated financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In December
2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amended guidance enhances income
tax disclosures primarily related to the effective tax rate reconciliation and income taxes paid information. This guidance requires disclosure
of specific categories in the effective tax rate reconciliation and further information on reconciling items meeting a quantitative threshold.
In addition, the amended guidance requires disaggregating income taxes paid (net of refunds received) by federal, state, and foreign taxes.
It also requires disaggregating individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than
5 percent of total income taxes paid (net of refunds received). The amended guidance is effective for fiscal years beginning after December
15, 2024. The guidance can be applied either prospectively or retrospectively. The Company is currently in the process of evaluating the
impact this amended guidance may have on the footnotes to its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In March
2024, the FASB issued ASU 2024-01, Compensation&#8212;Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar
Awards. The amended guidance added an illustrative example that includes four fact patterns to demonstrate how an entity should apply
the scope guidance in paragraph 718-10-15-3 to determine whether a profits interest award should be accounted for in accordance with Topic
718. The amendments guidance is effective for annual periods beginning after December 15, 2024, and interim periods within those annual
periods. The guidance can be applied either prospectively or retrospectively. The Company is currently in the process of evaluating the
impact this amended guidance may have on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In November
2024, the FASB issued ASU 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses. The amended guidance improves the disclosures about a public business entity&#8217;s
expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory,
employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions (such as cost of sales, SG&amp;A,
and research and development). The amended guidance is effective for annual reporting periods beginning after December 15, 2026, and interim
reporting periods beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective
application. The Company is currently in the process of evaluating the impact this amended guidance may have on the footnotes to its consolidated
financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In November
2024, the FASB issued ASU 2024-04, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible
Debt Instruments. This guidance clarifies the assessment of whether a transaction should be accounted for as an induced conversion or
extinguishment of convertible debt when changes are made to conversion features as part of an offer to settle the instrument. The amended
guidance is effective for all entities for annual reporting periods beginning after December 15, 2025, and interim reporting periods within
those annual reporting periods. The guidance can be applied either prospectively or retrospectively. The Company is currently in the process
of evaluating the impact this amended guidance may have on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In January
2025, the FASB issued ASU 2025-01, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic
220-40): Clarifying the Effective Date. This guidance amends the effective date of Update 2024-03 to clarify that all public business
entities are required to adopt the guidance in annual reporting periods beginning after December 15, 2026, and interim periods within
annual reporting periods beginning after December 15, 2027. Early adoption of Update 2024-03 is permitted. The Company is currently in
the process of evaluating the impact this amended guidance may have on the footnotes to its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Other accounting
standards that have been issued by FASB that do not require adoption until a future date are not expected to have a material impact on
the consolidated financial statements upon adoption. The Company does not discuss recent standards that are not anticipated to have an
impact on or are unrelated to its consolidated financial condition, results of operations, cash flows or disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>Accounts Receivable, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">ACCOUNTS RECEIVABLE, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
3 &#8212; ACCOUNTS RECEIVABLE, NET</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Accounts
receivable consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Accounts receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,040,903</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,014,908</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(135,082</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Accounts receivable, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12,905,821</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,014,908</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company&#8217;s accounts
receivable primarily includes the balance due from customers when the Company&#8217;s pharmaceutical products are sold and delivered to
customers. As of date of this report, approximately 98.4%</span>, or $12.8 <span style="background-color: white">million, of the Company&#8217;s
net account receivable balance as of September 30, 2024 has been subsequently collected, and the remaining balance is expected to be substantially
collected before June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Allowance
for doubtful accounts movement is as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Beginning balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Reversal of allowance for doubtful accounts</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">131,581</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,501</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Ending balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">135,082</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/310-10/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventories, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
4 &#8212; INVENTORIES, NET</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Inventories
consist of the following:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">720,041</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">635,395</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Finished goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,141,526</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,777,617</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Inventories valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(124,512</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(69,746</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total inventories, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">1,737,054</p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,343,266</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories valuation allowance <span style="background-color: white">movement
is as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Beginning balance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">69,746</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">120,286</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Reversal of inventories valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,651</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(49,166</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,115</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,374</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">124,512</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">69,746</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Advance to Suppliers<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_AdvancesToSuppliersAbstract', window );"><strong>Advance to Suppliers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_AdvancesToSuppliersTextBlock', window );">ADVANCE TO SUPPLIERS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
5 &#8212; ADVANCE TO SUPPLIERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Advances
to suppliers consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 76%; text-align: justify">Advances to suppliers for inventories raw material purchase</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">978,203</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">180,643</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Advances to suppliers</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">978,203</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">180,643</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Advances
to suppliers represent prepayments made to suppliers to ensure continuous high-quality supplies and favorable purchase prices of raw
materials. </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AdvancesToSuppliersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AdvancesToSuppliersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AdvancesToSuppliersTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the advances to suppliers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AdvancesToSuppliersTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepayment for Acquisition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAbstract', window );"><strong>Prepayment for Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">PREPAYMENT FOR ACQUISITION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE 6 &#8212; PREPAYMENT FOR ACQUISITION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
September 26, 2022, the Company entered into a letter of intent for an equity transfer with an individual, Mr. Xibo Liu, pursuant to
which, Mr. Xibo Liu transfers his&#160;51% ownership in Yunnan Faxi Pharmaceuticals Co., Ltd. (&#8220;Yunnan Faxi&#8221;) to the Company
at the price of RMB72&#160;million (approximately $10.0&#160;million). Based on contract terms, the Company prepaid RMB25&#160;million
(approximately $3.4&#160;million) within three (3) business days upon signing the letter of intent. As of September 30, 2023, the prepayment
was recorded as prepayment for acquisition on the balance sheets. However, due to unsatisfactory performance of Yunnan Faxi, the equity
transfer contract was terminated on December 20, 2024. The amount of $3,562,472 (RMB25&#160;million) was reclassified to other receivable
as of September 30, 2024, and collected back subsequently. </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrentAbstract', window );"><strong>Other Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">OTHER RECEIVABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>NOTE 7 &#8212; OTHER RECEIVABLE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Other receivable
consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivable from Yunan Faxi <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,562,472</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Redemption of short-term investment <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,377,873</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,367,052</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Prepaid value added tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">475,331</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">478,899</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Prepayment for advertising</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">219,830</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">31,090</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">74,300</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Other receivable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,666,596</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,920,251</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
September 26, 2022, the Company entered into a letter of intent for an equity transfer with an individual, Mr. Xibo Liu, pursuant to
which, Mr. Xibo Liu transfers his&#160;51% ownership in Yunnan Faxi to the Company at the price of RMB72&#160;million (approximately
$10.0&#160;million). Based on contract terms, the Company prepaid RMB25&#160;million (approximately $3.4&#160;million) within three (3)
business days upon signing the letter of intent. However, due to unsatisfactory performance of Yunnan Faxi, the equity transfer contract
was terminated on December 20, 2024. The amount of $3,562,472 (RMB25&#160;million) was recorded as other receivable as of September 30,
2024.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
September 24, 2024, the Company entered into an agreement with a third party to transfer its short-term investment at the price of $</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,377,873.
<span style="background-color: white">The amount was recorded as other receivable as of September 30, 2024 and 2023.</span></span></td>
</tr></table>



<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white">As of date of this report, approximately
</span>99.4%, or $5.6 <span style="background-color: white">million, of the Company&#8217;s other receivable balance as of September 30,
2024 has been subsequently collected.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, PLANT AND EQUIPMENT, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
8 &#8212; PROPERTY, PLANT AND EQUIPMENT, NET</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Property,
plant and equipment, net, consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Useful life</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: justify">Buildings</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">20&#160;years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,594,735</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,304,936</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: center">5-10&#160;years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,007,399</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,896,976</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Automobiles</td><td>&#160;</td>
    <td style="text-align: center">3-5&#160;years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,374</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,703</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Office and electric equipment</td><td>&#160;</td>
    <td style="text-align: center">3-5&#160;years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">527,336</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">474,830</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Construction-in-progress</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,971</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Subtotal</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,232,815</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,750,445</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,664,765</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,050,480</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Property, plant and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,568,050</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,699,965</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Depreciation
expense was $474,034, $503,687&#160;and $528,919&#160;for the years ended September 30, 2024, 2023 and 2022, respectively. Loss from
disposal of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">property, plant and equipment <span style="background-color: white">amounted
to $3,958, $114 and $983 for the years ended September 30, 2024, 2023 and 2022, respectively.</span></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
9 &#8212; INTANGIBLE ASSETS, NET</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Intangible
assets, net consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Useful life</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: justify">Land use rights</td><td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: center">50&#160;years</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">256,211</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">246,434</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Trademark</td><td>&#160;</td> <td style="text-align: center">5&#160;years</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">120,412</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Software</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">3&#160;years</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,506</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,687</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">398,129</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">267,121</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(135,251</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(118,537</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Intangible assets, net</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">262,878</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">148,584</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Amortization
expense was $11,700, $5,098 and $5,030 for the years ended September 30, 2024, 2023 and 2022,&#160;respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Estimated
future amortization expense for intangible assets is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; border-bottom: Black 1.5pt solid; font-weight: bold">Years Ending September 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortization<br/> expense</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,165</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,165</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,165</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,165</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,165</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">177,053</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">262,878</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepayment for CIP Project<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentForConstructionInProgressAbstract', window );"><strong>Prepayment for CIP Project [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentForConstructionInProgressTextBlock', window );">PREPAYMENT FOR CIP PROJECT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
10 &#8212; PREPAYMENT FOR CIP PROJECT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">CIP
represents direct costs of construction incurred for the Company&#8217;s manufacturing facilities. On June 25, 2021, the Company signed
a construction sub-contract with sub-contractor Jiangxi Chenyuan Construction Project Co., Ltd. (&#8220;Chenyuan&#8221;), pursuant to
which, Chenyuan agreed to help the Company construct four manufacturing factory buildings and an office building with a total estimated
budget of RMB165 million (approximately $23.5 million). The construction work started on August 8, 2021, with an originally estimated
completion date on August 7, 2023. However, due to resurgence of the COVID-19 pandemic, which resulted in lingering logistic disruption,
material and labor shortage, and domestic travel restriction, at the beginning of 2024, the Company estimated the construction work to
be completed in December 2024. During 2024, new information was discovered about the topographical and surface structures of the land,
which required Chenyuan to redo the geological survey. As a result, the construction work is further delayed, and the construction of
the four manufacturing factory buildings and the office building is expected to be fully completed and put into use by December 2025
and December 2026, respectively. As of September 30, 2024, the Company had made a prepayment of approximately RMB69.2 million (approximately
$9.9 million) to Chenyuan for land improvement, building foundation and the construction of the manufacturing factories.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During
the year ended September 30, 2022, $407,190 (approximately RMB2.9 million) of the prepayment for the CIP project was used for construction
work, and the amount was recorded as property, plant and equipment in the consolidated balance sheets. As of September 30, 2024, the
remaining $9.5 million prepayment to Chenyuan was recorded as a prepayment for CIP project on the balance sheets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of September 30, 2024, future additional capital expenditure on this CIP project is estimated to be approximately RMB95.8 million (equivalent
to $13.7 million), among which approximately $7.1 million is required for the next 12 months. The Company currently plans to support
its ongoing CIP project construction through cash collected from accounts receivable, and if necessary, borrowings from PRC banks in
the future. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of September 30, 2024, future minimum capital expenditures on the Company&#8217;s CIP project are estimated as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Twelve months ending September 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital<br/> Expenditure<br/> on CIP</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,124,943</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,350,832</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,175,616</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,651,391</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForConstructionInProgressAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForConstructionInProgressAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForConstructionInProgressTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for prepayment for construction in progress.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForConstructionInProgressTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepayment for Purchase of a Property<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentForPurchaseOfAPropertyAbstract', window );"><strong>Prepayment for Purchase of a Property [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentForPurchaseOfAPropertyTextBlock', window );">PREPAYMENT FOR PURCHASE OF A PROPERTY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
11 &#8212; PREPAYMENT FOR PURCHASE OF A PROPERTY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
May 6, 2021, the Company entered into a real estate property purchase agreement with related party Jiangxi Yueshang Investment Co., Ltd.
(&#8220;Jiangxi Yueshang&#8221;), an entity in which the Company&#8217;s chief executive officer, Mr. Gang Lai, owned 5% equity interest
as of the date of that agreement. Pursuant to the property purchase agreement, Jiangxi Yueshang will sell and the Company will purchase
a certain residential apartment and commercial office space totaling 2,749.30 square meters, with a total purchase price of RMB32 million
(approximately $4.6 million). Pursuant to this agreement, the Company was required to make a prepayment in the amount of 50% of the total
purchase price, with 20% of the total purchase price payable upon the availability of a certificate of occupancy, and 30% of the total
purchase price payable upon delivery of the property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of September 30, 2024, the Company had made a prepayment of RMB16 million (approximately $2.3 million) to Jiangxi Yueshang. The remaining
balance is expected to be paid by April 2025. Since the property is located in the urban downtown area of Ji&#8217;an City, the Company
plans to use the property for offices in June 2025.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForPurchaseOfAPropertyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForPurchaseOfAPropertyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForPurchaseOfAPropertyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForPurchaseOfAPropertyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Bank Loans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ShortTermBankLoansAbstract', window );"><strong>Short-Term Bank Loans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">SHORT-TERM BANK LOANS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
12 &#8212; SHORT-TERM BANK LOANS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Short-term
bank loans consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Note</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Short-term bank loans:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;)</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">(1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,849,976</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,467,105</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Bank of Communications Co., Ltd</td><td>&#160;</td>
    <td style="text-align: center">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,154,241</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,233,553</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Zhujiang Rural Bank</td><td>&#160;</td>
    <td style="text-align: center">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">427,497</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">411,184</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Beijing Bank</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">(4)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,424,989</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,370,614</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total short-term loans</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,856,703</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,482,456</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 13, 2023, a subsidiary of the Company, Universe Trade, signed a loan agreement with LRC Bank to borrow RMB8 million (equivalent to $1,096,491) as working capital for one year, with the maturity date on March 12, 2024. The fixed interest rate of the loan was 4.56% per annum. Mr. Gang Lai signed guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 15, 2023, a subsidiary of the Company, Jiangxi Universe, signed a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,370,614) as working capital for eleven months, with the maturity date on May 14, 2024. The fixed interest rate of the loan was 4.56% per annum. Mr. Gang Lai signed guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 4, 2024, a subsidiary of the Company, Universe
Trade, signed a loan agreement with LRC Bank to borrow RMB5 million (equivalent to $712,494) as working capital for one year, with the
maturity date on March 3, 2025. The fixed interest rate of the loan was 4.75% per annum. Mr. Gang Lai and Jiangxi Universe jointly signed
guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 26, 2024, a subsidiary of the Company, Jiangxi
Universe, signed a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,424,989) as working capital for one year, with
the maturity date on April 25, 2025. The fixed interest rate of the loan was 4.31% per annum. Mr. Gang Lai and Universe Technology jointly
signed guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 17, 2024, a subsidiary of the Company, Universe
trade, signed a loan agreement with LRC Bank to borrow RMB5 million (equivalent to $712,494) as working capital for one year, with the
maturity date on May 16, 2025. The fixed interest rate of the loan was 3.65% per annum. Mr. Gang Lai and Jiangxi Universe jointly signed
guarantee agreements with LRC Bank to provide credit guarantee for this loan.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
March 3, 2025, a subsidiary of the Company, Universe Trade, signed a loan agreement with LRC Bank to borrow RMB5 million (equivalent to
$712,494) as working capital for one year, with the maturity date on March 2, 2026. The fixed interest rate of the loan was 3.65% per
annum. Mr. Gang Lai and Jiangxi Universe jointly signed guarantee agreements with LRC Bank to provide credit guarantee for this loan.</span>
&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">On April 22, 2024, a subsidiary of the Company, Jiangxi Universe, signed
a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,424,989) as working capital for one year, with the maturity date
on April 21, 2026. The fixed interest rate of the loan was 3.60% per annum. Mr. Gang Lai and Universe Technology jointly signed guarantee
agreements with LRC Bank to provide credit guarantee for this loan. &#160;</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 15, 2023, the Company&#8217;s subsidiary, Jiangxi Universe, signed a loan agreement with Bank of Communications to borrow RMB9 million (equivalent to $1,246,486) as working capital for eleven months, with the maturity date on May 18, 2024. The fixed interest rate of the loan was 4.0% per annum. Mr. Gang Lai, Universe Trade, and an unrelated third party, Jiangxi Province Financing Guarantee Group Co., Ltd., jointly signed guarantee agreements with Bank of Communications to provide credit guarantee for this loan. The loan was fully repaid upon maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 16, 2024, the Company&#8217;s subsidiary, Jiangxi Universe, signed a loan agreement with Bank of Communications to borrow RMB8.1 million (equivalent to $1,154,241) as working capital for eleven months, with the maturity date on May 13, 2025. The fixed interest rate of the loan was 3.9% per annum. Mr. Gang Lai, Universe Trade, and an unrelated third party, Jiangxi Province Financing Guarantee Group Co., Ltd., jointly signed guarantee agreements with Bank of Communications to provide credit guarantee for this loan.</span></p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 5, 2023, a subsidiary of the Company, Jiangxi Universe, entered into a loan agreement with Zhujiang Rural Bank to borrow RMB 3 million (equivalent to $415,495) as working capital for one year, with the maturity date on May 4, 2024. The fixed interest rate of the loan was 3.65% per annum. The Company pledged certain patents owned by the Company as collateral to guarantee this loan. The loan was fully repaid upon maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 24, 2024, a subsidiary of the Company, Jiangxi
Universe, entered into a loan agreement with Zhujiang Rural Bank to borrow RMB3 million (equivalent to $427,497) as working capital for
one year, with the maturity date on April 24, 2025. The fixed interest rate of the loan was 3.65% per annum. The Company pledged certain
trademarks owned by the Company as collateral to guarantee this loan. The loan was fully repaid upon maturity</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="text-align: justify; margin: 0; font: 10pt Times New Roman, Times, Serif">On April 18, 2025, a subsidiary of the Company, Jiangxi Universe, signed
a loan agreement with Zhujiang Rural Bank to borrow RMB2.9 million (equivalent to $413,247&#160;) as working capital for one year, with
the maturity date on April 18, 2026. The fixed interest rate of the loan was 5.00% per annum. The Company pledged certain trademarks owned
by the Company as collateral to guarantee this loan.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 24, 2023, a subsidiary of the Company, Jiangxi Universe, entered into a loan agreement with Beijing Bank to borrow RMB 10 million (equivalent to $1,384,984) as working capital for one year, with the maturity date on July 18, 2024. The fixed interest rate of the loan was 4.25% per annum. There was no guarantee requirement for this loan. The loan was fully repaid upon maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 3, 2024, a subsidiary of the Company, Jiangxi Universe, entered into a loan agreement with Beijing Bank to borrow RMB 10 million (equivalent to $1,424,989) as working capital for one year, with the maturity date on July 3, 2025. The fixed interest rate of the loan was 4.15% per annum. Mr. Gang Lai provided credit guarantee for this loan.</span></p></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ShortTermBankLoansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ShortTermBankLoansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Bank Loans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Long-Term Bank Loans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">LONG-TERM BANK LOANS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
13 &#8212; LONG-TERM BANK LOANS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Long-term
bank loans consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Note</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Long-term bank loans:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">LRC Bank</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">(1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,137,483</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 23, 2023, a subsidiary of the Company, Jiangxi Universe, signed a loan agreement with LRC Bank to borrow RMB15 million (equivalent to $2,137,483) as working capital for two years, with the maturity date on November 14, 2025. The fixed interest rate of the loan was 3.95% per annum. The Company pledged buildings of Jiangxi Universe as collateral to guarantee this loan.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For
the above-mentioned loans, the Company recorded a total interest expense of $304,516, $190,184 and $199,852 for the years ended September
30, 2024, 2023 and 2022, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
14 &#8212; RELATED PARTY TRANSACTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)
Nature of relationships with related parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship with the Company</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Gang Lai</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and chairman of the Company&#8217;s Board of Directors</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Yajun Hu</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General Manager of Jiangxi Universe</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms. Lin Yang</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer of the Company</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guangzhou Ningjing Investment Co., Ltd (Guangzhou Ningjing)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under common control of Mr. Gang Lai</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>(b)
Due from related parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Mr. Yajun Hu</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">61,678</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total due from related parties</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">61,678</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023, the balance due from related parties consisted of advanced funds to the Company&#8217;s director and general manager,
Mr. Yajun Hu. These advances were non-interest bearing and fully repaid on October 12, 2023.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>(c)
Due to related parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Mr. Gang Lai</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,900,499</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">540,096</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Ms. Lin Yang</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">85</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total due to related parties</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,900,584</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">540,096</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of September 30, 2024, the balance due to related parties mainly consisted of advances from Mr. Gang Lai, the Company&#8217;s chief executive
officer and the chairman of the board of directors for working capital purposes during the Company&#8217;s normal course of business,
as well as payment of expenses made by Ms. Lin Yang on behalf of the Company. These advances are unsecured, non-interest bearing and
due on demand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>(d)
Loan guarantee provided by related parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In connection with the Company&#8217;s
bank borrowings from commercial banks in China, Mr. Gang Lai, the Company&#8217;s chairman of the board of directors and chief executive
officer, signed guarantee agreements with these banks to provide credit guarantee for the Company&#8217;s certain loans (see Note 13 and
14).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>(e)
Prepayment to related party for property purchase</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
disclosed in Note 12, on May 6, 2021, the Company entered into a real estate property purchase agreement with a related party, Jiangxi
Yueshang, to purchase certain residential apartment and commercial office space totaling 2,749.30 square meters with total purchase price
of RMB32 million (approximately $4.6 million).&#160;As of September 30, 2024, the Company had made a prepayment of RMB16&#160;million
($2.3 million) to Jiangxi Yueshang. The remaining balance is expected to be paid by April 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
January 13, 2022, Mr. Gang Lai transferred the&#160;5% equity interest he owned in Jiangxi Yueshang to a third party. As such, after
this date, Jiangxi Yueshang is no longer the Company&#8217;s related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>(f)
Prepaid expenses-related party, non-current</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of September 30, 2024 and 2023, the Company prepaid Guangzhou Ningjing <span style="-sec-ix-hidden: hidden-fact-74">nil</span> and $35,864 for right to use trademarks, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
15 &#8212; TAXES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>(a)
Corporate Income Taxes (&#8220;CIT&#8221;)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration:underline">Cayman
Islands</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Under
the current tax laws of the Cayman Islands, Universe INC is not subject to tax on its income or capital gains. In addition, no Cayman
Islands withholding tax will be imposed upon the payment of dividends by the Company to its shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration:underline">Hong
Kong</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Universe
HK is incorporated in Hong Kong and is subject to profit taxes in Hong Kong at a rate of 16.5%. However, Universe HK did not generate
any assessable profits derived from Hong Kong sources for the years ended September 30, 2024, 2023 and 2022, and accordingly no provision
for Hong Kong profits tax has been made in these periods.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration:underline">PRC</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Under
the Enterprise Income Tax (&#8220;EIT&#8221;) Law of PRC, domestic enterprises and Foreign Investment Enterprises (&#8220;FIEs&#8221;)
are usually subject to a unified 25% enterprise income tax rate while preferential tax rates, tax holidays and even tax exemption may
be granted on a case-by-case basis. EIT grants preferential tax treatment to High and New Technology Enterprises (&#8220;HNTEs&#8221;).
Under this preferential tax treatment, HNTEs are entitled to an income tax rate of 15%, subject to a requirement that they re-apply for
their HNTE status every three years. Jiangxi Universe, one of the Company&#8217;s main operating subsidiaries in the PRC, was approved
as a HNTE and is entitled to a reduced income tax rate of 15% beginning November 2016 with a term of three years. In December 2019 and
November 2022, Jiangxi Universe successfully renewed its HNTE certification with local government and will continue to enjoy the reduced
income tax rate of 15% for three years, respectively, through November 2025. Universe Trade, another operating subsidiary of the Company
in the PRC, was approved as a HNTE and was entitled to a reduced income tax rate of 15% beginning December 2020 with a term of three
years through December 2023. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe Trade did not
successfully renew its HNTE status at the end of December 2023 and, therefore, has been subject to the standard PRC enterprise income
tax rate of 25% starting from January 2024. <span style="background-color: white">EIT is typically governed by the local tax authority
in the PRC. Each local tax authority at times may grant tax holidays to local enterprises as a way to encourage entrepreneurship and
stimulate local economy. The corporate income taxes for the years ended September 30, 2024, 2023 and 2022 were reported at a blended
reduced rate as a result of certain of the PRC subsidiaries of the Company&#8217;s being approved as a HNTE and enjoying a 15% reduced
income tax rate. Although Jiangxi Universe was approved as a HNTE and enjoying a 15% reduced income tax rate, it incurred operating loss
for the year ended September 30, 2024, with no impact of the tax holidays on PRC corporate income taxes for the year ended September
30, 2024. The impact of the tax holidays noted above decreased PRC corporate income taxes by $309,840 and $694,955 for the years ended
September 30, 2023 and 2022, respectively. The benefit of the tax holidays on net income per share (basic and diluted) was $0.09 and
$0.19 for the years ended September 30, 2023 and 2022, respectively.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
components of the income tax </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expense <span style="background-color: white">(benefit)
are as follows:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current tax expense:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cayman</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Hong Kong</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 1.5pt">PRC</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">685,937</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,357,697</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Sub-total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">685,937</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,357,697</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax expense (benefit):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cayman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Hong Kong</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">PRC</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">606,704</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,567,656</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(542,375</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Sub-total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">606,704</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,567,656</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(542,375</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total income tax expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">606,704</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,253,593</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">815,322</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table reconciles the China statutory rates to the Company&#8217;s effective tax rate for the years ended September 30, 2024,
2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Statutory PRC income tax rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of income tax holiday</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5.9</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8.2</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9.2</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent difference</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.1</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(25.1</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-PRC entities not subject to PRC income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.7</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4.4</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.2</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23.9</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(64.4</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Effective tax rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(7.5</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(52.1</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(11.5</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative
rulings. As of September 30, 2024, all of the Company&#8217;s tax returns of its PRC subsidiaries remain open for statutory examination
by PRC tax authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Deferred
tax assets are composed of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Net operating loss carry-forwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">599,078</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">599,078</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total deferred tax assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">599,078</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company periodically evaluates the likelihood of the realization of deferred tax assets, and reduces the carrying amount of the deferred
tax assets by a valuation allowance to the extent it believes a portion will not be realized. Management considers new evidence, both
positive and negative, that could affect the Company&#8217;s future realization of deferred tax assets including its recent cumulative
earnings experience, expectation of future income, the carry forward periods available for tax reporting purposes and other relevant
factors. Jiangxi Universe and Universe Trade incurred net loss during the years ended September 30, 2024 and 2023, the Company determined
that its deferred tax assets might not be realized, and recognized valuation allowance for all deferred tax assets as of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September&#160;30,
2024<span style="background-color: white">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>(b)
Taxes payable</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Taxes
payable consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Value added tax payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">873,750</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">303,713</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other taxes payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">147,431</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">131,045</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total taxes payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,021,181</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">434,758</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Concentrations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">CONCENTRATIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
16 &#8212; CONCENTRATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">A
majority of the Company&#8217;s revenue and expense transactions are denominated in RMB and a significant portion of the Company&#8217;s
and its subsidiaries&#8217; assets and liabilities are denominated in RMB. RMB is not freely convertible into foreign currencies. In
the PRC, certain foreign exchange transactions are required by law to be transacted only by authorized financial institutions at exchange
rates set by the People&#8217;s Bank of China (&#8220;PBOC&#8221;). Remittances in currencies other than RMB by the Company in China
must be processed through the PBOC or other China foreign exchange regulatory bodies which require certain supporting documentation in
order to affect the remittance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of September 30, 2024 and 2023, $4,430,607&#160;and $5,223,573&#160;of the Company&#8217;s cash, respectively, was on deposit at financial
institutions in the PRC. For the years ended September 30, 2024, 2023 and 2022, the Company&#8217;s substantial assets were located in
the PRC and the Company&#8217;s substantial revenues were derived from its subsidiaries located in the PRC.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For
the years ended September 30, 2024, 2023 and 2022, no single customer accounted for more than 10% of the Company&#8217;s total revenue.
The Company&#8217;s top 10 customers aggregately accounted for 22.5%, 27.2% and 32.2% of the Company&#8217;s total revenue for the years
ended September 30, 2024, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Sales
of one of the Company&#8217;s major products, Guben Yanling Pill, accounted for&#160;37.2%, 36.4% and 42.5% of the Company&#8217;s total
revenue for the years ended September 30, 2024, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of September 30, 2024 and 2023, no customer accounted for more than&#160;10% of the total accounts receivable balance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For
the year ended September 30, 2024, two suppliers accounted for 28.0% and 13.4% of the total purchases, respectively. For the years ended
September 30, 2023 and 2022, one supplier accounted for 29.6% and 10.3% of the total purchases, respectively. </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Shareholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
17 &#8212; SHAREHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Ordinary
Shares</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Universe
INC was incorporated under the laws of the Cayman Islands on December 11, 2019. The original authorized number of ordinary shares upon
incorporation was&#160;50,000&#160;shares with par value of US$1.00&#160;per share and&#160;50,000&#160;shares were issued. On August
7, 2020, the Company amended its Memorandum of Association to increase the authorized number of shares to&#160;100,000,000&#160;shares
with par value of $0.003125&#160;per share, and subdivide the original issued shares from&#160;50,000&#160;shares at par value of $1.00&#160;per
share to&#160;16,000,000&#160;ordinary shares with par value of $0.003125&#160;per share.&#160;As a result of this forward split of the
outstanding ordinary shares at a ratio of 320-for-1 share, a total of 16,000,000 shares were issued and outstanding after the split.&#160;The
issuance of these&#160;16,000,000&#160;shares is considered as a part of the Reorganization of the Company, which was retroactively applied
as if the transaction occurred at the beginning of the period presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Increased
authorized share capital and share consolidation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 3, 2023, the Company held an annual general meeting of shareholders at which shareholders, among other things, resolved:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with immediate effect, to increase the Company&#8217;s authorized share capital from US$312,500 divided into 90,000,000 ordinary shares of par value US$0.003125 each and 10,000,000 preferred shares of par value US$0.003125 each, to US$3,125,000 divided into 900,000,000 ordinary shares of par value US$0.003125 each and 100,000,000 preferred shares of par value US$0.003125 each;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that, conditional upon the approval of the board of directors of the Company in its sole discretion, with effect as of the date the board of directors of the Company may determine, the authorized, issued and outstanding shares of the Company be consolidated by consolidating each 10 shares of the Company, or such lesser whole share amount as the board of directors may determine in its sole discretion, such amount not to be less than 2, into 1 share of the Company, with such consolidated shares having the same rights and being subject to the same restrictions (save as to nominal value) as the then existing shares of par value US$0.003125 each in the capital of the Company; and</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that, upon the effectiveness
    of the 2023 Share Consolidation, the Company adopt amended and restated articles of association, in substantially the form set out
    in Annex B in the proxy statement dated May 24, 2023, in substitution for and to the exclusion of, the memorandum of association
    of the Company in effect immediately prior to effectiveness of the 2023 Share Consolidation.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
board of directors of the Company resolved to effect the 2023 Share Consolidation on July 27, 2023 with the authorized, issued and outstanding
shares to be consolidated on a six (6) for one (1) ratio, which had the effect of reducing the number of: (a) authorized ordinary shares
from 900,000,000 ordinary shares with a par value of US$0.003125 per share to 150,000,000 ordinary shares with a par value of US$0.01875
per share; (b) issued and outstanding ordinary shares from 21,750,000 ordinary shares with a par value of US$0.003125 per share to 3,625,000
ordinary shares with a par value of US$0.01875 per share; and (c) authorized preferred shares from 100,000,000 preferred shares with
a par value of US$0.003125 per share to 16,666,666.6666 preferred shares with a par value of US$0.01875 per share. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 15, 2024, the Company closed its self-underwritten public offering of 20,000,000 ordinary shares, par value $0.01875 per share.
The ordinary shares were priced at $1.25 per share. The Company raised a total of $25 million through that offering, before deducting
offering-related expenses, and net proceeds of $24.625 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 27, 2024, the Company held an annual general meeting of shareholders at which shareholders, among other things, resolved:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with immediate effect, to increase the Company&#8217;s authorized share capital from US$3,125,000 divided into 150,000,000 ordinary shares of par value US$0.01875 each and 16,666,666.6666 preferred shares of par value US$0.01875 each, to US$140,625,000 divided into 6,750,000,000 ordinary shares of par value US$0.01875 each and 750,000,000 preferred shares of par value US$0.01875 each;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that, subject to and immediately
    following the Authorized Share Capital Increase being effected, the Company adopt an amended and restated memorandum of association
    in substitution for, and to the exclusion of, the Company&#8217;s existing memorandum of association, to reflect the Authorized Share
    Capital Increase; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that, conditional upon
    the approval of the board of directors of the Company in its sole discretion, with effect as of the date the board of directors of
    the Company may determine, the authorized, issued, and outstanding shares of the Company be consolidated by consolidating each 15
    Shares of the Company, or such lesser whole share amount as the board of directors of the Company may determine in its sole discretion,
    such amount not to be less than 2, into 1 Share of the Company, with such consolidated Shares having the same rights and being subject
    to the same restrictions (save as to nominal value) as the existing Shares of such class as set out in the Company&#8217;s memorandum
    and articles of association.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 12, 2024, the Company effected a
share consolidation of 15 ordinary shares with par value of US$0.01875 per share each in the Company&#8217;s issued and unissued share
capital into one (1) ordinary share with par value of US$0.28125. All fractional shares were rounded up to the whole number of shares.
Immediately following the Share Consolidation, the authorized share capital of the Company was US$140,625,000 divided into 450,000,000
ordinary shares, par value US$0.28125 per share and 50,000,000 preferred shares, par value US$0.28125 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 24, 2025, the Company effected a share consolidation
of 40 ordinary shares with par value of US$0.28125 per share each in the Company&#8217;s issued and unissued share capital into one ordinary
share with par value of US$11.25. All fractional shares were rounded up to the whole number of shares. Immediately following the Share
Consolidation, the authorized share capital of the Company was US$140,625,000 divided into 11,250,000 ordinary shares, par value US$11.25
per share and 1,250,000 preferred shares, par value US$11.25 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company&#8217;s
consolidated financial statements were retrospectively restated for effect of the 15-for-1 and 40-for-1 Shares Consolidations (see Note
1). Giving effect to the Share Consolidation, there were 42,880 ordinary shares issued and outstanding as of September 30, 2024.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">As of September
30, 2024 and 2023, the Company had a total of&#160;42,880 and 6,062&#160;ordinary shares issued and outstanding, respectively.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Underwriter
warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
connection with the Company&#8217;s IPO, the Company also agreed to issue warrants to the underwriter, for a nominal consideration of
$0.001&#160;per warrant, to purchase&#160;300,000&#160;ordinary shares of the Company (equal to&#160;6% of the total number of ordinary
shares sold in the IPO, not including any ordinary shares sold in the over-allotment option) (the &#8220;Underwriter Warrants&#8221;).
The Underwriter Warrants have a term of five years, each warrant is exercisable for 1/90 share, with an exercise price of $495 after
adjustments due to share consolidations. The Underwriter Warrants may be purchased in cash or via cashless exercise, are exercisable
for five (5) years, and will terminate on the fifth anniversary of the closing of the IPO. Management determined that the Underwriter
Warrants meet the requirements for equity classification under ASC 815-40 because they are indexed to its own stock. As of September
30, 2024, the Underwriter Warrants were issued and outstanding, but none of them had been exercised. For the years ended September 30,
2024, 2023 and 2022, the Underwriter Warrants were antidilutive and accordingly were not included in the diluted EPS calculation based
on treasury stock method.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Statutory
reserve and restricted net assets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company&#8217;s PRC subsidiaries are restricted in their ability to transfer a portion of their net assets to the Company. The payment
of dividends by entities organized in China is subject to limitations, procedures and formalities. Regulations in the PRC currently permit
payment of dividends only out of accumulated profits as determined in accordance with accounting standards and regulations in China.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company is required to make appropriations to certain reserve funds, comprising the statutory surplus reserve and the discretionary surplus
reserve, based on after-tax net income determined in accordance with generally accepted accounting principles of the PRC (&#8220;PRC
GAAP&#8221;). Appropriations to the statutory surplus reserve are required to be at least&#160;10% of the after-tax net income determined
in accordance with PRC GAAP until the reserve is equal to&#160;50% of the entity&#8217;s registered capital. Appropriations to the discretionary
surplus reserve are made at the discretion of the board of directors. The statutory reserve may be applied against prior year losses,
if any, and may be used for general business expansion and production or increase in registered capital, but are not distributable as
cash dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Relevant
PRC laws and regulations restrict the Company&#8217;s PRC subsidiaries from transferring a portion of their net assets, equivalent to
their statutory reserves and their share capital, to the Company in the form of loans, advances or cash dividends. Only PRC entities&#8217;
accumulated profits may be distributed as dividends to the Company without the consent of a third party. As of September 30, 2024 and
2023, the restricted amounts as determined pursuant to PRC statutory laws totaled $2,439,535, and total restricted net assets amounted
to $56,786,656 and $31,786,663, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
18 &#8212; COMMITMENTS AND CONTINGENCIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">From
time to time, the Company may become a party to various legal actions arising in the ordinary course of business. The Company accrues
costs associated with these matters when they become probable and the amount can be reasonably estimated. Legal costs incurred in connection
with loss contingencies are expensed as incurred. For the years ended September 30, 2024, 2023 and 2022, the Company did not have any
material legal claims or litigation that, individually or in aggregate, could have a material adverse impact on the Company&#8217;s consolidated
financial position, results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company has an ongoing CIP project associated with the construction of a new manufacturing facility. As of September 30, 2024, future
minimum capital expenditures on the Company&#8217;s CIP project amounted to approximately $13.7&#160;million, among which, approximately
$7.1&#160;million is required for the next 12 months from the date of this report (see Note 11).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
May 6, 2021, the Company entered into a real estate property purchase agreement with Jiangxi Yueshang, an entity in which the Company&#8217;s
chief executive officer, Mr. Gang Lai, owned 5% of its equity interests as of the date of that agreement. Pursuant to this purchase agreement,
Jiangxi Yueshang will sell and the Company will purchase certain residential apartments and commercial office space totaling 2,749.30
square meters, with a total purchase price of RMB32 million (approximately $4.6 million). As of September 30, 2024, the Company had made
a prepayment of RMB16 million (approximately $2.3 million) to Jiangxi Yueshang. The remaining balance is expected to be paid by April
2025 (see Note 12).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
19 &#8212; SUBSEQUENT EVENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 12, 2024, the Company effected a share consolidation of 15 ordinary shares with par value of US$0.01875 per share each in the
Company&#8217;s issued and unissued share capital into one (1) ordinary share with par value of US$0.28125. All fractional shares were
rounded up to the whole number of shares. Immediately following the Share Consolidation, the authorized share capital of the Company
was US$140,625,000 divided into 450,000,000 ordinary shares, par value US$0.28125 per share and 50,000,000 preferred shares, par value
US$0.28125 per share. The Company&#8217;s consolidated financial statements were retrospectively restated for effect of the 15-for-1
share consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 6, 2024, the Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with
certain purchasers named thereto, pursuant to which the Company agreed to issue and sell (i) 388,000 ordinary shares (the
&#8220;Offered Shares&#8221;), par value $0.28125 per share (the &#8220;ordinary shares&#8221;), (ii) 18,362,000 pre-funded warrants
to purchase 18,362,000 ordinary shares (the &#8220;Pre-funded Warrants&#8221;), and (iii) 18,750,000 common warrants to purchase
18,750,000 ordinary shares (the &#8220;Common Warrants&#8221;), at a combined purchase price of US0.80 per Offered Share and one
accompanying Common Warrant, or at a combined purchase price of US$0.79 per Pre-funded Warrant (in lieu of one Offered Share) and
one accompanying Common Warrant, in a registered direct offering (the &#8220;Offering&#8221;). The Company received approximately
$15.0 million in gross proceeds from the Offering, before deducting placement agent fees and estimated offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
December 20, 2024, the equity transfer contract to transfer 51% ownership in Yunnan Faxi was terminated due to unsatisfactory performance
of Yunnan Faxi. The prepayment for acquisition of $3,562,472 (RMB25&#160;million) was reclassified to other receivable as of September
30, 2024, and collected back subsequently. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On March 24, 2025, the Company
effected a share consolidation of 40 ordinary shares with par value of US$0.28125 per share each in the Company&#8217;s issued and unissued
share capital into one ordinary share with par value of US$11.25. All fractional shares were rounded up to the whole number of shares.
Immediately following the Share Consolidation, the authorized share capital of the Company was US$140,625,000 divided into 11,250,000
ordinary shares, par value US$11.25 per share and 1,250,000 preferred shares, par value US$11.25 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has assessed all subsequent events through the date that these consolidated financial statements are issued and there are no
further material subsequent events that require disclosure in these consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Information of the Parent Company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Financial Information of the Parent Company [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock', window );">FINANCIAL INFORMATION OF THE PARENT COMPANY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
20 &#8212;FINANCIAL INFORMATION OF THE PARENT COMPANY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Pursuant
to the requirements of Rule 12-04(a), 5-04(c) and 4-08(e)(3) of Regulation S-X, the financial information of the parent company shall
be filed when the restricted net assets of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the
most recently completed fiscal year. The Company performed a test on the restricted net assets of consolidated subsidiaries in accordance
with such requirement and concluded that it was applicable to the Company as the restricted net assets of the Company&#8217;s subsidiaries
exceeded&#160;25% of the consolidated net assets of the Company. Therefore, the financial statements for the parent company are included
herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For
purposes of the above test, restricted net assets of consolidated subsidiaries shall mean that amount of the Company&#8217;s proportionate
share of net assets of consolidated subsidiaries (after intercompany eliminations) which as of the end of the most recent fiscal year
may not be transferred to the parent company by subsidiaries in the form of loans, advances or cash dividends without the consent of
a third party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
financial information of the parent company has been prepared using the same accounting policies as set out in the Company&#8217;s consolidated
financial statements except that the parent company used the equity method to account for investment in its subsidiaries. Such investment
is presented on the balance sheets as &#8220;Investment in subsidiaries&#8221; and the respective profit or loss as &#8220;Equity in
earnings of subsidiaries&#8221; on the consolidated statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
footnote disclosures contain supplemental information relating to the operations of the Company and, as such, these statements should
be read in conjunction with the notes to the consolidated financial statements of the Company. Certain information and footnote disclosures
normally included in financial statements prepared in accordance with U.S GAAP have been or omitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of September 30, 2024 and 2023, there were no material contingencies, significant provisions for long-term obligations, or guarantees
of the Company, except for those which have been separately disclosed in the consolidated financial statements, if any.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PARENT
COMPANY BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 9pt">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,058,414</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,248</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Other receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,377,873</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,367,052</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Due from subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,863,833</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,878,344</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">37,300,120</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,254,644</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; text-indent: -9pt; padding-left: 9pt">Non-current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Investment in subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,749,310</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,715,509</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">46,049,430</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">27,970,153</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Due to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">497,014</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Accrued expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">49,475</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">TOTAL CURRENT LIABILITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">546,489</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">COMMITMENTS AND CONTINGENCIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Ordinary shares, $11.25 par value, 11,250,000 shares authorized, 42,880 and 6,062 shares issued and outstanding as of September 30, 2024 and 2023, respectively *</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">482,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,973</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,864,720</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,279,155</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">(Accumulated deficit) Retained earnings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,732,033</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">995,265</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Accumulated other comprehensive loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,112,146</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,372,240</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total shareholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45,502,941</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,970,153</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 27pt">Total liabilities and shareholders&#8217; equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">46,049,430</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">27,970,153</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retrospectively restated for effect of 15-for-1 and 40-for-1 shares
consolidations.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PARENT
COMPANY STATEMENTS OF <span style="background-color: white">OPERATIONS AND COMPREHENSIVE LOSS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Operating costs and expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">General and administrative expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(592,021</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(134,141</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(384,214</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expenses):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(87,292</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(730</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(420</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity in earnings of subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,047,985</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,446,153</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,525,004</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,727,298</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,581,024</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,909,638</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,260,094</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(779,351</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,752,143</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Comprehensive loss attributable to the Company</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(7,467,204</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(7,360,375</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(11,661,781</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PARENT
COMPANY STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(8,727,298</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(6,581,024</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(7,909,638</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Adjustments to reconcile net cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 11.3pt; padding-left: 10pt">Equity in earnings of subsidiary</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,047,985</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,446,153</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,525,004</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Due to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">497,014</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Accrued expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">49,475</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 3.3pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(132,824</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(134,871</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(384,634</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net proceeds from issuance of ordinary shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,999,992</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash repayment from subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,511</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">115,133</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">303,746</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,014,503</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">115,133</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">303,746</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 1.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">EFFECT OF CHANGES OF FOREIGN EXCHANGE RATES ON CASH</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">167,487</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">69</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(588</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CHANGES IN CASH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,049,166</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,669</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(81,476</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">CASH, beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,248</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28,917</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">110,393</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">CASH, end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25,058,414</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,248</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">28,917</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (8,727,298)<span></span>
</td>
<td class="num">$ (6,581,024)<span></span>
</td>
<td class="num">$ (7,909,638)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have established cybersecurity risk management
to identify, assess, and mitigate cybersecurity risks alongside other business risks. The process is in alignment with our strategic objectives
and risk appetite. We may engage assessors, consultants, auditors, or other third parties to enhance our cyber security risk management
processes. Any cybersecurity incidents are closely monitored for their potential impact on our business strategy, operations, and financial
condition. As of the date of this annual report, we have not experienced any cybersecurity incidents that have materially affected or
are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition. We continuously
adapt our business strategy to enhance resilience, strengthen defenses and ensure the sustainability of our operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have established cybersecurity risk management
to identify, assess, and mitigate cybersecurity risks alongside other business risks. The process is in alignment with our strategic objectives
and risk appetite. We may engage assessors, consultants, auditors, or other third parties to enhance our cyber security risk management
processes. Any cybersecurity incidents are closely monitored for their potential impact on our business strategy, operations, and financial
condition. As of the date of this annual report, we have not experienced any cybersecurity incidents that have materially affected or
are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition. We continuously
adapt our business strategy to enhance resilience, strengthen defenses and ensure the sustainability of our operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Any cybersecurity incidents are closely monitored for their potential impact on our business strategy, operations, and financial
condition.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text">As of the date of this annual report, we have not experienced any cybersecurity incidents that have materially affected or
are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration:underline">Basis
of Presentation and Principles of Consolidation</span></i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
accompanying consolidated financial statements include the Company and its subsidiaries, which include Universe HK, Universe Technology,
Jiangxi Universe, Universe Trade and Universe Hanhe. All inter-company balances and transactions are eliminated upon consolidation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">A
subsidiary is an entity in which (i) the Company directly or indirectly controls more than 50% of the voting power; or (ii) the Company
has the power to appoint or remove the majority of the members of the board of directors or to cast a majority of votes at the meetings
of the board of directors or to govern the financial and operating policies of the investee pursuant to a statute or under an agreement
among the shareholders or equity holders.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ReclassificationsPolicyTextBlock', window );">Reclassifications</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Reclassifications</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Certain
amounts on the prior-years&#8217; consolidated balance sheets and cash flows were reclassified to conform to current-year presentation,
with no effect on ending shareholders&#8217; equity.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Uses of estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Uses
of estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
preparing the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America
(&#8220;U.S. GAAP&#8221;), management makes estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses
during the reporting period. These estimates are based on information as of the date of the consolidated financial statements. Significant
estimates required to be made by management include, but are not limited to, the allowance for estimated uncollectible receivables, the
realizability of advance to suppliers, inventory valuations, useful lives of property, plant and equipment, intangible assets, the recoverability
of long-lived assets, provision necessary for contingent liabilities, revenue recognition and realization of deferred tax assets. Actual
results could differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Risks
and Uncertainties</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
business operations of the Company are located in the PRC. Accordingly, the Company&#8217;s business, financial condition, and results
of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC
economy. The Company&#8217;s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC.
Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations
including its organization and structure disclosed in Note 1, this may not be indicative of future results.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
development and commercialization of new pharmaceutical products is highly competitive, and the industry currently is characterized by
rapidly changing technologies, significant competition and a strong emphasis on intellectual property. The Company may face competition
with respect to its current and future pharmaceutical product candidates from major pharmaceutical companies in China.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company&#8217;s business, financial condition and results of operations may also be negatively impacted by risks related to natural disasters,
extreme weather conditions, health epidemics and other catastrophic incidents, which could significantly disrupt the Company&#8217;s
operations.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Cash</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Cash
includes currency on hand and deposits held by banks that can be added or withdrawn without limitation. The Company maintains most of
its bank accounts in the PRC. Cash maintained in banks within the People&#8217;s Republic of China of less than RMB0.5 million (equivalent
to $71,249) per bank are covered by &#8220;deposit insurance regulation&#8221; promulgated by the State Council of the People&#8217;s
Republic of China.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts receivable, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Accounts
receivable, net</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Accounts receivables are presented
net of allowance for doubtful accounts. The Company determines the adequacy of reserves for doubtful accounts based on individual account
analysis and historical collection trends. The Company establishes a provision for doubtful receivables when there is objective evidence
that the Company may not be able to collect amounts due. The allowance is based on management&#8217;s best estimate of specific losses
on individual exposures, as well as a provision on historical trends of collections. Actual amounts received may differ from management&#8217;s
estimate of credit worthiness and the economic environment. Delinquent account balances are written-off against the allowance for doubtful
accounts after management has determined that collection is not probable. </span>Allowance for uncollectable balances amounted to $135,082
and $<span style="-sec-ix-hidden: hidden-fact-62">Nil</span> as of September 30, 2024 and 2023, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Inventories,
net</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Inventories
are stated at net realizable value using weighted average method. Costs include the cost of raw materials, freight, direct labor and
related production overhead. Any excess of the cost over the net realizable value of each item of inventories is recognized as a provision
for diminution in the value of inventories. Net realizable value is the estimated selling price in the normal course of business less
any costs to complete and sell products. The Company evaluates inventories on a quarterly basis for its net realizable value adjustments,
and reduces the carrying value of those inventories that are obsolete or in excess of the forecasted usage to their estimated net realizable
value based on various factors including aging, expiration dates, as applicable, taking into consideration historical and expected future
product sales. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We recorded inventory reserve of $124,512
and $69,746 as of September 30, 2024 and 2023, respectively.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_AdvancesToSuppliersNetPolicyTextBlock', window );">Advances to suppliers, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Advances
to suppliers, net</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Advances
to suppliers represent prepayments made to ensure continuous high-quality supplies and favorable purchase prices of raw materials. These
advances are directly related to the purchases of raw materials used to fulfill sales orders. The Company is required from time to time
to make cash advances when placing its purchase orders. These advances are settled upon suppliers delivering raw materials to the Company
when the transfer of ownership occurs. The Company reviews its advances to suppliers on a periodic basis and makes general and specific
allowances when there is doubt as to the ability of a supplier to provide supplies to the Company or refund an advance. As of September
30, 2024 and 2023, the Company recorded no allowance for doubtful accounts, as the Company believed that all advances to suppliers were
fully realizable.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Fair
value of financial instruments</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The
hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of
inputs used to measure fair value are as follows:</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 62px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&#8201;&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8201;inputs to the valuation
    methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 62px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2&#8201;&#8212;&#8201;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inputs to the valuation
    methodology include quoted prices for similar assets and liabilities in active markets, quoted market prices for identical or similar
    assets in markets that are not active, inputs other than quoted prices that are observable and inputs derived from or corroborated
    by observable market data.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 62px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3&#8201;&#8212;&#8201;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inputs to the valuation
    methodology are unobservable.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Unless
otherwise disclosed, the fair value of the Company&#8217;s financial instruments, including cash, accounts receivable, inventories, advances
to suppliers, prepaid expenses and other current assets, accounts payable, short-term bank loans, accrued expenses and other current
liabilities, taxes payable and due to related parties, approximate the fair value of the respective assets and liabilities as of September
30, 2024 based upon the short-term nature of the assets and liabilities. The Company&#8217;s investment in equity securities is accounted
for using the measurement alternative in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 321, &#8220;Investments&#8212;Equity
Securities&#8221; (&#8220;ASC 321&#8221;), which also approximates its recorded value.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, plant and equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property,
plant and equipment</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Property,
plant and equipment are stated at cost less accumulated depreciation. Depreciation of property, plant and equipment is provided using
the straight-line method over their expected useful lives, as follows:</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    life</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 89%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Buildings</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20&#160;years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5&#8211;10&#160;years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Automobiles</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#8211;5&#160;years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office and electric equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#8211;5&#160;years</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Expenditures
for maintenance and repairs, which do not materially extend the useful lives of the assets, are charged to expense as incurred. Expenditures
for major renewals and betterments which substantially extend the useful life of assets are capitalized. The cost and related accumulated
depreciation of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized in the consolidated
statements of operations and comprehensive loss in other income or expenses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company reviews the carrying value of property, plant and equipment for impairment whenever events and circumstances indicate that the
carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition.
In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an
amount by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment
include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand,
competition and other economic factors. Based on this assessment, no impairment expenses for property, plant and equipment were recorded
in operating expenses for the years ended September 30, 2024, 2023 and 2022.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Intangible
Assets</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Intangible
assets consist primarily of land use rights, trademark and software. Under the PRC law, all land in the PRC is owned by the government
and cannot be sold to an individual or company. The government grants individuals and companies the right to use parcels of land for
specified periods of time. Land use rights are stated at cost less accumulated amortization. Intangible assets are amortized using the
straight-line method with the following estimated useful lives:</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; width: 89%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful life</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Land use rights</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50&#160;years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trademark</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5&#160;years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Software</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;years</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company reviews the carrying value of land use rights for impairment whenever events and circumstances indicate that the carrying value
of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In
cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount
by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include
current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition
and other economic factors.&#160;Based on this assessment, no impairment of land use rights was deemed necessary for the years ended
September 30, 2024, 2023 and 2022.&#160;&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ConstructioninProgressPolicyTextBlock', window );">Construction-in-Progress (&#8220;CIP&#8221;)</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Construction-in-Progress
(&#8220;CIP&#8221;)</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">CIP
represents property and buildings under construction and consists of construction expenditures, equipment procurement, and other direct
costs attributable to the construction. CIP is not depreciated. Upon completion and ready for intended use, CIP is reclassified to the
appropriate category within property, plant and equipment.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Impairment
of long-lived Assets</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Long-lived
assets with finite lives, primarily property, plant and equipment and intangible assets, are reviewed for impairment whenever events
or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the estimated undiscounted cash
flows from the use of the asset and its eventual disposition below are the asset&#8217;s carrying value, then the asset is deemed to
be impaired and written down to its fair value. The Company recorded no impairments of these assets for the years ended September 30,
2024, 2023 and 2022.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments in Equity Securities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Investments
in Equity Securities</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company accounts for its equity investments in accordance with ASC 321. In accordance with ASC 321, equity investment which the Company
has no significant influence (generally less than a 20% ownership interest) with readily determinable fair values are accounted for at
fair value based on quoted market prices with the changes in fair value recognized as unrealized gains or losses in earnings. Equity
investments without readily determinable fair values are accounted for either at fair value or using the measurement alternative. Under
the measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting
from observable price changes in orderly transactions for the identical or a similar investment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">From
March 2009 to September 2017, the Company invested approximately $0.7&#160;million (RMB5&#160;million) in Jiangxi Jian Rural Commercial
Bank (&#8220;JX RCB Bank&#8221;) in exchange for&#160;5% ownership interest in the bank. The purpose of entering into these equity investment
agreements with JX RCB Bank was to earn investment income as the bank continues to grow. The Company determined that this investment
in equity securities does not have a readily determinable fair value and, accordingly, elected the measurement alternative noted above.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company initially recorded the investments at historical cost and subsequently records any dividends received from the net accumulated
earnings of the investee as income. As of September 30, 2024 and 2023, the Company&#8217;s investment in JX RBC Bank amounted to $712,494&#160;(RMB5&#160;million)
and $685,307 (RMB5&#160;million), respectively, and was reported as long-term investment in equity investee on the consolidated balance
sheets. Investment income amounted to $31,942, $31,072 and $38,588 for the years ended September 30, 2024, 2023 and 2022, respectively.
</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
investments in equity securities are evaluated for impairment when facts or circumstances indicate that the fair value of the investments
is less than their carrying value. An impairment is recognized when a decline in fair value is determined to be other-than-temporary.
The Company reviews several factors to determine whether a loss is other-than-temporary. These factors include, but are not limited to,
the: (i) nature of the investment; (ii) cause and duration of the impairment; (iii) extent to which fair value is less than cost; (iv)
financial condition and near-term prospects of the investments; and (v) ability to hold the investment for a period of time sufficient
to allow for any anticipated recovery in fair value. There was no impairment for the Company&#8217;s investments in equity securities
as of September 30, 2024 and 2023.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Revenue
recognition</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">To
determine revenue recognition for contracts with customers, the Company performs the following five steps : (i) identify the contract(s)
with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable
consideration to the extent that it is probable that a significant future reversal will&#160;<i>not</i>&#160;occur, (iv) allocate the
transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies
the performance obligation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company recognizes revenue when it transfers its goods and services to customers in an amount that reflects the consideration to which
the Company expects to be entitled in such exchange. The Company accounts for the revenue generated from sales of its TCMD and third-party
products on a gross basis, as the Company is acting as a principal in these transactions, is subject to inventory risk, has latitude
in establishing prices, and is responsible for fulfilling the promise to provide customers the specified goods, which the Company has
control of the goods and has the ability to direct the use of goods to obtain substantially all the benefits. All of the Company&#8217;s
contracts have one single performance obligation, namely, the promise is to transfer the individual goods to customers, and there is
no separately identifiable other promise in the contracts. The Company&#8217;s revenue streams are recognized at a point in time when
title and risk of loss passes and the customer accepts the goods, which generally occurs at delivery. The Company&#8217;s products are
sold with no right of return and the Company does not provide other credits or sales incentive to customers. Revenue is reported net
of all value added taxes (&#8220;VAT&#8221;).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_DisaggregationOfRevenuesPolicyTextBlock', window );">Disaggregation of Revenues</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disaggregation
of Revenues</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company disaggregates its revenue from contracts by product types, as the Company believes it best depicts how the nature, amount, timing
and uncertainty of the revenue and cash flows are affected by economic factors. </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Cost
of Revenue</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Cost
of revenue consists primarily of the costs of raw materials, freight charges, direct labor, depreciation of buildings and machinery,
warehousing and overhead associated with the manufacturing process.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Research
and Development Expenses</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company expenses all internal research and development costs as incurred, which primarily comprise of employee costs, internal and external
costs related to execution of studies, manufacturing costs, facility costs of the research center, and amortization and depreciation
to intangible assets and property, plant and equipment used in the research and development activities. For the&#160;years ended September
30, 2024, 2023 and 2022, total research and development expenses were approximately $</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,031,115,
<span style="background-color: white">$4,858,548 and $7,644,375, respectively.</span></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock', window );">Shipping and handling costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Shipping
and handling costs</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Shipping
and handling costs are expensed as incurred. Inbound shipping and handling cost associated with bringing the purchased raw materials
and third-party products from suppliers to the Company&#8217;s warehouse are included in cost of revenue. Outbound shipping and handling
costs associated with shipping and delivery the products to customers are included in selling expenses.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Advertising
expense</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Advertising
expenses primarily relate to promotion of the Company&#8217;s brand name and products through outdoor billboards, social media such as
Weibo and WeChat, and TV advertisement. Advertising costs are expensed as incurred or deferred and then expensed the first time the advertising
takes place. Advertising expenses are included in selling expenses in the consolidated statements of operations and comprehensive loss.
Advertising expenses amounted to $5,144,579, $4,653,633&#160;and $17,527,318 for the&#160;years ended September 30, 2024, 2023 and 2022,
respectively.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Segment
Reporting</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company uses the management approach in determining reportable operating segments. The management approach considers the internal reporting
used by the Company&#8217;s chief operating decision maker for making operating decisions about the allocation of resources of the segment
and the assessment of its performance in determining the Company&#8217;s reportable operating segments. Management has determined that
the Company has one operating segment.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
taxes</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company accounts for current income taxes in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized
when temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the consolidated financial
statements. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years
in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a
change in tax rates is recognized in income in the period including the enactment date. Valuation allowances are established, when necessary,
to reduce deferred tax assets to the amount expected to be realized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">An
uncertain tax position is recognized only if it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax
examination. The amount recognized is the largest amount of tax benefit that is greater than&#160;50% likely of being realized on examination.
For tax positions not meeting the &#8220;more likely than not&#8221; test, no tax benefit is recorded. Penalties and interest incurred
related to underpayment of income tax are classified as income tax expense in the period incurred. No significant penalties or interest
relating to income taxes have been incurred during the years ended September 30, 2024, 2023 and 2022. The Company does not believe there
was any uncertain tax provision as of September 30, 2024 and 2023.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company&#8217;s operating subsidiaries in China are subject to the income tax laws of the PRC. No significant income was generated outside
the PRC for the years ended September 30, 2024, 2023 and 2022. As of September 30, 2024 and 2023, all of the tax returns of the Company&#8217;s
PRC subsidiaries remained open for statutory examination by PRC tax authorities.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ValueAddedTaxPolicyTextBlock', window );">Value added tax (&#8220;VAT&#8221;)</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Value
added tax (&#8220;VAT&#8221;)</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Sales
revenue represents the invoiced value of goods, net of VAT. The VAT is based on gross sales price and VAT rates range up to&#160;13%,
depending on the type of products sold. The VAT may be offset by VAT paid by the Company on raw materials and other materials included
in the cost of producing or acquiring its finished products. The Company recorded a VAT payable or receivable net of payments in the
accompanying consolidated financial statements.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Earnings
per Share</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company computes earnings per share (&#8220;EPS&#8221;) in accordance with ASC 260, &#8220;Earnings per Share&#8221; (&#8220;ASC 260&#8221;).
ASC 260 requires companies with complex capital structures to present basic and diluted EPS. Basic EPS is measured as net income divided
by the weighted average ordinary shares outstanding for the period. Diluted presents the dilutive effect on a per share basis of potential
ordinary shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented,
or issuance date, if later. Potential ordinary shares that have an anti-dilutive effect (i.e., those that increase income per share or
decrease loss per share) are excluded from the calculation of diluted EPS. For the years ended September 30, 2024, 2023 and 2022, there
were no dilutive shares.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Foreign
currency translation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
functional currency for Universe INC is the U.S. Dollar (&#8220;US$&#8221;). Universe HK uses Hong Kong dollar as its functional currency.
However, Universe INC and Universe HK currently only serve as holding companies and did not have active operations as of the date of
this report. The Company operates only in the PRC and the Company&#8217;s functional currency is the Chinese Yuan (&#8220;RMB&#8221;).
The Company&#8217;s consolidated financial statements have been translated into the reporting currency US$.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Assets
and liabilities of the Company are translated at the exchange rate at each reporting period end date. Equity is translated at historical
rates. Income and expense accounts are translated at the average rate of exchange during the reporting period. The resulting translation
adjustments are reported under other comprehensive income. Gains and losses resulting from the translations of foreign currency transactions
and balances are reflected in the results of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions.
No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table outlines the currency exchange rates that were used in creating the consolidated financial statements in this report:</span></p><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid">September 30, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid">September 30, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Period-end US$: RMB exchange rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.0176</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.2960</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.1135</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Period-end US$: HK exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.7693</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8308</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8498</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Period average US$: RMB exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.2043</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.0533</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.5532</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Period average US$: HK exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8127</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8310</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8228</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive income</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Comprehensive
Income</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Comprehensive
income consists of two components, net income and other comprehensive income. The foreign currency translation gain resulting from translation
of the financial statements expressed in RMB to US$ is reported in other comprehensive income in the consolidated statements of operations
and comprehensive loss.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_StatementOfCashFlowsPolicyTextBlock', window );">Statement of Cash Flows</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Statement
of Cash Flows</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
accordance with ASC 230, &#8220;Statement of Cash Flows&#8221;, cash flows from the Company&#8217;s operations are formulated based upon
the local currencies. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily
agree with changes in the corresponding balances on the balance sheets.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_EmployeeDefinedContributionPlanPolicyTextBlock', window );">Employee Defined Contribution Plan</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employee
Defined Contribution Plan</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company&#8217;s subsidiaries in the PRC participate in a government-mandated multi-employer defined contribution plan pursuant to which
pension, work-related injury benefits, maternity insurance, medical insurance, unemployment benefit and housing fund are provided to
eligible full-time employees. The relevant labor regulations require the Company&#8217;s subsidiaries in the PRC to pay the local labor
and social welfare authorities monthly contributions based on the applicable benchmarks and rates stipulated by the local government.
The contributions to the plan are expensed as incurred. Employee social security and welfare benefits included as expenses in the accompanying
consolidated statements of operations and comprehensive loss amounted to $247,249, $440,962&#160;and $465,689&#160;for the years ended
September 30, 2024, 2023 and 2022, respectively.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
Issued <span style="background-color: white">Accounting Pronouncements</span></i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
considers the applicability and impact of all accounting standards updates (&#8220;ASUs&#8221;). Management periodically reviews new accounting
standards that are issued. Under the Jumpstart Our Business Startups Act of 2012, as amended (the &#8220;JOBS Act&#8221;), the Company
meets the definition of an emerging growth company, or EGC, and has elected the extended transition period for complying with new or revised
accounting standards, which delays the adoption of these accounting standards until they would apply to private companies.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In November
2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amended guidance
requires incremental reportable segment disclosures, primarily about significant segment expenses. The amendments also require entities
with a single reportable segment to provide all disclosures required by these amendments, and all existing segment disclosures. The amendments
will be applied retrospectively to all prior periods presented in the financial statements and is effective for fiscal years beginning
after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. The guidance should be adopted retrospectively.
The Company is currently in the process of evaluating the impact this amended guidance may have on the footnotes to its consolidated financial
statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In December
2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amended guidance enhances income
tax disclosures primarily related to the effective tax rate reconciliation and income taxes paid information. This guidance requires disclosure
of specific categories in the effective tax rate reconciliation and further information on reconciling items meeting a quantitative threshold.
In addition, the amended guidance requires disaggregating income taxes paid (net of refunds received) by federal, state, and foreign taxes.
It also requires disaggregating individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than
5 percent of total income taxes paid (net of refunds received). The amended guidance is effective for fiscal years beginning after December
15, 2024. The guidance can be applied either prospectively or retrospectively. The Company is currently in the process of evaluating the
impact this amended guidance may have on the footnotes to its consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In March
2024, the FASB issued ASU 2024-01, Compensation&#8212;Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar
Awards. The amended guidance added an illustrative example that includes four fact patterns to demonstrate how an entity should apply
the scope guidance in paragraph 718-10-15-3 to determine whether a profits interest award should be accounted for in accordance with Topic
718. The amendments guidance is effective for annual periods beginning after December 15, 2024, and interim periods within those annual
periods. The guidance can be applied either prospectively or retrospectively. The Company is currently in the process of evaluating the
impact this amended guidance may have on its consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In November
2024, the FASB issued ASU 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses. The amended guidance improves the disclosures about a public business entity&#8217;s
expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory,
employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions (such as cost of sales, SG&amp;A,
and research and development). The amended guidance is effective for annual reporting periods beginning after December 15, 2026, and interim
reporting periods beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective
application. The Company is currently in the process of evaluating the impact this amended guidance may have on the footnotes to its consolidated
financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In November
2024, the FASB issued ASU 2024-04, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible
Debt Instruments. This guidance clarifies the assessment of whether a transaction should be accounted for as an induced conversion or
extinguishment of convertible debt when changes are made to conversion features as part of an offer to settle the instrument. The amended
guidance is effective for all entities for annual reporting periods beginning after December 15, 2025, and interim reporting periods within
those annual reporting periods. The guidance can be applied either prospectively or retrospectively. The Company is currently in the process
of evaluating the impact this amended guidance may have on its consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In January
2025, the FASB issued ASU 2025-01, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic
220-40): Clarifying the Effective Date. This guidance amends the effective date of Update 2024-03 to clarify that all public business
entities are required to adopt the guidance in annual reporting periods beginning after December 15, 2026, and interim periods within
annual reporting periods beginning after December 15, 2027. Early adoption of Update 2024-03 is permitted. The Company is currently in
the process of evaluating the impact this amended guidance may have on the footnotes to its consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Other accounting
standards that have been issued by FASB that do not require adoption until a future date are not expected to have a material impact on
the consolidated financial statements upon adoption. The Company does not discuss recent standards that are not anticipated to have an
impact on or are unrelated to its consolidated financial condition, results of operations, cash flows or disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AdvancesToSuppliersNetPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advances to suppliers net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AdvancesToSuppliersNetPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ConstructioninProgressPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for construction in progress.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ConstructioninProgressPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_DisaggregationOfRevenuesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_DisaggregationOfRevenuesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_EmployeeDefinedContributionPlanPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of employee defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_EmployeeDefinedContributionPlanPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ReclassificationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ReclassificationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_StatementOfCashFlowsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of statement of cash flows policy text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_StatementOfCashFlowsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ValueAddedTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of value added tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ValueAddedTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org/705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShippingAndHandlingCostPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business Description (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Business Description [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock', window );">Schedule of Subsidiaries</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Details
of the subsidiaries of the Company as of September 30, 2024 are set out below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date of</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Place of</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>% of</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of Entity</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporation</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporation</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal Activities</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe INC</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 11, 2019</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cayman Islands</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent, 100%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe HK</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 21, 2014</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 28%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe Technology</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 18, 2019</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WFOE, Investment holding</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Universe</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2, 1998</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development and manufacturing of modernized traditional Chinese medicines</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe Trade</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 10, 2010</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales of modernized traditional Chinese medicines</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe Hanhe</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 12, 2021</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development of new pharmaceutical products</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the key aspects of a subsidiary (partnership, corporation, or other entity) of the limited liability company or limited partnership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Schedule of Property Plant and Equipment Estimated Useful Lives</a></td>
<td class="text">Depreciation of property, plant and equipment is provided using
the straight-line method over their expected useful lives, as follows:<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    life</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 89%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Buildings</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20&#160;years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5&#8211;10&#160;years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Automobiles</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#8211;5&#160;years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office and electric equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#8211;5&#160;years</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock', window );">Schedule of Intangible Assets Estimated Useful Lives</a></td>
<td class="text">Intangible assets are amortized using the
straight-line method with the following estimated useful lives:<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; width: 89%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful life</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Land use rights</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50&#160;years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trademark</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5&#160;years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Software</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;years</span></td></tr> </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock', window );">Schedule of Currency Exchange Rate</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table outlines the currency exchange rates that were used in creating the consolidated financial statements in this report:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid">September 30, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid">September 30, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Period-end US$: RMB exchange rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.0176</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.2960</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.1135</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Period-end US$: HK exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.7693</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8308</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8498</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Period average US$: RMB exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.2043</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.0533</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.5532</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Period average US$: HK exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8127</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8310</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8228</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of property equipment estimated useful life during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of Intangible assets estimated useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>Accounts Receivable, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts Receivable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Accounts
receivable consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Accounts receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,040,903</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,014,908</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(135,082</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Accounts receivable, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12,905,821</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,014,908</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Schedule of Allowance for Doubtful Accounts</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Allowance
for doubtful accounts movement is as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Beginning balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Reversal of allowance for doubtful accounts</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">131,581</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,501</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Ending balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">135,082</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventories, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Inventories
consist of the following:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">720,041</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">635,395</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Finished goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,141,526</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,777,617</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Inventories valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(124,512</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(69,746</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total inventories, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">1,737,054</p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,343,266</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of Inventories Valuation Allowance</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories valuation allowance <span style="background-color: white">movement
is as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Beginning balance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">69,746</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">120,286</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Reversal of inventories valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,651</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(49,166</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,115</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,374</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">124,512</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">69,746</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Advance to Suppliers (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_AdvancesToSuppliersAbstract', window );"><strong>Advance to Suppliers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ScheduleOfAdvancesToSuppliersNet', window );">Schedule of Advances to Suppliers</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Advances
to suppliers consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 76%; text-align: justify">Advances to suppliers for inventories raw material purchase</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">978,203</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">180,643</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Advances to suppliers</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">978,203</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">180,643</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AdvancesToSuppliersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AdvancesToSuppliersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfAdvancesToSuppliersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of advances to suppliers net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfAdvancesToSuppliersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrentAbstract', window );"><strong>Other Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Other Receivable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Other receivable
consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivable from Yunan Faxi <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,562,472</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Redemption of short-term investment <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,377,873</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,367,052</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Prepaid value added tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">475,331</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">478,899</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Prepayment for advertising</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">219,830</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">31,090</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">74,300</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Other receivable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,666,596</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,920,251</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
September 26, 2022, the Company entered into a letter of intent for an equity transfer with an individual, Mr. Xibo Liu, pursuant to
which, Mr. Xibo Liu transfers his&#160;51% ownership in Yunnan Faxi to the Company at the price of RMB72&#160;million (approximately
$10.0&#160;million). Based on contract terms, the Company prepaid RMB25&#160;million (approximately $3.4&#160;million) within three (3)
business days upon signing the letter of intent. However, due to unsatisfactory performance of Yunnan Faxi, the equity transfer contract
was terminated on December 20, 2024. The amount of $3,562,472 (RMB25&#160;million) was recorded as other receivable as of September 30,
2024.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
September 24, 2024, the Company entered into an agreement with a third party to transfer its short-term investment at the price of $</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,377,873.
<span style="background-color: white">The amount was recorded as other receivable as of September 30, 2024 and 2023.</span></span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment, Net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Property,
plant and equipment, net, consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Useful life</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: justify">Buildings</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">20&#160;years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,594,735</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,304,936</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: center">5-10&#160;years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,007,399</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,896,976</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Automobiles</td><td>&#160;</td>
    <td style="text-align: center">3-5&#160;years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,374</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,703</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Office and electric equipment</td><td>&#160;</td>
    <td style="text-align: center">3-5&#160;years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">527,336</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">474,830</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Construction-in-progress</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,971</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Subtotal</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,232,815</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,750,445</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,664,765</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,050,480</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Property, plant and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,568,050</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,699,965</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets, Net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Intangible
assets, net consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Useful life</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: justify">Land use rights</td><td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: center">50&#160;years</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">256,211</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">246,434</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Trademark</td><td>&#160;</td> <td style="text-align: center">5&#160;years</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">120,412</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Software</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">3&#160;years</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,506</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,687</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">398,129</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">267,121</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(135,251</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(118,537</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Intangible assets, net</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">262,878</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">148,584</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Future Amortization Expense for Intangible Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Estimated
future amortization expense for intangible assets is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; border-bottom: Black 1.5pt solid; font-weight: bold">Years Ending September 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortization<br/> expense</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,165</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,165</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,165</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,165</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,165</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">177,053</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">262,878</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepayment for CIP Project (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentForConstructionInProgressAbstract', window );"><strong>Prepayment for CIP Project [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock', window );">Schedule of Future Minimum Capital Expenditures</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of September 30, 2024, future minimum capital expenditures on the Company&#8217;s CIP project are estimated as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Twelve months ending September 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital<br/> Expenditure<br/> on CIP</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,124,943</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,350,832</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,175,616</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,651,391</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForConstructionInProgressAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForConstructionInProgressAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum capital expenditure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Bank Loans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ShortTermBankLoansAbstract', window );"><strong>Short-Term Bank Loans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShortTermDebtTextBlock', window );">Schedule of Short-Term Bank Loans</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Short-term
bank loans consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Note</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Short-term bank loans:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;)</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">(1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,849,976</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,467,105</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Bank of Communications Co., Ltd</td><td>&#160;</td>
    <td style="text-align: center">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,154,241</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,233,553</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Zhujiang Rural Bank</td><td>&#160;</td>
    <td style="text-align: center">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">427,497</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">411,184</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Beijing Bank</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">(4)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,424,989</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,370,614</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total short-term loans</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,856,703</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,482,456</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 13, 2023, a subsidiary of the Company, Universe Trade, signed a loan agreement with LRC Bank to borrow RMB8 million (equivalent to $1,096,491) as working capital for one year, with the maturity date on March 12, 2024. The fixed interest rate of the loan was 4.56% per annum. Mr. Gang Lai signed guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 15, 2023, a subsidiary of the Company, Jiangxi Universe, signed a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,370,614) as working capital for eleven months, with the maturity date on May 14, 2024. The fixed interest rate of the loan was 4.56% per annum. Mr. Gang Lai signed guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 4, 2024, a subsidiary of the Company, Universe
Trade, signed a loan agreement with LRC Bank to borrow RMB5 million (equivalent to $712,494) as working capital for one year, with the
maturity date on March 3, 2025. The fixed interest rate of the loan was 4.75% per annum. Mr. Gang Lai and Jiangxi Universe jointly signed
guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 26, 2024, a subsidiary of the Company, Jiangxi
Universe, signed a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,424,989) as working capital for one year, with
the maturity date on April 25, 2025. The fixed interest rate of the loan was 4.31% per annum. Mr. Gang Lai and Universe Technology jointly
signed guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 17, 2024, a subsidiary of the Company, Universe
trade, signed a loan agreement with LRC Bank to borrow RMB5 million (equivalent to $712,494) as working capital for one year, with the
maturity date on May 16, 2025. The fixed interest rate of the loan was 3.65% per annum. Mr. Gang Lai and Jiangxi Universe jointly signed
guarantee agreements with LRC Bank to provide credit guarantee for this loan.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
March 3, 2025, a subsidiary of the Company, Universe Trade, signed a loan agreement with LRC Bank to borrow RMB5 million (equivalent to
$712,494) as working capital for one year, with the maturity date on March 2, 2026. The fixed interest rate of the loan was 3.65% per
annum. Mr. Gang Lai and Jiangxi Universe jointly signed guarantee agreements with LRC Bank to provide credit guarantee for this loan.</span>
&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">On April 22, 2024, a subsidiary of the Company, Jiangxi Universe, signed
a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,424,989) as working capital for one year, with the maturity date
on April 21, 2026. The fixed interest rate of the loan was 3.60% per annum. Mr. Gang Lai and Universe Technology jointly signed guarantee
agreements with LRC Bank to provide credit guarantee for this loan. &#160;</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 15, 2023, the Company&#8217;s subsidiary, Jiangxi Universe, signed a loan agreement with Bank of Communications to borrow RMB9 million (equivalent to $1,246,486) as working capital for eleven months, with the maturity date on May 18, 2024. The fixed interest rate of the loan was 4.0% per annum. Mr. Gang Lai, Universe Trade, and an unrelated third party, Jiangxi Province Financing Guarantee Group Co., Ltd., jointly signed guarantee agreements with Bank of Communications to provide credit guarantee for this loan. The loan was fully repaid upon maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 16, 2024, the Company&#8217;s subsidiary, Jiangxi Universe, signed a loan agreement with Bank of Communications to borrow RMB8.1 million (equivalent to $1,154,241) as working capital for eleven months, with the maturity date on May 13, 2025. The fixed interest rate of the loan was 3.9% per annum. Mr. Gang Lai, Universe Trade, and an unrelated third party, Jiangxi Province Financing Guarantee Group Co., Ltd., jointly signed guarantee agreements with Bank of Communications to provide credit guarantee for this loan.</span></p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 5, 2023, a subsidiary of the Company, Jiangxi Universe, entered into a loan agreement with Zhujiang Rural Bank to borrow RMB 3 million (equivalent to $415,495) as working capital for one year, with the maturity date on May 4, 2024. The fixed interest rate of the loan was 3.65% per annum. The Company pledged certain patents owned by the Company as collateral to guarantee this loan. The loan was fully repaid upon maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 24, 2024, a subsidiary of the Company, Jiangxi
Universe, entered into a loan agreement with Zhujiang Rural Bank to borrow RMB3 million (equivalent to $427,497) as working capital for
one year, with the maturity date on April 24, 2025. The fixed interest rate of the loan was 3.65% per annum. The Company pledged certain
trademarks owned by the Company as collateral to guarantee this loan. The loan was fully repaid upon maturity</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="text-align: justify; margin: 0; font: 10pt Times New Roman, Times, Serif">On April 18, 2025, a subsidiary of the Company, Jiangxi Universe, signed
a loan agreement with Zhujiang Rural Bank to borrow RMB2.9 million (equivalent to $413,247&#160;) as working capital for one year, with
the maturity date on April 18, 2026. The fixed interest rate of the loan was 5.00% per annum. The Company pledged certain trademarks owned
by the Company as collateral to guarantee this loan.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 24, 2023, a subsidiary of the Company, Jiangxi Universe, entered into a loan agreement with Beijing Bank to borrow RMB 10 million (equivalent to $1,384,984) as working capital for one year, with the maturity date on July 18, 2024. The fixed interest rate of the loan was 4.25% per annum. There was no guarantee requirement for this loan. The loan was fully repaid upon maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 3, 2024, a subsidiary of the Company, Jiangxi Universe, entered into a loan agreement with Beijing Bank to borrow RMB 10 million (equivalent to $1,424,989) as working capital for one year, with the maturity date on July 3, 2025. The fixed interest rate of the loan was 4.15% per annum. Mr. Gang Lai provided credit guarantee for this loan.</span></p></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ShortTermBankLoansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ShortTermBankLoansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Bank Loans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Long-Term Bank Loans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Bank Loans</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Long-term
bank loans consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Note</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Long-term bank loans:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">LRC Bank</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">(1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,137,483</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 23, 2023, a subsidiary of the Company, Jiangxi Universe, signed a loan agreement with LRC Bank to borrow RMB15 million (equivalent to $2,137,483) as working capital for two years, with the maturity date on November 14, 2025. The fixed interest rate of the loan was 3.95% per annum. The Company pledged buildings of Jiangxi Universe as collateral to guarantee this loan.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock', window );">Schedule of Nature of Relationships With Related Parties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)
Nature of relationships with related parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship with the Company</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Gang Lai</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and chairman of the Company&#8217;s Board of Directors</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Yajun Hu</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General Manager of Jiangxi Universe</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms. Lin Yang</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer of the Company</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guangzhou Ningjing Investment Co., Ltd (Guangzhou Ningjing)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under common control of Mr. Gang Lai</span></td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Parties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>(b)
Due from related parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Mr. Yajun Hu</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">61,678</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total due from related parties</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">61,678</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>(c)
Due to related parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Mr. Gang Lai</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,900,499</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">540,096</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Ms. Lin Yang</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">85</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total due to related parties</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,900,584</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">540,096</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of nature of relationship with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of the Income Tax Provision (Benefit)</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
components of the income tax </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expense <span style="background-color: white">(benefit)
are as follows:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current tax expense:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cayman</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Hong Kong</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 1.5pt">PRC</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">685,937</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,357,697</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Sub-total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">685,937</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,357,697</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax expense (benefit):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cayman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Hong Kong</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">PRC</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">606,704</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,567,656</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(542,375</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Sub-total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">606,704</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,567,656</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(542,375</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total income tax expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">606,704</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,253,593</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">815,322</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Table Reconciles the China Statutory Rates to the Company&#8217;s Effective Tax Rate</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table reconciles the China statutory rates to the Company&#8217;s effective tax rate for the years ended September 30, 2024,
2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Statutory PRC income tax rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of income tax holiday</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5.9</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8.2</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9.2</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent difference</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.1</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(25.1</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-PRC entities not subject to PRC income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.7</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4.4</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.2</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23.9</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(64.4</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Effective tax rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(7.5</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(52.1</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(11.5</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Deferred
tax assets are composed of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Net operating loss carry-forwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">599,078</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">599,078</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total deferred tax assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">599,078</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ScheduleOfTaxPayableTableTextBlock', window );">Schedule of Taxes Payable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Taxes
payable consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Value added tax payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">873,750</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">303,713</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other taxes payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">147,431</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">131,045</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total taxes payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,021,181</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">434,758</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfTaxPayableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of tax payable during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfTaxPayableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Information of the Parent Company (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Financial Information of the Parent Company [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock', window );">Schedule of Consolidated Financial Statements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PARENT
COMPANY BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 9pt">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,058,414</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,248</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Other receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,377,873</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,367,052</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Due from subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,863,833</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,878,344</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">37,300,120</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,254,644</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; text-indent: -9pt; padding-left: 9pt">Non-current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Investment in subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,749,310</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,715,509</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">46,049,430</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">27,970,153</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Due to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">497,014</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Accrued expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">49,475</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">TOTAL CURRENT LIABILITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">546,489</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">COMMITMENTS AND CONTINGENCIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Ordinary shares, $11.25 par value, 11,250,000 shares authorized, 42,880 and 6,062 shares issued and outstanding as of September 30, 2024 and 2023, respectively *</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">482,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,973</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,864,720</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,279,155</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">(Accumulated deficit) Retained earnings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,732,033</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">995,265</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Accumulated other comprehensive loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,112,146</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,372,240</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total shareholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45,502,941</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,970,153</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 27pt">Total liabilities and shareholders&#8217; equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">46,049,430</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">27,970,153</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retrospectively restated for effect of 15-for-1 and 40-for-1 shares
consolidations.</span></td>
</tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedStatementOfComprehensiveIncomeTableTextBlock', window );">Schedule of Parent Company Statements of Operations and Comprehensive Loss</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PARENT
COMPANY STATEMENTS OF <span style="background-color: white">OPERATIONS AND COMPREHENSIVE LOSS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Operating costs and expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">General and administrative expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(592,021</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(134,141</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(384,214</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expenses):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(87,292</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(730</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(420</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity in earnings of subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,047,985</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,446,153</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,525,004</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,727,298</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,581,024</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,909,638</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,260,094</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(779,351</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,752,143</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Comprehensive loss attributable to the Company</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(7,467,204</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(7,360,375</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(11,661,781</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock', window );">Schedule of Parent Company Statements of Cash Flows</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PARENT
COMPANY STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(8,727,298</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(6,581,024</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(7,909,638</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Adjustments to reconcile net cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 11.3pt; padding-left: 10pt">Equity in earnings of subsidiary</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,047,985</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,446,153</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,525,004</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Due to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">497,014</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Accrued expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">49,475</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 3.3pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(132,824</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(134,871</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(384,634</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net proceeds from issuance of ordinary shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,999,992</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash repayment from subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,511</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">115,133</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">303,746</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,014,503</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">115,133</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">303,746</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 1.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">EFFECT OF CHANGES OF FOREIGN EXCHANGE RATES ON CASH</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">167,487</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">69</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(588</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CHANGES IN CASH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,049,166</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,669</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(81,476</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">CASH, beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,248</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28,917</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">110,393</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">CASH, end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25,058,414</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,248</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">28,917</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedStatementOfComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedStatementOfComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedCashFlowStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Organization and Business Description (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2024</div></th>
<th class="th"><div>Jul. 15, 2024</div></th>
<th class="th"><div>Mar. 29, 2021</div></th>
<th class="th" colspan="2"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 24, 2025</div></th>
<th class="th"><div>Nov. 12, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jul. 27, 2023</div></th>
<th class="th"><div>Jul. 03, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 25, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PublicOfferingPrice', window );">Public offering price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Over allotment (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnits', window );">Share capital (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 140,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,250,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,880<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,880<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Ordinary price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=upc_UniverseIncMember', window );">Universe Inc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Incorporation date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 11,  2019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=upc_UniverseHKMember', window );">Universe HK [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Incorporation date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 21,  2014<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=upc_JiangxiUniverseMember', window );">Jiangxi Universe</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Incorporation date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  02,  1998<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=upc_UniverseTradeMember', window );">Jiangxi Universe [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=upc_UniverseTechnologyMember', window );">Universe Technology [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnits', window );">Share capital (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 312,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnits', window );">Share capital (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.01875<span></span>
</td>
<td class="nump">$ 0.01875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnits', window );">Share capital (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,880<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,042<span></span>
</td>
<td class="nump">6,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,333<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Ordinary price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.01875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.01875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,666,666.6666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.01875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,666,666.6666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Additional shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnits', window );">Share capital (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Board of Directors [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,666,666.6666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Board of Directors [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Board of Directors [Member] | Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Board of Directors [Member] | Common Stock [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Board of Directors [Member] | Common Stock [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Board of Directors [Member] | Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Board of Directors [Member] | Common Stock One [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Board of Directors [Member] | Common Stock One [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Board of Directors [Member] | Common Stock One [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors Chairman [Member] | Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.01875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsShares', window );">Ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnits', window );">Share capital (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 140,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.28125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="nump">$ 28,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Additional shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Over allotment (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="14"></td></tr>
<tr><td colspan="14"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retrospectively restated for effect of 15-for-1 and 40-for-1 share
consolidations.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retrospectively restated for effect of 15-for-1 and 40-for-1 share
consolidations.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OrganizationandBusinessDescriptionDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OrganizationandBusinessDescriptionDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PublicOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PublicOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=upc_UniverseIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=upc_UniverseIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=upc_UniverseHKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=upc_UniverseHKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=upc_JiangxiUniverseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=upc_JiangxiUniverseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=upc_UniverseTradeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=upc_UniverseTradeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=upc_UniverseTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=upc_UniverseTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=upc_CommonStockOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=upc_CommonStockOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business Description - Schedule of Subsidiaries (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=upc_UniverseINCMember', window );">Universe INC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate', window );">Date of Incorporation</a></td>
<td class="text">Dec. 11,  2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Place of Incorporation</a></td>
<td class="text">Cayman Islands<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">% of Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal Activities</a></td>
<td class="text">Investment holding<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=upc_UniverseHKMember', window );">Universe HK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate', window );">Date of Incorporation</a></td>
<td class="text">May 21,  2014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Place of Incorporation</a></td>
<td class="text">Hong Kong<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">% of Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal Activities</a></td>
<td class="text">Investment holding<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=upc_UniverseTechnologyMember', window );">Universe Technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate', window );">Date of Incorporation</a></td>
<td class="text">Apr. 18,  2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Place of Incorporation</a></td>
<td class="text">PRC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">% of Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal Activities</a></td>
<td class="text">WFOE, Investment holding<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=upc_JiangxiUniverseMember', window );">Jiangxi Universe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate', window );">Date of Incorporation</a></td>
<td class="text">Mar.  02,  1998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Place of Incorporation</a></td>
<td class="text">PRC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">% of Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal Activities</a></td>
<td class="text">Research and development and manufacturing of modernized traditional Chinese medicines<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=upc_UniverseTradeMember', window );">Universe Trade [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate', window );">Date of Incorporation</a></td>
<td class="text">Mar. 10,  2010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Place of Incorporation</a></td>
<td class="text">PRC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">% of Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal Activities</a></td>
<td class="text">Sales of modernized traditional Chinese medicines<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=upc_UniverseHanheMember', window );">Universe Hanhe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate', window );">Date of Incorporation</a></td>
<td class="text">May 12,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Place of Incorporation</a></td>
<td class="text">PRC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">% of Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal Activities</a></td>
<td class="text">Research and development of new pharmaceutical products<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of business purpose of the subsidiary of the limited liability company or limited partnership, for example, its day-to-day operating functions and whether it acts as a holding or operating company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the subsidiary of the limited liability company (LLC) or limited partnership (LP) was formed, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of units or percentage investment held in the subsidiary by the limited liability company or limited partnership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>State in which the subsidiary of the limited liability company or limited partnership was organized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=upc_UniverseINCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=upc_UniverseINCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=upc_UniverseHKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=upc_UniverseHKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=upc_UniverseTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=upc_UniverseTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=upc_JiangxiUniverseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=upc_JiangxiUniverseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=upc_UniverseTradeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=upc_UniverseTradeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=upc_UniverseHanheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=upc_UniverseHanheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> &#165; in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash in banks</a></td>
<td class="nump">$ 71,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for uncollectable balance amount</a></td>
<td class="nump">135,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserve</a></td>
<td class="nump">124,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,746<span></span>
</td>
<td class="nump">$ 120,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment amount</a></td>
<td class="nump">712,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">685,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 5.0<span></span>
</td>
<td class="nump">&#165; 5.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Investment income</a></td>
<td class="nump">31,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,072<span></span>
</td>
<td class="nump">38,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">3,031,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,858,548<span></span>
</td>
<td class="nump">7,644,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expenses</a></td>
<td class="nump">$ 5,144,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,653,633<span></span>
</td>
<td class="nump">17,527,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_TaxBenefitPercentage', window );">Tax benefit percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PercentageOfVatRate', window );">Percentage of vat rate</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Comprehensive income amount</a></td>
<td class="nump">$ 247,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 440,962<span></span>
</td>
<td class="nump">$ 465,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=upc_UniverseHKMember', window );">Universe HK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting power percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_UniversePharmaceuticalsIncMember', window );">Universe Pharmaceuticals Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_JxRcbBankMember', window );">JX RCB Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Investment amount</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">&#165; 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PercentageOfVatRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of VATrate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PercentageOfVatRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_TaxBenefitPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax benefit percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_TaxBenefitPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483385/720-35-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the entity's equity method investment which has been sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSoldCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=upc_UniverseHKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=upc_UniverseHKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_UniversePharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_UniversePharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_JxRcbBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_JxRcbBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Property Plant and Equipment Estimated Useful Lives (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property Plant and Equipment Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Expected useful lives</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property Plant and Equipment Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Expected useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Automobiles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property Plant and Equipment Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Expected useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Office and electric equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property Plant and Equipment Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Expected useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property Plant and Equipment Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Expected useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Automobiles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property Plant and Equipment Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Expected useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Office and electric equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property Plant and Equipment Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Expected useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=upc_OfficeAndElectricEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=upc_OfficeAndElectricEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Intangible Assets Estimated Useful Lives (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UseRightsMember', window );">Land use rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">50 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UseRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UseRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Currency Exchange Rate (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CNY', window );">RMB exchange rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Schedule of Currency Exchange Rate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeForwardExchangeRate1', window );">Period-end US$</a></td>
<td class="nump">7.0176<span></span>
</td>
<td class="nump">7.296<span></span>
</td>
<td class="nump">7.1135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAverageForwardExchangeRate1', window );">Period average US$</a></td>
<td class="nump">7.2043<span></span>
</td>
<td class="nump">7.0533<span></span>
</td>
<td class="nump">6.5532<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_HKD', window );">HK exchange rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Schedule of Currency Exchange Rate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeForwardExchangeRate1', window );">Period-end US$</a></td>
<td class="nump">7.7693<span></span>
</td>
<td class="nump">7.8308<span></span>
</td>
<td class="nump">7.8498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAverageForwardExchangeRate1', window );">Period average US$</a></td>
<td class="nump">7.8127<span></span>
</td>
<td class="nump">7.831<span></span>
</td>
<td class="nump">7.8228<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAverageForwardExchangeRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average contractual rate at which a foreign currency can be purchased or sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAverageForwardExchangeRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeForwardExchangeRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual rate at which a foreign currency can be purchased or sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeForwardExchangeRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CNY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CNY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_HKD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_HKD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable, Net (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>Accounts Receivable, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_NetAccountReceivablePercentage', window );">Net account receivable percentage</a></td>
<td class="nump">98.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Net account receivable amount</a></td>
<td class="nump">$ 12.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_NetAccountReceivablePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of net account receivable percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_NetAccountReceivablePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable, Net - Schedule of Accounts Receivable (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrentAbstract', window );"><strong>Schedule of Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 13,040,903<span></span>
</td>
<td class="nump">$ 11,014,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Less: allowance for doubtful accounts</a></td>
<td class="num">(135,082)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 12,905,821<span></span>
</td>
<td class="nump">$ 11,014,908<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net - Schedule of Allowance for Doubtful Accounts (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForCreditLossAbstract', window );"><strong>Schedule of Allowance for Doubtful Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Reversal of allowance for doubtful accounts</a></td>
<td class="nump">131,581<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease', window );">Foreign currency translation adjustments</a></td>
<td class="nump">3,501<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="nump">$ 135,082<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForCreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForCreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories, Net - Schedule of Inventories (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ScheduleOfInventoriesAbstract', window );"><strong>Schedule of inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 720,041<span></span>
</td>
<td class="nump">$ 635,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">1,141,526<span></span>
</td>
<td class="nump">2,777,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventories valuation allowance</a></td>
<td class="num">(124,512)<span></span>
</td>
<td class="num">(69,746)<span></span>
</td>
<td class="num">$ (120,286)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories, net</a></td>
<td class="nump">$ 1,737,054<span></span>
</td>
<td class="nump">$ 3,343,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories, Net - Schedule of Inventories Valuation Allowance (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ScheduleOfInventoryValuationAllowanceAbstract', window );"><strong>Schedule of Inventory Valuation Allowance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Beginning balance</a></td>
<td class="nump">$ 69,746<span></span>
</td>
<td class="nump">$ 120,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLIFOReservePeriodCharge', window );">Reversal of inventories valuation allowance</a></td>
<td class="nump">50,651<span></span>
</td>
<td class="num">(49,166)<span></span>
</td>
<td class="nump">$ 15,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments', window );">Foreign currency translation adjustments</a></td>
<td class="nump">4,115<span></span>
</td>
<td class="num">(1,374)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Ending balance</a></td>
<td class="nump">$ 124,512<span></span>
</td>
<td class="nump">$ 69,746<span></span>
</td>
<td class="nump">$ 120,286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign currency translation adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfInventoryValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfInventoryValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReservePeriodCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReservePeriodCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Advance to Suppliers - Schedule of Advances to Suppliers (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesAbstract', window );"><strong>Schedule of Advances to Suppliers Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSupplies', window );">Advances to suppliers for inventories raw material purchase</a></td>
<td class="nump">$ 978,203<span></span>
</td>
<td class="nump">$ 180,643<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Supplies', window );">Advances to suppliers</a></td>
<td class="nump">$ 978,203<span></span>
</td>
<td class="nump">$ 180,643<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Supplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Supplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepayment for Acquisition (Details)<br> &#165; in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 26, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 26, 2022 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Prepayment for Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentForAcquisitionCurrent', window );">Prepayment for acquisition current</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,426,535<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="nump">&#165; 25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivable</a></td>
<td class="nump">5,666,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,920,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=upc_YunnanFaxiPharmaceuticalsCoLtdMember', window );">Yunnan Faxi Pharmaceuticals Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Prepayment for Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentForAcquisition', window );">Prepayment for acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">&#165; 72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=upc_YunnanFaxiPharmaceuticalsCoLtdMember', window );">Yunnan Faxi Pharmaceuticals Co., Ltd. [Member] | Mr. Xibo Liu [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Prepayment for Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Equity interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_YunnanFaxiPharmaceuticalsCoLtdMember', window );">Yunnan Faxi Pharmaceuticals Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Prepayment for Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivable</a></td>
<td class="nump">$ 3,562,472<span></span>
</td>
<td class="nump">&#165; 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayment for acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForAcquisitionCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of prepayment for acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForAcquisitionCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=upc_YunnanFaxiPharmaceuticalsCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=upc_YunnanFaxiPharmaceuticalsCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrXiboLiuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrXiboLiuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_YunnanFaxiPharmaceuticalsCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_YunnanFaxiPharmaceuticalsCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Other Receivable (Details)<br> &#165; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th" colspan="2">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 24, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 26, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 26, 2022 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OtherReceivableDetailsLineItems', window );"><strong>Other Receivable (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Company price amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">&#165; 72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#165; 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables, Net, Current</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,562,472<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesGrossCurrent', window );">Other receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,600,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#165; 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,377,873<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,377,873<span></span>
</td>
<td class="nump">$ 1,367,052<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OtherReceivablePercentage', window );">Percentage of other receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">99.40%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_YunnanFaxiMember', window );">Yunnan Faxi [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OtherReceivableDetailsLineItems', window );"><strong>Other Receivable (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">51.00%<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
September 26, 2022, the Company entered into a letter of intent for an equity transfer with an individual, Mr. Xibo Liu, pursuant to
which, Mr. Xibo Liu transfers his&#160;51% ownership in Yunnan Faxi to the Company at the price of RMB72&#160;million (approximately
$10.0&#160;million). Based on contract terms, the Company prepaid RMB25&#160;million (approximately $3.4&#160;million) within three (3)
business days upon signing the letter of intent. However, due to unsatisfactory performance of Yunnan Faxi, the equity transfer contract
was terminated on December 20, 2024. The amount of $3,562,472 (RMB25&#160;million) was recorded as other receivable as of September 30,
2024.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
September 24, 2024, the Company entered into an agreement with a third party to transfer its short-term investment at the price of $</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,377,873.
<span style="background-color: white">The amount was recorded as other receivable as of September 30, 2024 and 2023.</span></span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OtherReceivableDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OtherReceivableDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OtherReceivablePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other receivable percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OtherReceivablePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_YunnanFaxiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_YunnanFaxiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Other Receivable - Schedule of Other Receivable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 24, 2024</div></th>
<th class="th" colspan="2"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ScheduleOfOtherReceivableAbstract', window );"><strong>Schedule of Other Receivable [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivable from Yunan Faxi</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 3,562,472<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Redemption of short-term investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,377,873<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 1,377,873<span></span>
</td>
<td class="nump">1,367,052<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">Prepaid value added tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">475,331<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478,899<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidAdvertising', window );">Prepayment for advertising</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">219,830<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Others</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31,090<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5,666,596<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,920,251<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
September 26, 2022, the Company entered into a letter of intent for an equity transfer with an individual, Mr. Xibo Liu, pursuant to
which, Mr. Xibo Liu transfers his&#160;51% ownership in Yunnan Faxi to the Company at the price of RMB72&#160;million (approximately
$10.0&#160;million). Based on contract terms, the Company prepaid RMB25&#160;million (approximately $3.4&#160;million) within three (3)
business days upon signing the letter of intent. However, due to unsatisfactory performance of Yunnan Faxi, the equity transfer contract
was terminated on December 20, 2024. The amount of $3,562,472 (RMB25&#160;million) was recorded as other receivable as of September 30,
2024.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
September 24, 2024, the Company entered into an agreement with a third party to transfer its short-term investment at the price of $</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,377,873.
<span style="background-color: white">The amount was recorded as other receivable as of September 30, 2024 and 2023.</span></span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfOtherReceivableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfOtherReceivableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidAdvertising">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for advertising that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidAdvertising</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 474,034<span></span>
</td>
<td class="nump">$ 503,687<span></span>
</td>
<td class="nump">$ 528,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss from disposal of property, plant and equipment</a></td>
<td class="num">$ (3,958)<span></span>
</td>
<td class="num">$ (114)<span></span>
</td>
<td class="num">$ (983)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment, Net (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 10,232,815<span></span>
</td>
<td class="nump">$ 9,750,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(6,664,765)<span></span>
</td>
<td class="num">(6,050,480)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 3,568,050<span></span>
</td>
<td class="nump">3,699,965<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 7,594,735<span></span>
</td>
<td class="nump">7,304,936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">2,007,399<span></span>
</td>
<td class="nump">1,896,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember', window );">Automobiles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">67,374<span></span>
</td>
<td class="nump">73,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office and electric equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">527,336<span></span>
</td>
<td class="nump">474,830<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 35,971<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Automobiles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Office and electric equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Automobiles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Office and electric equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 11,700<span></span>
</td>
<td class="nump">$ 5,098<span></span>
</td>
<td class="nump">$ 5,030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net - Schedule of Intangible Assets, Net (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total</a></td>
<td class="nump">$ 398,129<span></span>
</td>
<td class="nump">$ 267,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: accumulated amortization</a></td>
<td class="num">(135,251)<span></span>
</td>
<td class="num">(118,537)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">$ 262,878<span></span>
</td>
<td class="nump">148,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=upc_LandUseRightsMember', window );">Land use rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">50 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total</a></td>
<td class="nump">$ 256,211<span></span>
</td>
<td class="nump">246,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total</a></td>
<td class="nump">$ 120,412<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareDevelopmentMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total</a></td>
<td class="nump">$ 21,506<span></span>
</td>
<td class="nump">$ 20,687<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=upc_LandUseRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=upc_LandUseRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net - Schedule of Estimated Future Amortization Expense for Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Schedule of Estimated Future Amortization Expense for Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 17,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">17,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">17,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">17,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">17,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">177,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total</a></td>
<td class="nump">$ 262,878<span></span>
</td>
<td class="nump">$ 148,584<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepayment for CIP Project (Details)<br> &#165; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 25, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 25, 2021 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_ChenyuanMember', window );">Chenyuan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentforCIPProjectDetailsLineItems', window );"><strong>Prepayment for CIP Project [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentBuildingAndBuildingImprovements', window );">Total estimated budget</a></td>
<td class="nump">$ 9,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 69.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentforCIPProjectDetailsLineItems', window );"><strong>Prepayment for CIP Project [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentBuildingAndBuildingImprovements', window );">Total estimated budget</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,500,000<span></span>
</td>
<td class="nump">&#165; 165.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionContractCostProgressPaymentOffset', window );">Construction amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 407,190<span></span>
</td>
<td class="nump">&#165; 2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures</a></td>
<td class="nump">13,700,000<span></span>
</td>
<td class="nump">&#165; 95.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member] | Chenyuan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentforCIPProjectDetailsLineItems', window );"><strong>Prepayment for CIP Project [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaymentFeesOnAdvancesNet', window );">Prepayment</a></td>
<td class="nump">9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=upc_ConstructionInProgressTwoMember', window );">Construction In Progress for Next 12 Months [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentforCIPProjectDetailsLineItems', window );"><strong>Prepayment for CIP Project [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures</a></td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentforCIPProjectDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentforCIPProjectDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionContractCostProgressPaymentOffset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of progress payment netted against construction contract cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 20<br> -Topic 910<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482332/910-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionContractCostProgressPaymentOffset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentBuildingAndBuildingImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate of the carrying amounts as of the balance sheet date of investments in building and building improvements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentBuildingAndBuildingImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaymentFeesOnAdvancesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income earned, after hedging basis adjustments, from fees charged for prepayment of certain Federal Home Loan Bank (FHLBank) advances before original maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaymentFeesOnAdvancesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_ChenyuanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_ChenyuanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=upc_ConstructionInProgressTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=upc_ConstructionInProgressTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepayment for CIP Project - Schedule of Future Minimum Capital Expenditures (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationFiscalYearMaturityAbstract', window );"><strong>Schedule of Future Minimum Capital Expenditures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 7,124,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2026</a></td>
<td class="nump">5,350,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2027</a></td>
<td class="nump">1,175,616<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">$ 13,651,391<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepayment for Purchase of a Property (Details)<br> &#165; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 06, 2021 </div>
<div>USD ($) </div>
<div>m&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>May 06, 2021 </div>
<div>CNY (&#165;) </div>
<div>m&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentforPurchaseofaPropertyDetailsLineItems', window );"><strong>Prepayment for Purchase of a Property [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Office space square meters (in Square Meters)</a></td>
<td class="nump">2,749.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,749.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty', window );">Total purchase price</a></td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PercentageOfPrepayment', window );">Percentage of prepayment</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PercentageOfTotalPurchasePricePayable', window );">Percentage of total purchase price payable</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PayableDeliveryPropertyPercentage', window );">Payable delivery property percentage</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_JiangxiYueshangMember', window );">Jiangxi Yueshang [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentforPurchaseofaPropertyDetailsLineItems', window );"><strong>Prepayment for Purchase of a Property [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaymentFeesOnAdvancesNet', window );">Prepayment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">&#165; 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_JiangxiYueshangMember', window );">Jiangxi Yueshang [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentforPurchaseofaPropertyDetailsLineItems', window );"><strong>Prepayment for Purchase of a Property [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of equity interest</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PayableDeliveryPropertyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payable delivery property percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PayableDeliveryPropertyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PercentageOfPrepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of prepayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PercentageOfPrepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PercentageOfTotalPurchasePricePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of total purchase price payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PercentageOfTotalPurchasePricePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentforPurchaseofaPropertyDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentforPurchaseofaPropertyDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayments made to a related party for purchase of property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaymentFeesOnAdvancesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income earned, after hedging basis adjustments, from fees charged for prepayment of certain Federal Home Loan Bank (FHLBank) advances before original maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaymentFeesOnAdvancesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_JiangxiYueshangMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_JiangxiYueshangMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_JiangxiYueshangMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_JiangxiYueshangMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-Term Bank Loans (Details)<br> &#165; in Millions</strong></div></th>
<th class="th">
<div>Apr. 18, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 03, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 03, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 17, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 26, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 24, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 22, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 04, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 24, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 16, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 15, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 05, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 13, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 18, 2025 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Mar. 03, 2025 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 03, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>May 17, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Apr. 26, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Apr. 24, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Apr. 22, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Mar. 04, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 24, 2023 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 16, 2023 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 15, 2023 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>May 05, 2023 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Mar. 13, 2023 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Borrowing amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,856,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,482,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_JiangxiUniverseMember', window );">Jiangxi Universe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Borrowing amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,424,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTerms', window );">Short term debt term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 21,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate', window );">Fixed interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.65%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.65%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=upc_WorkingCapitalLoanMember', window );">Working Capital Loan [Member] | Jiangxi Universe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 14,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=upc_LRCBankMember', window );">LRC Bank [Member] | Universe Trade [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTerms', window );">Short term debt term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 16,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  03,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=upc_LRCBankMember', window );">LRC Bank [Member] | Jiangxi Universe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTerms', window );">Short term debt term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">eleven<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 25,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=upc_ZhujiangRuralBankMember', window );">Zhujiang Rural Bank [Member] | Jiangxi Universe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTerms', window );">Short term debt term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 24,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate', window );">Fixed interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=upc_BeijingBankMember', window );">Beijing Bank [Member] | Jiangxi Universe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTerms', window );">Short term debt term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  03,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 18,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate', window );">Fixed interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=upc_LRCBankMember', window );">LRC Bank [Member] | Universe Trade [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Borrowing amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 712,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 712,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,096,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 8.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate', window );">Fixed interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.56%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.56%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=upc_LRCBankMember', window );">LRC Bank [Member] | Jiangxi Universe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Borrowing amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,424,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,370,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate', window );">Fixed interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.31%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.56%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.31%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.56%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=upc_LRCBankMember', window );">LRC Bank [Member] | Working Capital Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTerms', window );">Short term debt term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 12,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=upc_BankOfCommunicationsCoLtdMember', window );">Bank of Communications Co., Ltd [Member] | Jiangxi Universe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Borrowing amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,154,241<span></span>
</td>
<td class="nump">$ 1,246,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 8.1<span></span>
</td>
<td class="nump">&#165; 9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTerms', window );">Short term debt term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">eleven<span></span>
</td>
<td class="text">eleven<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 13,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate', window );">Fixed interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=upc_ZhujiangRuralBankMember', window );">Zhujiang Rural Bank [Member] | Jiangxi Universe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Borrowing amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 427,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 415,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTerms', window );">Short term debt term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  04,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=upc_BeijingBankMember', window );">Beijing Bank [Member] | Jiangxi Universe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Borrowing amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,424,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,384,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Universe Trade [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Borrowing amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 712,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTerms', window );">Short term debt term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate', window );">Fixed interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Jiangxi Universe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Borrowing amount</a></td>
<td class="nump">$ 413,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTerms', window );">Short term debt term</a></td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate', window );">Fixed interest rate percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | LRC Bank [Member] | Universe Trade [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  02,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Zhujiang Rural Bank [Member] | Jiangxi Universe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Apr. 18,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the short-term debt arrangement, and disclosures pertaining to the underlying arrangements, including repayment terms, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_JiangxiUniverseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_JiangxiUniverseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=upc_WorkingCapitalLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=upc_WorkingCapitalLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=upc_LRCBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=upc_LRCBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_UniverseTradeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_UniverseTradeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=upc_ZhujiangRuralBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=upc_ZhujiangRuralBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=upc_BeijingBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=upc_BeijingBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=upc_LRCBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=upc_LRCBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=upc_BankOfCommunicationsCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=upc_BankOfCommunicationsCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=upc_ZhujiangRuralBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=upc_ZhujiangRuralBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=upc_BeijingBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=upc_BeijingBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Short-Term Bank Loans - Schedule of Short-Term Bank Loans (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowingsAbstract', window );"><strong>Short-term bank loans:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total short-term loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5,856,703<span></span>
</td>
<td class="nump">$ 5,482,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_JiangxiLulingRuralCommercialBankLRCBankMember', window );">Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowingsAbstract', window );"><strong>Short-term bank loans:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total short-term loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,849,976<span></span>
</td>
<td class="nump">2,467,105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_BankOfCommunicationsCoLtdMember', window );">Bank of Communications Co., Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowingsAbstract', window );"><strong>Short-term bank loans:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total short-term loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,154,241<span></span>
</td>
<td class="nump">1,233,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_ZhujiangRuralBankMember', window );">Zhujiang Rural Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowingsAbstract', window );"><strong>Short-term bank loans:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total short-term loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">427,497<span></span>
</td>
<td class="nump">411,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_BeijingBankMember', window );">Beijing Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowingsAbstract', window );"><strong>Short-term bank loans:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total short-term loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 1,424,989<span></span>
</td>
<td class="nump">$ 1,370,614<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 13, 2023, a subsidiary of the Company, Universe Trade, signed a loan agreement with LRC Bank to borrow RMB8 million (equivalent to $1,096,491) as working capital for one year, with the maturity date on March 12, 2024. The fixed interest rate of the loan was 4.56% per annum. Mr. Gang Lai signed guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 15, 2023, a subsidiary of the Company, Jiangxi Universe, signed a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,370,614) as working capital for eleven months, with the maturity date on May 14, 2024. The fixed interest rate of the loan was 4.56% per annum. Mr. Gang Lai signed guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 4, 2024, a subsidiary of the Company, Universe
Trade, signed a loan agreement with LRC Bank to borrow RMB5 million (equivalent to $712,494) as working capital for one year, with the
maturity date on March 3, 2025. The fixed interest rate of the loan was 4.75% per annum. Mr. Gang Lai and Jiangxi Universe jointly signed
guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 26, 2024, a subsidiary of the Company, Jiangxi
Universe, signed a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,424,989) as working capital for one year, with
the maturity date on April 25, 2025. The fixed interest rate of the loan was 4.31% per annum. Mr. Gang Lai and Universe Technology jointly
signed guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 17, 2024, a subsidiary of the Company, Universe
trade, signed a loan agreement with LRC Bank to borrow RMB5 million (equivalent to $712,494) as working capital for one year, with the
maturity date on May 16, 2025. The fixed interest rate of the loan was 3.65% per annum. Mr. Gang Lai and Jiangxi Universe jointly signed
guarantee agreements with LRC Bank to provide credit guarantee for this loan.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
March 3, 2025, a subsidiary of the Company, Universe Trade, signed a loan agreement with LRC Bank to borrow RMB5 million (equivalent to
$712,494) as working capital for one year, with the maturity date on March 2, 2026. The fixed interest rate of the loan was 3.65% per
annum. Mr. Gang Lai and Jiangxi Universe jointly signed guarantee agreements with LRC Bank to provide credit guarantee for this loan.</span>
&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
On April 22, 2024, a subsidiary of the Company, Jiangxi Universe, signed
a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,424,989) as working capital for one year, with the maturity date
on April 21, 2026. The fixed interest rate of the loan was 3.60% per annum. Mr. Gang Lai and Universe Technology jointly signed guarantee
agreements with LRC Bank to provide credit guarantee for this loan.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 15, 2023, the Company&#8217;s subsidiary, Jiangxi Universe, signed a loan agreement with Bank of Communications to borrow RMB9 million (equivalent to $1,246,486) as working capital for eleven months, with the maturity date on May 18, 2024. The fixed interest rate of the loan was 4.0% per annum. Mr. Gang Lai, Universe Trade, and an unrelated third party, Jiangxi Province Financing Guarantee Group Co., Ltd., jointly signed guarantee agreements with Bank of Communications to provide credit guarantee for this loan. The loan was fully repaid upon maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 16, 2024, the Company&#8217;s subsidiary, Jiangxi Universe, signed a loan agreement with Bank of Communications to borrow RMB8.1 million (equivalent to $1,154,241) as working capital for eleven months, with the maturity date on May 13, 2025. The fixed interest rate of the loan was 3.9% per annum. Mr. Gang Lai, Universe Trade, and an unrelated third party, Jiangxi Province Financing Guarantee Group Co., Ltd., jointly signed guarantee agreements with Bank of Communications to provide credit guarantee for this loan.</span></p></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 5, 2023, a subsidiary of the Company, Jiangxi Universe, entered into a loan agreement with Zhujiang Rural Bank to borrow RMB 3 million (equivalent to $415,495) as working capital for one year, with the maturity date on May 4, 2024. The fixed interest rate of the loan was 3.65% per annum. The Company pledged certain patents owned by the Company as collateral to guarantee this loan. The loan was fully repaid upon maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
On April 24, 2024, a subsidiary of the Company, Jiangxi
Universe, entered into a loan agreement with Zhujiang Rural Bank to borrow RMB3 million (equivalent to $427,497) as working capital for
one year, with the maturity date on April 24, 2025. The fixed interest rate of the loan was 3.65% per annum. The Company pledged certain
trademarks owned by the Company as collateral to guarantee this loan.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 24, 2023, a subsidiary of the Company, Jiangxi Universe, entered into a loan agreement with Beijing Bank to borrow RMB 10 million (equivalent to $1,384,984) as working capital for one year, with the maturity date on July 18, 2024. The fixed interest rate of the loan was 4.25% per annum. There was no guarantee requirement for this loan. The loan was fully repaid upon maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 3, 2024, a subsidiary of the Company, Jiangxi Universe, entered into a loan agreement with Beijing Bank to borrow RMB 10 million (equivalent to $1,424,989) as working capital for one year, with the maturity date on July 3, 2025. The fixed interest rate of the loan was 4.15% per annum. Mr. Gang Lai provided credit guarantee for this loan.</span></p></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_JiangxiLulingRuralCommercialBankLRCBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_JiangxiLulingRuralCommercialBankLRCBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_BankOfCommunicationsCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_BankOfCommunicationsCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_ZhujiangRuralBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_ZhujiangRuralBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_BeijingBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_BeijingBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Bank Loans (Details)<br> &#165; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 23, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 23, 2023 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_LongTermBankLoansDetailsLineItems', window );"><strong>Long-Term Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 304,516<span></span>
</td>
<td class="nump">$ 190,184<span></span>
</td>
<td class="nump">$ 199,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=upc_LRCBankMember', window );">LRC Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_LongTermBankLoansDetailsLineItems', window );"><strong>Long-Term Bank Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Borrowing amount</a></td>
<td class="nump">$ 2,137,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTerm', window );">Working capital term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">Nov. 14,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Fixed interest rate</a></td>
<td class="nump">3.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_LongTermBankLoansDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_LongTermBankLoansDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=upc_LRCBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=upc_LRCBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Long-Term Bank Loans - Schedule of Long-Term Bank Loans (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=upc_LRCBankMember', window );">LRC Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLoansPayableAbstract', window );"><strong>Long-term bank loans:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLoansFromBank', window );">Long-term bank loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 2,137,483<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 23, 2023, a subsidiary of the Company, Jiangxi Universe, signed a loan agreement with LRC Bank to borrow RMB15 million (equivalent to $2,137,483) as working capital for two years, with the maturity date on November 14, 2025. The fixed interest rate of the loan was 3.95% per annum. The Company pledged buildings of Jiangxi Universe as collateral to guarantee this loan.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansFromBank">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the operating cycle if longer, excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansFromBank</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=upc_LRCBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=upc_LRCBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br> &#165; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 13, 2022</div></th>
<th class="th">
<div>May 06, 2021 </div>
<div>USD ($) </div>
<div>m&#178;</div>
</th>
<th class="th">
<div>May 06, 2021 </div>
<div>CNY (&#165;) </div>
<div>m&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Office space totaling (in Square Meters) | m&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,749.3<span></span>
</td>
<td class="nump">2,749.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="nump">&#165; 32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=upc_JiangxiYueshangMember', window );">Jiangxi Yueshang [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaymentFeesOnAdvancesNet', window );">Prepayment amount</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">&#165; 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Rights to use trademarks | $</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_MrGangLaiMember', window );">Mr. Gang Lai [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayments made to a related party for purchase of property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaymentFeesOnAdvancesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income earned, after hedging basis adjustments, from fees charged for prepayment of certain Federal Home Loan Bank (FHLBank) advances before original maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaymentFeesOnAdvancesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=upc_JiangxiYueshangMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=upc_JiangxiYueshangMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_MrGangLaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_MrGangLaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Schedule of Nature of Relationships With Related Parties (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrGangLaiMember', window );">Mr. Gang Lai [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships', window );">Nature of relationships with related parties</a></td>
<td class="text">Chief Executive Officer and chairman of the Company&#8217;s Board of Directors<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrYajunHuMember', window );">Mr. Yajun Hu [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships', window );">Nature of relationships with related parties</a></td>
<td class="text">General Manager of Jiangxi Universe<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MsLinYangMember', window );">Ms. Lin Yang [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships', window );">Nature of relationships with related parties</a></td>
<td class="text">Chief Financial Officer of the Company<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_GuangzhouNingjingInvestmentCoLtdGuangzhouNingjingMember', window );">Guangzhou Ningjing Investment Co., Ltd (Guangzhou Ningjing) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships', window );">Nature of relationships with related parties</a></td>
<td class="text">Under common control of Mr. Gang Lai<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents a description of the nature of common ownership or management control relationships with other entities, regardless of there being transactions between the entities, when the existence of that control could result in operating results or financial position of the reporting entity significantly different from that which would have been obtained if the entities' were autonomous.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrGangLaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrGangLaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrYajunHuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrYajunHuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MsLinYangMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MsLinYangMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_GuangzhouNingjingInvestmentCoLtdGuangzhouNingjingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_GuangzhouNingjingInvestmentCoLtdGuangzhouNingjingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions - Schedule of Related Parties (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrYajunHuMember', window );">Mr. Yajun Hu [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">61,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="nump">6,900,584<span></span>
</td>
<td class="nump">540,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrGangLaiMember', window );">Mr. Gang Lai [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="nump">6,900,499<span></span>
</td>
<td class="nump">$ 540,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MsLinYangMember', window );">Ms. Lin Yang [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrYajunHuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrYajunHuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrGangLaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrGangLaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MsLinYangMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MsLinYangMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayLineItems', window );"><strong>Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Assessable profit rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayDescription', window );">Tax holiday description</a></td>
<td class="text">Under
the Enterprise Income Tax (&#8220;EIT&#8221;) Law of PRC, domestic enterprises and Foreign Investment Enterprises (&#8220;FIEs&#8221;)
are usually subject to a unified 25% enterprise income tax rate while preferential tax rates, tax holidays and even tax exemption may
be granted on a case-by-case basis. EIT grants preferential tax treatment to High and New Technology Enterprises (&#8220;HNTEs&#8221;).
Under this preferential tax treatment, HNTEs are entitled to an income tax rate of 15%, subject to a requirement that they re-apply for
their HNTE status every three years. Jiangxi Universe, one of the Company&#8217;s main operating subsidiaries in the PRC, was approved
as a HNTE and is entitled to a reduced income tax rate of 15% beginning November 2016 with a term of three years. In December 2019 and
November 2022, Jiangxi Universe successfully renewed its HNTE certification with local government and will continue to enjoy the reduced
income tax rate of 15% for three years, respectively, through November 2025. Universe Trade, another operating subsidiary of the Company
in the PRC, was approved as a HNTE and was entitled to a reduced income tax rate of 15% beginning December 2020 with a term of three
years through December 2023. Universe Trade did not
successfully renew its HNTE status at the end of December 2023 and, therefore, has been subject to the standard PRC enterprise income
tax rate of 25% starting from January 2024. EIT is typically governed by the local tax authority
in the PRC. Each local tax authority at times may grant tax holidays to local enterprises as a way to encourage entrepreneurship and
stimulate local economy. The corporate income taxes for the years ended September 30, 2024, 2023 and 2022 were reported at a blended
reduced rate as a result of certain of the PRC subsidiaries of the Company&#8217;s being approved as a HNTE and enjoying a 15% reduced
income tax rate. Although Jiangxi Universe was approved as a HNTE and enjoying a 15% reduced income tax rate, it incurred operating loss
for the year ended September 30, 2024, with no impact of the tax holidays on PRC corporate income taxes for the year ended September
30, 2024.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings', window );">Income tax rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayAggregateDollarAmount', window );">Tax holidays decreased PRC corporate income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 309,840<span></span>
</td>
<td class="nump">$ 694,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare', window );">Tax holidays on net income per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_HK', window );">Hong Kong [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayLineItems', window );"><strong>Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Assessable profit rate</a></td>
<td class="nump">16.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxHolidayAggregateDollarAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes from which a reporting entity is exempt or for which it will receive a reduction in income taxes as a result of the income tax holiday granted by the taxing jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxHolidayAggregateDollarAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxHolidayDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the factual circumstances giving rise to an income tax exemption or special reduction received from a taxing jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxHolidayDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount effect of the income tax benefit resulting from the income tax holidays granted by taxing jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxHolidayLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxHolidayLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_HK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_HK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes - Schedule of Components of the Income Tax Provision (Benefit) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current tax expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 685,937<span></span>
</td>
<td class="nump">$ 1,357,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred tax expense (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax expense</a></td>
<td class="nump">606,704<span></span>
</td>
<td class="nump">1,567,656<span></span>
</td>
<td class="num">(542,375)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">606,704<span></span>
</td>
<td class="nump">2,253,593<span></span>
</td>
<td class="nump">815,322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KY', window );">Cayman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current tax expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred tax expense (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_HK', window );">Hong Kong [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current tax expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred tax expense (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">PRC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current tax expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">685,937<span></span>
</td>
<td class="nump">1,357,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred tax expense (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax expense</a></td>
<td class="nump">$ 606,704<span></span>
</td>
<td class="nump">$ 1,567,656<span></span>
</td>
<td class="num">$ (542,375)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_HK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_HK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes - Schedule of Table Reconciles the China Statutory Rates to the Company&#8217;s Effective Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Schedule of Effective Tax Rate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory PRC income tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays', window );">Effect of income tax holiday</a></td>
<td class="num">(5.90%)<span></span>
</td>
<td class="num">(8.20%)<span></span>
</td>
<td class="num">(9.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness', window );">Permanent difference</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(25.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Non-PRC entities not subject to PRC income tax</a></td>
<td class="num">(2.70%)<span></span>
</td>
<td class="num">(4.40%)<span></span>
</td>
<td class="num">(2.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(23.90%)<span></span>
</td>
<td class="num">(64.40%)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(7.50%)<span></span>
</td>
<td class="num">(52.10%)<span></span>
</td>
<td class="num">(11.50%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income exempt from income tax because of a tax holiday.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry-forwards</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 599,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Allowance for doubtful accounts</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">599,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 599,078<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Taxes - Schedule of Taxes Payable (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrentAbstract', window );"><strong>Schedule of Taxes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ValueAddedTaxPayable', window );">Value added tax payable</a></td>
<td class="nump">$ 873,750<span></span>
</td>
<td class="nump">$ 303,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OtherTaxesPayable', window );">Other taxes payable</a></td>
<td class="nump">147,431<span></span>
</td>
<td class="nump">131,045<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Total taxes payable</a></td>
<td class="nump">$ 1,021,181<span></span>
</td>
<td class="nump">$ 434,758<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OtherTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of other taxes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OtherTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ValueAddedTaxPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of value added tax payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ValueAddedTaxPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignFinancialInstitutionsMandatedDeposits', window );">Deposit at financial institutions (in Dollars)</a></td>
<td class="nump">$ 4,430,607<span></span>
</td>
<td class="nump">$ 5,223,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Top 10 customers [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue percentage</a></td>
<td class="nump">22.50%<span></span>
</td>
<td class="nump">27.20%<span></span>
</td>
<td class="nump">32.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Customer [Member] | Revenue Benchmark [Member] | Guben Yanling Pill [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue percentage</a></td>
<td class="nump">37.20%<span></span>
</td>
<td class="nump">36.40%<span></span>
</td>
<td class="nump">42.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member] | Purchase [Member] | Supplier One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue percentage</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">29.60%<span></span>
</td>
<td class="nump">10.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member] | Purchase [Member] | Two Supplier [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue percentage</a></td>
<td class="nump">13.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignFinancialInstitutionsMandatedDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of mandated deposits required of branches of foreign institutions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 505<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477270/942-505-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignFinancialInstitutionsMandatedDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=upc_TopTenCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=upc_TopTenCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=upc_CustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=upc_CustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=upc_GubenYanlingPillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=upc_GubenYanlingPillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=upc_PurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=upc_PurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=upc_supplierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=upc_supplierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=upc_TwoSupplierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=upc_TwoSupplierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2024</div></th>
<th class="th"><div>Jul. 15, 2024</div></th>
<th class="th"><div>Mar. 29, 2021</div></th>
<th class="th"><div>Aug. 07, 2020</div></th>
<th class="th" colspan="2"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Mar. 24, 2025</div></th>
<th class="th"><div>Nov. 12, 2024</div></th>
<th class="th"><div>Jul. 27, 2023</div></th>
<th class="th"><div>Jul. 03, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 25, 2021</div></th>
<th class="th"><div>Dec. 11, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,250,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,880<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplit', window );">Outstanding ordinary shares ratio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">outstanding ordinary shares at a ratio of 320-for-1 share<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ShareIssuedAfterTheSplit', window );">Share issued after the split</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ShareOutstandingAfterTheSplit', window );">Share outstanding after the split</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnits', window );">Share capital (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 140,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Outstanding shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,880<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceed (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ReserveIsEqualPercentage', window );">Reserve is equal percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_StatutoryReserve', window );">Statutory amount (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,439,535<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,439,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_RestrictedNetAssets', window );">Restricted net assets (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,786,656<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 31,786,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=upc_UnderwriterWarrantsMember', window );">Underwriter warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per warrant (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OrdinarySharesSoldPercentage', window );">Ordinary shares sold</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant adjustments share (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 495<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnits', window );">Share capital (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 312,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnits', window );">Share capital (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.01875<span></span>
</td>
<td class="nump">$ 0.01875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Share issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,333<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnits', window );">Share capital (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Outstanding shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,880<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,042<span></span>
</td>
<td class="nump">6,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.01875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.01875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,666,666.6666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.01875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,666,666.6666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_UniverseINCMember', window );">Universe INC [Member] | Ordinary Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OriginalShareIssued', window );">Original issued shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_OriginalSharesParValue', window );">Original shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Share issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnits', window );">Share capital (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Excess Stock, Shares Issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Ordinary Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Share issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,666,666.6666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Outstanding shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Ordinary Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Ordinary Shares [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Ordinary Shares [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Ordinary Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Ordinary Shares [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Ordinary Shares [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Outstanding shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors Chairman [Member] | Ordinary Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.01875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsShares', window );">Ordinary shares divided</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnits', window );">Share capital (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceed (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="nump">$ 28,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=upc_UnderwriterWarrantsMember', window );">Underwriter warrants [Member] | Ordinary Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Purchase to warrant</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=upc_StatutoryReserveAndRestrictedNetAssetsMember', window );">Statutory Reserve and Restricted Net Assets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_StatutorySurplusPercentage', window );">Statutory surplus percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="16"></td></tr>
<tr><td colspan="16"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retrospectively restated for effect of 15-for-1 and 40-for-1 share
consolidations.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retrospectively restated for effect of 15-for-1 and 40-for-1 share
consolidations.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OrdinarySharesSoldPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares sold percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OrdinarySharesSoldPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OriginalShareIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the share of original share issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OriginalShareIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OriginalSharesParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Original shares par value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OriginalSharesParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ReserveIsEqualPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reserve is equal percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ReserveIsEqualPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_RestrictedNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted net assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_RestrictedNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ShareIssuedAfterTheSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the share of stock issued after the split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ShareIssuedAfterTheSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ShareOutstandingAfterTheSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the share outstanding after the split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ShareOutstandingAfterTheSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_StatutoryReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>StatutoryReserve</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_StatutoryReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_StatutorySurplusPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Statutory surplus percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_StatutorySurplusPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=upc_UnderwriterWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=upc_UnderwriterWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_UniverseINCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_UniverseINCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=upc_CommonStockOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=upc_CommonStockOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=upc_UnderwriterWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=upc_UnderwriterWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=upc_StatutoryReserveAndRestrictedNetAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=upc_StatutoryReserveAndRestrictedNetAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> &#165; in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th"><div>Jan. 13, 2022</div></th>
<th class="th">
<div>May 06, 2021 </div>
<div>USD ($) </div>
<div>m&#178;</div>
</th>
<th class="th">
<div>May 06, 2021 </div>
<div>CNY (&#165;) </div>
<div>m&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Capital expenditure cip project</a></td>
<td class="nump">$ 13,651,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">Future minimum capital expenditures for next 12 month</a></td>
<td class="nump">7,124,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Commercial office space totaling (in Square Meters) | m&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,749.3<span></span>
</td>
<td class="nump">2,749.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty', window );">Prepayments made to a related party for purchase of property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="nump">&#165; 32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepayment</a></td>
<td class="nump">3,400,000<span></span>
</td>
<td class="nump">&#165; 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_JiangxiYueshangMember', window );">Jiangxi Yueshang [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepayment</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">&#165; 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_MrGangLaiMember', window );">Mr. Gang Lai [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayments made to a related party for purchase of property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_JiangxiYueshangMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_JiangxiYueshangMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_MrGangLaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_MrGangLaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ / shares in Units, &#165; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 06, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 12, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 15, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th" colspan="2">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 24, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 20, 2024</div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 27, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Sep. 26, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,880<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnits', window );">Share capital (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,250,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from offering (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,625,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivable | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,666,596<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,920,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28125<span></span>
</td>
<td class="nump">$ 0.01875<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnits', window );">Share capital (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">33,333<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares par value (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_YunnanFaxiMember', window );">Yunnan Faxi [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,562,472<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnits', window );">Share capital (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Pre-funded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,362,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Purchase price of offered share (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Ordinary shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,362,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares par value (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary shares [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.28125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">388,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary shares [Member] | Subsequent Event [Member] | Common Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.28125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnits', window );">Share capital (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 140,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares par value (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Yunnan Faxi [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="12"></td></tr>
<tr><td colspan="12"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retrospectively restated for effect of 15-for-1 and 40-for-1 share
consolidations.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retrospectively restated for effect of 15-for-1 and 40-for-1 share
consolidations.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_YunnanFaxiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=upc_YunnanFaxiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=upc_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=upc_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=upc_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=upc_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Information of the Parent Company (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Financial Information of the Parent Company [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNetAssetsPercentage', window );">Net assets percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_MinorityInterestsOwnershipPercentageByParent', window );">Subsidiary exceeded percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_MinorityInterestsOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subsidiary exceeded percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_MinorityInterestsOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNetAssetsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of value of derivative contract to net assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNetAssetsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Information of the Parent Company - Schedule of Consolidated Financial Statements (Details) - Parent [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 25,058,414<span></span>
</td>
<td class="nump">$ 9,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,377,873<span></span>
</td>
<td class="nump">1,367,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investment in subsidiaries</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,749,310<span></span>
</td>
<td class="nump">15,715,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">46,049,430<span></span>
</td>
<td class="nump">27,970,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49,475<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">546,489<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS&#8217; EQUITY</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, $11.25 par value, 11,250,000 shares authorized, 42,880 and 6,062 shares issued and outstanding as of September 30, 2024 and 2023, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">482,400<span></span>
</td>
<td class="nump">67,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">53,864,720<span></span>
</td>
<td class="nump">29,279,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">(Accumulated deficit) Retained earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,732,033)<span></span>
</td>
<td class="nump">995,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,112,146)<span></span>
</td>
<td class="num">(2,372,240)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,502,941<span></span>
</td>
<td class="nump">27,970,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">46,049,430<span></span>
</td>
<td class="nump">27,970,153<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_ParentMember', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from subsidiaries</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,863,833<span></span>
</td>
<td class="nump">10,878,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37,300,120<span></span>
</td>
<td class="nump">12,254,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 497,014<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retrospectively restated for effect of 15-for-1 and 40-for-1 shares
consolidations.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Information of the Parent Company - Schedule of Consolidated Financial Statements (Parentheticals) (Details) - Parent [Member] - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems', window );"><strong>Condensed Balance Sheet Statements, Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="nump">$ 11.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">11,250,000<span></span>
</td>
<td class="nump">11,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">42,880<span></span>
</td>
<td class="nump">6,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">42,880<span></span>
</td>
<td class="nump">6,062<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retrospectively restated for effect of 15-for-1 and 40-for-1 shares
consolidations.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedBalanceSheetStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Information of the Parent Company - Schedule of Parent Company Statements of Operations and Comprehensive Loss (Details) - Parent [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">$ (592,021)<span></span>
</td>
<td class="num">$ (134,141)<span></span>
</td>
<td class="num">$ (384,214)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expenses</a></td>
<td class="num">(87,292)<span></span>
</td>
<td class="num">(730)<span></span>
</td>
<td class="num">(420)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of subsidiaries</a></td>
<td class="num">(8,047,985)<span></span>
</td>
<td class="num">(6,446,153)<span></span>
</td>
<td class="num">(7,525,004)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,727,298)<span></span>
</td>
<td class="num">(6,581,024)<span></span>
</td>
<td class="num">(7,909,638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">1,260,094<span></span>
</td>
<td class="num">(779,351)<span></span>
</td>
<td class="num">(3,752,143)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to the Company</a></td>
<td class="num">$ (7,467,204)<span></span>
</td>
<td class="num">$ (7,360,375)<span></span>
</td>
<td class="num">$ (11,661,781)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Information of the Parent Company - Schedule of Parent Company Statements of Cash Flows (Details) - Parent [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,727,298)<span></span>
</td>
<td class="num">$ (6,581,024)<span></span>
</td>
<td class="num">$ (7,909,638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_upc_ChangeInFairValueOfShorttermInvestments', window );">Equity in earnings of subsidiary</a></td>
<td class="nump">8,047,985<span></span>
</td>
<td class="nump">6,446,153<span></span>
</td>
<td class="nump">7,525,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Due to related parties</a></td>
<td class="nump">497,014<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accrued expense</a></td>
<td class="nump">49,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(132,824)<span></span>
</td>
<td class="num">(134,871)<span></span>
</td>
<td class="num">(384,634)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of ordinary shares</a></td>
<td class="nump">24,999,992<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromAffiliates', window );">Cash repayment from subsidiaries</a></td>
<td class="nump">14,511<span></span>
</td>
<td class="nump">115,133<span></span>
</td>
<td class="nump">303,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">25,014,503<span></span>
</td>
<td class="nump">115,133<span></span>
</td>
<td class="nump">303,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">EFFECT OF CHANGES OF FOREIGN EXCHANGE RATES ON CASH</a></td>
<td class="nump">167,487<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="num">(588)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">CHANGES IN CASH</a></td>
<td class="nump">25,049,166<span></span>
</td>
<td class="num">(19,669)<span></span>
</td>
<td class="num">(81,476)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, beginning of year</a></td>
<td class="nump">9,248<span></span>
</td>
<td class="nump">28,917<span></span>
</td>
<td class="nump">110,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, end of year</a></td>
<td class="nump">$ 25,058,414<span></span>
</td>
<td class="nump">$ 9,248<span></span>
</td>
<td class="nump">$ 28,917<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ChangeInFairValueOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of change in fair value of short-term investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ChangeInFairValueOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributionsFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributionsFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>140
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *Z G5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( *Z G5J$IW8A\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( *Z G5K:*52(& <  ) B   8
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M47],U5+7#X-Z8E7IF_%:66KM?IC36PJU$Z#]3-$9;";.0/LZF_T+4$L#!!0
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M84Q$3WO(6@G!_!)B8J19F1R61[/VG#N)CKZ:LWA[?Z7927S;<!=GJR&87T,
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M+"NR[='3[04EZ^*0X0.AE*R*CTL<LM<[;L"^GQ-"7RYX ]4!X/%_4$L#!!0
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M<'4;\HYD\79#Y]R50UL/1#ZD5.CZQ4W4VNF01\ ]L(F@?<IR_P1^1FKE&4I
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M/CWUJY1FK6MKFCIK]?+[O;/IB]='>#U=\+/1-S;Z.\.=S)OF*WZX*+_?.T"
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M7]Y_OGC_8_;QP]\OSB_>7HY!?O?:[S]\?JMFV5_^=#J;SEYF#W]4]KJPQBI
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M5K#N!MA-,/,0[G4@(LH(CB)(WTT0%5>ZAN.K@)#A=[W!!0UC#3@0/UUV! ,
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MQ771A,)*8[_F5 N-+0<=1KF0K5REO*^VE4P;B7-P> &19!G!AJ6HT)G_V*N
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M.]DJ6TVAE]!;B-10/ ;Q$74D_>R:*;*H-XTVX[O?R9#4T;R>7%&!$+:FCF[
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MI_K"J6@IS,%(KP/M07O".3/8'G]IQ=92F0!835"/1-,@T7P[[/5_HL+!.=7
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M[2;CHAD(O]V;L7K-U(8+395>4VCH?QQ[H)I1U1A&EFX\Q-+0L''+C*8[*NM
MW]=2FIUA#^C^7YC_ E!+ P04    " "N@)U:/VH9[(,$  #]"0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q-"YX;6R=5MMNVS@0?==7#-QLD0"JK(MO26P#
M<>HB!9I-X&2[NUCL VV-+:(2J9*4'?]]AY2M.($3+/;%YF7FZ)RYD!QNI/JA
M,T0#3T4N]*B5&5->M-MZD6'!="!+%+2SE*I@AJ9JU=:E0I8ZIR)OQV'8:Q>,
MB]9XZ-;NU7@H*Y-S@?<*=%443&TGF,O-J!6U]@LSOLJ,76B/AR5;X0.:/\I[
M1;-V@Y+R H7F4H#"Y:AU%5U,.M;>&7SGN-$'8[!*YE+^L).OZ:@56D*8X\)8
M!$9_:[S&/+= 1./G#K/5?-(Z'H[WZ%^<=M(R9QJO9?XG3TTV:@U:D.*25;F9
MR<T-[O1T+=Y"YMK]PJ:VC<EX46DCBYTS,2BXJ/_9TRX.!PZ#\ V'>.<0.][U
MAQS+S\RP\5#)#2AK36AVX*0Z;R+'A4W*@U&TR\G/C.],A@IFN$"^9O,<AVU#
MJ':OO=@A3&J$^ V$*(9;*4RF82I23%\"M(E.PRG><YK$[R(^8!E $OH0AW'G
M';RDT9@XO.0_:H1_KN;:*"J(?X_)K<$ZQ\%LDUSHDBUPU*(NT*C6V!I__!#U
MPLMWJ'8:JIWWT,=WCS?3&<RFU].OWZ\FWZ;'^+V/\/O=XQ3Z\/'#(([B2W@-
M"'4P5!,,;R&IP[31()= >["4.74J%ZL+[\HM4CH,%G/RHIQX-B<V,8EW$-"E
MD@7\70DFX M[XG :G<$))'ZW%_N=?DSC3V2>8E&Z5B10G4EE/AE4!7"Q1FVH
MT0V<QF<0^4F_[P_ZB1WU^G[8C;U[A27C*:Q97B&PE.H,#'N"3K_K)TE$_P-_
M<'Y>VVT=%)U79+A&9;@F,1!'Y_X@"8F(BX"&)/+#\Q#Z'3\)0^]U6(ARU^_U
M>G[WO$?CR#^/0S_N1IZ5=B>\YZ#$/5>HL>^B=RV+DHDM$ 54Q)(+(X%!CH;F
M5C@M-/0$X,^*FRU0,0J])(,--YE=YR+E:YY6+/?A5@7P%Y]+^,8K'\I*Z8H1
M@I'>)N.+[*5! Z4AXQJZT6\@-X*F&2\)U2:IR1(Q.Z3,C)N6BB_0,IW=3BAU
M!<]SF[-35I9*/G$Z"#'?>B=1&(3[S;, )G0RID!V5$ZNM<#F5K\,2KE+(R''
MW3>0X20).@VP"PC1-IE"A-/DS)M7E$[4&E*VU5"5!*#Y2M@4VT^]#G0 -W*#
M5 8^I%0Z)+D2FE%-+(FC5,0)E;O:1"WZ(#XU]]<9VNOS-DP[C5P0;R?],U5/
M71*[LRN 1T)@A:PH7P1^\MP1IR]B0#H)C:I/*EO:-):OZY&]T8N!9YOF945V
MZL^_5Y%T'ZXHI*Y5ZJ(C8ZY2*)FR<N6S8DYGP_%V?5TQ)\_-&W@'TO^/.*>
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MT;;=)#76-%852WSBL0\;#QP"_*7^$&!^"SKA$[?E,6S<5B[42KV9'2!+:#Q
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MF:0S4Y1"+^C2=NF+T'.Z$(K.,B5G=/XDDXJ52=>SF4JD):%32C*AH#G-KE<
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M"-AP7$J^0;,A:<0$-:7*)3DZ+V7.:EB,!%3@4BR@0!;78(TWDJ'V; \O G[
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M;E*?8)[-ZW/@I;!S!;GG<H:E_>Z'O0[9^FQ5WWA3AO/,U'B<CL)EAN.HM&R
M]S,#,3<W[&!YP#WY-U!+ P04    " "N@)U:SDX*-V8*  #?&@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970R,BYX;6R=66USVS82_LY?@5&=CC-#RWJU;"?Q
MC..XD[17-].XO;NYN0\0"4EH2((%0,NZ7W_/+DB*LF5=KI.)19' [K.[S[Z
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M#CGJ2Q(NNH7T^B8B-%V:/F$,UI?R-[J8K@2M&JS*VE,[SZ4!-J$K4#<YV,7
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M\'=(W6ASJ-9;X6WA((]<'=+QB'TOVOF<$]$?$)24N6>>;ZE9N[B+B\TVQ^_
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M?<MSV(\_Q)[KG?X#!]A=7:J:YY55%1KE4OQ1RU*@T"M%R-_7F6"N=^@$^_S
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MLFAM4VWD99C!QI3\;_9%-B)ZX?)XSPLS>8$VXAD/1+-\DS79JV_JZBZI\6F
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M-+U;F\7:/_^I!/*NK4[^\M<T?/BH%^NR*JK5?:J^-UFY^F+\C_%C=08@<)@
M)BO7>I)<%04,T>CZ2%8!3*" 6<-J\7' B=)FQ&'@BUHGNC! IK2\=@L[L(CW
M \ IOX;[Q"",!%9M&OA0RH*>F*>=Q>>F!A96 )K6\)#_!(";&J@_V50U[A9
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M<D 4J.LAZR4VR)-<@"ZUTGX"T9QKO6J+C.@%)VVK[G;$<YZHJP+PJ5VM.^>
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MJ+3#(8-N3W;$?8(.1=))*MMW*XF?)T[N4%$*2C?N)=%+F.4:TY%OM4 L10[
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M]Y/U+W1Y<F G1'$XSAKM^T"0--!R)S*5^9A7F/,D^0X&4#]@#!-0ZO@Y<I-
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MVJ! YRNM_4X(#OHG=_P54$L#!!0    ( *Z G5HS5CQ ] ,  *H)   9
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M*R9V0!10$4LNC 0&!1J:6^&TT-$3@#]J;G9 A2?TF@P:;G*[SD7&MSRK61'
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M!EK%1$LD5$MW/9UO8N-O'3XR.*J+-3&9[(7X;(R_RJ4;&$' H="&@>+K*SP
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MIQL#P7.@%O!1"+RT2BLC3-= *L'Q\K/V,'?6=A/;J*'9@S2]=#XHJ'I..*O
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MI'' [Y40^FR8 ..?:_4=4$L#!!0    ( *Z G5HH,FLJ/P,  )X'   9
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M:L-)8I@"T]010;-"C\^>=BA>*$'S+UG08OL/D[;P,V+4APL8N@$QN^Y%]F
M?3?J^^XH"JTYA, -AGUW$ S.GJ1E>@%!Y [Z@1M=!W"L0=Z!L')4VWI\:$AD
M59A&8]UI-Z%FC3#_N#?C[8&I+2\T"-Q0J'\U[#N@FI'1&$:6M4S7TI#HZVU&
M4Q:5=:#[C91F;]@$W=R.?P-02P,$%     @ KH"=6G"/'(,U!@  ]AT  !D
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MM9A?,9UQ>E<"E^3:[9P. M"U0-8+JTHO2HFR)'%^FM,_!;4SH/.EHC>V6;@
MS5]J\@=02P,$%     @ KH"=6F(=RHA= P  %0@  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#,N>&ULG59M;],P$/[>7W$*"'52:=+T9=UH*ZT;#- *TS9
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M&L=/L]SAO ^2!'!_(X0^O9"!YB^(^;]02P,$%     @ KH"=6@@)[L%1!P
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MH "L+\I2[5[00?O_B-N_ %!+ P04    " "N@)U:'?F[3$@<  "I(0( &0
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M'@]YE+ 7W\VO_3( 30VB6HIJ8J]%EP%H%!#5-*H95+.HYE#-HUJ@M')[YU'
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M% OEDI2BCS^C+W<TFV@[,[ARS- 4+BC-!J4YH#07E.9!T9K!4F=ZL/FMOA'
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MRYSQR*2GT., DC'(7ZLX.3'L@CE7&0VAYYD5H4 ^@]=__PZW@R\.AHV*8:-
M;ZS+^#^+_7AG -&MAD2MS*UQ@-R:56Y-9_5OYIE9E89Q7C+FEO$JDFX8$J 7
MH%(Y&+4J1BTGU("E+,F32@WH#QK0<&I&F<5AZPU5O5V"<4ZR9U';50KMHPJF
M?8#<3JO<3M]&,&Z8UD:]="I"G5WU<I&;S5J,&0?WIN($WK..9Q7MLZ-JY.P
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M';9Z6%9XMX#Q#GB^T=H=#=_O_6U5_ 902P,$%     @ KH"=6G(2$KUV @
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MU;;'-C"R=AUF)0WV*S?<X!\%E$W ]4)*\Q#8IM7_H])?4$L#!!0    ( *Z
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MK(NG),O&7PZTF-M6.!8:&ZO]G.%;":0QP/6)$'H],!O4KZ_D+U!+ P04
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M@KKYF8AF.B.::X*5!')>".2\?N7'?*$D@588V!+8 3- QC-W!]9HGY\[>Q-
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ME"Q,'WV,/,R3!JI^R9C<OB0=%-?GH_\ 4$L#!!0    ( *Z G5K#PT1:"P4
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M$!Z)X-K6Z%"#5O37:G#L,O1<RVI>^F'-</@\0RPWM\FXB>OPZ!S[01#XH^"
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MC"F)J- 3<'S)N=HVM(/ZWQ+3_P%02P,$%     @ KH"=6HSQ9H:N @  @0<
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M42%XB7(B*RXQ1;Q 55LX55LXL"V<+JGQB^#.PT'</U#:8>7[!^E(.XP&_?!
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M!+BB61_[^,4_QO&=, B?L;\,LT>A%XZZL(;*W-IH]2'G*Q4K5DB208)"ZR3
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M3_YJ-G@]F#Q_I07MV$4U!=545--034<U ]5,5+-0S48U!]5<5/,ZG<T^NL\
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M_AMV___W]7K[\(<W.__K>O/GW3[>_S]02P,$%     @ KH"=6FX07X"@!@
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M@L+6(%0':)]Q+M<W:H#\BZ+)/U!+ P04    " "N@)U:+ML/AK\#   B$P
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MP./Q _L'KYVTK)G!A1+?>&9WT^!= !EN627LE3I\Q$;/T/%ME##^"8?&=A#
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M(GND.&T5IZ?WMT-Q1XSSTRS?H\YS48-&'N1J[7X61\G;]!T=S/UQ DZ2=R<
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M66R_J^5'6!,:$5Z@8N/^LF4^=^2U69 9JY*U,7J0")G_\H>U$"6#HUT&_MK
MWS+H#W<8#-8&@^<:#-<&0Z=,3L7I,.663\ZT6C)-LQ&-'IR8SAKI"TEQO[$:
MOPJTLY-;_@"&O9V"Y2(V[]@!N[N9LK=_O#OK682G2;U@#7690_D[H/H^^Z*D
MC0Q[+T,(JP ]]*MPSM\X=^DW(MY VF4#K\-\SQ_6.'3U?/-!C?GT^>9^ YM!
M(?7 X0T:I?[Q&8?9M87$_%.G<8XQK,>@*G!B4A[ >1NWN0%]#^W)FU?]L7=:
MI\\^P:9[ JMH-RRT&S:A3RZ, 6/X+ :6:C47EFENH4Z_'.?(X5#1NY]X77]T
MUKLOZ_*<2=/_F%3A,2IXC!IY8 ZP2,4BY"NL3B;0(J7R5T>D&>@.MYANV0AP
MLUG0J18&LTH&*@%&B[Q]\^K(][W3]]>W[JE_^HY]YDNFYNS;]ZL."W&BL2)@
M4)@;QF7(L)IBK92(=8\3L,+;T@JFP/UP_=YL@%M< \M,QN-XA0?(["?6=&85
MXRR38BX@9/[H=6DA)G(_+?I)863+2+C PAPT3A,\+KZ9CGM<:Y:["/<@W2@\
M0.+TPXJX:LV +33'54)&!PH+\#@XF*T.Z)?.!F&Z#.7()YFGRUD\-W/"Z/M'
M/"_<8E_QZ+J%()(J5HM5K18?O]X^BM%MN= P&XFF-3K,63&2CK[;&-TFS>03
M=3!D_='K3E59#;\SH2%W-^+T!U8X>L#3%*. #0$EA]!N&68LMYDAX?0*9VH
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M^A)V$W-JG:Z>/7#\P*37_-HB@3@"J"]9-P6G$?K 89W57YR F#2.1>NKV94
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MJ5I;7O;YRAO)LJ+SM652%=C%Y1'P#K@V4/-[QN3E1C^@[K8N_P902P,$%
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MJ+4NQ]C)<26EJ9^-;:H3EKXZ\?O=<ADO#2_^,M/N?.F9O@%"-1?5/%3S42U
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MH,SR+66MW2?9=U@:D.5.&]ETP;B#AHOVFSUVB3@*B/(7 N(N(!X&I"\$)%U
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M;'^T&3S7"FU\=ERZLHA'\: 3/+ BH8,V\(#2F/I[H.@5%&<5?/BVX^8)FX
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M_E$ 90&XOI+2' ;V!_J_'M/_ 5!+ P04    " "N@)U:L=4%=%(%   ?%0
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M? ^/$KCF!'__VLVPE5WCVM!CU-XQU#@Q1NLC*>\DC($OS.#3-ABKM_"X-^!
M(6#$IOKOM1/"@,>^ 0>+LR)WZJ5E/$SR;+O"^+8VJ.@DI=8#X2-[0CB;"@:H
MA*2,K[79 \,LY[FPI%K:E!P7+.5/[79U#U:]FB=E62ZJV#J"_CNM']]S;'H@
MD''>"/1L;1@/"R(E%=FUZE0/5\9'+JMNWZT+I7 NR-KU+NTMH+JI(--<Q%1L
M5UI[8QH/.4U CF#S!=QE7CC@E#)/52-F9)YGI-*P0=0-13NCG-_"EO MV>%>
M):UYK5[JK&DJ0753T^@.\+?9-'>+UNL_B]<JV$,N/RY5.EG5AVJA-X(F;%7U
M5TDC &-W<792%'S]@;-YEE*=_-$!QT.RP5F+7+"?*AJ4RDP9J+"M!RHDF[4M
M/P0I[NA*;LIIE>":O0YJ_K?C/*<9%82W1:O:?\VC_&S%?OA2DJM595^P46/]
M;]YK%WG9!9%!%T1VHB8'71 9=4!D^&*KYE-$NET0Z75!I-\%D5W8<<(N[#AA
M%W:<\'7N.$Y]T&F=IG;.4HW5@C/KR/X*)V2^#6I-EXQ+EM6]!8MCFCTZ4BEZ
M2::<[O*KYV.:D"67=XUS9&_;7VC,EFG4/'4# U$_M6U_AO3<H#DPJU@LB^F*
MQI.Z*^;3JFFIAHI:7P#8]UQ7E]F#8;3/[ $?%@=3@&$T"HOS/^4S0//1/DS;
MP.@9H)@!BM$HDV=2?; X9DRD+G.F4>3[08"-Z&1B5##!QBT(X&MFP[0! HL#
MD9XVUOALXQ5RN ZP.3U4(5BF>"5BF>)C#1[SN $BBLRSC<4!!#8+6.U ?',<
MJ"DSQO=A5C%MV!N,>Z((\T MFFLT")#1">!CGA_L+?']*#)[P&=6X/N8!]Y&
MW(,I  V8Q_>K?7!O/W(V^Y2S_4%K_ =02P,$%     @ KH"=6I>*NQS
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ME5<:*U4&  !_.@  #P   'AL+W=O<FMB;V]K+GAM;,6;76_;-A2&_PKAFW5
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M3Y%T4F+I#$?3[9OS?>_=?X:DDQ%+I[_>:K#O9$@W&;%NAE9>#5,BVV3DJ];
M&BSVPL=$MLFHE[$=K\(:CB0R37;161^_%,^0:3)BTV!,OQ3/D'FR2ZYNZTT
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( *Z G5J$IW8A\@   "L"   1              "  <,   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( *Z G5J97)PC$ 8  )PG   3
M      "  >0!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ KH"=
M6MHI5(@8!P  D"(  !@              ("!)0@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( *Z G5IN/^#/U ,  *D)   8
M      " @7,/  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M" "N@)U:9C&6DT((  !P(P  &               @(%]$P  >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ KH"=6NQW?&L: P  9PD  !@
M             ("!]1L  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    ( *Z G5HFG-'NT@8  '8=   8              " @44?  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " "N@)U:WW"S:_X&   ,
M+   &               @(%-)@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ KH"=6LQZO1-;"0  72X  !@              ("!@2T
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( *Z G5KJGO3K
M=@X   XO   8              " @1(W  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    " "N@)U:L*.<.@ J  !:@P  &
M@(&^10  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ KH"=
M6BN!>PW! P  9@@  !D              ("!]&\  'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    " "N@)U:J_&IA!<#  "^!@  &0
M        @('L<P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   ( *Z G5K?TT^SP0(  # &   9              " @3IW  !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ KH"=6F^#F5O: P  .P@
M !D              ("!,GH  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    " "N@)U:/VH9[(,$  #]"0  &0              @(%#?@
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( *Z G5K%(!39
MK0,  .4'   9              " @?V"  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ KH"=6BZ=_)-K P  5P<  !D
M ("!X88  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "N
M@)U:=!R!3%,&  #(#@  &0              @(&#B@  >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( *Z G5HS%>7Z5@0  +4)   9
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M970R,BYX;6Q02P$"% ,4    " "N@)U:4YJTLN@$  "(#   &0
M    @('TL   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M *Z G5JI.>L,L@T  ,DK   9              " @1.V  !X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ KH"=6C:F#:Q-!0  >@L  !D
M             ("!_,,  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    " "N@)U:]P6OQA$&  "W#P  &0              @(& R0  >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( *Z G5J@'VXH+PH
M $H8   9              " @<C/  !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ KH"=6G_>N25@ @  ?P8  !D              ("!
M+MH  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " "N@)U:
M/+A7WA "  #=!   &0              @('%W   >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    ( *Z G5KF*] /DP0  !,2   9
M      " @0S?  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ KH"=6F-D.SNX*P  #),  !D              ("!UN,  'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " "N@)U:-N@ 6%D#  !^!P
M&0              @('%#P$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M 0(4 Q0    ( *Z G5HS5CQ ] ,  *H)   9              " @543 0!X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ KH"=6FT8J>WR
M @  40<  !D              ("!@!<! 'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"% ,4    " "N@)U:7$[W)2(#  !C!P  &0
M@(&I&@$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( *Z
MG5K!#(-=:P(  (D%   9              " @0(> 0!X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L! A0#%     @ KH"=6@_<4%$U!   5@D  !D
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M=#0Q+GAM;%!+ 0(4 Q0    ( *Z G5H\*Q';*0,  +$&   9
M  " @2\U 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @
MKH"=6F(=RHA= P  %0@  !D              ("!CS@! 'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6Q02P$"% ,4    " "N@)U:?! V?K<$  !-#   &0
M            @($C/ $ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4
M Q0    ( *Z G5H(">[!40<  )L0   9              " @1%! 0!X;"]W
M;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ KH"=6AWYNTQ('
MJ2$" !D              ("!F4@! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX
M;6Q02P$"% ,4    " "N@)U:VP9'I-,$  #L&0  &0              @($8
M90$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( *Z G5ID
M-VY?;08  / P   9              " @2)J 0!X;"]W;W)K<VAE971S+W-H
M965T-#@N>&UL4$L! A0#%     @ KH"=6OG;1@A< P  @!(  !D
M     ("!QG ! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *Z G5I$FZ<(V (  )@(   9              "
M@55_ 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ KH"=
M6F\O*,S' @  S0@  !D              ("!9((! 'AL+W=O<FMS:&5E=',O
M<VAE970U-2YX;6Q02P$"% ,4    " "N@)U:1DXDW!$#  ")"0  &0
M        @(%BA0$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0
M   ( *Z G5JVW#.=3@(  /@%   9              " @:J( 0!X;"]W;W)K
M<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ KH"=6D/KQIOV P  .AH
M !D              ("!+XL! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q0
M2P$"% ,4    " "N@)U:_U=O<@P&  !*'P  &0              @(%<CP$
M>&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( *Z G5K#PT1:
M"P4  *(0   9              " @9^5 0!X;"]W;W)K<VAE971S+W-H965T
M-C N>&UL4$L! A0#%     @ KH"=6HSQ9H:N @  @0<  !D
M ("!X9H! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " "N
M@)U:A>'+8F(%  #\)@  &0              @('&G0$ >&PO=V]R:W-H965T
M<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( *Z G5K3II6:9@(  'X&   9
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M970V-RYX;6Q02P$"% ,4    " "N@)U:#FI:72@$  "K%@  &0
M    @(%-M $ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    (
M *Z G5KHTAIQF!T  &E^ @ 9              " @:RX 0!X;"]W;W)K<VAE
M971S+W-H965T-CDN>&UL4$L! A0#%     @ KH"=6FX07X"@!@  720  !D
M             ("!>]8! 'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q02P$"
M% ,4    " "N@)U:+ML/AK\#   B$P  &0              @(%2W0$ >&PO
M=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( *Z G5JH1NK\4@,
M ,4(   9              " @4CA 0!X;"]W;W)K<VAE971S+W-H965T-S(N
M>&UL4$L! A0#%     @ KH"=6C04@1RD!    Q\  !D              ("!
MT>0! 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"% ,4    " "N@)U:
M#J TYV8#  "3#   &0              @(&LZ0$ >&PO=V]R:W-H965T<R]S
M:&5E=#<T+GAM;%!+ 0(4 Q0    ( *Z G5I>G\3((0,  !,/   9
M      " @4GM 0!X;"]W;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%
M  @ KH"=6IYOH82?!@  RQ8  !D              ("!H? ! 'AL+W=O<FMS
M:&5E=',O<VAE970W-BYX;6Q02P$"% ,4    " "N@)U:)GBSY$($  "D&P
M&0              @(%W]P$ >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+
M 0(4 Q0    ( *Z G5JMK9Q&<0,  "P,   9              " @?#[ 0!X
M;"]W;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @ KH"=6CT@[:&5
M @  BP@  !D              ("!F/\! 'AL+W=O<FMS:&5E=',O<VAE970W
M.2YX;6Q02P$"% ,4    " "N@)U:YG(4%F0"  !4!@  &0
M@(%D @( >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    ( *Z
MG5HUD/]=] ,  'D5   9              " @?\$ @!X;"]W;W)K<VAE971S
M+W-H965T.#$N>&UL4$L! A0#%     @ KH"=6@[O[,?C(   I(D" !D
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M=#@V+GAM;%!+ 0(4 Q0    ( *Z G5KG\"5)3@,  ,<)   9
M  " @6-& @!X;"]W;W)K<VAE971S+W-H965T.#<N>&UL4$L! A0#%     @
MKH"=6BAY[U;@ P  A@P  !D              ("!Z$D" 'AL+W=O<FMS:&5E
M=',O<VAE970X."YX;6Q02P$"% ,4    " "N@)U:L=4%=%(%   ?%0  &0
M            @('_30( >&PO=V]R:W-H965T<R]S:&5E=#@Y+GAM;%!+ 0(4
M Q0    ( *Z G5I/J^4\H0,  -T:   -              "  8A3 @!X;"]S
M='EL97,N>&UL4$L! A0#%     @ KH"=6I>*NQS     $P(   L
M     ( !5%<" %]R96QS+RYR96QS4$L! A0#%     @ KH"=6I57&BM5!@
M?SH   \              ( !/5@" 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( *Z G5HX96OGF@(  '(T   :              "  ;]> @!X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( *Z G5JGD>I9-P(  -\R
M   3              "  9%A @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0  !A &$ GAH  /EC @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>258</ContextCount>
  <ElementCount>349</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>93</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995300 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995301 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995302 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995303 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995304 - Statement - Consolidated Statements of Changes in Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Changes in Shareholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995305 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995306 - Disclosure - Organization and Business Description</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription</Role>
      <ShortName>Organization and Business Description</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995307 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995308 - Disclosure - Accounts Receivable, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet</Role>
      <ShortName>Accounts Receivable, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Inventories, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/InventoriesNet</Role>
      <ShortName>Inventories, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Advance to Suppliers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers</Role>
      <ShortName>Advance to Suppliers</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995311 - Disclosure - Prepayment for Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisition</Role>
      <ShortName>Prepayment for Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995312 - Disclosure - Other Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/OtherReceivable</Role>
      <ShortName>Other Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995313 - Disclosure - Property, Plant and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet</Role>
      <ShortName>Property, Plant and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995314 - Disclosure - Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet</Role>
      <ShortName>Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995315 - Disclosure - Prepayment for CIP Project</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProject</Role>
      <ShortName>Prepayment for CIP Project</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995316 - Disclosure - Prepayment for Purchase of a Property</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty</Role>
      <ShortName>Prepayment for Purchase of a Property</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995317 - Disclosure - Short-Term Bank Loans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoans</Role>
      <ShortName>Short-Term Bank Loans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995318 - Disclosure - Long-Term Bank Loans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoans</Role>
      <ShortName>Long-Term Bank Loans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995319 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995320 - Disclosure - Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/Taxes</Role>
      <ShortName>Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995321 - Disclosure - Concentrations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/Concentrations</Role>
      <ShortName>Concentrations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995322 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995323 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995324 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995325 - Disclosure - Financial Information of the Parent Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompany</Role>
      <ShortName>Financial Information of the Parent Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Organization and Business Description (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables</Role>
      <ShortName>Organization and Business Description (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Accounts Receivable, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables</Role>
      <ShortName>Accounts Receivable, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Inventories, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/InventoriesNetTables</Role>
      <ShortName>Inventories, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/InventoriesNet</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Advance to Suppliers (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables</Role>
      <ShortName>Advance to Suppliers (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Other Receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableTables</Role>
      <ShortName>Other Receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/OtherReceivable</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Property, Plant and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables</Role>
      <ShortName>Property, Plant and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables</Role>
      <ShortName>Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Prepayment for CIP Project (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectTables</Role>
      <ShortName>Prepayment for CIP Project (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProject</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Short-Term Bank Loans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansTables</Role>
      <ShortName>Short-Term Bank Loans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoans</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Long-Term Bank Loans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoansTables</Role>
      <ShortName>Long-Term Bank Loans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoans</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/TaxesTables</Role>
      <ShortName>Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/Taxes</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Financial Information of the Parent Company (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompanyTables</Role>
      <ShortName>Financial Information of the Parent Company (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompany</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Organization and Business Description (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails</Role>
      <ShortName>Organization and Business Description (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Organization and Business Description - Schedule of Subsidiaries (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofSubsidiariesTable</Role>
      <ShortName>Organization and Business Description - Schedule of Subsidiaries (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property Plant and Equipment Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesTable</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Property Plant and Equipment Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Summary of Significant Accounting Policies - Schedule of Intangible Assets Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsEstimatedUsefulLivesTable</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Intangible Assets Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Summary of Significant Accounting Policies - Schedule of Currency Exchange Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofCurrencyExchangeRateTable</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Currency Exchange Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Accounts Receivable, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetDetails</Role>
      <ShortName>Accounts Receivable, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Accounts Receivable, Net - Schedule of Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAccountsReceivableTable</Role>
      <ShortName>Accounts Receivable, Net - Schedule of Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Accounts Receivable, Net - Schedule of Allowance for Doubtful Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAllowanceforDoubtfulAccountsTable</Role>
      <ShortName>Accounts Receivable, Net - Schedule of Allowance for Doubtful Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Inventories, Net - Schedule of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesTable</Role>
      <ShortName>Inventories, Net - Schedule of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Inventories, Net - Schedule of Inventories Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesValuationAllowanceTable</Role>
      <ShortName>Inventories, Net - Schedule of Inventories Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Advance to Suppliers - Schedule of Advances to Suppliers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAdvancestoSuppliersTable</Role>
      <ShortName>Advance to Suppliers - Schedule of Advances to Suppliers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Prepayment for Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails</Role>
      <ShortName>Prepayment for Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisition</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Other Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableDetails</Role>
      <ShortName>Other Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Other Receivable - Schedule of Other Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofOtherReceivableTable</Role>
      <ShortName>Other Receivable - Schedule of Other Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Property, Plant and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails</Role>
      <ShortName>Property, Plant and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentNetTable</Role>
      <ShortName>Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetDetails</Role>
      <ShortName>Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsNetTable</Role>
      <ShortName>Intangible Assets, Net - Schedule of Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Intangible Assets, Net - Schedule of Estimated Future Amortization Expense for Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable</Role>
      <ShortName>Intangible Assets, Net - Schedule of Estimated Future Amortization Expense for Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Prepayment for CIP Project (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails</Role>
      <ShortName>Prepayment for CIP Project (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Prepayment for CIP Project - Schedule of Future Minimum Capital Expenditures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofFutureMinimumCapitalExpendituresTable</Role>
      <ShortName>Prepayment for CIP Project - Schedule of Future Minimum Capital Expenditures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Prepayment for Purchase of a Property (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails</Role>
      <ShortName>Prepayment for Purchase of a Property (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Short-Term Bank Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails</Role>
      <ShortName>Short-Term Bank Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Short-Term Bank Loans - Schedule of Short-Term Bank Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofShortTermBankLoansTable</Role>
      <ShortName>Short-Term Bank Loans - Schedule of Short-Term Bank Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996040 - Disclosure - Long-Term Bank Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoansDetails</Role>
      <ShortName>Long-Term Bank Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoansTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Long-Term Bank Loans - Schedule of Long-Term Bank Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofLongTermBankLoansTable</Role>
      <ShortName>Long-Term Bank Loans - Schedule of Long-Term Bank Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996042 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996043 - Disclosure - Related Party Transactions - Schedule of Nature of Relationships With Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofNatureofRelationshipsWithRelatedPartiesTable</Role>
      <ShortName>Related Party Transactions - Schedule of Nature of Relationships With Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996044 - Disclosure - Related Party Transactions - Schedule of Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofRelatedPartiesTable</Role>
      <ShortName>Related Party Transactions - Schedule of Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails</Role>
      <ShortName>Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/TaxesTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996046 - Disclosure - Taxes - Schedule of Components of the Income Tax Provision (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable</Role>
      <ShortName>Taxes - Schedule of Components of the Income Tax Provision (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Taxes - Schedule of Table Reconciles the China Statutory Rates to the Company???s Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTableReconcilestheChinaStatutoryRatestotheCompanysEffectiveTaxRateTable</Role>
      <ShortName>Taxes - Schedule of Table Reconciles the China Statutory Rates to the Company???s Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996048 - Disclosure - Taxes - Schedule of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofDeferredTaxAssetsTable</Role>
      <ShortName>Taxes - Schedule of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996049 - Disclosure - Taxes - Schedule of Taxes Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTaxesPayableTable</Role>
      <ShortName>Taxes - Schedule of Taxes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996050 - Disclosure - Concentrations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails</Role>
      <ShortName>Concentrations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/Concentrations</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996051 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996052 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>996053 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>996054 - Disclosure - Financial Information of the Parent Company (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompanyDetails</Role>
      <ShortName>Financial Information of the Parent Company (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompanyTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Financial Information of the Parent Company - Schedule of Consolidated Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable</Role>
      <ShortName>Financial Information of the Parent Company - Schedule of Consolidated Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>996056 - Disclosure - Financial Information of the Parent Company - Schedule of Consolidated Financial Statements (Parentheticals) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable_Parentheticals</Role>
      <ShortName>Financial Information of the Parent Company - Schedule of Consolidated Financial Statements (Parentheticals) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>996057 - Disclosure - Financial Information of the Parent Company - Schedule of Parent Company Statements of Operations and Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable</Role>
      <ShortName>Financial Information of the Parent Company - Schedule of Parent Company Statements of Operations and Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="ea0228075-20f_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>996058 - Disclosure - Financial Information of the Parent Company - Schedule of Parent Company Statements of Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable</Role>
      <ShortName>Financial Information of the Parent Company - Schedule of Parent Company Statements of Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" isDefinitelyFs="true" isUsgaap="true" original="ea0228075-20f_universe.htm">ea0228075-20f_universe.htm</File>
    <File>upc-20240930.xsd</File>
    <File>upc-20240930_cal.xml</File>
    <File>upc-20240930_def.xml</File>
    <File>upc-20240930_lab.xml</File>
    <File>upc-20240930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="1005">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="7">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="50">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="1">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>146
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0228075-20f_universe.htm": {
   "nsprefix": "upc",
   "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
   "dts": {
    "inline": {
     "local": [
      "ea0228075-20f_universe.htm"
     ]
    },
    "schema": {
     "local": [
      "upc-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_lab.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_pre.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "upc-20240930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "upc-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "upc-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "upc-20240930_pre.xml"
     ]
    }
   },
   "keyStandard": 301,
   "keyCustom": 48,
   "axisStandard": 27,
   "axisCustom": 0,
   "memberStandard": 33,
   "memberCustom": 39,
   "hidden": {
    "total": 109,
    "http://www.UniversePharmaceuticalsINC.com/20240930": 14,
    "http://fasb.org/us-gaap/2024": 92,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 258,
   "entityCount": 1,
   "segmentCount": 93,
   "elementCount": 814,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 1005,
    "http://xbrl.sec.gov/dei/2024": 50,
    "http://xbrl.sec.gov/cyd/2024": 7,
    "http://fasb.org/srt/2024": 3,
    "http://xbrl.sec.gov/ecd/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/dei/role/document/AuditInformation",
     "longName": "995300 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:Cash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:Cash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "995302 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R5": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement",
     "longName": "995303 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3",
     "longName": "995304 - Statement - Consolidated Statements of Changes in Shareholders\u2019 Equity",
     "shortName": "Consolidated Statements of Changes in Shareholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
     "longName": "995305 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription",
     "longName": "995306 - Disclosure - Organization and Business Description",
     "shortName": "Organization and Business Description",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "995307 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet",
     "longName": "995308 - Disclosure - Accounts Receivable, Net",
     "shortName": "Accounts Receivable, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/InventoriesNet",
     "longName": "995309 - Disclosure - Inventories, Net",
     "shortName": "Inventories, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers",
     "longName": "995310 - Disclosure - Advance to Suppliers",
     "shortName": "Advance to Suppliers",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "upc:AdvancesToSuppliersTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "upc:AdvancesToSuppliersTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisition",
     "longName": "995311 - Disclosure - Prepayment for Acquisition",
     "shortName": "Prepayment for Acquisition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/OtherReceivable",
     "longName": "995312 - Disclosure - Other Receivable",
     "shortName": "Other Receivable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ReceivablesPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ReceivablesPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet",
     "longName": "995313 - Disclosure - Property, Plant and Equipment, Net",
     "shortName": "Property, Plant and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet",
     "longName": "995314 - Disclosure - Intangible Assets, Net",
     "shortName": "Intangible Assets, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProject",
     "longName": "995315 - Disclosure - Prepayment for CIP Project",
     "shortName": "Prepayment for CIP Project",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "upc:PrepaymentForConstructionInProgressTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "upc:PrepaymentForConstructionInProgressTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty",
     "longName": "995316 - Disclosure - Prepayment for Purchase of a Property",
     "shortName": "Prepayment for Purchase of a Property",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "upc:PrepaymentForPurchaseOfAPropertyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "upc:PrepaymentForPurchaseOfAPropertyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoans",
     "longName": "995317 - Disclosure - Short-Term Bank Loans",
     "shortName": "Short-Term Bank Loans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoans",
     "longName": "995318 - Disclosure - Long-Term Bank Loans",
     "shortName": "Long-Term Bank Loans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions",
     "longName": "995319 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/Taxes",
     "longName": "995320 - Disclosure - Taxes",
     "shortName": "Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/Concentrations",
     "longName": "995321 - Disclosure - Concentrations",
     "shortName": "Concentrations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity",
     "longName": "995322 - Disclosure - Shareholders' Equity",
     "shortName": "Shareholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies",
     "longName": "995323 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents",
     "longName": "995324 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompany",
     "longName": "995325 - Disclosure - Financial Information of the Parent Company",
     "shortName": "Financial Information of the Parent Company",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables",
     "longName": "996001 - Disclosure - Organization and Business Description (Tables)",
     "shortName": "Organization and Business Description (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "996002 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "upc:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "upc:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables",
     "longName": "996003 - Disclosure - Accounts Receivable, Net (Tables)",
     "shortName": "Accounts Receivable, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/InventoriesNetTables",
     "longName": "996004 - Disclosure - Inventories, Net (Tables)",
     "shortName": "Inventories, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables",
     "longName": "996005 - Disclosure - Advance to Suppliers (Tables)",
     "shortName": "Advance to Suppliers (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "upc:ScheduleOfAdvancesToSuppliersNet",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "upc:AdvancesToSuppliersTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "upc:ScheduleOfAdvancesToSuppliersNet",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "upc:AdvancesToSuppliersTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableTables",
     "longName": "996006 - Disclosure - Other Receivable (Tables)",
     "shortName": "Other Receivable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ReceivablesPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ReceivablesPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables",
     "longName": "996007 - Disclosure - Property, Plant and Equipment, Net (Tables)",
     "shortName": "Property, Plant and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables",
     "longName": "996008 - Disclosure - Intangible Assets, Net (Tables)",
     "shortName": "Intangible Assets, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectTables",
     "longName": "996009 - Disclosure - Prepayment for CIP Project (Tables)",
     "shortName": "Prepayment for CIP Project (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "upc:ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "upc:ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansTables",
     "longName": "996010 - Disclosure - Short-Term Bank Loans (Tables)",
     "shortName": "Short-Term Bank Loans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ShortTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ShortTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoansTables",
     "longName": "996011 - Disclosure - Long-Term Bank Loans (Tables)",
     "shortName": "Long-Term Bank Loans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables",
     "longName": "996012 - Disclosure - Related Party Transactions (Tables)",
     "shortName": "Related Party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "upc:ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "upc:ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/TaxesTables",
     "longName": "996013 - Disclosure - Taxes (Tables)",
     "shortName": "Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompanyTables",
     "longName": "996014 - Disclosure - Financial Information of the Parent Company (Tables)",
     "shortName": "Financial Information of the Parent Company (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
     "longName": "996015 - Disclosure - Organization and Business Description (Details)",
     "shortName": "Organization and Business Description (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c53",
      "name": "upc:PublicOfferingPrice",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofSubsidiariesTable",
     "longName": "996016 - Disclosure - Organization and Business Description - Schedule of Subsidiaries (Details)",
     "shortName": "Organization and Business Description - Schedule of Subsidiaries (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c85",
      "name": "us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c85",
      "name": "us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "996017 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesTable",
     "longName": "996018 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property Plant and Equipment Estimated Useful Lives (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Property Plant and Equipment Estimated Useful Lives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c93",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c98",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsEstimatedUsefulLivesTable",
     "longName": "996019 - Disclosure - Summary of Significant Accounting Policies - Schedule of Intangible Assets Estimated Useful Lives (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Intangible Assets Estimated Useful Lives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c100",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c100",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofCurrencyExchangeRateTable",
     "longName": "996020 - Disclosure - Summary of Significant Accounting Policies - Schedule of Currency Exchange Rate (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Currency Exchange Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c103",
      "name": "us-gaap:DerivativeForwardExchangeRate1",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c103",
      "name": "us-gaap:DerivativeForwardExchangeRate1",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetDetails",
     "longName": "996021 - Disclosure - Accounts Receivable, Net (Details)",
     "shortName": "Accounts Receivable, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "upc:NetAccountReceivablePercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "upc:NetAccountReceivablePercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAccountsReceivableTable",
     "longName": "996022 - Disclosure - Accounts Receivable, Net - Schedule of Accounts Receivable (Details)",
     "shortName": "Accounts Receivable, Net - Schedule of Accounts Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAllowanceforDoubtfulAccountsTable",
     "longName": "996023 - Disclosure - Accounts Receivable, Net - Schedule of Allowance for Doubtful Accounts (Details)",
     "shortName": "Accounts Receivable, Net - Schedule of Allowance for Doubtful Accounts (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesTable",
     "longName": "996024 - Disclosure - Inventories, Net - Schedule of Inventories (Details)",
     "shortName": "Inventories, Net - Schedule of Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesValuationAllowanceTable",
     "longName": "996025 - Disclosure - Inventories, Net - Schedule of Inventories Valuation Allowance (Details)",
     "shortName": "Inventories, Net - Schedule of Inventories Valuation Allowance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:InventoryValuationReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "upc:InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAdvancestoSuppliersTable",
     "longName": "996026 - Disclosure - Advance to Suppliers - Schedule of Advances to Suppliers (Details)",
     "shortName": "Advance to Suppliers - Schedule of Advances to Suppliers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:InventoryRawMaterialsAndSupplies",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "upc:ScheduleOfAdvancesToSuppliersNet",
       "upc:AdvancesToSuppliersTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:InventoryRawMaterialsAndSupplies",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "upc:ScheduleOfAdvancesToSuppliersNet",
       "upc:AdvancesToSuppliersTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails",
     "longName": "996027 - Disclosure - Prepayment for Acquisition (Details)",
     "shortName": "Prepayment for Acquisition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "upc:PrepaymentForAcquisitionCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c111",
      "name": "upc:PrepaymentForAcquisitionCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:AssetAcquisitionTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableDetails",
     "longName": "996028 - Disclosure - Other Receivable (Details)",
     "shortName": "Other Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c111",
      "name": "us-gaap:EquityMethodInvestmentAggregateCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:ReceivablesPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c111",
      "name": "us-gaap:EquityMethodInvestmentAggregateCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:ReceivablesPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofOtherReceivableTable",
     "longName": "996029 - Disclosure - Other Receivable - Schedule of Other Receivable (Details)",
     "shortName": "Other Receivable - Schedule of Other Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ReceivablesNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:ReceivablesPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ValueAddedTaxReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:ReceivablesPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails",
     "longName": "996030 - Disclosure - Property, Plant and Equipment, Net (Details)",
     "shortName": "Property, Plant and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentNetTable",
     "longName": "996031 - Disclosure - Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment, Net (Details)",
     "shortName": "Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetDetails",
     "longName": "996032 - Disclosure - Intangible Assets, Net (Details)",
     "shortName": "Intangible Assets, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsNetTable",
     "longName": "996033 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets, Net (Details)",
     "shortName": "Intangible Assets, Net - Schedule of Intangible Assets, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable",
     "longName": "996034 - Disclosure - Intangible Assets, Net - Schedule of Estimated Future Amortization Expense for Intangible Assets (Details)",
     "shortName": "Intangible Assets, Net - Schedule of Estimated Future Amortization Expense for Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails",
     "longName": "996035 - Disclosure - Prepayment for CIP Project (Details)",
     "shortName": "Prepayment for CIP Project (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c133",
      "name": "us-gaap:InvestmentBuildingAndBuildingImprovements",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "upc:PrepaymentForConstructionInProgressTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c133",
      "name": "us-gaap:InvestmentBuildingAndBuildingImprovements",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "upc:PrepaymentForConstructionInProgressTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofFutureMinimumCapitalExpendituresTable",
     "longName": "996036 - Disclosure - Prepayment for CIP Project - Schedule of Future Minimum Capital Expenditures (Details)",
     "shortName": "Prepayment for CIP Project - Schedule of Future Minimum Capital Expenditures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ContractualObligationDueInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "upc:ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ContractualObligationDueInSecondYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "upc:ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails",
     "longName": "996037 - Disclosure - Prepayment for Purchase of a Property (Details)",
     "shortName": "Prepayment for Purchase of a Property (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c139",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "unitRef": "sqm",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "upc:PrepaymentForPurchaseOfAPropertyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c140",
      "name": "upc:PercentageOfPrepayment",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "upc:PrepaymentForPurchaseOfAPropertyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails",
     "longName": "996038 - Disclosure - Short-Term Bank Loans (Details)",
     "shortName": "Short-Term Bank Loans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c156",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "ix:continuation",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofShortTermBankLoansTable",
     "longName": "996039 - Disclosure - Short-Term Bank Loans - Schedule of Short-Term Bank Loans (Details)",
     "shortName": "Short-Term Bank Loans - Schedule of Short-Term Bank Loans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c177",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "us-gaap:ShortTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoansDetails",
     "longName": "996040 - Disclosure - Long-Term Bank Loans (Details)",
     "shortName": "Long-Term Bank Loans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InterestPaidNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c185",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofLongTermBankLoansTable",
     "longName": "996041 - Disclosure - Long-Term Bank Loans - Schedule of Long-Term Bank Loans (Details)",
     "shortName": "Long-Term Bank Loans - Schedule of Long-Term Bank Loans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c187",
      "name": "us-gaap:LongTermLoansFromBank",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c187",
      "name": "us-gaap:LongTermLoansFromBank",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails",
     "longName": "996042 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c139",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "unitRef": "sqm",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "upc:PrepaymentForPurchaseOfAPropertyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c189",
      "name": "us-gaap:PrepaymentFeesOnAdvancesNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofNatureofRelationshipsWithRelatedPartiesTable",
     "longName": "996043 - Disclosure - Related Party Transactions - Schedule of Nature of Relationships With Related Parties (Details)",
     "shortName": "Related Party Transactions - Schedule of Nature of Relationships With Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c193",
      "name": "us-gaap:NatureOfCommonOwnershipOrManagementControlRelationships",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "upc:ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c193",
      "name": "us-gaap:NatureOfCommonOwnershipOrManagementControlRelationships",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "upc:ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofRelatedPartiesTable",
     "longName": "996044 - Disclosure - Related Party Transactions - Schedule of Related Parties (Details)",
     "shortName": "Related Party Transactions - Schedule of Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c197",
      "name": "us-gaap:OtherReceivablesNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c197",
      "name": "us-gaap:OtherReceivablesNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails",
     "longName": "996045 - Disclosure - Taxes (Details)",
     "shortName": "Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxHolidayDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable",
     "longName": "996046 - Disclosure - Taxes - Schedule of Components of the Income Tax Provision (Benefit) (Details)",
     "shortName": "Taxes - Schedule of Components of the Income Tax Provision (Benefit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTableReconcilestheChinaStatutoryRatestotheCompanysEffectiveTaxRateTable",
     "longName": "996047 - Disclosure - Taxes - Schedule of Table Reconciles the China Statutory Rates to the Company\u2019s Effective Tax Rate (Details)",
     "shortName": "Taxes - Schedule of Table Reconciles the China Statutory Rates to the Company\u2019s Effective Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofDeferredTaxAssetsTable",
     "longName": "996048 - Disclosure - Taxes - Schedule of Deferred Tax Assets (Details)",
     "shortName": "Taxes - Schedule of Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTaxesPayableTable",
     "longName": "996049 - Disclosure - Taxes - Schedule of Taxes Payable (Details)",
     "shortName": "Taxes - Schedule of Taxes Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "upc:ValueAddedTaxPayable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "upc:ScheduleOfTaxPayableTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "upc:ValueAddedTaxPayable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "upc:ScheduleOfTaxPayableTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails",
     "longName": "996050 - Disclosure - Concentrations (Details)",
     "shortName": "Concentrations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ForeignFinancialInstitutionsMandatedDeposits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ForeignFinancialInstitutionsMandatedDeposits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
     "longName": "996051 - Disclosure - Shareholders' Equity (Details)",
     "shortName": "Shareholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails",
     "longName": "996052 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ContractualObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "upc:ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c234",
      "name": "us-gaap:PrepaidExpenseCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails",
     "longName": "996053 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c243",
      "name": "us-gaap:OtherReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompanyDetails",
     "longName": "996054 - Disclosure - Financial Information of the Parent Company (Details)",
     "shortName": "Financial Information of the Parent Company (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:DerivativeNetAssetsPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:DerivativeNetAssetsPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable",
     "longName": "996055 - Disclosure - Financial Information of the Parent Company - Schedule of Consolidated Financial Statements (Details)",
     "shortName": "Financial Information of the Parent Company - Schedule of Consolidated Financial Statements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c244",
      "name": "us-gaap:Cash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c244",
      "name": "us-gaap:Cash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable_Parentheticals",
     "longName": "996056 - Disclosure - Financial Information of the Parent Company - Schedule of Consolidated Financial Statements (Parentheticals) (Details)",
     "shortName": "Financial Information of the Parent Company - Schedule of Consolidated Financial Statements (Parentheticals) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c244",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c244",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable",
     "longName": "996057 - Disclosure - Financial Information of the Parent Company - Schedule of Parent Company Statements of Operations and Comprehensive Loss (Details)",
     "shortName": "Financial Information of the Parent Company - Schedule of Parent Company Statements of Operations and Comprehensive Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c248",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "srt:CondensedStatementOfComprehensiveIncomeTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c248",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "srt:CondensedStatementOfComprehensiveIncomeTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable",
     "longName": "996058 - Disclosure - Financial Information of the Parent Company - Schedule of Parent Company Statements of Cash Flows (Details)",
     "shortName": "Financial Information of the Parent Company - Schedule of Parent Company Statements of Cash Flows (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c251",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c251",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0228075-20f_universe.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r729"
     ]
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Allowance for Doubtful Accounts",
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableGrossCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAccountsReceivableTable": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAccountsReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r263",
      "r692"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net account receivable amount",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r608",
      "r671",
      "r745",
      "r1015",
      "r1016"
     ]
    },
    "us-gaap_AccountsReceivableNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAccountsReceivableTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAccountsReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts receivable, net",
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Receivable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expense",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r169",
      "r533"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r72",
      "r178",
      "r528",
      "r550",
      "r551"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r10",
      "r16",
      "r437",
      "r440",
      "r464",
      "r546",
      "r547",
      "r915",
      "r916",
      "r917",
      "r927",
      "r928",
      "r929",
      "r931"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid in capital",
        "verboseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r927",
      "r928",
      "r929",
      "r931",
      "r990",
      "r1048"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income to net cash provided by (used in) operating activities:",
        "verboseLabel": "Adjustments to reconcile net cash flows from operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_AdvancesToSuppliersAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "AdvancesToSuppliersAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Advance to Suppliers [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_AdvancesToSuppliersNetPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "AdvancesToSuppliersNetPolicyTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advances to suppliers, net",
        "documentation": "Disclosure of accounting policy for advances to suppliers net",
        "label": "Advances To Suppliers Net Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "upc_AdvancesToSuppliersTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "AdvancesToSuppliersTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADVANCE TO SUPPLIERS",
        "documentation": "The entire disclosure for the advances to suppliers.",
        "label": "Advances To Suppliers Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising expense",
        "label": "Advertising Cost [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising expenses",
        "label": "Advertising Expense",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r722"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r780",
      "r791",
      "r807",
      "r842"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r783",
      "r794",
      "r810",
      "r845"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r784",
      "r795",
      "r811",
      "r837",
      "r846",
      "r850",
      "r858"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_AllowanceForCreditLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForCreditLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Allowance for Doubtful Accounts [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAllowanceforDoubtfulAccountsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r267",
      "r276",
      "r277",
      "r279",
      "r1016"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAccountsReceivableTable": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAccountsReceivableTable",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: allowance for doubtful accounts",
        "terseLabel": "Allowance for uncollectable balance amount",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r267",
      "r276"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAllowanceforDoubtfulAccountsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign currency translation adjustments",
        "label": "Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r286",
      "r293",
      "r709"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office space square meters (in Square Meters)",
        "verboseLabel": "Office space totaling (in Square Meters)",
        "netLabel": "Commercial office space totaling (in Square Meters)",
        "label": "Area of Real Estate Property",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment for Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionLineItems",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment for Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PREPAYMENT FOR ACQUISITION",
        "label": "Asset Acquisition [Text Block]",
        "documentation": "The entire disclosure for asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "terseLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r117",
      "r171",
      "r205",
      "r235",
      "r239",
      "r255",
      "r256",
      "r273",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r432",
      "r434",
      "r448",
      "r523",
      "r614",
      "r703",
      "r704",
      "r729",
      "r752",
      "r972",
      "r973",
      "r1000"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL CURRENT ASSETS",
        "terseLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r183",
      "r205",
      "r273",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r432",
      "r434",
      "r448",
      "r729",
      "r972",
      "r973",
      "r1000"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT ASSETS",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL NONCURRENT ASSETS",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r273",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r432",
      "r434",
      "r448",
      "r972",
      "r973",
      "r1000"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r768",
      "r787"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r768",
      "r787"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r768",
      "r787"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AutomobilesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AutomobilesMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Automobiles [Member]",
        "label": "Automobiles [Member]",
        "documentation": "Vehicles that are used primarily for transporting people."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "upc_BankOfCommunicationsCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "BankOfCommunicationsCoLtdMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofShortTermBankLoansTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank of Communications Co., Ltd [Member]",
        "label": "Bank Of Communications Co Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Principles of Consolidation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "upc_BeijingBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "BeijingBankMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofShortTermBankLoansTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Beijing Bank [Member]",
        "label": "Beijing Bank Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board of Directors Chairman [Member]",
        "label": "Board of Directors Chairman [Member]",
        "documentation": "Leader of board of directors."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings [Member]",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r428",
      "r719",
      "r720"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r41",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r428",
      "r719",
      "r720"
     ]
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voting power percentage",
        "verboseLabel": "Equity interest percentage",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r768",
      "r787"
     ]
    },
    "country_CN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "CN",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PRC [Member]",
        "label": "CHINA"
       }
      }
     },
     "auth_ref": []
    },
    "currency_CNY": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "CNY",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofCurrencyExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RMB exchange rate [Member]",
        "label": "China, Yuan Renminbi"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital expenditures",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "us-gaap_CapitalUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalUnits",
     "crdr": "credit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital (in Dollars)",
        "label": "Capital Units, Value",
        "documentation": "Value of capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r526",
      "r579",
      "r606",
      "r729",
      "r752",
      "r904"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, beginning of year",
        "periodEndLabel": "Cash, end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r84",
      "r202"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash",
        "terseLabel": "CHANGES IN CASH",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r84"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash in banks",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r904",
      "r1014"
     ]
    },
    "us-gaap_ChangeInAccountingEstimateLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingEstimateLineItems",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "upc_ChangeInFairValueOfShorttermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ChangeInFairValueOfShorttermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred income tax expense (benefit)",
        "negatedTerseLabel": "Equity in earnings of subsidiary",
        "documentation": "Represent the amount of change in fair value of short-term investments.",
        "label": "Change In Fair Value Of Shortterm Investments"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "upc_ChenyuanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ChenyuanMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chenyuan [Member]",
        "label": "Chenyuan Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r173",
      "r174",
      "r175",
      "r205",
      "r227",
      "r228",
      "r230",
      "r232",
      "r237",
      "r238",
      "r273",
      "r310",
      "r312",
      "r313",
      "r314",
      "r317",
      "r318",
      "r338",
      "r339",
      "r342",
      "r345",
      "r352",
      "r448",
      "r559",
      "r560",
      "r561",
      "r562",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580",
      "r598",
      "r623",
      "r645",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r888",
      "r920",
      "r932"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders\u2019 Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r237",
      "r338",
      "r339",
      "r340",
      "r342",
      "r345",
      "r350",
      "r352",
      "r559",
      "r560",
      "r561",
      "r562",
      "r716",
      "r888",
      "r920"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per warrant (in Dollars per share)",
        "verboseLabel": "Purchase price of offered share (in Dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase to warrant",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r108",
      "r525",
      "r597"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r302",
      "r303",
      "r673",
      "r963",
      "r968"
     ]
    },
    "upc_CommitmentsandContingenciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "CommitmentsandContingenciesDetailsTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockDividendsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockDividendsShares",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "verboseLabel": "Ordinary shares divided",
        "label": "Common Stock Dividends, Shares",
        "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "verboseLabel": "Common Stock [Member]",
        "netLabel": "Ordinary Shares [Member]",
        "label": "Ordinary shares [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r742",
      "r743",
      "r744",
      "r746",
      "r747",
      "r748",
      "r749",
      "r927",
      "r928",
      "r931",
      "r990",
      "r1045",
      "r1048"
     ]
    },
    "upc_CommonStockOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "CommonStockOneMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock One [Member]",
        "verboseLabel": "Ordinary Shares [Member]",
        "label": "Common Stock One Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, par value (in Dollars per share)",
        "verboseLabel": "Ordinary shares par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares authorized",
        "verboseLabel": "Ordinary shares",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r598"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "terseLabel": "Ordinary shares, shares outstanding",
        "verboseLabel": "Outstanding shares",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r61",
      "r598",
      "r620",
      "r1048",
      "r1049"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, $11.25 par value, 11,250,000 shares authorized, 42,880 and 6,062 shares issued and outstanding as of September 30, 2024 and 2023, respectively *",
        "verboseLabel": "Ordinary shares, $11.25 par value, 11,250,000 shares authorized, 42,880 and 6,062 shares issued and outstanding as of September 30, 2024 and 2023, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r527",
      "r729"
     ]
    },
    "upc_CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "CommonWarrantsMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Warrants [Member]",
        "label": "Common Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "terseLabel": "Comprehensive loss attributable to the Company",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r185",
      "r187",
      "r193",
      "r517",
      "r539",
      "r540"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive income",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software [Member]",
        "label": "Computer Software, Intangible Asset [Member]",
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks."
       }
      }
     },
     "auth_ref": [
      "r687",
      "r690",
      "r951",
      "r952",
      "r953",
      "r954",
      "r956",
      "r958",
      "r961",
      "r962"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r43",
      "r44",
      "r261",
      "r672"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r43",
      "r44",
      "r261",
      "r553",
      "r672"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r43",
      "r44",
      "r261",
      "r672",
      "r896"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks and Uncertainties",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r129"
     ]
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/Concentrations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONCENTRATIONS",
        "label": "Concentration Risk Disclosure [Text Block]",
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r43",
      "r44",
      "r261"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r43",
      "r44",
      "r261",
      "r672"
     ]
    },
    "upc_ConcentrationsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ConcentrationsDetailsTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CondensedBalanceSheetStatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedBalanceSheetStatementTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Balance Sheet Statement [Table]",
        "documentation": "Disclosure of information about condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r209",
      "r893"
     ]
    },
    "srt_CondensedBalanceSheetStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedBalanceSheetStatementsCaptionsLineItems",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Balance Sheet Statements, Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r209",
      "r893"
     ]
    },
    "srt_CondensedCashFlowStatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedCashFlowStatementTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Cash Flow Statement [Table]",
        "documentation": "Disclosure of information about condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r209",
      "r893"
     ]
    },
    "srt_CondensedCashFlowStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedCashFlowStatementsCaptionsLineItems",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Cash Flow Statements, Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r209",
      "r893"
     ]
    },
    "us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompany"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCIAL INFORMATION OF THE PARENT COMPANY",
        "label": "Condensed Financial Information of Parent Company Only Disclosure [Text Block]",
        "documentation": "The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r893"
     ]
    },
    "srt_CondensedStatementOfComprehensiveIncomeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedStatementOfComprehensiveIncomeTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Statement of Comprehensive Income [Table]",
        "documentation": "Disclosure of information about condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r209",
      "r893"
     ]
    },
    "srt_CondensedStatementOfComprehensiveIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedStatementOfComprehensiveIncomeTableTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompanyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Parent Company Statements of Operations and Comprehensive Loss",
        "label": "Condensed Statement of Comprehensive Income [Table Text Block]",
        "documentation": "Tabular disclosure of condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r899",
      "r926"
     ]
    },
    "srt_CondensedStatementOfIncomeCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedStatementOfIncomeCaptionsLineItems",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Statement of Income Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r209",
      "r893"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "documentation": "Information by consolidated entity or group of entities."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r153",
      "r209",
      "r432",
      "r433",
      "r434",
      "r435",
      "r473",
      "r678",
      "r900",
      "r901",
      "r902",
      "r971",
      "r974",
      "r975"
     ]
    },
    "us-gaap_ConstructionContractCostProgressPaymentOffset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionContractCostProgressPaymentOffset",
     "crdr": "credit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction amount",
        "label": "Construction Contract Cost, Progress Payment Offset",
        "documentation": "Amount of progress payment netted against construction contract cost."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction-in-progress [Member]",
        "verboseLabel": "Construction in Progress [Member]",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "upc_ConstructionInProgressTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ConstructionInProgressTwoMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction In Progress for Next 12 Months [Member]",
        "label": "Construction In Progress Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "upc_ConstructioninProgressPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ConstructioninProgressPolicyTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction-in-Progress (\u201cCIP\u201d)",
        "documentation": "Disclosure of accounting policy for construction in progress.",
        "label": "Constructionin Progress Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofFutureMinimumCapitalExpendituresTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofFutureMinimumCapitalExpendituresTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Capital expenditure cip project",
        "label": "Contractual Obligation",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_ContractualObligationDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligationDueInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofFutureMinimumCapitalExpendituresTable": {
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofFutureMinimumCapitalExpendituresTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "verboseLabel": "Future minimum capital expenditures for next 12 month",
        "label": "Contractual Obligation, to be Paid, Year One",
        "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationDueInSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligationDueInSecondYear",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofFutureMinimumCapitalExpendituresTable": {
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofFutureMinimumCapitalExpendituresTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Contractual Obligation, to be Paid, Year Two",
        "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationDueInThirdYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligationDueInThirdYear",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofFutureMinimumCapitalExpendituresTable": {
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofFutureMinimumCapitalExpendituresTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Contractual Obligation, to be Paid, Year Three",
        "documentation": "Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationFiscalYearMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligationFiscalYearMaturityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Minimum Capital Expenditures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of revenue",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r205",
      "r273",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r448",
      "r703",
      "r972"
     ]
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenue",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofCurrencyExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]",
        "documentation": "Information by currency."
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current tax expense",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r923"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current tax expense:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk [Member]",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r261"
     ]
    },
    "upc_CustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "CustomerMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Member]",
        "label": "Customer Member"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]",
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r776",
      "r869"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]",
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r771",
      "r864"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r863"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r863"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r863"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Third Party Engaged [Flag]",
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r865"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]",
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r774",
      "r867"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]",
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r774",
      "r867"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Role of Management [Text Block]",
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r868"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]",
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r773",
      "r866"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Bank Loans [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r52",
      "r53",
      "r106",
      "r107",
      "r209",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r728",
      "r921",
      "r964",
      "r965",
      "r966",
      "r996",
      "r997"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoansDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity date",
        "verboseLabel": "Debt Instrument, Maturity Date",
        "label": "Debt Instrument, Maturity Date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r711",
      "r992",
      "r993"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r209",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r728",
      "r921",
      "r964",
      "r965",
      "r966",
      "r996",
      "r997"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofLongTermBankLoansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r36",
      "r37",
      "r47",
      "r99",
      "r100",
      "r209",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r728",
      "r921",
      "r996",
      "r997"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r394"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax expense",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r135",
      "r923"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax expense (benefit):",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofDeferredTaxAssetsTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofDeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofDeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofDeferredTaxAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofDeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofDeferredTaxAssetsTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofDeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carry-forwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofDeferredTaxAssetsTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofDeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for doubtful accounts",
        "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofDeferredTaxAssetsTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofDeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive income amount",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r799",
      "r800",
      "r814"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r34"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r235",
      "r243",
      "r256",
      "r703",
      "r704"
     ]
    },
    "us-gaap_DerivativeAverageForwardExchangeRate1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAverageForwardExchangeRate1",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofCurrencyExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period average US$",
        "label": "Derivative, Average Forward Exchange Rate",
        "documentation": "Average contractual rate at which a foreign currency can be purchased or sold."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeForwardExchangeRate1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeForwardExchangeRate1",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofCurrencyExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period-end US$",
        "label": "Derivative, Forward Exchange Rate",
        "documentation": "Contractual rate at which a foreign currency can be purchased or sold."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLineItems",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofCurrencyExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Currency Exchange Rate [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_DerivativeNetAssetsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeNetAssetsPercentage",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net assets percentage",
        "label": "Derivative, Net Assets, Percentage",
        "documentation": "Percentage of value of derivative contract to net assets."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r584",
      "r585",
      "r586",
      "r744",
      "r1046"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Director [Member]",
        "verboseLabel": "Board of Directors [Member]",
        "label": "Director [Member]",
        "documentation": "Person serving on board of directors."
       }
      }
     },
     "auth_ref": [
      "r903",
      "r940",
      "r1047"
     ]
    },
    "upc_DisaggregationOfRevenuesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "DisaggregationOfRevenuesPolicyTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenues",
        "label": "Disaggregation Of Revenues Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r799",
      "r800",
      "r814"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r768",
      "r787"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r768",
      "r787",
      "r838"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r768",
      "r787",
      "r838"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share - Basic (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r225",
      "r227",
      "r230",
      "r231",
      "r232",
      "r234",
      "r426",
      "r431",
      "r445",
      "r446",
      "r518",
      "r541",
      "r698"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share - Diluted (in Dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r227",
      "r230",
      "r231",
      "r232",
      "r234",
      "r426",
      "r431",
      "r445",
      "r446",
      "r518",
      "r541",
      "r698"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r233"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash",
        "verboseLabel": "EFFECT OF CHANGES OF FOREIGN EXCHANGE RATES ON CASH",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTableReconcilestheChinaStatutoryRatestotheCompanysEffectiveTaxRateTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTableReconcilestheChinaStatutoryRatestotheCompanysEffectiveTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r723"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Tax Rate [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTableReconcilestheChinaStatutoryRatestotheCompanysEffectiveTaxRateTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTableReconcilestheChinaStatutoryRatestotheCompanysEffectiveTaxRateTable",
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory PRC income tax rate",
        "verboseLabel": "Assessable profit rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r396",
      "r416",
      "r723"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTableReconcilestheChinaStatutoryRatestotheCompanysEffectiveTaxRateTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTableReconcilestheChinaStatutoryRatestotheCompanysEffectiveTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r723",
      "r924",
      "r978"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfBusiness",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTableReconcilestheChinaStatutoryRatestotheCompanysEffectiveTaxRateTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTableReconcilestheChinaStatutoryRatestotheCompanysEffectiveTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent difference",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r924",
      "r978",
      "r979"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTableReconcilestheChinaStatutoryRatestotheCompanysEffectiveTaxRateTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTableReconcilestheChinaStatutoryRatestotheCompanysEffectiveTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PRC entities not subject to PRC income tax",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r399",
      "r723",
      "r924",
      "r978"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings."
       }
      }
     },
     "auth_ref": [
      "r924",
      "r978",
      "r979"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxHolidays",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTableReconcilestheChinaStatutoryRatestotheCompanysEffectiveTaxRateTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTableReconcilestheChinaStatutoryRatestotheCompanysEffectiveTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Effect of income tax holiday",
        "label": "Effective Income Tax Rate Reconciliation, Tax Holiday, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income exempt from income tax because of a tax holiday."
       }
      }
     },
     "auth_ref": [
      "r924",
      "r978",
      "r980"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "upc_EmployeeDefinedContributionPlanPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "EmployeeDefinedContributionPlanPolicyTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Defined Contribution Plan",
        "documentation": "The entire disclosure of employee defined contribution plan.",
        "label": "Employee Defined Contribution Plan Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incorporation date",
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r163",
      "r189",
      "r190",
      "r191",
      "r210",
      "r211",
      "r212",
      "r214",
      "r219",
      "r221",
      "r223",
      "r236",
      "r274",
      "r275",
      "r301",
      "r354",
      "r414",
      "r415",
      "r423",
      "r424",
      "r425",
      "r427",
      "r430",
      "r431",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r444",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r458",
      "r461",
      "r462",
      "r464",
      "r538",
      "r546",
      "r547",
      "r548",
      "r568",
      "r645"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r422",
      "r890",
      "r891",
      "r892",
      "r985",
      "r986",
      "r987",
      "r988"
     ]
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentAggregateCost",
     "crdr": "debit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company price amount",
        "label": "Equity Method Investment, Aggregate Cost",
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership interest",
        "verboseLabel": "Ownership percentage",
        "netLabel": "Percentage of equity interest",
        "label": "Equity interest ownership percentage",
        "totalLabel": "Equity interests",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "us-gaap_EquityMethodInvestmentSoldCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentSoldCarryingAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment amount",
        "label": "Equity Method Investment, Amount Sold",
        "documentation": "Amount of the entity's equity method investment which has been sold."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in equity securities",
        "verboseLabel": "Investment amount",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r246",
      "r256",
      "r269",
      "r905",
      "r946"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r780",
      "r791",
      "r807",
      "r842"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r788",
      "r804",
      "r839"
     ]
    },
    "us-gaap_ExcessStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ExcessStockSharesIssued",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional shares",
        "verboseLabel": "Excess Stock, Shares Issued",
        "label": "Excess Stock, Shares Issued",
        "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of financial instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsEstimatedUsefulLivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsNetTable": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r283",
      "r292",
      "r709"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r959",
      "r1050"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r687",
      "r709"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r687",
      "r709"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r687",
      "r709"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r687",
      "r709"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r687",
      "r709"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r296",
      "r297",
      "r485",
      "r486",
      "r687"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Estimated Future Amortization Expense for Intangible Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsNetTable": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r292",
      "r486",
      "r709"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsEstimatedUsefulLivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Intangible Assets Estimated Useful Lives [Line Items]",
        "terseLabel": "Schedule of Intangible Assets, Net [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r292",
      "r296",
      "r297",
      "r299",
      "r485",
      "r687",
      "r709"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_ForeignFinancialInstitutionsMandatedDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignFinancialInstitutionsMandatedDeposits",
     "crdr": "debit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposit at financial institutions (in Dollars)",
        "label": "Foreign Financial Institutions, Mandated Deposits",
        "documentation": "The amount of mandated deposits required of branches of foreign institutions."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r784",
      "r795",
      "r811",
      "r846"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r784",
      "r795",
      "r811",
      "r846"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r784",
      "r795",
      "r811",
      "r846"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r784",
      "r795",
      "r811",
      "r846"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r784",
      "r795",
      "r811",
      "r846"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r767",
      "r798"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss from disposal of property, plant and equipment",
        "terseLabel": "Loss from disposal of property, plant and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "General and administrative expenses",
        "negatedTerseLabel": "General and administrative expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r625"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r76",
      "r116",
      "r205",
      "r273",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r448",
      "r700",
      "r703",
      "r933",
      "r935",
      "r936",
      "r937",
      "r938",
      "r972"
     ]
    },
    "upc_GuangzhouNingjingInvestmentCoLtdGuangzhouNingjingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "GuangzhouNingjingInvestmentCoLtdGuangzhouNingjingMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofNatureofRelationshipsWithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guangzhou Ningjing Investment Co., Ltd (Guangzhou Ningjing) [Member]",
        "label": "Guangzhou Ningjing Investment Co Ltd Guangzhou Ningjing Member"
       }
      }
     },
     "auth_ref": []
    },
    "upc_GubenYanlingPillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "GubenYanlingPillMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guben Yanling Pill [Member]",
        "label": "Guben Yanling Pill Member"
       }
      }
     },
     "auth_ref": []
    },
    "country_HK": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "HK",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable",
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hong Kong [Member]",
        "label": "HONG KONG"
       }
      }
     },
     "auth_ref": []
    },
    "currency_HKD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "HKD",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofCurrencyExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "HK exchange rate [Member]",
        "label": "Hong Kong, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO [Member]",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r768",
      "r787"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r95"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income tax expense",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r112",
      "r116",
      "r519",
      "r536",
      "r700",
      "r703",
      "r933",
      "r935",
      "r936",
      "r937",
      "r938"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity investment income",
        "verboseLabel": "Equity in earnings of subsidiaries",
        "netLabel": "Investment income",
        "label": "Income (Loss) from Equity Method Investments",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r75",
      "r111",
      "r235",
      "r244",
      "r256",
      "r269",
      "r535"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of the Income Tax Provision (Benefit) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/Taxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r390",
      "r396",
      "r401",
      "r402",
      "r403",
      "r404",
      "r409",
      "r417",
      "r419",
      "r420",
      "r421",
      "r564",
      "r723"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total income tax expense",
        "negatedLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r136",
      "r222",
      "r223",
      "r235",
      "r245",
      "r256",
      "r395",
      "r396",
      "r418",
      "r543",
      "r723"
     ]
    },
    "us-gaap_IncomeTaxHolidayAggregateDollarAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxHolidayAggregateDollarAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax holidays decreased PRC corporate income taxes",
        "label": "Income Tax Holiday, Aggregate Dollar Amount",
        "documentation": "The amount of income taxes from which a reporting entity is exempt or for which it will receive a reduction in income taxes as a result of the income tax holiday granted by the taxing jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_IncomeTaxHolidayDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxHolidayDescription",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax holiday description",
        "label": "Income Tax Holiday, Description",
        "documentation": "A description of the factual circumstances giving rise to an income tax exemption or special reduction received from a taxing jurisdiction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxHolidayIncomeTaxBenefitsPerShare",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax holidays on net income per share",
        "label": "Income Tax Holiday, Income Tax Benefits Per Share",
        "documentation": "Per share amount effect of the income tax benefit resulting from the income tax holidays granted by taxing jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_IncomeTaxHolidayLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxHolidayLineItems",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r391",
      "r392",
      "r404",
      "r405",
      "r408",
      "r412",
      "r558"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income tax",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r201",
      "r410",
      "r411"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expense",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes payable",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred tax assets",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDueToRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advances to related parties",
        "verboseLabel": "Due to related parties",
        "label": "Increase (Decrease) in Due to Related Parties",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory, net",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other receivable",
        "label": "Increase (Decrease) in Other Receivables",
        "documentation": "Amount of increase (decrease) in receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidAdvertising": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidAdvertising",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepayment for advertising",
        "label": "Increase (Decrease) in Prepaid Advertising",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for advertising that provides economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "upc_IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses-related party, non-current",
        "documentation": "Amount of increase (decrease) of prepaid expenses-related party, non-current.",
        "label": "Increase Decrease In Prepaid Expensesrelated Party Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidSupplies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidSupplies",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Advance to suppliers, net",
        "label": "Increase (Decrease) in Prepaid Supplies",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for supplies that provide economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r290",
      "r295",
      "r709"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r290",
      "r295",
      "r709"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r784",
      "r795",
      "r811",
      "r837",
      "r846",
      "r850",
      "r858"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r862"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r862"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r862"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INTANGIBLE ASSETS, NET",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r298",
      "r300",
      "r686",
      "r687"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r482",
      "r483",
      "r485",
      "r695",
      "r950"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsNetTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r958",
      "r960"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense, net",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r918"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "verboseLabel": "Interest expenses",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r199",
      "r200"
     ]
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/InventoriesNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVENTORIES, NET",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "us-gaap_InventoryLIFOReservePeriodCharge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryLIFOReservePeriodCharge",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesValuationAllowanceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance (reversal) of inventory reserve",
        "verboseLabel": "Reversal of inventories valuation allowance",
        "label": "Inventory, LIFO Reserve, Period Charge",
        "documentation": "The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total inventories, net",
        "terseLabel": "Inventories, net",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r691",
      "r729"
     ]
    },
    "us-gaap_InventoryNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories, net",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r167",
      "r180",
      "r280",
      "r281",
      "r282",
      "r480",
      "r696"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_InventoryRawMaterialsAndSupplies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterialsAndSupplies",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAdvancestoSuppliersTable": {
       "parentTag": "us-gaap_Supplies",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAdvancestoSuppliersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advances to suppliers for inventories raw material purchase",
        "label": "Inventory, Raw Materials and Supplies, Gross",
        "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterialsAndSuppliesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Advances to Suppliers Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesValuationAllowanceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustments",
        "documentation": "Foreign currency translation adjustments.",
        "label": "Inventory Valuation Allowancee Foreign Currency Translation Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofInventoriesValuationAllowanceTable",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "negatedLabel": "Inventories valuation allowance",
        "terseLabel": "Inventory reserve",
        "label": "Inventory Valuation Reserves",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r911"
     ]
    },
    "us-gaap_InvestmentBuildingAndBuildingImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentBuildingAndBuildingImprovements",
     "crdr": "debit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total estimated budget",
        "label": "Investment Building and Building Improvements",
        "documentation": "Aggregate of the carrying amounts as of the balance sheet date of investments in building and building improvements."
       }
      }
     },
     "auth_ref": [
      "r1009",
      "r1010"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r800",
      "r801",
      "r802",
      "r803"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in Equity Securities",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r554",
      "r555",
      "r556",
      "r557",
      "r655",
      "r656"
     ]
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in subsidiaries",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "upc_JiangxiLulingRuralCommercialBankLRCBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "JiangxiLulingRuralCommercialBankLRCBankMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofShortTermBankLoansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jiangxi Luling Rural Commercial Bank (\u201cLRC Bank\u201d) [Member]",
        "label": "Jiangxi Luling Rural Commercial Bank LRCBank Member"
       }
      }
     },
     "auth_ref": []
    },
    "upc_JiangxiUniverseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "JiangxiUniverseMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofSubsidiariesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jiangxi Universe [Member]",
        "verboseLabel": "Jiangxi Universe",
        "label": "Jiangxi Universe Member"
       }
      }
     },
     "auth_ref": []
    },
    "upc_JiangxiYueshangMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "JiangxiYueshangMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jiangxi Yueshang [Member]",
        "label": "Jiangxi Yueshang Member"
       }
      }
     },
     "auth_ref": []
    },
    "upc_JxRcbBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "JxRcbBankMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "JX RCB Bank [Member]",
        "label": "Jx Rcb Bank Member"
       }
      }
     },
     "auth_ref": []
    },
    "country_KY": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "KY",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cayman [Member]",
        "label": "CAYMAN ISLANDS"
       }
      }
     },
     "auth_ref": []
    },
    "upc_LRCBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "LRCBankMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoansDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofLongTermBankLoansTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LRC Bank [Member]",
        "label": "LRCBank Member"
       }
      }
     },
     "auth_ref": []
    },
    "upc_LandUseRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "LandUseRightsMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land use rights [Member]",
        "label": "Land Use Rights Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r52",
      "r53",
      "r54",
      "r56",
      "r57",
      "r58",
      "r59",
      "r205",
      "r273",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r433",
      "r434",
      "r435",
      "r448",
      "r596",
      "r699",
      "r752",
      "r972",
      "r1000",
      "r1001"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS\u2019 EQUITY",
        "terseLabel": "Total liabilities and shareholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r109",
      "r530",
      "r729",
      "r922",
      "r947",
      "r994"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL CURRENT LIABILITIES",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r166",
      "r205",
      "r273",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r433",
      "r434",
      "r435",
      "r448",
      "r729",
      "r972",
      "r1000",
      "r1001"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT LIABILITIES",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCOUNTS RECEIVABLE, NET",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r939"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "upc_LongTermBankLoansDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "LongTermBankLoansDetailsLineItems",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Bank Loans [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_LongTermBankLoansDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "LongTermBankLoansDetailsTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Bank Loans (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing amount",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r107",
      "r326",
      "r336",
      "r712",
      "r713",
      "r728",
      "r1013"
     ]
    },
    "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtPercentageBearingFixedInterestRate",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed interest rate",
        "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate",
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_LongTermDebtTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtTerm",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital term",
        "label": "Long-Term Debt, Term",
        "documentation": "Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r991",
      "r992",
      "r993"
     ]
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LONG-TERM BANK LOANS",
        "label": "Long-Term Debt [Text Block]",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_LongTermLoansFromBank": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermLoansFromBank",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofLongTermBankLoansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term bank loans",
        "label": "Loans Payable to Bank, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the operating cycle if longer, excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r107",
      "r593"
     ]
    },
    "us-gaap_LongTermLoansPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermLoansPayableAbstract",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofLongTermBankLoansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term bank loans:",
        "label": "Loans Payable, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofLongTermBankLoansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r964",
      "r965",
      "r966"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r309",
      "r386",
      "r710",
      "r969",
      "r970"
     ]
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Machinery and equipment [Member]",
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r718",
      "r738",
      "r741",
      "r977",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentNetTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r142",
      "r144",
      "r145",
      "r147",
      "r161",
      "r162",
      "r305",
      "r306",
      "r307",
      "r308",
      "r358",
      "r386",
      "r447",
      "r479",
      "r544",
      "r545",
      "r552",
      "r587",
      "r588",
      "r653",
      "r657",
      "r659",
      "r660",
      "r662",
      "r684",
      "r685",
      "r706",
      "r716",
      "r721",
      "r724",
      "r725",
      "r726",
      "r727",
      "r739",
      "r976",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentNetTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r142",
      "r144",
      "r145",
      "r147",
      "r161",
      "r162",
      "r305",
      "r306",
      "r307",
      "r308",
      "r358",
      "r386",
      "r447",
      "r479",
      "r544",
      "r545",
      "r552",
      "r587",
      "r588",
      "r653",
      "r657",
      "r659",
      "r660",
      "r662",
      "r684",
      "r685",
      "r706",
      "r716",
      "r721",
      "r724",
      "r725",
      "r726",
      "r739",
      "r976",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership interest percentage",
        "label": "Subsidiary, Ownership Percentage, Parent",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "upc_MinorityInterestsOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "MinorityInterestsOwnershipPercentageByParent",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary exceeded percentage",
        "documentation": "Subsidiary exceeded percentage.",
        "label": "Minority Interests Ownership Percentage By Parent"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "upc_MrGangLaiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "MrGangLaiMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofNatureofRelationshipsWithRelatedPartiesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mr. Gang Lai [Member]",
        "label": "Mr Gang Lai Member"
       }
      }
     },
     "auth_ref": []
    },
    "upc_MrXiboLiuMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "MrXiboLiuMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mr. Xibo Liu [Member]",
        "label": "Mr Xibo Liu Member"
       }
      }
     },
     "auth_ref": []
    },
    "upc_MrYajunHuMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "MrYajunHuMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofNatureofRelationshipsWithRelatedPartiesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mr. Yajun Hu [Member]",
        "label": "Mr Yajun Hu Member"
       }
      }
     },
     "auth_ref": []
    },
    "upc_MsLinYangMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "MsLinYangMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofNatureofRelationshipsWithRelatedPartiesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ms. Lin Yang [Member]",
        "label": "Ms Lin Yang Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r718",
      "r738",
      "r741",
      "r977",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfCommonOwnershipOrManagementControlRelationships",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofNatureofRelationshipsWithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of relationships with related parties",
        "label": "Nature of Common Ownership or Management Control Relationships",
        "documentation": "This element represents a description of the nature of common ownership or management control relationships with other entities, regardless of there being transactions between the entities, when the existence of that control could result in operating results or financial position of the reporting entity significantly different from that which would have been obtained if the entities' were autonomous."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION AND BUSINESS DESCRIPTION",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r137"
     ]
    },
    "upc_NetAccountReceivablePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "NetAccountReceivablePercentage",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net account receivable percentage",
        "documentation": "The percentage of net account receivable percentage.",
        "label": "Net Account Receivable Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "terseLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "verboseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by operating activities",
        "terseLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r86"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "verboseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss for the year",
        "netLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r86",
      "r113",
      "r164",
      "r184",
      "r186",
      "r191",
      "r205",
      "r213",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r222",
      "r223",
      "r229",
      "r273",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r426",
      "r431",
      "r446",
      "r448",
      "r537",
      "r622",
      "r643",
      "r644",
      "r750",
      "r972"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r800",
      "r801",
      "r802",
      "r803"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r784",
      "r795",
      "r811",
      "r837",
      "r846"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other expense, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expenses):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segment",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r934"
     ]
    },
    "upc_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued",
        "documentation": "Number of shares issued.",
        "label": "Number Of Shares Issued"
       }
      }
     },
     "auth_ref": []
    },
    "upc_OfficeAndElectricEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "OfficeAndElectricEquipmentMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office and electric equipment [Member]",
        "label": "Office And Electric Equipment Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office and electric equipment [Member]",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingCostsAndExpensesAbstract",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating costs and expenses:",
        "label": "Operating Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r700",
      "r933",
      "r935",
      "r936",
      "r937",
      "r938"
     ]
    },
    "upc_OrdinarySharesSoldPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "OrdinarySharesSoldPercentage",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares sold",
        "documentation": "Ordinary shares sold percentage.",
        "label": "Ordinary Shares Sold Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Business Description [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_OrganizationandBusinessDescriptionDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "OrganizationandBusinessDescriptionDetailsLineItems",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Business Description [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_OrganizationandBusinessDescriptionDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "OrganizationandBusinessDescriptionDetailsTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Business Description (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_OriginalShareIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "OriginalShareIssued",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Original issued shares",
        "documentation": "Represent the share of original share issued.",
        "label": "Original Share Issued"
       }
      }
     },
     "auth_ref": []
    },
    "upc_OriginalSharesParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "OriginalSharesParValue",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Original shares par value (in Dollars per share)",
        "documentation": "Original shares par value.",
        "label": "Original Shares Par Value"
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "upc_OtherComprehensiveIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "OtherComprehensiveIncomeLossAbstract",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss)",
        "label": "Other Comprehensive Income Loss Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustments",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r538"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r450",
      "r457"
     ]
    },
    "upc_OtherIncomeExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "OtherIncomeExpensesAbstract",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expenses)",
        "label": "Other Income Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due to related parties",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r729"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other expenses",
        "label": "Other Nonoperating Expense",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofOtherReceivableTable": {
       "parentTag": "us-gaap_OtherReceivables",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofOtherReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r912",
      "r949"
     ]
    },
    "upc_OtherReceivableDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "OtherReceivableDetailsLineItems",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivable (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_OtherReceivableDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "OtherReceivableDetailsTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivable (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_OtherReceivablePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "OtherReceivablePercentage",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of other receivable",
        "documentation": "Other receivable percentage.",
        "label": "Other Receivable Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofOtherReceivableTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofOtherReceivableTable",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivable",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r607",
      "r704",
      "r1015"
     ]
    },
    "us-gaap_OtherReceivablesGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesGrossCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivable",
        "label": "Other Receivables, Gross, Current",
        "documentation": "Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due from related parties",
        "verboseLabel": "Due from subsidiaries",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherReceivablesNetCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_OtherShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofOtherReceivableTable": {
       "parentTag": "us-gaap_OtherReceivables",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofOtherReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption of short-term investment",
        "verboseLabel": "Short-term investment",
        "label": "Other Short-Term Investments",
        "documentation": "Amount of short-term investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r521",
      "r522",
      "r913"
     ]
    },
    "upc_OtherTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "OtherTaxesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTaxesPayableTable": {
       "parentTag": "us-gaap_TaxesPayableCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTaxesPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other taxes payable",
        "documentation": "Represents the amount of other taxes payable.",
        "label": "Other Taxes Payable"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r782",
      "r793",
      "r809",
      "r844"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r785",
      "r796",
      "r812",
      "r847"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r785",
      "r796",
      "r812",
      "r847"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over-Allotment Option [Member]",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ParentMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofOperationsandComprehensiveLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Parent [Member]",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "upc_PayableDeliveryPropertyPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "PayableDeliveryPropertyPercentage",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payable delivery property percentage",
        "documentation": "Payable delivery property percentage.",
        "label": "Payable Delivery Property Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepayment for acquisition",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r429"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of intangible asset",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property, plant and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "upc_PercentageOfPrepayment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "PercentageOfPrepayment",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of prepayment",
        "documentation": "Percentage of prepayment.",
        "label": "Percentage Of Prepayment"
       }
      }
     },
     "auth_ref": []
    },
    "upc_PercentageOfTotalPurchasePricePayable": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "PercentageOfTotalPurchasePricePayable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of total purchase price payable",
        "documentation": "Percentage of total purchase price payable.",
        "label": "Percentage Of Total Purchase Price Payable"
       }
      }
     },
     "auth_ref": []
    },
    "upc_PercentageOfVatRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "PercentageOfVatRate",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of vat rate",
        "documentation": "Percentage of VATrate.",
        "label": "Percentage Of Vat Rate"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock [Member]",
        "verboseLabel": "Ordinary Shares [Member]",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r742",
      "r743",
      "r746",
      "r747",
      "r748",
      "r749",
      "r1045",
      "r1048"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred shares par value (in Dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r338"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred shares",
        "verboseLabel": "Preferred shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r598"
     ]
    },
    "upc_PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "PrefundedWarrantsMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded Warrants [Member]",
        "label": "Prefunded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidAdvertising": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidAdvertising",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofOtherReceivableTable": {
       "parentTag": "us-gaap_OtherReceivables",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofOtherReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment for advertising",
        "label": "Prepaid Advertising",
        "documentation": "Amount of consideration paid in advance for advertising that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r693",
      "r707",
      "r949"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses-related party, non-current",
        "verboseLabel": "Rights to use trademarks",
        "label": "Prepaid Expense and Other Assets, Noncurrent",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r906"
     ]
    },
    "us-gaap_PrepaidExpenseCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrentAndNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid amount",
        "verboseLabel": "Prepayment",
        "label": "Prepaid Expense",
        "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r182",
      "r613",
      "r1011"
     ]
    },
    "us-gaap_PrepaymentFeesOnAdvancesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaymentFeesOnAdvancesNet",
     "crdr": "credit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment",
        "verboseLabel": "Prepayment amount",
        "label": "Prepayment Fees on Advances, Net",
        "documentation": "Amount of income earned, after hedging basis adjustments, from fees charged for prepayment of certain Federal Home Loan Bank (FHLBank) advances before original maturity."
       }
      }
     },
     "auth_ref": []
    },
    "upc_PrepaymentForAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "PrepaymentForAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment for acquisition",
        "documentation": "Prepayment for acquisition.",
        "label": "Prepayment For Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "upc_PrepaymentForAcquisitionCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "PrepaymentForAcquisitionCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment for acquisition",
        "verboseLabel": "Prepayment for acquisition current",
        "documentation": "The amount of prepayment for acquisition.",
        "label": "Prepayment For Acquisition Current"
       }
      }
     },
     "auth_ref": []
    },
    "upc_PrepaymentForConstructionInProgressAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "PrepaymentForConstructionInProgressAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment for CIP Project [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_PrepaymentForConstructionInProgressTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "PrepaymentForConstructionInProgressTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProject"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PREPAYMENT FOR CIP PROJECT",
        "documentation": "The entire disclosure for prepayment for construction in progress.",
        "label": "Prepayment For Construction In Progress Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "upc_PrepaymentForPurchaseOfAPropertyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "PrepaymentForPurchaseOfAPropertyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment for Purchase of a Property [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_PrepaymentForPurchaseOfAPropertyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "PrepaymentForPurchaseOfAPropertyTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PREPAYMENT FOR PURCHASE OF A PROPERTY",
        "label": "Prepayment For Purchase Of AProperty Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "upc_PrepaymentforAcquisitionDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "PrepaymentforAcquisitionDetailsTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment for Acquisition (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_PrepaymentforCIPProjectDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "PrepaymentforCIPProjectDetailsLineItems",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment for CIP Project [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_PrepaymentforCIPProjectDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "PrepaymentforCIPProjectDetailsTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment for CIP Project (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_PrepaymentforPurchaseofaPropertyDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "PrepaymentforPurchaseofaPropertyDetailsLineItems",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment for Purchase of a Property [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_PrepaymentforPurchaseofaPropertyDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "PrepaymentforPurchaseofaPropertyDetailsTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment for Purchase of a Property (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_PrepaymentsForConstructionInProgress": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "PrepaymentsForConstructionInProgress",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments for construction in progress",
        "documentation": "Prepayments for construction in progress.",
        "label": "Prepayments For Construction In Progress"
       }
      }
     },
     "auth_ref": []
    },
    "upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments made to a related party for purchase of property",
        "documentation": "Amount of prepayments made to a related party for purchase of property.",
        "label": "Prepayments Made To ARelated Party For Purchase Of Property Non Current"
       }
      }
     },
     "auth_ref": []
    },
    "upc_PrepaymentsMadeToARelatedPartyForPurchasesOfProperty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "PrepaymentsMadeToARelatedPartyForPurchasesOfProperty",
     "crdr": "debit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total purchase price",
        "verboseLabel": "Prepayments made to a related party for purchase of property",
        "documentation": "Prepayments made to a related party for purchase of property.",
        "label": "Prepayments Made To ARelated Party For Purchases Of Property"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromBankDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromBankDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from bank loans",
        "label": "Proceeds from Bank Debt",
        "documentation": "The cash inflow from bank borrowing during the year."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ProceedsFromContributionsFromAffiliates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromContributionsFromAffiliates",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash repayment from subsidiaries",
        "label": "Proceeds from Contributions from Affiliates",
        "documentation": "The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over allotment (in Dollars)",
        "verboseLabel": "Net proceeds (in Dollars)",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds (in Dollars)",
        "verboseLabel": "Gross proceed (in Dollars)",
        "netLabel": "Gross proceeds from offering (in Dollars)",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from issuance of ordinary shares",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "upc_ProceedsFromPaymentForConstructionInProgress": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ProceedsFromPaymentForConstructionInProgress",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments for construction in progress",
        "documentation": "Prepayments for construction in progress.",
        "label": "Proceeds From Payment For Construction In Progress"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from (prepayments for) related parties borrowings",
        "label": "Proceeds from (Repayments of) Related Party Debt",
        "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from disposal of property, plant and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property Plant and Equipment Estimated Useful Lives",
        "documentation": "The entire disclosure of property equipment estimated useful life during the period.",
        "label": "Property And Equipment Estimated Useful Life Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r463"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY, PLANT AND EQUIPMENT, NET",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r130",
      "r133",
      "r134"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subtotal",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r168",
      "r534"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property Plant and Equipment Estimated Useful Lives [Line Items]",
        "terseLabel": "Schedule of Property and Equipment, Net [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r463",
      "r520",
      "r534",
      "r729"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r130",
      "r133",
      "r532"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property, Plant and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r463"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected useful lives",
        "verboseLabel": "Useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAllowanceforDoubtfulAccountsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for doubtful accounts",
        "verboseLabel": "Reversal of allowance for doubtful accounts",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r278"
     ]
    },
    "upc_PublicOfferingPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "PublicOfferingPrice",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offering price (in Dollars per share)",
        "documentation": "Public offering price.",
        "label": "Public Offering Price"
       }
      }
     },
     "auth_ref": []
    },
    "upc_PurchaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "PurchaseMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase [Member]",
        "label": "Purchase Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentNetTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r142",
      "r144",
      "r145",
      "r147",
      "r161",
      "r162",
      "r305",
      "r306",
      "r307",
      "r308",
      "r355",
      "r358",
      "r382",
      "r383",
      "r384",
      "r386",
      "r447",
      "r477",
      "r478",
      "r479",
      "r544",
      "r545",
      "r552",
      "r587",
      "r588",
      "r653",
      "r657",
      "r659",
      "r660",
      "r662",
      "r684",
      "r685",
      "r706",
      "r716",
      "r721",
      "r724",
      "r725",
      "r726",
      "r727",
      "r739",
      "r744",
      "r967",
      "r976",
      "r992",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentNetTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r142",
      "r144",
      "r145",
      "r147",
      "r161",
      "r162",
      "r305",
      "r306",
      "r307",
      "r308",
      "r355",
      "r358",
      "r382",
      "r383",
      "r384",
      "r386",
      "r447",
      "r477",
      "r478",
      "r479",
      "r544",
      "r545",
      "r552",
      "r587",
      "r588",
      "r653",
      "r657",
      "r659",
      "r660",
      "r662",
      "r684",
      "r685",
      "r706",
      "r716",
      "r721",
      "r724",
      "r725",
      "r726",
      "r727",
      "r739",
      "r744",
      "r967",
      "r976",
      "r992",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007"
     ]
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofOtherReceivableTable": {
       "parentTag": "us-gaap_OtherReceivables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofOtherReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable from Yunan Faxi",
        "verboseLabel": "Receivables, Net, Current",
        "label": "Receivables, Net, Current",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OtherReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER RECEIVABLE",
        "label": "Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r268",
      "r943"
     ]
    },
    "upc_ReclassificationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ReclassificationsPolicyTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassifications",
        "documentation": "Disclosure of accounting policy for reclassifications.",
        "label": "Reclassifications Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r788",
      "r804",
      "r839"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofShortTermBankLoansTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r356",
      "r468",
      "r469",
      "r524",
      "r531",
      "r590",
      "r591",
      "r592",
      "r594",
      "r595",
      "r619",
      "r621",
      "r652"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "verboseLabel": "Related Party [Member]",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r468",
      "r469",
      "r470",
      "r471",
      "r524",
      "r531",
      "r590",
      "r591",
      "r592",
      "r594",
      "r595",
      "r619",
      "r621",
      "r652"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoansDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r469",
      "r999"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoansDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofNatureofRelationshipsWithRelatedPartiesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r626",
      "r627",
      "r630"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofNatureofRelationshipsWithRelatedPartiesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofRelatedPartiesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofShortTermBankLoansTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r356",
      "r468",
      "r469",
      "r524",
      "r531",
      "r590",
      "r591",
      "r592",
      "r594",
      "r595",
      "r619",
      "r621",
      "r652",
      "r999"
     ]
    },
    "upc_RelatedPartyTransactionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "RelatedPartyTransactionsDetailsTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r466",
      "r467",
      "r469",
      "r472",
      "r565",
      "r566",
      "r567",
      "r628",
      "r629",
      "r630",
      "r649",
      "r651"
     ]
    },
    "upc_RelatedPartyTransactionsScheduleofNatureofRelationshipsWithRelatedPartiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "RelatedPartyTransactionsScheduleofNatureofRelationshipsWithRelatedPartiesDetailsTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofNatureofRelationshipsWithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions - Schedule of Nature of Relationships With Related Parties (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfBankDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfBankDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of bank loans",
        "label": "Repayments of Bank Debt",
        "documentation": "The cash outflow to settle a bank borrowing during the year."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development expenses",
        "terseLabel": "Research and development expenses",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r687",
      "r703",
      "r1008"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "upc_ReserveIsEqualPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ReserveIsEqualPercentage",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve is equal percentage",
        "documentation": "Reserve is equal percentage.",
        "label": "Reserve Is Equal Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r789",
      "r805",
      "r840"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r779",
      "r790",
      "r806",
      "r841"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r786",
      "r797",
      "r813",
      "r848"
     ]
    },
    "upc_RestrictedNetAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "RestrictedNetAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted net assets (in Dollars)",
        "documentation": "Restricted net assets.",
        "label": "Restricted Net Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "verboseLabel": "(Accumulated deficit) Retained earnings",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r101",
      "r529",
      "r549",
      "r551",
      "r563",
      "r599",
      "r729"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained Earnings (Accumulated Deficit)",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r210",
      "r211",
      "r212",
      "r214",
      "r219",
      "r221",
      "r223",
      "r274",
      "r275",
      "r301",
      "r414",
      "r415",
      "r423",
      "r424",
      "r425",
      "r427",
      "r430",
      "r431",
      "r436",
      "r438",
      "r439",
      "r441",
      "r444",
      "r461",
      "r462",
      "r546",
      "r548",
      "r568",
      "r1048"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r624",
      "r688",
      "r697"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r192",
      "r205",
      "r235",
      "r240",
      "r241",
      "r254",
      "r256",
      "r258",
      "r259",
      "r261",
      "r273",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r448",
      "r519",
      "r703",
      "r972"
     ]
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RisksAndUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary price per share (in Dollars per share)",
        "verboseLabel": "Offering price per share (in Dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Benchmark [Member]",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r895"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast [Member]",
        "label": "Forecast [Member]",
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r898",
      "r930"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r224",
      "r359",
      "r889",
      "r930"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Receivable",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r68"
     ]
    },
    "upc_ScheduleOfAdvancesToSuppliersNet": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ScheduleOfAdvancesToSuppliersNet",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Advances to Suppliers",
        "documentation": "Tabular disclosure of advances to suppliers net.",
        "label": "Schedule Of Advances To Suppliers Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of the Income Tax Provision (Benefit)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "upc_ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Components Of The Income Tax Provision Benefit Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompanyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Consolidated Financial Statements",
        "label": "Condensed Balance Sheet [Table Text Block]",
        "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r899",
      "r926"
     ]
    },
    "srt_ScheduleOfCondensedCashFlowStatementTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfCondensedCashFlowStatementTableTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/FinancialInformationoftheParentCompanyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Parent Company Statements of Cash Flows",
        "label": "Condensed Cash Flow Statement [Table Text Block]",
        "documentation": "Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r899",
      "r926"
     ]
    },
    "upc_ScheduleOfConsolidatedFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ScheduleOfConsolidatedFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Consolidated Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_ScheduleOfCurrencyExchangeRateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ScheduleOfCurrencyExchangeRateAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Currency Exchange Rate Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/LongTermBankLoansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Bank Loans",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r36",
      "r37",
      "r47",
      "r99",
      "r100",
      "r712",
      "r714",
      "r926",
      "r996"
     ]
    },
    "upc_ScheduleOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ScheduleOfDeferredTaxAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Table Reconciles the China Statutory Rates to the Company\u2019s Effective Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r723",
      "r978"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r422",
      "r890",
      "r891",
      "r892",
      "r985",
      "r986",
      "r987",
      "r988"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r292",
      "r296",
      "r297",
      "r299",
      "r485",
      "r687",
      "r709"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets, Net",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r709",
      "r957"
     ]
    },
    "us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Currency Exchange Rate",
        "label": "Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]",
        "documentation": "Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "upc_ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforCIPProjectTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Capital Expenditures",
        "documentation": "Tabular disclosure of future minimum capital expenditure.",
        "label": "Schedule Of Future Minimum Capital Expenditures Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Intangible Assets Estimated Useful Lives Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets Estimated Useful Lives",
        "documentation": "Tabular disclosure of Intangible assets estimated useful lives.",
        "label": "Schedule Of Intangible Assets Estimated Useful Lives Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "upc_ScheduleOfIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ScheduleOfIntangibleAssetsNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Intangible Assets Net Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "upc_ScheduleOfInventoriesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ScheduleOfInventoriesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of inventory [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/InventoriesNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventories",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r69",
      "r70",
      "r71"
     ]
    },
    "upc_ScheduleOfInventoryValuationAllowanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ScheduleOfInventoryValuationAllowanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory Valuation Allowance [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_ScheduleOfLongTermBankLoansAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ScheduleOfLongTermBankLoansAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Long Term Bank Loans Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "upc_ScheduleOfLongTermBankLoansLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ScheduleOfLongTermBankLoansLineItems",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofLongTermBankLoansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Bank Loans [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Nature Of Relationships With Related Parties Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Nature of Relationships With Related Parties",
        "documentation": "Tabular disclosure of nature of relationship with related parties.",
        "label": "Schedule Of Nature Of Relationships With Related Parties Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Receivable",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "upc_ScheduleOfOtherReceivableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ScheduleOfOtherReceivableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Receivable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_ScheduleOfParentCompanyStatementsOfOperationsAndComprehensiveLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ScheduleOfParentCompanyStatementsOfOperationsAndComprehensiveLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Parent Company Statements of Operations and Comprehensive Loss {Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property Plant And Equipment Estimated Useful Lives Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "upc_ScheduleOfPropertyPlantAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ScheduleOfPropertyPlantAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property Plant And Equipment Net Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r463"
     ]
    },
    "upc_ScheduleOfRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ScheduleOfRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Related Parties Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r626",
      "r627",
      "r630"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Parties",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "upc_ScheduleOfShortTermBankLoansAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ScheduleOfShortTermBankLoansAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Short Term Bank Loans Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofShortTermBankLoansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Table]",
        "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShortTermDebtTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Short-Term Bank Loans",
        "label": "Schedule of Short-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "upc_ScheduleOfSubsidiariesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ScheduleOfSubsidiariesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Subsidiaries Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Subsidiaries",
        "label": "Schedule of Subsidiary of Limited Liability Company or Limited Partnership, Description [Table Text Block]",
        "documentation": "Tabular disclosure of the key aspects of a subsidiary (partnership, corporation, or other entity) of the limited liability company or limited partnership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary of LLC or LP [Table]",
        "documentation": "Disclosure of information about subsidiary of limited liability company (LLC) or limited partnership (LP)."
       }
      }
     },
     "auth_ref": []
    },
    "upc_ScheduleOfTaxPayableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ScheduleOfTaxPayableTableTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Taxes Payable",
        "documentation": "The entire disclosure of tax payable during the period.",
        "label": "Schedule Of Tax Payable Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Future Amortization Expense for Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r709",
      "r959"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable",
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r143",
      "r146",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r259",
      "r260",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r581",
      "r583",
      "r585",
      "r654",
      "r658",
      "r661",
      "r663",
      "r670",
      "r674",
      "r675",
      "r676",
      "r677",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r689",
      "r717",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r740",
      "r744",
      "r977",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r257",
      "r259",
      "r701",
      "r702",
      "r705"
     ]
    },
    "us-gaap_SellingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Selling expenses",
        "label": "Selling Expense",
        "documentation": "Expenses recognized in the period that are directly related to the selling and distribution of products or services."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier [Axis]",
        "documentation": "Information by supplier."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier [Domain]",
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received."
       }
      }
     },
     "auth_ref": []
    },
    "upc_ShareIssuedAfterTheSplit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ShareIssuedAfterTheSplit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issued after the split",
        "documentation": "Represent the share of stock issued after the split.",
        "label": "Share Issued After The Split"
       }
      }
     },
     "auth_ref": []
    },
    "upc_ShareOutstandingAfterTheSplit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ShareOutstandingAfterTheSplit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share outstanding after the split",
        "documentation": "Represent the share outstanding after the split.",
        "label": "Share Outstanding After The Split"
       }
      }
     },
     "auth_ref": []
    },
    "upc_ShareholdersEquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ShareholdersEquityDetailsTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares par value (in Dollars per share)",
        "verboseLabel": "Shares Issued, Price Per Share (in Dollars per share)",
        "netLabel": "Shares issued price per share (in Dollars per share)",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShippingAndHandlingCostPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShippingAndHandlingCostPolicyTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shipping and handling costs",
        "label": "Shipping and Handling Cost, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs."
       }
      }
     },
     "auth_ref": []
    },
    "upc_ShortTermBankLoansAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ShortTermBankLoansAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Bank Loans [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_ShortTermBankLoansDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ShortTermBankLoansDetailsTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Bank Loans (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofShortTermBankLoansTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term bank loans",
        "verboseLabel": "Total short-term loans",
        "netLabel": "Borrowing amount",
        "label": "Short-Term Debt",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r106",
      "r729",
      "r1012"
     ]
    },
    "us-gaap_ShortTermBorrowingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermBorrowingsAbstract",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofShortTermBankLoansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term bank loans:",
        "label": "Short-Term Debt [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofShortTermBankLoansTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Short-Term Bank Loans [Line Items]",
        "terseLabel": "Short-Term Bank Loans [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtPercentageBearingFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtPercentageBearingFixedInterestRate",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed interest rate percentage",
        "label": "Short-Term Debt, Percentage Bearing Fixed Interest Rate",
        "documentation": "The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTerms",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short term debt term",
        "label": "Short-Term Debt, Terms",
        "documentation": "Description of the short-term debt arrangement, and disclosures pertaining to the underlying arrangements, including repayment terms, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "us-gaap_ShortTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHORT-TERM BANK LOANS",
        "label": "Short-Term Debt [Text Block]",
        "documentation": "The entire disclosure for short-term debt."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r964",
      "r965",
      "r966"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r964",
      "r965",
      "r966"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r203"
     ]
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SoftwareDevelopmentMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software [Member]",
        "label": "Software Development [Member]",
        "documentation": "Internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r173",
      "r174",
      "r175",
      "r205",
      "r227",
      "r228",
      "r230",
      "r232",
      "r237",
      "r238",
      "r273",
      "r310",
      "r312",
      "r313",
      "r314",
      "r317",
      "r318",
      "r338",
      "r339",
      "r342",
      "r345",
      "r352",
      "r448",
      "r559",
      "r560",
      "r561",
      "r562",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580",
      "r598",
      "r623",
      "r645",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r888",
      "r920",
      "r932"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofParentCompanyStatementsofCashFlowsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r61",
      "r65",
      "r66",
      "r163",
      "r189",
      "r190",
      "r191",
      "r210",
      "r211",
      "r212",
      "r214",
      "r219",
      "r221",
      "r223",
      "r236",
      "r274",
      "r275",
      "r301",
      "r354",
      "r414",
      "r415",
      "r423",
      "r424",
      "r425",
      "r427",
      "r430",
      "r431",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r444",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r458",
      "r461",
      "r462",
      "r464",
      "r538",
      "r546",
      "r547",
      "r548",
      "r568",
      "r645"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable",
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r143",
      "r146",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r259",
      "r260",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r581",
      "r583",
      "r585",
      "r654",
      "r658",
      "r661",
      "r663",
      "r670",
      "r674",
      "r675",
      "r676",
      "r677",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r689",
      "r717",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r740",
      "r744",
      "r977",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r236",
      "r462",
      "r484",
      "r554",
      "r580",
      "r589",
      "r590",
      "r591",
      "r592",
      "r594",
      "r595",
      "r598",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r609",
      "r610",
      "r611",
      "r612",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r621",
      "r624",
      "r625",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r645",
      "r745"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Parent Company Statements of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_StatementOfCashFlowsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "StatementOfCashFlowsPolicyTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows",
        "documentation": "The entire disclosure of statement of cash flows policy text block.",
        "label": "Statement Of Cash Flows Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Information of the Parent Company [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r224",
      "r359",
      "r889",
      "r894",
      "r930"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r236",
      "r262",
      "r462",
      "r484",
      "r554",
      "r580",
      "r589",
      "r590",
      "r591",
      "r592",
      "r594",
      "r595",
      "r598",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r609",
      "r610",
      "r611",
      "r612",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r621",
      "r624",
      "r625",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r645",
      "r745"
     ]
    },
    "upc_StatutoryReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "StatutoryReserve",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory reserve",
        "verboseLabel": "Statutory amount (in Dollars)",
        "documentation": "StatutoryReserve",
        "label": "Statutory Reserve"
       }
      }
     },
     "auth_ref": []
    },
    "upc_StatutoryReserveAndRestrictedNetAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "StatutoryReserveAndRestrictedNetAssetsMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory Reserve and Restricted Net Assets [Member]",
        "label": "Statutory Reserve And Restricted Net Assets Member"
       }
      }
     },
     "auth_ref": []
    },
    "upc_StatutoryReservesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "StatutoryReservesMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory reserve",
        "label": "Statutory Reserves Member"
       }
      }
     },
     "auth_ref": []
    },
    "upc_StatutorySurplusPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "StatutorySurplusPercentage",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory surplus percentage",
        "documentation": "Statutory surplus percentage.",
        "label": "Statutory Surplus Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r781",
      "r792",
      "r808",
      "r843"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares and additional shares under overallotment option in initial public offerings, gross (in Shares)",
        "verboseLabel": "Public offering ordinary shares",
        "netLabel": "Share issuance",
        "label": "Shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r60",
      "r61",
      "r101",
      "r559",
      "r645",
      "r665"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse share-split adjustment (in Shares)",
        "label": "Stock Issued During Period, Shares, Reverse Stock Splits",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares and additional shares under overallotment option in initial public offerings, gross",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r60",
      "r61",
      "r101",
      "r568",
      "r645",
      "r665",
      "r751"
     ]
    },
    "upc_StockIssuedDuringPeriodValueReverseShareSplitAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "StockIssuedDuringPeriodValueReverseShareSplitAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse share-split adjustment",
        "documentation": "Represents the value of reverse share-split adjustment.",
        "label": "Stock Issued During Period Value Reverse Share Split Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "upc_StockIssuedDuringPeriodValueStatutoryReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "StockIssuedDuringPeriodValueStatutoryReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory reserve",
        "documentation": "Represent the amount of statutory reserve.",
        "label": "Stock Issued During Period Value Statutory Reserve"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL SHAREHOLDERS\u2019 EQUITY",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "terseLabel": "Total shareholders\u2019 equity",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r65",
      "r66",
      "r90",
      "r600",
      "r620",
      "r646",
      "r647",
      "r729",
      "r752",
      "r922",
      "r947",
      "r994",
      "r1048"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHAREHOLDERS\u2019 EQUITY",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHAREHOLDERS' EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r204",
      "r337",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r354",
      "r443",
      "r648",
      "r650",
      "r669"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding ordinary shares ratio",
        "label": "Stockholders' Equity Note, Stock Split",
        "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r475"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r475"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r475"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r475"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r476"
     ]
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal Activities",
        "label": "Subsidiary of Limited Liability Company or Limited Partnership, Business Purpose",
        "documentation": "Description of business purpose of the subsidiary of the limited liability company or limited partnership, for example, its day-to-day operating functions and whether it acts as a holding or operating company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Date of Incorporation",
        "label": "Subsidiary of Limited Liability Company or Limited Partnership, Date",
        "documentation": "Date the subsidiary of the limited liability company (LLC) or limited partnership (LP) was formed, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Subsidiaries [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "% of Ownership",
        "label": "Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest",
        "documentation": "The number of units or percentage investment held in the subsidiary by the limited liability company or limited partnership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Place of Incorporation",
        "label": "Subsidiary of Limited Liability Company or Limited Partnership, State",
        "documentation": "State in which the subsidiary of the limited liability company or limited partnership was organized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/InventoriesNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventories Valuation Allowance",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "upc_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRateDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRateDetailsTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofCurrencyExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies - Schedule of Currency Exchange Rate (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_SummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsEstimatedUsefulLivesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "SummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsEstimatedUsefulLivesDetailsTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies - Schedule of Intangible Assets Estimated Useful Lives (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesDetailsTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyPlantandEquipmentEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies - Schedule of Property Plant and Equipment Estimated Useful Lives (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure information",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplierConcentrationRiskMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier Concentration Risk [Member]",
        "label": "Supplier Concentration Risk [Member]",
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_Supplies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Supplies",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAdvancestoSuppliersTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofAdvancestoSuppliersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Advances to suppliers",
        "terseLabel": "Advance to suppliers",
        "label": "Prepaid Supplies",
        "documentation": "Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r694",
      "r708",
      "r949"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "upc_TaxBenefitPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "TaxBenefitPercentage",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax benefit percentage",
        "documentation": "Tax benefit percentage.",
        "label": "Tax Benefit Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "upc_TaxesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "TaxesDetailsTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTaxesPayableTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedBalanceSheet",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTaxesPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total taxes payable",
        "terseLabel": "Taxes payable",
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53"
     ]
    },
    "us-gaap_TaxesPayableCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxesPayableCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Taxes Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "upc_TaxesScheduleofComponentsoftheIncomeTaxProvisionBenefitDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "TaxesScheduleofComponentsoftheIncomeTaxProvisionBenefitDetailsTable",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofComponentsoftheIncomeTaxProvisionBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes - Schedule of Components of the Income Tax Provision (Benefit) (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r940",
      "r998"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]",
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "upc_TopTenCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "TopTenCustomersMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Top 10 customers [Member]",
        "label": "Top Ten Customers Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r942",
      "r944",
      "r945"
     ]
    },
    "us-gaap_TrademarksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TrademarksMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsEstimatedUsefulLivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trademark [Member]",
        "label": "Trademarks [Member]",
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r709",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r958",
      "r960",
      "r961",
      "r962"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "upc_TwoSupplierMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "TwoSupplierMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Two Supplier [Member]",
        "label": "Two Supplier Member"
       }
      }
     },
     "auth_ref": []
    },
    "upc_UnderwriterWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "UnderwriterWarrantsMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriter warrants [Member]",
        "label": "Underwriter Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "upc_UniverseHKMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "UniverseHKMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofSubsidiariesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Universe HK [Member]",
        "label": "Universe HKMember"
       }
      }
     },
     "auth_ref": []
    },
    "upc_UniverseHanheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "UniverseHanheMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Universe Hanhe [Member]",
        "label": "Universe Hanhe Member"
       }
      }
     },
     "auth_ref": []
    },
    "upc_UniverseINCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "UniverseINCMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofSubsidiariesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Universe INC [Member]",
        "documentation": "Universe INC.",
        "label": "Universe INCMember"
       }
      }
     },
     "auth_ref": []
    },
    "upc_UniverseIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "UniverseIncMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Universe Inc [Member]",
        "label": "Universe Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "upc_UniversePharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "UniversePharmaceuticalsIncMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Universe Pharmaceuticals Inc [Member]",
        "label": "Universe Pharmaceuticals Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "upc_UniverseTechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "UniverseTechnologyMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Universe Technology [Member]",
        "label": "Universe Technology Member"
       }
      }
     },
     "auth_ref": []
    },
    "upc_UniverseTradeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "UniverseTradeMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofSubsidiariesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Universe Trade [Member]",
        "verboseLabel": "Jiangxi Universe [Member]",
        "label": "Universe Trade Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uses of estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r126",
      "r128",
      "r131",
      "r132"
     ]
    },
    "us-gaap_UseRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseRightsMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofIntangibleAssetsEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land use rights [Member]",
        "label": "Use Rights [Member]",
        "documentation": "Legal right to use or benefit from the use of natural resources or access. Examples include, but are not limited to, drilling rights, water rights, air rights, timber cutting rights and route authorities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r951",
      "r952",
      "r953",
      "r954",
      "r956",
      "r958",
      "r961",
      "r962"
     ]
    },
    "upc_ValueAddedTaxPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ValueAddedTaxPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTaxesPayableTable": {
       "parentTag": "us-gaap_TaxesPayableCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofTaxesPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value added tax payable",
        "documentation": "Represents the amount of value added tax payable.",
        "label": "Value Added Tax Payable"
       }
      }
     },
     "auth_ref": []
    },
    "upc_ValueAddedTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ValueAddedTaxPolicyTextBlock",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value added tax (\u201cVAT\u201d)",
        "documentation": "The entire disclosure of value added tax.",
        "label": "Value Added Tax Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValueAddedTaxReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValueAddedTaxReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofOtherReceivableTable": {
       "parentTag": "us-gaap_OtherReceivables",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofOtherReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid value added tax",
        "label": "Value Added Tax Receivable, Current",
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant adjustments share (in Dollars)",
        "label": "Warrants and Rights Outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r991",
      "r992",
      "r993"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants term",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r991",
      "r992",
      "r993"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of shares outstanding used in calculating diluted loss per share (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r232"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of shares outstanding used in calculating basic loss per share (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r232"
     ]
    },
    "upc_WorkingCapitalLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "WorkingCapitalLoanMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working Capital Loan [Member]",
        "label": "Working Capital Loan Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "upc_YunnanFaxiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "YunnanFaxiMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OtherReceivableDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Yunnan Faxi [Member]",
        "label": "Yunnan Faxi Member"
       }
      }
     },
     "auth_ref": []
    },
    "upc_YunnanFaxiPharmaceuticalsCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "YunnanFaxiPharmaceuticalsCoLtdMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Yunnan Faxi Pharmaceuticals Co., Ltd. [Member]",
        "label": "Yunnan Faxi Pharmaceuticals Co Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "upc_ZhujiangRuralBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "ZhujiangRuralBankMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofShortTermBankLoansTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermBankLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Zhujiang Rural Bank [Member]",
        "label": "Zhujiang Rural Bank Member"
       }
      }
     },
     "auth_ref": []
    },
    "upc_supplierMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20240930",
     "localname": "supplierMember",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier One [Member]",
        "label": "supplier Member"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(i)",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "505",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477270/942-505-50-3"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "910",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482332/910-20-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-5"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-21"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-11"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/705/tableOfContent"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "11",
   "Subsection": "03",
   "Publisher": "SEC"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "6",
   "Subsection": "04",
   "Paragraph": "12",
   "Subparagraph": "(b)(1)",
   "Publisher": "SEC"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/310-10/tableOfContent"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>147
<FILENAME>0001213900-25-036798-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-036798-xbrl.zip
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M432 <C,5QGD8"18,U;@43/BSB"%0<@'"V@6PV+S5!5A=@*\]&B>/%C-H7\-
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MOGO6#&=8 ES%P5C!S84'/H<Q7]?,(CM)@[I0D\GZYR2]@&NNHAS4@*'PAE8
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MW.3M^7<@Z04;=U=:L<]$+L8*?0<53A(\V11&, :!AT<R#*/)Q)R+>V!])0_
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M&[P+Q@E.)*+=U";\2O* N34"TD#.*V3S$FPB_2W\LP2I#U=AB6894_"H)@[
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M_ Q(6Y?4H9%-D(>Y.8-%F/5P8:,*06F4H"4/;V<IN=1,(V\'W0B#>+8*F?^
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M>E]0&D)]!=@WW,3PM9-(JE#S<</U*55@=LE-N[#I*_8=5XE*/=KKM^<Q(LO
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M)5J@LW_DM!W- W[30K%9>UGB%YRR[]:[S\+(Z1% E=LE?[!64TOJOP0(W\$
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M$B0:H9*/W+EI6RAE0J_&.?<*$"V?99B(Y2=#2-4^X:FC^(L:2EVR5$C5+33
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M#-,8:[0-AX249VJH"*&2PN&_4O!*IB9M2^Q:8X>#NH2P2T-ME0ER@,9.1MP
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MLYM79&MYK5,A$;6PZG=+<(BL^/ABIA50%IJ'AR:$+*']+J*L95V#)I!.%3B
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M=L[;P_K*XTTJ3F*3V-D2-?Q"#%B/KO2J2)G_!/SF(G;J VW+D T/H^IDW^$
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M*<]0+M@F_+JNOIW<@;H+-S3ZFZDUR*D]Q7F<+$#G#%ZS:@'E3^8)?Z'E--\
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M#/\D40B:2@PA)2&W#(0^Z^Q_]U:9]V&L^OWB*LRL5%CE@V/E387Y]I BP[Z
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M@B-+/A"Y1<82_E=Y,^)5T1A;5,8P+IEX/A&RL;/[Q.4>&C<-RS7JV%7R['Z
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MH^>?UG<W)DWRZ0^JS_HRWIWW"&='N&9U.PK7K":0?CN^6<$=_SUM=@=5H94
M=$_@#E@8J-;3R"HW:^WZQ>-QNZZQQXG8?<8$EP/U_@Y1OB3?F"-?UU).EA\&
M.09-/8&8%%240Y8MFM8=]ZET I&-N+,9BW&VW,D@6V[(5E@\UJ34MFC*<JE&
MPIA=P8O087?5EFFS\(GM5=?=T)K-6/C"=>,$PBB-CABSXBHM%;3/Z93"=D#F
M)DWSTZ'=&DR\>T?RU"#WZYF*W7#26M*ECUTK2W_P&=3RMKLV.HW3_@<RKE@\
M1_ 754K9#&>\S=I $8HD!CUGB44\SW1YYY?<PYA1_[X]^>Y;[I[LR&^!Z%G
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M+3F===5)&Y:KLX)C:AOOB&EMA567\>2)5(%<A[HIO4&-OFHT+X]8N-ODH#Y
M[9+\*R?RU^EN6)5G]8:3XYE9USP*,SWII^E9WN:.64AHY>5.54G$4<I3.MGL
M?=$8O<>']QB]/D;OV3U&[_-C]'H'EYBM3B>7FO60VR^SMNR9@7#Y.C-T$->
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M[_$I4)YX2JH'ZO1.,DI<15&6I<2R&$D93>;-O\#NV]VPT$ '"^GVIW_.=C<
MS4662+'%JIE8)(&+NYQ[]O,[O?!9[#0X%S[,0LSVF0H\@T(^K@4PWM:<"\:L
MFL&-F^G!R"HY3L!7#ERZ.+O?IE\S)V]10W )-?3"E_F%,J[HN:I0<<U,=HM.
MJ((Q<28R*9E&K--O1)BXL]"-V3G3C4V\ $XW,7#M.H7NBNW 3?7WKFM?6T7
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M^IWFIH;*8EQI_#,RAJ@0(BEK9A(.%(^M!M.:%8]C:D><MJ%&LA- 9V#:W;J
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M^7T%UI:^G\'+.(/+^!ID(MZBMTHZ%EE:DNL*:J"X(HW*I[(K53Z'[]%W3!Z
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ML_RW<#08#(["GTA#/(W/DY0$U<ODC& 5P;[<1B$8;* REE7X+-[":<7P/K_
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MBT.'UC,*0KS"+@YHGAQ+9:(N#0[>LC^,L:%N6<)W]SFX(_?)69&CO-8.0N.
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M:ZZ,?:9%I#T83]O5  H:\^D/E3J%+_,+#)-&LOD;^(*K,RS!MENRN[11<88
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M^+7 OT!K95J<YQ0!X+'+5<P&KA7_ESM7T,RV@:.\$.=#ILL].X<-1*XY[_%
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MG=7?=A2>%O(%'#B+NE]SWDVASE3E_XN34@*XH^JMG884QI7#8OQ   ",$Z4
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M@_LKG+"J"T?\32W%'&N0)EGVFB/0A4Q'2HK'ZF\2&6K@\"LK&HZ1:V#PI,B
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M,_GL)2!/O6>(ZC$)E56WEK7PULJ)J#(]%X@GE0\JG@"ZP)3DI:K\*?LO:A]
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M:0 X>98?;=@5!/?R1"3^E@/Z,( %*F9<$)_C,H.<"A'Y)4TFF!B6&IH4]U;
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M6_([.9)(#E8)C\*:A*Z%@81.BLY'&P"\(,S??V'I(OP)MD>R'A91TK%NDHR
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MB\;1WZ&UB%K$:MSFHTQJ+ 26NA66<_GX:"4-, F[=%:D+(V8G9#01\"UF*5
MR;D1>1 MSKV,&$:;^]'CJ26<>:XKU*2G]!CZI0%RE]B0[,L;W(3)0E;%9%?@
M,UNQ"=R)=W"1P#Q)_LEC%E;/8=H5&H#8M ?K\':E[1^ TK!9XH)W2ERH)B[T
M3HD+QW,<ZJP5;8R<W\&%,I%[ !_Z.>5"0IT#H,T3^[?D'HO7]L=,V4_S$*F(
M:(X(JT$709!9JE-;$-D?45?_): 6I'[3]RFCK^5*E^BFU_[QE8KZX"[(F_^8
MV__OS3RQ/X?\HM?O2_V4+ZF)'5>_Z)#CBUR^:3A(0 G[&]VZXT0N;KAE=*2-
MW4=H!Z"I0UY,O(+@)H2%IO=8AW!/;>OUL@A]'230-:HCV/<>-3W=;:5R'Y.=
M)4X)2]H_\HVJ'.3AY(:1(%G7HF],$/M))J]0D3#+-9N]-M6L":5Z@FJ-Q:0#
MGD\PN(%OX7!W".$XI7 D7_O4#4YT.C'].$#&^ES!ITSN8*K=3%$KMT,!88VT
MLE>G<&GM'%49N/Q9R1K-8_'+<\#5*BV4RF%$[2(M/[[/VYB5]1LZG[GJI8":
M='M*_)W:,!O>7TPT1\]GB#$0V(=I&@U0.>'3GD_-R/%$A0@M@$F(*V#WYSU*
M6+W@H=)?I'4O_+ODFM_;P\0A2Z#RK!H7MF&4A=*.\2N"S(34<Y%( 6_-*877
MB*3HF9'J=Q=J/2_3-([O=?2#69'Y+&<KRG*]"WE\RS2X]!18G9Y/\E&!=F .
M3F=F<&71\-@4KS YCK]P.(;ZY*"S7BF/%K. R>:TN5HFJP83^ 6LX29#"]ZF
MI'BV8V919C 'S2 0[ FEU<I4 O%034#JY=88M?73R]#ZK7Z DLZY9FR@F#P/
MCN?A->4M+,:;M4?1J;/&+&V)V=H2.W8/;=UUK!L*OTTRE6$F_&BT=0A)!.=A
MZG=HI( @'^S1C;PO2L^%:;2+&15EEG+9S)1T->2H.AY\(NE$Z&;VMDA)@C*^
M-1!.X'3@<# 9LS<Q7AGSB22^$Z!+R*=.86IR1U+CC"F+SYB/ !33G2>HF$I&
M,:8 L02^9,2X-4OP?8U5D1-*ZN11SG(#/@WN+'42,P']=$!5'_S%465\P<$[
M*<78MP%A#&N3_%C''F%)Z\V,1W<(?OJ&;EM*X:D&(7./#KWQBMN2!KI3!76@
M57O#3;Z$(NRS@$EK\9$QV#E=$F:G3[G>2T'B8JX+77_V+?4^)7JC_S*:C-A_
M@7%:;%!&;:&9D,I9@MC8BH=(,N+ZG!IN8B>7R-1I@D,5= 5RX"2*$%K0!Q9'
MNLDA=A?<9X0U%X<5G2G2G5[XG)C*%Q9_I2'I712Q3D6=,'?$B#VG4D[!!:.,
M=V,A"QN%&*@[)!-2&A7$O!"W['BDC<K"\@=2%3U?O DY\FQFZJ8+]D6!\,$-
M1QL!'YHX1G%)[FT*M2=[3!V-[A"0Z%X F[AP.9_\YP*'46X!/R/9"#.9MAJ;
M]23190PZH*YR;U\':F?*;_%NW>>^2,W\A8B<W*JE5 32N&=P9:J#6CC9L#C$
M:"\ Z:JZ,"5#7HDCM%#?JN4+[1373J]S-*V+(N]3D9CISF5B**<P3MS0^Q?+
M,%$*LEII4*B%1K/"8CY%8MR%%=Q$W'%EJV *1J3"<GI*&>$SJ-;3<,$@&XA;
M63HD"G25]KF5%%'=A-YB?'8D:E8ORE>);YO[XD2()U99/>O(5WGQE.8>F-.S
MJ33%M/WM*22;:E9H](2&(19O55W:>\T(KU%E[4\#/#U6U>B7 X3EIIE] U<\
MI;QJ\U',O22^E80X"2-^*>;%23G>&%0<3I\+U)6"RE QAFOIJ[KVBSD8C9YC
M'KI%^Q\&0_Y/T=.!N51I,(V&. :V8J#*OG!P,P%*7+-2ED>F+/T9I>(@]#.Z
M2D!X8HR)XCOH\*"\JSEW?*>:$+IBZ3".$*S!',@L[U>"I^IQ* >RU1TS0%@[
MS$R3##N.@2_*9#)VX%,RDW);-1E,^"!Y+NG38$@'PW <#2P3]-DQ,:P",%H'
M*NHDZ47SJQAC2'R3W1(.-G 0@0XE1LF4I.)(UP_]#&K!X5_";W;> 9ZL&PU]
M0="%J +P=614(W.X-A]M<?+E8IZK)W76L"ZE]:2Y14CM6E+B%<"P(#D' 9M=
M8YEQ6+JY!8!#J>YHJM.9TI1#K7-9'JEBAUE(1KDC*9IL;A,($]5K2;IFV?_&
M?S>T&PZ)P]EFY\Q0E?032H44DD]4*#8+)5J5*22V(A$0LT706O(-U$='%%%0
M?/DX2%L;CGO=%?5R' :C]A358)P_>KMAY-+$H.29)UAQ !_VNOFE(27@&RJ9
M>:KFDQ!X-!D3*R2IE5QE";9745>Z+G#FV\, ;W%*=[;R>^C28F2SO8C'[:=W
MG&>%-\5G=FC]B28@9O6"X8-:&#+F!0F=+RFBBHIO!.'.D,*_%V/YYUI_-M+_
M?C9S&? /[_6Q?*L<4OM#D6UH!@_1"F9$[CN$YL_Q<JP_0)4-AXR&Q@3E#&K$
MC 2A-V" *_02A&@4*^\F CZ.\#Q_TF CO^!!'L*NSL=3S+0FB(>AZ:2?"0OD
M8&J4>--V&(&+W#)Q%&C@I"P:1P@R,@:;BFWU/Q5L-\S_+\<F-+4<!>PF& H8
MX]#,L="?'=DN(:!,;%P87WW_-Y,8 -P4P+$19ML7WR%5W6TVOV-I1GW/IL',
M0!=GRIHH1+.[Q)@7C'D3746BRK,9!O\N/@])#TK)#T_V'RU+)3#]T;ALV"S-
M[K66=!TG5^C5YC\[M%NY*[YP=S7L=R(*2Q4&DBF/GA.<#]W)Z-$VAP8U(G_)
M03\"1IWPGZK3/ R4P]FI#RE83;F*5;=9-7ND ,%CX34,%SECER*=J;^'&D7\
M>NA>MW(5"('A.3W"9B<%]2Z&1<?)W1!;XHDW0-:1Y,$O143V5 M^YZ+<(3%.
MB_YPJ[Y8;H%/O-3<!JW$:()('G#_7\WC4'+T6.NE!M+"L'P_9B4'0CXARW1K
MLN-*=596KR)KAG!#QQ'8R$-\%OM:FQ5>SW<_*(&XPRJES7)&_%/.2#5GI'_*
M&=F@%N\Y>%QJ)K0@^F04@WZ88/D2:L_'7!V(\A83:W6Z;&UE+$5.586O%=B&
M2[Z^DE;I'V:"I#1$171H"3]-S)0_NA/@ERP3WYZS-/YC<5*D=A1N$ FB+^&7
M&;^(XQG<_#LW]2*]_:J?%*E[Z(!$C41JH_-.Q.;JRSFR1: IM,7G$QQ<[' S
M4(Q5*4-0JC)1'U2U2F$\BJ9DTT02%:98&BB=0I4_2LQ-0W_AFKL1PX\)GKGR
MQ#,HV4 Y5\RT#6D'BO-2F\J&\1WUUB5KEXE!#FYK*1U(<Z)FIS-L[ IKVUU-
MUC,:?^KC'V'MGYG;CQW.6XX4'6P-/1#RL4-H/=!:D6M"U/:P1(&P/E4OWG^>
M?]'%F70XBU'+)!9K9Y((0#\=(HQWJ5Q]\5:H3"!VV8&R/XPXSY^SLS 7>J*T
M^)SAK=+D&>*/^MW1:[=)/,<P!!;(B&!3U8?CZ"MYUM1\<:Y[X/A8M/DS<E@-
M8!U3U+HGU__^3?,;K7ZP"D8NR&D&&HCZMQ_10IW=_$ FWH_V^FN0$;-I@$%2
M7,O7'[]!!>2G6:J^2@D\8 .IQ;%B\XVH*;-A ;<@HK#S#_;K9@/LU&CRHRWK
M>!V'(_B[_#DGP&SXQA@#9_[ZC@+V^*%XF+^O]2E4.0OOZXD .1 .X=^_<7.:
MU8Q8IW.NUF[?BRTK&+G_0\4X[[ 8A[Y?*,@I+ZMV#;Q/A;EMF2S>TU/EGZ!W
M4"/CJ_3[-^SN1[\P_Z=!*BI1@D-=^X-_HE<M61;1RWL:>GT_2P__J&]ACY!5
M7PY'OJSS]W2GYQ!6^]UIJ5N2B76J77I]=>8U6X[G]QROW7[U.+FI=;H6JG0F
M4?"Q;]Z(V2(@VESA-T(->/2Z -I22#(L$TFIC=_5;UCYJ;IYU#.*O-(OO4+&
MP3=O.LU&?^%4ZCY2V=UGFGB[VV@?YL3[C=Y!3MQO5.[B@YCWF=>H7*M+/_+J
MN\=+H#_9N'R<V"E/;:&(KY= =3G5:\GFI?NSZ@)8?]LV&TEQ8;_AKGG!K,&2
M![?\EE<5>R]I^<W&NDKC,2[_K$8&K[W\5X>__AI)ONGN[Y-:N5J^>[PC7TPT
MFE44\!ZVBZTI-D+#IA2/W,1% \D>NLUFH[G6&AYTAD^K/ZU^3U=?/]+:R]_@
M]1=!@V=6S\MK64;R=2FZ-L%6#7B:S&DRFTUFG_6B;]Y<&L%E##9CO?3K>H?:
MEFCJNDZOYSK-7G=/-MGM.-VV[[3\BD'T7!-J.MU^'QB@8J(\TX3.O!I?P3*[
M:$OS:+?7F<;!.9WJSR0YG>PC<SIU'-]SG<[:P<B'*F][3XB>T^UVG5ZW(@1?
M&B% SGD=I^F]>$*<>;W5)MTQ^Z3.6M4(VL;KWV?M:X57RLS[.W#CU 4"-CVG
MZZZ,,!RWD>ZUG;;O.GYS)6,?.1V:#M83>KT7S@\HXU=>= M)L%K&[_GRO9I4
M@TV=EB=GU4%X04Z3.8C)[).ZM$!A/<?ZX^NP6 B!E5#+?%>[58*_?1+]UVVX
ME7RF@S""GFSY#\]'.?SE>XVULWCW:_E/Z1UZ?%;" :_^K+U&3'>K!O"3N#T?
M*L;W)L?NJ<19ZS#/\U,MO]UYT<OO/CR[\$BD^5G_A?LSW9J2@ ?+\^^IC':7
M9=SF_^^LI/NS;A17R, NPDJ;Q2 6!LRR4I,\+,;XSK&QM(&:Y-E8*["#)GD6
MHABX_I+IVCS=44#M%K 5'4)2!;/P.D%,JA_LL^B5/4-80PWEB1TFPA%-$U$=
MDHD]N$F3232P;\(@)J2M4H=JW=4:.Q]<3Z1/,?7G"//&U@@9I9$C"*V)\(+-
M3M%OY4,:OLW^HJ:F.QO3ZV<13'N -?,$NA3/I3$SS8IKW9>-9;3Z57B9O\ZO
MPHG]/\&$M(5/$796N+P))X1S^&<89?#OZN__-8?'YO(?_X--&.<A]GJYOIY'
M]N5].I\Z]I_SOR,+?OL;W[_ 'BJ_$0:38[^'@6;XU]\9D%5^0EQV_<'J3_^%
M,ZCY.XZ6@1Y5_Q9WA(RP_Y[U2W U7_ ((RO64[.&5I\0A36<!>,DMG]-@=MB
MQA-_>Q/%PQ0[GWW(X.4,CF4RTT_@V/^%G2_CR/H430.FU#'T+Z[]W(>)35*<
MH+(C1._"]@$F4&6"N"7 ;0S[HOXZCKX2TKE"#*/>)Z+$$HKU\O(T0K7).Y@O
M% I&C4D9GC;OG6T W:"<J+9#E\9'@B]F7\?S09*%"&D:#B=1AJ!L B*!'0Z!
MQ2+\;SJ],I)5Z*2NQL/A7X?QG$!NLIGZ$:A.J'QP5@6U_1X)B#.%,6%0ZL2>
M#X-KS= *H,L,?O@-CLDPF-C_'877\(\IG.#,L13<(4+D9'_-XW@03!%*+9O3
M2RQP;E_5=7?/OP7"+!A+'_$$*(5(>-/D#CA "!#$@V@^YJD0!KUY]5A+BW]*
MU\U/6 )J<NWK$7PZOO]A%=_2LUGT=\ALSD4Y<'%A<<IW1 :LT]C!Q?73][B$
MHP6*862<7PGWZ1/A/CT3.(]:]XX__JN!>(5@,R&V6$%!9D)CP6&99X1[A7!3
MUTDR%&@9ZH]C%_Y6O82R:M>30MN0!;U.LE7-3JSE#4T$%J?0$86O4&F*\JIV
M^MP?*E9(Y2'UXC#[2*"616/Q[R"3,L'L(K11:9N$@ENU=\]%<XZE+%X.1 ZJ
MH46A3P.UD"*,K\+22A+(RJ\5HA2W\]7=STKWEEH<XQL-A Q:?A2%6-=O=$#T
M='H@@6B@5ANUYSK18SUE7^D_%?"H:#VE29K=6PCGU![-4T):XL:^E@' EFO
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MO<>]WAT7<RQ/JZRH4#RU=8FRX5"GD?>@'D?/S#3>]JX>QW-ZO:8#BL%!UK.
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M?+$DN$K#Z_>FP<DW/NFV&H5.>/=N?/( ]M8N7MD:DVP=74J6O?W!L@'KR9S
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MMP96S^ZDX0I]=NAK*-?ZUK YQ)KV6I<2W^TD*8 [?U85V]D7:$@@=L!EZ3_
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MLF4]YR,Y$$C"CX-PJ3;)X' G<]3W=J-OZEU.65C"!E!(;6J&SET:(K.(\,_
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M$.CO *QT>,G8[UC]]@ZL\[CB2*<S7ZETP*=4)G=XSFG!?.V6U=GEI!^'>3K
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M8M^R,8]SWR:K!YM/UVIWF]:@7>C _DCSL2V[W[5Z]IY=,BO06$YJ]JOVUA-
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M7UFQK+1+K7>RT9&&%*7%#6K0_:14A2KF*A>C[ <QL8B-#'U-;7&+;XQCE"Y
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M0A!TR(R)&\W4V.-TCG# D0"8W:5P[BAA"I$VN/Q&C305B.XD"+H44Y/E94U
M9::(B$&)2?*&62TY)S*,#2(#(UDR:/9M,J2;-WR* [ )9&1-H.)31S.&C/N*
MB]H8VD<Z_.K /H=+@QEDC7#HDC-T?%OHFL3 4K' *WTR7E)F75YF$%-$*[$=
M!;;S.UT/*[N.#C"/+6]XJ:EISBHR]*GCA,\4;X>BI9R,G?&4'DBWKY[&>P\+
M&O^5@R64V;O9%3)@_1!Z<> L3K:>2>,XP=[ZD):VGEB?G4 T'F&&L3RTHR6?
M8?JKS#53]R^:&?@JWE$U8L06"B4JFT^ZVOQ!I6+XQDZ9R!(L3WXUF_TF@>\I
MEH?72,64"^J+ =/$HIW<;/S,+% C(M:>GXDQ;V"N# )O*;JC!1HMFIE3+[BC
M],#LG=$CW30^^(?6\SG]CV.ZD__ZSOG_FLTA?MWYZ<$^BPT0L:R]US!?OOGX
MZOKS^X^?X-E7[]Z\_VB^??'NQ2^OWKYZ]]E\\>ZE^>KMA]_>__'JU:?#)$X=
M[JS3,E\TS%W;9;RDZBQTI2DF*'R\84SSE0[:(^/H$N]SKB977?C&9-G&LUSH
M &T$ M0FW/M)CDJ%?NGE#=!7D>D/D,&XGH*\N+'PO 5>^_@W__5=\[O]OW;G
M3N(9/MI\HE-P$*O%643B!U/]2_\)>ZO#MW!V7Y]_AYDD/\:A^BJY-F/'4]O"
M&2K?R7R3>*)543[39[2:Z:-GU1H\V46U?5.]')PF3./A Y!I'+XR9T6G)V4I
M1>DNE;RY\VJ[:\9^T+6^N*G"4GM'6>L'67EP%3U=73.UA<]S;]% ^MOU]:M7
MKU\7&7B5T<&M.#B?_N* 1/O-<3?M7/D!W'L;MR[OX7>KVZ_"N@ZP;=<SQ\6B
M9:4]?@[PR@I^R.OEZYDKIN8KK7?>L]Y9P[*56-EOX+[] 4Q9A8U[>(;L#*NP
MKH,P)'+::^VQ2$[CCI:2)T];4O[L!!11-7]SDRILX@&8LUN%=1V,.=_KTJH3
M$(._NLZ=\,T/9RL)SU8UOP$G>8%!14IL/@?)]T?@WRSPW/QQIH*OYL6*2+V7
MR&7_=R;.5>AU+I[1_D$!IH?%=WCD>"#&Z\Q1B";&R TH[7"I 5%E \RRT!^U
M"Y'>V@&:YAS_7HC*B]^&#3,-*L@*XBQ&$2)Z)Z$Q)INL0!?NKK;BW8[0NVV8
M.#2,2J6BA/DY43!=ZP:#]\&0\F^^NMC#E_M_1]0AM=5L4DFZ,46U*R;IWS^'
M#@.EM9IVLV'^3%5SYI^!2[>6"=!$S8.P#Q K#N\9$?D:N#_$)"]?)/#(/Y%)
M>' UB=]N_YH%R3*!I0%]\=KS5P+MHNQ<XSIH6.9O,:R4OHZ7UXXJEC4]ET!<
M Y^*W-]1M!G\K%?_2?BZ]Y5$JR,"_D\2Q([,='GWZM7__& .VH/!L/TTK;5E
M,J1DQ Q817>CG.[ VI,DQ;K[%>@Q$7]AJLDU6-8(*XZY,6Z<$#BN!"R0%5-@
MXLP$F#8:L)S[O>)S<X$S)Q!8@5WMA @YF=^PAX/!4:/?#W"+\G@7;)O*:NVZ
MK+985MNORVJK>)U[6/44@2S3(4963SP1UDM2E:1%?%F]I-0UB,3,,"7Z*+VY
M5Z]L4$4O%J'KH;SO:0S%XOLHDE=4%+_M\C6DO'[<J+9@SC3?=*Z.KS(TJ(=5
MK*?X(@%N#4:N)\Q7&9G\P7. FN.,IB)-8 ^' \Q@H (56DDC_5I!:^2((-M@
M<>"0E=<KV:0BVJI$C%2)9( ;7!_F8Q\+]^41S:QL1-)4S)QC1B/EZ!182'$T
M\X].P&HU6[;4]3 <#H,@=:;=E_5G,@F>NQM3D4V^<RO,_0L5$S;,U[31:8I>
M$YDC]R$VHG(+N O@?7V"$.:74M\)*Q4_KL='/F6V^(3M3>Z<I?DA/Y5?PB!9
M,']>_?._7_WO#T9KT.\_9:#W++SM1%!-.([)>"T>92^D?0?)]M(V"_5N\S)+
M-;E ";OO/IPOU3"(?BH!&@]T=X6 ]K"$@'D1I!IF<_L5DC_O/U]CD8$3QKJ/
M<58\90EL7*,3/DG,_X;19]@VN)3$J1RX^O3/5\"WS5:_WRXA=$""2V0R\)C2
MNEJDA-Q&&9EIUJ.0_C=QO0GQ6X$4#! LJ#/1)M,S(S4XF3$E@I'I6T."ZY].
M.(('\G+KFOM 2W^!70J3VVQCP]Q<IPEG,@=AS,5PF'^-@[Y.)DYN3+!Z\< <
M/8?P6( UCR@N<R'UK.9/12;!U258XY>&,_0187FI=!P*RT_T&RGH,G(M\Z42
MXV!%M($T^P4<PAOT#,V7SBQQC-=!,#$_J];>R_28H4,XQ3\",1(LF618/PVH
M=$>8?#@%^C8A&FX\B*L2+B\U"-$0.3H]B=/$'TL@QHR01Y$T6!7RS2(Q)"'*
MY!.0 1\9"1=D"1YD\$6?FF\%85YEB&%<DU^ E)C+/TX$D70=%=!-WT*&XK+-
M\F6OB*J&L;K"%6OG,U@[?VZ4&KMZR:&8ANZ-0K'GXGC$PH(__X7B*N\Z@TDV
M&/)3.(U/"9JJH&;$BK#)?WZ[T((WN,OWF'#JD4:X"5A0*R7@!=A=N?L0%B0K
MQQP#7!MER)*Q+\V5X4JDQ2^2-=^F>OS_SA(X'.;_8 >W&_-?\ ',A;YV%B[B
M$+RA(D?BX30?,V.Q2Z<CN8&%25/",6_E(&,YB(HZ38-Q(OL X60R>X^U2< 6
MR^(:,NY%NG R[%5\SG@I%@GP7\G:_M?U00*2V3$'4?!/;BG_&;CTB_G9\;^8
M*ZX'DQ*,5! ^OR8>_3"4<\K8 0[8!WRT\"-O)<\J_X%&>@<."!D0^0.B4#'I
M3 VYM9 >-COHBS#.GE=YMA#FQX-1$T>&YCPWQD.,Q&8)@5A"*/0W?;9[ :<J
M>_=3$C:^MY+.CUT:/"Z)-N?5\L<@^1.' #D:S=#W?@6,>[-\%CFW*'O+5+6.
M,R,J ,XA_3QAF&RVUN'K_P1NP95D%?T5B>NG68- ?Z;+RH@_DV'\#3HE3N<M
MM-/-"D-J8-1M@?DY*!P+UALL\YM<<BW5A[%!?63/FV+\#0-WLY2+XF2"Q7KK
MQ@:2(2?^ 6YD9DB#EZ/A: F*%F6%-ESR7Z'+G#D_*_F!9Y2&ME&!XQ4;03I_
MX/*K%SJ*$L$FO;G^\.+I206NUY].SBQ\J>AY1$#81[G6DZU$X<#<*2"WR%30
MUN6)_HQ7D#'O4#B-5$)FI@2@:KG^#TM&?5M>X!D08G'H?CUV,<C&4H8--0FY
MVH7=9W7_4H8RU,KP9G35:G:L5GM@M;K=I\5,(#G-P6HQ@R>FF/*&XBA<,HJ/
MZB"UF@B,U\YX.5^2I+\QPV!-*C]_.?->\97AP1/T25KG4@_N,>]BBM;N._=O
MKG]<I5GQ@Z\EN-D'"2),>-RAFO,F^N]*],-2^@\1K:'SX8B[_5@4OYU6:R.@
MU<P=N=0-E1"Q_XFEX>JL_.;<G0[UWP5')_[.G/UPJ_Q,T'KO$F6/Z?*&E<4?
M:K^Z]Z-N+LOIL57=<:OV=LYJVU:S]4T%85L^NJHS#U(G]EK,'6]K65QIMMYN
M:O@TR/"V)L((I+7_C!?Q,Y@GX?+B"?+2G9CO@OC'4?B/GPRIH07_] O&=,(=
M2BM+B)1JIP>N^42 I#<_F#PW\\V$P>?6;B/(2OSM?WW7_VZ3>ME/,Q,3[% K
M\* )V27Z=I."?7AFL<L^O:N^/T *=[6FTZSP=.[/TG=Y2_,09QD.\TLQYW1M
M=XR1?#F'LS_3U N(\I0EKN2;%#;;]?,NT:\9&.UO(<H%<=AOO_S\^7_^W[,B
MUF$U#!D""E--K#V5U:7G:=6T[)LZWJI3QXNIXX,Z=;P2MU.OZ2";'ZD+:N!'
M,W<1G0GH%+B,0MTFI9=(06DMV<R)#,=DJ29;PC(Q\-*)^O%QMQ_",>LT;1SW
MH[A)^$'ST[/_/OT$ [YYVAW!+-L+X;S@REX7&[BN;_1KW GN5H*U !+CE/C.
M62S"X*N+$(K 5+]_^K[5L;'10!+1;7^40S=7^(7;ZARQ(VW*UG[@/U-@Z4;*
MXQ(N<4DY$IS9!\:H,XX97M1,)-JB:K2%"7VRB;-$;N0F#SJYF+_!^,7_%CP^
MPC1&(H:%X! !056&V \5/RR;5V>:>>%*)?YB+*'(J7]E0#"7$??$2&<AR;$-
M_ZU!33@+'6^=4'<\(UQ,S[G#$>?.%TD+=Y1P=9]N4*.NJ&5;&N=&PM9C#:HB
ML<X B1P/<Q^0;G@#C?]!^&->(J(])R%68U@JP]+(_"KQ4VIF'Z6\*":&[LZK
MR<'Y(<@[A 7+-,7$:CB/)WSEG=5$U[M+'KX>_X <C9>PYR5\]/5__K;F?+-&
MWI=G>U!OX(B!6J>8\ZC_9)EI"PELM"5*,]E -KQ(T]K<*(N'RZ"R 3;!02DY
M<[@SHD20Y<Q-> )E V%%RVPS(Y>2F1L?QO \_(25S]NTS-L@EOG'!(3.*/%+
M+9*M+)P]O!R&6(3,P/2$J+X((HXK4 ,N@[KH:CQ<U7&'FW-=Q<$-@^1S/K*_
M3)^0GP7Q%@78',/W&>M7]7N8/Y6I6QKQ5[UY15+ISHT(RQ[;A!NW;A@G,@-'
MN*%^%K:&%VY2GQ_^-VZ7HC&5#(TX5S;*B'^0Z]QM',9,U0)]$[<%U3%XL3<S
M@BHWKGF+GG+-R90["_,.3&"K CDKHKS>&,2KEQT"+/@YY#V1!AQ^3> VT],T
M7OJX2B?]3Q*$R=R0<1_,E\/?R@YPE@DJ!9N;<.N"443^#+84P7 0+[-(6^R%
MAG2GHJD C4S*G'J*FEW1-R(H;KIV1Y5E\!Q5"^4?S"OG*:= NK=<G295/Y%T
M:9DWB0,\%0LA-T7,?9DJF+(DC.(^->?P45"6DO>"$1Q41_5_(WAPU7ISCOC+
MHR5]B)<F^6HJ+2>IN'0&H#Q3E,=,.36HU+(J^SG^[<J%23C<@2$W@?)QC))Q
M: 9\&C+)TY0T&D7)G)I=RDH&[C-.!ROP)'&XD0.RE6XWX=%.A%0)&JL&*;3H
MR. <"&<=B9E(^;U1^_+<O!H]E946NY$(^82:2W!S4W5B#-V;3W:>H&RZ5.QA
MHQZ'V)FN7#P6?KA.B;#- @NE(:<(9 ]CJ'B?5GJ'O\9EA 9,[%G^=U,YB]7O
M<_,_G$+FF[#Z\=/[R$&'(?ZQ9ZKFO5$PP7'"14#-SC0]9M170YTU//8\+^Y-
MH<23M\SO=R2;>*!]:;'<8MI8YAA.@$O%?J&1"JA9<!<%XA8?D(;91"*TBU6)
MS*<D*A>_DT"PDHJ5 /OB!W>P7S="Z2J]&$.'GXGV/MK7H3F6U*+&3$K/>$ZD
M\R91^\52X>E2!=QR;(.T0L8KSLHG53AS03OG_VY(B:QHG:$T4AWHQ4T@ YT&
M#.(8)QNZ-S.T:&\=L/@QZP(-<_*I]#1!+(M;+*C.?Q*89L),0R#P(79(@P$G
M\H#"."/!/Q75;9:?U@@I9>5'NTLM*0 TXR]3 'OJ<%=2Q;&DGO>N)V[8:9K@
M0C&<A&_)+'9D2?6^ZIVJ)P>_ ($UISTSLLMB)'R0I%>"J32G;H ES*8;;_')
MQ'WCZO&IG&*VJE6[*.#=.MC(QF0T%8<%*&J"*S7)KS%.1/>64-*/"8D"Y07L
MR-5'<0OG!GE#TME98O7 F\B#@Q@]U0)4=FV=.K<\DXP!2-XY$)\E#[<N@Z.)
M*6KP3<D0W)],&Y0NIL]/!;]$S2T$_C/2ZYJY<S8UA/HO<%.J4IG;8*E + (P
MQT.3P@MDG57L%G(;4.M:U)LDL/'IS#Q9X4WO)02UA,O*6F.F>A[E;$)I^)88
M=MS2)YTTBFCPL,,Q"C5I!IF+X"YS,#.V\2@(P^".308+21W? !<;%$' 0Q$[
M7\@JPDG#3RQD$Q^<8=1 4O;(%BB8M[G-+L2.3"ADI9&"9<DT ZRM(JFM%*NA
MF+AH/HS3 YV3;*B8EL<.X!W;K=SKSJ)=WUD4[RR&]9U%14,(&#X*YJ1T4O5]
M65$4%98%P0[:R8UF9(6&W$1348;-%72ABP&7'RB G8!V2M]0^&DZ2IW]"X4D
ML>8-X\02 "(U'V^P0IRM"OU2&CRFSD 8*\;BP1"M%)3:$O"/&X>NS!W;6L%?
M]2]T+%;9CMRVW9<-RQUJ31J-0W>DG.K3OZ%9Q_WN3R]HW_09:&#!)\\"HVLK
MNVID0VN9VGLK6X5L2>1Q5?>9JP&E:%A45O\9%#^7[KIN'LT.DK'KMTWDOFC*
MQB1N?*OY/ WYC8D76O;S?)O38,H$^)B K=;M-;M7SM.KEC8Z?P,"X ?PSY'"
MZWOG1!/G/XPFB#6P7T3,@^!\:""[^>)9.SU'L$W:0M$ @F#D\KV$+(3%:M49
MW2/FEI]=($<:T:.0H%)Y$F;PK A"*$[[5F, RO&EE4HS>G5MAK@H,AD#ZJ&)
M<9&T2U>PF.'B99ORTI&,##5*SS1]03:S7)FKA(;@&N,5@)AT%IG.=MQG3D+3
MQ&K$2$VCM+^89#4%(U$ZD2)Z!W4-Q@62=4D&_2&00_<4"Q4J/M@I,WBE&JS5
M@0$VKWA]"=R&EQ\NZ^CO?QOV^L/GNZ;@'F &SF*!X4,-WY2YKR"N53><BU \
MHWMC"A=2G!?_K(X/WO?J7\C+W4PO1QD"@9^QS#;UO\L^]_Q;<L,W4FW'W-F'
M>/Y1YWU._!F*6U<0&+..$:WAT:44L\"C(+7FLELBADL3+U;X8BD,D#;3I"06
M-=_5?)?.0'8#57)1EO(3AZWK+$H,NH(SM9^0.T2Z::WR:Y6_3J029T\PTVC,
M85#=I]KGGN=EEC)%:7UN71N'@0>FO.>.E8 EFWG"W>=]F<40BP7X8\X70<ED
M8.>Z"C=*#3%W_H3?9&QP-_J"#@4WNJTE<RV9R]B7&"QGD_)%!-VE<_-E"J!G
M[RYJ9JJ9*3,#F2,#+@MP"N?#DA03V-,>R:GR*G;5Z_C7FL-J#DLYC-6= G/U
M7(I2<:X.Q8DF(@?+B0WADS%SF8AG[CB75;BO[LZH8[H?)JP4OOG,3*=156OT
M<''I;(W NO"T47[#8-XO2EU R\V'J66>&N_;FB^O#5CO/(T= ];&O0/6YAX!
MZ^MG=FG VL@'K#_+"_*2G7 BWH@4W)$2;,H-A'AUG"@.$\1?%-D3!B(?+^KG
MM)+LXY9,RN14B]UK -9U,,*L!IG]F4G<Q.S!='U*/4T8)#+-:,JM@[*:/'>$
MZ*-BLI%@6R+/QL$BS[7'67N<I2<R#A0JL697V)HOF!- <-X))M9$6-'CNZ4E
M<K5!7YM;N?L,Y0]BV5(>#'X'7M/\%>F[.$?>0=9<6'/AO00>6 G8%H#S.V5&
M*ELKY :HA&#YEQQ[KE8)UVQ6LUD9F^4"%BMQ,4R*!@OO&7H,:.AB;O[M*I^%
M*@5_X3EUD*QFL^P,(N%Q:<NJ5^%'B4?(Z);IB1M2K8D/3Z=YTL[DUHW(0YIB
M+AWG7N,50L!>]$2W/?$\$]'P\5E=94$2T8EE=8J^L<TZK(PXGT;GZ@!<S;UK
MA62(\$.<&:#J^C.5#)&EKGE'@9]$.*8J;M$5]%20);PI9G&J*AV2F&<;0MLW
M0;]3)^@7$O0'S3I!OP+X!>Y/[_))X=<Z@?27-(%T73!XKX3RG6+$A1!QH==2
M68C8T! K>R6XGT*$F$.7>RW,*(: <V -6.&OS1=7PR%&.K%9YB:.J1B^$-2E
MTCP.M6=#R$'D9LNWZ+O43H]ZK6=* _9>S^/E!M<1V@N.T!)H#XQ9&K(@!A82
MPH /$[N,H7BF?Y1W(B5',. :&IEI3%?H\/#4Q1QB\$UOG3$<@67M<M9&>WD
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MZQQVY<H@ZD_Z_D=/VY C*&PK.*$4TK$0^HR!SSABDX1QM&:*E$XY$YY,I,Q
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MM[.674/VE)!6@#-.LX;#NZZ3.G<*Y\.?F@EE7".HZ<Q$,$5T(@-7F\-F/CQ
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M>/%E6D=ZZ-3"U@M?>H2.$1B..$D-F"\K!GBTO0HL/O#P27,&'5^[L@H9RSU
M\%;JSUU6[BI85%O^<)46U+0>CCDC.FL=]9LO4FQ\ST=[SY[3X[P17$O+G%TN
M\S?E2PWLPW[SA.@*4W[M KU'[]%-^K ^8;^HA9VV!&B5"B"^ KX32C-Q!DVS
M+\K[L$750(>/P%EA31JU3>95AI)5T7V]@##B<J,_(BN6?OOE8_4VK:_%JGA:
M/1 9#T.)$9LY+J\X_6'J3*%.,+HP8.%AVV_%G4?%$=_IR/HU.7\+Y#Q^8'+&
MG1N@7_+_MG,E6B;@IAQ_3J2(05\E9DQ_X8<Z+XK2/#%%22T*UFSZ&Z'KR4/2
M==V.G@EKMLRX]B@<=(]9ERG#T,*0ZQG<!P+F2T79(+4&@=P]J%/MQ$56HXQ7
MD[-/4B*T3\G(-)<(-N*I23;UU_W.H=6W!0=?"O9%@G':CFTRIOK\)=8SHP8<
M68/V;LRQD]#9PM5F;"5S2,K_&G4V 1W+3-9!Z6_E8IH'%3B8O)-;)PV296([
MZECT44->$.OB&M;V$P<.2%@^3?K94#YD>E89ZXWAWZ+7KECX\8))1NU-@@9
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M5HS3.1$1#J9V3+3$CHF(6Z\0P..:\*^"9KD_PJ<&DI*(IL7Y"XEL_EY6D@I
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MI]-EK)^RD\=E)<G>(@4BKOTN)>.+0'Z0%@?VC(K&LZGH[UC'3O@9TY0ZT5=
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MDTB; RGLO*H;H)UFY21L(X5SFIEF*_[!C+'K%S->' FN9G]+M"'A<HW])%T
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MA#B]:?-7Y%6)M*8!:7(:3L,FNSH0Y06NIZY*5(:X3Z)A=6MJHU*EQH^Q[VQ
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M0=CSJ![PH6V!S8Z6>;*$L^9H#H$M9-&]\.=!0=3+G/1*TFU)M450ZLX_6A)
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M/X=H! J8Y:U4@M#,=TPR8_!+\=R^4 "Q(:H'1^7!>Q02*T:JY(93*YQ:A[>
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M:/!%$KL-=074IV;N#UX'FT9O[-\ORA<K'ABG3ZW7W/SBOFL^-_$/;.$)AVC
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M.:P:FNEAZ>&(-Y:G_HU/.%,HOENT/-/C@!<2>3%OYL\1S;ZPZNW!IMXA>)G
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M>434O0;5 3GS4?5UR F+ZC="R[\?[:GT?Q^G_XM?"_20J%F0+_P8J=5#'".
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M%D-WG>9^]W3'QV0G(+Z95/6%3.* -[W%W. Y:MMK0K"J%&/5R,TR@F-((=J
M(%W= Z!(*?,@6SQ&'=;!7K\"S0AL.<#X!]ZJSN.-8J/T2+4>\#P#/J'ICF%!
MA_HQUC6_SWJ)\Z;;I>2I%>$!DEAZG@PM>&BA2M&FU*A@)<W&O7SOF>K745US
MOOF.KZQRG*/&NGDD:!'B>P?R"4)YZEB\]>QND#ZE0JA25@@54PBE9H50I]"-
MJMOZ=EOO_>PTS[S!UDP_-B=,+L Y+_>O- K('-(,+AK;Y$ECQCPW9XR"(8(S
M$Y"&U,*59A\N,!Q1VL\?@^/;!IC%W#>FKNC 8TR]1]L!KL8[ )!/!&?,\)Z
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MU'2K^(K8G'N?*>#Q\#T9]!\E#WPSS*>1"%Y6P& N5C6YJ&3(/C"R#U[!5U;
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M25%"'9I1;3!_6G+-%^E#^2/1L0WJU0?UHT01/+_0ZM$81,XQ;@7,W&G?UX9
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M1E17E]O+62Z25"6.<JXI?LE_N;I>W$=RF(<9^UOB'I>,]DGWN'20L%P,\EL
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M6[F)A2]5^^ O52GMK"IG/:N<"04*HMP%U<LAF;H-3Y=:T$>S$[[NF *]ZIK
MH0@3M0,S"-&ITX 2/GB8H)M-N)*^H@D-?0I^$BHEN'Z(+^4*R>,?,T,3K]9L
M"LX"1B<L#C+EJ73N+2D7T\%T>N!'LS#/0M&2;;U9=B_N6YG!],*U\#]7X#:#
MJXV471,]5^AA*7^K=]@WC/M;N-\?R+GBTK,DWQSR*>,FA37,I X>OZ)NGY+6
MIYJ1F1>@AIXRAX3AR'3_$N8W2"3N.E@8V//)]+9\\\6E?R$@G )K1-QYNP#C
M5X@>?_("+$;1\!7X:!FO33D0.BXT_A(WQ_DZ\$7R@\R;.2S6!W=L%HW@T C-
MB18 _L/A10:P[KLO'Y;"C5HJVNBT6PIN-,<[%^&EZ?L("J3,9@PKZBFHHK'[
MF@85@?AHG'4SJ"(=.,#!Q;YC\0LTT$C_4WPSC3KVTE#V$@56>B^=D_-^TVAU
MAIGMO,>(L3AWK"C V"77N2+8+M@/*S! XZ)_ESAR(OY.Y1^1\V@*;8V\0-%[
MX+8(-*H3N\0I!M$R#'+X.K,03J2P!B6H*(C"&[141(HRN(N#WEPD%M6@A1Z6
MTJ#]_D'+5GX6<J=:DBPPP,P,?S2M6I:7MG/RBV&N4@DI.1Z24 +FPRP-#I%2
M/*E4D>5%HQ#3.%*+I=6>Q<!9>**R.4HS62#$S?$K3[(%S,? 5NYCU.2993_;
M%KK<XH^:Z9K.:V!SMV)J8W&6<()YK@K!4*#8K;G%L  K..U@BEM3<D*I!:C[
M?YDRTK1 !@P C/[-Z]=T]HQ>RYAI9!2$<^Z_B)+A(SA^BA85YQ>MB/%E)82T
ME>TFF;O$T8.%Q_DB)!T&$M _$M%#+4TE]GU&^=(@%3I5-XSF3D(U3BJ>797T
MB_-8\;(Y79A%6U336=D%:^I:Q^2*ZR^>'TYYH%H&<6006(W\GND?F6.[B/8)
MY7$KJ'PXB!??#D/FGGH38,5'M*C"G RF/$XMYB=S IRHYD4Q&ANSIR7LNX2!
M;!ZK!:*-\"3/=''G+U+OB?.C=-K)0HEHW'6NS5")5_+)\S^*_68%S26/,Q6S
M6[HGY\UVUV@,6AG#A9)0_Y,2)J<!&Y_:WT^G-MC#('+X?T^QIO:TUSHY_VH[
M@F@BZWV/N .$<.MM:NK9ZA SP#_:AHR/43#B; DFL,;BR@42M"ZHX"*!70X_
MV#OB!W/P@\W&$4"X=^9XC1C#]GH8PU9)C.&U1+*L&59;]'W5#^@UWH(?('>*
MF1;M![3_"W#*(1^R<KP:FF64BK<0?8=N@L2%@4V$B"^F8ZKB$6Q1^W%*'T/$
MUB,68H531,]=>L%<>>B81\ETWWS1T93T;>K+,/'I$8:HU-(=$[05X01ELD)D
MS<C,A;=,F0G/OT#K__N88!(3Y?G/6'TV9?EK1B2MB56H8+/@#W:R9;0.!3;L
MOP0S4\UKC0Q0+!6-.#OP:%W\4.4Y9W 4.6^VN;>4P/"P7X? <Z*[P!_HHJF(
M3D^$-:WPX!@*XO!6(:^TRX [(4\S!XQ=GNY'ET"F6N=<) [0HS1BLEM,)^G@
MN/DAM2\943X4=XDQS%S:F18R(^\?HO%4%+Q->(%C$5!+2,(A<>HK.6H409\C
M,#H8KYR#C:=/$94S%OLA4C% AN*-5FP5PIA>G\;?&;M;SZ9O>U& .5NJ^TN0
M$M1XQ4!ORN8I)@)L<J?*1&CCF,<V0O,O E:XO%8F -=0?%[QL220E!)L/-TK
M>Y=0UYD@]B\J');,\8N^1>%CB< 4;C=2L#;/))9]_Y1PSSOA[!=S0WK@AK0Z
M1K>YT U9MO#V[A8.BKLW-/J=7C:,7=X#.H9FTW6?%QQ;'#QX]Q):#-)SC>+/
M0@]*662MPX;DB,BLV+:6!F?_>+;9.LQTR,>?>_!8P\!#NSK5G+QRX"45$,#G
MF$LE%X)VJ"$1CW4*1@!!_<5C>#!O8CY[/BG_6>2/IZ!:N:$29 PX42>AB3(!
M'M&+&R0H>!/"7HJ'91^#I0/TL4GD3&PP9@+>^M^G&OF406,K)1(<9 E$I#?
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M7]<??9//0)(?3MQ*/M>0O%G<!3X6MS0S_3'OF,&7"2I'$WVL$$+,L.T5#P,
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MC1DMA1ZDIGX&E31JWW7J1]WVJ>V>RHUKL@G#Y?6M;,#P V6%9/BT+'L=,D/
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MMLP(&*9])(2B_6Q%_BLS_<(& ;\IG^&BI#V+%I[0O(W.MX'/WVRS]==W##>
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MCZ?-H0X<:[$G>VSHQ.'T40>79;NZ P1AQ+6.]VC# L8@"0(_FN'+#0V7X]O
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M)%)\ </V*7K*X:S%$/CF@3?P7"G:GSA1\N1Z($W@^6R%RM8F/",1]$?(_)Y
MYLO#6'*QX1S1*T0@ABD.&#HO[CU'S2NWG_\"6!W8^HBB/Z+HJP7&R.A39#HW
M(W@C.1L?(W;MKH68[W3 DC&:(,#!J#F"YG=_BO<,WF']05W)BIP?E7&VNPUC
MT-ZTT]UV(7$+47HJ>OZ(NRS,. ]3VR_!-V"&-HUFOVOTFC4U3ML")'@A0*]"
M2#!O\U4(#?SCP31SV;$8 V*I5MOH=9M&>UB^#5!ET$PU9E=Q1'*_!Y7, R-O
M(W\\-0/P;B_DG*5\#[;_1E"1S46HR-MO=Y>_7=Q?Z3>?] O$1]Y>W3W\<8
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M0QC#R5].].]/SL^.B:?+W--O]_N/[\$R%_V+Z8^G(+1Y[V%#-[$?=V!;MIE
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M[K[H'RZ^_@-^O/AZ__>_C<ZKG1._DUC6^HR03#%(:_$@ERLZ6.>X1Y,;EC
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M@^H,C]G8;S/_!)FT;!37LO$P9O.41-[-^9A;=(%UG:PU0$@JD+.'S6#[G>9
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M/.GB;.T;&#5LS)4_L$3F;5UACDF>B>ZPD(8W%Q<$6;>86F+E%E.B&[0 !Z[
MJB[<7GVFGU=HT:8Z W="MY<!J/@7-? +&,((EORX?US&'. CFE_!LN;5)_3]
M*FO/-#,)T6AM%/5K$ 54==M 98X=7P0:E-$G6"$D7.H-7-C-[:@I3.#36&SD
M?8Z\LD*HZ-Y-\I>C8G#DX8U61\'#'_R/80F*#@O D!VK1L)@RPP6#"^EHUB
MV;;C/LY>OJ?!VM/#MO&K=%G$6&ADR9?/BOXGDI*UM?^ OY=:/]U\'H_HC^)/
M'X$.9*[:-H9R:/V6OU<WDF7#JRBQW%=XD27X+'UL8PZBB+M9F 8\ ^MI["<0
MH\<GMB)XF6"8[L/80B+T,LDC!NVP2NO!F.*[0?0F3Q[9EH2VG(47<YL:$P<C
MD6XIG]Z@EAT)&X@MFLN]%5S:Q66X9X\:Q&K$5OL%@I;_MRQOV&W;=.&=ILO
M8;J"]Z-2.",T9)TRC[ /_A=<B5O-;BO:C8PQ#O>U>4=;.([%[PC3RYL2L*'3
MBT)#;$=K-/]$L9Z:<,ZL!2O7U]Z:P@N&?778'ET"*JRE*FN$5!F6BS)=>B)<
MI)N<(80F9S1CUX3& 0X]]N3RC,(+ 2T"#I1K 3P53A^4] C7N+D/ 24#VP3M
M;!KSB"D*O&*YLZ"?N>I)[\)O+JLIP#IMDJU3@%1W"HCK%-"M.P54P.:F:!^0
M\0)8>2IL,.*@H1LY-+1N@(.O/V)D'19K@.;S:GI0BX+6GX.,,B]3;/VPMO2?
M G^N*CYIW,=^9 %/6+X%/.7'1Q.3S]"W#[]RLZ\A;M$^*B(/-\3$7\")$-.U
MN!9%['0KQ32H^:&9M'!QOPO'!JV]F(Z6/U!Q2%B[M-^U2T>G<EPWSG02&1[\
MU4A].(*.4WU%V:=VNP,AH;<40R?K6$YA$+SG3IT)9N?^[#P07?BNZ-C41+A1
M-:T95C0NB38+OKQ?P<>@<.RA3=0V[?TNO T+[\:TM$RE;3K[77L'KI"Q*GZC
MMFG$:IOTIGAGVL9K#E #J]O"(N ]);E-C"X!WXE9)J]PFB;&J\\TM_%!T6HP
M;-]<#_K1&\ZN_6)0O%-3J2^;Q7_=HG=F$<JM"VY@/V8D5"K%O$7/R"+6WL-4
MBEBC$CI<\,7)DV(A_T-*-0[&:D2X&]3)Z&YX;,[&Y?Y^*=4'+@].NOFX/-CO
MV@? Y=9)%.I,R^553*^.AM-H^)UM3/Y\,C2L"SO_RU'MMVL#9R3D#HFG?F H
M+MXIHEWC;D/@O64(_.[+\/;\R_CKV?GMG1?9//_GM\O[[_P5S51G?9MY\ _U
M=&Q.55TQWQIW3PJ<=3C5I^^/WOOSB;PZR,;E]8C&C[ @TUP8)HVFP.<),ZN:
M\F(MKTC*&[Q3N+3 IYW2B-,9>+K4SHHBVEEQ<"(@4&B8*NP176(_N Y&!C^(
M]WV7\X)%.2\X"T-O^*^GU;"*E>8F+[7RQ_3@OC<W=*KOF 0.EVN-#>&QQ8:L
MFH3]35K-5BOJ>;'5NQM\4>TG80&^YS.M20 2?+M+B+Z&=R;EW=F-8HY-'#=*
MIC3H Y:;;G9=D!+^'K=/$:SWR=I=+H"M]%OHA^R<;9>6Y61@F92291AY5.FC
M3X2Q+@R=1SB<C1[U)EOABE]8'[U38&SRBL M$<C@S)'-0\LR)FS4".9)@(R;
M1,%,'?AV[-%PWVX;J<@H[E?Z9?3I*"T3Z=F('H&D Q#:7'?/!Z"-<P9;+?@I
MBB"M' )6PFTY#^#,J5/&ZZ4^9!+EL1DCVJ4Q&I/;W=?2'6<\)YUTYT2QLW%5
MRJ'65G=B 5,I,S,RL9NDQ1I,B^WA]&5D#MZ9NPD';]7*<GX"^^E/X G[]Q#;
M:\!S',VMDU:M98\)"V[_7O5T4JEYF@L28R4^-+QJN/8:CHV)+;1KQBI/X/0H
M G5Y<"VRU,(.IL<B^_-J[@HH%O>6C!T>2JA8"JB)X<PF)GAR[I;2B:7<*J>2
MBJYK[),QW^+$C6<F\@LAZ@BP9B,!=BJX$*K@J3RY<H?M:? +M%<'$S&+I-(H
M6^3<40%DO#NC#4QN:!<5IEW@ND#_%)^;%D<L*86"<0D$I\IK38,DHCUM%'/9
MFN"6&.:CH@<:RP1<IZ:;=8KW#Y/8IJ&X@(^@4'QNVL"+B0L0^1F^@C%QN[8H
M+.OT@8!UT.D)8Q]F/62$!2P0 R/3&G_?Z=W^TG5T@7^^E\N,ZT19J#18HB]_
M ])#1Y(C:\N! ;CD5^RB-Y&^L-V,]<8O#AQ"N1G3W^B)8#<I'?X/AYH(CT0G
M)OSOG!#;/8"4K:Z)Q!/*SGCPMTWLIH4?=O/=L6<417P-[9E,=S$,8B=TS-SR
M)/T.0QU0XON:!*M'TS]XM<[4-A;T4=/<:VR=2!U5+Y&N]K1J"_R@?-Q^=26K
M+'H?4.=S,E7!-Q<(K>%H1F"*U;2(M0J=IF<GX5J=WA:7)O:B;WK:)'L9$VU$
MJ=F)<6$$=CN?LK*CS6ON[Q5FD=M'IX/U*$OD3@$*V+_E9>/'GN]X<F?#'4\@
M"AB1Q$!G9Y"?63>FVU!O.WXAS+"!7POO+3MG6'A_!?&LE\0SJE*2MM7=!A'.
MK!?ZH!>:L.!X!J77#%NMN@#-,$#-4)9JZ%8)_FFWME<-W2T NV)40UO<C)AO
MJ1NVX5@9NJ$M)3$MY,/1+@C+'@A5NN_6GOS[]>0?JN_)8YOA)JJ"J8I'"WQQ
MC*BS(.-B81K/RG*^YX.!Z#=V=U9-0MLDKR!R6$=):RP-D.VI:L%- )_99.$#
M=DEPFPS3-MAX=4CWX+D2Z(W<7 F!-M=!K+X>##[K(8@:L1K_ (H$7Z,606S%
M?[V)U?&6 Y_0L'K>A(L_[M8-8;,VWXJU;ENA?:PE%WV\^RQL>,#:#^#[6.&5
MU&3^A8OU1W%1)#=]2&BC[GZ>E&>O1[4%:ISUS6&-&!X()9OS\ <MR3<"'R*6
M;:INBX0/EH+=PC'4++!.#1JS,A^]K</_8[\ U;+#?$AOC]JM*GD0<J('X980
M>Q?:,$M^0NK6YBJ-N0HW+MO28*WVI*J 38@:K0HN\L/D8S$KW(GQ6AHL9F'4
M9Z*#JJ2+=H\A3>*FYQY.9"!@L)**,S5@1UY"#NNE;U'5(2@H7!K388J?EX-Z
M.-A\0'MS.VJ;<]KF!8P1709\:JCKY%7X[.D)L*RO<+7"I],!#4Q#7X%Y\ J!
M_&>[#1A8ZW[L@.!-A)AHCL7B8FPC\U#^4&"=05H$;+5KD9<X'BQ_8:H&;<L2
MHF42'4\BNFU30S*:L%S8//JR&B9D[HT@U[T1XGHC].K>"+LUUYO;(&Q; B Q
MQRA7\4#ERRL2Y@8EWU.\**2O03?J3<R"IL%2J>=6&E'7/=WUIK',]XQ<:7#B
MBV"IK\*'[D=J-K!LZ8/XD:4+>8D33\HT8#9Q*W1VD7<Y6":6?A(^*!^#L9L5
M:+!!HS>;T:4MLE,* #O;[8Q@)V6#DBWM.KS'?=]8-H9#_*3K))1:DK;H?%4$
MYS @TBF9<Y(4JHWO[)EU+"HB]GM1SC66G/M)^/#P<1WPL4J4% >TL[>$U'8_
M(?.OT+4%4@%3+W!P="J)..4@9?9?(=JD4R%MTMD804FO3;K=O4E91TR2LB+7
MED/*L Q2;G;7!!:CFJ 0(>M62.]UY/5Z3PCH/51V'R8AAR02^DJA\+9()BDF
MH-=I9PWH(8L;65E<L9A_IR#'I!M*K&GO@W]=FN?<[=+_/X'_CU;7Q_,P\S'M
MYS^FI?!P@X?BLS!4=U_GX9:T:"_=5NPL.Y$$[J-X&7>+"RVBS8YI:>Z+J=HV
MT86%\Z"I$Q! $! W^S;!3=["$2NVQJ"#[2S2WPJ:@?.6=!6HE$D<I#IH#58V
MO>(/8.W)PE0GK-)A\[9[6U0,8RNV\8SM&E^7;ZO=%A;8;;0)K#Q\";4H*HIV
MH*PIB;,A2WB<U10:$T*FU@4X%I=N?<XE;$I5M!MZC,;N*5KNNKLAB:R+K1=C
MM@HJ0*/EOLN.[(J]/)]-@8&@L EL:(<(D/>G8Y-H%/AQN_F[HZAQ+/'"77@R
M@7HA_.(X6YN7('W.R(-]3>SQS"/4R+ "V74;"0-.L-0^Z6X@3EV-L^?J#K\_
MDHM:MNL:CZJ'VN.WL@PQQ8W)K;/)*K; NBYDG>':(FT_<_YW5RXH_WNK56\/
MK'?;&8'U3-E;X<WMV8ON=C9XT>G2OR5I[W!#-Q?<D(EK*[O</]#0W00TI*X/
MZ>VR;JS;QQFLK;5 ;A8-44SMV!E]H3ZU[EP"IY0WN'MVO:!'"2I"DJJD(WJM
MK75$;XL 0C$JH@?7RHT,VTX]]+: 1LK0#CTI@6=UA4AI]X Z3;<"BURI+ZEX
MFFZ@K(#.A?2S3NG"9R!QQHN7?.0K/R]ORKT1>-U!W%H%=L/ )*F83%X]/IEW
M<YIL3-9M<W/:[>IM9EGWL/9%U&T!C:AY"6*KVZ4K6=UR?!5!(-.V5FJU4N-?
MJ7%5>[!:.$>7N__BN>4R,A70-8NMH.O05=P57T6WJ3AP'1GI6M(7UMUE*:R[
MRU98QYB3O[AN:5]\TK(U:6!B\$-NZ8E7:Q*9B[0T2W0E=*IS?'W+QKJ.TF(O
M?H)^>?&=L2Y<&\]N^VDI+HSA>1:"THAI-988+._OKTUQ#WOKQER)DIMZP@W0
MO5 %,G&"Y8VKHA3(/X45!?K3-CP$-QGFZ&]HK7!LD0E2ZP76;A%]E5#GKSC"
M.C^AVD>GADZBE,)4^3"U<K3A#N]KW_@&Q4"E?ES6U8DPU!!J9_\$G@4S"*AC
MA4W=%Y[*8JIZM>WT2>,R4$86=N;75MZMQ?U7-#RV>,Q&[I)1OEZW,)2O4$61
M S/J'9VV-V!&JWFFS0R 4;5.0'_]"0AHNT28K[]%041!,-_ :Z^=#N7+Q#*Y
M6AA?OY6&:R?E.@N%.23KG9$KQ00KZ];^=M9Y(G%-3QN)GDA[;YX(*(#3=MJB
MG6S&=8N*G>!.MLA8ZTNI%$HN]TD(N4]TQJDW\2:W.]+.G^)7N#+NHXL:F^Y7
MC#,B)#@CC;*=D6W.7%9GI-\NSADI4E=DMVS]#HI%4UI3:;4IK9<O\>^N$_]&
M%D]D"V85XXGT<9;$>G9MY8ALP:]2')'^.I85ZX;LR04)X:*;BN!7;5@CA(3-
MX'CJ$Q75MM?:Q%/=V*'?'\KH1V.P/-VO0$=%*W;<219X MK>6 L7[ HI;D3+
M"!&P\T!#_'@B_*P^^T$AST2LNWVB%<7_%#YUHB#?:5#"0(P"ZQ4'+1R*W>SW
M\U3$KIN)00'(Z'C=4,YWY;W\M&GE&P9-A\C0B!DT'4JX5H)E$&F&A>Q-J =)
M5;C[%FHI@U G&N@B6R=DI+.<0.<BEY:'SFU,+FMUI60RQP^DBE<@*X-_=Z$U
MJETHLL.Q+=^\TD)06"^*:2I@^NNYK+MM4G2IHSNF$W;@E[V$5F&'RYOQ2KZ,
M9AF"\F@2UKF('B[!8Z+G1SD^@YNL%]TR/NG-</)"8XV$U$\YA'EG'"B.4<[Q
M['>VNK%YBU'6\U=B3E2+4#AG^4?+_:LE9O/U!VZ-NKAA6)Q+'9K)XPT>3V-Z
MY6W"%'%;SZ-]X?HI9YK_MP*!?"!_86E7NEF'869G&=O(UL",S)VA3?W1\2DG
MQP_@?AHW\CXT-CXZ6]CKK 47AJD'W=$S@SD#JC[1'.:M B56"17\BO%,3- "
MFF'3%H_& M_^4?B ?\.S*+5^"BA-P1-:^B?QIX^LK#?N$YAI0-#E(^8\$(B.
MG4$H1>.I4\=<$T_U7C#4I^S@!(3K'EX6)B[<B&=@:(4WHIA6=. @!3[=8X*#
MW@@[HS0##-6'^..@Y4T]95T1=.\S;N%RBJ+>L'!E.TZ;=IL*>!O %:T]B$$$
MZ&R_AC)%W<_NP%.'MK2(P>\M5M8<RV?,;'D@2_U")6NB6$^8/?.L*O1GFKWB
MT:TI4,C9IW0#*4VY]&&CE,@Q<7>0$V3M-D(BM7#*]:IL?&0BP]*-7E1-$UCR
M#J8TN:U<9^J,2@0;-(X'S#VSV-$@,*L/CN6)<*7HH!-8'U4O#VC*BJ?M,&D;
M/FD)87\U09>II@M54#""=C-DV33J3)TPH\:&F@_O1D)?[!RW6\"7B>*P>K8W
M2G45/O'J&E!XE/&"QAZ<Y!-AW7VNN;H\G_,;)D<VA0<'TY=T+S]I3F^ #X3X
MYV=Z(EP8;+HD);7 TF!#-^L&6P)M.^A>+*6D%6&;VZFJ.>A@L\2AR82JP$?M
MC7W"5Y%DJ0CI-^"?YS=W(++:Q-$831_HE#_D..:W.JA%D6# &_O)"(U=I!(4
M[&-9<$/.1$A@)Z_+V'"V73><C6LXVZ\;SE;@\KJY"VW.%K)2 2UD=W@EQJ"#
M8QO@4()K2$Q797K9GH0UZ  K0^J;\C[:^:Y>BV]N1[3T RR<8JKP'L4D06XQ
M:Z;"Q?=!U=!%P(LQ#A:>$;P,+PS3RPQE'_.YZUVAW3<RCV^AO*'3T:"IS6Z)
M)J92P^]4&U_OSCYF;QX]@7^$;G2@C$93YZK-G,@F:_0"+AMA&<?4F=/H@TZ$
M6_+HVES+L\FX63H'6;>Q[3LZ37;#79(06I*APP<PG1AS@R<39^ZP7C/PPADZ
M.HH5]+K@\<PGH!.LF5\/_W9T-@D$?1@%[A[N20@MBVZQ;N]2D6.!LN;ZQM2G
MG2M_NE4-<#=SF0:_GA#35H!YGH:;P4,MK(N8P\>L93Z\IPE!?,V%YEA"4",R
M']%+U5?\3WEZL\E<1=K7&J]6Q[;R2H\7>)K&G"3(G]N!!@>#3R;H 4^#(@G+
MU"?J0O-1#CP:']P+.OS<^'DXO%E>RH5AA 0)&S1)B(YPGX-[B08.KYT*/9'R
MH2=+VW/'UI,5.Y%:=-[<>O D@1&-&$8@89&8 I)><V]?C$J(#Z3'E'(B2K?L
M99?H;2A:=HI(F'>YGB)4<?OF!+2;:METL+V;2;1.>$*RWX@3H+DR)=Z\>O_3
MZVN+F(7QA=)[E@LHP#'65#P&CW!T+=N=^H$W10%<+^P?UE!G BUYP?/I?LNQ
MW'"]U]+IP8$#SN 'T!BT)A(_#END#<IP@:;?^(4JB562L,NLXEX<86M@;.$W
M%"12K 8%.Y:FJ+8-^[0-MT0CSPHX+'B,->4E:L,]7RDVZ!#QKFAO'\]_H@TH
M-_I030K,/,,YU='Y:;"_1T3<\BR*:H;3^)HK3ICG"-%A/? ^S5#0C5*FSZBP
MT/L25J1/&*,GA/OP7#1W<XTXM\@]-$N1QN-F!=RJE=6@@D0GBV)<0$S7#5.P
M^1D<[H5BVF\1)$D(9@8T_,R @-/*JMU6O330;=B:CWJ1E#%+,E+&4F </I8
MON: 7H.6R57'::!6J24?G4K-MCQH=N0HX.H5:".<'WN]<LD 9@DVO'E7>0!E
M9EO<UUX3>TA?FFYC;3 JW6:OWVUV.S$=?7!C"=V!=[S@#@Y&9PONRC&L6!>"
MWQ.&MTN,8QV\#O0D0-H%XF:F0^(R*E06*!CJTQ$E$=C8"6B8&#0DP VQ+;4X
M@D2NQ_?G#;%/@U^B]),P&E]=7=Y?G5_?WPG#ZS/X]_7]Y?7/Y]>CR_.[&@W9
MG6G'KJT-&[Y,K1+\;S@]@)DRZN KS!+AYY[!C!O@IVKD$=2NXI8O*^ZMSXN!
M>O%1N&^9%HU8>%YCN)TOF% X&9A.:E%KQ6J0R729Q6"A]VK;V#+T!:>+TKB+
MNRJPN0_,971ODVZ-]P0(]X#F4+' MWX ZPU*#Q2AC0&2KW3=['W@I#HT45FE
MRM7-H&C0=Z-'[([-<@^E&V2CK7:I5?>^GB+J(JR-NGB4F*I3Z@RS(*_^UL#U
MFIA3RR@]T11U3OT3A'<>&:#*NA&H.O4O''K9I;XWN/B/X*+!$_!.[FA3+W:\
M?"@X/ 0YH\+;,0<WOE(EF.7;\+-\%X:ELH1:T/J.9E/WQ%BXF2#,%Z->U$PS
M7FK_O3+8SI."O %F/QIX6$>7-WB&_F M)B)'CW(?#-?$\\T5<*U>8%^Z,P.9
MH>W<!?B)HJ+KG=2F,'/@PZ0!/J@Z=^;+ AMZE*:J3<'+-0(86J+KS-%60GBC
M?J5G&F0^@\-ZG+4>5;?QH7"VQ@^:>^S2]+266ECL(9_TUJ3:N&VMO8['M!=R
M,[RMI'2JHK=UYI!+_1J>?_]"M&=R!9]Y2M6_6VKUCDY[)^ORIKSVYD%D<>8J
M3!U>)XB2,*<O<R^'7I\3>AVDW\(+HI_T+XCBQX*52O'ZX["TR%AOX)3:+CW2
MXDJAJLZP'5IGIJ#9U016YH%'%ZP". Y>+@M+-Z31!JIF?E$5_?%5%;Z#$_"D
M8)8#I@-11 W-&&L1'J,8&I,GE<PP\6'"LA*,V4R=8(KBE7DB_ Q/$KXJ:A/3
M,4A2DU=9SE]SQ *85S1SX5)_)BSQ9PQO-:TG=9$=;.P'$F?"6".B"VZ2BDHI
MSCRF4&<@^K-B^U0^$6X"=WYZFJ*L:#96V<#2<RP"__%\*Q^Q@%\NGQ&( R#
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M\.E6Y^Q#PW('9QJBU7Z0S[8YB_I.AK./S[BC)\]NHB1=^8(FB6Z\R<:7Q!_
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M#T6+&C)/I02=B1*3BPD<QOBV 6%V/&RDX0ZH/6A,5#8@=_B[C%NKZB=UXG9
MXG;94C4FB5..RA7@Y5*;@3!RI$3779U\/:K;A6B<TC01F+ZV"(8ZU94I_$,H
MBZX344&2A7CG3K .2+#&[00+(0*H6M1:AZT&$51.VW7; (# XFUKM=N6YQLV
MQ"2+.!5<Z>J"V&_\((O*$/_FMT/X1H#Q&X2>HXZ%D[LLC$]N[YKZO"R:@L=M
MEB8\&"CZ+"SIM/=&3,SEC7=;@!;;8;2NVR2KQMDWLTDLN-:G#(?76?N6%0:B
M];<=6RBZPX9WYQJVP@,6><>096.[GHO8[JN([VU6^-1FA5$ QR;:.)\.Y/AC
MH4/-B^*/KED"AR!;)9J/;DH15Z;A9IKJ&] I)_<<G?*T0Z=L$9WR!/?5AZ:.
MF4;<.[S*[0[?YAZ63UN?KGY*$_$JPK"_F 72[LLO<:Z*X&LXEE&)+:)T+L^
M+AV][\(;NIPY!6L6I5E1I>H3#M0G5[AK#F&3QR&<#><&;9_OUF?<.E+L37@%
MW;^N0]0@;IOLL'N[T]"\F(-(&83NEJ!+K8#*:^FWS]DU)NLS7?"JD<4H6ME4
M4QH3OAR9DMB*ZO=LG^;X<EQT:JJ- 772LH?NUW+XEXVT21]*5],N=:MKB/8M
M(P,B.9G:GLS3,@_'&*33U_,"#SCEZUJ.C<65M!QD>%V9AAC)P_O@)R4L/14.
M8"P\24#E/*R)!6JV48RL5Y=:,-@;3N%.')]^-,#@(H* IAKB?(4A2--3@="
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MDQ@,E(1S$76-J;2JM8FM"Y\3L*!)OGZ,8O9]/\*.G[02E%]T?%JC2JE!J.W
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M\P]SR\[G*I':CF9>O\B!+AH@IX1Q^&6L*,_ /T (!RDI"_6P/26)1YU)(AC
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MV4P7E'HYX'!(15A 7R#?&#K8\V@8C9E!>C!*<U.L:Q#HEA:19OUBO^A:-N7
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M^F!+0!<(#8I(11H['=12!SF2Y4_IHMGM7.*]=HEWP!7G%8S/4Y"%4BCC9%G
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MQ;^J7:F!9;")T6$1V]4IG4BL336ARN%CK1!0#LPJYIX],^&%]A=8:X%^3TU
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M2-O?K( 7,HAO&=F*<PN4@[^QH*/@R"+].BIM];F->&"H.<PFU.T,AP'^".%
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MJXW&+N[14A.U YN?5ZQW0F73=">S@8M_:+.]L@[6A*3^3=4NC$V_!V4D4V9
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M^O>%Z%2T)K6AG0S.A#7RF(>=$"O421RCM$(ID[PH)@O:TX)BF\/4>W'.UVG
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M="D00S;2FSG @?=-WM*3(5E7G"?!I9]B^=BM&Z<C\1I!SOCXLXHG=09[QY%
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M51ATJ['C6 KAHD=;)O<K12!J%<I6SBJO+LA^@>33B*R#]HJY/NT[CV6D8N"
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M(2[$Z6V&?NQ-6R&$[=)1-]J-,E;JK5N07<YG'H++)I>2)O;*/YA9EE4_8T9
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M+#'#7\ 4O"$:QZ"09>"*&D/M<P_#3 *[/+D6^!F<+G'CBS^-*.^]EDEK.J/
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M?Z(E**\B\)4&CU3M1#QQ*UPVVA 7TW23'2V8:M^Q%ATW;"^2#A9<MW3Z72,
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M#&S;P;3<L-ZSK4Q;W*NE0;BE%.UI]:'KVG2DO<7C-W#LVDN:_IF])H8#ICS
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MX@H7@9'<D0;*WZ9:])F%$]G'!HJ2INIL8%3MJJZZ*^3DX&JT?QQLX(E5V<*
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MJ<&ZFY8;!M*G8^K2-B&QV08[:[0I,9O"O$P B6[_]'9,PI5INU,L18;</&P
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M[=__^>N;_T..[E]__/S?\(__#U!+ P04    " "N@)U: \X\_U4'   :(@
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MK(%*1<1#.C !AD@3EQGFY5@/4Q)AV*@OXSZS)?V:"1@)(RHIV ++I%6")Q(
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M1V3^>D#^Y>[_ X\.-,N[3GWY*>](/P!02P,$%     @ KH"=6E"C.]Q/ P
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M$%'COR,E]QE1C"?% O:U>&[Z*5(TI]=,TN#9\<&*IGG7F]_=OC]X,?AB8YS
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M_<U8=HD\E\]/SDPBUUYSC'0Y(C!V"R,=4CSY0E33H *SYLON;Q?>D$$2%>"
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M(K[_8JPN\UH/1T:$_?$^S("#XN),89I58J.8J0MLE0@T(<PP"+R2_.YNTD[
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M-IW&?*O[C'B)XTK5E#'4*=F$W44K68W)#:CCRDTLFY@4Z(2@DY#-HG2A2-/
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M[62_?KO+?KUWV:]GLZ@-#"DK#BXP*"QY-D>;;HPHUIA2M\#ZE^#G2\J$L('
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M.*]H(^1L7+60]L@RBAO6TF8ALK3(TR5LU.H(CPK6HFIX*+C[U)2?DUZWZ(=
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M#%WR*Z9+N)Z#K5;.\LL,5@X\F<9;T8MPX=%,X3V7<,]WS/:C* $FG>%J"I7
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M=8C:EDKTG<H%!]7MKAK0.Y^/" O/@X/)N7#2?#<?O\-T!JP*&<)[L#WMP7A
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M!>HA':.Y>8[F74&X&C$'8"C-;:-.*@85F%B1.Z4) #$\L>"6UDD^G^MBHCO
M VPS ^/62M<Q>8*H42>B3R?)19)&-/>ME%LRHCDY-%0HK7UP@2"%9.P,=SNR
M/OOF_>VV=A;)N/3@CR1"6%$TS[0<=6'M2T]RZ9.T;-C^B*^+ORQJCD!DK(UQ
M^WB6&1HWJ"T;_=]A#56[^K45%I>#2NL\*<M\DKC"I/$2K1C>8*KSE8(Q,'6X
MR,/D&;*E]&EQ#'3B.UV2D*5ENOHMLE?&";?,$\1[TZ)M(.+[;XZWI?7(6#>#
MCF5>%A8CB8>1&?<VLL]6QL+CD^>=*NEBIDAE[%N?H0/:#W[>ZY)40,OS/(^Q
MY!"VAVK3A+1>?:PSF"GL*%==YL=B;?#.^UT7%C:AF8LWX$UB.';5;Z&QC<=A
M9%$3J!NCMIZUN!0$ZH0Q*ZKJGZK4NLNPRCE:J;CT?)Z4,@L#O(:D3+4B5G2O
M)&%4][9$#HZSX3=!P.5%Y4-!A%5A!54U+%3!OD&SN/WI#&.NVK]C*0BEI@:Y
MJ+$L ?:B2)><.#!OGB*N">G4[D,M?8C"R<;:73H/IR=,O&^8V&^?<X-<.YRX
MPA@CS2J^!&6E[#()JQ%)NZG@2B!*&$HPB=R4MMYTGF=Z"=X>L2Q07-@F#/.8
M2M:\+KAWV LR 9^ _%6%>_)6]+?OT(_M;2=64 LHEE$"T(('MBY';AP.N8_V
MG(^5_28+ 3Y;]MMHWN"V-Z>!XIY/:703LI +D*SH S;[\XOQ.5UQ>4=XH8G3
MY*(;#:6WT3+1CSVWQ<PNUH"2;9*J9([B1^"_)*C((8N><(F-RX]#+,(%UO:8
M?I*QEV'""C0IJ(FM48Q4GL.M)TE>ERG6'T]5G0IT*U<OV!JS,(UE8[P<#(%U
M8"U\C^I\P9V[OR+%:>+G%OXXR'MT]'-Q 03R?U='LR?Y9#/CU@S7C&>1T:Q4
M>**KZ@>VAETP,X"GR0>*-2(4 #E68!I6R\ N,5\O4=2#/9_FEUR/PKFL22U^
M$]#HO3:M2F#V,_8D7Z6P/0F+'(/^&+WSEL5/LCH#3(59 N?3QCNK(IE(#:#-
M!J+)+=V"YX+=7?8I6_Y@!2O%.DTNN"RST\3T6W;'-4W;8KP+-KT4X2*/HK]
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M&@^*C,Q[XX&.@M(1D"WV-ABY,!Y!=CZRMZ'6(1OE(C=74G<8\?'C[U0U5$H
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M-.7!V\$&]81>&R4!=_N>!-R]20)^G7)J[.^F40Z>G2(&S=MZ;.=W =DHF.6
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M3\P?78$DL8$P#AI35TCCD0='2$T%*UNT$?@^Z1=,"6?P)+AMHZ1>U\-XV3G
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MIA&I&_1WL.[LP3NTW4+SL/)HGI0-^A51G-=CD*AC-#6:SY5!2F[3_6<^R9L
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MT=/G+U^>GCQ[]N+U+S_=VKY%?[\]/7EJ_O[(E8B=D61M.P.O729Q-</[;?\
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M[G,H-&)/54:Y.Q@P<+[4$/A64:*[0%-M._HYDLI 2>6@%ZG\D1L5!].T&3'
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M<-6\_O!=D=3!D]V0ZR9W=^YX'&EWYWX&DD:6>066N7D;M".'=X=<3E=7^9V
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M;L'0[BKF=UMTN=[!6I)R14DC70V6KC:+L%BP  =J02!^Z*I"&8<D1#G\V&_
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M1)\J#0_?H0]KP9XG=2F>['Q+,X#9I&%2733O>&:S!^S7#FP46P8WJCMUF69
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MC2V' ]0@*8;OX9F%OB>K7E^C-_/2T6$TD'J;RKK$O'YTCG%7)%1.]A[]2S0
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M>!SJC5*&VQ,:0#S/8+$C\W[4*IV)G4:8Z".%S==D=)F:2&0=AF;!3QM/.XC
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MQ$[Z063 BXTA+FE6Z;.G:MZ>;.9*"=7=OB=4=V\3JM\GH0H2-E6L>E35)3[
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M    96$P,C(X,#<U,#%E>#0M-E]U;FEV97)S92YH=&WM?7ESVTB2[_^*T'?
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M6%F!J$1K?)#;GZS'KA?@L6GL6PHD4T<+DI^3#"1, KK@FRS&S->\P&:5O<D
M?/;FW2_1A_<O?[JG/^\_./QS>WMO^-?\[%YT_/;TIWOW^O*6;O^?8#[]'/LK
MO]>@W'$KX?[LY\XP.IY47%_K][VLZ"K6A$4TX!9?0@95)"7>J?;2U;;#<EX@
MOA@HAS/*Q),F#CEEZ('$RA#7*,],AEZKS2;A"7A($-B:VN24PN_!S#R;1ID^
MRRNNU"78)\(Q\#[D@K9!)&V)\/$%-2J:))A!2GW"ZZ1R:8)A<W!84EU4V'N(
M(*_^JN%MX1SSZYD2\SDH_ [?3:]*0H3I>J)M[ ZC5P0JSTJ;88?"GHJ!J>-K
M5'V:7\:Y9E *1KB2.B#'+D)/AK)'#IN[AMWMIG&X[UC\V/%C9B:\(I.L)M3X
MD9U)QSW9CCU[<'WF'^GJ0@L(6Y"-;8X1G@2@3%S#!L!>P&'^7SDVTB\(2P3K
MM,R+1:0S^'"L#01(HW] 4'C#'?MLC[WVT;;-O):,SY(&6 .AC))*\$MP>;!C
M43<Z2D<-*V_RY@9V+<A'0#)ZN;*KM>_ /[W4*9#Z)DF1Y0JI$ 5" >FVY)TL
MU!S0)>^1)/";SF]'KQFO#K:&2@/X$!LBPR)Z<U6>=K U7I.&=^V%R.B@!(88
M7&$@]Y+/^(ND<*V.2M+N2ZV @_'"K/*><,EIHV4[/!2#D*_)K <+**[G*2K(
M9 $-I#(//O=/=G!&\7?3/(VE#V.>L>U$!46Z("@01.8:1J\1G\O_N"&"J!5L
MJL] 2>>MZPG%_7.YPZXFWV;ISTEL&R'[@1%R1XC!UW \'ZX=S^)X/EP[GN_J
MO/"NDUQX.55SU*QVHP\5W#>JB*,3IS!_1<E@UG#W$G#7M4GUVZ+V1PJ>!I I
M'3@>5B%I>JD0,;S"QD7-GFJDBG0A@C1!D]O/"W@RCH!M>,GC+KB!/;E>+3O]
M#"8&$.:I8["?X#09D+ ?*QSY"+$6B$:OD!+R(?R1@(T1=@?L!W5.2?'%MPLA
M.$#Q\Q@)^Q(CD#WHQ\ <>X?;S"B*.ET-45W$^G@\IY;('20#>DOGK?#CASAB
M3^CIB[*]#F"/E]@I0G 5^B/3N+?S:=AEO$;,8ZTKBQ;J*GO'E@K+4#A<K;IG
M2G@&099[C@(4;^9Q<GJFU&6ZT7<0P0&I#M['$2$'2/"\ATEC H_]ZUAX1P$9
M!!@EKK &)0%P8ON*^1QV(/D,,]!^CO0XGQF;/#GO#2K5[E;C6$P5ALI+79PC
M9&KN,V/7G1_%^;@F0W! [4B2.?Z+_ Z#*$T0>A<D\ARD+QXF4@3F>@SKS'Q?
M!;!RH5-S5@3DS_K_&7*NX='UO0#X@TF2I@8%#KV]J8:C447G>3V&DUKV9;_V
M.O9KT%:D>,?L)A5@#R6%EGU"("-"V+-01AGL7%EB"U#CKUU%[[[0<K]!RX$!
M#=X+,SSF18)48<HZW71 9Z6L1[.DJCH/RT6!WV2^/BLM9TWHW?)I6<_G><$-
M4>R1<I>/H-^ZSKZ8HP*G"Z]L&Q0R/U)E$[D/I\/%HD<YU;18?W)O??,B'^L8
M#V5?=OF@2\*MVC47>B*Z ;W0Q$7<Q!I;KYO(AKBD1[GB#BHQ'+ QQN4Q,LD@
MQ4AN37LDCU+@!'VXN(NT1V;^JTN[ONS+(8-2-J.;EBD+?8;:/48_O" <8;NJ
M3)VQNNH+MC!R.H@2#[-&?Q[#>4"+8*P+2O0R'8 *T@%!VS5;9C2_04NSZY"S
MK>O0-UWG[(FVFVJ VWPV(CPW#UM'>F2;W^:COS & *M"?O FMF<]:+_'C5!4
MEH4,J]WD JG$K]475GHDK!3SUAD:29,C)&R('44B@)@J%E$8MLES"5'*WIUQ
M2+I+1.KFAAO#B=2NE"LXV1PSP*_.%>92]V17'G<)7@S4H]<5\U,;6IP O=MS
M2)^6+@$-Z(\T\F/1+E <='SO"06IE]05NQ]@CBN1SQ- J#WL<38KWBWGTFRL
M=!X\F^_GKA^&J6\9M9A# TM(*(D&YANCQ$[E!L3%X+FAY@H]=)3L1Q_0:,&6
M[ 4<VS.;K8<IU^=Y2N%[\J7<?Z<^)[-Z1G]MK<WR&V>/^3E!"#B'UUEA:=U@
M.>;7LIX%.'6NP<)(I4:54A6=$O2;"F>C1&+U0"3XDDF.>#'MWC:-4]<YZJ6O
M<,>G9G58\=$ZK"AAQ4?KL.*WN/:.,99D,4#];)>.JPE[=>:9&J4+@O&D.)*+
M&IF31]W5W/$C"=%2Y\NQ2MDX'R]0\F-_ZDXU'W0ZS'4SJGT.!AOGCO;O\A/X
M;T'0.V'AM[[9;GRSD4Y\F64&1JG*2J?PR:=S=$?9"VZ"+1>6&:*2J/2 ,Y7)
M, 15+RL5<ZVS*&T<HMNDO);)ZWFW.JW=GAR/$V.=3[HIXG8'57#R]K <<6V'
M5839[JFV=.I();5>"Q)-J(%.$O3;\B VH$X)<%>U_#<WF)5ZLA-!!J]LQZ7O
MWG &,"')@-*?YP5&X#J9E]F:O09BI3J_N:LM),<=_?X^Z)]I36<GP]Q 6%]P
M*M$1F'/4Y%S;20?.*T]HYO@852,$S[(KP?&3/+QE B"M0\D/L-\S='HR:SH'
M=+3"_TP+ 3-^5 /[(J6<G6[])":$H#\KD"]*2BJD.P_VH.FXPT,,9E^PA7*L
M<>*B\T1U'T%#0P*S]E;"9,-.(.<J;62 !_Y#E]2"-G9=:"\1/ KSP$V;(YHK
M9!G7K9ML;EA1 =]/ZA2)AY4-Y'@:5_PG=_\S'B4_\=EC*TIQ6,Z@UG_J27O8
MR+K(DG+JO%B=J;#.=!EAF4T:@VV"73-I2VGK#2TNX&(J<TT=](SOI;4'(848
MJ+VV;O9&RK/,RD4<F)Q_ZM9U8;JNV_>V^4+CKC[N;N_:MV!',<T5;S2N=^#Y
MT8L,TGA,V4W+?(1]E+$-C630.F"#S8TX*<=8U.3I+[>6+DL9F%B2/%)X;!9V
M5[V8/LNC@GRMSL,8:^2T+H,"JUX]5Q=N+C<Y\V:%S_&=4DD' >;&XJT!WB I
MAA=@SD(_D%5O;M";>:'RT%])=2)E76+*072&CF$D5$[Z'OU+;@ D5NFUD P\
MJXY"RP@NR^@FL+& 8!/+B2B)@4#L-3>+('E@"@%&W(B&[R0OYW\!NUH!H4O>
M$!$'E/M@!+U<P(T(O'>)D&">Z,+?TTNT>)X:X[I6M]G<:!X$UO&!(.E"-,'E
MPOURN1Y=1ZQO;EQ=KO_!4;Z@NR!>^*60UAWQ)9L2-?=D66,0<_P"R=V^,;^Z
M]C-P=V13Z>DVYH)=_\(J3S].\;&D[(&XU5E)&43CNO!NX+DST8)DNX"TL>8<
MI(Y;Y7)[JLM@L_?'* =&;@[:S$ ,N4"-X,YT+Q3F)8B8(K?U<C/'N+EZE!U]
MVK;44**<)SEF_GJ$<SD"M-=Q'I_IU>:@H2W\=4%]XRDP26D_]9Q*NHLS:[(G
M&=[X*!C1Q3_#=? WY7?EN7^\]MR+Y_[QVG/_+3SWKS^/];P"H]G4?2L49A>D
M?E_I-%):-BH,<3ZG&A%0M:ID+HG^HES-T6E".H'M]FNSIYM=Q$A1"D,(GKQD
M6X"5L-"CUKH1JE*GDP&Y<E+TOU!-N;=RDZ'M/+1+]3I.>T*Y JI%62MGT2[)
M'W+Y:IWVNUTD7B;P"UZK[=U<-11)4GO)7DJTW[RRG4 H]+;E^?VX5"ZI^\_8
MZ9HC_F!V)FAB"D5"J1*_?:=I^^7!B(F#3=G<3W\7PSL=.\QMM_'$@FS3&29(
M)ZBJ4/&W%]YV-B2OLFM=:/#"@O[R-&VS+/3_)\91*3QUPN>C)YN\=WGVC-UH
M>%X+-6V+NV8.[=6V&%4P'*QL[3>\J>EV?-4-CSKW.[ A8CU&=S0(6!)D, IK
M^EK48UD*>3H)B8(B/LY(,4NED(2#&Y,I#6@84P4=$H0=%GLY=?),7MA?8_JK
M_#(WRU1IF0,WEK5V=-O<\+UHN #KEF4-GN$-> !2+%@+4\#IF28)::K0V\)8
MJ%!VD*'-$1V 6_Z>(K4<I1)!F^$)&BZ_SM ",&3::E1INBVVXFN%:ZO<9L.>
MG,UG+Q"KD=M^2N9M1]_/$W-?)Q.^P/GJ-UD]YCR8PD#8-% R3*?QR_W<H9MO
M<T..DC2_+$5C9#< ;0IM4K $.49V!4>>?]MF$B-K)UE9P9R2LVPC/?!BQJ:@
M@Z_]'Y;L-C OY'\#[)B4G2;HY>Y,><WP'2DU299UY"\KKZL22[M);!#C^IF9
M">EJ+A_3[MB-%A$0&AVU8Z=VK-,-;C+-0;?+H2&*+#\/_+.$K$=WBMBYJ%N2
MT]!*KHP*;\DG$4@Q'S.K(K5=A-?F1MN<'T1L;;%8SF(O2NK\;'D6BD975D[^
M#E>N3BAO]A<#TTC<KID.)CJ*4+S:EQTTI$KW>S?ELXL^<3U5HP?\H.5!-7>A
M,8$"Y8 B&&EJ$,S8(]K]W@VITWQK\WUCVI%V3DJ:C).6:#]!@XQ3FV\9AA#1
M4^U2V)>!9EDWR1(:)>BB*^L)W/:)!/ ,#S(S\?,HZ#!2&J9===ZJ4CZ#"S!8
M>>4U9 RNKB>WZ:&<\E4"U^>M1O6PX;*1*A,;<!ZK>5*%4 P-1W1/B/=H2/EM
MFQN_Y95^2E%GH@_H>!ZT+A&LTF=X)1+V4QNXKO-<<- QHRP/$)!\/H+K6@XK
MYR/2(1#0J@  8^ ?*?F$,XB=*%QA.EBC9F VW\=2H"HW/\Y!$6U<+WI/FDOF
MH]RN/\0'S5-&#EA*#L(_C>N[ #F3W'5,8K4']<G:@RH>U"=K#^HW3;P];("O
M_TN_6%LZHH(O>5=C4,E:OE*P"XNFAX$RLU5M?*RF:!>16--$GXLZ /H> 6^V
M\& )VD/-@=W3I".RVISO2#[QB_F<]8/&9HSN!_)1)QG5[@VD, HQ:0JN)#[7
ML1GHZNNP:Z W\>+G8*;65A6--<B*).?4<Y&Y21%-+%BX9X,6'?ZO1C4B%N"1
M"7I.J\8!RWJ$YE^%@QF(8_K9**D*DXYFRITY$;\\:A'25/R5_L<!,;V2:?-1
M0YVVHZ(F [<6WL3G**A1S\.9T9.-E-,5)N"6K$M:0N%/.1@/U^,,Y,6 ?X0>
M*L[O*92?\^)F.;K4F!6UVBK\+7O+0D0V<@8EES2#@V6),O#RBIB'&!8Z)"@\
M[74!F')"!W(3>LR<6\ E0?5$6_/EXZ/HO<9T72"4JDQQ^.;&1WS[BN*X9>_\
M!BT4(TQI,Z"CR)(+SBF=HU#0,:J-9ZBF%83W$;/+AB+<UD^E8I!'B>7_">&J
MQS!AP?6VXWPVT\58=\ :V#H&QJ&5BFBRYU"\C46XC9/S)(VH[50I0S)2--DE
ME".M?=B#(.1DA+X;CK3(OMEPN\V-12HN//PG<2E6Y/XSA4U=".92+UWZ%"T;
M*CS"Y>*31<UNA(PE(^X>]\'!BP8E5Z,T/<R>:N>]MMSH<EAIG<=EF8\3EY(T
M6N"-POM+&;Z2*@;7#J=WF+A$MI!J,'::CGW;2>*WM$R7N45WQRCA:GY"SFYJ
M%PV@<?_-<5A:C[0$,O!@YF5A,1*H&)A600,[MS*W+1\\[U!)B36Y-F-?$PCM
MR'ZP\UZ'G )2GN5YC+F&L#N4E":4]1)CG>Y"KD/YU 6*+ @(;[Q?;F$!'9J1
M>X,H)7=X5^(6ZCUX&@86SX'*,&IK'XMV1TA3Z'>B=/Z)2JW1"ZN<H<* 2\]G
M22D-!D"!2\I4*^)$]TKB"G5O2^1@7QG^$L1;7E0^2$68#E90#L1<%:RF-;/:
M7T[1;ZK]$4L!:#7)QT6-20RP%T6ZX$"#>?,4 5?H6NT^TU+L*(QL%(^%4S9[
MPL/[PL-^V9QK3-FA3A=&'6EF[R4H*663250-2-9-!/$"D<M0?HG[I;1YIK,\
MTPO0NXEC@>#"-:&OQF2PYG7!)>Z>IPC8!*2O*MS,P^C6(_1C=UNA$;P"%$LH
M 8[!XUJ7 ]=AA/1X>\I'ROZ210"?+/MK5&UPUYMMY'#+)]0,!SG(6:I+2HW-
M]OQBE'^74]YAYS71HYR9V;CQKK1,-"C.; ZS,_I0KHU3E<Q0^ @FF3@&V7;L
M"9,8S_HH1$><8QJ0J2(9>2$B3%:3W)O8ZL-(Y!F,/$[RNDPQZWBBZE1@:SG3
MP::CA7$HZZ9EHQ36@1GP/<KN!=OI47>(TGC +?)S$+CH*.+B7 GD_JXR9D_L
MR5[&K6Y\&?=VHJYW,*-+Y0>FADTPK2,GR6=R^2#6 )E4H!56BT G,3\O4<Z#
M*I_F%YRZPK&H<2T6$Y#HDS;U2:#Q,Q@F?TJ.=Q(5.;KMT8GB+8MGLA<&J G3
M!$ZG=3M513*6;$$;S4-M6TH$SP2VO+RKR+H_S6K_^\[VV@$O#OB=[;4'_LY%
MTN-N>13K-#GG+.!.&\4O]A[5U 2+@7U8=U>$*SZ(_H9+'-@K97E!<%SIPFC[
M6YX0<4!RSJH-E4K"/.>C;,:3XB\.Y"Z1D\L1$X^ZHNPZ*ZEL#505UD_<RR>V
M$R6;RXT"3,^X$C,/ET?-]3B)JAM!!4F46EOO(5R;6 _C9;+:4AZF::2 Z-*X
M;<FSM+JY$F1M>2PHD/*N[9[<K$]67ZL23V[?KF&Z?:^2#G>VD?D:O:%10;,(
M@\;Q(Q\X5G:.]T[G@04I\( C;6HJ1AA $*2J\#Z$<ZNDAQM*%/><UUUNP--<
M>VSK2P-K]"\X'&,&!FQ"0J,[MNMU^K+;+5>YI V-L4"%W:ELO"49U:(:2536
M((HX?\TXJMM9OCX4B)?5!#(F04>+( :8'"L8ZFASPW4V-2#R7J9&$\[<)H5C
M,?V4*M%R(SB[3 2CV?&YM56$5L=MULB*8YG<3B8?K1E4A>LIJ40YO2S7C<4I
MO[;*5+J0]+8K(V=M;JR^0<7_#9IMYZVQ#(H'IL-+HY1VUP0B$2\R6.S8O!]5
MV&>BZ1/*_UAAS3ZI[28#%UF'$7WPT\9L1Q&HN%TI:LQK[-O##4\77MZ=I6&S
M5M?G0"Q%LJ7>[N;'O^I2G05Y/I(TZ,AHOS V$4*HRD;2)@&W8NYCSAG*P2E(
M*F/X. \ :O&6BF4]FR'R#2LO7# [QW!TC*3ERMF^0V-@7Y%FY,:RWDS#J86C
M$2>\EP,;J::@&"?8#8S]:'(M!U1J4&2D8!E#<A $XF&#[3#H?S Z678VL,-0
MK9!U59&U*K$W=-OX+G3*P2C%BX/>*/)RJ1@!/&P32I,4C\Z=;-Q.6;!Q\>YR
M(P1BH4!)"U*B9_'9.\KK/FW3_@SO$V7P:AJ51]+7X-G'YX^H_HB[(YFFN-S;
MA((5Y32OTSAH>:(NJ*R"<4YE^[Q..4D!Y@G?>>73?IQJ[ KS4DK_Y(67Q#$'
M+D6]'(-<#^+M]H2S=[_PDA7.]>7)1SVAY6Y 2P^Z?Y;'#E'CKSS!C]RW@?/+
MTZ/XUD37!LS#56&@$)6X*N]7+DB,/.J&Q?W)BS.5&?1];/5-*0>D<Z5X:\74
MM@:>Z\L.["$Z/KOER:EH;P7GW6_D=''5]B#,C (%JJK4>&H-#T]+(<\U4I_<
MFM2ZVJ1/D>L2!E%@V)3R\ 2[BU_X"W')2W+3>/E7/=F&_:WHCT0*J>HYJ@6E
M:W&?)J %Q$+GLLKG<U:#1;APU<+8Q<!-GF$J?R&PK:M M<^)!V00W:=Z1G8>
M;S4*03&H4-3S:KSH"ZD/MJ(/8#-I! X"+88@R4QS%M*!N ((^#M+*,42Y4/!
M*9T$PT4F'Q)2,Z*32XBT/,O !LC;(&IR-"=@0^>8>&,S%;OD_D-NA44'4>RZ
MCA5)K@C6K^*:)KF  W%V# 8>IUJE( AM*,"MR[6NLQ%J^/\%#51GXB%ST8T$
MU(._\M%WU=9X9V<= S Q@)UU#.";]"9Z?<XEN&1C4<"VE5?$SK-&WG)?9.BC
MK>A5@HXM>/,%B2M7C6F5,<IW")+0@5PN0D"UE^C\Z@E-'F]="BF!#MLT+S'U
M5@ =\9_D"B#_,H-U"$0,.LQ8=3(N,<E9YU\-.)(+7U$S#),Z:_1:2G>W3B23
MD^@2V$WOL1CSQ$P\NLW E?K$&:8K+$A*\\"@-:Q";,D\DW8RFQL!@ 45<Q3:
M=BZSP&;G+G/5]VIR< V3*"@HWYAV-M,QF%HZ70RC#Z%KH=.C,&BX]]&?8:M8
MN1)@Y")I#+V,+R6YTW)Q@W*:AHG4Y@?WVY;WP($2Y6.![,59)'&,7#HFGVX9
M!'.8!<E &;$ ^71TD5NX6@CFA@?XA, A\;<VZF]'W3K:W)C"LL^-,YA<1RT2
M$/Z2"8 HJDT(ROZ9X[PF6"TXE :J!Z_3:Z]ERVGR &Y#N!<WW90_!(41"(E?
MNBY:?M6X;5XDT^%S+DO8(W.C'(-B(!1/Q 2N\X!%6EW.!V$65K/*VNNU27C>
MA=]JIB?NSIV]8?3662K6.^*=WW;N[1+ZD] @QV?N_-2,P^.&*3TMONDQ,4$8
M1 (3C"99!_^N1,CU3PGZ.9<L3&YNB@*!:< 8.=)#;A"UPS4^(+<-ULCR"07A
M8HJN3A/N7@JKP*UN@083[57KZ# ;F7/,)I/.VG>,C3!:JN?\Q_6BO/")UA?&
MVV<P)P,;ZP<]&B$N(ZR,$60\3$'5F6WQR+4D**E@M]B#[JXF@QK0S"SWJS3R
MHLW?(VK_+:V\E?@SQ,##=##*\_+7:,<W&<',F7ZJ!1"BJGN47+US,,2@65>$
M=H3IQBS7F^"N"6UM)G$J+X!VK5;1P=ATSJAPS"1QAL$V=KW \EW;5[J416HT
MXND>,ZZ,9BYWO:%,&*!.1>XT2<4OSL4OEQ-:B0*#K<#4</HQW-Q4XD)7IGQB
MRQWE R7ZI?Q%0=HLKS/OJ74PYA9!P,-A=,R!U<V-=];=O*;HS0,P)!F68NTT
M;_-&/D)TW\]9"/%#3?WHP1873Y;2VK$#\40&L!V;X?>4@=O 4PF;QY8*XT0%
MVCNUQ>(QH07W0ABK'T9_6&#458-@\AMA_+ #'VVT[ $F*40^SOORS#T,\E%6
MT(CNLMF\2IU9Q'+5&%5+B<"PXJ3<SON2(X3!J=,6<DYH'DBG!PIUZ$MH=(G0
MIZ0-G,@@JC6S/:Q"39DFDHS"9;OH24A(;S!6M9ER"<J4R4ZRAJ 7'@-A5=ED
M4%=?L,2&%G:R)J$Y,/9X>8$@/PLM.)$]X9B=)>4*Z/O/A3\DV<)'D*=#://R
MX,358X;E=?)@::&.[Z2Q#OV\LM! EFE:EJA-) FZ36L, 9#Y4W@ZZI_X'[)B
M2J/B9+KB=W$\YL]KH$[#&<#\*:,+C<E/DF[;;GGFF?1JT>R42N>EC?J,"UH2
MA#\B7L.29L\M9*FR I>3<R3YF'AH"CF;[=.DB)T_Q9@6I:L?:36B00.L0WM'
MF6W5=\]AQVR"JJH;S'1X:9J$WQ5$TL[N.CQCPC.[Z_#,-P4!>4S'Y#WGO4J;
MKU-7L&M3G_R3VC^U_.???SOUAWXP4;,D73Q=/3CLUW\\>;2_?V16BL,\WQF>
M-BOW45""D,PJCAR'!K+(>:R*GD?C-#'9.QVU)[_4"=;19"[-P]E**-3?)^4G
MDNXOR;HN-S=^(:%,4[YD'!+4/%ZH[!,Y\7^A25_2I&5TG\L5.*^MT*+;BN+U
M8QKCK>B6\&-!'VSU1#/YHCRP.VP52F!%T1=E 0]175*(&Q@'E&YH$4F]\^T7
MY+>;7JWWL[V?>^TS[27JDHO4Q.>P_O0O3(J1[&4U_KM.2@LBULB?,\7??)KS
M>9*U^L8UL-@V-THUT0[UK%_5S/9>>A*](,PSDF:>\W%SXX-%Z^W=/;2DY(;*
M-E#_U5+&++!YP'J<:,SH<'$C"(*VL?&G>_WJ1I:N-B19>P(CS$_>W.AK@G)(
M:.S?5_H=:NDXNEHRKT6PH+;8*%Y3[#;[$1@[S SC;U)?$CMVE]*S!3T0P*9@
MW[!F=Z( 9VO92!T@!":4)..#G&RU/;)D;T%\VUG.<-/@'C[CZ];S43D,[P9,
M17/#_6=2A3G2C;R5Q@\"\[M192C6>'O!7* <X'RU S74Q$W<"%[CRZ_2QJTO
MK+S79&7Q<&#HF?M/ZR EE:]UZ:=7.A\E(R@REBKWEP_VIR_DVM^BFF#J-N'=
M%'*E?*A'ML$8&.#D>'+PDTH*#QJ->02+5MQU#23:2S![^,JZ&C3L@'S,P==@
M]-32/+(37-1EH+EN/WE+YO=PFP^:I\(R/.Z\=\7YND3E)W8&?4Y:"+J=" K+
MYC#=<O%CMG2CU[:]T,M+Y[LD0: O6W8H6^;8-!!276I)&UF8JD^08":'UY@Y
M>'0[$W@#NMNYFQU\^T+D1\US0<FK)=R\%W0O@"C@.I5S3&.UH$Q>U8B.^T*+
MQUL<CFTZ/KCZ@_05[&N6EV4RHO10][FMOF@5@PQ\##4_T8,XDS))))Q(05Z%
M&AE6!Y6:=1TL!N'TCMA'$97G23/R\'NQKA#-<Y?V1  0A$G)G^-#ZK-D;SOP
MWH& "1#NK\&C'%N/&[!_ R4X$6LL*!&GPX9].T&)S4RUETG;-"X_)\O\6R<%
MKF)?PI30U"<I.=(I9QJO4/L)[TXKQV<9 O:WNLDNB:#LK2,H)H*RMXZ@W+VL
M>Q+(NAG"'&-M(FB,M04>,-5RG_3"E,A140<5L&6ZU1"(P4*E&:D:97@^4P29
M!5FHYG/,ZG,=!D1H\ $GMR"/2T"46L><>UMHC$67-HD";+RF0+N9%(DN%R)&
M2^NE/KRS'3" (.$$OK+6]J;XWW2#L-Z)^QC#?=3^I;E\P :9P-W&MLR TK,?
MF/9^YD.+)LQVS]A@*5)Z$X&ME%A>),B9IM2(W2\D! )_!ZW((G^WG JV7-(#
M7C89*[WQ .RTO(.</4+MOBH/,X;AJUW'C946#MBPL&-T8B4*DQN =.E59U+I
MFTBRR&*R0RYP4SJO$7HDNC&6!\MGOUD$@_2I,(1Q_0A&U Y@=/BW$%5?F@N?
M*VE#UTP:WMS@%+-P-D.MI4&O_G!JR^\JS7T8>]@X04#$4^C15,>AUAQX#B<(
MVLR[,O"KZ<Q'.CM/BCPC?'YRA%8>TE$3;[$+)G5@_LB+A=_>TO7*$#1(AEA?
MWT%7VOV]I>64Y"/O@MJ#?Y])2D"S:Z&!XJ;+),SW<N[H\#>-^XDRLAY8OH/3
MB;L_H$0X=QV1=/,P\+$TR#5 ,1# %AHSSAD 6NMN!SFOJ%&UTI(GTA/0>-F]
M+NX=-9 .;D.7MH7W0V[='?H".[/?Z!6DAP8=->K\X=W3G+DV^&)<_AV8:U^/
MR?>WHM\K@I4.M2OK'%X!M]6H.^FZ0DQ;G? *Z2^LXR[ES(O44&C]E5C 8QN,
MD6-O8#)2$*0#B3S2C010TU?'"!SOHD=ER0.XLNX+J3UC%#\&WJQ3V$Q-NFF/
M(LOO&;&OX09#X1;T'V,\&@K!)38J;[+M8&(VVGK"=A@A?B7H?2"+I;2?I+0N
M"+R1*]E1IJJB"D]K)"EOO>R?BP''#TP.[MBXBAX60H+@B 2PZ+XQ%UU<>:ME
M4G8I QU- \6$Z>!=/TJ#2^)#3 GM\$]O0QE8B?1,+,,?1 8GV6C@$B.5(GW*
MV.[+7NX3EZ>*3[^JNO80=!!;O[*R784 2B_MIWZ5+::,J26;O"H29S.'J(0&
M[08?2J(GNW6P!0.<Y16^%>N'(4FX<LF *>!7MF<<I[, !UNL8DFJL)KG)251
M$D6VVQPGY:@&#6;&;0'=@'Z=\Y*<T*#=SE)G$KF?#*HM!B-F]<RO+K$)(F;F
M5F',5=_- H:@)\*](A5EL<X;+! 58*HBQGB(Q!F_KWJ-_76TP40;]M?1AF\3
MRC=J 2D))J8<-7I7MB]FIT[XC]W@1NB+T'^T3$&GHN09HAH@M3PQ%V)46,,Q
MS<N2_6W+VW=^&VGV-2/\SUX\?X7EEY6'Q]]NN2:5K;;J6ZK.Q4G\OL;LP48]
M2E0NRDK/(J_>Z*\:C-$X&1O[_=<$[LS/282IV'3Y"=06RQ4Z&%R[@@_'6KR8
M UQSF9-)VP3.:JAF'?OGH5T).]B,4ZXSA7]2#VW":C-OJ R6@4W =BG;ODZ5
M<5!AK-?@$;>(Q+[^C'Q$*;_<&VQA5>DC\433@0]3DFA;T5?AG'<,(% F4D?<
MCU,+&T'ARLN0]VP*-'>V(;=C&X')[],$AUJE'K%-TLL\KSUK9LO9F6+!.*@8
M/Y$Z !I#1Q(>U=04A9O\,[]A;2M^WNSTZ%I6D"'E [8(QK*6*D<_!DIVCA?J
MQ/[/Z_-Y&^[;V8K^ 5:"U*(9,X$EM&!@CI)*]ID$*0<#**&"PH!R*V!<ZQ(D
MDRO<,4%1ZY)+9N A+5*YPE*0 &P_D:SA?VX7Q107OW46>[4;HT5GYT7A&[I5
M,XW D=A,A0QGSC#4?>V88C+H=[=!DW785E3_B[&,-2/>;)ICZBN<I @2@XU^
M7)Z&%@7#UQG).T(0)!Q <H5(QKWO= [I-FJ&,S5F>$&593UKZ:)!X5D1JB48
M[W/P&ZXT<'-#11>*@#-A!'+ZF- 61^>5$V+^^'RL&A.8$6C)/3DYN+U5GNH"
M]>T!AL''6A*2*WA[IQ?(;E.HUEY8G4%6VJM,1R>TLVY7)-?%XXY0GC6L]NZ,
M"5>_"4-24UV1=M1GNW.K>[)3OHS;03I-N')>H5:^EFXWF^:U,N>Y 5O]2>LY
MRA%+9$XG!=Z,J=ER0;D*E1Y/LV1,R:U6 _?:]_AZN0M9N.X^/(YDO&$NOG$>
M^+*1_068X4JGZ!R$,9H)3CV?UR"YQN0\SW1:#J,_VLA%5LC!F4@R99&\"O.%
M_V8#T[5:5F#1J-CR".4RBP/_\0ZPHP&0EV"AZ,4N\-:X@C)CK WZO73>AM^.
MX$,:EA7,/ASN-ZQV>U9HL &-NE8;@W"I"N-0'GB7F8>((?<JLX4/#.BRXI;4
MPAL;5OR $Y->C>X^;1U^N&(]NNNK\9(PQ<$Z3&'"% ?K,,4WO;9WHY^QYBIZ
MI_[2H$_3!?>UINV%6#R5Z')(-W*0(5PD@08U:\BI^1JF&IK6$93/G;AF$21>
MQ^CXPK),ZOI6:HVE;Z [HA>:RSO/<P+/1LG'R711"8NC%@18\C^;*TZI0U57
M[K@ IW-SHP.H,U,5N6"P> 4;^KF2NDF:Y_$@TC#2].\:U)!!-$%+B13>BAK6
M-3 0":HP-6]ETUV4N/SJ8I8G:6_O1_S36AQN-\6*Q")'L@A@;]%!:K2?H(T(
M%4!B6C\Q%=.1_:U\Z[+!XKQIX>_Y2O420"CPPJEKOOYF+VM>O.MYPL:,.-T>
M4??,@<V=-;FXKGT'-\!8F%R%6%?DFL8D!9/);ER]F%"&^A->TPCJZR7*<J!4
MIY1,&V30<EW4,/HXSTT*<%F7MFX@DYP05G!1 SMA#8S3&_V :J5GV."D2*BX
M)C5N\R!;E[7&GJ61^K)^+SI.*]LX\ACV,#8X.9L;)FX-WZTMMYM>#;[+88SH
M-VB9<)-4 C28<=,/.7#4+Y@<3/6E#&[$A7"X@;9?\/B9L^>4VU:V3K#0:.$_
MVP:K4M2FK])G> ^X.&O_DJK#'3*@O"/MA$6,T#%)B@9EX%0B4]GWQF&WPAH3
M-^;<6!7C8JL,2MCS90:E,R,I==039+TA.Y7"8GF%8+T@Y]KRHA:WF7"\YZ*C
MY#1J,^D/(W>:K5-:;\%5[H']Z-C6@J)X^("HYF.]%ONW P-$SP25;GD>-B\(
M/P/=B.JHXA@T0/+4I7H^15T]JV<C+&>:J,_VW[H:#[>:#7D:T5-?F)D$%G0(
MUJRC<SU3 "]('AI> *EB)6^].9*2IQ/6V)BT*IO/C^VCQA*E(#PI29&U[>HJ
M.L.!_S',=&WIJ7#QQ0^10CP$#^@3TNO+)_,TZ-DBE:G);5(*^^M1':P;7.8+
M4JEM,RR^G#ORRJ1%A"V!X$&8A#V1&KN@>Y- E=QTDJCZ,X*JE>DB;.?4I'-'
M/SI@0&J^E[+U27T8PRZ,/G]WPUS.=#7-XY)SNE:-/I[F)B>%K"!3A<$#H%U*
MF0P)(BQ/DBH,X^!@4YW&/AXGKD?#\N!PYK.D+$V9M35=$.\7[/4%<B!R)QUH
M[YP/HC_T2S04\Q!W:S:K,[,Z3GSP^Z68=PRJL.3M2@/Q1Y9]\QW%<D0),UIX
M"=U"<L+A*<Z=)\ 2'RS^-/$:;&AT\/>$I;'PZ\4",_==EA$SDY"E,Q/04$HD
M04QF9>;15':)XAY4CDJ2UL]DRKFWPX4>E4F%#IT,JZ4V-Q!?B@MY[7T@'Q'Z
ME.U%6P-C]P>[89=W 61F_ 6H[VX6F*:T-Y9(:$:@:N2@>0B"^!!WB \>ZIZ*
MEE)0LAH[<[#,PZP,!")JI1-WK_+GY3SO3:'O'N\<7=:>>B.W@@B^LBXF:LR7
M-.<UG"4E&\+XT9:_YP-J)VGN\;8XLA=N\\9/55E%G[+\(J/6INX8#NZ.C6PR
MYK68B,B2E-+:\LZ1Y2X)3QVNPU,F/'6X#D\]!;M[4MV9>-EG\4*:TRP?(?P>
M7XH?WGWP%2A6GC0F!A=YAKD&@1X5J(F!G*'4@V4BQK? Z*#2"C8W0CM-5F$2
M7/EC7)2F@VWD4ZQ1**BJPWRS!1=.AD67BC#*+;I,AOG*7=87O]W>T)(.-#<'
M:6#]/9X*)FVI.QI;>ZV[A4I@JXYUD9D AIAP<'^WC?7.JA-$P"3^P)+.+EST
MI&RD-FA3AFJ\!3(#&=5DZE#37-.X7 P*<S=2;&5$"=(XH;2Z]_/C_<]M1SQV
MG"%T;B&1&X;&MW"6+J0C6$Q^L^KNC+K0-@@[N6'K142,IFO9"T&99O>9ZR(M
MY/&/KD^=MI4^\'Q[1".[=*%6NVF+ <ZS6L+5YENVIZ;!I/40<$R)YQYX$2^A
MOH5*):+C5G!_YR"1$^$\A U!,T7.-=.,L -N2X"86=XQZDU>#*-7M:T:%E!6
M:::)Y!D8S05$5E&Q%"G9PVV!!ATIK7QMQ_S$MKVYZM>R-N6L(?1J4Z]KR43T
MW+BU?#$M+W3E4%/B0(\_$M6O6^WK&*)E"7RGFN#7]/@SIU&\M\*4?P*CZ_35
M;&Z0*\CS0#9Y!-.\X5NYU3D/+#C#[+\W9_7$8MGOLFBZXEI(0GB.HRZ=XLMX
MCJ*5CB/1?SS/$?[S\_4<1TO>>:4?*1S4>MNNZDAJ(A_WV9'D1U0.HN,Y-:[]
MO ZBW%Q@**&A+CEWU/0+]9-KF94HV.*BU]'JX+5W0"T&1JEF)J H4&24PM2_
MD+?/IH=<ON6%_];L>KN87T>C70NJ@I)Z2?9 ET(M5Y[?CM<@(:Y$0>P)G^X.
M@P[E4\DH;&/5T-6V!!SP:G1ME.P8ZZ1G>&5[2- $=/Q6B)CE'ES^!CZ:(IQ!
M IV8%PFA$F'-IL%(5R5JO&A_&^:$6YTL" >I&0#']C.1:'\8'9L,H0#LN1/;
M"^'B55%@:C!2C&K7L)R!RM$L#R.D-UZ U/%+9QI42W0+3 9=<%+.ME<7#K47
ME\"@5)TPO@,O"331-ATYP*3FZ+<8L!:'FFH-BP"=FE#L&WB< SA/4F0W4PN$
M>="?J/3&ZPNEDH(#6I/6Y$@<PS A*#3]A:\P3>;?5RW'H[6SW#C+'ZV=Y7<N
MB [DVIQJA:*<A;0-&F<*)VAYL% @4754GJ4+@=C(SG5&_8RI5$%G["]'2R\P
M;6L)T!%HR+P0K&<G8A@:<WG>)/HO^Y===S@DU):K"^EHA8QNI<VT@?M,2GXU
M#;.D1&B*H[-I H4 \"L16HRC5&#$#4L8[">3C*SS>:KM!4;('=@&>)IDRLT(
MQAH/XT\8JTJ-,(?,07C'[18G[%@SD^.(V%Q4?*%>*S@#4"]]7033&Z@$MU3T
M-WQB4V/,)KE).C*)8(2\@^JTDM"WNY*&DL6]A(BV".-J5(QN140ZI-+/U=1^
MF 9;G/_?0B[OG](&MB%NM=%GX(;-\@L&BV^C+!%1O*-([$ =0A4E?@?)^0G9
M9IDT6R#F0SXB_<8@D3:2$$_]H4M"H8!=E-[0_CE$URAH4EA<AO"S: B:;L8.
M-8DJ80L]Q=Z*YWQ2%!86H;^95%*+9(LYFVGJJ^B-(-ARP<VN<;\ 84H]2&+*
M"4Q5)C\5X6$/B3>7S:5LQ=*$ (U($DX JK/F5'O0%#B?E?^4%\MSK*P2<F,@
MQT:XFG:(;M#?=>-@=Y/#22_(JPG*["PI&_0KHCBO1R!11ZBN-N>5_HENT_TY
M7^1-Y-H&F&_HGFIMW#5>D-=!XV6Y*3AT/;"O2J:U?^A6HF;E/GO"9'/CBM)D
ME65]/9$2=4D4YIJ[%2E1IT39W/C&(N5Z)QMG>/;S[[^=6JN&[#EKR#DSSJSC
MV4/\.3/CB^?+)-#5QLQ@X[H$E9J-DK,::V7"V;I%UQ)9<+4E&%*$$PW10WIG
M,B]:)?*X/F,M\[XN@F!PTEB9GF >@V#XN6XCHP5O2*'*:FM-\1LFRYV23,2N
MEA8V)RG)A\+X+"+9R=F+67R;&Z,4S0LJ_:'<- 3QV_JN'&J/UPXUXU![O':H
M+3<23X]?O'T=O7S]]NW)\:M7;W[[Y:=[V_?H[P\GQR_-W]Y*'I3)_VI>SI4V
M[0A4K[B:XA/;/P!Q3M^;T<X1]V"L4K-$&&7)FG&=K\QC,MSN]@]=^;56;-[_
M?3+AA*P/6J5;3Y\]/'WUW!NF8R*[U,>X4HN__3%+N-O6R52!:3_6-2V[-'"K
MFG6:4P+*>ID/!V^K>!CM'6X_WM[9V][>?W)X$/TW]NK^'UH#O,S#T_? !$1Z
M.<O?[WY?;24B)S"'4LU+X _SK\;VXPK>7W_X2UF%-Q^/E+?%5Q]?UGA('.IK
M:L3Q$S5+TL73RP9IG(Y[S]]REF(4O=>8VH?M)*7G>G3LVH\<GZ&_^/X'<Y%$
M/ZK9_,ARK2B"Q#@W?+O+A+A]__TO^_X/RX>XYK<JB7Z!H^2_"QV![Y(9OB0!
MS-F[]1Y^W46M-^.;+>K9Q^?O,,0;13N/!G"G[>X_>_CQ>=?FV.NB)\!BU[J(
M5EPOUQ;R'1?1S9C8CO<#BGJR'>Y[ND;WKTFU^#41[XK*/.1VFS!:DA81H1KQ
M*UAYGU3R=QV]0"#?:?1!_$TX$1D@+SF@\<($*ZT9#PH(O.KVSN/=[</#X>:&
MIX+TE:>^]EOTAF>_AJ*S4LO!9=Q4T?G&ZLO/<$A_K56V^L:\WG;<Q;5VQRI#
MKPG U_35[VA?%ED)T\,K<*YB]# _P"_A#8<[NP=)9J?9/?C!N;2Q;9%$RD_@
M!,,+K+@E'QU<X9;<W* @__*[\F[ONKNYB[[4+)?X;-J^O'O/=Y[<V47K.<7>
MUZE^8!QCRQR85_0]>4_[1]QS=-)H'5Y.0W9TW,E_^XZ[8)%WN/T/7_S^ZI_$
MW?\X???V^?\'4$L#!!0    ( *Z G5JL=LAWS%0  !+B 0 =    96$P,C(X
M,#<U,#%E>#0M-U]U;FEV97)S92YH=&WM??MSV\B5[N^JXO^ ZZVDI"U:3[_&
M<EPEV9Z)]WIF7+9FD]Q4:@HDFR+&(,  H&3EK[_GV0^@04E^:#2F4KN)18)
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MGTAN]B)?ULD_'Z/3B__Y5S):U E^ZXUTGA5X$8X4OV8O_'R6C6>$RQYLH&(
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MM6Z_HP'T>ZO3_:W6Z8Q[T*D?ES=V>M#FC2^"34'%5%J&Y74\HYI#G/#X[@X
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M^C$>QEY-YK(:I=JD=B1_(,Y\R\T;A5.C$\?D*CA]#E+GS_:BE([FW+K3&WK
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M20/9=7*,U"$('3+9;SAK+THP9-XTX(414 0;?LT\C C&#S)E/:3V.&S%@/5
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MPY&-R@%!*6/2'/P%7U#,:@G%&'P\3LXE4V?-1Z%5P608=%-QDCY\&ZPS6T#
M*S,*8%G,%X:[:X"^D.W1?M.J+E<8E<(L9]*<,6>S:<?8V0[N2-T[.N[0]!*%
MA@;K>7$DF-G1O,X3"R6($'<<Y>,P'-Q/9KZ]ZBVA@]R*M='#=Z$(/Q1Q?' 2
M:H) =ZOJD;/%L]$I_H!)^*)F^I4@)MW8"UD81=T8/B:-F\ *T4S-ZJ6QG)KH
M6N-19P#J@%AFJU@5N9HR74B BFTQ.N7^5U'/%KN5/S@U*V]DK(U$;4U@D(Q@
MLX(\PSTF5H9[7[>K?\*A0^/^,7(29;?@;I&D[8B(200AS&^'"6"?!ESC)BR?
ME<54*A"4:77#L]FJPH.(SPX0^""N<TK9-6!1"1A 44I?AMYE-$]=ZI'X!+"G
M13!ZWYRWFHKY+ALO#C_, [)#LP_]I;K(:0Z7\1"S^4,V?^A\9)Y_9JK(3<;9
M&GX:6N"Z+DH3,)0LJE82D*D+H,-K;A8!GX#U7&'_A=?Q96!*+U@6C4>D?R&O
MZAI..G2F$H3O3'&DM\Y)<G6!WS=2VB(VEQH3%\7(.*% ]:W9597SN<@;!2MC
MZ3[/6V^VIGO_F@L*O)0H<2*2GPO?M/=WE1.4S,]R >;XSKN?@+O5JAK\^6L2
M9$ZXS@ZK@=Z2@##_'(]>QME,_(&DX[QA7\_0*'5R< 3"$5,,V5.*;-DZ(FQ)
M%8K" 5)(\HOB/*^=7F88B2$5=8I!'GMYOQ,"VIY-@L3= XFZG6; Z4!>*XSQ
M2%&Z2P7?'8H6D'&:A$M32?!.M=;!WBK,Y/C13/;-AD?P0#=EV#[.^;9?MLIJ
M'>W!M&J0:*LB1=5V[X@R837_&S6"PX/#(XR@S2@SVOX5/0CFGO'HZ/#0?VZ
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MWOYF7M6HL[PPQURA3LU $7[5$B403Z*-C0$HR&O\>B87PX5H>8%A!7\O4H1
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M/3BTXY'IQ8-7&XC$=BP3&M^97UZ#K<,_3<I#ASD.)\&T*'/5R('P\!P&E^*
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M->9%+%.I$0_DA!4A?D*58Q"LM;>M?P35@8I[YNC\-[%'K/OVRDZ]:1!F/Y,
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M#4+?X,[UK?(&'N_R!AIY X]W>0.[O(%=WL N;^ *G\5);Z6\M46[7#XQ.:#
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MC;OA?]=Q+J\YBUY5Y%:=4L)<0M6LWSW Z6_XH'_"'L%]HJ/C>]^_D=NCSR9
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MZHLWW(V+C'O?[U$]-Y9$H)<<"_FXLU)=.NIL3.M'RE)-6TK+ (M#]$)NCZ;
M$A_W;W"VM^0BW7X^MQ1./WWZ%Z?;1GN_SN<IN:#?J3C;WQ ,/_Z+HTE_-@B^
M7#;NWCOF:'HS+;=9Q_T@E/RYW]4QFRLN??&(+2O@JL'[VF/<Q&2:K5RNFHOG
M_[F)X</7;1AWK]TYY(88H&'A;I[&#:L@/),VBS-@H&FBTH[Q_TDYOVF+2^I&
M.W$#:(*TP&Z>SU_Q5T?TWS7>@';DP?_5\)[_QW5OM[6RUTA D?66;WO_ZR]_
M[_ZX6Y_"_UFD"RS-=O1I<-6-I.9<J04T;MNJQO1X5V/:J#$]_I/7F-Z2RKBK
M!]W5@]Y0/>C67H'V$MRE'\!DH%[3UN\_L> TCKQS-6(J15<: C<QJ[:+X,:<
M#=O8&M>+0G6OQY=\;4-EN8WW?H4/L\]^N4ZQ96 A*DJG8]W L,_K:E&40,"D
M,;8O,6YHK'?&LX&^)&3*&WU[H!7?^7(V%PX_^6O2>J]%[/W;H?9.?-SH!&[N
M%/A!FA6^8S\OK-RC!T>/L"'AZ<9(_I]J]AN]O%UFRXWJ<MLE%'][0Q^?W*!/
M^6:,@5#;M[IGMW'P-8V!/COPP;1(UN2:6%3+[/O_#U!+ P04    " "N@)U:
M?1>V7?A#   (V@$ '0   &5A,#(R.# W-3 Q97@T+3E?=6YI=F5R<V4N:'1M
M[7UY;]M(MN__!OP=>'/1C1A0'*_9G#;@+-V3@9/V2YS;F/OP,"B))8D)1:JY
MV-%\^G>VVDA*EMU9.HP']\[$$D463YTZ^_F=I_\X?WUZO+GQ]!\O3U[ _T;X
MGZ?GK\Y/7QX_O<__"]_>EZ^?/OO]Q;^B=^?_.GWYRYUQGE5/HMV=>16=)S-=
M1F_T9?0VGZELP!\,HG>Z2,9WX(?PT[/K_NXHFJEBDF1/(KQTYRBJ]*?JGDJ3
M"7Q4))-I=>?XZ;/CEY^FR3"IHH/MQT_O/X-5GWV)YXUT5NGBSO'/V;"<'WVA
MA\A+_=^]G;W#_Q>=;I]NO]E^M_T/^-]_;O_O=O0FWWX2/7U_O/MP;^\Q7K-S
ML+>WN[.SO[-S\/3^>_OJW^?+?]6' -^8YWQQEGGZZ^]OSOT[WQNK69(NGEQU
M;[JV3/ZC>2F.-'C#[V?5#5I_7XO_;DG^1UY\3++)YL9S-4\JE4:GN<JBYW!E
MH495=+L7M^Q_2_*_X^)O2?XW(?GYR;/3E]'SEZ>G9R<O7KQZ\]LO=W;NT-_O
MSDZ>F[]O^&;WJGP.;Y=D]H-A7E7Y3#Z[3.)JBO?;^0E>]/RM><R%+JIDI%)#
M"[A+2)P/=5DEXP7:W$_/7YB?R>UVMA\>)MF=XV=Y4>27N@ +_\6Q=UGGC3XC
MC[PZ!NOUGXG*)I\2\36N_L_[+(&W+G5T-E7%3(UT310H09=M#Z+3*MYFV_>5
M8[MS\E7NG[_]"Z2S3+$&B?Q+\:G6C[KQPT]U%J^[/SY5H],Z!:T?O:T+4/G/
M\]E,%Z,$_OE,91^[*-9<\GWB^N_>ON_M0YQ0\H504TB%QQZE"!_']58US M@
MOGNC/$W5O(3C:_YUA]AD-5O?$59J2Y]=7$4'"Q]%J5KD=75O4B3QO5D>XQ/A
MK'=*D->_1>_>/O_ECOYT<._QOW=V'FY_F$_N1">GY[_<N6..?N/YS57.DCA.
M]74H(F_PN/D&J1Y7RY;_F;5K(#8[CW>@>?US[0[U]WP0[.W_Z]Z]Z-=$I_&3
MZ$Q-8!_?Z3]KG8V06D?1[_,JR;/R"3[KG1[A']&]>X8I7KSZ'[,X7P_O[LVK
MEB)^@)_)63"?/4O5Z&.TNWT(ZRSS-(EA76?A'>DE?)H\O0]/[5C L-#JX[VA
M'N<%+'U.K^(OZD''FG"AUWVD1Z_[2# FQ_?)#%;KO9MK8OPW.1QM(-^K+**=
M A$4S8N\@IV/JJF&$SI)JF2F*KVY0>&U,E)9'"6X5EW"7_F8KC,FT8#^8O4;
M3>&:X2(JD+_P6O]"?- $+)-H7*=II*H*7A]Y#3Y6\ &LX2(ID1-!>@)O%AFJ
M9;A!L(Q\"*^EB&'-0N8*A!420Y?\BND"/L_!_BFG^64&*P>>3./MZ%6X\&BJ
M\)X+N.<'9OM!E "33G$UA4K@!GBY_79S U;JWG4[^AW^*"[AND&DQA6^X#0I
M7<  _DT;K(EX>01TP3<8ZNI2ZRQ<"G[A;CT@@N#?\/,9OSC0)$[HO3<WD,KP
M5H6>PX[ ,_C2HM:T2TQ5( X<@:FCCBJTV6=8$2PF59<#NC6_\9"VGJ@W3.!9
M0/P\"^X1\7.WOS2G?IWSL(YTW.N4CD?1_ZBTQJ^_EIQL2XV&5]3Q$%:#WLN9
MUSJ*SA=S6/U)H8;)Z"AZHV::7_U-CB^T%\@_\RO\Y@>2S5^'&;W@ND0?HU7!
MQ^_7-@_S-&VC]%%@E$;+[<!W*BOOM8V^Q\A=8'3GQ9/HK8Z)HIYU=_K/_]W<
M6)4,BOQLT)=Y]Z\CU8Q&H3<U+NZ2@ !YMYL;SKWM@UA_5I=)ILLR.@4K)X-W
M-MO^>'?_P<ZCO=V'#Q[N[.T^.MC?Z<]+GZ+B!L87>P#L(S"S[D=GL.DY&4#/
M8>,GFNAP>O)J<^,W8(POR?/?:M-/XAA(4-*+PL9'>P\.!]$_0:Y^2.KHY$)G
MM0:.QP\F0 $P?++H)5A6^2P9D2ETKD?3#,3(A,['"WVATWP^0Q/K?_-,XZU^
M+LH_Z_R(A'.=58O^$/&U2B@2YM/P' S+$NR#"$WE87ZA^_.Z9WE9D0R,^5SL
M'^R#,L#W.]>I:(K]QP]W'CS8W7N\C]'1OKSYRQ3LV"+/@.?1P$#[XE4&=MN,
M_*KH[LL9< (=AS\T"(YJ<^-D-$)F1UFZ!93I!178U0KTY*I0\.:&C07W2'!>
M1W'\HU:8'?^0J#^3'T5][(#Z^+4>3>'5X?8J#C0 LD2_5$"W3.S13EO1#O;?
MX>$^%8%%OZI/3_[=]1^\L$<O?U87)3!R%4D<*U67'%LJ]*1.PZ#:F<[GJ196
M+S<W0$34PQ0T!GS_?)IDBJ-Q& &#GZ?Z N_KW6>P*KX5316(F4*KT53'\%VD
M)H769&9=)M44OL%(GEWG#&.%&%U#5>3=95+ 0^$-HDOQG4?B.Z?H.\N/79@2
MUR#Q2?U)C^I*-P)V\ 78@B 'RQK6?SE-1E,7&VO$Q#8W)"CV?4?#O  $2/HY
MDGDW>DG405/@S,5DO_<(A(O[/3L^P>Q6JN%5*<IR,B/C!OGC>5T4.ALMON3K
M?FT5[[WB7=#H<%CB<HN$X/,W_P*/)XM>)VD*F]PGP^;NJRSZ-9G4($JVS*ON
M[@QV=NC_M^'_>O2RZ*61S%.\S36)QV8VXDE'6,VE3"6<ME:^%=[KOQ\_/#@X
MBB2^5NB+/+V@XLDAR5N4E&DR2ZK/_<P'IN@HRO+LGGVN__K?MT3NDE-[+*?.
M=3'KD6!"KKV #V/1U_AV79Q+*A@8BTW2W3VRV6;P[;2,QD4^PT]/Y@6XK'OT
MW0 _P/@N70AF@/M^U__^ ?[1$V:1\_CY#ILYV:\R-KGT!><9E22)/6F#-A7O
M6X+&F#N3#5$PL!E-3DZ&<L(:6I47<JH,BVQN.![!4!3:B[')1T;GWGW1J.3E
MV3N6-:5PC45(5Q9ZA/DW3,VZ%\KR2O>$(;Z8V(VNSQ&AI.[D"K>[J_D@\ME@
M<Z.##Z@&8 R.2L<M?TA&>':\K.XAUF-5IU4T2HI1/0///QMI.&A)63$YK)G\
MF+U"3R@/K$?G7#S<B](QA#AI,[4@&E^07!?ZPLU5?('/H^W/FC]060:,A*NQ
MMXL5^&NP#+F7U(8T;X<,1U?7[A?FLNT>Z<YUBA?V>UZGL'];I_ MC=)]-DK/
MZF*.M5;].5O6FV)-)?J%]9E5)74)GP,/@82JBXRD&X@:$X@" U-B43VR,?](
MJFE>LS2^+!*LWY-X667$K"E?HZH]JQE0HF<ZH5CA:*JRB7:B>R[LD^4%TM1]
M ;3EXCSZF5Q6LHX73<&;0;%$_!G56:!N+^NY+BZD?L^MPP0SZ3F^7NC']GA'
M\X"/YBLIV8S>@B8<V#^QP3$=2:"6]/@[754IQU_[<XR!'KO;$5%B<R,@18]>
M$D_#3,.YC-%,CG4Y*I(A6V_C/$W9SGY5:7*2[^YNH3C:W."#H^;S=$'GC"PF
MC>9PDBE3/2J6E="M0+HAKZ@("%LFLWFJW;<CQU!(6R<F\1F)CI_T@]KPYD##
M"/3Z)QTWF(HE$QBNM4H;9+/4P(S:-H4=?NJ5,?K9NC;.45ZS7BC@2B;?W=.S
MMUMH]X-\ H:E/%2)B2/@4W%. P^AA-4IT,J:]#9\8(*5F%N*"W4)&T37(NMC
M1(GB1 NMBE)4!*_!I(# I=C?WMUAE\<\,,E&8$BB$0"Z!E>&)MX\3S A99X7
MZZ77>/>&%1Q2V4DTG$=W=^&_?MG<V-G>V?UIZ]H\A9=W75?HF0*1 "X5J=\8
M_*/0@\*SO_UEFU"_P5G=P[,*[U=19+IQ7&_/WZKSMX3;C);@#@)GQ:UW6LER
M%!,Y!J.0O3#^.#R;FQMX.#D)[Y],"3.9@WCP.0\B/6PXWT8%1X1PMX:UK+C'
M&H?,1">#(,HV]N",%%NC:.NJ&/>4[# .46UN #6Q*Z7L4L>ARA8SP&X5+").
M,;T^P@ 7+83#7@W#H)&:OTS@YUE><:N.@HVH"S+!,^H;:J;5GWSY[O6O'TK?
MW]T[BDY8[)[8/=F.?L5LPS\5?%XLHEW8-8Z$9G ;XM*!'Y+J/#^\PSH>F.,P
M5&5BBRY@LSM.SH#B6[2+%.*B$HGJ6@P:Q$F_/ 6_WC[M+]\GHA 0#8M)<J[=
M\"."X3>43C(AX/"KO[BQ4K%RK9V-;C<6I/;_@6,&M :"77=OQTD!&[1B3__D
M6__%\TK2^79;K[.MAU=M*^_=Y@::!U]W-X,SNKEQNYM7[R;X0:]Q6VYP1#O$
M[Q?2GJ@F/^/^17<YG590KBG+H^8[+@R3,L>B!G!VG;RC@E<3#B]KL#[Y4I?Z
MA*5@#DXRGZTG;/6)B1[^@$S4I_U[=!2]FLUTG""5.T4Z.W2)N8B"CL8%\0,W
M1/^W9YT:]:_M:@9OR9Y4!J?QLVUC3S('=_>WHNB:KC^G9=CG+)]$IF+^?K.$
MOB<D6B???M#S?/O!;;[][U"],YKFF FE#W].8XR*8:!S;..<P?G]N: KY*1R
M#/O25-QTQ^Z\U"BN\:.NK'B4MHZ9Z.M"S]6"PE52^-6 AMG<H&B2^74;@07>
M$KZ?J8_R/MX-FU&KUK,D>-BTK9:M3=8R1%E?UN-Q,DKH-T"I.D7"H=DVUYE*
MJX43@8R\,IO#'>+P4S4>(QJ(J#!XP3BII)BL289>Q9J?'>]M1UXNV<L=O^8(
M9']>]MSG56*?DMY63 ;A!K0,Y7R!<7%U%A8.*Z9K>I(3I82H]>F]+(MC#,Y+
M[>T\???^[+B:/KV/_QMY'C[Y0\9=X@I>\>G#<E!+\M(Q74RU#2:(O;=+#RDK
M?@C'$;KO8<0#WJ G5@HEO,29NOY.$-V;GNA-J![Y1.?X9Z^I;LUG1RE;<4PD
M6VHQM\SEWAG.K]C2:!2+.^4<%.DJ5"B@GBN@WDS*RHR-DHV2.6;!2TI.+>6I
M 0=4EC\@6GW_-=@6/4Q.&H:V#/UR3F=I; '<'&P>?*.&:5^8'NR ?; #SMA@
MZF^!%:FW)2T/=NO'*DE+-%2)[9SUC.$%"09*W*!"6UOZ'MK2PI1145-T3)BH
MF$>VM?/XC[C6W'L<R2I:-FMA:EOD<JFG--$8\RD(Z4$$AG'"C.J.@ I,740-
M5 G:M..>1*U(2UZUI;5QL8)B5%.&*L*\0OP@AIH,XD+7W%M>R2PIU7Q>Y+ 1
M=-5Z>]S\5;C7P;=8), B<LFN>PJLC]N^OWS;.>Y5VK.!.]2@[#7V]+J;QG&W
MOI#Y ,B,I>*;&PT8A\!];A%GA51%F0I^58EH$76*6]%VR:_8$W#,5FV*G%Z2
MU0FJZ@(^47.;;^PR@5W9K?OUF?WAGA0?]F57#^7PK"Q7ZJP9#@5CYQYT1UDZ
MM[3BG) )]S</EQ%\WM)0Y/5E%QYL+3.Y^O&"Y^O;,[8KW!70_A1-DXFGEU?Q
M8W!8=\UAO8FR#18B"')_>27]\1),3\HA]Z2\2,IA790L0O'<OS6>FD.9ZX_W
M<-YV$'-@+X(\DI<%_<$QPA(CU)*.E%I,Y9F@<9-P8:R\QEAV [+(]*BU;S"P
M#FUPIYYP'4UN 1T5:S#6DXI13U= ^_4'",;B-%+J[FH$X+*?J(:6#/5L*!"/
M!/K\>&\'!/3.SN[#PT<]>MUUDM.'/4].']XFI[^E=G_@]'B/U/?[+$544 KV
MX)P/8[))ZXL=K1'FO$TW2! *]"!1N@O)G#HW?B[YO+I"#<Z5KR:#R UK0PU&
M0T^2B-BH2PS$T9DVQ6AD3#V7VB[]:9X4RC2JVE]($UL?"+)W%4&Z6,CEFMO,
M]+49Y5I3U]9?23"?[>93UUB6PQU ?4T*##O<D^$18$)7>OE$MD/ON:0A1 ,:
M_6>_Q#EG'=_.58Q%+:( MW<.<72E^= J0?F\2X&N/SFM,0W-R6>D:-0<??:7
M7YC0%[Y+>@@VYO)A<%<,I5R?B;X%X\@!O2FE=K>CE6SR-V2-*]^X:_BHM\F]
MWL^]*_:SF\/[M\D_WDG>__%.\H^WR0>WF]S_33[\\3:YU_OYX,?;SQ_OT#[\
M\3:YU_OYZ-:0_EHGN9%M^/8D6<T9C]<ZZ?W;PZ^]37\M!'2>XZ2@=43R%0?R
M;\>=G9M]GP*RQ]][7!QKSFGL.DVDD@#>.Q/C7MZ&W,/."G#UHC\P)\ I @]M
M%[LI70; QUJW<Q;R8:4LE@I#^-K:.2D^06!!3C2IS""VE=[=>D)&+XGY,/JM
M5CA33/>I@X'1[)HI) ><@!L],>\=,T#L7>YGO1^Y+[8$0Q_O93^-JL4\Q**T
M7Q'KW+5_WH]F>5%-U 3^-4]U/-%;KG_,W6^4-X>^F%EM<51JK,M%_(B>-=0:
M_GOD9MZ<F(%XI>!9=,!8_YID< ZQB.E5%H/ZKO("9SQ]?<JX7)^?VVOF_FZX
M$E&0J 6;M2+XF9<0!%I>8=)TO@R^0#/KM;.]U]*[J,<Q'[+25EA:&&-7NI]D
MH8IV]UA):WHHZ?.__I;MUPJ>(J]VPU5:FR.ZVL:\R5+W;K@#-Z7ZEWZ?[XCT
M^]^2]-:"_=XE_E?7*X^QZGJ.\T[?:M@/'NW9'PV*Q4,GXXK[Z/S!<159PIJ
M.@8\\4CHH(JD1)/6VKS:CCS-"T1]HFGH6%PC$.(Y%=V =9(AZ$>>F:*;UIPZ
M:AWVNKYQ5JPI%(/KP9^>3*-,3_**._(($X5:EKT/N?5I$,G,#/SY@J9HC!,L
M"Z/!O752N<J?<%HO+*DN*AR,07@P'VIX6S 0^/5,+^D<#JE#W=*KZHK@<3TQ
M]K&LZ@6A,K/39/BAL.=B8%J^&AV"YLHXU]R!SO@OTC#B^$4(REC0R&)S-T*W
M/40+-Q[[Y#HN9FY">SC):H)='MHGZ;@G^['OCJ[/_D-=76K!* J*+,U!PK,
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M-=N^MRV4&77-X79[U]:"'?U>:VHT;LCAYV.4%J3QB,IZEH7@^BAC&Q;)H'7
M!IL;<5*.L._.LU_^LG19RL#$DA3NP6.SL+OJ)<Y9'A44RG3QNU@CIW49^0C"
MX,61<'-Y8IOW5/@<WRF5.@A@;NPO'* &23%\#\\L]#U9]>8&O9F7C@ZC@=3(
M5-8EYO6C"<9=D5 YV7OT+]$ 2*S2FV88Q"T=A9817);136#CE< FEF,Q$@.!
MV&MN%D%RSW0,#'FD#NLDKSE@ ;M: :%+WA 1!U1?8 2]*.!&DMM3(B28Q[KP
M]_0**YX?C9E3:]ML;C0/ MOX0)!T(9;@<N%^M5R/KB/6-S?6E^M_<!8M&)6(
M"K\4TKHCOF13HN:>+!M(88Y?(+G;&O.+6S\#IR.;1D^W,Q?L^F<V>?IQBD^D
M5@W$K<Y*JM(9U86G@>?.10NJS +2QIKK?#JTRM7^5)?#9O7', =&;MYTNY%M
M"KE #4%GNA<*$_\BIB@.N-S-,:&G'I4%G[<]-90H%TF.):\>X5P.GO8ZSN.)
M7NT.&MK"7Y<TQ9S2?E184\\)=:"86)<]R5#CHV#$F.D,U\'?E#TA]#K)I$<]
M3R8]NDTF?9,0_,M/(SVOP-,V: 8*)> EV>QK'6$J8D8K(\[GU%$!]EF5S*4L
M7BRR.49:R)"P\XYMK7%SY!595V$NP!.R[$"PY1:&X5IJI"IU.AY0_"?%H TA
M)7@K-_7,+JR[U!CD6B041F"/E+5R;O"2HAY71=;I]-M%H@:"*WBM=GIUU; ^
MR58F)RO1_NS.=EV?T-N"3O1#0%Z!9I%QI#9'4-)L(B"5"F5"B7/EVQ.J/'1*
MB<HI6Y+I[V)H"-#,W39,95 $.L/*Y03M&VHM]Y*,SO'D57:M"[UD6- 'SSPW
MR\*D06*BF\)39WP^>K+)^VL4M-B=AAMH(:>=Q]:L;5UOC]%PPYN5K0V'5WU_
MO'^M'8\Z-SSP/&(]PB V2%B29' 7]@^T&-6R%(J/$L *Y8F<:V.62HD,AYDI
MCS3(ETP5#&,0 &;L%;K);_+"7HU5J7)E;I:ITC('=BQK[>BVN>''WG !-IC+
M=C^C)_ -R&!@VTT!JV>:1*1I<F]+8Z%"V4&&-D=T0%3Z>XK4<I1*!$6)'] (
M%'8F)( CT]9813,:L)65*]Q8Z38;]N1P/GU&(, \I5(*8CO&5)X9C9V,686S
M\C?5%>9 F$8ZV#4P,\RL]:O#XV%T<'-#SI*,:BS%:.3H >T*[5*P!#E'=@5'
M7EC<%O@B;R=96<$SI938)HC@Q8PK0B=?^Q>6'&TP+^1_ _R8E)V>Z]514'G-
M\!VI1$26=>0O*Z^K$CNA26X0Y_KED@E9:ZY(TN[8C181$!KCN^91?8+-/6PU
M[G6.7;4\-O#Y&]F!!+VXK&CQ4?S/BI.,FD<IO!"(%A^@K2)C6B3*YD;;,Q]$
M[ 2QK,QB+^'I0F9Y%LHKUQI-H0O7<DV8@O:*@9EN;M=,AP5C/BCS[,L.&B>]
M^[V;0M,EDKC[J#&8?M *AAH%91R30&-3,B)-#5P>!S>[W[LA"9IO;;YO/':H
M7;R1'L8U0;2?8-?%J:U%"[.!&'1VQ=[+ -ILQ&,)C1*,MI7U&%1P(KDXPX/,
M3/Q[%#Z8] RKFCI5G;2:X (,,F-YC7./J^N)BGM@CODJ*>@S5Z,%UK#94)6)
M31Z/U#RI0CR!1E"Y)]1["-0[I6COF[S23RB%3 0"T\N#;2>*57J"BHH0G]HP
MB9TG@S.(&95L@(CD$Q(H43FN7/!'QT"@J@(8AX%_J.03KJ]TPG"%16]]C8'9
M?1\1@'K"_*0%I:=QO1C5:"Z9#W.[70]_:'YE)(&EY"#\T\2Q"Y T25\2#'Y5
MXH->SDEHLSC:3E(),P+-V@I$@<E=-+TWJE]5M0E@F3Y%1&]-$WTA4AW4-F%U
MMC!D"65 S=4P29..7%?S>4?RB=^]Y Q+M.-C=.TH )ADU*PTD#X0A,<HN'D2
M_"]SH_778== ;^)E-,$#J*U%$6LXB^"8LPO(!R<IHK$=7>"9]T5';*'1?H4-
M1V3=7]"J\89E/43+NL*;&5QDNFR85(4I$#(=GERN7!ZU"&DZG$K_XX"87I>H
M^:AA%=F[TACRBNS^"TP/H+K&)V.8$"FG*RR)+-DDL(3"2Z7%,%8S-=$#O@B]
M?ZZX"$?>NZ<<7>DGB'5D[;:6V6S1_1I57%+=E\'!LD09>)4>S$.,)1T2%'[M
MC0F9<HH=N0FC$<[C<F4I?1&4:^2-'O<\;_3X-F_T317TP^BMQL)=V&=5F3;L
MS8WW>.HJRNCV"<^RC>&#=6T&HA2EX((+2^>HAW2,YN8$S;N"<#5B#L!0FMM&
MG50,*C"Q(G=,^/\Q/+'@EM91/IOI8J0[P -L,P.CUDK7,7F"J%%'HD]'R462
M1C1;KI1;,IXY.314**U]<($@A63L#'<[LC[[YOWMM786R;CPX(\D0EA1-,^T
M''4A[4M/<NF3M&S8_HBNB[\L:HY 9*R-<?MX7AH:-Z@M&_W?80U5N_JU%1:7
M@TKK/"G+?)2XPJ3A JT8WF"J\Y6",3!UN,C#Y!FRA?1I<0QTY#M=DI"E9;KZ
M+;)7A@FWS!/ >].B;>#A^V^.MZ7UR.@X@XYE7A86(XF'@1DI-[#/5L;"XY/G
MG2KI8J9(9>Q;GZ$#V@]^WN^25$#+29['6'((VT.U:4):KS[6&<P4=I1/7>;'
M8FWPSOM=%Q8VH9F+-^!-8CAVU6^AL8W'86!1$Z@;H[:>M;@4!.J$,2NJZA^K
MU+K+L,H96JFX]'R6E#() [R&I$RU(E9TKR1A5/>V1 Z.L^&5(.#RHO*A(,*J
ML(*J&N:J8-^@6=S^?(HQ5^W?L11\4E.#7-18E@![4:0+3AR8-T\1UX1T:O>A
MECY$X61C[2Z<A],3)CXP3.RWS[EAL1U.7&&,D6857X*R4G:9A-6 I-U8<"40
M)0PEF$1N2EMO.LLSO0!OCU@6*"YL$X9Y3"5K7A?<.^P%F8!/0/ZJPCUY._K+
M=^C']K83*Z@%%,LH 6C! UN7 S<,A]Q'>\Z'RE[)0H#/EKT:S1O<]N;$4=SS
M,0UN0A9R 9(E?<!F?WXS/J<K+N\(+S1QFEQTHZ'TUEHF^K$36\SL8@THV4:I
M2F8H?@3^2X**'++H"9?8N/PPQ"*<8VV/Z2<9>ADFK$"3@IK8&L5(Y1G<>I3D
M=9EB_?%8U:D@MW+U@JTQ"]-8-L;+P1!8!];"]ZC.%]RYATM2G"9^;M&/@[Q'
M1S\7%T @_W=U-'N23S8S;LV)S7@2&<UCA2>ZJGY@:]@%,V=XG'RB6"-" 9!C
M!:9AM0CL$G-YB:(>[/DTO^1Z%,YEC6KQFX!&'[5I50*SG[$G^5,*VY.PR#'H
MC]$[;UG\)*LSP%28)G ^;;RS*I*1U #:;"":W-(M.!'H[K)/V?)'2U@IUFER
MP669G2:FW[([K&G6%N-=L.FE"!9Y$/T)$AB8+.6M)L2B=&&,M2UO_QW:EO-*
M0I. ()MY%\S]I(6'4WA+6'PYKMQ15X)59R4U'X&>8>7B7CZQLW39W6FTT7FV
ML5CIN#R:XL<U+=W8%$BBU)KJ]T'D85>#5UIH&S*8IN!2QHD,B%OR6UK=7 DP
ML/PL:'/Q1&Y/I.+C*T2B9!+;DC$L@.Y5%=CN#M9H-L!22+U:'#;CNLL'CIE=
MN+[3^[/-YAZ^GBT6Q+P$B()4%=Z'<'*5#(M#F>)^YXVQ&_!CKGUO&PT!;^(#
M'(\1HZ<UT7,QHM;U.GW9[G:X4XI&1M@TP!$Q-KZ3C)H*C3 J:Y!&7+UD@HWM
MPDL?T\&K:0$QDZ"K+*W?IL(&;G6TN>&FJ!K(;2]+W\1^MG6ZV!4]I9:BW,C.
M+@O/Z&4^N;8=S%HHS69'B0U2X,!4(S5SL:"ADDI,BZLJG5BB\FNK3*4+*6Y:
M&Y9H<V.U$I40)M@EG8IC&:8*/ [U1KDUD/J(CT#U10:+'9GWHU;I3.PTPD0?
M*6R^)J/+U$0BZS T"W[:>-I1!'9H5X$2\QI'9W##TX57=65IV&RZ]#D0VT-L
MSZY3_OA77:I)4.,A)6..C/8+8]$BTJ1L)&T2<"M6ON5<,QJ<@J0R9JOSX-#2
MLU0LZ]D,(4S8?N'.QSEFL6,D+;= ]AWC8)TLYNY.S].8NSNW><QO,I2CE?>Q
M4F^F06& 5(X3%B,#6UM!.34N[!L8Q],4>0ZH\:#(R+PW'N@@*!T!V6)O@Y$+
MXQ%DDX&]#;4.V2@7N;F2NL.(CQ]_IZJA4@) &,BB )F*$03$3KPT%?(8%\I&
M[2(;6\G1W7V$8"Z49FG 4O3(;3UODV."UH4R,#2-UB 9"/#T_?%#:A#B:3]F
M&#//!:'D0SG-ZS0.QH6H2VI[8#Q(H:@W^24IP%]E"ZA\T@_JTDB5Y]*=)V^\
M)#,Y</7JY0C4?)!"MZ>.H_6%5WIPH:\N8>L),?="8GJ8][,\=E 9'_($/W+?
M!J$LSZYF*PIU"#R(&[? 0"YQ6=Y5+N^+7.INBQN4%Q.5&=AZG#)/901D@Z=H
MQ<0T\P5^UY<MV"=8>8ZS4XS0RFH7KF_4!G)K]2"LL .+NJK4:&I=4<]LI4@T
MDI^BE#0UW93A4202;J+ U2WEQV,<;'_I+\05P8G\]^KX>K(/.*KECT2:G>HY
M:NO2S.C 04.@G&,A= D6T9P=(Y$OW,4P<GEM4[":RE^((^O:1.WO)"PVB.Y2
MTR$'@[<:W9J8)2CJ>35:](76."_E';C1&D&!P+H@N#$SV81L$VX) @[/$BK6
M11%1<'$P06Q1%  IJ1FMR9766JYE_ 'D;I V.7J8L*-S+*>Q-:]=LO\^CY*B
MHRBN?L>*I ($NTQQ3>-<@'^XY@5SB5.M4I"%-K;OUN7FL=FL,_S_@FY49Q(W
M=>F*!&R$#_FP+WN/(UE>7G"+(YFME#UKU7EP+*Q1O-P7&N HD1<)QJG@U1?$
M:JZUSNI22C\'I>A +Q?SIT8ZC&7UA"B/MJ[NVL<(;)J76 XI2'OX3_*O*&#,
M@ @"PX$!,-9\)L0EI>M\U8#S:O 5P;Z;<D9CEU#5NPT*F3(Q5\=NIB[%6+EC
MLH-M%J[41R[Z6^$#4-H=4XBP"O$&\DR&:&QN!!@!U--1:#NSR2).7;AB0C]*
MR?DRS&E3BK3QV-E,QV KZW2Q';T+_;5.-VW0B->CDVA[$KDA8.B28XR)BR\E
M]:PB=<&V2,/B5G/!W;;O-'# +_E(L%3Q*5+)0WZRJ7!:AHT;UJ4Q%D$L8"D=
M\[,6KB6"N>$>_D(@9_A;FX.U=]TZVMR8PK(O3'"7_/$6"0CCQF0T%+4H!(W5
MS''>\)\6XD0#.('7Z8T5LETU>8!H(-R+FVZZ((+^",0J+]WT(+\'V(YLD<?A
M[USAID?F1E<&)34H18@%-1<!B[3F+@_"JIAFSZPW9Y" E@M_J$)/PI>[6&EY
MZ@Q-Z]]Z![A=#KED TAJ4#@I=X%GQCIQMRD]&ZSI\YJL"L(M"1".K(.O*Q$,
M^V."T:,E"Q/E36D=,.P8AT2&9PVB=O[%ATJVV1=9/C6U7TXQ@&12V$N[Y'G0
M)]!@K+VN'1T6B'+-SWC<V<J,R0[&L?2B^;A>%!@^T?K">0>"F&,0/?TT1B-I
M9<25L6%-C"!H/[/3[;C"'V45;!<')IUR,EW@S6I?OW0^+]H,/J21Q#)>6(E#
M*O8YEN=0W8V_1GM_4Z3)K.G73P EJKI'!:]KY4)V^YX+V;W-A7Q]88+%N$^?
M'7>E^X=8?,Q&11/R-2&IDDG2T\O&7FM(<W!ODO'41&8*.L/,+4=M8/UNVBI9
MA**Q&M49GAQ<F1I?'K9#?31 @YY"<5*97UQ(3"\GX!,%[%1@H3A=#&8CM;R0
MO2:?V)9;^4")<R-_4<8_R^O,^U6?TBN8:L-"WA/.G&]NO'9AZ?Z\I9L<OQ3>
MIFEQ-8I HKM^H4@(I&EZ+@^WN.NPE.EO'1@C<@,[4!BNIZ+5!H)).-FT5)B-
M*= IK2W\C8G?NQ?" HGMZ ^+$+KJ)EAT2+ Z'"1'1SJ[AY4AD8^2OKQB$G-I
M5(LU)'-C-J]2Y[NR_#&>[U(B,"BW#*'OB9U *:#S%EA-Z,3)H 3*)^@KB'2%
M=*12&7R0019KUMA8KX?J>Z0$B!M>,=Z3D&UG8A_FD4N0G4Q-F'77O234=G12
MV2I<5Y2_)-(A_&0==W-B[/GRLBU^\5]P)'O",KO+:OPQOIX+@TBA@8_ 3L?0
MUD/"F:M'C%#K),+2_A8_EF:#YGEET7@LU[0"!K:((AB&K#',3DYJX3D2_\;_
MD*]9&F,@TQ6_BV,R_[D&]#-\ CBI972IL>9,"IW;(\.\R(M:-$<WTH%I R#C
M@I8DNX^(V; 9V(O>6:JL0*CDVE0^)Q[V1<[1E6E2Q"[L9?R_TC5=M :YH)O<
MX6*AU+8^EA=7939!H\[=S$Q(:3KN/3D_/NC!(WK!MUPH*@..SEV+HJT."6C<
M'S/GZ:^_OSGW;WVO3/ZC^?Y'$7TP5K,D73Q9_318[W\_?GAP< 2TP5L>[S:Q
M#06Z%;@\JSB]UABT+B Z15[/HU&:F"J'CK:-W^H$6U REPWW3% X<&^3\F-)
M6?3GY$F4T6]TJNB1SQF# 77',Y5]I&#Y;_30Y_30,KK+A?Y< 51H,4]$=?Z<
MQBC6W!)^+NB#K;Z<C2_%$'O $*\:53W8F?-9^<%#BI8ZW$:K-\(?B$@N@C/O
MMR6W1P#=;N[JS=WO..U>_2&%*$V&#/OQ/F!-@11EJM&?=5):-*]&!9)IA^5S
MGL^3K#52J]7S6ZJQ=O!C_6KOM(KK<?2,P,?P-?T(S.;&.X=^VA]%M:Q_A7H@
MT*K1TM$IT'7 =5RGR0AM<2,!@2Z/"65[4[R&EJ0V'UC;[NUF>>?F1F_K.T-*
MXUBSTA_<24?1M69YDU,%Q<*FT)KRMS6^6\QK<QM_E_I25[&WG*"M/NP 1@+G
M*34'L 3(0\ONU-&1;?(X<O_-C?9D%TOW%EZR?<H$=PTT\H05KQ=\<(#(C:;]
MYH[[OTD5EI@VRD8:%P1N5:-K3[RL]H*YY3= /FJ'JFFXE;B'WD# +S+>JB^\
MO-_B97%=,?/+@WEU4,_'2ET&C94N^L2 <@QIRH.W@PWJ";W62@+N]3T)N'>;
M!/PVY=38WTVC'#P[10R:=_70SN\"LE$PRP%!*ND9:(R]$31B"0$VL(BO@,]A
M@VD]<. !!:Z#K\$/KV6@8R>\K"L^=+-T\I;!T3\)0Z7<H42VPA:WWC.P?%.V
M\LMZ@RDB+1#E3D",9<\P(VSQ8PZ^1"_M])[G5S[OBM*0ONS9 [-GCE$##=EE
M%;?1I:ES!"EF2KB-AXV'M[-^.R"\?79SKFY?J/RP=3*H=+D$P^^2K!*0!MQC
M<H%%S!8@R>OXT'%?B('%W93H;>35I'.#[&6<'):793*DZF#WN>V<:#5R#'Q(
M,[_4@GB3:CDD3TGI8X4> ;;VE)IM;6SDX *+V,?UE-^39>Y!ZF)?(,:&7,T;
M 7H02"1_CC]2GZ1ZW^'I#@0;@J!X#4#DR :"X0 T@'L3B0<$'?]TW' T)CA1
MF>G5,E6[)A+MQ)FO>5)@*PYD30E3?YR2"40E\ZA&[2>\.ZTJFV4XZ+W39H]#
M-ITA9BSVA('"KVT?MFE2^J@7IC.)^C&H;RC3K;DLC+LHHQK5,$/2I@C8"6RL
MYG,LB7(C F2_>6^H%I+O2Y!^6L=<-%MH3$^6-K$.[F&3%V_& -'5^^_&Q/>0
M 79W0@X04)H@TM;:WQ3_FTX_FPVXD3'(DO:51G" #3D&N<2VZ( *J^^9V6?F
M0PO-RG;KR(#24=$+X9Z4V!HD&(2F38A#-^2\!+$26I'%46X%)&R;FH=B:\H8
M>A,]V&W'%KFD@.8N51Y^"X,!NZ$9*RU4<$)@R^C,2C(G-WC3,C7,5,$W43F1
MQV2+7/ZG="$GC&9T ]8.EC_]9KD/4H9A\N-ZN8^H._71$1Q#D'*9O7JA9"!8
ML^9R<X,+C\*G&6HMS9WUAU7;45L9T,- KL:-!2E/*4S3VH8V3Q!W'","+F_+
MP&^%,Q_I["(I\HSPSBF,6GFP0TW\PR[$R8'Y(R\6_J1!-WQ T!D9L?I6#:VU
M_?O+FR$IQ-Z%? ?_GDBA07. G $V)GT2E@&Y:'9X34-%4:'./<MX<#YQ^P=4
M'^4T$LDW#U,<^WK<2 D#IVJQ*N.<T72U[HZO\XH:'2<MB2+3V4R0WIMSW='!
MZ+ .=&EG'-_GV<9A.*>S*(I>0882T%FC40J>JN:"IL%G8_,^6]N[&"3\O2*,
MWM#"L@&^%1!$C<K]+BUB)I6$6J2_,(L(0?4'-<FQ96#FUMLY812;&9CB%D1(
M0"H/=:,RT(PJ,2+'4_9H,'D00];_E,XQ1M5C),PZA=W49*#V*3G]EB'T&H$,
ME&_!'#&& Z$D7F(S^Z::#Y[,OEM/&(^2S"\$U SDL33GDZ36!<$I<B\ZRE55
M5.&!C:28KI?C3"EG^8[IP;,75Q'$PD#X0^CO&K?1Y::W6JYEET70,?Y//)D.
M[O6#[;@D/L=4[ S_]':4D6W(VL1.^D%DP(N-(2YI5NFSIVK>GFSF6@G5_;XG
M5/=O$ZK?)J$*$C95K'I4U24^P :V?34K9T\(P/C2V>KK2!>J]ELB7U;E\FSI
M&[7VH./J Y'T0U!07O2-GN05OA8[*"%-N*7*8''@5W8*')=C@?2TT-52%&1=
MGRMZM203;?<Y3LIA#1;TC"?]N1OZ3?)+JIN#Z3E+ YH4 C4@QYC,F-4SO^O%
M%CB9)[<:=M9]-XLW@\$P]XK4+<9.5[! ],"H#QCS*9*I[ N/41[76!-D6YA\
M8M08)-C6Y\X*\7]V@]/<%V(^7&K:4ZOK#'O*D5P>BX;@%-;I3/.RY&C=\F&*
M/>-$3.\^?7;\ GOZ*@];OSW^2OHE;3.Q-#-+D/EMC:6+C1Z9J%R4E9Y%7BO4
MAQH<V3@9&>?_GPD(O$\)%9R3Y!*8+;8VZ&AP/PW^.-82!!W@FLN<W.$F:%9#
ML79LH(=T)?Q@RUVY>1'^26.T":C-O*$R;>NV_MM5C/L:,>.DQ$CWJ7>?\JLO
M/^'>4@TP3TY:6./D2(++= K#*A$B-<8>7#B.>\7+1!I&^T$BX$A.0EX%A6>+
MHGEX#$42VXA(_BPD.&DJ]:AMRA#F>>T9B%O.:Q2CT,%G^*75 ?(71H;P_*2F
M_=?4!/DS/5MI\>8H/#<3@FQ3'\1",&NU=$7ZF4TR';T$)L[([=.A(8[ P-,_
MP!9BGK#&$(LR08H<)I70GB0.Q]RI=H'R;2(^,7]T!9+$&L(X:$Q=(HT''APA
M-14L;=%&X/ND7S EG,&3X+:-DGI=#\-%YP WV4M2"9E&Q$,ET[NE-DKW<W2'
M:RW;VP$[S.'B4$,M1?'[PQPG-#,T21'* H? N+H!+<K1MT'(52*<!*:#ZZHQ
MD6:G+V6.H+F=Z9A"V0K^Y*QEVP1M5$6H4C'[Y# "7*<;>)#1I2(01K@#>8 F
MS\+)8N7.NG]_YO3& \P=:,D]86;<WBI/=8'VVP"3LB,MU8T5O+U3:;+;E#BT
M<KTSY4=[E>GHC';6[8K47GC<$8J8AA_8G<!W[8AP2QJ7*0*(9NAV;G5/=LH7
M.[M(IS$WA"LJKNB/P'FIS!%KH!)_U'J.1]N^-]<< KO$--FTH&1VI4?3+!E1
M!:2UY[SQ&KZ5YV**;OH&WT>*HK#6UOB'OKABEQ#+((FQ+T ^HM'IC+UY#<)D
M1,&M3*=@+?S11CRQ<@?8-,F4A0 JS!?^FPW,B%A9@46Q83LV%)5\0OV?=X"D
M#("\!"=#+W:)@GP-E6]L5[I>QMS"M4/XD&Z+IE$_^/ 5&XR>3Q-L0*-OTL8(
M729[U#BB3K]XV NBZI@M?$@Q5S>UI-O:>$02ZQF;&EP,Z6@;U,$5ZV%?M)4O
M _>B7[$:/GJM/F@T3OHC <\EP-YX0?1H$<J+$$":7: T?@;+?0SX.E55)@YN
MG3AXA)XJ]K;0W)M2:^P> (V)L1SND;G("7R6!X@3"GP)BR,0;^S:G<T55[6@
M@A<Q$F"H;6YT@*AEJB+_#(O(<::1ZTH8IWD.[KF&.TW_K$'2#Z(QVH>DYBL:
MV=. IR(4J=2\E<TV*_'1ZV*6)VE/V+TM@O!/:V>YW13;&?M$R Z"O<6(AE$P
M 1 _]9!@<2TQ%=.1 R0LV-A,<ZYV>#U++2\)1N%+KAWQ5:25A[QX-S6 33CQ
MR!_2!+&!K5\S]7 . )\AY!<F71/KBF))F*<QY:0F-H,%':BB4!(BXJ)7K,8)
M!YU205M0Q<;]"=O1^WENRO#*NK35NYFDQ=B&0"5WQDJ."XS\Q$2E9S@BH$BH
MQCTU<:Z@8HX5<\\JN=8J-#CH>Z'!P6VAP3<U!_:CD[2R0]M.0'K$!F5E<\-D
M'M'H[Y.=X'O=(T0S04^ AP92C_",1RB(]*69EA1CJ:^4=D9WB+@S8,T+OG_F
M_"?E*,W> /9^+/S?MN&'%(VLJO0$C0*7NNI?D6NX0P8\<ZB=YH@1"21)T8$+
MXBKDFOH!*9S<56,V?,YS!C&KL<J!@SU?YL YMXW*^#RMUANR4W\BUKL+?@)R
MKFWX:'&;R7!Z42HJUJ"1:_YMQ,"QG2.W6[".:#Z(3FQ_'HJ'=P@_/.J3QV8A
MU] [I_X6+\KDI35G8+Q2LTD<@XE.T:I4SZ?H3&7U;(@]'V/UR?Y;5Z/MK>;$
MD4;NRQ<P)D^/0;&:G2AN^@A W"A*P0L@6[F4[9!C(N4(81^"*1^Q!<\X(&<D
MP7/"39$R+CN1JZ)S%<3@PFJLEB,!RBB^CQ3B6_ -?4)ZH\?D.0UZMDAE6A>;
ME,(18M0NZ&XNSPOJ_>RX'U:8'?4S K!N:\3Y)DS"GIQD;-1X3U).*BA)S.E/
M"%Q5IHMP8$V3T!TSMX #:<!8RO$!FC473IKS&;P;37"FJVD>EUR[LNKNHVEN
MTOSDIYHR=;X!1@XH$9T@NNTXJ<+T MYL"C:S#WN(Z]&P/#B=^2PI2]..:IU+
MA%>]T,4"61#9DTZT=] 'T1_Z.;KR>8@O,YO5F5D=YZW]<0/F'8-.%7F[TN"H
M4>RE^8[BVZ.(&2Z\JD,A.8%-%!<N5F.)KU61)AX\O<8H=T]XFIICGBVPOM15
M;C W"5TZ2YX,J406Q.3Y9QY199LH^D]=>R1K_>J0G)'1+_6P3"J,N6784+*Y
M@3 JW.]H-8)\1" K=N)F#9S=GR[W/=D&$)OQ9R"_4R[PG-(J+1'2#+32*.SQ
MP++P1SS%./A1]Z-H*055 '' #:N1S<I )**Q.':JE3\OYWEO&B+W9>M(87LF
MCB@&D7UE78S5B!4UI]SM5'O\:,O?] $-S3.ZO"V1K-)M:OU4E57T,<LO,YK@
MZ [BX.OQD2UQNQ87$5F24@;X]0="Z4"8@U3?+!\B2! +M7>OW_D:D+6?QF*Y
M(L\P8QHHPD#/!UQ""=1E#.+;T$1F6L'F1FAIRRI,@1E_3$.X:5L,=\4:MU15
M'0:XK0QV'!A=R8!4M' 5!_K:.>M+- 1GAAK:@>IUC;O6C?9TJ Q/[1B_Z@V8
M%3*!NS'216:2!&*%@_QM^UN=]=$(U$4,@ITC7?#!2=G(T&K3[6(</GD"^45D
MK-)@1S->5TQ"(]HH?S&D"D5\H QD]HM&_<_M1"".1R#(7R'9$8:0MJA;+FTB
MJ"/^1-7N6IW0N@L'V>#L*02W)*GJI7G<).@JD5&G0A[_[/K4:3M: R]D0C2R
M2Q=JM:<<&) H*^37>]ZR/343MJR3QWD;?O; RRH)]2VB&Q$=MX)GD 8E8MBT
M+FP(E@5RKGG,$$?EM22(><IK1G?(P;%^4=OF),&.DVEB2)Z!43P@LXJ*Q4C)
M@4,+JN5(:05L.Z\FWLG--7?+7Y"SA@AQ3;7<$HKH?+NU?#8E'7KC-+TPL,..
M1'-W:^V.6[0LN1],D:^5VCOL>VKO\#:U]TU"^"SC*)M?864Y 7YUQGDV-RB,
MY(4OF]()2Y?A6S$HN9 JT!X<D#=:XLP"/N^Q4EQS+:2;O*!3ESG[>:).T<J@
MDYC>7M0)__GI>D&G)>^\,@85WM1&ZM8-0C6A0?L<A/)3)(?1R9Q&1G[J458$
MSXV2U](EUT.:V7E^P2CO+B5/7(8X6IT@]LZ,[;LNU<PD[01^B6K&^I=6]CGG
M 3?N^"FV_G#0LE%&*"9M<ST*M"59\RZ/1S2#/R[20+*MA&/K">_L;8<S=*=2
M5]D&+2 5L 2E;#W"-MHUC/_8,]2D?:)H FY8*Q'+T@BTI &SI3QB4$<H'F!"
M^!380V<@FU6)3@F&2 Q[@OHC)\^A^P4@EOTLH3G ^>FF.": GNW$>4'X:E44
M6"*-)*/.):R<IV8DR\6(,(QZB887Z4R#$8:AF_&@"UG$Q5_4I8,0Q24P/DDG
MINC *X9-M"W+#A!R.<DL00:+BDN=9D6 E4NHV@UHP &<*&FQFJD%-JCKC]3E
MX8T944G!6:-QZ^%(',,Q(40M_86O,$WF/>&A0R/SIEKA,>0#9I-JF<(GM )$
MR$O40Y%GZ4+:NK,+G=%\3:JVUQG'H]&<#>QW,W:>&M7GA4"&.NY@<+7EU5X8
M'NQ?3="#;88*6/^ 12O.5ZNPH(V_8\K*JVE82"(,+X'$IE49(@FOA 4P@4B!
MHS4\85! 3 VESN>IML*'6M-Q%"4X@,H]$>Q?OHW_P%A5:HAE-@X*-F[#Y7/@
MRCP<[X@S[B36Z V%,4C',B- L&&!2B!A(IPR;HL'S":YAW346L =\@ZJTTK"
MV.E*&DKQZ1(BVD:"]:@8_24BTBF5L8*F?\',V>!*XA8";O\T+G@7N-5&%ZD1
MQG 9=+@-[4%$\8XBL0/-J5-4KQK4%"=D6F>"VDW,AWQ$NLD BC7JM,[]6Y?4
M/PZ[*$-*_7.( 2#0@M@@A3!R:,>;J9H.JH,:Y@H]Q2E+%WQ2%#;'8#R7S F+
M2(=E;6GJVU>-)--RR<VA9[]N>DIH]C%53:4JDTM%>-A#XCW+EINU<E5"@$:F
M!A\ 9H_F"N$"M!P]E_^4%\MS[ X2<F.BQ&:0FD:D;M#?P;JS!^_0=@O-P\JC
M65(VZ%=$<5X/0:(.T=1H/E<&*;E-]Y_Y+&\"T#5 ^4*/O[5QUWA!7@?=+\M-
MTYR;Q;HVF?KC<J\5\G_0]Y#_@]N0_[?2.RL/O:=9-C?65"VK?.3KZ9>H2[VP
M"/FZ^B7J5"^;&]]8OUQ/S.,3GO[Z^YMS>WQ('%@YX*2 6<?3^WCY,0G;9\?+
MU-%Z]\Q@X[JTEIH-DTG-D!K^T[KUV!+%L-X2#"G"!VUCM/.K*<!HE?[C?H8?
M30$^.[X;,#\[.V.LXQ 0,3=38+A@&A4*T>CZ0P2B0(&%<)D%)$E*4FF,?"'R
MCX*;J1XC%$^*'ADUE%"]'(*(;7UE:IR?/#M]&3U_>7IZ=O+BQ:LWO_UR9^<.
M_?WN[.2Y^?N&*Q$[(\G:=@9^=IG$U13OM_,3,-'Y6_.8"^Q@'ZG4K!WNLN1E
M\ 5>F)_-58S'V=D):!:%/T2ZV^?N'?YT%#6?Q3]V C2Z^_MXS%5"[[1*MYX\
MO7_^XMA[ZE46F7O<SD_A8M@F@S=_]?JWZ-W;Y[_<T9\.[CW^]\[.[O:'^>1.
M=')Z_LL=2_RI1OU&Y)I_<L3;@[_<KEYW;1U4M;<^//PIN#$0^_[Y6SBNQ#-_
M:R:]5R;_T;R<;\.+2YGNX4X'T\V2.$[UG>-3RL2^]2;<TU32Z,0!;)],,)9Z
M]YT1&-'/:C8_6L*;JW9W?\?M;HL!]WT&/%ZZ^W\;X8%K^:M;=KW#PIO:+3T<
MC?$$W2_O1Z<JB7Y3V40H22Z)>[)YE<9Y\ZY8]IRE;'9(;/S^V#$**);WP4[2
M_W2<Y.!\?F'M228[+?1D7B1IM+<W #FY=\AK_9*/[*\:O)F^$S/Y[DV5G%&^
M^,0GT;V=[?V'A_ARRP7AX0KY<[!2 >[NM17@-]907^@I-U (FQN^1HB^SCK[
M>YINHA6<]%]^WD@KU'GT6O^]M,)W?W9N5<KG/P1RNP.ZVYI,Z,S,3F+9:,I+
MFRT\@[.E;Z!Z;FSE/EC/ROT:S'+C9ZP,Y2_Q-]?)5SP\BGZ?4U3T"5BO9=7/
MI,7#]9,6GS^#<(.M:W#-_6>_O_@7\>P_SE^?'O]_4$L#!!0    ( *Z G5J.
M'R!P#>,  "@) 0 -    :6UA9V5?,# Q+FIP9]R["5036=LN6LP"8I@$ :%4
M%%1$G! ;8J*B(B(=AU8$A+0C((UI&Y"H(04BA#EMVTH++4%1Z1:15AD48P(D
M(6W3RJ" @DTF%120*H>X)97**?]SUG_O.?W]YWSW?&?]Z]X;U@XKJ5J[]KOW
M^SY#U8[AB4$)V6Y<'[H>,C(R@KXF_R## !3\^=._]/K<R;_:AY&A&;*;9&QK
MA)H8S8*,[8Q,[(P,4@B&(".S_WH"]-]>1L8FIF;F%I,LK:S)$^IM(6,C$Q-C
M4Q,S,U-3\F@Z>1PRM3.SG[EXM;G#EMT6LPX[+LD\=6&2YYH;+5.W=J&SE^[Y
M[H2EE9/S-!?7.5[><^?-7^:_/&#%%X'!:]>M#]D0NG';5]MW1.R,C-J[;_^!
MN/B$@\DIJ4?2V$>/99W,SN'EYN7_</K',V=+?CI7>K'RTN4K5;_\>O7FK;KZ
MAL;;=YI:)5)9F_SW^W]T/WK<T]OWY&F_2JUY_N+ET/"KU]C;=^\_:#^"3Q.?
MXS*"3/X]]'\8EQT9E[&IJ8FIQ>>XC(S3/I]@9VHV<[&Y_>HM%KL/.\Q:DCG)
M<<VI"S=:+#V7;D6G[OFNR\II]C+5'.QS:/\6V3\7V(G_K<C^/;#_*ZY^:+*)
M$;EX)G80'2*(N1?SH?]9 QI-Q%BF4IS%M%_&.@FC-30J9P?(N@9@PFE#)]>:
MX]/#2=.?5B%CCU2/>U/;\K^*<:3=^TD5&K!A2O?K/Z^Y%1J@G#'&Q%+6P",#
M9'?? 'VJ^K72 /U8_I<!>LI[Q9SH=/TK_=4JV-@ 28Y4Z5T:QUX9H-SG!@A_
MU&6 ;/H%[P\H&JL(S],&Z!V#F;[EGSPS]D4%\1B^Y9V?HO 8$3GK*[GFH&PU
MV \)0>6U>+HSU_WU!%.2N#:D!1/]>A%D/VKMRG#'.^S;K0+H0I<'QR(RA>E*
M),_#J0N/0X?:1 X@4WGO.Z=T-QG7"O/@JP531K9D_ICD'=UY?4[G]46?8KHV
MMOSL^(FQS.@MC <<1+K*N(,"4,PP0 ]6PNA?OQJ@]4FZ8XCZ"[H!6O;AP\M3
M&G<XJD_(4)7Y%%07[6WUJ2PZUCN^KF?TF_>JF@2?:PEFJ0D5KN8-W6V;_^ $
M'?ZV=W3-)L_%=M[I_\=GBAF&,\ K=*\RN_ST+_@A< \5J\P%-8,U.7G5G#"0
MJ8)YI4?N_G(FING #X177Y+S5TU6JDL-V<]/;3_3:?>[*L4 ];=K#_:F,DY,
M./.(0(XW9F: QARNL37KP3Q*-G[X KN(.^>U :+4%27&8MU@II!^> %WEH<3
M+[AW#K:ZT2LH<E;*[7/[_S*#CCK_KR?O8X^C$>KWGW_>AROW-./6;.[<DJV/
MX3]H/J@B:W9C]VAJ^'=OY5)B1DE(N-O&QX^"\_=W73Y57^3*5-QL_OI.\8Y3
M9UEE7;^8*)G@T&,#5+E<?X^.31<8H-)C=-7=;43A@/:] 9)^AQ )(Z^8>717
MD0-G5J_(=9AICR>K%.8C3&=A6A7''T1?>=U'Q%9J$/>1Q>U7)17Q37$/EO4M
MD5]N]]I^;E;_8&)S]]HX;10$G FW>OKP S&+@8=X&Z"7Y?R_7?E]M6 @3;OT
MUF/O[NL&*+'V:4[']OH^L<JUZ=%" Q0/9V,'EW-G?W/Z G4)6W",S7,+9G]S
M\=FAZ2&-X\>J<FE+.+/0JB)\'MHAHSO1W$"BFE'<'X*&2#ILP7AK5%P1)^)M
M$HSR0?#.OCT8)7>'MZD A/A6_77BDM>25;3=?X>$RO]QS**<6_H*D=%KT8H>
MPB5!X":R?8TX<.:Q&T0S ;(7@UM=><74E;_<6OACUXB'=?A1/.2BG2]^<(=Z
M$G/O2;^FS7,^;ORG9D+WFL2XM&:XH>\D)PT+:Q9;I/*SX#IQJY\3'EJ/K1L_
MP>(NPF?T<!Q4#UB$[8,9B4UOSCC53;Q_I1=/R12E9K^UW)HF/NN)W*Y6TOL=
M"$868?G. #&9]2SBU_-.(KS".'_NO]0H)S1_@TNFF=P S5MYUP#=HG2+/U3X
M-^FZ,ZSF7LR@FW)-.8G 2+><G4585:-EFI \#@4M4=,+Z(GB?-A1Z(W*929K
MT(XBF@_;02T?-4!H$L>F&E_<^6;=O8XV9RPN-^4\(ME2=?("MI<RK>6P\NCF
M+WW'G@.>ME)_1;288]1'9H@!FA*/-' KT2B%-L( G4CDWA>X"ZUU*Q+2!.;"
MY50ZIB <8%N Q*!QQ2;L)"%##8.P59VGY1Y3-YD8(&L+27@A;#XT45>VH7N\
MUK?>^L'RUI<3G8=N-=VISZNM27ZRX8^'7Q C,Z9I9K^\*%C=Y3>[5)WNQ[A]
M^S:\[*-3O.ZVTFGW[8GSURZ5?ZJ@O'RGAL>\,41M?LL F4W#2-CS&PAJB_5'
MY:.ANB^Y?\+NUX0N*$.*3#['0O:] %^@!7)Q743+GA3*%/8-/%@U#D*>@VM=
MX'P([A6F23([$S/M^ILL;2.0ZT)>N99(]'XJP9AW,KI7)1\+5M+YS#I&JZ)(
M4>?<)@5A2M8D/*QL)SJ$SR4S^]CZ>N]1#;8?EM <07*U'/,7&8%?V%OP@P[2
M%LZAD),Q$1/SZ[K>5_L%C1Y+S;YQF_Z*&==01)44%]6O#VE8M.)W]5G=ES<>
MS\AWT_E$CQPV0 O\%O3JDT?>Y5B%;/H^Y) $@O^LXG&#N(\(*A:".S*E@;5C
M$]K^CZ,*2G.-]2J06!$) B2(S?MPAH8WJD=S0;]["AM1"0II7P '2:PC*%+[
MV=-/<+9X9V]K$UEB%Y(U)/)3??RR]KY-C]/VZ'^C>>$!(%*EH'"._J8O+]N&
MPF,.U>PXC7S,"-.T>KBBM NZM?A"4$GA"6V48[ FHI5R@NDD<N8^@2D<=]6#
MY+4&*#^NM1W-8?3O@%=X^A4+_30_X;!^(Y!(!XW ;I7"#HRT]5?QJ%-510L[
M%>PRV;&["4U'2F\LG"K8>7O_CN\N_WA>6C+YR&]JH4Y&=Q''U9HR =Q"T$$9
MBK0TE10]"K\-TI1B&-2V$)8]G%4#C!*_+*J;>EZ2_\A%JY]E-M>*)A=V9;D,
M[C1Y^XBPNH<M[).(;XA'SZCAW E%BXZ1=XP_ME=G 8HEH:!*G8S6MH@\,3I/
MY \LHK'J9:*9Z/O!^2BYI$[+%)J LM8.>C85/GQX=E?P;,9+CIM&_+1D*S#3
M;>'^V50K0_A,2\*8K=&2A7JB&$\#[_M#FOV<7TVPLHFIP)&0T:A@JT6KPHX3
M@HJSPSND?@6+APF8X8Y'\EH()PNY!^T4=;*KFC[I E&UENN!A6>?5_(V8!YE
MJ4G:ZK";I4<N5PT:W[9Q6W1FMKMDQMO'Z)_7+A\<:^-?'BPX(GSTS2'N_0<_
MW;Y5)/I]<5=:3MND(;?50^[)J^ V1B%=^2O3Q8]^0)!!PJTP2!<73A8@786T
M^EFS:Z5GT\H7@CBEP!J\C;'0=F.4UO/)3*S5 +7ZJ\?M<00+**!-!C,:BVG3
M0%C+H V:UL(W)X^&81WRP4#T,,8Z4?V,YD60P.KNS\@R0 WC8\Y*/IC?6W^%
M?U* ;C% $/<ATRKEO"5R()VAJ@ !6(2:-RI5[A8N9S)34*(>6XW;J6M!V%O1
M%'*Z\S;L:==0D0@Q6@32/M*QF5UBL@@\%)C/(U$L_87@3=NBI1^/)'=L*;7@
M4:EYSXLLUMGN)58B-^LZ[ZT(XOS&$VQFO"-!P7A ^R>6)A$4<[?+<4>36$R<
M+7(T0"T[<3N=S_"@'<8HYMHR7Y'16V/1REH>Y[#FAB9/&*2JP_R*+Z%54H9M
M8J*2X7!+[I=EGL&Q<[&>G$WU5)$JRO&X]@0O KPXJO+KSY(B]LL4T[A_>#@!
M^15R7D(")!V.[/&6@ +=GE<>IN %YAT*?,FX5F]!3TMA2W&<P&YDT)=N?)W*
MU-0Z@8 6D2DZ5"A,IV0=>N[A4# !#-#)Y& #5.'$)U/I/*D]<FMGH6*9X*E&
M)@HDJ<\ F>!?@L5J.)^8$LC#YR@H^#P-;/&ZG(;^F!L1VC.P"XTMN$[/IP9:
MKC:]\G;08O*W?W8[+H&X4TAJT&#)+>4N8"_:H92/?;I(7DS)E)*3+H9/A^IK
M"4\\ 1UO94T&#ELZ11[ ;1>(1CVC]+\*?5&6QCD;1VKC13-[.<F:%1R%-7L]
MRR7D8@@:.-1F%P-HK_N%GIKQ,8%N'<<.[-8QPK%$;7,?-0C+(/ZDHU\BQ; U
MLV7%(SQ W9%7JBC$@Y7,?GJD_CP^5<W@><MB/4&RNF-T)45*!* WT*S&+%BZ
M+A<]%,-[?^\74J.Z7>%L0Q6C3Z^RRYK/BJ=RF,IQ6WP-VM>ZHV0#T_:UQR0T
M]DYEB!J>*J]84#2CLZ;^K[BU"\;MI8\V7$YKMVG.>C+TZ)LKY?W'"X*.7O=-
M<PO*BK_T%&OKCIZ_9 7$#RZVA(@M5&NL?9O^9V$DYIM2.T"7BRA]PCB24CK0
MVASN++:/NH\O=+]Z_SJW(S8H$-;.$L:N1/O!:=5''I6ANL>2O(@-^J%#.68A
M.6BZVRETI>!+?:WP.$L7Q#FNOTB-UJ6"D5;8@QJ$\K0GNVF!1/M$B*36DMVQ
M75\F\F8CZMPNH5E-/'=R7W3+D,J8Y,M@520G!#L8K!1/]Q(.!MS&*E>K,N80
M9*K6<.@H(X<3CIG(^_G9PB]4\*2$",(;X^5S-DW$Y)14O(KR.#M^=63B96WU
M@CQ'#[ASZ_K2EWOKUC5]$9VP?Q/?"E\#(C2LG 9X.G7.M7C1+)"LH1N]$JW\
M#1L\M2=U99 ,H7PH,DN]YQP;5VSI?SYN?;KQSJ'LV;GG=L<90W:]MI07MUH5
M]<_IMBFLD[%V)$^N SYMI#2P$"OOTLUQ?[1;)X7=J-Z8M_0L;.%?FP&CYX=;
M1/-!FL3#KD#.]?"8A;V\H?H)WV: )E7ALY;..]T\HF%-*SBR=X)E@$S;])>Y
M/IQH<!\;5\EES+S^/NE3W*\J(791=WV2M]2#@HDEH>9BC9]MO*+_*5\BF@PN
MHR;RP2,\9]Y"9']'OHCR VP1K+J#)RH[W-BM%.==5*0V=NIM<%S#G,)&VFA3
MR#J+D):[]-85^>U ^W+?&UU^?2RV\LJ2G*X77?7L&]-/C5F_6'+^E]&]OFXY
M6_I7[]V?L.!=2QS+3/:P[6[Y8,_VZ[D6XTN,'XS?+C]VEMII\<Z#DZAS9*L[
M"*LN)2.?2]/_7-_!*P\BB_@4]^$QY\(4V(&S&J3NWG\=N$5W&J!]X19M(PO'
M;5\R*(LZ.4?VE<:%FI;#V/S1 ZCDFRXL(@?YAI_MVIA'WR.VJ<T3S6,;H&;Z
M3?Y8O88.O%ACR:FSH\JKU'SK1+&Y)XDOK;4Y@X%8^Q_V]'YKE1__PP.+52R'
M%_NPJDQ$Y8+U2Q\U%IX27ZH%ZZE?O$-D 1>Y.A>R[M>?>:5X_NGV<TU:30KM
M*^8SYA\9=&MDGY\#TA)$9>I\N6T*\QH'E5XNX_-*F.:'1FDVT0D+D 1&CKB.
MF>E?.T7@D4A;B7HZ X&JPX$=IE["SJ0M8[=+?V*^%SB4U4Y]]AD3[4H^1MW0
M=-7=9KWLJ:D;F.1O?=D A3XVNVH]U#S#Q.O!4.T7'(_+.U.?_%?)2Q)5/.,3
MC0*\._3IW![QQ)64*-U;D8G^ OTYH"L%] \?=#L,T.MS78GC?_Q/[U_\,PTL
MI'\*'5/H?^*>,4 U1C5]@V?07<C;TP-BW2*]CP&*,HFNO3<7NIC_[\WD7:*V
M_6[O=7H" W@ILOSC3RHLA%MTZX'VG=QK]$#K.S4EDPOAZS!%L]X[:HI5O1B?
M7>IT0WU\57M' ?Z%ZKO5IE8@1!N/\4<_*"GY"+JUUA1I6?-A/"?6!?R%N6GK
M0-EU:X3?/9S@+>MX\G%7Y_LB:^WA+MJ4U>J=L\KDB$V2R$-RE;V3'=*2YK&X
MK+5\99GL;&,OQI;+'(XJ&NB.7"?V4HUSU@>F*1A9EQ0A:2R).E!)>5+K'PY'
M=?L+**\[1V(]^H3TZ\,O8;MXC]EHF_A0T_A)?)WJ4]*+AA^F3MJRIMTOB2S-
MP3/^UTNF_,I*JGDV?$0S>JS\'FO*Y5\^7<VOVOQ,>?Y-\UG/O4.57K2O*2^=
MU<@8B]Z"#%"T" A#3VM/856M_!,>DP&F\R(>EBC,B1F UR*V3!FWYMB &ATM
M\:H[UPF<EA!^X)RFV[Q1R;>OE0N<&UO&S4@P8:+YP#940W$/T6R:6'@#2]86
M@>.HI[8;Q&G@_D;-QQPB &E9+G(C>FE+^H@@<)W!HS\5.[FIS^:I&?9$6ZDB
M-R27YBJ8G#A?,"6D785,OC3+SWW8VBZ9VA7"[&J[7)%0*A!0>P,1[8^];8\/
MED3M*$E'#DR:8?[=R249[%611FUL$X_%Z&GE>\6497RG&/:(/+"DC0^#@9W1
MI-KAK,8BLCGS5.=2?W^?$D.1N,XEJY!7YY-DL0$=RA'23MB9"?V&=G6H8:?Y
MU,'9=TA-8J&.&VO!DIL5%"( 9(61T/!](FTVYBQA/0G63M77XDL>J,49&R>&
MY'QWP(OM%,V(K[X8'^L< D_A[*V0J#Y%J[X[<7KYG>E_=,\M#AZ)I9$]9+-+
M.[3JWF^H=%U*/XA0Q>5R8G1)^.R>RQB_D#:9S6H1&9-0YZGE>JP$GM>!CZKX
M=KDO8]3/AK.^,PV$:4@7/XV]G%[4H39G& -W$7S[ '&)KG)&Q7KK0)BP6L8G
MEH8+6HGI30[I59)2?[F@;RQP_9F%[/$?VX^]_2YPJ 9": (TC-+?I_8N%BTE
M'GI H$BW9Q>WLU0^9D:">3MJ,>:BH5, /P+L$S]!7%)8+FQ$TJ3 9S1Y9P@7
MJQ9?V, )JAVQUOA9S0]]&5;A77@C)^GG6BF]*!9&J\9(CC KO0N"L!)5P$G:
M@JAA4DZ,V=5;8 ]/J]*W=(XT#66(YL??8K=+1"[8D7LH<8 ?R\Q^BW]%FX(Q
M\7F(VXC('>LH\JWDM=X,H;Q/9U4,']EF71 ^J[5?;?>V@Q7G>E-GG+GSY[T7
M]JQ<;9S=N8P1^!H93:=V'+'H?T.3>QP"'=ZF/Y_N\\W2O[&!$)\)_AA_KW<1
M?3^_N'P9D/\"$C46V09H-QWXS'D],CCS)MB-N:F_//<+<&@34PS0#7_$>!BA
MU+]3\?M-)%Q2A9YTBV69@JI64@UK&%D<<\ZWLXL8!7]R0U6L@2'-ZI[WXUGW
MR:"MZ]$S53C50;L W7%*[;Y7XSS:AU6JOQ2C?AIQ,SQE1.&T+ 3CXYYT-/]W
MSF)L^H9!)#NBC6N#AA1^T*)4[@KL(CNA'6'"3P)GW:N3;WC4'A55X+->MP 9
M+N72>^;NG[E:_M?F2:_*I_4@8"UGGDX +@MIM Y2<(LQ[^Z'#S\+;O!!<^A+
M2A1$1(W1DY)8:K\<?WX&TY&>Y![22K<0+D7(D<Y#(WCB> 8((UQ?Q\X!71IQ
MIL!!$0S<T+@VPI]I@[0NBB0FCPQ)AR33V1T:NM;YIQ<GD@YP)?3Z1JFOYW8R
MD2/Q0/2C5&#W%^Z!,48_ZKSP92(T)/--RG&;Z-781MS9IF9X<#EPTRALV&$R
M[BR0KA;;7>+.8_3S5=Z%U#V$-6M*5:8P58F U9PHT3+X\3CNR75_*Q2,KG0;
M-4 ).N93Y-:R,7'2B-B#63)D@.J+@.;/ =E7?1S_W=>>/(MB"3;=OMU=OW+^
MHUW=%EHD+V5_SX\^#;QK5UU2$ASF[YUK9#]'[++JFA'J-SJY+RHB7\RB6 U_
M^[O $G?7?<L>6 >8IG-IDCW]?1*_D[$S04UE?*_F?O%*:PGBZB_VF#$_[^8K
MX1K3??,O<D_W_<#Q :2$S2*LNG$S9?CT8<*U:T?D[IMG(U-7KA_:>C:N;$M/
M:E%R].UTEI3FV9=:,_% D9?:<#9]#6-A0NQ2'BOZO[]-])_,F1I-P&B6BE^H
ML$]A%=[@Q()/:)9\(H+4&M'N<<I:_@4T*K'<,1TA[/U&:UBAO?AB-=O=.8;V
MS?XMN^;&C/X92N7CB]HJ#5!(K>ZH 5*-HB4&*&B^KI?LVX>8MI>TC95]>J$!
M0K5L$B?/GX%1B2M?[R$>(]>-=ZN5B8]6CT?--5'6@MU%(02?J7UG@"1/57[$
MD:\0R>2#]/?'#%"C@/#HL$3>W:R]%U]!.2%6Y?C#$RN1 3*]*7$GQ9^>DE>9
MO/@7 ]0U0@PBX#AUC@%Z^(?HP\4,FA7I^Z<]1H8_&" 6'5]9;F^ AO:'_&</
MN0W0#XQ/#]?%O*:;\<?NZKXCQ93#%>Z#)H;T(J(Z!.BZM: R&I2I;8Q"M"T@
M\>Z>X<"9K<ZM%Q;,-NU[A/S]^B'K4TH(*Q_-@TM&%J/IRJFW.QB?%@S2]X_K
M>^BG:N_\_WT^_Q\-V16U& U3B<TYV]& -MB.<T1_A;N$7:N2"?(7<!P2L2SU
MV3-J>/+P:7;?>M<I]Z[*+L2+'-"K[H>8E#>%?TK'\GYJD_U^BO;B7RRU_V4I
M)DHVEL#H9G'!VQLSOR%MQ7B64P8_AJDND=WYD7N87Q5[_)BSG-D?URJ .+MU
M*T&0C&L'LJ[OXG8IG.O$61YN??B\"S;1DD$'[,OZBXE-HQ&TY3T/;S@,N\[.
MJ]B0WQ6RQ,EMUKN-4V,I+66'#)"R JY;/II)9B%\*[O" !W?@<GE=Q!M291,
M?U-DB2>!OFKN?6<#9'F-ZQ8C0QG:&ZB%7 &'8-;R6%\T4<'>VQ(['6O+6EBD
M?(PJ) *WX!IVSGKLQFY*WDOTLN@OLWT)^Q.,I4;^'6,/T(8^M>B.<B4S!#M2
MI PW:2N?#;XT0-,_+.^L!#''L;)FKH5 W5',=98O[N,7D.O-\295V(;>6-;4
M@).,$\\QA$?=KIR#Y6*-V9=OE,CJ_<!\6!+CV1(0ZW\;^&)7VW?U>H(D-2M;
M0'D3(@D/DHI=N"Z<:)9=J!+)FW"ZJK#O.(D'53 N@B!Y28"'"[B@KC5C*R2^
MJN$B158FYGQBQ\<2+ UW$+?!ML((-9(3.ZM7.).E6Y(HJ&.UU?:WZ]+">E,?
M@P9J*B96"?BX*==M^8G!Z2PKP11VG%3A*$S":+!S0.&<<]^#N.8NX/;U':RB
M%R3H;#G!38\X#$07 K9IV:#EJ(KU])9*,%J+WFUVO5:J*"1<P4<)T]+_/C7A
M(KX!5,.YQ'2S3N%JM6+J<I[:&:W-H;IIUJ'!PXNO>?ACA<0F%$J_@]9J\U!Z
MVS#AH>#0;F'FMS[?!%(QLKE+W/<<-W_T#<=7I? 8;EIX3QD#M]D5EK$<V&6K
M^L+_C/58\FS)PKSO]D_ZQ;OV4O7;TU'Z(B[M%5+'&U5HQGE,UVQ>J\+H_I77
M!LAQ+$)&+$:UEVM'%HES'>3!Q%06SQ+LU=RS5C?D70/>K7-%BQ;?1YFM @IU
MB8#2<FH]LF/X_^ZP_L\U43!XH&.R2920)GFK?,<SB!5X*/;FELH/[*1<X$P%
MJS64_+%+[ C=MR ]M2B-L'OR/,;)JZ]8^N[(K;D[W+?+K0V0S8<+2%<U=Y )
M<L4.")!!Z6/K. Y__QY&%5'.>M?&L1<&*+< "S! A9LM!A]'M-#_?F#+_TN[
M[<FJ/M@;12M!KC&/5N^]$GG0N4\<UQA0V!NXZFSHMU>GE4QR:?TP>\6SNV&4
M/#)Q1'5^$_ZL@78#9.>L9AF@:96$V\@:$KIWZ(5BS([K98"P? @7 0M2)9(X
M>^)KSF??<X*SZ1%NI]L&DJ6N9.7D&*";BA9Q]K'PDBQB3KT!*L;3X2*"MOS6
MA?B]A-U)^\1\8CFZ2M.^Q_^W)6Z'X:Y[B+WXIC-9=2KZZ"NRYTI]I5AY(8!^
M,V[L7$!+6?52C*(]@%*1FPQI'&*)[P._^6=AR=N37-24BRVJ1:6M;/=]N]:+
M;</6_A:JVM.C#T0DZ?',]P<5C27$+#^I@EB\"CZ^A6E*,LK_\'T('M!+BOWU
M-;JCB'H6'FZ -(Y&'^NGHHQ_<.#_^[W.XTS2_\JQQ(:D!!4MYBG'29"E")FH
M(A3UNJ6&;?#=(%I=F^UZJ=P=^R O4J%';E7*U*:9_O><U P3=K>[5O=CV*6P
ME[,W.2 ]=="6=8[_2C/Z^YT9'^5M _3"NQ'1[IZ((.K,&YG'-ALQ2;TAV8R3
M5)'S^0G.4@.4':1B@;6(:CW22I"?N@R0=6($T4M:,:8NC;!EC=+!=C%:_=GZ
M6%)P;P,TK*.KODDBCX<0/G#0&(*%]/VU_5,[5J),DS]8JA6BR%BZ+N@5?;(P
M/=E[5'>-VP';T:9Q(C%Y/N&X9M"5+P_#&!*/)2BSB.J/]JGK% ,8^/[@X'0L
M@,<)52IGWWI\\>=!Z5<\B'M>=PSX- ?*"]\S^D=V G]=8*P$8\CH%-J4^+-B
MUU0X=W V6:XGZH)8;HG'1)FJEX"E%-@A21)53=SZ\\)YJE]PUN$_[SM63&TX
M78&%C+W2+8N_"> V&.T6F_ER71(%)M0DW7K%[!+7AE\UX4SE$ ]13?^-[O*>
M/GK\;+BG:CQ;$;.3$Y>F]K-\V-!]WW%+G5_B=Z_>,0K$^RC]T3% KG/!$YO0
M<=)&J6L=<"_]!6X0T6F 7&OJ^1Y WCIQY-15?">9"?#))N\LD=U]%AHA^R&Q
MFQTB:1K\_@=0*8MK<0 U^*(W76O*?2.I,]7TFWZXPR/M+R!4(W@ZB7,0[1M5
M7&,[*TM&7^DBN1T*QS="/VP;R?>/.<PK1)?8 5^IT=O[.J_%X&9R[9 D]E[)
M8G:J<.Z@&Q91,.DK;'+)8N/741ET!EU5+SXPMVZ,OD.@H>3(<FZ@R1*XSN-T
MJF]CKJ?K4$OM])&0-:B\,&5SR@Y^!-,QL94^A>QLRP4LO=W<]LG].<W!O[\6
MH%LZGL2%WD1M!JMU6SGPHQ#I ]\/?./^6-#44\^R?;492-:BM,LK&_*\_#^D
MDLJ)I>JAL!J"2IZ;%37@D>D&R!0%']-T,'N;DI<GFA?OL104H&&:D!/44/3(
MFP$9XLAU9<?)%"9<4Z"16J-!JK1B#DMI++;'K=5Q(/D:!82)O$'@%T,HOU"L
M<BNE@$TUPKD>\82Y 6I929O!\=1?H\>-%[HZM]*?CC<KK#A3E?3^-HEZ2N9N
MK%+-DHW#\;25^DNIB!&;'].W#''%(\&>06_0%->'3WJ@@1U!K:S<*K),3<G5
M-*+KR5E=13U@-#'38NRT;N%!FCO@J=WHQ1Z638]HTU[[58&_*N\EU-N8ZS\4
MG+=>8[%Z+3'8R\^OO[<DFF5\7W4W4EX4M:*O)8DSN&VI<)MNTW )<E-12#\(
M9SQ0,8O[S0N4?O;LCZU';K!?"=U5@FD)Q!0=0SO(]R[T%?JIJSH__(+<^%#]
M'5_E)O"4.?VJ*FBKLUSY&.:7QN'VI[5G8RB[ZLABE+>Z[LA6CN?#YJ(%N \(
MN$QTBF$-ZG5#C60/R9D#_7 6=^XPS0/EMW4\+5 YYZ=07-O*+<!V%<,9CT,%
MF9S$BZ2).I3O6<HTIP_33R#[^=/P>7H>;2%G$F"@ RKF"=$,?%,7L7C7*SI%
M#6JQ;5*:::<P&A.E?\>P?4W,! .8B42T%)S6/$@MV]5#W:XV0$Z[V//V8R7Y
MPE>^N*=JYZ'+I8LH)P@2HEH.T!;C 6!;FCHF31N-TK-HWD"CG8=6C;6C'MTZ
MC:A&P\@>G =6>A<*32YR(KJ$2355$KHYNZQ98,]U8L>ID1-4$IXGC8HH@I9!
MO_ C\178,XO61F/&XR[=4>+W<"73#@]G\LLM2UH(<_ CUYY=MJ,AL/?"\21L
M<5UJ;U^+4__DJ.DBSU[_YVAO-5RP-M:M[B>DU?Z^)B45C2Q]A2RJI2M/<V<_
M0I1E_0:HN<.$\P58FJ0[",:UR6"_;@G[HYI93*S$X\!IY7VJB=)WV_JX1G2\
MF)..?I1QYW9R+-3GELW&XD&D"C8&C)97ZGN[NW=&"@-8J3%^4OJ3*JT"8XX9
M825JT9F+W(Z)@$QB#N<8<,#\.9Z5> KVDJ=1@/4T9^Z?M%D OC[<%" SU9?M
M1[+*9])F]"[;P73D^&S'J@J$I(2Q])-\P,0GTFH+IYF\=X[^_*R=:"%<[J!%
MY?6Z"-SZMSN8_"35#+-NG4>7VDR=W4NUQ!@[7.D9G 2C'S;_JNJ8NLLI'[;=
M%3;=*NQNTX7)1]L1,&\<=]#JUO;@X?MU._'9CU-B?"3ET[":P=HJ=I8N))QF
MA\T[5<=R'B:V;A3-1#_<.<!T8?-:VU,3E<A?C<5#Z#FW1^]XVN7D8 Y_)A3(
M?Z43(Y<PT9_Y4!/0C*!?+M6YL ^]DRBF"5F_'*3Y8@H>,0?PY%%>=VMA6^+A
M_'(/M"J_LK>.:6,_U$;S15FXY\A\ONL&[%9RK!O9:SS1/S@=1"I)U]OK,4U_
MQO<-QX^$EW.@C'Q_$[ <=B6\GB2T:\0>B<?L_:1C[A%:UA&&#?(U^]BJ/]>P
MI<MO_VZ 4M\:Z4+3=$SN@UZZVWOZTR[1$N UH''.0VZ6K4<7B>'^TL*)-WG7
MV4/KNB\^[NW52!3H]V28I>:WU-$L2^M3&FN!>=O@0J?[^[Z^\\WX%"Z9*S=K
M\S_XY6FYKF <U>V\"P*NV"2J-RT&&=+!Z5TY5<FJ=]?77*MVSJNC@-#WX8Q6
M;R8J+??*8-^!6ZN_((U],.MW4DT ;^^Q.]?Q< "K'\3"3\=UWBI>&_E?[5+7
MR0WB;$9?GJL"B<W(S:_UI3ARR<8M6/^S!;Z 7NBS($M*EC:&;?K-8W(G[JM<
M(:0H?U%_+3I/4DNU-@\+&;U\@=LNFG=#?SZ%;XM#:(>$,@F? 3ZI?)GJ]24:
MO^)R1^""54H01YRB%.3S*]C)+0('FA% 9'0T8_@F&">FAK3!T\-9FI7I>)(R
M(I>]I]<E@[Z>0]<E<^][S$<F17[>%I.=:A.LGEHKLQXW3W!*K&ZO'I$KO^V0
M%7GXVB?9I(Z#4*KK\\8"JL_*)M"D2#2KWYW_Z0\8^ 2,)E=SONP5N0*6!CY9
MT5U#WZ\ !Q/AHG[M.;4/\T0OS:*I)";</"91^C:>\$!!_89EZ1&Q/S?F)UFM
MO$38/Q 73OY6KBZ%1\VP,I4@3V3*.0A\T%O*N!,B3SQ07TD$<>(P1:O"EDOJ
M'0^N5T+L_!*-@"3Q2HYE'R>AEMN%V-)<@42=5DQXKA]T[^)LOOE V6$N(0$G
MGP^9ZU;1%K'*B>DDCBTR0$F,'+$%BS8])E%P\R.?$ZP6 -(G&: ]?+L?^X@Y
M[*6M#33O/MILSBZL,1./JW1GJ@2%S)@LNB-,.*2))CWPYCT;  MDZER\@M(W
M1M=*]>??%R%*12LI)/ T<-A9AA264C+K*9,22O</5E4ET!;V<.(NA5P?]KGP
M:3QPV$:SHR"BI)GKAH7D(:H%V/92??E3:OBWUZ*E-%+BM:SEVB>0)2%.Y#L0
M[400V(+=TK!&Q6B:7.!4RW4_..C=4\>@'#P%3!/M7D^4C?33LK_M[^.)53,[
M.2&JHYQUJA6'E&5MQ^:AWY=;?YKNG4=TB&\@8]XH;]=7F,5)9/]X;JP#J%3Q
MGXSO D6D6'($$FE@57-'(?.FO%5LS)E']('MEQ(%9J1H04?S4/%J+"US/[;)
M )ES]BL5TQ,'9YZ?8V(N6D."[3D#U)A^E;/OCI#QM"P*LY JGC"T^7H^MR\!
MNZ5&<G#KO=6<G:""6-*),Y7\;)$'F?;97%N<Q@_>/5UA)?1Y.6WVP$OP2/9P
M[WY(7P52=='X=(Q;B6I4;^HQZY:H@#;$'3@WB^8W@22GJ[M['79@C5G.<O$3
MUT5G^.>O%T'A:C:^8!]?ID"S/W']?N@;O5!5&P#.ZZ+8(H6V@'ZSL=DOJP%V
MI2V-%TP9I2W -[.FXIOH5B)GCC=*R4TMBEN%6O;AA_>B&G5MKC?(U*Q$)$T#
M;'J+"$;7/0I1/9@U(B,6B]#ZLJ@ZQ3Q\OCZ'GH!8<1\I3$3^?QU$K#DV%]EI
M(>!;P;3W3$O.-G!*TV$#WI%B_&GE*A"R\*P!LJ+-PE<R)HME3ZB,RO@N-EU;
MCB(%-#LP0#@^+( S\%0ERWG6&.T!YJ.- I]0G;8=:R3ERZ)P]&Z;1%/5VF&*
M^^@K16:<W=CR>E01CCDRK112%BI0,R2*_%A[D(1M_"@AO'[CDPN9+=ROXCL"
M3QEW*L8Z*;N1KVGM^[[NN<E=QL"0\J.DUCR:G:6]]SA%\40B:RHI)#Q!V$:4
M+NN8-MS7Q,]/XCJ%+!N<A2&9'XJ6[@&*YHBFV0CZ SM.BO9?:W79&UGC.SX=
MI ?UZ>^*]_EC5VZA;YE\8I+'LJXZW^,R9Z[KB9&MM\O'-W5R/"G%J;_7Q9SM
MAFU!EH28OK^/1?53Y7EAZ?4_E:J$_E8SSR$+B:E(RT)2!"T"5;HO.)LZB>E$
M>Z]M/-S(E#/[V]4?<]Z3ECQQ<:B29</9 A+4E).QDP +K=W%R!Q6V/):]2:Q
M/?A&6-J)PR>_%TUJW&'O5UC]&/<D"^@=Z&'5L+V5'POQ4+2-E8&8BI,8><R&
MM-:.0E>/:O4T>KS-$09,ZJC#UR7H7;F'55EK%V"N8DUA5ZD5A4F<&"RDE>G4
MCTP'8:O0,6&L"7IRT*LIWY;2=/GS$TNNS,EU&6U6#SV!?[+?F[=09)D@J,L6
MY.+KU&SA%Q4*W+HOM0.$I"!Y>=4CIP::J?X!N:L[\:&? Q^.NCZ#9C'"P5+=
M)HZ5_F)TVSPT6,W*%GEVH+KH1RE,IVC W'IT?)G;O>0-?&;GH86SXBL9H_!4
MP%FMIEBPBZ@=5D#4]?3:PN?QEU.(> .42'G2H?U)_S-]#Q-F5VD:<\7[[[FI
M0D;_^@PD8$0W(Y+$K,:VV)E8@)1N![)DA!E&R:0F5,K5L#4(DB"4[67-I3-(
M:1HST/:-UX'"PL/P6.-H-DI70Z 1<]:V@N]ICO%-'6V43 -DQ)W,9K0BQIR8
MZVQ%<W])!M>QD4\-J<0W]N!' WC46=1@-7T:.TLMNF.: &==9EJP ]:@/1?9
M"EG^S=!#1A.[USENMI *IM"?&R DD:5;SGI28H"VL09B10.U>;3IR'V"Z%5H
MOU'<\".N*!KNI3>N,G/<\B\U^!_L-A99\XFMQ],,T 'X,C*R*C'UXV7(<<NZ
M?VOLD#&SSYQZ2]$J<,"_PLP%R=5(7"Q@!:,?>=>NY*6RG-D?V_JU14JF,3MX
M_>!. W2(72T+U!:IVK^^^U!WRM.OY&6<.A<YQ,P3VR#Q]X*5R-@\=$C9)V%8
M 6?MEW ]7P;W3QG07+\JLD3YV:K>RZ3)SWW/ FL^"'(:=,X2#^_@BC!U6*UK
MC5!D;])VU_?E3VS?]!+M>[!875ND,/Y&A;I?Z.7.X,P [2A=6X#R<MJ_IT;\
MBEM_WL:22U$^G5JZAI*/K[R0*/*HOU\4(2VQO3WMKT:5HHB<A;ZQQ3H&'@W&
M,84*R2 HX2BB(35DEHQ^,RUC3+20LY%4RH*\8ZP\SN$:=I;<[SH84AW5E^&[
MFEQ!M#10 PXQ;4(U#EXIVSRO;?H]U^A]K8P/YG>,AJ-]JI "[J($L2L>@'FN
M1=-RN;;L@V\5S3;5[%,/JS!-5*!WZ_D=\SC^*H5]'7<Z-I<?_588^1O8NKHB
M<># NU/=]R9TVH?ZDAKA01I\D#F=8W(1U'#@= QZ%3L+,^6Z.1&NG2E\$,K9
M]#8Q\'6+JNLZ")$<EJL9T]B;8VH+J7[*3W.P]!<_.JW:U?B<F8<HS],;#MR[
MD.@ZGV366P)>38KX*86P-$ HLT7;*W:FS7D==>0"%JQUT5](8?"W2*[-YU#6
M=W$]V+=<%2=KA&%688=5R][&<"@KOF_WOOB49.D VKPG)-@7:!!;3A!8A[$V
M]Q*+\'C]96(ZF>;TNK2QF54)7!-P'I,W-Y&*E/,%?"NO4QB#AE;F,%T3"0M6
M\6')G"%\_A>GTR0OL(L%)XRT/]/1KP3 ^]"5&\&5W"<&R,3?\M#[I."8&X_J
M6-/Z7Y<VW+URWF0#)GG=/R6[,L0[C[JV4A(H$^>FL0]81EX\?S-LYN)C1ZIU
M+.)^J7,>S8$=O 6\0]7MN\"C2VP_*3(Y21%5BN';+W-6.4W$97R(3]UBVM"T
MA_W[G8)69P_/4CMU0Z3OV*[?;RY 2F%K _0ULY^GHI':UK0AD<Z#;THG&D=]
MT0!-K<0O]\HC=5S1M>A8S+F8-FT 6+1$566F7M*?CWRS+')?UQS,N=!-.J)L
M<V#GS8R.?)XI-4"+^TFDIRLK&@R0!=<<7]1C@%2E]2X$!81I9ST:A4FUYDZ;
MR_;9\)BS73>/P^W%D9K&8B_TXVC_H">X7;X0'<C%)P\NBL<=T$.(+;M\+FZG
M"<W%3D/<JYSY)""?Y7;0/19>ZB;<.%$H,^M# :.?O):66?\;J*D$@C4]-&]V
MR2I!+/&DBSMMN.D=>YU8Y84Y'H-S#Z _8B0-;+/RRGV@;E]_[L\MQS<)&AM'
MC[.NXU^B>@6IG21?W@-!JG%'=H<:ULKSG(,?U<&3V;8P8/@W]M4_J43?W+G
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M_Z%W/D'79XGC/P"^#F''*1N;21C9(9["G;^3D(IF@S2U'^D0Z@X48-X2A8=
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M_YY72M##\4L*=O6Q8IA9A++@NL6CTUN:+O,<$GQPNWIK2&K6HOR)1RWT-WQ
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M0C[L/ ^W*O2<NH&(6/.AWBE'Q8U.=]1Q^(M>:U"BH9ZDFM%GH&4J2Y2J+1=
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M'0FZ15^$LA0$XZI)U25D;=!0HV$*E J.><F<:]3F!^_+S)@QX>::WKQNQJT
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MO/$N,KKP>MRC50MJ!2R!#S)2J$,=5$)VXX$E95DK>FXI_PD;\' VULCVM;@
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M4SJ5E>VZL5@KRB\FAG9]RV5L&5I\\LL$R6_CGCE*NYO<^&$+&H=Y>9@'>R%
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MEN(Q%RG/@-QT"B)8=BH-TP5<F!E1E&$4R3271V.5S$SF776Z=,XN[AA)1?7
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MLI![L'N.%Q*1E8@Y$H%\LXFLX%>G#-Z50+'@-!*FD\F'A1'LR;P@;'(5^D$
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M72F<_>-=MY/?<3MYF)X,I3KWL-5SL-,VB>*3?U7_M=EV* ]00Z5VHJV [&:
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MOKT*2NTEB[,"C<DJ17>O2O*+H B.-#**R(6=[)DZ5%KP"3E2B06J[]DWD;/
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M ^&1$-L^3$LQT.$5=3)\H%BQG>+ S6PBUKHZ'F9C44V7'[/G KJZAP:>ET\
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M%;M;"AH-*C%]"XAJZEF(L\^>6Y2%&=3D8LGFSAV83B1;?U-F<UR.M0/X4(:
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MQ; #<WN;"B]#56@*;BF[ 41-'<"]]X?G26[Z V(O@M-:)_4-EQ980)#RUU:
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M20ZZ M2;-W<*'2 E*AC:A,<2/O)B(1W.N(=7Y&<@N7+?T'3_Y2VL0S<@1@)
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M_2BE>6*[UT,-(\MQ7NF&'D6ERY*NMU0:HEA%+(0]QU1#\BBE *D5*/03X,F
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MYBSO@$-^OOSW!U6;6EF1:1,:J^Y?.^TX=]67KKJLKSYUJ&[]-Y98)Q.1-SL
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M[(\7!?KS1929. /O3:+NVR?&%1NL:W1SO'UWCT_L.HYTB*D:;A/"W3"0^?=
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M9BRO7RK^\'(#@,:/P/LC2(":W\2&PQ7EV+[NLJ_MVO=0*KH[I4ZEZQ,L@^_
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M%)=?T8'\K>L;IB1K!@LZ$0S:+>?=[ F*3%;[U'BW'..T(QSMY \Z5:AU9@U
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MTGG?@18. Q)XX2I*B@DCPWDIIP)<%3067<JDGVB)!%2I%@X*#RHVL!0V.&[
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MTM%_@=(ET=."_#,N0Q'T=K;_^\ ,.T_1AI&S?UR!^$UBQ <])$#47&%;8+_
MUYJUY.IQ>7)9&=$)(;Z0-0KUSM&RB&%$05:P%G$JV[N/_N^*/F1H3,EPX1S
M\L(L$LM;PE]^$7)KQ5%!;9 >?A_1H+BJ96::"! 81F9NJPGM(<S'Z#3F/K)@
M?7(^-]QW:U4("1A%FG^ D.ABN#T!+S5"9N80)/AO4'$V)ZV_-6A.GA<_Z7L!
MMJED5.+T;?"F8MJJ)&7<5=6/((TK6:\XS7+BNC7.!3;>BF_U(0&5!8Q35%S,
MRSSOP_1F;'(60<UJ&M)Q>Y!C]A%_I_%YX3ZH78=#?*G]"_<I_K2B/#@("408
M!TV3/V9X>0,T1<J]K?85KRHQWXE\RR;F@QW5TAOXF6Z!$>NH!>5O>O3)5Q<?
M_#/1HN7W,X5:\,\4ZG\E2D&QP0IJ+#4MF86J/I@XQW%L()7]4QVP,Q?*#H_V
ME1'#@E%?D4 (>X9)0_@ @8)O9EI>P5.G](6EJI?@F3AP9Y)3IF^'4X,L\UDO
M5@D]U^EBVG$[C%A.E#ZJ.?_4* I^(8,$GD:=]&\,RBMR] PIP%RX+$ET07P:
MZO4$O)"/YY!46[)^NHN+['9QR4FP^DZ6))>F;N:GJM?OXUB=M^*"3RE+D[UD
MJ&5O<]P-U+^\3?;P'[?)-%$;BN"?<9)OX-7L"*8TEQ>PMZV-:(-O==T'>^FC
MRJ?<-XF+1%DKL+V."HA./2]//>2B-G50%,4A[?S 00YZYXL-Q#X7?GYY\3M+
M_J@ TE/9<W$FD"5[\T%^RD5!VOXFBI0]C0!=9BPE1L#'WX<C2 Q#<[Q^M>3_
MW=N(7].:\O7,WRW[?G>W[9-]9?__<Z Q 7ZK!T<.J<\@!0*YLIQZ6*H\-.*"
M4XSD+@'7Y)6J?Z05?Y)FEC4DL$>8A,!  AEXJ?)7:.85&GOF-.PO:]_\K"W[
MJNOER!'R#4=;>U#.W0B1(!AY5J&_4Y5&;G&,"2\,#NW)(<*I-RNO@6[UWWT!
M>L++N?B(.-J7QJ'[8:^ 9>9:8JD=GW^81J3B] @+M1-?N*4G]R3/<O:GYRVJ
M>:>)B1_KZYBZ.O!)\H_K2H.#)G2#T46?,N79Y%#VU UM.'(5;5A_4-@JYJ63
M&8I:"CP9P:SZQ!Q^%]_?7B$K.J#(Y9-5X%P3V(_\NML$=7Y1ML/#Y0]QJH/C
M%QNT$=G&[_6]P<(X+B(8JZD^Z42J6J[=;-P/VT5H*E>2'R:]<*(?F!_*&CK&
MA]P1<RL 3LVG;0G;&<C%TEK+-RM*KMN-J\(J4U*+S3I>*@A97J'_JAR7.$L"
M/X<"!Z<Y"JD"UDW1<][,3-DFJ5FD*ZQV\\*.CKE2Q?Q[ZFY' ?T9=)XQ%$W"
M;2J6NZ0I[D]D['+JW_44RNW7-R0>D[%1RH\^Z:L1;L3!P:!()U(8JG3@H,&L
M&>2\B6L8A$W[MO2[,';V@ >[N-9DST.7.#GR?#9<-GD+(MH+AYA!CJVM.HS<
MB;&<+!\1[Y?1I'R$18D6AN_5YQV83/F^V&6L0:PJ!AD2ET\ZJ#)EE1--7TW/
M&: +60(T*;88@RPEPJDSK3?:W(?7\V3O5+GF[UN9L(=CXV*8EZZDLAL8.;B>
ML'(LQ![YE=+R^L L4^:G.H.N8EAF]#A5H(T.:BO$Y'/./E!L>[_FT+.%(G_7
M)7*MALO7=NUV&\5@G"6T+FKWOE1KMQ)UZ]Z2'EX(;87+%BOF^0?-"[FYX[>Q
MGN=B584C&,8#[M9&7;/SK.8V5O=]*39+GM4TV7BP0/54(/M*$V.DL,!R$J5U
MA0!^BO0M0D-G1F.N:<87,H^0@ &W,?GZJ%>+*O5SZ,(;S=AE527WV(7CWB_?
M,S)GD, =!1'":N!B^@ -M?D=[1K,C>?\B<8HX*6<2""^RC7\; 7:9[2_#B%:
MTWHBZ,^QD1VZJ-8O?T.TXHU8=V/P@*?XV7$N+#*7:$S(= :G)EE!;]CA\[*\
MT\EGJAN)6D0,;Z_Q25+O_CZ*TIN/ZGQ!:TTG"91VS'J)K\%^Y2;N_V\CJF18
M;MKTS]^)9W/S5ZAH*9;N:H &TQX,QWI*RQ27:*'619%GE9(@#@$R"I#R\NK^
MDD."<K\NJ9";ZWH<'%I8EK%[/%VU'I8(/]UHELI6O=!OTX"**]OYH8 E:2=<
MTMBSU_%+\]2K:4D&X_ -9N]VX17R;_Z%\5#E-*SU4,&&:D^>5NL7A3&5B\(*
M%^B1KY=3HFG>L3IT;=0Y%MH+%=K0P&SPQ;9(QR<7VY:2<"@::<,MQ5<_0B(/
M11@KA)*&"4H63U]2<=2\Q+#RF"WNA<Q*:F,,YI7P#]0YY,TTOS@^\MQB<CYX
M_BS>-4"/%QP2J>X6KI'*.WRL+-Y47EUAW,"QG^A]8QDDW(9#Y[/"C[9Z3\M<
M/W'4NT0K<7V3+&E'+5;Y49]1!=;3O>N>J>E;U.HR+<9UNXDPF]QQ$\XLF[L=
M@BNZ@?%L!-:"C&^Y5V9RE?0P>FVJ0EU?TNO3S!>\4=QL$JS&)#I=8KT-P1C4
M<PZV#G+ 7W!D\98]F% 0 9QZ#HMCD]C0$^IWO(A50BEZ=JIW_8E\:T0'A?1V
M)UNORZ+X@HN_?67VM]AZ6-,4HR4;"HO-S$J*;J$)7B8F)OYYT3!]$/(S]IHX
MU3GZXZ*A$4MFQ:^_COO?E+_^A*#A%Q?3_C,L<G'/6Z-KABK]<1[SX"3Y6+VZ
MJKJZONS\21+O1G4%'GG[K$T#!L:'HLZFW:MAKOGJN3,&)K#ZBV>A"N%A'ZB(
M0^6H7>1=!TA,\/B\BZDYQWLG[?0]HV^%5$23:E0M7O2[^-P/IL\9%C.D2<KO
MRFUYX.K%+YBSIDVL02K52,'H9OC>6WI7;Z5'$-.>C)!CGEX836D3C==;_'2[
M/Q."ZZ#$G1P2WU)Q5)YH.._8?]W',O2@,7/6V9:&,<JHIK;*P;"(LRB(/T9)
MZM34BY7@"A5T&D?D70/1ZLTSP232.KVJ7L7*)PM.;W1'"6R&*VUK_CYTLL>I
M"BQ.7,K0%LV7XIQYK=\+4BJ5)4/+@FG^.*U" D/@!#.!7\Q&E^OR>#@36OJO
M!U>/GOZ\PL]*XC1LDC;[# NN#NY,_/Q7NHZU.B,]^>X09@%Z61YB=4N\1?99
M!)JRYI=UQ@<QP:Q4Q-/9I';A<K*NH1J?)ZW+#]^<F[*U3YO(-RSCOBC 5_@R
MI^,79R20,$_(4>DH;A'IS.2=;9@1'=%DJB8W-^D+-=<O']J<%KF/Z%UUO/$,
M[(!;T!(J-_SM%MR^RUY4Z2Z[Z6@AW6<,^H=JKD%\;<*@!$M[T:NE^2TD(_IZ
MJBZU,7,\-[!;R1G1W6H_J?FS7W5^7GV2P+$TX-*J4::(3_:9/C-6:C'<.N"N
M^R!_K%74IJ=Q!M:B&0]O@ >C3;A-G/Q19/Q&'M>=UTM-NM=9N;Y+]@@TK4Z3
M#PHP#9,7U6<5#0:)T PEP"Q>9,?Z9M#&1#Y&ZU9WG%75FQJ6XDRJ%\2$L!YC
M&N(G=(CO0X%-CD-""9V0\*H.1J@I2?NSLG#X9YS<)]#*1\,C&E<><'?A4Q7F
M4!C/0.?2=TA'QLUK/B1W3]&S2+\+M 0+36J,-A%^@^"M/>&"=6?9QHRI[?(5
M\DAHT,FI25(L7J@"C]C8"-A":#Z35&AIH.EP21A/,&,L\Y+ \6(A"::6X=;E
M<TQ'QYL8$BHB.N 9IY5533I>?YE?E^34?Q,EJ3S(CSLBU7OYF[^NF, &K2HT
M96TO\TK_VX(EKL:<W*JP<.OM H;P-UQP?R99TBN4W:$"L9F6(DHV$\F><Y3U
M8*0A$!R@1RB:G/[S"1[KXU(*)/"[)FLS*>W@*N3\I#)#ENK='9N+LGU$8 \2
M@-R,JKH/Z15! MOSPR$DC]^7IAUU]9SA@"_@1A(37DA <@45D(89D6AV8D,F
MG%"DB H)'._:GCO._!S5UB)<LY/R]?\\%@$2^'N$OK]E]V9&ZMWD0XSY_!I!
M?H(+_%.V@S14Q,#@?]"+9>F!Y=U-K^>(!S\FG]C$+$3&ITJ6L$PZ7EO>JQ="
MLH%Z;;H$_^UZO(F3?6H: O4./A'MD?K&CBIT._P_RUQS8^\,7DG+C(A_J]^_
M#8Z^?]@Z1^6X?L43Z8CZ^5G;LKB[,]:)YVQ<W5]XJ=NN65UDZSR=9]W_;-\M
M"?Q[DNV#_?K77JK[^M_?7K+XFOG!/_T_+I8I_15U>"7-_UXW+Z!^Y^[_#(YG
M@;W_&R?3Y=\KRE_J;CW])93_;;;>_ QY'_D/2_]=WO+F35U'_:&YAYZ^TFK_
MUI'\>W=U^R\W]\]'V:IO^BEO%>Q_[_77'MB[E](3UQ<.79?W<#OSF<F\-T-2
M^R^$J%U[E?_U>JK[]R3I^KBMIGOGB#V9\8CQ?)C-Y*\FZVZ(]I2+/_]^<.'V
MUT_[@?Z/=WP;_MBUUVE1:P # ]^4CUU1F1%<LR#3.+.1-\IT8^O:!'V7U!4)
M#",E$5."&3+YO7@5EQQ &09:L]M[A>*LKRGS3/*WR$E^J.+:^NUW_,^?[?]^
MBTP.$]*5\EH+Y]?NN_ZO+O$_P[ZCU@OO;'8-^UV[_L^?P_\9:KOL[F?_9[ W
M  T63[V0$;GDP)=5_QGRMP+[73/JWV]TO_VV_ODS^=]O DNDQ,Q6_A-TNV 5
M6K_]%K#7?L;^^XW%;[_M__R9_^\WC5UBK7,"0_<A#.N'*UKTHDHL8]5]3#.#
M=W$ONBH:#C<#X2B]IH=85M>NDFI]NSGSNI:>DLJQPXS'E\8AZO_E*X0#745Q
M[5NG/FZ?I;&$A3^7>6-ZJV1_4+C)_)1MP+:A(-#C3%V:$8[?O/-_/I3_^T'C
MM^KV/Q_Z__T :IH087<2Z!4;96 LL,HCJ=?8Q,U^4W?_\Y;Z[P<6OYEV__,A
M^]\/ EW%'!/@NFLGW?Y7X?Z?H0;8:3RA@Z2Y?U-T_7D.8)G2Z"H2R=H,UPUW
MP*)NA0T(W4@N$ E,$1.)O"W\;Y'][R<ACV]U:6PX__\F %!+ P04    " "N
M@)U:J_*CN-L7  "?)0$ $    '5P8RTR,#(T,#DS,"YX<V3M7>U3XSC2_[Y_
MA1^NZI[9VF5"$E@&;I@K""_## ,L!%CFZFK+L>7$,XZ<L6P@_/4GR79B6Z].
MPJQVUY\(MM3ZM;I;:K5:\MM_/XT#ZP%$R _AWEK[]<::!: 3NCX<[JW=7*_O
M7_=.3]?^_<ZR?GC[?^OKU@F (+)CX%J#J=4+QY-KQ[?ZD0V1%T9CZU4\_M%:
MMT9Q/-EMM1X?'U\[N QR_ B@,(D<@,@#:WT=$\Q)]B) ".Y:_018^Y/(ZNQ8
M[<W=;GMWXXUUT^]9G8W.5EKEA[=/:!<Y(S"V+0P<HMUDXNRM%9J[@3[A!ER.
M[&AL.R")?<<.T.EYCS3<PJ0V-W:ZA,L C &,CS'J0^#921#OK7U+[,#W?."N
M9=11%*_'TPE LS8\&PU>A]&P-7M%::Y9L1T-07QNCP&:X'87 Y6V&OCP:ZG^
MTR *:*.=C8UNB[P>V CDQ9^8\H]=6KJ]L[/3HF_SH@D2L9._R;C)*",>60RB
MW?KMT]DUE<.L+,;HQK/R1<A;K?1E7M2-(SY[^$6+H" @.NL;W?5NNTC>EW2*
M#U%L0P>L$<7ZP;*(HM@0AK$=8\W.'F:/)Q,?>N&[[!%^2+IH-^_6*^!9M--V
M"92]->2/)P'I;/IL% %O;PUKW7HNM=\#>_ :@\Q+V)$3A0&0"Z0UB<()B&(?
M]WA!GI0 4[O,*7G=PFV"X&R.>*U%#6I%'$TB\-TYPFTB;(]47%7&5L.5"[SO
MSA5NTX<^CZ>5"0N/)-^=+=RFDP0\695X(F7[F N+_+BY.JTS*-)V>B%$8>"[
M9'XXL -BX-<C /!(XKNT&WZ/?A>6*75R#FDND'<[.UO=C3:>K:ZQUM') /\N
M4K,R<A:EA]ZVJA08Z@D"[@5\1W]7%3JKGA615BUK3;4BRU2Q;D4TE<JY>%HE
M^;RSK.\DN-\O[0AWR@BD=73D6*VB)=:.OEBM5^4&?N3)N9&TCJ1/L><X!K-^
M%TFW6NR=2II=F31G+Y 5>M;%A+BGN":R;.A2#S4"(P 1YL0Z"Q'7BAOQ"L5[
MC=^!41BXN.#1M\2/IX1<)XRZ1>E*2O&,IRK?37WY]D8V' )D^= J-OK/?[SI
MM+?_9:6--Q:\J 7W;#0Z#L)'D>G.WK.=4A7J5@VA8JH6(=O,L37D=A$-;>@_
M4QAXK#M(D \!0H< .9$_(4^+4M0HK36S_H)%>>@C)PA1$@'\3Y$P'7-STE:!
M-M<B&\$*QMQD/+:C:>A=^T/H>[@ C/<=)TQ@[,/A)38B!SONI?%7KP:GTZOB
MW:Z*-R--S+1 W)I3MW+RC8QKR#CK/W0%'. _V(, G)>7-?P".K/IFZH(<U+6
MG-;/%J;6N$*U1'8*'S#O8815O2*KRANM<72G*J4"$:%T&M$(K,E]("NZ.+Q.
M)I/ Q\5+IL2^58^$[0W&C%(R5AQ:,T(<(34RXLOH,@(3>TI\/B^,]AWLJ"._
MZJ0(R^B85+M=E=B<G(7I606"C7'5\#/C$8CF4T?)J:R\4JX*VAW&?20D"C-3
M(YDZ)D6CN-/+ +MDV/4FJ]\)4??*_"0MIS$4=EG#2@G^;%&2U.V?$6U\BT5\
M"RR7H8_U?Q\A$+,.!OM::TC<9+V,G)*5DA)+JY&5QD36.[W$QO %.+%P'BL4
MT;"U+<4DAJE9&;EFJ%Q0:)=)Y(QL!$+/SD<RH?1X954!ZS83)*D(,2=*5M7V
M;#1MK+!68#J,XCZ(Q@<V_'H6VK <$&'?:M@>&_P@9-8)'8L0LBBEQNSTI706
MPJ%02.Q+I6$QL0U"0T- C7SX\KD" 8G'7]IX^*%97+9#-\^*8A*6T?) F#A'
M1LZB]*PBP<:P] 77MY_*(>#T@7(!UF'"&K1B8S)UMLL<S'RVRUS9*"N^T3&/
M#A.S*!-IEE%+[E;+=ZDUG((.$[$HDOE_\8YS(R.1_8S'?DSW?FWH8G4GFT@
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M%*,\8.3P>+%':P;12C%:%*1J7&ET2Z5;U9AC3972KZ[C2##!KX5UB8E^+J9
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M7MZ'WK4_A-1QAW'VR6H2H2*3">XNC<]7\<:;[#A3=F+K.V_*N/'N"->,G&0
M3LL=]MUX7EV_ZPSO?Y'NKLVJ=!ZKV3@O\?8OTJ]*UL3:FJ?K3MF/;8/C, (8
M0$Z=7H^:CKWS&+;!0<7E61-WF^A.ZMJ7&!NJ@2_#G[@_Z95K]>\2-;3W5L&-
MT*<KK_A3I\#<;5(N6K$>T/R*XKU^YG+&0A6GMD1#&V;?7L->QD&"\/H>8=M
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M6X!.(_%&%8S(M;/69=V!=0[-6CF8<#QDDJ.B:_4UP@3X77HMD,W14QXD,A-
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MZ2K?[):G_4K,?1*F=@=/%LGLQ"*3RI<O'.+J_.UZ-I/\2!"EVY$E;V9_.$F
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MBLI&@Q0D65@&8(E6SI.N$Q<9RBG:6OR><+<]K"#[8G$=U;D@Y?JH@E<,XY^
M\,Z+MX$(;#]R)^$":S;M,N7.-.^4#RC<0AF5!EZ,"JBC/7"P_G.,+=8D72Z9
M0#NN<0&[9'+AR03;7IMWFN4B8&5CS9?:/>3<1+*\8I  #\Z687C[X9K5UTRC
M9_N9\B&YT!-9NL!R7;]LQ&3!#68L3_4_UAGLB"+RE"4C-O:3DJ.9%%2%+RGQ
MI/-T\QOD:*:-C'.-V#Q,9?Z%.W&]G; .&IFZ">VO91"X#]T\"VZ@FQ\A 9XC
M&$D;7ZXP\^3Q*^1<\\,#\%[V5M*K/:CR0BKQL'=TL)EKK]P?2157G36=1#@D
M'GK2[)_7X3*76V<M?D+#=M@81[8.'PXE2=I#3A*!DR=-[-E;BIZ2S\D?&AOG
M6Y0>>HD5'PBC&#[WDG-H?"+,)/8)'H%[!N&6<WLS3\AVP0?IJMG2>ZL _:A7
M$KP_<#34QI1-@G[SX"8PW';5(=Y (F[3ZOG3I)?' NU'?Q\:/$\ZUG[^!11D
M6>N&H!=/HHV7&PY(28E,"!MPR$9?+H/KE32RV.34,B:F;5*'Z_.$U&"?)JW4
MI:%,7*3B!92[N3*Y%+%W&#-Y'684+.SE^JHA)UG6'HR3%+!D.X0[&=-U(*?*
MG(8D5(2#^#M'1DAXAI.8JLJ_A*"_R>;B?!WH"MLXJHJ:02V7D]\H><L91;U
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M>N$V55S92TP[L98.IC0_,W=(19!&40<M_]NS.RX:XE!=&?CY.)O,/><Q$ZS
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M/KC>&B?_8)U-HY#$)*F5G!ER\)B(;,(%1*(8YT.#BWI@<PU_YO\!4$L#!!0
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M$R&GUR\JKWMP?"%=B[3%C#UE?C>"CS1P'9/HU,R;@%9<WT61]^P' 06E2>J
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M BJXOFXIX0ET.3) TU+/HLMPAZ&5OD6ZU-%8;^#W4CT@]50$3;3!JQ@KSF2
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MA P9/=I39*HFN@H528PJ@84L.3N*MVPKY6Z'.Y*0^ G<.R8@9"^AW9!U(M#
M$RW*X/5.&TI',A4PW]3I3HZ-&I"B)71T3N$^"KSRBI^MV9(&86H'V2E>K.J8
MRO,^ )D*WB.>0\52? \&SQ*%W VS1\^-UN0J2O)$@V'8I4;3IAW$^#%4 E,A
M;</LM+&GEZZ2M<L^(T\DB#:Y<^%EPYIS S-13&MZ:J($.VE^AYE:X3V1.*5:
M*6MWC\&E#@*3O!2[@$))WKC)V-SGB_F&L)(+X?*^B&B O@/Y=*8H9PA04TK1
MT+5(/C@O)R2DX*0\8;_3+-GYV71D=>["E=R'^CGM52N9D][1>2E@W/75I+8T
M;^7@K3O+"9XQ1(AW&H5I[#]FN8$R<$*6XWE'W&@9(J2-J=&<H BF"*8\VV&@
MN,^VF>N&I-(P3U,K9A>QV6.2QHX+;K44TC)Q0['OBT$/8VI=_Y(![#T$2GPI
M+R<9#$@5HCKG.,2>F01?Q""I.26&N&YN8[)QMDPT6T1QQ2,FOW&,]DR2L,VZ
MI]*ZN:'V#9>.834?,4JJ<>-*PZ"]L=Q8<2E7]F*0$@R]8\*/0>&#A3'J;.S!
MPL"/<>#'./!C'/@Q#GP*<>"Z%RA,Y/<Q]/L8^GT,_1YQZ/?>AQ2P,C:W3IQN
M*TW=DI-M]3<(UZ4&X6D)H";(HAEJJZ10KM . M;O3/T]S>,;2IM:/B'P>Y+#
M'8L7(S1O,#K<LE/_,0M#)[QP7OR&;>HTNDH]Y:P"I6%L-0S12S900P3VI%"R
MU_&__,?HRL^4,6]^8<\8R[]]2U!;JU.5T,:?9P6T7X[Y*D-Z#Y3LK./*4JF)
M:!<U$4W+X-WXU&H @(&]N[ERZ*P2 ;'.'!(MM&N9(%/%7"?9P^Q6FZ<K$A\<
M== J66MXBVY,G8NH#8MB&L<0[LO&Y!3B)'2/93>%%F*"8RD;P>BVZ!Y4U1$I
M^AI1P6Q[(-4!+N\'X<+[NQX-?!A'[Z.I\4=A$P_G=#QZ'8]>QZ/7<?1>QYKN
M:V IFJA5",<"=,R?%5><U1!-C/-FAV#E;+F,R=))\SY!@S"Q3M%>S6 H#C80
M1/,8YNJO[^URFG9*[RST;J+012DFH4#05E5U?=ZIH*=B/S!S..U5Y!N2XE3^
MZ*8QF<N1 Y'4G@!AS7D71TF"PQ4A*8LM)?09) 9-H="#,:?N5U&</I!XC9=E
MSJ<SI>=)@)9"R8;>AB:M_!K^M^._LL1+5RF],$SZ1K0A<;IE*6VL<P\37O(\
M=96D,3/YI$)P5B&(E#4FI]=#V#HCFYBXOM/V9@'D4U:&MNEX4698/6FR"@R2
M%_D=G3HKC3$/B\XWM9GNIPG,%T6B=FLB&/%,%4[%>)XA;J]+=F<M?7JWYAZI
M1"G3U6BK19'W[ <!Q;))\\Q/& !93)!N,#W:YOK';$UE@EU[G/FB20IX41)B
M5MW[1LRN)6U*D%2[#P?/WCR]O*5G_G?B K_\S2C=%IV6 *6: BD8"2!/LS6Z
M49HF9Y3!^OGHH]^9K<D#8] &/M+W[63[0#]'B(=7H8AW:>E'PHOW;J,MO!Q+
MN?\3E(V,,$H\O I%Q+='*3Y>8W,K\;$*)HK+0($R>.B\(B,MAM+CL1$EJ/Z8
M<(1[S9KD&T'7'#^F&QW3C8[I1H:'YY3.BPZ13_ RI*=^&9,DZ0H@Z=]E041J
MI):EMLA6[W,L @\\*ZF;W,-SI!SO(QMAE!99#@]4 $%I7G6Z(N$V<T)UU.L?
M6+4"R;/#FLM#>1<.#KJ3S \\5F"=M:XN_GFYWL31$\$IJ:U*UXXKSL2FH0^I
M@J6N]V.25Y:D#Q\+#"I/YFVQM/EBD8#7Q-.C;<VUW8/!FN@B=?BI)"(1DLS#
MF??$.M(D\%4.192L/%3]V"<$#BU[Z]39^*D3Y*%?GI]F=*-<%D%?]&Y(;Z+T
M(TEO'1\Z"U69["0/HC*F"BEA-EPBMUGLKIR$1 NGE+IDOI%>+@<^/6,?B<J0
M_;)ZA42,?":RX?#.@MQ_HL&B3D>*%"J('+1C"IH5<Z#B,1@J)^V8D'9,2#LF
MI(T](>WH>4&^:I%<,$</S-$#<_3 #%3P[6??"9<O_L>,)*R-BWK?^,[OII&\
MRUFSXN8?H<'<=$''IKYH]AQ=;58?6ZSN,3%QYHL[X@3G24KW73E[8&9RR5C*
M:85@'A\Z\$H+A^DFUXY''J)9]9:X."PA.>0;:!F+-(:UET@)9S_201'>4MYH
M9'>8E@K+NC^<,%,X2*@4-^L%^T.4.D$YX=O8=\FMLU6ULBJ-\^=@B@ GE8[S
M^CPJ1C\C 7,R;/=1&CH)K_(QIOCNJ($CS3X^.F%M2 LJWEA^&O-P?KM]2ON)
M$WZZBJ@JBY*_O"=S1AY3CE.N]U[B$#$J],C%1=4S)QE@L$0F)0:4]XULU0!.
M-FT?&Y.UV9CW],IS8C^"<IYUCFN[KY':MMM[PKJQP>CU5E)X'R8;XOH+GWA@
M_BW^V#9=6Z)]=W!%<E&!CH$3D@-Q54G88,]+U8L3:J;5WF\:4@)E-PVDQP/X
MAI+@A.0K:E%#<1CQJ%CW&@DWI9 K.A<7)&? W44BWECT&?7EC**/R*P@SV-Z
MF0?_YM5.X*^Q#@+3D;1$**'U.*L3TPLG,F9,(S#%WBW&WY!\AB#&"LD(@E]A
M0K98O<7Z<>88!C2A^\XD\$<2B7Z,_#E&_APC?X:(_+FZ.V4'73GBI_[W-MPE
M:OI;::ELK ]>::$T&('YXC1:K[/0=_.Z9)J=,F4CV,R'5@1:"@)"3[9_K[+?
M6=#3718[@=8VYGTY_@W-73-*0,()\7_WPZ46MNUO[!954-W [:4J=E(SLLU>
M1#%QG215+W&A:)9M#&QA1ROY 9H&V28>\(TR2S<G?8X]HKR;N[X:>>6$SH6"
M5P'9A9N6Q'1CAAO?V7SAE$-KFVM%>-(^1/$G>@OM4GN9_J4,+/=3J]M59J J
M(>8O?+1=H567UBV#R@P;HUV.N00R\H492@#]G!PG41Q'SY0LFDNP0F$LXNV5
M*"2J$QJL4C%UX9#^+ZYG-B<P(G%8C1$5; ;Q+%T[:1;[]#&FSS*JQ;Q&R-X%
MI<X2$4Z*UV^/\W&()STA5&8/EQ?^"_'*+O=W\-S2I3X:.XGZN5+!5/X*#10%
M>A6%2ZT@4&US)(= "T^1B5(ZAHGVR!M5-<Y3_/W )5>48=Z+L.+5#UU416)E
M'\Y_-P*'G=+&5/#7*<>$ C(*W577IF4W8$%APRJP2CU\ 9Q7J*Z[;FZ-T8]G
MQ#!5']Z7X\13NA9,77DF>[^\3)ED!KS1:T/;2EG2>_@[0<'2Q*M4V/\BPI\/
M;Z<\0&\&%- <U? Q\*67-M[_E RNCFL2GQ G=6%5*ZAJ4(Z\(,*JML+GT#9'
MMU;SUHA%+6SD:>8#645XL5XXS3(YU#@6$BSY_*I?VJP$,E6CBM(P:+(6-XE6
ME46E9*N&QK%R[90JU^KL\*$JUD)7/@7@\+%F[;%F[;%F[=&Z#76-:AFYA^KO
M>#1S'\W<1S-W;S/W]*O4&MF]S>NZ]CX7*/T7.PC8C8A2YX8 (I0=?QV_HQR_
M<GSEO=[\8G@;G'XEYM8JT4I+?(EE;4UL$E*XP"^?8S7;'O:C7A5LCXWYQG#4
M>G;E.U9PM\]"_:KM?/>1\<'SO;P=8$)FH3=/5R2>)0E)DYNH: S8+"8-<P;E
M1"=TGVJBJ5#L>" WU(/S0A1\3H:.24J&4 H_18'O.5LL;Q.?CIE,4<5$U:G4
M_@9Q]W)]2%+$R\>_8XDVRZ^^(]$R=C8KMC^A2["VQK9KF^1NKE;=U38H*LX:
M?284;*U2@RN^RAU[#,57>;MNSPD^,@B^%RXUF/JK8D[8K[]JS QP3XH;96$:
M;W_[Z1<![@EQOUY&3V]V?UQ O_N/ _*5H6R55)"=;H9O=<4H$;+GBP6ATM,3
MV3]0+"+JCM GQO4#/R_\,J-*#"7M!&Q+9'2L;>V/H?4)@!G95!?57GI(^-'L
M:\VEG)'$C?U-6GD^D03%*J7),%,(%[Q!66,+W5'E)XV+?\\7K#:+OPS/G3A$
M2%3O/Q^K!2[ CZ\$>Z3 XN8R9LME3)9T<F=1$#CQ;,T>%N1#W$USLL>9 R%:
M38DF_?U_GY"0 I<FMR2^7SDQ] .L3M>>0:\7(P5 JO2Z&LC^<TKO$"H?Q@YB
M\'&-QIV??,(R! D(&=2JZH1&U1XD^'CXT&(Y TJ[D&C- QN(N),_V38+W&-M
MGPHENT8C^5:LWD1"Q,!M2%RJ[:J)6'RJ4+)D5]+8K$).53%#4[@$5,%#V*2\
MLAK!!L<NA 8:S'QS[?P>Q:=9DE)1(DZ 3.,=@^(I0X#W&P\0>62N+NPL[&B^
MJ-$"LXGSQ[9H$^?OLQ)X 22@)D,A+1!3N(0!UDSA/7B 4NB=?T=2C<9=K9WX
MTS!"6)W<Q"6Q!G9H/7[:I$O"P\AD37+C$\PZ=[&8>TT(AQ/1&J3QY;1._HU-
M6.O-0L2^9[FMY\2A([V+(B^9A=Y-%)+U)HBVA-R3^,EW25()+#K9WF>;3>"3
M&*758Z_)3.G.[8N[2K>A039$.2VD'I.])F/Y-H<Y6WUV39,YB(TM^TP,H?]E
M_WUCN5/FN+8.X@MT3 76?3N4$H!E;IMC O Q ?B8 *S+,+0$X'?TA@@_.B']
M^?+6#P+EK$C.AZ/,2NC.D>0M':6AW4.T>2#AWGZE#'/W=S;B-Y0LO_L(^N[E
M@G=,*BDHX]GXP$J8DQ:2S15B&3+OG8 D=^2)A!FY(1H]U'3$XTX:]B)85*V
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M"IS,N;,Z=[<3=V?/Y#$S^RQ9EKN5V))&4G>F9]:L+)J$+*0I4B$IV\K]\Q<
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MB"<#N2;Q+!^#I\-QDR\T] -1( <2LLJCUT .1 YZP@.QS,\&+G[N;&SAU\1
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M$2L^XT:655W%XNTJ"@XI*EJT5W@#PX?(V6])2>:.JKWRUS8B)$(4..)1'C:
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MOF4 ,GV/YZ/"\YP/-P&7SS=6&BYGQ_W<];%]XAJ_[I> VKF R: F>>N_J!C
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M[Z3=H-7=75[AH^@(>?&1?@("O!(4VV=YQ_)T]H;;'5TUBY#=H  E\!8]D@K
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MTUS$%1\)CDSDHS.U0T7$NAPT<"#GOVBGFDE;5Q#]BE61$M?K<TR'0]0PX"F
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M 5"V!M@7<ZV^LFIPO=)44Y$TVI&Y-(@@GL;Q 7I]A)_D2YM/H"^#YX;QDR$
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M?X^P5DJ]V;;-#0WV5NN#R5%$5?L2,V>)"<4,A]&R/\NK&;J@GH$5W$I13--
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M6)/I(J$4T:JMHAP[\?;&#Y_Z,QLY$,S>-42H-,H<F0;(/)&Q:$_(Q"RL"9:
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MZ&?@KZ&/'F%TS(L)-G\"V43@93.)?R^MMSB0<[AQ9^<\D22%X1/Y!'Z^.96
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M:;&)#J-"H_.UK;&D:9?G_)&CBOE#;@EC&#W"*<EO=_QFQWTV'J"8*#KBG!Q
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MR*3D2P.GM%RGUJ<RL[97ENPHNP"H+Y5Q&Z!ZURFPN7!<B6A)UX&K^]OT_DE
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M7V2/VR[<=Y8E8%5=YM^%.U;<9/<.$#Z@\A.084#'C((R18H)6JWJT'ODOH_
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MDK0DBF EF8VJ*-A=QD(R$SI9Q5 95"(V.6-;$N6O2:)NK<J-,WZ351(/_2K
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M^^P,VK%EGWES[+-CUF?'V&6LY6C,&LS878/M-";4A:<'+&QG\6D8Q$F4NAS
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M%BQ?U6&0!5K"USONIH5?<*I[:59S$#I1.\8N#K7XNK36_L,!_H6G7V75]W"
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MGZ4\7A&5\9]/O3@A!O@U6;+C>A/202Y[TZ.[/>(#L;D%XUM*[6RC@?H&H2T
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MUJ]3:/U:\WJ]PIYVBL=5?T<[PR[E8-([-K5#:&K'UW;* R%J3>GZ37/1EQ-
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MC%S*UU'%TW.X%3$\I'+J7(#<@D(CZ5$9VI,T9F9L7BN*;=>]L<_]\+:/B/0
MHXZR !#(VN'M6^_?WW(^'IR8\/_Z_U!+ 0(4 Q0    ( *Z G5K!*@W/Y.\#
M  8[(0 :              "  0    !E83 R,C@P-S4M,C!F7W5N:79E<G-E
M+FAT;5!+ 0(4 Q0    ( *Z G5IT\'N, ,<  ,EB!P =              "
M 1SP P!E83 R,C@P-S4P,65X,2TQ7W5N:79E<G-E+FAT;5!+ 0(4 Q0    (
M *Z G5H#SCS_50<  !HB   >              "  5>W! !E83 R,C@P-S4P
M,65X,3(M,5]U;FEV97)S92YH=&U02P$"% ,4    " "N@)U:EM%E^$4'  !0
M(@  '@              @ 'HO@0 96$P,C(X,#<U,#%E>#$R+3)?=6YI=F5R
M<V4N:'1M4$L! A0#%     @ KH"=6F#F7CCV P  BPX  !X
M ( !:<8$ &5A,#(R.# W-3 Q97@Q,RTQ7W5N:79E<G-E+FAT;5!+ 0(4 Q0
M   ( *Z G5JP,FY-^ ,  +(.   >              "  9O*! !E83 R,C@P
M-S4P,65X,3,M,E]U;FEV97)S92YH=&U02P$"% ,4    " "N@)U:"EB"E2$&
M   5&P  '@              @ '/S@0 96$P,C(X,#<U,#%E>#$U+3%?=6YI
M=F5R<V4N:'1M4$L! A0#%     @ KH"=6GG)SX=X @  *@D  !X
M     ( !+-4$ &5A,#(R.# W-3 Q97@Q-2TR7W5N:79E<G-E+FAT;5!+ 0(4
M Q0    ( *Z G5I0HSO<3P,  !T-   =              "  >#7! !E83 R
M,C@P-S4P,65X,BTQ7W5N:79E<G-E+FAT;5!+ 0(4 Q0    ( *Z G5I4UDUS
M)CL  +1L 0 =              "  6K;! !E83 R,C@P-S4P,65X,BTS7W5N
M:79E<G-E+FAT;5!+ 0(4 Q0    ( *Z G5KR1CW7GT0  #K@ 0 >
M      "  <L6!0!E83 R,C@P-S4P,65X-"TQ,%]U;FEV97)S92YH=&U02P$"
M% ,4    " "N@)U:I":&4?D]   \$0( '@              @ &F6P4 96$P
M,C(X,#<U,#%E>#0M,3%?=6YI=F5R<V4N:'1M4$L! A0#%     @ KH"=6G>D
M,V4U1   X-@! !X              ( !VYD% &5A,#(R.# W-3 Q97@T+3$R
M7W5N:79E<G-E+FAT;5!+ 0(4 Q0    ( *Z G5I[J>31*T4  //E 0 =
M          "  4S>!0!E83 R,C@P-S4P,65X-"TV7W5N:79E<G-E+FAT;5!+
M 0(4 Q0    ( *Z G5JL=LAWS%0  !+B 0 =              "  ;(C!@!E
M83 R,C@P-S4P,65X-"TW7W5N:79E<G-E+FAT;5!+ 0(4 Q0    ( *Z G5K5
MPS69VE@   '< @ =              "  ;EX!@!E83 R,C@P-S4P,65X-"TX
M7W5N:79E<G-E+FAT;5!+ 0(4 Q0    ( *Z G5I]%[9=^$,   C: 0 =
M          "  <[1!@!E83 R,C@P-S4P,65X-"TY7W5N:79E<G-E+FAT;5!+
M 0(4 Q0    ( *Z G5J.'R!P#>,  "@) 0 -              "  0$6!P!I
M;6%G95\P,#$N:G!G4$L! A0#%     @ KH"=6OV! %_@10  >D\   T
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M              "  2EY"0!U<&,M,C R-# Y,S!?<')E+GAM;%!+!08
.&  8 +T&  "@U0D    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>ea0228075-20f_universe_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:currency="http://xbrl.sec.gov/currency/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:upc="http://www.UniversePharmaceuticalsINC.com/20240930"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="upc-20240930.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">upc:UniverseIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">upc:UniverseIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">upc:UniverseHKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">upc:UniverseTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-29</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-29</startDate>
            <endDate>2021-03-29</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-29</startDate>
            <endDate>2021-03-29</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-03</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-03</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-03</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-03</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-03</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-27</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-27</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:CommonStockOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-27</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:CommonStockOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-27</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-27</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-27</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-27</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-15</startDate>
            <endDate>2024-07-15</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-15</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2024-07-15</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <startDate>2024-07-15</startDate>
            <endDate>2024-07-15</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-27</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-27</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-27</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-27</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2024-09-27</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-27</startDate>
            <endDate>2024-09-27</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-27</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-12</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-12</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-12</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-12</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-24</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">upc:UniverseINCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">upc:UniverseTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">upc:UniverseHanheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">upc:UniverseHKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:UniversePharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:JxRcbBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:JxRcbBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">upc:OfficeAndElectricEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">upc:OfficeAndElectricEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">upc:YunnanFaxiPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrXiboLiuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-26</instant>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">upc:YunnanFaxiPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-26</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2022-09-26</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:YunnanFaxiPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:YunnanFaxiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-26</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2024-09-24</instant>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">upc:LandUseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">upc:LandUseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-25</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:ChenyuanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:ChenyuanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">upc:ConstructionInProgressTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:JiangxiYueshangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-06</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2021-05-06</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <startDate>2021-05-06</startDate>
            <endDate>2021-05-06</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiYueshangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:LRCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-13</instant>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:WorkingCapitalLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:LRCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-13</startDate>
            <endDate>2023-03-13</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:LRCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-15</instant>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:LRCBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-15</startDate>
            <endDate>2023-06-15</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:WorkingCapitalLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-15</startDate>
            <endDate>2023-06-15</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:LRCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-04</instant>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:LRCBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-04</startDate>
            <endDate>2024-03-04</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:LRCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:LRCBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-26</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:LRCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-17</instant>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:LRCBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-17</startDate>
            <endDate>2024-05-17</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-03</instant>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-03</startDate>
            <endDate>2025-03-03</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:LRCBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-03</startDate>
            <endDate>2025-03-03</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-22</instant>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-22</startDate>
            <endDate>2024-04-22</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:BankOfCommunicationsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-15</instant>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:BankOfCommunicationsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-15</startDate>
            <endDate>2023-06-15</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:BankOfCommunicationsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-16</instant>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:BankOfCommunicationsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-16</startDate>
            <endDate>2023-06-16</endDate>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:ZhujiangRuralBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-05</instant>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:ZhujiangRuralBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-05</startDate>
            <endDate>2023-05-05</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:ZhujiangRuralBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-24</instant>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:ZhujiangRuralBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-24</instant>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:ZhujiangRuralBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-24</startDate>
            <endDate>2024-04-24</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-24</instant>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-18</instant>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-18</startDate>
            <endDate>2025-04-18</endDate>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:ZhujiangRuralBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-18</startDate>
            <endDate>2025-04-18</endDate>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:BeijingBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-24</instant>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:BeijingBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-24</startDate>
            <endDate>2023-07-24</endDate>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:BeijingBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-24</instant>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">upc:BeijingBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-03</instant>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:BeijingBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-03</startDate>
            <endDate>2024-07-03</endDate>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">upc:BeijingBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-03</instant>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiLulingRuralCommercialBankLRCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiLulingRuralCommercialBankLRCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:BankOfCommunicationsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:BankOfCommunicationsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:ZhujiangRuralBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:ZhujiangRuralBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:BeijingBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:BeijingBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">upc:LRCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-23</instant>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">upc:LRCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-23</startDate>
            <endDate>2023-11-23</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">upc:LRCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">upc:LRCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">upc:JiangxiYueshangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:MrGangLaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-13</instant>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrGangLaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrYajunHuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MsLinYangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:GuangzhouNingjingInvestmentCoLtdGuangzhouNingjingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrYajunHuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrGangLaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrGangLaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MsLinYangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:TopTenCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:TopTenCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:TopTenCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">upc:GubenYanlingPillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">upc:GubenYanlingPillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">upc:GubenYanlingPillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">upc:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:supplierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">upc:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:TwoSupplierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">upc:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:supplierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">upc:PurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:supplierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseINCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-11</instant>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseINCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-07</instant>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseINCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-27</instant>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:CommonStockOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-27</instant>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-15</startDate>
            <endDate>2024-07-15</endDate>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-15</instant>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-15</startDate>
            <endDate>2024-07-15</endDate>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-27</instant>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-27</instant>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">upc:UnderwriterWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:UnderwriterWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:StatutoryReserveAndRestrictedNetAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:MrGangLaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-06</instant>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:JiangxiYueshangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-12</startDate>
            <endDate>2024-11-12</endDate>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-06</startDate>
            <endDate>2024-12-06</endDate>
        </period>
    </context>
    <context id="c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-06</instant>
        </period>
    </context>
    <context id="c238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">upc:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-06</instant>
        </period>
    </context>
    <context id="c239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-06</instant>
        </period>
    </context>
    <context id="c240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">upc:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-06</instant>
        </period>
    </context>
    <context id="c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">upc:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-06</instant>
        </period>
    </context>
    <context id="c242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:YunnanFaxiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-20</instant>
        </period>
    </context>
    <context id="c243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">upc:YunnanFaxiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:ParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:ParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="cny">
        <measure>iso4217:CNY</measure>
    </unit>
    <unit id="sqm">
        <measure>utr:sqm</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-22388">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c0" id="ixv-22389">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-22390">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-22391">2024-09-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-22392">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-22393">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-22394">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c0" id="ixv-22395">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-22396">001-40231</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-87">Universe Pharmaceuticals INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-102">E9</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-22397">265 Jingjiu Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0" id="ixv-22398">Jinggangshan Economic and Technological Development Zone</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-22399">Ji&#x2019;an, Jiangxi</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c0" id="ixv-22400">CN</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="c1" id="ixv-22401">343100</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-22402">343100</dei:EntityAddressPostalZipCode>
    <dei:ContactPersonnelName contextRef="c1" id="ixv-22403">Gang Lai</dei:ContactPersonnelName>
    <dei:CityAreaCode contextRef="c1" id="ixv-22404">+86</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1" id="ixv-22405">0796-8403309</dei:LocalPhoneNumber>
    <dei:ContactPersonnelEmailAddress contextRef="c1" id="ixv-22406">gang.lai@universe-pharmacy.com</dei:ContactPersonnelEmailAddress>
    <dei:EntityAddressAddressLine1 contextRef="c1" id="ixv-22407">265 Jingjiu Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c1" id="ixv-22408">Jinggangshan Economic and Technological Development Zone</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c1" id="ixv-135">Ji&#x2019;an, Jiangxi Province</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c1" id="ixv-22409">CN</dei:EntityAddressCountry>
    <dei:Security12bTitle contextRef="c0" id="ixv-165">Ordinary Shares</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-170">UPC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-22410">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-22411"
      unitRef="shares">23645974</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-22412">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-22413">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-22414">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-22415">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-273">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-281">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c0" id="ixv-22416">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-22417">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-22418">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard contextRef="c0" id="ixv-22419">U.S. GAAP</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="c0" id="ixv-22420">false</dei:EntityShellCompany>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c0" id="ixv-22421">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c0" id="ixv-15000">false</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c0" id="ixv-15001">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We have established cybersecurity risk management
to identify, assess, and mitigate cybersecurity risks alongside other business risks. The process is in alignment with our strategic objectives
and risk appetite. We may engage assessors, consultants, auditors, or other third parties to enhance our cyber security risk management
processes. Any cybersecurity incidents are closely monitored for their potential impact on our business strategy, operations, and financial
condition. As of the date of this annual report, we have not experienced any cybersecurity incidents that have materially affected or
are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition. We continuously
adapt our business strategy to enhance resilience, strengthen defenses and ensure the sustainability of our operations.&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c0" id="ixv-15002">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We have established cybersecurity risk management
to identify, assess, and mitigate cybersecurity risks alongside other business risks. The process is in alignment with our strategic objectives
and risk appetite. We may engage assessors, consultants, auditors, or other third parties to enhance our cyber security risk management
processes. Any cybersecurity incidents are closely monitored for their potential impact on our business strategy, operations, and financial
condition. As of the date of this annual report, we have not experienced any cybersecurity incidents that have materially affected or
are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition. We continuously
adapt our business strategy to enhance resilience, strengthen defenses and ensure the sustainability of our operations.&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c0" id="ixv-22422">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c0" id="ixv-22423">Any cybersecurity incidents are closely monitored for their potential impact on our business strategy, operations, and financial
condition.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="c0" id="ixv-22424">As of the date of this annual report, we have not experienced any cybersecurity incidents that have materially affected or
are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition.</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c0" id="ixv-22425">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <dei:AuditorFirmId contextRef="c0" id="ixv-22426">6907</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock contextRef="c0" id="ixv-15491">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Opinion
on the Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have audited the accompanying consolidated balance sheets of Universe Pharmaceuticals INC and its subsidiaries. (the
&#x201c;Company&#x201d;) as of September&#160;30, 2024 and 2023, the related consolidated statements of operations and comprehensive
loss, changes in shareholders&#x2019; equity and cash flows for the year ended September 30, 2024, 2023 and 2022 and the related
notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial
statements present fairly, in all material respects, the financial position of the Company as of September 30, 2024 and 2023, and
the results of its operations and its cash flows for the year ended September 30, 2024, 2023 and 2022, in conformity with accounting
principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="c0" id="ixv-22427">Enrome LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0" id="ixv-15542">Singapore</dei:AuditorLocation>
    <us-gaap:Cash contextRef="c2" decimals="0" id="ixv-22428" unitRef="usd">29497693</us-gaap:Cash>
    <us-gaap:Cash contextRef="c3" decimals="0" id="ixv-22429" unitRef="usd">5285247</us-gaap:Cash>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c2" decimals="0" id="ixv-22430" unitRef="usd">12905821</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="0" id="ixv-22431" unitRef="usd">11014908</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c5" decimals="0" id="ixv-22432" unitRef="usd">61678</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:InventoryNet contextRef="c2" decimals="0" id="ixv-22433" unitRef="usd">1737054</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c3" decimals="0" id="ixv-22434" unitRef="usd">3343266</us-gaap:InventoryNet>
    <us-gaap:Supplies contextRef="c2" decimals="0" id="ixv-22435" unitRef="usd">978203</us-gaap:Supplies>
    <us-gaap:Supplies contextRef="c3" decimals="0" id="ixv-22436" unitRef="usd">180643</us-gaap:Supplies>
    <upc:PrepaymentForAcquisitionCurrent contextRef="c3" decimals="0" id="ixv-22437" unitRef="usd">3426535</upc:PrepaymentForAcquisitionCurrent>
    <us-gaap:OtherReceivables contextRef="c2" decimals="0" id="ixv-22438" unitRef="usd">5666596</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables contextRef="c3" decimals="0" id="ixv-22439" unitRef="usd">1920251</us-gaap:OtherReceivables>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="0" id="ixv-22440" unitRef="usd">852417</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="0" id="ixv-22441" unitRef="usd">37178</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="0" id="ixv-22442" unitRef="usd">51637784</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="0" id="ixv-22443" unitRef="usd">25269706</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" id="ixv-22444" unitRef="usd">3568050</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" id="ixv-22445" unitRef="usd">3699965</us-gaap:PropertyPlantAndEquipmentNet>
    <upc:PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent contextRef="c4" decimals="0" id="ixv-22446" unitRef="usd">2279982</upc:PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent>
    <upc:PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent contextRef="c5" decimals="0" id="ixv-22447" unitRef="usd">2192982</upc:PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent>
    <upc:PrepaymentsForConstructionInProgress contextRef="c2" decimals="0" id="ixv-22448" unitRef="usd">9492205</upc:PrepaymentsForConstructionInProgress>
    <upc:PrepaymentsForConstructionInProgress contextRef="c3" decimals="0" id="ixv-22449" unitRef="usd">9092996</upc:PrepaymentsForConstructionInProgress>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c2" decimals="0" id="ixv-22450" unitRef="usd">262878</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c3" decimals="0" id="ixv-22451" unitRef="usd">148584</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:EquityMethodInvestments contextRef="c2" decimals="0" id="ixv-22452" unitRef="usd">712494</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c3" decimals="0" id="ixv-22453" unitRef="usd">685307</us-gaap:EquityMethodInvestments>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c3" decimals="0" id="ixv-22454" unitRef="usd">599078</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent contextRef="c5" decimals="0" id="ixv-22455" unitRef="usd">35864</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c2" decimals="0" id="ixv-22456" unitRef="usd">16315609</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c3" decimals="0" id="ixv-22457" unitRef="usd">16454776</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c2" decimals="0" id="ixv-22458" unitRef="usd">67953393</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="0" id="ixv-22459" unitRef="usd">41724482</us-gaap:Assets>
    <us-gaap:ShortTermBorrowings contextRef="c2" decimals="0" id="ixv-22460" unitRef="usd">5856703</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c3" decimals="0" id="ixv-22461" unitRef="usd">5482456</us-gaap:ShortTermBorrowings>
    <us-gaap:AccountsPayableCurrent contextRef="c2" decimals="0" id="ixv-22462" unitRef="usd">4914762</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c3" decimals="0" id="ixv-22463" unitRef="usd">4585283</us-gaap:AccountsPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c2" decimals="0" id="ixv-22464" unitRef="usd">1021181</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c3" decimals="0" id="ixv-22465" unitRef="usd">434758</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c4" decimals="0" id="ixv-22466" unitRef="usd">6900584</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c5" decimals="0" id="ixv-22467" unitRef="usd">540096</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-22468" unitRef="usd">1619739</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-22469" unitRef="usd">2711736</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-22470" unitRef="usd">20312969</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-22471" unitRef="usd">13754329</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermLoansFromBank contextRef="c2" decimals="0" id="ixv-22472" unitRef="usd">2137483</us-gaap:LongTermLoansFromBank>
    <us-gaap:Liabilities contextRef="c2" decimals="0" id="ixv-22473" unitRef="usd">22450452</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c3" decimals="0" id="ixv-22474" unitRef="usd">13754329</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="2"
      id="ix_6_fact"
      unitRef="usdPershares">11.25</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="2"
      id="ix_7_fact"
      unitRef="usdPershares">11.25</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c2"
      decimals="0"
      id="ix_2_fact"
      unitRef="shares">11250000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c3"
      decimals="0"
      id="ix_3_fact"
      unitRef="shares">11250000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="0"
      id="ix_4_fact"
      unitRef="shares">42880</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c2"
      decimals="0"
      id="ix_5_fact"
      unitRef="shares">42880</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c3"
      decimals="0"
      id="ix_8_fact"
      unitRef="shares">6062</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c3"
      decimals="0"
      id="ix_9_fact"
      unitRef="shares">6062</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c2" decimals="0" id="ix_0_fact" unitRef="usd">482400</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="0" id="ix_1_fact" unitRef="usd">67973</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c2" decimals="0" id="ixv-22485" unitRef="usd">53864720</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c3" decimals="0" id="ixv-22486" unitRef="usd">29279155</us-gaap:AdditionalPaidInCapitalCommonStock>
    <upc:StatutoryReserve contextRef="c2" decimals="0" id="ixv-22487" unitRef="usd">2439535</upc:StatutoryReserve>
    <upc:StatutoryReserve contextRef="c3" decimals="0" id="ixv-22488" unitRef="usd">2439535</upc:StatutoryReserve>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="0" id="ixv-22489" unitRef="usd">-10171568</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="0" id="ixv-22490" unitRef="usd">-1444270</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c2" decimals="0" id="ixv-22491" unitRef="usd">-1112146</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c3" decimals="0" id="ixv-22492" unitRef="usd">-2372240</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" id="ixv-22493" unitRef="usd">45502941</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" id="ixv-22494" unitRef="usd">27970153</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="0" id="ixv-22495" unitRef="usd">67953393</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="0" id="ixv-22496" unitRef="usd">41724482</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c0" decimals="0" id="ixv-22497" unitRef="usd">23024458</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c6" decimals="0" id="ixv-22498" unitRef="usd">32308735</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c7" decimals="0" id="ixv-22499" unitRef="usd">40143151</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c0" decimals="0" id="ixv-22500" unitRef="usd">16952556</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c6" decimals="0" id="ixv-22501" unitRef="usd">21993601</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c7" decimals="0" id="ixv-22502" unitRef="usd">18251815</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c0" decimals="0" id="ixv-22503" unitRef="usd">6071902</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c6" decimals="0" id="ixv-22504" unitRef="usd">10315134</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c7" decimals="0" id="ixv-22505" unitRef="usd">21891336</us-gaap:GrossProfit>
    <us-gaap:SellingExpense contextRef="c0" decimals="0" id="ixv-22506" unitRef="usd">8170975</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="c6" decimals="0" id="ixv-22507" unitRef="usd">6783703</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="c7" decimals="0" id="ixv-22508" unitRef="usd">19083135</us-gaap:SellingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" id="ixv-22509" unitRef="usd">2889652</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c6" decimals="0" id="ixv-22510" unitRef="usd">2638984</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c7" decimals="0" id="ixv-22511" unitRef="usd">2183270</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" id="ixv-22512" unitRef="usd">3031115</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c6" decimals="0" id="ixv-22513" unitRef="usd">4858548</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c7" decimals="0" id="ixv-22514" unitRef="usd">7644375</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" id="ixv-22515" unitRef="usd">14091742</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c6" decimals="0" id="ixv-22516" unitRef="usd">14281235</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c7" decimals="0" id="ixv-22517" unitRef="usd">28910780</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" id="ixv-22518" unitRef="usd">-8019840</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c6" decimals="0" id="ixv-22519" unitRef="usd">-3966101</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c7" decimals="0" id="ixv-22520" unitRef="usd">-7019444</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating contextRef="c0" decimals="0" id="ixv-22521" unitRef="usd">278172</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c6" decimals="0" id="ixv-22522" unitRef="usd">156788</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c7" decimals="0" id="ixv-22523" unitRef="usd">162400</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c0" decimals="0" id="ixv-22524" unitRef="usd">145476</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c6" decimals="0" id="ixv-22525" unitRef="usd">-235614</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c7" decimals="0" id="ixv-22526" unitRef="usd">48940</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c0" decimals="0" id="ixv-22527" unitRef="usd">31942</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c6" decimals="0" id="ixv-22528" unitRef="usd">31072</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c7" decimals="0" id="ixv-22529" unitRef="usd">38588</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="0" id="ixv-22530" unitRef="usd">-100754</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c6" decimals="0" id="ixv-22531" unitRef="usd">-361330</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c7" decimals="0" id="ixv-22532" unitRef="usd">-74872</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="0" id="ixv-22533" unitRef="usd">-8120594</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c6" decimals="0" id="ixv-22534" unitRef="usd">-4327431</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c7" decimals="0" id="ixv-22535" unitRef="usd">-7094316</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-22536" unitRef="usd">606704</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c6" decimals="0" id="ixv-22537" unitRef="usd">2253593</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c7" decimals="0" id="ixv-22538" unitRef="usd">815322</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-22539" unitRef="usd">-8727298</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="0" id="ixv-22540" unitRef="usd">-6581024</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="0" id="ixv-22541" unitRef="usd">-7909638</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c0" decimals="0" id="ixv-22542" unitRef="usd">-1260094</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c6" decimals="0" id="ixv-22543" unitRef="usd">779351</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c7" decimals="0" id="ixv-22544" unitRef="usd">3752143</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c0" decimals="0" id="ixv-22545" unitRef="usd">-7467204</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c6" decimals="0" id="ixv-22546" unitRef="usd">-7360375</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c7" decimals="0" id="ixv-22547" unitRef="usd">-11661781</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-22548"
      unitRef="usdPershares">-626.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-22549"
      unitRef="usdPershares">-626.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c6"
      decimals="2"
      id="ixv-22550"
      unitRef="usdPershares">-1089.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c6"
      decimals="2"
      id="ixv-22551"
      unitRef="usdPershares">-1089.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c7"
      decimals="2"
      id="ixv-22552"
      unitRef="usdPershares">-1309.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c7"
      decimals="2"
      id="ixv-22553"
      unitRef="usdPershares">-1309.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="ix_10_fact"
      unitRef="shares">13920</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="0"
      id="ix_11_fact"
      unitRef="shares">13920</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c6"
      decimals="0"
      id="ix_12_fact"
      unitRef="shares">6042</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c6"
      decimals="0"
      id="ix_13_fact"
      unitRef="shares">6042</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c7"
      decimals="0"
      id="ix_14_fact"
      unitRef="shares">6042</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c7"
      decimals="0"
      id="ix_15_fact"
      unitRef="shares">6042</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c8"
      decimals="0"
      id="ix_16_fact"
      unitRef="shares">6042</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="0" id="ixv-22561" unitRef="usd">67973</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="0" id="ixv-22562" unitRef="usd">29279155</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="0" id="ixv-22563" unitRef="usd">2439535</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c11" decimals="0" id="ixv-22564" unitRef="usd">13046392</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c12" decimals="0" id="ixv-22565" unitRef="usd">2159254</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c13" decimals="0" id="ixv-22566" unitRef="usd">46992309</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c17" decimals="0" id="ixv-22567" unitRef="usd">-7909638</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="0" id="ixv-22568" unitRef="usd">-7909638</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c18" decimals="0" id="ixv-22569" unitRef="usd">3752143</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c7" decimals="0" id="ixv-22570" unitRef="usd">3752143</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c19"
      decimals="0"
      id="ix_17_fact"
      unitRef="shares">6042</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="0" id="ixv-22572" unitRef="usd">67973</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="0" id="ixv-22573" unitRef="usd">29279155</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="0" id="ixv-22574" unitRef="usd">2439535</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="0" id="ixv-22575" unitRef="usd">5136754</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c23" decimals="0" id="ixv-22576" unitRef="usd">-1592889</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c24" decimals="0" id="ixv-22577" unitRef="usd">35330528</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c28" decimals="0" id="ixv-22578" unitRef="usd">-6581024</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="0" id="ixv-22579" unitRef="usd">-6581024</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c29" decimals="0" id="ixv-22580" unitRef="usd">779351</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c6" decimals="0" id="ixv-22581" unitRef="usd">779351</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c30"
      decimals="0"
      id="ix_18_fact"
      unitRef="shares">6042</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c30" decimals="0" id="ixv-22583" unitRef="usd">67973</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c31" decimals="0" id="ixv-22584" unitRef="usd">29279155</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c32" decimals="0" id="ixv-22585" unitRef="usd">2439535</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c33" decimals="0" id="ixv-22586" unitRef="usd">-1444270</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c34" decimals="0" id="ixv-22587" unitRef="usd">-2372240</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" id="ixv-22588" unitRef="usd">27970153</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c35"
      decimals="0"
      id="ix_19_fact"
      unitRef="shares">33333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c35" decimals="0" id="ixv-22590" unitRef="usd">374996</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c36" decimals="0" id="ixv-22591" unitRef="usd">24624996</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c0" decimals="0" id="ixv-22592" unitRef="usd">24999992</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="c35"
      decimals="0"
      id="ix_20_fact"
      unitRef="shares">3505</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <upc:StockIssuedDuringPeriodValueReverseShareSplitAdjustment contextRef="c35" decimals="0" id="ixv-22594" unitRef="usd">39431</upc:StockIssuedDuringPeriodValueReverseShareSplitAdjustment>
    <upc:StockIssuedDuringPeriodValueReverseShareSplitAdjustment contextRef="c36" decimals="0" id="ixv-22595" unitRef="usd">-39431</upc:StockIssuedDuringPeriodValueReverseShareSplitAdjustment>
    <us-gaap:NetIncomeLoss contextRef="c38" decimals="0" id="ixv-22596" unitRef="usd">-8727298</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-22597" unitRef="usd">-8727298</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c39" decimals="0" id="ixv-22598" unitRef="usd">-1260094</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c0" decimals="0" id="ixv-22599" unitRef="usd">-1260094</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c40"
      decimals="0"
      id="ix_21_fact"
      unitRef="shares">42880</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c40" decimals="0" id="ixv-22601" unitRef="usd">482400</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c41" decimals="0" id="ixv-22602" unitRef="usd">53864720</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c42" decimals="0" id="ixv-22603" unitRef="usd">2439535</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c43" decimals="0" id="ixv-22604" unitRef="usd">-10171568</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c44" decimals="0" id="ixv-22605" unitRef="usd">-1112146</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" id="ixv-22606" unitRef="usd">45502941</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-22607" unitRef="usd">-8727298</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="0" id="ixv-22608" unitRef="usd">-6581024</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="0" id="ixv-22609" unitRef="usd">-7909638</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c0" decimals="0" id="ixv-22610" unitRef="usd">485734</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c6" decimals="0" id="ixv-22611" unitRef="usd">508785</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c7" decimals="0" id="ixv-22612" unitRef="usd">533949</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c0" decimals="0" id="ixv-22613" unitRef="usd">-3958</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c6" decimals="0" id="ixv-22614" unitRef="usd">-114</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c7" decimals="0" id="ixv-22615" unitRef="usd">-983</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c0" decimals="0" id="ixv-22616" unitRef="usd">131581</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:InventoryLIFOReservePeriodCharge contextRef="c0" decimals="0" id="ixv-22617" unitRef="usd">50651</us-gaap:InventoryLIFOReservePeriodCharge>
    <us-gaap:InventoryLIFOReservePeriodCharge contextRef="c6" decimals="0" id="ixv-22618" unitRef="usd">-49166</us-gaap:InventoryLIFOReservePeriodCharge>
    <us-gaap:InventoryLIFOReservePeriodCharge contextRef="c7" decimals="0" id="ixv-22619" unitRef="usd">15774</us-gaap:InventoryLIFOReservePeriodCharge>
    <upc:ChangeInFairValueOfShorttermInvestments contextRef="c0" decimals="0" id="ixv-22620" unitRef="usd">-606704</upc:ChangeInFairValueOfShorttermInvestments>
    <upc:ChangeInFairValueOfShorttermInvestments contextRef="c6" decimals="0" id="ixv-22621" unitRef="usd">-1567656</upc:ChangeInFairValueOfShorttermInvestments>
    <upc:ChangeInFairValueOfShorttermInvestments contextRef="c7" decimals="0" id="ixv-22622" unitRef="usd">542375</upc:ChangeInFairValueOfShorttermInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c0" decimals="0" id="ixv-22623" unitRef="usd">1547834</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c6" decimals="0" id="ixv-22624" unitRef="usd">-4718118</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c7" decimals="0" id="ixv-22625" unitRef="usd">1526243</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="0" id="ixv-22626" unitRef="usd">-1643131</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c6" decimals="0" id="ixv-22627" unitRef="usd">1183823</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c7" decimals="0" id="ixv-22628" unitRef="usd">-16586</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidSupplies contextRef="c0" decimals="0" id="ixv-22629" unitRef="usd">769911</us-gaap:IncreaseDecreaseInPrepaidSupplies>
    <us-gaap:IncreaseDecreaseInPrepaidSupplies contextRef="c6" decimals="0" id="ixv-22630" unitRef="usd">170016</us-gaap:IncreaseDecreaseInPrepaidSupplies>
    <us-gaap:IncreaseDecreaseInPrepaidSupplies contextRef="c7" decimals="0" id="ixv-22631" unitRef="usd">-2681214</us-gaap:IncreaseDecreaseInPrepaidSupplies>
    <us-gaap:IncreaseDecreaseInPrepaidAdvertising contextRef="c7" decimals="0" id="ixv-22632" unitRef="usd">-7385695</us-gaap:IncreaseDecreaseInPrepaidAdvertising>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="c7" decimals="0" id="ixv-22633" unitRef="usd">236982</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c0" decimals="0" id="ixv-22634" unitRef="usd">158011</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c6" decimals="0" id="ixv-22635" unitRef="usd">-391568</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c7" decimals="0" id="ixv-22636" unitRef="usd">1030121</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="0" id="ixv-22637" unitRef="usd">792675</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c6" decimals="0" id="ixv-22638" unitRef="usd">-696147</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c7" decimals="0" id="ixv-22639" unitRef="usd">659017</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="c6" decimals="0" id="ixv-22640" unitRef="usd">947964</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <upc:IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent contextRef="c0" decimals="0" id="ixv-22641" unitRef="usd">-36321</upc:IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c0" decimals="0" id="ixv-22642" unitRef="usd">143747</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c6" decimals="0" id="ixv-22643" unitRef="usd">1641426</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c7" decimals="0" id="ixv-22644" unitRef="usd">-1919691</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c0" decimals="0" id="ixv-22645" unitRef="usd">554425</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c6" decimals="0" id="ixv-22646" unitRef="usd">280939</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c7" decimals="0" id="ixv-22647" unitRef="usd">-904127</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c0" decimals="0" id="ixv-22648" unitRef="usd">-1167206</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c6" decimals="0" id="ixv-22649" unitRef="usd">244015</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c7" decimals="0" id="ixv-22650" unitRef="usd">2318474</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" id="ixv-22651" unitRef="usd">-9506683</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c6" decimals="0" id="ixv-22652" unitRef="usd">1116775</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c7" decimals="0" id="ixv-22653" unitRef="usd">-1301555</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="0" id="ixv-22654" unitRef="usd">208320</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c6" decimals="0" id="ixv-22655" unitRef="usd">44169</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c7" decimals="0" id="ixv-22656" unitRef="usd">93703</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <upc:ProceedsFromPaymentForConstructionInProgress contextRef="c0" decimals="0" id="ixv-22657" unitRef="usd">-37478</upc:ProceedsFromPaymentForConstructionInProgress>
    <upc:ProceedsFromPaymentForConstructionInProgress contextRef="c7" decimals="0" id="ixv-22658" unitRef="usd">523</upc:ProceedsFromPaymentForConstructionInProgress>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c0" decimals="0" id="ixv-22659" unitRef="usd">117291</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c7" decimals="0" id="ixv-22660" unitRef="usd">3814925</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c0" decimals="0" id="ixv-22661" unitRef="usd">1804</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="0" id="ixv-22662" unitRef="usd">-361285</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c6" decimals="0" id="ixv-22663" unitRef="usd">-44169</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c7" decimals="0" id="ixv-22664" unitRef="usd">-3908105</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c0" decimals="0" id="ixv-22665" unitRef="usd">24999992</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromBankDebt contextRef="c0" decimals="0" id="ixv-22666" unitRef="usd">7787016</us-gaap:ProceedsFromBankDebt>
    <us-gaap:ProceedsFromBankDebt contextRef="c6" decimals="0" id="ixv-22667" unitRef="usd">5671104</us-gaap:ProceedsFromBankDebt>
    <us-gaap:ProceedsFromBankDebt contextRef="c7" decimals="0" id="ixv-22668" unitRef="usd">4272716</us-gaap:ProceedsFromBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c0" decimals="0" id="ixv-22669" unitRef="usd">5552240</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c6" decimals="0" id="ixv-22670" unitRef="usd">3969773</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c7" decimals="0" id="ixv-22671" unitRef="usd">4272716</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="c0" decimals="0" id="ixv-22672" unitRef="usd">6719557</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="c6" decimals="0" id="ixv-22673" unitRef="usd">-3091977</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="c7" decimals="0" id="ixv-22674" unitRef="usd">3317943</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="0" id="ixv-22675" unitRef="usd">33954325</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c6" decimals="0" id="ixv-22676" unitRef="usd">-1390646</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c7" decimals="0" id="ixv-22677" unitRef="usd">3317943</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c0" decimals="0" id="ixv-22678" unitRef="usd">126089</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c6" decimals="0" id="ixv-22679" unitRef="usd">-108171</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c7" decimals="0" id="ixv-22680" unitRef="usd">-474733</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="0" id="ixv-22681" unitRef="usd">24212446</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c6" decimals="0" id="ixv-22682" unitRef="usd">-426211</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c7" decimals="0" id="ixv-22683" unitRef="usd">-2366450</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" id="ixv-22684" unitRef="usd">5285247</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c24" decimals="0" id="ixv-22685" unitRef="usd">5711458</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c13" decimals="0" id="ixv-22686" unitRef="usd">8077908</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="0" id="ixv-22687" unitRef="usd">29497693</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" id="ixv-22688" unitRef="usd">5285247</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c24" decimals="0" id="ixv-22689" unitRef="usd">5711458</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="0" id="ixv-22690" unitRef="usd">304516</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c6" decimals="0" id="ixv-22691" unitRef="usd">190184</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c7" decimals="0" id="ixv-22692" unitRef="usd">199852</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c6" decimals="0" id="ixv-22693" unitRef="usd">863800</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c7" decimals="0" id="ixv-22694" unitRef="usd">2748629</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:NatureOfOperations contextRef="c0" id="ixv-18026">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;NOTE
1 &#x2014; ORGANIZATION AND BUSINESS DESCRIPTION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Universe
Pharmaceuticals INC (&#x201c;Universe INC&#x201d; or the &#x201c;Company&#x201d;) was incorporated under the laws of the Cayman Islands on
December 11, 2019 as an exempted company with limited liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Universe
INC owns&#160;100% equity interest of Universe Pharmaceuticals (International) Group (&#x201c;Universe HK&#x201d;), an entity incorporated
on May 21, 2014 in accordance with the laws and regulations in Hong Kong.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Jiangxi
Universe Pharmaceuticals Technology Co., Ltd. (&#x201c;Universe Technology&#x201d;) was formed on April 8, 2019, as a wholly foreign-owned
enterprise (&#x201c;WFOE&#x201d;) in the People&#x2019;s Republic of China (the &#x201c;PRC&#x201d; or &#x201c;China&#x201d;). &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Universe
INC, Universe HK and Universe Technology are currently not engaging in any active business operations and are merely acting as holding
companies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Jiangxi
Universe Pharmaceuticals Co., Ltd.&#160;(&#x201c;Jiangxi Universe&#x201d;) was incorporated on March 2, 1998 in accordance with PRC laws
and is engaged in the research and development and manufacturing of modernized traditional Chinese medicines.&#160;Jiangxi Universe owns&#160;100%
of the equity interests of Jiangxi Universe Pharmaceuticals Commercial Trade Co., Ltd. (&#x201c;Universe Trade&#x201d;), which was incorporated
on March 10, 2010 for the purposes of handling the sales and distribution of the pharmaceutical products manufactured by Jiangxi Universe.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Reorganization&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;A
reorganization of the Company&#x2019;s legal structure (the &#x201c;Reorganization&#x201d;) was completed on December 11, 2019. The Reorganization
involved the incorporation of Universe INC and Universe Technology, and the transfer of&#160;100% of the equity interests of Jiangxi
Universe to Universe Technology. Consequently, Universe INC, through its subsidiary Universe HK, directly controls Universe Technology
and Jiangxi Universe, and became the ultimate holding company of all other entities mentioned above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Reorganization has been accounted for as a recapitalization among entities under common control, since the same controlling shareholders
controlled all these entities before and after the Reorganization. Results of operations for the periods presented eliminate the effects
of intra-entity transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
March 25, 2021, the Company closed its initial public offering (the &#x201c;IPO&#x201d;) of&#160;5,000,000&#160;ordinary shares, par value
$0.003125&#160;per share at a public offering price of $5.00&#160;per share. On March 29, 2021, the underwriter exercised in full its
over-allotment option to purchase an additional&#160;750,000&#160;ordinary shares. The closing for the sale of the over-allotment shares
took place on September 30, 2021. Gross proceeds from the IPO totaled $28.75&#160;million. Net proceeds of the IPO, including over-allotment
shares, were approximately $25.6&#160;million. In connection with the IPO, the Company&#x2019;s ordinary shares began trading on the Nasdaq
Global Market under the symbol &#x201c;UPC&#x201d; on March 23, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
May 12, 2021, through the Company&#x2019;s PRC subsidiary, Jiangxi Universe, the Company established an indirect wholly controlled subsidiary,
Guangzhou Universe Hanhe Medical Research Co., Ltd. (&#x201c;Universe Hanhe&#x201d;) in Guangzhou City, China, for the business purpose
of conducting research and development of new pharmaceutical products in order to diversify the Company&#x2019;s product offerings. As
of September 30, 2024 and as of the date of this report, Universe Hanhe has no active business operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 3, 2023, the Company held an annual general meeting of shareholders at which shareholders, among other things, resolved:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;with immediate effect, to increase the Company&#x2019;s authorized share capital from US$312,500 divided into 90,000,000 ordinary shares of par value US$0.003125 each and 10,000,000 preferred shares of par value US$0.003125 each, to US$3,125,000 divided into 900,000,000 ordinary shares of par value US$0.003125 each and 100,000,000 preferred shares of par value US$0.003125 each;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;that, conditional upon the approval of the board of directors of the Company in its sole discretion, with effect as of the date the board of directors of the Company may determine, the authorized, issued and outstanding shares of the Company be consolidated by consolidating each 10 shares of the Company, or such lesser whole share amount as the board of directors may determine in its sole discretion, such amount not to be less than 2, into 1 share of the Company, with such consolidated shares having the same rights and being subject to the same restrictions (save as to nominal value) as the then existing shares of par value US$0.003125 each in the capital of the Company (the &#x201c;2023 Share Consolidation&#x201d;); and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(c)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;that, upon the effectiveness
    of the 2023 Share Consolidation, the Company adopt amended and restated articles of association, in substantially the form set out
    in Annex B in the proxy statement dated May 24, 2023, in substitution for and to the exclusion of, the memorandum of association
    of the Company in effect immediately prior to effectiveness of the Share Consolidation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
board of directors of the Company resolved to effect the 2023 Share Consolidation on July 27, 2023 with the authorized, issued and outstanding
shares to be consolidated on a six (6) for one (1) ratio, which had the effect of reducing the number of: (a) authorized ordinary shares
from 900,000,000 ordinary shares with a par value of US$0.003125 per share to 150,000,000 ordinary shares with a par value of US$0.01875
per share; (b) issued and outstanding ordinary shares from 21,750,000 ordinary shares with a par value of US$0.003125 per share to 3,625,000
ordinary shares with a par value of US$0.01875 per share; and (c) authorized preferred shares from 100,000,000 preferred shares with
a par value of US$0.003125 per share to 16,666,666.6666 preferred shares with a par value of US$0.01875 per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 15, 2024, the Company closed its self-underwritten public offering of 20,000,000 ordinary shares, par value $0.01875 per share.
The ordinary shares were priced at $1.25 per share. The Company raised a total of $25 million through that offering, before deducting
offering-related expenses, and net proceeds of $24.625 million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 27, 2024, the Company held an annual general meeting of shareholders at which shareholders, among other things, resolved:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;with immediate effect, to increase the Company&#x2019;s authorized share capital from US$3,125,000 divided into 150,000,000 ordinary shares of par value US$0.01875 each and 16,666,666.6666 preferred shares of par value US$0.01875 each, to US$140,625,000 divided into 6,750,000,000 ordinary shares of par value US$0.01875 each and 750,000,000 preferred shares of par value US$0.01875 each (the &#x201c;Authorized Share Capital Increase&#x201d;);&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;that, subject to and immediately
    following the Authorized Share Capital Increase being effected, the Company adopt an amended and restated memorandum of association
    in substitution for, and to the exclusion of, the Company&#x2019;s existing memorandum of association, to reflect the Authorized Share
    Capital Increase; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(c)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;that, conditional upon
    the approval of the board of directors of the Company in its sole discretion, with effect as of the date the board of directors of
    the Company may determine, the authorized, issued, and outstanding shares of the Company (collectively, the &#x201c;Shares&#x201d;)
    be consolidated by consolidating each 15 Shares of the Company, or such lesser whole share amount as the Company&#x2019;s board of
    directors may determine in its sole discretion, such amount not to be less than 2, into 1 Share of the Company, with such consolidated
    Shares having the same rights and being subject to the same restrictions (save as to nominal value) as the existing Shares of such
    class as set out in the Company&#x2019;s memorandum and articles of association (the &#x201c;2024 Share Consolidation&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 12, 2024, the Company effected a share consolidation of 15 ordinary shares with par value of US$0.01875 per share each in the
Company&#x2019;s issued and unissued share capital into one (1) ordinary share with par value of US$0.28125. All fractional shares were
rounded up to the whole number of shares. Immediately following the 2024 Share Consolidation, the authorized share capital of the Company
was US$140,625,000 divided into 450,000,000 ordinary shares, par value US$0.28125 per share and 50,000,000 preferred shares, par value
US$0.28125 per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 24, 2025, the Company effected a share consolidation
of 40 ordinary shares with par value of US$0.28125 per share each in the Company&#x2019;s issued and unissued share capital into one ordinary
share with par value of US$11.25. All fractional shares were rounded up to the whole number of shares (the &#x201c;2025 Share Consolidation&#x201d;).
Immediately following the Share Consolidation, the authorized share capital of the Company was US$140,625,000 divided into 11,250,000
ordinary shares, par value US$11.25 per share and 1,250,000 preferred shares, par value US$11.25 per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Company&#x2019;s consolidated
financial statements were retrospectively restated for effect of the 15-for-1 and 40-for-1 share consolidations. Giving effect to the
share consolidations, there were 42,880 ordinary shares issued and outstanding as of September 30, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Details
of the subsidiaries of the Company as of September 30, 2024 are set out below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Date of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Place of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;% of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name of Entity&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Incorporation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Incorporation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ownership&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principal Activities&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Universe INC&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December 11, 2019&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cayman Islands&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Parent, 100%&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment holding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 25%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Universe HK&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 18%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;May 21, 2014&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 15%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Hong Kong&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 10%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 28%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment holding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Universe Technology&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;April 18, 2019&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PRC&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;WFOE, Investment holding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jiangxi Universe&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;March 2, 1998&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PRC&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development and manufacturing of modernized traditional Chinese medicines&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Universe Trade&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;March 10, 2010&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PRC&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sales of modernized traditional Chinese medicines&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Universe Hanhe&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;May 12, 2021&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PRC&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development of new pharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company, through its wholly-owned subsidiaries, is primarily engaged in the development, manufacturing and sale of traditional Chinese
medicines derivatives (&#x201c;TCMD&#x201d;) products targeted to the elderly to address their physical conditions in the aging process
and to promote their general well-being. In addition, the Company also sells biochemical drugs, medical instruments, traditional Chinese
medicine pieces products and dietary supplements (collectively, &#x201c;third-party products&#x201d;). All of these TCMD and third-party
products are currently sold to customers including pharmaceutical companies, hospitals, clinics and drugstore chains throughout China.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c45" id="ixv-22695">2019-12-11</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c46" decimals="2" id="ixv-22696" unitRef="pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c47" id="ixv-22697">2014-05-21</dei:EntityIncorporationDateOfIncorporation>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c48" id="ixv-22698">1998-03-02</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c49" decimals="2" id="ixv-22699" unitRef="pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c50" decimals="2" id="ixv-22700" unitRef="pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:SharesIssued
      contextRef="c51"
      decimals="0"
      id="ixv-22701"
      unitRef="shares">5000000</us-gaap:SharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c52"
      decimals="6"
      id="ixv-22702"
      unitRef="usdPershares">0.003125</us-gaap:CommonStockParOrStatedValuePerShare>
    <upc:PublicOfferingPrice
      contextRef="c53"
      decimals="2"
      id="ixv-22703"
      unitRef="usdPershares">5</upc:PublicOfferingPrice>
    <us-gaap:ExcessStockSharesIssued
      contextRef="c54"
      decimals="0"
      id="ixv-22704"
      unitRef="shares">750000</us-gaap:ExcessStockSharesIssued>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c55" decimals="-4" id="ixv-22705" unitRef="usd">28750000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c56" decimals="-5" id="ixv-22706" unitRef="usd">25600000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:CapitalUnits contextRef="c57" decimals="0" id="ixv-22707" unitRef="usd">312500</us-gaap:CapitalUnits>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c58"
      decimals="0"
      id="ixv-22708"
      unitRef="shares">90000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c57"
      decimals="6"
      id="ixv-22709"
      unitRef="usdPershares">0.003125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c59"
      decimals="0"
      id="ixv-22710"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c57"
      decimals="6"
      id="ixv-22711"
      unitRef="usdPershares">0.003125</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CapitalUnits contextRef="c60" decimals="0" id="ixv-22712" unitRef="usd">3125000</us-gaap:CapitalUnits>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c60"
      decimals="0"
      id="ixv-22713"
      unitRef="shares">900000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c61"
      decimals="6"
      id="ixv-22714"
      unitRef="usdPershares">0.003125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c61"
      decimals="0"
      id="ixv-22715"
      unitRef="shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c61"
      decimals="6"
      id="ixv-22716"
      unitRef="usdPershares">0.003125</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c40"
      decimals="6"
      id="ixv-22717"
      unitRef="usdPershares">0.003125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c62"
      decimals="0"
      id="ixv-22718"
      unitRef="shares">900000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c62"
      decimals="6"
      id="ixv-22719"
      unitRef="usdPershares">0.003125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c63"
      decimals="0"
      id="ixv-22720"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c64"
      decimals="5"
      id="ixv-22721"
      unitRef="usdPershares">0.01875</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="c65"
      decimals="0"
      id="ixv-22722"
      unitRef="shares">21750000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c65"
      decimals="0"
      id="ixv-22723"
      unitRef="shares">21750000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c65"
      decimals="6"
      id="ixv-22724"
      unitRef="usdPershares">0.003125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="c66"
      decimals="0"
      id="ixv-22725"
      unitRef="shares">3625000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c66"
      decimals="0"
      id="ixv-22726"
      unitRef="shares">3625000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c66"
      decimals="5"
      id="ixv-22727"
      unitRef="usdPershares">0.01875</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c67"
      decimals="0"
      id="ixv-22728"
      unitRef="shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c67"
      decimals="6"
      id="ixv-22729"
      unitRef="usdPershares">0.003125</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c68"
      decimals="4"
      id="ixv-22730"
      unitRef="shares">16666666.6666</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c68"
      decimals="5"
      id="ixv-22731"
      unitRef="usdPershares">0.01875</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c69"
      decimals="0"
      id="ixv-22732"
      unitRef="shares">20000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c70"
      decimals="5"
      id="ixv-22733"
      unitRef="usdPershares">0.01875</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c71"
      decimals="2"
      id="ixv-22734"
      unitRef="usdPershares">1.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c72" decimals="-6" id="ixv-22735" unitRef="usd">25000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c72" decimals="-3" id="ixv-22736" unitRef="usd">24625000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:CapitalUnits contextRef="c73" decimals="0" id="ixv-22737" unitRef="usd">3125000</us-gaap:CapitalUnits>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c73"
      decimals="0"
      id="ixv-22738"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c74"
      decimals="5"
      id="ixv-22739"
      unitRef="usdPershares">0.01875</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c75"
      decimals="4"
      id="ixv-22740"
      unitRef="shares">16666666.6666</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c76"
      decimals="5"
      id="ixv-22741"
      unitRef="usdPershares">0.01875</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CapitalUnits contextRef="c77" decimals="0" id="ixv-22742" unitRef="usd">140625000</us-gaap:CapitalUnits>
    <us-gaap:CommonStockDividendsShares
      contextRef="c78"
      decimals="0"
      id="ixv-22743"
      unitRef="shares">6750000000</us-gaap:CommonStockDividendsShares>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c79"
      decimals="5"
      id="ixv-22744"
      unitRef="usdPershares">0.01875</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c76"
      decimals="0"
      id="ixv-22745"
      unitRef="shares">750000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c76"
      decimals="5"
      id="ixv-22746"
      unitRef="usdPershares">0.01875</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="c80"
      decimals="0"
      id="ixv-22747"
      unitRef="shares">15</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c80"
      decimals="5"
      id="ixv-22748"
      unitRef="usdPershares">0.01875</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ExcessStockSharesIssued
      contextRef="c81"
      decimals="0"
      id="ixv-22749"
      unitRef="shares">1</us-gaap:ExcessStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c82"
      decimals="5"
      id="ixv-22750"
      unitRef="usdPershares">0.28125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CapitalUnits contextRef="c81" decimals="0" id="ixv-22751" unitRef="usd">140625000</us-gaap:CapitalUnits>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c80"
      decimals="0"
      id="ixv-22752"
      unitRef="shares">450000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c80"
      decimals="5"
      id="ixv-22753"
      unitRef="usdPershares">0.28125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c83"
      decimals="0"
      id="ixv-22754"
      unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c83"
      decimals="5"
      id="ixv-22755"
      unitRef="usdPershares">0.28125</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="c84"
      decimals="0"
      id="ixv-22756"
      unitRef="shares">40</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c84"
      decimals="5"
      id="ixv-22757"
      unitRef="usdPershares">0.28125</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c84"
      decimals="2"
      id="ixv-22758"
      unitRef="usdPershares">11.25</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CapitalUnits contextRef="c84" decimals="0" id="ixv-22759" unitRef="usd">140625000</us-gaap:CapitalUnits>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c84"
      decimals="0"
      id="ixv-22760"
      unitRef="shares">11250000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c84"
      decimals="2"
      id="ixv-22761"
      unitRef="usdPershares">11.25</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c84"
      decimals="0"
      id="ixv-22762"
      unitRef="shares">1250000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c84"
      decimals="2"
      id="ixv-22763"
      unitRef="usdPershares">11.25</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="0"
      id="ixv-22764"
      unitRef="shares">42880</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c2"
      decimals="0"
      id="ixv-22765"
      unitRef="shares">42880</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock contextRef="c0" id="ixv-18189">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Details
of the subsidiaries of the Company as of September 30, 2024 are set out below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Date of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Place of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;% of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name of Entity&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Incorporation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Incorporation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ownership&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principal Activities&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Universe INC&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December 11, 2019&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cayman Islands&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Parent, 100%&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment holding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 25%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Universe HK&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 18%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;May 21, 2014&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 15%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Hong Kong&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 10%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 28%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment holding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Universe Technology&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;April 18, 2019&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PRC&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;WFOE, Investment holding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jiangxi Universe&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;March 2, 1998&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PRC&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development and manufacturing of modernized traditional Chinese medicines&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Universe Trade&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;March 10, 2010&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PRC&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sales of modernized traditional Chinese medicines&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Universe Hanhe&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;May 12, 2021&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PRC&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development of new pharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate contextRef="c85" id="ixv-18247">2019-12-11</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c85" id="ixv-18252">Cayman Islands</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c85" decimals="2" id="ixv-22766" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c85" id="ixv-18261">Investment holding</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate contextRef="c47" id="ixv-18288">2014-05-21</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c47" id="ixv-18293">Hong Kong</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c47" decimals="2" id="ixv-22767" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c47" id="ixv-18302">Investment holding</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate contextRef="c86" id="ixv-18329">2019-04-18</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c86" id="ixv-18334">PRC</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c86" decimals="2" id="ixv-22768" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c86" id="ixv-18343">WFOE, Investment holding</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate contextRef="c48" id="ixv-18370">1998-03-02</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c48" id="ixv-18375">PRC</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c48" decimals="2" id="ixv-22769" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c48" id="ixv-18384">Research and development and manufacturing of modernized traditional Chinese medicines</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate contextRef="c87" id="ixv-18411">2010-03-10</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c87" id="ixv-18416">PRC</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c87" decimals="2" id="ixv-22770" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c87" id="ixv-18425">Sales of modernized traditional Chinese medicines</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate contextRef="c88" id="ixv-18452">2021-05-12</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c88" id="ixv-18457">PRC</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c88" decimals="2" id="ixv-22771" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c88" id="ixv-18466">Research and development of new pharmaceutical products</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-18476">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;NOTE
2 &#x2014; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Basis
of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
accompanying consolidated financial statements include the Company and its subsidiaries, which include Universe HK, Universe Technology,
Jiangxi Universe, Universe Trade and Universe Hanhe. All inter-company balances and transactions are eliminated upon consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;A
subsidiary is an entity in which (i) the Company directly or indirectly controls more than 50% of the voting power; or (ii) the Company
has the power to appoint or remove the majority of the members of the board of directors or to cast a majority of votes at the meetings
of the board of directors or to govern the financial and operating policies of the investee pursuant to a statute or under an agreement
among the shareholders or equity holders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Certain
amounts on the prior-years&#x2019; consolidated balance sheets and cash flows were reclassified to conform to current-year presentation,
with no effect on ending shareholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Uses
of estimates&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;In
preparing the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America
(&#x201c;U.S. GAAP&#x201d;), management makes estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses
during the reporting period. These estimates are based on information as of the date of the consolidated financial statements. Significant
estimates required to be made by management include, but are not limited to, the allowance for estimated uncollectible receivables, the
realizability of advance to suppliers, inventory valuations, useful lives of property, plant and equipment, intangible assets, the recoverability
of long-lived assets, provision necessary for contingent liabilities, revenue recognition and realization of deferred tax assets. Actual
results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Risks
and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
business operations of the Company are located in the PRC. Accordingly, the Company&#x2019;s business, financial condition, and results
of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC
economy. The Company&#x2019;s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC.
Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations
including its organization and structure disclosed in Note 1, this may not be indicative of future results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
development and commercialization of new pharmaceutical products is highly competitive, and the industry currently is characterized by
rapidly changing technologies, significant competition and a strong emphasis on intellectual property. The Company may face competition
with respect to its current and future pharmaceutical product candidates from major pharmaceutical companies in China.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company&#x2019;s business, financial condition and results of operations may also be negatively impacted by risks related to natural disasters,
extreme weather conditions, health epidemics and other catastrophic incidents, which could significantly disrupt the Company&#x2019;s
operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Cash&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Cash
includes currency on hand and deposits held by banks that can be added or withdrawn without limitation. The Company maintains most of
its bank accounts in the PRC. Cash maintained in banks within the People&#x2019;s Republic of China of less than RMB0.5 million (equivalent
to $71,249) per bank are covered by &#x201c;deposit insurance regulation&#x201d; promulgated by the State Council of the People&#x2019;s
Republic of China.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Accounts
receivable, net&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Accounts receivables are presented
net of allowance for doubtful accounts. The Company determines the adequacy of reserves for doubtful accounts based on individual account
analysis and historical collection trends. The Company establishes a provision for doubtful receivables when there is objective evidence
that the Company may not be able to collect amounts due. The allowance is based on management&#x2019;s best estimate of specific losses
on individual exposures, as well as a provision on historical trends of collections. Actual amounts received may differ from management&#x2019;s
estimate of credit worthiness and the economic environment. Delinquent account balances are written-off against the allowance for doubtful
accounts after management has determined that collection is not probable. &lt;/span&gt;Allowance for uncollectable balances amounted to $135,082
and $&lt;span style="-sec-ix-hidden: hidden-fact-62"&gt;Nil&lt;/span&gt; as of September 30, 2024 and 2023, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Inventories,
net&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Inventories
are stated at net realizable value using weighted average method. Costs include the cost of raw materials, freight, direct labor and
related production overhead. Any excess of the cost over the net realizable value of each item of inventories is recognized as a provision
for diminution in the value of inventories. Net realizable value is the estimated selling price in the normal course of business less
any costs to complete and sell products. The Company evaluates inventories on a quarterly basis for its net realizable value adjustments,
and reduces the carrying value of those inventories that are obsolete or in excess of the forecasted usage to their estimated net realizable
value based on various factors including aging, expiration dates, as applicable, taking into consideration historical and expected future
product sales. &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We recorded inventory reserve of $124,512
and $69,746 as of September 30, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Advances
to suppliers, net&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Advances
to suppliers represent prepayments made to ensure continuous high-quality supplies and favorable purchase prices of raw materials. These
advances are directly related to the purchases of raw materials used to fulfill sales orders. The Company is required from time to time
to make cash advances when placing its purchase orders. These advances are settled upon suppliers delivering raw materials to the Company
when the transfer of ownership occurs. The Company reviews its advances to suppliers on a periodic basis and makes general and specific
allowances when there is doubt as to the ability of a supplier to provide supplies to the Company or refund an advance. As of September
30, 2024 and 2023, the Company recorded no allowance for doubtful accounts, as the Company believed that all advances to suppliers were
fully realizable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Fair
value of financial instruments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The
hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of
inputs used to measure fair value are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 62px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1&#x2009;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2009;inputs to the valuation
    methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 62px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2&#x2009;&#x2014;&#x2009;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;inputs to the valuation
    methodology include quoted prices for similar assets and liabilities in active markets, quoted market prices for identical or similar
    assets in markets that are not active, inputs other than quoted prices that are observable and inputs derived from or corroborated
    by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 62px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3&#x2009;&#x2014;&#x2009;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;inputs to the valuation
    methodology are unobservable.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Unless
otherwise disclosed, the fair value of the Company&#x2019;s financial instruments, including cash, accounts receivable, inventories, advances
to suppliers, prepaid expenses and other current assets, accounts payable, short-term bank loans, accrued expenses and other current
liabilities, taxes payable and due to related parties, approximate the fair value of the respective assets and liabilities as of September
30, 2024 based upon the short-term nature of the assets and liabilities. The Company&#x2019;s investment in equity securities is accounted
for using the measurement alternative in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 321, &#x201c;Investments&#x2014;Equity
Securities&#x201d; (&#x201c;ASC 321&#x201d;), which also approximates its recorded value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Property,
plant and equipment&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Property,
plant and equipment are stated at cost less accumulated depreciation. Depreciation of property, plant and equipment is provided using
the straight-line method over their expected useful lives, as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful
    life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 89%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Buildings&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;20&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&#x2013;10&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Automobiles&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#x2013;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office and electric equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#x2013;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Expenditures
for maintenance and repairs, which do not materially extend the useful lives of the assets, are charged to expense as incurred. Expenditures
for major renewals and betterments which substantially extend the useful life of assets are capitalized. The cost and related accumulated
depreciation of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized in the consolidated
statements of operations and comprehensive loss in other income or expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company reviews the carrying value of property, plant and equipment for impairment whenever events and circumstances indicate that the
carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition.
In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an
amount by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment
include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand,
competition and other economic factors. Based on this assessment, no impairment expenses for property, plant and equipment were recorded
in operating expenses for the years ended September 30, 2024, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Intangible
Assets&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Intangible
assets consist primarily of land use rights, trademark and software. Under the PRC law, all land in the PRC is owned by the government
and cannot be sold to an individual or company. The government grants individuals and companies the right to use parcels of land for
specified periods of time. Land use rights are stated at cost less accumulated amortization. Intangible assets are amortized using the
straight-line method with the following estimated useful lives:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 89%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Land use rights&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trademark&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Software&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company reviews the carrying value of land use rights for impairment whenever events and circumstances indicate that the carrying value
of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In
cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount
by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include
current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition
and other economic factors.&#160;Based on this assessment, no impairment of land use rights was deemed necessary for the years ended
September 30, 2024, 2023 and 2022.&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Construction-in-Progress
(&#x201c;CIP&#x201d;)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;CIP
represents property and buildings under construction and consists of construction expenditures, equipment procurement, and other direct
costs attributable to the construction. CIP is not depreciated. Upon completion and ready for intended use, CIP is reclassified to the
appropriate category within property, plant and equipment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Impairment
of long-lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Long-lived
assets with finite lives, primarily property, plant and equipment and intangible assets, are reviewed for impairment whenever events
or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the estimated undiscounted cash
flows from the use of the asset and its eventual disposition below are the asset&#x2019;s carrying value, then the asset is deemed to
be impaired and written down to its fair value. The Company recorded no impairments of these assets for the years ended September 30,
2024, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Investments
in Equity Securities&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company accounts for its equity investments in accordance with ASC 321. In accordance with ASC 321, equity investment which the Company
has no significant influence (generally less than a 20% ownership interest) with readily determinable fair values are accounted for at
fair value based on quoted market prices with the changes in fair value recognized as unrealized gains or losses in earnings. Equity
investments without readily determinable fair values are accounted for either at fair value or using the measurement alternative. Under
the measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting
from observable price changes in orderly transactions for the identical or a similar investment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;From
March 2009 to September 2017, the Company invested approximately $0.7&#160;million (RMB5&#160;million) in Jiangxi Jian Rural Commercial
Bank (&#x201c;JX RCB Bank&#x201d;) in exchange for&#160;5% ownership interest in the bank. The purpose of entering into these equity investment
agreements with JX RCB Bank was to earn investment income as the bank continues to grow. The Company determined that this investment
in equity securities does not have a readily determinable fair value and, accordingly, elected the measurement alternative noted above.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company initially recorded the investments at historical cost and subsequently records any dividends received from the net accumulated
earnings of the investee as income. As of September 30, 2024 and 2023, the Company&#x2019;s investment in JX RBC Bank amounted to $712,494&#160;(RMB5&#160;million)
and $685,307 (RMB5&#160;million), respectively, and was reported as long-term investment in equity investee on the consolidated balance
sheets. Investment income amounted to $31,942, $31,072 and $38,588 for the years ended September 30, 2024, 2023 and 2022, respectively.
&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
investments in equity securities are evaluated for impairment when facts or circumstances indicate that the fair value of the investments
is less than their carrying value. An impairment is recognized when a decline in fair value is determined to be other-than-temporary.
The Company reviews several factors to determine whether a loss is other-than-temporary. These factors include, but are not limited to,
the: (i) nature of the investment; (ii) cause and duration of the impairment; (iii) extent to which fair value is less than cost; (iv)
financial condition and near-term prospects of the investments; and (v) ability to hold the investment for a period of time sufficient
to allow for any anticipated recovery in fair value. There was no impairment for the Company&#x2019;s investments in equity securities
as of September 30, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Revenue
recognition&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;To
determine revenue recognition for contracts with customers, the Company performs the following five steps : (i) identify the contract(s)
with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable
consideration to the extent that it is probable that a significant future reversal will&#160;&lt;i&gt;not&lt;/i&gt;&#160;occur, (iv) allocate the
transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies
the performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company recognizes revenue when it transfers its goods and services to customers in an amount that reflects the consideration to which
the Company expects to be entitled in such exchange. The Company accounts for the revenue generated from sales of its TCMD and third-party
products on a gross basis, as the Company is acting as a principal in these transactions, is subject to inventory risk, has latitude
in establishing prices, and is responsible for fulfilling the promise to provide customers the specified goods, which the Company has
control of the goods and has the ability to direct the use of goods to obtain substantially all the benefits. All of the Company&#x2019;s
contracts have one single performance obligation, namely, the promise is to transfer the individual goods to customers, and there is
no separately identifiable other promise in the contracts. The Company&#x2019;s revenue streams are recognized at a point in time when
title and risk of loss passes and the customer accepts the goods, which generally occurs at delivery. The Company&#x2019;s products are
sold with no right of return and the Company does not provide other credits or sales incentive to customers. Revenue is reported net
of all value added taxes (&#x201c;VAT&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Disaggregation
of Revenues&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company disaggregates its revenue from contracts by product types, as the Company believes it best depicts how the nature, amount, timing
and uncertainty of the revenue and cash flows are affected by economic factors. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Cost
of Revenue&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Cost
of revenue consists primarily of the costs of raw materials, freight charges, direct labor, depreciation of buildings and machinery,
warehousing and overhead associated with the manufacturing process.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Research
and Development Expenses&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company expenses all internal research and development costs as incurred, which primarily comprise of employee costs, internal and external
costs related to execution of studies, manufacturing costs, facility costs of the research center, and amortization and depreciation
to intangible assets and property, plant and equipment used in the research and development activities. For the&#160;years ended September
30, 2024, 2023 and 2022, total research and development expenses were approximately $&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,031,115,
&lt;span style="background-color: white"&gt;$4,858,548 and $7,644,375, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Shipping
and handling costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Shipping
and handling costs are expensed as incurred. Inbound shipping and handling cost associated with bringing the purchased raw materials
and third-party products from suppliers to the Company&#x2019;s warehouse are included in cost of revenue. Outbound shipping and handling
costs associated with shipping and delivery the products to customers are included in selling expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Advertising
expense&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Advertising
expenses primarily relate to promotion of the Company&#x2019;s brand name and products through outdoor billboards, social media such as
Weibo and WeChat, and TV advertisement. Advertising costs are expensed as incurred or deferred and then expensed the first time the advertising
takes place. Advertising expenses are included in selling expenses in the consolidated statements of operations and comprehensive loss.
Advertising expenses amounted to $5,144,579, $4,653,633&#160;and $17,527,318 for the&#160;years ended September 30, 2024, 2023 and 2022,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Segment
Reporting&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company uses the management approach in determining reportable operating segments. The management approach considers the internal reporting
used by the Company&#x2019;s chief operating decision maker for making operating decisions about the allocation of resources of the segment
and the assessment of its performance in determining the Company&#x2019;s reportable operating segments. Management has determined that
the Company has one operating segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Income
taxes&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company accounts for current income taxes in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized
when temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the consolidated financial
statements. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years
in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a
change in tax rates is recognized in income in the period including the enactment date. Valuation allowances are established, when necessary,
to reduce deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;An
uncertain tax position is recognized only if it is &#x201c;more likely than not&#x201d; that the tax position would be sustained in a tax
examination. The amount recognized is the largest amount of tax benefit that is greater than&#160;50% likely of being realized on examination.
For tax positions not meeting the &#x201c;more likely than not&#x201d; test, no tax benefit is recorded. Penalties and interest incurred
related to underpayment of income tax are classified as income tax expense in the period incurred. No significant penalties or interest
relating to income taxes have been incurred during the years ended September 30, 2024, 2023 and 2022. The Company does not believe there
was any uncertain tax provision as of September 30, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company&#x2019;s operating subsidiaries in China are subject to the income tax laws of the PRC. No significant income was generated outside
the PRC for the years ended September 30, 2024, 2023 and 2022. As of September 30, 2024 and 2023, all of the tax returns of the Company&#x2019;s
PRC subsidiaries remained open for statutory examination by PRC tax authorities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Value
added tax (&#x201c;VAT&#x201d;)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Sales
revenue represents the invoiced value of goods, net of VAT. The VAT is based on gross sales price and VAT rates range up to&#160;13%,
depending on the type of products sold. The VAT may be offset by VAT paid by the Company on raw materials and other materials included
in the cost of producing or acquiring its finished products. The Company recorded a VAT payable or receivable net of payments in the
accompanying consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Earnings
per Share&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company computes earnings per share (&#x201c;EPS&#x201d;) in accordance with ASC 260, &#x201c;Earnings per Share&#x201d; (&#x201c;ASC 260&#x201d;).
ASC 260 requires companies with complex capital structures to present basic and diluted EPS. Basic EPS is measured as net income divided
by the weighted average ordinary shares outstanding for the period. Diluted presents the dilutive effect on a per share basis of potential
ordinary shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented,
or issuance date, if later. Potential ordinary shares that have an anti-dilutive effect (i.e., those that increase income per share or
decrease loss per share) are excluded from the calculation of diluted EPS. For the years ended September 30, 2024, 2023 and 2022, there
were no dilutive shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Foreign
currency translation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
functional currency for Universe INC is the U.S. Dollar (&#x201c;US$&#x201d;). Universe HK uses Hong Kong dollar as its functional currency.
However, Universe INC and Universe HK currently only serve as holding companies and did not have active operations as of the date of
this report. The Company operates only in the PRC and the Company&#x2019;s functional currency is the Chinese Yuan (&#x201c;RMB&#x201d;).
The Company&#x2019;s consolidated financial statements have been translated into the reporting currency US$.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Assets
and liabilities of the Company are translated at the exchange rate at each reporting period end date. Equity is translated at historical
rates. Income and expense accounts are translated at the average rate of exchange during the reporting period. The resulting translation
adjustments are reported under other comprehensive income. Gains and losses resulting from the translations of foreign currency transactions
and balances are reflected in the results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&#160;
&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions.
No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
following table outlines the currency exchange rates that were used in creating the consolidated financial statements in this report:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Period-end US$: RMB exchange rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.0176&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.2960&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.1135&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Period-end US$: HK exchange rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.7693&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8308&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8498&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Period average US$: RMB exchange rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.2043&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.0533&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.5532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Period average US$: HK exchange rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8127&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8310&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8228&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Comprehensive
Income&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Comprehensive
income consists of two components, net income and other comprehensive income. The foreign currency translation gain resulting from translation
of the financial statements expressed in RMB to US$ is reported in other comprehensive income in the consolidated statements of operations
and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Statement
of Cash Flows&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;In
accordance with ASC 230, &#x201c;Statement of Cash Flows&#x201d;, cash flows from the Company&#x2019;s operations are formulated based upon
the local currencies. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily
agree with changes in the corresponding balances on the balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Employee
Defined Contribution Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company&#x2019;s subsidiaries in the PRC participate in a government-mandated multi-employer defined contribution plan pursuant to which
pension, work-related injury benefits, maternity insurance, medical insurance, unemployment benefit and housing fund are provided to
eligible full-time employees. The relevant labor regulations require the Company&#x2019;s subsidiaries in the PRC to pay the local labor
and social welfare authorities monthly contributions based on the applicable benchmarks and rates stipulated by the local government.
The contributions to the plan are expensed as incurred. Employee social security and welfare benefits included as expenses in the accompanying
consolidated statements of operations and comprehensive loss amounted to $247,249, $440,962&#160;and $465,689&#160;for the years ended
September 30, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Recently
Issued &lt;span style="background-color: white"&gt;Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
considers the applicability and impact of all accounting standards updates (&#x201c;ASUs&#x201d;). Management periodically reviews new accounting
standards that are issued. Under the Jumpstart Our Business Startups Act of 2012, as amended (the &#x201c;JOBS Act&#x201d;), the Company
meets the definition of an emerging growth company, or EGC, and has elected the extended transition period for complying with new or revised
accounting standards, which delays the adoption of these accounting standards until they would apply to private companies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In November
2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amended guidance
requires incremental reportable segment disclosures, primarily about significant segment expenses. The amendments also require entities
with a single reportable segment to provide all disclosures required by these amendments, and all existing segment disclosures. The amendments
will be applied retrospectively to all prior periods presented in the financial statements and is effective for fiscal years beginning
after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. The guidance should be adopted retrospectively.
The Company is currently in the process of evaluating the impact this amended guidance may have on the footnotes to its consolidated financial
statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In December
2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amended guidance enhances income
tax disclosures primarily related to the effective tax rate reconciliation and income taxes paid information. This guidance requires disclosure
of specific categories in the effective tax rate reconciliation and further information on reconciling items meeting a quantitative threshold.
In addition, the amended guidance requires disaggregating income taxes paid (net of refunds received) by federal, state, and foreign taxes.
It also requires disaggregating individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than
5 percent of total income taxes paid (net of refunds received). The amended guidance is effective for fiscal years beginning after December
15, 2024. The guidance can be applied either prospectively or retrospectively. The Company is currently in the process of evaluating the
impact this amended guidance may have on the footnotes to its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In March
2024, the FASB issued ASU 2024-01, Compensation&#x2014;Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar
Awards. The amended guidance added an illustrative example that includes four fact patterns to demonstrate how an entity should apply
the scope guidance in paragraph 718-10-15-3 to determine whether a profits interest award should be accounted for in accordance with Topic
718. The amendments guidance is effective for annual periods beginning after December 15, 2024, and interim periods within those annual
periods. The guidance can be applied either prospectively or retrospectively. The Company is currently in the process of evaluating the
impact this amended guidance may have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In November
2024, the FASB issued ASU 2024-03, Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses. The amended guidance improves the disclosures about a public business entity&#x2019;s
expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory,
employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions (such as cost of sales, SG&amp;amp;A,
and research and development). The amended guidance is effective for annual reporting periods beginning after December 15, 2026, and interim
reporting periods beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective
application. The Company is currently in the process of evaluating the impact this amended guidance may have on the footnotes to its consolidated
financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In November
2024, the FASB issued ASU 2024-04, Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible
Debt Instruments. This guidance clarifies the assessment of whether a transaction should be accounted for as an induced conversion or
extinguishment of convertible debt when changes are made to conversion features as part of an offer to settle the instrument. The amended
guidance is effective for all entities for annual reporting periods beginning after December 15, 2025, and interim reporting periods within
those annual reporting periods. The guidance can be applied either prospectively or retrospectively. The Company is currently in the process
of evaluating the impact this amended guidance may have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In January
2025, the FASB issued ASU 2025-01, Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic
220-40): Clarifying the Effective Date. This guidance amends the effective date of Update 2024-03 to clarify that all public business
entities are required to adopt the guidance in annual reporting periods beginning after December 15, 2026, and interim periods within
annual reporting periods beginning after December 15, 2027. Early adoption of Update 2024-03 is permitted. The Company is currently in
the process of evaluating the impact this amended guidance may have on the footnotes to its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Other accounting
standards that have been issued by FASB that do not require adoption until a future date are not expected to have a material impact on
the consolidated financial statements upon adoption. The Company does not discuss recent standards that are not anticipated to have an
impact on or are unrelated to its consolidated financial condition, results of operations, cash flows or disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0" id="ixv-18482">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Basis
of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
accompanying consolidated financial statements include the Company and its subsidiaries, which include Universe HK, Universe Technology,
Jiangxi Universe, Universe Trade and Universe Hanhe. All inter-company balances and transactions are eliminated upon consolidation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;A
subsidiary is an entity in which (i) the Company directly or indirectly controls more than 50% of the voting power; or (ii) the Company
has the power to appoint or remove the majority of the members of the board of directors or to cast a majority of votes at the meetings
of the board of directors or to govern the financial and operating policies of the investee pursuant to a statute or under an agreement
among the shareholders or equity holders.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="c89" decimals="2" id="ixv-22772" unitRef="pure">0.50</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <upc:ReclassificationsPolicyTextBlock contextRef="c0" id="ixv-18500">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Certain
amounts on the prior-years&#x2019; consolidated balance sheets and cash flows were reclassified to conform to current-year presentation,
with no effect on ending shareholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;</upc:ReclassificationsPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-18529">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Uses
of estimates&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;In
preparing the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America
(&#x201c;U.S. GAAP&#x201d;), management makes estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses
during the reporting period. These estimates are based on information as of the date of the consolidated financial statements. Significant
estimates required to be made by management include, but are not limited to, the allowance for estimated uncollectible receivables, the
realizability of advance to suppliers, inventory valuations, useful lives of property, plant and equipment, intangible assets, the recoverability
of long-lived assets, provision necessary for contingent liabilities, revenue recognition and realization of deferred tax assets. Actual
results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0" id="ixv-18541">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Risks
and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
business operations of the Company are located in the PRC. Accordingly, the Company&#x2019;s business, financial condition, and results
of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC
economy. The Company&#x2019;s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC.
Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations
including its organization and structure disclosed in Note 1, this may not be indicative of future results.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
development and commercialization of new pharmaceutical products is highly competitive, and the industry currently is characterized by
rapidly changing technologies, significant competition and a strong emphasis on intellectual property. The Company may face competition
with respect to its current and future pharmaceutical product candidates from major pharmaceutical companies in China.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company&#x2019;s business, financial condition and results of operations may also be negatively impacted by risks related to natural disasters,
extreme weather conditions, health epidemics and other catastrophic incidents, which could significantly disrupt the Company&#x2019;s
operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0" id="ixv-18563">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Cash&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Cash
includes currency on hand and deposits held by banks that can be added or withdrawn without limitation. The Company maintains most of
its bank accounts in the PRC. Cash maintained in banks within the People&#x2019;s Republic of China of less than RMB0.5 million (equivalent
to $71,249) per bank are covered by &#x201c;deposit insurance regulation&#x201d; promulgated by the State Council of the People&#x2019;s
Republic of China.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c2" decimals="-5" id="ixv-22773" unitRef="cny">500000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c2" decimals="0" id="ixv-22774" unitRef="usd">71249</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c0" id="ixv-18577">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Accounts
receivable, net&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Accounts receivables are presented
net of allowance for doubtful accounts. The Company determines the adequacy of reserves for doubtful accounts based on individual account
analysis and historical collection trends. The Company establishes a provision for doubtful receivables when there is objective evidence
that the Company may not be able to collect amounts due. The allowance is based on management&#x2019;s best estimate of specific losses
on individual exposures, as well as a provision on historical trends of collections. Actual amounts received may differ from management&#x2019;s
estimate of credit worthiness and the economic environment. Delinquent account balances are written-off against the allowance for doubtful
accounts after management has determined that collection is not probable. &lt;/span&gt;Allowance for uncollectable balances amounted to $135,082
and $&lt;span style="-sec-ix-hidden: hidden-fact-62"&gt;Nil&lt;/span&gt; as of September 30, 2024 and 2023, respectively.&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c2" decimals="0" id="ixv-22775" unitRef="usd">135082</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:InventoryPolicyTextBlock contextRef="c0" id="ixv-18607">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Inventories,
net&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Inventories
are stated at net realizable value using weighted average method. Costs include the cost of raw materials, freight, direct labor and
related production overhead. Any excess of the cost over the net realizable value of each item of inventories is recognized as a provision
for diminution in the value of inventories. Net realizable value is the estimated selling price in the normal course of business less
any costs to complete and sell products. The Company evaluates inventories on a quarterly basis for its net realizable value adjustments,
and reduces the carrying value of those inventories that are obsolete or in excess of the forecasted usage to their estimated net realizable
value based on various factors including aging, expiration dates, as applicable, taking into consideration historical and expected future
product sales. &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We recorded inventory reserve of $124,512
and $69,746 as of September 30, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryValuationReserves contextRef="c2" decimals="0" id="ixv-22776" unitRef="usd">124512</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="c3" decimals="0" id="ixv-22777" unitRef="usd">69746</us-gaap:InventoryValuationReserves>
    <upc:AdvancesToSuppliersNetPolicyTextBlock contextRef="c0" id="ixv-18622">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Advances
to suppliers, net&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Advances
to suppliers represent prepayments made to ensure continuous high-quality supplies and favorable purchase prices of raw materials. These
advances are directly related to the purchases of raw materials used to fulfill sales orders. The Company is required from time to time
to make cash advances when placing its purchase orders. These advances are settled upon suppliers delivering raw materials to the Company
when the transfer of ownership occurs. The Company reviews its advances to suppliers on a periodic basis and makes general and specific
allowances when there is doubt as to the ability of a supplier to provide supplies to the Company or refund an advance. As of September
30, 2024 and 2023, the Company recorded no allowance for doubtful accounts, as the Company believed that all advances to suppliers were
fully realizable.&lt;/span&gt;&lt;/p&gt;</upc:AdvancesToSuppliersNetPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c0" id="ixv-18635">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Fair
value of financial instruments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The
hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of
inputs used to measure fair value are as follows:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 62px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1&#x2009;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2009;inputs to the valuation
    methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 62px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2&#x2009;&#x2014;&#x2009;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;inputs to the valuation
    methodology include quoted prices for similar assets and liabilities in active markets, quoted market prices for identical or similar
    assets in markets that are not active, inputs other than quoted prices that are observable and inputs derived from or corroborated
    by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 62px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3&#x2009;&#x2014;&#x2009;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;inputs to the valuation
    methodology are unobservable.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Unless
otherwise disclosed, the fair value of the Company&#x2019;s financial instruments, including cash, accounts receivable, inventories, advances
to suppliers, prepaid expenses and other current assets, accounts payable, short-term bank loans, accrued expenses and other current
liabilities, taxes payable and due to related parties, approximate the fair value of the respective assets and liabilities as of September
30, 2024 based upon the short-term nature of the assets and liabilities. The Company&#x2019;s investment in equity securities is accounted
for using the measurement alternative in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 321, &#x201c;Investments&#x2014;Equity
Securities&#x201d; (&#x201c;ASC 321&#x201d;), which also approximates its recorded value.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0" id="ixv-18706">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Property,
plant and equipment&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Property,
plant and equipment are stated at cost less accumulated depreciation. Depreciation of property, plant and equipment is provided using
the straight-line method over their expected useful lives, as follows:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful
    life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 89%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Buildings&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;20&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&#x2013;10&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Automobiles&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#x2013;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office and electric equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#x2013;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Expenditures
for maintenance and repairs, which do not materially extend the useful lives of the assets, are charged to expense as incurred. Expenditures
for major renewals and betterments which substantially extend the useful life of assets are capitalized. The cost and related accumulated
depreciation of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized in the consolidated
statements of operations and comprehensive loss in other income or expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company reviews the carrying value of property, plant and equipment for impairment whenever events and circumstances indicate that the
carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition.
In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an
amount by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment
include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand,
competition and other economic factors. Based on this assessment, no impairment expenses for property, plant and equipment were recorded
in operating expenses for the years ended September 30, 2024, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <upc:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock contextRef="c0" id="ixv-22778">Depreciation of property, plant and equipment is provided using
the straight-line method over their expected useful lives, as follows:&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful
    life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 89%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Buildings&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;20&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&#x2013;10&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Automobiles&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#x2013;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office and electric equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#x2013;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</upc:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c93" id="ixv-22779">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c94" id="ixv-22780">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c95" id="ixv-22781">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c96" id="ixv-22782">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c97" id="ixv-22783">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c98" id="ixv-22784">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c99" id="ixv-22785">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c0" id="ixv-18784">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Intangible
Assets&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Intangible
assets consist primarily of land use rights, trademark and software. Under the PRC law, all land in the PRC is owned by the government
and cannot be sold to an individual or company. The government grants individuals and companies the right to use parcels of land for
specified periods of time. Land use rights are stated at cost less accumulated amortization. Intangible assets are amortized using the
straight-line method with the following estimated useful lives:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 89%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Land use rights&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trademark&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Software&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company reviews the carrying value of land use rights for impairment whenever events and circumstances indicate that the carrying value
of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In
cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount
by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include
current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition
and other economic factors.&#160;Based on this assessment, no impairment of land use rights was deemed necessary for the years ended
September 30, 2024, 2023 and 2022.&#160;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <upc:ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock contextRef="c0" id="ixv-22786">Intangible assets are amortized using the
straight-line method with the following estimated useful lives:&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 89%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Land use rights&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trademark&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Software&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</upc:ScheduleOfIntangibleAssetsEstimatedUsefulLivesTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c100" id="ixv-22787">P50Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c101" id="ixv-22788">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c102" id="ixv-22789">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <upc:ConstructioninProgressPolicyTextBlock contextRef="c0" id="ixv-18835">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Construction-in-Progress
(&#x201c;CIP&#x201d;)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;CIP
represents property and buildings under construction and consists of construction expenditures, equipment procurement, and other direct
costs attributable to the construction. CIP is not depreciated. Upon completion and ready for intended use, CIP is reclassified to the
appropriate category within property, plant and equipment.&lt;/span&gt;&lt;/p&gt;</upc:ConstructioninProgressPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0" id="ixv-18849">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Impairment
of long-lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Long-lived
assets with finite lives, primarily property, plant and equipment and intangible assets, are reviewed for impairment whenever events
or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the estimated undiscounted cash
flows from the use of the asset and its eventual disposition below are the asset&#x2019;s carrying value, then the asset is deemed to
be impaired and written down to its fair value. The Company recorded no impairments of these assets for the years ended September 30,
2024, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c0" id="ixv-18862">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Investments
in Equity Securities&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company accounts for its equity investments in accordance with ASC 321. In accordance with ASC 321, equity investment which the Company
has no significant influence (generally less than a 20% ownership interest) with readily determinable fair values are accounted for at
fair value based on quoted market prices with the changes in fair value recognized as unrealized gains or losses in earnings. Equity
investments without readily determinable fair values are accounted for either at fair value or using the measurement alternative. Under
the measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting
from observable price changes in orderly transactions for the identical or a similar investment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;From
March 2009 to September 2017, the Company invested approximately $0.7&#160;million (RMB5&#160;million) in Jiangxi Jian Rural Commercial
Bank (&#x201c;JX RCB Bank&#x201d;) in exchange for&#160;5% ownership interest in the bank. The purpose of entering into these equity investment
agreements with JX RCB Bank was to earn investment income as the bank continues to grow. The Company determined that this investment
in equity securities does not have a readily determinable fair value and, accordingly, elected the measurement alternative noted above.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company initially recorded the investments at historical cost and subsequently records any dividends received from the net accumulated
earnings of the investee as income. As of September 30, 2024 and 2023, the Company&#x2019;s investment in JX RBC Bank amounted to $712,494&#160;(RMB5&#160;million)
and $685,307 (RMB5&#160;million), respectively, and was reported as long-term investment in equity investee on the consolidated balance
sheets. Investment income amounted to $31,942, $31,072 and $38,588 for the years ended September 30, 2024, 2023 and 2022, respectively.
&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
investments in equity securities are evaluated for impairment when facts or circumstances indicate that the fair value of the investments
is less than their carrying value. An impairment is recognized when a decline in fair value is determined to be other-than-temporary.
The Company reviews several factors to determine whether a loss is other-than-temporary. These factors include, but are not limited to,
the: (i) nature of the investment; (ii) cause and duration of the impairment; (iii) extent to which fair value is less than cost; (iv)
financial condition and near-term prospects of the investments; and (v) ability to hold the investment for a period of time sufficient
to allow for any anticipated recovery in fair value. There was no impairment for the Company&#x2019;s investments in equity securities
as of September 30, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c90" decimals="2" id="ixv-22790" unitRef="pure">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c91" decimals="-5" id="ixv-22791" unitRef="usd">700000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c91" decimals="-6" id="ixv-22792" unitRef="cny">5000000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c92" decimals="2" id="ixv-22793" unitRef="pure">0.05</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments contextRef="c2" decimals="0" id="ixv-22794" unitRef="usd">712494</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c2" decimals="-6" id="ixv-22795" unitRef="cny">5000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c3" decimals="0" id="ixv-22796" unitRef="usd">685307</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c3" decimals="-6" id="ixv-22797" unitRef="cny">5000000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c0" decimals="0" id="ixv-22798" unitRef="usd">31942</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c6" decimals="0" id="ixv-22799" unitRef="usd">31072</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c7" decimals="0" id="ixv-22800" unitRef="usd">38588</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0" id="ixv-18906">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Revenue
recognition&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;To
determine revenue recognition for contracts with customers, the Company performs the following five steps : (i) identify the contract(s)
with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable
consideration to the extent that it is probable that a significant future reversal will&#160;&lt;i&gt;not&lt;/i&gt;&#160;occur, (iv) allocate the
transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies
the performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company recognizes revenue when it transfers its goods and services to customers in an amount that reflects the consideration to which
the Company expects to be entitled in such exchange. The Company accounts for the revenue generated from sales of its TCMD and third-party
products on a gross basis, as the Company is acting as a principal in these transactions, is subject to inventory risk, has latitude
in establishing prices, and is responsible for fulfilling the promise to provide customers the specified goods, which the Company has
control of the goods and has the ability to direct the use of goods to obtain substantially all the benefits. All of the Company&#x2019;s
contracts have one single performance obligation, namely, the promise is to transfer the individual goods to customers, and there is
no separately identifiable other promise in the contracts. The Company&#x2019;s revenue streams are recognized at a point in time when
title and risk of loss passes and the customer accepts the goods, which generally occurs at delivery. The Company&#x2019;s products are
sold with no right of return and the Company does not provide other credits or sales incentive to customers. Revenue is reported net
of all value added taxes (&#x201c;VAT&#x201d;).&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <upc:DisaggregationOfRevenuesPolicyTextBlock contextRef="c0" id="ixv-18924">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Disaggregation
of Revenues&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company disaggregates its revenue from contracts by product types, as the Company believes it best depicts how the nature, amount, timing
and uncertainty of the revenue and cash flows are affected by economic factors. &lt;/span&gt;&lt;/p&gt;</upc:DisaggregationOfRevenuesPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c0" id="ixv-18937">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Cost
of Revenue&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Cost
of revenue consists primarily of the costs of raw materials, freight charges, direct labor, depreciation of buildings and machinery,
warehousing and overhead associated with the manufacturing process.&lt;/span&gt;&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0" id="ixv-18967">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Research
and Development Expenses&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company expenses all internal research and development costs as incurred, which primarily comprise of employee costs, internal and external
costs related to execution of studies, manufacturing costs, facility costs of the research center, and amortization and depreciation
to intangible assets and property, plant and equipment used in the research and development activities. For the&#160;years ended September
30, 2024, 2023 and 2022, total research and development expenses were approximately $&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,031,115,
&lt;span style="background-color: white"&gt;$4,858,548 and $7,644,375, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" id="ixv-22801" unitRef="usd">3031115</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c6" decimals="0" id="ixv-22802" unitRef="usd">4858548</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c7" decimals="0" id="ixv-22803" unitRef="usd">7644375</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ShippingAndHandlingCostPolicyTextBlock contextRef="c0" id="ixv-18984">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Shipping
and handling costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Shipping
and handling costs are expensed as incurred. Inbound shipping and handling cost associated with bringing the purchased raw materials
and third-party products from suppliers to the Company&#x2019;s warehouse are included in cost of revenue. Outbound shipping and handling
costs associated with shipping and delivery the products to customers are included in selling expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShippingAndHandlingCostPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="c0" id="ixv-19000">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Advertising
expense&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Advertising
expenses primarily relate to promotion of the Company&#x2019;s brand name and products through outdoor billboards, social media such as
Weibo and WeChat, and TV advertisement. Advertising costs are expensed as incurred or deferred and then expensed the first time the advertising
takes place. Advertising expenses are included in selling expenses in the consolidated statements of operations and comprehensive loss.
Advertising expenses amounted to $5,144,579, $4,653,633&#160;and $17,527,318 for the&#160;years ended September 30, 2024, 2023 and 2022,
respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense contextRef="c0" decimals="0" id="ixv-22804" unitRef="usd">5144579</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c6" decimals="0" id="ixv-22805" unitRef="usd">4653633</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c7" decimals="0" id="ixv-22806" unitRef="usd">17527318</us-gaap:AdvertisingExpense>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0" id="ixv-19014">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Segment
Reporting&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company uses the management approach in determining reportable operating segments. The management approach considers the internal reporting
used by the Company&#x2019;s chief operating decision maker for making operating decisions about the allocation of resources of the segment
and the assessment of its performance in determining the Company&#x2019;s reportable operating segments. Management has determined that
the Company has one operating segment.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments contextRef="c0" decimals="0" id="ixv-22807" unitRef="pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0" id="ixv-19026">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Income
taxes&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company accounts for current income taxes in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized
when temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the consolidated financial
statements. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years
in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a
change in tax rates is recognized in income in the period including the enactment date. Valuation allowances are established, when necessary,
to reduce deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;An
uncertain tax position is recognized only if it is &#x201c;more likely than not&#x201d; that the tax position would be sustained in a tax
examination. The amount recognized is the largest amount of tax benefit that is greater than&#160;50% likely of being realized on examination.
For tax positions not meeting the &#x201c;more likely than not&#x201d; test, no tax benefit is recorded. Penalties and interest incurred
related to underpayment of income tax are classified as income tax expense in the period incurred. No significant penalties or interest
relating to income taxes have been incurred during the years ended September 30, 2024, 2023 and 2022. The Company does not believe there
was any uncertain tax provision as of September 30, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company&#x2019;s operating subsidiaries in China are subject to the income tax laws of the PRC. No significant income was generated outside
the PRC for the years ended September 30, 2024, 2023 and 2022. As of September 30, 2024 and 2023, all of the tax returns of the Company&#x2019;s
PRC subsidiaries remained open for statutory examination by PRC tax authorities.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <upc:TaxBenefitPercentage contextRef="c0" decimals="2" id="ixv-22808" unitRef="pure">0.50</upc:TaxBenefitPercentage>
    <upc:ValueAddedTaxPolicyTextBlock contextRef="c0" id="ixv-19063">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Value
added tax (&#x201c;VAT&#x201d;)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Sales
revenue represents the invoiced value of goods, net of VAT. The VAT is based on gross sales price and VAT rates range up to&#160;13%,
depending on the type of products sold. The VAT may be offset by VAT paid by the Company on raw materials and other materials included
in the cost of producing or acquiring its finished products. The Company recorded a VAT payable or receivable net of payments in the
accompanying consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</upc:ValueAddedTaxPolicyTextBlock>
    <upc:PercentageOfVatRate contextRef="c0" decimals="2" id="ixv-22809" unitRef="pure">0.13</upc:PercentageOfVatRate>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-19075">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Earnings
per Share&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company computes earnings per share (&#x201c;EPS&#x201d;) in accordance with ASC 260, &#x201c;Earnings per Share&#x201d; (&#x201c;ASC 260&#x201d;).
ASC 260 requires companies with complex capital structures to present basic and diluted EPS. Basic EPS is measured as net income divided
by the weighted average ordinary shares outstanding for the period. Diluted presents the dilutive effect on a per share basis of potential
ordinary shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented,
or issuance date, if later. Potential ordinary shares that have an anti-dilutive effect (i.e., those that increase income per share or
decrease loss per share) are excluded from the calculation of diluted EPS. For the years ended September 30, 2024, 2023 and 2022, there
were no dilutive shares.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0" id="ixv-19089">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Foreign
currency translation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
functional currency for Universe INC is the U.S. Dollar (&#x201c;US$&#x201d;). Universe HK uses Hong Kong dollar as its functional currency.
However, Universe INC and Universe HK currently only serve as holding companies and did not have active operations as of the date of
this report. The Company operates only in the PRC and the Company&#x2019;s functional currency is the Chinese Yuan (&#x201c;RMB&#x201d;).
The Company&#x2019;s consolidated financial statements have been translated into the reporting currency US$.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Assets
and liabilities of the Company are translated at the exchange rate at each reporting period end date. Equity is translated at historical
rates. Income and expense accounts are translated at the average rate of exchange during the reporting period. The resulting translation
adjustments are reported under other comprehensive income. Gains and losses resulting from the translations of foreign currency transactions
and balances are reflected in the results of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions.
No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
following table outlines the currency exchange rates that were used in creating the consolidated financial statements in this report:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Period-end US$: RMB exchange rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.0176&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.2960&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.1135&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Period-end US$: HK exchange rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.7693&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8308&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8498&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Period average US$: RMB exchange rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.2043&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.0533&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.5532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Period average US$: HK exchange rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8127&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8310&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8228&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock contextRef="c0" id="ixv-19110">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
following table outlines the currency exchange rates that were used in creating the consolidated financial statements in this report:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Period-end US$: RMB exchange rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.0176&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.2960&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.1135&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Period-end US$: HK exchange rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.7693&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8308&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8498&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Period average US$: RMB exchange rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.2043&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.0533&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.5532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Period average US$: HK exchange rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8127&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8310&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8228&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock>
    <us-gaap:DerivativeForwardExchangeRate1
      contextRef="c103"
      decimals="4"
      id="ixv-22810"
      unitRef="pure">7.0176</us-gaap:DerivativeForwardExchangeRate1>
    <us-gaap:DerivativeForwardExchangeRate1
      contextRef="c104"
      decimals="4"
      id="ixv-22811"
      unitRef="pure">7.296</us-gaap:DerivativeForwardExchangeRate1>
    <us-gaap:DerivativeForwardExchangeRate1
      contextRef="c105"
      decimals="4"
      id="ixv-22812"
      unitRef="pure">7.1135</us-gaap:DerivativeForwardExchangeRate1>
    <us-gaap:DerivativeForwardExchangeRate1
      contextRef="c106"
      decimals="4"
      id="ixv-22813"
      unitRef="pure">7.7693</us-gaap:DerivativeForwardExchangeRate1>
    <us-gaap:DerivativeForwardExchangeRate1
      contextRef="c107"
      decimals="4"
      id="ixv-22814"
      unitRef="pure">7.8308</us-gaap:DerivativeForwardExchangeRate1>
    <us-gaap:DerivativeForwardExchangeRate1
      contextRef="c108"
      decimals="4"
      id="ixv-22815"
      unitRef="pure">7.8498</us-gaap:DerivativeForwardExchangeRate1>
    <us-gaap:DerivativeAverageForwardExchangeRate1
      contextRef="c103"
      decimals="4"
      id="ixv-22816"
      unitRef="pure">7.2043</us-gaap:DerivativeAverageForwardExchangeRate1>
    <us-gaap:DerivativeAverageForwardExchangeRate1
      contextRef="c104"
      decimals="4"
      id="ixv-22817"
      unitRef="pure">7.0533</us-gaap:DerivativeAverageForwardExchangeRate1>
    <us-gaap:DerivativeAverageForwardExchangeRate1
      contextRef="c105"
      decimals="4"
      id="ixv-22818"
      unitRef="pure">6.5532</us-gaap:DerivativeAverageForwardExchangeRate1>
    <us-gaap:DerivativeAverageForwardExchangeRate1
      contextRef="c106"
      decimals="4"
      id="ixv-22819"
      unitRef="pure">7.8127</us-gaap:DerivativeAverageForwardExchangeRate1>
    <us-gaap:DerivativeAverageForwardExchangeRate1
      contextRef="c107"
      decimals="4"
      id="ixv-22820"
      unitRef="pure">7.831</us-gaap:DerivativeAverageForwardExchangeRate1>
    <us-gaap:DerivativeAverageForwardExchangeRate1
      contextRef="c108"
      decimals="4"
      id="ixv-22821"
      unitRef="pure">7.8228</us-gaap:DerivativeAverageForwardExchangeRate1>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c0" id="ixv-19190">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Comprehensive
Income&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Comprehensive
income consists of two components, net income and other comprehensive income. The foreign currency translation gain resulting from translation
of the financial statements expressed in RMB to US$ is reported in other comprehensive income in the consolidated statements of operations
and comprehensive loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <upc:StatementOfCashFlowsPolicyTextBlock contextRef="c0" id="ixv-19203">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Statement
of Cash Flows&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;In
accordance with ASC 230, &#x201c;Statement of Cash Flows&#x201d;, cash flows from the Company&#x2019;s operations are formulated based upon
the local currencies. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily
agree with changes in the corresponding balances on the balance sheets.&lt;/span&gt;&lt;/p&gt;</upc:StatementOfCashFlowsPolicyTextBlock>
    <upc:EmployeeDefinedContributionPlanPolicyTextBlock contextRef="c0" id="ixv-19215">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Employee
Defined Contribution Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company&#x2019;s subsidiaries in the PRC participate in a government-mandated multi-employer defined contribution plan pursuant to which
pension, work-related injury benefits, maternity insurance, medical insurance, unemployment benefit and housing fund are provided to
eligible full-time employees. The relevant labor regulations require the Company&#x2019;s subsidiaries in the PRC to pay the local labor
and social welfare authorities monthly contributions based on the applicable benchmarks and rates stipulated by the local government.
The contributions to the plan are expensed as incurred. Employee social security and welfare benefits included as expenses in the accompanying
consolidated statements of operations and comprehensive loss amounted to $247,249, $440,962&#160;and $465,689&#160;for the years ended
September 30, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;</upc:EmployeeDefinedContributionPlanPolicyTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c0" decimals="0" id="ixv-22822" unitRef="usd">247249</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c6" decimals="0" id="ixv-22823" unitRef="usd">440962</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c7" decimals="0" id="ixv-22824" unitRef="usd">465689</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-19246">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Recently
Issued &lt;span style="background-color: white"&gt;Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
considers the applicability and impact of all accounting standards updates (&#x201c;ASUs&#x201d;). Management periodically reviews new accounting
standards that are issued. Under the Jumpstart Our Business Startups Act of 2012, as amended (the &#x201c;JOBS Act&#x201d;), the Company
meets the definition of an emerging growth company, or EGC, and has elected the extended transition period for complying with new or revised
accounting standards, which delays the adoption of these accounting standards until they would apply to private companies.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In November
2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amended guidance
requires incremental reportable segment disclosures, primarily about significant segment expenses. The amendments also require entities
with a single reportable segment to provide all disclosures required by these amendments, and all existing segment disclosures. The amendments
will be applied retrospectively to all prior periods presented in the financial statements and is effective for fiscal years beginning
after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. The guidance should be adopted retrospectively.
The Company is currently in the process of evaluating the impact this amended guidance may have on the footnotes to its consolidated financial
statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In December
2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amended guidance enhances income
tax disclosures primarily related to the effective tax rate reconciliation and income taxes paid information. This guidance requires disclosure
of specific categories in the effective tax rate reconciliation and further information on reconciling items meeting a quantitative threshold.
In addition, the amended guidance requires disaggregating income taxes paid (net of refunds received) by federal, state, and foreign taxes.
It also requires disaggregating individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than
5 percent of total income taxes paid (net of refunds received). The amended guidance is effective for fiscal years beginning after December
15, 2024. The guidance can be applied either prospectively or retrospectively. The Company is currently in the process of evaluating the
impact this amended guidance may have on the footnotes to its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In March
2024, the FASB issued ASU 2024-01, Compensation&#x2014;Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar
Awards. The amended guidance added an illustrative example that includes four fact patterns to demonstrate how an entity should apply
the scope guidance in paragraph 718-10-15-3 to determine whether a profits interest award should be accounted for in accordance with Topic
718. The amendments guidance is effective for annual periods beginning after December 15, 2024, and interim periods within those annual
periods. The guidance can be applied either prospectively or retrospectively. The Company is currently in the process of evaluating the
impact this amended guidance may have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In November
2024, the FASB issued ASU 2024-03, Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses. The amended guidance improves the disclosures about a public business entity&#x2019;s
expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory,
employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions (such as cost of sales, SG&amp;amp;A,
and research and development). The amended guidance is effective for annual reporting periods beginning after December 15, 2026, and interim
reporting periods beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective
application. The Company is currently in the process of evaluating the impact this amended guidance may have on the footnotes to its consolidated
financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In November
2024, the FASB issued ASU 2024-04, Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible
Debt Instruments. This guidance clarifies the assessment of whether a transaction should be accounted for as an induced conversion or
extinguishment of convertible debt when changes are made to conversion features as part of an offer to settle the instrument. The amended
guidance is effective for all entities for annual reporting periods beginning after December 15, 2025, and interim reporting periods within
those annual reporting periods. The guidance can be applied either prospectively or retrospectively. The Company is currently in the process
of evaluating the impact this amended guidance may have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In January
2025, the FASB issued ASU 2025-01, Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic
220-40): Clarifying the Effective Date. This guidance amends the effective date of Update 2024-03 to clarify that all public business
entities are required to adopt the guidance in annual reporting periods beginning after December 15, 2026, and interim periods within
annual reporting periods beginning after December 15, 2027. Early adoption of Update 2024-03 is permitted. The Company is currently in
the process of evaluating the impact this amended guidance may have on the footnotes to its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Other accounting
standards that have been issued by FASB that do not require adoption until a future date are not expected to have a material impact on
the consolidated financial statements upon adoption. The Company does not discuss recent standards that are not anticipated to have an
impact on or are unrelated to its consolidated financial condition, results of operations, cash flows or disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="c0" id="ixv-19307">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;NOTE
3 &#x2014; ACCOUNTS RECEIVABLE, NET&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Accounts
receivable consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,040,903&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,014,908&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(135,082&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Accounts receivable, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12,905,821&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11,014,908&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company&#x2019;s accounts
receivable primarily includes the balance due from customers when the Company&#x2019;s pharmaceutical products are sold and delivered to
customers. As of date of this report, approximately 98.4%&lt;/span&gt;, or $12.8 &lt;span style="background-color: white"&gt;million, of the Company&#x2019;s
net account receivable balance as of September 30, 2024 has been subsequently collected, and the remaining balance is expected to be substantially
collected before June 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Allowance
for doubtful accounts movement is as follows:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Beginning balance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Reversal of allowance for doubtful accounts&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;131,581&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-66"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Foreign currency translation adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,501&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-67"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;135,082&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-68"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="c0" id="ixv-19314">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Accounts
receivable consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,040,903&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,014,908&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(135,082&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Accounts receivable, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12,905,821&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11,014,908&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="c2" decimals="0" id="ixv-22825" unitRef="usd">13040903</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="c3" decimals="0" id="ixv-22826" unitRef="usd">11014908</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c2" decimals="0" id="ixv-22827" unitRef="usd">135082</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c2" decimals="0" id="ixv-22828" unitRef="usd">12905821</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="0" id="ixv-22829" unitRef="usd">11014908</us-gaap:AccountsReceivableNetCurrent>
    <upc:NetAccountReceivablePercentage contextRef="c2" decimals="3" id="ixv-22830" unitRef="pure">0.984</upc:NetAccountReceivablePercentage>
    <us-gaap:AccountsReceivableNet contextRef="c2" decimals="-5" id="ixv-22831" unitRef="usd">12800000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock contextRef="c0" id="ixv-19374">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Allowance
for doubtful accounts movement is as follows:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Beginning balance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Reversal of allowance for doubtful accounts&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;131,581&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-66"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Foreign currency translation adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,501&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-67"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;135,082&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-68"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c0" decimals="0" id="ixv-22832" unitRef="usd">131581</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease contextRef="c0" decimals="0" id="ixv-22833" unitRef="usd">-3501</us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c2" decimals="0" id="ixv-22834" unitRef="usd">135082</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c0" id="ixv-19441">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;NOTE
4 &#x2014; INVENTORIES, NET&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Inventories
consist of the following:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;720,041&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;635,395&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Finished goods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,141,526&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,777,617&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Inventories valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(124,512&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(69,746&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total inventories, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;1,737,054&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,343,266&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventories valuation allowance &lt;span style="background-color: white"&gt;movement
is as follows:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Beginning balance&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;69,746&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;120,286&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Reversal of inventories valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,651&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(49,166&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Foreign currency translation adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,115&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,374&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;124,512&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;69,746&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c0" id="ixv-19447">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Inventories
consist of the following:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;720,041&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;635,395&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Finished goods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,141,526&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,777,617&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Inventories valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(124,512&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(69,746&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total inventories, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;1,737,054&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,343,266&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="c2" decimals="0" id="ixv-22835" unitRef="usd">720041</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="c3" decimals="0" id="ixv-22836" unitRef="usd">635395</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryFinishedGoods contextRef="c2" decimals="0" id="ixv-22837" unitRef="usd">1141526</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c3" decimals="0" id="ixv-22838" unitRef="usd">2777617</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryValuationReserves contextRef="c2" decimals="0" id="ixv-22839" unitRef="usd">124512</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="c3" decimals="0" id="ixv-22840" unitRef="usd">69746</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet contextRef="c2" decimals="0" id="ixv-22841" unitRef="usd">1737054</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c3" decimals="0" id="ixv-22842" unitRef="usd">3343266</us-gaap:InventoryNet>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="c0" id="ixv-19510">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventories valuation allowance &lt;span style="background-color: white"&gt;movement
is as follows:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Beginning balance&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;69,746&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;120,286&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Reversal of inventories valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,651&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(49,166&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Foreign currency translation adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,115&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,374&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;124,512&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;69,746&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:InventoryValuationReserves contextRef="c3" decimals="0" id="ixv-22843" unitRef="usd">69746</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="c24" decimals="0" id="ixv-22844" unitRef="usd">120286</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryLIFOReservePeriodCharge contextRef="c0" decimals="0" id="ixv-22845" unitRef="usd">50651</us-gaap:InventoryLIFOReservePeriodCharge>
    <us-gaap:InventoryLIFOReservePeriodCharge contextRef="c6" decimals="0" id="ixv-22846" unitRef="usd">-49166</us-gaap:InventoryLIFOReservePeriodCharge>
    <upc:InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments contextRef="c0" decimals="0" id="ixv-22847" unitRef="usd">4115</upc:InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments>
    <upc:InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments contextRef="c6" decimals="0" id="ixv-22848" unitRef="usd">-1374</upc:InventoryValuationAllowanceeForeignCurrencyTranslationAdjustments>
    <us-gaap:InventoryValuationReserves contextRef="c2" decimals="0" id="ixv-22849" unitRef="usd">124512</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="c3" decimals="0" id="ixv-22850" unitRef="usd">69746</us-gaap:InventoryValuationReserves>
    <upc:AdvancesToSuppliersTextBlock contextRef="c0" id="ixv-19573">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;NOTE
5 &#x2014; ADVANCE TO SUPPLIERS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Advances
to suppliers consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 76%; text-align: justify"&gt;Advances to suppliers for inventories raw material purchase&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;978,203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;180,643&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Advances to suppliers&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;978,203&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;180,643&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Advances
to suppliers represent prepayments made to suppliers to ensure continuous high-quality supplies and favorable purchase prices of raw
materials. &lt;/span&gt;&lt;/p&gt;</upc:AdvancesToSuppliersTextBlock>
    <upc:ScheduleOfAdvancesToSuppliersNet contextRef="c0" id="ixv-19579">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Advances
to suppliers consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 76%; text-align: justify"&gt;Advances to suppliers for inventories raw material purchase&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;978,203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;180,643&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Advances to suppliers&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;978,203&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;180,643&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</upc:ScheduleOfAdvancesToSuppliersNet>
    <us-gaap:InventoryRawMaterialsAndSupplies contextRef="c2" decimals="0" id="ixv-22851" unitRef="usd">978203</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryRawMaterialsAndSupplies contextRef="c3" decimals="0" id="ixv-22852" unitRef="usd">180643</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:Supplies contextRef="c2" decimals="0" id="ixv-22853" unitRef="usd">978203</us-gaap:Supplies>
    <us-gaap:Supplies contextRef="c3" decimals="0" id="ixv-22854" unitRef="usd">180643</us-gaap:Supplies>
    <us-gaap:AssetAcquisitionTextBlock contextRef="c0" id="ixv-19640">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;NOTE 6 &#x2014; PREPAYMENT FOR ACQUISITION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
September 26, 2022, the Company entered into a letter of intent for an equity transfer with an individual, Mr. Xibo Liu, pursuant to
which, Mr. Xibo Liu transfers his&#160;51% ownership in Yunnan Faxi Pharmaceuticals Co., Ltd. (&#x201c;Yunnan Faxi&#x201d;) to the Company
at the price of RMB72&#160;million (approximately $10.0&#160;million). Based on contract terms, the Company prepaid RMB25&#160;million
(approximately $3.4&#160;million) within three (3) business days upon signing the letter of intent. As of September 30, 2023, the prepayment
was recorded as prepayment for acquisition on the balance sheets. However, due to unsatisfactory performance of Yunnan Faxi, the equity
transfer contract was terminated on December 20, 2024. The amount of $3,562,472 (RMB25&#160;million) was reclassified to other receivable
as of September 30, 2024, and collected back subsequently. &lt;/span&gt;&lt;/p&gt;</us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="c109"
      decimals="2"
      id="ixv-22855"
      unitRef="pure">0.51</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <upc:PrepaymentForAcquisition
      contextRef="c110"
      decimals="-6"
      id="ixv-22856"
      unitRef="cny">72000000</upc:PrepaymentForAcquisition>
    <upc:PrepaymentForAcquisition
      contextRef="c110"
      decimals="-5"
      id="ixv-22857"
      unitRef="usd">10000000</upc:PrepaymentForAcquisition>
    <upc:PrepaymentForAcquisitionCurrent
      contextRef="c111"
      decimals="-6"
      id="ixv-22858"
      unitRef="cny">25000000</upc:PrepaymentForAcquisitionCurrent>
    <upc:PrepaymentForAcquisitionCurrent
      contextRef="c111"
      decimals="-5"
      id="ixv-22859"
      unitRef="usd">3400000</upc:PrepaymentForAcquisitionCurrent>
    <us-gaap:OtherReceivables contextRef="c112" decimals="0" id="ixv-22860" unitRef="usd">3562472</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="c112"
      decimals="-6"
      id="ixv-22861"
      unitRef="cny">25000000</us-gaap:OtherReceivables>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="c0" id="ixv-19653">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;NOTE 7 &#x2014; OTHER RECEIVABLE&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Other receivable
consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Receivable from Yunan Faxi &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,562,472&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-69"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Redemption of short-term investment &lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,377,873&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,367,052&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Prepaid value added tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;475,331&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;478,899&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Prepayment for advertising&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;219,830&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;31,090&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;74,300&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Other receivable&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,666,596&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,920,251&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
September 26, 2022, the Company entered into a letter of intent for an equity transfer with an individual, Mr. Xibo Liu, pursuant to
which, Mr. Xibo Liu transfers his&#160;51% ownership in Yunnan Faxi to the Company at the price of RMB72&#160;million (approximately
$10.0&#160;million). Based on contract terms, the Company prepaid RMB25&#160;million (approximately $3.4&#160;million) within three (3)
business days upon signing the letter of intent. However, due to unsatisfactory performance of Yunnan Faxi, the equity transfer contract
was terminated on December 20, 2024. The amount of $3,562,472 (RMB25&#160;million) was recorded as other receivable as of September 30,
2024.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
September 24, 2024, the Company entered into an agreement with a third party to transfer its short-term investment at the price of $&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,377,873.
&lt;span style="background-color: white"&gt;The amount was recorded as other receivable as of September 30, 2024 and 2023.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;



&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;As of date of this report, approximately
&lt;/span&gt;99.4%, or $5.6 &lt;span style="background-color: white"&gt;million, of the Company&#x2019;s other receivable balance as of September 30,
2024 has been subsequently collected.&lt;/span&gt;&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="c0" id="ixv-19658">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Other receivable
consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Receivable from Yunan Faxi &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,562,472&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-69"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Redemption of short-term investment &lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,377,873&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,367,052&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Prepaid value added tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;475,331&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;478,899&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Prepayment for advertising&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;219,830&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;31,090&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;74,300&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Other receivable&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,666,596&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,920,251&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
September 26, 2022, the Company entered into a letter of intent for an equity transfer with an individual, Mr. Xibo Liu, pursuant to
which, Mr. Xibo Liu transfers his&#160;51% ownership in Yunnan Faxi to the Company at the price of RMB72&#160;million (approximately
$10.0&#160;million). Based on contract terms, the Company prepaid RMB25&#160;million (approximately $3.4&#160;million) within three (3)
business days upon signing the letter of intent. However, due to unsatisfactory performance of Yunnan Faxi, the equity transfer contract
was terminated on December 20, 2024. The amount of $3,562,472 (RMB25&#160;million) was recorded as other receivable as of September 30,
2024.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
September 24, 2024, the Company entered into an agreement with a third party to transfer its short-term investment at the price of $&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,377,873.
&lt;span style="background-color: white"&gt;The amount was recorded as other receivable as of September 30, 2024 and 2023.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:ReceivablesNetCurrent contextRef="c2" decimals="0" id="ix_22_fact" unitRef="usd">3562472</us-gaap:ReceivablesNetCurrent>
    <us-gaap:OtherShortTermInvestments contextRef="c2" decimals="0" id="ix_23_fact" unitRef="usd">1377873</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c3" decimals="0" id="ix_24_fact" unitRef="usd">1367052</us-gaap:OtherShortTermInvestments>
    <us-gaap:ValueAddedTaxReceivableCurrent contextRef="c2" decimals="0" id="ixv-22865" unitRef="usd">475331</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent contextRef="c3" decimals="0" id="ixv-22866" unitRef="usd">478899</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:PrepaidAdvertising contextRef="c2" decimals="0" id="ixv-22867" unitRef="usd">219830</us-gaap:PrepaidAdvertising>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c2" decimals="0" id="ixv-22868" unitRef="usd">31090</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c3" decimals="0" id="ixv-22869" unitRef="usd">74300</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherReceivables contextRef="c2" decimals="0" id="ixv-22870" unitRef="usd">5666596</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables contextRef="c3" decimals="0" id="ixv-22871" unitRef="usd">1920251</us-gaap:OtherReceivables>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c113"
      decimals="2"
      id="ixv-22872"
      unitRef="pure">0.51</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="c111"
      decimals="-6"
      id="ixv-22873"
      unitRef="cny">72000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="c111"
      decimals="-5"
      id="ixv-22874"
      unitRef="usd">10000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="c2" decimals="-6" id="ixv-22875" unitRef="cny">25000000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="c2" decimals="-5" id="ixv-22876" unitRef="usd">3400000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="c2" decimals="0" id="ixv-22877" unitRef="usd">3562472</us-gaap:ReceivablesNetCurrent>
    <us-gaap:OtherReceivablesGrossCurrent contextRef="c2" decimals="-6" id="ixv-22878" unitRef="cny">25000000</us-gaap:OtherReceivablesGrossCurrent>
    <us-gaap:OtherShortTermInvestments contextRef="c114" decimals="0" id="ixv-22879" unitRef="usd">1377873</us-gaap:OtherShortTermInvestments>
    <upc:OtherReceivablePercentage contextRef="c0" decimals="3" id="ixv-22880" unitRef="pure">0.994</upc:OtherReceivablePercentage>
    <us-gaap:OtherReceivablesGrossCurrent contextRef="c2" decimals="-5" id="ixv-22881" unitRef="usd">5600000</us-gaap:OtherReceivablesGrossCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0" id="ixv-19772">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;NOTE
8 &#x2014; PROPERTY, PLANT AND EQUIPMENT, NET&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Property,
plant and equipment, net, consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Useful life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: justify"&gt;Buildings&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;20&#160;years&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,594,735&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,304,936&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;5-10&#160;years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,007,399&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,896,976&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Automobiles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3-5&#160;years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67,374&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73,703&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Office and electric equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3-5&#160;years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;527,336&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;474,830&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Construction-in-progress&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;35,971&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-71"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,232,815&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,750,445&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,664,765&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,050,480&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Property, plant and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,568,050&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,699,965&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Depreciation
expense was $474,034, $503,687&#160;and $528,919&#160;for the years ended September 30, 2024, 2023 and 2022, respectively. Loss from
disposal of &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;property, plant and equipment &lt;span style="background-color: white"&gt;amounted
to $3,958, $114 and $983 for the years ended September 30, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-19778">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Property,
plant and equipment, net, consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Useful life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: justify"&gt;Buildings&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;20&#160;years&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,594,735&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,304,936&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;5-10&#160;years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,007,399&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,896,976&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Automobiles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3-5&#160;years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67,374&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73,703&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Office and electric equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3-5&#160;years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;527,336&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;474,830&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Construction-in-progress&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;35,971&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-71"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,232,815&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,750,445&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,664,765&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,050,480&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Property, plant and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,568,050&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,699,965&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c93" id="ixv-22882">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c93" decimals="0" id="ixv-22883" unitRef="usd">7594735</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c115" decimals="0" id="ixv-22884" unitRef="usd">7304936</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c94" id="ixv-22885">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c95" id="ixv-22886">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c116" decimals="0" id="ixv-22887" unitRef="usd">2007399</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c117" decimals="0" id="ixv-22888" unitRef="usd">1896976</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c96" id="ixv-22889">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c97" id="ixv-22890">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c118" decimals="0" id="ixv-22891" unitRef="usd">67374</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c119" decimals="0" id="ixv-22892" unitRef="usd">73703</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c120" id="ixv-22893">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c121" id="ixv-22894">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c122" decimals="0" id="ixv-22895" unitRef="usd">527336</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c123" decimals="0" id="ixv-22896" unitRef="usd">474830</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c124" decimals="0" id="ixv-22897" unitRef="usd">35971</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c2" decimals="0" id="ixv-22898" unitRef="usd">10232815</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="0" id="ixv-22899" unitRef="usd">9750445</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="0" id="ixv-22900" unitRef="usd">6664765</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="0" id="ixv-22901" unitRef="usd">6050480</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" id="ixv-22902" unitRef="usd">3568050</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" id="ixv-22903" unitRef="usd">3699965</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c0" decimals="0" id="ixv-22904" unitRef="usd">474034</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c6" decimals="0" id="ixv-22905" unitRef="usd">503687</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c7" decimals="0" id="ixv-22906" unitRef="usd">528919</us-gaap:Depreciation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c0" decimals="0" id="ixv-22907" unitRef="usd">-3958</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c6" decimals="0" id="ixv-22908" unitRef="usd">-114</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c7" decimals="0" id="ixv-22909" unitRef="usd">-983</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c0" id="ixv-19920">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;NOTE
9 &#x2014; INTANGIBLE ASSETS, NET&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Intangible
assets, net consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Useful life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 66%; text-align: justify"&gt;Land use rights&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: center"&gt;50&#160;years&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;256,211&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;246,434&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Trademark&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;5&#160;years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;120,412&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Software&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;3&#160;years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,506&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,687&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;398,129&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;267,121&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(135,251&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(118,537&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Intangible assets, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;262,878&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;148,584&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Amortization
expense was $11,700, $5,098 and $5,030 for the years ended September 30, 2024, 2023 and 2022,&#160;respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Estimated
future amortization expense for intangible assets is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Years Ending September 30,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amortization&lt;br/&gt; expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17,165&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;177,053&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;262,878&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c0" id="ixv-19926">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Intangible
assets, net consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Useful life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 66%; text-align: justify"&gt;Land use rights&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: center"&gt;50&#160;years&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;256,211&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;246,434&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Trademark&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;5&#160;years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;120,412&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Software&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;3&#160;years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,506&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,687&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;398,129&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;267,121&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(135,251&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(118,537&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Intangible assets, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;262,878&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;148,584&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c126" id="ixv-22910">P50Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c126" decimals="0" id="ixv-22911" unitRef="usd">256211</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c127" decimals="0" id="ixv-22912" unitRef="usd">246434</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c128" id="ixv-22913">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c128" decimals="0" id="ixv-22914" unitRef="usd">120412</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c130" id="ixv-22915">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c130" decimals="0" id="ixv-22916" unitRef="usd">21506</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c131" decimals="0" id="ixv-22917" unitRef="usd">20687</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c2" decimals="0" id="ixv-22918" unitRef="usd">398129</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c3" decimals="0" id="ixv-22919" unitRef="usd">267121</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c2" decimals="0" id="ixv-22920" unitRef="usd">135251</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c3" decimals="0" id="ixv-22921" unitRef="usd">118537</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c2" decimals="0" id="ixv-22922" unitRef="usd">262878</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c3" decimals="0" id="ixv-22923" unitRef="usd">148584</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c0" decimals="0" id="ixv-22924" unitRef="usd">11700</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c6" decimals="0" id="ixv-22925" unitRef="usd">5098</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c7" decimals="0" id="ixv-22926" unitRef="usd">5030</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c0" id="ixv-20028">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Estimated
future amortization expense for intangible assets is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Years Ending September 30,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amortization&lt;br/&gt; expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17,165&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;177,053&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;262,878&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c2" decimals="0" id="ixv-22927" unitRef="usd">17165</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c2" decimals="0" id="ixv-22928" unitRef="usd">17165</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c2" decimals="0" id="ixv-22929" unitRef="usd">17165</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c2" decimals="0" id="ixv-22930" unitRef="usd">17165</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c2" decimals="0" id="ixv-22931" unitRef="usd">17165</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c2" decimals="0" id="ixv-22932" unitRef="usd">177053</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c2" decimals="0" id="ixv-22933" unitRef="usd">262878</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <upc:PrepaymentForConstructionInProgressTextBlock contextRef="c0" id="ixv-20093">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;NOTE
10 &#x2014; PREPAYMENT FOR CIP PROJECT&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;CIP
represents direct costs of construction incurred for the Company&#x2019;s manufacturing facilities. On June 25, 2021, the Company signed
a construction sub-contract with sub-contractor Jiangxi Chenyuan Construction Project Co., Ltd. (&#x201c;Chenyuan&#x201d;), pursuant to
which, Chenyuan agreed to help the Company construct four manufacturing factory buildings and an office building with a total estimated
budget of RMB165 million (approximately $23.5 million). The construction work started on August 8, 2021, with an originally estimated
completion date on August 7, 2023. However, due to resurgence of the COVID-19 pandemic, which resulted in lingering logistic disruption,
material and labor shortage, and domestic travel restriction, at the beginning of 2024, the Company estimated the construction work to
be completed in December 2024. During 2024, new information was discovered about the topographical and surface structures of the land,
which required Chenyuan to redo the geological survey. As a result, the construction work is further delayed, and the construction of
the four manufacturing factory buildings and the office building is expected to be fully completed and put into use by December 2025
and December 2026, respectively. As of September 30, 2024, the Company had made a prepayment of approximately RMB69.2 million (approximately
$9.9 million) to Chenyuan for land improvement, building foundation and the construction of the manufacturing factories.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;During
the year ended September 30, 2022, $407,190 (approximately RMB2.9 million) of the prepayment for the CIP project was used for construction
work, and the amount was recorded as property, plant and equipment in the consolidated balance sheets. As of September 30, 2024, the
remaining $9.5 million prepayment to Chenyuan was recorded as a prepayment for CIP project on the balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;As
of September 30, 2024, future additional capital expenditure on this CIP project is estimated to be approximately RMB95.8 million (equivalent
to $13.7 million), among which approximately $7.1 million is required for the next 12 months. The Company currently plans to support
its ongoing CIP project construction through cash collected from accounts receivable, and if necessary, borrowings from PRC banks in
the future. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;As
of September 30, 2024, future minimum capital expenditures on the Company&#x2019;s CIP project are estimated as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Twelve months ending September 30,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Capital&lt;br/&gt; Expenditure&lt;br/&gt; on CIP&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,124,943&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,350,832&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,175,616&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;13,651,391&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</upc:PrepaymentForConstructionInProgressTextBlock>
    <us-gaap:InvestmentBuildingAndBuildingImprovements
      contextRef="c132"
      decimals="-6"
      id="ixv-22934"
      unitRef="cny">165000000</us-gaap:InvestmentBuildingAndBuildingImprovements>
    <us-gaap:InvestmentBuildingAndBuildingImprovements
      contextRef="c132"
      decimals="-5"
      id="ixv-22935"
      unitRef="usd">23500000</us-gaap:InvestmentBuildingAndBuildingImprovements>
    <us-gaap:InvestmentBuildingAndBuildingImprovements
      contextRef="c133"
      decimals="-5"
      id="ixv-22936"
      unitRef="cny">69200000</us-gaap:InvestmentBuildingAndBuildingImprovements>
    <us-gaap:InvestmentBuildingAndBuildingImprovements
      contextRef="c133"
      decimals="-5"
      id="ixv-22937"
      unitRef="usd">9900000</us-gaap:InvestmentBuildingAndBuildingImprovements>
    <us-gaap:ConstructionContractCostProgressPaymentOffset contextRef="c134" decimals="0" id="ixv-22938" unitRef="usd">407190</us-gaap:ConstructionContractCostProgressPaymentOffset>
    <us-gaap:ConstructionContractCostProgressPaymentOffset
      contextRef="c134"
      decimals="-5"
      id="ixv-22939"
      unitRef="cny">2900000</us-gaap:ConstructionContractCostProgressPaymentOffset>
    <us-gaap:PrepaymentFeesOnAdvancesNet
      contextRef="c135"
      decimals="-5"
      id="ixv-22940"
      unitRef="usd">9500000</us-gaap:PrepaymentFeesOnAdvancesNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="c136"
      decimals="-5"
      id="ixv-22941"
      unitRef="cny">95800000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="c136"
      decimals="-5"
      id="ixv-22942"
      unitRef="usd">13700000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="c137"
      decimals="-5"
      id="ixv-22943"
      unitRef="usd">7100000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <upc:ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock contextRef="c0" id="ixv-20126">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;As
of September 30, 2024, future minimum capital expenditures on the Company&#x2019;s CIP project are estimated as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Twelve months ending September 30,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Capital&lt;br/&gt; Expenditure&lt;br/&gt; on CIP&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,124,943&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,350,832&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,175,616&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;13,651,391&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</upc:ScheduleOfFutureMinimumCapitalExpendituresTableTextBlock>
    <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="c2" decimals="0" id="ixv-22944" unitRef="usd">7124943</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInSecondYear contextRef="c2" decimals="0" id="ixv-22945" unitRef="usd">5350832</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInThirdYear contextRef="c2" decimals="0" id="ixv-22946" unitRef="usd">1175616</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligation contextRef="c2" decimals="0" id="ixv-22947" unitRef="usd">13651391</us-gaap:ContractualObligation>
    <upc:PrepaymentForPurchaseOfAPropertyTextBlock contextRef="c0" id="ixv-20173">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;NOTE
11 &#x2014; PREPAYMENT FOR PURCHASE OF A PROPERTY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
May 6, 2021, the Company entered into a real estate property purchase agreement with related party Jiangxi Yueshang Investment Co., Ltd.
(&#x201c;Jiangxi Yueshang&#x201d;), an entity in which the Company&#x2019;s chief executive officer, Mr. Gang Lai, owned 5% equity interest
as of the date of that agreement. Pursuant to the property purchase agreement, Jiangxi Yueshang will sell and the Company will purchase
a certain residential apartment and commercial office space totaling 2,749.30 square meters, with a total purchase price of RMB32 million
(approximately $4.6 million). Pursuant to this agreement, the Company was required to make a prepayment in the amount of 50% of the total
purchase price, with 20% of the total purchase price payable upon the availability of a certificate of occupancy, and 30% of the total
purchase price payable upon delivery of the property.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;As
of September 30, 2024, the Company had made a prepayment of RMB16 million (approximately $2.3 million) to Jiangxi Yueshang. The remaining
balance is expected to be paid by April 2025. Since the property is located in the urban downtown area of Ji&#x2019;an City, the Company
plans to use the property for offices in June 2025.&lt;/span&gt;&lt;/p&gt;</upc:PrepaymentForPurchaseOfAPropertyTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c138"
      decimals="2"
      id="ixv-22948"
      unitRef="pure">0.05</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:AreaOfRealEstateProperty contextRef="c139" decimals="2" id="ixv-22949" unitRef="sqm">2749.3</us-gaap:AreaOfRealEstateProperty>
    <upc:PrepaymentsMadeToARelatedPartyForPurchasesOfProperty
      contextRef="c139"
      decimals="-6"
      id="ixv-22950"
      unitRef="cny">32000000</upc:PrepaymentsMadeToARelatedPartyForPurchasesOfProperty>
    <upc:PrepaymentsMadeToARelatedPartyForPurchasesOfProperty
      contextRef="c139"
      decimals="-5"
      id="ixv-22951"
      unitRef="usd">4600000</upc:PrepaymentsMadeToARelatedPartyForPurchasesOfProperty>
    <upc:PercentageOfPrepayment
      contextRef="c140"
      decimals="2"
      id="ixv-22952"
      unitRef="pure">0.50</upc:PercentageOfPrepayment>
    <upc:PercentageOfTotalPurchasePricePayable
      contextRef="c139"
      decimals="2"
      id="ixv-22953"
      unitRef="pure">0.20</upc:PercentageOfTotalPurchasePricePayable>
    <upc:PayableDeliveryPropertyPercentage
      contextRef="c140"
      decimals="2"
      id="ixv-22954"
      unitRef="pure">0.30</upc:PayableDeliveryPropertyPercentage>
    <us-gaap:PrepaymentFeesOnAdvancesNet
      contextRef="c141"
      decimals="-6"
      id="ixv-22955"
      unitRef="cny">16000000</us-gaap:PrepaymentFeesOnAdvancesNet>
    <us-gaap:PrepaymentFeesOnAdvancesNet
      contextRef="c141"
      decimals="-5"
      id="ixv-22956"
      unitRef="usd">2300000</us-gaap:PrepaymentFeesOnAdvancesNet>
    <us-gaap:ShortTermDebtTextBlock contextRef="c0" id="ixv-20191">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;NOTE
12 &#x2014; SHORT-TERM BANK LOANS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Short-term
bank loans consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Note&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Short-term bank loans:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Jiangxi Luling Rural Commercial Bank (&#x201c;LRC Bank&#x201d;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;(1)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,849,976&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,467,105&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Bank of Communications Co., Ltd&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;(2)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,154,241&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,233,553&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Zhujiang Rural Bank&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;(3)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;427,497&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;411,184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Beijing Bank&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;(4)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,424,989&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,370,614&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total short-term loans&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,856,703&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,482,456&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On March 13, 2023, a subsidiary of the Company, Universe Trade, signed a loan agreement with LRC Bank to borrow RMB8 million (equivalent to $1,096,491) as working capital for one year, with the maturity date on March 12, 2024. The fixed interest rate of the loan was 4.56% per annum. Mr. Gang Lai signed guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On June 15, 2023, a subsidiary of the Company, Jiangxi Universe, signed a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,370,614) as working capital for eleven months, with the maturity date on May 14, 2024. The fixed interest rate of the loan was 4.56% per annum. Mr. Gang Lai signed guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 4, 2024, a subsidiary of the Company, Universe
Trade, signed a loan agreement with LRC Bank to borrow RMB5 million (equivalent to $712,494) as working capital for one year, with the
maturity date on March 3, 2025. The fixed interest rate of the loan was 4.75% per annum. Mr. Gang Lai and Jiangxi Universe jointly signed
guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 26, 2024, a subsidiary of the Company, Jiangxi
Universe, signed a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,424,989) as working capital for one year, with
the maturity date on April 25, 2025. The fixed interest rate of the loan was 4.31% per annum. Mr. Gang Lai and Universe Technology jointly
signed guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 17, 2024, a subsidiary of the Company, Universe
trade, signed a loan agreement with LRC Bank to borrow RMB5 million (equivalent to $712,494) as working capital for one year, with the
maturity date on May 16, 2025. The fixed interest rate of the loan was 3.65% per annum. Mr. Gang Lai and Jiangxi Universe jointly signed
guarantee agreements with LRC Bank to provide credit guarantee for this loan.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
March 3, 2025, a subsidiary of the Company, Universe Trade, signed a loan agreement with LRC Bank to borrow RMB5 million (equivalent to
$712,494) as working capital for one year, with the maturity date on March 2, 2026. The fixed interest rate of the loan was 3.65% per
annum. Mr. Gang Lai and Jiangxi Universe jointly signed guarantee agreements with LRC Bank to provide credit guarantee for this loan.&lt;/span&gt;
&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;On April 22, 2024, a subsidiary of the Company, Jiangxi Universe, signed
a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,424,989) as working capital for one year, with the maturity date
on April 21, 2026. The fixed interest rate of the loan was 3.60% per annum. Mr. Gang Lai and Universe Technology jointly signed guarantee
agreements with LRC Bank to provide credit guarantee for this loan. &#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On June 15, 2023, the Company&#x2019;s subsidiary, Jiangxi Universe, signed a loan agreement with Bank of Communications to borrow RMB9 million (equivalent to $1,246,486) as working capital for eleven months, with the maturity date on May 18, 2024. The fixed interest rate of the loan was 4.0% per annum. Mr. Gang Lai, Universe Trade, and an unrelated third party, Jiangxi Province Financing Guarantee Group Co., Ltd., jointly signed guarantee agreements with Bank of Communications to provide credit guarantee for this loan. The loan was fully repaid upon maturity.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On June 16, 2024, the Company&#x2019;s subsidiary, Jiangxi Universe, signed a loan agreement with Bank of Communications to borrow RMB8.1 million (equivalent to $1,154,241) as working capital for eleven months, with the maturity date on May 13, 2025. The fixed interest rate of the loan was 3.9% per annum. Mr. Gang Lai, Universe Trade, and an unrelated third party, Jiangxi Province Financing Guarantee Group Co., Ltd., jointly signed guarantee agreements with Bank of Communications to provide credit guarantee for this loan.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On May 5, 2023, a subsidiary of the Company, Jiangxi Universe, entered into a loan agreement with Zhujiang Rural Bank to borrow RMB 3 million (equivalent to $415,495) as working capital for one year, with the maturity date on May 4, 2024. The fixed interest rate of the loan was 3.65% per annum. The Company pledged certain patents owned by the Company as collateral to guarantee this loan. The loan was fully repaid upon maturity.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 24, 2024, a subsidiary of the Company, Jiangxi
Universe, entered into a loan agreement with Zhujiang Rural Bank to borrow RMB3 million (equivalent to $427,497) as working capital for
one year, with the maturity date on April 24, 2025. The fixed interest rate of the loan was 3.65% per annum. The Company pledged certain
trademarks owned by the Company as collateral to guarantee this loan. The loan was fully repaid upon maturity&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;On April 18, 2025, a subsidiary of the Company, Jiangxi Universe, signed
a loan agreement with Zhujiang Rural Bank to borrow RMB2.9 million (equivalent to $413,247&#160;) as working capital for one year, with
the maturity date on April 18, 2026. The fixed interest rate of the loan was 5.00% per annum. The Company pledged certain trademarks owned
by the Company as collateral to guarantee this loan.&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On July 24, 2023, a subsidiary of the Company, Jiangxi Universe, entered into a loan agreement with Beijing Bank to borrow RMB 10 million (equivalent to $1,384,984) as working capital for one year, with the maturity date on July 18, 2024. The fixed interest rate of the loan was 4.25% per annum. There was no guarantee requirement for this loan. The loan was fully repaid upon maturity.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On July 3, 2024, a subsidiary of the Company, Jiangxi Universe, entered into a loan agreement with Beijing Bank to borrow RMB 10 million (equivalent to $1,424,989) as working capital for one year, with the maturity date on July 3, 2025. The fixed interest rate of the loan was 4.15% per annum. Mr. Gang Lai provided credit guarantee for this loan.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ShortTermDebtTextBlock>
    <us-gaap:ScheduleOfShortTermDebtTextBlock contextRef="c0" id="ixv-20197">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Short-term
bank loans consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Note&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Short-term bank loans:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Jiangxi Luling Rural Commercial Bank (&#x201c;LRC Bank&#x201d;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;(1)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,849,976&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,467,105&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Bank of Communications Co., Ltd&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;(2)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,154,241&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,233,553&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Zhujiang Rural Bank&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;(3)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;427,497&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;411,184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Beijing Bank&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;(4)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,424,989&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,370,614&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total short-term loans&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,856,703&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,482,456&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On March 13, 2023, a subsidiary of the Company, Universe Trade, signed a loan agreement with LRC Bank to borrow RMB8 million (equivalent to $1,096,491) as working capital for one year, with the maturity date on March 12, 2024. The fixed interest rate of the loan was 4.56% per annum. Mr. Gang Lai signed guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On June 15, 2023, a subsidiary of the Company, Jiangxi Universe, signed a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,370,614) as working capital for eleven months, with the maturity date on May 14, 2024. The fixed interest rate of the loan was 4.56% per annum. Mr. Gang Lai signed guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 4, 2024, a subsidiary of the Company, Universe
Trade, signed a loan agreement with LRC Bank to borrow RMB5 million (equivalent to $712,494) as working capital for one year, with the
maturity date on March 3, 2025. The fixed interest rate of the loan was 4.75% per annum. Mr. Gang Lai and Jiangxi Universe jointly signed
guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 26, 2024, a subsidiary of the Company, Jiangxi
Universe, signed a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,424,989) as working capital for one year, with
the maturity date on April 25, 2025. The fixed interest rate of the loan was 4.31% per annum. Mr. Gang Lai and Universe Technology jointly
signed guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 17, 2024, a subsidiary of the Company, Universe
trade, signed a loan agreement with LRC Bank to borrow RMB5 million (equivalent to $712,494) as working capital for one year, with the
maturity date on May 16, 2025. The fixed interest rate of the loan was 3.65% per annum. Mr. Gang Lai and Jiangxi Universe jointly signed
guarantee agreements with LRC Bank to provide credit guarantee for this loan.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
March 3, 2025, a subsidiary of the Company, Universe Trade, signed a loan agreement with LRC Bank to borrow RMB5 million (equivalent to
$712,494) as working capital for one year, with the maturity date on March 2, 2026. The fixed interest rate of the loan was 3.65% per
annum. Mr. Gang Lai and Jiangxi Universe jointly signed guarantee agreements with LRC Bank to provide credit guarantee for this loan.&lt;/span&gt;
&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;On April 22, 2024, a subsidiary of the Company, Jiangxi Universe, signed
a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,424,989) as working capital for one year, with the maturity date
on April 21, 2026. The fixed interest rate of the loan was 3.60% per annum. Mr. Gang Lai and Universe Technology jointly signed guarantee
agreements with LRC Bank to provide credit guarantee for this loan. &#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On June 15, 2023, the Company&#x2019;s subsidiary, Jiangxi Universe, signed a loan agreement with Bank of Communications to borrow RMB9 million (equivalent to $1,246,486) as working capital for eleven months, with the maturity date on May 18, 2024. The fixed interest rate of the loan was 4.0% per annum. Mr. Gang Lai, Universe Trade, and an unrelated third party, Jiangxi Province Financing Guarantee Group Co., Ltd., jointly signed guarantee agreements with Bank of Communications to provide credit guarantee for this loan. The loan was fully repaid upon maturity.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On June 16, 2024, the Company&#x2019;s subsidiary, Jiangxi Universe, signed a loan agreement with Bank of Communications to borrow RMB8.1 million (equivalent to $1,154,241) as working capital for eleven months, with the maturity date on May 13, 2025. The fixed interest rate of the loan was 3.9% per annum. Mr. Gang Lai, Universe Trade, and an unrelated third party, Jiangxi Province Financing Guarantee Group Co., Ltd., jointly signed guarantee agreements with Bank of Communications to provide credit guarantee for this loan.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On May 5, 2023, a subsidiary of the Company, Jiangxi Universe, entered into a loan agreement with Zhujiang Rural Bank to borrow RMB 3 million (equivalent to $415,495) as working capital for one year, with the maturity date on May 4, 2024. The fixed interest rate of the loan was 3.65% per annum. The Company pledged certain patents owned by the Company as collateral to guarantee this loan. The loan was fully repaid upon maturity.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 24, 2024, a subsidiary of the Company, Jiangxi
Universe, entered into a loan agreement with Zhujiang Rural Bank to borrow RMB3 million (equivalent to $427,497) as working capital for
one year, with the maturity date on April 24, 2025. The fixed interest rate of the loan was 3.65% per annum. The Company pledged certain
trademarks owned by the Company as collateral to guarantee this loan. The loan was fully repaid upon maturity&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;On April 18, 2025, a subsidiary of the Company, Jiangxi Universe, signed
a loan agreement with Zhujiang Rural Bank to borrow RMB2.9 million (equivalent to $413,247&#160;) as working capital for one year, with
the maturity date on April 18, 2026. The fixed interest rate of the loan was 5.00% per annum. The Company pledged certain trademarks owned
by the Company as collateral to guarantee this loan.&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On July 24, 2023, a subsidiary of the Company, Jiangxi Universe, entered into a loan agreement with Beijing Bank to borrow RMB 10 million (equivalent to $1,384,984) as working capital for one year, with the maturity date on July 18, 2024. The fixed interest rate of the loan was 4.25% per annum. There was no guarantee requirement for this loan. The loan was fully repaid upon maturity.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On July 3, 2024, a subsidiary of the Company, Jiangxi Universe, entered into a loan agreement with Beijing Bank to borrow RMB 10 million (equivalent to $1,424,989) as working capital for one year, with the maturity date on July 3, 2025. The fixed interest rate of the loan was 4.15% per annum. Mr. Gang Lai provided credit guarantee for this loan.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShortTermDebtTextBlock>
    <us-gaap:ShortTermBorrowings
      contextRef="c177"
      decimals="0"
      id="ix_25_fact"
      unitRef="usd">2849976</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="c178"
      decimals="0"
      id="ix_26_fact"
      unitRef="usd">2467105</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="c179"
      decimals="0"
      id="ix_27_fact"
      unitRef="usd">1154241</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="c180"
      decimals="0"
      id="ix_28_fact"
      unitRef="usd">1233553</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="c181"
      decimals="0"
      id="ix_29_fact"
      unitRef="usd">427497</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="c182"
      decimals="0"
      id="ix_30_fact"
      unitRef="usd">411184</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="c183"
      decimals="0"
      id="ix_31_fact"
      unitRef="usd">1424989</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="c184"
      decimals="0"
      id="ix_32_fact"
      unitRef="usd">1370614</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c2" decimals="0" id="ixv-22965" unitRef="usd">5856703</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c3" decimals="0" id="ixv-22966" unitRef="usd">5482456</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="c142"
      decimals="-6"
      id="ixv-22967"
      unitRef="cny">8000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c142" decimals="0" id="ixv-22968" unitRef="usd">1096491</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermDebtTerms contextRef="c143" id="ixv-22969">one</us-gaap:ShortTermDebtTerms>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c143" id="ixv-22970">2024-03-12</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate
      contextRef="c142"
      decimals="4"
      id="ixv-22971"
      unitRef="pure">0.0456</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:ShortTermBorrowings
      contextRef="c144"
      decimals="-6"
      id="ixv-22972"
      unitRef="cny">10000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c144" decimals="0" id="ixv-22973" unitRef="usd">1370614</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermDebtTerms contextRef="c145" id="ixv-22974">eleven</us-gaap:ShortTermDebtTerms>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c146" id="ixv-22975">2024-05-14</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate
      contextRef="c144"
      decimals="4"
      id="ixv-22976"
      unitRef="pure">0.0456</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:ShortTermBorrowings
      contextRef="c147"
      decimals="-6"
      id="ixv-22977"
      unitRef="cny">5000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c147" decimals="0" id="ixv-22978" unitRef="usd">712494</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermDebtTerms contextRef="c148" id="ixv-22979">one</us-gaap:ShortTermDebtTerms>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c148" id="ixv-22980">2025-03-03</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate
      contextRef="c147"
      decimals="4"
      id="ixv-22981"
      unitRef="pure">0.0475</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:ShortTermBorrowings
      contextRef="c149"
      decimals="-6"
      id="ixv-22982"
      unitRef="cny">10000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c149" decimals="0" id="ixv-22983" unitRef="usd">1424989</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermDebtTerms contextRef="c150" id="ixv-22984">one</us-gaap:ShortTermDebtTerms>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c150" id="ixv-22985">2025-04-25</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate
      contextRef="c149"
      decimals="4"
      id="ixv-22986"
      unitRef="pure">0.0431</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:ShortTermBorrowings
      contextRef="c151"
      decimals="-6"
      id="ixv-22987"
      unitRef="cny">5000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c151" decimals="0" id="ixv-22988" unitRef="usd">712494</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermDebtTerms contextRef="c152" id="ixv-22989">one</us-gaap:ShortTermDebtTerms>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c152" id="ixv-22990">2025-05-16</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate
      contextRef="c151"
      decimals="4"
      id="ixv-22991"
      unitRef="pure">0.0365</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:ShortTermBorrowings
      contextRef="c153"
      decimals="-6"
      id="ixv-22992"
      unitRef="cny">5000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c153" decimals="0" id="ixv-22993" unitRef="usd">712494</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermDebtTerms contextRef="c154" id="ixv-22994">one</us-gaap:ShortTermDebtTerms>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c155" id="ixv-22995">2026-03-02</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate
      contextRef="c153"
      decimals="4"
      id="ixv-22996"
      unitRef="pure">0.0365</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:ShortTermBorrowings
      contextRef="c156"
      decimals="-6"
      id="ixv-22998"
      unitRef="cny">10000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c156" decimals="0" id="ixv-22999" unitRef="usd">1424989</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermDebtTerms contextRef="c157" id="ixv-23000">one</us-gaap:ShortTermDebtTerms>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c157" id="ixv-23001">2026-04-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate
      contextRef="c156"
      decimals="4"
      id="ixv-23002"
      unitRef="pure">0.036</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:ShortTermBorrowings
      contextRef="c158"
      decimals="-6"
      id="ixv-23003"
      unitRef="cny">9000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c158" decimals="0" id="ixv-23004" unitRef="usd">1246486</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermDebtTerms contextRef="c159" id="ixv-23005">eleven</us-gaap:ShortTermDebtTerms>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate
      contextRef="c158"
      decimals="3"
      id="ixv-23006"
      unitRef="pure">0.04</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:ShortTermBorrowings
      contextRef="c160"
      decimals="-5"
      id="ixv-23007"
      unitRef="cny">8100000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c160" decimals="0" id="ixv-23008" unitRef="usd">1154241</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermDebtTerms contextRef="c161" id="ixv-23009">eleven</us-gaap:ShortTermDebtTerms>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c161" id="ixv-23010">2025-05-13</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate
      contextRef="c160"
      decimals="3"
      id="ixv-23011"
      unitRef="pure">0.039</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:ShortTermBorrowings
      contextRef="c162"
      decimals="-6"
      id="ixv-23012"
      unitRef="cny">3000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c162" decimals="0" id="ixv-23013" unitRef="usd">415495</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermDebtTerms contextRef="c163" id="ixv-23014">one</us-gaap:ShortTermDebtTerms>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c163" id="ixv-23015">2024-05-04</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate
      contextRef="c164"
      decimals="4"
      id="ixv-23016"
      unitRef="pure">0.0365</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:ShortTermBorrowings
      contextRef="c165"
      decimals="-6"
      id="ixv-23019"
      unitRef="cny">3000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c165" decimals="0" id="ixv-23020" unitRef="usd">427497</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermDebtTerms contextRef="c166" id="ixv-23021">one</us-gaap:ShortTermDebtTerms>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c166" id="ixv-23022">2025-04-24</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate
      contextRef="c167"
      decimals="4"
      id="ixv-23023"
      unitRef="pure">0.0365</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:ShortTermBorrowings
      contextRef="c168"
      decimals="-5"
      id="ixv-23024"
      unitRef="cny">2900000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c168" decimals="0" id="ixv-23025" unitRef="usd">413247</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermDebtTerms contextRef="c169" id="ixv-23026">one</us-gaap:ShortTermDebtTerms>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c170" id="ixv-23027">2026-04-18</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate
      contextRef="c168"
      decimals="4"
      id="ixv-23028"
      unitRef="pure">0.05</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:ShortTermBorrowings
      contextRef="c171"
      decimals="-6"
      id="ixv-23029"
      unitRef="cny">10000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c171" decimals="0" id="ixv-23030" unitRef="usd">1384984</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermDebtTerms contextRef="c172" id="ixv-23031">one</us-gaap:ShortTermDebtTerms>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c172" id="ixv-23032">2024-07-18</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate
      contextRef="c173"
      decimals="4"
      id="ixv-23033"
      unitRef="pure">0.0425</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:ShortTermBorrowings
      contextRef="c174"
      decimals="-6"
      id="ixv-23034"
      unitRef="cny">10000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c174" decimals="0" id="ixv-23035" unitRef="usd">1424989</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermDebtTerms contextRef="c175" id="ixv-23036">one</us-gaap:ShortTermDebtTerms>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c175" id="ixv-23037">2025-07-03</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate
      contextRef="c176"
      decimals="4"
      id="ixv-23038"
      unitRef="pure">0.0415</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:LongTermDebtTextBlock contextRef="c0" id="ixv-20395">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;NOTE
13 &#x2014; LONG-TERM BANK LOANS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Long-term
bank loans consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Note&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Long-term bank loans:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;LRC Bank&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;(1)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,137,483&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On November 23, 2023, a subsidiary of the Company, Jiangxi Universe, signed a loan agreement with LRC Bank to borrow RMB15 million (equivalent to $2,137,483) as working capital for two years, with the maturity date on November 14, 2025. The fixed interest rate of the loan was 3.95% per annum. The Company pledged buildings of Jiangxi Universe as collateral to guarantee this loan.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;For
the above-mentioned loans, the Company recorded a total interest expense of $304,516, $190,184 and $199,852 for the years ended September
30, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c0" id="ixv-20401">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Long-term
bank loans consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Note&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Long-term bank loans:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;LRC Bank&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;(1)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,137,483&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On November 23, 2023, a subsidiary of the Company, Jiangxi Universe, signed a loan agreement with LRC Bank to borrow RMB15 million (equivalent to $2,137,483) as working capital for two years, with the maturity date on November 14, 2025. The fixed interest rate of the loan was 3.95% per annum. The Company pledged buildings of Jiangxi Universe as collateral to guarantee this loan.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:LongTermLoansFromBank
      contextRef="c187"
      decimals="0"
      id="ix_33_fact"
      unitRef="usd">2137483</us-gaap:LongTermLoansFromBank>
    <us-gaap:LongTermDebt
      contextRef="c185"
      decimals="-6"
      id="ixv-23040"
      unitRef="cny">15000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c185" decimals="0" id="ixv-23041" unitRef="usd">2137483</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtTerm contextRef="c185" id="ixv-23042">P2Y</us-gaap:LongTermDebtTerm>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c186" id="ixv-23043">2025-11-14</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="c185"
      decimals="4"
      id="ixv-23044"
      unitRef="pure">0.0395</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="0" id="ixv-23045" unitRef="usd">304516</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c6" decimals="0" id="ixv-23046" unitRef="usd">190184</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c7" decimals="0" id="ixv-23047" unitRef="usd">199852</us-gaap:InterestPaidNet>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-20465">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;NOTE
14 &#x2014; RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(a)
Nature of relationships with related parties&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Relationship with the Company&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mr. Gang Lai&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chief Executive Officer and chairman of the Company&#x2019;s Board of Directors&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mr. Yajun Hu&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General Manager of Jiangxi Universe&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ms. Lin Yang&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chief Financial Officer of the Company&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Guangzhou Ningjing Investment Co., Ltd (Guangzhou Ningjing)&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under common control of Mr. Gang Lai&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;(b)
Due from related parties&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Name&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt"&gt;Mr. Yajun Hu&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;61,678&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total due from related parties&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;61,678&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2023, the balance due from related parties consisted of advanced funds to the Company&#x2019;s director and general manager,
Mr. Yajun Hu. These advances were non-interest bearing and fully repaid on October 12, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;(c)
Due to related parties&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Name&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Mr. Gang Lai&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,900,499&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;540,096&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Ms. Lin Yang&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;85&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total due to related parties&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,900,584&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;540,096&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;As
of September 30, 2024, the balance due to related parties mainly consisted of advances from Mr. Gang Lai, the Company&#x2019;s chief executive
officer and the chairman of the board of directors for working capital purposes during the Company&#x2019;s normal course of business,
as well as payment of expenses made by Ms. Lin Yang on behalf of the Company. These advances are unsecured, non-interest bearing and
due on demand.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;(d)
Loan guarantee provided by related parties&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In connection with the Company&#x2019;s
bank borrowings from commercial banks in China, Mr. Gang Lai, the Company&#x2019;s chairman of the board of directors and chief executive
officer, signed guarantee agreements with these banks to provide credit guarantee for the Company&#x2019;s certain loans (see Note 13 and
14).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;(e)
Prepayment to related party for property purchase&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;As
disclosed in Note 12, on May 6, 2021, the Company entered into a real estate property purchase agreement with a related party, Jiangxi
Yueshang, to purchase certain residential apartment and commercial office space totaling 2,749.30 square meters with total purchase price
of RMB32 million (approximately $4.6 million).&#160;As of September 30, 2024, the Company had made a prepayment of RMB16&#160;million
($2.3 million) to Jiangxi Yueshang. The remaining balance is expected to be paid by April 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
January 13, 2022, Mr. Gang Lai transferred the&#160;5% equity interest he owned in Jiangxi Yueshang to a third party. As such, after
this date, Jiangxi Yueshang is no longer the Company&#x2019;s related party.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;(f)
Prepaid expenses-related party, non-current&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;As
of September 30, 2024 and 2023, the Company prepaid Guangzhou Ningjing &lt;span style="-sec-ix-hidden: hidden-fact-74"&gt;nil&lt;/span&gt; and $35,864 for right to use trademarks, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <upc:ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock contextRef="c0" id="ixv-20471">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(a)
Nature of relationships with related parties&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Relationship with the Company&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mr. Gang Lai&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chief Executive Officer and chairman of the Company&#x2019;s Board of Directors&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mr. Yajun Hu&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General Manager of Jiangxi Universe&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ms. Lin Yang&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chief Financial Officer of the Company&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Guangzhou Ningjing Investment Co., Ltd (Guangzhou Ningjing)&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under common control of Mr. Gang Lai&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</upc:ScheduleOfNatureOfRelationshipsWithRelatedPartiesTableTextBlock>
    <us-gaap:NatureOfCommonOwnershipOrManagementControlRelationships contextRef="c193" id="ixv-20493">Chief Executive Officer and chairman of the Company&#x2019;s Board of Directors</us-gaap:NatureOfCommonOwnershipOrManagementControlRelationships>
    <us-gaap:NatureOfCommonOwnershipOrManagementControlRelationships contextRef="c194" id="ixv-20501">General Manager of Jiangxi Universe</us-gaap:NatureOfCommonOwnershipOrManagementControlRelationships>
    <us-gaap:NatureOfCommonOwnershipOrManagementControlRelationships contextRef="c195" id="ixv-20509">Chief Financial Officer of the Company</us-gaap:NatureOfCommonOwnershipOrManagementControlRelationships>
    <us-gaap:NatureOfCommonOwnershipOrManagementControlRelationships contextRef="c196" id="ixv-20517">Under common control of Mr. Gang Lai</us-gaap:NatureOfCommonOwnershipOrManagementControlRelationships>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c0" id="ixv-20522">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;(b)
Due from related parties&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Name&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt"&gt;Mr. Yajun Hu&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;61,678&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total due from related parties&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;61,678&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;(c)
Due to related parties&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Name&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Mr. Gang Lai&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,900,499&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;540,096&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Ms. Lin Yang&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;85&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total due to related parties&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,900,584&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;540,096&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c197" decimals="0" id="ixv-23048" unitRef="usd">61678</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c5" decimals="0" id="ixv-23049" unitRef="usd">61678</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c198" decimals="0" id="ixv-23050" unitRef="usd">6900499</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c199" decimals="0" id="ixv-23051" unitRef="usd">540096</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c200" decimals="0" id="ixv-23052" unitRef="usd">85</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c4" decimals="0" id="ixv-23053" unitRef="usd">6900584</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c5" decimals="0" id="ixv-23054" unitRef="usd">540096</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AreaOfRealEstateProperty contextRef="c139" decimals="2" id="ixv-23055" unitRef="sqm">2749.3</us-gaap:AreaOfRealEstateProperty>
    <upc:PrepaymentsMadeToARelatedPartyForPurchasesOfProperty
      contextRef="c139"
      decimals="-6"
      id="ixv-23056"
      unitRef="cny">32000000</upc:PrepaymentsMadeToARelatedPartyForPurchasesOfProperty>
    <upc:PrepaymentsMadeToARelatedPartyForPurchasesOfProperty
      contextRef="c139"
      decimals="-5"
      id="ixv-23057"
      unitRef="usd">4600000</upc:PrepaymentsMadeToARelatedPartyForPurchasesOfProperty>
    <us-gaap:PrepaymentFeesOnAdvancesNet
      contextRef="c189"
      decimals="-6"
      id="ixv-23058"
      unitRef="cny">16000000</us-gaap:PrepaymentFeesOnAdvancesNet>
    <us-gaap:PrepaymentFeesOnAdvancesNet
      contextRef="c189"
      decimals="-5"
      id="ixv-23059"
      unitRef="usd">2300000</us-gaap:PrepaymentFeesOnAdvancesNet>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c190"
      decimals="2"
      id="ixv-23060"
      unitRef="pure">0.05</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent contextRef="c192" decimals="0" id="ixv-23061" unitRef="usd">35864</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-20677">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
15 &#x2014; TAXES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;(a)
Corporate Income Taxes (&#x201c;CIT&#x201d;)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Cayman
Islands&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Under
the current tax laws of the Cayman Islands, Universe INC is not subject to tax on its income or capital gains. In addition, no Cayman
Islands withholding tax will be imposed upon the payment of dividends by the Company to its shareholders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span style="text-decoration:underline"&gt;Hong
Kong&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Universe
HK is incorporated in Hong Kong and is subject to profit taxes in Hong Kong at a rate of 16.5%. However, Universe HK did not generate
any assessable profits derived from Hong Kong sources for the years ended September 30, 2024, 2023 and 2022, and accordingly no provision
for Hong Kong profits tax has been made in these periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span style="text-decoration:underline"&gt;PRC&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Under
the Enterprise Income Tax (&#x201c;EIT&#x201d;) Law of PRC, domestic enterprises and Foreign Investment Enterprises (&#x201c;FIEs&#x201d;)
are usually subject to a unified 25% enterprise income tax rate while preferential tax rates, tax holidays and even tax exemption may
be granted on a case-by-case basis. EIT grants preferential tax treatment to High and New Technology Enterprises (&#x201c;HNTEs&#x201d;).
Under this preferential tax treatment, HNTEs are entitled to an income tax rate of 15%, subject to a requirement that they re-apply for
their HNTE status every three years. Jiangxi Universe, one of the Company&#x2019;s main operating subsidiaries in the PRC, was approved
as a HNTE and is entitled to a reduced income tax rate of 15% beginning November 2016 with a term of three years. In December 2019 and
November 2022, Jiangxi Universe successfully renewed its HNTE certification with local government and will continue to enjoy the reduced
income tax rate of 15% for three years, respectively, through November 2025. Universe Trade, another operating subsidiary of the Company
in the PRC, was approved as a HNTE and was entitled to a reduced income tax rate of 15% beginning December 2020 with a term of three
years through December 2023. &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Universe Trade did not
successfully renew its HNTE status at the end of December 2023 and, therefore, has been subject to the standard PRC enterprise income
tax rate of 25% starting from January 2024. &lt;span style="background-color: white"&gt;EIT is typically governed by the local tax authority
in the PRC. Each local tax authority at times may grant tax holidays to local enterprises as a way to encourage entrepreneurship and
stimulate local economy. The corporate income taxes for the years ended September 30, 2024, 2023 and 2022 were reported at a blended
reduced rate as a result of certain of the PRC subsidiaries of the Company&#x2019;s being approved as a HNTE and enjoying a 15% reduced
income tax rate. Although Jiangxi Universe was approved as a HNTE and enjoying a 15% reduced income tax rate, it incurred operating loss
for the year ended September 30, 2024, with no impact of the tax holidays on PRC corporate income taxes for the year ended September
30, 2024. The impact of the tax holidays noted above decreased PRC corporate income taxes by $309,840 and $694,955 for the years ended
September 30, 2023 and 2022, respectively. The benefit of the tax holidays on net income per share (basic and diluted) was $0.09 and
$0.19 for the years ended September 30, 2023 and 2022, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
components of the income tax &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;expense &lt;span style="background-color: white"&gt;(benefit)
are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Years Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Current tax expense:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cayman&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Hong Kong&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; padding-bottom: 1.5pt"&gt;PRC&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;685,937&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;1,357,697&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 9pt"&gt;Sub-total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;685,937&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,357,697&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax expense (benefit):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Cayman&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Hong Kong&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;PRC&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;606,704&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,567,656&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(542,375&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Sub-total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;606,704&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,567,656&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(542,375&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;606,704&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,253,593&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;815,322&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
following table reconciles the China statutory rates to the Company&#x2019;s effective tax rate for the years ended September 30, 2024,
2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Years Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Statutory PRC income tax rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Effect of income tax holiday&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5.9&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8.2&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(9.2&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Permanent difference&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.1&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(25.1&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-PRC entities not subject to PRC income tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.7&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4.4&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.2&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(23.9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(64.4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(7.5&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(52.1&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(11.5&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative
rulings. As of September 30, 2024, all of the Company&#x2019;s tax returns of its PRC subsidiaries remain open for statutory examination
by PRC tax authorities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Deferred
tax assets are composed of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September&#160;30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Net operating loss carry-forwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;599,078&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;599,078&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;599,078&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company periodically evaluates the likelihood of the realization of deferred tax assets, and reduces the carrying amount of the deferred
tax assets by a valuation allowance to the extent it believes a portion will not be realized. Management considers new evidence, both
positive and negative, that could affect the Company&#x2019;s future realization of deferred tax assets including its recent cumulative
earnings experience, expectation of future income, the carry forward periods available for tax reporting purposes and other relevant
factors. Jiangxi Universe and Universe Trade incurred net loss during the years ended September 30, 2024 and 2023, the Company determined
that its deferred tax assets might not be realized, and recognized valuation allowance for all deferred tax assets as of &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;September&#160;30,
2024&lt;span style="background-color: white"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;(b)
Taxes payable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Taxes
payable consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September&#160;30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Value added tax payable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;873,750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;303,713&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Other taxes payable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;147,431&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;131,045&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total taxes payable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,021,181&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;434,758&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c201"
      decimals="3"
      id="ixv-23062"
      unitRef="pure">0.165</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxHolidayDescription contextRef="c0" id="ixv-20729">Under
the Enterprise Income Tax (&#x201c;EIT&#x201d;) Law of PRC, domestic enterprises and Foreign Investment Enterprises (&#x201c;FIEs&#x201d;)
are usually subject to a unified 25% enterprise income tax rate while preferential tax rates, tax holidays and even tax exemption may
be granted on a case-by-case basis. EIT grants preferential tax treatment to High and New Technology Enterprises (&#x201c;HNTEs&#x201d;).
Under this preferential tax treatment, HNTEs are entitled to an income tax rate of 15%, subject to a requirement that they re-apply for
their HNTE status every three years. Jiangxi Universe, one of the Company&#x2019;s main operating subsidiaries in the PRC, was approved
as a HNTE and is entitled to a reduced income tax rate of 15% beginning November 2016 with a term of three years. In December 2019 and
November 2022, Jiangxi Universe successfully renewed its HNTE certification with local government and will continue to enjoy the reduced
income tax rate of 15% for three years, respectively, through November 2025. Universe Trade, another operating subsidiary of the Company
in the PRC, was approved as a HNTE and was entitled to a reduced income tax rate of 15% beginning December 2020 with a term of three
years through December 2023. Universe Trade did not
successfully renew its HNTE status at the end of December 2023 and, therefore, has been subject to the standard PRC enterprise income
tax rate of 25% starting from January 2024. EIT is typically governed by the local tax authority
in the PRC. Each local tax authority at times may grant tax holidays to local enterprises as a way to encourage entrepreneurship and
stimulate local economy. The corporate income taxes for the years ended September 30, 2024, 2023 and 2022 were reported at a blended
reduced rate as a result of certain of the PRC subsidiaries of the Company&#x2019;s being approved as a HNTE and enjoying a 15% reduced
income tax rate. Although Jiangxi Universe was approved as a HNTE and enjoying a 15% reduced income tax rate, it incurred operating loss
for the year ended September 30, 2024, with no impact of the tax holidays on PRC corporate income taxes for the year ended September
30, 2024.</us-gaap:IncomeTaxHolidayDescription>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings contextRef="c0" decimals="2" id="ixv-23065" unitRef="pure">0.15</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <us-gaap:IncomeTaxHolidayAggregateDollarAmount contextRef="c6" decimals="0" id="ixv-23066" unitRef="usd">309840</us-gaap:IncomeTaxHolidayAggregateDollarAmount>
    <us-gaap:IncomeTaxHolidayAggregateDollarAmount contextRef="c7" decimals="0" id="ixv-23067" unitRef="usd">694955</us-gaap:IncomeTaxHolidayAggregateDollarAmount>
    <us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare
      contextRef="c6"
      decimals="2"
      id="ixv-23068"
      unitRef="usdPershares">0.09</us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare>
    <us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare
      contextRef="c7"
      decimals="2"
      id="ixv-23069"
      unitRef="usdPershares">0.19</us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c0" id="ixv-20735">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
components of the income tax &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;expense &lt;span style="background-color: white"&gt;(benefit)
are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Years Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Current tax expense:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cayman&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Hong Kong&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; padding-bottom: 1.5pt"&gt;PRC&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;685,937&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;1,357,697&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 9pt"&gt;Sub-total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;685,937&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,357,697&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax expense (benefit):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Cayman&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Hong Kong&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;PRC&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;606,704&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,567,656&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(542,375&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Sub-total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;606,704&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,567,656&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(542,375&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;606,704&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,253,593&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;815,322&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c208" decimals="0" id="ixv-23070" unitRef="usd">685937</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c209" decimals="0" id="ixv-23071" unitRef="usd">1357697</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c6" decimals="0" id="ixv-23072" unitRef="usd">685937</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c7" decimals="0" id="ixv-23073" unitRef="usd">1357697</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c207" decimals="0" id="ixv-23074" unitRef="usd">606704</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c208" decimals="0" id="ixv-23075" unitRef="usd">1567656</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c209" decimals="0" id="ixv-23076" unitRef="usd">-542375</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-23077" unitRef="usd">606704</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c6" decimals="0" id="ixv-23078" unitRef="usd">1567656</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c7" decimals="0" id="ixv-23079" unitRef="usd">-542375</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-23080" unitRef="usd">606704</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c6" decimals="0" id="ixv-23081" unitRef="usd">2253593</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c7" decimals="0" id="ixv-23082" unitRef="usd">815322</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0" id="ixv-20925">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
following table reconciles the China statutory rates to the Company&#x2019;s effective tax rate for the years ended September 30, 2024,
2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Years Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Statutory PRC income tax rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Effect of income tax holiday&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5.9&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8.2&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(9.2&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Permanent difference&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.1&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(25.1&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-PRC entities not subject to PRC income tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.7&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4.4&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.2&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(23.9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(64.4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(7.5&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(52.1&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(11.5&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="3" id="ixv-23083" unitRef="pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c6" decimals="3" id="ixv-23084" unitRef="pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c7" decimals="3" id="ixv-23085" unitRef="pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays contextRef="c0" decimals="3" id="ixv-23086" unitRef="pure">0.059</us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays contextRef="c6" decimals="3" id="ixv-23087" unitRef="pure">0.082</us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays contextRef="c7" decimals="3" id="ixv-23088" unitRef="pure">0.092</us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness contextRef="c6" decimals="3" id="ixv-23089" unitRef="pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness contextRef="c7" decimals="3" id="ixv-23090" unitRef="pure">-0.251</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c0" decimals="3" id="ixv-23091" unitRef="pure">-0.027</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c6" decimals="3" id="ixv-23092" unitRef="pure">-0.044</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c7" decimals="3" id="ixv-23093" unitRef="pure">-0.022</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="3" id="ixv-23094" unitRef="pure">-0.239</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c6" decimals="3" id="ixv-23095" unitRef="pure">-0.644</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c0" decimals="3" id="ixv-23096" unitRef="pure">-0.075</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c6" decimals="3" id="ixv-23097" unitRef="pure">-0.521</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c7" decimals="3" id="ixv-23098" unitRef="pure">-0.115</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0" id="ixv-21054">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Deferred
tax assets are composed of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September&#160;30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Net operating loss carry-forwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;599,078&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;599,078&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;599,078&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c3" decimals="0" id="ixv-23099" unitRef="usd">599078</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross contextRef="c3" decimals="0" id="ixv-23100" unitRef="usd">599078</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsNet contextRef="c3" decimals="0" id="ixv-23101" unitRef="usd">599078</us-gaap:DeferredTaxAssetsNet>
    <upc:ScheduleOfTaxPayableTableTextBlock contextRef="c0" id="ixv-21150">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Taxes
payable consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September&#160;30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Value added tax payable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;873,750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;303,713&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Other taxes payable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;147,431&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;131,045&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total taxes payable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,021,181&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;434,758&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</upc:ScheduleOfTaxPayableTableTextBlock>
    <upc:ValueAddedTaxPayable contextRef="c2" decimals="0" id="ixv-23102" unitRef="usd">873750</upc:ValueAddedTaxPayable>
    <upc:ValueAddedTaxPayable contextRef="c3" decimals="0" id="ixv-23103" unitRef="usd">303713</upc:ValueAddedTaxPayable>
    <upc:OtherTaxesPayable contextRef="c2" decimals="0" id="ixv-23104" unitRef="usd">147431</upc:OtherTaxesPayable>
    <upc:OtherTaxesPayable contextRef="c3" decimals="0" id="ixv-23105" unitRef="usd">131045</upc:OtherTaxesPayable>
    <us-gaap:TaxesPayableCurrent contextRef="c2" decimals="0" id="ixv-23106" unitRef="usd">1021181</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c3" decimals="0" id="ixv-23107" unitRef="usd">434758</us-gaap:TaxesPayableCurrent>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="c0" id="ixv-21203">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;NOTE
16 &#x2014; CONCENTRATIONS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;A
majority of the Company&#x2019;s revenue and expense transactions are denominated in RMB and a significant portion of the Company&#x2019;s
and its subsidiaries&#x2019; assets and liabilities are denominated in RMB. RMB is not freely convertible into foreign currencies. In
the PRC, certain foreign exchange transactions are required by law to be transacted only by authorized financial institutions at exchange
rates set by the People&#x2019;s Bank of China (&#x201c;PBOC&#x201d;). Remittances in currencies other than RMB by the Company in China
must be processed through the PBOC or other China foreign exchange regulatory bodies which require certain supporting documentation in
order to affect the remittance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;As
of September 30, 2024 and 2023, $4,430,607&#160;and $5,223,573&#160;of the Company&#x2019;s cash, respectively, was on deposit at financial
institutions in the PRC. For the years ended September 30, 2024, 2023 and 2022, the Company&#x2019;s substantial assets were located in
the PRC and the Company&#x2019;s substantial revenues were derived from its subsidiaries located in the PRC.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;For
the years ended September 30, 2024, 2023 and 2022, no single customer accounted for more than 10% of the Company&#x2019;s total revenue.
The Company&#x2019;s top 10 customers aggregately accounted for 22.5%, 27.2% and 32.2% of the Company&#x2019;s total revenue for the years
ended September 30, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Sales
of one of the Company&#x2019;s major products, Guben Yanling Pill, accounted for&#160;37.2%, 36.4% and 42.5% of the Company&#x2019;s total
revenue for the years ended September 30, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;As
of September 30, 2024 and 2023, no customer accounted for more than&#160;10% of the total accounts receivable balance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;For
the year ended September 30, 2024, two suppliers accounted for 28.0% and 13.4% of the total purchases, respectively. For the years ended
September 30, 2023 and 2022, one supplier accounted for 29.6% and 10.3% of the total purchases, respectively. &lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:ForeignFinancialInstitutionsMandatedDeposits contextRef="c2" decimals="0" id="ixv-23108" unitRef="usd">4430607</us-gaap:ForeignFinancialInstitutionsMandatedDeposits>
    <us-gaap:ForeignFinancialInstitutionsMandatedDeposits contextRef="c3" decimals="0" id="ixv-23109" unitRef="usd">5223573</us-gaap:ForeignFinancialInstitutionsMandatedDeposits>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c210"
      decimals="3"
      id="ixv-23110"
      unitRef="pure">0.225</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c211"
      decimals="3"
      id="ixv-23111"
      unitRef="pure">0.272</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c212"
      decimals="3"
      id="ixv-23112"
      unitRef="pure">0.322</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c213"
      decimals="3"
      id="ixv-23113"
      unitRef="pure">0.372</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c214"
      decimals="3"
      id="ixv-23114"
      unitRef="pure">0.364</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c215"
      decimals="3"
      id="ixv-23115"
      unitRef="pure">0.425</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c216"
      decimals="3"
      id="ixv-23116"
      unitRef="pure">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c217"
      decimals="3"
      id="ixv-23117"
      unitRef="pure">0.134</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c218"
      decimals="3"
      id="ixv-23118"
      unitRef="pure">0.296</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c219"
      decimals="3"
      id="ixv-23119"
      unitRef="pure">0.103</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-21252">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;NOTE
17 &#x2014; SHAREHOLDERS&#x2019; EQUITY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Ordinary
Shares&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Universe
INC was incorporated under the laws of the Cayman Islands on December 11, 2019. The original authorized number of ordinary shares upon
incorporation was&#160;50,000&#160;shares with par value of US$1.00&#160;per share and&#160;50,000&#160;shares were issued. On August
7, 2020, the Company amended its Memorandum of Association to increase the authorized number of shares to&#160;100,000,000&#160;shares
with par value of $0.003125&#160;per share, and subdivide the original issued shares from&#160;50,000&#160;shares at par value of $1.00&#160;per
share to&#160;16,000,000&#160;ordinary shares with par value of $0.003125&#160;per share.&#160;As a result of this forward split of the
outstanding ordinary shares at a ratio of 320-for-1 share, a total of 16,000,000 shares were issued and outstanding after the split.&#160;The
issuance of these&#160;16,000,000&#160;shares is considered as a part of the Reorganization of the Company, which was retroactively applied
as if the transaction occurred at the beginning of the period presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Increased
authorized share capital and share consolidation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 3, 2023, the Company held an annual general meeting of shareholders at which shareholders, among other things, resolved:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;with immediate effect, to increase the Company&#x2019;s authorized share capital from US$312,500 divided into 90,000,000 ordinary shares of par value US$0.003125 each and 10,000,000 preferred shares of par value US$0.003125 each, to US$3,125,000 divided into 900,000,000 ordinary shares of par value US$0.003125 each and 100,000,000 preferred shares of par value US$0.003125 each;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;that, conditional upon the approval of the board of directors of the Company in its sole discretion, with effect as of the date the board of directors of the Company may determine, the authorized, issued and outstanding shares of the Company be consolidated by consolidating each 10 shares of the Company, or such lesser whole share amount as the board of directors may determine in its sole discretion, such amount not to be less than 2, into 1 share of the Company, with such consolidated shares having the same rights and being subject to the same restrictions (save as to nominal value) as the then existing shares of par value US$0.003125 each in the capital of the Company; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(c)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;that, upon the effectiveness
    of the 2023 Share Consolidation, the Company adopt amended and restated articles of association, in substantially the form set out
    in Annex B in the proxy statement dated May 24, 2023, in substitution for and to the exclusion of, the memorandum of association
    of the Company in effect immediately prior to effectiveness of the 2023 Share Consolidation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
board of directors of the Company resolved to effect the 2023 Share Consolidation on July 27, 2023 with the authorized, issued and outstanding
shares to be consolidated on a six (6) for one (1) ratio, which had the effect of reducing the number of: (a) authorized ordinary shares
from 900,000,000 ordinary shares with a par value of US$0.003125 per share to 150,000,000 ordinary shares with a par value of US$0.01875
per share; (b) issued and outstanding ordinary shares from 21,750,000 ordinary shares with a par value of US$0.003125 per share to 3,625,000
ordinary shares with a par value of US$0.01875 per share; and (c) authorized preferred shares from 100,000,000 preferred shares with
a par value of US$0.003125 per share to 16,666,666.6666 preferred shares with a par value of US$0.01875 per share. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 15, 2024, the Company closed its self-underwritten public offering of 20,000,000 ordinary shares, par value $0.01875 per share.
The ordinary shares were priced at $1.25 per share. The Company raised a total of $25 million through that offering, before deducting
offering-related expenses, and net proceeds of $24.625 million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 27, 2024, the Company held an annual general meeting of shareholders at which shareholders, among other things, resolved:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;with immediate effect, to increase the Company&#x2019;s authorized share capital from US$3,125,000 divided into 150,000,000 ordinary shares of par value US$0.01875 each and 16,666,666.6666 preferred shares of par value US$0.01875 each, to US$140,625,000 divided into 6,750,000,000 ordinary shares of par value US$0.01875 each and 750,000,000 preferred shares of par value US$0.01875 each;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;that, subject to and immediately
    following the Authorized Share Capital Increase being effected, the Company adopt an amended and restated memorandum of association
    in substitution for, and to the exclusion of, the Company&#x2019;s existing memorandum of association, to reflect the Authorized Share
    Capital Increase; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(c)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;that, conditional upon
    the approval of the board of directors of the Company in its sole discretion, with effect as of the date the board of directors of
    the Company may determine, the authorized, issued, and outstanding shares of the Company be consolidated by consolidating each 15
    Shares of the Company, or such lesser whole share amount as the board of directors of the Company may determine in its sole discretion,
    such amount not to be less than 2, into 1 Share of the Company, with such consolidated Shares having the same rights and being subject
    to the same restrictions (save as to nominal value) as the existing Shares of such class as set out in the Company&#x2019;s memorandum
    and articles of association.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 12, 2024, the Company effected a
share consolidation of 15 ordinary shares with par value of US$0.01875 per share each in the Company&#x2019;s issued and unissued share
capital into one (1) ordinary share with par value of US$0.28125. All fractional shares were rounded up to the whole number of shares.
Immediately following the Share Consolidation, the authorized share capital of the Company was US$140,625,000 divided into 450,000,000
ordinary shares, par value US$0.28125 per share and 50,000,000 preferred shares, par value US$0.28125 per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 24, 2025, the Company effected a share consolidation
of 40 ordinary shares with par value of US$0.28125 per share each in the Company&#x2019;s issued and unissued share capital into one ordinary
share with par value of US$11.25. All fractional shares were rounded up to the whole number of shares. Immediately following the Share
Consolidation, the authorized share capital of the Company was US$140,625,000 divided into 11,250,000 ordinary shares, par value US$11.25
per share and 1,250,000 preferred shares, par value US$11.25 per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company&#x2019;s
consolidated financial statements were retrospectively restated for effect of the 15-for-1 and 40-for-1 Shares Consolidations (see Note
1). Giving effect to the Share Consolidation, there were 42,880 ordinary shares issued and outstanding as of September 30, 2024.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;As of September
30, 2024 and 2023, the Company had a total of&#160;42,880 and 6,062&#160;ordinary shares issued and outstanding, respectively.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Underwriter
warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;In
connection with the Company&#x2019;s IPO, the Company also agreed to issue warrants to the underwriter, for a nominal consideration of
$0.001&#160;per warrant, to purchase&#160;300,000&#160;ordinary shares of the Company (equal to&#160;6% of the total number of ordinary
shares sold in the IPO, not including any ordinary shares sold in the over-allotment option) (the &#x201c;Underwriter Warrants&#x201d;).
The Underwriter Warrants have a term of five years, each warrant is exercisable for 1/90 share, with an exercise price of $495 after
adjustments due to share consolidations. The Underwriter Warrants may be purchased in cash or via cashless exercise, are exercisable
for five (5) years, and will terminate on the fifth anniversary of the closing of the IPO. Management determined that the Underwriter
Warrants meet the requirements for equity classification under ASC 815-40 because they are indexed to its own stock. As of September
30, 2024, the Underwriter Warrants were issued and outstanding, but none of them had been exercised. For the years ended September 30,
2024, 2023 and 2022, the Underwriter Warrants were antidilutive and accordingly were not included in the diluted EPS calculation based
on treasury stock method.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Statutory
reserve and restricted net assets&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company&#x2019;s PRC subsidiaries are restricted in their ability to transfer a portion of their net assets to the Company. The payment
of dividends by entities organized in China is subject to limitations, procedures and formalities. Regulations in the PRC currently permit
payment of dividends only out of accumulated profits as determined in accordance with accounting standards and regulations in China.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company is required to make appropriations to certain reserve funds, comprising the statutory surplus reserve and the discretionary surplus
reserve, based on after-tax net income determined in accordance with generally accepted accounting principles of the PRC (&#x201c;PRC
GAAP&#x201d;). Appropriations to the statutory surplus reserve are required to be at least&#160;10% of the after-tax net income determined
in accordance with PRC GAAP until the reserve is equal to&#160;50% of the entity&#x2019;s registered capital. Appropriations to the discretionary
surplus reserve are made at the discretion of the board of directors. The statutory reserve may be applied against prior year losses,
if any, and may be used for general business expansion and production or increase in registered capital, but are not distributable as
cash dividends.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Relevant
PRC laws and regulations restrict the Company&#x2019;s PRC subsidiaries from transferring a portion of their net assets, equivalent to
their statutory reserves and their share capital, to the Company in the form of loans, advances or cash dividends. Only PRC entities&#x2019;
accumulated profits may be distributed as dividends to the Company without the consent of a third party. As of September 30, 2024 and
2023, the restricted amounts as determined pursuant to PRC statutory laws totaled $2,439,535, and total restricted net assets amounted
to $56,786,656 and $31,786,663, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c220"
      decimals="0"
      id="ixv-23120"
      unitRef="shares">50000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c220"
      decimals="2"
      id="ixv-23121"
      unitRef="usdPershares">1</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="c220"
      decimals="0"
      id="ixv-23122"
      unitRef="shares">50000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c221"
      decimals="0"
      id="ixv-23123"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c221"
      decimals="6"
      id="ixv-23124"
      unitRef="usdPershares">0.003125</us-gaap:CommonStockParOrStatedValuePerShare>
    <upc:OriginalShareIssued
      contextRef="c221"
      decimals="0"
      id="ixv-23125"
      unitRef="shares">50000</upc:OriginalShareIssued>
    <upc:OriginalSharesParValue
      contextRef="c222"
      decimals="2"
      id="ixv-23126"
      unitRef="usdPershares">1</upc:OriginalSharesParValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="c221"
      decimals="0"
      id="ixv-23127"
      unitRef="shares">16000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c221"
      decimals="6"
      id="ixv-23128"
      unitRef="usdPershares">0.003125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockholdersEquityNoteStockSplit contextRef="c0" id="ixv-23129">outstanding ordinary shares at a ratio of 320-for-1 share</us-gaap:StockholdersEquityNoteStockSplit>
    <upc:ShareIssuedAfterTheSplit
      contextRef="c2"
      decimals="0"
      id="ixv-23130"
      unitRef="shares">16000000</upc:ShareIssuedAfterTheSplit>
    <upc:ShareOutstandingAfterTheSplit
      contextRef="c2"
      decimals="0"
      id="ixv-23131"
      unitRef="shares">16000000</upc:ShareOutstandingAfterTheSplit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c222"
      decimals="0"
      id="ixv-23132"
      unitRef="shares">16000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CapitalUnits contextRef="c57" decimals="0" id="ixv-23133" unitRef="usd">312500</us-gaap:CapitalUnits>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c58"
      decimals="0"
      id="ixv-23134"
      unitRef="shares">90000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c57"
      decimals="6"
      id="ixv-23135"
      unitRef="usdPershares">0.003125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c59"
      decimals="0"
      id="ixv-23136"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c57"
      decimals="6"
      id="ixv-23137"
      unitRef="usdPershares">0.003125</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CapitalUnits contextRef="c60" decimals="0" id="ixv-23138" unitRef="usd">3125000</us-gaap:CapitalUnits>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c60"
      decimals="0"
      id="ixv-23139"
      unitRef="shares">900000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c61"
      decimals="6"
      id="ixv-23140"
      unitRef="usdPershares">0.003125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c61"
      decimals="0"
      id="ixv-23141"
      unitRef="shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c61"
      decimals="6"
      id="ixv-23142"
      unitRef="usdPershares">0.003125</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c40"
      decimals="6"
      id="ixv-23143"
      unitRef="usdPershares">0.003125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c62"
      decimals="0"
      id="ixv-23144"
      unitRef="shares">900000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c62"
      decimals="6"
      id="ixv-23145"
      unitRef="usdPershares">0.003125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c223"
      decimals="0"
      id="ixv-23146"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c224"
      decimals="5"
      id="ixv-23147"
      unitRef="usdPershares">0.01875</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="c65"
      decimals="0"
      id="ixv-23148"
      unitRef="shares">21750000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c65"
      decimals="0"
      id="ixv-23149"
      unitRef="shares">21750000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c65"
      decimals="6"
      id="ixv-23150"
      unitRef="usdPershares">0.003125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="c66"
      decimals="0"
      id="ixv-23151"
      unitRef="shares">3625000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c66"
      decimals="0"
      id="ixv-23152"
      unitRef="shares">3625000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c66"
      decimals="5"
      id="ixv-23153"
      unitRef="usdPershares">0.01875</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c67"
      decimals="0"
      id="ixv-23154"
      unitRef="shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c67"
      decimals="6"
      id="ixv-23155"
      unitRef="usdPershares">0.003125</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c68"
      decimals="4"
      id="ixv-23156"
      unitRef="shares">16666666.6666</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c68"
      decimals="5"
      id="ixv-23157"
      unitRef="usdPershares">0.01875</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c225"
      decimals="0"
      id="ixv-23158"
      unitRef="shares">20000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c226"
      decimals="5"
      id="ixv-23159"
      unitRef="usdPershares">0.01875</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c70"
      decimals="2"
      id="ixv-23160"
      unitRef="usdPershares">1.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="c227"
      decimals="-6"
      id="ixv-23161"
      unitRef="usd">25000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c72" decimals="-3" id="ixv-23162" unitRef="usd">24625000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:CapitalUnits contextRef="c79" decimals="0" id="ixv-23163" unitRef="usd">3125000</us-gaap:CapitalUnits>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c79"
      decimals="0"
      id="ixv-23164"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c79"
      decimals="5"
      id="ixv-23165"
      unitRef="usdPershares">0.01875</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c228"
      decimals="4"
      id="ixv-23166"
      unitRef="shares">16666666.6666</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c228"
      decimals="5"
      id="ixv-23167"
      unitRef="usdPershares">0.01875</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CapitalUnits contextRef="c77" decimals="0" id="ixv-23168" unitRef="usd">140625000</us-gaap:CapitalUnits>
    <us-gaap:CommonStockDividendsShares
      contextRef="c78"
      decimals="0"
      id="ixv-23169"
      unitRef="shares">6750000000</us-gaap:CommonStockDividendsShares>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c229"
      decimals="5"
      id="ixv-23170"
      unitRef="usdPershares">0.01875</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c76"
      decimals="0"
      id="ixv-23171"
      unitRef="shares">750000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c76"
      decimals="5"
      id="ixv-23172"
      unitRef="usdPershares">0.01875</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="c80"
      decimals="0"
      id="ixv-23173"
      unitRef="shares">15</us-gaap:CommonStockSharesIssued>
    <us-gaap:ExcessStockSharesIssued
      contextRef="c81"
      decimals="0"
      id="ixv-23174"
      unitRef="shares">1</us-gaap:ExcessStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c81"
      decimals="5"
      id="ixv-23175"
      unitRef="usdPershares">0.28125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CapitalUnits contextRef="c81" decimals="0" id="ixv-23176" unitRef="usd">140625000</us-gaap:CapitalUnits>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c80"
      decimals="0"
      id="ixv-23177"
      unitRef="shares">450000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c81"
      decimals="5"
      id="ixv-23178"
      unitRef="usdPershares">0.28125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c83"
      decimals="0"
      id="ixv-23179"
      unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c83"
      decimals="5"
      id="ixv-23180"
      unitRef="usdPershares">0.28125</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="c84"
      decimals="0"
      id="ixv-23181"
      unitRef="shares">40</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c84"
      decimals="5"
      id="ixv-23182"
      unitRef="usdPershares">0.28125</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c84"
      decimals="2"
      id="ixv-23183"
      unitRef="usdPershares">11.25</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CapitalUnits contextRef="c84" decimals="0" id="ixv-23184" unitRef="usd">140625000</us-gaap:CapitalUnits>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c84"
      decimals="0"
      id="ixv-23185"
      unitRef="shares">11250000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c84"
      decimals="2"
      id="ixv-23186"
      unitRef="usdPershares">11.25</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c84"
      decimals="0"
      id="ixv-23187"
      unitRef="shares">1250000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c84"
      decimals="2"
      id="ixv-23188"
      unitRef="usdPershares">11.25</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="0"
      id="ixv-23189"
      unitRef="shares">42880</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c2"
      decimals="0"
      id="ixv-23190"
      unitRef="shares">42880</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="0"
      id="ixv-23191"
      unitRef="shares">42880</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c2"
      decimals="0"
      id="ixv-23192"
      unitRef="shares">42880</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c3"
      decimals="0"
      id="ixv-23193"
      unitRef="shares">6062</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c3"
      decimals="0"
      id="ixv-23194"
      unitRef="shares">6062</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c230"
      decimals="3"
      id="ixv-23195"
      unitRef="usdPershares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c231"
      decimals="0"
      id="ixv-23196"
      unitRef="shares">300000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <upc:OrdinarySharesSoldPercentage
      contextRef="c230"
      decimals="2"
      id="ixv-23197"
      unitRef="pure">0.06</upc:OrdinarySharesSoldPercentage>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c2" id="ixv-23198">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c230" decimals="0" id="ixv-23199" unitRef="usd">495</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c230" id="ixv-23200">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <upc:StatutorySurplusPercentage
      contextRef="c232"
      decimals="2"
      id="ixv-23201"
      unitRef="pure">0.10</upc:StatutorySurplusPercentage>
    <upc:ReserveIsEqualPercentage contextRef="c0" decimals="2" id="ixv-23202" unitRef="pure">0.50</upc:ReserveIsEqualPercentage>
    <upc:StatutoryReserve contextRef="c2" decimals="0" id="ixv-23203" unitRef="usd">2439535</upc:StatutoryReserve>
    <upc:RestrictedNetAssets contextRef="c0" decimals="0" id="ixv-23204" unitRef="usd">56786656</upc:RestrictedNetAssets>
    <upc:RestrictedNetAssets contextRef="c6" decimals="0" id="ixv-23205" unitRef="usd">31786663</upc:RestrictedNetAssets>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-21420">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;NOTE
18 &#x2014; COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;From
time to time, the Company may become a party to various legal actions arising in the ordinary course of business. The Company accrues
costs associated with these matters when they become probable and the amount can be reasonably estimated. Legal costs incurred in connection
with loss contingencies are expensed as incurred. For the years ended September 30, 2024, 2023 and 2022, the Company did not have any
material legal claims or litigation that, individually or in aggregate, could have a material adverse impact on the Company&#x2019;s consolidated
financial position, results of operations and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company has an ongoing CIP project associated with the construction of a new manufacturing facility. As of September 30, 2024, future
minimum capital expenditures on the Company&#x2019;s CIP project amounted to approximately $13.7&#160;million, among which, approximately
$7.1&#160;million is required for the next 12 months from the date of this report (see Note 11).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
May 6, 2021, the Company entered into a real estate property purchase agreement with Jiangxi Yueshang, an entity in which the Company&#x2019;s
chief executive officer, Mr. Gang Lai, owned 5% of its equity interests as of the date of that agreement. Pursuant to this purchase agreement,
Jiangxi Yueshang will sell and the Company will purchase certain residential apartments and commercial office space totaling 2,749.30
square meters, with a total purchase price of RMB32 million (approximately $4.6 million). As of September 30, 2024, the Company had made
a prepayment of RMB16 million (approximately $2.3 million) to Jiangxi Yueshang. The remaining balance is expected to be paid by April
2025 (see Note 12).&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ContractualObligation contextRef="c2" decimals="-5" id="ixv-23206" unitRef="usd">13700000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="c2" decimals="-5" id="ixv-23207" unitRef="usd">7100000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c233"
      decimals="2"
      id="ixv-23208"
      unitRef="pure">0.05</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:AreaOfRealEstateProperty contextRef="c139" decimals="2" id="ixv-23209" unitRef="sqm">2749.3</us-gaap:AreaOfRealEstateProperty>
    <upc:PrepaymentsMadeToARelatedPartyForPurchasesOfProperty
      contextRef="c139"
      decimals="-6"
      id="ixv-23210"
      unitRef="cny">32000000</upc:PrepaymentsMadeToARelatedPartyForPurchasesOfProperty>
    <upc:PrepaymentsMadeToARelatedPartyForPurchasesOfProperty
      contextRef="c139"
      decimals="-5"
      id="ixv-23211"
      unitRef="usd">4600000</upc:PrepaymentsMadeToARelatedPartyForPurchasesOfProperty>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="c234"
      decimals="-6"
      id="ixv-23212"
      unitRef="cny">16000000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="c234"
      decimals="-5"
      id="ixv-23213"
      unitRef="usd">2300000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-21452">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;NOTE
19 &#x2014; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 12, 2024, the Company effected a share consolidation of 15 ordinary shares with par value of US$0.01875 per share each in the
Company&#x2019;s issued and unissued share capital into one (1) ordinary share with par value of US$0.28125. All fractional shares were
rounded up to the whole number of shares. Immediately following the Share Consolidation, the authorized share capital of the Company
was US$140,625,000 divided into 450,000,000 ordinary shares, par value US$0.28125 per share and 50,000,000 preferred shares, par value
US$0.28125 per share. The Company&#x2019;s consolidated financial statements were retrospectively restated for effect of the 15-for-1
share consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 6, 2024, the Company entered into a securities purchase agreement (the &#x201c;Securities Purchase Agreement&#x201d;) with
certain purchasers named thereto, pursuant to which the Company agreed to issue and sell (i) 388,000 ordinary shares (the
&#x201c;Offered Shares&#x201d;), par value $0.28125 per share (the &#x201c;ordinary shares&#x201d;), (ii) 18,362,000 pre-funded warrants
to purchase 18,362,000 ordinary shares (the &#x201c;Pre-funded Warrants&#x201d;), and (iii) 18,750,000 common warrants to purchase
18,750,000 ordinary shares (the &#x201c;Common Warrants&#x201d;), at a combined purchase price of US0.80 per Offered Share and one
accompanying Common Warrant, or at a combined purchase price of US$0.79 per Pre-funded Warrant (in lieu of one Offered Share) and
one accompanying Common Warrant, in a registered direct offering (the &#x201c;Offering&#x201d;). The Company received approximately
$15.0 million in gross proceeds from the Offering, before deducting placement agent fees and estimated offering expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
December 20, 2024, the equity transfer contract to transfer 51% ownership in Yunnan Faxi was terminated due to unsatisfactory performance
of Yunnan Faxi. The prepayment for acquisition of $3,562,472 (RMB25&#160;million) was reclassified to other receivable as of September
30, 2024, and collected back subsequently. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;On March 24, 2025, the Company
effected a share consolidation of 40 ordinary shares with par value of US$0.28125 per share each in the Company&#x2019;s issued and unissued
share capital into one ordinary share with par value of US$11.25. All fractional shares were rounded up to the whole number of shares.
Immediately following the Share Consolidation, the authorized share capital of the Company was US$140,625,000 divided into 11,250,000
ordinary shares, par value US$11.25 per share and 1,250,000 preferred shares, par value US$11.25 per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has assessed all subsequent events through the date that these consolidated financial statements are issued and there are no
further material subsequent events that require disclosure in these consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="c80"
      decimals="0"
      id="ixv-23214"
      unitRef="shares">15</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c80"
      decimals="5"
      id="ixv-23215"
      unitRef="usdPershares">0.01875</us-gaap:SharesIssuedPricePerShare>
    <upc:NumberOfSharesIssued
      contextRef="c235"
      decimals="0"
      id="ixv-23216"
      unitRef="shares">1</upc:NumberOfSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c80"
      decimals="5"
      id="ixv-23217"
      unitRef="usdPershares">0.28125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CapitalUnits contextRef="c81" decimals="0" id="ixv-23218" unitRef="usd">140625000</us-gaap:CapitalUnits>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c80"
      decimals="0"
      id="ixv-23219"
      unitRef="shares">450000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c81"
      decimals="5"
      id="ixv-23220"
      unitRef="usdPershares">0.28125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c83"
      decimals="0"
      id="ixv-23221"
      unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c83"
      decimals="5"
      id="ixv-23222"
      unitRef="usdPershares">0.28125</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c236"
      decimals="0"
      id="ixv-23223"
      unitRef="shares">388000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c237"
      decimals="5"
      id="ixv-23224"
      unitRef="usdPershares">0.28125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c238"
      decimals="0"
      id="ixv-23225"
      unitRef="shares">18362000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c239"
      decimals="0"
      id="ixv-23226"
      unitRef="shares">18362000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c240"
      decimals="0"
      id="ixv-23227"
      unitRef="shares">18750000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c241"
      decimals="0"
      id="ixv-23228"
      unitRef="shares">18750000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c238"
      decimals="2"
      id="ixv-23229"
      unitRef="usdPershares">0.79</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c0" decimals="-5" id="ixv-23230" unitRef="usd">15000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c242"
      decimals="2"
      id="ixv-23231"
      unitRef="pure">0.51</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:OtherReceivables contextRef="c243" decimals="0" id="ixv-23232" unitRef="usd">3562472</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="c243"
      decimals="-6"
      id="ixv-23233"
      unitRef="cny">25000000</us-gaap:OtherReceivables>
    <us-gaap:CommonStockSharesIssued
      contextRef="c84"
      decimals="0"
      id="ixv-23234"
      unitRef="shares">40</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c84"
      decimals="5"
      id="ixv-23235"
      unitRef="usdPershares">0.28125</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c84"
      decimals="2"
      id="ixv-23236"
      unitRef="usdPershares">11.25</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CapitalUnits contextRef="c84" decimals="0" id="ixv-23237" unitRef="usd">140625000</us-gaap:CapitalUnits>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c84"
      decimals="0"
      id="ixv-23238"
      unitRef="shares">11250000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c84"
      decimals="2"
      id="ixv-23239"
      unitRef="usdPershares">11.25</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c84"
      decimals="0"
      id="ixv-23240"
      unitRef="shares">1250000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c84"
      decimals="2"
      id="ixv-23241"
      unitRef="usdPershares">11.25</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock contextRef="c0" id="ixv-21478">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;NOTE
20 &#x2014;FINANCIAL INFORMATION OF THE PARENT COMPANY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Pursuant
to the requirements of Rule 12-04(a), 5-04(c) and 4-08(e)(3) of Regulation S-X, the financial information of the parent company shall
be filed when the restricted net assets of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the
most recently completed fiscal year. The Company performed a test on the restricted net assets of consolidated subsidiaries in accordance
with such requirement and concluded that it was applicable to the Company as the restricted net assets of the Company&#x2019;s subsidiaries
exceeded&#160;25% of the consolidated net assets of the Company. Therefore, the financial statements for the parent company are included
herein.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;For
purposes of the above test, restricted net assets of consolidated subsidiaries shall mean that amount of the Company&#x2019;s proportionate
share of net assets of consolidated subsidiaries (after intercompany eliminations) which as of the end of the most recent fiscal year
may not be transferred to the parent company by subsidiaries in the form of loans, advances or cash dividends without the consent of
a third party.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
financial information of the parent company has been prepared using the same accounting policies as set out in the Company&#x2019;s consolidated
financial statements except that the parent company used the equity method to account for investment in its subsidiaries. Such investment
is presented on the balance sheets as &#x201c;Investment in subsidiaries&#x201d; and the respective profit or loss as &#x201c;Equity in
earnings of subsidiaries&#x201d; on the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
footnote disclosures contain supplemental information relating to the operations of the Company and, as such, these statements should
be read in conjunction with the notes to the consolidated financial statements of the Company. Certain information and footnote disclosures
normally included in financial statements prepared in accordance with U.S GAAP have been or omitted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;As
of September 30, 2024 and 2023, there were no material contingencies, significant provisions for long-term obligations, or guarantees
of the Company, except for those which have been separately disclosed in the consolidated financial statements, if any.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PARENT
COMPANY BALANCE SHEETS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;ASSETS&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; padding-left: 9pt"&gt;Cash&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25,058,414&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,248&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in"&gt;Other receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,377,873&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,367,052&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Due from subsidiaries&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,863,833&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,878,344&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Total current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;37,300,120&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,254,644&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Non-current assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt"&gt;Investment in subsidiaries&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,749,310&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15,715,509&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x3000;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;46,049,430&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27,970,153&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;LIABILITIES AND SHAREHOLDERS&#x2019; EQUITY&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;CURRENT LIABILITIES&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in"&gt;Due to related parties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;497,014&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Accrued expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;49,475&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;TOTAL CURRENT LIABILITIES&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;546,489&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;COMMITMENTS AND CONTINGENCIES&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;SHAREHOLDERS&#x2019; EQUITY&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Ordinary shares, $11.25 par value, 11,250,000 shares authorized, 42,880 and 6,062 shares issued and outstanding as of September 30, 2024 and 2023, respectively *&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;482,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67,973&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in"&gt;Additional paid-in capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53,864,720&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,279,155&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in"&gt;(Accumulated deficit) Retained earnings&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,732,033&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;995,265&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Accumulated other comprehensive loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,112,146&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,372,240&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt"&gt;Total shareholders&#x2019; equity&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,502,941&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27,970,153&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 27pt"&gt;Total liabilities and shareholders&#x2019; equity&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;46,049,430&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27,970,153&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Retrospectively restated for effect of 15-for-1 and 40-for-1 shares
consolidations.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PARENT
COMPANY STATEMENTS OF &lt;span style="background-color: white"&gt;OPERATIONS AND COMPREHENSIVE LOSS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Years Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Operating costs and expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;General and administrative expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(592,021&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(134,141&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(384,214&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other income (expenses):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x3000;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(87,292&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(730&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(420&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equity in earnings of subsidiaries&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,047,985&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,446,153&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7,525,004&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,727,298&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,581,024&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,909,638&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Foreign currency translation adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,260,094&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(779,351&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,752,143&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Comprehensive loss attributable to the Company&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(7,467,204&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(7,360,375&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(11,661,781&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PARENT
COMPANY STATEMENTS OF CASH FLOWS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Years Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;CASH FLOWS FROM OPERATING ACTIVITIES:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(8,727,298&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(6,581,024&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(7,909,638&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Adjustments to reconcile net cash flows from operating activities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 11.3pt; padding-left: 10pt"&gt;Equity in earnings of subsidiary&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,047,985&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,446,153&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,525,004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Changes in operating assets and liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 20pt"&gt;Due to related parties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;497,014&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt"&gt;Accrued expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;49,475&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 3.3pt"&gt;Net cash used in operating activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(132,824&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(134,871&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(384,634&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;CASH FLOWS FROM FINANCING ACTIVITIES:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net proceeds from issuance of ordinary shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,999,992&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cash repayment from subsidiaries&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,511&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;115,133&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;303,746&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Net cash provided by financing activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25,014,503&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;115,133&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;303,746&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 1.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;EFFECT OF CHANGES OF FOREIGN EXCHANGE RATES ON CASH&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;167,487&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;69&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(588&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;CHANGES IN CASH&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,049,166&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(19,669&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(81,476&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;CASH, beginning of year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,248&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28,917&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;110,393&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;CASH, end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25,058,414&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,248&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;28,917&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock>
    <us-gaap:DerivativeNetAssetsPercentage contextRef="c2" decimals="2" id="ixv-23242" unitRef="pure">0.25</us-gaap:DerivativeNetAssetsPercentage>
    <upc:MinorityInterestsOwnershipPercentageByParent contextRef="c2" decimals="2" id="ixv-23243" unitRef="pure">0.25</upc:MinorityInterestsOwnershipPercentageByParent>
    <srt:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="c0" id="ixv-21522">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PARENT
COMPANY BALANCE SHEETS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;ASSETS&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; padding-left: 9pt"&gt;Cash&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25,058,414&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,248&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in"&gt;Other receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,377,873&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,367,052&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Due from subsidiaries&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,863,833&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,878,344&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Total current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;37,300,120&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,254,644&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Non-current assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt"&gt;Investment in subsidiaries&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,749,310&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15,715,509&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x3000;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;46,049,430&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27,970,153&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;LIABILITIES AND SHAREHOLDERS&#x2019; EQUITY&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;CURRENT LIABILITIES&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in"&gt;Due to related parties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;497,014&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Accrued expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;49,475&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;TOTAL CURRENT LIABILITIES&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;546,489&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;COMMITMENTS AND CONTINGENCIES&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;SHAREHOLDERS&#x2019; EQUITY&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Ordinary shares, $11.25 par value, 11,250,000 shares authorized, 42,880 and 6,062 shares issued and outstanding as of September 30, 2024 and 2023, respectively *&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;482,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67,973&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in"&gt;Additional paid-in capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53,864,720&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,279,155&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in"&gt;(Accumulated deficit) Retained earnings&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,732,033&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;995,265&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Accumulated other comprehensive loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,112,146&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,372,240&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt"&gt;Total shareholders&#x2019; equity&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,502,941&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27,970,153&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 27pt"&gt;Total liabilities and shareholders&#x2019; equity&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;46,049,430&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27,970,153&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Retrospectively restated for effect of 15-for-1 and 40-for-1 shares
consolidations.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <us-gaap:Cash contextRef="c244" decimals="0" id="ixv-23244" unitRef="usd">25058414</us-gaap:Cash>
    <us-gaap:Cash contextRef="c245" decimals="0" id="ixv-23245" unitRef="usd">9248</us-gaap:Cash>
    <us-gaap:OtherReceivables contextRef="c244" decimals="0" id="ixv-23246" unitRef="usd">1377873</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables contextRef="c245" decimals="0" id="ixv-23247" unitRef="usd">1367052</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c246" decimals="0" id="ixv-23248" unitRef="usd">10863833</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c247" decimals="0" id="ixv-23249" unitRef="usd">10878344</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AssetsCurrent contextRef="c246" decimals="0" id="ixv-23250" unitRef="usd">37300120</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c247" decimals="0" id="ixv-23251" unitRef="usd">12254644</us-gaap:AssetsCurrent>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c244" decimals="0" id="ixv-23252" unitRef="usd">8749310</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c245" decimals="0" id="ixv-23253" unitRef="usd">15715509</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:Assets contextRef="c244" decimals="0" id="ixv-23254" unitRef="usd">46049430</us-gaap:Assets>
    <us-gaap:Assets contextRef="c245" decimals="0" id="ixv-23255" unitRef="usd">27970153</us-gaap:Assets>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c246" decimals="0" id="ixv-23256" unitRef="usd">497014</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c244" decimals="0" id="ixv-23257" unitRef="usd">49475</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c244" decimals="0" id="ixv-23258" unitRef="usd">546489</us-gaap:LiabilitiesCurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c244"
      decimals="2"
      id="ix_40_fact"
      unitRef="usdPershares">11.25</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c245"
      decimals="2"
      id="ix_41_fact"
      unitRef="usdPershares">11.25</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c244"
      decimals="0"
      id="ix_36_fact"
      unitRef="shares">11250000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c245"
      decimals="0"
      id="ix_37_fact"
      unitRef="shares">11250000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c244"
      decimals="0"
      id="ix_38_fact"
      unitRef="shares">42880</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c244"
      decimals="0"
      id="ix_39_fact"
      unitRef="shares">42880</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c245"
      decimals="0"
      id="ix_42_fact"
      unitRef="shares">6062</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c245"
      decimals="0"
      id="ix_43_fact"
      unitRef="shares">6062</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="c244"
      decimals="0"
      id="ix_34_fact"
      unitRef="usd">482400</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="c245"
      decimals="0"
      id="ix_35_fact"
      unitRef="usd">67973</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c244" decimals="0" id="ixv-23269" unitRef="usd">53864720</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c245" decimals="0" id="ixv-23270" unitRef="usd">29279155</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c244" decimals="0" id="ixv-23271" unitRef="usd">-7732033</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c245" decimals="0" id="ixv-23272" unitRef="usd">995265</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c244" decimals="0" id="ixv-23273" unitRef="usd">-1112146</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c245" decimals="0" id="ixv-23274" unitRef="usd">-2372240</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c244" decimals="0" id="ixv-23275" unitRef="usd">45502941</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c245" decimals="0" id="ixv-23276" unitRef="usd">27970153</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c244" decimals="0" id="ixv-23277" unitRef="usd">46049430</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c245" decimals="0" id="ixv-23278" unitRef="usd">27970153</us-gaap:LiabilitiesAndStockholdersEquity>
    <srt:CondensedStatementOfComprehensiveIncomeTableTextBlock contextRef="c0" id="ixv-21856">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PARENT
COMPANY STATEMENTS OF &lt;span style="background-color: white"&gt;OPERATIONS AND COMPREHENSIVE LOSS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Years Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Operating costs and expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;General and administrative expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(592,021&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(134,141&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(384,214&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other income (expenses):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x3000;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(87,292&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(730&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(420&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equity in earnings of subsidiaries&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,047,985&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,446,153&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7,525,004&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,727,298&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,581,024&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,909,638&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Foreign currency translation adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,260,094&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(779,351&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,752,143&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Comprehensive loss attributable to the Company&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(7,467,204&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(7,360,375&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(11,661,781&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</srt:CondensedStatementOfComprehensiveIncomeTableTextBlock>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c248" decimals="0" id="ixv-23279" unitRef="usd">592021</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c249" decimals="0" id="ixv-23280" unitRef="usd">134141</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c250" decimals="0" id="ixv-23281" unitRef="usd">384214</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OtherNonoperatingExpense contextRef="c248" decimals="0" id="ixv-23282" unitRef="usd">87292</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense contextRef="c249" decimals="0" id="ixv-23283" unitRef="usd">730</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense contextRef="c250" decimals="0" id="ixv-23284" unitRef="usd">420</us-gaap:OtherNonoperatingExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c248" decimals="0" id="ixv-23285" unitRef="usd">-8047985</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c249" decimals="0" id="ixv-23286" unitRef="usd">-6446153</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c250" decimals="0" id="ixv-23287" unitRef="usd">-7525004</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NetIncomeLoss contextRef="c248" decimals="0" id="ixv-23288" unitRef="usd">-8727298</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c249" decimals="0" id="ixv-23289" unitRef="usd">-6581024</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c250" decimals="0" id="ixv-23290" unitRef="usd">-7909638</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c248" decimals="0" id="ixv-23291" unitRef="usd">1260094</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c249" decimals="0" id="ixv-23292" unitRef="usd">-779351</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c250" decimals="0" id="ixv-23293" unitRef="usd">-3752143</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c248" decimals="0" id="ixv-23294" unitRef="usd">-7467204</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c249" decimals="0" id="ixv-23295" unitRef="usd">-7360375</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c250" decimals="0" id="ixv-23296" unitRef="usd">-11661781</us-gaap:ComprehensiveIncomeNetOfTax>
    <srt:ScheduleOfCondensedCashFlowStatementTableTextBlock contextRef="c0" id="ixv-22053">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PARENT
COMPANY STATEMENTS OF CASH FLOWS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Years Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;CASH FLOWS FROM OPERATING ACTIVITIES:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(8,727,298&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(6,581,024&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(7,909,638&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Adjustments to reconcile net cash flows from operating activities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 11.3pt; padding-left: 10pt"&gt;Equity in earnings of subsidiary&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,047,985&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,446,153&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,525,004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Changes in operating assets and liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 20pt"&gt;Due to related parties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;497,014&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt"&gt;Accrued expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;49,475&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 3.3pt"&gt;Net cash used in operating activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(132,824&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(134,871&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(384,634&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;CASH FLOWS FROM FINANCING ACTIVITIES:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net proceeds from issuance of ordinary shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,999,992&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cash repayment from subsidiaries&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,511&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;115,133&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;303,746&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Net cash provided by financing activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25,014,503&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;115,133&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;303,746&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 1.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;EFFECT OF CHANGES OF FOREIGN EXCHANGE RATES ON CASH&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;167,487&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;69&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(588&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;CHANGES IN CASH&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,049,166&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(19,669&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(81,476&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;CASH, beginning of year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,248&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28,917&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;110,393&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;CASH, end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25,058,414&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,248&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;28,917&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</srt:ScheduleOfCondensedCashFlowStatementTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c251" decimals="0" id="ixv-23297" unitRef="usd">-8727298</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c252" decimals="0" id="ixv-23298" unitRef="usd">-6581024</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c253" decimals="0" id="ixv-23299" unitRef="usd">-7909638</us-gaap:NetIncomeLoss>
    <upc:ChangeInFairValueOfShorttermInvestments contextRef="c251" decimals="0" id="ixv-23300" unitRef="usd">-8047985</upc:ChangeInFairValueOfShorttermInvestments>
    <upc:ChangeInFairValueOfShorttermInvestments contextRef="c252" decimals="0" id="ixv-23301" unitRef="usd">-6446153</upc:ChangeInFairValueOfShorttermInvestments>
    <upc:ChangeInFairValueOfShorttermInvestments contextRef="c253" decimals="0" id="ixv-23302" unitRef="usd">-7525004</upc:ChangeInFairValueOfShorttermInvestments>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="c251" decimals="0" id="ixv-23303" unitRef="usd">497014</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c251" decimals="0" id="ixv-23304" unitRef="usd">49475</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c251" decimals="0" id="ixv-23305" unitRef="usd">-132824</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c252" decimals="0" id="ixv-23306" unitRef="usd">-134871</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c253" decimals="0" id="ixv-23307" unitRef="usd">-384634</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c251" decimals="0" id="ixv-23308" unitRef="usd">24999992</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromContributionsFromAffiliates contextRef="c251" decimals="0" id="ixv-23309" unitRef="usd">14511</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:ProceedsFromContributionsFromAffiliates contextRef="c252" decimals="0" id="ixv-23310" unitRef="usd">115133</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:ProceedsFromContributionsFromAffiliates contextRef="c253" decimals="0" id="ixv-23311" unitRef="usd">303746</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c251" decimals="0" id="ixv-23312" unitRef="usd">25014503</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c252" decimals="0" id="ixv-23313" unitRef="usd">115133</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c253" decimals="0" id="ixv-23314" unitRef="usd">303746</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c251" decimals="0" id="ixv-23315" unitRef="usd">167487</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c252" decimals="0" id="ixv-23316" unitRef="usd">69</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c253" decimals="0" id="ixv-23317" unitRef="usd">-588</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c251" decimals="0" id="ixv-23318" unitRef="usd">25049166</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c252" decimals="0" id="ixv-23319" unitRef="usd">-19669</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c253" decimals="0" id="ixv-23320" unitRef="usd">-81476</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c254" decimals="0" id="ixv-23321" unitRef="usd">9248</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c255" decimals="0" id="ixv-23322" unitRef="usd">28917</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c256" decimals="0" id="ixv-23323" unitRef="usd">110393</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c257" decimals="0" id="ixv-23324" unitRef="usd">25058414</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c254" decimals="0" id="ixv-23325" unitRef="usd">9248</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c255" decimals="0" id="ixv-23326" unitRef="usd">28917</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="c4"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:PrepaymentForAcquisitionCurrent
      contextRef="c2"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="c2"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="c4"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermLoansFromBank
      contextRef="c3"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c14"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c15"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c16"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c18"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c14"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c15"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c16"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c17"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c25"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c26"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c27"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c29"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:StockIssuedDuringPeriodValueStatutoryReserve
      contextRef="c25"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:StockIssuedDuringPeriodValueStatutoryReserve
      contextRef="c26"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:StockIssuedDuringPeriodValueStatutoryReserve
      contextRef="c27"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:StockIssuedDuringPeriodValueStatutoryReserve
      contextRef="c28"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:StockIssuedDuringPeriodValueStatutoryReserve
      contextRef="c29"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:StockIssuedDuringPeriodValueStatutoryReserve
      contextRef="c6"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c25"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c26"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c27"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c28"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c37"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c38"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c39"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:StockIssuedDuringPeriodValueReverseShareSplitAdjustment
      contextRef="c37"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:StockIssuedDuringPeriodValueReverseShareSplitAdjustment
      contextRef="c38"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:StockIssuedDuringPeriodValueReverseShareSplitAdjustment
      contextRef="c39"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:StockIssuedDuringPeriodValueReverseShareSplitAdjustment
      contextRef="c0"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c35"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c36"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c37"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c39"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c35"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c36"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c37"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c38"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInPrepaidAdvertising
      contextRef="c0"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInPrepaidAdvertising
      contextRef="c6"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="c0"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="c6"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="c0"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="c7"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent
      contextRef="c6"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:IncreaseDecreaseInPrepaidExpensesrelatedPartyNoncurrent
      contextRef="c7"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:ProceedsFromPaymentForConstructionInProgress
      contextRef="c6"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="c6"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="c7"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="c0"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="c6"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="c6"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="c7"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c6"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c7"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c0"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="c3"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="c3"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="c3"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="c24"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="c6"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
      contextRef="c6"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="c3"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ReceivablesNetCurrent
      contextRef="c3"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PrepaidAdvertising
      contextRef="c3"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c125"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c129"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermLoansFromBank
      contextRef="c188"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="c191"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c202"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c203"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c204"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c201"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c205"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c206"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c207"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c202"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c203"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c204"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c201"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c205"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c206"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
      contextRef="c0"
      id="hidden-fact-89"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c7"
      id="hidden-fact-90"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="c2"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="c2"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="c2"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c2"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c3"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c2"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c247"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c245"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesCurrent
      contextRef="c245"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c244"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c245"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="c252"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="c253"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c252"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c253"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-23435">0001809616</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-23436">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-23437">FY</dei:DocumentFiscalPeriodFocus>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retrospectively restated for effect of 15-for-1 and 40-for-1 share
consolidations.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_11_fact"
          xlink:label="ix_11_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_13_fact"
          xlink:label="ix_13_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_12_fact"
          xlink:label="ix_12_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_14_fact"
          xlink:label="ix_14_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_15_fact"
          xlink:label="ix_15_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retrospectively restated for effect of 15-for-1 and 40-for-1 share
consolidations.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_13_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_12_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_14_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_15_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_16_fact"
          xlink:label="ix_16_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_21_fact"
          xlink:label="ix_21_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_20_fact"
          xlink:label="ix_20_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_17_fact"
          xlink:label="ix_17_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_19_fact"
          xlink:label="ix_19_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_18_fact"
          xlink:label="ix_18_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retrospectively restated for effect of 15-for-1 and 40-for-1 share
consolidations.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_16_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_21_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_20_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_17_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_19_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_18_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-69"
          xlink:label="hidden-fact-69"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_22_fact"
          xlink:label="ix_22_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
September 26, 2022, the Company entered into a letter of intent for an equity transfer with an individual, Mr. Xibo Liu, pursuant to
which, Mr. Xibo Liu transfers his&#160;51% ownership in Yunnan Faxi to the Company at the price of RMB72&#160;million (approximately
$10.0&#160;million). Based on contract terms, the Company prepaid RMB25&#160;million (approximately $3.4&#160;million) within three (3)
business days upon signing the letter of intent. However, due to unsatisfactory performance of Yunnan Faxi, the equity transfer contract
was terminated on December 20, 2024. The amount of $3,562,472 (RMB25&#160;million) was recorded as other receivable as of September 30,
2024.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-69"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_22_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_24_fact"
          xlink:label="ix_24_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_23_fact"
          xlink:label="ix_23_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_4_footnote" xlink:label="ix_4_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
September 24, 2024, the Company entered into an agreement with a third party to transfer its short-term investment at the price of $</xhtml:span><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,377,873.
<xhtml:span style="background-color: white">The amount was recorded as other receivable as of September 30, 2024 and 2023.</xhtml:span></xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_24_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_23_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_26_fact"
          xlink:label="ix_26_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_25_fact"
          xlink:label="ix_25_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_5_footnote" xlink:label="ix_5_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 13, 2023, a subsidiary of the Company, Universe Trade, signed a loan agreement with LRC Bank to borrow RMB8 million (equivalent to $1,096,491) as working capital for one year, with the maturity date on March 12, 2024. The fixed interest rate of the loan was 4.56% per annum. Mr. Gang Lai signed guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.</xhtml:span></xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</xhtml:span></xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 15, 2023, a subsidiary of the Company, Jiangxi Universe, signed a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,370,614) as working capital for eleven months, with the maturity date on May 14, 2024. The fixed interest rate of the loan was 4.56% per annum. Mr. Gang Lai signed guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.</xhtml:span></xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</xhtml:span></xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 4, 2024, a subsidiary of the Company, Universe
Trade, signed a loan agreement with LRC Bank to borrow RMB5 million (equivalent to $712,494) as working capital for one year, with the
maturity date on March 3, 2025. The fixed interest rate of the loan was 4.75% per annum. Mr. Gang Lai and Jiangxi Universe jointly signed
guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.</xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 26, 2024, a subsidiary of the Company, Jiangxi
Universe, signed a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,424,989) as working capital for one year, with
the maturity date on April 25, 2025. The fixed interest rate of the loan was 4.31% per annum. Mr. Gang Lai and Universe Technology jointly
signed guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.</xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 17, 2024, a subsidiary of the Company, Universe
trade, signed a loan agreement with LRC Bank to borrow RMB5 million (equivalent to $712,494) as working capital for one year, with the
maturity date on May 16, 2025. The fixed interest rate of the loan was 3.65% per annum. Mr. Gang Lai and Jiangxi Universe jointly signed
guarantee agreements with LRC Bank to provide credit guarantee for this loan.</xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><xhtml:span style="font-family: Times New Roman, Times, Serif">On
March 3, 2025, a subsidiary of the Company, Universe Trade, signed a loan agreement with LRC Bank to borrow RMB5 million (equivalent to
$712,494) as working capital for one year, with the maturity date on March 2, 2026. The fixed interest rate of the loan was 3.65% per
annum. Mr. Gang Lai and Jiangxi Universe jointly signed guarantee agreements with LRC Bank to provide credit guarantee for this loan.</xhtml:span>
&#160;</xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</xhtml:p>
On April 22, 2024, a subsidiary of the Company, Jiangxi Universe, signed
a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,424,989) as working capital for one year, with the maturity date
on April 21, 2026. The fixed interest rate of the loan was 3.60% per annum. Mr. Gang Lai and Universe Technology jointly signed guarantee
agreements with LRC Bank to provide credit guarantee for this loan.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_26_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_25_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_28_fact"
          xlink:label="ix_28_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_27_fact"
          xlink:label="ix_27_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_6_footnote" xlink:label="ix_6_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 15, 2023, the Company&#x2019;s subsidiary, Jiangxi Universe, signed a loan agreement with Bank of Communications to borrow RMB9 million (equivalent to $1,246,486) as working capital for eleven months, with the maturity date on May 18, 2024. The fixed interest rate of the loan was 4.0% per annum. Mr. Gang Lai, Universe Trade, and an unrelated third party, Jiangxi Province Financing Guarantee Group Co., Ltd., jointly signed guarantee agreements with Bank of Communications to provide credit guarantee for this loan. The loan was fully repaid upon maturity.</xhtml:span></xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</xhtml:span></xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 16, 2024, the Company&#x2019;s subsidiary, Jiangxi Universe, signed a loan agreement with Bank of Communications to borrow RMB8.1 million (equivalent to $1,154,241) as working capital for eleven months, with the maturity date on May 13, 2025. The fixed interest rate of the loan was 3.9% per annum. Mr. Gang Lai, Universe Trade, and an unrelated third party, Jiangxi Province Financing Guarantee Group Co., Ltd., jointly signed guarantee agreements with Bank of Communications to provide credit guarantee for this loan.</xhtml:span></xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_28_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_27_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_30_fact"
          xlink:label="ix_30_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_29_fact"
          xlink:label="ix_29_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_7_footnote" xlink:label="ix_7_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 5, 2023, a subsidiary of the Company, Jiangxi Universe, entered into a loan agreement with Zhujiang Rural Bank to borrow RMB 3 million (equivalent to $415,495) as working capital for one year, with the maturity date on May 4, 2024. The fixed interest rate of the loan was 3.65% per annum. The Company pledged certain patents owned by the Company as collateral to guarantee this loan. The loan was fully repaid upon maturity.</xhtml:span></xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</xhtml:span></xhtml:p>
On April 24, 2024, a subsidiary of the Company, Jiangxi
Universe, entered into a loan agreement with Zhujiang Rural Bank to borrow RMB3 million (equivalent to $427,497) as working capital for
one year, with the maturity date on April 24, 2025. The fixed interest rate of the loan was 3.65% per annum. The Company pledged certain
trademarks owned by the Company as collateral to guarantee this loan.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_30_fact"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_29_fact"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_31_fact"
          xlink:label="ix_31_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_32_fact"
          xlink:label="ix_32_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_8_footnote" xlink:label="ix_8_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 24, 2023, a subsidiary of the Company, Jiangxi Universe, entered into a loan agreement with Beijing Bank to borrow RMB 10 million (equivalent to $1,384,984) as working capital for one year, with the maturity date on July 18, 2024. The fixed interest rate of the loan was 4.25% per annum. There was no guarantee requirement for this loan. The loan was fully repaid upon maturity.</xhtml:span></xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</xhtml:span></xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 3, 2024, a subsidiary of the Company, Jiangxi Universe, entered into a loan agreement with Beijing Bank to borrow RMB 10 million (equivalent to $1,424,989) as working capital for one year, with the maturity date on July 3, 2025. The fixed interest rate of the loan was 4.15% per annum. Mr. Gang Lai provided credit guarantee for this loan.</xhtml:span></xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_31_fact"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_32_fact"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_33_fact"
          xlink:label="ix_33_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-73"
          xlink:label="hidden-fact-73"
          xlink:type="locator"/>
        <link:footnote id="ix_9_footnote" xlink:label="ix_9_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 23, 2023, a subsidiary of the Company, Jiangxi Universe, signed a loan agreement with LRC Bank to borrow RMB15 million (equivalent to $2,137,483) as working capital for two years, with the maturity date on November 14, 2025. The fixed interest rate of the loan was 3.95% per annum. The Company pledged buildings of Jiangxi Universe as collateral to guarantee this loan.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_33_fact"
          xlink:to="ix_9_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-73"
          xlink:to="ix_9_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_38_fact"
          xlink:label="ix_38_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_41_fact"
          xlink:label="ix_41_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_35_fact"
          xlink:label="ix_35_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_40_fact"
          xlink:label="ix_40_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_42_fact"
          xlink:label="ix_42_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_34_fact"
          xlink:label="ix_34_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_39_fact"
          xlink:label="ix_39_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_43_fact"
          xlink:label="ix_43_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_36_fact"
          xlink:label="ix_36_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_37_fact"
          xlink:label="ix_37_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_10_footnote" xlink:label="ix_10_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retrospectively restated for effect of 15-for-1 and 40-for-1 shares
consolidations.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_38_fact"
          xlink:to="ix_10_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_41_fact"
          xlink:to="ix_10_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_35_fact"
          xlink:to="ix_10_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_40_fact"
          xlink:to="ix_10_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_42_fact"
          xlink:to="ix_10_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_34_fact"
          xlink:to="ix_10_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_39_fact"
          xlink:to="ix_10_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_43_fact"
          xlink:to="ix_10_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_36_fact"
          xlink:to="ix_10_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_37_fact"
          xlink:to="ix_10_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
